{"id": "25202264", "sentence": "The majority of these patients also had other coexisting @GENE$ mutations . The coexisting point mutations on exon 20 that rendered the patients resistant to @DRUG$ were @VARIANT$ , V769L , W731 Stop , L858R , L 861Q and delE749_T751insVA [ ] .", "label": "None"}
{"id": "17877814", "sentence": "The @VARIANT$ mutation abrogated the effect of erlotinib on L858R , and the L858R/T790M double mutant readily induced Akt phosphorylation even in the presence of 10 μM erlotinib . Discussion In a subset of NSCLC patients , the presence of somatic mutations in the kinase domain of EGFR may predict the outcome of treatment with the @GENE$ TKIs erlotinib and @DRUG$ .", "label": "resistance or non-response"}
{"id": "25364578", "sentence": "The emergence of the @VARIANT$ EGFR gatekeeper mutation and up-regulation of downstream signaling by MET amplification have been described as the two main mechanisms responsible for acquired resistance . However a phase III trial enrolling only patients with MET positive tumors was stopped in early March 2014 due to futility ; there was no evidence to suggest a positive effect of addition of onartuzumab to @DRUG$ . Other mechanisms include EGFR amplifications , @GENE$ mutations or a transition from epithelial to mesenchymal differentiation .", "label": "None"}
{"id": "22916202", "sentence": "This indicates that in C. roseus the major bisindole alkaloid stored in vacuoles is anhydrovinblastine and there might be other factors involved in regulating the biosynthesis of vinblastine and @DRUG$ . In previous studies , overexpression of @VARIANT$ and ORCA3 in C. roseus hairy roots improved catharanthine production but has no effect on other alkaloids . When ORCA3 alone was overexpressed in the hairy roots , a decrease in several @GENE$ ( included catharanthine ) was observed , .", "label": "None"}
{"id": "21333004", "sentence": "Yun et al [ ] showed that gefitinib directly binds more tightly to the @VARIANT$ mutant than to the wild type EGFR in vitro , while Fabian et al [ ] indicated that @GENE$ with gefitinib sensitive mutations does not differ from wild type EGFR in terms of @DRUG$ binding affinity .", "label": "sensitivity"}
{"id": "23552882", "sentence": "For example , HCC827 cells undergo @GENE$ amplification and AXL induction upon adaption to @DRUG$ , , , and PC9 cells acquire the T790M mutation in EGFR that confers resistance to erlotinib and gefitinib . In addition , studies with TKI-resistant tumor specimens suggest alternative mechanisms that remain to be defined . In addition , H1975 cells , which express EGFR bearing the activating @VARIANT$ mutation and the T790M gate-keeper mutation , were selected for resistance to the irreversible EGFR inhibitor , BIBW2992 .", "label": "None"}
{"id": "PMC4041556", "sentence": "Second-generation EGFR TKIs – such as neratinib , afatinib and dacomitinib – are effective in preclinical gefitinib- and erlotinib-resistant @GENE$ @VARIANT$ models , but to date their delivery in EGFR TKI-resistant patients have shown disappointing results in the clinic .", "label": "resistance or non-response"}
{"id": "20146801", "sentence": "These cells lines are different in K-RAS and B-RAF pathways , as HT-29 harbors the @VARIANT$ B-Raf heterozygotic mutation [ ] , SW-480 which harbors K-Ras mutation and Caco-2 is K-Ras and B-Raf wild type . The association between the expression of @GENE$ and the presence/absence of K-Ras and B-Raf mutations in response to @DRUG$ supports their possible apoptotic function and helps to understand the action mechanism of this drug .", "label": "None"}
{"id": "19238632", "sentence": "Many tumours with intrinsic resistance to erlotinib/gefitinib were found to have wild-type @GENE$ and/or mutant KRAS . At present , no FDA approved inhibitor drugs have been shown to be successful in overcoming @VARIANT$ mediated resistance clinically .", "label": "resistance or non-response"}
{"id": "22439647", "sentence": "We have not observed any response to sunitinib in group of patients with @GENE$ mutations ( mainly @VARIANT$ ) , which has been also shown in preclinical data . We did not analyze the impact of secondary mutations , although patients from clinical trials with tumors harboring a secondary mutation in exon 13 or exon 14 KIT have a longer PFS than patients with exon 17 or 18 mutations [ , - ] . On the other hand , utility of analysis of secondary mutations is very challenging because imatinib-resistant GISTs are very heterogeneous with multiple clones having different secondary mutations within the same or different nodules [ - ] .", "label": "resistance or non-response"}
{"id": "23493838", "sentence": "A complete hematological response and a major cytogenetic response were observed broadly across the @GENE$ mutants , including individuals harboring the dasatinib-resistant F317L , the nilotinib-resistant Y253H , and F359C/I/V mutations , but not T315I . Nine individuals developed new mutations in the course of bosutinib treatment ( @VARIANT$ , n = 4 ; L248V , n = 2 ; T315I , n = 2 ; F359C , n = 1 ; G250E , n = 1 ) and eight of these individuals discontinued bosutinib because of progressive disease or unsatisfactory response .", "label": "None"}
{"id": "25033171", "sentence": "Energetic contribution of important residues to the binding of @DRUG$ . Energetic spectrums ( enthalpy ) were decomposed into drug-residue pairs for ( A ) wild-type ROS1 , and ( B ) @VARIANT$ mutated @GENE$ , and their corresponding structural descriptions are shown in panel D and panel E , where the P-loop region and important residues on it ( Leu18 and Val26 ) are illustrated in orange cartoon model and stick model , respectively .", "label": "resistance"}
{"id": "23082072", "sentence": "However , in patients with acquired resistance , tumor cells bearing EGFR @VARIANT$ represented a minority of cells , and as such , part of the tumor may remain responsive to @DRUG$ or gefitinib. , The other signal pathway related @GENE$ followed the same principles .", "label": "resistance or non-response"}
{"id": "23937717", "sentence": "Two @DRUG$ resistance NSCLC cell lines A549 ( EGFR wt ) and H1975 ( @GENE$ @VARIANT$ + T790M ) were used .", "label": "sensitivity"}
{"id": "18974847", "sentence": "B. HT29 colon cells were left untreated or pretreated for 30 min with 5 mM mßCD or 100 µg/ml @DRUG$ , incubated with 25 µg/ml @GENE$ for 30 min prior to fixation and labeling with the 3F3A anti-gp78/AMFR monoclonal antibody followed by appropriate secondary antibodies . AMF/PGI-FITC labeling is presented in green and the anti-gp78/AMFR labeled smooth endoplasmic reticulum in red . C. HT29 cells were infected with adenoviruses expressing the tTA alone ( control ) or coinfected with the tTA adenovirus and adenoviruses coding for Cav1 , clathrin hub , wild-type dynamin-1 ( DynWT ) or mutant dynamin-1 @VARIANT$ (DynK44A) .", "label": "None"}
{"id": "25099740", "sentence": "As @GENE$ and RAS mutants stimulate mTOR downstream of EGFR , we asked whether their expression is sufficient to confer @DRUG$ resistance . For these studies , we genetically engineered Cal27 cells to express activating PIK3CA @VARIANT$ or KRAS G12V mutations , the latter as a GFP fusion protein to distinguish it from the endogenous gene product .", "label": "resistance or non-response"}
{"id": "21108851", "sentence": "Further clinical studies of @DRUG$ are ongoing , most notably a single-arm phase 2 study in patients with CML or Ph+ acute lymphoblastic leukemia ( ALL ) who either are resistant or intolerant to either dasatinib or nilotinib , or who harbor the @VARIANT$ mutation ( Ponatinib Ph+ ALL and CML evaluation [PACE ] ; NCT01207440 ) . Switch pocket kinase inhibitors , such as DCC-2036 and @GENE$ , target the sites involved in controlling the conformation of BCR-ABL , which ultimately controls the activity state of the kinase .", "label": "None"}
{"id": "22738081", "sentence": "Constitutive activation of the @GENE$ kinase via the PI3K and AKT signalling network results in activation of substrates , such as the ribosomal subunit S6 kinase ( @VARIANT$ ) and eukaryotic initation factor 4E , which are critical for synthesis of proteins involved in cellular growth and survival . Activation of the AKT pathway can occur through homozygous loss of the PTEN tumour suppressor gene , but there is no definite prognostic significance for PTEN loss in mRCC [ , ] , and there does not appear to be a correlation between tumour PTEN expression and benefit from @DRUG$ [ ] .", "label": "None"}
{"id": "24982846", "sentence": "Pertuzumab @GENE$ HER2 protein overexpression positive Indications and usage , warnings and precautions , adverse reactions , clinical studies , clinical pharmacology @DRUG$ BCR/ABL1 Philadelphia chromosome [ t ( 9 ; 22 ) ] positive , BCR–ABL @VARIANT$ mutation Indications and usage , warnings and precautions , adverse reactions , use in specific populations , clinical pharmacology , clinical studies", "label": "None"}
{"id": "22655263", "sentence": "When tested in @GENE$ cells driven by ALK mutants identified in crizotinib relapsed patients , NMS-E628 is circa fivefold more potent than @DRUG$ in inhibiting the proliferation of @VARIANT$ ALK and C1156Y ALK-driven-cells in vitro and in vivo ( Ardini et al. , ) .", "label": "None"}
{"id": "24982846", "sentence": "@DRUG$ ERBB2 HER2 protein overexpression positive Indications and usage , warnings and precautions , adverse reactions , clinical studies , clinical pharmacology Ponatinib BCR/ABL1 Philadelphia chromosome [ t ( 9 ; 22 ) ] positive , @GENE$ @VARIANT$ mutation Indications and usage , warnings and precautions , adverse reactions , use in specific populations , clinical pharmacology , clinical studies", "label": "None"}
{"id": "23071808", "sentence": "@DRUG$ was injected into CAGGCre-ER™ X @VARIANT$ mice on P13 and P14 or @GENE$ and P28 to induce recombination at the start of the third or fifth postnatal week , respectively and harvested at 6 weeks of age .", "label": "None"}
{"id": "19452042", "sentence": "Emerging data suggest that patients with NSCLC and @GENE$ exon 19 deletion have a longer survival following treatment with @DRUG$ or erlotinib compared with those with the @VARIANT$ mutation [ - ] .", "label": "sensitivity"}
{"id": "22034911", "sentence": "Consistent with this , we found that the introduction of R1275Q into EML4-ALK had no negative impact on sensitivity to @DRUG$ ( IC50 47 ± 8 nm ) . As expected , the IC50 values for viability of @GENE$ cells expressing these mutants were all above that for Ba/F3 cells expressing native EML4-ALK , with IC50s ranging from 231 to 981 nm . The three most resistant mutants , L1196M , S1206R , and @VARIANT$ , all had IC50s within twofold of parental , ALK negative , Ba/F3 cells ( IC50 1176 nm ) .", "label": "None"}
{"id": "20102612", "sentence": "In addition , we could not detect basal occupancy of the cIAP2 promoter by p65 , RAR or RXRα , but significant occupancy of the promoter by these transcription factors was observed after exposure of @VARIANT$ cells to 9-cis-RA . In contrast with the results obtained with the cIAP2 promoter , @GENE$ was not recruited to the RARβ gene promoter , a well characterized @DRUG$ acid-responsive gene , where we were able to detect basal and induced recruitment of RAR and RXRα ( Fig. , middle panel ) .", "label": "None"}
{"id": "25221748", "sentence": "This agent is also being assessed in a phase II trial in patients with de novo resistant @VARIANT$ mutations not previously treated with EGFR-TKIs ( www.clinicaltrials.gov : NCT01854034 ) and in patients with EGFR mutations and/or EGFR-TKI resistant disease , as part of a phase II cluster study in Chinese patients evaluating five novel inhibitors of HSP90 , PI3K , ALK , MET , and MEK ( ) . Further , AUY922 is also being assessed in combination with @DRUG$ in patients who have previously responded to @GENE$ and/or whose tumors harbor activating EGFR mutations ( www.clinicaltrials.gov : NCT01259089 ) , with results expected in the near future .", "label": "resistance or non-response"}
{"id": "23994953", "sentence": "Somatic mutations in exons encoding the tyrosine kinase ( TK ) domain of the epidermal growth factor receptor (EGFR) are positively associated with increased sensitivity of non-small cell lung cancer ( NSCLC ) patients to the selective @GENE$ TK inhibitors ( TKIs ) @DRUG$ ( Iressa™ ) and erlotinib ( Tarceva™ ) . Prospective trials have demonstrated an impressive ~75 % response rate for patients whose tumors harbor these mutations , which occur as either multinucleotide in-frame deletions in exon 19 ( e.g. , delE746-A750 ) or as single missense mutations ( e.g. , @VARIANT$ ) .", "label": "sensitivity"}
{"id": "24789720", "sentence": "The possibility of detection of @VARIANT$ mutation in EGFR-TKIs naive patients forces to expand the diagnostics of @GENE$ gene status during qualification for erlotinib or @DRUG$ treatment and to consider the new therapy modalities in carriers of this mutation .", "label": "resistance or non-response"}
{"id": "23238683", "sentence": "As shown in Figure , BaF3 cells expressing native BCR-ABL were highly sensitive to imatinib , dasatinib and ponatinib , whereas BaF3-T315I-BCR-ABL and @GENE$ cells were resistant to both @DRUG$ and dasatinib . By contrast , ponatinib induced loss of cell viability in BaF3 cells carrying the T315I or @VARIANT$ mutation , in agreement with previous results from the literature [ , ] .", "label": "None"}
{"id": "23994953", "sentence": "Our data appear to support a previously unrecognized scenario in which , in the presence of @DRUG$ sensitizing @GENE$ mutations ( delE746-A750 , @VARIANT$ ) , an aberrant/incomplete epithelial differentiation might determine the intrinsic ability of EGFR mutant-NSCLC cells to rapidly shift toward the erlotinib-refractory mesenchymal end of the epithelial-mesenchymal spectrum .", "label": "sensitivity"}
{"id": "22162641", "sentence": "Resistance to tyrosine inhibitors invariably develops , and usually involves development of a gatekeeper mutation in the kinase domain , such as @VARIANT$ in chronic myelogenous leukemia , and T790M in @GENE$ mutated NSCLC . Similarly , a patient developed resistance to @DRUG$ after 5 months of treatment and molecular analyses revealed the resistant tumor harbored two acquired but independent mutations within the kinase domain of EML4-ALK , C1156Y , and the gatekeeper mutation L1196M .", "label": "None"}
{"id": "19680652", "sentence": "An acquired @GENE$ mutation ( @VARIANT$ ) has been reported to occur upon failure of @DRUG$ and is also predictive of resistance to erlotinib [ , ] .", "label": "resistance or non-response"}
{"id": "22751098", "sentence": "NSCLC patients whose tumors harbor activating kinase domain mutations in the epidermal growth factor receptor (EGFR) often initially respond to treatment with an EGFR tyrosine kinase inhibitor ( TKI ) such as erlotinib.–However , acquired resistance to EGFR TKI treatment invariably develops. , There is no effective therapy for patients who develop such resistance . Work by our group and others has shown that resistance to EGFR TKI treatment can occur through a secondary resistance mutation in EGFR ( @VARIANT$ ) , activation of the @GENE$ kinase , and activation of the NF-kB pathway.– .", "label": "None"}
{"id": "22433462", "sentence": "Two small molecule @GENE$ tyrosine kinase inhibitors ( EGFR-TKI ) , gefitinib ( @DRUG$ , AstraZeneca International ) and erlotinib ( Tarveca , OSI Pharmaceuticals ) have been evaluated in patients with NSCLC [ , ] . These ATP competitive , reversible EGFR-TKIs have been effective only in a small subset of NSCLC patients bearing somatic mutations ( deletions in exon 19 and the @VARIANT$ mutation ) in the kinase domain of EGFR [ ] .", "label": "sensitivity"}
{"id": "21801448", "sentence": "Consistent with these results , p53 restoration resulted in an 8-fold increase of caspase-3/7 activity after etoposide treatment , whereas the activity was increased regardless of p53 function after @DRUG$ treatment ( Figure ) . These results demonstrate that both caspase-8 and p53 functions are critical for etoposide induced caspase-9 activation , and also the subsequent cleavage of procaspase-3 and @GENE$ in HOC313 cells . To confirm the requirement of caspase-8 activity in the etoposide induced apoptosis , HOC313 cells were transiently transfected with the empty vector , wild-type ( WT ) , or @VARIANT$ inactive mutant of Flag tagged caspase-8 by electroporation , then treated with etoposide at 32.5°C .", "label": "None"}
{"id": "22577569", "sentence": "Primary @DRUG$ resistance is observed in roughly 10 % of all genotypic subtypes of GIST . Most cases that show primary resistance are kit and @GENE$ wild type , those with kit exon 9 mutations and those with PDGFRA @VARIANT$ mutation .", "label": "None"}
{"id": "22233865", "sentence": "@GENE$ , autoimmune regulator ; CB-SCs , cord blood stem cells ; IgG , @DRUG$ PCR , polymerase chain reaction ; PHA , phytohaemagglutinin ; siRNA , small interfering RNA ; @VARIANT$ , type 1 diabetes ; Tregs , regulatory T cells .", "label": "None"}
{"id": "24501009", "sentence": "These observations could be due to the presence of concurrent drug resistance mechanisms ( such as @GENE$ amplification ) , or to the inability of dacomitinib to fully inhibit EGFR in tumors harboring EGFR T790M at the doses currently under clinical investigation . Strategies to improve EGFR inhibition in EGFR @VARIANT$ cancers include the combination of irreversible EGFR inhibitors with the EGFR‐directed antibody cetuximab ( as reported for @DRUG$ plus cetuximab ) 19 ; the development of more potent and specific inhibitors of EGFR T790M20,21 ; and the use of intermittent but high doses of existing irreversible EGFR inhibitors .", "label": "None"}
{"id": "19568750", "sentence": "G1249A polymorphism is a G→A base change that results in amino acid alterations from Val to Ile at 417 , and 1,249 AA is associated with decreased mRNA [ ] ; whereas @VARIANT$ is the ‘silent’ mutation at 1 ,324 ( Ile1324Ile ) . several studies have suggested their association with altered MRP2 expression or function [ , ] . Besides being able to quickly export glutathione conjugated platinum , upregulated expression of @GENE$ is also associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in the cisplatin-resistant cell lines [ ] .", "label": "None"}
{"id": "22436374", "sentence": "Afatinib is an irreversible @GENE$ inhibitor , with activity against wild-type and mutant forms of EGFR [ ] . Afatinib was more potent than gefitinib , erlotinib , and @DRUG$ in inducing the cell death of NSCLC cell lines , including those harboring wild-type EGFR , and the erlotinib-resistant @VARIANT$ mutation [ ] .", "label": "None"}
{"id": "24223798", "sentence": "In particular , epidermal growth factor receptor tyrosine kinase inhibitors ( EGFR-TKIs ) , such as gefitinib and @DRUG$ , have been developed as a novel treatment option for patients with non–small cell lung cancers ( NSCLCs ) that possess somatic mutations in the tyrosine kinase domain of the @GENE$ – . Prospective clinical trials of EGFR-TKI treatment in NSCLC patients with activating EGFR mutations , such as delE746-A750 ( exon 19 ) and @VARIANT$ ( exon 21 ) , have demonstrated high clinical response rates of approximately 80 % – .", "label": "sensitivity"}
{"id": "23139867", "sentence": "In contrast , silencing of RB1 , indicated by an increase in CYCLIN E due to the activation of @VARIANT$ , had no detectable effect on RRM2B in the presence or absence of @DRUG$ .", "label": "None"}
{"id": "25505694", "sentence": "@DRUG$ is an orally , irreversible EGFR , @GENE$ and HER4 inhibitor , showing preclinical activity against cancer cells harboring common activating EGFR mutations and the @VARIANT$ mutation , albeit with a lower potency [ ] .", "label": "None"}
{"id": "24212940", "sentence": "We also found that DIM plus Herceptin could reverse EMT phenotype by modulating @GENE$ expression ( unpublished data ) . We believe that combination of DIM and Herceptin is more potent than individual compounds , which could maximize the effect of Herceptin based therapies . Interestingly , other researchers have demonstrated such action of @VARIANT$ where this indole enhanced doxorubicin as well as @DRUG$ induced cytotoxicity [ ] .", "label": "None"}
{"id": "25505694", "sentence": "@DRUG$ , an oral small-molecule inhibitor of EGFR , VEGFR-2 , @GENE$ and Ephrin type-B receptor 4 (EphB4) , in preclinical studies showed efficacy against EGFR-driven tumors , including those harboring @VARIANT$ [ ] .", "label": "None"}
{"id": "19707322", "sentence": "The sensitivity of @GENE$ mutants to @DRUG$ can be summarized into 4 categories : high ( IC50 ≤ 70 nmol/L : M244V , @VARIANT$ , Q252H , F3llL , F317L , M351T , V379I , L387M , H396P , H396R ) , medium ( IC50 ≤ 200 nmol/L : Y253F , E255K , F359V ) , low ( IC50 ≤ 450 nmol/L : Y253H , E255V ) , and insensitive ( IC50 & gt ; 2 μmol/L : T315I ) ( ) ( ) .", "label": "None"}
{"id": "17973572", "sentence": "To prove the functional significance of the @VARIANT$ mutation , we generated Ba/F3 cell lines stably expressing mutant EGFR constructs [ ] . These cell lines , including L858R-L747S , proliferated in the absence of IL3 . Ba/F3-L858R cells were extremely sensitive to @DRUG$ ( D ) , whereas @GENE$ cells were highly resistant up to 1 μM gefitinib .", "label": "None"}
{"id": "24523596", "sentence": "Several studies have reported renal failure and tumor lysis syndrome during TKI based molecular targeted therapies , including with sorafenib for hepatocellular carcinoma , with imatinib for chronic myelogenous leukemia , and with flavopiridol for chronic lymphocytic leukemia.– Because the @VARIANT$ variant of ABCG2/BCRP corresponding to SNP 421C&gt ; A reduces uric acid transport and those TKIs are substrates/inhibitors of ABCG2/BCRP , TKI therapy in patients with the SNP 421C&gt ; A ( Q141K ) may be at higher risk of tumor lysis syndrome . A defect in the pharmacological interaction has been suggested between sunitinib and another ABCG2/BCRP germ-line mutant allele , 1291T & gt ; C. Remarkably , @DRUG$ reversed wild-type ABCG2/BCRP mediated drug resistance and competitively inhibited @GENE$ mediated estrone 3-sulfate transport and the binding of 125I-iodoarylazidoprazosin to ABCG2/BCRP .", "label": "None"}
{"id": "18382681", "sentence": "While our body of data represents a total of 157 patients , additional studies will be needed to confirm the trends observed , especially the benefit of @DRUG$ treatment in @VARIANT$ activated breast cancer cell lines resistant to other commonly used agents .", "label": "None"}
{"id": "21188126", "sentence": "This @VARIANT$ allele mutation occurs in approximately 10 % of colorectal cancer patients . It is associated with microsatellite instability and poor survival of colon cancer patients. , BRAF mutations in colorectal cancer cause resistance to @GENE$ targeted therapy with shorter PFS and OS compared to nonmutated patients . Remarkably , treatment with the BRAF-inhibitor sorafenib in in vitro experiments restored sensitivity to @DRUG$ in colon cancer cells .", "label": "None"}
{"id": "24292070", "sentence": "Note that the lack of bosutinib activity towards the TKL kinases is explained by the prevalence of the @VARIANT$ substitution in this family , which , as noted above , interferes with @DRUG$ binding without compromising the hydrogen bond network . To confirm that the hydrogen bond network is responsible for this subfamily selectivity we verified the hydrogen bond status in compatible and incompatible members of two kinase subfamilies , the @GENE$ and the EGFR family .", "label": "None"}
{"id": "19949544", "sentence": "The @VARIANT$ mutation is most common ( comprising 50 % of mutations ) . KIT gene amplification also occurs [ , ] . KIT mutations are mutually exclusive with BRAF and NRAS , and may identify a subset of melanoma that preferentially respond to the @GENE$ inhibitors such as @DRUG$ ( Gleevec ) [ , ] or sorafenib [ , ] .", "label": "resistance or non-response"}
{"id": "24516334", "sentence": "For example , three BCR-ABL mutations ( T315I , @VARIANT$ , and F317L ) have a predicted role in abrogating binding of imatinib to BCR-ABL in resistant patients . The second-generation BCR-ABL kinase inhibitor , @DRUG$ , binds to @GENE$ with less stringent conformational requirements and was shown to be effective in inhibition of imatinib-resistant mutants .", "label": "None"}
{"id": "23976869", "sentence": "Vo n Bubnoff et al reported that @DRUG$ suppresses the growth of @GENE$ cells transfected with the @VARIANT$ FIP1L1-PDGFRA mutant .", "label": "None"}
{"id": "23145123", "sentence": "First , we generated the PC9-ER cell line by culturing PC9 lung cancer cells , which express the transforming EGFR delE745-A750 allele , in the presence of escalating doses of the @GENE$ inhibitor @DRUG$ ( ) . Screening of a cDNA library generated from PC9-ER in Ba/F3 cells resulted in multiple full-length clones that harbored EGFR with both delE745-A750 and @VARIANT$ ( ) and were sensitive to the mutant-selective EGFR inhibitor WZ4002 ( LD99 & lt ; 1 µM ) .", "label": "resistance or non-response"}
{"id": "23566546", "sentence": "Case Histrogical type @GENE$ mutation status Brinkman index Treatment agent Response IL-8 ( ng/mL ) IL-10 ( ng/mL ) RANTES ( pg/ml ) 1 Ad Ex21 @VARIANT$ 900 gefitinib PR 5.79 1.67 2 2 Ad Ex21 L858R 0 erlotinib PR_3.33 94.2 1.41 3 Ad Ex19 del 0 erlotinib PR 4.09 126 2.13 4 Ad Ex21 L858R 0 gefitinib PR_3.92 18.1 1.85 5 Ad Ex21 L858R + Ex19 del 370 erlotinib PR 21.9 1.23 2.11 6 Ad Ex19 del 0 erlotinib PR 7.05 1.37 2.56 7 Ad Ex19 del 0 gefitinib PR 4.82 1.59 2.02 8 Ad Ex21 L858R 1640 gefitinib PR 54.9 2.7 2.38 9 Ad negative 400 erlotinib SD 34.9 3.39 3.66 10 Ad negative 0 erlotinib SD 27.1 4.94 2.25 11 Ad unknown 1800 erlotinib SD NE NE NE 12 Sq Ex19 del 3840 gefitinib SD 12.6 1.1 1.98 13 Ad Ex19 del 30 erlotinib SD 5.27 0.69 2.66 14 Ad Ex19 del 0 erlotinib SD 10.5 0.85 2.5 15 Ad unknown 300 erlotinib SD 7.69 2.61 1.7 16 La negative 2080 erlotinib SD NE NE NE 17 Sq Ex21 L858R 750 erlotinib SD 11.6 56.3 3.06 18 Ad unknown 600 erlotinib SD 13.7 1.1 2.82 19 Ad Ex21 L858R 0 erlotinib SD 20.6 11.6 0.783 20 Ad Ex19 del 0 erlotinib SD 14.8 2.07 2.02 21 Ad Ex21 L858R + Ex19 del 0 gefitinib SD 3.04 1.3 1.76 22 Ad Ex19 del 200 gefitinib SD 10.9 1.59 1.91 23 Sq unknown 1560 erlotinib PD NE NE NE 24 Ad negative 1080 erlotinib PD 25.2 8.15 1.57 25 Ad unknown 0 erlotinib PD NE NE NE 26 Ad Ex18 G719A 2000 erlotinib PD 11.6 4.48 3.12 27 Ad unknown 1410 erlotinib PD NE NE NE 28 Ad Ex19 del 1000 gefitinib PD 9.44 2.25 2.89 29 Ad negative 1100 erlotinib PD 56.3 5.63 2.16 30 Ad negative 2000 erlotinib PD 15.6 0.85 0.292 31 Ad negative 825 erlotinib PD 8.27 1.59 2.13 32 Ad Ex21 L858R 0 erlotinib PD 5.34 7.05 1.7 33 Ad negative 1680 @DRUG$ PD 57.7 1.63 2.06", "label": "sensitivity"}
{"id": "23992330", "sentence": "Briefly , they demonstrated the different effects of the G12 and G13 K-Ras alleles on response to cetuximab and found a significant association between the presence of a G13D mutation and survival benefit after @DRUG$ treatment in metastatic colorectal cancer patients [ ] . Moreover , a paper by Di Nicolantonio et al. demonstrated the different role of @GENE$ and K-Ras mutations in the response to the mammalian Target Of Rapamycin (mTOR) inhibitor everolimus . In fact , while cells knocked-in for the PIK3-CA alleles @VARIANT$ and E545K showed an increased response to everolimus , oncogenic K-Ras mutations conferred resistance to this agents [ ] .", "label": "resistance or non-response"}
{"id": "25333255", "sentence": "In addition , bosutinib ( @GENE$ ) was developed , a second line inhibitor which has the broadest target spectrum inhibiting SRC , ABL and TEC , as well as serine kinases CAMK2G and STE20 , but @DRUG$ does not target PDGFR and KIT [ , ] . Finally , the third line inhibitor ponatinib has been developed and shown to exhibit substantial efficacy in patients with CML in whom the polyresistant BCR-ABL1 @VARIANT$ mutation is expressed in leukemic cells [ ] .", "label": "None"}
{"id": "23986642", "sentence": "In contrast , @DRUG$ was designed to avoid binding with the side chain of @VARIANT$ in native @GENE$ , and instead forms beneficial van der Waals interactions with the isoleucine side chain of the T315I mutant .", "label": "response"}
{"id": "23525126", "sentence": "@GENE$ mutation analysis was positive for a @VARIANT$ mutation in codon 13 of the KRAS gene . Chemotherapy with @DRUG$ 1000 mg/m2 on days 1 to 14 , oxaliplatin 130 mg/m2 on day 1 , and bevacizumab 7.5 mg/kg on day 1 of a 21-day cycle was initiated , as was treatment with zoledronic acid every 28 days .", "label": "None"}
{"id": "23986642", "sentence": "@DRUG$ is an orally administered , synthetic , multi targeting TKI structurally designed as a @GENE$ inhibitor . This is reflected by the inhibition of in vitro tyrosine kinase activity of ABL and @VARIANT$ mutant ABL with a half maximal inhibitory concentration ( IC50 ) of 0.4 nM and 2.0 nM , respectively .", "label": "response"}
{"id": "24349524", "sentence": "Several causes of @DRUG$ resistance have been described : @VARIANT$ mutation in the kinase domain of @GENE$ [ - ] , overexpression of BCR-ABL1 itself or overexpression of multidrug resistance protein 1 (MDR1) or the Src kinase [ ] and down-regulation of apoptotic BAX and CERS1 ( ceramide synthase 1 ) [ ] .", "label": "None"}
{"id": "24594844", "sentence": "Synergistic antitumor effect of combined treatment with cDzT and @DRUG$ in vitro and in vivo cDzT could be used as single agent or as part of combination therapy with second generation TKIs to increase efficacy in the treatment of NSCLCs that harbor the @GENE$ @VARIANT$ mutant .", "label": "response"}
{"id": "21687596", "sentence": "An experiment using cell lines transfected concurrently with activating mutations and a @VARIANT$ mutation also proved that resistance to gefitinib and @DRUG$ is evident when this mutation is present [ – ] . Analogous secondary mutations of the BCR-ABL gene in case of chronic myelogenous leukemia ( CML ) [ ] and the KIT gene in case of gastrointestinal stromal tumor [ ] have previously been reported as mechanisms of imatinib resistance , which is also a TKI . The structural similarity between ABL and @GENE$ tyrosine kinases is considerably high , and T315I in ABL corresponds to T790M in EGFR [ ] .", "label": "resistance or non-response"}
{"id": "25505694", "sentence": "BMS-690514 , a reversible oral inhibitor of @GENE$ , HER-2 and −4 , VEGFRs-1 to −3 , showed antitumour activity in tumour xenograft models and in cell lines containing the EGFR @VARIANT$ mutation , suggesting a role against erlotinib-resistant tumours [ ] .", "label": "resistance or non-response"}
{"id": "24811491", "sentence": "HER2 amplified patient derived xenografts Combination of cetuximab/pertuzumab with @DRUG$ induced overt long lasting tumor regression . MET amplified patient derived xenografts @GENE$ inhibition achieved long lasting abolition of tumor growth in vivo . Acquired resistance EGFR mutations Mutations in the EC domain ( @VARIANT$ ) and in the kinase domain ( codons 714 and 794 ) of EGFR found in patients Panitumumab remained active in a patient with S492R mutation , which abrogated cetuximab binding .", "label": "None"}
{"id": "24789720", "sentence": "The new therapy methods , which could be effective in patients with @VARIANT$ mutation includes irreversible EGFR-TKIs ( afatinib , neratinib ) . In LUX-Lung 1 study in patients after failure of @DRUG$ or gefitinib treatment with afatinib led to partial responses and prolongation of progression-free survival compared to placebo to 3,3 months [ , ] . Recently the studies are conducted with combining of irreversible @GENE$ and monoclonal antibody against extracellular domain of EGFR – cetuximab .", "label": "resistance or non-response"}
{"id": "24244732", "sentence": "Although this hypothesis has not been directly tested for @DRUG$ specifically , @GENE$ hypomorphs in C. elegans do have reduced sensitivity to volatile anaesthetics [ ] emphasizing a potential convergence of cellular effectors of various anaesthetics at the presynaptic terminal . On the other hand , the @VARIANT$ mutation acts to increase Rab3 binding , at least for Munc18 [ ] .", "label": "None"}
{"id": "22132735", "sentence": "EGFR gene mutations indicate sensitivity to gefitinib , and it was demonstrated that about 85 % of patients with NSCLC who obtained benefit from @DRUG$ treatment were found to have mutations in exons 18 to 21 of the tyrosine kinase domain of the EGFR gene [ - ] . EGFR mutations in exon 19 ( short in-frame deletions ) or 21 @VARIANT$ ( point mutation ) affect the adenosine triphosphate ( ATP ) pocket of the tyrosine kinase domain leading to the activation of 4-anilinoquinazoline compounds , which function to compete with ATP [ ] . Anti-EGFR therapy can consequently lead to the downregulation of downstream signaling cascades , such as the PI3K/Akt , RAS/Erk , @GENE$ , and STAT pathways , responsible for cell proliferation and survival , resulting in the inhibition of cell proliferation and induction of cell apoptosis , respectively .", "label": "None"}
{"id": "24025253", "sentence": "The patient remained on this regimen for 7 mo with an excellent performance status , exceeding the expected survival of a patient expressing @GENE$ @VARIANT$ colon cancer . After 7 mo the patient’s therapy was switched from sorafenib to single agent regorafenib ; regorafenib is an analog of sorafenib that was approved by the FDA in September 2012 . Finally the patient’s therapy became regorafenib combined with another anti-ERBB1 antibody @DRUG$ , and has been on this therapy for & gt ; 4 mo with stable disease .", "label": "resistance or non-response"}
{"id": "23959225", "sentence": "Previous studies showed that Ile , Met , and several non-standard amino acids could be misactivated by LeuRS in vitro , and further charged to tRNALeu by editing defective mutants such as E. coli LeuRS ( EcLeuRS ) @VARIANT$ , yielding mischarged tRNALeu . Therefore , SptRNALeu was methionylated at 37°C in a 300-μL volume containing 100 mM @GENE$ ( pH 7.8 ) , 30 mM KCl , 12 mM MgCl2 , 0.5 mM dithiothreitol ( DTT ) , 4 mM ATP , 40 μM [ 3H ] Met , 20 μM purified SptRNALeu , and 0.5 μM EcLeuRS-D345A mutant for 30 min . The mixtures were isolated by acid phenol/chloroform extraction ( pH 4.5 ) and @DRUG$ precipitation followed by resuspension in 50 mM potassium phosphate buffer ( pH 5.2 ) .", "label": "None"}
{"id": "17973573", "sentence": "H1975 cells harbor two mutations ( @VARIANT$ and T790M ) in the EGFR gene . All cells were maintained in RPMI-1640 medium supplemented with 10 % heat inactivated fetal calf serum ( FCS , JRH Biosciences , Lenexa , Kansas ) . The @GENE$ inhibitor QVD-OPH ( MP Biomedicals , Aurora , Ohio ) was used at 25 μM and added to cells 30 min prior to treatment with @DRUG$ .", "label": "None"}
{"id": "23423768", "sentence": "Molecular studies on the receptors harbouring a known @VARIANT$ mutation demonstrated a decreased affinity of the tyrosine kinase for ATP and an increase in the affinity for the tyrosine kinase inhibitors ( TKI ) . These are drugs studied to specifically target the pathways of oncogenesis mediated by the @GENE$ hyper-activation and causing little harm to non-tumoral cells . There is evidence supporting a different sensitivity of NSCLCs to the TKI @DRUG$ depending on the presence of an exon 21 mutation or an exon 19 deletion , having deletions at exon 19 been associated with a better response .", "label": "sensitivity"}
{"id": "15736989", "sentence": "T790M in the context of either transiently expressed wild-type @GENE$ or the mutant alleles del L474–E749 ; A750P or @VARIANT$ impairs inhibition by gefitinib or @DRUG$ as assessed by autophosphorylation .", "label": "sensitivity"}
{"id": "21445332", "sentence": "Our results define the functional defect in @VARIANT$ and identify the initial disease related mutation in MCP that results exclusively in impaired ability to bind @GENE$ and mediate C4b @DRUG$ activity .", "label": "None"}
{"id": "24810093", "sentence": "Associations between IC50 and ABCB1 genotypes at @VARIANT$ ( a ) and ( b ) , G2677T/A ( c ) and ( d ) and C3435T ( e ) and ( f ) were analysed by Jonckheere-Terpstra test . Correlation matrix between @GENE$ relative expression , bodipy-FL-paclitaxel accumulation and efflux constant KE in lymphoblastoid cell lines and ovarian cancer cell lines using Spearman or Pearson correlation test Lymphoblastoid cell lines Ovarian cancer cell lines ABCB1 expression Paclitaxel accumulation Paclitaxel efflux ABCB1 expression @DRUG$ accumulation Paclitaxel efflux", "label": "None"}
{"id": "24992720", "sentence": "The co-crystallized ligand ( @DRUG$ ) was first extracted from the catalytic site of @VARIANT$ @GENE$ mutant ( PDB ID: 2ITZ ) and re-docked to calculate the root mean square difference ( RMSD ) between the top docking pose and original crystallographic geometry .", "label": "sensitivity"}
{"id": "23233201", "sentence": "Intriguingly , the imatinib-resistant BCR/ABL mutants @VARIANT$ and T315I showed increased ability as compared with native BCR/ABL to induce tyrosine phosphorylation of PECAM-1 when expressed in the murine model hematopoietic cell line @GENE$ cells or in 293T cells ( ) .", "label": "None"}
{"id": "25493630", "sentence": "D ) SUDHL10 ( EZH2 @VARIANT$ ) xenograft bearing mice were treated for 28 days as indicated ( Pred-1 = @DRUG$ at 0.15 mg/kg BID×5 on days 1–5 and 22–26 ; Pred-2 = Prednisone at 0.15 mg/kg @GENE$ ) .", "label": "None"}
{"id": "23788917", "sentence": "In vitro studies have shown that these drugs exhibit activity against cells with the wild-type or mutated ( with activating mutation ) form of the EGFR gene , as well as against cells which are resistant to them because of the presence of the @VARIANT$ mutation in the EGFR gene and insertion- deletion changes in the HER2 gene . However , in the case of wild-type EGFR and mutations which cause resistance to drugs , the concentration of agents required to effectively induce apoptosis in tumour cells may exceed the tolerated dose level in therapy . Currently , it is known that @DRUG$ , which is in the most advanced trials , is effective in some patients who have benefited from pre-treatment with reversible @GENE$ TKI .", "label": "response"}
{"id": "24348666", "sentence": "2. Acquired resistance mechanism 1 ) Secondary @VARIANT$ mutation of the @GENE$ gene Unfortunately , many of those patients who originally had responded eventually become insensitive to @DRUG$ or erlotinib therapy through acquired resistance .", "label": "resistance or non-response"}
{"id": "22655263", "sentence": "Additionally , AP26113 was evaluated on the @DRUG$ resistant gatekeeper mutant @VARIANT$ both in vitro and in vivo and appeared to be able to overcome resistance to crizotinib . Ki determination demonstrated a very similar biochemical potency on wild-type ALK and the L1196M ALK mutant ( 0.09 and 0.08 nM respectively ) , with both cellular and in vivo data ( using engineered Ba/F3 cells ) indicating that growth of @GENE$ mutant driven-cells is inhibited at similar , albeit slightly higher , doses which inhibit cells harboring wild-type ALK ( Katayama et al. , ) .", "label": "resistance"}
{"id": "24375389", "sentence": "Other examples of useful biomarkers are KRAS mutation testing to predict benefit from monoclonal antibodies against EGFR , @DRUG$ and panitumumab , in metastatic colon cancer [ ] and @GENE$ @VARIANT$ mutation analysis in metastatic melanoma in order to predict responsiveness to BRAF inhibitors such as vemurafenib [ ] .", "label": "resistance or non-response"}
{"id": "24304820", "sentence": "Montagut et al. reported an acquired @GENE$ ectodomain mutation ( @VARIANT$ ) that prevented @DRUG$ binding , thus conferring resistance to this drug .", "label": "resistance"}
{"id": "19774209", "sentence": "This alteration leads to increased affinity for ATP , which can then out-compete gefitinib and/or @DRUG$ for binding to the receptor . Irreversible inhibitors of @GENE$ tyrosine kinase are currently in development that form permanent covalent bonds to the binding domain rather than having to compete with ATP for temporary interactions . They have been shown to successfully inhibit EGFR bearing the @VARIANT$ mutation in vitro .", "label": "resistance or non-response"}
{"id": "PMC3760629", "sentence": "The most common mechanism of acquired drug resistance @DRUG$ is the secondary EGFR @VARIANT$ mutation , which is detected in up to 60 % of EGFR mutant NSCLC patients . The EGFR mutant @GENE$ cell line harbouring EGFR T790M , PC9R , has been used as in vitro model of drug resistance .", "label": "None"}
{"id": "23696715", "sentence": "A subgroup analysis of progression-free survival in sporadic MTC patients suggested that RET @VARIANT$ mutation positive patients had a higher response rate to @DRUG$ compared with @GENE$ M918T mutation negative patients. ,", "label": "response"}
{"id": "18544172", "sentence": "Responders 1 F 70 0 - PR 10 Wild-type R521K high polysomy 2 M 62 0 Folfirinox PR 94* Wild-type trisomy 3 F 56 0 Folfiri , Folfox PR 9 Wild-type high polysomy 4 M 37 0 Folfiri , Folfox , xelox PR 44 Wild-type low polysomy 5 F 44 0 Folfiri , Folfiri PR 33 Wild-type R521K disomy 6 F 54 1 LV5FU Folfiri PR 67 Gly13Asp disomy 7 @GENE$ 1 Fufol Folfirinox , Folfiri , LV5FU-mitomycine PR 42 Gly12Asp R521K disomy 8 M 56 0 Foflfox PR 25 Wild-type disomy 9 M 66 1 Fufol Folfiri , Folfox PR 24* Wild-type R521K trisomy Non-responders 10 F 68 0 Folfiri , Xeloda , Xelox SD 17 Wild-type @VARIANT$ trisomy 11 F 74 1 LV5FU Folfiri SD 10 Gly12Val disomy 12 M 61 0 Folfirinox SD 18 Gly13Asp R521K disomy 13 F 71 0 Xelox Avastin-Xeliri SD 15 Gly12Asp disomy 14 M 59 0 LV5FU , Folfiri , Folfox SD 24 Gly12Cys R521K trisomy 15 M 71 0 Folfox , Irinotecan SD 14 Wild-type disomy 16 F 60 1 Fufol Folfiri , Folfox , Cape , LV5FU SD 17 Wild-type trisomy 17 M 65 0 Folfirinox , Folfiri SD 18 Wild-type low polysomy 18 M 66 0 Folfiri SD 17 Wild-type R521K disomy 19 F 45 0 Folfox , Xelox SD 17 Wild-type R521K NE 20 F 42 0 Folfirinox SD 21 Gly12Asp R521K trisomy 21 M 62 1 Folfox Xeliri SD 36 Gly13Asp R521K disomy 22 M 58 1 Folfiri Xelox , Xeliri PD NA Gly13Asp disomy 23 M 75 1 Xelox Xeliri PD NA Wild-type trisomy 24 M 81 0 Xelox , Folfiri PD NA Gly12Val disomy 25 F 55 0 Xelox Avastin-Xeliri PD NA Gly12Asp disomy 26 M 60 1 LV5FU Folfiri , Folfiri , Folfox PD NA Wild-type NE 27 M 59 0 Folfiri , Folfiri/Folfox , Folfox PD NA Gly12Asp NE 28 F 58 1 LV5FU Folfiri , Xelox PD NA Gly12Asp disomy 29 M 51 0 Folfox , Folfiri PD NA Wild-type disomy 30 F 66 0 Folfiri , Xelox PD NA Wild-type R521K trisomy 31 F 56 0 - PD NA Wild-type disomy 32 F 78 0 Folfox , Folfiri , Cape PD NA Gly12Val disomy F = female , M = Male , Folfox = oxaliplatin , fluorouracil , and folinic acid ; Xelox = capecitabine , oxaliplatin ; Folfiri = irinotecan , fluorouracil , and folinic acid ; Xeliri = Capecitabine , irinotecan ; Folfirinox = oxaliplatin , irinotecan , fluorouracil , and folinic acid ; LV5FU = infusional FU and folinic acid ; Fufol = bolus @DRUG$ and folinic acid ; PR = partial response .", "label": "None"}
{"id": "22970424", "sentence": "In xenografts derived from the breast cancer cell line MCF7 and the pancreatic carcinoid cell line BON , both harboring an activating PIK3CA mutation , treatment with the allosteric @GENE$ inhibitor Rapamycin ( Sirolimus ) was associated with a significant decrease in tumor volume ( Meric-Bernstam et al. , ) . Moreover , using PIK3CA wild-type human breast immortalized epithelial cells ( hTERT-HME1 ) or non-malignant MCF10A breast cells , knock-in of the @VARIANT$ or H1047R PIK3CA mutant alleles sensitized non transformed human breast cells to the rapalog @DRUG$ ( Di Nicolantonio et al. , ) .", "label": "None"}
{"id": "22815900", "sentence": "In addition to the well characterized causes of drug resistance in lung cancer patients , elucidation of further mechanism for acquired resistance is essential for the development of new @GENE$ targeted drugs . In this present study , erlotinib- and gefitinib-resistant cell lines were established from two human lung cancer cell lines , PC9 cells harboring delE746-A750 mutation and 11–18 cells harboring @VARIANT$ mutation , respectively .", "label": "sensitivity"}
{"id": "15737014", "sentence": "The EGFR @VARIANT$ mutation , in conjunction with either wild-type EGFR or the drug-sensitive L858R EGFR mutant , prevents inhibition of tyrosine phosphorylation ( A ) or @GENE$ ( B ) by @DRUG$ .", "label": "resistance or non-response"}
{"id": "20406486", "sentence": "In fact , there was a markedly increased pErk signal in one NRAS @VARIANT$ mutated cell line ( M207 ) , an observation consistent with data from others that has been attributed to loss of negative regulatory pathways [ , ] and enhanced signaling through C-Raf [ , ] . Therefore , @DRUG$ inhibits @GENE$ pathway signaling specifically in cell lines that harbor the BRAFV600E mutation .", "label": "None"}
{"id": "19707322", "sentence": "Nilotinib is approximately 30-fold more sensitive than imatinib in the killing of BCR-ABL dependent cells derived from patients with CML ( K562 and Ku-812F cells ) and cell lines ( 32D and baF3 ) , and it is active against 32/33 imatinib-resistant cell lines with @GENE$ mutations . The sensitivity of Bcr-Abl mutants to AMN107 can be summarized into 4 categories : high ( IC50 ≤ 70 nmol/L : M244V , G250E , Q252H , F3llL , F317L , @VARIANT$ , V379I , L387M , H396P , H396R ) , medium ( IC50 ≤ 200 nmol/L : Y253F , E255K , F359V ) , low ( IC50 ≤ 450 nmol/L : Y253H , E255V ) , and insensitive ( IC50 & gt ; 2 μmol/L : T315I ) ( ) ( ) .", "label": "None"}
{"id": "22096483", "sentence": "Certain chemicals such as Doxorubicin and Epirubicin activate versican G3-expressing cells ' endogenous @GENE$ ( S9P ) signaling promoting chemical resistance while others chemicals appear to enhance these cells ' sensitivity to chemotherapy through increased expression of EGFR/JNK signaling and subsequent effects on apoptosis . Results demonstrated that G3-expressing cells enhanced GSK-3β ( @VARIANT$ ) expression when treated with a serum free medium , Doxorubicin or Epirubicin ; they also expressed decreased GSK-3β ( S9P ) and activated pSAPK/JNK when treated with C2-ceramide or @DRUG$ .", "label": "None"}
{"id": "24410791", "sentence": "Second generation @GENE$ TKIs e.g. , @DRUG$ afatinib ) and PF00299804 ( dacomitinib ) , and third generation EGFR TKIs e.g. , CO-1686 and AZD9291 are irreversible inhibitors that could overcome the AR caused by @VARIANT$ .", "label": "response"}
{"id": "24944510", "sentence": "Multiple secondary mutations have already been identified in patients treated with @DRUG$ . Homologous to the gatekeeper @GENE$ T790M mutation is the @VARIANT$ substitution , which , unlike EGFR T790M , does not appear to confer a growth disadvantage to cells .", "label": "None"}
{"id": "25146448", "sentence": "MTNR1B , located on human chromosome 11q21–22 , is a member of the @GENE$ , and one of the functional and high-affinity @DRUG$ membrane receptors . MTNR1B is expressed in human and rodent pancreatic islets . Studies have shown that MTNR1B is a novel candidate gene for @VARIANT$ .", "label": "None"}
{"id": "23805327", "sentence": "Approximately half of the patients that acquire resistance to @DRUG$ are found to harbor the @VARIANT$ @GENE$ mutation , .", "label": "resistance or non-response"}
{"id": "24920920", "sentence": "In 40 patients harboring L858R , five revealed complex mutations , including two with @VARIANT$ . In 61 patients with @GENE$ TKI as first-line therapy , 46 received gefitinib , 13 received @DRUG$ , and two received afatinib .", "label": "resistance or non-response"}
{"id": "22428003", "sentence": "Reduced @DRUG$ and transition-state analog @GENE$ @VARIANT$ in the closed conformation", "label": "None"}
{"id": "22098950", "sentence": "Interestingly , the IC50 values of SN38 , mitoxantrone , doxorubicin , daunorubicin , and @DRUG$ for Flp-ln-293 cells expressing other variants were significantly lower than those for cells expressing wild-type @GENE$ . Notably , F208S and S441N were not expressed in the cells , suggesting that the rest of the variants ( S248P , F431L , and F489L ) may also impart impaired function of BCRP . Another study showed that the P269S ( C.805OT , Ex7 ; rs34678167 ) and Q126Stop ( C.376OT , Ex4 ; rs72552713 ) alleles were found among Korean subjects , and that the transport activity of the @VARIANT$ variant decreased based on methotrexate uptake by vesicles expressing this variant .", "label": "None"}
{"id": "16953242", "sentence": "In these CML-BC patients , @DRUG$ resistance often depends on reactivation of @GENE$ tyrosine kinase activity via mechanisms involving BCR/ABL overexpression , gene amplification or mutations that suppress imatinib mediated kinase inhibition ( i.e. E255V and G250E ) or disrupt imatinib binding ( i.e. @VARIANT$ ) ( ) .", "label": "None"}
{"id": "16495921", "sentence": "Unconditional logistic regression adjusted for age , previous endoscopy , year of endoscopy , family history of colorectal cancer , pack-years smoking , aspirin use , BMI , PMH use ( NHS only ) , physical activity , and intake of red meat , charred meat , folate , and @DRUG$ . Relationship between family history of colorectal cancer and risk of colorectal cancer and adenoma among postmenopausal women in the NHS and men in the HPFS , stratified by @GENE$ @VARIANT$ genotype Family history of colorectal cancer No Yes Case/control OR ( reference ) Case/control OR ( 95 % CI ) P for interaction", "label": "None"}
{"id": "24594844", "sentence": "cDzT specifically degraded @GENE$ @VARIANT$ mRNA and decreased EGFR protein levels , whereas @DRUG$ inhibited autophosphorylation of EGFR without affecting EGFR protein level .", "label": "response"}
{"id": "23354482", "sentence": "Thus , decreased expression of Pcyt2 likely contributed to the observed decrease in PE level in @VARIANT$ null mice . Another study showed that @GENE$ mRNA was reduced in a mouse model of Wilsone disease , a severe metabolic disorder characterized by significant liver damage caused by genetic inactivation of copper-transporter , ATP7B [ ] . Thiamine is an essential @DRUG$ in carbohydrate metabolism and individuals suffering from diabetes and/or metabolic syndrome are generally thiamine deficient [ ] .", "label": "None"}
{"id": "24348666", "sentence": "This figure is reprinted from the article by Giroux S. ( A ) @DRUG$ bound to the @GENE$ kinase , the gatekeeper residue ( T790 ) is highlighted in green ; cysteine-797 , which forms a covalent bond with 2nd and 3rd generation irreversible EGFR inhibitors , is highlighted in green . ( B ) Structure of WZ-4002 covalently bound to EGFR @VARIANT$ via cysteine-797 .", "label": "resistance or non-response"}
{"id": "18212750", "sentence": "A549 cells were exposed to different concentrations of docetaxel , @DRUG$ and 5-fluorouracil , which had been preincubated with microsomes containing either human @GENE$ and cytochrome P450 NADPH reductase (P450R) or @VARIANT$ cDNA alone .", "label": "None"}
{"id": "22613958", "sentence": "More than 90 % of these mutations are observed in two hotspots : in-frame deletions including amino acids at codons 747 to 749 in exon 19 , and an amino acid substitution at codon 858 ( @VARIANT$ ) in exon 21 [ - ] . These mutations are postulated to mediate oncogenic effects by altering downstream signaling and anti-apoptotic mechanisms [ - ] . Prior trials confirmed that the response rate to EGFR-TKI in NSCLC patients with EGFR mutations is approximately 70–80 % [ , , ] , and results of recent phase III trials showed that the oral EGFR-TKI @DRUG$ has a superior progression-free survival ( PFS ) to standard chemotherapy as the first-line therapy for NSCLC with mutated @GENE$ [ , ] .", "label": "sensitivity"}
{"id": "21687596", "sentence": "An experiment using cell lines transfected concurrently with activating mutations and a T790M mutation also proved that resistance to @DRUG$ and erlotinib is evident when this mutation is present [ – ] . Analogous secondary mutations of the @GENE$ gene in case of chronic myelogenous leukemia ( CML ) [ ] and the KIT gene in case of gastrointestinal stromal tumor [ ] have previously been reported as mechanisms of imatinib resistance , which is also a TKI . The structural similarity between ABL and EGFR tyrosine kinases is considerably high , and @VARIANT$ in ABL corresponds to T790M in EGFR [ ] .", "label": "None"}
{"id": "21556318", "sentence": "The eight @GENE$ mutations in the @DRUG$ 300 mg twice daily group were identified in six patients . These included Y253H , Y253H/F359V , E255K/T315I , @VARIANT$ , F359V , and E2459K .", "label": "None"}
{"id": "23976869", "sentence": "Importantly , both FIP1L1-PDGFRA @VARIANT$ and FIP1L1-PDGFRA-D842V mutant kinase were also sensitive to ponatinib. , @DRUG$ in vitro can also strongly inhibit CUX1 ( @GENE$ -FGFR1 fusion .", "label": "None"}
{"id": "25429239", "sentence": "Alectinib ( CH5424802 ) is a potent , selective inhibitor of ALK that also potently inhibits the activity of ALK containing the @VARIANT$ gatekeeper mutation. , This compound is also known to work in patients with central nervous system metastasis as it crosses the blood–brain barrier . Ceritinib ( LDK378 ) is a second-generation @GENE$ inhibitor that was granted an accelerated approval by FDA in April 2014 for treatment of patients with ALK+ metastatic NSCLC following treatment with @DRUG$ .", "label": "resistance"}
{"id": "24501009", "sentence": "In contrast to patients with EGFR‐mutation‐positive tumors , patients with KRAS‐mutant NSCLC are unlikely to respond to gefitinib or @DRUG$ and do not have an improved progression‐free survival ( PFS ) compared with those who have placebo following erlotinib therapy . Dacomitinib ( PF‐00299804 ) is a potent , irreversible , oral small‐molecule inhibitor of HER1/EGFR , @GENE$ , and HER4 tyrosine kinases with antitumor activity in both gefitinib‐sensitive and gefitinib‐resistant , including EGFR @VARIANT$ , preclinical NSCLC models .", "label": "None"}
{"id": "23994953", "sentence": "Unfortunately , the @GENE$ TKI-driven improvement in patient outcome is notably limited because virtually all NSCLC patients with erlotinib/gefitinib sensitizing EGFR mutations eventually acquire resistance after a median of 6–12 months of EGFR TKI therapy . In approximately half of cases , the tumor cells present after disease progression contain second-site mutations that alter drug binding to the EGFR TK domain . The most common lesion ( & gt ; 90 % ) is the so-called “gatekeeper mutation , ” which involves a substitution of methionine for threonine at position 790 ( @VARIANT$ ) .", "label": "resistance or non-response"}
{"id": "23776587", "sentence": "Recently , BRAF mutation ( & gt ; 95 % of BRAF point mutations occure at BRAF @VARIANT$ ) is introduced to be associated with resistance to targeted agents . BRAF protein , a serine-threonine kinase , is the principal downstream molecular of KRAS . A meta-analysis by Bokemeyer C , et al , in 2012 based on two RCTs ( the OPUS and CRYSTAL trials ) reported that in KRAS wild-type ( WT ) patients , adding @DRUG$ to chemotherapy was beneficial for BRAF WT patients , but not for @GENE$ mutant patients .", "label": "resistance or non-response"}
{"id": "24349829", "sentence": "Correspondingly , direct injection of a liposome encapsulated miR-7 plasmid into established EGFR-TKI sensitive and resistant tumors bearing the @VARIANT$ EGFR mutant resulted in significant tumor regression in conjunction with repression of EGFR , RAF-1 and IRS-1 expression . In head and neck cancer , miR-7 functioned in a synergistic manner with @DRUG$ to render FaDu Erlotinib-resistant cells susceptible to the growth inhibitory activities of the drug . Interestingly , expression profiling analysis suggested that the downregulation of RAF-1 and EGFR and its ligand TGF-α by miR-7 was a possible mechanism by which miR-7 orchestrates the inhibition of @GENE$ signaling at multiple levels115 .", "label": "resistance or non-response"}
{"id": "23144978", "sentence": "One mechanism to resistance was recently elucidated : cetuximab resistant cells contain an @GENE$ mutation in the extracellular domain ( @VARIANT$ ) that impairs @DRUG$ , but not epidermal growth factor (EGF) binding .", "label": "resistance"}
{"id": "23493883", "sentence": "Combinations of therapy such as cetuximab plus @DRUG$ and gefitinib plus everolimus have also been tried . The most promising drug thus far has been afatinib ( BIBW2992 ; Boehringer-Ingelheim Pharma , Ingelheim , Germany ) , , an @GENE$ family blocker with reported in vitro and in vivo activity against EGFR mutant tumors harboring exon 19 deletions , exon 21 @VARIANT$ mutations and the exon 20 T790M “resistance” mutations .", "label": "sensitivity"}
{"id": "22436374", "sentence": "H1650 and HCC827 have an in-frame deletion in the EGFR tyrosine kinase domain ( @GENE$ tyrosine kinase domainΔE746-A750 , exon 19 ) . H1650 cells have also a deletion of the 3 ' part of exon 8 and the entire exon 9 of PTEN , which causes loss of the protein [ ] and in addition express the insulin-like growth factor receptor ( IGF1R ) [ ] . The cell line H1975 has a sensitizing L858R kinase domain mutation in exon 21 , but also a second mutation ( @VARIANT$ , in cis , in the kinase domain ) rendering them resistant to the reversible TKIs gefitinib and @DRUG$ [ ] .", "label": "resistance or non-response"}
{"id": "24924344", "sentence": "@DRUG$ ( A/T ) Chr16 : 56671632 MT1A ( near-gene 5 ) 0.047628 0.138 Oxaliplatin rs562 ( C/T ) Chr3 : 183637845 ABCC5 ( UTR3 ) 0.049494 0.392 rs3749445 ( A/G ) Chr3 : 183638506 ABCC5 ( UTR3 ) 0.044895 0.410 rs2292998 ( C/T ) Chr3 : 183663833 ABCC5 ( intronic ) 0.039882 0.277 rs1016752 ( C/G ) Chr3 : 183665062 ABCC5 ( intronic ) 0.039781 0.232 rs4148585 ( C/T ) Chr3 : 183670642 ABCC5 ( intronic ) 0.039781 0.283 rs6443924 ( A/G ) Chr3 : 183679532 ABCC5 ( intronic ) 0.039781 0.279 rs4148579 ( A/G ) Chr3 : 183685249 ABCC5 ( intronic ) 0.039781 0.279 rs939336 ( A/G =&gt ; @VARIANT$ ) Chr3 : 183685534 @GENE$ ( exonic ) 0.039781 0.279 rs1132776 ( C/T = & gt ; A395A ) Chr3 : 183696402 ABCC5 ( exonic ) 0.044895 0.289 rs2313212 ( C/T ) Chr3 : 183700928 ABCC5 ( intronic ) 0.039781 0.279 rs4148575 ( C/T ) Chr3 : 183702275 ABCC5 ( UTR3 ) 0.044895 0.289 rs1846692 ( C/T ) Chr16 : 56671696 MT1A ( near - gene 5 ) 0.049494 0.360 rs35346959 ( A/G ) Chr16 : 56671867 MT1A ( near- gene 5 ) 0.044895 0.137 rs9922957 ( C/G ) Chr16 : 56672380 MT1A ( near - gene 5 ) 0.039781 0.185 rs9922409 ( A/G ) Chr16 : 56672400 MT1A ( near - gene 5 ) 0.04532 0.103 rs7190725 ( G/T ) Chr16 : 56673290 MT1A ( intronic ) 0.044895 0.170 rs8052394 ( A/G =&gt ; K51R ) Chr16 : 56673828 MT1A ( missense ) 0.044895 0.152 rs1800566 ( C/T = & gt ; P187S ) chr16 : 69745145 NQO1 ( exonic ) 0.039781 0.258 rs689455 ( A/C ) Chr16 : 69761661 NQO1 ( near- gene 5 ) 0.039781 0.242", "label": "None"}
{"id": "22654561", "sentence": "Verbeek and coworkers set out to compare the efficiency of four recently developed TK inhibitors , XL184 , @DRUG$ , Sunitinib and Axitinib , using three cell lines : the first derived from sporadic MTC expressing a C634W RET mutation , the second derived from metastatic sporadic MTC expressing a @VARIANT$ @GENE$ mutation .", "label": "response"}
{"id": "23817662", "sentence": "Further studies of gefitinib revealed that this 4-anilinoquinazoline inhibitor , structurally similar to @DRUG$ , binds the EGFR c.2573T & gt ; G ( @VARIANT$ ) mutant with a 20-fold higher affinity compared to the wild-type enzyme . Both mutations , the activating EGFR c.2573T & gt ; G ( L858R ) and the inhibiting EGFR @GENE$ ; T ( T790M ) were found in our cytological assessment .", "label": "None"}
{"id": "23940741", "sentence": "Somatic activating mutations of the EGFR gene have been identified as a major determinant of the clinical response to @GENE$ tyrosine kinase inhibitors ( TKIs ) such as gefitinib and @DRUG$ in patients with NSCLC . Most of these mutations occur in exons 19 to 21 , which encode the tyrosine kinase domain of the receptor , the most common being deletions in exon 19 ( such as delE746-A750 ) and the @VARIANT$ point mutation in exon 21 .", "label": "sensitivity"}
{"id": "22363766", "sentence": "@GENE$ TKIs ( such as erlotinib or @DRUG$ ) are selective inhibitors of EGFR 's kinase domain that work by competing with ATP for binding at the ATP binding site , thereby preventing autophosphorylation and activation . The @VARIANT$ mutation affects the gatekeeper residue in the catalytic kinase domain and confers drug resistance by increasing EGFR 's affinity for ATP – thus reducing the potency of the ATP-competitive kinase inhibitors .", "label": "resistance or non-response"}
{"id": "PMC3920415", "sentence": "One important issue raised by this case concerns acquired resistance to @DRUG$ . Recent data have shown that almost all patients with known EGFR mutations who initially respond to TKIs , subsequently become resistant due to emergence of mutations , such as @VARIANT$ ( in 50 % of cases ) and @GENE$ overexpression .", "label": "None"}
{"id": "21457545", "sentence": "These observations are the basis for a number of ongoing clinical trials which are exploring the role of monoclonal antibodies against EGFR such as cetuximab and @GENE$ tyrosine kinase inhibitors such as @DRUG$ in triple negative breast cancer . Many mutations in the EGFR gene have been reported in NSCLC but only a few have been validated , either from in vitro studies or from tumour responses in NSCLC patients , to be associated with responses to EGFR tyrosine kinase drugs [ , ] . These mutations are usually found in exons 18 , 19 , 20 and 21 , and include missense substitutions such as G719A/S and @VARIANT$ and deletions like E746 to A750 ( removal of amino acids Glucine-Leucine-Arginine-Glucine-Alanine ( ELREA ) ) which are associated with sensitivity to tyrosine kinase inhibitors [ , ] .", "label": "sensitivity"}
{"id": "23319867", "sentence": "Of note was that a response was seen in three patients with medullary thyroid cancer who had been pretreated with vandetanib or sorafenib ( which also target VEGFR and RET ) , supporting the concept of @GENE$ being a VEGF inhibition escape pathway and thus a valid target . Mutational analysis was carried out as part of the trial , and identified 15 patients harboring @VARIANT$ , a RET mutation associated with poor prognosis . Of these , 12 had a response or stable disease with @DRUG$ , noted by the authors to be in contrast with motesanib , which showed no activity in this subset of patients .", "label": "None"}
{"id": "25278773", "sentence": "For example , the combination trial of cetuximab and afatinib has shown promising results , with an overall response rate of 29 % and a median duration of response of 5.7 months in patients with advanced lung adenocarcinoma and acquired resistance to erlotinib/gefitinib . Importantly , this combination conferred robust and durable clinical responses irrespective of @VARIANT$ status ( T790M positive , 32 % , versus T790M negative , 25 % ; P=0.341 ) , as well as an acceptable safety profile . More recently , third-generation EGFR mutation-specific inhibitors have shown potential in circumventing toxicities related to wild-type @GENE$ and overcoming resistance resulting from the acquired T790M mutation .", "label": "resistance or non-response"}
{"id": "23006410", "sentence": "Accordingly , these results point to S140 residue of MabA as a residue whose main role appears to be in catalysis , in agreement with S138 of the catalytic triad of Drosophila @GENE$ also an SDR protein [ ] . Notwithstanding , the S140 side chain may also play an indirect role in NADPH binding as the @VARIANT$ showed impaired dinucleotide binding , in agreement with both the MabA : NADPH ( Figures , , and ) and MabA : @DRUG$ : substrate molecular models [ ] .", "label": "None"}
{"id": "24419415", "sentence": "The clinical efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors ( @GENE$ ) , such as gefitinib and @DRUG$ , has been demonstrated in non–small-cell lung cancer ( NSCLC ) patients in whom standard chemotherapy has failed. , Further studies have revealed that the presence of activating mutations in the EGFR kinase domain is strongly associated with the therapeutic efficacy of EGFR-TKIs. , Randomized phase 3 trials have demonstrated that EGFR-TKIs significantly improve median progression-free survival ( PFS ) compared with platinum-doublet therapy in EGFR mutated patients.– However , not all mutations in the EGFR kinase domain are responsive to EGFR-TKI treatment . These phase 3 trials have shown that EGFR-TKIs are effective for patients with common EGFR mutations , such as an exon 19 deletion or the @VARIANT$ point mutation , which account for more than 90 % of EGFR mutations .", "label": "sensitivity"}
{"id": "25285017", "sentence": "Although more than 188 @GENE$ mutations have been identified , 85 % of TKI-sensitive clinical cases harbor only two major mutations : in-frame deletions of exon 19 ( 45 % –50 % ) and a point mutation @VARIANT$ in exon 21 ( 40 % –45 % ; ) . In addition , deletion mutation in exon 19 seems to have a better response to @DRUG$ and erlotinib than mutations at other sites. ,", "label": "sensitivity"}
{"id": "24944510", "sentence": "It is thought that primary resistance to these agents will still be encountered for the @GENE$ T790M mutation as well as exon 20 insertions . Thus , an alternate schedule of drug administration , such as intermittent or pulse high-dose therapy using @DRUG$ to determine its activity against @VARIANT$ ( NCT01647711 ) , is under investigation .", "label": "response"}
{"id": "24742823", "sentence": "Of note , responding patients had a @GENE$ ratio of more than 5 and both of our MET amplified patients treated with a c-MET inhibitor had a ratio inferior to this . Interestingly , a recent series showed that the level of HER-2 amplification predicted sensitivity to trastuzumab. [ ] In this study , a ratio of 4.7 was discriminative of sensitive patients , which suggests that a similar relation can be explored for MET amplification and sensitivity to c-MET inhibitors . Additionally , one of the patients receiving a c-MET inhibitor in our series had a @VARIANT$ MET variant .", "label": "None"}
{"id": "23691449", "sentence": "However , the @VARIANT$ mutation may exist in only a small fraction of tumor cells before drug treatment , and the tumor cells harboring this mutation may be enriched over time during treatment with gefitinib or @DRUG$ [ ] . @GENE$ amplification", "label": "None"}
{"id": "23566546", "sentence": "Case Histrogical type @GENE$ mutation status Brinkman index Treatment agent Response IL-8 ( ng/mL ) IL-10 ( ng/mL ) RANTES ( pg/ml ) 1 Ad Ex21 @VARIANT$ 900 gefitinib PR 5.79 1.67 2 2 Ad Ex21 L858R 0 erlotinib PR_3.33 94.2 1.41 3 Ad Ex19 del 0 erlotinib PR 4.09 126 2.13 4 Ad Ex21 L858R 0 gefitinib PR_3.92 18.1 1.85 5 Ad Ex21 L858R + Ex19 del 370 erlotinib PR 21.9 1.23 2.11 6 Ad Ex19 del 0 erlotinib PR 7.05 1.37 2.56 7 Ad Ex19 del 0 gefitinib PR 4.82 1.59 2.02 8 Ad Ex21 L858R 1640 gefitinib PR 54.9 2.7 2.38 9 Ad negative 400 erlotinib SD 34.9 3.39 3.66 10 Ad negative 0 erlotinib SD 27.1 4.94 2.25 11 Ad unknown 1800 erlotinib SD NE NE NE 12 Sq Ex19 del 3840 gefitinib SD 12.6 1.1 1.98 13 Ad Ex19 del 30 erlotinib SD 5.27 0.69 2.66 14 Ad Ex19 del 0 erlotinib SD 10.5 0.85 2.5 15 Ad unknown 300 erlotinib SD 7.69 2.61 1.7 16 La negative 2080 erlotinib SD NE NE NE 17 Sq Ex21 L858R 750 erlotinib SD 11.6 56.3 3.06 18 Ad unknown 600 erlotinib SD 13.7 1.1 2.82 19 Ad Ex21 L858R 0 erlotinib SD 20.6 11.6 0.783 20 Ad Ex19 del 0 erlotinib SD 14.8 2.07 2.02 21 Ad Ex21 L858R + Ex19 del 0 gefitinib SD 3.04 1.3 1.76 22 Ad Ex19 del 200 gefitinib SD 10.9 1.59 1.91 23 Sq unknown 1560 erlotinib PD NE NE NE 24 Ad negative 1080 erlotinib PD 25.2 8.15 1.57 25 Ad unknown 0 erlotinib PD NE NE NE 26 Ad Ex18 G719A 2000 erlotinib PD 11.6 4.48 3.12 27 Ad unknown 1410 erlotinib PD NE NE NE 28 Ad Ex19 del 1000 gefitinib PD 9.44 2.25 2.89 29 Ad negative 1100 @DRUG$ PD 56.3 5.63 2.16 30 Ad negative 2000 erlotinib PD 15.6 0.85 0.292 31 Ad negative 825 erlotinib PD 8.27 1.59 2.13 32 Ad Ex21 L858R 0 erlotinib PD 5.34 7.05 1.7 33 Ad negative 1680 erlotinib PD 57.7 1.63 2.06", "label": "sensitivity"}
{"id": "25532027", "sentence": "In particular , @GENE$ inhibitors ( EGFR-TKIs ) , such as @DRUG$ and erlotinib , demonstrated marked clinical activity against NSCLC harboring an activating EGFR mutation ( – ) . Additionally , some reports suggest that the EGFR @VARIANT$ mutation may not be rare and may exist in a small population of in tumor cells before TKI treatment ( – ) .", "label": "resistance or non-response"}
{"id": "25364578", "sentence": "Lazzara and colleagues found that SHP2 Y542 phosphorylation was not induced in response to EGF in the H3255 cells , which harbor the missense @VARIANT$ exon 21 mutation , suggesting that SHP2 activity may be less efficiently promoted by EGFR L858R and the STAT3 pathway may be more active . The main problem is that @GENE$ activation is not abrogated by single EGFR TKI treatment with gefitinib , @DRUG$ , afatinib or dacomitinib , - .", "label": "None"}
{"id": "23493883", "sentence": "Combinations of therapy such as cetuximab plus @DRUG$ and gefitinib plus everolimus have also been tried . The most promising drug thus far has been afatinib ( BIBW2992 ; Boehringer-Ingelheim Pharma , Ingelheim , Germany ) , , an ErbB family blocker with reported in vitro and in vivo activity against @GENE$ mutant tumors harboring exon 19 deletions , exon 21 @VARIANT$ mutations and the exon 20 T790M “resistance” mutations .", "label": "sensitivity"}
{"id": "23818899", "sentence": "EGFR KRAS ( mutation ) Colorectal Cancer ( expressing metastatic colorectal carcinoma , EGFR ) **Therascreen KRAS Test ( Qiagen , Corporate Headquarters , Nederland 's ) **Erbitux , @DRUG$ ( ImClone , ImClone Systems , NJ ) **Vectibix , panitumumab ( Amgen , Amgen Inc , . CA ) [ , , ] BRAF @VARIANT$ ( mutation ) Melanoma ( metastatic melanoma with BRAFV600E mutation ) **Cobas 4800 @GENE$ V600 Mutation Test ( Panagene , Corporate Headquarters , Korea ) **Zelboraf , vemurafenib ( Genentech/Roche ) [ , ]", "label": "resistance or non-response"}
{"id": "25221748", "sentence": "In the advanced NSCLC EGFR-TKI resistant setting , the HSP90 small molecule inhibitor AUY922 is being evaluated as monotherapy in a phase II clinical trial vs. pemetrexed or @DRUG$ in patients with tumors with activating EGFR mutations ( www.clinicaltrials.gov : NCT016461250 ) . This agent is also being assessed in a phase II trial in patients with de novo resistant @VARIANT$ mutations not previously treated with EGFR-TKIs ( www.clinicaltrials.gov : NCT01854034 ) and in patients with EGFR mutations and/or EGFR-TKI resistant disease , as part of a phase II cluster study in Chinese patients evaluating five novel inhibitors of HSP90 , PI3K , ALK , @GENE$ , and MEK ( ) .", "label": "None"}
{"id": "24594844", "sentence": "cDzT cleaves EGFR @VARIANT$ mRNA , which leads to a decrease in @GENE$ protein levels , whereas @DRUG$ is a second-line TKI that irreversibly binds to the intracellular kinase domain of EGFR and suppresses its downstream signaling .", "label": "response"}
{"id": "23104988", "sentence": "This analysis included @VARIANT$ , from the SH-SY5Y neuroblastoma cell line , as well as a number of additional previously uncharacterised ALK mutations , and looked at their transfomation potential . However , this work did not examine whether the various @GENE$ mutants were able to respond to activation by external ligand or agonist antibodies or examine their sensitivity to treatment with @DRUG$ .", "label": "resistance"}
{"id": "24339922", "sentence": "Finally , we repeated same experiments on PC-9 cells with a deletion mutation on exon 19 of @GENE$ to validate our observation . Previously , we established gefitinib-resistant cells ( PC-9/GR ) from PC-9 cells . Although PC-9/GR cells acquired @VARIANT$ mediated resistance , decreased expression of IGFBP-3 was also found in them ( Supplementary ) .", "label": "resistance or non-response"}
{"id": "22654561", "sentence": "Verbeek and coworkers set out to compare the efficiency of four recently developed TK inhibitors , @DRUG$ , Vandetanib , Sunitinib and Axitinib , using three cell lines : the first derived from sporadic MTC expressing a @VARIANT$ RET mutation , the second derived from metastatic sporadic MTC expressing a M918T @GENE$ mutation .", "label": "None"}
{"id": "21437184", "sentence": "Loupakis et al. analyzed 87 patients with KRAS WT tumors for the @GENE$ @VARIANT$ mutation who were receiving irinotecan and @DRUG$ for refractory metastatic CRC .", "label": "resistance or non-response"}
{"id": "17224926", "sentence": "Sir , report the second prospective trial of @DRUG$ as front-line therapy for @GENE$ non-small-cell lung cancer ( NSCLC ) . However , it is still elusive if different types of EGFR tyrosine kinase mutations have different clinical impact . The two most common activating mutations seen in patients are exon 19 deletions and the exon 21 @VARIANT$ .", "label": "sensitivity"}
{"id": "21437184", "sentence": "BRAF , which is located directly downstream from @GENE$ , can have activating mutations leading to stimulation of the MEK pathway [ , ] . BRAF mutations appear to confer a poor prognosis , and it appears that BRAF mutations also predict for a lack of response to antiEGFR monoclonal antibodies [ , , , ] . Loupakis et al. analyzed 87 patients with KRAS WT tumors for the BRAF @VARIANT$ mutation who were receiving @DRUG$ and cetuximab for refractory metastatic CRC .", "label": "None"}
{"id": "19384426", "sentence": "Transfection of PTEN into the PTEN negative decreased the activation of Akt and the downstream p70 ( @VARIANT$ ) and reversed the resistance to doxorubicin in these cells , indicating that changes in @GENE$ status/Akt activation modulate the cellular response to @DRUG$ [ ] .", "label": "None"}
{"id": "21687596", "sentence": "An experiment using cell lines transfected concurrently with activating mutations and a @VARIANT$ mutation also proved that resistance to gefitinib and erlotinib is evident when this mutation is present [ – ] . Analogous secondary mutations of the @GENE$ gene in case of chronic myelogenous leukemia ( CML ) [ ] and the KIT gene in case of gastrointestinal stromal tumor [ ] have previously been reported as mechanisms of @DRUG$ resistance , which is also a TKI .", "label": "None"}
{"id": "25536104", "sentence": "Bose et al. , noted that @VARIANT$ mutation was associated with negative @GENE$ protein expression and resistance to @DRUG$ .", "label": "sensitivity"}
{"id": "23085539", "sentence": "Furthermore , pharmacologic doses of FTY720 suppressed in vivo BCR-ABL-driven leukemogenesis ( including leukemogenesis promoted by the BCR-ABL @VARIANT$ mutant which is resistant to @DRUG$ and second generation TKIs ) without exerting any toxicity in mice [ ] . Increasing the Effectiveness of Targeting the Raf/MEK/ERK and @GENE$ Pathways by Simultaneous Treatment with Two Pathway Inhibitors", "label": "None"}
{"id": "25091415", "sentence": "Therefore , to elucidate the structural and dynamic consequences of the DM on the catalytic domain of @GENE$ and its affinity toward @DRUG$ , we performed molecular dynamic simulations ( 50 ns ) of the wild type ( WT ) -EGFR and three oncogenic mutants : @VARIANT$ , T790M , and DM in complex with gefitinib .", "label": "sensitivity"}
{"id": "20740181", "sentence": "Zhang et al. described 5 cases with @GENE$ double activating mutation in Chinese patients [ ] . In the Zhang report , exon 19 deletion + @VARIANT$ double mutations were located on the same allele and the double mutant had a higher sensitivity to TKIs than the other two single activating mutation in the in vitro study . Although it remains unknown whether the double mutant shows good clinical response to @DRUG$ , this may be the 2nd reason of the patient 's good clinical response .", "label": "sensitivity"}
{"id": "25364260", "sentence": "Our study revealed that Mus81 suppression by siRNA could affect the cell cycle distribution of MCF-7 and @VARIANT$ cells by 5-FU treatment and that the proportion of G2 period was significantly increased in the siMus81 group compared to in the siCtrl group . Moreover , another study has shown that @GENE$ silenced by gene targeting could activate the intra-S-phase and G2/M checkpoints of cancer cells , thereby inducing an increase in sensitivity to MMC , MMS , cisplatin , ultraviolet radiation , ionizing radiation , and @DRUG$ .", "label": "None"}
{"id": "20385023", "sentence": "According to a compendium of studies that include 1170 patients , more than 70 % of NSCLCs with @GENE$ mutations respond to EGFR-TKIs , whereas only 10 % of tumors without EGFR mutations do so . Unfortunately , upon treatment of these patients with gefitinib and @DRUG$ , two major mechanisms of resistance have been observed . The first is the appearance of a `` resistance '' point mutation in the kinase domain ( @VARIANT$ ) , observed in 50 % of the gefitinib-resistant patients [ ] .", "label": "resistance or non-response"}
{"id": "24410791", "sentence": "CO-1686 is a third-generation EGFR TKI , which may be more effective in patients with @VARIANT$ . NCT01526928 is an ongoing phase I/II trial that has enrolled patients who have failed prior chemotherapy and @GENE$ targeted therapy including erlotinib , gefitinib , neratinib , @DRUG$ , or dacomitinib .", "label": "response"}
{"id": "20559549", "sentence": "describe the expression of 66 miRNAs in human NTera2 and mouse P19 cells following @DRUG$ RA ) treatment and establish that 19 of them are coordinately up-regulated in both cell lines indicating that their functions might be conserved between the species . In another study , Hohjoh and Fukushima examine the profiles of 180 mouse and 127 human miRNAs in human ( NTera2/D1 ) and rodent ( @VARIANT$ and Neuro2a ) cell lines , and report that the ES cell specific miR-302 cluster , and miR-124a show the opposite patterns of expression in response to the RA treatment and may mark the onset of neural differentiation .", "label": "None"}
{"id": "22970367", "sentence": "One possibility is that the @VARIANT$ mutation could lead to altered drug binding in the ATP pocket of @GENE$ in a manner analogous to the effects of the T315I mutation in the ABL kinase in the context of @DRUG$ resistance [ ] .", "label": "None"}
{"id": "23994953", "sentence": "NSCLC tumors carrying @GENE$ activating mutations ( e.g. , exon 19 deletions or @VARIANT$ ) respond preferentially to the EGFR TKIs @DRUG$ and erlotinib .", "label": "sensitivity"}
{"id": "24348666", "sentence": "The presence of a secondary mutation of the @GENE$ gene in the T790M was reported in 2005 . The threonine residue 790 is known as the `` gatekeeper residue '' and is located in the ATP binding site , adjacent to the catalytic cleft of the kinase domain . It was initially proposed that the @VARIANT$ mutation might prevent the proper binding of tyrosine kinase inhibitors via steric hindrance , similar to the corresponding gatekeeper mutations in BCR-ABL ( T315I ) and KIT ( T670I ) that confer resistance to @DRUG$ ( Gleevec ) in chronic myelogenous leukemia and in patients with gastrointestinal stromal tumors .", "label": "None"}
{"id": "23992330", "sentence": "In the colorectal cancer setting , preclinical in vitro models of resistance to the anti-EGFR mAbs cetuximab and @DRUG$ include cell lines showing mutations of the K-Ras gene , most frequently in codon 12 of exon 2 , such as SW480 , LS174T , HCT116 , LoVo cells . These mutations produce a single amino acid change resulting in mutant Ras proteins that are insensitive to GAP function and constitutively active , with consequent activation of the @GENE$ signaling [ ] . Furthermore , several colorectal cancer cell lines ( VAC0432 , SNU-C5 , HT29 , KM20 , WiDr ) are considered valuable models of resistance to the B- Raf ( @VARIANT$ ) inhibitor vemurafenib [ ] because of the high levels of EGFR expression .", "label": "None"}
{"id": "17877814", "sentence": "In a subset of NSCLC patients , the presence of somatic mutations in the kinase domain of EGFR may predict the outcome of treatment with the @GENE$ TKIs erlotinib and @DRUG$ . The favorable clinical response of tumors harboring the common exon 19 deletions or the @VARIANT$ mutation correlates with the high TKI sensitivity of these EGFR mutant proteins at the molecular level .", "label": "sensitivity"}
{"id": "23696715", "sentence": "A subgroup analysis of progression-free survival in sporadic MTC patients suggested that @GENE$ @VARIANT$ mutation positive patients had a higher response rate to @DRUG$ compared with RET M918T mutation negative patients. ,", "label": "response"}
{"id": "22382702", "sentence": "Furthermore , De Roock and colleagues recently reported that chemotherapy-refractory metastatic colorectal cancers harboring a @VARIANT$ @GENE$ mutation were more sensitive to treatment with the epidermal growth factor receptor (EGFR) inhibitor @DRUG$ compared to tumors with other KRAS mutations [ ] .", "label": "resistance or non-response"}
{"id": "25505694", "sentence": "@DRUG$ , an oral small-molecule inhibitor of EGFR , VEGFR-2 , HER2 and Ephrin type-B receptor 4 (EphB4) , in preclinical studies showed efficacy against @GENE$ tumors , including those harboring @VARIANT$ [ ] .", "label": "None"}
{"id": "25562798", "sentence": "These mutations including @VARIANT$ in the @GENE$ kinase domain may be susceptible to inhibition with novel ALK inhibitors e.g. , LDK378 , AP26113 , or AF802 . However , other mechanisms of resistance including activation of alternative kinases e.g. , EGFR have also been implicated in resistance to @DRUG$ [ ] .", "label": "resistance"}
{"id": "24292439", "sentence": "From lane 1 to 4 , d-nLDH wild-type ( wt ) , d-nLDH Y52L , d-nLDH @VARIANT$ , and d-nLDH Y52L/F299Y , respectively . Asymmetric reduction of PPA ( 8a ) with NADH @DRUG$ recycling by using whole-cell system . Construction of E. coli BL21 ( DE3 ) harboring @GENE$ .", "label": "None"}
{"id": "24348666", "sentence": "Therefore , PTEN downregulation or @GENE$ activation may be one of the mechanisms for acquired resistance to @DRUG$ . 2. Acquired resistance mechanism 1 ) Secondary @VARIANT$ mutation of the EGFR gene", "label": "None"}
{"id": "23109866", "sentence": "The second-generation TKIs may overcome resistance to the treatment of erlotinib or gefitinib via the @VARIANT$ gatekeeper mutation . However , this activity needs to be further validated since it has also been reported that @DRUG$ , a second-generation TKI , was not qualitatively superior in preventing the acquired resistance [ ] . Several irreversible EGFR inhibitors blocked multiple EGFR family members , interrupting the cooperative signal pathway among @GENE$ members and resulted in a more complete blockage .", "label": "response"}
{"id": "24810093", "sentence": "Associations between IC50 and ABCB1 genotypes at @VARIANT$ ( a ) and ( b ) , G2677T/A ( c ) and ( d ) and C3435T ( e ) and ( f ) were analysed by Jonckheere-Terpstra test . Correlation matrix between @GENE$ relative expression , bodipy-FL-paclitaxel accumulation and efflux constant KE in lymphoblastoid cell lines and ovarian cancer cell lines using Spearman or Pearson correlation test Lymphoblastoid cell lines Ovarian cancer cell lines ABCB1 expression Paclitaxel accumulation Paclitaxel efflux ABCB1 expression Paclitaxel accumulation Paclitaxel efflux", "label": "None"}
{"id": "15736989", "sentence": "The mechanism of resistance in three patients was acquisition of a @VARIANT$ substitution in @GENE$ that was not present at time of diagnosis , but was detected with progression of disease after initial response to @DRUG$ or erlotinib .", "label": "resistance or non-response"}
{"id": "24276379", "sentence": "Approximately 90 % of the B-Raf mutations codes for a substitution of glutamic acid for the wild-type valine in residue 600 ( i.e. , @VARIANT$ ) , resulting in a constitutively active protein [ ] . In two clinical studies , only 2 out of 26 patients with mutant @GENE$ responded to cetuximab or @DRUG$ , even if these patients had wild type K-Ras [ , ] .", "label": "resistance or non-response"}
{"id": "24523596", "sentence": "Several studies have reported renal failure and tumor lysis syndrome during TKI based molecular targeted therapies , including with sorafenib for hepatocellular carcinoma , with imatinib for chronic myelogenous leukemia , and with flavopiridol for chronic lymphocytic leukemia.– Because the @VARIANT$ variant of ABCG2/BCRP corresponding to SNP 421C&gt ; A reduces uric acid transport and those TKIs are substrates/inhibitors of ABCG2/BCRP , TKI therapy in patients with the SNP 421C&gt ; A ( Q141K ) may be at higher risk of tumor lysis syndrome . A defect in the pharmacological interaction has been suggested between @DRUG$ and another ABCG2/BCRP germ-line mutant allele , 1291T & gt ; C. Remarkably , sunitinib reversed wild-type @GENE$ mediated drug resistance and competitively inhibited ABCG2/BCRP mediated estrone 3-sulfate transport and the binding of 125I-iodoarylazidoprazosin to ABCG2/BCRP .", "label": "None"}
{"id": "22815900", "sentence": "In addition to the well characterized causes of drug resistance in lung cancer patients , elucidation of further mechanism for acquired resistance is essential for the development of new @GENE$ targeted drugs . In this present study , erlotinib- and gefitinib-resistant cell lines were established from two human lung cancer cell lines , PC9 cells harboring delE746-A750 mutation and 11–18 cells harboring @VARIANT$ mutation , respectively .", "label": "sensitivity"}
{"id": "24187524", "sentence": "Indeed , there are three currently approved antibodies in clinical use : herceptin ( an anti-HER2 approved to treat breast cancer overexpressing HER2 ) , @DRUG$ , and panitumumab ( @GENE$ approved for treating metastatic colorectal cancer ) [ ] . Furthermore , there are three small-molecule inhibitors of the tyrosine kinase domain ( TKIs ) that interfere with the binding of ATP , also approved to treat non-small cell lung cancer ( i.e. , gefitinib , erlotinib , and lapatinib ) [ ] . These therapeutic molecules are limited by the development of resistance mutations such as @VARIANT$ in EGFR , which necessitates the screening of new inhibitors .", "label": "response"}
{"id": "20387067", "sentence": "This finding suggests that @DRUG$ is a much stronger @GENE$ kinase inhibitor than an SRC inhibitor . For the leukemic counterpart , we used the SKNO-1 cell line , which is GM-CSF dependent expressing homozygous @VARIANT$ KIT mutation .", "label": "sensitivity"}
{"id": "22815900", "sentence": "Partial Loss of the Activating Mutant @GENE$ ( @VARIANT$ ) Gene in Erlotinib- or Gefitinib-resistant Cell Lines from 11–18", "label": "sensitivity"}
{"id": "24634705", "sentence": "@GENE$ Secondary Mutations Similar to other tyrosine kinase inhibitors , patients treated with @DRUG$ eventually develop resistance and mutations that lead to resistance have been reported [ , ] . In one report , the patient developed two de novo mutations within the kinase domain of EML4-ALK , C1156Y and @VARIANT$ [ ] .", "label": "resistance"}
{"id": "25405807", "sentence": "Inhibition of @GENE$ activity by EGFR tyrosine kinase inhibitors ( EGFR-TKIs ) , such as @DRUG$ and erlotinib , can result in improved response and prolonged progression-free survival ( PFS ) in selected non-small cell lung cancer ( NSCLC ) patients harboring sensitizing EGFR mutations , especially the exon 19del and exon 21 L858R mutations – . Unfortunately , almost all patients will ultimately develop resistance to EGFR-TKI , in whom more than 50 % cases were detected harboring the EGFR @VARIANT$ mutation in tumor specimens after EGFR-TKI , .", "label": "resistance or non-response"}
{"id": "23329883", "sentence": "The interactions between genotypes of the @GENE$ @VARIANT$ and @DRUG$ consumption on serum TC and LDL-C levels are also shown in Table .", "label": "None"}
{"id": "25514649", "sentence": "A recent report claimed that @DRUG$ IFN-α and lymphotoxin beta ( LT-β ) pathways might cause the destruction of cccDNA by certain endonucleases following deamination of the minus strand DNA by APOBEC3A @VARIANT$ and A3B .", "label": "None"}
{"id": "23208557", "sentence": "Cancer @GENE$ exon18 G719X Drug efficacy prediction of gefitinib and @DRUG$ exon19 deletion exon20 T790M exon21 @VARIANT$", "label": "sensitivity"}
{"id": "21734647", "sentence": "HIS3 activity was detected by the restoration of growth in the absence of @DRUG$ ( see below for details on the analysis of the @VARIANT$ data ) . We also tested expression in yeast for all the constructs using standard western blot analysis with an anti-HA antibody ( clone 3F10 , Roche ) for the fusions to Gal4-AD and a Gal4-BD monoclonal antibody ( Clontech ) for the fusions to Gal4-BD . We confirmed expression for all the Gal4-BD fusions , but a few Gal4-AD fusion were very weak or could not be detected , indicating that the number of interactors might be underestimated for ARF9 , @GENE$ , IAA11 , IAA20 and IAA30 .", "label": "None"}
{"id": "24279718", "sentence": "Furthermore , the identified L862R EGFR mutation , although not reported before , was located near mutations known to be sensitive to EGFR-TKI , such as @VARIANT$ and L861X . Therefore , the tumor clone bearing this EGFR mutation could have been potentially responsive to @GENE$ therapy . However , a previously described single case of L862V EGFR mutation was associated with lack of response to @DRUG$ and the same could have been the scenario with the L862R EGFR mutation .", "label": "None"}
{"id": "24523596", "sentence": "Several studies have reported renal failure and tumor lysis syndrome during TKI based molecular targeted therapies , including with sorafenib for hepatocellular carcinoma , with imatinib for chronic myelogenous leukemia , and with flavopiridol for chronic lymphocytic leukemia.– Because the @VARIANT$ variant of ABCG2/BCRP corresponding to SNP 421C&gt ; A reduces uric acid transport and those TKIs are substrates/inhibitors of ABCG2/BCRP , TKI therapy in patients with the SNP 421C&gt ; A ( Q141K ) may be at higher risk of tumor lysis syndrome . A defect in the pharmacological interaction has been suggested between sunitinib and another @GENE$ germ-line mutant allele , 1291T & gt ; C. Remarkably , @DRUG$ reversed wild-type ABCG2/BCRP mediated drug resistance and competitively inhibited ABCG2/BCRP mediated estrone 3-sulfate transport and the binding of 125I-iodoarylazidoprazosin to ABCG2/BCRP .", "label": "None"}
{"id": "22093436", "sentence": "Combination of chemotherapy and/or new monoclonal antibody that overcomes CTLA-4 mediated T-cell suppression ( @DRUG$ ) improved overall survival [ , ] . Phase 1 and 2 clinical trials of the @GENE$ kinase inhibitor vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF @VARIANT$ mutation [ ] .", "label": "None"}
{"id": "15737014", "sentence": "To determine how the @VARIANT$ mutation would affect EGFR proteins already containing mutations associated with sensitivity to EGFR tyrosine kinase inhibitors , we introduced the specific mutation into EGFR cDNAs that encoded the exon 21 and 19 mutations found in patients 1 and 2 , respectively . Various lysates from cells that were serum starved and pre treated with @DRUG$ or erlotinib were analyzed by immunoblotting . Amounts of total EGFR ( t-EGFR ) were determined using an @GENE$ monoclonal antibody , and actin served as an indicator of relative levels of protein per sample .", "label": "resistance or non-response"}
{"id": "24964744", "sentence": "Cells with @GENE$ mutations H1047R and @VARIANT$ showed greatest single agent sensitivity to the PI3K inhibitor . Interestingly , cells with these mutations also showed greater sensitivity to @DRUG$ and erlotinib than cells with the EGFR mutation ( exon 19 deletion ) , which are associated with sensitivity to EGFR inhibitors in NSCLC .", "label": "resistance or non-response"}
{"id": "23493838", "sentence": "A complete hematological response and a major cytogenetic response were observed broadly across the @GENE$ mutants , including individuals harboring the dasatinib-resistant F317L , the nilotinib-resistant @VARIANT$ , and F359C/I/V mutations , but not T315I . Nine individuals developed new mutations in the course of @DRUG$ treatment ( V299L , n = 4 ; L248V , n = 2 ; T315I , n = 2 ; F359C , n = 1 ; G250E , n = 1 ) and eight of these individuals discontinued bosutinib because of progressive disease or unsatisfactory response .", "label": "response"}
{"id": "25486409", "sentence": "10.1371/journal.pone.0114000.g003CX-4945 enhanced the efficacy of @GENE$ to overcome drug resistance caused by @VARIANT$ . Cells were treated with CX-4945 ( 5 µM ) , @DRUG$ ( 1 µM ) , and erlotinib ( 1 µM ) or a combination of CX-4945 and gefitinib or CX-4945 and erlotinib for 48 h .", "label": "resistance or non-response"}
{"id": "21995722", "sentence": "Our biological model of sensitive and resistant cells consisted of two NSCLC cell lines , HCC827 and H1975 , with different sensitivities to the @GENE$ inhibitor erlotinib. ( ) The HCC827 cell line harbors a mutation in the EGFR tyrosine kinase domain ( E746–A750 ) that renders these cells sensitive to EGFR TKI therapies , whereas the H1975 cells harbor both the @VARIANT$ and T790M mutations and are resistant to EGFR TKIs .", "label": "sensitivity"}
{"id": "24982846", "sentence": "@DRUG$ @GENE$ TPMT intermediate or poor metabolizers Clinical pharmacology , warnings , precautions Crizotinib ALK ALK gene rearrangement positive Indications and usage , dosage and administration , drug interactions , warnings and precautions , adverse reactions , clinical pharmacology , clinical studies Dabrafenib BRAF BRAF @VARIANT$ mutation positive Indications and usage , dosage and administration , warnings and precautions , clinical pharmacology , clinical studies , patient counseling information G6PD G6PD deficient Warnings and precautions , adverse reactions , patient counseling information", "label": "None"}
{"id": "22034911", "sentence": "Consistent with this , we found that the introduction of R1275Q into EML4-ALK had no negative impact on sensitivity to @DRUG$ ( IC50 47 ± 8 nm ) . As expected , the IC50 values for viability of Ba/F3 cells expressing these mutants were all above that for @GENE$ cells expressing native EML4-ALK , with IC50s ranging from 231 to 981 nm . The three most resistant mutants , @VARIANT$ , S1206R , and G1269S , all had IC50s within twofold of parental , ALK negative , Ba/F3 cells ( IC50 1176 nm ) .", "label": "None"}
{"id": "PMC3760629", "sentence": "The EGFR mutant PC9 cell line harbouring @GENE$ @VARIANT$ , PC9R , has been used as in vitro model of drug resistance . Tumour microvesicles ( TMVs ) shed from cancer cells contain genetic and other molecular information that might be useful for diagnostic purposes to differentiate gefitinib-resistant NSCLC ( non-responders ) from sensitive patients ( drug responders ) .", "label": "resistance or non-response"}
{"id": "23673380", "sentence": "Bacterial endotoxins , @GENE$ and collagenase PrtC protein are important virulence factors that elicit host immune responses and result in tissue lesions . For example , encoding genes of enzymes that mediate sulfur and peroxide metabolism were under represented in the H-2 group . These enzymes include CysN/D/H/J/I , which deoxidizes sulfate to @VARIANT$ , and PatB , MetB/C and CysK/M/O , which catalyze H2S to the reductive carboxylate cycle and Cys/Met metabolism , as well as CAT , which catabolizes toxic substances ( e.g. , H2O2 , formaldehyde , phenol and @DRUG$ ) .", "label": "None"}
{"id": "20684776", "sentence": "The promoter of the cyclin A1 gene , CCNA1 is not @VARIANT$ dependent and , consistently , increasing doses of Roscovitine did not repress cyclin A1 basal transcription levels in contrast to cyclins A2 , B , D and E . However , we demonstrated that Roscovitine at doses preferentially inhibiting CDK2 but not CDK7 and 9 completely abolished cyclin A1 DNA damage induced upregulation , thus suggesting that residual @GENE$ activity is required for cyclin A1 upregulation . In addition Roscovitine co-administered with doxorubicin was able to largely modify the patterns of cell cycle phase distribution in comparison to @DRUG$ only treatment .", "label": "None"}
{"id": "25228590", "sentence": "The strategies described here could also benefit patients with @GENE$ translocated cancers , where the @VARIANT$ mutation modulates @DRUG$ resistance and the same signaling pathways that drive tumor cells without translocated ALK are active .", "label": "resistance"}
{"id": "16434996", "sentence": "Thus , 1 μM of genistein by itself caused only a modest increase in @GENE$ levels ; but the combination of ( I3C+genistein ) caused a much larger increase in BRCA2 levels than did @VARIANT$ alone .", "label": "None"}
{"id": "23816254", "sentence": "Due to their ability to potently inhibit @GENE$ , both afatinib and neratinib have been assessed in lung cancer that has become resistant to gefitinib and @DRUG$ due to the @VARIANT$ point mutation in the kinase domain [ , ] .", "label": "resistance or non-response"}
{"id": "15685238", "sentence": "of four independent experiments ( *significantly different from untreated @DRUG$ control , P & lt ; 0.05 ANOVA ) . Intracellular calcium release . Quiescent @GENE$ ( A , B ) or @VARIANT$ ( C , D ) receptor expressing CHO cells were incubated with FURA-2AM for 15 min at 37°C and ratiometric fluorescence monitored at 37°C .", "label": "None"}
{"id": "24787964", "sentence": "One of the proposed mechanisms of resistance to @DRUG$ and erlotinib is the @VARIANT$ mutation on exon 20 . As the theoretical advantage of afatinib versus the first-generation @GENE$ did not translate into progression-free survival gains , maybe the clinical relevance of possible inhibition of T790M is minimal , at least in the first-line setting , when T790M positive clones are rarely detected .", "label": "resistance or non-response"}
{"id": "25203004", "sentence": "The two most common genetic mutations are the in-frame deletion in exon 19 ( E746-A750 ) and the substitution of leucine 858 by arginine in the exon 21 ( @VARIANT$ ) . These two mutations constitute about 90 % of all mutations and are known as the “classical” mutations . These two @GENE$ mutations are strong predictors of the response to small-molecule EGFR-tyrosine kinase inhibitors such as gefitinib , and @DRUG$ .", "label": "sensitivity"}
{"id": "21333004", "sentence": "Therefore , Mig6 could be one of the critical factors to explain @DRUG$ sensitivity at cellular level . We constructed the model by referring to the earlier studies on Mig6 functions [ - ] . However , the model could be modified and improved when novel mechanism of Mig6 in the regulation of EGFR or new regulators associated with the @GENE$ @VARIANT$ mutation are identified by further studies .", "label": "sensitivity"}
{"id": "20672050", "sentence": "Emerging data suggest that patients with NSCLC and EGFR exon 19 deletion have a longer survival following treatment with gefitinib or erlotinib compared with those with @VARIANT$ mutation [ – ] . Recently , IPASS study showed that , in the subgroup of 261 patients who were positive for the @GENE$ mutation , PFS was significantly longer among those receiving gefitinib that than among those receiving carboplatin-paclitaxel as first-line treatment ( P & lt ; .001 ) [ ] .", "label": "None"}
{"id": "24501009", "sentence": "Strategies to improve EGFR inhibition in @GENE$ @VARIANT$ cancers include the combination of irreversible EGFR inhibitors with the EGFR‐directed antibody @DRUG$ ( as reported for afatinib plus cetuximab ) 19 ; the development of more potent and specific inhibitors of EGFR T790M20,21 ; and the use of intermittent but high doses of existing irreversible EGFR inhibitors .", "label": "response"}
{"id": "23292247", "sentence": "These results suggest that the level of H3S10p was increased via activated @GENE$ pathways in @DRUG$ exposed @VARIANT$ cells .", "label": "None"}
{"id": "22043994", "sentence": "The introduction of @GENE$ @VARIANT$ allele impaired the therapeutic effect of cetuximab or @DRUG$ .", "label": "resistance or non-response"}
{"id": "23817662", "sentence": "In fact , the patient with @GENE$ c.2573T & gt ; G ( @VARIANT$ ) and EGFR c.2369C&gt ; T ( T790M ) was treated with @DRUG$ and a short-term improvement was observed .", "label": "sensitivity"}
{"id": "23166857", "sentence": "Self-interaction of AtDMC1G138D was initially analysed by @VARIANT$ assay wherein interaction of the bait and prey fusion proteins results in expression of a @GENE$ reporter gene enabling growth of his3 auxotrophic yeast cells on a selective medium lacking @DRUG$ .", "label": "None"}
{"id": "22933967", "sentence": "In another phase II POCHER trial , the proportion of R0 resection was even higher ; it was achieved in 60 % of patients who were treated with chronomodulated chemotherapy with irinotecan , oxaliplatin , 5- fluorouracil and @DRUG$ . In conclusion , the results of our retrospective study showed that the patients with @GENE$ @VARIANT$ mutation had worse prognosis than those with wt-BRAF , with lower response rates and progressed early during systemic treatment , consequently , with less possibilities to achieve resectability of metastatic disease .", "label": "None"}
{"id": "21573178", "sentence": "Depicted is the average read frequency of T790M separately for EGFR wildtype and @GENE$ mutated tumor specimens . Tumor specimen 10b with a high allele frequency of @VARIANT$ and clinical resistance to @DRUG$ treatment is not shown in this diagram .", "label": "resistance or non-response"}
{"id": "24672248", "sentence": "In fact , there appears to be a close relationship between @GENE$ and PDGFRA , and the correlation between them has been widely investigated. , PDGFRA mutation @VARIANT$ confers @DRUG$ resistance .", "label": "None"}
{"id": "23579627", "sentence": "Although we could not perform an @GENE$ mutation test at the time of progression after @DRUG$ retreatment , the patient had another partial response with irreversible EGFR inhibitor , which is believed to overcome secondary resistance to reversible EGFR-TKI related with @VARIANT$ mutation .", "label": "resistance or non-response"}
{"id": "24419415", "sentence": "Our group has undertaken a randomized phase 3 trial to compare gefitinib plus carboplatin plus pemetrexed with @DRUG$ monotherapy for patients with NSCLC with an exon 19 deletion or an L858R , G719X , or @VARIANT$ EGFR mutation ( NEJ009 ; University Hospital Medical Information Network Clinical Trials Registry [ @GENE$ ] number , UMIN000006340 ) .", "label": "None"}
{"id": "19680652", "sentence": "However , subsequent resistance to @DRUG$ is inevitable even among the initial good responders , mostly related to acquired @GENE$ mutation ( @VARIANT$ ) or c-met amplification [ , ] .", "label": "resistance or non-response"}
{"id": "20972475", "sentence": "Also available is a second assay , the @GENE$ ( @VARIANT$ Sequencing ) ( V6S ) , which uses sequencing to detect the BRAF p.Val600Glu sequence variant . Public Health Importance Available evidence indicates that the clinical benefit from treatment with EGFR monoclonal antibody inhibitors @DRUG$ and panitumumab is limited to a subgroup of only 10 % to 30 % of CRC patients .", "label": "resistance or non-response"}
{"id": "15737014", "sentence": "@DRUG$ inhibited the activity of wild-type and L858R EGFRs progressively with increasing concentrations of drug , as demonstrated by a reduction of tyrosine phosphorylated proteins ( A ) and a decrease in p-EGFR : @GENE$ ratios ( B ) . By contrast , wild-type and mutant EGFRs containing the @VARIANT$ mutation did not display a significant change in either phosphotyrosine induction or p-EGFR : t-EGFR ratios ( A and B ) .", "label": "resistance or non-response"}
{"id": "23520442", "sentence": "The acquired resistance hypothesis purports that exposing to EGFR-TKIs induces a second point mutation , resulting in a threonine-to-methionine change at position 790 of @GENE$ . Alternatively , the selective resistance hypothesis suggests that the @VARIANT$ mutation might exist in patients as small clones prior to treatment ; these resistant clones may proliferate after exposed to gefitinib or @DRUG$ .", "label": "resistance or non-response"}
{"id": "21333004", "sentence": "When RY is defined as the ratios of Y with @DRUG$ to Y without gefitinib , Figure shows RE11P/ShcP/Grb2/SOS/RY by varying the values of k3 and k8 ( Y : RasGTP , Raf1A , MEKP , MEKPP , ERKP , and ERKPP ) . The values in each panel indicate RE11P/ShcP/Grb2/SOS/RY calculated by using the values of k3 and k8 in @VARIANT$ model A and k5 and k7 in @GENE$ model .", "label": "sensitivity"}
{"id": "25156441", "sentence": "After phenol-chloroform extraction and @DRUG$ precipitation , the RNAs were incubated with 100 μM preadenylated 3′-adaptor oligonucleotide ( Linker-1 , IDT Inc ; Coralville , Iowa ) , 5 % DMSO ( Sigma-Aldrich ) and 200 units T4 RNA ligase 2 ( truncated @VARIANT$ ; New England Biolabs , Ipswich , MA ) at 16°C for overnight . Next , the ligated products were purified on a 12 % denaturing polyacrylamide gel , followed by incubation with T4 polynucleotide kinase ( New England Biolabs ) at 37°C for 30 min and a second ligation reaction with a 5′-adaptor oligonucleotide , 5′-ACG CTC @GENE$ CGA TCTv−3′ ( uppercase , DNA ; v represents barcode with triple RNA molecules , aaa , ggg , ccc or uuu ; IDT ) at 37oC for 1 hr .", "label": "None"}
{"id": "23994953", "sentence": "Indeed , the fact that the combination of @DRUG$ plus IGF-1R inhibitors ( I-OMe-AG538 or AG1024 ) fully prevents the acquired erlotinib-resistant phenotype is consistent with IGF-1R playing a major role in this process . While preparing this manuscript , Cortot et al. reported that PC-9 derived clones with acquired resistance to mutant-selective EGFR inhibitors and irreversible quinazoline EGFR inhibitors in the absence of @GENE$ @VARIANT$ demonstrate a significantly activated IGF-1R signaling , and pharmacological inhibition of IGF-1R restored sensitivity to EGFR inhibitors .", "label": "resistance or non-response"}
{"id": "25431951", "sentence": "Several strategies targeting @VARIANT$ @GENE$ including blockade of kinase-addiction by the third-generation of tyrosine kinase inhibitor @DRUG$ [ ] , down-modulation of BCR-ABL by inhibition of heat shock protein [ , ] were documented .", "label": "response"}
{"id": "23414419", "sentence": "Our findings are in accordance with a prior report by Carlson and colleagues , who demonstrated that @DRUG$ causes cell cytotoxicity by G1-S phase arrest in MDA-MB-468 breast carcinoma cells [ ] . RB protein , a tumor suppressor that blocks @VARIANT$ transcription factor , regulates transcription of @GENE$ genes involved in cell cycle progression from G1 to S phase .", "label": "None"}
{"id": "24944510", "sentence": "Poziotinib ( also known as HM781-36B ) , a new potent irreversible inhibitor of EGFR , HER2 , HER4 , and transient erythroblastopenia of childhood family of kinases inhibitor ( @GENE$ , BLK , and BMX ) , demonstrated preclinical efficacy against @VARIANT$ mutant at eightfold lower doses compared to afatinib . A different approach in addressing EGFR-TKI resistance involves the use of combination regimens . Therefore , the combination of erlotinib with cetuximab , and the combination of @DRUG$ with MM-121 ( a fully human mAb that targets HER3 ) , in patients with acquired resistance to EGFR-TKIs did not show sufficient clinical activity for further investigation in this population .", "label": "None"}
{"id": "22970367", "sentence": "The most common activating mutations ( ~90 % ) are in-frame deletions in exon 19 of EGFR and a missense mutation at 858 in exon 21 of EGFR resulting in an arginine to leucine substitution ( @VARIANT$ ) [ ] . Therapeutic agents targeting the @GENE$ signaling pathway , including two EGFR kinase inhibitors gefitinib and @DRUG$ , are clinically effective in treating lung cancer patients harboring these EGFR activating mutations [ – ] .", "label": "sensitivity"}
{"id": "23493804", "sentence": "EGFR–TKIs such as @DRUG$ or erlotinib attain a response rate of approximately 70 % and progression-free survival of 9–13 months , although subgroups of patients experience long lasting remission. , Use of @GENE$ as a first-line treatment in patients with advanced NSCLC harboring EGFR mutations improved progression-free survival with acceptable toxicity , compared with standard chemotherapy . EGFR–TKIs are currently considered a standard first-line treatment for this disease entity.– However , these tumors eventually develop resistance to EGFR–TKIs , possibly as a result of a secondary threonine–methionine substitution mutation at position 790 in exon 20 ( @VARIANT$ ) , MET amplification , or hepatocyte growth factor overexpression in relapsed tumors .", "label": "resistance or non-response"}
{"id": "21457545", "sentence": "Patients with exon 19 harboring deletions were found to have longer survival following treatment with @DRUG$ or erlotinib compared with those having @VARIANT$ mutations in NSCLC [ , ] ; however , Marks et al. reported no difference in survival between exon 19 deletions and L858R mutations in the absence of @GENE$ targeted therapy [ ] .", "label": "sensitivity"}
{"id": "24594844", "sentence": "Taken together , these results indicate that the combination of cDzT and @DRUG$ synergistically inhibits @GENE$ protein expression and downstream signaling , triggering @VARIANT$ harboring cells to undergo apoptosis and suppressing xenograft tumor growth .", "label": "response"}
{"id": "23691449", "sentence": "Some of the molecular mechanisms of acquired resistance include T790M second mutation , mesenchymal epithelial transition factor ( MET ) amplification , @GENE$ ( ABCG2 ) and hepatocyte growth factor (HGF) overexpression , insulin-like growth factor (IGF) binding protein-3 ( IGFBP3 ) downregulation , as well as ERBB3 activation . T790M mutation The @VARIANT$ second mutation accounts for half of all resistances to @DRUG$ and erlotinib [ ] .", "label": "None"}
{"id": "21479127", "sentence": "SDHB status @GENE$ mutation Clinical features Sensitivity to imatinib SDHB positive KIT exon 9 , 11 , 13 , and 17 ; PDGFRA exon 12 , 14 , and 18 Sporadic or familial tumors ( adult type ) Generally high , but varies ( lower for KIT exon 9 mutants and poor response for the most common PDGFRA exon 18 mutant ( D842V )", "label": "resistance or non-response"}
{"id": "24586840", "sentence": "Indeed , our mutations , not only N273D but also @VARIANT$ , conferred sensitivity to sCD4 , suggesting that these substitutions affect the CD4 binding affinity . It has been reported that @DRUG$ directly interacts with Asp171 and @GENE$ of CXCR4 , as well as ECL2 and TM4 .", "label": "None"}
{"id": "20385023", "sentence": "According to a compendium of studies that include 1170 patients , more than 70 % of NSCLCs with EGFR mutations respond to @GENE$ , whereas only 10 % of tumors without EGFR mutations do so . Unfortunately , upon treatment of these patients with gefitinib and @DRUG$ , two major mechanisms of resistance have been observed . The first is the appearance of a `` resistance '' point mutation in the kinase domain ( @VARIANT$ ) , observed in 50 % of the gefitinib-resistant patients [ ] .", "label": "resistance or non-response"}
{"id": "25465236", "sentence": "( C ) EGFR T790M mutant does not resemble pEGFR unlike the EGFR @VARIANT$ mutant shown in B. ( D–F ) increased inhibition potency for Erlotinib against EGFR L858R mutant compared to @GENE$ WT protein and subsequent decrease in potency for @DRUG$ against EGFR L858R + E884K double mutant .", "label": "sensitivity"}
{"id": "25462529", "sentence": "The fact that @VARIANT$ or K substitutions do not reduce IN enzymatic activity , but slightly affect RT and interaction with p75/LEDGF , points to a change in @GENE$ processing due to a modified trend of interactions between IN monomers , between IN and RT , or between IN and a cellular factor such as p75/LEDGF . @DRUG$ is a versatile amino acid that can assume positive charge , but remains usually neutral at physiological pH .", "label": "None"}
{"id": "23029123", "sentence": "The importance of D2 receptor involvement in @DRUG$ actions on PRL production and cell proliferation is evident in the experiment where ethanol actions on lactotropes ' function were evaluated in clonal cell lines expressing various levels of D2 receptor isoforms . It was found that V cells , which lacked functional D2 receptors and had high basal levels of PRL , showed a significant reduction in PRL production following @VARIANT$ and D2L receptor transfection . As described by an extended allosteric ternary complex model of @GENE$ , receptors spontaneously isomerize between active and inactive conformations , so receptors can modulate signaling pathways in the absence of an agonist .", "label": "None"}
{"id": "25562798", "sentence": "Although irreversible inhibitors of the @GENE$ such as dacomitinib or @DRUG$ inhibit @VARIANT$ in vitro their clinical activity in the setting of tumors with T790M mutations remains to be demonstrated and novel mutation specific T790M inhibitors are in clinical development .", "label": "response"}
{"id": "24686514", "sentence": "S1P is a lipid @GENE$ that regulates many kinds of biological processes including proliferation , migration , and cytoskeletal reorganization [ ] . S1P is excreted from activated platelets and interacts with endothelial cells under the conditions of thrombosis , angiogenesis , atherosclerosis , and liver regeneration [ – ] . Zheng et al. revealed that @VARIANT$ protects LSECs from @DRUG$ induced apoptosis via activation of eNOS [ ] .", "label": "None"}
{"id": "24349829", "sentence": "While the @VARIANT$ mutation represents a direct mechanism for drug resistance that occurs at the level of drug accessibility to the target , there are a number of indirect mechanisms that involve the increased expression or activation of alternative growth factor receptors to maintain signal flux , despite EGFR inhibition . Perhaps the best characterized of these is the amplification of the Met receptor and/or elevated levels of its ligand @GENE$ . In @DRUG$ resistant NSCLC cell lines , Met drives ErbB3 dependent activation of the PI3K pathway .", "label": "None"}
{"id": "24947048", "sentence": "The @VARIANT$ mutation was detected only twice in CTCs captured from nine blood samples : one week after bone marrow biopsy , with 10/20 EpCAM captured cells having the mutation , and six weeks after bone marrow biopsy , with 2/7 EpCAM captured cells having the mutation . Drug treatments are noted ( @GENE$ = @DRUG$ , an mTOR inhibitor ) .", "label": "None"}
{"id": "24410791", "sentence": "Second generation EGFR TKIs e.g. , @DRUG$ afatinib ) and PF00299804 ( dacomitinib ) , and third generation @GENE$ TKIs e.g. , CO-1686 and AZD9291 are irreversible inhibitors that could overcome the AR caused by @VARIANT$ .", "label": "response"}
{"id": "23527257", "sentence": "In the erlotinib-resistant cells from PC9 established by Tabara et al , constitutive PI3K/Akt activation was effectively inhibited by afatinib . Moreover , HER2 overexpression and amplification were reported recently to be a potential mechanism of acquired resistance to EGFR inhibition in EGFR mutant lung cancers that lack the second-site @GENE$ @VARIANT$ mutation .", "label": "resistance or non-response"}
{"id": "23691449", "sentence": "Such mutations include multiple overlapping deletion mutations of exon 19 in 45 % of patients , point mutations in exon 21 in 40 % of patients ( predominantly @VARIANT$ ) , and point or insertion mutations in exons 18 to 21 in the remaining 15 % of patients [ ] . Clinical trials on @DRUG$ efficacy for advanced NSCLC with @GENE$ mutations in Japan were summarized by Morita et al. [ ] A total of 148 NSCLC patients with EGFR mutations from seven eligible trials were identified .", "label": "sensitivity"}
{"id": "17973572", "sentence": "After the cells were exposed to @DRUG$ for 24 h , @GENE$ cells were unable to proliferate while Ba/F3-L858R-L747S and Ba/F3-L858R-T790M cells continued to grow even in the presence of 1 μM gefitinib ( E ) . These results suggest that execution of apoptosis may be impaired by the presence of @VARIANT$ and , to a lesser extent , L747S .", "label": "None"}
{"id": "25222496", "sentence": "Thirdly , exon 21 L858R mutation co-existing with other uncommon mutations might affect the hypersensitivity of L858R to @GENE$ . A retrospective study which investigated the frequency of complex mutations in 783 NSCLC patients found the majority was @VARIANT$ plus L858R mutation ( n = 8 ) , the result also suggested poor response to @DRUG$ in patients with G719S plus L858R mutation .", "label": "sensitivity"}
{"id": "22615883", "sentence": "Prior to immunostaining , sections were deparaffinized , hydrated in graded @DRUG$ , and microwave treated for 10 min at 750 W and 15 min at 350 W. Heat induced epitope retrieval was performed by heating the TMA slides immersed in retrieval buffer pH 6 ( Lab Vision , Freemont , CA ) for 4 min at 125°C in a pressure boiler ( Decloaking chamber , Biocare medical ) . Immunostaining was performed by avidin-biotin peroxidase staining technique ( Vector elite ) , using 3,3-diaminobenzidine as a substrate . The presence of heterogeneous cell populations in the TMA was documented using the following immunohistochemical markers : GFAP ( 1∶500 ; polyclonal rabbit , DAKO , Denmark ) , @GENE$ ( 1∶80 ; Mouse clone V9 , Sigma ) , neuronal nuclear protein ( 1∶1000 ; Mouse clone MAB377 , Chemicon , Temecula , CA ) , microtubule associated protein ( 1∶100 ; Mouse clone HM2 , Sigma ) , CD34 ( 1∶100 ; Mouse monoclonal , DAKO ) , Ki67 ( 1∶500 ; Rabbit polyclonal , DAKO ) , and mutated isocitrate dehydrogenase 1 (IDH1) R132H protein ( 1∶100 ; monoclonal mouse antibody , mIDH1R132 ) .", "label": "None"}
{"id": "25465236", "sentence": "( C ) EGFR @VARIANT$ mutant does not resemble pEGFR unlike the EGFR L858R mutant shown in B. ( D–F ) increased inhibition potency for @DRUG$ against EGFR L858R mutant compared to EGFR WT protein and subsequent decrease in potency for Erlotinib against @GENE$ L858R + E884K double mutant .", "label": "resistance or non-response"}
{"id": "19636371", "sentence": "A polymorphic variant in the EGFR gene arising from a single nucleotide substitution ( 142285G&gt;A ) leading to an Arginine ( R ) /Lysine ( K ) substitution in codon 521 in the extracellular subdomain IV of the EGFR gene ( rs11543848 , also known as HER-1 @VARIANT$ ) has been identified [ ] . Compared with the “wild-type” HER-1 142285G ( 521R ) allele , that the 142285A ( 521K ) variant has attenuated function in ligand binding , growth stimulation , tyrosine kinase activation , and induction of the proto-oncogenes myc , fos , and jun [ ] . Among the steroid receptors , @GENE$ ( ERα or ESR1 , MIM : 133430 ) and the ER-regulated @DRUG$ receptor ( PGR , MIM : 607311 ) are of special interest because of their elevated protein levels in some premalignant and malignant breast cells [ ] .", "label": "None"}
{"id": "19758442", "sentence": "The region important for interaction with the @GENE$ ubiquitin ligase complex is marked in green and includes a conserved histidine-cysteine-cysteine-histidine motif and a suppressor of cytokine signaling Box domain . The scale at the bottom indicates amino acid positions . The structural determination of full-length @VARIANT$ has so far been unsuccessful .", "label": "None"}
{"id": "24523596", "sentence": "Lapatinib @GENE$ EGFR + + Polli et al and Dai et al @DRUG$ BCR-ABL with mutations , including @VARIANT$ + + Sen et al", "label": "None"}
{"id": "23992330", "sentence": "Briefly , they demonstrated the different effects of the G12 and G13 K-Ras alleles on response to @DRUG$ and found a significant association between the presence of a G13D mutation and survival benefit after cetuximab treatment in metastatic colorectal cancer patients [ ] . Moreover , a paper by Di Nicolantonio et al. demonstrated the different role of @GENE$ and K-Ras mutations in the response to the mammalian Target Of Rapamycin (mTOR) inhibitor everolimus . In fact , while cells knocked-in for the PIK3-CA alleles @VARIANT$ and E545K showed an increased response to everolimus , oncogenic K-Ras mutations conferred resistance to this agents [ ] .", "label": "None"}
{"id": "25100284", "sentence": "Furthermore , although common mutations , such as exon 19 deletions and @VARIANT$ mutations in exon 21 have been associated with response to EGFR TKIs , many other mutations are detected only occasionally , and correlations with response are not defined . A recent study screened 681 cases and found 18 rare mutations ; responses to @GENE$ TKIs were reported on a case by case basis and varied by mutation [ ] . For example , exon 20 and 21 mutations were more likely to confer resistance to erlotinib or @DRUG$ , while exon 18 and 19 mutations were more often associated with improved efficacy outcome .", "label": "sensitivity"}
{"id": "23055691", "sentence": "In adenocarcinoma tumor samples from never smokers , a Memorial Sloan Kettering group similarly identified @GENE$ mutations that were associated with sensitivity to @DRUG$ and erlotinib . These EGFR mutations activate the EGFR signaling pathway that promotes survival , and commonly include exon 19 deletions or the @VARIANT$ point mutation on exon 21 .", "label": "sensitivity"}
{"id": "24919804", "sentence": "As NF-κB is active in CTCL and supports growth of dasatinib/imatinib-resistant cells , , we tested dasatinib in combination with NF-κB inhibitors . Interestingly , dasatinib and NF-κB inhibitors had an additive effect on malignant proliferation in vitro ( data not shown ) , which might explain why Blk ( @VARIANT$ ) -transformed @GENE$ cells were more sensitive to dasatinib than the malignant MyLa cells .", "label": "None"}
{"id": "24367611", "sentence": "First , immediately N-terminal to the SET domain , a unique CXC domain , coordinated by 2 clusters of three zinc ions , differentiates @GENE$ from other SET-domain PMT structures ( no structural homolog of the CXC domains was found by the DALI server [ ] ) . Missense mutations at residues coordinating the first and second zinc of the CXC domain were reported in acute myeloid leukemia ( H525N ) and myelodysplastic syndrome ( @VARIANT$ ) suggesting that disruption of the CXC domain can be associated with specific cancer types [ , ] . Second , the conformation of the first five residues of the post-SET domain diverges drastically from previous structures of active SET-domain methyltransferases , and folds in a direction diametrically opposite to its expected position , where it would otherwise contribute to formation of the @DRUG$ binding site ( and ) .", "label": "None"}
{"id": "25538894", "sentence": "The other EGFR mutations , e.g. , the @VARIANT$ mutation on exon 20 , represent less than 10 % of all mutations , and are associated with drug resistance ( ) . Treatment of patients with advanced NSCLC with EGFR mutation Both the European Society of Medical Oncology ( ESMO ) ( ) and the American College of Chest Physicians ( ACCP ) ( ) recommend first-line treatment with a TKI ( erlotinib or @DRUG$ ) in metastatic NSCLC bearing an activating @GENE$ mutation because of higher response rate , longer progression free survival ( PFS ) , and better quality of life when compared with first-line chemotherapy .", "label": "resistance or non-response"}
{"id": "23533466", "sentence": "H1975 cancer cell line with mutations in @GENE$ exons 21 ( L858R ) and 20 ( @VARIANT$ ) was refractory to reversible EGFR-TKIs , gefitinib , and erlotinib [ ] , but was sensitive to irreversible EGFR-TKIs , such as BIBW2992 ( @DRUG$ ) .", "label": "response"}
{"id": "23836985", "sentence": "The supernatant was divided into two portions ( one with 5 μg of @VARIANT$ antibody , the other with 4 μg of @DRUG$ G as the negative control ) , and followed by mild shaking overnight at 4°C .", "label": "None"}
{"id": "24348666", "sentence": "However , a small percentage of cells with MET gene amplification selectively grew during the long periods under the EGFR-TKI treatment , and they became a major population , similar to the cells with the @VARIANT$ mutation . ( 1 ) Met inhibitors ( @DRUG$ , heat shock protein 90 [HSP90 ] ) The concomitant inhibition of MET and EGFR using the monoclonal antiboby MetMab and erlotinib proved to beefficacious in a phase II trial and early clinical trials of small-molecule inhibitors of MET given with @GENE$ inhibitors are now currently underway ( ) .", "label": "None"}
{"id": "24303221", "sentence": "Interestingly , studies on different lung cancer cell lines suggested that NCI-H292 , a pulmonary MEC cell line that has wild-type @GENE$ , is more sensitive to @DRUG$ than other wild-type EGFR non-small cell lung cancer cell lines [ ] . O'Neill analyzed the data from multiple studies and raised the interesting question that different ethnic populations may have different EGFR mutations in their pulmonary MEC tumors [ ] . Per review of the literature , 48 pulmonary MEC tumors were tested for EGFR mutations , and nine tumors ( 19 % ) tested positive for mutations including two reports of @VARIANT$ mutations , five L861Q mutations , one I760I mutation , and one exon 19 deletion .", "label": "sensitivity"}
{"id": "23566546", "sentence": "Case Histrogical type @GENE$ mutation status Brinkman index Treatment agent Response IL-8 ( ng/mL ) IL-10 ( ng/mL ) RANTES ( pg/ml ) 1 Ad Ex21 @VARIANT$ 900 gefitinib PR 5.79 1.67 2 2 Ad Ex21 L858R 0 erlotinib PR_3.33 94.2 1.41 3 Ad Ex19 del 0 erlotinib PR 4.09 126 2.13 4 Ad Ex21 L858R 0 gefitinib PR_3.92 18.1 1.85 5 Ad Ex21 L858R + Ex19 del 370 erlotinib PR 21.9 1.23 2.11 6 Ad Ex19 del 0 erlotinib PR 7.05 1.37 2.56 7 Ad Ex19 del 0 gefitinib PR 4.82 1.59 2.02 8 Ad Ex21 L858R 1640 gefitinib PR 54.9 2.7 2.38 9 Ad negative 400 erlotinib SD 34.9 3.39 3.66 10 Ad negative 0 erlotinib SD 27.1 4.94 2.25 11 Ad unknown 1800 erlotinib SD NE NE NE 12 Sq Ex19 del 3840 gefitinib SD 12.6 1.1 1.98 13 Ad Ex19 del 30 erlotinib SD 5.27 0.69 2.66 14 Ad Ex19 del 0 erlotinib SD 10.5 0.85 2.5 15 Ad unknown 300 erlotinib SD 7.69 2.61 1.7 16 La negative 2080 erlotinib SD NE NE NE 17 Sq Ex21 L858R 750 erlotinib SD 11.6 56.3 3.06 18 Ad unknown 600 erlotinib SD 13.7 1.1 2.82 19 Ad Ex21 L858R 0 @DRUG$ SD 20.6 11.6 0.783 20 Ad Ex19 del 0 erlotinib SD 14.8 2.07 2.02 21 Ad Ex21 L858R + Ex19 del 0 gefitinib SD 3.04 1.3 1.76 22 Ad Ex19 del 200 gefitinib SD 10.9 1.59 1.91 23 Sq unknown 1560 erlotinib PD NE NE NE 24 Ad negative 1080 erlotinib PD 25.2 8.15 1.57 25 Ad unknown 0 erlotinib PD NE NE NE 26 Ad Ex18 G719A 2000 erlotinib PD 11.6 4.48 3.12 27 Ad unknown 1410 erlotinib PD NE NE NE 28 Ad Ex19 del 1000 gefitinib PD 9.44 2.25 2.89 29 Ad negative 1100 erlotinib PD 56.3 5.63 2.16 30 Ad negative 2000 erlotinib PD 15.6 0.85 0.292 31 Ad negative 825 erlotinib PD 8.27 1.59 2.13 32 Ad Ex21 L858R 0 erlotinib PD 5.34 7.05 1.7 33 Ad negative 1680 erlotinib PD 57.7 1.63 2.06", "label": "sensitivity"}
{"id": "24924344", "sentence": "@DRUG$ rs562 ( C/T ) Chr3 : 183637845 ABCC5 ( UTR3 ) 0.049494 0.392 rs3749445 ( A/G ) Chr3 : 183638506 ABCC5 ( UTR3 ) 0.044895 0.410 rs2292998 ( C/T ) Chr3 : 183663833 ABCC5 ( intronic ) 0.039882 0.277 rs1016752 ( C/G ) Chr3 : 183665062 ABCC5 ( intronic ) 0.039781 0.232 rs4148585 ( C/T ) Chr3 : 183670642 ABCC5 ( intronic ) 0.039781 0.283 rs6443924 ( A/G ) Chr3 : 183679532 @GENE$ ( intronic ) 0.039781 0.279 rs4148579 ( A/G ) Chr3 : 183685249 ABCC5 ( intronic ) 0.039781 0.279 rs939336 ( A/G =&gt ; C594C ) Chr3 : 183685534 ABCC5 ( exonic ) 0.039781 0.279 rs1132776 ( C/T = & gt ; @VARIANT$ ) Chr3 : 183696402 ABCC5 ( exonic ) 0.044895 0.289 rs2313212 ( C/T ) Chr3 : 183700928 ABCC5 ( intronic ) 0.039781 0.279 rs4148575 ( C/T ) Chr3 : 183702275 ABCC5 ( UTR3 ) 0.044895 0.289 rs1846692 ( C/T ) Chr16 : 56671696 MT1A ( near - gene 5 ) 0.049494 0.360 rs35346959 ( A/G ) Chr16 : 56671867 MT1A ( near- gene 5 ) 0.044895 0.137 rs9922957 ( C/G ) Chr16 : 56672380 MT1A ( near - gene 5 ) 0.039781 0.185 rs9922409 ( A/G ) Chr16 : 56672400 MT1A ( near - gene 5 ) 0.04532 0.103 rs7190725 ( G/T ) Chr16 : 56673290 MT1A ( intronic ) 0.044895 0.170 rs8052394 ( A/G =&gt ; K51R ) Chr16 : 56673828 MT1A ( missense ) 0.044895 0.152 rs1800566 ( C/T = & gt ; P187S ) chr16 : 69745145 NQO1 ( exonic ) 0.039781 0.258 rs689455 ( A/C ) Chr16 : 69761661 NQO1 ( near- gene 5 ) 0.039781 0.242", "label": "None"}
{"id": "22162641", "sentence": "Moreover , addition of Hsp90 inhibitors resulted in cell death in an ALK dependent cell line , tumor regression in an EML4-ALK xenograft , and regression of lung adenocarcinoma in the @GENE$ transgenic mouse . Most importantly , Hsp90 inhibitors lead to cell death in both crizotinib-sensitive and crizotinib-resistant ALK dependent cell lines , , including NSCLC cell lines harboring the ALK @VARIANT$ gatekeeper mutation which provides another alternate pathway to overcome resistance to crizotinib .", "label": "None"}
{"id": "23326540", "sentence": "The dosing and treatment schedule of fenretinide and S1P injection was based on previously published reports , . Control rats received only solvents ( ( 1∶1 : 6 of @DRUG$ , Cremophor® , normal saline ) and 3 % fatty acid free bovine serum albumin ( Sigma ) ) in PBS . For the entire study we used the following numbers of rats : control ( n = 6 ) , fenretinide ( n = 5 ) , @VARIANT$ ( n = 5 ) , and fenretinide and S1P ( n = 4 ) .", "label": "None"}
{"id": "22209766", "sentence": "On the other hand , @DRUG$ could not inhibit EGFR phosphorylation in H1975 cells because the @VARIANT$ mutation in EGFR causes a conformation change at the ATP binding pocket , thus decreasing the affinity between erlotinib and @GENE$ .", "label": "resistance or non-response"}
{"id": "21687501", "sentence": "Consistently HTR3A rs1062613 ( @VARIANT$ ) and two polymorphisms in HTR3B ( −100 −102 AAG deletion variant and rs1176744 ) have been found to be associated with chemotherapy and @DRUG$ treatment induced vomiting and nausea ( Tremblay et al. , ; Kato et al. , ; Sugai et al. , ; Tanaka et al. , ) . 5-HT6 receptor The 5-HT6 receptor is a @GENE$ is expressed almost exclusively in the brain .", "label": "None"}
{"id": "23566546", "sentence": "Case Histrogical type @GENE$ mutation status Brinkman index Treatment agent Response IL-8 ( ng/mL ) IL-10 ( ng/mL ) RANTES ( pg/ml ) 1 Ad Ex21 @VARIANT$ 900 gefitinib PR 5.79 1.67 2 2 Ad Ex21 L858R 0 erlotinib PR_3.33 94.2 1.41 3 Ad Ex19 del 0 erlotinib PR 4.09 126 2.13 4 Ad Ex21 L858R 0 gefitinib PR_3.92 18.1 1.85 5 Ad Ex21 L858R + Ex19 del 370 erlotinib PR 21.9 1.23 2.11 6 Ad Ex19 del 0 erlotinib PR 7.05 1.37 2.56 7 Ad Ex19 del 0 gefitinib PR 4.82 1.59 2.02 8 Ad Ex21 L858R 1640 gefitinib PR 54.9 2.7 2.38 9 Ad negative 400 erlotinib SD 34.9 3.39 3.66 10 Ad negative 0 erlotinib SD 27.1 4.94 2.25 11 Ad unknown 1800 erlotinib SD NE NE NE 12 Sq Ex19 del 3840 gefitinib SD 12.6 1.1 1.98 13 Ad Ex19 del 30 erlotinib SD 5.27 0.69 2.66 14 Ad Ex19 del 0 @DRUG$ SD 10.5 0.85 2.5 15 Ad unknown 300 erlotinib SD 7.69 2.61 1.7 16 La negative 2080 erlotinib SD NE NE NE 17 Sq Ex21 L858R 750 erlotinib SD 11.6 56.3 3.06 18 Ad unknown 600 erlotinib SD 13.7 1.1 2.82 19 Ad Ex21 L858R 0 erlotinib SD 20.6 11.6 0.783 20 Ad Ex19 del 0 erlotinib SD 14.8 2.07 2.02 21 Ad Ex21 L858R + Ex19 del 0 gefitinib SD 3.04 1.3 1.76 22 Ad Ex19 del 200 gefitinib SD 10.9 1.59 1.91 23 Sq unknown 1560 erlotinib PD NE NE NE 24 Ad negative 1080 erlotinib PD 25.2 8.15 1.57 25 Ad unknown 0 erlotinib PD NE NE NE 26 Ad Ex18 G719A 2000 erlotinib PD 11.6 4.48 3.12 27 Ad unknown 1410 erlotinib PD NE NE NE 28 Ad Ex19 del 1000 gefitinib PD 9.44 2.25 2.89 29 Ad negative 1100 erlotinib PD 56.3 5.63 2.16 30 Ad negative 2000 erlotinib PD 15.6 0.85 0.292 31 Ad negative 825 erlotinib PD 8.27 1.59 2.13 32 Ad Ex21 L858R 0 erlotinib PD 5.34 7.05 1.7 33 Ad negative 1680 erlotinib PD 57.7 1.63 2.06", "label": "sensitivity"}
{"id": "25364578", "sentence": "CO-1686 is a novel covalent inhibitor that irreversibly and selectively targets both the initial activating EGFR mutations and the @VARIANT$ secondary acquired resistance mutation . To investigate its use as a single agent , CO-1686 is being evaluated in a phase I/II trial in @GENE$ NSCLC patients previously treated with first-line @DRUG$ or erlotinib ( NCT01526928 ) .", "label": "resistance or non-response"}
{"id": "24092989", "sentence": "The antitumoral activity is increased with the association of @DRUG$ . Another critical serine-threonine protein kinase involved in the @GENE$ pathway that has been targeted to block its constitutive kinase activation is BRAF . , BRAF mutation ( @VARIANT$ ) is reported in 24 % of papillary derived ATC .", "label": "None"}
{"id": "22350019", "sentence": "Many chronic myeloid leukemia ( CML ) patients acquire resistance to the @GENE$ inhibitor @DRUG$ by specific BCR-ABL mutations , particularly the @VARIANT$ gate-keeper mutation .", "label": "None"}
{"id": "25238247", "sentence": "http : //en.wikipedia.org/wiki/HER2/neu - cite_note-3Inhibition of @GENE$ tyrosine autophosphorylation by lapatinib abrogates downstream Ras-Raf-ERK1/2 and PI3K-AKT growth/survival signaling in ErbB2 overexpressing breast cancer cell lines and in patients with ErbB2 overexpressing breast cancers . The uniform development of acquired resistance to lapatinib unfortunately limits its clinical efficacy . In analogous settings , secondary mutations , such as KIT exon 17 mutations in imatinib-resistant GIST and EGFR @VARIANT$ in EGFR mutated lung cancers are common mechanisms of resistance , .", "label": "None"}
{"id": "24260231", "sentence": "We finally examined cells expressing the @VARIANT$ mutant of BCR/ABL , which is resistant not only to @DRUG$ but also to dasatinib or nilotinib . We first examined the effect of the multi-kinase inhibitor sorafenib , which we found to inhibit the kinase activity of BCR/ABL including the T315I mutant . As shown in , sorafenib much more significantly enhanced etoposide induced apoptosis of @GENE$ cells when they were driven by the T315I mutant as compared with when cultured with IL-3 , which correlated with its inhibitory activity on Chk1 activation as well as on phosphorylation of the BCR/ABL substrate STAT5 and GSK3 .", "label": "None"}
{"id": "23940741", "sentence": "Prospective clinical trials of EGFR-TKI treatment for NSCLC patients with activating EGFR mutations , such as delE746-A750 ( exon 19 ) and @VARIANT$ ( exon 21 ) , have demonstrated high clinical response rates of approximately 80 % – . In the IPASS study comparing @DRUG$ with carboplatin and paclitaxel as the first-line therapy in Asian patients , NSCLC patients with EGFR mutation had a higher response rate than patients without @GENE$ mutations when they received carboplatin and paclitaxel .", "label": "sensitivity"}
{"id": "22768234", "sentence": "Tyrosine kinase inhibitors ( TKI ) targeting @GENE$ , including @DRUG$ and erlotinib , have become the standard first line therapy for patients with advanced non-small cell lung cancer ( NSCLC ) that harbor activating EGFR mutations , . However , almost all patients eventually develop resistance to EGFR TKIs . A number of mechanisms of resistance including KRAS mutation , EGFR exon 20 @VARIANT$ mutation , and MET gene amplification , have been reported .", "label": "resistance or non-response"}
{"id": "24920919", "sentence": "Consequently , inhibition of mTORC1 releases the @VARIANT$ mediated negative feedback loop , resulting in a paradoxical increase of @GENE$ and Akt activity . Therefore , there is legitimate concern that the efficacy of selective mTORC1 inhibitors , which include rapamycin and its analogs ( rapalogs ) , eg , @DRUG$ , is limited .", "label": "None"}
{"id": "24999473", "sentence": "Deletion in exon 19 , which removes the conserved sequence LREA , and a single point mutation in exon 21 , which leads to the substitution of arginine for leucine at position 858 ( @VARIANT$ ) , are the most clinically relevant and extensively studied drug-sensitive mutations [ ] . Studies have shown that these mutations preferentially bind to first generation @GENE$ , @DRUG$ and erlotinib [ , ] .", "label": "sensitivity"}
{"id": "25465236", "sentence": "The differential genetically induced drug sensitivities for the FDA approved targeted lung cancer drugs Erlotinib and @DRUG$ was examined . Patients harboring the oncogenic @GENE$ kinase double mutation @VARIANT$ + E884K have a clearly defined differential clinical response to these drugs .", "label": "sensitivity"}
{"id": "23696715", "sentence": "A recent study compared the effect of four TKIs ( axitinib , sunitinib , @DRUG$ , and XL184 ) on cell proliferation , RET autophosphorylation , and extracellular signal regulated kinase activation in three cell lines : MZ-CRC-1 ( @VARIANT$ RET mutation ) , MTC-TT ( C634W RET mutation ) , and TPC-1 ( @GENE$ rearrangement ) cells .", "label": "response"}
{"id": "21605429", "sentence": "Lastly , knowledge of the predictive and prognostic value of mutational status could lead physicians to establish the dose of imatinib , identify those patients who would not benefit from imatinib treatment ( PDGFRA exon @GENE$ tumors are @DRUG$ resistant ) , chose a second line therapy , and evaluate the different risk of relapse during follow-up .", "label": "None"}
{"id": "22191026", "sentence": "The investigated @GENE$ sensitive mutations included G719C , G719S , G719A , L858R , @VARIANT$ , and exon 19 deletions , as well as a gefitinib-resistant mutation , T790M .", "label": "None"}
{"id": "22185641", "sentence": "Further studies showed that introduction of a conditionally expressed @GENE$ p16 (INK4A) gene , sensitized GC-resistant leukemia cells , through induction of cell cycle arrest [ ] . Thus , p16 inactivation may change GR levels , affecting GR-mediated gene regulation and resulting in resistance to GCs . For this purpose , the parental CCRF-CEM cell line was chosen as the system of study for the effects of @DRUG$ treatment , a T-cell leukemia cell line characterized by a mutation ( @VARIANT$ ) on one GR gene allele that impairs ligand binding [ ] .", "label": "None"}
{"id": "21980499", "sentence": "In the HOXA1 gene , the @VARIANT$ variant causing a histidine to arginine has been shown to disrupt the string of @DRUG$ repeats , which was believed to be the binding site of other proteins . According to the function of this variant , studies continuously measure this variant in @GENE$ risk , but with mixed or conflicting results .", "label": "None"}
{"id": "25431951", "sentence": "Clinical trials of new small molecule TKIs ( e.g. @DRUG$ , sorafenib and midostaurin ) were not ideal against T674I PDGFRα despite these drugs in vitro activity . For instance , one @GENE$ patient in blast crisis harboring T674I FIP1L1-PDGFRα showed a short response , followed by a rapid emergence of pan-resistance @VARIANT$ mutation in FIP1L1-PDGFRα .", "label": "None"}
{"id": "21687501", "sentence": "Consistently @GENE$ rs1062613 ( @VARIANT$ ) and two polymorphisms in HTR3B ( −100 −102 AAG deletion variant and rs1176744 ) have been found to be associated with chemotherapy and @DRUG$ treatment induced vomiting and nausea ( Tremblay et al. , ; Kato et al. , ; Sugai et al. , ; Tanaka et al. , ) .", "label": "None"}
{"id": "24280348", "sentence": "In addition , 2nd generation @GENE$ TKI ( @DRUG$ ) aiming to overcome the EGFR @VARIANT$ mutation has failed to show the expected clinical efficacy [ , ] .", "label": "response"}
{"id": "24116271", "sentence": "To modulate the activity of adenosine @VARIANT$ receptor , an antagonist ( 50 nM of ZM241385 ) and an agonist ( 20 nM of CGS21680 ) was used . Western blot : Treated cells were lysed with 2× sample buf-fer ( 4 % w/v SDS , 20 % glycerol , 200 mM DTT , 0.1 M Tris-HCl , pH 6.8 , and 0.02 % bromophenol blue ) and the samples were fractionated by 8-12 % SDS-PAGE and electrotransferred to nitrocellulose ( NC ) membrane . The NC membrane was blocked with 1 μg/ml polyvinyl @DRUG$ (PVA) for 0.5 hr at room temperature ( RT ) and incubated overnight at 4℃ with the appropriate primary antibodies which were diluted @GENE$ 5000 in 5 % skim milk ( Roth , Germany ) .", "label": "None"}
{"id": "24789720", "sentence": "T790M mutation in @GENE$ gene seems to be one of the most important genetic abnormalities involving the resistance for reversible epidermal growth factor receptor tyrosine kinases inhibitors ( EGFR-TKI ) —erlotinib and @DRUG$ in NSCLC patients [ – ] . T790M mutation is detected with highest prevalence in patients with common activating mutations of EGFR gene ( @VARIANT$ in exon 21 and deletions in exon 19 ) after long-term and initially effective treatment with EGFR-TKIs .", "label": "sensitivity"}
{"id": "23208557", "sentence": "It is well known that the efficacy of targeted therapies such as gefitinib or @DRUG$ with NSCLC patients depends on the presence of @GENE$ activating mutations including in-frame deletion in exon 19 or @VARIANT$ in exon 21 [ – ] .", "label": "sensitivity"}
{"id": "25505694", "sentence": "The lack of efficacy could probably be related to the high concentrations of neratinib required in preclinical studies to inhibit EGFR @VARIANT$ and the limitations of clinical dosing . Dacomitinib Dacomitinib is an irreversible @GENE$ , HER2 and HER4 inhibitor with a higher kinase inhibition than gefitinib/erlotinib in both gefitinib/erlotinib-sensitive and in EGFR-T790M and HER2 mutated cell lines [ ] .", "label": "resistance or non-response"}
{"id": "22034911", "sentence": "However , analogous Ba/F3 xenografts expressing @VARIANT$ , S1206R , or G1269S mutants were completely insensitive to these doses , with no statistically significant changes in tumor growth rate . @DRUG$ is not efficacious in mouse @GENE$ xenograft models expressing EML4-ALK mutants .", "label": "None"}
{"id": "21264348", "sentence": "While 10 µM dasatinib was not able to inhibit @GENE$ autophosphorylation and STAT5 phosphorylation in @VARIANT$ Bcr-Abl expressing Ba/F3 cells , the combined treatment with 10 µM @DRUG$ plus 0.5 , 5 , or 10 µM GNF-5 significantly blocked T315I Bcr-Abl signaling ( Supplemental ) .", "label": "None"}
{"id": "25426553", "sentence": "Age PIK3CA mutation PTEN loss or mutation Best tumor response PFS ( months ) OS ( months ) Matched therapy Treatment 55 Amplification P_−100 % 29.3 + 29.3 + Y Everolimus and Anastrozole 61 @VARIANT$ Y −52 % 18.7 19.4 Y Bevacizumab and Temsirolimus 51 H1047L N 21 % 1.7 4.3 Y Sirolimus and Metformin 63 N Y −24 % 1.7 7.9 Y Bevacizumab and Temsirolimus plus Doxil 41_N Y −11 % 28.5 + 28.5 + N An Aurora Kinase Inhibitor 50 N R173C −6 % 7.7 11.3 N @DRUG$ and Pemetrexate 44 N P_−21 % 9.8 15.7 N A @GENE$ Inhibitor and Docetaxol 62 N P 20 % 2.1 19.7 N A Meteasome Inhibitor 43 N P −13 % 40.4 + 40.4 + N A c-Prot Inhibitor 51 N ND −21 % 6.0 6.4 ?", "label": "None"}
{"id": "16187797", "sentence": "Transformation induced by expression of @VARIANT$ , G719S , and L747_E749del A750P EGFR , but not EGF stimulated wild-type EGFR or D770_N771insNPG @GENE$ , was inhibited by 0.1 μM @DRUG$ .", "label": "sensitivity"}
{"id": "24276379", "sentence": "The H1047R , E542K and @VARIANT$ mutations , all detected in colorectal cancers , code for mutant proteins with higher lipid kinase activity than the wild-type protein [ , ] . These mutations result in @GENE$ activation and cellular transformation [ ] . In a clinical study involving 110 patients , none of the patients with the abovementioned PIK3CA gene mutations respond to panitumumab or @DRUG$ [ ] .", "label": "None"}
{"id": "23989631", "sentence": "Input 2 ( see centre right in ) represents the action of the @VARIANT$ RNase III mutant , which is catalytically inactive but retains dsRNA binding capability ( see dsRNA binding sequence framed in magenta in ) . Input 3 in ( bottom-right ) refers to different control experiments ( see ) , including incubation in buffer without enzyme , or including @GENE$ omitting the catalytic @DRUG$ Mg2+ ( see line profile in ) .", "label": "None"}
{"id": "19920910", "sentence": "A combination of low doses of @DRUG$ and low doses of nilotinib may effectively suppress the emergence of mutations other than @VARIANT$ with an acceptable safety profile ( ; ) . This approach needs to be eventually extended to include specific inhibitors of T315I @GENE$ kinase domain mutations .", "label": "None"}
{"id": "25580271", "sentence": "A randomized phase II trial compared erlotinib to @DRUG$ plus bevacizumab in patients with activating @GENE$ mutations ( defined as exon 19 deletion and exon 21 @VARIANT$ point mutations ) and advanced stage NSCLC ( n = 152 ) [ ] .", "label": "sensitivity"}
{"id": "24789720", "sentence": "The possibility of detection of @VARIANT$ mutation in EGFR-TKIs naive patients forces to expand the diagnostics of @GENE$ gene status during qualification for @DRUG$ or gefitinib treatment and to consider the new therapy modalities in carriers of this mutation .", "label": "resistance or non-response"}
{"id": "23407898", "sentence": "In addition , other @GENE$ mutations have also demonstrated contribution to the development of drug resistance to @DRUG$ and gefitinib , including secondary EGFR kinase mutations , L858R mutations , and secondary @VARIANT$ point mutations .", "label": "None"}
{"id": "25617895", "sentence": "Finally , we didn’t adjust the other confounding factors , such as diet , @DRUG$ consumption and cigarette smoking , as these may bias the association between uric acid associated genes and @VARIANT$ , glucose metabolism and insulin secretion . We analysed the effects of the SNPs from eleven uric acid associated loci on the risk of T2D , glucose metabolism and insulin secretion and showed that GCKR rs780094 and SF1 rs606458 variants have an impact on the risk of T2D and @GENE$ , SLC22A11 and SLC22A12 play roles in regulating glucose metabolism and insulin secretion in Chinese males as well as ABCG2 , SLC17A1 and LRP2 in Chinese females .", "label": "None"}
{"id": "25278773", "sentence": "OS was significantly improved with @DRUG$ versus chemotherapy ( median , 27.3 versus 24.3 months ; HR , 0.81 [ 95 % confidence interval [ CI ] , 0.66–0.99 ; P=0.037 ] ) . Individual @GENE$ for OS in both studies were consistent with the pooled analysis . Among patients with EGFR Del19 mutations , HR was 0.59 ( 95 % CI , 0.45–0.77 ; P & lt ; 0.001 ) , with a median OS of 31.7 months , and in those with EGFR @VARIANT$ mutations , the HR was 1.25 ( 95 % CI , 0.92–1.71 ; P=0.160 ) .", "label": "None"}
{"id": "22970367", "sentence": "Second-generation irreversible EGFR inhibitors , which bind irreversibly in the ATP binding pocket of @GENE$ through a covalent bond at C797 , were shown to be more potent inhibitors of the second-site @VARIANT$ mutation than @DRUG$ or gefitinib in pre-clinical models [ , ] ( ) .", "label": "resistance or non-response"}
{"id": "24236082", "sentence": "Additionally , cells bearing the mutant EGFR were in general more sensitive to @GENE$ than cells expressing the wild type kinase . The @VARIANT$ mutant was 10–100 fold more sensitive to @DRUG$ and gefitinib than the wild type kinase , .", "label": "sensitivity"}
{"id": "21687596", "sentence": "An experiment using cell lines transfected concurrently with activating mutations and a @VARIANT$ mutation also proved that resistance to @DRUG$ and erlotinib is evident when this mutation is present [ – ] . Analogous secondary mutations of the BCR-ABL gene in case of chronic myelogenous leukemia ( CML ) [ ] and the KIT gene in case of gastrointestinal stromal tumor [ ] have previously been reported as mechanisms of imatinib resistance , which is also a TKI . The structural similarity between ABL and EGFR tyrosine kinases is considerably high , and T315I in ABL corresponds to T790M in @GENE$ [ ] .", "label": "resistance or non-response"}
{"id": "15737014", "sentence": "Using this insight , new small-molecule inhibitors have been identified that retain activity against the majority of imatinib-resistant BCR-ABL mutants [ , ] . For example , in CML , a commonly found mutation is a C→T single nucleotide change that replaces threonine with isoleucine at position 315 ( @VARIANT$ ) in the ABL kinase domain [ , , ] . In GIST and @GENE$ , respectively , the analogous T670I mutation in KIT and T674I mutation in PDGFR-alpha have been associated with acquired resistance to this drug [ , ] .", "label": "None"}
{"id": "25058005", "sentence": "Activating mutations such as exon 21 missense point mutation L858R and in-frame deletions in exon 19 are the most commonly studied predictive biomarkers of response to @GENE$ ( gefitinib and @DRUG$ ) , . Development of resistance to TKI is a thorny problem in non-small cell lung cancer ( NSCLC ) treatment . Despite the initial promising response to EGFR-TKIs in majority of NSCLC patients harboring sensitizing EGFR mutations , , most patients eventually relapse due to the emergence of acquired resistance such as the EGFR @VARIANT$ mutation or MET amplification , both accounting for about 70 % of the acquired resistance .", "label": "resistance or non-response"}
{"id": "23099808", "sentence": "Acquired clinical resistance to EGFR-TKI was also documented in lung cancer patients , who had an @GENE$ mutation in exon 20 ( @VARIANT$ ) ( ) . Therefore , in this study , we first examined the effects of @DRUG$ or erlotinib on cell proliferation of the cell lines including those originated from lung adenocarcinoma ( LADCA ) .", "label": "resistance or non-response"}
{"id": "24586514", "sentence": "( B ) Immunohistochemical staining for hematoxylin and eosin ( HE ) at a magnification of 40× , Ki67 ( magnification , 400× ) , and TUNEL ( magnification , 400× ) in Ba/F3 @VARIANT$ xenograft sections . ( C ) Tumor cells treated with or without @DRUG$ and vorinostat were examined by immunoblot analysis . Analysis of @GENE$ TKI resistant Ba/F3 BCR-ABL cells", "label": "response"}
{"id": "25530783", "sentence": "The median inhibitory concentrations ( IC50s ) for ethanolic extract of S. campanulatum and @GENE$ were then calculated authentically and with the accurate precision from the dose response curves and were found to be 90 and 12.6 μg/mL , respectively . For further advancement and accuracy , @DRUG$ , a standard therapeutic drug for cancer , was used as a positive control , and it showed significant toxicity towards HT-29 cells with an IC50 of 27.6 μg/mL . In comparison to previous study in which hexane and methanolic extracts of S. campanulatum were reported active against HCT-116 , HT-29 , MCF-7 , @VARIANT$ , and rat hepatoma cells using cell-enzyme based in vitro assay [ ] unlikely in present study ethanolic extract of S. campanulatum and pure DMC are studied for the first time against HT-29 cell line using three different assays .", "label": "None"}
{"id": "24790411", "sentence": "In addition , @DRUG$ should be active in patients with the @VARIANT$ mutation and in those with @GENE$ amplification , representing 60 % –70 % of the resistant population .", "label": "None"}
{"id": "15737014", "sentence": "These results suggest that the @VARIANT$ mutation may impair the ability of @DRUG$ or erlotinib to inhibit @GENE$ tyrosine kinase activity , even in EGFR mutants ( i.e. , L858R or an exon 19 deletion ) that are clinically associated with drug sensitivity .", "label": "resistance or non-response"}
{"id": "23937717", "sentence": "Our results suggested that @DRUG$ could enhance the ability of NK cell degradulation to lung cancer cells with @GENE$ @VARIANT$ + T790M .", "label": "sensitivity"}
{"id": "22787558", "sentence": "For example , mutant animals show decreased chemotaxis to isoamyl @DRUG$ , which is sensed by AWC olfactory neurons ( ) . MAPK is activated within 10 sec by odorant stimuli in the AWC neurons , and the activity of the @GENE$ pathway in AWC is important for behavioural response to the odour . Constitutive activation of LET-60 Ras in the let-60 ( n1046gf ) mutant , which carries the @VARIANT$ mutation , also reduces olfactory responses ( ) .", "label": "None"}
{"id": "24959087", "sentence": "A final mechanism of resistance in gastric cancer cell lines has been demonstrated when MET amplified SNU6838 gastric cancer cell lines were treated with the MET inhibitors PHA-665752 and PF2341066 ; a novel mutation occurred in the activation loop of MET , causing a conformal change that blocked inhibitor binding analogous to the gatekeeper mutations seen in EGFR ( @VARIANT$ ) following @DRUG$ treatment and in @GENE$ ( T315I ) following imatinib .", "label": "None"}
{"id": "23516476", "sentence": "To further identify @GENE$ activation as downstream effector of VEGFR2 signal in Klotho mediated anoikis resistance , functional alterations were analyzed after PAK1 activation with constitutive active mutant PAK1 @VARIANT$ cotransfection in the presence of VEGFR2 inhibition with VEGR2 inhibitor @DRUG$ or its blocking antibody treatment in Klotho overexpressed hepatoma cells .", "label": "None"}
{"id": "23994953", "sentence": "NSCLC tumors carrying EGFR activating mutations ( e.g. , exon 19 deletions or @VARIANT$ ) respond preferentially to the @GENE$ TKIs gefitinib and @DRUG$ .", "label": "sensitivity"}
{"id": "25344762", "sentence": "MTS assay was used to evaluate the effects of erlotinib ( a ) , @DRUG$ ( c ) , and combination of erlotinib and bevacizumab ( d ) on the growth of NSCLC cell lines , which included cell lines with EGFR mutations : PC9 ( EGFR exon 19 deletion ) , 11–18 ( @GENE$ L858 ) , H1975 ( EGFR @VARIANT$ and T790 M mutations ) and EGFR wild-type cell lines : H157 , H460 and A549 .", "label": "None"}
{"id": "25538894", "sentence": "In May 2010 , an EGFR mutation ( @VARIANT$ c.2573T & gt ; G ) positive adenocarcinoma of the right lower lobe of the lung with metastasis in the contra-lateral lung was diagnosed ( Figure A ) . In June 2010 , afatinib , a irreversible @GENE$ , was started in a clinical trial ( Gilotrif® in BIBW 2992 trial ) .", "label": "None"}
{"id": "25594040", "sentence": "The fundamental roles of @GENE$ and PI3K signalling were also demonstrated in c-Kit mutant melanoma cell models with acquired resistance to c-Kit inhibitors imatinib and @DRUG$ [ ] . Multiple independent mechanisms of resistance developed in the c-KITL576P mutant M230 melanoma cell line after prolonged exposure to these c-Kit inhibitors . The genetic effectors of resistance included additional secondary c-Kit mutations ( A829P or @VARIANT$ ) and c-Kit independent mechanisms [ ] .", "label": "None"}
{"id": "24212832", "sentence": "Now used to predict response to cetuximab and @DRUG$ [ ] . @GENE$ @VARIANT$ mutation Likely unfavorable [ , ,, ] Appear to predict resistance to anti-EGFR Therapy [ ] .", "label": "resistance or non-response"}
{"id": "18030354", "sentence": "Of the five EGFR-mutant cell lines , three had exon 19 deletion mutations ( Δ746–750 ) ( HCC827 , HCC2279 , H4006 ) , one had an exon 21 point mutation ( L858R ) ( H3255 ) , and one had L858R in combination with the @VARIANT$ gatekeeper mutation that confers resistance to EGFR TKIs ( H1975 ) . Of the three EGFR-wild-type cell lines , one had a somatic mutation in N-ras ( H1299 ) , and one had a K-ras mutation ( H460 ) . RNA was extracted and prepared from cells after they had been cultured for 2 h at 70 % confluence in the presence or absence of the @GENE$ TKI @DRUG$ ( 1.0 µM ) .", "label": "resistance or non-response"}
{"id": "22721004", "sentence": "Our results with the mutants agree with Gontarewicz et al. , who reported that PHA-739358 was effective against imatinib-resistant @GENE$ mutants including those with the @VARIANT$ mutation in human and mouse leukemia cell lines as well as in CD34+ cells from an imatinib-resistant CML patient [ ] .", "label": "None"}
{"id": "23493883", "sentence": "The most promising drug thus far has been @DRUG$ ( BIBW2992 ; Boehringer-Ingelheim Pharma , Ingelheim , Germany ) , , an @GENE$ family blocker with reported in vitro and in vivo activity against EGFR mutant tumors harboring exon 19 deletions , exon 21 @VARIANT$ mutations and the exon 20 T790M “resistance” mutations .", "label": "sensitivity"}
{"id": "24885169", "sentence": "For example , large phase III clinical trials have demonstrated that ADC is a strong predictive factor for improved outcome following treatment with the combination of pemetrexed with @DRUG$ compared with SQC [ ] . In addition , the presence of common activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene ( exon 19 deletion and exon 21 @VARIANT$ mutation ) confers strong sensitivity to gefitinib and erlotinib , which are selective tyrosine kinase inhibitors of @GENE$ [ , ] .", "label": "None"}
{"id": "23937717", "sentence": "We also found @DRUG$ or NK cells could enhance MHC-I expression , which impairs the recognization of NK cells , in lung tumor cells with wild type @GENE$ , while not in those with EGFR @VARIANT$ + T790M .", "label": "sensitivity"}
{"id": "24982846", "sentence": "Tamoxifen ESR1 , PGR Hormone receptor positive Indications and usage , precautions , medication guide F5 Factor V Leiden carriers Warnings F2 Prothrombin mutation @VARIANT$ @DRUG$ @GENE$ TPMT poor metabolizer Dosage and administration , precautions , warnings", "label": "None"}
{"id": "21188109", "sentence": "Cyclin D1 , in association with cyclin dependent kinase-4 and -6 , induces the cell to enter the S phase by phosphorylating the retinoblastoma tumor suppressing protein , which binds to transcription factors , including @VARIANT$ . In addition to the overexpression of cyclin D1 , other genes that overexpress in MCL , such as VEGF and Raf-1 , represent further possible targets for mTOR inhibitors . Indeed , a constitutive activation of Akt and mTOR pathways either in MCL cell lines ( Granta 519 , Jeko-1 , and SP-53 ) or in primary cultures from 30 % of MCL patients has been reported. , Moreover , mTOR inhibitors in MCL could synergize with other “canonical” agents , such as vincristine , doxorubicin , bortezomib , and @DRUG$ , with resulting inhibition of Raf-1 , @GENE$ , and mTOR . ,", "label": "None"}
{"id": "24590311", "sentence": "Pretreatment with carfilzomib for 24 h followed by addition of a TKI resulted in a significant reduction in viability and proliferation compared with carfilzomib alone in 4 out of 5 imatinib-resistant cell lines ( P⩽0.04 ; P=0.06 for @GENE$ @VARIANT$ cells ) and synergy in all imatinib-resistant cell lines ( CI 0.609–0.895 ; IC50 ) .", "label": "None"}
{"id": "24326041", "sentence": "Two of these mutations were located in the kinase domain and are known to mediate resistance to @DRUG$ ( L755S ) [ ] or to activate @GENE$ ( @VARIANT$ ) [ ] .", "label": "sensitivity"}
{"id": "24071646", "sentence": "Atorvastatin could still enhance gefitinib efficacy in H460 cells ( @DRUG$ treatment versus 1 or 5 μM atorvastatin+gefitinib treatment , IC50=16.4 versus 4.06 or 1 μM ) . Besides , we transfected @GENE$ mutation plasmid-PIK3CA ( @VARIANT$ ) into A549 and Calu1 cells .", "label": "resistance or non-response"}
{"id": "17973572", "sentence": "Transient transfection experiments utilizing COS-7 cells demonstrated that auto-phosphorylation of the original @VARIANT$ EGFR was inhibited by lower concentrations of gefitinib or @DRUG$ than the L858R-L747S or L858R-T790M constructs ( A ) . CL-387,785 partially overcame the observed inhibition ( B ) . To prove the functional significance of the L747S mutation , we generated @GENE$ cell lines stably expressing mutant EGFR constructs [ ] .", "label": "None"}
{"id": "22815900", "sentence": "We finally examined whether expression of activating mutant @GENE$ could restore drug sensitivity to @DRUG$ in drug resistant cell lines , PC9/ER1 and 11–18/ER1-7 . As shown in , out of 11 patients who first received gefitinib after lung surgery and then showed recurrence , 8 patients had the delE746-A750 mutation and 3 had @VARIANT$ mutation in their primary lung tumors .", "label": "sensitivity"}
{"id": "22655263", "sentence": "When tested in @GENE$ cells driven by ALK mutants identified in crizotinib relapsed patients , NMS-E628 is circa fivefold more potent than @DRUG$ in inhibiting the proliferation of L1196M ALK and @VARIANT$ ALK-driven-cells in vitro and in vivo ( Ardini et al. , ) .", "label": "None"}
{"id": "22970367", "sentence": "Moreover , dual inhibition of EGFR with an irreversible EGFR inhibitor ( afatinib ) and the EGFR neutralizing antibody cetuximab has recently shown promising activity in EGFR mutant lung cancers with acquired EGFR TKI resistance that harbor an EGFR @VARIANT$ mutation [ ] . Recently , a clinical trial was conducted to investigate whether there would be any additional clinical benefit with the addition of systemic chemotherapy to an EGFR TKI in lung cancer patients . In the subgroup of 66 patients with an @GENE$ mutation who received either single-agent erlotinib or concurrent combination of chemotherapy and @DRUG$ , progression free survival was 15.7 and 17.2 months , respectively , in this trial .", "label": "resistance or non-response"}
{"id": "24419415", "sentence": "The NEJ002 study , comparing gefitinib and standard carboplatin-paclitaxel chemotherapy as the first-line treatment for patients with @GENE$ mutations , demonstrated no significant difference in OS between @DRUG$ and carboplatin-paclitaxel . In contrast to other phase 3 trials investigating EGFR-TKIs for patients with common EGFR mutations of exon 19 deletion and L858R , the NEJ002 is the only study that included uncommon EGFR mutations of @VARIANT$ and L861Q .", "label": "None"}
{"id": "23238683", "sentence": "As shown in Figure , BaF3 cells expressing native BCR-ABL were highly sensitive to imatinib , dasatinib and ponatinib , whereas BaF3-T315I-BCR-ABL and @GENE$ cells were resistant to both @DRUG$ and dasatinib . By contrast , ponatinib induced loss of cell viability in BaF3 cells carrying the @VARIANT$ or G250E mutation , in agreement with previous results from the literature [ , ] .", "label": "None"}
{"id": "24244732", "sentence": "Consequently the @DRUG$ phenotype of @VARIANT$ alternatively could be a secondary consequence of the reduction in @GENE$ binding in favour of Rab3 .", "label": "None"}
{"id": "24490172", "sentence": "Our data also support a recent previous report in which mice exposed both to @VARIANT$ receptor agonist and @DRUG$ showed increased mobilization of HSPCs compared with mice exposed to AMD3100 alone [ ] . Based on our data , we conclude that hemolysis , even if it significantly elevates the S1P level in PB , requires attenuation of the @GENE$ axis mediated retention of HSPCs in BM niches in order to affect mobilization of HSPCs .", "label": "None"}
{"id": "15737014", "sentence": "Using this insight , new small-molecule inhibitors have been identified that retain activity against the majority of imatinib-resistant BCR-ABL mutants [ , ] . For example , in CML , a commonly found mutation is a C→T single nucleotide change that replaces threonine with isoleucine at position 315 ( T315I ) in the ABL kinase domain [ , , ] . In GIST and @GENE$ , respectively , the analogous @VARIANT$ mutation in KIT and T674I mutation in PDGFR-alpha have been associated with acquired resistance to this drug [ , ] .", "label": "None"}
{"id": "23724098", "sentence": "In addition , there was no difference in PFS for EGFR TKI therapy according to the @GENE$ genotypes ( P = 0.73 ) . Regarding the response for @DRUG$ based chemotherapy , there was one response ( 11 % , respectively ) in each of nine @VARIANT$ and G12D mutations , zero in seven of G12C , and two responses in the other types .", "label": "None"}
{"id": "15737014", "sentence": "@DRUG$ inhibited the activity of wild-type and @VARIANT$ EGFRs progressively with increasing concentrations of drug , as demonstrated by a reduction of tyrosine phosphorylated proteins ( A ) and a decrease in @GENE$ : t-EGFR ratios ( B ) .", "label": "sensitivity"}
{"id": "23055691", "sentence": "Patients who had progressed on erlotinib or @DRUG$ were given afatinib and cetuximab , a monoclonal antibody against @GENE$ . Approximately 94 % of patients , regardless of @VARIANT$ mutation status , had a partial response or stable disease .", "label": "resistance or non-response"}
{"id": "25054154", "sentence": "We utilised three complexes , namely , native ( ALK-crizotinib ) , @VARIANT$ ( ALK F1174L-crizotinib ) , and R1275Q ( @GENE$ R1275Q-crizotinib ) for our analysis .", "label": "resistance"}
{"id": "25027595", "sentence": "The interaction between TM4SF5 and EGFR is observed by a co-immunoprecipitation approach using NSCLC expressing @GENE$ , where the interaction is positively correlated with the @DRUG$ resistance even without EGFR mutation ( e.g. , @VARIANT$ ) following TM4SF5 overexpression .", "label": "None"}
{"id": "21444946", "sentence": "Since the first reports of an association between somatic mutations in @GENE$ exons 19 and 21 and response to gefitinib , treatment of NSCLC has changed dramatically [ , ] . It has been shown that exon 19 deletions are more sensitive to @DRUG$ inhibition than the @VARIANT$ mutation , a finding demonstrated by kinetic analysis [ ] and also confirmed in clinical studies [ - ] .", "label": "sensitivity"}
{"id": "19920910", "sentence": "The pattern of resistance to nilotinib and @DRUG$ differed ; those with greatest resistance to nilotinib ( Y253H and E255V ) were susceptible to dasatinib . @VARIANT$ remained resistant to all the three drugs . In vivo experiments with CML xenografts in mice demonstrated that nilotinib treatment , compared with treatment with vehicle , improved survival of mice infused with either wild type @GENE$ or the imatinib-resistant Bcr-Abl mutant ( E255V ) ( ; ) .", "label": "None"}
{"id": "16173832", "sentence": "In the case of our patient , the patient received no prior systemic chemotherapy , and we identified an initial gefitinib sensitizing @VARIANT$ @GENE$ mutation , followed by a T790M mutation concomitantly with L858R in the biopsy taken from the growing tumor nine months after @DRUG$ use .", "label": "sensitivity"}
{"id": "23238683", "sentence": "We first investigated the effect of these ITKs on the viability of murine Ba/F3 cells , carrying wild type ( WT ) BCR-ABL , @VARIANT$ or G250E-BCR-ABL mutation . As shown in Figure , @GENE$ cells expressing native BCR-ABL were highly sensitive to @DRUG$ , dasatinib and ponatinib , whereas BaF3-T315I-BCR-ABL and BaF3-G250E-BCR-ABL cells were resistant to both imatinib and dasatinib .", "label": "None"}
{"id": "24367680", "sentence": "Since 1/1/2007 until 31/12/2012 , we prospectively analyzed for @GENE$ @VARIANT$ all patients with newly diagnosed mCRC at the Department of Medical Oncology , University Hospital of Heraklion ( Crete , Greece ) . Five hundred and four consecutive patients , with histologically confirmed mCRC and available tumor material for molecular analysis , who were treated with at least one cycle of systemic chemotherapy with or without the addition of @DRUG$ , cetuximab or panitumumab were enrolled .", "label": "sensitivity"}
{"id": "15737014", "sentence": "@GENE$ Mutants Containing the @VARIANT$ Mutation Are Resistant to Inhibition by @DRUG$ or Erlotinib 293T cells were transiently transfected with plasmids encoding wild-type ( WT ) EGFR or EGFR mutants with the following changes : T790M , L858R , L858R + T790M , del L747–E749 ; A750P , or del L747–E749 ; A750P + T790M .", "label": "resistance or non-response"}
{"id": "17848188", "sentence": "Relapse of hypereosinophilia during treatment with @DRUG$ has been reported in two F/P+ patients , and was associated with appearance of a @VARIANT$ point mutation in the ATP binding site of the @GENE$ moiety , similar to the T315I mutation observed in patients with CML that become refractory to treatment [ , ] .", "label": "resistance"}
{"id": "24676216", "sentence": "Furthermore , we performed highly sensitive deep sequencing for mutations in KRAS ( exon 2 ) , PIK3CA ( exons 9 and 20 ) , BRAF ( V600E ) , and @GENE$ ( @VARIANT$ mutation in patients who received @DRUG$ ) .", "label": "resistance"}
{"id": "20504328", "sentence": "B. Diagram and molecular weight of mfVII protein determined in @GENE$ . fVII , peptide , and His are murine fVII with a mutation of K341A , and S peptide ( WT or @VARIANT$ mutant ) and an 8-histidine tag .", "label": "None"}
{"id": "23566546", "sentence": "Case Histrogical type @GENE$ mutation status Brinkman index Treatment agent Response IL-8 ( ng/mL ) IL-10 ( ng/mL ) RANTES ( pg/ml ) 1 Ad Ex21 @VARIANT$ 900 gefitinib PR 5.79 1.67 2 2 Ad Ex21 L858R 0 erlotinib PR_3.33 94.2 1.41 3 Ad Ex19 del 0 erlotinib PR 4.09 126 2.13 4 Ad Ex21 L858R 0 gefitinib PR_3.92 18.1 1.85 5 Ad Ex21 L858R + Ex19 del 370 erlotinib PR 21.9 1.23 2.11 6 Ad Ex19 del 0 erlotinib PR 7.05 1.37 2.56 7 Ad Ex19 del 0 gefitinib PR 4.82 1.59 2.02 8 Ad Ex21 L858R 1640 gefitinib PR 54.9 2.7 2.38 9 Ad negative 400 erlotinib SD 34.9 3.39 3.66 10 Ad negative 0 erlotinib SD 27.1 4.94 2.25 11 Ad unknown 1800 erlotinib SD NE NE NE 12 Sq Ex19 del 3840 gefitinib SD 12.6 1.1 1.98 13 Ad Ex19 del 30 erlotinib SD 5.27 0.69 2.66 14 Ad Ex19 del 0 erlotinib SD 10.5 0.85 2.5 15 Ad unknown 300 erlotinib SD 7.69 2.61 1.7 16 La negative 2080 erlotinib SD NE NE NE 17 Sq Ex21 L858R 750 erlotinib SD 11.6 56.3 3.06 18 Ad unknown 600 erlotinib SD 13.7 1.1 2.82 19 Ad Ex21 L858R 0 erlotinib SD 20.6 11.6 0.783 20 Ad Ex19 del 0 erlotinib SD 14.8 2.07 2.02 21 Ad Ex21 L858R + Ex19 del 0 gefitinib SD 3.04 1.3 1.76 22 Ad Ex19 del 200 @DRUG$ SD 10.9 1.59 1.91 23 Sq unknown 1560 erlotinib PD NE NE NE 24 Ad negative 1080 erlotinib PD 25.2 8.15 1.57 25 Ad unknown 0 erlotinib PD NE NE NE 26 Ad Ex18 G719A 2000 erlotinib PD 11.6 4.48 3.12 27 Ad unknown 1410 erlotinib PD NE NE NE 28 Ad Ex19 del 1000 gefitinib PD 9.44 2.25 2.89 29 Ad negative 1100 erlotinib PD 56.3 5.63 2.16 30 Ad negative 2000 erlotinib PD 15.6 0.85 0.292 31 Ad negative 825 erlotinib PD 8.27 1.59 2.13 32 Ad Ex21 L858R 0 erlotinib PD 5.34 7.05 1.7 33 Ad negative 1680 erlotinib PD 57.7 1.63 2.06", "label": "sensitivity"}
{"id": "24455544", "sentence": "When considering a change in therapy , it is important to consider a BCR-ABL kinase domain mutational analysis. [ ] @GENE$ mutation T315I is resistant to all of the currently approved TKIs . Some mutations ( Y253H , E255K/V , and F359V/C ) are less sensitive to nilotinib , and others ( @VARIANT$ and V299L ) are less sensitive to @DRUG$ .", "label": "None"}
{"id": "25296354", "sentence": "@GENE$ TKIs ( gefitinib , @DRUG$ , and afatinib ) lead to responses in most patients with advanced NSCLCs harboring sensitizing EGFR activating mutations when given as first or further lines of treatment . It is important to note that the most predominant somatic mutations that were included in these trials were EGFR exon 19 deletions ( the most common is delE746_A750 ) and @VARIANT$ ; therefore , all current genomic based approvals for EGFR TKIs are limited to tumors with the aforementioned classic mutations .", "label": "sensitivity"}
{"id": "22751098", "sentence": "To test this hypothesis and to clinically validate our preclinical findings , we measured the expression of AXL by IHC ( immunohistochemistry ) in 35 matched EGFR-mutant NSCLC specimens obtained from patients both prior to treatment with the EGFR TKIs erlotinib or @DRUG$ and upon the development of @GENE$ TKI acquired resistance . In cases where enough material was available for additional studies , we also examined the specimens for GAS6 and vimentin ( as a marker for EMT ) expression by IHC ( scoring system shown in ) , EGFR @VARIANT$ by sequencing , and MET amplification by FISH .", "label": "resistance or non-response"}
{"id": "22039538", "sentence": "In S. pneumoniae @DRUG$ extracts the following phosphorylated metabolites were detected : @VARIANT$ , FBP , 3-PGA , PEP , α-Gal1P , α-G1P , TBP , UDP-Glc , UDP-N-acetylmuramoyl-pentapeptide , UDP-N-acetylglucosamine , UDP-glucosamine , CDP-choline , NAD+ , @GENE$ , ATP and ADP .", "label": "None"}
{"id": "17973572", "sentence": "Transient transfection experiments utilizing COS-7 cells demonstrated that auto-phosphorylation of the original @VARIANT$ EGFR was inhibited by lower concentrations of @DRUG$ or erlotinib than the L858R-L747S or L858R-T790M constructs ( A ) . CL-387,785 partially overcame the observed inhibition ( B ) . To prove the functional significance of the L747S mutation , we generated @GENE$ cell lines stably expressing mutant EGFR constructs [ ] .", "label": "None"}
{"id": "20126530", "sentence": "However , a higher concentration of E2 ( 1.0 nM ) prolonged APD ( 168.89 ms ) ( Figure @VARIANT$ – left panel ) . For endocardial cells , APD is lengthened by 1 nM E2 from 184.22 ms ( 0 nM E2 ) to 189.54 ms. APD is slightly increased to 184.95 ms in the presence of 0.1 nM E2 . Figure S2B shows that @DRUG$ reduced APD @GENE$ nM to 157.64 ms in epicardial and 175.79 ms in endocardial cell .", "label": "None"}
{"id": "17551678", "sentence": "The relation of @DRUG$ treatment and JAK2 mutation is explored by Jones et al. in 9 PV patients for whom pre-treatment samples were available [ ] . There are two cases that achieved complete haematologic remission and a 2–3-fold reduction in the percentage of @VARIANT$ alleles . According to these authors , the observed clinical benefit may be a consequence of @GENE$ rather than JAK2 inhibition .", "label": "None"}
{"id": "21188109", "sentence": "Cyclin D1 , in association with cyclin dependent kinase-4 and -6 , induces the cell to enter the S phase by phosphorylating the retinoblastoma tumor suppressing protein , which binds to transcription factors , including @VARIANT$ . In addition to the overexpression of cyclin D1 , other genes that overexpress in MCL , such as @GENE$ and Raf-1 , represent further possible targets for mTOR inhibitors . Indeed , a constitutive activation of Akt and mTOR pathways either in MCL cell lines ( Granta 519 , Jeko-1 , and SP-53 ) or in primary cultures from 30 % of MCL patients has been reported. , Moreover , mTOR inhibitors in MCL could synergize with other “canonical” agents , such as vincristine , doxorubicin , bortezomib , and @DRUG$ , with resulting inhibition of Raf-1 , MAPK , and mTOR . ,", "label": "None"}
{"id": "21333004", "sentence": "In this study , we used experimental and computational approaches to investigate regulatory mechanisms that distinguish cell-specific @DRUG$ sensitivity in H1299 human NSCLC cell lines . We have modified the existing kinetic model of the @GENE$ signaling pathway and built new models for H1299 wild type ( H1299WT ) , H1299 with overexpressed wild type EGFR ( H1299EGFR-WT ) , and H1299 overexpressing the EGFR with @VARIANT$ mutation ( H1299L858R ) .", "label": "sensitivity"}
{"id": "23091721", "sentence": "Although attempts at developing drugs targeting @GENE$ have largely been unsuccessful , several BRAF inhibitors have been discovered . Sorafenib is an oral multikinase inhibitor that targets both wtBRAF and oncogenic BRAF @VARIANT$ and has in vitro activity in CRC cell lines with this mutation . The NEXIRI phase II trial combining sorafenib with @DRUG$ showed that this combination in patients with chemotherapy-resistant mutKRAS tumors has encouraging activity .", "label": "None"}
{"id": "17177598", "sentence": "However , @DRUG$ did induce dose dependent cell death in @GENE$ subclones expressing the EGFR ectodomain mutants ( missense and vIII truncation ) or EGFR kinase domain mutants ( @VARIANT$ and L861Q ) ( A ) .", "label": "None"}
{"id": "23888935", "sentence": "@DRUG$ is a novel , synthetic , orally active , potent pan–BCR-ABL inhibitor and multi targeted TKI that was discovered using a computational and structure based drug design approach.– Ponatinib was specifically designed to inhibit native @GENE$ and mutant forms that can arise during treatment with other TKIs and cause resistance , including the @VARIANT$ gatekeeper mutant .", "label": "None"}
{"id": "23776354", "sentence": "Activating mutations Frequency at diagnosis , Predictive value for @DRUG$ Secondary mutations of imatinib resistance , – Predictive value for sunitinib KIT Exon 9 10 % 70 % –75 % 58 % Exon 11 67 % 90 % –95 % 34 % Exon 13 1 % ± Yes + Exon 14 0 % Yes + Exon 17 1 % ± Yes − Exon 18 0 % Yes − @GENE$ 33 % –60 % Exon 12 1 % + Exon 14 & lt ; 1 % + Exon 18 5 % ± excepted for @VARIANT$ Yes − for D842V", "label": "resistance or non-response"}
{"id": "23429289", "sentence": "In addition to the wild-type TRAIL construct containing the consensus TRAIL cDNA sequence , we integrated two TRAIL-R-specific variants , one selective for @GENE$ ( DR4 ) and one for TRAIL-R2 ( DR5 ) into our expression construct . These variants were designed by using the automatic design algorithm FOLD-X and have been previously described and tested as recombinant proteins ( without the ILZ ) . One amino-acid sequence change was introduced into the TRAIL segment , namely an aspartate to @DRUG$ change at position 269 ( D269H ) to generate the DR5-specific variant ( sTRAILDR5 ) , whereas the DR4-specific variant ( sTRAILDR4 ) was generated by a serine to argenine change at position 159 ( @VARIANT$ ) ( ) .", "label": "None"}
{"id": "17973572", "sentence": "After the cells were exposed to gefitinib for 24 h , Ba/F3-L858R cells were unable to proliferate while Ba/F3-L858R-L747S and @GENE$ cells continued to grow even in the presence of 1 μM @DRUG$ ( E ) . These results suggest that execution of apoptosis may be impaired by the presence of @VARIANT$ and , to a lesser extent , L747S .", "label": "None"}
{"id": "23567620", "sentence": "Finally , although molecularly targeted therapies ( that is , gefitinib or @DRUG$ for @GENE$ and crizotinib for ALK fusions ) are effective in NSCLC , intrinsic or acquired resistances inevitably lead to recurrence and/or metastatic dissemination . This is the case of MET activation/amplification , , or acquired somatic mutations of EGFR ( T790M ) or ALK fusions ( @VARIANT$ , L1196M and ALK amplification ) . , ,", "label": "None"}
{"id": "21970876", "sentence": "For example , in glioblastoma and non-small-cell lung carcinoma ( NSCLC ) patients the presence of EGFRvIII or @VARIANT$ @GENE$ was found to be associated with resistance to treatment with @DRUG$ and erlotinib , respectively ( ; ; ) .", "label": "resistance or non-response"}
{"id": "25580271", "sentence": "When cross-over to @GENE$ tyrosine kinase inhibitor therapy was examined , 75 % of patients who received cisplatin and pemetrexed received an EGFR tyrosine kinase inhibitor and 56 % of patients who received @DRUG$ and gemcitabine received an EGFR tyrosine kinase inhibitor . The rate of second-line EGFR tyrosine kinase inhibitors in countries with insurance coverage was 91 % and without insurance coverage was 52 % . Overall survival of patients with common EGFR mutations ( defined as exon 19 deletion and exon 21 @VARIANT$ point mutation ) in LUX-3 , LUX-6 , and combined cohorts [ ]", "label": "None"}
{"id": "23937717", "sentence": "Our results suggest that making use of immunoregulatory property of @DRUG$ may be a potential new therapeutical option for lung cancer with @GENE$ L858 + @VARIANT$ resistance mutation .", "label": "resistance or non-response"}
{"id": "24386407", "sentence": "Several strategies have been proposed to overcome resistance to reversible EGFR-TKIs , including treatment with @DRUG$ , an anti-EGFR antibody [ ] , Hsp90 inhibitors [ ] , PI3K/mTOR inhibitor [ ] , and mutant-selective @GENE$ [ ] . Of them , mutant-selective EGFR-TKIs have shown activity not only against tumors harboring exon19 deletions and the @VARIANT$ mutation , but against tumors with the T790M resistance mutation .", "label": "sensitivity"}
{"id": "24348666", "sentence": "Interestingly , it was discovered that the @VARIANT$ mutation does not confer resistance to gefitinib and @DRUG$ by preventing their binding as originally thought . Instead , the T790M mutation induces resistance by increasing the binding affinity of ATP by one order of magnitude , which is near the affinity for wild-type @GENE$ , thus enabling ATP to compete effectively with the kinase inhibitors .", "label": "resistance or non-response"}
{"id": "15737014", "sentence": "Such mutations rarely , if ever , accompany @GENE$ mutations and are associated with primary resistance to @DRUG$ or erlotinib [ ] . To evaluate the possibility that secondary KRAS mutations confer acquired resistance to these drugs , we performed mutational profiling of KRAS2 exon 2 from tumor specimens from patients 1 to 3 , as well as the three additional patients lacking evidence of the T790M mutation . An Established NSCLC Cell Line Also Contains Both T790M and @VARIANT$ Mutations", "label": "sensitivity"}
{"id": "23566546", "sentence": "Case Histrogical type @GENE$ mutation status Brinkman index Treatment agent Response IL-8 ( ng/mL ) IL-10 ( ng/mL ) RANTES ( pg/ml ) 1 Ad Ex21 @VARIANT$ 900 gefitinib PR 5.79 1.67 2 2 Ad Ex21 L858R 0 erlotinib PR_3.33 94.2 1.41 3 Ad Ex19 del 0 erlotinib PR 4.09 126 2.13 4 Ad Ex21 L858R 0 gefitinib PR_3.92 18.1 1.85 5 Ad Ex21 L858R + Ex19 del 370 erlotinib PR 21.9 1.23 2.11 6 Ad Ex19 del 0 erlotinib PR 7.05 1.37 2.56 7 Ad Ex19 del 0 gefitinib PR 4.82 1.59 2.02 8 Ad Ex21 L858R 1640 gefitinib PR 54.9 2.7 2.38 9 Ad negative 400 erlotinib SD 34.9 3.39 3.66 10 Ad negative 0 erlotinib SD 27.1 4.94 2.25 11 Ad unknown 1800 erlotinib SD NE NE NE 12 Sq Ex19 del 3840 gefitinib SD 12.6 1.1 1.98 13 Ad Ex19 del 30 erlotinib SD 5.27 0.69 2.66 14 Ad Ex19 del 0 erlotinib SD 10.5 0.85 2.5 15 Ad unknown 300 erlotinib SD 7.69 2.61 1.7 16 La negative 2080 erlotinib SD NE NE NE 17 Sq Ex21 L858R 750 erlotinib SD 11.6 56.3 3.06 18 Ad unknown 600 erlotinib SD 13.7 1.1 2.82 19 Ad Ex21 L858R 0 erlotinib SD 20.6 11.6 0.783 20 Ad Ex19 del 0 erlotinib SD 14.8 2.07 2.02 21 Ad Ex21 L858R + Ex19 del 0 gefitinib SD 3.04 1.3 1.76 22 Ad Ex19 del 200 gefitinib SD 10.9 1.59 1.91 23 Sq unknown 1560 erlotinib PD NE NE NE 24 Ad negative 1080 erlotinib PD 25.2 8.15 1.57 25 Ad unknown 0 erlotinib PD NE NE NE 26 Ad Ex18 G719A 2000 erlotinib PD 11.6 4.48 3.12 27 Ad unknown 1410 @DRUG$ PD NE NE NE 28 Ad Ex19 del 1000 gefitinib PD 9.44 2.25 2.89 29 Ad negative 1100 erlotinib PD 56.3 5.63 2.16 30 Ad negative 2000 erlotinib PD 15.6 0.85 0.292 31 Ad negative 825 erlotinib PD 8.27 1.59 2.13 32 Ad Ex21 L858R 0 erlotinib PD 5.34 7.05 1.7 33 Ad negative 1680 erlotinib PD 57.7 1.63 2.06", "label": "sensitivity"}
{"id": "16187797", "sentence": "This compound was previously found to be active against @GENE$ containing the exon 20 point mutation @VARIANT$ , associated with resistance to gefitinib and @DRUG$ [ ] .", "label": "resistance or non-response"}
{"id": "19238210", "sentence": "21 @VARIANT$ T790M 2.8 25.0 26 shows the clinico-pathologic and molecular data for the 10 NSCLC cell lines , which harbor @GENE$ mutations . These cell lines are arranged in decreasing order of @DRUG$ sensitivity .", "label": "sensitivity"}
{"id": "23805327", "sentence": "We anticipate that DISSECT-PNA-LNA PCR will prove useful in detecting low-level mutations in tumor tissue prior to , or after administering @DRUG$ treatment to NSCLC patients . Moreover , the combined method can be used to detect other mutations , such as those identified in KRAS via FLAG ( Fluorescent Amplicon Generation ) or CO-amplification at Lower Denaturation temperature-PCR ( COLD-PCR ) – , or other @GENE$ mutations in NSCLC ( ie . @VARIANT$ EGFR mutation ) to help improve lung cancer diagnosis and follow-up treatment options .", "label": "sensitivity"}
{"id": "23994953", "sentence": "Intense research efforts over the past few years have identified two major mechanisms of acquired resistance to gefitinib/erlotinib : secondary resistance mutations ( e.g. , @VARIANT$ ) and “oncogene kinase switch” systems ( e.g. , MET amplification and AXL activation ) . However , the precise mechanisms underlying acquired resistance in the 30–40 % of EGFR TKI-resistant @GENE$ mutated tumors that do not carry secondary resistance mutations or MET amplification remain largely unclear .", "label": "resistance or non-response"}
{"id": "24591840", "sentence": "Using a cell viability assay , BEZ235 has also demonstrated an additive effect when combined with dexamethasone , doxorubicin , and @DRUG$ . In a recent preclinical study , BEZ235 has been shown to be effective against follicular lymphoma cell lines . BEZ235 successfully inhibited @GENE$ , mTOR , and @VARIANT$ phosphorylation in K422 , SUDHL16 , FL-18 , and SUDHL4 cell lines .", "label": "None"}
{"id": "25275314", "sentence": "To prepare the mutants , we mutated arginines of the WT sequence inside the transformed PKA model and obtained the models that contain @GENE$ and the peptides LARASLG ( R18A ) , LRAASLG ( R19A ) , LKRASLG ( R18K ) , LRKASLG ( R19K ) , LHRASLG ( R18H ) , and LRHASLG ( @VARIANT$ ) . We also prepared the models including the shorter chain peptides RRASLG , RASLG , and LRRASL . For the mutants that contain @DRUG$ we prepared the models containing neutral histidine with the hydrogen atoms at position δ or ε ( Hδ and Hε ) , and the models containing the protonated histidine Hp ( see the next section ) .", "label": "None"}
{"id": "25566506", "sentence": "Similarly , the H792D2-down small cell lung cancer cells had 58 % viable cells and the @VARIANT$ had 86 % viable , 48 h post treatment ( Figure B ) . Analysis of cell viability post treatment of small cell lung cancer cells with @GENE$ inhibitor @DRUG$ ( navitoclax ) .", "label": "None"}
{"id": "23056078", "sentence": "It has been suggested that ALL patients with the 3435 CC genotype of the MDR1 gene could more efficiently eliminate P-gp substrates such as anthracyclines , daunorubicin , @DRUG$ and mitoxantrone , resulting in poor prognosis [ ] . We would like to evaluate the association between the MDR1 @VARIANT$ , MRP2 G1249A and/or @GENE$ G34A SNPs and response to specific chemotherapy regimens in our pediatric ALL patient population .", "label": "None"}
{"id": "21165163", "sentence": "These measured changes in apparent Ki therefore provide a mechanism for selective inhibition of mutant @GENE$ by small molecules such as @DRUG$ and imatinib [ ] . Alterations in ATP dependent reaction rates and inhibitor binding affinities are probably the mechanism for acquired resistance by the @VARIANT$ mutation [ ] .", "label": "resistance or non-response"}
{"id": "23904849", "sentence": "The @VARIANT$ mutation was not found in our patient ; it seems that the expression of the mutation does not occur at a high frequency . Validation of the available evidence and clarification of its clinical significance through clinical studies is anticipated . In summary , the present case implies that there are likely to be multiple or unknown mechanisms of drug resistance of @GENE$ targeting antibodies , including @DRUG$ .", "label": "response"}
{"id": "22087316", "sentence": "In addition , Y321N increases resistance to cyclosporine , and all of the nonsynonymous mutations removing tyrosine in our study occurred at this position ( @VARIANT$ ) , and Y321C increased the replicative fitness of HCV in the presence of cyclosporine A ( ) . @DRUG$ and reactive species also generated mutations in the @GENE$ T cell-specific epitopes previously associated with treatment response ( ) .", "label": "None"}
{"id": "24724051", "sentence": "In addition , the recently approved @DRUG$ is active against the most common mutation that causes resistance to both first and second generation @GENE$ TKIs , the “gatekeeper” @VARIANT$ mutation ( Table ; Figure ) .", "label": "response"}
{"id": "22292001", "sentence": "( E ) Schematic diagram for Fbh1 WT and Fbh1-D485N ( the helicase-dead form ) , Fbh1-L14A P15A and @GENE$ L26A ( the F-box-deficient form ) mutant proteins . ( F ) Sensitivity to 5 µM CPT ( @DRUG$ ) was tested for the indicated strains . ( G ) fbh1-D485N and fbh1-P15A @VARIANT$ mutants exhibited the bent-spindle phenotype , whereas fbh1-L14A P15A did not .", "label": "None"}
{"id": "23994953", "sentence": "However , it should be noted that these studies were largely based on NSCLC cells expressing wild-type EGFR ; therefore , these studies did not mimic clinical usage of EGFR TKIs because EGFR wild-type NSCLC cells are intrinsically resistant to @GENE$ TKIs . In this scenario , it might appear reasonable to suggest that in addition to the presence of the @VARIANT$ mutation , immunohistochemical and/or microarray based transcriptional profiling studies dedicated to specific alterations of EMT drivers ( e.g. , SLUG ) and/or effectors ( e.g. , vimentin ) may be helpful in monitoring for @DRUG$ responders and non-responders based on the loss of biomarkers associated with epithelial status and gain of biomarkers associated with mesenchymal status .", "label": "resistance or non-response"}
{"id": "22363766", "sentence": "EGFR TKIs ( such as erlotinib or @DRUG$ ) are selective inhibitors of @GENE$ 's kinase domain that work by competing with ATP for binding at the ATP binding site , thereby preventing autophosphorylation and activation . The @VARIANT$ mutation affects the gatekeeper residue in the catalytic kinase domain and confers drug resistance by increasing EGFR 's affinity for ATP – thus reducing the potency of the ATP-competitive kinase inhibitors .", "label": "resistance or non-response"}
{"id": "23922685", "sentence": "By the sequential action of cinnamoyl-CoA reductase (CCR) , ferulate 5-hydroxylase ( @VARIANT$ ) , caffeic acid 3-O-methyltransferase ( COMT ) and cinnamyl @DRUG$ dehydrogenase ( CAD ) , the @GENE$ thioesters are converted into p-coumaryl , coniferyl and sinapyl alcohols .", "label": "None"}
{"id": "24276379", "sentence": "On the other hand , there are a number of in vitro results that show that cells possessing the @GENE$ @VARIANT$ mutation are resistant to @DRUG$ [ , ] .", "label": "resistance or non-response"}
{"id": "23864840", "sentence": "However , acquired resistance to EGFR-TKIs is inevitable due to various mechanisms , such as @VARIANT$ , c-Met amplification , activation of alternative pathways ( IGF-1 , @GENE$ , PI3CA , AXL [ ] ) , transformation to mesenchymal cells [ ] or small cell features [ ] , and tumor heterogeneity [ ] . A randomized trial comparing the irreversible ErbB-family blocker @DRUG$ versus placebo in patients with NSCLC after prior EGFR-TKI exposure failed to prove a benefit of overall survival [ ] .", "label": "None"}
{"id": "24789720", "sentence": "The new therapy methods , which could be effective in patients with @VARIANT$ mutation includes irreversible @GENE$ ( afatinib , neratinib ) . In LUX-Lung 1 study in patients after failure of @DRUG$ or gefitinib treatment with afatinib led to partial responses and prolongation of progression-free survival compared to placebo to 3,3 months [ , ] .", "label": "resistance or non-response"}
{"id": "23533466", "sentence": "H1975 cancer cell line with mutations in EGFR exons 21 ( L858R ) and 20 ( @VARIANT$ ) was refractory to reversible EGFR-TKIs , gefitinib , and @DRUG$ [ ] , but was sensitive to irreversible @GENE$ , such as BIBW2992 ( afatinib ) .", "label": "resistance or non-response"}
{"id": "23788917", "sentence": "In vitro studies demonstrated that the effective concentration of @DRUG$ in tumour cells harbouring both the @VARIANT$ and T790M mutations has to be 300 times higher to induce apoptosis than in cells only with an activating mutation in codon 858 [ , ] . Presence of a mutation in exon 20 of the @GENE$ gene is a potential prognostic and predictive marker of EGFR TKI therapy and may play an important role in the planning of therapy .", "label": "sensitivity"}
{"id": "25221748", "sentence": "In the advanced NSCLC EGFR-TKI resistant setting , the HSP90 small molecule inhibitor AUY922 is being evaluated as monotherapy in a phase II clinical trial vs. pemetrexed or @DRUG$ in patients with tumors with activating @GENE$ mutations ( www.clinicaltrials.gov : NCT016461250 ) . This agent is also being assessed in a phase II trial in patients with de novo resistant @VARIANT$ mutations not previously treated with EGFR-TKIs ( www.clinicaltrials.gov : NCT01854034 ) and in patients with EGFR mutations and/or EGFR-TKI resistant disease , as part of a phase II cluster study in Chinese patients evaluating five novel inhibitors of HSP90 , PI3K , ALK , MET , and MEK ( ) .", "label": "None"}
{"id": "23922791", "sentence": "In CML , this can result from further point mutations leading to additional changes in @GENE$ , for example T315I , @VARIANT$ , and F255K . In GIST , secondary KIT mutations in exons 13 , 14 , or 17 other than exon 11 are reported to be important events in acquired @DRUG$ resistance .", "label": "None"}
{"id": "23986642", "sentence": "@DRUG$ inhibited native ABL with an IC50 of 0.37 nM and clinically relevant @GENE$ mutations @VARIANT$ , G252H , T253P , M351T , and H396A with IC50 values of 2.0 nM , 0.44 nM , 0.30 nM , 0.30 nM , and 0.35 nM , respectively .", "label": "None"}
{"id": "24321281", "sentence": "For example , BRCA1 can inhibit @DRUG$ receptor (PR) activity in the PR-positive human breast cancer cell line @VARIANT$ [ , ] and repress @GENE$ in MCF-7 cells [ ] .", "label": "None"}
{"id": "23374602", "sentence": "Regarding @GENE$ , the same group reported in a pooled dataset of 579 @DRUG$ treated CRC patients that those with codon 13 KRAS mutant tumours ( @VARIANT$ ) had better outcomes ( HR for death 0.50 ) compared to patients with other KRAS mutant tumours [ ] .", "label": "resistance or non-response"}
{"id": "25486409", "sentence": "These results suggest that the addition of CX-4945 to EGFR-TKI may overcome @VARIANT$ mediated resistance through the increased activity of EGFR-TKI to suppress EGFR signals by the down-regulation of EGFR . 10.1371/journal.pone.0114000.g004Addition of CX-4945 to @GENE$ substantially suppressed the EGFR signaling pathway in gefitinib/erlotinib-resistant , PC-9 cells .", "label": "resistance or non-response"}
{"id": "21192840", "sentence": "Intriguingly , @DRUG$ treated NSCLC that metastasized to the liver and the central nervous system ( CNS ) acquired the @VARIANT$ mutation in the primary tumor and liver metastases , conferring drug resistance to these tumors , whereas the CNS tumors that did not acquire this mutation remained sensitive to erlotinib . In addition , somatic mutations in K-Ras are very rare in GBM but occur at a high frequency in NSCLC . This pattern may indicate a situation in which tumors are dependent on @GENE$ in both settings , but perhaps in unique and different ways that are dictated by the specific tumor type , genetic context , and/or microenvironment in which they must adapt .", "label": "resistance or non-response"}
{"id": "22815900", "sentence": "@GENE$ mutation status including wild-type ( WT ) , E746-A750 del ( del ) , L858R and @VARIANT$ was determined by both IHC and RNA-LNA PCR clamp assays with 11 clinical samples of cancer patients refractory to @DRUG$ treatment .", "label": "resistance or non-response"}
{"id": "21437184", "sentence": "An additional retrospective analysis of 113 patients treated with antiEGFR monoclonal antibodies found the @VARIANT$ BRAF mutation in 14 % of the KRAS WT patients and was associated with no response to therapy and a statistically significant shorter progression-free survival and overall survival compared with BRAF WT patients [ ] . In De Roock 's retrospective analysis of tumor samples from patients treated with @DRUG$ plus chemotherapy , a @GENE$ mutation was discovered in 4.7 % of tumors [ ] .", "label": "resistance or non-response"}
{"id": "23691449", "sentence": "Such mutations include multiple overlapping deletion mutations of exon 19 in 45 % of patients , point mutations in exon 21 in 40 % of patients ( predominantly @VARIANT$ ) , and point or insertion mutations in exons 18 to 21 in the remaining 15 % of patients [ ] . Clinical trials on @DRUG$ efficacy for advanced NSCLC with EGFR mutations in Japan were summarized by Morita et al. [ ] A total of 148 NSCLC patients with @GENE$ mutations from seven eligible trials were identified .", "label": "sensitivity"}
{"id": "23566546", "sentence": "Case Histrogical type @GENE$ mutation status Brinkman index Treatment agent Response IL-8 ( ng/mL ) IL-10 ( ng/mL ) RANTES ( pg/ml ) 1 Ad Ex21 @VARIANT$ 900 gefitinib PR 5.79 1.67 2 2 Ad Ex21 L858R 0 @DRUG$ PR_3.33 94.2 1.41 3 Ad Ex19 del 0 erlotinib PR 4.09 126 2.13 4 Ad Ex21 L858R 0 gefitinib PR_3.92 18.1 1.85 5 Ad Ex21 L858R + Ex19 del 370 erlotinib PR 21.9 1.23 2.11 6 Ad Ex19 del 0 erlotinib PR 7.05 1.37 2.56 7 Ad Ex19 del 0 gefitinib PR 4.82 1.59 2.02 8 Ad Ex21 L858R 1640 gefitinib PR 54.9 2.7 2.38 9 Ad negative 400 erlotinib SD 34.9 3.39 3.66 10 Ad negative 0 erlotinib SD 27.1 4.94 2.25 11 Ad unknown 1800 erlotinib SD NE NE NE 12 Sq Ex19 del 3840 gefitinib SD 12.6 1.1 1.98 13 Ad Ex19 del 30 erlotinib SD 5.27 0.69 2.66 14 Ad Ex19 del 0 erlotinib SD 10.5 0.85 2.5 15 Ad unknown 300 erlotinib SD 7.69 2.61 1.7 16 La negative 2080 erlotinib SD NE NE NE 17 Sq Ex21 L858R 750 erlotinib SD 11.6 56.3 3.06 18 Ad unknown 600 erlotinib SD 13.7 1.1 2.82 19 Ad Ex21 L858R 0 erlotinib SD 20.6 11.6 0.783 20 Ad Ex19 del 0 erlotinib SD 14.8 2.07 2.02 21 Ad Ex21 L858R + Ex19 del 0 gefitinib SD 3.04 1.3 1.76 22 Ad Ex19 del 200 gefitinib SD 10.9 1.59 1.91 23 Sq unknown 1560 erlotinib PD NE NE NE 24 Ad negative 1080 erlotinib PD 25.2 8.15 1.57 25 Ad unknown 0 erlotinib PD NE NE NE 26 Ad Ex18 G719A 2000 erlotinib PD 11.6 4.48 3.12 27 Ad unknown 1410 erlotinib PD NE NE NE 28 Ad Ex19 del 1000 gefitinib PD 9.44 2.25 2.89 29 Ad negative 1100 erlotinib PD 56.3 5.63 2.16 30 Ad negative 2000 erlotinib PD 15.6 0.85 0.292 31 Ad negative 825 erlotinib PD 8.27 1.59 2.13 32 Ad Ex21 L858R 0 erlotinib PD 5.34 7.05 1.7 33 Ad negative 1680 erlotinib PD 57.7 1.63 2.06", "label": "sensitivity"}
{"id": "21165163", "sentence": "Median PFS and OS for the 217 patients who received erlotinib were 14 and 27 months , patients with @VARIANT$ had longer PFS than patients with exon 19 deletions and outcomes did not seem to differ whether erlotinib was given in the first or second-line setting . A combined survival analysis ( I-CAMP ) of seven prospective Japanese trials of 148 patients with @GENE$ mutations who received @DRUG$ demonstrated a response rate of 76.4 % , median PFS of 9.7 months and overall survival of 24.3 months [ ] .", "label": "sensitivity"}
{"id": "17973572", "sentence": "BIM expression correlated with the amount of apoptosis in @VARIANT$ , L858R-L747S , and L858R-T790M cells . ( B ) Modulation of signaling following @DRUG$ treatment in @GENE$ cells expressing EGFR mutants .", "label": "None"}
{"id": "22829915", "sentence": "For example , substitution of two catalytic @DRUG$ residues with phenylalanine ( H87F and @VARIANT$ ) produces a catalytically inactive @GENE$ , referred to as rny1-ci .", "label": "None"}
{"id": "24634705", "sentence": "The @VARIANT$ mutation is hypothesized to induce steric interference of @DRUG$ binding similar to those in @GENE$ and EGFR [ , ] .", "label": "None"}
{"id": "23674887", "sentence": "Bosutinib effectively targets most IM-resistance conferring @GENE$ mutations , with the exception of the highly resistant T315I ( resistant to IM , dasatinib , nilotinib , and bosutinib ) and @VARIANT$ mutations ( resistant to dasatinib and @DRUG$ ) .", "label": "None"}
{"id": "24586842", "sentence": "Successful examples of this include the co-development ( and co-approval ) of the BRAF inhibitor vemurafenib and its companion diagnostic BRAF @VARIANT$ mutation assay for BRAF-mutant metastatic melanoma , and the @GENE$ inhibitor crizotinib and its companion diagnostic ALK fusion gene test in advanced ALK-fusion positive non-small cell lung cancer ( NSCLC ) patients. , , However , in some cases , predictive biomarkers for a targeted therapy are not recognized until after the drug is first approved . As an example , the anti-EGFR antibody @DRUG$ was first approved in the US for the treatment of metastatic colorectal cancer in 2004 .", "label": "None"}
{"id": "23937717", "sentence": "B ) . Those results suggested that @DRUG$ enhanced cytotoxicity of NK cells to human lung cancer with @GENE$ @VARIANT$ + T790M .", "label": "sensitivity"}
{"id": "24790411", "sentence": "Eight patients enrolled in the study were known to harbor a @VARIANT$ mutation on archival tissue collected at diagnosis , but authors provided no information on the outcome of these patients . It is likely that better selection on the basis of @GENE$ mutational status and acquired resistance mechanism would have translated into positive results also for the principal end point ( OS ) . LUX-Lung 4 is an exploratory Phase II trial in Japanese patients with advanced lung adenocarcinoma who failed one to two lines of chemotherapy and progressed on erlotinib and/or @DRUG$ .", "label": "resistance or non-response"}
{"id": "25505694", "sentence": "In 2004 , EGFR gene mutations were firstly identified : classical activating EGFR mutations are localized in exon 19 , mainly consisting of an in-frame deletion ( 45-50 % ) , and in exon 21 , consisting of the @VARIANT$ point mutation ( 40-45 % ) , even if there are less common mutations localized in other exons [ – ] . Since their identification , it was clear that EGFR mutations , more frequently observed in never smokers , adenocarcinoma histology , women and Asiatic patients , outline a distinct subgroup of NSCLC . During the last years , six phase III trials ( Table ) established that patients harboring activating @GENE$ mutations benefit more from a first line treatment with an EGFR tyrosine kinase inhibitor ( TKI ) , such as erlotinib or @DRUG$ , than from standard chemotherapy , at least in terms of response rate ( RR ) , progression-free survival ( PFS ) and quality of life [ – ] .", "label": "sensitivity"}
{"id": "25155131", "sentence": "@DRUG$ IgG ) and IgM assays for anti-cardiolipin and @GENE$ antibodies were below diagnostic values , as were anti-nuclear antibody tests . However , the patient’s serum homocysteine levels were markedly high at 70μmol/L ( normal 4μmol/L to 12μmol/L ) . The results of a test for the methyltetrahydrofolate reductase (MTHFR) gene was negative for any remarkable polymorphisms , including the @VARIANT$ mutation .", "label": "None"}
{"id": "24252457", "sentence": "A predictor of TKI resistance [ , ] , a mutation at exon 20 ( @VARIANT$ ) was also identified in 4.2 % of these patients . Among patients who harbored activating @GENE$ mutations on exon 19 and 21 , a noticeably increased ORR in patients who received @DRUG$ was found when compared with those who received chemotherapy ( 71.2 % vs. 47.3 % , p & lt ; 0.001 ) .", "label": "resistance or non-response"}
{"id": "25538894", "sentence": "For neratinib , a phase II trial showed disappointing results ( ) and the dacomitinib data showed possible benefit in patients with @DRUG$ resistance ( ) , but further investigations are necessary . In preclinical studies , third-generation @GENE$ inhibitors ( WZ4002 and CO-1686 ) showed hopeful results , with activity against @VARIANT$ mutations and sparing wild-type EGFR ( – ) .", "label": "resistance or non-response"}
{"id": "25364578", "sentence": "Lazzara and colleagues found that SHP2 Y542 phosphorylation was not induced in response to EGF in the H3255 cells , which harbor the missense @VARIANT$ exon 21 mutation , suggesting that SHP2 activity may be less efficiently promoted by EGFR L858R and the STAT3 pathway may be more active . The main problem is that @GENE$ activation is not abrogated by single EGFR TKI treatment with gefitinib , erlotinib , @DRUG$ or dacomitinib , - .", "label": "None"}
{"id": "25505694", "sentence": "Overall , the study emphasize the potential role of @DRUG$ as an agent that do not necessarily select for @VARIANT$ mediated resistance and allow the sequential use of non-cross-resistant @GENE$ TKIs .", "label": "None"}
{"id": "25115383", "sentence": "@DRUG$ is an irreversible HER2/ErbB-family blocker that shows high affinity for @GENE$ @VARIANT$ mutation .", "label": "response"}
{"id": "23520442", "sentence": "However , it is unknown whether the status of EGFR mutation and downstream resistance related genes aberrances ( i.e. , KRAS mutations , @VARIANT$ , or c-MET amplification ) are consistent in pre- and post-chemotherapy samples . Therefore , it is necessary to evaluate the impact of chemotherapy on tumor molecular profiles . Chin et al reported that prior exposure to platinum agents may reduce the benefit from subsequent treatment with EGFR-TKI for an erlotinib-sensitive @GENE$ NSCLC cell via the phosphatidylinositol 3-kinase/AKT survival pathway .", "label": "resistance or non-response"}
{"id": "25429239", "sentence": "Other amino acid substitutions observed include @VARIANT$ , G1202R , and S1206Y substitutions , as well as a 1151 threonine insertion . Another described resistance mechanism involves amplification of the ALK fusion gene and activation of other bypass mechanisms.– KIT gene amplification and @GENE$ activation have also been reported as mechanisms of acquired @DRUG$ resistance. , ,", "label": "None"}
{"id": "23874486", "sentence": "In a multivariate analysis , patients with @VARIANT$ mutation tumors treated with @DRUG$ had longer overall survival ( median , 7.6 months vs 5.7 months ) and longer progression-free survival ( median , 4.0 months vs 1.9 months ) than other @GENE$ mutant tumors .", "label": "resistance or non-response"}
{"id": "15736989", "sentence": "Although there are many potential mechanisms for development of clinical resistance , most cases of imatinib-resistant CML are due to point mutations in the @GENE$ kinase domain itself , including @VARIANT$ [ , ] .", "label": "None"}
{"id": "22013387", "sentence": "These physiological effects of adenosine are mediated by a family of four G-protein coupled receptors : A1 , A2A , A2B , and A3 ( A1R , A2AR , A2BR , and @VARIANT$ ) , each of which has a unique pharmacological profile , tissue distribution , and effector coupling [ ] . Recently , Peng et al. reported that @DRUG$ mediated increases in extracellular adenosine , which act via @GENE$ A2BR , link the ingestion and metabolism of ethanol to the development of hepatic steatosis .", "label": "None"}
{"id": "25563355", "sentence": "The second-generation @GENE$ , such as dacomitinib and @DRUG$ , have shown promising effects in pre-clinical models , but limited activity in clinical trials for patients with acquired resistance to previous EGFR-TKIs , due to their toxicity . A new class of TKIs is under development to target @VARIANT$ .", "label": "response"}
{"id": "24959087", "sentence": "A final mechanism of resistance in gastric cancer cell lines has been demonstrated when MET amplified SNU6838 gastric cancer cell lines were treated with the MET inhibitors PHA-665752 and PF2341066 ; a novel mutation occurred in the activation loop of MET , causing a conformal change that blocked inhibitor binding analogous to the gatekeeper mutations seen in @GENE$ ( @VARIANT$ ) following @DRUG$ treatment and in ABL ( T315I ) following imatinib .", "label": "resistance or non-response"}
{"id": "23610714", "sentence": "@GENE$ mutations observed in patients with metastatic tumors are most frequently observed in exons 11 ( 67 % ) , 9 ( 10 % ) , 13 ( 1 % ) , or 17 ( 1 % ) , while platelet derived growth factor receptor-α ( PDGFRA ) mutations ( 10 % ) , which are less common than KIT mutations , occur mostly in exons 18 ( 6 % ) , 12 ( 0.7 % ) , or 14 ( 0.1 % ) . Mutational analysis is helpful in detecting the development of secondary mutations in tumors that are responding poorly to tyrosine kinase inhibitors and in identifying the PDGFRA exon 18 codon @VARIANT$ missense mutation , which is associated with a good prognosis , but conversely confers resistance to imatinib. , Exon 9 is reported to benefit from a high dose ( 800 mg/day ) of @DRUG$ in some studies .", "label": "None"}
{"id": "21165163", "sentence": "At least one study has demonstrated prolonged PFS with the combination of erlotinib with the MET TKI , ARQ197 as compared to @DRUG$ alone [ ] and phase III studies in the @GENE$ TKI-naïve setting are ongoing . Other strategies Several preclinical reports showed that other agents , such as the anti-EGFR monoclonal Ab cetuximab or PI3K/mTOR inhibitors combined with irreversible EGFR inhibitors hold promise to overcome resistance mediated by @VARIANT$ [ ] .", "label": "resistance or non-response"}
{"id": "24348397", "sentence": "The @GENE$ mutation @VARIANT$ , sporadic wild-type GISTs , mutations with succinate dehydrogenase or BRAF mutated GISTs are unlikely to respond to imatinib [ ] . Sunitinib is used as second-line treatment in advanced imatinib failed patients . Ongoing trials involve sorafenib , @DRUG$ , pazopanib , regorafenib and cediranib for advanced GISTs [ , , , , ] .", "label": "None"}
{"id": "24939055", "sentence": "The EGF receptor tyrosine kinase inhibitors ( @GENE$ ) gefitinib and @DRUG$ have shown marked therapeutic effects against NSCLCs with EGFR activating mutations , such as exon 19 deletions and @VARIANT$ point mutations [ ] .", "label": "sensitivity"}
{"id": "23836985", "sentence": "Jin et al also reported that the HDAC inhibitor , @DRUG$ , inhibits HDAC activity by downregulating cyclin D1 protein expression in colonic carcinoma cells in xenografted mice . In conclusion , our study confirms that valproic acid significantly suppresses growth of Kasumi-1 cell xenograft tumors in nude mice via cell cycle arrest . The antitumor activity of valproic acid is possibly attributable to its direct downregulation of cyclin D1 , CDK4/6 , and cyclin E1 expression , blockage of Rb phosphorylation , reduction of free @VARIANT$ , inhibition of HDAC activity , attenuation of histone acetylation in the p21 promoter region , upregulation of p21 expression , and induction of cell cycle arrest .", "label": "None"}
{"id": "15737014", "sentence": "This study revealed that the quinazoline rings of erlotinib and lapatinib interact differently with the @GENE$ kinase domain , suggesting that while the @VARIANT$ mutation may affect inhibition by @DRUG$ and gefitinib , it may not affect inhibition of EGFR by compounds similar to lapatinib .", "label": "resistance or non-response"}
{"id": "24924344", "sentence": "@DRUG$ ( A/T ) Chr16 : 56671632 MT1A ( near-gene 5 ) 0.047628 0.138 Oxaliplatin rs562 ( C/T ) Chr3 : 183637845 ABCC5 ( UTR3 ) 0.049494 0.392 rs3749445 ( A/G ) Chr3 : 183638506 ABCC5 ( UTR3 ) 0.044895 0.410 rs2292998 ( C/T ) Chr3 : 183663833 ABCC5 ( intronic ) 0.039882 0.277 rs1016752 ( C/G ) Chr3 : 183665062 ABCC5 ( intronic ) 0.039781 0.232 rs4148585 ( C/T ) Chr3 : 183670642 ABCC5 ( intronic ) 0.039781 0.283 rs6443924 ( A/G ) Chr3 : 183679532 ABCC5 ( intronic ) 0.039781 0.279 rs4148579 ( A/G ) Chr3 : 183685249 ABCC5 ( intronic ) 0.039781 0.279 rs939336 ( A/G =&gt ; @VARIANT$ ) Chr3 : 183685534 ABCC5 ( exonic ) 0.039781 0.279 rs1132776 ( C/T = & gt ; A395A ) Chr3 : 183696402 @GENE$ ( exonic ) 0.044895 0.289 rs2313212 ( C/T ) Chr3 : 183700928 ABCC5 ( intronic ) 0.039781 0.279 rs4148575 ( C/T ) Chr3 : 183702275 ABCC5 ( UTR3 ) 0.044895 0.289 rs1846692 ( C/T ) Chr16 : 56671696 MT1A ( near - gene 5 ) 0.049494 0.360 rs35346959 ( A/G ) Chr16 : 56671867 MT1A ( near- gene 5 ) 0.044895 0.137 rs9922957 ( C/G ) Chr16 : 56672380 MT1A ( near - gene 5 ) 0.039781 0.185 rs9922409 ( A/G ) Chr16 : 56672400 MT1A ( near - gene 5 ) 0.04532 0.103 rs7190725 ( G/T ) Chr16 : 56673290 MT1A ( intronic ) 0.044895 0.170 rs8052394 ( A/G =&gt ; K51R ) Chr16 : 56673828 MT1A ( missense ) 0.044895 0.152 rs1800566 ( C/T = & gt ; P187S ) chr16 : 69745145 NQO1 ( exonic ) 0.039781 0.258 rs689455 ( A/C ) Chr16 : 69761661 NQO1 ( near- gene 5 ) 0.039781 0.242", "label": "None"}
{"id": "24419415", "sentence": "Progression-free survival curves in the gefitinib group ( A ) and the carboplatin-paclitaxel group ( B ) according to the type of @GENE$ . DISCUSSION Recent studies suggest that NSCLC patients with uncommon EGFR mutations are less responsive to EGFR-TKIs compared with patients with @VARIANT$ and exon 19 deletions.– However , the efficacy of EGFR-TKIs in NSCLC patients with uncommon mutations has not been fully elucidated .", "label": "None"}
{"id": "25285017", "sentence": "Although more than 188 EGFR mutations have been identified , 85 % of TKI-sensitive clinical cases harbor only two major mutations : in-frame deletions of exon 19 ( 45 % –50 % ) and a point mutation @VARIANT$ in exon 21 ( 40 % –45 % ; ) . In addition , deletion mutation in exon 19 seems to have a better response to @DRUG$ and erlotinib than mutations at other sites. , Variations in the expression of enzymes associated with @GENE$ signaling may also account for diverse responses to EGFR inhibition .", "label": "sensitivity"}
{"id": "20849661", "sentence": "Five mutations led to amino acid changes , mostly yielding conserved mutations of @VARIANT$ ( valine to alanine ) and H130R ( @DRUG$ to arginine ) . Zhang et al. [ ] reported variants of BARF1 gene on EBV cell lines from EBV associated @GENE$ lymphoma showing change of G to A at the position of 165554 , change of T to C at 165589 , and change of T to C at 165545 .", "label": "None"}
{"id": "23690929", "sentence": "@GENE$ mutations , such as exon 19 deletion and exon 21 @VARIANT$ point mutation , are found in a population of NSCLC , and are associated with a clinical response to the EGFR tyrosine kinase inhibitors ( EGF-TKIs ) , gefitinib and @DRUG$ – .", "label": "sensitivity"}
{"id": "25295230", "sentence": "The first case report described a novel FLT3-TKD mutation @VARIANT$ , discovered at relapse in an FLT3-ITD AML patient after midostaurin monotherapy ( ) . 32D cells transfected with ITD-N676K FLT3 confirmed in vitro resistance to midostaurin , relative to cells transfected with FLT3-ITD . @GENE$ cells with ITD-A848P FLT3 were resistant to both @DRUG$ and sorafenib , but maintained sensitivity to midostaurin .", "label": "None"}
{"id": "24982846", "sentence": "Afatinib EGFR @GENE$ exon 19 deletion or exon 21 substitution ( @VARIANT$ ) mutation positive Indications and usage , dosage and administration , adverse reactions , clinical pharmacology , clinical studies , patient counseling information Anastrozole ESR1 , PGR Hormone receptor positive Indications and usage , clinical pharmacology , clinical studies @DRUG$ PML/RARα [ t ( 15 ; 17 ) ] gene expression positive Boxed warning , clinical pharmacology , indications and usage , warnings", "label": "None"}
{"id": "22038681", "sentence": "Preliminary results from an ongoing phase 1 dose-escalation study of the multikinase , @GENE$ inhibitor @DRUG$ ( AP24534 ) showed antileukemic activity in patients with refractory CML , including patients with the @VARIANT$ mutation .", "label": "None"}
{"id": "24920920", "sentence": "In 40 patients harboring @VARIANT$ , five revealed complex mutations , including two with T790M . In 61 patients with @GENE$ TKI as first-line therapy , 46 received gefitinib , 13 received @DRUG$ , and two received afatinib .", "label": "sensitivity"}
{"id": "PMC4036652", "sentence": "It has been shown that urothelial cells express various receptors and channels including receptors for bradykinin ( B1 and B2 ) , prostaglandin ( EP1 and EP3 ) , neurotrophins ( @GENE$ ) , purines ( P2X and @VARIANT$ ) , noradrenalin ( α1 and β3 ) , acetylcholine ( muscarinic and nicotinic ) , pituitary adenylate cyclase activating peptide , protease activated receptors and several members of Deg/ENaC and TRP channel families ( see below ; ) [ , ] . Activation of these receptors and channels can leads to ATP release from the urothelial cells . These agonist induced ATP release may increase in @DRUG$ induced cystitis [ ] .", "label": "None"}
{"id": "24244732", "sentence": "Applying the same logic of R39C and syntaxin , this would imply that increased @DRUG$ sensitivity of the @VARIANT$ mutation would be a consequence of increased @GENE$ binding .", "label": "None"}
{"id": "17877814", "sentence": "Several uncommon EGFR mutants identified in the course of this analysis were tested using the @GENE$ assay . Mutations in exon 20 , most notably @VARIANT$ , are usually associated with resistance to gefitinib and @DRUG$ [ reviewed in [ ] ] .", "label": "resistance or non-response"}
{"id": "15737014", "sentence": "Consistent with this , the T790M mutation has been shown not to abrogate the catalytic activity of wild-type @GENE$ [ ] . The T790M mutation could also affect the kinase activity or alter the substrate specificity of mutant EGFRs , such that a proliferative advantage would be conferred upon cells bearing the mutation . Consistent with this , the H1975 NSCLC cell line reported here to contain both T790M and @VARIANT$ did not to our knowledge undergo any prior treatment with gefitinib or @DRUG$ ; the doubly mutated cells must have become dominant over time through multiple passages in vitro .", "label": "sensitivity"}
{"id": "24256696", "sentence": "The mTORC1 activates protein synthesis through modulation of the 40S ribosomal protein S6 kinase ( @VARIANT$ ) and the translational initiation factor eIF-4E binding protein 1 ( 4E-BP1 ) . mTORC1 is acutely sensitive to inhibition by Sirolimus/Everolimus . Both drugs interact in mammalian cells with the immunophilin FKBP12 , and the @GENE$ complex then binds to the FRB domain in mTOR .", "label": "None"}
{"id": "23994953", "sentence": "Indeed , the fact that the combination of erlotinib plus IGF-1R inhibitors ( I-OMe-AG538 or AG1024 ) fully prevents the acquired erlotinib-resistant phenotype is consistent with IGF-1R playing a major role in this process . While preparing this manuscript , Cortot et al. reported that PC-9 derived clones with acquired resistance to mutant-selective EGFR inhibitors and irreversible quinazoline EGFR inhibitors in the absence of @GENE$ @VARIANT$ demonstrate a significantly activated IGF-1R signaling , and pharmacological inhibition of IGF-1R restored sensitivity to EGFR inhibitors .", "label": "resistance or non-response"}
{"id": "24419415", "sentence": "Recent studies suggest that NSCLC patients with uncommon EGFR mutations are less responsive to @GENE$ compared with patients with L858R and exon 19 deletions.– However , the efficacy of EGFR-TKIs in NSCLC patients with uncommon mutations has not been fully elucidated . We conducted a post-hoc analysis of the NEJ002 study to evaluate the effectiveness of @DRUG$ against NSCLC with G719X or @VARIANT$ .", "label": "None"}
{"id": "24959087", "sentence": "Further evidence of the efficacy of combination therapy in overcoming resistance is demonstrated by NSCLC cell lines resistant to erlotinib and the MET inhibitor SU11274 , which display upregulation of both mTOR ( mammalian target of rapamycin ) and @GENE$ pathway components and restoration of sensitivity to EGFR/MET inhibition by the addition of @DRUG$ . A final mechanism of resistance in gastric cancer cell lines has been demonstrated when MET amplified SNU6838 gastric cancer cell lines were treated with the MET inhibitors PHA-665752 and PF2341066 ; a novel mutation occurred in the activation loop of MET , causing a conformal change that blocked inhibitor binding analogous to the gatekeeper mutations seen in EGFR ( T790M ) following erlotinib treatment and in ABL ( @VARIANT$ ) following imatinib .", "label": "None"}
{"id": "16288556", "sentence": "As previously demonstrated [ , , ] , cells with the deletion mutant and the point mutation L858R were inhibited by the TKIs @DRUG$ and erlotinib , while the exon 20 insertion mutation was resistant . Three patients with lung adenocarcinoma and with exon 20 deletion mutants of EGFR failed to show a clinical response ( contrary to the expectation that , since the general response rate of tumors with @GENE$ mutations to TKIs is about 80 % , two or all three of these particular ones would be responsive ) . However , the cells with the insertion mutation demonstrated increased sensitivity to the irreversible inhibitor CL-387,785 , previously demonstrated to be active against cells with both an activating mutation and the resistance associated point mutation @VARIANT$ on exon 20 .", "label": "resistance or non-response"}
{"id": "19568750", "sentence": "Besides being able to quickly export glutathione conjugated platinum , upregulated expression of @GENE$ is also associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in the cisplatin-resistant cell lines [ ] . Amino acid substitution due to SNPs might weaken this effectiveness , and therefore , might enhance the sensitivity to platinating agents . Yang et al. [ ] reported that variant in exon 10 ( @VARIANT$ ) was significantly correlated with response to chemotherapy .", "label": "None"}
{"id": "19758442", "sentence": "The region important for interaction with the @GENE$ ubiquitin ligase complex is marked in green and includes a conserved histidine-cysteine-cysteine-histidine motif and a suppressor of cytokine signaling Box domain . The scale at the bottom indicates amino acid positions . The structural determination of full-length @VARIANT$ has so far been unsuccessful .", "label": "None"}
{"id": "22970367", "sentence": "Second-generation irreversible @GENE$ inhibitors , which bind irreversibly in the ATP binding pocket of EGFR through a covalent bond at C797 , were shown to be more potent inhibitors of the second-site @VARIANT$ mutation than @DRUG$ or gefitinib in pre-clinical models [ , ] ( ) .", "label": "resistance or non-response"}
{"id": "22536370", "sentence": "@GENE$ W557R V559A/D @VARIANT$ K642E D816H 23 % Acral 16 % Mucosal 28 % CSD , , Sensitive to : Imatinib @DRUG$ Sunitinib Dasatinib Decreased sensitivity to : Imatinib ( D816H only ) , , , ,", "label": "resistance or non-response"}
{"id": "24959087", "sentence": "Again , the activity of this resistance mechanism could be suppressed through combined MET and BRAF or @GENE$ inhibition . Further evidence of the efficacy of combination therapy in overcoming resistance is demonstrated by NSCLC cell lines resistant to erlotinib and the MET inhibitor SU11274 , which display upregulation of both mTOR ( mammalian target of rapamycin ) and Wnt pathway components and restoration of sensitivity to EGFR/MET inhibition by the addition of @DRUG$ . A final mechanism of resistance in gastric cancer cell lines has been demonstrated when MET amplified SNU6838 gastric cancer cell lines were treated with the MET inhibitors PHA-665752 and PF2341066 ; a novel mutation occurred in the activation loop of MET , causing a conformal change that blocked inhibitor binding analogous to the gatekeeper mutations seen in EGFR ( @VARIANT$ ) following erlotinib treatment and in ABL ( T315I ) following imatinib .", "label": "None"}
{"id": "25580271", "sentence": "There are several promising agents for patients with activating EGFR mutations who experience disease progression of an EGFR tyrosine kinase inhibitor and have a @VARIANT$ resistance mutation , and multiple clinical trials will be available . Trials investigating adjuvant erlotinib in EGFR mutant NSCLC and comparing erlotinib to @DRUG$ plus bevacizumab in metastatic @GENE$ mutant NSCLC are ongoing .", "label": "resistance or non-response"}
{"id": "24212825", "sentence": "The inhibition of @VARIANT$ by resveratrol was also shown to impair the autophagic response [ ] and S6K positively regulated @DRUG$ induced autophagy in colorectal cancer cells [ ] . The mechanism by which S6K promotes autophagy may involve synthesis of proteins that participate in autophagosome formation and maturation [ , ] or modulation of pathways that directly regulate autophagy . For example , activation of S6K inhibits @GENE$ signaling via a negative feedback loop that involves phosphorylation of insulin receptor substrate [ - ] .", "label": "None"}
{"id": "24958351", "sentence": "E ) . In contrast , treatment of SKBR3-L cells with trastuzumab and okadaic acid did not result in enhanced growth inhibition compared to okadaic acid alone ( Additional file : Figure @VARIANT$ ) . To determine if okadaic acid combined with @DRUG$ was cytostatic or cytocidal , cell cycle assays were performed . The role of @GENE$ in eEF2 phosphorylation .", "label": "None"}
{"id": "22087096", "sentence": "Many studies have proposed several factors which could make it possible to predict the response to @DRUG$ in patients with advanced NSCLC , for example , Asian female , non-smoker , with adenocarcinoma , and the presence of an @GENE$ mutation . To our knowledge , the most common types of EGFR mutation are an exon 19 deletion and an exon 21 @VARIANT$ mutation [ ] .", "label": "sensitivity"}
{"id": "20234366", "sentence": "Such a low percentage compared with that in previous reports is probably due to the fact that after Health Authorities approval to limit the use of anti-EGFR moAb to KRAS wild-type mCRC patients , @GENE$ mutant cases have not received @DRUG$ based therapy at our Institution . KRAS mutations were as follows : G13D in five patients ; @VARIANT$ in three patients ; G12V in three patients ; and G12A in one patient .", "label": "sensitivity"}
{"id": "18828913", "sentence": "In various biological assays , P-loop mutants @VARIANT$ and E255K exhibited an increased transformation potency relative to unmutated BCR-ABL. Overall , the relative transformation potencies of various mutations were found to be as follows : Y253F & gt ; E255K & gt ; native BCR-ABL ≥ T315I & gt ; H396P &gt ; M351T . Transformation potency also correlated with intrinsic @GENE$ kinase activity in this study . Two agents are currently approved for second-line treatment of patients with CML who demonstrate resistance ( or intolerance ) to imatinib : @DRUG$ and nilotinib [ , ] .", "label": "None"}
{"id": "11556834", "sentence": "To date , only 2-6 % of all analysed melanoma families have been found to carry amino acid substitutions , specifically the replacement of arginine 24 with either cysteine or @DRUG$ ( Wolfel et al , 1995 ; Brotherton et al , 1998 ) . Another missense mutation in the p16 binding region ( @VARIANT$ ) has been demonstrated in a cell line derived from a CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families : functional characterization of a novel @GENE$ germ line mutation", "label": "None"}
{"id": "23986642", "sentence": "While the first and second-generation TKIs have demonstrated improved outcomes in patients with CML and Ph+ ALL , resistance still occurs in a subset of patients who harbor @GENE$ mutations , particularly the @VARIANT$ mutant . Until the recent approval of ponatinib ( Iclusig® , ARIAD Pharmaceuticals , Cambridge , MA , USA ) , there were no approved therapies for patients who had developed resistance , refractoriness , or intolerance to commercially available TKIs .", "label": "response"}
{"id": "25562700", "sentence": "Molecule Target Biomarker Indication vemurafenib BRAF kinase BRAF @VARIANT$ mutant melanoma vandetanib VEGFR , EGFR , RETR not included on the label thyroid cancer abiraterone CYP 17A1 not included on the label prostate cancer ipilimumab @GENE$ not included on the label melanoma brentuximab vedotin CD30 ( ACD technology ) not included on the label lymphoma @DRUG$ ALK ALK-EML4 fusion protein lung cancer", "label": "None"}
{"id": "25221644", "sentence": "In analysis of signaling downstream from HER2 , we observed that @DRUG$ treatment routinely down-regulates @GENE$ activity in both SKBR3 and HER2/MCF10A models , leading to the suppression of Cyclin D1 levels and the attenuation of @VARIANT$ target genes such as MCM7 ( Figure ) .", "label": "None"}
{"id": "21188109", "sentence": "Cyclin D1 , in association with cyclin dependent kinase-4 and -6 , induces the cell to enter the S phase by phosphorylating the retinoblastoma tumor suppressing protein , which binds to transcription factors , including @VARIANT$ . In addition to the overexpression of cyclin D1 , other genes that overexpress in MCL , such as VEGF and Raf-1 , represent further possible targets for mTOR inhibitors . Indeed , a constitutive activation of Akt and mTOR pathways either in MCL cell lines ( Granta 519 , Jeko-1 , and SP-53 ) or in primary cultures from 30 % of MCL patients has been reported. , Moreover , mTOR inhibitors in MCL could synergize with other “canonical” agents , such as @DRUG$ , doxorubicin , bortezomib , and rituximab , with resulting inhibition of Raf-1 , MAPK , and mTOR . ,", "label": "None"}
{"id": "17931419", "sentence": "In this study , we used a group of cancer cell lines with either overexpressed or tyrosine kinase domain mutated ( ΔE746-A750 or @VARIANT$ ) @GENE$ to assess their responsiveness to cetuximab and @DRUG$ treatment and to evaluate HIF-1α as novel molecular marker for the therapeutic responses of the cancer cells to EGFR targeted therapy .", "label": "sensitivity"}
{"id": "22675625", "sentence": "The activating @VARIANT$ BRAF mutation is present in an additional 10 % of patients , and it may be predictive of a lack of response to anti-EGFR therapy [ ] in addition to a clear poor prognostic factor . The anti-EGFR monoclonal antibodies and their predictive biomarkers have taken CRC treatment another step closer to personalized therapy . However , the recent results of the large UK COIN study and a Belgian study have not confirmed a benefit in terms of PFS or OS from the addition of cetuximab to oxaliplatin based chemotherapy in wild-type @GENE$ patients versus 5-FU and @DRUG$ alone [ , ] .", "label": "None"}
{"id": "24501009", "sentence": "In contrast to patients with @GENE$ tumors , patients with KRAS‐mutant NSCLC are unlikely to respond to gefitinib or erlotinib and do not have an improved progression‐free survival ( PFS ) compared with those who have placebo following @DRUG$ therapy . Dacomitinib ( PF‐00299804 ) is a potent , irreversible , oral small‐molecule inhibitor of HER1/EGFR , HER2 , and HER4 tyrosine kinases with antitumor activity in both gefitinib‐sensitive and gefitinib‐resistant , including EGFR @VARIANT$ , preclinical NSCLC models .", "label": "resistance or non-response"}
{"id": "15736989", "sentence": "Resistance mutations identified via in vitro screens have shown a high degree of correlation with those that develop in vivo , as shown in screens for imatinib-resistant BCR-ABL mutants [ ] and PKC412-resistant FLT3 mutants [ ] , as well as the @VARIANT$ resistance mutation to @DRUG$ in the context of @GENE$ [ ] .", "label": "resistance or non-response"}
{"id": "24294007", "sentence": "Although a retrospective study and the PICCOLO ( Panitumumab , @DRUG$ and Ciclosporin in Colorectal Cancer Therapy ) trial have demonstrated a reduced response to cetuximab and panitumumab for patients with NRAS mutations , , further work is required to demonstrate the predictive capacity of these mutations . The serine/threonine-protein kinase B-Raf is an effector in the @GENE$ signaling pathway , downstream of K-Ras . Mutations in the proto-oncogene BRAF are present in 5 % –10 % of the metastatic CRC population and are also mutually exclusive of KRAS mutations . BRAF @VARIANT$ is the most common of all BRAF mutations ( present in 90 % of cases ) , and is enriched in a subset of patients who are female , greater than 70 years of age , with KRAS WT right sided colon cancer .", "label": "None"}
{"id": "24348666", "sentence": "Although the resistant cell line @GENE$ does not have the EGFR @VARIANT$ mutation , it was found to have MET amplification . MET is a receptor tyrosine kinase that binds to hepatocyte growth factor (HGF) and is associated with the development of various human cancers . Therefore , EGFR-TKIs fail to inhibit the PI3K/Akt pathway dependent growth signal because the constitutive phosphorylation of HER3 by MET occurs independent of EGFR activation , which causes the cells to acquire resistance to @DRUG$ .", "label": "None"}
{"id": "23994953", "sentence": "Somatic mutations in exons encoding the tyrosine kinase ( TK ) domain of the epidermal growth factor receptor (EGFR) are positively associated with increased sensitivity of non-small cell lung cancer ( NSCLC ) patients to the selective @GENE$ TK inhibitors ( TKIs ) gefitinib ( Iressa™ ) and erlotinib ( Tarceva™ ) . Prospective trials have demonstrated an impressive ~75 % response rate for patients whose tumors harbor these mutations , which occur as either multinucleotide in-frame deletions in exon 19 ( e.g. , delE746-A750 ) or as single missense mutations ( e.g. , @VARIANT$ ) .", "label": "sensitivity"}
{"id": "25562700", "sentence": "Molecule Target Biomarker Indication vemurafenib BRAF kinase BRAF @VARIANT$ mutant melanoma vandetanib VEGFR , EGFR , RETR not included on the label thyroid cancer abiraterone CYP 17A1 not included on the label prostate cancer ipilimumab CTLA-4 not included on the label melanoma @DRUG$ ( ACD technology ) not included on the label lymphoma crizotinib ALK ALK-EML4 fusion protein lung cancer BRAF : Serine/threonine-protein kinase B-Raf ; VEGFR : Vascular endothelial growth factor receptor ; EGFR : epidermal growth factor receptor ; RETR : @GENE$ proto-oncogen receptor ; CYP 17A1 : cytochrome P450 17A1 ; CTLA-4 : Cytotoxic T-Lymphocyte Antigen 4 ; CD30 : Cluster of Differentiation 30 ; ADC : Antibody Conjugated Drug ; ALK-EML4 : anaplastic lymphoma kinase (ALK) ; echinoderm microtubule associated protein-like 4 ( EML4 ) fusion .", "label": "None"}
{"id": "23976869", "sentence": "@DRUG$ is a dual SRC/ABL1 inhibitor that also inhibits PDGFRs and @GENE$ fusion but has no effect on imatinib-resistant FIP1L1-PDGFRA T674I and @VARIANT$ mutants .", "label": "sensitivity"}
{"id": "25146448", "sentence": "MTNR1B , located on human chromosome 11q21–22 , is a member of the @GENE$ , and one of the functional and high-affinity @DRUG$ membrane receptors . MTNR1B is expressed in human and rodent pancreatic islets . Studies have shown that MTNR1B is a novel candidate gene for @VARIANT$ .", "label": "None"}
{"id": "15737014", "sentence": "These results suggest that the T790M mutation may impair the ability of gefitinib or @DRUG$ to inhibit EGFR tyrosine kinase activity , even in @GENE$ mutants ( i.e. , @VARIANT$ or an exon 19 deletion ) that are clinically associated with drug sensitivity .", "label": "sensitivity"}
{"id": "22405425", "sentence": "The tumor tissue was analyzed for the presence of an EGFR mutation using the PNAClamp™ @GENE$ Mutation Detection kit ( PANAGENE , INC. Daejeon , Korea ) . In the cell blocks from the pleural fluid and the ascites , an @VARIANT$ mutation in exon 21 was detected . @DRUG$ therapy was therefore commenced .", "label": "sensitivity"}
{"id": "24924344", "sentence": "@DRUG$ ( A/T ) Chr16 : 56671632 MT1A ( near-gene 5 ) 0.047628 0.138 Oxaliplatin rs562 ( C/T ) Chr3 : 183637845 ABCC5 ( UTR3 ) 0.049494 0.392 rs3749445 ( A/G ) Chr3 : 183638506 ABCC5 ( UTR3 ) 0.044895 0.410 rs2292998 ( C/T ) Chr3 : 183663833 ABCC5 ( intronic ) 0.039882 0.277 rs1016752 ( C/G ) Chr3 : 183665062 ABCC5 ( intronic ) 0.039781 0.232 rs4148585 ( C/T ) Chr3 : 183670642 ABCC5 ( intronic ) 0.039781 0.283 rs6443924 ( A/G ) Chr3 : 183679532 ABCC5 ( intronic ) 0.039781 0.279 rs4148579 ( A/G ) Chr3 : 183685249 ABCC5 ( intronic ) 0.039781 0.279 rs939336 ( A/G =&gt ; C594C ) Chr3 : 183685534 ABCC5 ( exonic ) 0.039781 0.279 rs1132776 ( C/T = & gt ; A395A ) Chr3 : 183696402 @GENE$ ( exonic ) 0.044895 0.289 rs2313212 ( C/T ) Chr3 : 183700928 ABCC5 ( intronic ) 0.039781 0.279 rs4148575 ( C/T ) Chr3 : 183702275 ABCC5 ( UTR3 ) 0.044895 0.289 rs1846692 ( C/T ) Chr16 : 56671696 MT1A ( near - gene 5 ) 0.049494 0.360 rs35346959 ( A/G ) Chr16 : 56671867 MT1A ( near- gene 5 ) 0.044895 0.137 rs9922957 ( C/G ) Chr16 : 56672380 MT1A ( near - gene 5 ) 0.039781 0.185 rs9922409 ( A/G ) Chr16 : 56672400 MT1A ( near - gene 5 ) 0.04532 0.103 rs7190725 ( G/T ) Chr16 : 56673290 MT1A ( intronic ) 0.044895 0.170 rs8052394 ( A/G =&gt ; K51R ) Chr16 : 56673828 MT1A ( missense ) 0.044895 0.152 rs1800566 ( C/T = & gt ; @VARIANT$ ) chr16 : 69745145 NQO1 ( exonic ) 0.039781 0.258 rs689455 ( A/C ) Chr16 : 69761661 NQO1 ( near- gene 5 ) 0.039781 0.242", "label": "None"}
{"id": "24250268", "sentence": "Human M132 is conserved between all species , suggesting that this amino acid may play an important role in the structure and or function of @GENE$ . The R372H variant is a conservative amino acid change ( i.e. , both arginine and @DRUG$ are positively charged amino acids ) . Human Q556 aligns with an arginine residue in 10 species , including chimpanzee , rhesus monkey , dog , rat , and mouse , demonstrating that SAT1 sequence containing @VARIANT$ is conserved with other species .", "label": "None"}
{"id": "22815900", "sentence": "A , Comparison of the expression of EGFR , @GENE$ , HER2 , p-HER2 , HER3 , p-HER3 , PTEN , Akt , p-Akt , ERK1/2 , and p-ERK1/2 in 11–18 , 11–18/GEF10-1 , and 11–18/GEF20-1 cells by western blot analysis . B , Exponentially growing 11–18 , 11–18/GEF10-1 , and 11–18/GEF20-1 cells were exposed to various doses of @DRUG$ for 5 hr , and followed by Western blot analysis . C , Western blots showing expression of @VARIANT$ EGFR protein in 11–18 cells and resistant clones .", "label": "sensitivity"}
{"id": "23320171", "sentence": "Primary results from the EMILIA study , a randomized trial comparing Trastuzumab DM-1 to @DRUG$ and capecitabine , have shown that Trastuzumab @GENE$ significantly improved progression-free survival in patients with metastatic HER2 positive breast cancer . Further research is looking into inhibiting other targets such as mTOR , @VARIANT$ , or AKT pathways .", "label": "None"}
{"id": "25405807", "sentence": "Inhibition of epidermal growth factor receptor (EGFR) kinase activity by EGFR tyrosine kinase inhibitors ( EGFR-TKIs ) , such as gefitinib and @DRUG$ , can result in improved response and prolonged progression-free survival ( PFS ) in selected non-small cell lung cancer ( NSCLC ) patients harboring sensitizing @GENE$ mutations , especially the exon 19del and exon 21 @VARIANT$ mutations – .", "label": "sensitivity"}
{"id": "23990708", "sentence": "The first generation TKIs ( erlotinib , @DRUG$ , and lapatinib , for instance ) are reversible small-molecule inhibitors . They prevent autophosphorylation of the @GENE$ TK by competing with ATP . It was shown by our detailed review that the main group of currently known EGFR TKIs are almost all based on a quinazoline/quinoline scaffold. , ,– It is believed that the quinazoline/quinoline scaffold may not be the most potent or specific for inhibiting @VARIANT$ EGFR .", "label": "resistance or non-response"}
{"id": "21333004", "sentence": "Overexpression of wild type EGFR induced high and sustained phosphorylation of EGFR , Shc , MEK ( mitogen activated protein kinase kinase ) and ERK ( extracellular signal regulated kinase ) , while the @VARIANT$ mutation reduced these response levels . In addition , H1299L858R , which is supposed to be more sensitive to @DRUG$ than H1299EGFR-WT , was effectively inhibited by gefitinib administration at the downstream part of the signaling pathway ( MEK and ERK ) compared with @GENE$ , but , surprisingly , not at the upstream part of the pathway ( EGFR and Shc ) .", "label": "sensitivity"}
{"id": "25580271", "sentence": "Two phase III trials compared afatinib to a platinum-doublet in patients with advanced EGFR mutant NSCLC , and a combined analysis for overall survival was presented at ASCO , as well as subset analyses based on EGFR mutation subtype ( exon 19 deletion and exon 21 @VARIANT$ point mutation ) [ ] . In subgroup analysis based on EGFR mutation type the benefit appeared to be limited to patients with exon 19 mutations . When cross-over to @GENE$ tyrosine kinase inhibitor therapy was examined , 75 % of patients who received cisplatin and @DRUG$ received an EGFR tyrosine kinase inhibitor and 56 % of patients who received cisplatin and gemcitabine received an EGFR tyrosine kinase inhibitor .", "label": "None"}
{"id": "25429239", "sentence": "In the case of @DRUG$ , the median PFS in the PROFILE studies was 7.7 months . Similarly , in EGFR mutated tumors , the efficacy of TKIs is limited by the development of resistance mechanisms , the commonest of which is the secondary @VARIANT$ mutation within exon 20 of the EGFR gene. , The presence of T790M gatekeeper resistance resulting in failure of treatment accounts for about 50 % of secondary resistance with other mechanisms including activation of bypass mechanisms such as amplification of the @GENE$ transformation into small-cell lung cancer .", "label": "None"}
{"id": "24419415", "sentence": "The NEJ002 study , comparing gefitinib and standard carboplatin-paclitaxel chemotherapy as the first-line treatment for patients with @GENE$ mutations , demonstrated no significant difference in OS between gefitinib and carboplatin-paclitaxel . In contrast to other phase 3 trials investigating EGFR-TKIs for patients with common EGFR mutations of exon 19 deletion and L858R , the NEJ002 is the only study that included uncommon EGFR mutations of G719X and @VARIANT$ .", "label": "None"}
{"id": "17106442", "sentence": "In exon 21 , a missense point mutation substitutes an amino acid at position 858 ( @VARIANT$ ) . All such mutations result in conformational changes that lead to increased sensitivity to tyrosine kinase inhibitors . These results indicate that screening of patients for @GENE$ tyrosine kinase domain mutations before treatment with @DRUG$ or other EGFR inhibitors may predict the clinical benefit of the treatment .", "label": "sensitivity"}
{"id": "23423475", "sentence": "Exon 19 deletions and the @VARIANT$ mutation constitute ∼90 % of the EGFR mutations identified to date . @GENE$ MuT+ lead to structural changes , which stabilize the active form of the tyrosine kinase domain and result in a high affinity for binding EGFR tyrosine kinase inhibitors ( TKIs ; Carey et al. , ) . In patients with tumors that are positive for these mutations , the current data supports sensitivity to @DRUG$ or erlotinib ( NCCN Practice Guidelines in Oncology , , ) .", "label": "sensitivity"}
{"id": "24996846", "sentence": "Potentiation of gemcitabine , camptothecin , @DRUG$ and oxaliplatin cytotoxicity by V158411 was dependent on @GENE$ status . In the p53 wild-type colon cancer cell line HCT116 , V158411 did not potentiate any of the four cytotoxic chemotherapeutic agents tested ( Figure A ) . In comparison , V158411 potentiated all four agents by greater than 5-fold in the HT29 colon carcinoma cell line which harbors a @VARIANT$ mutation in p53 .", "label": "None"}
{"id": "25056273", "sentence": "However , mutations of the PP1 binding motif not only affect BRCA1 interaction with PP1α but may also reduce BRCA1 dephosphorylation as the PP1 binding motif deleted BRCA1 protein ( BRCA1GFP DEL ) displayed increased S1423 phosphorylation at the basal level and after @DRUG$ treatment when expressed in the @GENE$ ovarian cancer cell line . BRCA1 interacts with many proteins , and it is possible that inappropriate phosphorylation patterns may affect these interactions , thereby impacting other BRCA1 functions such as transcription or E3 ubiquitin ligase activity . These additional adverse effects to BRCA1 function may underlie the DNA repair deficiencies observed for @VARIANT$ .", "label": "None"}
{"id": "25431951", "sentence": "In addition , mutations such as S601P [ ] , L629P [ ] were reported to be associated with primary resistance to @DRUG$ in @GENE$ positive patient . In the present study , we reported that S116836 synthesized in our lab is a novel multiple TKI , and showing strikingly inhibitory effect on the activity of gate-keeper mutant T315I BCR-ABL and @VARIANT$ PDGFRα at low nanomolar concentrations .", "label": "None"}
{"id": "22970367", "sentence": "Although MET amplification can coexist with the EGFR @VARIANT$ mutation , approximately 60 % of MET amplification is independent of T790M mutation [ , ] . MET amplification was originally identified in a laboratory-model of @DRUG$ resistance using HCC827 human EGFR mutant NSCLC cells . In this model , cells with EGFR TKI resistance relied on MET signaling to activate AKT through ERBB3 mediated activation of @GENE$ in the presence of EGFR TKIs [ ] .", "label": "None"}
{"id": "17374153", "sentence": "One possibility is that the passage of time or cytotoxic chemotherapy may have reduced the number of clones containing modified genes and proteins that confer resistance to @DRUG$ . The mechanism of this phenomenon may involve a second point-mutation , resulting in a threonine-to-methionine amino acid change at position 790 of @GENE$ ( @VARIANT$ ) [ , ] , mutation in the KRAS protein [ ] , or upregulation of epithelial membrane protein-1 [ ] .", "label": "resistance or non-response"}
{"id": "25563355", "sentence": "Of the second generation EGFR-TKIs , neratinib , dacomitinib and @DRUG$ have been getting more attention recently ( ) . Neratinib ( HKI-272 ) is an oral , irreversible inhibitor of EGFR and @GENE$ [ ] . In pre-clinical studies , neratinib inhibited the growth of NCI-H1975 bronchoalveolar cancer cells harboring both substitution of arginine for leucine at position 858 ( @VARIANT$ ) and T790M and cell lines harboring the HER2 mutation [ ] .", "label": "None"}
{"id": "25221748", "sentence": "This agent is also being assessed in a phase II trial in patients with de novo resistant @VARIANT$ mutations not previously treated with EGFR-TKIs ( www.clinicaltrials.gov : NCT01854034 ) and in patients with EGFR mutations and/or EGFR-TKI resistant disease , as part of a phase II cluster study in Chinese patients evaluating five novel inhibitors of @GENE$ , PI3K , ALK , MET , and MEK ( ) . Further , AUY922 is also being assessed in combination with @DRUG$ in patients who have previously responded to EGFR-TKIs and/or whose tumors harbor activating EGFR mutations ( www.clinicaltrials.gov : NCT01259089 ) , with results expected in the near future .", "label": "None"}
{"id": "17973572", "sentence": "To prove the functional significance of the @VARIANT$ mutation , we generated Ba/F3 cell lines stably expressing mutant EGFR constructs [ ] . These cell lines , including L858R-L747S , proliferated in the absence of IL3 . Ba/F3-L858R cells were extremely sensitive to @DRUG$ ( D ) , whereas @GENE$ cells were highly resistant up to 1 μM gefitinib .", "label": "None"}
{"id": "23232076", "sentence": "The deletion of the four amino acid sequence ( del 746–750 ) in the exon 19 and the substitution of leucine by arginine at codon 858 ( @VARIANT$ ) in exon 21 are two of the most common mutations in the kinase domain of EGFR gene in NSCLC patients [ ] . The small-molecule tyrosine kinase inhibitors including @DRUG$ and erlotinib have recently been approved for the treatment of patients with NSCLC [ , - ] . In addition , mutations in the epidermal growth factor receptor (EGFR) have been confirmed as predictors of the efficacy of treatment with @GENE$ kinase inhibitors .", "label": "sensitivity"}
{"id": "15737014", "sentence": "Specific mutations in the tyrosine kinase domain of @GENE$ are associated with sensitivity to either gefitinib or @DRUG$ , but mechanisms of acquired resistance have not yet been reported . Based upon analogous studies in other diseases with another kinase inhibitor , imatinib , a single amino acid substitution from threonine to methionine at position 790 in the wild-type EGFR kinase domain was predicted to lead to drug resistance , even before the association of exon 19 and 21 mutations of EGFR with drug responsiveness in NSCLC was reported . The @VARIANT$ mutation was shown in vitro in the context of wild-type EGFR to confer resistance to gefitinib [ ] and a related quinazoline inhibitor , PD153035 [ ] .", "label": "resistance or non-response"}
{"id": "22844461", "sentence": "While the authors found little overlap in the actual genes between datasets , they did find a general theme of cell cycle and proliferation @GENE$ including an increase in activation of various @VARIANT$ 's in @DRUG$ resistant cells in all three studies .", "label": "None"}
{"id": "25506699", "sentence": "Rabbit anti-human AMPKα , p44/42 MAP kinase , phospho-p44/p42 MAPK ( Thr202/Tyr204 ) , Akt , phospho-Akt ( Ser473 ) ( @VARIANT$ ) XP , and @GENE$ polyclonal antibodies ; and rabbit anti-human phospho-AMPKα ( Thr172 ) ( 40H9 ) and phospho-LKB1 ( Ser428 ) ( C6743 ) monoclonal antibodies , were obtained from Cell Signaling Technology Inc ( Danvers , MA ) . Peroxidase conjugated @DRUG$ were from DAKO Diagnostics , S.A. ( Barcelona , Spain ) .", "label": "None"}
{"id": "23145123", "sentence": "A. Selection of PC9 cells in media containing increasing concentrations of erlotinib resulted in the PC9-ER line , which is unaffected by doses of @DRUG$ up to 1 µM . B. The IL3 independent Ba/F3 clone 1C8 recovered by cDNA library screening of PC9-ER cells contains both the Δex19 activating mutation and the @VARIANT$ mutation in @GENE$ .", "label": "resistance or non-response"}
{"id": "22970367", "sentence": "One of these agents , BIBW2992 ( @DRUG$ ) , is able to target both @GENE$ and ERBB2 and overcome T790M-driven acquired resistance [ ] . However , in clinical studies , BIBW2992 did not prolong survival compared to placebo in NSCLC patients who have developed acquired resistance to gefitinib or erlotinib [ ] . Another agent in this class of next generation EGFR TKIs , PF-002999804 , inhibits all ERBB family members and has been shown to be effective against tumors harboring @VARIANT$ [ , ] .", "label": "response"}
{"id": "24787964", "sentence": "As the theoretical advantage of @DRUG$ versus the first-generation @GENE$ did not translate into progression-free survival gains , maybe the clinical relevance of possible inhibition of @VARIANT$ is minimal , at least in the first-line setting , when T790M positive clones are rarely detected .", "label": "response"}
{"id": "24244732", "sentence": "Although this hypothesis has not been directly tested for @DRUG$ specifically , syntaxin hypomorphs in C. elegans do have reduced sensitivity to volatile anaesthetics [ ] emphasizing a potential convergence of cellular effectors of various anaesthetics at the presynaptic terminal . On the other hand , the @VARIANT$ mutation acts to increase @GENE$ binding , at least for Munc18 [ ] .", "label": "None"}
{"id": "24236021", "sentence": "The amino acid Glu286 from the αC- helix also has variable electrostatic interactions due to mutations in @GENE$ kinase domain . The Phe359 caps @DRUG$ binding site close to the activation loop and undergoes conformational changes with most mutations in particular , the P-loop residues ( G250E and @VARIANT$ ) and the gatekeeper mutation T315I on the β5- strand .", "label": "None"}
{"id": "19654571", "sentence": "We examined the antiproliferative effects of isolated RxT , cisplatin and @DRUG$ treatments on A431 , Caski and @VARIANT$ cells ( ) , which express high to low @GENE$ levels , respectively ( see Figures 3A and 5A ) .", "label": "None"}
{"id": "19305511", "sentence": "Acrosome reaction experiments indicate that the basic problem in sperm from hyh mice is a reduced capacity to undergo exocytosis upon stimulation with @DRUG$ and even with a calcium ionophore . The fact that exogenous αSNAP can rescue acrosomal exocytosis in these cells is a strong evidence that the principal defect is a malfunction in the endogenous protein . Worth noticing is that the @VARIANT$ mutation is in a region of αSNAP that does not interact with the @GENE$", "label": "None"}
{"id": "25110867", "sentence": "Crenolanib displayed strong anti-proliferative activity in @GENE$ D842V and EOL-1 cell lines with PDGFRα dependent growth . Data indicated that crenolanib was significantly more potent than @DRUG$ in inhibiting the kinase activity of imatinib-resistant mutated PDGFRα including D842I , @VARIANT$ , D842Y , DI842-843IM , and deletion I843 .", "label": "None"}
{"id": "24594844", "sentence": "cDzT remains its suppression effect on @GENE$ @VARIANT$ expression and downstream signaling after EGF treatment in H1975TM/LR . Figure S6 . Combined treatment of cDzT and @DRUG$ significantly suppresses the phosphorylation of STAT3 , AKT , and ERK in CL97TM/GA cells .", "label": "response"}
{"id": "22654561", "sentence": "Verbeek and coworkers set out to compare the efficiency of four recently developed TK inhibitors , XL184 , @DRUG$ , Sunitinib and Axitinib , using three cell lines : the first derived from sporadic MTC expressing a C634W @GENE$ mutation , the second derived from metastatic sporadic MTC expressing a @VARIANT$ RET mutation .", "label": "response"}
{"id": "23801357", "sentence": "Ponatinib ( @DRUG$ ) is a novel @GENE$ inhibitor developed using a computational and structure based approach.– It was designed to bind to and inhibit native BCR-ABL and BCR-ABL mutants that can arise during treatment with other TKIs and cause resistance , including the @VARIANT$ mutant .", "label": "None"}
{"id": "21165163", "sentence": "Median PFS and OS for the 217 patients who received @DRUG$ were 14 and 27 months , patients with @VARIANT$ had longer PFS than patients with exon 19 deletions and outcomes did not seem to differ whether erlotinib was given in the first or second-line setting . A combined survival analysis ( I-CAMP ) of seven prospective Japanese trials of 148 patients with @GENE$ mutations who received gefitinib demonstrated a response rate of 76.4 % , median PFS of 9.7 months and overall survival of 24.3 months [ ] .", "label": "sensitivity"}
{"id": "25033171", "sentence": "Energetic spectrums ( enthalpy ) were decomposed into drug-residue pairs for ( A ) wild-type ROS1 , and ( B ) @VARIANT$ mutated @GENE$ , and their corresponding structural descriptions are shown in panel D and panel E , where the P-loop region and important residues on it ( Leu18 and Val26 ) are illustrated in orange cartoon model and stick model , respectively . The mutated residue and @DRUG$ are modeled in green stick model ( Gly99 in panel D and Arg99 in panel E ) and pink stick model , respectively .", "label": "resistance"}
{"id": "25580271", "sentence": "There are several promising agents for patients with activating EGFR mutations who experience disease progression of an EGFR tyrosine kinase inhibitor and have a @VARIANT$ resistance mutation , and multiple clinical trials will be available . Trials investigating adjuvant erlotinib in EGFR mutant NSCLC and comparing @DRUG$ to erlotinib plus bevacizumab in metastatic @GENE$ mutant NSCLC are ongoing .", "label": "resistance or non-response"}
{"id": "21698178", "sentence": "This effect was then described in the context of @DRUG$ induced resistance , . The structure of @GENE$ D816V mutant has not yet been determined . Nevertheless , recent crystallographic data have suggested that the JMR auto-inhibitory conformation is destabilized in the @VARIANT$ mutant , advocating a regulatory impact of this catalytic mutation .", "label": "None"}
{"id": "21556318", "sentence": "Patients who developed a @GENE$ mutation were as follows : nilotinib 300 mg twice daily ( 8 [ 3 % ] ) , nilotinib 400 mg twice daily ( 5 [ 2 % ] ) , and @DRUG$ ( 16 [ 6 % ] ) . The eight BCR–ABL mutations in the nilotinib 300 mg twice daily group were identified in six patients . These included Y253H , Y253H/F359V , E255K/T315I , T315I , @VARIANT$ , and E2459K .", "label": "None"}
{"id": "23888935", "sentence": "Ponatinib is a novel , synthetic , orally active , potent pan–BCR-ABL inhibitor and multi targeted TKI that was discovered using a computational and structure based drug design approach.– @DRUG$ was specifically designed to inhibit native @GENE$ and mutant forms that can arise during treatment with other TKIs and cause resistance , including the @VARIANT$ gatekeeper mutant .", "label": "None"}
{"id": "25514649", "sentence": "A recent report claimed that @DRUG$ IFN-α and lymphotoxin beta ( LT-β ) pathways might cause the destruction of cccDNA by certain endonucleases following deamination of the minus strand DNA by @GENE$ A3B .", "label": "None"}
{"id": "25100284", "sentence": "Exon 19 deletions and @VARIANT$ mutations have shown similar in vitro sensitivity to gefitinib [ ] ; however , @DRUG$ and gefitinib have shown different clinical efficacy depending on whether exon 19 deletions and L858R mutations are present [ , ] . Despite these differences , both drugs have efficacy in patients with both of these mutations and these differences would not influence treatment selection . As the number of clinical trials evaluating @GENE$ TKIs continues to increase , the number of patients eligible for pooled analyses such as this one will increase .", "label": "sensitivity"}
{"id": "17973572", "sentence": "The Secondary Resistant Mutations L747S and T790M Affect Gefitinib Induced Apoptosis and Inhibit BIM Up-Regulation ( A ) Top : Annexin V apoptosis assay : @GENE$ cells expressing @VARIANT$ (LR) , L858R-L747S # 4 ( LR-LS ) , or L858R-T790M (LR-TM) cells were grown in the absence or presence of @DRUG$ for 24 h .", "label": "None"}
{"id": "24279718", "sentence": "Nevertheless , the possibility of treating the patient with the @GENE$ @DRUG$ was considered . Indeed , even if the co-existence of KRAS and EGFR mutations could be interpreted as double mutation occurring in the crizotinib-resistant tumor cells , the possibility of different tumor clones with activation of EGFR and KRAS signaling as different mechanisms of crizotinib-resistance appeared to be an alternative , perhaps more likely explanation . Furthermore , the identified L862R EGFR mutation , although not reported before , was located near mutations known to be sensitive to EGFR-TKI , such as @VARIANT$ and L861X .", "label": "sensitivity"}
{"id": "24386407", "sentence": "Lung cancers with mutations that activate epidermal growth factor receptor (EGFR) , including exon 19 deletions and the exon 21 @VARIANT$ point mutation , respond to the reversible EGFR-tyrosine kinase inhibitors ( EGFR-TKIs ) gefitinib and erlotinib [ ] . These mutations have been shown to promote the activation of EGFR signaling and tumor dependency on EGFR . Recent clinical trials have shown that progression-free survival ( PFS ) in patients with EGFR mutant lung cancer is prolonged by treatment with a reversible EGFR-TKI and the irreversible @GENE$ @DRUG$ , which was designed to covalently bind to EGFR [ - ] .", "label": "sensitivity"}
{"id": "25143820", "sentence": "The 2 patients with mutations in PDGFRA had them in exon 18 @VARIANT$ or exon 12 . The small series does not permit any conclusive considerations on the correlation of DMD involvement with @GENE$ kinase genotype . But as the clinical use of sunitinib and regorafenib after @DRUG$ failure does not completely cover the molecular landscape of the progressing GIST , a novel approach that targets dystrophin deregulation may have relevance in GIST treatment .", "label": "resistance or non-response"}
{"id": "16552419", "sentence": "In conclusion , our established methods are thus considered to be very useful for identifying a deletion of exon 19 and a point mutation ( @VARIANT$ ) of exon 21 of the EGFR gene as a screening . The mutations within the tyrosine kinase domain of @GENE$ associated with @DRUG$ sensitivity were thus found to specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking .", "label": "sensitivity"}
{"id": "25525597", "sentence": "Another research by Mancuso et al. , also about the effects of @DRUG$ in SOD1 ( @VARIANT$ ) ALS mice , showed that the protective effects of resveratrol were associated with increased expression and activation of sirtuin 1 and @GENE$ in the ventral spinal cord .", "label": "None"}
{"id": "23085539", "sentence": "NVP-BEZ235 has been evaluated also in a mouse model consisting of BA/F3 cells overexpressing either WT BCR-ABL or its imatinib-resistant @GENE$ mutants ( E255K and @VARIANT$ ) [ ] .", "label": "None"}
{"id": "24884501", "sentence": "The mutational frequencies of the 195 KRAS mutations in the NORDIC VII cohort were ; G12A ( 9.7 % ) , G12R ( 1.5 % ) , G12D ( 35.4 % ) , G12C ( 9.7 % ) , G12S ( 6.2 % ) , G12V ( 15.4 % ) , and @VARIANT$ ( 22.1 % ) . @DRUG$ did not add significant benefit to Nordic FLOX and @GENE$ mutation was not predictive for cetuximab effect .", "label": "resistance or non-response"}
{"id": "23994953", "sentence": "While preparing this manuscript , Cortot et al. reported that PC-9 derived clones with acquired resistance to mutant-selective EGFR inhibitors and irreversible quinazoline EGFR inhibitors in the absence of EGFR @VARIANT$ demonstrate a significantly activated IGF-1R signaling , and pharmacological inhibition of IGF-1R restored sensitivity to EGFR inhibitors . Despite no patient data supporting the role of IGF-1R in acquired resistance to gefitinib/erlotinib , we are beginning to accumulate evidence from preclinical models indicating that clinical trials of @GENE$ inhibitors with demonstrated activity in unselected NSCLC patients might play a role in association with EGFR inhibitors in the management of NSCLCs with acquired resistance to gefitinib/erlotinib .", "label": "None"}
{"id": "24612546", "sentence": "A number of small-molecule tyrosine kinase inhibitors ( TKIs ) ( e.g. , gefitinib , erlotinib , lapatinib ) and antibodies ( eg , trastuzumab , @DRUG$ , panitumumab ) targeting the erbB family have been developed to treat breast , colorectal , lung , gastric and head and neck squamous cell cancers [ ] . Despite the improvements achieved in patients treated with reversible inhibitors of @GENE$ or EGFR and HER2 , primary and acquired resistances to these agents remain a clinical challenge . This is exemplified by the development of resistance to EGFR tyrosine kinase inhibitor ( TKI ) , through emergence of a secondary @VARIANT$ EGFR mutation in non-small-cell lung carcinoma ( NSCLC ) [ ] , which occurs in 50 % of the patients with lung adenocarcinoma [ ] .", "label": "response"}
{"id": "21687596", "sentence": "A recent analysis showed that T790M mutations do not considerably affect the binding affinity between EGFR and EGFR-TKIs but instead increase the binding affinity between EGFR and ATP , causing a relative decrease in binding with @GENE$ [ ] . The authors reported that increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance . An experiment using cell lines transfected concurrently with activating mutations and a @VARIANT$ mutation also proved that resistance to @DRUG$ and erlotinib is evident when this mutation is present [ – ] .", "label": "resistance or non-response"}
{"id": "24634705", "sentence": "Targeting the oncogenic fusion protein echinoderm microtubule associated protein-like @GENE$ EML4-ALK ) with TKIs such as @DRUG$ has also been shown to be negatively affected by the development of secondary gate keeper residue mutations such as @VARIANT$ , and the emergence of fusion negative tumors that render the disease insensitive to the drug .", "label": "resistance"}
{"id": "17551677", "sentence": "Finally , a recent study shows not only that EGFR mutations are statistically associated with Asian ethnicity and never-smoker status , but also that patients with EGFR exon 19 deletions have significantly longer median survival than patients with @GENE$ @VARIANT$ mutation ( 34 vs. 8 months , p=0.01 ) after treatment with @DRUG$ or erlotinib [ ] .", "label": "sensitivity"}
{"id": "23992330", "sentence": "For tyrosine kinase inhibitors ( TKIs ) [ ] , mutations within the ATP pocket of the kinase domain may affect the interaction of the drug with its target : for example , the single amino acid mutation tyrosine/methionine ( @VARIANT$ ) in the ATP binding pocket of the @GENE$ mediates secondary resistance to the EGFR TKIs @DRUG$ and gefitinib in non-small cell lung cancer ( NSCLC ) [ , ] .", "label": "resistance or non-response"}
{"id": "24920920", "sentence": "In 40 patients harboring @VARIANT$ , five revealed complex mutations , including two with T790M . In 61 patients with EGFR TKI as first-line therapy , 46 received gefitinib , 13 received erlotinib , and two received @DRUG$ . The ORR and @GENE$ of EGFR TKI were 67.2 % ( 47 of 61 ) and 90.2 % ( 55 of 61 ) , respectively .", "label": "None"}
{"id": "23606169", "sentence": "Because mutations in the KRAS gene result in activation of the epidermal growth factor receptor (EGFR) signaling pathway , only metastatic colorectal cancer patients with wild-type @GENE$ tumors qualify for anti-EGFR targeted therapies with cetuximab or @DRUG$ [ ] . Also , a clinical trial with the BRAF inhibitor ( PLX4032 ) demonstrated antitumor activity in tumors with the BRAF @VARIANT$ mutation and confirmed that V600E BRAF is a valid therapeutic target in human cancer [ ] .", "label": "None"}
{"id": "23569389", "sentence": "Dasatinib is active against at least 100 of the @GENE$ mutations known to confer resistance to @DRUG$ that have been tested to date , ( including many in the p-loop region ) , except for the @VARIANT$ mutation and a few other mutations ( V299L , F317L/V , and T315A ) .", "label": "None"}
{"id": "24004697", "sentence": "A : K562 and @VARIANT$ cells treated with PPP2R5C-siRNA799 , B : 32D-Bcr-Abl WT and 32D-Bcr-Abl T315I cells treated with PPP2R5C-siRNA799 , C : K562 and K562R cells treated with PPP2R5C-siRNA991 , D : 32D-Bcr-Abl WT and 32D-Bcr-Abl T315I cells treated with PPP2R5C-siRNA991 . The apoptosis induction effect of PPP2R5C-siRNAs on imatinib-sensitive and imatinib-resistant cell lines . A : K562 and K562R cells treated with PPP2R5C-siRNA799 , B : 32D-Bcr-Abl WT and 32D-Bcr-Abl T315I cells treated with PPP2R5C-siRNA799 , C : K562 and K562R cells treated with PPP2R5C-siRNA991 , D : 32D-Bcr-Abl WT and @GENE$ T315I cells treated with PPP2R5C-siRNA991 .", "label": "None"}
{"id": "23921604", "sentence": "It is often associated with mutations in KIT exon 9 or PDGFRA exon 18 ( e.g. , @VARIANT$ ) but is also found in wild-type GIST ( i.e. , GIST without known mutations in KIT or PDGFRA ) [ , ] . In contrast , secondary resistance generally occurs 6 to 24 months after patients’ initial response to the treatment and is rarely seen in patients with @GENE$ mutations [ ] . By definition , only secondary resistance is potentially amenable to @DRUG$ reintroduction .", "label": "resistance or non-response"}
{"id": "23994953", "sentence": "Unfortunately , the @GENE$ TKI-driven improvement in patient outcome is notably limited because virtually all NSCLC patients with erlotinib/gefitinib sensitizing EGFR mutations eventually acquire resistance after a median of 6–12 months of EGFR TKI therapy . In approximately half of cases , the tumor cells present after disease progression contain second-site mutations that alter drug binding to the EGFR TK domain . The most common lesion ( & gt ; 90 % ) is the so-called “gatekeeper mutation , ” which involves a substitution of methionine for threonine at position 790 ( @VARIANT$ ) .", "label": "resistance or non-response"}
{"id": "24204619", "sentence": "Cinnamic acid is hydroxylated by cinnamate 4-hydroxylase ( @VARIANT$ ) to generate ρ-coumaric acid , which is converted to ρ-coumaroyl-CoA by 4-coumarate : CoA ligase ( 4CL ) . This product proceeds through a series of transformation into monolignol by the action of caffeoyl-CoA O-methyltransferase ( CCoAOMT ) , ferulate 5-hydroxylase ( F5H ) @GENE$ and cinnamoyl @DRUG$ dehydrogenase ( CAD ) , respectively .", "label": "None"}
{"id": "23569389", "sentence": "No differences in overall response rate were observed in patients with @GENE$ mutations at baseline , in particular for p-loop mutations . A subanalysis was conducted by Branford et al on the emergence of new detectable mutations in 479 patients treated with dasatinib after @DRUG$ failure , and development of new mutations , including @VARIANT$ , F317L , and V299L , was rare ( 13 % ) .", "label": "None"}
{"id": "24278698", "sentence": "Indeed , the genetic variants of OCT1 P283L and P341L and of OCT2 @VARIANT$ , T201 M , and A270S , which were identified in a Korean population , decreased the transport of lamivudine in vitro [ ] . Another example of the pharmacological importance of OCT genetic variation is furnished by the demonstration that the presence of the @GENE$ polymorphism A270S significantly changes the renal clearance and the net secretion of metformin in healthy volunteers [ ] . Focusing on cisplatin , the first direct demonstration of @DRUG$ transport by OCT came from in vitro studies with HEK293 cells stably transfected with hOCT .", "label": "None"}
{"id": "21165163", "sentence": "Given that @VARIANT$ and MET amplification collectively account for approximately 60 % of the acquired resistance cases , there are clearly additional mechanisms that underlie resistance to EGFR TKIs . Other mechanisms that have been implicated in acquired resistance include overexpression of AXL tyrosine kinase receptor [ ] , altered @GENE$ trafficking [ ] , expression of insulin-like growth factor-1 [ ] , amplification of mutant EGFR or hyperactivation of components of downstream signaling pathways [ ] , and expression of the ABCG2 drug-efflux transporter [ ] . Recently , it has been shown that activation of TGF-β/IL-6 signaling leads to epithelial-to-mesenchymal transition and @DRUG$ resistance [ ] .", "label": "resistance or non-response"}
{"id": "15736989", "sentence": "Similar mutations in the homologous residues of the kinase domains of PDGFRA ( @VARIANT$ ) and @GENE$ ( T670I ) account for @DRUG$ resistance in some patients with hypereosinophilic syndrome and gastrointestinal stromal cell tumors , respectively [ , ] .", "label": "None"}
{"id": "17973573", "sentence": "However , we found that @DRUG$ treatment of these cells did not result in dephosphorylation of @GENE$ substantial apoptosis ( B ) , presumably due to the presence of the additional ( @VARIANT$ ) mutation , known to reduce the kinase activity of EGFR , rendering it effectively wild type [ ] .", "label": "None"}
{"id": "22675625", "sentence": "The activating @VARIANT$ BRAF mutation is present in an additional 10 % of patients , and it may be predictive of a lack of response to anti-EGFR therapy [ ] in addition to a clear poor prognostic factor . The @GENE$ monoclonal antibodies and their predictive biomarkers have taken CRC treatment another step closer to personalized therapy . However , the recent results of the large UK COIN study and a Belgian study have not confirmed a benefit in terms of PFS or OS from the addition of cetuximab to @DRUG$ based chemotherapy in wild-type KRAS patients versus 5-FU and oxaliplatin alone [ , ] .", "label": "None"}
{"id": "23788917", "sentence": "In case of occurrence of both @VARIANT$ and T790M mutations , the concentration of @DRUG$ should be three times higher in order to achieve a therapeutic effect . Analysis of the EGFR structure in patients harbouring the T854A mutation suggests the presence of an additional side chain , localised near the @GENE$ TKI binding site [ ] .", "label": "sensitivity"}
{"id": "24419415", "sentence": "In contrast to @DRUG$ , irreversible TKIs inhibited the growth of cells with G719X or @VARIANT$ at a lower concentration than those with wild-type @GENE$ .", "label": "None"}
{"id": "25364578", "sentence": "To investigate its use as a single agent , CO-1686 is being evaluated in a phase I/II trial in @GENE$ NSCLC patients previously treated with first-line @DRUG$ or erlotinib ( NCT01526928 ) . In the phase I study , and based on early findings from the ongoing phase II trial , the agent yielded a 58 % ORR across all dose levels in trial participants with biopsy confirmed EGFR @VARIANT$ mutations .", "label": "resistance or non-response"}
{"id": "21901086", "sentence": "Dissection of the stress response in S. pombe revealed that an Swr1 independent @VARIANT$ .Z binding at gene coding regions was obvious after genotoxic stress ( ) . Genes induced after exposure to MMS and @DRUG$ showed similar patterns . Recently , it was shown in S. cerevisiae that the roles of the Swr1 containing complex and H2A .Z become decoupled after treatment with MMS .", "label": "None"}
{"id": "25562798", "sentence": "Despite initial sensitivity and responses that in many cases can be maintained over periods of many months or even years , tumors with EGFR mutations or @GENE$ gene rearrangements treated with specific inhibitors will ultimately progress—a process termed acquired resistance . In the case of acquired resistance to @DRUG$ and erlotinib in EGFR mutant tumors two major mechanisms have been identified . Firstly , a secondary mutation , the @VARIANT$ mutation within exon 20 of EGFR , is responsible for about 50 % of instances of acquired resistance [ , ] .", "label": "None"}
{"id": "23817662", "sentence": "Further studies of @DRUG$ revealed that this 4-anilinoquinazoline inhibitor , structurally similar to erlotinib , binds the @GENE$ c.2573T & gt ; G ( L858R ) mutant with a 20-fold higher affinity compared to the wild-type enzyme . Both mutations , the activating EGFR c.2573T & gt ; G ( L858R ) and the inhibiting EGFR c.2369C&gt ; T ( @VARIANT$ ) were found in our cytological assessment .", "label": "resistance or non-response"}
{"id": "24981574", "sentence": "As stimulated , IκB is phosphorylated by activated @GENE$ ( IκB kinase ) and degraded by proteasome , leading to the release of NF-κB and subsequent nuclear translocation to modulate gene expression . Since previous studies have suggested that a putative NFκB response element ( 5′-GGGRNWYYCC-3′ ) is located at 5′-flanking region of BTG2 gene , we further evaluated whether @DRUG$ modulates BTG2 through the NFκB pathway in PC-3 cells . These results are in agreement with previous study showing curcumin upregulated BTG2 expression by blocking the NFκB activity in U937 cells , a human leukemic monocyte lymphoma cell line although other early study indicated that NFκB is the activator of BTG2 expression in @VARIANT$ cells , a human ductal breast epithelial tumor cell line .", "label": "None"}
{"id": "24955213", "sentence": "@VARIANT$ EML-ALKpm Lowers crizotinib-protein affinity by eliminating two H-bonds between @DRUG$ and the @GENE$ binding site [ , , ]", "label": "resistance"}
{"id": "22933967", "sentence": "In another phase II POCHER trial , the proportion of R0 resection was even higher ; it was achieved in 60 % of patients who were treated with chronomodulated chemotherapy with irinotecan , oxaliplatin , 5- fluorouracil and @DRUG$ . In conclusion , the results of our retrospective study showed that the patients with BRAF @VARIANT$ mutation had worse prognosis than those with wt-BRAF , with lower response rates and progressed early during systemic treatment , consequently , with less possibilities to achieve resectability of metastatic disease . The definitive role of the BRAF V600E mutation as a prognostic and predictive factor to response to the @GENE$ monoclonal antibodies needs to be analyzed in large prospective clinical studies .", "label": "None"}
{"id": "24155950", "sentence": "Additionally , we have used the Baf3 Bcr-Abl @VARIANT$ cell line , derived from Baf3 ( an immortalized murine pro-B cell line ) , which is also resistant to 1μM imatinib and at least partially resistant to dasatinib and nilotinib treatments ( -6 ) . In addition to its effect on imatinib-sensitive cell lines , the bortezomib/paclitaxel regimen was able to induce @GENE$ cleavage , a measure of caspase activation [ - ] , in K562-R cells and significant downregulation of the total levels and phosphorylation of Bcr-Abl in all tested TKIs-resistant cell lines .", "label": "None"}
{"id": "19238632", "sentence": "Acquired MET amplification was identified to be a potential alternative mechanism to enable the mutant EGFR expressing HCC827 to become secondarily resistant ( HCC827-GR ) without a @VARIANT$ mutation . In the course of our study , reported the presence of MET amplification that occurred independently with and without T790M-EGFR mutation in lung tumours . Interestingly , another recent report adopted a global phosphoproteomic approach using cell lines sensitive to gefitinib ( HCC827 ) and sensitive to SU11274 ( MKN45 ) , and showed that besides @GENE$ inhibition , @DRUG$ also inhibited p-MET ( that is indeed constitutively activated ) in HCC827 , but not vice versa ( ) .", "label": "resistance or non-response"}
{"id": "22815900", "sentence": "Furthermore , these activating mutations gained addiction to EGFR in lung cancer cells , resulting in enhanced susceptibility to @GENE$ such as gefitinib and @DRUG$ , – . One serious problem with EGFR-TKI treatment is the appearance of drug-resistant tumors . For acquired resistance , secondary mutation in the EGFR gene @VARIANT$ – or alternative EGFR independent activation of cell growth signaling pathways including c-Met activation is well-known , .", "label": "resistance or non-response"}
{"id": "24070194", "sentence": "We next tested the expression of Pint in different mouse cell types at different time points after induction of p53 by @DRUG$ induced DNA damage , including p53+/+ and @GENE$ MEFs ( Figure ) , and K-RAS lung tumor and sarcoma cells ( Figure ; see Additional file : Figure @VARIANT$ ) after genetic restoration of the p53 gene [ ] .", "label": "None"}
{"id": "25408851", "sentence": "In this respect , @DRUG$ ( a third generation TKI ) has been recently shown to overcome the pharmacologic resistance mediated by some mutations of the @GENE$ protein such as the @VARIANT$ , and achieve impressive frequency of molecular CR .", "label": "response"}
{"id": "25364578", "sentence": "Studies of @GENE$ rearranged lung cancers with acquired resistance to @DRUG$ have identified ALK fusion gene amplification and secondary ALK TK domain mutations ( @VARIANT$ and G1269A ) in about one third of cases .", "label": "resistance"}
{"id": "22363766", "sentence": "These trials will test the efficacy of second-generation @GENE$ inhibitors or approved EGFR inhibitors ( such as @DRUG$ ) in combination with other inhibitor drugs such as MET/VEGFR2 inhibitors . Subtype 1.2 – Overview Subtype 1.2 is defined as NSCLC that harbors a @VARIANT$ mutation in exon 20 of the EGFR gene .", "label": "resistance or non-response"}
{"id": "24189400", "sentence": "Furthermore , common proteins utilized by @DRUG$ sensitive and resistant ( @VARIANT$ @GENE$ ) could be candidate targets to overcome resistance to EGFR TKI .", "label": "resistance or non-response"}
{"id": "25364578", "sentence": "Lazzara and colleagues found that @GENE$ Y542 phosphorylation was not induced in response to EGF in the H3255 cells , which harbor the missense @VARIANT$ exon 21 mutation , suggesting that SHP2 activity may be less efficiently promoted by EGFR L858R and the STAT3 pathway may be more active . The main problem is that STAT3 activation is not abrogated by single EGFR TKI treatment with gefitinib , @DRUG$ , afatinib or dacomitinib , - .", "label": "None"}
{"id": "25238247", "sentence": "In analogous settings , secondary mutations , such as KIT exon 17 mutations in imatinib-resistant GIST and EGFR @VARIANT$ in EGFR mutated lung cancers are common mechanisms of resistance , . There is no in vivo data currently available on potential mechanisms of resistance to lapatinib . In an in vitro model system , the secondary mutation , ErbB2 T798I imparts the strongest lapatinib resistance effect in @GENE$ cells and is analogous to the epidermal growth factor receptor T790M – .", "label": "None"}
{"id": "22436374", "sentence": "H1650 and HCC827 have an in-frame deletion in the EGFR tyrosine kinase domain ( @GENE$ tyrosine kinase domainΔE746-A750 , exon 19 ) . H1650 cells have also a deletion of the 3 ' part of exon 8 and the entire exon 9 of PTEN , which causes loss of the protein [ ] and in addition express the insulin-like growth factor receptor ( IGF1R ) [ ] . The cell line H1975 has a sensitizing L858R kinase domain mutation in exon 21 , but also a second mutation ( @VARIANT$ , in cis , in the kinase domain ) rendering them resistant to the reversible TKIs @DRUG$ and erlotinib [ ] .", "label": "resistance or non-response"}
{"id": "23690929", "sentence": "Epidermal growth factor receptor (EGFR) activating mutations , such as exon 19 deletion and exon 21 @VARIANT$ point mutation , are found in a population of NSCLC , and are associated with a clinical response to the @GENE$ tyrosine kinase inhibitors ( EGF-TKIs ) , @DRUG$ and erlotinib – .", "label": "sensitivity"}
{"id": "24124608", "sentence": "In addition to upregulation of IGF1R and VEGF , frequent CN gain and increased mRNA expression of GSTT1 as well as significant overexpression of ZNF subfamily members were observed in @GENE$ @VARIANT$ GISTs compared to KIT-mutant GISTs . CN gain of GSTT1 was closely associated with @DRUG$ resistance .", "label": "resistance or non-response"}
{"id": "17325698", "sentence": "We also limit our mutation search to deletions in exon 19 and @VARIANT$ , because it would be less laborious and these two are most reliable predictor for response or survival . In this way , the survival benefit of @GENE$ , especially @DRUG$ , should be demonstrated in future clinical trials in a defined subset of patients with lung cancer .", "label": "sensitivity"}
{"id": "23785245", "sentence": "Similar to mutations in @GENE$ ( T315I ) or in KIT ( T670I ) that underlie resistance to @DRUG$ , @VARIANT$ is thought to interfere with the binding of EGFR-TKIs at the adenosine triphosphate binding cleft of EGFR . , , On the other hand , the affinity of this cleft for adenosine triphosphate is increased by T790M .", "label": "None"}
{"id": "25465236", "sentence": "( G–I ) increased inhibition potency for @DRUG$ against EGFR L858R mutant compared to EGFR WT protein and subsequent further increase in potency for Gefitinib against @GENE$ L858R + E884K double mutant . ( J ) EGFR L861Q activated more than @VARIANT$ but less than L858R .", "label": "resistance or non-response"}
{"id": "23606169", "sentence": "Because mutations in the @GENE$ gene result in activation of the epidermal growth factor receptor (EGFR) signaling pathway , only metastatic colorectal cancer patients with wild-type KRAS tumors qualify for anti-EGFR targeted therapies with cetuximab or panitumumab [ ] . Also , a clinical trial with the BRAF inhibitor ( @DRUG$ ) demonstrated antitumor activity in tumors with the BRAF @VARIANT$ mutation and confirmed that V600E BRAF is a valid therapeutic target in human cancer [ ] .", "label": "None"}
{"id": "21503901", "sentence": "Whilst most substrates of @GENE$ remained unaltered in @VARIANT$ lungs , we showed a significant increase in Klf5 and Tgif1 . Both Klf5 and Tgif1 are involved in multiple pathways , several of which are known to be important in lung development . Tgif1 knockdown in vitro causes disruption of both Tgf-β and @DRUG$ @DRUG$ pathways .", "label": "None"}
{"id": "22361010", "sentence": "Another group of @GENE$ mutations is clustered in the ROC-COR bidomain . The R1441 position in the ROC/GTPase is mutated to cysteine , glycine or @DRUG$ ( that is , R1441C/G/H ) in families with PD [ , - ] . Several families who have a @VARIANT$ mutation in the adjacent COR domain have been described [ , ] .", "label": "None"}
{"id": "23976869", "sentence": "@DRUG$ is a dual SRC/ABL1 inhibitor that also inhibits PDGFRs and FIP1L1-PDGFRA fusion but has no effect on imatinib-resistant @GENE$ T674I and D842V mutants . Third generation of TKIs : ponatinib Ponatinib has a potent activity towards BCR-ABL1 , as well as numerous imatinib-resistant BCR-ABL1 kinase domain mutants , including the @VARIANT$ mutation .", "label": "None"}
{"id": "23520446", "sentence": "In addition to the EGFR overexpressed cells , we also showed the phosphorylation status of @GENE$ and -Ser1046 in endogenous @VARIANT$ mutant cells ( H1975 ) under treatment of VE-465 and @DRUG$ ( ) .", "label": "sensitivity"}
{"id": "23606169", "sentence": "These samples were found not to carry mutations in KRAS codons 12 and 13 ; however , the patients , after @DRUG$ treatment and a short remission ( 2 months ) , had new metastasis . Finally , three additional controls were added to our study : the HT29 cell line was included as an internal control for the V600E BRAF mutation and KRAS WT . Then two KRAS controls ( @GENE$ 8 with the @VARIANT$ mutation and Ctrl 9 with the G13D mutation found previously by the TheraScreen® : K-RAS Mutation Kit for the detection of seven mutations ( by DxS Diagnostic Innovations ) [ ] .", "label": "None"}
{"id": "23520446", "sentence": "Approximately 50 % of EGFR mutations consist of deletions in exon 19 , whereas 35–45 % consist of the @VARIANT$ mutation and 5 % consist of insertions in exon 20 or the L861Q mutation – . @DRUG$ ( Iressa ) and Erlotinib ( Tarceva ) are @GENE$ inhibitors that are used clinically for the treatment of advanced NSCLC , primarily that with EGFR mutations in the tyrosine kinase domains – .", "label": "sensitivity"}
{"id": "15737014", "sentence": "Importantly , we find that the T790M mutation confers drug resistance not just to wild-type EGFR but also to mutant EGFRs associated with clinical responsiveness to @GENE$ tyrosine kinase inhibitors [ , , ] . In tumors from patients not treated with either @DRUG$ or erlotinib , the 2369 C→T mutation ( T790M ) appears to be extremely rare . We have not identified this mutation in 155 tumors ( see above ) , and among nearly 1,300 lung cancers in which analysis of EGFR exons 18 to 21 has been performed [ , ,, , , ] , only one tumor ( which also harbored an @VARIANT$ mutation ) was reported to contain the T790M mutation .", "label": "sensitivity"}
{"id": "24928511", "sentence": "More than 50 % of lung adenocarcinomas (LAD) from East Asian non-smokers harbor EGFR mutations , and these tumors have been termed oncogene addicted to reflect their dependence on @GENE$ mediated pro-survival signaling and their high susceptibility to apoptosis induced by EGFR-TKIs ( e.g. gefitinib and @DRUG$ ) ( ) . The most frequently occurring mutations in the EGFR gene ( in-frame deletion in exon 19 at codons 746–750 or a single-base substitution @VARIANT$ in exon 21 ) predict an improved clinical response to first-line oral EGFR-TKIs compared with standard platinum based chemotherapy in patients with advanced non-small-cell lung carcinoma ( NSCLC ) ( , ) .", "label": "sensitivity"}
{"id": "18828913", "sentence": "Sensitivity of Bcr-Abl kinase domain P-loop mutants to imatinib , nilotinib and dasatinib @GENE$ cellular proliferation IC50 value @DRUG$ ( nM ) Nilotinib ( nM ) Dasatinib ( nM ) @VARIANT$ P-loop 2000 38 1.3", "label": "None"}
{"id": "25580271", "sentence": "Two phase III trials compared afatinib to a platinum-doublet in patients with advanced EGFR mutant NSCLC , and a combined analysis for overall survival was presented at ASCO , as well as subset analyses based on EGFR mutation subtype ( exon 19 deletion and exon 21 @VARIANT$ point mutation ) [ ] . In subgroup analysis based on EGFR mutation type the benefit appeared to be limited to patients with exon 19 mutations . When cross-over to EGFR tyrosine kinase inhibitor therapy was examined , 75 % of patients who received cisplatin and pemetrexed received an @GENE$ tyrosine kinase inhibitor and 56 % of patients who received cisplatin and @DRUG$ received an EGFR tyrosine kinase inhibitor .", "label": "None"}
{"id": "17325698", "sentence": "High response rate in patients with @GENE$ mutations to @DRUG$ was confirmed in the recently published prospective phase II study ( and . In this study , @VARIANT$ of exon 18 showed intermediate sensitivity , suggesting the mutation-specific treatment strategy for patient care .", "label": "sensitivity"}
{"id": "24502453", "sentence": "Nilotinib1 Tasigna® Novartis @GENE$ , KIT , PDGFR-A , PDGFR-B CML 19th November 2007 No CML Pazopanib Votrient® Glaxo Smith Kline VEGFR , PDGFR , KIT Renal cell carcinoma , STS 14th June 2010 No Withdrawn Ponatinib2 Iclusig® Ariad BCR-ABL Patients with CML for which Imatinib , Nilotinib , and Dasatinib are not appropriate ( or patients carrying a @VARIANT$ single-point-mutation ) 1st July 2013 CML , ALL", "label": "None"}
{"id": "24298448", "sentence": "Vemurafenib ( @DRUG$ ) and dabrafenib ( GSK2118436 ) are approved for treatment of unresectable or metastatic melanoma ( Food and Drug Administration ) and vemurafenib is also approved by the European commission/European Medicines Agency . Both selectively inhibit the BRAF V600 mutated form of @GENE$ , inhibit phosphorylation of ERK , and have high clinical response rates in melanoma patients ( Figure C ) ( , ) . It has been noted already in xenografts from BRAF @VARIANT$ mutant colorectal cancer cell lines that tumor growth inhibition was most efficient when vemurafenib was combined with EGRF or Akt inhibitors and/or chemotherapeutic agents ( ) .", "label": "None"}
{"id": "24279718", "sentence": "The @GENE$ mutation L862R has to our knowledge not previously been described in the literature , but given its proximity to mutations known to be sensitive to EGFR-TKI ( @VARIANT$ and L861X ) , tumor clones bearing the L862R mutation could also be potentially responsive to EGFR-TKI . Meanwhile , because of rapid worsening while waiting for these new molecular tests the patient received third-line pemetrexed , showing further progression in abdomen and pelvis , but still no sign of relapse in the thorax . Unfortunately , the patient rapidly deteriorated and died before being able to attempt a palliative radiation of the lymph nodes in pelvis and a fourth-line treatment with @DRUG$ .", "label": "sensitivity"}
{"id": "23994953", "sentence": "While preparing this manuscript , Cortot et al. reported that PC-9 derived clones with acquired resistance to mutant-selective EGFR inhibitors and irreversible quinazoline EGFR inhibitors in the absence of EGFR @VARIANT$ demonstrate a significantly activated IGF-1R signaling , and pharmacological inhibition of IGF-1R restored sensitivity to EGFR inhibitors . Despite no patient data supporting the role of IGF-1R in acquired resistance to gefitinib/erlotinib , we are beginning to accumulate evidence from preclinical models indicating that clinical trials of IGF-1R inhibitors with demonstrated activity in unselected NSCLC patients might play a role in association with @GENE$ inhibitors in the management of NSCLCs with acquired resistance to gefitinib/erlotinib .", "label": "resistance or non-response"}
{"id": "20972475", "sentence": "Also available is a second assay , the BRAF ( @VARIANT$ Sequencing ) ( V6S ) , which uses sequencing to detect the @GENE$ p.Val600Glu sequence variant . Public Health Importance Available evidence indicates that the clinical benefit from treatment with EGFR monoclonal antibody inhibitors @DRUG$ and panitumumab is limited to a subgroup of only 10 % to 30 % of CRC patients .", "label": "resistance or non-response"}
{"id": "17973572", "sentence": "The activation loop is orange , helix αC yellow , the glycine-rich P-loop green , and the inhibitor @DRUG$ yellow . The figure was made using the program PYMOL ( http : //pymol.sourceforge.net/ ) . ( D ) Top : Dose dependent growth inhibition of Ba/F3 cells expressing @GENE$ @VARIANT$ (LR) , L858R-T790M (LR-TM) , or L858R-L747S ( LR-LS ) detected by the MTS assay .", "label": "sensitivity"}
{"id": "20532504", "sentence": "The possible presence of associations between 1236C &gt ; T , @GENE$ ; W ( W = T or A ) , and 3435C &gt ; T in MDR1 and @VARIANT$ in MRP1 and the response rate of the bortezomib or PLD + @DRUG$ groups , as well as response durability measures , were then evaluated .", "label": "None"}
{"id": "22101934", "sentence": "While clearly an increase , this 5–8-fold change is substantially lower than the 50- to 200-fold Km differences for ATP among these @GENE$ forms , suggesting that the ATP Km differences result largely from changes in rate determining steps in catalysis , rather than simply changes in binding affinities for nucleotide . The @VARIANT$ and Δ746–750 tEGFR forms were potently inhibited by @DRUG$ with apparent Kis in the range of 0.1–0.4 µM , about equal to the apparent Ki of erlotinib for WT tEGFR complexed with EGF .", "label": "sensitivity"}
{"id": "25465236", "sentence": "( C ) EGFR @VARIANT$ mutant does not resemble pEGFR unlike the EGFR L858R mutant shown in B. ( D–F ) increased inhibition potency for Erlotinib against EGFR L858R mutant compared to EGFR WT protein and subsequent decrease in potency for Erlotinib against EGFR L858R + E884K double mutant . ( G–I ) increased inhibition potency for Gefitinib against @GENE$ L858R mutant compared to EGFR WT protein and subsequent further increase in potency for @DRUG$ against EGFR L858R + E884K double mutant .", "label": "resistance or non-response"}
{"id": "24894453", "sentence": "Although high-level expression of @GENE$ ligands and/or increased EGFR gene copy numbers may be predictive markers for antitumor response by @DRUG$ in colon cancer [ - ] , and patients with RAS driven cancers are known not to benefit from cetuximab treatment , a clear molecular explanation of cancer response to cetuximab has remained elusive . Genomic studies identify @VARIANT$ mutant in colorectal carcinomas", "label": "sensitivity"}
{"id": "25079768", "sentence": "The second-line treatment , after @DRUG$ failure , is provided by less specific kinase inhibitors , such as sunitinib that shows potency against imatinib-resistant @GENE$ mutated in the ATP binding pocket ( @VARIANT$ and T670I ) .", "label": "resistance"}
{"id": "23984412", "sentence": "Moreover , this work reveals that @DRUG$ , a common drug used to treat breast cancer ( ER+ ) patients , induces heparanase expression in MCF-7 and @VARIANT$ cells . Other transcriptional factors can modulate heparanase expression in breast carcinoma , such as the @GENE$", "label": "None"}
{"id": "23696715", "sentence": "A recent study compared the effect of four TKIs ( axitinib , sunitinib , @DRUG$ , and XL184 ) on cell proliferation , @GENE$ autophosphorylation , and extracellular signal regulated kinase activation in three cell lines : MZ-CRC-1 ( @VARIANT$ RET mutation ) , MTC-TT ( C634W RET mutation ) , and TPC-1 ( RET/PTC-1 rearrangement ) cells .", "label": "response"}
{"id": "24789720", "sentence": "Mechanism of achieving resistance to @DRUG$ and gefitinib remains unclear . The recent reports confirmed , that @VARIANT$ substitution could be detected in EGFR-TKIs naïve patients independently of other @GENE$ gene mutations ( predominantly L858R substitution and deletions in exon 19 ) .", "label": "resistance or non-response"}
{"id": "24944676", "sentence": "The aim of the present study was to investigate the Twist2 expression pattern in a cisplatin-sensitive ovarian cancer cell line ( OV2008 ) and the resistant variant ( @VARIANT$ ) , and to determine the effect Twist2 has on the regulation of cell growth and @DRUG$ induced apoptosis in ovarian cancer cells . Furthermore , the effect Twist2 has on the protein kinase B ( @GENE$ ) /glycogen synthase kinase (GSK)-3β signaling pathway was investigated .", "label": "None"}
{"id": "24586514", "sentence": "@DRUG$ induced growth arrest and apoptosis , thus aggravating the apoptotic and cytotoxic effects of ponatinib on @GENE$ @VARIANT$ mutant cells .", "label": "None"}
{"id": "15737014", "sentence": "We have not identified this mutation in 155 tumors ( see above ) , and among nearly 1,300 lung cancers in which analysis of @GENE$ exons 18 to 21 has been performed [ , ,, , , ] , only one tumor ( which also harbored an @VARIANT$ mutation ) was reported to contain the T790M mutation . Whether the patient from which this tumor was resected had received @DRUG$ or erlotinib is unclear , and the report did not note an association with acquired resistance to either drug [ ] .", "label": "sensitivity"}
{"id": "22123319", "sentence": "In a melanoma study of 21 patients who received a sufficiently high dose of vemurafenib , 5 without the @VARIANT$ BRAF mutation did not respond to the drug ; however , of 16 patients with the mutation , 9 responded to vemurafenib and 7 did not [ ] . In a phase II study of imatinib for advanced melanoma , a substantial proportion of patients with tumors characterized by mutation or amplification of KIT responded to the drug whereas it had limited activity in a nonselected population of melanoma patients [ ] . Results of the CRYSTAL trial indicate that the clinical activity of cetuximab against metastatic colorectal cancer is enhanced in patients with wild-type KRAS compared with individuals having @GENE$ mutations , none of whom benefited from @DRUG$ treatment [ ] .", "label": "None"}
{"id": "24367701", "sentence": "This @GENE$ to the endoplasmic reticulum and has been shown to play a critical role in @DRUG$ ( RIG-I ) gene signaling , acting as a sensor of RNA virus infection [ ] . In fact , many elements of the regulatory pathways governing both the RIG-I pathway and IFN gene expression are themselves regulated by IFN . In turn , IFN may coordinate the upregulation of antiviral factors , as revealed by the A3G , @VARIANT$ , TRIM , tetherin and MxA mRNA expression levels in paired maternal blood and CB samples .", "label": "None"}
{"id": "24634705", "sentence": "Targeting the oncogenic fusion protein echinoderm microtubule associated protein-like 4-anaplastic lymphoma kinase ( EML4-ALK ) with TKIs such as @DRUG$ has also been shown to be negatively affected by the development of secondary gate keeper residue mutations such as @VARIANT$ , and the emergence of fusion negative tumors that render the disease insensitive to the drug . EGF ( @GENE$ , IGF ( insulin-like growth factor , HGF ( hepatocyte growth factor ) , GTP ( guanosine triphosphate ) .", "label": "None"}
{"id": "22043165", "sentence": "In addition , chemical chaperones and pharmacological agonists efficiently restore cell surface expression and endogenous agonist response of mutated melanocortin 4 receptors [ , ] , but in vivo beneficial effects in @GENE$ deficient monogenic patients remain to be demonstrated . To date , the two main anti-obesity drugs used are @DRUG$ and sibutramine ( a saturated derivative of lipstatin and a serotonin-norepinephrine reuptake inhibitor , respectively ) . The guanine nucleotide binding protein beta polypeptide 3 ( GNB3 ) gene @VARIANT$ polymorphism is highly predictive for the identification of obese individuals who will benefit from sibutramine treatment .", "label": "None"}
{"id": "24348666", "sentence": "This leads to dacomitinib and @DRUG$ to be irreversible inhibitors of @GENE$ . More specifically , they covalently bind to Cys-797 of EGFR via the sulfur atom ( ) . Due to their covalent binding mode , irreversible inhibitors have activity towards EGFR @VARIANT$ , EGFR T790M/L858R as well as wild-type EGFR .", "label": "response"}
{"id": "19707313", "sentence": "Resistance against @DRUG$ is an emerging problem in the treatment of CML. Dose-adjustments , new @GENE$ targeting drugs , and other antileukemic approaches may be sufficient to overcome resistance in many cases . A specific challenge remains the @VARIANT$ mutant of BCR/ABL that is resistant against most available TK inhibitors .", "label": "None"}
{"id": "25032048", "sentence": "Hereditary @GENE$ is an autosomal recessive disorder where a mutation occurs at on chromosome 6 of the short arm of HFE resulting in two changes : the substitution of tyrosine for cysteina at position 282 ( C282Y ) and the substitution of aspartic acid for @DRUG$ at position 63 ( @VARIANT$ ) of HFE protein .", "label": "None"}
{"id": "25429239", "sentence": "It inhibits both @VARIANT$ in ALK+ NSCLC and the T790M in EGFR mutants . Phase I/II data for AP26113 have demonstrated efficacy in both @DRUG$ naive and resistant patients . It also has the ability to cross the blood–brain barrier and is active in @GENE$ brain metastasis .", "label": "resistance"}
{"id": "18937829", "sentence": "Control patients 18 f 72 Rectum 5FU 1 1 0 - 20 0 19 f 54 Gastric 5FU-FA-P 2 1 0 c.1679T & gt ; G , I560S_21 0 20 m 59 Pancreas 5FU-FA-P 0 1 0 c.85T & gt ; C , C29R ; c.1627A&gt ; G , I543V ( H ) 20 0 21 m 62 Colon 5FU-FA-P 0 1 0 c.85T & gt ; C , C29R ( H ) ; c.496A&gt ; G , M166V , c.1236G&gt;A , E412E 19 0 22 f 64 Colon 5FU-FA 0 0 0 c.85T & gt ; C , C29R ; c.1627A&gt ; G , I543V 20 0 23 m 63 Oesophagus 5FU-P_1 0 0 - 20 0 24 f 69 Colon 5FU-FA 0 1 0 c.85T & gt ; C , C29R ( H ) ; c.496A&gt ; G , M166V ; c.2194G&gt;A , @VARIANT$ 20 0 25 m 59 Gastric 5FU-FA_1 1 0 c.85T & gt ; C , C29R ; c.1627A&gt ; G , I543V ; 1896T & gt ; C , F632F 21 0 26 m 59 Colon 5FU-FA-P 1 1 0 c.85T & gt ; C , C29R ( H ) ; c.496A&gt ; G , M166V ; @GENE$ ; G , I543V 20 0 27 m 62 Gastric E-CAPE-P_2_1 2 c.85T & gt ; C , C29R ( H ) ; c.496A&gt ; G , M166V ; c.1236G&gt;A , E412E c.1627A&gt ; G , I543V 30 0 Abbreviations : FA , folinic acid ; CAPE , capecitabine ; P , platinum compound ; E , epirubicin ; C , @DRUG$ ; H , homozygous carrier a adenocarcinoma of unknown origin", "label": "None"}
{"id": "22970367", "sentence": "One of these agents , BIBW2992 ( @DRUG$ ) , is able to target both EGFR and @GENE$ and overcome T790M-driven acquired resistance [ ] . However , in clinical studies , BIBW2992 did not prolong survival compared to placebo in NSCLC patients who have developed acquired resistance to gefitinib or erlotinib [ ] . Another agent in this class of next generation EGFR TKIs , PF-002999804 , inhibits all ERBB family members and has been shown to be effective against tumors harboring @VARIANT$ [ , ] .", "label": "None"}
{"id": "24410791", "sentence": "Second generation EGFR TKIs e.g. , BIBW 2992 ( @DRUG$ ) and PF00299804 ( dacomitinib ) , and third generation @GENE$ TKIs e.g. , CO-1686 and AZD9291 are irreversible inhibitors that could overcome the AR caused by @VARIANT$ .", "label": "response"}
{"id": "25162713", "sentence": "Many evidences showed that patients with advanced lung adenocarcinomas harbor EGFR mutations , @VARIANT$ missense mutations at exon 21 or deletions in exon 19 were more sensitive to the @GENE$ @DRUG$ or gefitinib , , .", "label": "sensitivity"}
{"id": "16953242", "sentence": "In fact , the pleiotropic effect of BCR/ABL transformation is mostly dependent on post-translational modifications ( e.g. phosphorylation ) of signalling molecules , like those involved in the @GENE$ , PI3K/Akt and STATs pathways , which control cell growth , survival and differentiation of haematopoietic cells by modulating the expression and/or activity of downstream effectors ( ; ) ( ) . Being the deregulated BCR/ABL kinase activity the cause of CML , targeting its catalytic domain was the most rationale approach for the rational development of small molecules that inhibit ABL kinase activity . In these CML-BC patients , imatinib resistance often depends on reactivation of BCR/ABL tyrosine kinase activity via mechanisms involving BCR/ABL overexpression , gene amplification or mutations that suppress @DRUG$ mediated kinase inhibition ( i.e. E255V and @VARIANT$ ) or disrupt imatinib binding ( i.e. T315I ) ( ) .", "label": "None"}
{"id": "24124608", "sentence": "In addition to upregulation of IGF1R and VEGF , frequent CN gain and increased mRNA expression of GSTT1 as well as significant overexpression of @GENE$ subfamily members were observed in wild-type/PDGFRA @VARIANT$ GISTs compared to KIT-mutant GISTs . CN gain of GSTT1 was closely associated with @DRUG$ resistance .", "label": "None"}
{"id": "22363766", "sentence": "Sub-type Description Pathway Potentially relevant therapies Relevant histological subtypes Strength of evidence for clinical use* 1 .1 EGFR sensitizing mutations EGFR TKIs & amp ; chemotherapy Adenocarcinoma High 1.2 EGFR resistance mutations including @VARIANT$ EGFR Dual EGFR/HER2 TKI , c-MET inhibitors +/− 1st or 2nd generation @GENE$ TKIs , Hsp90 inhibitors , dual MET/VEGFR2 inhibitors , Chk1 inhibitors Adenocarcinoma High 1.3 VeriStrat proteomic signature EGFR TKIs & amp ; @DRUG$ Adenocarcinoma High 2.1 K-ras mutations K-ras Dual MAPK & amp ; AKT/PI3K inhibitors , Hsp90 inhibitors Adenocarcinoma High 3.1 EML4-ALK EML4-ALK ALK inhibitors , Hsp90 inhibitors Adenocarcinoma High 10.1371/journal.pone.0031906.t002Secondary lung cancer molecular subtypes .", "label": "None"}
{"id": "24386407", "sentence": "Among the mechanisms by which cancer cells become resistant to reversible EGFR-TKIs are 1 ) gatekeeper mutations in EGFR , such as the @VARIANT$ second mutation [ , ] ; 2 ) activation of bypass signaling caused by Met amplification [ ] , hepatocyte growth factor (HGF) overexpression [ ] , or Gas6-Axl activation [ ] ; 3 ) activation of downstream molecules ( PTEN loss or PIK3CA mutation ) [ , ] ; 4 ) small-cell lung cancer transformation [ ] ; and 5 ) epithelial-to-mesenchymal transition [ ] . The gatekeeper EGFR-T790M mutation is the most frequent , occurring in half of tumors with acquired resistance to reversible EGFR-TKIs . The methionine residue at position 790 generates a bulkier side chain , which enhances the affinity of the @GENE$ tyrosine kinase pocket with ATP [ ] , decreasing the effective binding of gefitinib and @DRUG$ to the tyrosine kinase pocket of EGFR [ ] .", "label": "resistance or non-response"}
{"id": "24586842", "sentence": "Successful examples of this include the co-development ( and co-approval ) of the BRAF inhibitor vemurafenib and its companion diagnostic BRAF @VARIANT$ mutation assay for @GENE$ metastatic melanoma , and the ALK inhibitor crizotinib and its companion diagnostic ALK fusion gene test in advanced ALK-fusion positive non-small cell lung cancer ( NSCLC ) patients. , , However , in some cases , predictive biomarkers for a targeted therapy are not recognized until after the drug is first approved . As an example , the anti-EGFR antibody @DRUG$ was first approved in the US for the treatment of metastatic colorectal cancer in 2004 .", "label": "resistance or non-response"}
{"id": "25562700", "sentence": "Molecule Target Biomarker Indication vemurafenib BRAF kinase BRAF @VARIANT$ mutant melanoma @DRUG$ VEGFR , EGFR , RETR not included on the label thyroid cancer abiraterone CYP 17A1 not included on the label prostate cancer ipilimumab CTLA-4 not included on the label melanoma brentuximab vedotin CD30 ( ACD technology ) not included on the label lymphoma crizotinib ALK ALK-EML4 fusion protein lung cancer BRAF : Serine/threonine-protein kinase B-Raf ; VEGFR : Vascular endothelial growth factor receptor ; EGFR : epidermal growth factor receptor ; RETR : RET proto-oncogen receptor ; CYP 17A1 : cytochrome P450 17A1 ; CTLA-4 : Cytotoxic @GENE$ ; CD30 : Cluster of Differentiation 30 ; ADC : Antibody Conjugated Drug ; ALK-EML4 : anaplastic lymphoma kinase (ALK) ; echinoderm microtubule associated protein-like 4 ( EML4 ) fusion .", "label": "None"}
{"id": "16187797", "sentence": "Sensitivity of Cell Transformation Induced by Expression of Mutant EGFR Characterized by Missense Mutation or Exon 19 Deletion , but not Exon 20 Insertion , to @DRUG$ and Erlotinib ( A ) Anchorage independent growth of clonal NIH-3T3 cells transformed with mutant EGFR or EGF stimulated wild-type @GENE$ treated with the indicated concentrations of erlotinib immediately prior to suspension in soft agar . Transformation induced by expression of L858R , G719S , and L747_E749del @VARIANT$ EGFR , but not EGF stimulated wild-type EGFR or D770_N771insNPG EGFR , was inhibited by 0.1 μM erlotinib .", "label": "None"}
{"id": "24276379", "sentence": "It is possible that the benefit seen among patients with @GENE$ @VARIANT$ mutants in response to @DRUG$ but not panitumumab is brought about in part by the ability of cetuximab to induce antibody dependent cellular cytotoxicity ( ADCC ) [ ] .", "label": "resistance or non-response"}
{"id": "25090269", "sentence": "Transcription factors are sequence specific DNA binding proteins that interact with the @GENE$ acting element in the promoter regions of respective target genes , and modulate gene expression . The TFs exhibiting down-representation during WD included those encoding cysteine-3/histidine zinc finger domain ( @VARIANT$ ) , cysteine-rich polycomb-like protein ( CPP ) , E2 promoter binding factor-dimerization partner ( E2F-DP ) , forkhead associated domain ( FHA ) , and mitochondria transcription termination factor ( mTERF ) ( ) .", "label": "None"}
{"id": "23320171", "sentence": "Primary results from the EMILIA study , a randomized trial comparing Trastuzumab DM-1 to lapatinib and @DRUG$ , have shown that Trastuzumab DM-1 significantly improved progression-free survival in patients with metastatic HER2 positive breast cancer . Further research is looking into inhibiting other targets such as mTOR , @VARIANT$ , or @GENE$ pathways .", "label": "None"}
{"id": "22933967", "sentence": "The KRAS status is the first molecular marker to predict the response to anti-EGFR monoclonal antibodies cetuximab and @DRUG$ in metastatic CRC ( mCRC ) patients , and it needs to be determined before deciding in favor of treatment with anti-EGFR antibodies . Previous retrospective studies suggested that mt-BRAF was a marker of resistance to anti-EGFR therapy and that the patients with @GENE$ had significantly shorter PFS and OS than the patients with wt-BRAF tumours . The mutations in the KRAS and BRAF genes have been reported to be mutually exclusive. , In the retrospective analysis by Fariña- Sarasqueta et al. , it was also shown that the BRAF @VARIANT$ mutation was an independent prognostic factor for the survival of patients with colon cancer in stages II and III , while the KRAS mutations did not have any effect on the overall survival of these patients .", "label": "resistance or non-response"}
{"id": "23082072", "sentence": "However , in patients with acquired resistance , tumor cells bearing @GENE$ @VARIANT$ represented a minority of cells , and as such , part of the tumor may remain responsive to @DRUG$ or gefitinib. , The other signal pathway related EGFR followed the same principles .", "label": "resistance or non-response"}
{"id": "23874880", "sentence": "However , despite these dramatic benefits of @GENE$ TKIs , all of these patients inevitably develop resistance to @DRUG$ and erlotinib , usually 6–12 months after initiation of TKI treatment . Several mechanisms , including a @VARIANT$ mutation in the EGFR , MET amplification , and overexpression of hepatocyte growth factor (HGF) , induce acquired resistance to reversible EGFR-TKIs for NSCLC with EGFR activating mutations – .", "label": "resistance or non-response"}
{"id": "23788917", "sentence": "However , this resistance to @GENE$ TKI has been many times lower than the resistance in cells harbouring both the L858R and T790M mutations . In case of occurrence of both @VARIANT$ and T790M mutations , the concentration of @DRUG$ should be three times higher in order to achieve a therapeutic effect .", "label": "sensitivity"}
{"id": "22662320", "sentence": "Helman described their preclinical results on @DRUG$ , an old antibiotic from streptomyces , which they have identified in a 56,000 natural product EWS-FLI1 signature based screen ( Grohar et al. , ) ( Table ) . He reviewed published molecular ( inhibition of EWS-FLI1 cooperating transcription factors SP1 , @VARIANT$ , and ETS ) and first clinical results in a patient with ES ( Kofman et al. , ) , and reported on their own findings of tumor regression in TC32 xenografts .", "label": "None"}
{"id": "24523596", "sentence": "@DRUG$ BCR-ABL with mutations , including @VARIANT$ + + @GENE$ et al", "label": "None"}
{"id": "21108851", "sentence": "@DRUG$ ( AP24534 ) is a multitargeted @GENE$ kinase inhibitor with potent in vitro activity against all tested mutants of BCR-ABL including @VARIANT$ , and clinical activity has been reported in patients with a T315I mutation [ - ] .", "label": "response"}
{"id": "23937717", "sentence": "Our results suggested that @DRUG$ could enhance the ability of NK cell degradulation to lung cancer cells with @GENE$ L858R + @VARIANT$ .", "label": "resistance or non-response"}
{"id": "25381831", "sentence": "We confirmed stage IV ( T3N1M1b ) adenocarcinoma with activating @GENE$ , exon 21 @VARIANT$ . Subsequently , she received @DRUG$ as palliative treatment for primary and metastatic tumor and palliative whole brain radiation therapy to a total dose of 30 Gy in 10 fractions .", "label": "sensitivity"}
{"id": "24964744", "sentence": "It could be therefore be assumed that because @GENE$ mutations drive HER related receptor addiction in these cells it would make them more susceptible to RTK inhibition ( as seen here with @DRUG$ and erlotinib ) ( Figure ) . Cells containing the PIK3CA mutation @VARIANT$ were found to be more sensitive than those with the PIK3CA mutation H1047R , suggesting that not all activating mutations found within a given gene will result in the same activity to targeted therapy .", "label": "resistance or non-response"}
{"id": "25465236", "sentence": "The subsequent decrease in potency for @DRUG$ against the oncogenic @GENE$ L858R + @VARIANT$ double mutant correlates well with the increased global connectivity of the hub residues ( – wild type , – L858R + E884K mutant ) .", "label": "None"}
{"id": "25275314", "sentence": "shows that the side chain groups of the mutated residues Lys and the protonated histidine at position 19 of the WT substrate ( in mutants R19K and R19Hp ) also form HB interactions with the side chain carboxylate group of the PKA residue Glu170 , while the mutated residue @DRUG$ δ at the same position 19 ( in mutant R19Hδ ) also forms an HB interaction with the side chain carboxylate group of the @GENE$ residue Glu203 ( ) .", "label": "None"}
{"id": "15737014", "sentence": "To our knowledge , no NSCLC patient who initially responded to but then progressed on either @DRUG$ or erlotinib has yet been treated with lapatinib . In some of the patient specimens analyzed , the actual sequencing peaks demonstrating the @VARIANT$ mutation were smaller than originally anticipated . These results differ from those of acquired resistance mutation in CML [ ] , GIST [ , ] , and @GENE$ [ ] .", "label": "None"}
{"id": "22038681", "sentence": "Preliminary results from an ongoing phase 1 dose-escalation study of the multikinase , pan–BCR-ABL inhibitor ponatinib ( AP24534 ) showed antileukemic activity in patients with refractory CML , including patients with the @VARIANT$ mutation . Phase 1 and 2 trials of ponatinib are ongoing in patients with refractory CML and acute lymphoblastic leukemia . Danusertib ( PHA-739358 ) is a multikinase aurora inhibitor with in vitro activity against wild-type ABL and @GENE$ ; preliminary results from an ongoing phase 1 dose-escalation study indicate antileukemic activity in patients with AP or BC who failed imatinib and/or @DRUG$ or dasatinib .", "label": "None"}
{"id": "24634705", "sentence": "The D761Y mutation is located on the α-C-helix of EGFR and is similar to a mutation in @GENE$ , D276G , that is associated with acquired resistance after @DRUG$ treatment [ ] . The L747S mutation lies at the start of the β3 strand and the α-C-helix [ ] and has analogous residues in BCR-ABL ( L237M ) and ERBB2 ( L755S or P ) that have been identified in TKI resistant disease [ ] . The occurrence of these secondary mutations spurred development of second and third generation irreversible TKIs which bind covalently to the cysteinyl-797 residue in the pocket of the EGFR-kinase domain and overcome resistance driven by the @VARIANT$ mutation [ ] .", "label": "None"}
{"id": "25031955", "sentence": "AP26113 has a fivefold greater potency than does @DRUG$ in inhibiting @GENE$ as well as the @VARIANT$ gatekeeper mutation ( Katayama et al. , 2011 ) .", "label": "resistance"}
{"id": "24373626", "sentence": "5-AzadC treatment of I83-E95 and WAC3CD5+ cells resulted in demethylation of miR-9-3 and the emergence of U-MSP signal on day 5 respectively ( Figure ; Additional file : Figure @VARIANT$ ) , with the re-expression of @GENE$ as shown by TaqMan stem-loop quantitative RT-PCR ( Figure ) .", "label": "None"}
{"id": "23208557", "sentence": "Cancer @GENE$ exon18 G719X Drug efficacy prediction of @DRUG$ and erlotinib exon19 deletion exon20 @VARIANT$ exon21 L858R", "label": "resistance or non-response"}
{"id": "23320171", "sentence": "Primary results from the EMILIA study , a randomized trial comparing Trastuzumab DM-1 to lapatinib and capecitabine , have shown that @DRUG$ DM-1 significantly improved progression-free survival in patients with metastatic HER2 positive breast cancer . Further research is looking into inhibiting other targets such as @GENE$ , @VARIANT$ , or AKT pathways .", "label": "None"}
{"id": "23497317", "sentence": "In addition IC50 estimates for the proapoptotic effect of quizartinib in the imatinib-sensitive GIST solid tumor cell line GIST882 , harboring a @VARIANT$ mutation , and the imatinib-insensitive cell line GIST48 , harboring a V560D mutation in addition to a D820A mutation in the tyrosine kinase domain , are provided , revealing sensitivity profiles similar to imatinib . Estimated IC50s for the proapoptotic and antiproliferative effects of quizartinib in an isogenic cell model of @GENE$ cells transfected with various mutant TKs", "label": "None"}
{"id": "25295230", "sentence": "@VARIANT$ AML AC220 Smith et al. ( ) @GENE$ AML @DRUG$ Albers et al. ( ) Ba/F3 AML ( pediatric ) Sorafenib Baker et al. ( )", "label": "None"}
{"id": "24789720", "sentence": "Mechanism of achieving resistance to erlotinib and @DRUG$ remains unclear . The recent reports confirmed , that @VARIANT$ substitution could be detected in @GENE$ naïve patients independently of other EGFR gene mutations ( predominantly L858R substitution and deletions in exon 19 ) .", "label": "resistance or non-response"}
{"id": "22038681", "sentence": "Preliminary results from an ongoing phase 1 dose-escalation study of the multikinase , @GENE$ inhibitor ponatinib ( AP24534 ) showed antileukemic activity in patients with refractory CML , including patients with the @VARIANT$ mutation . Phase 1 and 2 trials of ponatinib are ongoing in patients with refractory CML and acute lymphoblastic leukemia . Danusertib ( PHA-739358 ) is a multikinase aurora inhibitor with in vitro activity against wild-type ABL and ABL/T315I ; preliminary results from an ongoing phase 1 dose-escalation study indicate antileukemic activity in patients with AP or BC who failed @DRUG$ and/or nilotinib or dasatinib .", "label": "None"}
{"id": "PMC4036652", "sentence": "It has been shown that urothelial cells express various receptors and channels including receptors for bradykinin ( B1 and B2 ) , prostaglandin ( EP1 and EP3 ) , neurotrophins ( TrkA ) , purines ( @VARIANT$ and P2Y ) , noradrenalin ( α1 and β3 ) , acetylcholine ( muscarinic and nicotinic ) , pituitary @GENE$ peptide , protease activated receptors and several members of Deg/ENaC and TRP channel families ( see below ; ) [ , ] . Activation of these receptors and channels can leads to ATP release from the urothelial cells . These agonist induced ATP release may increase in @DRUG$ induced cystitis [ ] .", "label": "None"}
{"id": "23976869", "sentence": "However , Stover et al reported that nilotinib could not overcome the @DRUG$ resistance conferred by the point mutation @VARIANT$ in @GENE$ in the same cellular model , even at high concentrations .", "label": "resistance"}
{"id": "23569464", "sentence": "The MDA-MB-361 cells were plated in 96-well plates and grown to 70 - 80 % confluence before being treated with S1P at concentrations of 1 µM and 10 µM . Treatment with @DRUG$ was used as negative control . The @VARIANT$ cytotoxicity was measured at exposure time of 6 h , 12 h , 24 h , 48 h and 72 h , respectively , using the CytoTox96® Non-Radioactive Cytotoxicity Assay from Promega Corporation .", "label": "None"}
{"id": "25032026", "sentence": "Hematologic and cytogenetic responses to @DRUG$ were observed in patients with mutations within the @GENE$ kinase domain except for the @VARIANT$ mutation .", "label": "None"}
{"id": "25462529", "sentence": "The fact that @VARIANT$ or K substitutions do not reduce IN enzymatic activity , but slightly affect RT and interaction with @GENE$ , points to a change in PIC processing due to a modified trend of interactions between IN monomers , between IN and RT , or between IN and a cellular factor such as p75/LEDGF . @DRUG$ is a versatile amino acid that can assume positive charge , but remains usually neutral at physiological pH .", "label": "None"}
{"id": "17106442", "sentence": "In contrast to previous retrospective analyses ( ; ) , patients with exon 19 deletions were equally responsive compared to those with @VARIANT$ in this study . This might be due to our small sample size , so these data need to be confirmed in a larger trial . In @GENE$ mutation positive patients treated by gefitinib , TTP ( 9.4 months ) of after the @DRUG$ treatment and MST ( 19.1 months ) after the initial treatment were longer than in patients treated with the regimens using platinum doublet .", "label": "sensitivity"}
{"id": "16434996", "sentence": "Pretreatment with BRCA1-siRNA severely attenuated the ability of @VARIANT$ to upregulate ERSEwt and ERSE-II reporter activity in T47D and MCF-7 cells ( P & lt ; 0.001 ) ( ) . Finally , pretreatment with @GENE$ ( but not control ) siRNA , blocked the ability of @DRUG$ to stimulate ERSEwt and ERSE-II activity ( P & lt ; 0.001 ) ( ) .", "label": "None"}
{"id": "25562798", "sentence": "Although irreversible inhibitors of the EGFR such as dacomitinib or @DRUG$ inhibit @VARIANT$ in vitro their clinical activity in the setting of tumors with T790M mutations remains to be demonstrated and novel mutation specific T790M inhibitors are in clinical development . A second mechanism for resistance which is seen in 5–20 % of patients is amplification of CMET which causes resistance to EGFR TKIs by activating PI3 Kinase signaling through @GENE$ [ , ,, ] .", "label": "None"}
{"id": "21687501", "sentence": "For @DRUG$ , venlafaxine , and fluoxetine the data indicate that they might be Pgp substrates ; for citalopram the data are conflicting ( Rochat et al. , ; Uhr et al. , ) . Several variants of @GENE$ are known ( Kioka et al. , ; Mickley et al. , ; Hoffmeyer et al. , ; Ito et al. , ) , among these three – @VARIANT$ ( rs1045642 ) , C1236 ( rs1128503 ) , and G2677T ( rs2032582 ) – have been associated with altered Pgp activity .", "label": "None"}
{"id": "25505694", "sentence": "The lack of efficacy could probably be related to the high concentrations of neratinib required in preclinical studies to inhibit EGFR @VARIANT$ and the limitations of clinical dosing . Dacomitinib Dacomitinib is an irreversible EGFR , HER2 and HER4 inhibitor with a higher kinase inhibition than gefitinib/erlotinib in both gefitinib/erlotinib-sensitive and in @GENE$ and HER2 mutated cell lines [ ] .", "label": "resistance or non-response"}
{"id": "24422746", "sentence": "Furthermore , @GENE$ mutations in PSCCE are rare but do exist , especially @DRUG$ associated mutations such as @VARIANT$ , therefore gefitinib based gene targeted therapy at EGFR but not KRAS and PIK3CA genes , probably should be included in this carcinoma treatment regimens for patients harboring L858R mutation .", "label": "sensitivity"}
{"id": "23937717", "sentence": "Collectively , these results suggested that @DRUG$ and NK cells could up-regulate the MHC-I in human lung cells with wild type EGFR , while not significantly influence the MHC-I expression on human lung cells with wild type @GENE$ L858R + @VARIANT$ .", "label": "resistance or non-response"}
{"id": "24894453", "sentence": "Although high-level expression of EGFR ligands and/or increased @GENE$ gene copy numbers may be predictive markers for antitumor response by cetuximab in colon cancer [ - ] , and patients with RAS driven cancers are known not to benefit from @DRUG$ treatment , a clear molecular explanation of cancer response to cetuximab has remained elusive . Genomic studies identify @VARIANT$ mutant in colorectal carcinomas", "label": "sensitivity"}
{"id": "19680652", "sentence": "However , the acquired resistance is not completely explained by the @VARIANT$ mutation in all cases [ ] . The presence of heterogenous malignant clones with different EGFR mutation status may confer differential sensitivity to the two EGFR-TKIs [ ] . Also , the different treatment efficacy between the two @GENE$ has been proposed to be related to drug pharmacokinetics [ ] , with gefitinib given at largely sub-maximal tolerated dose ( MTD ) in contrast to @DRUG$ at MTD .", "label": "resistance or non-response"}
{"id": "PMC3300146", "sentence": "The @GENE$ antibody @DRUG$ blocked TGF-β induced motility but not Smad dependent reporter activity . Infection with an adenovirus encoding a constitutively active Tβ RI mutant ( @VARIANT$ ) induced motility of MCF-10A/HER2 but not control cells .", "label": "None"}
{"id": "24121633", "sentence": "Based on our data , we hypothesized that PRR of hnRNP L binds to PTB and cooperatively suppresses inclusion of exon @VARIANT$ . We thus examined the role of PRR of hnRNP L on the interaction with PTB . Histidine tagged hnRNP L ( His-L ) , its PRR deleted variant ( His-L-ΔPRR ) , @DRUG$ tagged hnRNP LL ( His-LL ) , and its PRR inserted variant ( @GENE$ ) were expressed in SH-SY5Y cells , and they were immunoprecipitated with anti-histidine antibody in the presence of RNase .", "label": "None"}
{"id": "23493838", "sentence": "Transformation to accelerated phase CML occurred in four third-line patients ( dasatinib-resistant , n = 3 ; nilotinib-resistant , n = 1 ) and one fourth-line patient . Response rates were analyzed with respect to the mutational status of @GENE$ . The most frequent BCR-ABL mutations at baseline were F317L , @VARIANT$ , G250E , and Y253H .", "label": "None"}
{"id": "25105411", "sentence": "The human lung adenocarcinoma cell lines , A549 ( EGFR wild type ) , H1975 ( @GENE$ L858R/T790M , gefitinib-resistant ) , H1299 ( EGFR wild type , p53 null ) , and H3255 ( EGFR @VARIANT$ ) were purchased from American Type Culture Collection ( ATCC ; Manassas , VA , USA ) .", "label": "sensitivity"}
{"id": "17177598", "sentence": "However , @DRUG$ did induce dose dependent cell death in Ba/F3 subclones expressing the @GENE$ ectodomain mutants ( missense and vIII truncation ) or EGFR kinase domain mutants ( @VARIANT$ and L861Q ) ( A ) .", "label": "sensitivity"}
{"id": "23994953", "sentence": "More recently , Chang et al. confirmed that in the absence of the common second-site @GENE$ mutation @VARIANT$ or MET amplification , acquired resistance to @DRUG$ occurs in EGFR mutated PC9 cells that have undergone EMT .", "label": "resistance or non-response"}
{"id": "25033171", "sentence": "The mutated site @VARIANT$ , P-loop region , and @DRUG$ in @GENE$ and G2032R-ROS1 are shown in green surface , orange surface , green stick , and pink stick models , respectively , in panels A and B .", "label": "resistance"}
{"id": "19604390", "sentence": "E2-selected MCF-7 line ( P35E ) was found to show a drastically low mRNA level of ERα , but E2-selected MCF10AT1 line ( i.e. P20E ) did not show such a decrease in the mRNA expression of ERα as compared to the matched `` mock '' -selected control cell line ( designated as @VARIANT$ ) ( not shown ) . However , P20E @GENE$ cells showed no detectable level of expression of either @DRUG$ receptor (PR) as in the case of P35E ( shown in Figure ) or PS2 ( not shown ) .", "label": "None"}
{"id": "25254214", "sentence": "The @VARIANT$ @GENE$ E2F3 ) , a target of miR-34a , and E2F3 's downstream target sirtuin ( silent mating type information regulation 2 homolog ) 1 ( Sirt1 ) were downregulated following treatment , suggesting that @DRUG$ exerted its anticancer activity through miR-34a/E2F3/Sirt1 cascade [ ] .", "label": "None"}
{"id": "22912935", "sentence": "Our results for the CT and TT MTHFR genotypes were null , although the ORs below one that we observed are consistent with one meta-analysis ( @GENE$ et al. , ) , while another shows no association between the MTHFR @VARIANT$ polymorphism and prostate cancer risk ( Collin et al. , ) . Although this is a relatively small study that lacked power to detect most interactions , our finding of an over two-fold increase in prostate cancer risk for the interaction of low folate and high @DRUG$ intake is consistent biologically with prostate carcinogenesis resulting from folate deficiency ( Bistulfi et al. , ) .", "label": "None"}
{"id": "25539768", "sentence": "However , the acquired @VARIANT$ mutation of @GENE$ leads to @DRUG$ resistance .", "label": "resistance or non-response"}
{"id": "21297994", "sentence": "Surprisingly , for @DRUG$ and 2C4 , upstream pathway inhibition was not accompanied by a decrease in the phosphorylation of Akt . The T47D cell line is known to contain a strongly activating mutation in the kinase domain of PI3-kinase ( @VARIANT$ ) , which signals through Akt . This mutation upregulates the phospholipid kinase activity of the protein independent of @GENE$ interaction .", "label": "None"}
{"id": "23874880", "sentence": "For example , the second generation of irreversible TKIs such as @DRUG$ patients with a @VARIANT$ mutation and MET inhibitors combined with @GENE$ TKIs for MET amplification , – .", "label": "response"}
{"id": "22500155", "sentence": "It is considered an important problem to deal with how @GENE$ studies should be conducted in the case of such a compound . Rapid improvement of therapeutic responses using combined vemurafenib plus @DRUG$ therapy for BRAF @VARIANT$ mutation positive melanoma is expected .", "label": "None"}
{"id": "23493838", "sentence": "A complete hematological response and a major cytogenetic response were observed broadly across the @GENE$ mutants , including individuals harboring the dasatinib-resistant @VARIANT$ , the nilotinib-resistant Y253H , and F359C/I/V mutations , but not T315I . Nine individuals developed new mutations in the course of bosutinib treatment ( V299L , n = 4 ; L248V , n = 2 ; T315I , n = 2 ; F359C , n = 1 ; G250E , n = 1 ) and eight of these individuals discontinued @DRUG$ because of progressive disease or unsatisfactory response .", "label": "None"}
{"id": "24349829", "sentence": "As would be predicted from the prior studies cited above , miR-7 blunted @GENE$ signaling and reversed the radio-resistance . Correspondingly , direct injection of a liposome encapsulated miR-7 plasmid into established EGFR-TKI sensitive and resistant tumors bearing the @VARIANT$ EGFR mutant resulted in significant tumor regression in conjunction with repression of EGFR , RAF-1 and IRS-1 expression . In head and neck cancer , miR-7 functioned in a synergistic manner with erlotinib to render FaDu Erlotinib-resistant cells susceptible to the growth inhibitory activities of the drug .", "label": "None"}
{"id": "21333004", "sentence": "In this study , we used experimental and computational approaches to investigate regulatory mechanisms that distinguish cell-specific @DRUG$ sensitivity in H1299 human NSCLC cell lines . We have modified the existing kinetic model of the EGFR signaling pathway and built new models for H1299 wild type ( H1299WT ) , H1299 with overexpressed wild type EGFR ( H1299EGFR-WT ) , and H1299 overexpressing the @GENE$ with @VARIANT$ mutation ( H1299L858R ) .", "label": "sensitivity"}
{"id": "24397796", "sentence": "For example , altered protein profiles of lymphocytes were investigated in an antigen-specific model of colitis induced by colonic administration of trinitrobenzene sulfonic acid/ethanol [ ] . Of 1,100 protein spots , 26 proteins had more than at least two-fold differences between colitis and control , among which 17 up-regulated and 9 down-regulated , including @GENE$ and PYD domain containing protein , proteasome activator complex subunit 2 , IL-12 p40 precursor , nucleoside diphosphate kinase , ubiquitin conjugating enzyme @VARIANT$ , myeloid related protein-14 , ATP-citrate synthase , phosphoglycerate mutase and dismutase .", "label": "None"}
{"id": "25278773", "sentence": "These second-generation EGFR inhibitors have also been shown to drive drug resistance through the acquisition of @VARIANT$ in both preclinical and clinical settings , suggesting low potency against T790M. , As a potential solution , afatinib was combined with the @GENE$ antibody @DRUG$ in a Phase IIB study , which demonstrated an impressive response rate of 32 % in patients with EGFR mutant lung cancers resistant to first-generation EGFR inhibitors .", "label": "response"}
{"id": "23994953", "sentence": "Prospective trials have demonstrated an impressive ~75 % response rate for patients whose tumors harbor these mutations , which occur as either multinucleotide in-frame deletions in exon 19 ( e.g. , delE746-A750 ) or as single missense mutations ( e.g. , @VARIANT$ ) . Unfortunately , the @GENE$ TKI-driven improvement in patient outcome is notably limited because virtually all NSCLC patients with erlotinib/gefitinib sensitizing EGFR mutations eventually acquire resistance after a median of 6–12 months of EGFR TKI therapy .", "label": "sensitivity"}
{"id": "21753873", "sentence": "The identification of expressed @VARIANT$ analog was performed by employing the mouse monoclonal antibody against rhEPO ( GeneTex Inc , Irvine , CA ) and goat antimouse @DRUG$ ( GeneTex Inc ) as a primary and secondary antibody for 1 hour at room temperature . The band was developed using a @GENE$ chromogenic substrate ( Sigma-Aldrich ) .", "label": "None"}
{"id": "24634705", "sentence": "Afatinib , an @GENE$ and HER2 irreversible inhibitor has been shown to reverse the effects of the @VARIANT$ mutation in preclinical lung cancer studies [ ] . In clinical trials , afatinib did not improve overall survival but showed a modest improvement in progression free survival after failure of erlotinib or @DRUG$ [ , ] .", "label": "resistance or non-response"}
{"id": "24729716", "sentence": "@DRUG$ sensitizing @GENE$ mutations , such as @VARIANT$ and exon 19 in-frame deletions , selectively activate antiapoptosis signaling pathways .", "label": "sensitivity"}
{"id": "25563355", "sentence": "A phase II study supported by the above preclinical data was then conducted using the combination of @DRUG$ and afatinib in NSCLC patients who developed acquired resistance to first-generation @GENE$ by clinical definition [ , ] . There were confirmed partial responses reported in eight of 22 patients ( 36 % , 95 % CI : 0.17–0.59 ) , including 4/13 patients ( 29 % ) with a positive @VARIANT$ mutation .", "label": "response"}
{"id": "23992330", "sentence": "Through this approach , they showed that Src Family Kinases (SFKs) , as well as @GENE$ , are relevant targets for the Src inhibitor dasatinib and that acquired @VARIANT$ mutations render cells resistant not only to erlotinib and gefitinib , but also to dasatinib [ ] . In a recent report , human glioblastoma cells have been transduced with retroviruses encoding Notch delta-like ligand 4 (DLL4) , grown as tumor xenografts and then treated with the anti-VEGF mAb @DRUG$ .", "label": "None"}
{"id": "24495353", "sentence": "Rank Entrez ID Gene symbol Entrez ID Gene symbol Entrez ID Gene symbol 1 28978 TMEM14A 79776 ZFHX4 1727 CYB5R3 2 1843 DUSP1 4701 NDUFA7 7083 TK1 3 51022 GLRX2 715 @VARIANT$ 1292 COL6A2 4 1434 CSE1L 79818 ZNF552 857 CAV1 5 8522 GAS7 4046 LSP1 5437 POLR2H 6 51668 HSPB11 1727 CYB5R3 9833 MELK 7 10456 HAX1 357 SHROOM2 54861 SNRK 8 9902 MRC2 283298 OLFML1 4830 NME1 9 4706 NDUFAB1 23179 RGL1 231 AKR1B1 10 23560 GTPBP4 1809 DPYSL3 10418 SPON1 11 79633 FAT4 857 CAV1 2350 FOLR2 12 10418 SPON1 274 BIN1 10979 FERMT2 13 471 ATIC 79833 GEMIN6 11096 ADAMTS5 14 6403 @GENE$ 11222 MRPL3 4638 MYLK 15 23421 ITGB3BP 23244 PDS5A 9448 MAP4K4 16 23452 ANGPTL2 6241 RRM2 54922 RASIP1 17 54861 SNRK 1289 COL5A1 6934 TCF7L2 18 2034 EPAS1 8434 RECK 4072 EPCAM 19 30008 EFEMP2 429 ASCL1 4701 NDUFA7 20 25999 CLIP3 3426 CFI 404672 GTF2H5 21 4311 MME 332 BIRC5 6241 RRM2 22 4747 NEFL 2 A2M 2192 FBLN1 23 1809 DPYSL3 10730 YME1L1 25959 KANK2 24 28998 MRPL13 11130 ZWINT 55651 NHP2 25 25959 KANK2 1292 COL6A2 5050 PAFAH1B3 Lists of the top 25 of most influential genes in influence networks based on coexpression among genes in ER + breast tumors before , during , and after a course of neoadjuvant treatment with the drug @DRUG$ .", "label": "None"}
{"id": "15736989", "sentence": "Resistance mutations identified via in vitro screens have shown a high degree of correlation with those that develop in vivo , as shown in screens for imatinib-resistant BCR-ABL mutants [ ] and PKC412-resistant @GENE$ mutants [ ] , as well as the @VARIANT$ resistance mutation to gefitinib in the context of EGFR [ ] .", "label": "None"}
{"id": "25505694", "sentence": "The lack of efficacy could probably be related to the high concentrations of neratinib required in preclinical studies to inhibit EGFR @VARIANT$ and the limitations of clinical dosing . Dacomitinib Dacomitinib is an irreversible @GENE$ , HER2 and HER4 inhibitor with a higher kinase inhibition than gefitinib/erlotinib in both gefitinib/erlotinib-sensitive and in EGFR-T790M and HER2 mutated cell lines [ ] .", "label": "resistance or non-response"}
{"id": "24634705", "sentence": "Afatinib , an @GENE$ and HER2 irreversible inhibitor has been shown to reverse the effects of the @VARIANT$ mutation in preclinical lung cancer studies [ ] . In clinical trials , afatinib did not improve overall survival but showed a modest improvement in progression free survival after failure of @DRUG$ or gefitinib [ , ] .", "label": "resistance or non-response"}
{"id": "24281378", "sentence": "All benzodiazepine-sensitive GABAA channels contain a conserved @DRUG$ residue in the N-terminal domain , while the benzodiazepine-insensitive subunits ( α4 and α6 ) carry an arginine at the same site [ ] . Rudolph and Mohler used an elegant approach to attribute the different in vivo actions of benzodiazepines to molecularly defined @GENE$ [ ] . They generated knock-in point mutations for all four benzodiazepine-sensitive GABAA receptor α subunits ( α1 ( @VARIANT$ ) , α2 ( H101R ) , α3 ( H126R ) , and α5 ( H105R ) ) .", "label": "None"}
{"id": "23419122", "sentence": "Studies support that some of these activating mutations are not only reliable predictors of response to the small molecule @GENE$ tyrosine kinase inhibitors ( TKIs ) gefitinib and @DRUG$ but also prognostic factors for survival [ - ] . Among numerous TK domain mutations , 85–90 % are exon 19 E746_A750 deletions or exon 21 @VARIANT$ point mutations [ ] .", "label": "sensitivity"}
{"id": "24419415", "sentence": "The clinical efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors ( EGFR-TKIs ) , such as gefitinib and @DRUG$ , has been demonstrated in non–small-cell lung cancer ( NSCLC ) patients in whom standard chemotherapy has failed. , Further studies have revealed that the presence of activating mutations in the @GENE$ kinase domain is strongly associated with the therapeutic efficacy of EGFR-TKIs. , Randomized phase 3 trials have demonstrated that EGFR-TKIs significantly improve median progression-free survival ( PFS ) compared with platinum-doublet therapy in EGFR mutated patients.– However , not all mutations in the EGFR kinase domain are responsive to EGFR-TKI treatment . These phase 3 trials have shown that EGFR-TKIs are effective for patients with common EGFR mutations , such as an exon 19 deletion or the @VARIANT$ point mutation , which account for more than 90 % of EGFR mutations .", "label": "sensitivity"}
{"id": "17973572", "sentence": "Based on the data obtained from lung cancer cell lines , we further explored the mechanisms by which @VARIANT$ and L747S resistant mutations affect BIM up-regulation and apoptosis . @DRUG$ effectively induced apoptosis in @GENE$ cells , whereas Ba/F3-L858R-L747S cells were intermediately resistant and Ba/F3-L858R-T790M completely resistant ( A , top ) .", "label": "None"}
{"id": "15737014", "sentence": "By contrast , wild-type and mutant EGFRs containing the T790M mutation did not display a significant change in either phosphotyrosine induction or p-EGFR : @GENE$ ratios ( A and B ) . Similar results were obtained using @DRUG$ against wild-type and del E747–L747 ; A750P EGFRs in comparison to the corresponding mutants containing the @VARIANT$ mutation ( C ) .", "label": "resistance or non-response"}
{"id": "24312144", "sentence": "Sequist et al that studied neratinib to overcome @VARIANT$ resistance mutation reported responses in G719X @GENE$ mutation , supporting the need of genetic information on trials of targeted agents . According to Ramalingam et al , dacomitinib demonstrated significantly improved PFS versus @DRUG$ , with acceptable toxicity .", "label": "resistance or non-response"}
{"id": "24803900", "sentence": "Carboplatin was discontinued and @GENE$ was initiated as a second-line chemotherapy . For the first cycle , a total of 85 mg ( 40 mg/m2 ) of liposomal @DRUG$ in 250 ml of @VARIANT$ ( 5 % glucose solution ) was prescribed with the same premedications used for the prior carboplatin .", "label": "None"}
{"id": "24634705", "sentence": "The D761Y mutation is located on the α-C-helix of EGFR and is similar to a mutation in BCR-ABL , D276G , that is associated with acquired resistance after @DRUG$ treatment [ ] . The L747S mutation lies at the start of the β3 strand and the α-C-helix [ ] and has analogous residues in BCR-ABL ( L237M ) and @GENE$ ( L755S or P ) that have been identified in TKI resistant disease [ ] . The occurrence of these secondary mutations spurred development of second and third generation irreversible TKIs which bind covalently to the cysteinyl-797 residue in the pocket of the EGFR-kinase domain and overcome resistance driven by the @VARIANT$ mutation [ ] .", "label": "None"}
{"id": "23584600", "sentence": "Rarer mutations include c.1798_1799delinsAG p.Val600Arg ( V600R ) , c.1801A &gt ; G p.Lys601Glu ( @VARIANT$ ) and c.1799_1800delinsAA p.Val600Glu ( V600E2 ) . BRAF mutation results in hyperactivation of the MAPK signalling pathway , causing deregulation of cell proliferation and oncogenesis without the requirement for Ras activation . @GENE$ is the most potent of the Raf proteins to activate the downstream signalling cascade , hence mutant Braf was identified as a novel target for kinase inhibitors such as vemurafenib ( PLX4032/RG7204 ) and dabrafenib .", "label": "None"}
{"id": "22970367", "sentence": "Moreover , dual inhibition of EGFR with an irreversible EGFR inhibitor ( @DRUG$ ) and the EGFR neutralizing antibody cetuximab has recently shown promising activity in EGFR mutant lung cancers with acquired @GENE$ TKI resistance that harbor an EGFR @VARIANT$ mutation [ ] .", "label": "response"}
{"id": "24884501", "sentence": "@GENE$ mutations ( @VARIANT$ ) were present in 12 % of the tumors . The mutational frequencies of the 195 KRAS mutations in the NORDIC VII cohort were ; G12A ( 9.7 % ) , G12R ( 1.5 % ) , G12D ( 35.4 % ) , G12C ( 9.7 % ) , G12S ( 6.2 % ) , G12V ( 15.4 % ) , and G13D ( 22.1 % ) . Cetuximab did not add significant benefit to Nordic FLOX and KRAS mutation was not predictive for @DRUG$ effect .", "label": "resistance or non-response"}
{"id": "23992330", "sentence": "In addition , they showed that two dominant activating mutations in the @GENE$ catalytic , alpha polypeptide ( PI3K-CA ) , @VARIANT$ and H1047R , which are prevalent in breast cancer , also confer resistance to lapatinib [ ] . Conversely , Li et al. infected cells with lentiviruses expressing either wild-type kinases ( Src , Fyn Lyn , EGFR and others ) or kinase alleles with gatekeeper mutations . Through this approach , they showed that Src Family Kinases (SFKs) , as well as EGFR , are relevant targets for the Src inhibitor dasatinib and that acquired T790M mutations render cells resistant not only to erlotinib and @DRUG$ , but also to dasatinib [ ] .", "label": "resistance or non-response"}
{"id": "24676216", "sentence": "Recent investigations have identified genes and proteins downstream of KRAS in the mitogen activated protein kinase signaling pathway , which affect unresponsiveness to anti-EGFR therapy , including the @GENE$ @VARIANT$ mutation , mutations in NRAS or PIK3CA ( exons 9 and 20 ) , or loss of PTEN or AKT expression – . Furthermore , several mechanisms of acquired ( secondary ) resistance to anti-EGFR therapies , such as expression of EGFR ligands , deregulation of the EGFR recycling process , amplifications of the genes ERBB2 ( also called HER2 ) , , KRAS , , and MET , have been identified . In addition , the EGFR ectodomain mutation S492R has recently been found to confer resistance to @DRUG$ .", "label": "resistance or non-response"}
{"id": "23994953", "sentence": "Intense research efforts over the past few years have identified two major mechanisms of acquired resistance to gefitinib/erlotinib : secondary resistance mutations ( e.g. , @VARIANT$ ) and “oncogene kinase switch” systems ( e.g. , MET amplification and AXL activation ) . However , the precise mechanisms underlying acquired resistance in the 30–40 % of @GENE$ TKI-resistant EGFR mutated tumors that do not carry secondary resistance mutations or MET amplification remain largely unclear .", "label": "resistance or non-response"}
{"id": "24924344", "sentence": "@DRUG$ rs562 ( C/T ) Chr3 : 183637845 ABCC5 ( UTR3 ) 0.049494 0.392 rs3749445 ( A/G ) Chr3 : 183638506 ABCC5 ( UTR3 ) 0.044895 0.410 rs2292998 ( C/T ) Chr3 : 183663833 ABCC5 ( intronic ) 0.039882 0.277 rs1016752 ( C/G ) Chr3 : 183665062 ABCC5 ( intronic ) 0.039781 0.232 rs4148585 ( C/T ) Chr3 : 183670642 ABCC5 ( intronic ) 0.039781 0.283 rs6443924 ( A/G ) Chr3 : 183679532 ABCC5 ( intronic ) 0.039781 0.279 rs4148579 ( A/G ) Chr3 : 183685249 ABCC5 ( intronic ) 0.039781 0.279 rs939336 ( A/G =&gt ; C594C ) Chr3 : 183685534 ABCC5 ( exonic ) 0.039781 0.279 rs1132776 ( C/T = & gt ; @VARIANT$ ) Chr3 : 183696402 ABCC5 ( exonic ) 0.044895 0.289 rs2313212 ( C/T ) Chr3 : 183700928 ABCC5 ( intronic ) 0.039781 0.279 rs4148575 ( C/T ) Chr3 : 183702275 ABCC5 ( UTR3 ) 0.044895 0.289 rs1846692 ( C/T ) Chr16 : 56671696 MT1A ( near - gene 5 ) 0.049494 0.360 rs35346959 ( A/G ) Chr16 : 56671867 MT1A ( near- gene 5 ) 0.044895 0.137 rs9922957 ( C/G ) Chr16 : 56672380 MT1A ( near - gene 5 ) 0.039781 0.185 rs9922409 ( A/G ) Chr16 : 56672400 MT1A ( near - gene 5 ) 0.04532 0.103 rs7190725 ( G/T ) Chr16 : 56673290 MT1A ( intronic ) 0.044895 0.170 rs8052394 ( A/G =&gt ; K51R ) @GENE$ : 56673828 MT1A ( missense ) 0.044895 0.152 rs1800566 ( C/T = & gt ; P187S ) chr16 : 69745145 NQO1 ( exonic ) 0.039781 0.258 rs689455 ( A/C ) Chr16 : 69761661 NQO1 ( near- gene 5 ) 0.039781 0.242", "label": "None"}
{"id": "22019782", "sentence": "The @VARIANT$ mutation has been shown to compromise C-terminal @GENE$ function ; mutant CFH protein has normal @DRUG$ activity but exhibits defective binding to C3d , C3b , heparin , and endothelial cells , , .", "label": "None"}
{"id": "24939055", "sentence": "The EGF receptor tyrosine kinase inhibitors ( EGFR-TKIs ) @DRUG$ and erlotinib have shown marked therapeutic effects against NSCLCs with @GENE$ activating mutations , such as exon 19 deletions and @VARIANT$ point mutations [ ] .", "label": "sensitivity"}
{"id": "23864840", "sentence": "Another approach for @VARIANT$ mediated resistance is the dual inhibition of EGFR with @DRUG$ and cetuximab , an EGFR blocking antibody resembling the synergistic combination of lapatinib and trastuzumab in ErbB2 positive breast cancer . Due to promising preliminary results of activity and tolerability , final results of this regimen are being eagerly anticipated [ ] . In selected patients with acquisition of resistance by activated compensatory pathways such as MET and @GENE$ , addition of a MET [ ] or AXL [ ] inhibitor to EGFR-TKIs could be beneficial .", "label": "None"}
{"id": "24729716", "sentence": "Two patients harboring EGFR @VARIANT$ mutation had received @GENE$ treatment : one received gefitinib and had an occurrence of brain metastasis in the sixth month ; the other received @DRUG$ to control the metastasis to the liver .", "label": "resistance or non-response"}
{"id": "22433462", "sentence": "Two small molecule @GENE$ tyrosine kinase inhibitors ( EGFR-TKI ) , @DRUG$ ( Iressa , AstraZeneca International ) and erlotinib ( Tarveca , OSI Pharmaceuticals ) have been evaluated in patients with NSCLC [ , ] . These ATP competitive , reversible EGFR-TKIs have been effective only in a small subset of NSCLC patients bearing somatic mutations ( deletions in exon 19 and the @VARIANT$ mutation ) in the kinase domain of EGFR [ ] .", "label": "sensitivity"}
{"id": "23862152", "sentence": "In order to build the mutant structures , we made a point mutation in native Tyrp1 protein at @VARIANT$ ( arginine to @DRUG$ ) and R356Q ( arginine to @GENE$ ) using SPDB viewer [ ] .", "label": "None"}
{"id": "16173832", "sentence": "However , all of the patients received systemic chemotherapy prior to gefitinib or @DRUG$ therapy , and the original lung tissue was obtained long before @GENE$ were used . We describe a chemonaive patient with gefitinib-sensitive lung adenocarcinoma harboring @VARIANT$ .", "label": "sensitivity"}
{"id": "23049365", "sentence": "In a phase I clinical trial ponatinib was used to treat 67 patients resistant to imatinib , @DRUG$ and nilotinib and passed safety requirements . Among these patients , 72 % presented mutations in @GENE$ at the beginning of the study or had a documented mutation story , including the @VARIANT$ and F317L mutations .", "label": "None"}
{"id": "24495353", "sentence": "Rank Entrez ID Gene symbol Entrez ID Gene symbol Entrez ID Gene symbol 1 28978 TMEM14A 79776 ZFHX4 1727 CYB5R3 2 1843 DUSP1 4701 NDUFA7 7083 TK1 3 51022 GLRX2 715 C1R 1292 COL6A2 4 1434 CSE1L 79818 ZNF552 857 CAV1 5 8522 GAS7 4046 LSP1 5437 POLR2H 6 51668 HSPB11 1727 CYB5R3 9833 MELK 7 10456 @GENE$ 357 SHROOM2 54861 SNRK 8 9902 MRC2 283298 OLFML1 4830 NME1 9 4706 NDUFAB1 23179 RGL1 231 AKR1B1 10 23560 GTPBP4 1809 DPYSL3 10418 SPON1 11 79633 FAT4 857 CAV1 2350 FOLR2 12 10418 SPON1 274 BIN1 10979 FERMT2 13 471 ATIC 79833 GEMIN6 11096 ADAMTS5 14 6403 SELP 11222 MRPL3 4638 MYLK 15 23421 ITGB3BP 23244 PDS5A 9448 MAP4K4 16 23452 ANGPTL2 6241 RRM2 54922 RASIP1 17 54861 SNRK 1289 COL5A1 6934 TCF7L2 18 2034 EPAS1 8434 RECK 4072 EPCAM 19 30008 EFEMP2 429 ASCL1 4701 NDUFA7 20 25999 CLIP3 3426 CFI 404672 GTF2H5 21 4311 MME 332 BIRC5 6241 RRM2 22 4747 NEFL 2 @VARIANT$ 2192 FBLN1 23 1809 DPYSL3 10730 YME1L1 25959 KANK2 24 28998 MRPL13 11130 ZWINT 55651 NHP2 25 25959 KANK2 1292 COL6A2 5050 PAFAH1B3 Lists of the top 25 of most influential genes in influence networks based on coexpression among genes in ER + breast tumors before , during , and after a course of neoadjuvant treatment with the drug @DRUG$ .", "label": "None"}
{"id": "23994953", "sentence": "@VARIANT$ and MET amplification , which can be detected in up to 20 % of EGFR NSCLCs secondarily refractory to @GENE$ TKIs , account for approximately 60–70 % of all known causes of acquired resistance to gefitinib/erlotinib .", "label": "resistance or non-response"}
{"id": "24621249", "sentence": "Clinically approved patient selection biomarkers for anti-EGFR treatments @DRUG$ and panitumumab include assessment of EGFR levels and @GENE$ @VARIANT$ mutation status .", "label": "sensitivity"}
{"id": "24523596", "sentence": "Recently , genome-wide screening for the genetic determinants of gout found that an SNP of ABCG2/BCRP ( @VARIANT$ ) is associated with high uric acid levels , and demonstrated that uric acid is a natural substrate of ABCG2/BCRP. , @GENE$ also appears to play a protective role against xenobiotics and their metabolites. , The typical ABCG2/BCRP substrates , @DRUG$ and SN-38 , are detoxified by glucuronidation with uridine-diphosphate–glucuronyltransferase , and ABCG2/BCRP can extrude SN-38–glucuronide .", "label": "None"}
{"id": "23976869", "sentence": "Other small molecules have been tested against imatinib-resistant @GENE$ @VARIANT$ .", "label": "resistance"}
{"id": "22933967", "sentence": "The results of a small study of 74 patients , conducted by Loupakis with his colleagues , suggested that rare KRAS mutations in codon 61 and in codon 146 might also be responsible for in the treatment resistance to anti-EGFR monoclonal antibodies. , In contrast , in their large retrospective analysis , De Roock et al. concluded that the codon 146 mutations did not affect the response to @DRUG$ and that the patients with codon 61 mutant tumours had lower response rate . According to the analysis of other mutations , they proposed testing of KRAS status , if not mutated , then of BRAF and NRAS status , and @GENE$ exon 20 mutation in order to improve the objective response up to 40 % in selected patients . In our retrospective study , 26.7 % of patients , all with KRAS wild-type tumours , who had previously unresectable liver-only metastases , underwent surgical resection after systemic therapy , with R0 resection achieved in 38 patients ( 21.6 % ) ; one of those was patient with the BRAF @VARIANT$ mutation .", "label": "None"}
{"id": "25465236", "sentence": "( C ) @GENE$ @VARIANT$ mutant does not resemble pEGFR unlike the EGFR L858R mutant shown in B. ( D–F ) increased inhibition potency for Erlotinib against EGFR L858R mutant compared to EGFR WT protein and subsequent decrease in potency for @DRUG$ against EGFR L858R + E884K double mutant .", "label": "resistance or non-response"}
{"id": "23493838", "sentence": "Transformation to accelerated phase CML occurred in four third-line patients ( dasatinib-resistant , n = 3 ; nilotinib-resistant , n = 1 ) and one fourth-line patient . Response rates were analyzed with respect to the mutational status of @GENE$ . The most frequent BCR-ABL mutations at baseline were F317L , @VARIANT$ , G250E , and Y253H .", "label": "None"}
{"id": "24811491", "sentence": "Acquired resistance EGFR mutations Mutations in the EC domain ( @VARIANT$ ) and in the kinase domain ( codons 714 and 794 ) of EGFR found in patients @DRUG$ remained active in a patient with S492R mutation , which abrogated cetuximab binding . RAS/BRAF activation CRC cell lines with acquired KRAS/BRAF point mutations and/or KRAS amplification and one patient derived xenograft Combination of cetuximab with pimasertib ( @GENE$ inhibitor ) induced moderate tumor shrinkage in vivo .", "label": "None"}
{"id": "24944510", "sentence": "EGFR-TKI ( such as gefitinib or @DRUG$ ) treatment of lung-cancer harboring @GENE$ gene mutation is one of the prototypes of such therapies . Several clinical trials clearly demonstrated that progression-free survival of patients treated with EGFR-TKI therapy is significantly longer than that of those treated by conventional platinum doublet chemotherapy.– EGFR-TKI therapy dramatically changed the paradigm of lung cancer treatment . Which strategy is better in the management of advanced NSCLCs – the inhibition of mutated EGFR with TKIs ( @VARIANT$ mutation increases tyrosine kinase affinity for TKIs ) or a combined approach with cetuximab ( an anti-EGFR monoclonal antibody ) plus first-line chemotherapy – is yet to be determined .", "label": "sensitivity"}
{"id": "23566546", "sentence": "Case Histrogical type @GENE$ mutation status Brinkman index Treatment agent Response IL-8 ( ng/mL ) IL-10 ( ng/mL ) RANTES ( pg/ml ) 1 Ad Ex21 @VARIANT$ 900 gefitinib PR 5.79 1.67 2 2 Ad Ex21 L858R 0 erlotinib PR_3.33 94.2 1.41 3 Ad Ex19 del 0 @DRUG$ PR 4.09 126 2.13 4 Ad Ex21 L858R 0 gefitinib PR_3.92 18.1 1.85 5 Ad Ex21 L858R + Ex19 del 370 erlotinib PR 21.9 1.23 2.11 6 Ad Ex19 del 0 erlotinib PR 7.05 1.37 2.56 7 Ad Ex19 del 0 gefitinib PR 4.82 1.59 2.02 8 Ad Ex21 L858R 1640 gefitinib PR 54.9 2.7 2.38 9 Ad negative 400 erlotinib SD 34.9 3.39 3.66 10 Ad negative 0 erlotinib SD 27.1 4.94 2.25 11 Ad unknown 1800 erlotinib SD NE NE NE 12 Sq Ex19 del 3840 gefitinib SD 12.6 1.1 1.98 13 Ad Ex19 del 30 erlotinib SD 5.27 0.69 2.66 14 Ad Ex19 del 0 erlotinib SD 10.5 0.85 2.5 15 Ad unknown 300 erlotinib SD 7.69 2.61 1.7 16 La negative 2080 erlotinib SD NE NE NE 17 Sq Ex21 L858R 750 erlotinib SD 11.6 56.3 3.06 18 Ad unknown 600 erlotinib SD 13.7 1.1 2.82 19 Ad Ex21 L858R 0 erlotinib SD 20.6 11.6 0.783 20 Ad Ex19 del 0 erlotinib SD 14.8 2.07 2.02 21 Ad Ex21 L858R + Ex19 del 0 gefitinib SD 3.04 1.3 1.76 22 Ad Ex19 del 200 gefitinib SD 10.9 1.59 1.91 23 Sq unknown 1560 erlotinib PD NE NE NE 24 Ad negative 1080 erlotinib PD 25.2 8.15 1.57 25 Ad unknown 0 erlotinib PD NE NE NE 26 Ad Ex18 G719A 2000 erlotinib PD 11.6 4.48 3.12 27 Ad unknown 1410 erlotinib PD NE NE NE 28 Ad Ex19 del 1000 gefitinib PD 9.44 2.25 2.89 29 Ad negative 1100 erlotinib PD 56.3 5.63 2.16 30 Ad negative 2000 erlotinib PD 15.6 0.85 0.292 31 Ad negative 825 erlotinib PD 8.27 1.59 2.13 32 Ad Ex21 L858R 0 erlotinib PD 5.34 7.05 1.7 33 Ad negative 1680 erlotinib PD 57.7 1.63 2.06", "label": "sensitivity"}
{"id": "21333004", "sentence": "Yun et al [ ] showed that gefitinib directly binds more tightly to the @VARIANT$ mutant than to the wild type EGFR in vitro , while Fabian et al [ ] indicated that EGFR with gefitinib sensitive mutations does not differ from wild type @GENE$ in terms of @DRUG$ binding affinity .", "label": "sensitivity"}
{"id": "23579627", "sentence": "( G ) Both lung nodules were markedly aggravated 1 month after @DRUG$ retreatment . ( H ) Dramatic response was shown after PF-00299804 trial , but metastatic subcarinal lymphadenopathy was noted in 11-month follow-up scan . The epidermal growth factor receptor (EGFR) status detected by peptide nucleic acid ( PNA ) clamping after treatment with @GENE$ kinase inhibitor indicate two mutations in exon 21 ( L858R/L861Q ) and exon 20 ( @VARIANT$ ) .", "label": "resistance or non-response"}
{"id": "24472312", "sentence": "In contrast to @DRUG$ , 300 nM ponatinib inhibited phosphorylation of @VARIANT$ FIP1L1-PDGFRα to a similar degree as 1000 nM sorafenib ( Figure A ) . It also inhibited the phosphorylation of FIP1L1-PDGFRα in EOL-1 , BaF3-WT FIP1L1-PDGFRα and @GENE$ FIP1L1-PDGFRα cells in concentration- and time dependent manners ( Figure B and C ) .", "label": "None"}
{"id": "22343623", "sentence": "Non-small cell lung cancer patients with @VARIANT$ or exon 19 deletion mutations in @GENE$ show good responses to the tyrosine kinase inhibitor @DRUG$ .", "label": "sensitivity"}
{"id": "16187797", "sentence": "Sensitivity of Cell Transformation Induced by Expression of Mutant EGFR Characterized by Missense Mutation or Exon 19 Deletion , but not Exon 20 Insertion , to @DRUG$ and Erlotinib ( A ) Anchorage independent growth of clonal NIH-3T3 cells transformed with mutant @GENE$ or EGF stimulated wild-type EGFR treated with the indicated concentrations of erlotinib immediately prior to suspension in soft agar . Transformation induced by expression of L858R , @VARIANT$ , and L747_E749del A750P EGFR , but not EGF stimulated wild-type EGFR or D770_N771insNPG EGFR , was inhibited by 0.1 μM erlotinib .", "label": "sensitivity"}
{"id": "24637492", "sentence": "Previous studies showed that a shRNA against @VARIANT$ inhibited angiogenesis , reduced tumor growth and inhibited metastasis formation by & gt ; 50 % in a mouse model of NSCLC cells . Furthermore , treatments with Cromolyn alone and in combination with @DRUG$ inhibited pancreatic tumor growth and metastasis .", "label": "None"}
{"id": "25505694", "sentence": "The study showed that , among the 5 tumor samples collected at the time of @DRUG$ failure , only one harbored the @VARIANT$ mutation and that three patients treated with second line erlotinib derived additional long-term benefit from the @GENE$ TKI [ ] .", "label": "None"}
{"id": "23237215", "sentence": "Tumors from patients in this study harbored several EGFR mutations—exon 19 deletion , exon 21 point mutation ( @VARIANT$ ) , or exon 18 point mutation ( G719C , G719S , and G719A ) —as determined by direct sequencing or the PNA-LNA PCR Clamp method . Patients with @GENE$ exon 20 T790M mutation before treatment were excluded from this study . The TKI used in this study was gefitinib or @DRUG$ .", "label": "sensitivity"}
{"id": "17973572", "sentence": "Identification of a Novel Secondary Resistant EGFR Mutation , L747S ( A ) Sequencing chromatograms with the EGFR L747S exon 19 and @VARIANT$ exon 21 by RT-PCR . ( B ) Amino acid alignments of the tyrosine kinase domain in EGFR , ErbB2 , and @GENE$ . ( C ) Active conformation crystal structure of the kinase domain of EGFR in complex with @DRUG$ [ ] .", "label": "None"}
{"id": "20694077", "sentence": "It is also reported that @DRUG$ and nilotinib might be taken up in cells by different mechanisms , with the influx , intracellular concentrations of imatinib , and consequently patient sensitivity to imatinib depending upon the organic cation transporter ( OCT-1 ) , whereas nilotinib transport appears to be independent of @GENE$ . Both nilotinib and dasatinib efficiently block Bcr-Abl tyrosine kinase catalytic activity by binding to distinct , partially overlapping sites in the kinase domain . Cross resistance with dasatinib is limited to @VARIANT$ , which is also the only mutant isolated at drug concentrations equivalent to maximal achievable plasma trough levels .", "label": "None"}
{"id": "24634705", "sentence": "The @VARIANT$ mutation is hypothesized to induce steric interference of @DRUG$ binding similar to those in BCR-ABL and EGFR [ , ] . An in vitro model of @GENE$ with the L1196M mutation showed that the cells were still dependent on ALK mediated signaling for tumor maintenance but are resistant to ALK inhibition [ , ] .", "label": "None"}
{"id": "23082072", "sentence": "Further , patients with nonsmall cell lung cancer who initially responded to erlotinib or @DRUG$ therapy showed progression after a median of 12–13 months. , After patients developed acquired resistance confirmed on medical imaging , continuing use of erlotinib or gefitinib would lead to a surge in the rate of @GENE$ @VARIANT$ mutation which , in vitro , conferred resistance to treatment with erlotinib and gefitinib .", "label": "resistance or non-response"}
{"id": "23690929", "sentence": "@GENE$ mutations , such as exon 19 deletion and exon 21 @VARIANT$ point mutation , are found in a population of NSCLC , and are associated with a clinical response to the EGFR tyrosine kinase inhibitors ( EGF-TKIs ) , @DRUG$ and erlotinib – .", "label": "sensitivity"}
{"id": "23584600", "sentence": "Rarer mutations include c.1798_1799delinsAG p.Val600Arg ( @VARIANT$ ) , c.1801A &gt ; G p.Lys601Glu ( K601E ) and c.1799_1800delinsAA p.Val600Glu ( V600E2 ) . BRAF mutation results in hyperactivation of the MAPK signalling pathway , causing deregulation of cell proliferation and oncogenesis without the requirement for @GENE$ activation . Braf is the most potent of the Raf proteins to activate the downstream signalling cascade , hence mutant Braf was identified as a novel target for kinase inhibitors such as vemurafenib ( PLX4032/RG7204 ) and dabrafenib .", "label": "None"}
{"id": "23186157", "sentence": "In ( C ) and ( D ) percentage of viable @GENE$ p185 Bcr-Abl ( C ) and Ba/F3 p185 Bcr-Abl @VARIANT$ ( D ) cells treated with suboptimal concentration of @DRUG$ and Dasatinib for 72 h as described in Materials and Methods .", "label": "None"}
{"id": "15737014", "sentence": "Importantly , we find that the T790M mutation confers drug resistance not just to wild-type EGFR but also to mutant EGFRs associated with clinical responsiveness to @GENE$ tyrosine kinase inhibitors [ , , ] . In tumors from patients not treated with either gefitinib or @DRUG$ , the 2369 C→T mutation ( @VARIANT$ ) appears to be extremely rare .", "label": "resistance or non-response"}
{"id": "20672050", "sentence": "Emerging data suggest that patients with NSCLC and @GENE$ exon 19 deletion have a longer survival following treatment with gefitinib or @DRUG$ compared with those with @VARIANT$ mutation [ – ] .", "label": "sensitivity"}
{"id": "15123883", "sentence": "I293H , @VARIANT$ , and S296H ( along with serine in place of lysine 281 ) in the channel lumen partially removes the pH block especially in case of S296H . Our data indicated that a properly placed @DRUG$ residue is an important structural element for functional expression as well as for pH regulation of @GENE$ .", "label": "None"}
{"id": "22363766", "sentence": "Preclinical data have demonstrated that @DRUG$ is a potent irreversible inhibitor of @GENE$ receptors including the @VARIANT$ variant .", "label": "response"}
{"id": "23520442", "sentence": "However , it is unknown whether the status of EGFR mutation and downstream resistance related genes aberrances ( i.e. , @GENE$ mutations , @VARIANT$ , or c-MET amplification ) are consistent in pre- and post-chemotherapy samples . Therefore , it is necessary to evaluate the impact of chemotherapy on tumor molecular profiles . Chin et al reported that prior exposure to platinum agents may reduce the benefit from subsequent treatment with EGFR-TKI for an erlotinib-sensitive EGFR-mutant NSCLC cell via the phosphatidylinositol 3-kinase/AKT survival pathway .", "label": "None"}
{"id": "22740817", "sentence": "Whether the survival difference between @GENE$ WT and mutant patients is only due to the fact that BRAF mutational status has prognostic value or if BRAF mutational status may also be predictive for a combination treatment with @DRUG$ and temozolomide can not be concluded definitively from our data set , but should be prospectively studied . If the 2 most frequent BRAF mutations , @VARIANT$ and V600K , are the alterations with predictive value in melanoma patients , techniques identical or similar to method 1 described in this paper may be the detection system of choice .", "label": "sensitivity"}
{"id": "23232076", "sentence": "The deletion of the four amino acid sequence ( del 746–750 ) in the exon 19 and the substitution of leucine by arginine at codon 858 ( @VARIANT$ ) in exon 21 are two of the most common mutations in the kinase domain of EGFR gene in NSCLC patients [ ] . The small-molecule tyrosine kinase inhibitors including gefitinib and @DRUG$ have recently been approved for the treatment of patients with NSCLC [ , - ] . In addition , mutations in the @GENE$ been confirmed as predictors of the efficacy of treatment with EGFR-tyrosine kinase inhibitors .", "label": "sensitivity"}
{"id": "23664091", "sentence": "In NSCLC , resistance to the @GENE$ TKI gefitinib is associated with the positive selection of cells harbouring the gatekeeper @VARIANT$ mutation known to confer insensitivity to @DRUG$ [ ] .", "label": "resistance or non-response"}
{"id": "24212826", "sentence": "An objective response rate of 25 % for @DRUG$ treatment was reported in 16 patients with exon 20 mutations , and it was much lower than the response rate of patients with deletions in exon 19 and @VARIANT$ mutations . Furthermore , three of the four responders with exon 20 mutations also had concurrent sensitizing @GENE$ mutations ( L858R ) [ ] .", "label": "sensitivity"}
{"id": "24004697", "sentence": "A : K562 and @VARIANT$ cells treated with PPP2R5C-siRNA799 , B : @GENE$ WT and 32D-Bcr-Abl T315I cells treated with PPP2R5C-siRNA799 , C : K562 and K562R cells treated with PPP2R5C-siRNA991 , D : 32D-Bcr-Abl WT and 32D-Bcr-Abl T315I cells treated with PPP2R5C-siRNA991 . The apoptosis induction effect of PPP2R5C-siRNAs on imatinib-sensitive and imatinib-resistant cell lines .", "label": "None"}
{"id": "15736989", "sentence": "These observations provide convincing evidence that , at least in some patients with NSCLC , resistance to gefitinib or @DRUG$ can be attributed to acquisition of a @VARIANT$ mutation in the context of @GENE$ .", "label": "resistance or non-response"}
{"id": "24236021", "sentence": "Importantly , the αC- helix is flexible and residues Glu286 and Met290 located at ligand entrance site show reduced interactions with @VARIANT$ . Also decrease in electrostatic interactions for E255 , Q252 and Y253 are responsible for imatinib resistance . In this study of ponatinib binding to native and mutant BCR-ABL kinases , we have also observed high fluctuations of Glu286 and Met290 amino acid residues while binding to @DRUG$ , although the effect of @GENE$ is lower compared to Glu286 .", "label": "None"}
{"id": "23992330", "sentence": "In addition , they showed that two dominant activating mutations in the PI3K catalytic , alpha polypeptide ( PI3K-CA ) , @VARIANT$ and H1047R , which are prevalent in breast cancer , also confer resistance to lapatinib [ ] . Conversely , Li et al. infected cells with lentiviruses expressing either wild-type kinases ( Src , Fyn Lyn , EGFR and others ) or kinase alleles with gatekeeper mutations . Through this approach , they showed that Src Family Kinases (SFKs) , as well as EGFR , are relevant targets for the @GENE$ inhibitor @DRUG$ and that acquired T790M mutations render cells resistant not only to erlotinib and gefitinib , but also to dasatinib [ ] .", "label": "None"}
{"id": "19452042", "sentence": "The more common EGFR mutations are an in frame deletion in exon 19 around codons 746 to 750 and a missense mutation leading to leucine to arginine substitution at codon 858 ( @VARIANT$ ) in exon 21 [ ] . In a large number of retrospective clinical trials , it has been suggested that NSCLC patients treated with EGFR-TKIs , whose tumors are carrying sensitizing EGFR mutations achieve an improvement of survival [ - ] , although this effect has not always been demonstrated [ , - ] . Different somatic @GENE$ gene mutations may confer diverse tumor activation profiles that lead to variations in both natural history and clinical course after treatment with @DRUG$ or gefitinib .", "label": "sensitivity"}
{"id": "22363766", "sentence": "T790M mutations emerge in response to treatment with @GENE$ TKIs . The @VARIANT$ mutation accounts for approximately 50 % of cases in which acquired resistance to @DRUG$ or gefitinib occurs , , .", "label": "resistance or non-response"}
{"id": "22436374", "sentence": "The combination of afatinib and @DRUG$ can even overcome resistance due to the @VARIANT$ mutation both preclinically [ ] as well as clinically [ ] . In the present study , the combined treatment of @GENE$ siRNA and TKIs or antibody achieved increased tumor cell growth suppression ( about 30 % more at the most ) ( Figures , , , , and ) in all the five NSCLC cell lines and increased apoptosis as high as by 100 % ( Figures and ) .", "label": "response"}
{"id": "24876815", "sentence": "The cause of refractoriness has been identified in ca. 15 % of mCRC patients as mutations in the BRAF gene , primarily @VARIANT$ substitution . Raf family proteins are downstream of Ras proteins in the signal transduction pathway originating at EGFR . It comes as no surprise , then , that activating mutations in the @GENE$ gene occurring in cancer cells have a similar clinical effect to KRAS gene mutations , making them refractory both to @DRUG$ and panitumumab [ , , – ] .", "label": "resistance or non-response"}
{"id": "21845098", "sentence": "@DRUG$ @GENE$ was kindly donated by Cipla Pharmaceutical Co , India . Total protein kit ( Micro Lowry ) was from Sigma ( Saint Louis , USA ) . @VARIANT$ , a human breast cancer cell line and SKOV3 , a human ovarian cancer cell line , were obtained from American Type Culture .", "label": "None"}
{"id": "21333004", "sentence": "Yun et al [ ] showed that gefitinib directly binds more tightly to the @VARIANT$ mutant than to the wild type EGFR in vitro , while Fabian et al [ ] indicated that @GENE$ with @DRUG$ sensitive mutations does not differ from wild type EGFR in terms of gefitinib binding affinity .", "label": "sensitivity"}
{"id": "15737014", "sentence": "For example , in CML , a commonly found mutation is a C→T single nucleotide change that replaces threonine with isoleucine at position 315 ( @VARIANT$ ) in the ABL kinase domain [ , , ] . In GIST and @GENE$ , respectively , the analogous T670I mutation in KIT and T674I mutation in PDGFR-alpha have been associated with acquired resistance to this drug [ , ] . To determine whether lung cancers that acquire clinical resistance to either gefitinib or @DRUG$ display additional mutations in the EGFR kinase domain , we have examined the status of EGFR exons 18 to 24 in tumors from five patients who initially responded but subsequently progressed while on these drugs .", "label": "None"}
{"id": "24124608", "sentence": "To explore potential target genes or mechanisms underlying @DRUG$ resistance in wild-type GISTs , we integrated CGH and expression profiling in 32 gastric GISTs , including four wild-type GISTs and one imatinib-resistant @GENE$ @VARIANT$ mutant GIST .", "label": "resistance or non-response"}
{"id": "22970367", "sentence": "The data suggest that low @GENE$ level may neutralize the negative effects of the EGFR T790M mutation on @DRUG$ sensitivity and that high BRCA1 expression may lead to de novo EGFR TKI resistance potentially through increased DNA damage repair capacity [ ] . In addition to EGFR T790M , primary EGFR TKI resistance may also be due to other secondary mutations in EGFR ( e.g. , @VARIANT$ ) that occur in cis with an activating EGFR kinase domain mutation ( e.g. , L858R ) [ ] .", "label": "None"}
{"id": "22649765", "sentence": "( B ) The percentages of dead cells ( PI+ , black ) and vital cells characterized by loss of mitochondrial membrane potential ( PI− , ΔΨm low , white ) were determined following treatment with vehicle ( @DRUG$ ) or indicated concentrations of sagopilone for 72 h. Mean percentages and @GENE$ given ( n = 2 ) . In order to analyze the colony forming potential of cells remaining vital in the presence of sagopilone , clonogenic assays were performed ( Figure A ) . A 2-h incubation with 100 nM sagopilone completely inhibited colony forming in @VARIANT$ , SKBR3 , and A549 cancer cells , but only partially in MCF7 cancer cells .", "label": "None"}
{"id": "17973572", "sentence": "To prove the functional significance of the @VARIANT$ mutation , we generated Ba/F3 cell lines stably expressing mutant EGFR constructs [ ] . These cell lines , including L858R-L747S , proliferated in the absence of IL3 . @GENE$ cells were extremely sensitive to @DRUG$ ( D ) , whereas Ba/F3-L858R-T790M cells were highly resistant up to 1 μM gefitinib .", "label": "None"}
{"id": "25382104", "sentence": "As shown in , DB07107 and DB06977 showed better docking scores than existing drugs while others showed results comparable to those of marketed drugs like ponatinib , bosutinib , bafetinib , dasatinib , nilotinib and @DRUG$ . In the case of DB06977 , although one H_bond is missing ( Met318 ) with the wild-type of @GENE$ complex compared to @VARIANT$ mutant type , it still exhibits a favorable binding score of −10.94 kcal/mol .", "label": "None"}
{"id": "22701522", "sentence": "To evaluate the performance of the method , we analyzed the binding of @DRUG$ (MTX) to Escherichia coli dihydrofolate reductase ( eDHFR ) . The binding between MTX and eDHFR is well characterized and a series of eDHFR mutants are available , which bind to MTX with wide range of affinity , . We prepared @GENE$ tagged constructs of eDHFR wild-type ( WT ) and three eDHFR mutants ( eDHFR @VARIANT$ , eDHFR L54G and eDHFR F31V , L54G ) for which the reported Kd values to free MTX range from low pM to low µM , .", "label": "None"}
{"id": "25431951", "sentence": "Several strategies targeting @VARIANT$ BCR-ABL including blockade of kinase-addiction by the third-generation of tyrosine kinase inhibitor @DRUG$ [ ] , down-modulation of @GENE$ by inhibition of heat shock protein [ , ] were documented .", "label": "response"}
{"id": "22909314", "sentence": "HC Stain 1 Actin , muscle specific 26 CK17 51 Myogenin 1 Alcian blue- PAS 2 AE1/AE3 27 CK19 52 Napsin A 2 Argentaffin 3 AFP 28 CK5/6 53 NSE 3 Argyrophil 4 hCG 29 Pancytokeratin 54 OCT-4 4 Colloidal iron stain 5 CA-125 30 Desmin 55 @VARIANT$ 5 Elastic , Verhoeff’s 6 Calcitonin 31 E-cadherin 56 p53 6 Mucicarmine 7 Caldesmon 32 EMA 57 p63 7 PAS 8 Calretinin 33 Estrogen Receptor 58 PAX-2 8 PASD 9 CAM 5.2 34 GCDFP-15 59 PAX5 9 PTAH 10 CD10 35 GFAP 60 PAX-8 10 Reticulum , Gomori’s 11 CD117 36 Glypican-3 61 PLAP 11 Trichrome , Masson’s 12 CD138 37 Hep-Par1 62 @DRUG$ Receptor 13 CD20 38 HMB 45 63 Prostate Specific Antigen 14 CD3_39 HMW Keratin 64 RCC 15 CD30 40 HNF-1 65 S-100 16 CD34 41 Inhibin 66 Synaptophysin 17 CD43 42 CK , Oscar 67 @GENE$ 18 CD45RO 43 Leucocyte Common Antigen 68 Thyroglobulin 19 CD56 44 Mammaglobin 69 TTF1 20 CD99 45 Melan-A 70 Uroplakin 21 CDX2 46 MOC-31 71 Villin 22 CEA-polyclonal 47 MUC 1 72 Vimentin 23 Chromogranin 48 MUC 2 73 WT-1 24 CK 20 49 MUC5AC 25 CK 7 50 Myeloperoxidase", "label": "None"}
{"id": "25562700", "sentence": "Molecule Target Biomarker Indication vemurafenib BRAF kinase BRAF @VARIANT$ mutant melanoma vandetanib VEGFR , EGFR , RETR not included on the label thyroid cancer abiraterone CYP 17A1 not included on the label prostate cancer ipilimumab CTLA-4 not included on the label melanoma brentuximab vedotin CD30 ( ACD technology ) not included on the label lymphoma @DRUG$ ALK ALK-EML4 fusion protein lung cancer BRAF : Serine/threonine-protein kinase B-Raf ; VEGFR : Vascular endothelial growth factor receptor ; EGFR : epidermal growth factor receptor ; RETR : RET proto-oncogen receptor ; CYP 17A1 : cytochrome P450 17A1 ; CTLA-4 : Cytotoxic @GENE$ ; CD30 : Cluster of Differentiation 30 ; ADC : Antibody Conjugated Drug ; ALK-EML4 : anaplastic lymphoma kinase (ALK) ; echinoderm microtubule associated protein-like 4 ( EML4 ) fusion .", "label": "None"}
{"id": "24348666", "sentence": "It was initially proposed that the T790M mutation might prevent the proper binding of tyrosine kinase inhibitors via steric hindrance , similar to the corresponding gatekeeper mutations in BCR-ABL ( T315I ) and @GENE$ ( @VARIANT$ ) that confer resistance to imatinib ( @DRUG$ ) in chronic myelogenous leukemia and in patients with gastrointestinal stromal tumors .", "label": "resistance"}
{"id": "24348666", "sentence": "The two mutations were shown to independently induce @DRUG$ resistance in @GENE$ cells engineered to express the L1196M and @VARIANT$ mutations .", "label": "None"}
{"id": "23787070", "sentence": "@DRUG$ ( AP24534 ) an orally active @GENE$ Tyrosine Kinase Inhibitor effective against the @VARIANT$ mutation had been approved for a phase II clinical trial [ ] .", "label": "response"}
{"id": "24789720", "sentence": "@VARIANT$ mutation in EGFR gene seems to be one of the most important genetic abnormalities involving the resistance for reversible @GENE$ kinases inhibitors ( EGFR-TKI ) —erlotinib and @DRUG$ in NSCLC patients [ – ] .", "label": "resistance or non-response"}
{"id": "24189400", "sentence": "On the basis of these results , we reasoned that combined erlotinib and midostaurin could overcome @VARIANT$ mediated resistance , as @DRUG$ would target wild-type and exon 19 deletion E746-A750 EGFR activity while midostaurin would inhibit exon 19 deletion E746-A750+T790M @GENE$ .", "label": "resistance or non-response"}
{"id": "21122157", "sentence": "@GENE$ activation status was positively correlated with IL-6 expression and @DRUG$ resistance in AS2 derived cells In this current study , we used @VARIANT$ as active form Stat3 , and S3D and S3F as inactivated forms of Stat3 .", "label": "None"}
{"id": "21122163", "sentence": "Kim et al. [ ] showed instead that the SLC22A1 @VARIANT$ polymorphism ( rs683369 ) , which leads to Leu160Phe replacement , is associated with IM response in CML. Patients with the 480GG genotype showed a higher risk of treatment failure or loss of response than other genotypes . Finally , Takahashi et al. [ ] showed that the @GENE$ A1222G polymorphism ( rs628031 ) , which leads to Met408Val replacement , is associated with molecular response in the group of patients treated with IM doses lower than 400 mg. Patients with the 1222GG genotype showed a higher MMR rate . Uptake of @DRUG$ has also been described , in vitro , to be mediated to a modest extent by SLCO1B3 , which encodes the organic anion transporting polypeptide 1B3 [ ] , but Takahashi et al. [ ] did not find any association with IM response ( Table ) .", "label": "None"}
{"id": "19238210", "sentence": "Depending on the previously determined in vitro threshold for @DRUG$ and the bimodal curve we classified our NSCLC cell lines into 3 categories : sensitive , intermediate and resistant . We had nine sensitive cell lines which included seven of the 10 EGFR mutant cell lines , one cell line with @GENE$ CNG and one with HER2 CNG . Of the remaining 3 EGFR mutant cell lines , two had the resistance associated secondary @VARIANT$ mutation .", "label": "resistance or non-response"}
{"id": "21687596", "sentence": "Deletion mutations , mainly occurring around codons 746–750 in exon 19 , and the substitution of leucine with arginine at codon 858 in exon 21 ( @VARIANT$ ) comprise approximately 90 % of these mutations [ ] . These mutations are more prevalent in Asians , women , non smokers , and patients with adenocarcinoma , groups that match the highly gefitinib-sensitive clinical subset [ ] . Many investigators have reported results from retrospective analyses of associations between @GENE$ gene mutations and EGFR-TKI sensitivity .", "label": "sensitivity"}
{"id": "25197663", "sentence": "As a result , HSC are attracted to the circulation through a positive signal , most likely the sphingolipid sphingosine-1-phosphate @VARIANT$ . Alternatively HSC passively move to the blood . ( b ) @DRUG$ targets @GENE$ that is produced by BM stromal cells , causing a decrease of its levels and leading ultimately to mobilization .", "label": "None"}
{"id": "23963283", "sentence": "@VARIANT$ and MET amplification account for approximately 60–70 % of all known causes of acquired resistance to @DRUG$ or erlotinib ; these amplifications are not mutually exclusive and can be detected in the same resistant tumor or may occur independently in different metastatic sites in the same patient . Consequently , ongoing research has been focused on identifying the molecular mechanisms accounting for the 30–40 % of EGFR TKI-resistant , EGFR-mutant tumors that do not carry @GENE$ mutations or MET amplification .", "label": "resistance or non-response"}
{"id": "25054154", "sentence": "From docking analysis of @GENE$ with @DRUG$ , it is well revealed that both the mutations perturbed the binding pocket quite significantly . The most notable change was seen in @VARIANT$ mutation which was well supported by an increase in binding energy and loss of hydrogen bond interaction with the neighboring protein when compared to the native protein .", "label": "resistance"}
{"id": "15737014", "sentence": "Mutations in exon 2 of @GENE$ occur in about one-fourth of NSCLCs . Such mutations rarely , if ever , accompany EGFR mutations and are associated with primary resistance to gefitinib or @DRUG$ [ ] . To evaluate the possibility that secondary KRAS mutations confer acquired resistance to these drugs , we performed mutational profiling of KRAS2 exon 2 from tumor specimens from patients 1 to 3 , as well as the three additional patients lacking evidence of the @VARIANT$ mutation .", "label": "None"}
{"id": "15737014", "sentence": "@GENE$ Mutants Containing the @VARIANT$ Mutation Are Resistant to Inhibition by Gefitinib or @DRUG$ 293T cells were transiently transfected with plasmids encoding wild-type ( WT ) EGFR or EGFR mutants with the following changes : T790M , L858R , L858R + T790M , del L747–E749 ; A750P , or del L747–E749 ; A750P + T790M .", "label": "resistance or non-response"}
{"id": "25607805", "sentence": "Data analyses were performed for each of the 13 agonists : PDGF , @VARIANT$ , RZN , TGFβ , IL-13 , @GENE$ , IFNα , TNFα , Polyinosinic : polycytidylic acid ( poly ( I-C ) ) , ionomycin-phorbol 12-myristate 13-acetate ( ionomycin-PMA ) , dexamethasone ( DEX ) , lipopolysaccharide (LPS) , and @DRUG$ mesylate .", "label": "None"}
{"id": "21505228", "sentence": "An NRAS Q61K mutation was also identified in an isolated nodal metastasis from a patient with BRAF mutant melanoma , which progressed after an initial response to @DRUG$ . Interestingly , a distinct NRAS mutation ( @VARIANT$ ) was identified in a second progression site in the same patient . In resistant cells in vitro , both @GENE$ and P-ERK levels were maintained despite the presence of BRAF inhibitor .", "label": "None"}
{"id": "23185274", "sentence": "In this study , we design , synthesize and evaluated a number of novel quinazoline derivatives by exchanging the positions of the C5 and C6 substituents and varying the C4-amino functionality of @DRUG$ , and report that compound V1801 having a trifluoromethyl group at the C5'-position and a bromine at the C2'-position of the aniline moiety substituted at the C4 position of quinazoline core overcomes gefitinib resistance via up-regulation of Noxa , suggesting a novel strategy to fight against NSCLC with @GENE$ @VARIANT$ mutation .", "label": "resistance or non-response"}
{"id": "24348666", "sentence": "However , almost every patient who responds well to @DRUG$ will , without exception , experience recurrence due to acquired resistance . The mechanisms for acquired resistance include gatekeeper L1196M mutations , @GENE$ gene amplification , and other ALK gene mutations ( @VARIANT$ , C1156Y , F1174L ) - .", "label": "resistance"}
{"id": "22436374", "sentence": "H1650 and HCC827 have an in-frame deletion in the @GENE$ tyrosine kinase domain ( EGFR tyrosine kinase domainΔE746-A750 , exon 19 ) . H1650 cells have also a deletion of the 3 ' part of exon 8 and the entire exon 9 of PTEN , which causes loss of the protein [ ] and in addition express the insulin-like growth factor receptor ( IGF1R ) [ ] . The cell line H1975 has a sensitizing L858R kinase domain mutation in exon 21 , but also a second mutation ( @VARIANT$ , in cis , in the kinase domain ) rendering them resistant to the reversible TKIs @DRUG$ and erlotinib [ ] .", "label": "resistance or non-response"}
{"id": "23986642", "sentence": "@DRUG$ inhibited native ABL with an IC50 of 0.37 nM and clinically relevant @GENE$ mutations @VARIANT$ , G252H , T253P , M351T , and H396A with IC50 values of 2.0 nM , 0.44 nM , 0.30 nM , 0.30 nM , and 0.35 nM , respectively .", "label": "response"}
{"id": "22970367", "sentence": "The most common activating mutations ( ~90 % ) are in-frame deletions in exon 19 of EGFR and a missense mutation at 858 in exon 21 of EGFR resulting in an arginine to leucine substitution ( @VARIANT$ ) [ ] . Therapeutic agents targeting the EGFR signaling pathway , including two EGFR kinase inhibitors gefitinib and @DRUG$ , are clinically effective in treating lung cancer patients harboring these @GENE$ activating mutations [ – ] .", "label": "sensitivity"}
{"id": "PMC3760629", "sentence": "The EGFR mutant @GENE$ cell line harbouring EGFR @VARIANT$ , PC9R , has been used as in vitro model of drug resistance . Tumour microvesicles ( TMVs ) shed from cancer cells contain genetic and other molecular information that might be useful for diagnostic purposes to differentiate gefitinib-resistant NSCLC ( non-responders ) from sensitive patients ( drug responders ) .", "label": "None"}
{"id": "24944510", "sentence": "Multiple secondary mutations have already been identified in patients treated with @DRUG$ . Homologous to the gatekeeper @GENE$ T790M mutation is the L1196M substitution , which , unlike EGFR T790M , does not appear to confer a growth disadvantage to cells . Other secondary mutations such as G1269A , C1156Y , @VARIANT$ , and 1151Tins may affect affinity of the mutant ALK for either ATP or drug , and these differences have ramifications on the development of next-generation ALK inhibitors , which have varied mutation-specific efficacy among different agents .", "label": "None"}
{"id": "22933967", "sentence": "The KRAS status is the first molecular marker to predict the response to anti-EGFR monoclonal antibodies cetuximab and @DRUG$ in metastatic CRC ( mCRC ) patients , and it needs to be determined before deciding in favor of treatment with anti-EGFR antibodies . Previous retrospective studies suggested that mt-BRAF was a marker of resistance to anti-EGFR therapy and that the patients with mt-BRAF had significantly shorter PFS and OS than the patients with @GENE$ tumours . The mutations in the KRAS and BRAF genes have been reported to be mutually exclusive. , In the retrospective analysis by Fariña- Sarasqueta et al. , it was also shown that the BRAF @VARIANT$ mutation was an independent prognostic factor for the survival of patients with colon cancer in stages II and III , while the KRAS mutations did not have any effect on the overall survival of these patients .", "label": "resistance or non-response"}
{"id": "24634705", "sentence": "Targeting the oncogenic fusion protein echinoderm microtubule associated protein-like 4-anaplastic lymphoma kinase ( @GENE$ ) with TKIs such as @DRUG$ has also been shown to be negatively affected by the development of secondary gate keeper residue mutations such as @VARIANT$ , and the emergence of fusion negative tumors that render the disease insensitive to the drug .", "label": "resistance"}
{"id": "18794843", "sentence": "Mutation at the analogous position to Thr315 in other @DRUG$ targets such as c-KIT ( Thr670 ) and PDGFRA ( Thr674 ) have been linked to imatinib resistance in patients with GIST and @GENE$ , respectively , . Similarly , the gatekeeper mutation @VARIANT$ in EGFR causes resistance to gefitinib and erlotinib , and has been detected in lung cancer patients before drug treatment and in the germ line of a family pedigree with several cases of lung cancer , .", "label": "None"}
{"id": "24634705", "sentence": "The D761Y mutation is located on the α-C-helix of EGFR and is similar to a mutation in BCR-ABL , D276G , that is associated with acquired resistance after @DRUG$ treatment [ ] . The L747S mutation lies at the start of the β3 strand and the α-C-helix [ ] and has analogous residues in BCR-ABL ( L237M ) and @GENE$ ( @VARIANT$ or P ) that have been identified in TKI resistant disease [ ] .", "label": "None"}
{"id": "23208557", "sentence": "KRAS mutations have recently been reported to be markers of resistance for EGFR-TKI and monoclonal antibodies against EGFR , @DRUG$ and panitumumab [ – ] . @GENE$ is one of the kinase types that most frequently mutate in human tumors . In melanoma , colon and thyroid cancers , the tumor types with highest frequency of BRAF mutation , a single nucleotide substitution resulting in a gulutamic acid for valine substitution within the kinase domain at codon 600 ( @VARIANT$ ) , accounts for the majority of cases [ ] .", "label": "resistance or non-response"}
{"id": "PMC4041556", "sentence": "Second-generation @GENE$ TKIs – such as neratinib , afatinib and dacomitinib – are effective in preclinical gefitinib- and erlotinib-resistant EGFR @VARIANT$ models , but to date their delivery in EGFR TKI-resistant patients have shown disappointing results in the clinic .", "label": "resistance or non-response"}
{"id": "22110503", "sentence": "In a recently concluded phase I clinical trial , the multikinase and @GENE$ inhibitor , ponatinib ( @DRUG$ ) induced a complete cytogenetic and major molecular response rates of 89 % and 78 % , respectively , in CML patients with @VARIANT$ , and most responses were maintained after 12 months of follow-up [ , ] .", "label": "response"}
{"id": "19707313", "sentence": "Taking their in vitro activity into consideration , the following rank order of ( oncogenic ) potency is found : Y253F = E255K & gt ; wt BCR-ABL & gt ; @VARIANT$ & gt ; H396P &gt ; M351T & gt ; others . These mutations should not count in the evaluation of drug resistance and the consecutive treatment plan in the same way as clinically relevant ( oncogenic ) mutations . A number of different strategies have been proposed to treat patients with @DRUG$ resistant CML , in whom @GENE$ mutations are detected .", "label": "None"}
{"id": "15737014", "sentence": "Analogously , the T790M mutation , in conjunction with the drug-responsive del L747–E749 ; @VARIANT$ EGFR mutant , prevents inhibition of p-EGFR by @DRUG$ ( C ) . Sensitivity to Gefitinib Differs Among NSCLC Cell Lines Containing Various Mutations in EGFR or @GENE$", "label": "None"}
{"id": "23610714", "sentence": "@GENE$ mutations observed in patients with metastatic tumors are most frequently observed in exons 11 ( 67 % ) , 9 ( 10 % ) , 13 ( 1 % ) , or 17 ( 1 % ) , while platelet derived growth factor receptor-α ( PDGFRA ) mutations ( 10 % ) , which are less common than KIT mutations , occur mostly in exons 18 ( 6 % ) , 12 ( 0.7 % ) , or 14 ( 0.1 % ) . Mutational analysis is helpful in detecting the development of secondary mutations in tumors that are responding poorly to tyrosine kinase inhibitors and in identifying the PDGFRA exon 18 codon @VARIANT$ missense mutation , which is associated with a good prognosis , but conversely confers resistance to imatinib. , Exon 9 is reported to benefit from a high dose ( 800 mg/day ) of imatinib in some studies .", "label": "None"}
{"id": "22205962", "sentence": "Recently , TGS was shown to be induced in human cells by exogenous siRNAs that have sequence complementarity to the genomic DNA in the promoter regions of several genes containing Elongation factor-1 ( EF1A ) in 293FT cells – , E-cadherin ( CDH1 ) in HCT116 cells , immunodeficiency virus-1 ( HIV-1 ) coreceptor ( CCR5 ) in HEK293T cells , @DRUG$ receptor (PR) in @VARIANT$ cells , , ubiquitin C (UbC) in 293Gt cells , and vascular endothelial growth factor ( VEGF ) in HeLa and ARPE-19 cells . Recent studies demonstrated that TGS is associated with biochemical modification of critical residues in the histone tails and silent-state chromatin marks , not only at the target promoter region but also at the downstream region , which in turn is associated with repressive chromatin structures , , , . The protein components responsible for TGS were partially identified and found to contain Ago proteins , DNA methyltransferase 3a (DNMT3a) , DNMT1 , and @GENE$ HDAC1 ) , , , , , .", "label": "None"}
{"id": "24303221", "sentence": "Interestingly , studies on different lung cancer cell lines suggested that NCI-H292 , a pulmonary MEC cell line that has wild-type @GENE$ , is more sensitive to @DRUG$ than other wild-type EGFR non-small cell lung cancer cell lines [ ] . O'Neill analyzed the data from multiple studies and raised the interesting question that different ethnic populations may have different EGFR mutations in their pulmonary MEC tumors [ ] . Per review of the literature , 48 pulmonary MEC tumors were tested for EGFR mutations , and nine tumors ( 19 % ) tested positive for mutations including two reports of L858R mutations , five L861Q mutations , one @VARIANT$ mutation , and one exon 19 deletion .", "label": "None"}
{"id": "24348666", "sentence": "Specifically , a leucine to methionine mutation at position 1196 ( @VARIANT$ ) and a cysteine to tyrosine mutation at position 1156 ( C1156Y ) were found . With regard to resistance due to ligands , EGFR ligands ( @GENE$ amphiregulin , HB-EGF , and transforming growth factor-α ) are reported to induce @DRUG$ resistance .", "label": "None"}
{"id": "23533466", "sentence": "H1975 cancer cell line with mutations in EGFR exons 21 ( @VARIANT$ ) and 20 ( T790M ) was refractory to reversible @GENE$ , gefitinib , and @DRUG$ [ ] , but was sensitive to irreversible EGFR-TKIs , such as BIBW2992 ( afatinib ) .", "label": "sensitivity"}
{"id": "22433462", "sentence": "Two small molecule EGFR tyrosine kinase inhibitors ( @GENE$ ) , @DRUG$ ( Iressa , AstraZeneca International ) and erlotinib ( Tarveca , OSI Pharmaceuticals ) have been evaluated in patients with NSCLC [ , ] . These ATP competitive , reversible EGFR-TKIs have been effective only in a small subset of NSCLC patients bearing somatic mutations ( deletions in exon 19 and the @VARIANT$ mutation ) in the kinase domain of EGFR [ ] .", "label": "sensitivity"}
{"id": "24106980", "sentence": "Cyclin D1 binds to CDK4 and CDK6 to form a complex , supporting G1–S transition [ ] . Kastl et al. reported that reduced cyclin D1 expression modulated by miR-34a could induce G1 phase arrest , where docetaxel exerts little cytotoxicity , in turn leading to the resistance of docetaxel in breast cancer cells [ ] . Cyclin D1 is also a target of let-7i , and a chimera that combines Mucin 1 (MUC1) aptamer and let-7i miRNA was proved to reverse @DRUG$ resistance in EOC cells through down-regulation of cyclin D1 , cyclin D2 , Dicer 1 , and @GENE$ expressions [ ] .", "label": "None"}
{"id": "21660144", "sentence": "Several phase 2 studies showed a high response rate ( 55–90 % ) and a prolonged progression-free survival ( of approximately 9 months ) with first-line @DRUG$ in Asiatic patients selected on the basis of the presence of activating @GENE$ gene mutations [ – ] . The results of these studies are summarized in . Yang and colleagues observed in 43 patients with exon 19 deletions and @VARIANT$ mutations a response rate of 95 % and 73.9 % and a progression-free survival of 8.9 and 9.1 months , respectively [ ] .", "label": "sensitivity"}
{"id": "24256696", "sentence": "In mammals , mTOR associates with mammalian lethal with SEC13 protein 8 ( mLST8 ) , @GENE$ AKT substrate of 40 kDa ( AKT1S1 ) and regulatory associated protein of mTOR ( RAPTOR ) to form the rapamycin-sensitive mTOR complex 1 (mTORC1) . The mTORC1 activates protein synthesis through modulation of the 40S ribosomal protein S6 kinase ( @VARIANT$ ) and the translational initiation factor eIF-4E binding protein 1 ( 4E-BP1 ) . mTORC1 is acutely sensitive to inhibition by Sirolimus/Everolimus .", "label": "None"}
{"id": "24501009", "sentence": "Strategies to improve EGFR inhibition in EGFR @VARIANT$ cancers include the combination of irreversible EGFR inhibitors with the EGFR‐directed antibody cetuximab ( as reported for afatinib plus @DRUG$ ) 19 ; the development of more potent and specific inhibitors of EGFR T790M20,21 ; and the use of intermittent but high doses of existing irreversible EGFR inhibitors . In contrast , where resistance is mediated by compensatory signaling pathways , or tumors harbor more than one concomitant drug resistance mechanism , combination strategies with targeted agents in appropriately selected patients will be necessary to treat such cancers ( eg , inhibition of the @GENE$ pathway ) .", "label": "None"}
{"id": "21829508", "sentence": "Ihle et al. demonstrated that a @VARIANT$ mutation activates both PI3K/AKT/mTOR and MAPK pathways , whereas a G12C mutation causes robust RAL signaling . The prevalence of NRAS mutations was higher than reported in other studies or in the COSMIC database ( 14–20 % ) . , BRAF mutations have been mainly reported in melanoma , colorectal , papillary thyroid , and ovarian cancer. , In colorectal cancer they are associated with a dismal prognosis , however , unlike @GENE$ mutations , BRAF mutations might not be predictive of lack of @DRUG$ benefit .", "label": "sensitivity"}
{"id": "21362200", "sentence": "To illustrate the inhibitory activities of BGT226 , BKM120 and @DRUG$ on PI3K pathway signaling , the phosphorylation levels of Akt ( p-Akt ) and S6 ( p-S6 ) were assessed by western blotting in MDA-MB-231 , MCF7 , @VARIANT$ , or HCC712 cell lines in the presence of increasing dose of drug .", "label": "None"}
{"id": "24790411", "sentence": "Erlotinib and @DRUG$ belong to the first generation of TKIs and have reversible binding features . The principal predictive factor for response to such drugs is the presence of somatic “activating” mutations in the @GENE$ gene that cause an aberrant and constitutive activation of the receptor at the membrane level , resulting in a growth advantage of tumor cells through the activation of Ras/MAPK , PI3K/Akt , and STAT signaling pathways . In about 50 % of cases , a secondary mutation ( @VARIANT$ ) is supposed to be responsible for resistance. , Other mechanisms involve MET gene amplification ( 5 % –20 % ) ,", "label": "resistance or non-response"}
{"id": "23702846", "sentence": "In the cell proliferation and malignancy of MCF7 and SUM149 breast cancer cells , Src dependent ( i.e. , dasatinib-sensitive ) Y845 phosphorylation ( i.e. , @VARIANT$ mutation-sensitive ) signaling was shown to require the activity of p38 MAPK , but not the activity of the EGFR/kinase ERK/MAPK , as well as Akt [ ] . ROS that are produced by @DRUG$ and nocodazole , both of which disrupt microtubules , have also been reported to promote Y845 phosphorylation in vascular smooth muscle cells , R22 , by which @GENE$ signaling is triggered to activate plasminogen activator inhibitor-1 ( PAI-1 ) expression [ ] .", "label": "None"}
{"id": "24894453", "sentence": "Given the role of @DRUG$ in therapy of these cancers , initial efforts to identify activating @GENE$ mutations identified few such events , though potentially activating events such as @VARIANT$ were seen [ ] .", "label": "sensitivity"}
{"id": "16255777", "sentence": "This drug was designed as a specific inhibitor of the @GENE$ oncogene protein tyrosine kinase , known to be responsible for chronic myeloid leukemia ( CML ) cells [ ] . The therapeutic effectiveness of @DRUG$ and relative absence of detrimental side-effects has made it a model for the development of an array of new therapeutic agents targeted to inhibit signal transduction enzymes , especially protein kinases . The recent discovery that 60–70 % of human melanomas have activating mutations in B-Raf ( with 80 % of these mutations caused by a single substitution @VARIANT$ ) make this protein kinase an especially promising target for inhibition [ , ] .", "label": "None"}
{"id": "25364578", "sentence": "Lazzara and colleagues found that @GENE$ Y542 phosphorylation was not induced in response to EGF in the H3255 cells , which harbor the missense @VARIANT$ exon 21 mutation , suggesting that SHP2 activity may be less efficiently promoted by EGFR L858R and the STAT3 pathway may be more active . The main problem is that STAT3 activation is not abrogated by single EGFR TKI treatment with gefitinib , erlotinib , @DRUG$ or dacomitinib , - .", "label": "None"}
{"id": "19707322", "sentence": "The sensitivity of Bcr-Abl mutants to @DRUG$ can be summarized into 4 categories : high ( IC50 ≤ 70 nmol/L : M244V , G250E , Q252H , F3llL , F317L , M351T , V379I , L387M , H396P , H396R ) , medium ( IC50 ≤ 200 nmol/L : Y253F , E255K , F359V ) , low ( IC50 ≤ 450 nmol/L : Y253H , @VARIANT$ ) , and insensitive ( IC50 & gt ; 2 μmol/L : T315I ) ( ) ( ) .", "label": "None"}
{"id": "24052078", "sentence": "In addition , previous reports showed the presence of signaling cross-activation between MET and EGFR in both A549 and H1975 cells , and both the @VARIANT$ mutation of EGFR and c-Met amplification are known mechanisms of acquired gefitinib ( TKI ) resistance in lung cancer . As c-Met has a critical role in NSCLC , co-treatment with a c-Met inhibitor plus a reversible or irreversible EGFR kinase inhibitor ( i.e. , to achieve dual c-Met /EGFR inhibition ) may represent an alternative strategy to circumvent @GENE$ mediated resistance in lung cancer . Here , we report for the first time that erlotinib/MPT0E028 co-treatment inhibits HER-2 , IGF-IR , and c-Met in erlotinib-resistant lung cancer cells .", "label": "resistance or non-response"}
{"id": "23139670", "sentence": "In our case , a biopsy ( ‘re-biopsy’ ) revealed the @VARIANT$ mutation in the EGFR gene , which was widely known as a second mutation resistant to @GENE$ TKIs , such as gefitinib and @DRUG$ .", "label": "resistance or non-response"}
{"id": "24155950", "sentence": "Murine @GENE$ Bcr-Abl and Baf3 Bcr-Abl @VARIANT$ cells were plated in 75cm2 flasks ( 4 x 106 cells/35 ml/flask ) and treated with 0.5 or 1 µM imatinib . For @DRUG$ and dasatinib treatments , the cells were plated in 25cm2 flasks ( 2 x 106 cells/10 ml/flask ) and treated with 0.125 µM or 0.5 µM nilotinib and 0.056 µM or 0.112 µM dasatinib for 48h .", "label": "None"}
{"id": "24495353", "sentence": "Rank Entrez ID Gene symbol Entrez ID Gene symbol Entrez ID Gene symbol 1 28978 TMEM14A 79776 ZFHX4 1727 CYB5R3 2 1843 DUSP1 4701 NDUFA7 7083 TK1 3 51022 GLRX2 715 @VARIANT$ 1292 COL6A2 4 1434 CSE1L 79818 ZNF552 857 CAV1 5 8522 GAS7 4046 @GENE$ 5437 POLR2H 6 51668 HSPB11 1727 CYB5R3 9833 MELK 7 10456 HAX1 357 SHROOM2 54861 SNRK 8 9902 MRC2 283298 OLFML1 4830 NME1 9 4706 NDUFAB1 23179 RGL1 231 AKR1B1 10 23560 GTPBP4 1809 DPYSL3 10418 SPON1 11 79633 FAT4 857 CAV1 2350 FOLR2 12 10418 SPON1 274 BIN1 10979 FERMT2 13 471 ATIC 79833 GEMIN6 11096 ADAMTS5 14 6403 SELP 11222 MRPL3 4638 MYLK 15 23421 ITGB3BP 23244 PDS5A 9448 MAP4K4 16 23452 ANGPTL2 6241 RRM2 54922 RASIP1 17 54861 SNRK 1289 COL5A1 6934 TCF7L2 18 2034 EPAS1 8434 RECK 4072 EPCAM 19 30008 EFEMP2 429 ASCL1 4701 NDUFA7 20 25999 CLIP3 3426 CFI 404672 GTF2H5 21 4311 MME 332 BIRC5 6241 RRM2 22 4747 NEFL 2 A2M 2192 FBLN1 23 1809 DPYSL3 10730 YME1L1 25959 KANK2 24 28998 MRPL13 11130 ZWINT 55651 NHP2 25 25959 KANK2 1292 COL6A2 5050 PAFAH1B3 Lists of the top 25 of most influential genes in influence networks based on coexpression among genes in ER + breast tumors before , during , and after a course of neoadjuvant treatment with the drug @DRUG$ .", "label": "None"}
{"id": "23520442", "sentence": "The acquired resistance hypothesis purports that exposing to @GENE$ induces a second point mutation , resulting in a threonine-to-methionine change at position 790 of EGFR . Alternatively , the selective resistance hypothesis suggests that the @VARIANT$ mutation might exist in patients as small clones prior to treatment ; these resistant clones may proliferate after exposed to gefitinib or @DRUG$ .", "label": "resistance or non-response"}
{"id": "21192840", "sentence": "Tumor type EGFR mutation @GENE$ expression changes EGFR targeting agents ( FDA approved for clinical use ) Resistance mechanisms Non-small cell lung cancer Kinase domain deletions ( exon 19 ) , point mutations ( exon 21 ) Gene amplification Erlotinib , Gefitinib @VARIANT$ gatekeeper mutation ( 50 % ) , , elevated c-Met/HGF expression ( 20 % ) – Colorectal cancer ( metastatic ) Rare , Overexpression , copy number increase @DRUG$ , Panitumumab K-ras– , B-raf , PIK3CA , PTEN mutations", "label": "response"}
{"id": "24523596", "sentence": "Δ-235A −113A&gt ; G −29A&gt ; G 34G&gt;A @VARIANT$ N-terminal 114T & gt ; C No change N-terminal 151G&gt ; T G51C N-terminal 369C&gt ; T No change NBD 376C&gt ; T Q126stop NBD @GENE$ ; A Q141K NBD Increased bioavailability of topotecan and lactone form of 9-aminocamptotecin . Increased plasma concentration of diflomotecan . Increased risk of @DRUG$ induced diarrhea .", "label": "None"}
{"id": "24294007", "sentence": "On the other hand , a number of studies have demonstrated no benefit for either @DRUG$ or panitumumab by specific @GENE$ mutations . Although the preclinical work delineating different KRAS mutations is promising , prospective , multicenter clinical studies are required to recruit the numbers of patients necessary for the validation of @VARIANT$ and other mutations in KRAS as positive biomarkers of response to EGFR targeted therapies .", "label": "resistance or non-response"}
{"id": "24586514", "sentence": "( B ) K562 or @GENE$ @VARIANT$ cells were treated with ponatinib and/or @DRUG$ for 24 h , and total extracts were examined by immunoblot analysis with anti-phospho ABL , Crk-L , γH2A.X , cleaved caspase 3 , PARP , acetyl histone H4 , and tubulin antibodies .", "label": "None"}
{"id": "25119968", "sentence": "Indeed , also the basal level of @GENE$ was higher in S3R than in S4 cells indicating p53 dependent apoptosis . It seems that DDR can be a culprit of cell senescence , therefore we wondered whether @VARIANT$ cells would be able to senesce after treatment with @DRUG$ .", "label": "None"}
{"id": "21188109", "sentence": "Cyclin D1 , in association with cyclin dependent kinase-4 and -6 , induces the cell to enter the S phase by phosphorylating the retinoblastoma tumor suppressing protein , which binds to transcription factors , including @VARIANT$ . In addition to the overexpression of cyclin D1 , other genes that overexpress in MCL , such as VEGF and Raf-1 , represent further possible targets for mTOR inhibitors . Indeed , a constitutive activation of Akt and mTOR pathways either in MCL cell lines ( Granta 519 , Jeko-1 , and SP-53 ) or in primary cultures from 30 % of MCL patients has been reported. , Moreover , mTOR inhibitors in MCL could synergize with other “canonical” agents , such as @DRUG$ , doxorubicin , bortezomib , and rituximab , with resulting inhibition of Raf-1 , @GENE$ , and mTOR . ,", "label": "None"}
{"id": "24790411", "sentence": "Compared to @DRUG$ and gefitinib , afatinib shows lower EC50 values and greater potency against wild type ( afatinib vs erlotinib vs gefitinib : 60 nM vs 110 nM vs 157 nM ) and L858R mutated @GENE$ ( afatinib vs erlotinib vs gefitinib : 0.7 nM vs 40 nM vs 5 nM ) . Moreover , afatinib is able to inhibit the kinase activity in vitro and in animal models when a resistant @VARIANT$ mutation is concomitant to a sensitivity mutation .", "label": "resistance or non-response"}
{"id": "21264348", "sentence": "For example , compared with wild-type @GENE$ , residues 336–343 displayed no changes in deuterium incorporation when @DRUG$ was incubated with @VARIANT$ ( ) .", "label": "None"}
{"id": "15737014", "sentence": "For example , in CML , a commonly found mutation is a C→T single nucleotide change that replaces threonine with isoleucine at position 315 ( @VARIANT$ ) in the ABL kinase domain [ , , ] . In GIST and HES , respectively , the analogous T670I mutation in KIT and T674I mutation in @GENE$ have been associated with acquired resistance to this drug [ , ] . To determine whether lung cancers that acquire clinical resistance to either @DRUG$ or erlotinib display additional mutations in the EGFR kinase domain , we have examined the status of EGFR exons 18 to 24 in tumors from five patients who initially responded but subsequently progressed while on these drugs .", "label": "None"}
{"id": "21556318", "sentence": "Y253H , @VARIANT$ , and F359V were deemed less sensitive , but not inherently resistant , as was the T315I identified in three patients receiving nilotinib . Six of 16 @DRUG$ treated patients ( 38 % ) with @GENE$ mutations progressed to accelerated phase/blast crisis CML , as compared with 1/13 ( 8 % ) of nilotinib treated patients .", "label": "None"}
{"id": "17565683", "sentence": "Histology Immunohistochemistry Mutations KIT CD34 S100 SMA @GENE$ Gene Site 15 Spindle Positive + - - - C-kit Exon11 , MS 16 Spindle Positive + - - - C-kit Exon11 , IFD 17 Spindle Positive + - - - C-kit Exon11 , MS 18 Spindle Positive + - - - C-kit Exon11 , MS 19 Spindle Positive + - Weak - C-kit Exon11 , IFD 22 Myxoid epithelioid Weak + - + - PDGFRA Exon18 del D842V 23 Epithelioid Weak - - - - PDGFRA Exon18 DIMH842-845 26 Epithelioid Weak + NA NA NA PDGFRA Exon18 28 Myxoid epithelioid Weak + - - - PDGFRA Exon12 , @VARIANT$ MS : miss sense , IFD : in-frame deletion , NA : not available Because of possible relapse even after complete resection of omental GISTs [ - ] and the objective response rate of 67 % of @DRUG$ to the mutation in PDGFRA exon 12 [ ] , our patient received daily oral administration of 300 mg Glevec® , ( we applied 15 % reduced dose , referring to a report by Cormier , et al. after took account of a smaller average of Japanese build than American ) [ , ] .", "label": "None"}
{"id": "25580271", "sentence": "The National Cancer Institute ( NCI ) Adjuvant Lung Cancer Enrichment Marker identification and Sequencing Trial ( ALCHEMIST ) investigating adjuvant @DRUG$ in patients with @GENE$ mutant NSCLC with the primary end-point of overall survival will define the role of adjuvant erlotinib [ ] . First-line therapy for EGFR mutant NSCLC Two phase III trials compared afatinib to a platinum-doublet in patients with advanced EGFR mutant NSCLC , and a combined analysis for overall survival was presented at ASCO , as well as subset analyses based on EGFR mutation subtype ( exon 19 deletion and exon 21 @VARIANT$ point mutation ) [ ] .", "label": "sensitivity"}
{"id": "21283586", "sentence": "Transplantation of a TASK-2-type sensor in the background of the pHo-insensitive TASK-3-H98N channel was done by mutating residue V221 to H. @DRUG$ was chosen , rather than the much more basic arginine present in @GENE$ , because it should allow us to work at less extreme pH values given that TASK-3 lacks the hydrophobic environment thought to lower the pKa of the sensing arginine of TASK-2 . Although TASK-3-H98N-V221H double mutant could be readily expressed in HEK-293 cells , it had low currents and poor selectivity towards K+ over Na+ when assayed at 5 mM extracellular K+ . Loss of selectivity has been associated with gate closure occurring at the outer part of the pore in @VARIANT$ channels and is thought to occur by what has been termed collapse of the selectivity filter .", "label": "None"}
{"id": "22792530", "sentence": "In this study , SW480 and HCT116 cells were more resistant to apoptosis when treated with regimens containing @DRUG$ than when treated with regimens containing bevacizumab . This finding is related to the fact that both cell lines harbor a @GENE$ mutation , with SW480 and HCT116 cells expressing @VARIANT$ and G13D KRAS mutants , respectively .", "label": "None"}
{"id": "25486409", "sentence": "Second generation @GENE$ , such as BIBW2992 ( @DRUG$ ) and PF00299804 ( dacomitinib ) , have been recommended in order to overcome the @VARIANT$ mediated resistance considering that these potent , irreversible EGFR-TKIs no longer compete with ATP once they have become covalently bound to the kinase domain , .", "label": "response"}
{"id": "24982846", "sentence": "@DRUG$ EGFR @GENE$ exon 19 deletion or exon 21 substitution ( @VARIANT$ ) mutation positive Indications and usage , dosage and administration , adverse reactions , clinical pharmacology , clinical studies , patient counseling information", "label": "sensitivity"}
{"id": "24555578", "sentence": "Since a secondary @VARIANT$ mutation was found on a liver biopsy , but not in the @GENE$ , the patient received @DRUG$ , and the brain metastasis responded well to treatment .", "label": "None"}
{"id": "23515752", "sentence": "Total @GENE$ was only decreased in tumors of mice that received either 17-DMAG or the combination of 17-DMAG and @DRUG$ ( Fig. d ) .Combination of 17-DMAG and belinostat inhibited the in vivo growth of human TKI-resistant NSCLC xenografts . H1975 cells [ TKI-resistant , EGFR exons 20 ( @VARIANT$ ) and 21 mutations ] were injected in the flanks of nude mice ( day 1 ) .", "label": "None"}
{"id": "21188137", "sentence": "· The presence of any @GENE$ mutation ( that is when considering all mutations together ) does not appear to predict differential response to tyrosine kinase inhibitor ( TKI ) treatments ( defined as imatinib- , dasatinib- , and nilotinib based regimens ) . · There is consistent evidence that presence of the relatively rare @VARIANT$ mutation can predict TKI treatment failure , mainly in terms of hematologic and cytogenetic response .", "label": "None"}
{"id": "23208557", "sentence": "Cancer @GENE$ exon18 @VARIANT$ Drug efficacy prediction of gefitinib and erlotinib exon19 deletion exon20 T790M exon21 L858R KRAS codon12 , 13 Drug efficacy prediction of @DRUG$", "label": "None"}
{"id": "21605429", "sentence": "These data emphasize that mutational status must play a predominant role in the clinical management of patients and that new findings are necessary to establish the mechanisms responsible for @DRUG$ resistance in specific subsets of tumors like @GENE$ @VARIANT$ mutant and WT GIST .", "label": "resistance or non-response"}
{"id": "25562700", "sentence": "Molecule Target Biomarker Indication vemurafenib BRAF kinase BRAF @VARIANT$ mutant melanoma vandetanib VEGFR , EGFR , RETR not included on the label thyroid cancer abiraterone CYP 17A1 not included on the label prostate cancer @DRUG$ CTLA-4 not included on the label melanoma brentuximab vedotin CD30 ( ACD technology ) not included on the label lymphoma crizotinib @GENE$ ALK-EML4 fusion protein lung cancer", "label": "None"}
{"id": "23049365", "sentence": "In a phase I clinical trial @DRUG$ was used to treat 67 patients resistant to imatinib , dasatinib and nilotinib and passed safety requirements . Among these patients , 72 % presented mutations in @GENE$ at the beginning of the study or had a documented mutation story , including the @VARIANT$ and F317L mutations .", "label": "response"}
{"id": "23994953", "sentence": "Prospective trials have demonstrated an impressive ~75 % response rate for patients whose tumors harbor these mutations , which occur as either multinucleotide in-frame deletions in exon 19 ( e.g. , delE746-A750 ) or as single missense mutations ( e.g. , @VARIANT$ ) . Unfortunately , the EGFR TKI-driven improvement in patient outcome is notably limited because virtually all NSCLC patients with erlotinib/gefitinib sensitizing EGFR mutations eventually acquire resistance after a median of 6–12 months of @GENE$ TKI therapy .", "label": "sensitivity"}
{"id": "23785245", "sentence": "Most NSCLC patients who harbor activating EGFR mutations , including deletions in exon 19 or the point mutation L858R in exon 21 , experience an initial marked response to the @GENE$ gefitinib or @DRUG$ . However , almost all such individuals eventually develop acquired resistance to these drugs within 1 year . In addition , 20 % –30 % of NSCLC patients with EGFR mutations do not show an initial response to EGFR-TKIs. , , Therapeutic strategies to overcome EGFR-TKI resistance in NSCLC patients with EGFR mutations have been developed on the basis of the biological mechanisms of such resistance , which include a @VARIANT$ secondary mutation in EGFR as well as amplification of the gene for the receptor tyrosine kinase MET , which serves as the receptor for hepatocyte growth factor .", "label": "resistance or non-response"}
{"id": "24348666", "sentence": "However , almost every patient who responds well to @DRUG$ will , without exception , experience recurrence due to acquired resistance . The mechanisms for acquired resistance include gatekeeper @VARIANT$ mutations , ALK gene amplification , and other @GENE$ gene mutations ( L1152R , C1156Y , F1174L ) - .", "label": "resistance"}
{"id": "16187797", "sentence": "( B ) Number of colonies formed in soft agar by clonal NIH-3T3 cells expressing @VARIANT$ @GENE$ and D770_N771insNPG EGFR treated with the indicated concentrations of @DRUG$ or erlotinib immediately prior to suspension in soft agar .", "label": "sensitivity"}
{"id": "25122428", "sentence": "The dual inhibition of PI3K and mTOR might be advantageous over single inhibition by suppressing a @VARIANT$ feedback loop that leads to the pathway reactivation . Based on this idea , an on-going phase I study of the PI3K and @GENE$ dual inhibitor , BEZ235 , was designed for the patients with advanced solid tumors harboring PIK3CA or PTEN alteration ( NCT01195376 ) . In this study , we showed that the survival of the cisplatin-resistant SCLC cell lines was well suppressed by BEZ235 , accompanied by the suppression of S6RP phosphorylation .", "label": "None"}
{"id": "24326041", "sentence": "Two of these mutations were located in the kinase domain and are known to mediate resistance to @DRUG$ ( @VARIANT$ ) [ ] or to activate @GENE$ ( D769H ) [ ] .", "label": "resistance or non-response"}
{"id": "24982846", "sentence": "@DRUG$ ESR1 , PGR Hormone receptor positive Indications and usage , precautions , medication guide F5 Factor V Leiden carriers Warnings F2 Prothrombin mutation @VARIANT$ Thioguanine @GENE$ TPMT poor metabolizer Dosage and administration , precautions , warnings", "label": "None"}
{"id": "15737014", "sentence": "In GIST and @GENE$ , respectively , the analogous @VARIANT$ mutation in KIT and T674I mutation in PDGFR-alpha have been associated with acquired resistance to this drug [ , ] . To determine whether lung cancers that acquire clinical resistance to either @DRUG$ or erlotinib display additional mutations in the EGFR kinase domain , we have examined the status of EGFR exons 18 to 24 in tumors from five patients who initially responded but subsequently progressed while on these drugs .", "label": "None"}
{"id": "23723712", "sentence": "T790M mutation occurs by substitution of the amino acid threonine by methionine in amino acid position 790 ( T790M ) on exon 20 and is similar to the KIT @VARIANT$ gatekeeper mutation observed in imatinib-resistant gastrointestinal stromal tumor . Although the majority of @GENE$ mutations reduce the receptor’s affinity to ATP , the acquisition of T790M restores EGFR affinity for ATP to wild type levels , reducing the effect of TKIs .", "label": "None"}
{"id": "22909314", "sentence": "HC Stain 1 Actin , muscle specific 26 CK17 51 Myogenin 1 Alcian blue- PAS 2 AE1/AE3 27 CK19 52 Napsin A 2 Argentaffin 3 AFP 28 CK5/6 53 NSE 3 Argyrophil 4 hCG 29 Pancytokeratin 54 OCT-4 4 Colloidal iron stain 5 CA-125 30 Desmin 55 @VARIANT$ 5 Elastic , Verhoeff’s 6 Calcitonin 31 E-cadherin 56 p53 6 Mucicarmine 7 Caldesmon 32 EMA 57 p63 7 PAS 8 Calretinin 33 Estrogen Receptor 58 PAX-2 8 PASD 9 CAM 5.2 34 GCDFP-15 59 PAX5 9 PTAH 10 CD10 35 GFAP 60 PAX-8 10 Reticulum , Gomori’s 11 CD117 36 Glypican-3 61 PLAP 11 Trichrome , Masson’s 12 CD138 37 Hep-Par1 62 @DRUG$ Receptor 13 CD20 38 HMB 45 63 Prostate Specific Antigen 14 CD3_39 HMW Keratin 64 RCC 15 CD30 40 @GENE$ 65 S-100 16 CD34 41 Inhibin 66 Synaptophysin 17 CD43 42 CK , Oscar 67 Thrombomodulin 18 CD45RO 43 Leucocyte Common Antigen 68 Thyroglobulin 19 CD56 44 Mammaglobin 69 TTF1 20 CD99 45 Melan-A 70 Uroplakin 21 CDX2 46 MOC-31 71 Villin 22 CEA-polyclonal 47 MUC 1 72 Vimentin 23 Chromogranin 48 MUC 2 73 WT-1 24 CK 20 49 MUC5AC 25 CK 7 50 Myeloperoxidase", "label": "None"}
{"id": "24124608", "sentence": "In addition to upregulation of IGF1R and VEGF , frequent CN gain and increased mRNA expression of GSTT1 as well as significant overexpression of @GENE$ subfamily members were observed in wild-type/PDGFRA @VARIANT$ GISTs compared to KIT-mutant GISTs . CN gain of GSTT1 was closely associated with @DRUG$ resistance .", "label": "None"}
{"id": "24959087", "sentence": "Again , the activity of this resistance mechanism could be suppressed through combined MET and BRAF or @GENE$ inhibition . Further evidence of the efficacy of combination therapy in overcoming resistance is demonstrated by NSCLC cell lines resistant to erlotinib and the MET inhibitor SU11274 , which display upregulation of both mTOR ( mammalian target of rapamycin ) and Wnt pathway components and restoration of sensitivity to EGFR/MET inhibition by the addition of @DRUG$ . A final mechanism of resistance in gastric cancer cell lines has been demonstrated when MET amplified SNU6838 gastric cancer cell lines were treated with the MET inhibitors PHA-665752 and PF2341066 ; a novel mutation occurred in the activation loop of MET , causing a conformal change that blocked inhibitor binding analogous to the gatekeeper mutations seen in EGFR ( T790M ) following erlotinib treatment and in ABL ( @VARIANT$ ) following imatinib .", "label": "None"}
{"id": "15737014", "sentence": "Such mutations rarely , if ever , accompany EGFR mutations and are associated with primary resistance to gefitinib or @DRUG$ [ ] . To evaluate the possibility that secondary KRAS mutations confer acquired resistance to these drugs , we performed mutational profiling of @GENE$ exon 2 from tumor specimens from patients 1 to 3 , as well as the three additional patients lacking evidence of the @VARIANT$ mutation .", "label": "None"}
{"id": "24348666", "sentence": "The two mutations were shown to independently induce @DRUG$ resistance in @GENE$ cells engineered to express the L1196M and C1156Y mutations . By mid-2012 , additional patient studies led to the discovery of several other secondary mutations , . That is , three other mutations in the a-Chelix were discovered : a threonine insertion at amino acid 1151 ( 1151Tins ) , a leucine to arginine ( L1152R ) and phenylalanine to leucine ( @VARIANT$ ) .", "label": "None"}
{"id": "25486409", "sentence": "As the second-generation , irreversible @GENE$ , such as @DRUG$ and dacomitinib , failed to overcome the resistance caused by @VARIANT$ , , other measures , such as EGFR dual targeting with cetuximab and afatinib and third-geneneration , mutant-selective EGFR-TKIs – are being actively evaluated .", "label": "response"}
{"id": "17877814", "sentence": "These results are in line with previous data showing increased @DRUG$ resistance for a similar ( Ins770NPG ) mutant [ ] . Furthermore , our results show that both insertions confer higher kinase activity than @VARIANT$ , thus underscoring an important difference between these two types of exon 20 alterations . In this regard , there has been some controversy regarding the enhanced kinase activity of T790M-mutant @GENE$ [ ] .", "label": "resistance or non-response"}
{"id": "23606169", "sentence": "In the current clinical settings , broad knowledge regarding the KRAS and @GENE$ genes has been used to personalize treatment . Because mutations in the KRAS gene result in activation of the epidermal growth factor receptor (EGFR) signaling pathway , only metastatic colorectal cancer patients with wild-type KRAS tumors qualify for anti-EGFR targeted therapies with @DRUG$ or panitumumab [ ] . Also , a clinical trial with the BRAF inhibitor ( PLX4032 ) demonstrated antitumor activity in tumors with the BRAF @VARIANT$ mutation and confirmed that V600E BRAF is a valid therapeutic target in human cancer [ ] .", "label": "resistance or non-response"}
{"id": "17973572", "sentence": "Transient transfection experiments utilizing COS-7 cells demonstrated that auto-phosphorylation of the original L858R EGFR was inhibited by lower concentrations of gefitinib or @DRUG$ than the L858R-L747S or L858R-T790M constructs ( A ) . CL-387,785 partially overcame the observed inhibition ( B ) . To prove the functional significance of the @VARIANT$ mutation , we generated @GENE$ cell lines stably expressing mutant EGFR constructs [ ] .", "label": "None"}
{"id": "22970367", "sentence": "Similar to the @GENE$ T790M mutation , alteration of the drug contact residue T854 to a smaller hydrophobic alanine may increase the size of the selectivity pocket and negatively impact @DRUG$ binding . @VARIANT$ is thought to shift the equilibrium towards the active conformation of the receptor , while D761Y may affect the catalytic cleft of the receptor .", "label": "None"}
{"id": "24481412", "sentence": "( B ) @VARIANT$ cells were cultured with @DRUG$ ( 10 nM ) or control media for 12 h. Cells were subjected to immunostaining using @GENE$ NF-κB ( green ) and DAPI ( blue ) followed by confocal microscopic analysis .", "label": "None"}
{"id": "23320171", "sentence": "@DRUG$ Trastuzumab-DM1 ) is a new product in which the Trastuzumab moiety binds to @GENE$ on tumor cell surfaces and , upon internalization , the DM1 moiety is released and binds to tubulin , thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and proliferation . Primary results from the EMILIA study , a randomized trial comparing Trastuzumab DM-1 to lapatinib and capecitabine , have shown that Trastuzumab DM-1 significantly improved progression-free survival in patients with metastatic HER2 positive breast cancer . Further research is looking into inhibiting other targets such as mTOR , @VARIANT$ , or AKT pathways .", "label": "None"}
{"id": "24155950", "sentence": "The sensitivity of K562 , K562-R , LAMA84 , LAMA84-R , @GENE$ Bcr-Abl , and Baf3 Bcr-Abl @VARIANT$ cell lines to the most used Bcr-Abl inhibitors in CML : imatinib , dasatinib ( Santa Cruz Biotechnology , CA , USA , Cat. # sc-218081 ) and @DRUG$ ( Santa Cruz Biotechnology , CA , USA , Cat. # sc-202245 ) was investigated by treating these cells with increasing concentrations of each drug and measuring cell death using an automated Trypan Blue exclusion method ( see ) .", "label": "None"}
{"id": "24501009", "sentence": "Strategies to improve EGFR inhibition in EGFR @VARIANT$ cancers include the combination of irreversible EGFR inhibitors with the EGFR‐directed antibody cetuximab ( as reported for @DRUG$ plus cetuximab ) 19 ; the development of more potent and specific inhibitors of @GENE$ T790M20,21 ; and the use of intermittent but high doses of existing irreversible EGFR inhibitors .", "label": "response"}
{"id": "21915126", "sentence": "The mechanistic reasons behind the resistance to EGFR TKI are different , probably involving @VARIANT$ secondary mutation and MET amplification . Recently , some irreversible EGFR-TKIs and @GENE$ inhibitors have shown antitumour activity in patients resistant to gefitinib or erlotinib in pre-clinical studies ( ; ; ; ; ) . The RRs were 3.4 % ( EGFR mutant ) and 0 % ( EGFR wild-type ) in neratinib , 4.3 % in @DRUG$ , and 7.0 % in PF-00299804 .", "label": "None"}
{"id": "21333004", "sentence": "The inhibitory effects of Mig6 and @DRUG$ are indicated by red lines . E11 : EGFR homodimer ; ShcP : free phosphorylated Shc ; E11P : phosphorylated EGFR homodimer ; Raf1A : activated Raf1 ; MEKP : singly phosphorylated MEK ; MEKPP : doubly phosphorylated @GENE$ ; ERKP : singly phosphorylated ERK ; ERKPP : doubly phosphorylated ERK . To investigate cell-specific EGFR signaling dynamics , we constructed an H1299WT model ( WT model ) , an H1299EGFR-WT model ( EGFR-WT model ) , and two alternate H1299L858R models ( @VARIANT$ model A with Mig6 overexpression and L858R model B with Cbl overexpression ) .", "label": "None"}
{"id": "25378985", "sentence": "Possible mechanisms of acquired or secondary resistance to @DRUG$ include second mutations in the @GENE$ gene such as @VARIANT$ , activation of an alternative pathway including Met or HER2 amplification , histological transformation to small cell lung cancer ( SCLC ) and epithelial to mesenchymal transition [ ] .", "label": "resistance or non-response"}
{"id": "24251962", "sentence": "As shown in Figure @VARIANT$ , there was no significant change in the proportion of CD45/COL-I/α-SMA cells between these two groups . These data suggest that inhibition of LPA-LPA1 signal pathway selectively prevents BMSC differentiation into myofibroblasts in the fibrotic lung . To test the effect of Antapla1 on lung fibrosis in mice challenged with @DRUG$ , we measured the production of @GENE$ as well as collagens in the damaged lung tissues .", "label": "None"}
{"id": "16953242", "sentence": "In fact , the pleiotropic effect of BCR/ABL transformation is mostly dependent on post-translational modifications ( e.g. phosphorylation ) of signalling molecules , like those involved in the @GENE$ , PI3K/Akt and STATs pathways , which control cell growth , survival and differentiation of haematopoietic cells by modulating the expression and/or activity of downstream effectors ( ; ) ( ) . Being the deregulated BCR/ABL kinase activity the cause of CML , targeting its catalytic domain was the most rationale approach for the rational development of small molecules that inhibit ABL kinase activity . In these CML-BC patients , @DRUG$ resistance often depends on reactivation of BCR/ABL tyrosine kinase activity via mechanisms involving BCR/ABL overexpression , gene amplification or mutations that suppress imatinib mediated kinase inhibition ( i.e. @VARIANT$ and G250E ) or disrupt imatinib binding ( i.e. T315I ) ( ) .", "label": "None"}
{"id": "25435999", "sentence": "Gold standard bisulfite based methodologies using a standard sodium bisulfite treatment are able to reveal an overall profile of 5meC modifications , rather than a @GENE$ profile alone , although caution is required when interpreting the changes in DNA methylation as they do not reflect the changes in the individual 5meC metabolites . The present study identified that the DAPK1 gene is significantly methylated ( including possible hydroxymethylation ) in CML patients and this is correlated with mutations that result in resistance to @DRUG$ . Notably , one in two of the patients exhibiting both @VARIANT$ and M351T mutations demonstrated DNA methylation in the DAPK1 promoter region compared with non-resistant patients ; however , none of the patients with T315I alone demonstrated DAPK1 methylation .", "label": "None"}
{"id": "24958351", "sentence": "E ) . In contrast , treatment of SKBR3-L cells with @DRUG$ and okadaic acid did not result in enhanced growth inhibition compared to okadaic acid alone ( Additional file : Figure @VARIANT$ ) .", "label": "None"}
{"id": "20298590", "sentence": "Interestingly , lovastatin synergized significantly with @DRUG$ in CEMVBL cells ( Figure ) using the same experimental design as above . We also determined that lovastatin did not synergize with cisplatin in either parental A2780 cells ( Additional file : Supplemental Figure @VARIANT$ ) or the drug-resistant @GENE$ cells ( Additional file : Supplemental Figure S1B ) , both of which had little to no P-gp expression compared to A2780ADR cells ( Additional file : Supplemental Figure S1C ) .", "label": "None"}
{"id": "23292247", "sentence": "To further investigate the role of @DRUG$ in the activation of the @GENE$ pathway , cell proliferation was examined in the alcohol- and/or MEK1/2 inhibitor U0126 treated @VARIANT$ cells .", "label": "None"}
{"id": "22220249", "sentence": "Similarly , the analysis of oncogenic signaling pathway showed that older patients have a lower probability of @VARIANT$ and PI3-kinase pathway activation , but a higher probability of @GENE$ , TNF , Src , and EPI pathway activation . Using genomic derived signatures of anthracycline-sensitivity , elderly patients presented a uniformly anthracycline resistant signature irrespective of tumor biology , while younger patients were much more likely to be sensitive to @DRUG$ .", "label": "None"}
{"id": "23866929", "sentence": "The entry of tyrosine kinase inhibitors ( TKIs ) gefitinib ( Iressa® , AstraZeneca , Wilmington , Delaware ) and @DRUG$ ( Tarceva® , Genentech , South San Francisco , California ) , which target @GENE$ is one of the most recent , gratifying events in the treatment of advanced non-small-cell lung cancer ( NSCLC ) . Clinical trials have revealed significant variability in response to EGFR-TKIs , and patient characteristics such as sex , dominantly female , East Asian ethnicity , non smoking history , and adenocarcinoma (ADC) histology have been associated with an increased likelihood of EGFR-TKI effectiveness [ - ] . Furthermore , a high response rate ( 60 to 90 % ) to treatment with EGFR-TKIs has been observed in patients harboring mutations in exons 18 to 21 of the tyrosine kinase domain of EGFR , with exon 19 deletions and exon 21 @VARIANT$ point mutations comprising about 90 % of all mutations [ , ] .", "label": "sensitivity"}
{"id": "24071646", "sentence": "Atorvastatin could still enhance gefitinib efficacy in H460 cells ( gefitinib treatment versus 1 or 5 μM atorvastatin+gefitinib treatment , IC50=16.4 versus 4.06 or 1 μM ) . Besides , we transfected PI3K mutation @GENE$ ( @VARIANT$ ) into A549 and Calu1 cells .", "label": "resistance or non-response"}
{"id": "23029123", "sentence": "The importance of D2 receptor involvement in ethanol actions on PRL production and cell proliferation is evident in the experiment where @DRUG$ actions on lactotropes ' function were evaluated in clonal cell lines expressing various levels of D2 receptor isoforms . It was found that V cells , which lacked functional D2 receptors and had high basal levels of PRL , showed a significant reduction in PRL production following @VARIANT$ and D2L receptor transfection . As described by an extended allosteric ternary complex model of @GENE$ , receptors spontaneously isomerize between active and inactive conformations , so receptors can modulate signaling pathways in the absence of an agonist .", "label": "None"}
{"id": "21042543", "sentence": "The @VARIANT$ B-RAF mutation appears in 4 % –15 % of CRC.– The possible relationship between of @GENE$ mutational status and response to treatment with @DRUG$ in 48 patients with mCRC was investigated by Benvenuti et al . B-RAF mutations were detected in 12,5 % tumors and they were mutually exclusive with K-RAS alterations .", "label": "resistance or non-response"}
{"id": "19384426", "sentence": "Transfection of PTEN into the PTEN negative decreased the activation of @GENE$ and the downstream p70 ( @VARIANT$ ) and reversed the resistance to @DRUG$ in these cells , indicating that changes in PTEN status/Akt activation modulate the cellular response to doxorubicin [ ] .", "label": "None"}
{"id": "24955213", "sentence": "@VARIANT$ EML-ALKpm A mutation-specific strong H-bond pulls crizotinib out of the position found in the non-crizotinib resistant @GENE$ fusion gene [ , ] 1151Tins Thr insertion is predicted to alter ATP binding to ALK [ ]", "label": "resistance"}
{"id": "25405807", "sentence": "Inhibition of epidermal growth factor receptor (EGFR) kinase activity by EGFR tyrosine kinase inhibitors ( EGFR-TKIs ) , such as @DRUG$ and erlotinib , can result in improved response and prolonged progression-free survival ( PFS ) in selected non-small cell lung cancer ( NSCLC ) patients harboring sensitizing @GENE$ mutations , especially the exon 19del and exon 21 L858R mutations – . Unfortunately , almost all patients will ultimately develop resistance to EGFR-TKI , in whom more than 50 % cases were detected harboring the EGFR @VARIANT$ mutation in tumor specimens after EGFR-TKI , .", "label": "resistance or non-response"}
{"id": "23185274", "sentence": "Compared with the parental compound @DRUG$ , V1801 is a relatively weak @GENE$ inhibitor which bears a much more potent cytotoxicity in @VARIANT$ EGFR harboring NCI-H1975 cells ( ) .", "label": "resistance or non-response"}
{"id": "23606169", "sentence": "Moreover , the presence of the @VARIANT$ mutation in the @GENE$ gene is more and more frequently taken into consideration before patient targeted therapy qualification , because wild-type BRAF is required for a response to panitumumab or @DRUG$ [ , ] .", "label": "resistance or non-response"}
{"id": "25465236", "sentence": "( G–I ) increased inhibition potency for @DRUG$ against EGFR @VARIANT$ mutant compared to @GENE$ WT protein and subsequent further increase in potency for Gefitinib against EGFR L858R + E884K double mutant .", "label": "sensitivity"}
{"id": "24212826", "sentence": "Furthermore , three of the four responders with exon 20 mutations also had concurrent sensitizing @GENE$ mutations ( L858R ) [ ] . According to previous studies , the average response rate for @DRUG$ treatment in patients with exon 20 mutations was only 34 % . These mutations in exon 20 could be point mutations , such as V765M , S768I , @VARIANT$ , and T790M .", "label": "None"}
{"id": "24944510", "sentence": "Poziotinib ( also known as HM781-36B ) , a new potent irreversible inhibitor of EGFR , HER2 , HER4 , and transient erythroblastopenia of childhood family of kinases inhibitor ( @GENE$ , BLK , and BMX ) , demonstrated preclinical efficacy against @VARIANT$ mutant at eightfold lower doses compared to @DRUG$ .", "label": "None"}
{"id": "23792636", "sentence": "Since @GENE$ and the mitochondria play an important role in sensitivity to @DRUG$ , , we determined if the various PXN mutants exhibited a differential response to cisplatin . Compared with control , HEK-293 cells overexpressing PXN mutations A127T and @VARIANT$ were found to be more sensitive .", "label": "None"}
{"id": "22124674", "sentence": "Wild-type patients do not seem to benefit from adjuvant imatinib [ ] ; however , in vivo studies evaluating sunitinib [ ] and in vitro studies for nilotinib and @DRUG$ [ ] are promising . As for PDGFRA mutated GIST , PDGFRA exon 18 generally benefits from adjuvant imatinib therapy , with the exception of PDGFRA exon @GENE$ GIST [ ] .", "label": "None"}
{"id": "22655263", "sentence": "Ki determination demonstrated a very similar biochemical potency on wild-type ALK and the @VARIANT$ @GENE$ mutant ( 0.09 and 0.08 nM respectively ) , with both cellular and in vivo data ( using engineered Ba/F3 cells ) indicating that growth of ALK–L1196M mutant driven-cells is inhibited at similar , albeit slightly higher , doses which inhibit cells harboring wild-type ALK ( Katayama et al. , ) . AP26113 was also described to be active on a series of in vitro induced crizotinib resistant mutations , which however have not been observed to date in clinical cases of acquired @DRUG$ resistance ( Zhang et al. , ) .", "label": "resistance"}
{"id": "22662154", "sentence": "Group Cell line Mutational status Copy number alterations IC50 ( nM ) PIK3CA @GENE$ ( mutated exons ) K-Ras PIK3CA PTEN K-Ras BEZ235 @DRUG$ C HEC-1B Mut ( G1049R ) wild type Mut ( @VARIANT$ ) Gain nl nl 220 200 HHUA Mut ( R88Q ) Mut 5 ( F ) , 8 ( F ) Mut ( G12V ) nl nl nl 250 & gt ; 1000", "label": "None"}
{"id": "PMC3760629", "sentence": "The most common mechanism of acquired drug resistance @DRUG$ is the secondary @GENE$ @VARIANT$ mutation , which is detected in up to 60 % of EGFR mutant NSCLC patients .", "label": "resistance or non-response"}
{"id": "19758442", "sentence": "The regions responsible for interaction with @VARIANT$ ( red ) and A3F ( blue ) are discontinuous . They overlap but are not identical . The region important for interaction with the Cul5 @GENE$ marked in green and includes a conserved histidine-cysteine-cysteine-histidine motif and a suppressor of cytokine signaling Box domain .", "label": "None"}
{"id": "22933967", "sentence": "In an abstract recently published in the 2011 ASCO Annual Meeting Proceedings , Tejpar et al. retrospectively analyzed the influence of @GENE$ @VARIANT$ mutations on the efficacy of treatment with @DRUG$ as the first-line systemic therapy and compared it with the pooled results of randomized studies CRYSTAL and OPUS .", "label": "resistance or non-response"}
{"id": "21192840", "sentence": "Tumor type EGFR mutation @GENE$ expression changes EGFR targeting agents ( FDA approved for clinical use ) Resistance mechanisms Non-small cell lung cancer Kinase domain deletions ( exon 19 ) , point mutations ( exon 21 ) Gene amplification @DRUG$ , Gefitinib @VARIANT$ gatekeeper mutation ( 50 % ) , , elevated c-Met/HGF expression ( 20 % ) –", "label": "resistance or non-response"}
{"id": "22970367", "sentence": "Second-generation irreversible EGFR inhibitors , which bind irreversibly in the ATP binding pocket of EGFR through a covalent bond at C797 , were shown to be more potent inhibitors of the second-site @VARIANT$ mutation than erlotinib or gefitinib in pre-clinical models [ , ] ( ) . These inhibitors are currently under clinical trials in patients with acquired resistance . One of these agents , BIBW2992 ( @DRUG$ ) , is able to target both @GENE$ and ERBB2 and overcome T790M-driven acquired resistance [ ] .", "label": "response"}
{"id": "23340652", "sentence": "In this case , the presence of somatic mutation in @GENE$ gene has been associated with a higher responsiveness to @DRUG$ . The authors sequenced exons 18–21 of the EGFR gene using DNA extracted from tumor and normal lung tissue obtained at a previous resection : the @VARIANT$ mutation was detected .", "label": "sensitivity"}
{"id": "17973572", "sentence": "After the cells were exposed to gefitinib for 24 h , Ba/F3-L858R cells were unable to proliferate while Ba/F3-L858R-L747S and @GENE$ cells continued to grow even in the presence of 1 μM @DRUG$ ( E ) . These results suggest that execution of apoptosis may be impaired by the presence of T790M and , to a lesser extent , @VARIANT$ .", "label": "None"}
{"id": "25562700", "sentence": "Molecule Target Biomarker Indication vemurafenib BRAF kinase BRAF @VARIANT$ mutant melanoma vandetanib VEGFR , EGFR , RETR not included on the label thyroid cancer abiraterone CYP 17A1 not included on the label prostate cancer @DRUG$ CTLA-4 not included on the label melanoma brentuximab vedotin CD30 ( @GENE$ technology ) not included on the label lymphoma crizotinib ALK ALK-EML4 fusion protein lung cancer", "label": "None"}
{"id": "23994953", "sentence": "Using the erlotinib-sensitive EGFR mutant NSCLC cell line HCC4006 harboring the delL747-E749 , A750P mutation in @GENE$ exon 19 , Suda et al. established that mesenchymal status , not a specific oncogenic activated protein , could sufficiently promote loss of EGFR dependence to confer resistance to @DRUG$ . More recently , Chang et al. confirmed that in the absence of the common second-site EGFR mutation @VARIANT$ or MET amplification , acquired resistance to gefitinib occurs in EGFR mutated PC9 cells that have undergone EMT .", "label": "resistance or non-response"}
{"id": "21984124", "sentence": "Disruption of the microtubule network by chemical agents , such as nocodazole and colchicine , leads to ligand independent @GENE$ nuclear accumulation and transcription of TGF-β-responsive genes . @DRUG$ is an anticancer agent which , by stabilizing polymerized microtubules and maintaining microtubular assembly , arrests the cell cycle in the G0–G1 and G2–M phases and induces cell death , .", "label": "None"}
{"id": "23785245", "sentence": "Furthermore , it potently inhibits TKI-resistant forms of these kinases harboring gatekeeper mutations ( @VARIANT$ in ALK and T790M in EGFR ) . , As of September 2012 , 15 patients with advanced malignancies , including eleven individuals with NSCLC , had been enrolled in a phase I/II trial of AP26113 . The NSCLC patients included four with @GENE$ rearrangement positive tumors that developed resistance to prior @DRUG$ treatment .", "label": "resistance"}
{"id": "24155950", "sentence": "In conclusion , the combination of @DRUG$ and mitotic inhibitors such as paclitaxel , docetaxel , vincristine or BI 2536 is an effective strategy for targeting of both TKIs -resistant and -sensitive Bcr-Abl positive leukemic cells . These regimens are able to inhibit @GENE$ activity and its downstream signaling , and to activate caspase dependent cell death . In addition , these regimens are able to overcome the resistance to imatinib , dasatinib and nilotinib , brought about by Bcr-Abl protein overexpression or Bcr-Abl mutations ( including @VARIANT$ ) , making them attractive potential therapies for Bcr-Abl positive leukemias such as CML , especially for those resistant to current treatments .", "label": "None"}
{"id": "20920219", "sentence": "The estrogen induced activation of PGR , which encodes the @DRUG$ @GENE$ increases upon Sin3A knockdown ( Figure ) . PR status is often used as a marker of estrogen sensitivity and predictor of response to endocrine therapy in breast cancer [ , ] . Additionally , knockdown of Sin3A only prevents growth of ERα positive MCF7 and @VARIANT$ cells , not ERα negative MDA-MB-231 and Hs578T cells , further supporting the notion that components intrinsic to the ERα signaling pathway are involved in mediating the ability of Sin3A to promote survival .", "label": "None"}
{"id": "698035", "sentence": "( 2 ) @DRUG$ ( Cyclo ) at 10 mg/kg will cure CBA mice which have received i.p . injections of 107 @GENE$ , but this dose , and more intensive treatment with this drug , fails to cure @VARIANT$ mice .", "label": "None"}
{"id": "17973572", "sentence": "The Secondary Resistant Mutations L747S and T790M Affect @DRUG$ Induced Apoptosis and Inhibit BIM Up-Regulation ( A ) Top : Annexin V apoptosis assay : @GENE$ cells expressing @VARIANT$ (LR) , L858R-L747S # 4 ( LR-LS ) , or L858R-T790M (LR-TM) cells were grown in the absence or presence of gefitinib for 24 h .", "label": "None"}
{"id": "25465236", "sentence": "( G–I ) increased inhibition potency for @DRUG$ against @GENE$ @VARIANT$ mutant compared to EGFR WT protein and subsequent further increase in potency for Gefitinib against EGFR L858R + E884K double mutant .", "label": "sensitivity"}
{"id": "25054154", "sentence": "We utilised three complexes , namely , native ( @GENE$ ) , F1174L ( ALK F1174L-crizotinib ) , and @VARIANT$ ( ALK R1275Q-crizotinib ) for our analysis .", "label": "sensitivity"}
{"id": "22933967", "sentence": "According to the analysis of other mutations , they proposed testing of KRAS status , if not mutated , then of BRAF and NRAS status , and @GENE$ exon 20 mutation in order to improve the objective response up to 40 % in selected patients . In our retrospective study , 26.7 % of patients , all with KRAS wild-type tumours , who had previously unresectable liver-only metastases , underwent surgical resection after systemic therapy , with R0 resection achieved in 38 patients ( 21.6 % ) ; one of those was patient with the BRAF @VARIANT$ mutation . Although it is difficult to make any comparison , because our patients were not selected according to specific systemic therapy , these results are comparable with those reported in previous studies claiming that 19 to 23 % patients treated with bevacizumab- and irinotecan based chemotherapy and with previously unresectable liver-only metastases underwent resection.– In a recently published clinical study BOXER , where the patients with unresectable liver-only metastases were treated with oxaliplatin , @DRUG$ and bevacizumab , R0 resection was achieved in 40 % of patients .", "label": "None"}
{"id": "24036898", "sentence": "@DRUG$ and bevacizumab were provided by Chugai Pharmaceutical Co. ( Tokyo , Japan ) . Rabbit polyclonal antibodies ( Abs ) against ubiquitin and actin ( Santa Cruz Biotechnology , Santa Cruz , CA ) , @GENE$ , phospho-Erk , and Erk ( Cell Signaling Technology , Danvers , MA ) , and CD31 and Ki67 ( Abcam , Cambridge , England ) were used . Mouse monoclonal Abs against CD16 ( 3G8 ) and CD54 ( HCD54 ) ( BioLegend , San Diego , CA ) and CD11a ( Ancell , North Bayport , MN ) , rabbit monoclonal Abs against HER2 ( D8F12 ) , phospho-HER2 ( 6B12 ) and phospho-Akt ( @VARIANT$ ) ( Cell Signaling Technology ) , and rat monoclonal Ab against CD18 ( YFC118.3 ) ( Chemicon International , Temecula , CA ) are also commercially available .", "label": "None"}
{"id": "25033171", "sentence": "The mutated site @VARIANT$ , P-loop region , and @DRUG$ in WT-ROS1 and @GENE$ are shown in green surface , orange surface , green stick , and pink stick models , respectively , in panels A and B .", "label": "resistance"}
{"id": "23109843", "sentence": "To examine the role of Rad16 further we decided to create mutants at each of its two active sites , namely the ATPase domain and the site for E3 @GENE$ associated with the C3HC4 RING domain that is embedded within the ATPase domain . We mutated either each one alone or both of these in combination [ ] . Creation of the point mutations within the Rad16 ATPase domain ( K216A ) , RING-finger domain ( C552A , @VARIANT$ ) and double mutation of ATPase and RING-finger domains ( K216A , C552A , H554A ) , resulting in the amino-acid substitutions , lysine 216 to alanine , cysteine 552 to alanine and @DRUG$ 554 to alanine .", "label": "None"}
{"id": "22655263", "sentence": "When tested in Ba/F3 cells driven by @GENE$ mutants identified in @DRUG$ relapsed patients , NMS-E628 is circa fivefold more potent than crizotinib in inhibiting the proliferation of @VARIANT$ ALK and C1156Y ALK-driven-cells in vitro and in vivo ( Ardini et al. , ) .", "label": "resistance"}
{"id": "25505694", "sentence": "The lack of efficacy could probably be related to the high concentrations of neratinib required in preclinical studies to inhibit EGFR @VARIANT$ and the limitations of clinical dosing . Dacomitinib Dacomitinib is an irreversible @GENE$ , HER2 and HER4 inhibitor with a higher kinase inhibition than gefitinib/erlotinib in both gefitinib/erlotinib-sensitive and in EGFR-T790M and HER2 mutated cell lines [ ] .", "label": "resistance or non-response"}
{"id": "22415797", "sentence": "MK-0646 ( dalotuzumab ) Humanized IgG1 II @DRUG$ +/− MK-0646 ER+ neo-adjuvant NA @GENE$ studies suggest that mTOR inhibitors are able to up-regulate PI3K-Akt pathway by the release of the negative feedback of @VARIANT$ on IRS-1 [ , ] .", "label": "None"}
{"id": "25580271", "sentence": "Overall survival of patients with common @GENE$ mutations ( defined as exon 19 deletion and exon 21 @VARIANT$ point mutation ) in LUX-3 , LUX-6 , and combined cohorts [ ] Patient cohort @DRUG$ ( median OS ) Platinum based chemotherapy ( median OS ) Hazard ratio ( 95 % confidence interval )", "label": "sensitivity"}
{"id": "25157335", "sentence": "Both median PFS and ORR were significantly better in patients treated with @DRUG$ compared with chemotherapy . AZD9291 and CO-1686 are irreversible selective @GENE$ inhibitors , which demonstrate significant activity in patients with acquired resistance to first-generation EGFR-TKI , and are currently under development . In patients with tumors harboring @VARIANT$ mutation , AZD9291 and CO-1686 show promising 64 and 58 % ORR , respectively ( , ) .", "label": "response"}
{"id": "23805327", "sentence": "Mutations in the epidermal growth factor receptor (EGFR) are found in many advanced lung cancer patients who respond positively to @GENE$ tyrosine kinase inhibitors , gefitinib or @DRUG$ , . However , many of these patients eventually relapse and develop resistance to these EGFR inhibitors . The @VARIANT$ mutation on exon 20 of the EGFR receptor has been reported as one of the driving mutations for the acquired resistance to gefitinib treatment .", "label": "resistance or non-response"}
{"id": "21333004", "sentence": "The inhibitory effects of Mig6 and @DRUG$ are indicated by red lines . E11 : EGFR homodimer ; ShcP : free phosphorylated Shc ; E11P : phosphorylated @GENE$ homodimer ; Raf1A : activated Raf1 ; MEKP : singly phosphorylated MEK ; MEKPP : doubly phosphorylated MEK ; ERKP : singly phosphorylated ERK ; ERKPP : doubly phosphorylated ERK . To investigate cell-specific EGFR signaling dynamics , we constructed an H1299WT model ( WT model ) , an H1299EGFR-WT model ( EGFR-WT model ) , and two alternate H1299L858R models ( @VARIANT$ model A with Mig6 overexpression and L858R model B with Cbl overexpression ) .", "label": "sensitivity"}
{"id": "22655263", "sentence": "X-296/X-396 ( Xcovery ) are aminopyridazine based ALK kinase inhibitors which display good anti-tumor activity in vitro and in vivo on different @GENE$ dependent tumor models . X-396 was also evaluated on @VARIANT$ and C1156Y mutations and data suggest that it can potentially overcome at least these @DRUG$ resistance mutations .", "label": "resistance"}
{"id": "24348666", "sentence": "2. Acquired resistance mechanism 1 ) Secondary @VARIANT$ mutation of the @GENE$ gene Unfortunately , many of those patients who originally had responded eventually become insensitive to gefitinib or @DRUG$ therapy through acquired resistance .", "label": "resistance or non-response"}
{"id": "23976869", "sentence": "Vo n Bubnoff et al reported that nilotinib suppresses the growth of @GENE$ cells transfected with the T674I FIP1L1-PDGFRA mutant . However , Stover et al reported that nilotinib could not overcome the @DRUG$ resistance conferred by the point mutation @VARIANT$ in FIP1L1-PDGFRA in the same cellular model , even at high concentrations .", "label": "None"}
{"id": "23799845", "sentence": "Before @DRUG$ therapy , the @VARIANT$ mutation was not detectable by either mutation detection method . Owing to the complex mixture of mutations detected in patient 20 , the samples assessed by Sanger sequencing and mass spectrometry based mutation analysis have been labelled ( a–e ) , and the mutations detected at these time points are indicated in the adjacent box . Details of patients with imatinib-resistant mutant @GENE$ clones that became undetectable by Sanger sequencing after changing therapy", "label": "None"}
{"id": "23610714", "sentence": "Imatinib has been found to be effective not only for GIST with C-KIT mutations but also for GIST with @GENE$ mutations and for wild-type GISTs. , However , no adjuvant treatment is recommended in GISTs with the @VARIANT$ missense mutation in the PDGFRA exon 18 , which are known to be unresponsive to @DRUG$ and showed very favorable outcome after surgery .", "label": "resistance or non-response"}
{"id": "24386407", "sentence": "Recent clinical trials have shown that progression-free survival ( PFS ) in patients with @GENE$ mutant lung cancer is prolonged by treatment with a reversible EGFR-TKI and the irreversible EGFR-TKI @DRUG$ , which was designed to covalently bind to EGFR [ - ] . Nevertheless , almost all responders relapse after acquiring resistance to these EGFR-TKIs [ , ] . Among the mechanisms by which cancer cells become resistant to reversible EGFR-TKIs are 1 ) gatekeeper mutations in EGFR , such as the @VARIANT$ second mutation [ , ] ; 2 ) activation of bypass signaling caused by Met amplification [ ] , hepatocyte growth factor (HGF) overexpression [ ] , or Gas6-Axl activation [ ] ; 3 ) activation of downstream molecules ( PTEN loss or PIK3CA mutation ) [ , ] ; 4 ) small-cell lung cancer transformation [ ] ; and 5 ) epithelial-to-mesenchymal transition [ ] .", "label": "response"}
{"id": "19758442", "sentence": "The regions responsible for interaction with A3G ( red ) and @VARIANT$ ( blue ) are discontinuous . They overlap but are not identical . The region important for interaction with the Cul5 @GENE$ marked in green and includes a conserved histidine-cysteine-cysteine-histidine motif and a suppressor of cytokine signaling Box domain .", "label": "None"}
{"id": "25032217", "sentence": "Notably , the Evaluation of Genomic Applications in Practice and Prevention ( EGAPP ) Working Group ( EWG ) found insufficient evidence to recommend or discourage testing for mutations in BRAF @VARIANT$ , NRAS , or PIK3CA and/or loss of PTEN or AKT protein . Therefore , the EWG discourages the use of these tests for deciding whether to introduce @GENE$ therapy with @DRUG$ or panitumumab until more evidence supports improved clinical outcomes [ ] .", "label": "None"}
{"id": "24775716", "sentence": "Combined daily treatment with intravenous hydroxocobalamin ( 2 mg ) , oral betaine ( 9 g ) , L-carnitine ( 3 g ) , and @DRUG$ 10 mg ) was started , and a dramatic clinical improvement , with the recovery of arm function and the disappearance of psychotic features and lethargy , was observed after 6 weeks . In a different approach , a recent meta-analysis examining the association between @GENE$ gene polymorphisms and psychiatric disorders demonstrated a strong association between the MTHFR @VARIANT$ gene variant and unipolar depression , schizophrenia and bipolar disorder , with odds ratios of 1.36 , 1.44 and 1.82 , respectively [ ] .", "label": "None"}
{"id": "24982846", "sentence": "@DRUG$ EGFR @GENE$ protein expression positive EGFR exon 19 deletion or exon 21 substitution ( @VARIANT$ ) positive Clinical pharmacology Indications and usage , dosage and administration , clinical pharmacology , clinical studies", "label": "sensitivity"}
{"id": "24944510", "sentence": "Multiple secondary mutations have already been identified in patients treated with @DRUG$ . Homologous to the gatekeeper EGFR T790M mutation is the L1196M substitution , which , unlike EGFR T790M , does not appear to confer a growth disadvantage to cells . Other secondary mutations such as G1269A , @VARIANT$ , L1152R , and 1151Tins may affect affinity of the mutant ALK for either ATP or drug , and these differences have ramifications on the development of next-generation @GENE$ inhibitors , which have varied mutation-specific efficacy among different agents .", "label": "resistance"}
{"id": "24971999", "sentence": "DNA sequence at the site of putative gefitinib-responsive mutations in the @GENE$ gene of PC-3 cells . DNA sequences of the EGFR gene around the E746-A750 deletion ( A ) and around the mutations T790M ( B ) , D761Y ( C ) and @VARIANT$ ( D ) in non-small-cell lung cancer cells were determined in PC-3 cells .", "label": "sensitivity"}
{"id": "25562700", "sentence": "Molecule Target Biomarker Indication vemurafenib BRAF kinase @GENE$ @VARIANT$ mutant melanoma vandetanib VEGFR , EGFR , RETR not included on the label thyroid cancer abiraterone CYP 17A1 not included on the label prostate cancer @DRUG$ CTLA-4 not included on the label melanoma brentuximab vedotin CD30 ( ACD technology ) not included on the label lymphoma crizotinib ALK ALK-EML4 fusion protein lung cancer", "label": "None"}
{"id": "21814597", "sentence": "The most common PDGFRA mutation , D842V in exon 18 , is resistant to imatinib. , , In contrast , the substitution @VARIANT$ in exon 12 results in an isoform of @GENE$ that is highly sensitive to imatinib. , Lasota et al. and Heinrich et al. reported @DRUG$ sensitivities for a deletion/substitution ( SPDGHE566-571R ) and an in-frame insertion mutation ( ER561-562 ) in exon 12 .", "label": "None"}
{"id": "24803900", "sentence": "Carboplatin was discontinued and @GENE$ was initiated as a second-line chemotherapy . For the first cycle , a total of 85 mg ( 40 mg/m2 ) of liposomal @DRUG$ in 250 ml of @VARIANT$ ( 5 % glucose solution ) was prescribed with the same premedications used for the prior carboplatin .", "label": "None"}
{"id": "25580271", "sentence": "Most patients with EGFR mutant NSCLC receive an @GENE$ tyrosine kinase inhibitor ( e.g. gefitinib , @DRUG$ , or afatinib ) as first-line therapy , and unfortunately most patients experience disease progression after approximately 10–15 months of treatment . The most common mechanism of resistance is an EGFR exon 20 @VARIANT$ mutation , which is detected in approximately 50–60 % of tumor samples when a biopsy is performed after disease progression on EGFR tyrosine kinase inhibitors [ , ] .", "label": "resistance or non-response"}
{"id": "24982846", "sentence": "@DRUG$ ERBB2 HER2 protein overexpression positive Indications and usage , warnings and precautions , adverse reactions , clinical studies , clinical pharmacology Ponatinib BCR/ABL1 Philadelphia chromosome [ t ( 9 ; 22 ) ] positive , @GENE$ @VARIANT$ mutation Indications and usage , warnings and precautions , adverse reactions , use in specific populations , clinical pharmacology , clinical studies", "label": "None"}
{"id": "24894453", "sentence": "C ) . Taken together , we found that @VARIANT$ and G724S mutants are oncogenic in the absence of ligand stimulation and effectively respond to @DRUG$ in vivo and in vitro . Asymmetric dimerization is required for oncogenic activity of G719S and G724S mutant Recently , we reported that a subset of lung cancer derived oncogenic EGFR mutants such as L858R require asymmetric dimerization for biochemical activation and oncogenic transforming activity , meaning that their oncogenic ability depend on formation of an @GENE$ homodimer in which two distinct regions of the two molecule dimerize [ ] .", "label": "sensitivity"}
{"id": "23852704", "sentence": "Thus , in two trials , administration of @DRUG$ to patients with this mutation was associated with a significantly better outcome than that seen in patients with other types of K-RAS mutations. , Indeed , patients with the @VARIANT$ mutation appeared to benefit to approximately the same extent as patients with @GENE$ wild-type tumors from the addition of cetuximab to first-line chemotherapy .", "label": "resistance or non-response"}
{"id": "23877358", "sentence": "NAD+ was found to be a requisite for both SAH-hydrolytic and @GENE$ activities . NAD+ bound SahH was active and did not require any other @DRUG$ or metal ion . Further , loss in SAH-hydrolytic and decrease in SAH-synthetic activity by @VARIANT$ mutation strengthens the earlier structural observation , where His363 needs to flip out in order to accommodate ethylthioadenosine ( ETA , a partial analog of SAH ) .", "label": "None"}
{"id": "22076124", "sentence": "L1196M represents a mutation of the “gatekeeper” residue , similar to the T790M gefitinib-resistance mutations observed in EGFR , and @VARIANT$ mutations in @GENE$ . Mutations in the gatekeeper site are thought to increase the affinity for ATP significantly , outcompeting the effects of ATP competitive inhibitors [ ] .", "label": "None"}
{"id": "25054154", "sentence": "@VARIANT$ −7.34 Q 1197 3.07 L 1122 , A 1148 , M 1196 , M 1199 , A 1200 , G 1201 , G 1202 , R 1253 , L 1256 . R1275Q −8.07 M 1199 3.01 L 1122 , A1148 , Q 1197 , L 1196 , Q 1197 L 1198 , A 1200 , G 1202 , L 1256 , R 1253 , D 1203 , N 1254 , D 1270 , L 1150 . Docking results of @GENE$ with @DRUG$ using Patchdock .", "label": "resistance"}
{"id": "22655263", "sentence": "When tested in Ba/F3 cells driven by @GENE$ mutants identified in crizotinib relapsed patients , NMS-E628 is circa fivefold more potent than @DRUG$ in inhibiting the proliferation of L1196M ALK and @VARIANT$ ALK-driven-cells in vitro and in vivo ( Ardini et al. , ) .", "label": "resistance"}
{"id": "22098950", "sentence": "Overexpression of both the wild-type and @VARIANT$ forms of BCRP conferred resistance to 9-aminocamptothecin , which was associated with reduced intracellular drug accumulation , but did not confer resistance to 9-nitrocamptothecin . These observations , in addition to the knowledge that @GENE$ confers resistance to @DRUG$ and SN-38 , suggest that polar residues at the 9 or 10 position of camptothecin may be important to facilitate interactions with BCRP .", "label": "None"}
{"id": "24955213", "sentence": "@VARIANT$ EML-ALKpm Alters @GENE$ crizotinib binding cavity , reducing crizotinib-protein interactions [ , , ]", "label": "resistance"}
{"id": "24367701", "sentence": "This @GENE$ to the endoplasmic reticulum and has been shown to play a critical role in @DRUG$ ( RIG-I ) gene signaling , acting as a sensor of RNA virus infection [ ] . In fact , many elements of the regulatory pathways governing both the RIG-I pathway and IFN gene expression are themselves regulated by IFN . In turn , IFN may coordinate the upregulation of antiviral factors , as revealed by the @VARIANT$ , A3F , TRIM , tetherin and MxA mRNA expression levels in paired maternal blood and CB samples .", "label": "None"}
{"id": "24009492", "sentence": "Abbreviations : 6PDG , 6-phospho-d-gluconate ; ADE , Adenosine ; ALA , Alanine ; ARG , Arginine ; ATP , ATP ; CHO , Choline ; CTP , CTP ; CYD , Cytidine ; CYT , Cytosine ; DHAP , Dihydroxyacetone-Phosphate ; DOG , Deoxyguanosine ; DS7P , D-sedoheptulose-7-phosphate ; @VARIANT$ , Fructose-1,6-bisphosphate ; GLN , Glutamine ; GLU , Glutamate ; GUA , Guanosine ; @GENE$ , @DRUG$ ; INO , Inosine ; LEU , Leucine/isoleucine ; LYS , Lysine ; NAD , NAD+ ; NAG1P , N-acetyl-glucosamine-1-phosphate ; NIC , Nicotinate ; ORN , Ornithine ; PHP , Phenylpyruvate ; PYR , Pyruvate ; RIBP , Ribose-phosphate ; SER , Serine ; SUC , Sucrose ; THR , Threonine ; TRE , Trehalose ; TRP , Tryptophan ; UDPG , UDP-D-glucose ; UTP , UTP .", "label": "None"}
{"id": "25119968", "sentence": "It seems that DDR can be a culprit of cell senescence , therefore we wondered whether @VARIANT$ cells would be able to senesce after treatment with @DRUG$ . Indeed , in both L5 and S4 cells we observed the appearance of the common and widely used marker of senescence , which is increased @GENE$ activity .", "label": "None"}
{"id": "25562798", "sentence": "An illustrative historic example is that in chronic myelogenous leukemia which is initially sensitive to treatment with imatinib mesylate ( targets the BCR-ABL ) treatment resistance may emerge due to the acquisition of secondary mutations in @GENE$ that are resistant to @DRUG$ but that are sensitive to second generation BCR-ABL inhibitors such as dasatinib or nilotinib . Nilotinib and dasatinib are effective in nearly all such cases with the exception of cases that acquire the @VARIANT$ mutation .", "label": "None"}
{"id": "15737014", "sentence": "The @GENE$ T790M mutation , in conjunction with either wild-type EGFR or the drug-sensitive @VARIANT$ EGFR mutant , prevents inhibition of tyrosine phosphorylation ( A ) or p-EGFR ( B ) by @DRUG$ .", "label": "sensitivity"}
{"id": "23238683", "sentence": "We first investigated the effect of these ITKs on the viability of murine Ba/F3 cells , carrying wild type ( WT ) BCR-ABL , @VARIANT$ or G250E-BCR-ABL mutation . As shown in Figure , BaF3 cells expressing native @GENE$ were highly sensitive to imatinib , dasatinib and @DRUG$ , whereas BaF3-T315I-BCR-ABL and BaF3-G250E-BCR-ABL cells were resistant to both imatinib and dasatinib .", "label": "response"}
{"id": "23584600", "sentence": "Rarer mutations include c.1798_1799delinsAG p.Val600Arg ( @VARIANT$ ) , c.1801A &gt ; G p.Lys601Glu ( K601E ) and c.1799_1800delinsAA p.Val600Glu ( V600E2 ) . BRAF mutation results in hyperactivation of the @GENE$ signalling pathway , causing deregulation of cell proliferation and oncogenesis without the requirement for Ras activation . Braf is the most potent of the Raf proteins to activate the downstream signalling cascade , hence mutant Braf was identified as a novel target for kinase inhibitors such as vemurafenib ( PLX4032/RG7204 ) and dabrafenib .", "label": "None"}
{"id": "24009732", "sentence": "A , EOL-1 cells and BaF3 cells harboring WT or T674I FIP1L1-PDGFRα were incubated with indicated concentrations of DCC-2036 for 24 h ( EOL-1 ) or 36 h ( BaF3-WT and -T674I mutant ) , the phosphorylated and total levels of PDGFRα , STAT3 , @GENE$ and Erk1/2 were analyzed by immunoblotting . B , EOL-1 cells and BaF3 cells expressing WT or @VARIANT$ FIP1L1-PDGFRα were treated with DCC-2036 for indicated durations with different concentrations ( 6 nM for EOL-1 cells , 400 nM for BaF3 cells ) , the phosphorylated and total levels of indicated proteins were analyzed by immunoblotting . C , BaF3-T674I cells were exposed to the indicated concentrations of DCC-2036 , @DRUG$ or sorafenib for 36 h , the phosphorylated PDGFRα and total PDGFRα were analyzed by immunoblotting .", "label": "None"}
{"id": "25277176", "sentence": "( B ) Drugs such as the 4-anilinoquinazolines @DRUG$ ( Iressa ) [ ] and erlotinib ( Tarceva ) [ ] can inhibit the activity of @GENE$ @VARIANT$ mutant .", "label": "sensitivity"}
{"id": "24312144", "sentence": "Screening for such mutations in lung cancers identifies patients who will have a clinical responsiveness to @DRUG$ , . Since the existence of @GENE$ gene mutations ( exon 19 deletions or the exon 21 @VARIANT$ ) were reported as a predictive factor for sensitivity to EGFR-TKIs , several studies based their research on this conclusion , .", "label": "sensitivity"}
{"id": "24964744", "sentence": "Interestingly , cells with these mutations also showed greater sensitivity to gefitinib and @DRUG$ than cells with the @GENE$ mutation ( exon 19 deletion ) , which are associated with sensitivity to EGFR inhibitors in NSCLC . Mutations in PI3K ( @VARIANT$ ) have been shown to enhance HER2 mediated transformation by amplifying the ligand induced signaling output of the HER family of RTKs [ ] .", "label": "None"}
{"id": "25486409", "sentence": "As the second-generation , irreversible EGFR-TKIs , such as afatinib and dacomitinib , failed to overcome the resistance caused by @VARIANT$ , , other measures , such as @GENE$ dual targeting with @DRUG$ and afatinib and third-geneneration , mutant-selective EGFR-TKIs – are being actively evaluated .", "label": "response"}
{"id": "23579627", "sentence": "Although we could not perform an EGFR mutation test at the time of progression after @DRUG$ retreatment , the patient had another partial response with irreversible @GENE$ inhibitor , which is believed to overcome secondary resistance to reversible EGFR-TKI related with @VARIANT$ mutation .", "label": "resistance or non-response"}
{"id": "21556318", "sentence": "At the time of publication , only one patient who had achieved a complete cytogenetic remission at 3 months relapsed to blast crisis with a @VARIANT$ @GENE$ mutation at 6 months . Updated information from this trial was presented at the 2009 American Society of Hematology meeting . Seventy-four percent of study participants received a median daily @DRUG$ dose of 600–800 mg .", "label": "None"}
{"id": "22811760", "sentence": "PDB Description Dscore 1DX6 acetylcholinesterase 0.048 1CFE pathogenesis related protein @VARIANT$ 0.06 1QMG acetohydroxy-acid isomeroreductase 0.068 2EFJ 3,7-dimethylxanthine methyltransferase 0.069 1W1O cytokinin dehydrogenase 1 0.076 3DM0 maltose binding periplasmic protein 0.077 1E1E beta-glucosidase 0.077 1AIR pectate lyase c 0.084 2V6G @DRUG$ 5-beta-reductase 0.084 3HGO 12-oxophytodienoate reductase 3 0.087 The acetylcholinesterase protein figures in the set of proteins being queried since it has a plant alkaloid galanthamine bound in active site , and we used a keyword search for ‘plant’ in http : //www.pdb.org/to obtain the query set of 288 proteins . Hence , the best match was with the P14A protein from Solanum lycopersicum ( tomato ) .", "label": "None"}
{"id": "22655263", "sentence": "Additionally , AP26113 was evaluated on the crizotinib resistant gatekeeper mutant @VARIANT$ both in vitro and in vivo and appeared to be able to overcome resistance to @DRUG$ . Ki determination demonstrated a very similar biochemical potency on wild-type ALK and the L1196M @GENE$ mutant ( 0.09 and 0.08 nM respectively ) , with both cellular and in vivo data ( using engineered Ba/F3 cells ) indicating that growth of ALK–L1196M mutant driven-cells is inhibited at similar , albeit slightly higher , doses which inhibit cells harboring wild-type ALK ( Katayama et al. , ) .", "label": "resistance"}
{"id": "24106980", "sentence": "Kastl et al. reported that reduced @GENE$ modulated by miR-34a could induce G1 phase arrest , where docetaxel exerts little cytotoxicity , in turn leading to the resistance of @DRUG$ in breast cancer cells [ ] . Cyclin D1 is also a target of let-7i , and a chimera that combines Mucin 1 (MUC1) aptamer and let-7i miRNA was proved to reverse paclitaxel resistance in EOC cells through down-regulation of cyclin D1 , cyclin D2 , Dicer 1 , and PGRMC1 expressions [ ] . @VARIANT$ family members play an important role in the control of gene expression in several phases of the cell cycle and in multiple checkpoints .", "label": "None"}
{"id": "24634705", "sentence": "Targeting the oncogenic fusion protein echinoderm @GENE$ lymphoma kinase ( EML4-ALK ) with TKIs such as @DRUG$ has also been shown to be negatively affected by the development of secondary gate keeper residue mutations such as @VARIANT$ , and the emergence of fusion negative tumors that render the disease insensitive to the drug .", "label": "None"}
{"id": "22655263", "sentence": "When tested in Ba/F3 cells driven by ALK mutants identified in @DRUG$ relapsed patients , NMS-E628 is circa fivefold more potent than crizotinib in inhibiting the proliferation of @VARIANT$ ALK and C1156Y @GENE$ in vitro and in vivo ( Ardini et al. , ) .", "label": "resistance"}
{"id": "25114575", "sentence": "In vitro studies have shown that IC50 of @DRUG$ was less than 0.16 mol/L in A431 , HN5 , BT474 , N87 , and CaLu-3 cell lines , and was about 3 mol/L in MCF-7 and @VARIANT$ cell lines . Compared to EGFR- or/and HER2 positive cell lines , breast cancer cells with low @GENE$ or/and HER2 expression had 25 times higher IC50 .", "label": "None"}
{"id": "23186157", "sentence": "Presence of @DRUG$ ( Figure ) , Nilotinib ( Figure ) and Dasatinib ( Figure ) reduced the IC50 of GNF-2 to 10.5 , 13 , and 3.3 μM , respectively ( Figure ) . Interestingly , Dasatinib was the most efficient AKI in cooperation with GNF-2 in inhibiting clonigenicity of @GENE$ cells containing the @VARIANT$ mutated Bcr-Abl .", "label": "None"}
{"id": "23986642", "sentence": "In summary , preclinical data supports the conclusion that @DRUG$ is an orally active , pan-TKI that inhibits native @GENE$ and most BCR-ABL mutants , including the clinically relevant @VARIANT$ mutant , with high potency .", "label": "response"}
{"id": "24922058", "sentence": "It would be interesting to study in the future if @VARIANT$ , CTBP , MECP2 , LSD1 or other yet-to-be identified REST interactors are involved . Notably , we did not observe pathways specifically enriched in any group of REST targets with different @DRUG$ occupancies . In summary , our results indicate that SIN3 co-localization was correlated with higher expression while EZH2/CoREST co-occupancy was associated with lower levels of expression of REST targets , with SIN3 seemingly dominant over @GENE$ .", "label": "None"}
{"id": "23567620", "sentence": "Finally , although molecularly targeted therapies ( that is , @DRUG$ or erlotinib for @GENE$ and crizotinib for ALK fusions ) are effective in NSCLC , intrinsic or acquired resistances inevitably lead to recurrence and/or metastatic dissemination . This is the case of MET activation/amplification , , or acquired somatic mutations of EGFR ( @VARIANT$ ) or ALK fusions ( G1269A , L1196M and ALK amplification ) . , ,", "label": "resistance or non-response"}
{"id": "21687596", "sentence": "A recent analysis showed that T790M mutations do not considerably affect the binding affinity between EGFR and EGFR-TKIs but instead increase the binding affinity between EGFR and ATP , causing a relative decrease in binding with @GENE$ [ ] . The authors reported that increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance . An experiment using cell lines transfected concurrently with activating mutations and a @VARIANT$ mutation also proved that resistance to gefitinib and @DRUG$ is evident when this mutation is present [ – ] .", "label": "resistance or non-response"}
{"id": "25486409", "sentence": "As the second-generation , irreversible EGFR-TKIs , such as @DRUG$ and dacomitinib , failed to overcome the resistance caused by @VARIANT$ , , other measures , such as @GENE$ dual targeting with cetuximab and afatinib and third-geneneration , mutant-selective EGFR-TKIs – are being actively evaluated .", "label": "response"}
{"id": "20576107", "sentence": "Cell death induced by combination treatment was @GENE$ dependent as it was blocked by the caspase-inhibitor zVAD-fmk ( Additional file , Figure @VARIANT$ ) . ABT-737 thus can sensitize RCC cell lines for treatment with @DRUG$ , paclitaxel or etoposide .", "label": "None"}
{"id": "25110867", "sentence": "Moreover , dacomitinib showed significant effects in vitro and in vivo against NCI-H1975 cells containing the EGFR @VARIANT$ , T790M mutation . These preclinical models suggest that dacomitinib may be quite effective against lung cancer that becomes resistant to @DRUG$ or erlotinib via acquisition of a T790M mutation in @GENE$ [ ] .", "label": "sensitivity"}
{"id": "24349829", "sentence": "Correspondingly , direct injection of a liposome encapsulated miR-7 plasmid into established @GENE$ sensitive and resistant tumors bearing the @VARIANT$ EGFR mutant resulted in significant tumor regression in conjunction with repression of EGFR , RAF-1 and IRS-1 expression . In head and neck cancer , miR-7 functioned in a synergistic manner with erlotinib to render FaDu Erlotinib-resistant cells susceptible to the growth inhibitory activities of the drug .", "label": "resistance or non-response"}
{"id": "24969320", "sentence": "@DRUG$ ( Yervoy® ) 2011 CTLA4 expressed on T cells Immunotherapy ( mAb ) Humanised mAb targeting the inhibitory receptor CTLA4 activates immune system enhancing T cell activation and targeting CTLA4 expressing Tregs Verumafenib ( Zelboraf® ) 2011 BRAF @VARIANT$ , mutated form of BRAF Small molecule inhibitor Blocks @GENE$ reducing protein proliferation of melanoma cells carrying mutation", "label": "None"}
{"id": "25054154", "sentence": "Comparing the binding free energy of @GENE$ to the drug , mutant @VARIANT$ exhibited the weakest interaction with the energy value of −7.34 Kcal/mol when compared to the mutant R1275Q ( −8.07 Kcal/mol ) and native complex ( −9.21 Kcal/mol ) , respectively . Detailed analysis showed that the @DRUG$ acquired an altered mode of binding in both the mutant complexes .", "label": "resistance"}
{"id": "24724051", "sentence": "CDKN2A/B is rarely deleted in ALL with translocations of @VARIANT$ @GENE$ in t ( 1 ; 19 ) ( q23 ; p13 ) and E2A–HLF in t ( 17 ; 19 ) ( q21–22 ; p13 ) ALL ] ( ) . Introduction of p190BCR–ABL1 into Arf -null murine bone marrow decreases the latency and increases resistance to @DRUG$ in the lymphoid malignancy that develops in recipient mice .", "label": "None"}
{"id": "25462529", "sentence": "The fact that D167A or K substitutions do not reduce IN enzymatic activity , but slightly affect RT and interaction with p75/LEDGF , points to a change in @GENE$ processing due to a modified trend of interactions between IN monomers , between IN and RT , or between IN and a cellular factor such as p75/LEDGF . @DRUG$ is a versatile amino acid that can assume positive charge , but remains usually neutral at physiological pH . In fact , this mutation affects later time points of our analysis with vector @VARIANT$ still integrating between 48 and 72 hours following transduction .", "label": "None"}
{"id": "22034911", "sentence": "( B) PK/PD analysis after treating tumor bearing mice with a single dose of vehicle ( V , for 6 h ) or 200 mg/kg @DRUG$ . In pharmacodynamic studies ( ) , xenografts expressing native EML4-ALK exhibited a 60–70 % inhibition in @GENE$ levels at 6 h postdose , with more pronounced inhibition at 24 h . By contrast , p-ALK levels were reduced by approximately 25–35 % at 6 h in tumors expressing @VARIANT$ or S1206R , with a partial recovery at 24 h .", "label": "resistance"}
{"id": "25562363", "sentence": "@DRUG$ ( critozinib , Pfizer ) 115,200 Vysis ALK Break Apart In Situ Hybridisation FISH Probe Kit ( Abbott Molecular ) 1,500 Rescue ( ALK positivity ~7 % ) TBD Zelboraf ( vemurafenib , Plexxikon / Diiachi-Sankyo/ Roche ) 56,400 Cobas 4800 BRAF V600 Mutation Test ( Roche Molecular ) 120-150 Co-development ( @GENE$ @VARIANT$ mutation ~40 % ) 144M ( 213M* )", "label": "None"}
{"id": "24263064", "sentence": "As in our study , iTARGET and EURTAC reported generally mild to moderate AEs ( rash and diarrhoea ) , although 13 % of patients ( 11 out of 84 ) in EURTAC did experience grade-3/4 rash with erlotinib ( there were no grade-3/4 rash events with @DRUG$ reported in our study ) . Mutation subtype analysis results in iTARGET and EURTAC were also similar to our study , with exon 19 deletions and @VARIANT$ the most common mutation subtypes detected . Consistent with the mechanism of action of @GENE$ TKIs , rash and diarrhoea were the most commonly reported AEs .", "label": "sensitivity"}
{"id": "22815900", "sentence": "@GENE$ mutation status including wild-type ( WT ) , E746-A750 del ( del ) , @VARIANT$ and T790M was determined by both IHC and RNA-LNA PCR clamp assays with 11 clinical samples of cancer patients refractory to @DRUG$ treatment .", "label": "sensitivity"}
{"id": "25429239", "sentence": "It inhibits both L1196M in ALK+ NSCLC and the @VARIANT$ in @GENE$ mutants . Phase I/II data for AP26113 have demonstrated efficacy in both @DRUG$ naive and resistant patients .", "label": "None"}
{"id": "23788917", "sentence": "In vitro studies demonstrated that the effective concentration of @DRUG$ in tumour cells harbouring both the @VARIANT$ and T790M mutations has to be 300 times higher to induce apoptosis than in cells only with an activating mutation in codon 858 [ , ] . Presence of a mutation in exon 20 of the EGFR gene is a potential prognostic and predictive marker of @GENE$ TKI therapy and may play an important role in the planning of therapy .", "label": "sensitivity"}
{"id": "24349829", "sentence": "Correspondingly , direct injection of a liposome encapsulated miR-7 plasmid into established EGFR-TKI sensitive and resistant tumors bearing the @VARIANT$ @GENE$ mutant resulted in significant tumor regression in conjunction with repression of EGFR , RAF-1 and IRS-1 expression . In head and neck cancer , miR-7 functioned in a synergistic manner with @DRUG$ to render FaDu Erlotinib-resistant cells susceptible to the growth inhibitory activities of the drug .", "label": "resistance or non-response"}
{"id": "22997553", "sentence": "The water was replaced every 12 h with freshly prepared @DRUG$ and spNO . Plasmid and primers pcDNA-eNOS @VARIANT$ ( Plasmid # 22485 ) , @GENE$ S1179D ( Plasmid # 22484 ) , pcDNA-eNOS GFP ( Plasmid # 22444 ) , constructs were purchased from Addgene deposited by Prof.William Sessa 's Lab .", "label": "None"}
{"id": "22721004", "sentence": "Our results with the mutants agree with Gontarewicz et al. , who reported that PHA-739358 was effective against imatinib-resistant @GENE$ mutants including those with the @VARIANT$ mutation in human and mouse leukemia cell lines as well as in CD34+ cells from an imatinib-resistant CML patient [ ] .", "label": "None"}
{"id": "23209719", "sentence": "To verify whether the effect was solely due to the @VARIANT$ exchange or a combination of several mutations , we introduced the mutation in the hPR alone and measured individual IC50 values for @DRUG$ and @GENE$ .", "label": "None"}
{"id": "24348666", "sentence": "However , almost every patient who responds well to @DRUG$ will , without exception , experience recurrence due to acquired resistance . The mechanisms for acquired resistance include gatekeeper L1196M mutations , ALK gene amplification , and other @GENE$ gene mutations ( L1152R , C1156Y , @VARIANT$ ) - .", "label": "resistance"}
{"id": "4878639", "sentence": "@GENE$ . 2 . Blood asparagine levels in @VARIANT$ mice injected with 150 units E. coli @DRUG$ intravenously .", "label": "None"}
{"id": "22787448", "sentence": "Such discrepancy can be explained by the difference in the nature of the substituted amino-acid ( cysteine in one case and @DRUG$ in the other ) or by differences in experimental conditions ( whole-cell configuration on oocytes and giant-patch configuration on COS-7 cells , respectively ) . Furthermore , Matavel et al. showed that @VARIANT$ and R243C mutants exhibited an impaired activation by both @GENE$ and PKC , whereas C-terminal KCNQ1 mutants presented an increased activation .", "label": "None"}
{"id": "22076124", "sentence": "L1196M represents a mutation of the “gatekeeper” residue , similar to the T790M gefitinib-resistance mutations observed in EGFR , and @VARIANT$ mutations in ABL . Mutations in the gatekeeper site are thought to increase the affinity for ATP significantly , outcompeting the effects of ATP competitive inhibitors [ ] . The effect of the C1156Y mutation is unclear , although it may have an indirect effect on @DRUG$ binding , and further studies will be required to establish its mechanism . A number of ALK inhibitors that are able to inhibit @GENE$ variants with “gatekeeper” mutations at L1196M have been developed .", "label": "None"}
{"id": "17551677", "sentence": "These were clustered in exons 18 , 19 and 21 and were either small in-frame deletion ( 746–750 , adjacent to K745 : ELREA aminoacids ) or heterozygous missense mutations ( mainly @VARIANT$ adjacent to the DFG motif in the COOH-terminal lobe in the activation loop of the kinase ) around the ATP binding pocket . Pooled data from these three studies show that 25 of 31 ( 81 % ) patients with partial response or marked clinical improvement have an EGFR mutation , vs. none of 29 specimens from refractory patients ( p=0.0001 ) . Several other studies investigate the role of these mutations in the treatment of NSCLC with @GENE$ TK inhibitors , demonstrating a statistically significant correlation between the response to @DRUG$ and erlotinib and the presence of the biological data , but this correspondence is not always 100 % [ – ] ( Table ) .", "label": "sensitivity"}
{"id": "24348666", "sentence": "To test this possibility , two types of gefitinib-sensitive cells ( PC9 cells that endogenously express @GENE$ deletion mutant in exon19 of EGFR gene and HEK293T cells that exogenously express EGFR @VARIANT$ mutant ) were transfected with an expression vector encoding the oncogenic K-Ras G12V mutant .", "label": "sensitivity"}
{"id": "24924344", "sentence": "@DRUG$ ( A/T ) Chr16 : 56671632 MT1A ( near-gene 5 ) 0.047628 0.138 Oxaliplatin rs562 ( C/T ) Chr3 : 183637845 ABCC5 ( UTR3 ) 0.049494 0.392 rs3749445 ( A/G ) Chr3 : 183638506 ABCC5 ( UTR3 ) 0.044895 0.410 rs2292998 ( C/T ) Chr3 : 183663833 @GENE$ ( intronic ) 0.039882 0.277 rs1016752 ( C/G ) Chr3 : 183665062 ABCC5 ( intronic ) 0.039781 0.232 rs4148585 ( C/T ) Chr3 : 183670642 ABCC5 ( intronic ) 0.039781 0.283 rs6443924 ( A/G ) Chr3 : 183679532 ABCC5 ( intronic ) 0.039781 0.279 rs4148579 ( A/G ) Chr3 : 183685249 ABCC5 ( intronic ) 0.039781 0.279 rs939336 ( A/G =&gt ; C594C ) Chr3 : 183685534 ABCC5 ( exonic ) 0.039781 0.279 rs1132776 ( C/T = & gt ; @VARIANT$ ) Chr3 : 183696402 ABCC5 ( exonic ) 0.044895 0.289 rs2313212 ( C/T ) Chr3 : 183700928 ABCC5 ( intronic ) 0.039781 0.279 rs4148575 ( C/T ) Chr3 : 183702275 ABCC5 ( UTR3 ) 0.044895 0.289 rs1846692 ( C/T ) Chr16 : 56671696 MT1A ( near - gene 5 ) 0.049494 0.360 rs35346959 ( A/G ) Chr16 : 56671867 MT1A ( near- gene 5 ) 0.044895 0.137 rs9922957 ( C/G ) Chr16 : 56672380 MT1A ( near - gene 5 ) 0.039781 0.185 rs9922409 ( A/G ) Chr16 : 56672400 MT1A ( near - gene 5 ) 0.04532 0.103 rs7190725 ( G/T ) Chr16 : 56673290 MT1A ( intronic ) 0.044895 0.170 rs8052394 ( A/G =&gt ; K51R ) Chr16 : 56673828 MT1A ( missense ) 0.044895 0.152 rs1800566 ( C/T = & gt ; P187S ) chr16 : 69745145 NQO1 ( exonic ) 0.039781 0.258 rs689455 ( A/C ) Chr16 : 69761661 NQO1 ( near- gene 5 ) 0.039781 0.242", "label": "None"}
{"id": "23788917", "sentence": "The role of rare mutations in exon 20 such as @VARIANT$ and V769L in development of acquired resistance to EGFR TKI is still unknown . These substitutions were reported for the first time in NSCLC patients with progression , bearing activating mutations , after @DRUG$ therapy . In vitro cultures of cell lines harbouring the S768I substitution showed slightly more resistance to @GENE$ TKI than cells with wild type EGFR .", "label": "None"}
{"id": "24348666", "sentence": "To test this possibility , two types of gefitinib-sensitive cells ( PC9 cells that endogenously express EGFR deletion mutant in exon19 of @GENE$ gene and HEK293T cells that exogenously express EGFR @VARIANT$ mutant ) were transfected with an expression vector encoding the oncogenic K-Ras G12V mutant .", "label": "sensitivity"}
{"id": "22615750", "sentence": "Oral administration of Sunitinib ( Sutent ) and @DRUG$ ( Gleevec ) , two TKIs , have been shown to prevent and reverse @VARIANT$ in the NOD mouse . In several publications successful remission of T1D has been reported – ; however , when it comes to monotherapy approach long lasting remission of diabetes is still challlenging . The @GENE$ signaling pathway plays a critical role in mediating inflammatory immune response to a variety of signals – .", "label": "None"}
{"id": "24618737", "sentence": "One common hypothesis of Cetuximab-resistance is @GENE$ or downstream molecular mutation within tumor cells , such as acquired EGFR ectodomain mutation @VARIANT$ .", "label": "resistance"}
{"id": "24876815", "sentence": "In the study by Pentheroudakis et al. , patients with a mutation in codon 12 of the KRAS gene who received chemotherapy combined with @DRUG$ had a median overall survival of 19 months , whereas patients with other KRAS mutations and @GENE$ type gene subjects treated with the same modality had a considerably longer median survival of nearly 30 months [ – ] . Furthermore , there are many reports on patients with the wild-type KRAS gene who are refractory to anti-EGFR treatment . The cause of refractoriness has been identified in ca. 15 % of mCRC patients as mutations in the BRAF gene , primarily @VARIANT$ substitution .", "label": "None"}
{"id": "23109866", "sentence": "The tumor cells harboring either C1156Y or L1196M mutations had a very low response to @GENE$ inhibitors . @VARIANT$ mutant cells were more resistant to @DRUG$ than C1156Y mutant cells .", "label": "resistance"}
{"id": "25580271", "sentence": "Two phase III trials compared @DRUG$ to a platinum-doublet in patients with advanced EGFR mutant NSCLC , and a combined analysis for overall survival was presented at ASCO , as well as subset analyses based on @GENE$ mutation subtype ( exon 19 deletion and exon 21 @VARIANT$ point mutation ) [ ] .", "label": "sensitivity"}
{"id": "23299535", "sentence": "A similar theme exists in NSCLCs with a mutation in the @GENE$ – secondary mutations confer insensitivity to the EGFR tyrosine kinase inhibitor ( EGFR-TKI ) @DRUG$ , and have been identified in patients with clinical resistance to gefitinib , but also in untreated patients ( ) . analysed NSCLC samples for one such mutation in EGFR , the @VARIANT$ mutation , from treatment-naïve patients , and from patients before and during treatment with EGFR-TKIs .", "label": "resistance or non-response"}
{"id": "25238247", "sentence": "In a random mutagenesis based resistance screen , a number of potential secondary ErbB2 mutations , including mutations of the gatekeeper T798 residue were identified that might mediate acquired lapatinib-resistance . T798I is analogous to the common gatekeeper mutations of EGFR and BCR-ABL , @GENE$ and BCR-ABL @VARIANT$ .", "label": "None"}
{"id": "23149688", "sentence": "This flux increase is apparent from the increased extracellular yields of α-ketoglutarate and @GENE$ at unchanged biomass yields . Of the three individually tested Pfk2 sites S163 , S167 and S171 , only the Pfk2 [ S163A ] mutant exhibited a growth phenotype on gluconeogenic carbon sources , namely a 20 % lower biomass yield on @DRUG$ than the reference strain ( ; ) . As expected from the silent phenotype of the Pfk2 [ @VARIANT$ ] and Pfk2 [ S171A ] mutants , their intracellular concentrations were indistinguishable from the reference strain .", "label": "None"}
{"id": "24244732", "sentence": "For the @DRUG$ phenotype , either the R39C or @VARIANT$ unc-18 mutations increased sensitivity . The R39C mutation is characterised to decrease binding to closed conformation @GENE$ for mammalian Munc18 in vitro [ ] and in vivo [ ] as well as C. elegans UNC-18 in vitro [ ] .", "label": "None"}
{"id": "24894453", "sentence": "To test the hypothesis that @DRUG$ sensitivity of G719S and @VARIANT$ mutants is a function of their dimerization dependence , we generated G719S and G724S mutants with compound substitution mutations at the dimerization interface in the N-lobe or C-lobe that disrupt the asymmetric dimerization of @GENE$ [ ] .", "label": "sensitivity"}
{"id": "23009336", "sentence": "A secondary point mutation in exon 20 of EGFR ( @VARIANT$ ) is associated with acquired resistance to gefitinib or @DRUG$ , but this can be overcome by the irreversible @GENE$ kinase inhibitor BIBW2992 ( BIBW ) .", "label": "resistance or non-response"}
{"id": "23994953", "sentence": "Using the erlotinib-sensitive @GENE$ mutant NSCLC cell line HCC4006 harboring the delL747-E749 , A750P mutation in EGFR exon 19 , Suda et al. established that mesenchymal status , not a specific oncogenic activated protein , could sufficiently promote loss of EGFR dependence to confer resistance to @DRUG$ . More recently , Chang et al. confirmed that in the absence of the common second-site EGFR mutation @VARIANT$ or MET amplification , acquired resistance to gefitinib occurs in EGFR mutated PC9 cells that have undergone EMT .", "label": "resistance or non-response"}
{"id": "25210769", "sentence": "In the Y67R variant , the mutation from Tyr67 to @GENE$ may produce not only a distal arginine ( although its structure is not available ) , but also a room for substrate coordination ( because Fe-S bond is broken in the Y67R variant ) . Our current NMR structure of the Y67H variant ( determined at pH 7.0 ) suggests that the sixth ligation bond Fe-S is attenuated due to the disruption of hydrogen bond between Met80 and Tyr67 existed in the native cyt c . The distance between Nε atom of His67 and heme ferric iron is measured as 5.48 Å in the @VARIANT$ variant , very close to the distances of 5.84 Å and 5.55 Å between Nε2 atom of the distal @DRUG$ and heme iron ion in horseradish peroxidase ( HRP , pdb codes 1H5A ) and cytochrome c peroxidase ( CcP , pdb codes 2CYP ) , , respectively .", "label": "None"}
{"id": "22191026", "sentence": "The investigated @GENE$ sensitive mutations included G719C , G719S , @VARIANT$ , L858R , L861Q , and exon 19 deletions , as well as a gefitinib-resistant mutation , T790M .", "label": "None"}
{"id": "23606169", "sentence": "Because mutations in the KRAS gene result in activation of the epidermal growth factor receptor (EGFR) signaling pathway , only metastatic colorectal cancer patients with wild-type KRAS tumors qualify for anti-EGFR targeted therapies with @DRUG$ or panitumumab [ ] . Also , a clinical trial with the BRAF inhibitor ( PLX4032 ) demonstrated antitumor activity in tumors with the @GENE$ @VARIANT$ mutation and confirmed that V600E BRAF is a valid therapeutic target in human cancer [ ] .", "label": "resistance or non-response"}
{"id": "24982846", "sentence": "Denileukin diftitox @GENE$ CD25 antigen positive Indications and usage , warnings and precautions , clinical studies Erlotinib EGFR EGFR protein expression positive EGFR exon 19 deletion or exon 21 substitution ( @VARIANT$ ) positive Clinical pharmacology Indications and usage , dosage and administration , clinical pharmacology , clinical studies @DRUG$ ERBB2 HER2 protein overexpression negative Indications and usage , boxed warning , adverse reactions , use in specific populations , clinical pharmacology , clinical studies", "label": "None"}
{"id": "25071018", "sentence": "We also observed drastically downregulated @GENE$ expression and significant inhibition of growth in @DRUG$ treated wild-type SHP-1 expressing cells but no significant p-STAT3Tyr705 expression either in @VARIANT$ or dN1 mutant SHP-1 transfected cells following treatment with regorafenib ( Figure ) .", "label": "None"}
{"id": "24586514", "sentence": "Until now , no viable treatment options were available for patients in whom @GENE$ TKIs fail because of the presence of T315I mutation . Thus , alternative strategies are required to improve the outcome of CML patients carrying the @VARIANT$ mutation . Ponatinib , also known as @DRUG$ , is an oral , multi targeted TKI .", "label": "response"}
{"id": "PMC4041556", "sentence": "Second-generation EGFR TKIs – such as neratinib , @DRUG$ and dacomitinib – are effective in preclinical gefitinib- and erlotinib-resistant @GENE$ @VARIANT$ models , but to date their delivery in EGFR TKI-resistant patients have shown disappointing results in the clinic .", "label": "response"}
{"id": "22132735", "sentence": "EGFR gene mutations indicate sensitivity to @DRUG$ , and it was demonstrated that about 85 % of patients with NSCLC who obtained benefit from gefitinib treatment were found to have mutations in exons 18 to 21 of the tyrosine kinase domain of the EGFR gene [ - ] . EGFR mutations in exon 19 ( short in-frame deletions ) or 21 @VARIANT$ ( point mutation ) affect the adenosine triphosphate ( ATP ) pocket of the tyrosine kinase domain leading to the activation of 4-anilinoquinazoline compounds , which function to compete with ATP [ ] . Anti-EGFR therapy can consequently lead to the downregulation of downstream signaling cascades , such as the PI3K/Akt , @GENE$ , MAPK , and STAT pathways , responsible for cell proliferation and survival , resulting in the inhibition of cell proliferation and induction of cell apoptosis , respectively .", "label": "None"}
{"id": "17973572", "sentence": "The Secondary Resistant Mutations L747S and @VARIANT$ Affect Gefitinib Induced Apoptosis and Inhibit BIM Up-Regulation ( A ) Top : Annexin V apoptosis assay : @GENE$ cells expressing L858R (LR) , L858R-L747S # 4 ( LR-LS ) , or L858R-T790M (LR-TM) cells were grown in the absence or presence of @DRUG$ for 24 h .", "label": "None"}
{"id": "23691449", "sentence": "The types of @GENE$ mutations in @DRUG$ responding patients worldwide are quite similar [ ] . Such mutations include multiple overlapping deletion mutations of exon 19 in 45 % of patients , point mutations in exon 21 in 40 % of patients ( predominantly @VARIANT$ ) , and point or insertion mutations in exons 18 to 21 in the remaining 15 % of patients [ ] .", "label": "sensitivity"}
{"id": "25562700", "sentence": "Molecule Target Biomarker Indication vemurafenib BRAF kinase BRAF @VARIANT$ mutant melanoma @DRUG$ VEGFR , EGFR , RETR not included on the label thyroid cancer abiraterone CYP 17A1 not included on the label prostate cancer ipilimumab CTLA-4 not included on the label melanoma brentuximab vedotin CD30 ( ACD technology ) not included on the label lymphoma crizotinib ALK ALK-EML4 fusion protein lung cancer BRAF : Serine/threonine-protein kinase B-Raf ; VEGFR : Vascular endothelial growth factor receptor ; EGFR : epidermal growth factor receptor ; RETR : RET proto-oncogen receptor ; CYP 17A1 : cytochrome P450 17A1 ; CTLA-4 : Cytotoxic @GENE$ ; CD30 : Cluster of Differentiation 30 ; ADC : Antibody Conjugated Drug ; ALK-EML4 : anaplastic lymphoma kinase (ALK) ; echinoderm microtubule associated protein-like 4 ( EML4 ) fusion .", "label": "None"}
{"id": "25101695", "sentence": "Previous studies have shown that the ERα antagonist @DRUG$ is effective in the treatment of ERα positive breast cancer and mammary hyperplasia , , . In this study , we demonstrated that @GENE$ , a traditional Chinese medicine that has likewise been effectively used to treat mammary hyperplasia , predominately inhibits ERα positive breast cancer cell growth , potentially by down regulating of ERα expression , thus making ERα positive breast epithelial cells less sensitive to estrogen induced cell proliferation . Our results showed that in MCF7 and @VARIANT$ , TSC actually reduced ESR1 mRNA .", "label": "None"}
{"id": "21042543", "sentence": "Di Nicolantonio et al also demonstrated that introduction of the B-RAF @VARIANT$ allele could confer resistance to either cetuximab or @DRUG$ in wild-type @GENE$ colorectal cancer cells .", "label": "resistance or non-response"}
{"id": "24502453", "sentence": "Pazopanib Votrient® Glaxo Smith Kline VEGFR , PDGFR , KIT Renal cell carcinoma , STS 14th June 2010 No Withdrawn Ponatinib2 Iclusig® Ariad BCR-ABL Patients with CML for which Imatinib , Nilotinib , and Dasatinib are not appropriate ( or patients carrying a @VARIANT$ single-point-mutation ) 1st July 2013 CML , ALL Sorafenib Nexavar® Bayer VEGFR-2 , @GENE$ Renal cell carcinoma , hepatocellular carcinoma 19th July 2006 No Renal cell carcinoma , Hepatocellular carcinoma", "label": "None"}
{"id": "21573178", "sentence": "For example , we detected the @DRUG$ resistance mutation , T790M , in tumor sample 10 ( 80 % tumor cell content ) obtained at the time of relapse ( Supplementary ) and this sample also harbored the L747_S752del_P753S deletion initially detected by dideoxy sequencing ( and ) . We further found a previously undetected @VARIANT$ substitution in exon 2 of @GENE$ in sample 11 ( 50 % tumor cell content , Supplementary ) and confirmed this mutation by subcloning of KRAS exon 2 amplicons and subsequent dideoxy sequencing ( data not shown ) .", "label": "resistance or non-response"}
{"id": "23527257", "sentence": "When @VARIANT$ and c-MET siRNAs were combined , the cooperative effect was less potent . The dual targeting of @GENE$ and c-MET was then verified using TKIs ( @DRUG$ , erlotinib and afatinib plus su11274 ) .", "label": "resistance or non-response"}
{"id": "22815900", "sentence": "For acquired resistance , secondary mutation in the EGFR gene @VARIANT$ – or alternative EGFR independent activation of cell growth signaling pathways including c-Met activation is well-known , . The loss of PTEN expression is one of the acquired resistant mechanisms , which was demonstrated by isolating gefitinib-resistant mutants from PC9 cells which harbor activating mutation of @GENE$ , .", "label": "resistance or non-response"}
{"id": "23994953", "sentence": "Using the erlotinib-sensitive EGFR mutant NSCLC cell line HCC4006 harboring the delL747-E749 , A750P mutation in @GENE$ exon 19 , Suda et al. established that mesenchymal status , not a specific oncogenic activated protein , could sufficiently promote loss of EGFR dependence to confer resistance to erlotinib . More recently , Chang et al. confirmed that in the absence of the common second-site EGFR mutation @VARIANT$ or MET amplification , acquired resistance to gefitinib occurs in EGFR mutated PC9 cells that have undergone EMT .", "label": "resistance or non-response"}
{"id": "25414829", "sentence": "The first example of a clinically relevant NSCLC driver oncogene was the identification of somatic mutations in the epidermal growth factor receptor (EGFR) gene ( – ) .Common @GENE$ alterations ( the @VARIANT$ point mutation and exon 19 deletions ) are present in 10–30 % of patients with NSCLC and confer sensitivity to @DRUG$ , erlotinib , and afatinib .", "label": "sensitivity"}
{"id": "24410402", "sentence": "BCRP substrates include glucuronide and sulfate conjugates [ e.g. , estrone-sulfate , estradiol-17β-d-glucuronide ( @VARIANT$ ) , SN-38 glucuronide ] , anticancer drugs ( e.g. , irinotecan , SN-38 , methotrexate , @DRUG$ , doxorubicin ) , and some statins [ e.g. , pitavastatin , rosuvastatin ( RSV ) ] .− The pharmacokinetics and pharmacodynamics of these drugs may be affected by modulation of @GENE$ expression and/or function resulting from genetic polymorphisms or drug–drug interactions ( DDIs ) .", "label": "None"}
{"id": "25486409", "sentence": "Chen et al. demonstrated that @GENE$ siRNAs strongly inhibited cell growth and induced apoptosis in H1975 cells harboring both @VARIANT$ and T790M . Even knock-down of the T790M transcript by siRNAs , when combined with @DRUG$ , was efficacious in controlling T790M-mutant , lung cancer cells .", "label": "sensitivity"}
{"id": "18544172", "sentence": "Non-responders 10 F 68 0 Folfiri , Xeloda , Xelox SD 17 Wild-type @VARIANT$ trisomy 11 F 74 1 LV5FU Folfiri SD 10 Gly12Val disomy 12 M 61 0 Folfirinox SD 18 @GENE$ R521K disomy 13 F 71 0 Xelox Avastin-Xeliri SD 15 Gly12Asp disomy 14 M 59 0 LV5FU , Folfiri , Folfox SD 24 Gly12Cys R521K trisomy 15 M 71 0 Folfox , Irinotecan SD 14 Wild-type disomy 16 F 60 1 Fufol Folfiri , Folfox , Cape , LV5FU SD 17 Wild-type trisomy 17 M 65 0 Folfirinox , Folfiri SD 18 Wild-type low polysomy 18 M 66 0 Folfiri SD 17 Wild-type R521K disomy 19 F 45 0 Folfox , Xelox SD 17 Wild-type R521K NE 20 F 42 0 Folfirinox SD 21 Gly12Asp R521K trisomy 21 M 62 1 Folfox Xeliri SD 36 Gly13Asp R521K disomy 22 M 58 1 Folfiri Xelox , Xeliri PD NA Gly13Asp disomy 23 M 75 1 Xelox Xeliri PD NA Wild-type trisomy 24 M 81 0 Xelox , Folfiri PD NA Gly12Val disomy 25 F 55 0 Xelox Avastin-Xeliri PD NA Gly12Asp disomy 26 M 60 1 LV5FU Folfiri , Folfiri , Folfox PD NA Wild-type NE 27 M 59 0 Folfiri , Folfiri/Folfox , Folfox PD NA Gly12Asp NE 28 F 58 1 LV5FU Folfiri , Xelox PD NA Gly12Asp disomy 29 M 51 0 Folfox , Folfiri PD NA Wild-type disomy 30 F 66 0 Folfiri , Xelox PD NA Wild-type R521K trisomy 31 F 56 0 - PD NA Wild-type disomy 32 F 78 0 Folfox , Folfiri , Cape PD NA Gly12Val disomy F = female , M = Male , Folfox = oxaliplatin , fluorouracil , and folinic acid ; Xelox = capecitabine , oxaliplatin ; Folfiri = irinotecan , fluorouracil , and folinic acid ; Xeliri = Capecitabine , irinotecan ; Folfirinox = oxaliplatin , irinotecan , fluorouracil , and folinic acid ; LV5FU = infusional FU and folinic acid ; Fufol = bolus @DRUG$ and folinic acid ; PR = partial response .", "label": "None"}
{"id": "25580271", "sentence": "Two phase III trials compared afatinib to a platinum-doublet in patients with advanced EGFR mutant NSCLC , and a combined analysis for overall survival was presented at ASCO , as well as subset analyses based on EGFR mutation subtype ( exon 19 deletion and exon 21 @VARIANT$ point mutation ) [ ] . In subgroup analysis based on EGFR mutation type the benefit appeared to be limited to patients with exon 19 mutations . When cross-over to EGFR tyrosine kinase inhibitor therapy was examined , 75 % of patients who received cisplatin and @DRUG$ received an EGFR tyrosine kinase inhibitor and 56 % of patients who received cisplatin and gemcitabine received an @GENE$ tyrosine kinase inhibitor .", "label": "None"}
{"id": "15737014", "sentence": "Surprisingly , one cell line—H1975—contained the same C→T mutation at position 2369 ( @VARIANT$ ) as described above ( D , lower panel ) . This cell line had previously been shown by others to contain a 2573 T→G mutation in exon 21 ( L858R ) [ ] , which we confirmed ( D , upper panel ) ; in addition , H1975 was reported to be more sensitive to @DRUG$ inhibition than other lung cancer cell lines bearing wild-type @GENE$ [ ] .", "label": "resistance or non-response"}
{"id": "7734314", "sentence": "N ' - rssm i r 1 @VARIANT$ 912 or T24 ADM-2 cells might be more closely related to MRP overexpression . The cross-resistance to vincristine at low levels ( 1.2- to 1.9-fold higher ) might be also correlated with the MRP gene in @GENE$ and T24/ADM-2 cells which overproduced only multidrug resistance associated protein . Grant et al. ( 1994 ) have demonstrated that the transfectants of a full-length MRP cDNA expression vector display in- creased resistance to doxorubicin , vincristine and @DRUG$ and increased expression of the 190 kDa MRP .", "label": "None"}
{"id": "24349829", "sentence": "Correspondingly , direct injection of a liposome encapsulated miR-7 plasmid into established EGFR-TKI sensitive and resistant tumors bearing the @VARIANT$ EGFR mutant resulted in significant tumor regression in conjunction with repression of EGFR , RAF-1 and IRS-1 expression . In head and neck cancer , miR-7 functioned in a synergistic manner with @DRUG$ to render FaDu Erlotinib-resistant cells susceptible to the growth inhibitory activities of the drug . Interestingly , expression profiling analysis suggested that the downregulation of RAF-1 and @GENE$ and its ligand TGF-α by miR-7 was a possible mechanism by which miR-7 orchestrates the inhibition of EGFR signaling at multiple levels115 .", "label": "resistance or non-response"}
{"id": "25078331", "sentence": "The vascular endothelial growth factor ( VEGF ) inhibitor @DRUG$ has also shown limited impact on the outcome of this disease . Case 13 . A pleomorphic adrenocortical carcinoma liver metastasis derived from a 48-year-old man harboured CDK4 and @GENE$ amplifications , CUL4A ( @VARIANT$ ) and TP53 ( S241Y ) mutations .", "label": "None"}
{"id": "24155950", "sentence": "Additionally , we have used the @GENE$ Bcr-Abl @VARIANT$ cell line , derived from Baf3 ( an immortalized murine pro-B cell line ) , which is also resistant to 1μM imatinib and at least partially resistant to dasatinib and nilotinib treatments ( -6 ) . In addition to its effect on imatinib-sensitive cell lines , the bortezomib/paclitaxel regimen was able to induce caspase cleavage , a measure of caspase activation [ - ] , in K562-R cells and significant downregulation of the total levels and phosphorylation of Bcr-Abl in all tested TKIs-resistant cell lines .", "label": "None"}
{"id": "23852704", "sentence": "Thus , in two trials , administration of @DRUG$ to patients with this mutation was associated with a significantly better outcome than that seen in patients with other types of @GENE$ mutations. , Indeed , patients with the @VARIANT$ mutation appeared to benefit to approximately the same extent as patients with K-RAS wild-type tumors from the addition of cetuximab to first-line chemotherapy .", "label": "resistance or non-response"}
{"id": "24924344", "sentence": "@DRUG$ ( A/T ) Chr16 : 56671632 MT1A ( near-gene 5 ) 0.047628 0.138 Oxaliplatin rs562 ( C/T ) Chr3 : 183637845 ABCC5 ( UTR3 ) 0.049494 0.392 rs3749445 ( A/G ) Chr3 : 183638506 ABCC5 ( UTR3 ) 0.044895 0.410 rs2292998 ( C/T ) Chr3 : 183663833 ABCC5 ( intronic ) 0.039882 0.277 rs1016752 ( C/G ) Chr3 : 183665062 ABCC5 ( intronic ) 0.039781 0.232 rs4148585 ( C/T ) Chr3 : 183670642 @GENE$ ( intronic ) 0.039781 0.283 rs6443924 ( A/G ) Chr3 : 183679532 ABCC5 ( intronic ) 0.039781 0.279 rs4148579 ( A/G ) Chr3 : 183685249 ABCC5 ( intronic ) 0.039781 0.279 rs939336 ( A/G =&gt ; @VARIANT$ ) Chr3 : 183685534 ABCC5 ( exonic ) 0.039781 0.279 rs1132776 ( C/T = & gt ; A395A ) Chr3 : 183696402 ABCC5 ( exonic ) 0.044895 0.289 rs2313212 ( C/T ) Chr3 : 183700928 ABCC5 ( intronic ) 0.039781 0.279 rs4148575 ( C/T ) Chr3 : 183702275 ABCC5 ( UTR3 ) 0.044895 0.289 rs1846692 ( C/T ) Chr16 : 56671696 MT1A ( near - gene 5 ) 0.049494 0.360 rs35346959 ( A/G ) Chr16 : 56671867 MT1A ( near- gene 5 ) 0.044895 0.137 rs9922957 ( C/G ) Chr16 : 56672380 MT1A ( near - gene 5 ) 0.039781 0.185 rs9922409 ( A/G ) Chr16 : 56672400 MT1A ( near - gene 5 ) 0.04532 0.103 rs7190725 ( G/T ) Chr16 : 56673290 MT1A ( intronic ) 0.044895 0.170 rs8052394 ( A/G =&gt ; K51R ) Chr16 : 56673828 MT1A ( missense ) 0.044895 0.152 rs1800566 ( C/T = & gt ; P187S ) chr16 : 69745145 NQO1 ( exonic ) 0.039781 0.258 rs689455 ( A/C ) Chr16 : 69761661 NQO1 ( near- gene 5 ) 0.039781 0.242", "label": "None"}
{"id": "PMC4041556", "sentence": "Later rechallenge with @GENE$ TKI may result in some modest degree of response ( range 4–24 % ) and a significant disease control rate ( range 45–67 % ) . Resistance mechanisms to @DRUG$ are multiple , and include ALK-dominant mechanisms such as resistance mutations and copy number gain , and ALK non-dominant mechanisms through the outgrowth of clones containing a separate activated oncogene . In contrast to the EGFR setting , where the @VARIANT$ mutation predominates , the spectrum of ALK resistance mutations is broad .", "label": "None"}
{"id": "24121633", "sentence": "Based on our data , we hypothesized that PRR of hnRNP L binds to PTB and cooperatively suppresses inclusion of exon @VARIANT$ . We thus examined the role of PRR of hnRNP L on the interaction with PTB . @DRUG$ tagged hnRNP L ( His-L ) , its PRR deleted variant ( His-L-ΔPRR ) , histidine tagged hnRNP LL ( His-LL ) , and its @GENE$ inserted variant ( His-LL-PRR ) were expressed in SH-SY5Y cells , and they were immunoprecipitated with anti-histidine antibody in the presence of RNase .", "label": "None"}
{"id": "25090459", "sentence": "Furthermore , although @GENE$ mutations are typically associated with non-responsiveness to anti-EGFR antibodies , recent data indicate that KRAS @VARIANT$ mutations may be a positive predictor of @DRUG$ response .", "label": "resistance or non-response"}
{"id": "23361053", "sentence": "# P & lt ; 0.01 EBP1 @VARIANT$ transfected cells vs GFP transfected cells @GENE$ OHT . Expression levels of the 80 kDa EBP1–GFP fusion proteins were measured by western blotting using a GFP antibody ( inset ) . A PAK inhibitor prevents @DRUG$ induced growth of PAK1 overexpressing hormone resistant cells .", "label": "None"}
{"id": "23986642", "sentence": "In summary , preclinical data supports the conclusion that @DRUG$ is an orally active , pan-TKI that inhibits native BCR-ABL and most @GENE$ mutants , including the clinically relevant @VARIANT$ mutant , with high potency .", "label": "None"}
{"id": "17973572", "sentence": "@GENE$ cells expressing @VARIANT$ (LR) , L858R-L747S # 4 ( LR-LS ) , or L858R-T790M (LR-TM) were plated in 24-well plates at a density of 1 × 105/well and treated with 0.1 % DMSO ( control ) or @DRUG$ for 24 h .", "label": "None"}
{"id": "24175297", "sentence": "BRAF V600E mutation leads to constitutive activation of the @GENE$ pathway , promoting cancer cell survival and proliferation [ ] . In the current study , significant downregulation of mRNA expression of BRAF V600E was observed for human melanoma SK-MEL-28 cells treated with α-mangostin , γ-mangostin , and 8-deoxygartanin ( ) . RG7204 ( @DRUG$ ) , a selective BRAF @VARIANT$ inhibitor , has potent inhibitory effects on the growth of melanoma harboring this mutation both in vitro and in vivo [ ] .", "label": "None"}
{"id": "25419154", "sentence": "For example , MetXia-P450 is a recombinant retroviral vector that delivers @GENE$ a gene directed enzyme prodrug therapy ( GDEPT ) strategy to improve metabolism of @DRUG$ (CPA) . Initial preclinical studies determined that MetXia-P450 sensitized @VARIANT$ breast cancer cells to CPA , produced a bystander effect , and significantly reduced growth of MDA-MB-231 breast tumors in vivo .", "label": "None"}
{"id": "23621958", "sentence": "However , clinical trials with these agents revealed that in most cases , responders harbored specific activating mutations in exons 18–21 which collectively encode the kinase domain of the @GENE$ gene [ - ] . The majority of mutations that have been associated with sensitivity to gefitinib and @DRUG$ are located in exon 19 ( 45 % ) and exon 21 ( 40–45 % ) , although ~5 % are located in exon 18 and & lt ; 1 % in exon 20 [ ] . In addition , certain mutations in exon 20 , such as @VARIANT$ , predict resistance to these TKIs [ ] .", "label": "resistance or non-response"}
{"id": "24375389", "sentence": "Other examples of useful biomarkers are KRAS mutation testing to predict benefit from monoclonal antibodies against EGFR , @DRUG$ and panitumumab , in metastatic colon cancer [ ] and BRAF @VARIANT$ mutation analysis in metastatic melanoma in order to predict responsiveness to BRAF inhibitors such as vemurafenib [ ] . Salient to this review , testing for promoter CpG island methylation of DNA repair gene @GENE$ MGMT , guides the clinical management of glioblastoma .", "label": "None"}
{"id": "15737014", "sentence": "The EGFR T790M mutation , in conjunction with either wild-type EGFR or the drug-sensitive @VARIANT$ EGFR mutant , prevents inhibition of tyrosine phosphorylation ( A ) or @GENE$ ( B ) by @DRUG$ .", "label": "sensitivity"}
{"id": "24419415", "sentence": "Because previous phase 3 trials that investigated @DRUG$ or irreversible TKIs for NSCLC with @GENE$ mutations did not include uncommon EGFR mutations , further clinical studies may need to be performed. , , Another possible strategy for the treatment of uncommon EGFR mutations is the combination of EGFR-TKIs and cytotoxic agents . Our group has undertaken a randomized phase 3 trial to compare gefitinib plus carboplatin plus pemetrexed with gefitinib monotherapy for patients with NSCLC with an exon 19 deletion or an @VARIANT$ , G719X , or L861Q EGFR mutation ( NEJ009 ; University Hospital Medical Information Network Clinical Trials Registry [ UMIN-CTR ] number , UMIN000006340 ) .", "label": "sensitivity"}
{"id": "25364578", "sentence": "Lazzara and colleagues found that SHP2 Y542 phosphorylation was not induced in response to EGF in the H3255 cells , which harbor the missense @VARIANT$ exon 21 mutation , suggesting that @GENE$ activity may be less efficiently promoted by EGFR L858R and the STAT3 pathway may be more active . The main problem is that STAT3 activation is not abrogated by single EGFR TKI treatment with @DRUG$ , erlotinib , afatinib or dacomitinib , - .", "label": "None"}
{"id": "23144605", "sentence": "Prior work provided evidence that CCR1 and cinnamyl @DRUG$ dehydrogenase ( CAD ) may organize into a functional complex through which the substrate coniferyl aldehyde is transferred from @GENE$ to CAD without much leakage , thereby acting as a channel leading specifically to the synthesis of G lignin . Similarly , caffeic acid O-methyltransferase (COMT) and ferulate 5-hydroxylase ( @VARIANT$ ) were suggested to form an analogous complex contributing specifically to the synthesis of S lignin .", "label": "None"}
{"id": "24672788", "sentence": "A Bio-Rad 125-0131 guard cartridge ( @GENE$ Labs , Richmond , CA , USA ) was used to protect column . The eluted compounds ( sugars , glycerol , @DRUG$ and organic acids ) were detected with an G1314B VWD detector ( Agilent 1200 Series , Santa Clara , CA , USA ) and an @VARIANT$ RID detector ( Agilent 1200 Series , Santa Clara , CA , USA ) simultaneously .", "label": "None"}
{"id": "23099808", "sentence": "Acquired clinical resistance to EGFR-TKI was also documented in lung cancer patients , who had an EGFR mutation in exon 20 ( @VARIANT$ ) ( ) . Therefore , in this study , we first examined the effects of @DRUG$ or erlotinib on cell proliferation of the cell lines including those originated from lung adenocarcinoma ( LADCA ) . We then evaluated gene profiles of @GENE$ cells using a microarray analysis in order to further characterise the possible differential mRNA expression patterns among EGFR-TKI-sensitive cells .", "label": "resistance or non-response"}
{"id": "17973572", "sentence": "To prove the functional significance of the @VARIANT$ mutation , we generated Ba/F3 cell lines stably expressing mutant EGFR constructs [ ] . These cell lines , including L858R-L747S , proliferated in the absence of @GENE$ . Ba/F3-L858R cells were extremely sensitive to gefitinib ( D ) , whereas Ba/F3-L858R-T790M cells were highly resistant up to 1 μM @DRUG$ .", "label": "None"}
{"id": "22815900", "sentence": "We finally examined whether expression of activating mutant @GENE$ could restore drug sensitivity to erlotinib in drug resistant cell lines , PC9/ER1 and 11–18/ER1-7 . As shown in , out of 11 patients who first received @DRUG$ after lung surgery and then showed recurrence , 8 patients had the delE746-A750 mutation and 3 had @VARIANT$ mutation in their primary lung tumors .", "label": "sensitivity"}
{"id": "25364578", "sentence": "Studies of ALK rearranged lung cancers with acquired resistance to @DRUG$ have identified @GENE$ fusion gene amplification and secondary ALK TK domain mutations ( @VARIANT$ and G1269A ) in about one third of cases .", "label": "resistance"}
{"id": "24523596", "sentence": "MCF7/AdVp3000 and S1-M1-80 cells express @VARIANT$ and R482G variants of @GENE$ , respectively , and are highly resistant to both mitoxantrone and @DRUG$ .", "label": "None"}
{"id": "24621983", "sentence": "Intracellular accumulation of Rhodamine123 ( 5 μM ) in presence ( 0.1 and 0.2 μM ) or absence of ABCB1 inhibitor ( LY335979 ) ( N = 6 ) in ( @GENE$ , CTL HEKpcDNA3.1 , HEK1199G and HEK1199A and ( B ) CTL K562 , CTL K562pcDNA3.1 , @VARIANT$ and K5621199A . * compared without inhibitor *p & lt ; 0.05 **p & lt ; 0.01 ***p & lt ; 0.001 , # compared to CTL pcDNA3.1 # p & lt ; 0.05 # # p & lt ; 0.01 # # # p & lt ; 0.001 . Impact of ABCB1 1199G&gt;A polymorphism on the cytostatic effects of @DRUG$ and vinblastine", "label": "None"}
{"id": "24787964", "sentence": "Preclinical studies have shown superior activity of afatinib over first-generation TKIs , mainly due to ( 1 ) irreversible binding , which confers stronger binding affinity and potency , ( 2 ) ability to circumvent first-generation TKI resistance mechanism @VARIANT$ mutation in exon 20 , and ( 3 ) effectiveness against multiple HER-endothelial growth factor receptors . Recently , TKIs have been investigated in eight phase 3 trials as first-line treatment in patients with advanced NSCLC harboring @GENE$ activating mutations , in comparison with platinum based chemotherapy doublets : gefitinib trials IPASS , , West Japan , North-East Japan , , and First-SIGNAL ; @DRUG$ trials OPTIMAL , and EURTAC ; and afatinib trials LUX-Lung 3 and LUX-Lung 6 .", "label": "resistance or non-response"}
{"id": "21264348", "sentence": "10.1371/journal.pone.0015929.g002Deuterium incorporation curves for wild-type and @VARIANT$ @GENE$ in the presence of @DRUG$ , GNF-5 or both dasatinib and GNF-5 .", "label": "None"}
{"id": "22536370", "sentence": "@GENE$ W557R V559A/D @VARIANT$ K642E D816H 23 % Acral 16 % Mucosal 28 % CSD , , Sensitive to : @DRUG$ Nilotinib Sunitinib Dasatinib Decreased sensitivity to : Imatinib ( D816H only ) , , , ,", "label": "resistance or non-response"}
{"id": "24009732", "sentence": "Several mutations in the kinase domains such as @VARIANT$ , T674I , S601P and L629P , have been demonstrated to be responsible for the drug-resistance . Of note , the “gate-keeper” mutant T674I FIP1L1-PDGFRα in @GENE$ , similar to T315I Bcr-Abl in CML , was also refractory to some second-generation TKIs , such as @DRUG$ , sorafenib .", "label": "None"}
{"id": "25079768", "sentence": "The second-line treatment , after imatinib failure , is provided by less specific kinase inhibitors , such as @DRUG$ that shows potency against imatinib-resistant @GENE$ mutated in the ATP binding pocket ( @VARIANT$ and T670I ) .", "label": "None"}
{"id": "22152101", "sentence": "Oncogenic activation of EGFR downstream effectors in the RAS-RAF-MAPK signalling pathway can negatively influence @DRUG$ therapy . As reported earlier , @GENE$ mutations were examined by direct sequencing of exon 2 [ ] . One single KRAS mutation at nucleotide position 35 ( G &gt ; A , Patient 36 ) that changes codon 12 from glycine to aspartic acid ( @VARIANT$ ) was detected in 1 of 32 patients ( 3 % , Table ) .", "label": "sensitivity"}
{"id": "23520446", "sentence": "Approximately 50 % of EGFR mutations consist of deletions in exon 19 , whereas 35–45 % consist of the @VARIANT$ mutation and 5 % consist of insertions in exon 20 or the L861Q mutation – . Gefitinib ( Iressa ) and Erlotinib ( @DRUG$ ) are EGFR inhibitors that are used clinically for the treatment of advanced NSCLC , primarily that with @GENE$ mutations in the tyrosine kinase domains – .", "label": "sensitivity"}
{"id": "17973572", "sentence": "Based on the data obtained from lung cancer cell lines , we further explored the mechanisms by which @VARIANT$ and L747S resistant mutations affect BIM up-regulation and apoptosis . @DRUG$ effectively induced apoptosis in Ba/F3-L858R cells , whereas Ba/F3-L858R-L747S cells were intermediately resistant and @GENE$ completely resistant ( A , top ) .", "label": "None"}
{"id": "21687596", "sentence": "An experiment using cell lines transfected concurrently with activating mutations and a @VARIANT$ mutation also proved that resistance to @DRUG$ and erlotinib is evident when this mutation is present [ – ] . Analogous secondary mutations of the @GENE$ gene in case of chronic myelogenous leukemia ( CML ) [ ] and the KIT gene in case of gastrointestinal stromal tumor [ ] have previously been reported as mechanisms of imatinib resistance , which is also a TKI .", "label": "None"}
{"id": "15736989", "sentence": "Resistance mutations identified via in vitro screens have shown a high degree of correlation with those that develop in vivo , as shown in screens for imatinib-resistant BCR-ABL mutants [ ] and PKC412-resistant FLT3 mutants [ ] , as well as the @VARIANT$ resistance mutation to gefitinib in the context of @GENE$ [ ] .", "label": "None"}
{"id": "17973572", "sentence": "Based on the data obtained from lung cancer cell lines , we further explored the mechanisms by which T790M and @VARIANT$ resistant mutations affect BIM up-regulation and apoptosis . @DRUG$ effectively induced apoptosis in Ba/F3-L858R cells , whereas @GENE$ cells were intermediately resistant and Ba/F3-L858R-T790M completely resistant ( A , top ) .", "label": "None"}
{"id": "23785245", "sentence": "( A ) The @VARIANT$ secondary mutation in exon 20 of EGFR is present in 50 % –70 % of NSCLC patients who acquire resistance to @GENE$ , such as gefitinib or @DRUG$ .", "label": "resistance or non-response"}
{"id": "17973572", "sentence": "The Secondary Resistant Mutations L747S and T790M Affect @DRUG$ Induced Apoptosis and Inhibit BIM Up-Regulation ( A ) Top : Annexin V apoptosis assay : @GENE$ cells expressing @VARIANT$ (LR) , L858R-L747S # 4 ( LR-LS ) , or L858R-T790M (LR-TM) cells were grown in the absence or presence of gefitinib for 24 h .", "label": "None"}
{"id": "17177598", "sentence": "We identified the ectodomain mutant @GENE$ in 14 % ( 1/7 ) gliomas that responded to @DRUG$ . This tumor , however , also expressed EGFRvIII , raising the possibility of independent clones arising from a common progenitor with EGFR amplification . We also identified the @VARIANT$ EGFR mutation in 7 % ( 1/5 ) gliomas that failed EGFR kinase inhibitor therapy , but loss of PTEN in this tumor provides a potential explanation for treatment failure ( ) .", "label": "sensitivity"}
{"id": "24790411", "sentence": "Compared to erlotinib and gefitinib , afatinib shows lower EC50 values and greater potency against wild type ( afatinib vs erlotinib vs gefitinib : 60 nM vs 110 nM vs 157 nM ) and L858R mutated @GENE$ ( afatinib vs erlotinib vs @DRUG$ : 0.7 nM vs 40 nM vs 5 nM ) . Moreover , afatinib is able to inhibit the kinase activity in vitro and in animal models when a resistant @VARIANT$ mutation is concomitant to a sensitivity mutation .", "label": "resistance or non-response"}
{"id": "22970367", "sentence": "Amplification of MET , a receptor tyrosine kinase , was detected in up to 20 % of lung cancer specimens that developed acquired resistance to gefitinib or @DRUG$ . Although MET amplification can coexist with the @GENE$ @VARIANT$ mutation , approximately 60 % of MET amplification is independent of T790M mutation [ , ] .", "label": "resistance or non-response"}
{"id": "21042543", "sentence": "Di Nicolantonio et al also demonstrated that introduction of the @GENE$ @VARIANT$ allele could confer resistance to either cetuximab or @DRUG$ in wild-type B-RAF colorectal cancer cells .", "label": "resistance or non-response"}
{"id": "25114510", "sentence": "Furthermore , @DRUG$ , an irreversible @GENE$ , can also be used , and this novel drug seems to have a significant effect on NSCLCs harboring an EGFR exon 19 deletion . Thus , clinicians should use each of these drugs in appropriate settings . Acquired resistance , including EGFR secondary mutations ( @VARIANT$ and other rare mutations ) , MET gene amplification , PTEN gene downregulation , high-level hepatocyte growth factor expression , epithelial–mesenchymal transition , and conversion to small cell lung cancer , – continues to restrict the durable long-term outcomes of erlotinib .", "label": "response"}
{"id": "23861935", "sentence": "The latter binds the @GENE$ to mediate HASMC contraction . Unlike our data showing a decreased expression of CysLT1R in response to Pam3CSK4 , poly ( I:C ) , LPS , @DRUG$ and iE-DAP , Morishima et al. have recently shown that poly ( I:C ) decreased the muscarinic acetylcholine receptor @VARIANT$ and increased M3R expression without affecting histamine receptor H1R or CysLT1R , which correlated to intracellular calcium mobilization .", "label": "None"}
{"id": "23533466", "sentence": "H1975 cancer cell line with mutations in EGFR exons 21 ( L858R ) and 20 ( @VARIANT$ ) was refractory to reversible @GENE$ , gefitinib , and erlotinib [ ] , but was sensitive to irreversible EGFR-TKIs , such as BIBW2992 ( @DRUG$ ) .", "label": "response"}
{"id": "22751098", "sentence": "To test this hypothesis and to clinically validate our preclinical findings , we measured the expression of AXL by IHC ( immunohistochemistry ) in 35 matched EGFR-mutant NSCLC specimens obtained from patients both prior to treatment with the EGFR TKIs erlotinib or @DRUG$ and upon the development of EGFR TKI acquired resistance . In cases where enough material was available for additional studies , we also examined the specimens for @GENE$ and vimentin ( as a marker for EMT ) expression by IHC ( scoring system shown in ) , EGFR @VARIANT$ by sequencing , and MET amplification by FISH .", "label": "None"}
{"id": "22751098", "sentence": "Together , the data indicate that AXL kinase activation is necessary and sufficient to promote @DRUG$ resistance in these @GENE$ mutant NSCLC models . The analysis indicated that an @VARIANT$ mutation in AXL would be expected to result in steric clash with XL-880 and would block the ability of XL-880 to inhibit AXL .", "label": "None"}
{"id": "21108851", "sentence": "Further clinical studies of ponatinib are ongoing , most notably a single-arm phase 2 study in patients with CML or Ph+ acute lymphoblastic leukemia ( ALL ) who either are resistant or intolerant to either dasatinib or nilotinib , or who harbor the @VARIANT$ mutation ( @DRUG$ Ph+ ALL and CML evaluation [PACE ] ; NCT01207440 ) . Switch pocket kinase inhibitors , such as DCC-2036 and DCC-2157 , target the sites involved in controlling the conformation of @GENE$ , which ultimately controls the activity state of the kinase .", "label": "response"}
{"id": "23320171", "sentence": "Primary results from the EMILIA study , a randomized trial comparing Trastuzumab DM-1 to lapatinib and capecitabine , have shown that @DRUG$ DM-1 significantly improved progression-free survival in patients with metastatic HER2 positive breast cancer . Further research is looking into inhibiting other targets such as mTOR , @VARIANT$ , or @GENE$ pathways .", "label": "None"}
{"id": "23569389", "sentence": "Baseline @GENE$ mutation data were available for 95 % of patients . Very high imatinib resistance mutations ( M244V , G250E , Y253H , @VARIANT$ , E255V , T315I , F359V , H396R ) were associated with the lowest response rates to @DRUG$ .", "label": "None"}
{"id": "25364578", "sentence": "Lazzara and colleagues found that SHP2 Y542 phosphorylation was not induced in response to @GENE$ in the H3255 cells , which harbor the missense @VARIANT$ exon 21 mutation , suggesting that SHP2 activity may be less efficiently promoted by EGFR L858R and the STAT3 pathway may be more active . The main problem is that STAT3 activation is not abrogated by single EGFR TKI treatment with gefitinib , @DRUG$ , afatinib or dacomitinib , - .", "label": "None"}
{"id": "21188137", "sentence": "· The presence of any @GENE$ mutation ( that is when considering all mutations together ) does not appear to predict differential response to tyrosine kinase inhibitor ( TKI ) treatments ( defined as imatinib- , dasatinib- , and nilotinib based regimens ) . · There is consistent evidence that presence of the relatively rare @VARIANT$ mutation can predict TKI treatment failure , mainly in terms of hematologic and cytogenetic response .", "label": "None"}
{"id": "16187797", "sentence": "Transformation induced by expression of L858R , @VARIANT$ , and L747_E749del A750P EGFR , but not EGF stimulated wild-type EGFR or D770_N771insNPG @GENE$ , was inhibited by 0.1 μM @DRUG$ .", "label": "None"}
{"id": "25364578", "sentence": "In fact , using a PCR-PNA assay pretreatment , @VARIANT$ mutations were detected in 65.26 % of patients . These results reinforce the need for 2nd and 3rd generation @GENE$ TKIs , while taking into account existing data that suggest use of erlotinib or @DRUG$ beyond progression , with added chemotherapy , radiotherapy or best supportive care may improve survival .", "label": "resistance or non-response"}
{"id": "23386666", "sentence": "Approximately 90 % of all activating mutations are exon 19 deletions and a point mutation ( @VARIANT$ ) in exon 21 . At present , although it is recommended that the presence of activating mutations in the @GENE$ gene should be identified before treatment with @DRUG$ or erlotinib , there is no consensus regarding the specific mutations that should be tested nor methods that should be used .", "label": "sensitivity"}
{"id": "24944510", "sentence": "Multiple secondary mutations have already been identified in patients treated with @DRUG$ . Homologous to the gatekeeper EGFR T790M mutation is the L1196M substitution , which , unlike EGFR T790M , does not appear to confer a growth disadvantage to cells . Other secondary mutations such as @VARIANT$ , C1156Y , L1152R , and 1151Tins may affect affinity of the mutant ALK for either ATP or drug , and these differences have ramifications on the development of next-generation @GENE$ inhibitors , which have varied mutation-specific efficacy among different agents .", "label": "resistance"}
{"id": "24759962", "sentence": "Samowitz et al. reported that the BRAF @VARIANT$ mutation in MSS colon cancer was associated with a significantly poorer survival in stage II to IV colon cancer , but did not have an effect on the excellent prognosis of @GENE$ tumors [ ] . Some patients in these trials were treated with @DRUG$ after relapse .", "label": "None"}
{"id": "25222496", "sentence": "Thirdly , exon 21 L858R mutation co-existing with other uncommon mutations might affect the hypersensitivity of L858R to @GENE$ . A retrospective study which investigated the frequency of complex mutations in 783 NSCLC patients found the majority was G719S plus @VARIANT$ mutation ( n = 8 ) , the result also suggested poor response to @DRUG$ in patients with G719S plus L858R mutation .", "label": "sensitivity"}
{"id": "25538894", "sentence": "In May 2010 , an EGFR mutation ( @VARIANT$ c.2573T & gt ; G ) positive adenocarcinoma of the right lower lobe of the lung with metastasis in the contra-lateral lung was diagnosed ( Figure A ) . In June 2010 , afatinib , a irreversible @GENE$ , was started in a clinical trial ( Gilotrif® in BIBW 2992 trial ) .", "label": "sensitivity"}
{"id": "25120654", "sentence": "However , following the detection of the @VARIANT$ @GENE$ substitution mutation in the tumor cells , the patient exhibited poor curative effect when treatment with @DRUG$ was continued .", "label": "resistance or non-response"}
{"id": "21333004", "sentence": "Overexpression of wild type EGFR induced high and sustained phosphorylation of EGFR , Shc , MEK ( mitogen activated protein kinase kinase ) and ERK ( extracellular signal regulated kinase ) , while the @VARIANT$ mutation reduced these response levels . In addition , H1299L858R , which is supposed to be more sensitive to gefitinib than H1299EGFR-WT , was effectively inhibited by @DRUG$ administration at the downstream part of the signaling pathway ( MEK and ERK ) compared with H1299EGFR-WT , but , surprisingly , not at the upstream part of the pathway ( @GENE$ and Shc ) .", "label": "sensitivity"}
{"id": "PMC3991357", "sentence": "Epidermal growth factor receptor tyrosine kinase inhibitors ( EGFR-TKIs ) , such as gefitinib and @DRUG$ , have achieved high clinical response rates in patients with non-small cell lung cancers ( NSCLCs ) , which possess somatic mutations in the tyrosine kinase domain of the @GENE$ . However , over time ( median of 6-12 months ) , most tumors are known to develop acquired resistance to EGFR TKIs . Currently , there have been no effective treatment options against NSCLC patients with the secondary @VARIANT$ resistance mutation , which occurs in 50 % of patients with acquired resistance to EGFR-TKIs .", "label": "resistance or non-response"}
{"id": "24091670", "sentence": "Induced apoptosis was measured and calculated as described in a ( b ) , and mTOR and @VARIANT$ phosphorylation was analyzed by western blot ( c ) . ( d ) K562 and LAMA-84 cells were treated with @DRUG$ 20 nM in the presence or absence of 100 ng/ml SCF and with 1 μM CAL-101 ( dark grey bars ) or 1 μM @GENE$ ( light grey bars ) or 1 μM BEZ-235 ( middle grey bars ) or 10 μM LY294002 ( white bars ) as indicated .", "label": "None"}
{"id": "22655263", "sentence": "The L1196M gatekeeper mutation and the C1156Y and L1152R mutants were identified in the relapsed NSCLC cases , and the @VARIANT$ mutation in the relapsed IMT ( Choi et al. , ; Sasaki et al. , , ) . The mechanisms underlying decreased activity of @DRUG$ on these secondary @GENE$ mutants were investigated by structural and biochemical analyses , together with cellular data generated in engineered in vitro models .", "label": "resistance"}
{"id": "25033171", "sentence": "The energetic difference between G2032R-ROS1 and WT-ROS1 are shown in panel C ( ΔΔG = ΔGG2032R−ΔGWT , a positive ΔG indicates a weaker binding affinity in the mutated protein , and a negative ΔG indicates a stronger binding affinity ) , where the residue Leu18 ( on the P-loop region ) contributes the most to the attenuated binding of @DRUG$ to G2032R mutated @GENE$ , indicating that the P-loop conformation governs the binding of crizotinib .", "label": "resistance"}
{"id": "21646685", "sentence": "Also , in MCF10A cells expressing high levels of HER2/Neu , a kinase domain mutant of PIK3CA ( @VARIANT$ ) induced expression of Heregulin , the ligand that activates @GENE$ signaling through the PI3K pathway [ ] . In contrast , a helical domain mutant ( E545K ) enhanced transformation without inducing Heregulin expression [ ] . Therefore , in HER2 subtype breast cancers with PIK3CAH1047R or other kinase domain mutant alleles , therapy with Herceptin/Trastuzumab together with an antibody that blocks Heregulin could be particularly effective .", "label": "None"}
{"id": "19543508", "sentence": "These 20 patients were treated with @DRUG$ as third-line therapy . Overall , @GENE$ mutations were found in 3 ( 15 % ) out of the 20 patients , including in-frame deletions within exon 19 ( n=2 ) and @VARIANT$ missence mutaion in exon 21 ( n=1 ) .", "label": "sensitivity"}
{"id": "24386407", "sentence": "Lung cancers with mutations that activate epidermal growth factor receptor (EGFR) , including exon 19 deletions and the exon 21 @VARIANT$ point mutation , respond to the reversible EGFR-tyrosine kinase inhibitors ( EGFR-TKIs ) gefitinib and erlotinib [ ] . These mutations have been shown to promote the activation of EGFR signaling and tumor dependency on EGFR . Recent clinical trials have shown that progression-free survival ( PFS ) in patients with EGFR mutant lung cancer is prolonged by treatment with a reversible @GENE$ and the irreversible EGFR-TKI @DRUG$ , which was designed to covalently bind to EGFR [ - ] .", "label": "sensitivity"}
{"id": "19216789", "sentence": "To investigate the effects of AZD0530 on Bcr-Abl harbouring mutations conferring Imatinib-resistance ( Y253F , @VARIANT$ and T315I ) Ba/F3 cells expressing these mutants were treated with the dual Src/Abl kinase inhibitor AZD0530 , and proliferation was assessed comparing them with the @GENE$ infected p185Bcr-Abl cells treated in a similar manner ( Figure ) .", "label": "None"}
{"id": "15737014", "sentence": "This study revealed that the quinazoline rings of erlotinib and @DRUG$ interact differently with the @GENE$ kinase domain , suggesting that while the @VARIANT$ mutation may affect inhibition by erlotinib and gefitinib , it may not affect inhibition of EGFR by compounds similar to lapatinib .", "label": "None"}
{"id": "23664091", "sentence": "In NSCLC , resistance to the @GENE$ TKI @DRUG$ is associated with the positive selection of cells harbouring the gatekeeper @VARIANT$ mutation known to confer insensitivity to gefitinib [ ] .", "label": "resistance or non-response"}
{"id": "25505694", "sentence": "In vitro studies showed that exposing EGFR-mutant lung cancer cell lines to a mutagen and culturing them in the presence of an EGFR-TKI , the resistant clones with the @VARIANT$ mutation maintained a persistent phosphorylation [ ] . Given this role of persistent EGFR signaling , many trials evaluated the intensification of EGFR inhibition through the use of drug molecules with additional activity against other receptors in the @GENE$ family , as the second-generation neratinib , dacomitinib and @DRUG$ [ ] .", "label": "response"}
{"id": "24894453", "sentence": "To test whether @VARIANT$ and G724S EGFR mutants are cetuximab-sensitive in vitro , we ectopically expressed these mutants in Ba/F3 cells , rendering these cells IL-3 independent but dependent on exogenous oncogenic @GENE$ signaling [ ] .", "label": "sensitivity"}
{"id": "20234366", "sentence": "KRAS mutations were as follows : G13D in five patients ; @VARIANT$ in three patients ; G12V in three patients ; and G12A in one patient . In all , 11 out of 36 @GENE$ wild-type patients ( 30 % ) responded to @DRUG$ , whereas none of the 12 patients ( 0 % ) harbouring a KRAS mutation had a partial response ( P=0.04 ) .", "label": "sensitivity"}
{"id": "15737014", "sentence": "Using this insight , new small-molecule inhibitors have been identified that retain activity against the majority of imatinib-resistant BCR-ABL mutants [ , ] . For example , in CML , a commonly found mutation is a C→T single nucleotide change that replaces threonine with isoleucine at position 315 ( @VARIANT$ ) in the ABL kinase domain [ , , ] . In GIST and HES , respectively , the analogous T670I mutation in @GENE$ and T674I mutation in PDGFR-alpha have been associated with acquired resistance to this drug [ , ] .", "label": "None"}
{"id": "23388220", "sentence": "ACTH , Adrenocorticotropic hormone ; DHEAS , Dehydroepiandrosterone-sulfate ; min , Minute ; 17-OHP , 17-hydroxyprogesterone ; RV ♂ , Reference values for the male population . After informed consent was obtained from the patient , a genetic study was performed with deoxyribonucleic acid ( DNA ) extraction from whole blood followed by polymerase chain reaction and direct genetic sequencing techniques . Two distinct mutations affecting the @GENE$ gene were detected : heterozygous @VARIANT$ ( moderate defect ) ; and homozygous R356W ( severe defect ) .", "label": "None"}
{"id": "24386407", "sentence": "Several strategies have been proposed to overcome resistance to reversible EGFR-TKIs , including treatment with @DRUG$ , an @GENE$ antibody [ ] , Hsp90 inhibitors [ ] , PI3K/mTOR inhibitor [ ] , and mutant-selective EGFR-TKIs [ ] . Of them , mutant-selective EGFR-TKIs have shown activity not only against tumors harboring exon19 deletions and the @VARIANT$ mutation , but against tumors with the T790M resistance mutation .", "label": "sensitivity"}
{"id": "23593401", "sentence": "The striking stability of our gene expression results on @GENE$ mutated tumors could be explained by the @VARIANT$ mutation found on 4/5 samples . The fifth tumor exhibited an exon 10 polymorphism and had expression values in the range of exon 18 mutated tumors . The response to targeted therapies , such as @DRUG$ and sunitinib , is also dependent of the type of mutation , , .", "label": "resistance or non-response"}
{"id": "22536370", "sentence": "NRAS G12C/S/R/V/A/D G13A/V/R/D Q61E/H/L/K/P/R 10 % Acral 24 % Mucosa 15 % CSD 22 % non-CSD , Sensitive to : ( pre-clinical ) MEK +/− @GENE$ inhibition , , , MET inhibition Resistant to : BRAF inhibitors KIT @VARIANT$ V559A/D L576P K642E D816H 23 % Acral 16 % Mucosal 28 % CSD , , Sensitive to : Imatinib Nilotinib Sunitinib Dasatinib Decreased sensitivity to : @DRUG$ ( D816H only ) , , , ,", "label": "None"}
{"id": "24348666", "sentence": "This figure is reprinted from the article by Giroux S. ( A ) @DRUG$ bound to the epidermal growth factor receptor (EGFR) tyrosine kinase , the gatekeeper residue ( T790 ) is highlighted in green ; cysteine-797 , which forms a covalent bond with 2nd and 3rd generation irreversible @GENE$ inhibitors , is highlighted in green . ( B ) Structure of WZ-4002 covalently bound to EGFR @VARIANT$ via cysteine-797 .", "label": "resistance or non-response"}
{"id": "23374602", "sentence": "Regarding KRAS , the same group reported in a pooled dataset of 579 @DRUG$ treated CRC patients that those with codon 13 @GENE$ mutant tumours ( @VARIANT$ ) had better outcomes ( HR for death 0.50 ) compared to patients with other KRAS mutant tumours [ ] .", "label": "resistance or non-response"}
{"id": "24472312", "sentence": "Our molecular docking analysis revealed that ponatinib could target native or T674I FIP1L1-PDGFRα in the DFG-out ( inactive ) binding mode , similar to @DRUG$ docking in @VARIANT$ @GENE$ .", "label": "response"}
{"id": "25562700", "sentence": "Molecule Target Biomarker Indication vemurafenib BRAF kinase BRAF @VARIANT$ mutant melanoma vandetanib VEGFR , EGFR , RETR not included on the label thyroid cancer abiraterone CYP 17A1 not included on the label prostate cancer @DRUG$ CTLA-4 not included on the label melanoma brentuximab vedotin CD30 ( ACD technology ) not included on the label lymphoma crizotinib ALK ALK-EML4 fusion protein lung cancer BRAF : Serine/threonine-protein kinase B-Raf ; VEGFR : Vascular endothelial growth factor receptor ; EGFR : epidermal growth factor receptor ; RETR : RET proto-oncogen receptor ; CYP 17A1 : cytochrome P450 17A1 ; CTLA-4 : Cytotoxic @GENE$ ; CD30 : Cluster of Differentiation 30 ; ADC : Antibody Conjugated Drug ; ALK-EML4 : anaplastic lymphoma kinase (ALK) ; echinoderm microtubule associated protein-like 4 ( EML4 ) fusion .", "label": "None"}
{"id": "25077070", "sentence": "PIK3CA Not distinctive 2-4 % Mixed reports Not distinctive @GENE$ and SqCC Mutations in E545K AND H1047R ( most common ) , also @VARIANT$ and H1047L @DRUG$ , Tensirolimus , GDC-0941 , XL-147 , Others", "label": "None"}
{"id": "25247240", "sentence": "Another study compared miR-34a the levels of human colorectal cancer DLD-1 cells @DRUG$ ( 5-FU ) -resistant with the parental counterpart of DLD-1 cells . It was not only found that 5-FU-resistant cells expressed significant higher levels of miR-34a , but also that the introduction of miR-34a into resistant cells significantly inhibited cell growth and induced a considerable attenuation of 5-FU-resistance , which was accompanied by reduced expression of @GENE$ and @VARIANT$ family proteins .", "label": "None"}
{"id": "24705275", "sentence": "10.1371/journal.pone.0092948.g002Cervical cancer patients with @VARIANT$ or E542K mutant tumors have inferior survival outcomes after standard chemoradiation ( @DRUG$ plus pelvic RT ) . Kaplan Meier curve for progression-free survival for cervical cancer patients with wild type PIK3CA versus E545K or E542K mutant tumors ( p = .05 ) . @GENE$ inhibitors SC-66 and MK-2206 induce non-apoptotic cell death in PIK3CA and PTEN mutant C33A cells", "label": "None"}
{"id": "22916261", "sentence": "The JAK2 @VARIANT$ mutation is thought to relieve the negative regulatory role of the dual-specificity kinase domain and is thus is weakly oncogenic , able to transform specific cell lines to cytokine independence . Chronic myeloid leukemia ( CML ) is a Philadelphia chromosome positive MPN characterized by the presence of the t ( 9 ; 22 ) ( q34 ; q11 ) chromosomal translocation and the consequent expression of the BCR-ABL fusion protein . Treatment of CML was revolutionized in 2001 with the development of the small-molecule inhibitor @DRUG$ mesylate ( IM ) , , , which binds to the @GENE$ kinase domain and that prevents its ability to phosphorylate target substrates , .", "label": "None"}
{"id": "24367701", "sentence": "This @GENE$ to the endoplasmic reticulum and has been shown to play a critical role in @DRUG$ ( RIG-I ) gene signaling , acting as a sensor of RNA virus infection [ ] . In fact , many elements of the regulatory pathways governing both the RIG-I pathway and IFN gene expression are themselves regulated by IFN . In turn , IFN may coordinate the upregulation of antiviral factors , as revealed by the A3G , @VARIANT$ , TRIM , tetherin and MxA mRNA expression levels in paired maternal blood and CB samples .", "label": "None"}
{"id": "22252115", "sentence": "In our study , carcinoma of esophagogastric junction rarely presents @GENE$ mutations , especially @DRUG$ associated mutations such as @VARIANT$ and delE746-A750 .", "label": "sensitivity"}
{"id": "25486409", "sentence": "As the second-generation , irreversible EGFR-TKIs , such as afatinib and dacomitinib , failed to overcome the resistance caused by @VARIANT$ , , other measures , such as @GENE$ dual targeting with cetuximab and @DRUG$ and third-geneneration , mutant-selective EGFR-TKIs – are being actively evaluated .", "label": "response"}
{"id": "23606169", "sentence": "SSCP analysis indicated KRAS WT status , which qualified him for concomitant targeted therapy ( @DRUG$ : first dose , 400 mg/m2 day 1 ; subsequent doses : 250 mg/m2 ) and chemotherapy ( irinotecan 180 mg/m2 day 1 , 5-fluorouracil 400 mg/m2 bolus and then 2,400 mg/m2 over 48 h ; leucovorin 200 mg/m2 before 5-fluorouracil ) . At first , partial remission was observed , but therapy was stopped after seven cycles due to clinical and radiological progression of the disease . As further genetic analysis showed , the patient did not have mutations in KRAS ( codons 12 , 13 , and 61 ) or @VARIANT$ @GENE$ .", "label": "resistance or non-response"}
{"id": "24885169", "sentence": "In addition , the presence of common activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene ( exon 19 deletion and exon 21 @VARIANT$ mutation ) confers strong sensitivity to @DRUG$ and erlotinib , which are selective tyrosine kinase inhibitors of EGFR [ , ] . These EGFR mutations are more commonly encountered in ADCs [ ] . Furthermore , the use of vascular endothelial growth factor ( @GENE$ ) inhibitors ( eg , bevacizumab ) has been demonstrated to be associated with an increased risk of fatal pulmonary hemorrhage in patients with SQC [ ] .", "label": "None"}
{"id": "23969856", "sentence": "The 6 DIV cortical neurons were treated for 24 h with 4 μg/ml of @DRUG$ or for 1 h with 10 nM of thapsigargin in the presence of @GENE$ inhibitor Q-VD-OPh , or left untreated . Immunoblot was probed with anti-Bak antibodies . The position of ∼20 kD N-Bak is shown on the lane of HeLa cells overexpressing the apoptotically inactive @VARIANT$ mutant .", "label": "None"}
{"id": "24137394", "sentence": "A chemotherapy regimen based on carboplatin , @DRUG$ and bevacizumab was initiated . A partial response was observed , but the treatment had to be stopped due to hematological toxicity . @GENE$ mutations were identified involving a mutation in exon 18 , @VARIANT$ .", "label": "None"}
{"id": "PMC4034024", "sentence": "Intensive , continuous insulin treatment during the first two weeks after the diagnosis of @VARIANT$ mellitus may improve beta-cell function during the subsequent year [ ] . More recent intervention trials used monoclonal antibody based therapies such as @DRUG$ ( anti-CD-20 ) [ ] , daclizumab ( anti-CD25 ) in combination with mycophenylate mofetil [ ] , anti-CD3 [ , , ] , and @GENE$ ] .", "label": "None"}
{"id": "25414829", "sentence": "The first example of a clinically relevant NSCLC driver oncogene was the identification of somatic mutations in the @GENE$ ( – ) .Common EGFR alterations ( the @VARIANT$ point mutation and exon 19 deletions ) are present in 10–30 % of patients with NSCLC and confer sensitivity to gefitinib , @DRUG$ , and afatinib .", "label": "sensitivity"}
{"id": "24959087", "sentence": "Again , the activity of this resistance mechanism could be suppressed through combined MET and BRAF or @GENE$ inhibition . Further evidence of the efficacy of combination therapy in overcoming resistance is demonstrated by NSCLC cell lines resistant to erlotinib and the MET inhibitor SU11274 , which display upregulation of both mTOR ( mammalian target of rapamycin ) and Wnt pathway components and restoration of sensitivity to EGFR/MET inhibition by the addition of @DRUG$ . A final mechanism of resistance in gastric cancer cell lines has been demonstrated when MET amplified SNU6838 gastric cancer cell lines were treated with the MET inhibitors PHA-665752 and PF2341066 ; a novel mutation occurred in the activation loop of MET , causing a conformal change that blocked inhibitor binding analogous to the gatekeeper mutations seen in EGFR ( @VARIANT$ ) following erlotinib treatment and in ABL ( T315I ) following imatinib .", "label": "None"}
{"id": "23292247", "sentence": "To further investigate the role of alcohol in the activation of the @GENE$ pathway , cell proliferation was examined in the alcohol- and/or MEK1/2 inhibitor U0126 treated @VARIANT$ cells .", "label": "None"}
{"id": "23864840", "sentence": "However , acquired resistance to EGFR-TKIs is inevitable due to various mechanisms , such as @VARIANT$ , c-Met amplification , activation of alternative pathways ( IGF-1 , HGF , PI3CA , @GENE$ [ ] ) , transformation to mesenchymal cells [ ] or small cell features [ ] , and tumor heterogeneity [ ] . A randomized trial comparing the irreversible ErbB-family blocker @DRUG$ versus placebo in patients with NSCLC after prior EGFR-TKI exposure failed to prove a benefit of overall survival [ ] .", "label": "None"}
{"id": "25382104", "sentence": "To compare their efficacy and binding pattern with our screened compounds we again docked FDA approved drugs with wild-type of @GENE$ . As shown in , DB07107 and DB06977 showed better docking scores than existing drugs while others showed results comparable to those of marketed drugs like @DRUG$ , bosutinib , bafetinib , dasatinib , nilotinib and imatinib . In the case of DB06977 , although one H_bond is missing ( Met318 ) with the wild-type of BCR-ABL complex compared to @VARIANT$ mutant type , it still exhibits a favorable binding score of −10.94 kcal/mol .", "label": "response"}
{"id": "25505694", "sentence": "The lack of efficacy could probably be related to the high concentrations of neratinib required in preclinical studies to inhibit EGFR @VARIANT$ and the limitations of clinical dosing . Dacomitinib Dacomitinib is an irreversible @GENE$ , HER2 and HER4 inhibitor with a higher kinase inhibition than gefitinib/erlotinib in both gefitinib/erlotinib-sensitive and in EGFR-T790M and HER2 mutated cell lines [ ] .", "label": "resistance or non-response"}
{"id": "15737014", "sentence": "Using this insight , new small-molecule inhibitors have been identified that retain activity against the majority of imatinib-resistant @GENE$ mutants [ , ] . For example , in CML , a commonly found mutation is a C→T single nucleotide change that replaces threonine with isoleucine at position 315 ( T315I ) in the ABL kinase domain [ , , ] . In GIST and HES , respectively , the analogous @VARIANT$ mutation in KIT and T674I mutation in PDGFR-alpha have been associated with acquired resistance to this drug [ , ] .", "label": "None"}
{"id": "24167634", "sentence": "These data support the role of EGFR in cell motility and invasiveness and suggest the importance of @GENE$ maintenance treatment after tumor progression . Of note , the continuous exposure of H1975 cells , carrying the @VARIANT$ mutation , to @DRUG$ did not modify their migratory phenotype , possibly because of the low affinity of the mutated receptor for this drug .", "label": "resistance or non-response"}
{"id": "17877814", "sentence": "Graph shows that the common L858R mutation confers higher autophosphorylation levels to @GENE$ than P848L and @VARIANT$ . Images show that , unlike L858R , these uncommon exon 21 mutants did not induce phosphorylation of endogenous Akt . @DRUG$ blocked L858R induced pAkt at 10 nM , and caused relocation of the ectopic protein into fibrils at 100 nM .", "label": "None"}
{"id": "21108851", "sentence": "Ponatinib ( AP24534 ) is a multitargeted BCR-ABL/SRC kinase inhibitor with potent in vitro activity against all tested mutants of @GENE$ including T315I , and clinical activity has been reported in patients with a T315I mutation [ - ] . Further clinical studies of ponatinib are ongoing , most notably a single-arm phase 2 study in patients with CML or Ph+ acute lymphoblastic leukemia ( ALL ) who either are resistant or intolerant to either dasatinib or @DRUG$ , or who harbor the @VARIANT$ mutation ( Ponatinib Ph+ ALL and CML evaluation [PACE ] ; NCT01207440 ) .", "label": "None"}
{"id": "24348666", "sentence": "Sasaki et al. reported that cells derived from pleural effusions of patients with EML4-ALK lung cancer who developed acquired resistance to @DRUG$ displayed the gatekeeper @VARIANT$ mutation and high levels of expression of @GENE$ ligands ( EGF and amphiregulin ) .", "label": "None"}
{"id": "24924344", "sentence": "@DRUG$ rs562 ( C/T ) Chr3 : 183637845 ABCC5 ( UTR3 ) 0.049494 0.392 rs3749445 ( A/G ) Chr3 : 183638506 ABCC5 ( UTR3 ) 0.044895 0.410 rs2292998 ( C/T ) Chr3 : 183663833 ABCC5 ( intronic ) 0.039882 0.277 rs1016752 ( C/G ) Chr3 : 183665062 ABCC5 ( intronic ) 0.039781 0.232 rs4148585 ( C/T ) Chr3 : 183670642 ABCC5 ( intronic ) 0.039781 0.283 rs6443924 ( A/G ) Chr3 : 183679532 ABCC5 ( intronic ) 0.039781 0.279 rs4148579 ( A/G ) Chr3 : 183685249 ABCC5 ( intronic ) 0.039781 0.279 rs939336 ( @GENE$ @VARIANT$ ) Chr3 : 183685534 ABCC5 ( exonic ) 0.039781 0.279 rs1132776 ( C/T = & gt ; A395A ) Chr3 : 183696402 ABCC5 ( exonic ) 0.044895 0.289 rs2313212 ( C/T ) Chr3 : 183700928 ABCC5 ( intronic ) 0.039781 0.279 rs4148575 ( C/T ) Chr3 : 183702275 ABCC5 ( UTR3 ) 0.044895 0.289 rs1846692 ( C/T ) Chr16 : 56671696 MT1A ( near - gene 5 ) 0.049494 0.360 rs35346959 ( A/G ) Chr16 : 56671867 MT1A ( near- gene 5 ) 0.044895 0.137 rs9922957 ( C/G ) Chr16 : 56672380 MT1A ( near - gene 5 ) 0.039781 0.185 rs9922409 ( A/G ) Chr16 : 56672400 MT1A ( near - gene 5 ) 0.04532 0.103 rs7190725 ( G/T ) Chr16 : 56673290 MT1A ( intronic ) 0.044895 0.170 rs8052394 ( A/G =&gt ; K51R ) Chr16 : 56673828 MT1A ( missense ) 0.044895 0.152 rs1800566 ( C/T = & gt ; P187S ) chr16 : 69745145 NQO1 ( exonic ) 0.039781 0.258 rs689455 ( A/C ) Chr16 : 69761661 NQO1 ( near- gene 5 ) 0.039781 0.242", "label": "None"}
{"id": "23937717", "sentence": "MPR expression induced by @DRUG$ can facilitate NK cell cytotoxicity in human lung cancer cells with @GENE$ L858R + @VARIANT$ resistance mutation .", "label": "resistance or non-response"}
{"id": "23717811", "sentence": "There is some evidence that in pilocytic astrocytomas , the fusion protein is associated with a favorable outcome ( Hawkins et al. , ) , while another series did not find any correlation with the BRAF fusion protein and disease progression ( @GENE$ et al. , ) . The prevalence of oncogenic BRAF V600E mutations in several solid tumors has led to the development of anti-cancer agents that specifically inhibit BRAF V600E . @DRUG$ or vemurafenib ( F. Hoffman-La Roche AG ) was the first inhibitor developed to demonstrate preferential activity against the BRAF @VARIANT$ mutant protein versus the wild-type protein .", "label": "None"}
{"id": "23864840", "sentence": "Another approach for @VARIANT$ mediated resistance is the dual inhibition of @GENE$ with afatinib and @DRUG$ , an EGFR blocking antibody resembling the synergistic combination of lapatinib and trastuzumab in ErbB2 positive breast cancer .", "label": "response"}
{"id": "25333255", "sentence": "Finally , the third line inhibitor @DRUG$ has been developed and shown to exhibit substantial efficacy in patients with CML in whom the polyresistant @GENE$ @VARIANT$ mutation is expressed in leukemic cells [ ] .", "label": "response"}
{"id": "25120654", "sentence": "Following the initial treatment , a mutation in the @GENE$ gene was identified ( exon 21 ; @VARIANT$ , in which the leucine at amino acid position 858 is replaced by arginine ; ) . The second-line chemotherapy was @DRUG$ ( 250 mg ) once a day , administered between March and July 2012 .", "label": "sensitivity"}
{"id": "22970367", "sentence": "The most common activating mutations ( ~90 % ) are in-frame deletions in exon 19 of EGFR and a missense mutation at 858 in exon 21 of EGFR resulting in an arginine to leucine substitution ( @VARIANT$ ) [ ] . Therapeutic agents targeting the EGFR signaling pathway , including two @GENE$ kinase inhibitors gefitinib and @DRUG$ , are clinically effective in treating lung cancer patients harboring these EGFR activating mutations [ – ] .", "label": "sensitivity"}
{"id": "17106442", "sentence": "In exon 21 , a missense point mutation substitutes an amino acid at position 858 ( @VARIANT$ ) . All such mutations result in conformational changes that lead to increased sensitivity to tyrosine kinase inhibitors . These results indicate that screening of patients for EGFR tyrosine kinase domain mutations before treatment with @DRUG$ or other @GENE$ inhibitors may predict the clinical benefit of the treatment .", "label": "sensitivity"}
{"id": "22382702", "sentence": "This was confirmed in vitro , and G12V mutated cancer cells were resistant to @DRUG$ , whereas @VARIANT$ mutated and KRAS wild-type cancer cells were sensitive .", "label": "None"}
{"id": "16187797", "sentence": "Although exon 20 mutations were not widely reported at first , recently five large-scale studies that sequenced EGFR exons 18 through 21 reported a total of 18 exon 20 insertions out of 350 @GENE$ mutations identified in 1,108 non-small-cell lung cancers [ – ] . Patients who responded to @DRUG$ and subsequently relapsed were found to have @VARIANT$ secondary mutations , also in exon 20 [ , ] .", "label": "resistance or non-response"}
{"id": "22719242", "sentence": "For each given position , we considered the mutation from the amino acid present in E. coli @GENE$ ( the “Ec” aminoacid ) to the amino acid “X” defined as the amino acid different from “Ec” that has the highest frequency ( largest number of occurrences in the sequence alignment ) when there @DRUG$ a @DRUG$ at position 34 . Large positive values for the score indicate that the P34H substitution shifts the statistics strongly towards amino acid X . We retained for experimental analysis the 10 positions ( and the corresponding Ec→X mutations ) for which the score was positive ( see ) : I4V , D26E , W28Y , E30P , I38L , @VARIANT$ , N59D , D61T , I75Y , L94R .", "label": "None"}
{"id": "16173832", "sentence": "Citation : Gow CH , Shih JY , Chang YL , Yu CJ ( 2005 ) Acquired gefitinib-resistant mutation of @GENE$ a chemonaive lung adenocarcinoma harboring gefitinib-sensitive mutation @VARIANT$ .", "label": "sensitivity"}
{"id": "21333004", "sentence": "Also , we found that @GENE$ model at lower concentrations of EGF is as sensitive to @DRUG$ for ERK phosphorylation as @VARIANT$ model A ( data not shown ) .", "label": "sensitivity"}
{"id": "25228590", "sentence": "The strategies described here could also benefit patients with ALK translocated cancers , where the @VARIANT$ mutation modulates @DRUG$ resistance and the same signaling pathways that drive tumor cells without translocated @GENE$ are active .", "label": "resistance"}
{"id": "22166800", "sentence": "Indeed , @VARIANT$ and @DRUG$ combination induced apoptosis and inhibited several signal transduction pathways that promote cell survival , including @GENE$ , TGFβ , NFkB and PI3K-AKT .", "label": "None"}
{"id": "21814597", "sentence": "The most common PDGFRA mutation , @VARIANT$ in exon 18 , is resistant to imatinib. , , In contrast , the substitution V561D in exon 12 results in an isoform of @GENE$ that is highly sensitive to imatinib. , Lasota et al. and Heinrich et al. reported imatinib sensitivities for a deletion/substitution ( SPDGHE566-571R ) and an in-frame insertion mutation ( ER561-562 ) in exon 12 .", "label": "resistance or non-response"}
{"id": "15737014", "sentence": "Using this insight , new small-molecule inhibitors have been identified that retain activity against the majority of imatinib-resistant BCR-ABL mutants [ , ] . For example , in CML , a commonly found mutation is a C→T single nucleotide change that replaces threonine with isoleucine at position 315 ( T315I ) in the ABL kinase domain [ , , ] . In GIST and HES , respectively , the analogous T670I mutation in KIT and @VARIANT$ mutation in @GENE$ have been associated with acquired resistance to this drug [ , ] .", "label": "resistance"}
{"id": "23691449", "sentence": "Some of the molecular mechanisms of acquired resistance include T790M second mutation , mesenchymal epithelial transition factor ( MET ) amplification , ATP binding cassette (ABC)-G2 transporter ( ABCG2 ) and @GENE$ , insulin-like growth factor (IGF) binding protein-3 ( IGFBP3 ) downregulation , as well as ERBB3 activation . T790M mutation The @VARIANT$ second mutation accounts for half of all resistances to gefitinib and @DRUG$ [ ] .", "label": "None"}
{"id": "PMC3920415", "sentence": "One important issue raised by this case concerns acquired resistance to @DRUG$ . Recent data have shown that almost all patients with known @GENE$ mutations who initially respond to TKIs , subsequently become resistant due to emergence of mutations , such as @VARIANT$ ( in 50 % of cases ) and c-MET overexpression .", "label": "resistance or non-response"}
{"id": "25505694", "sentence": "Neratinib is an oral , irreversible inhibitor of both EGFR and HER2 ; in preclinical studies conducted on cell lines with both an activating @GENE$ mutation and the @VARIANT$ , neratinib was more effective at suppressing cell proliferation than @DRUG$ [ ] .", "label": "resistance or non-response"}
{"id": "22719242", "sentence": "For each given position , we considered the mutation from the amino acid present in E. coli thioredoxin ( the “Ec” aminoacid ) to the amino acid “X” defined as the amino acid different from “Ec” that has the highest frequency ( largest number of occurrences in the sequence alignment ) when there @DRUG$ a @DRUG$ at position 34 . Large positive values for the score indicate that the @GENE$ substitution shifts the statistics strongly towards amino acid X . We retained for experimental analysis the 10 positions ( and the corresponding Ec→X mutations ) for which the score was positive ( see ) : I4V , D26E , W28Y , E30P , I38L , K57A , N59D , @VARIANT$ , I75Y , L94R .", "label": "None"}
{"id": "20459863", "sentence": "Clinical responsiveness to @DRUG$ and erlotinib in NSCLC have been shown to correlate with somatic mutations in the @GENE$ gene , which result in increased sensitivity to inhibition of growth by the drugs [ , - ] . EGFR mutations have been found more frequently in non smoking East Asian women with adenocarcinoma with bronchioalvelar features [ , - ] . A protocol based on mutant enriched PCR followed by primer extension of the PCR products was used to detect EGFR @VARIANT$ mutation in NSCLC [ ] .", "label": "resistance or non-response"}
{"id": "22034911", "sentence": "The 16 mutations are located around the kinase active site and can be categorized into five groups , involved in either direct or indirect contacts with @DRUG$ . The three mutations that conferred the strongest resistance were the L1196M gatekeeper residue , S1206R at the solvent front , and @VARIANT$ near the DFG motif . @GENE$ cells expressing native EML4-ALK grew robustly as subcutaneous xenografts in SCID mice .", "label": "None"}
{"id": "23493838", "sentence": "A complete hematological response and a major cytogenetic response were observed broadly across the @GENE$ mutants , including individuals harboring the dasatinib-resistant @VARIANT$ , the nilotinib-resistant Y253H , and F359C/I/V mutations , but not T315I . Nine individuals developed new mutations in the course of bosutinib treatment ( V299L , n = 4 ; L248V , n = 2 ; T315I , n = 2 ; F359C , n = 1 ; G250E , n = 1 ) and eight of these individuals discontinued @DRUG$ because of progressive disease or unsatisfactory response .", "label": "None"}
{"id": "23690929", "sentence": "HGF induces resistance to irreversible EGFR-TKIs and mutant EGFR-selective TKIs , which were developed to overcome @VARIANT$ mediated EGFR-TKI resistance . Recent clinical trials with irreversible TKI monotherapy failed to demonstrate an objective response in EGFR mutant lung cancer patients that were refractory to treatment with the reversible EGFR-TKIs—gefitinib and @DRUG$ . These findings suggest that co-existence of altered @GENE$ signaling contributes to the unfavorable response to irreversible EGFR-TKIs in these patients .", "label": "None"}
{"id": "23773228", "sentence": "@DRUG$ is a @GENE$ inhibitor with activity against all IM-resistant mutants , including the @VARIANT$ mutation .", "label": "response"}
{"id": "23801357", "sentence": "Ponatinib ( @DRUG$ ) is a novel pan–BCR-ABL inhibitor developed using a computational and structure based approach.– It was designed to bind to and inhibit native @GENE$ and BCR-ABL mutants that can arise during treatment with other TKIs and cause resistance , including the @VARIANT$ mutant .", "label": "response"}
{"id": "23579627", "sentence": "So , we suggest that the patient had acquired @VARIANT$ mutation in addition to the original L858R/L861Q after @DRUG$ retreatment . We report an adenocarcinoma case responded three times to reversible and irreversible @GENE$ .", "label": "resistance or non-response"}
{"id": "17973572", "sentence": "BIM expression correlated with the amount of apoptosis in @VARIANT$ , L858R-L747S , and L858R-T790M cells . ( B ) Modulation of signaling following @DRUG$ treatment in @GENE$ cells expressing EGFR mutants .", "label": "None"}
{"id": "22928112", "sentence": "In order to study the effects of the most common EGFR mutations in vivo , Politi et al. created doxycylcine inducible , transgenic mice that expressed an exon 19 deletion mutant or the @VARIANT$ mutant in type II pneumocytes [ ] . Not surprisingly , both models could recapitulate the human lung adenocarcinoma development , and were responsive to dox removal , or treatment with @DRUG$ . Additional studies revealed an @GENE$ network in the plasma of these mice that included a 21-protein-network signature [ ] .", "label": "sensitivity"}
{"id": "21687596", "sentence": "Inukai et al. hypothesized that gefitinib treatment may lead to the selection of @VARIANT$ mutant cells and that even a small fraction of T790M positive tumor cells at the beginning of treatment could lead to clinical @DRUG$ resistance because of selective proliferation of T790M mutant cells . Maheswaran et al. proved this hypothesis by analyzing circulating tumor cells using a highly sensitive method [ ] . They analyzed pretreatment tumor samples from 26 NSCLC cases with activating @GENE$ gene mutations and found low levels of T790M in 10 of these cases ( 38 % ) .", "label": "resistance or non-response"}
{"id": "23788917", "sentence": "In case of occurrence of both L858R and T790M mutations , the concentration of @DRUG$ should be three times higher in order to achieve a therapeutic effect . Analysis of the EGFR structure in patients harbouring the @VARIANT$ mutation suggests the presence of an additional side chain , localised near the @GENE$ TKI binding site [ ] .", "label": "None"}
{"id": "23937717", "sentence": "Collectively , these results suggested that @DRUG$ and NK cells could up-regulate the MHC-I in human lung cells with wild type @GENE$ , while not significantly influence the MHC-I expression on human lung cells with wild type EGFR @VARIANT$ + T790M .", "label": "sensitivity"}
{"id": "24339922", "sentence": "The secondary @VARIANT$ mutation was not detected in the HCC827/GR and HCC827/ER cell lines by sequencing ( data not shown ) . To assess the inhibitory effects of EGFR-TKIs on MET further , @GENE$ and their downstream signals , HCC827 , HCC827/GR and HCC827/ER cells were treated with @DRUG$ and erlotinib for 72 h .", "label": "resistance or non-response"}
{"id": "15737014", "sentence": "A tumor-rich pre-treatment specimen did not demonstrate @GENE$ mutations other than the del E746–A750 exon 19 deletion ; specifically , in exon 20 , no secondary changes were detected ( C , upper panels ; ) . However , analysis of DNA from cells in the pleural effusion that developed after treatment with @DRUG$ showed the C→T mutation at nucleotide 2369 in exon 20 ( C , lower panels ; ) , corresponding to the @VARIANT$ mutation described above .", "label": "resistance or non-response"}
{"id": "25532027", "sentence": "In particular , @GENE$ inhibitors ( EGFR-TKIs ) , such as gefitinib and @DRUG$ , demonstrated marked clinical activity against NSCLC harboring an activating EGFR mutation ( – ) . Additionally , some reports suggest that the EGFR @VARIANT$ mutation may not be rare and may exist in a small population of in tumor cells before TKI treatment ( – ) .", "label": "resistance or non-response"}
{"id": "24894453", "sentence": "Although high-level expression of @GENE$ ligands and/or increased EGFR gene copy numbers may be predictive markers for antitumor response by cetuximab in colon cancer [ - ] , and patients with RAS driven cancers are known not to benefit from cetuximab treatment , a clear molecular explanation of cancer response to @DRUG$ has remained elusive . Genomic studies identify @VARIANT$ mutant in colorectal carcinomas", "label": "sensitivity"}
{"id": "24594844", "sentence": "cDzT remains its suppression effect on @GENE$ @VARIANT$ expression and downstream signaling after EGF treatment in H1975TM/LR . Click here for additional data file . Combined treatment of cDzT and @DRUG$ significantly suppresses the phosphorylation of STAT3 , AKT , and ERK in CL97TM/GA cells .", "label": "response"}
{"id": "22995644", "sentence": "We next tested whether @DRUG$ could induce PRL-3 protein down-regulation in @GENE$ murine hematopoietic cells engineered to express either wild-type , or the Imatinib resistant @VARIANT$ mutant P210 BCR-ABL .", "label": "None"}
{"id": "17927446", "sentence": "Specifically , we examined the relationship between levels of @GENE$ and Bim in tumors induced in transgenic mice that conditionally express mutant @VARIANT$ EGFRs in lung epithelial cells under the control of tetracycline regulation [ ] . We previously showed that treatment with @DRUG$ eliminated disease within lung tumor bearing animals [ ] .", "label": "sensitivity"}
{"id": "15736989", "sentence": "T790M in the context of either transiently expressed wild-type @GENE$ or the mutant alleles del L474–E749 ; A750P or @VARIANT$ impairs inhibition by @DRUG$ or erlotinib as assessed by autophosphorylation .", "label": "sensitivity"}
{"id": "21182469", "sentence": "cAMP ( cyclic adenosine monophosphate ) , cGMP ( cyclic guanosine monophosphate ) , LTC4 ( leukotriene C4 ) , DNP-SG ( S- ( 2,4-dinitrophenyl ) -glutathione ) , E13S ( estrone 3-sulfate ) , DHEAS ( dehydroepiandrosterone 3-sulfate ) , and E217βG ( estradiol 17-β-D-glucuronide ) . ( B ) Anticancer drugs that are transported by ABCC11 . @GENE$ ( pemetrexed ) , MTX , ( methotrexate ) , @DRUG$ ( Cytosine arabinoside ) , PMEA ( 9’- ( 2’-phosphonyl-methoxyethyl ) adenine ) are substrate for ABCC11 .", "label": "None"}
{"id": "18382681", "sentence": "For the @DRUG$ validation , an independent dataset of 24 samples treated neoadjuvantly with docetaxel was used . Application of oncogenic pathway activation and alternative chemotherapeutic agent signatures Oncogenic pathway signatures described previously were used to create predictive probability values for activation of the β-catenin , @VARIANT$ , Myc , PI3K , Ras , and Src pathways .", "label": "None"}
{"id": "24386407", "sentence": "Lung cancers with mutations that activate @GENE$ including exon 19 deletions and the exon 21 @VARIANT$ point mutation , respond to the reversible EGFR-tyrosine kinase inhibitors ( EGFR-TKIs ) gefitinib and @DRUG$ [ ] .", "label": "sensitivity"}
{"id": "24939055", "sentence": "The EGF receptor tyrosine kinase inhibitors ( @GENE$ ) @DRUG$ and erlotinib have shown marked therapeutic effects against NSCLCs with EGFR activating mutations , such as exon 19 deletions and @VARIANT$ point mutations [ ] .", "label": "sensitivity"}
{"id": "21687596", "sentence": "An experiment using cell lines transfected concurrently with activating mutations and a @VARIANT$ mutation also proved that resistance to gefitinib and @DRUG$ is evident when this mutation is present [ – ] . Analogous secondary mutations of the BCR-ABL gene in case of chronic myelogenous leukemia ( CML ) [ ] and the KIT gene in case of gastrointestinal stromal tumor [ ] have previously been reported as mechanisms of imatinib resistance , which is also a TKI . The structural similarity between ABL and EGFR tyrosine kinases is considerably high , and T315I in ABL corresponds to T790M in @GENE$ [ ] .", "label": "resistance or non-response"}
{"id": "21188111", "sentence": "In a recent report , the c-KIT mutation @VARIANT$ was associated with resistance to multiple @GENE$ inhibitors including @DRUG$ , nilotinib , and sorafenib , but objective tumor responses could be induced in 2 patients bearing the KIT L576P mutation after treatment with dasatinib .", "label": "resistance or non-response"}
{"id": "25364578", "sentence": "Studies of ALK rearranged lung cancers with acquired resistance to @DRUG$ have identified @GENE$ fusion gene amplification and secondary ALK TK domain mutations ( L1196M and @VARIANT$ ) in about one third of cases .", "label": "resistance"}
{"id": "24501009", "sentence": "The remaining members of the HER family comprise @GENE$ and HER4 tyrosine kinases , and the kinase‐null HER3 .1 HER family members act together via hetero‐ and homodimerization to enable downstream signaling pathways modulating a range of cellular activities , including growth , proliferation , differentiation , and migration . In contrast to patients with EGFR‐mutation‐positive tumors , patients with KRAS‐mutant NSCLC are unlikely to respond to gefitinib or @DRUG$ and do not have an improved progression‐free survival ( PFS ) compared with those who have placebo following erlotinib therapy . Dacomitinib ( PF‐00299804 ) is a potent , irreversible , oral small‐molecule inhibitor of HER1/EGFR , HER2 , and HER4 tyrosine kinases with antitumor activity in both gefitinib‐sensitive and gefitinib‐resistant , including EGFR @VARIANT$ , preclinical NSCLC models .", "label": "None"}
{"id": "24281101", "sentence": "In contrast to sorafenib , @DRUG$ is a selective inhibitor of the oncogenic @VARIANT$ mutant @GENE$ kinase .", "label": "None"}
{"id": "22815900", "sentence": "Partial Loss of the Activating Mutant @GENE$ ( @VARIANT$ ) Gene in Erlotinib- or Gefitinib-resistant Cell Lines from 11–18", "label": "sensitivity"}
{"id": "23785245", "sentence": "Similar to mutations in @GENE$ ( T315I ) or in KIT ( T670I ) that underlie resistance to @DRUG$ , @VARIANT$ is thought to interfere with the binding of EGFR-TKIs at the adenosine triphosphate binding cleft of EGFR . , , On the other hand , the affinity of this cleft for adenosine triphosphate is increased by T790M .", "label": "None"}
{"id": "25580271", "sentence": "When cross-over to EGFR tyrosine kinase inhibitor therapy was examined , 75 % of patients who received cisplatin and pemetrexed received an EGFR tyrosine kinase inhibitor and 56 % of patients who received cisplatin and @DRUG$ received an @GENE$ tyrosine kinase inhibitor . The rate of second-line EGFR tyrosine kinase inhibitors in countries with insurance coverage was 91 % and without insurance coverage was 52 % . Overall survival of patients with common EGFR mutations ( defined as exon 19 deletion and exon 21 @VARIANT$ point mutation ) in LUX-3 , LUX-6 , and combined cohorts [ ]", "label": "None"}
{"id": "22740817", "sentence": "Whether the survival difference between BRAF WT and mutant patients is only due to the fact that @GENE$ mutational status has prognostic value or if BRAF mutational status may also be predictive for a combination treatment with @DRUG$ and temozolomide can not be concluded definitively from our data set , but should be prospectively studied . If the 2 most frequent BRAF mutations , V600E and @VARIANT$ , are the alterations with predictive value in melanoma patients , techniques identical or similar to method 1 described in this paper may be the detection system of choice .", "label": "None"}
{"id": "25333949", "sentence": "Compound Human Cell Line MCF7 HOS A549 G361 HeLa A2780 @VARIANT$ 22Rv1 @GENE$ HEP220 1 3.1±0.2* 3.3±0.1* 20.7±0.1 3.5±0.2* 22.0±0.6 4.8±0.1* 5.2±0.3* 3.5±0.1* 0.8±0.1 24.0±1.9 2 0.6±0.1* 0.9±0.2* 17.2±0.7 3.4±0.1* 16.0±0.2 4.0±0.2* 5.3±0.4* 4.0±0.1* 0.8±0.1 18.5±1.5 3 2.2±0.2* 4.0±0.6* 21.4±0.2 3.4±0.2* 20.7±0.2 4.6±0.3* 5.3±0.4* 21.0±0.7 1.0±0.1 24.1±2.4 4 4.0±0.9* 1.8±0.3* & gt ; 20 3.5±0.2* 14.3±0.2 4.6±0.2* 5.1±0.3* 3.5±0.2* 1.7±0.1 23.7±2.1 5 & gt ; 50 2.9±0.1* 18.3±0.5 3.5±0.2* 22.8±0.5 4.4±0.3* 5.0±0.3* 3.7±0.1* 1.4±0.1 19.0±1.8 cisplatin 17.9±1.2 20.5±0.1 & gt ; 50 5.3±0.2 & gt ; 50 11.5±0.5 27.0±1.5 26.9±1.2 n.d. & gt ; 50", "label": "None"}
{"id": "24944584", "sentence": "Somatic mutations included two different @GENE$ mutations : an activating mutation in a dominant tumor clone as well as a second @VARIANT$ mutation present in an erlotinib-resistant subclone .", "label": "resistance or non-response"}
{"id": "23292247", "sentence": "The phosphorylation of ERK1/2 , on the other hand , was inhibited during the entire observation period and was not affected by activated @GENE$ . When @VARIANT$ cells were exposed to @DRUG$ , the cell numbers exhibited a greater increase than that of the unexposed cells after 12 and 24 h of incubation .", "label": "None"}
{"id": "25344919", "sentence": "More recently , Hall et al. reported that melanoma cells were addicted to glycolytic activity , which was up-regulated by the presence of mutant @GENE$ ( @VARIANT$ ) in these cancer cells [ ] . Our current data of in vitro and in vivo model assays indicated that , while overexpression of Id1 promoted the cancer growth of NSCLC cells , co-treatment of paclitaxel and @DRUG$ caused a greater effect of reduction on cancer cell growth in the Id1 overexpressing NSCLC cells compared with the control cells ( Figure and ) .", "label": "None"}
{"id": "23109866", "sentence": "Pietanza et al. [ ] Phase II XL647 41 patients with relapsed or recurrent advanced NSCLC who progressed after ≥ 12 weeks of stable disease or response to erlotinib or @DRUG$ and/or those patients with a documented @GENE$ @VARIANT$ Objective RR The objective RR was 3 % , 67 % of the patients harbored T790M had progression of disease , while14 % of those without this mutation , 11 patients ( 28 % ) had a dose reduction due to toxicity .", "label": "resistance or non-response"}
{"id": "25025064", "sentence": "@VARIANT$ NA£ SD 99 Systemic ( bone marrow ) 3 49 c-ALL GMALL-protocol , alloSCT , and @DRUG$ 28 Facial palsy headache Clinical signs and symptoms , csf @GENE$ qPCR , and positive csf cytology on 2nd relapse Intrathecal triple therapy∗ [ d+848 , d+851 , d+855 , d+858 , d+864 , d+871 , d+878 , d+892 , d+1310 , d+1421 , d+1531 , d+1544 , d+1547 , d+1551 ]", "label": "None"}
{"id": "20684776", "sentence": "The promoter of the cyclin A1 gene , CCNA1 is not @VARIANT$ dependent and , consistently , increasing doses of Roscovitine did not repress cyclin A1 basal transcription levels in contrast to cyclins A2 , B , D and E . However , we demonstrated that Roscovitine at doses preferentially inhibiting CDK2 but not CDK7 and 9 completely abolished cyclin A1 DNA damage induced upregulation , thus suggesting that residual CDK2 activity is required for cyclin A1 upregulation . In addition Roscovitine co-administered with @DRUG$ was able to largely modify the patterns of cell cycle phase distribution in comparison to doxorubicin only treatment .", "label": "None"}
{"id": "24386407", "sentence": "Several strategies have been proposed to overcome resistance to reversible EGFR-TKIs , including treatment with @DRUG$ , an anti-EGFR antibody [ ] , @GENE$ inhibitors [ ] , PI3K/mTOR inhibitor [ ] , and mutant-selective EGFR-TKIs [ ] . Of them , mutant-selective EGFR-TKIs have shown activity not only against tumors harboring exon19 deletions and the L858R mutation , but against tumors with the @VARIANT$ resistance mutation .", "label": "None"}
{"id": "25025064", "sentence": "@VARIANT$ 406 CR with MRD positivity 431 Systemic ( intracerebral chloromas ) 2 19 c-ALL GMALL-protocol , alloSCT , and dasatinib 17 Headache and anisocoria Clinical signs and symptoms , csf cytology , csf @GENE$ qPCR , and decrease in csf donor chimerism Intrathecal triple therapy∗ [ d+10 , d+29 , d+52 , d+78 ] , 375 mg/m2 rituximab i.v . [ d+30 , d+38 , d+53 ] 2 mg @DRUG$ i.v .", "label": "None"}
{"id": "24348666", "sentence": "Although the resistant cell line @GENE$ does not have the EGFR @VARIANT$ mutation , it was found to have MET amplification . MET is a receptor tyrosine kinase that binds to hepatocyte growth factor (HGF) and is associated with the development of various human cancers . Therefore , EGFR-TKIs fail to inhibit the PI3K/Akt pathway dependent growth signal because the constitutive phosphorylation of HER3 by MET occurs independent of EGFR activation , which causes the cells to acquire resistance to @DRUG$ .", "label": "None"}
{"id": "PMC4041556", "sentence": "Second-generation @GENE$ TKIs – such as neratinib , afatinib and dacomitinib – are effective in preclinical gefitinib- and erlotinib-resistant EGFR @VARIANT$ models , but to date their delivery in EGFR TKI-resistant patients have shown disappointing results in the clinic .", "label": "resistance or non-response"}
{"id": "22038681", "sentence": "Preliminary results from an ongoing phase 1 dose-escalation study of the multikinase , @GENE$ inhibitor ponatinib ( AP24534 ) showed antileukemic activity in patients with refractory CML , including patients with the @VARIANT$ mutation . Phase 1 and 2 trials of ponatinib are ongoing in patients with refractory CML and acute lymphoblastic leukemia . Danusertib ( PHA-739358 ) is a multikinase aurora inhibitor with in vitro activity against wild-type ABL and ABL/T315I ; preliminary results from an ongoing phase 1 dose-escalation study indicate antileukemic activity in patients with AP or BC who failed imatinib and/or nilotinib or @DRUG$ .", "label": "None"}
{"id": "25414829", "sentence": "The first example of a clinically relevant NSCLC driver oncogene was the identification of somatic mutations in the @GENE$ ( – ) .Common EGFR alterations ( the @VARIANT$ point mutation and exon 19 deletions ) are present in 10–30 % of patients with NSCLC and confer sensitivity to gefitinib , erlotinib , and @DRUG$ .", "label": "sensitivity"}
{"id": "24244732", "sentence": "Previously , we have biochemically characterised other point mutations in Munc18 that affect binding to other proteins including R39C ( inhibits binding to closed-conformation syntaxin ) [ , ] , P242S ( inhibits binding to Mint proteins ) [ ] and E466K ( enhances binding to @GENE$ ) [ ] . Despite a strong reduction in @DRUG$ sensitivity , worms that express the unc-18 @VARIANT$ mutation have relatively normal , but statistically elevated locomotion rates [ ] .", "label": "None"}
{"id": "17973572", "sentence": "To prove the functional significance of the @VARIANT$ mutation , we generated Ba/F3 cell lines stably expressing mutant @GENE$ constructs [ ] . These cell lines , including L858R-L747S , proliferated in the absence of IL3 . Ba/F3-L858R cells were extremely sensitive to gefitinib ( D ) , whereas Ba/F3-L858R-T790M cells were highly resistant up to 1 μM @DRUG$ .", "label": "None"}
{"id": "19680652", "sentence": "However , the acquired resistance is not completely explained by the @VARIANT$ mutation in all cases [ ] . The presence of heterogenous malignant clones with different EGFR mutation status may confer differential sensitivity to the two EGFR-TKIs [ ] . Also , the different treatment efficacy between the two @GENE$ has been proposed to be related to drug pharmacokinetics [ ] , with @DRUG$ given at largely sub-maximal tolerated dose ( MTD ) in contrast to erlotinib at MTD .", "label": "resistance or non-response"}
{"id": "17927446", "sentence": "Here , tumor bearing transgenic animals ( as determined by magnetic resonance imaging ) were treated with a single dose of vehicle ( n = 5 ) or @DRUG$ ( 50 mg/kg ; n = 5 ) intraperitoneally and humanely killed 13 h later . Lungs from all EGFR-transgenic animals expressed the induced oncoprotein , as measured by immunoreactivity of lysates with antisera against the specific @VARIANT$ @GENE$ [ ] ( A ) .", "label": "sensitivity"}
{"id": "21646685", "sentence": "In contrast , a helical domain mutant ( @VARIANT$ ) enhanced transformation without inducing Heregulin expression [ ] . Therefore , in @GENE$ subtype breast cancers with PIK3CAH1047R or other kinase domain mutant alleles , therapy with Herceptin/Trastuzumab together with an antibody that blocks Heregulin could be particularly effective .", "label": "None"}
{"id": "15737014", "sentence": "Since tumor specimens from three additional patients with acquired resistance to EGFR tyrosine kinase inhibitors did not demonstrate the @VARIANT$ mutation , this specific lesion does not account for all mechanisms of acquired resistance to gefitinib or erlotinib . Given the paradigm established with @DRUG$ , other drug-resistance mutations in @GENE$ , either within or outside the tyrosine kinase domain , are likely to exist .", "label": "None"}
{"id": "25566076", "sentence": "Anti-nociceptive tolerance induced by morphine , meperidine , and @DRUG$ was shown to be reduced by PKC inhibitors while DAMGO induced tolerance and MOR desensitization was shown to rely on @GENE$ ( Hull et al. , ) . Whereas in vitro experiments showed that S375 is phosphorylated by GRK5 upon morphine exposure ( Doll et al. , ) and S375 phosphorylation plays a major role in MOR desensitization ( Schulz et al. , ) , @VARIANT$ knock-in mice still present anti-nociceptive tolerance upon acute and chronic exposure to morphine ( Grecksch et al. , ) .", "label": "None"}
{"id": "23437362", "sentence": "Metformin , like rapamycin , virtually abolished mTORC1 activation induced by insulin and neurotensin in PANC-1 and MiaPaCa-2 cells ( pS6K , pS6 in ) without changing the total levels of either @VARIANT$ or S6 . However , metformin did not over stimulated @GENE$ phosphorylation on Ser473 in the PDAC cells ( p-Akt473 in ) , a result strikingly different from that obtained with rapamycin and @DRUG$ .", "label": "None"}
{"id": "24555578", "sentence": "Here we reported the autopsy case of a patient whose brain metastases responded well to @DRUG$ , even after acquiring resistance to @GENE$ at extracranial sites . An analysis of the EGFR mutation using a PNA-LNA PCR clamp method showed that no resistant mutations ( @VARIANT$ ) were detected in the sites of brain metastasis , although this mutation was detected in the extracranial sites .", "label": "resistance or non-response"}
{"id": "24982846", "sentence": "@DRUG$ BCR/ABL1 Philadelphia chromosome [ t ( 9 ; 22 ) ] positive , @GENE$ @VARIANT$ mutation Indications and usage , warnings and precautions , adverse reactions , use in specific populations , clinical pharmacology , clinical studies", "label": "response"}
{"id": "21034468", "sentence": "Since @DRUG$ exposure causes the accumulation of intracellular oxygen species ( ROS ) and many biological effects of ethanol are believed to be mediated by ROS , we hypothesize that @VARIANT$ may inhibit ethanol induced migration/invasion of breast cancer cells .", "label": "None"}
{"id": "24789720", "sentence": "In study conducted by Janjigian et al. all patients treated with afatinib and @DRUG$ achieved disease control , and part of them ( 36 % ) partial response . Additionally , 4 of 13 patients ( 31 % ) with @VARIANT$ mutations gained confirmed partial response after combined therapy with monoclonal antibody and irreversible @GENE$ [ ] .", "label": "response"}
{"id": "15737014", "sentence": "Importantly , we find that the T790M mutation confers drug resistance not just to wild-type EGFR but also to mutant EGFRs associated with clinical responsiveness to @GENE$ tyrosine kinase inhibitors [ , , ] . In tumors from patients not treated with either @DRUG$ or erlotinib , the 2369 C→T mutation ( @VARIANT$ ) appears to be extremely rare .", "label": "resistance or non-response"}
{"id": "23994953", "sentence": "Intense research efforts over the past few years have identified two major mechanisms of acquired resistance to gefitinib/erlotinib : secondary resistance mutations ( e.g. , @VARIANT$ ) and “oncogene kinase switch” systems ( e.g. , MET amplification and AXL activation ) . However , the precise mechanisms underlying acquired resistance in the 30–40 % of EGFR TKI-resistant @GENE$ mutated tumors that do not carry secondary resistance mutations or MET amplification remain largely unclear .", "label": "resistance or non-response"}
{"id": "19738166", "sentence": "Di Nicolantonio et al. ( ) also demonstrated that introduction of the BRAF @VARIANT$ allele could confer resistance to either @DRUG$ or panitumumab in wild-type @GENE$ colorectal cancer cells .", "label": "resistance or non-response"}
{"id": "15737014", "sentence": "We show here , through molecular analysis of tumor material from three patients and one NSCLC cell line , as well as additional biochemical studies , that acquired clinical drug resistance to gefitinib or @DRUG$ is indeed associated with the @VARIANT$ mutation . Importantly , we find that the T790M mutation confers drug resistance not just to wild-type EGFR but also to mutant EGFRs associated with clinical responsiveness to @GENE$ tyrosine kinase inhibitors [ , , ] .", "label": "resistance or non-response"}
{"id": "17973572", "sentence": "A similar clinical benefit is observed in patients with lung cancers harboring the two most common EGFR activating mutations , @VARIANT$ and exon 19 deletions [ – , ] . The striking initial response to small molecule tyrosine kinase inhibitors is thought to stem from the phenomenon of “oncogene addiction” [ ] , and a common signaling cascade may be involved in the apoptosis induced by multiple TKIs [ ] . Rapid inactivation of phosphorylated ERK , AKT , and STAT3/5 , and the delayed accumulation of phosphorylated p38 are commonly observed in SRC- , @GENE$ , and EGFR dependent cells after exposure to the specific inhibitors SU6655 , imatinib , and @DRUG$ , respectively [ ] .", "label": "None"}
{"id": "23776354", "sentence": "Activating mutations Frequency at diagnosis , Predictive value for @DRUG$ Secondary mutations of imatinib resistance , – Predictive value for sunitinib @GENE$ Exon 9 10 % 70 % –75 % 58 % Exon 11 67 % 90 % –95 % 34 % Exon 13 1 % ± Yes + Exon 14 0 % Yes + Exon 17 1 % ± Yes − Exon 18 0 % Yes − PDGFRA 33 % –60 % Exon 12 1 % + Exon 14 & lt ; 1 % + Exon 18 5 % ± excepted for @VARIANT$ Yes − for D842V", "label": "None"}
{"id": "23937717", "sentence": "Therapeutic significance of our finding is that administration of @DRUG$ may offer a novel adjuvant strategy to enhance NK cells based immunotherapy in NSCLC with @GENE$ @VARIANT$ + T790M resistance mutation .", "label": "sensitivity"}
{"id": "15737014", "sentence": "Analogously , the @VARIANT$ mutation , in conjunction with the drug-responsive del L747–E749 ; A750P EGFR mutant , prevents inhibition of @GENE$ by @DRUG$ ( C ) .", "label": "resistance or non-response"}
{"id": "22363766", "sentence": "A second therapeutic strategy thus adds various drugs or antibodies capable of inhibiting c-MET ( e.g. crizotinib , foretinib , ARQ 197 , MetMAb ) to first- ( @DRUG$ ) or second- ( PF-00299804 ) generation @GENE$ , , . c-MET is a proto-oncogene that encodes a protein known as hepatocyte growth factor receptor (HGFR) that possesses tyrosine-kinase activity . Recent research has indicated a reciprocal and complementary relationship between @VARIANT$ and MET amplification .", "label": "resistance or non-response"}
{"id": "24964744", "sentence": "MCF10a cells containing the PI3K mutation H1047R showed little sensitivity to single agent sirolimus , and in combination with EGFR inhibitors were still seen to be more resistant than their parental counterpart , and were more resistant than MCF10a cells containing the @GENE$ @VARIANT$ mutation . Chou and Talalay combination indices for each cell line examined @DRUG$ + ZSTK474 Erlotinib + ZSTK474 Gefitinib + Rapamycin Erlotinib + Rapamycin Gefitinib + ZSTK474 Erlotinib + ZSTK474 Gefitinib + Rapamycin Erlotinib + Rapamycin", "label": "resistance or non-response"}
{"id": "23994953", "sentence": "Indeed , the fact that the combination of erlotinib plus IGF-1R inhibitors ( I-OMe-AG538 or AG1024 ) fully prevents the acquired erlotinib-resistant phenotype is consistent with IGF-1R playing a major role in this process . While preparing this manuscript , Cortot et al. reported that PC-9 derived clones with acquired resistance to mutant-selective EGFR inhibitors and irreversible quinazoline @GENE$ inhibitors in the absence of EGFR @VARIANT$ demonstrate a significantly activated IGF-1R signaling , and pharmacological inhibition of IGF-1R restored sensitivity to EGFR inhibitors .", "label": "resistance or non-response"}
{"id": "20195368", "sentence": "This pathway involves the cleavage of caspase 8 , which can cleave Bid ( an antiapoptotic protein ) and subsequently stimulate Bax to induce the release of @GENE$ and cause cell death . The detrimental role of TNF-α in ALS is supported by the use of @DRUG$ and lenalidomide to successfully inhibt TNF-α production , and significantly increase lifespan in @VARIANT$ mice .", "label": "None"}
{"id": "24876815", "sentence": "Analyses were also performed for other polymorphisms in the EGFR gene : G216T and G497A , and in the EGF gene : @VARIANT$ . Graziano et al. demonstrated the presence of the short variant of the @GENE$ gene intron-1 and the G allele in codon 61 of the EGF gene ( higher EGF production ) to be a favourable predictive factor for cetuximab-irinotecan therapy .", "label": "None"}
{"id": "24868171", "sentence": "The CYP2D6 .10 enzyme has a @VARIANT$ substitution that results in an unstable enzyme with reduced affinity for CYP2D6 substrates. , In vitro studies demonstrated that @DRUG$ showed an approximately 13-fold greater inhibition constant , ie , Ki , value in CYP2D6 .10 than in CYP2D6 .1 .", "label": "None"}
{"id": "25364578", "sentence": "Since the introduction of erlotinib and @DRUG$ , patients with metastatic @GENE$ positive lung cancer can be offered a therapeutic alternative that has proven its superiority over standard platinum based chemotherapy , . In the EURTAC study , in which erlotinib was compared with platinum-doublet chemotherapy as first-line treatment for patients with EGFR-mutant NSCLC , erlotinib demonstrated a significant improvement in the overall response rate ( ORR ) and median progression free survival ( PFS ) . On the basis of this study , in May 2013 the U.S Food and Drug Administration ( FDA ) approved erlotinib for use in patients with lung cancers harboring EGFR exon 19 deletions and EGFR @VARIANT$ substitutions .", "label": "sensitivity"}
{"id": "19672324", "sentence": "Compared with mitochondrial @VARIANT$ , which resides within the monoamine oxidase protein [ ] , the @DRUG$ preferring imidazoline binding sites ( known as I1R ) are localized to plasma membrane fractions [ , ] and specifically to synaptic plasma membranes [ ] . A strong candidate for I1R , known as imidazoline receptor antisera selected protein ( IRAS ) , has been cloned from human hippocampus [ ] . hIRAS is a larger protein of 1504 amino acids consisting of an NH2-terminal phox ( PX ) domain , 5 putative @GENE$ repeats , a predicted coiled-coil domain , and a long COOH-terminal region .", "label": "None"}
{"id": "24348666", "sentence": "It was initially proposed that the @VARIANT$ mutation might prevent the proper binding of tyrosine kinase inhibitors via steric hindrance , similar to the corresponding gatekeeper mutations in BCR-ABL ( T315I ) and @GENE$ ( T670I ) that confer resistance to imatinib ( @DRUG$ ) in chronic myelogenous leukemia and in patients with gastrointestinal stromal tumors .", "label": "None"}
{"id": "21165163", "sentence": "The most commonly seen activating point mutation in EGFR , @VARIANT$ , is incompatible with the inactive state of the kinase [ , ] , and the crystal structure of the L858R mutant revealed that additional hydrogen bonds are formed which serve to further stabilize the active state of the kinase [ ] . The mechanism by which this and other mutations activate EGFR , however , is not completely explained by a conformational predisposition to the active-state . Kinetic analyses found that clinically relevant mutations in @GENE$ alter binding to both ATP and inhibitors ( e.g. @DRUG$ and imatinib ) in such a way that the ratio of Kd to Km [ ATP ] is altered in favor of the inhibitors [ - ] .", "label": "sensitivity"}
{"id": "23082072", "sentence": "Further , patients with nonsmall cell lung cancer who initially responded to erlotinib or gefitinib therapy showed progression after a median of 12–13 months. , After patients developed acquired resistance confirmed on medical imaging , continuing use of erlotinib or gefitinib would lead to a surge in the rate of @GENE$ @VARIANT$ mutation which , in vitro , conferred resistance to treatment with @DRUG$ and gefitinib .", "label": "resistance or non-response"}
{"id": "25221748", "sentence": "The newer second-generation pan-HER irreversible inhibitors provide compensatory pathway inhibition by direct targeting of the resistant @VARIANT$ mutation and bind irreversibly to 2 or more receptors of the EGFR domain , thus providing enhanced @GENE$ pathway blockade . Of the second-generation inhibitors , @DRUG$ and dacomitinib have been the most extensively studied , in both heavily pre treated patients and in the first-line setting .", "label": "response"}
{"id": "PMC3991357", "sentence": "Epidermal growth factor receptor tyrosine kinase inhibitors ( @GENE$ ) , such as gefitinib and @DRUG$ , have achieved high clinical response rates in patients with non-small cell lung cancers ( NSCLCs ) , which possess somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene . However , over time ( median of 6-12 months ) , most tumors are known to develop acquired resistance to EGFR TKIs . Currently , there have been no effective treatment options against NSCLC patients with the secondary @VARIANT$ resistance mutation , which occurs in 50 % of patients with acquired resistance to EGFR-TKIs .", "label": "resistance or non-response"}
{"id": "23407898", "sentence": "The irreversible TKI BIBW 2992 ( @DRUG$ ) is currently being investigated in advanced clinical trials ( Yap et al. , ; Murakami et al. , ) . Another novel irreversible pan-HER inhibitor HM781-36B has recently shown promise in the inhibition of EGFR , HER2 , and HER4 as well as against the gatekeeper mutation – @GENE$ @VARIANT$ that is responsible for acquired drug resistance in lung cancer patients ( Cha et al. , ) .", "label": "response"}
{"id": "19654571", "sentence": "We speculated that cells expressing higher EGFR/HER2 ratios , such as A431 cells , rely more on EGFR signalling for @GENE$ pathway activation and cell proliferation , whereas cells with a lower EGFR/HER2 ratio , such as C33A cells , depend more on EGFR/HER2 heterodimer signalling . Based on this assumption , the inhibition of the EGFR/HER2 heterodimer by anti-EGFR ( @DRUG$ ) and anti-HER2 ( trastuzumab ) MAbs should interfere with @VARIANT$ cell proliferation .", "label": "None"}
{"id": "25120654", "sentence": "A diagnosis of lung adenocarcinoma was determined and the patient was treated with first-line chemotherapy consisting of @DRUG$ ( 80 mg/m2 ) and docetaxel ( 60 mg/m2 ) , every three weeks for up to three cycles . However , no marked response was observed . Following the initial treatment , a mutation in the @GENE$ gene was identified ( exon 21 ; @VARIANT$ , in which the leucine at amino acid position 858 is replaced by arginine ; ) .", "label": "None"}
{"id": "25221748", "sentence": "This agent is also being assessed in a phase II trial in patients with de novo resistant @VARIANT$ mutations not previously treated with EGFR-TKIs ( www.clinicaltrials.gov : NCT01854034 ) and in patients with EGFR mutations and/or EGFR-TKI resistant disease , as part of a phase II cluster study in Chinese patients evaluating five novel inhibitors of HSP90 , PI3K , ALK , MET , and @GENE$ ( ) . Further , AUY922 is also being assessed in combination with @DRUG$ in patients who have previously responded to EGFR-TKIs and/or whose tumors harbor activating EGFR mutations ( www.clinicaltrials.gov : NCT01259089 ) , with results expected in the near future .", "label": "None"}
{"id": "24036898", "sentence": "Trastuzumab and @DRUG$ were provided by Chugai Pharmaceutical Co. ( Tokyo , Japan ) . Rabbit polyclonal antibodies ( Abs ) against ubiquitin and actin ( Santa Cruz Biotechnology , Santa Cruz , CA ) , Akt , phospho-Erk , and @GENE$ ( Cell Signaling Technology , Danvers , MA ) , and CD31 and Ki67 ( Abcam , Cambridge , England ) were used . Mouse monoclonal Abs against CD16 ( 3G8 ) and CD54 ( HCD54 ) ( BioLegend , San Diego , CA ) and CD11a ( Ancell , North Bayport , MN ) , rabbit monoclonal Abs against HER2 ( D8F12 ) , phospho-HER2 ( 6B12 ) and phospho-Akt ( @VARIANT$ ) ( Cell Signaling Technology ) , and rat monoclonal Ab against CD18 ( YFC118.3 ) ( Chemicon International , Temecula , CA ) are also commercially available .", "label": "None"}
{"id": "15737014", "sentence": "Such mutations rarely , if ever , accompany @GENE$ mutations and are associated with primary resistance to gefitinib or @DRUG$ [ ] . To evaluate the possibility that secondary KRAS mutations confer acquired resistance to these drugs , we performed mutational profiling of KRAS2 exon 2 from tumor specimens from patients 1 to 3 , as well as the three additional patients lacking evidence of the T790M mutation . An Established NSCLC Cell Line Also Contains Both T790M and @VARIANT$ Mutations", "label": "sensitivity"}
{"id": "25349473", "sentence": "Despite the fact that the a dose of 30 mg/day showed excellent results in the Phase I trial , researchers proceeded to Phase II study using the 45 mg/day dose to ensure coverage of any and all @GENE$ TKI resistant clones.– The Phase II Ponatinib Ph+ALL and CML Evaluation (PACE) trial enrolled 449 patients : 267 with CP-CML , 83 with accelerated phase ( AP ) -CML , and 94 with blast crisis ( BC ) -CML or Ph+ALL ( ) . Patients were eligible for the study if they were resistant or had unacceptable side effects to dasatinib or @DRUG$ , or harbored the @VARIANT$ mutation .", "label": "None"}
{"id": "15737014", "sentence": "The EGFR T790M mutation , in conjunction with either wild-type EGFR or the drug-sensitive @VARIANT$ EGFR mutant , prevents inhibition of tyrosine phosphorylation ( A ) or p-EGFR ( B ) by gefitinib . Analogously , the T790M mutation , in conjunction with the drug-responsive del L747–E749 ; A750P EGFR mutant , prevents inhibition of @GENE$ by @DRUG$ ( C ) .", "label": "sensitivity"}
{"id": "23497317", "sentence": "We treated an imatinib-sensitive GIST cell line ( GIST822 ) harboring a @GENE$ exon 13 mutation ( @VARIANT$ ) and a second cell line , GIST48 , harboring an imatinib-sensitive V560D mutation plus a secondary imatinib-insensitive activation loop mutation ( D820A ) with varying concentrations of quizartinib .", "label": "None"}
{"id": "18577988", "sentence": "Interestingly , four EGFR FISH+ patients with @GENE$ mutations ( G12V in one case , G12D in another one , @VARIANT$ in the remaining two cases ) responded to @DRUG$ therapy .", "label": "resistance or non-response"}
{"id": "24655440", "sentence": "( B ) Garcinol promotes apoptosis : @VARIANT$ cells were treated with 50 μM garcinol and the whole cell extracts were subjected to immune blotting with antibodies against pro-caspase-3 , cleaved caspase-3 and @GENE$ taking β-actin as loading control . ( C ) Garcinol potentiates the apoptotic effect of @DRUG$ and paclitaxel .", "label": "None"}
{"id": "25465236", "sentence": "On the other hand , the increased inhibition potency for @DRUG$ against @GENE$ @VARIANT$ mutant ( compared to EGFR WT protein ) and subsequent further increase in potency for Gefitinib against the EGFR L858R + E884K double mutant correlates well with the increased global connectivity of the hub residues in the mutants ( – wild type , – L858R , – L858R + E884K ) .", "label": "sensitivity"}
{"id": "23329883", "sentence": "There was no significant difference in the levels of TG , HDL-C , ApoA1 , @GENE$ , and the ratio of ApoA1 to ApoB between AA and AG genotypes in the both groups ( P &gt ; 0.05 for all ) . Interactions between genotypes and alcohol consumption on serum lipid parameters The interactions between genotypes of the PCSK9 @VARIANT$ and @DRUG$ consumption on serum TC and LDL-C levels are also shown in Table .", "label": "None"}
{"id": "24009732", "sentence": "@VARIANT$ FIP1L1-PDGFRα , analogous to T315I Bcr-Abl in CML , is also resistant to the second-generation TKIs , such as @DRUG$ . Novel agents for imatinib-resistant @GENE$ are needed .", "label": "None"}
{"id": "17106442", "sentence": "In contrast to previous retrospective analyses ( ; ) , patients with exon 19 deletions were equally responsive compared to those with @VARIANT$ in this study . This might be due to our small sample size , so these data need to be confirmed in a larger trial . In @GENE$ mutation positive patients treated by @DRUG$ , TTP ( 9.4 months ) of after the gefitinib treatment and MST ( 19.1 months ) after the initial treatment were longer than in patients treated with the regimens using platinum doublet .", "label": "sensitivity"}
{"id": "23407898", "sentence": "The irreversible TKI @DRUG$ afatinib ) is currently being investigated in advanced clinical trials ( Yap et al. , ; Murakami et al. , ) . Another novel irreversible pan-HER inhibitor HM781-36B has recently shown promise in the inhibition of EGFR , HER2 , and HER4 as well as against the gatekeeper mutation – @GENE$ @VARIANT$ that is responsible for acquired drug resistance in lung cancer patients ( Cha et al. , ) .", "label": "response"}
{"id": "20349044", "sentence": "The two main neurotransmitters eliciting contraction in human and rodent urinary bladder are adenosine triphosphate and acetylcholine , which act on a ligand gated ion channel ( @VARIANT$ receptor ) and two G-protein coupled receptors ( M2 and M3 muscarinic ) , respectively ( de Groat and Yoshimura ) . A common approach for studying how the functions of these receptors change in diabetes mellitus is to examine their contractile roles in isolated urinary bladder from animals treated with @DRUG$ (STZ) . In smooth muscle , cAMP mediates relaxation , and activation of the M2 receptor inhibits @GENE$ the relaxation elicited by forskolin and activation of β-adrenoceptors in gastrointestinal and urinary bladder smooth muscle ( Ehlert ) .", "label": "None"}
{"id": "23082072", "sentence": "However , in patients with acquired resistance , tumor cells bearing @GENE$ @VARIANT$ represented a minority of cells , and as such , part of the tumor may remain responsive to erlotinib or gefitinib. , The other signal pathway related EGFR followed the same principles .", "label": "resistance or non-response"}
{"id": "24523596", "sentence": "@GENE$ + + Polli et al and Dai et al @DRUG$ BCR-ABL with mutations , including T315I + + Sen et al Bosutinib BCR-ABL mutations , except @VARIANT$ and T315I SRC family ± ± Hegedus et al", "label": "None"}
{"id": "22192458", "sentence": "Inhibition of ALK activity in NB cell lines has already been approached by using specific small molecule ALK inhibitors , such as @DRUG$ [ ] , NVP-TAE684 [ ] and @GENE$ [ ] , and more recently by RNA interference molecules [ ] . Particularly , NB cells harboring either @VARIANT$ mutation or ALK amplification showed sensitivity to PF-02341066 and these results were also confirmed in xenografts ( Wood AC et al. , ASCO Annual Meeting , 2009 ) .", "label": "None"}
{"id": "24244732", "sentence": "The results of these mutations in the lof rab-3 genetic background , however , argue against the simple interpretation that the effects are solely the result of the same @GENE$ interaction . For the stimulatory @DRUG$ phenotype , the effects of @VARIANT$ or E465K mutations were blocked .", "label": "None"}
{"id": "24634705", "sentence": "An in vitro model of EML4-ALK with the @VARIANT$ mutation showed that the cells were still dependent on ALK mediated signaling for tumor maintenance but are resistant to ALK inhibition [ , ] . Several other drugs have shown activity in inhibiting mutations induced by @DRUG$ and are in various stages of pre-clinical and clinical testing [ ] . @GENE$ Copy Number Gain and Emergence of ALK - Fusion Negative Tumors", "label": "resistance"}
{"id": "21687596", "sentence": "Deletion mutations , mainly occurring around codons 746–750 in exon 19 , and the substitution of leucine with arginine at codon 858 in exon 21 ( @VARIANT$ ) comprise approximately 90 % of these mutations [ ] . These mutations are more prevalent in Asians , women , non smokers , and patients with adenocarcinoma , groups that match the highly gefitinib-sensitive clinical subset [ ] . Many investigators have reported results from retrospective analyses of associations between EGFR gene mutations and @GENE$ sensitivity .", "label": "sensitivity"}
{"id": "20459770", "sentence": "In NSCLC , approximately 85 % of patients who responded favourably to gefitinib or @DRUG$ , two FDA approved small-molecule @GENE$ inhibitors , were shown to have somatic mutations in the EGFR gene . Somatic EGFR mutations are primarily located in exons 18 through 21 around the ATP binding pocket of the tyrosine kinase domain [ - ] . The most common mutations are short deletions in exon 19 affecting the amino acid sequence LREA ( DelE746-A750 ) or a point mutation in exon 21 resulting in the amino acid change @VARIANT$ .", "label": "sensitivity"}
{"id": "21403834", "sentence": "Secondary resistance to @DRUG$ in an IMT with ALK translocation ( @GENE$ ) has been recently documented in another patient . This resistance was suspected to occur via the neuroblastoma associated @VARIANT$ ALK mutation that has been well studied in neuroblastomas as a mechanism of resistance to some ALK inhibitors [ ] .", "label": "resistance"}
{"id": "18937829", "sentence": "Control patients 18 f 72 Rectum 5FU 1 1 0 - 20 0 19 f 54 Gastric 5FU-FA-P 2 1 0 c.1679T & gt ; G , I560S_21 0 20 m 59 Pancreas 5FU-FA-P 0 1 0 c.85T & gt ; C , C29R ; c.1627A&gt ; G , I543V ( H ) 20 0 21 m 62 Colon 5FU-FA-P 0 1 0 c.85T & gt ; C , C29R ( H ) ; c.496A&gt ; G , M166V , c.1236G&gt;A , E412E 19 0 22 f 64 Colon 5FU-FA 0 0 0 c.85T & gt ; C , C29R ; c.1627A&gt ; G , I543V 20 0 23 m 63 Oesophagus 5FU-P_1 0 0 - 20 0 24 f 69 Colon 5FU-FA 0 1 0 c.85T & gt ; C , C29R ( H ) ; c.496A&gt ; G , M166V ; c.2194G&gt;A , @VARIANT$ 20 0 25 m 59 Gastric 5FU-FA_1 1 0 c.85T & gt ; C , C29R ; c.1627A&gt ; G , I543V ; 1896T & gt ; C , F632F 21 0 26 m 59 Colon 5FU-FA-P 1 1 0 c.85T & gt ; C , C29R ( H ) ; c.496A&gt ; G , M166V ; c.1627A&gt ; G , I543V 20 0 27 m 62 Gastric E-CAPE-P_2_1 2 c.85T & gt ; C , C29R ( H ) ; c.496A&gt ; G , M166V ; @GENE$ , E412E c.1627A&gt ; G , I543V 30 0 Abbreviations : FA , @DRUG$ CAPE , capecitabine ; P , platinum compound ; E , epirubicin ; C , cyclophosphamide ; H , homozygous carrier a adenocarcinoma of unknown origin", "label": "None"}
{"id": "25033171", "sentence": "The energetic difference between G2032R-ROS1 and @GENE$ are shown in panel C ( ΔΔG = ΔGG2032R−ΔGWT , a positive ΔG indicates a weaker binding affinity in the mutated protein , and a negative ΔG indicates a stronger binding affinity ) , where the residue Leu18 ( on the P-loop region ) contributes the most to the attenuated binding of crizotinib to G2032R mutated ROS1 , indicating that the P-loop conformation governs the binding of @DRUG$ .", "label": "resistance"}
{"id": "20234366", "sentence": "Such a low percentage compared with that in previous reports is probably due to the fact that after Health Authorities approval to limit the use of anti-EGFR moAb to KRAS wild-type mCRC patients , @GENE$ mutant cases have not received @DRUG$ based therapy at our Institution . KRAS mutations were as follows : @VARIANT$ in five patients ; G12D in three patients ; G12V in three patients ; and G12A in one patient .", "label": "resistance or non-response"}
{"id": "24155950", "sentence": "Bortezomib/paclitaxel combination induces a downregulation of the phosphorylation of Bcr-Abl in TKIs-sensitive ( K562 , LAMA84 , @GENE$ Bcr-Abl ) and TKIs-resistant ( K562-R , LAMA84-R , Baf3 Bcr-Abl @VARIANT$ ) cell lines In order to evaluate if the combined bortezomib/paclitaxel regimen can efficiently shut down Bcr-Abl and induce cell death in Bcr-Abl positive leukemic cell lines that are resistant to imatinib , we developed two different cell lines derived from K562 ( K562-R ) and LAMA84 ( LAMA84-R ) cell lines , which are resistant to 1μM @DRUG$ .", "label": "None"}
{"id": "19758442", "sentence": "The regions responsible for interaction with @VARIANT$ ( red ) and A3F ( blue ) are discontinuous . They overlap but are not identical . The region important for interaction with the Cul5 @GENE$ marked in green and includes a conserved histidine-cysteine-cysteine-histidine motif and a suppressor of cytokine signaling Box domain .", "label": "None"}
{"id": "22481926", "sentence": "A clinical trial is currently underway to study the efficacy of liposomal adenoviral @VARIANT$ , which interferes with @GENE$ signaling , in combination with @DRUG$ in patients with recurrent ovarian cancer .", "label": "None"}
{"id": "25078331", "sentence": "The vascular endothelial growth factor ( VEGF ) inhibitor @DRUG$ has also shown limited impact on the outcome of this disease . Case 13 . A pleomorphic adrenocortical carcinoma liver metastasis derived from a 48-year-old man harboured CDK4 and MDM2 amplifications , CUL4A ( @VARIANT$ ) and @GENE$ ( S241Y ) mutations .", "label": "None"}
{"id": "22363766", "sentence": "These trials will test the efficacy of second-generation EGFR inhibitors or approved @GENE$ inhibitors ( such as @DRUG$ ) in combination with other inhibitor drugs such as MET/VEGFR2 inhibitors . Subtype 1.2 – Overview Subtype 1.2 is defined as NSCLC that harbors a @VARIANT$ mutation in exon 20 of the EGFR gene .", "label": "resistance or non-response"}
{"id": "22701522", "sentence": "To evaluate the performance of the method , we analyzed the binding of @DRUG$ @GENE$ coli dihydrofolate reductase ( eDHFR ) . The binding between MTX and eDHFR is well characterized and a series of eDHFR mutants are available , which bind to MTX with wide range of affinity , . We prepared SNAP tagged constructs of eDHFR wild-type ( WT ) and three eDHFR mutants ( eDHFR L54I , eDHFR @VARIANT$ and eDHFR F31V , L54G ) for which the reported Kd values to free MTX range from low pM to low µM , .", "label": "None"}
{"id": "23866929", "sentence": "@GENE$ @VARIANT$ mutation was detected in exon 21 ( PNA LNA PCR-Clamp method ) of another brushing and aspiration specimen . The patient received four cycles of systemic chemotherapy with @DRUG$ ( area under curve 5 ) and etoposide ( 80 mg/m2 ) for three months , at the end of which the size of the tumor decreased by one half .", "label": "None"}
{"id": "23493883", "sentence": "Additionally , @DRUG$ has higher potency than reversible @GENE$ in reducing survival of NSCLC cell lines with the @VARIANT$ resistance mutation ( ) and in cell lines with the less common secondary resistance mutation T854A .", "label": "response"}
{"id": "24789720", "sentence": "The new therapy methods , which could be effective in patients with @VARIANT$ mutation includes irreversible @GENE$ ( afatinib , neratinib ) . In LUX-Lung 1 study in patients after failure of erlotinib or @DRUG$ treatment with afatinib led to partial responses and prolongation of progression-free survival compared to placebo to 3,3 months [ , ] .", "label": "resistance or non-response"}
{"id": "17973572", "sentence": "Based on the data obtained from lung cancer cell lines , we further explored the mechanisms by which T790M and @VARIANT$ resistant mutations affect BIM up-regulation and apoptosis . @DRUG$ effectively induced apoptosis in Ba/F3-L858R cells , whereas Ba/F3-L858R-L747S cells were intermediately resistant and @GENE$ completely resistant ( A , top ) .", "label": "None"}
{"id": "23691449", "sentence": "Some of the molecular mechanisms of acquired resistance include T790M second mutation , mesenchymal epithelial transition factor ( MET ) amplification , ATP binding cassette (ABC)-G2 transporter ( ABCG2 ) and hepatocyte growth factor (HGF) overexpression , @GENE$ protein-3 ( IGFBP3 ) downregulation , as well as ERBB3 activation . T790M mutation The @VARIANT$ second mutation accounts for half of all resistances to @DRUG$ and erlotinib [ ] .", "label": "None"}
{"id": "24789720", "sentence": "T790M mutation in @GENE$ gene seems to be one of the most important genetic abnormalities involving the resistance for reversible epidermal growth factor receptor tyrosine kinases inhibitors ( EGFR-TKI ) —erlotinib and gefitinib in NSCLC patients [ – ] . T790M mutation is detected with highest prevalence in patients with common activating mutations of EGFR gene ( @VARIANT$ in exon 21 and deletions in exon 19 ) after long-term and initially effective treatment with EGFR-TKIs .", "label": "sensitivity"}
{"id": "24612546", "sentence": "One NSCLC patient with SD lasting ≥ 6 months , and who had a mutation in @GENE$ had progressed after 15-month @DRUG$ treatment ; he then subsequently developed a @VARIANT$ mutation which was defined prior to entry to this study .", "label": "resistance or non-response"}
{"id": "22060015", "sentence": "B ) Representative flow cytometric analysis of @GENE$ of decitabine treated and untreated @VARIANT$ glioma cells ( solid filled , NY-ESO-1 specific T cells alone ; dashed line , NY-ESO-1 specific T cells co-cultured with untreated T98G glioma cells ; solid line , NY-ESO-1 specific T cells co-cultured with @DRUG$ treated T98G glioma cells ) .", "label": "None"}
{"id": "23493883", "sentence": "The most promising drug thus far has been @DRUG$ ( BIBW2992 ; Boehringer-Ingelheim Pharma , Ingelheim , Germany ) , , an @GENE$ family blocker with reported in vitro and in vivo activity against EGFR mutant tumors harboring exon 19 deletions , exon 21 L858R mutations and the exon 20 @VARIANT$ “resistance” mutations .", "label": "response"}
{"id": "24876815", "sentence": "Analyses were also performed for other polymorphisms in the EGFR gene : @VARIANT$ and G497A , and in the EGF gene : A61G . Graziano et al. demonstrated the presence of the short variant of the @GENE$ gene intron-1 and the G allele in codon 61 of the EGF gene ( higher EGF production ) to be a favourable predictive factor for cetuximab-irinotecan therapy .", "label": "None"}
{"id": "25100284", "sentence": "@DRUG$ Yang et al. [ ] Ph II ; randomized , single-arm n = 129 ; Taiwanese and US ; chemo-naïve , or one previous line of chemotherapy ; exon 19 deletion ( n = 52 ) ; @VARIANT$ ( n = 54 ) ; other ( n = 23 ) Afatinib 40 mg or 50 mg/day PFS : 14 months Icotinib Ren et al. [ ] Ph I ; single-arm n = 7 : Chinese ; previously treated ; exon 19 deletion ( n = 3 ) ; L858R ( n = 4 ) Icotinib ( varied dose and schedule ) PFS : 141 days ( 4.6 months ) Sun et al. [ ] Ph III ; randomized comparison with gefitinib ( ICOGEN ) n = 27 : Chinese ; previously treated ; @GENE$ mutation Icotinib 125 mg three times/day PFS : 198 days ( 6.5 months )", "label": "sensitivity"}
{"id": "24586514", "sentence": "We previously reported that an HDACi , depsipeptide , is effective against @GENE$ positive leukemia cells . Therefore , we examined the activity of an HDACi against T315I mutant cells . We examined whether treatment with ponatinib and @DRUG$ induced cell death in @VARIANT$ mutant cells .", "label": "None"}
{"id": "25221748", "sentence": "This agent is also being assessed in a phase II trial in patients with de novo resistant @VARIANT$ mutations not previously treated with EGFR-TKIs ( www.clinicaltrials.gov : NCT01854034 ) and in patients with EGFR mutations and/or EGFR-TKI resistant disease , as part of a phase II cluster study in Chinese patients evaluating five novel inhibitors of HSP90 , PI3K , @GENE$ , MET , and MEK ( ) . Further , AUY922 is also being assessed in combination with @DRUG$ in patients who have previously responded to EGFR-TKIs and/or whose tumors harbor activating EGFR mutations ( www.clinicaltrials.gov : NCT01259089 ) , with results expected in the near future .", "label": "None"}
{"id": "23492773", "sentence": "Furthermore , chemotherapeutic drugs that induced miR-128 , caused moderate increase in SIRT1 levels in p53 null cells ( HCT116 p53−/− ) and mutant p53 ( MDA-MB-231 , p53 @VARIANT$ ) cells , whereas they caused insignificant change in SIRT1 levels in wild-type p53 expressing MCF7 , NCI-H460 and HCT116 p53+/+ cells ( ) . We simultaneously examined whether miR-128 would have any effect on the sensitivity of cells that have functional p53/mutated p53 or are null for p53 towards chemotherapeutics . As expected , @GENE$ augmented the cisplatin ( 33 % in MCF-7 cells , 27.8 % in HCT116 p53+/+ cells and 21.45 % in HCT116 p53−/− cells ) as well as @DRUG$ ( 44 % in MCF-7 cells , 32.25 % in HCT116 p53+/+ cells and 25.55 % in HCT116 p53−/− cells ) -induced apoptosis as compared with their respective controls ( ) .", "label": "None"}
{"id": "22098950", "sentence": "Compared to wild-type BCRP , overexpression of either the @VARIANT$ or R482G @GENE$ mutants conferred greater resistance to anthracyclines , including @DRUG$ , daunorubicin and epirubicin , and bisantrene , , .", "label": "None"}
{"id": "22363766", "sentence": "Of note , mutations within ALK that lead to crizotinib resistance have already been described , analogous to the @VARIANT$ mutation leading to erlotinib and @DRUG$ resistance in @GENE$ .", "label": "resistance or non-response"}
{"id": "25580271", "sentence": "There are several promising agents for patients with activating EGFR mutations who experience disease progression of an EGFR tyrosine kinase inhibitor and have a @VARIANT$ resistance mutation , and multiple clinical trials will be available . Trials investigating adjuvant erlotinib in EGFR mutant NSCLC and comparing erlotinib to erlotinib plus bevacizumab in metastatic @GENE$ mutant NSCLC are ongoing . @DRUG$ , when compared to platinum pemetrexed , results in a superior ORR and progression-free survival in patients with ALK rearranged NSCLC , and ceritinib is a second-line option for this patient population , but patients need to be monitored closely for adverse events and the need for dose reductions .", "label": "None"}
{"id": "22034911", "sentence": "The 16 mutations are located around the kinase active site and can be categorized into five groups , involved in either direct or indirect contacts with @DRUG$ . The three mutations that conferred the strongest resistance were the @VARIANT$ gatekeeper residue , S1206R at the solvent front , and G1269S near the DFG motif . Ba/F3 cells expressing native @GENE$ grew robustly as subcutaneous xenografts in SCID mice .", "label": "resistance"}
{"id": "21188111", "sentence": "In addition to the phase II imatinib trial , a case report describes 70 % tumor shrinkage after treatment with @DRUG$ in a patient with metastatic mucosal melanoma bearing a mutation in @GENE$ exon 11 . In a recent report , the c-KIT mutation @VARIANT$ was associated with resistance to multiple KIT inhibitors including imatinib , nilotinib , and sorafenib , but objective tumor responses could be induced in 2 patients bearing the KIT L576P mutation after treatment with dasatinib .", "label": "None"}
{"id": "23610714", "sentence": "KIT mutations observed in patients with metastatic tumors are most frequently observed in exons 11 ( 67 % ) , 9 ( 10 % ) , 13 ( 1 % ) , or 17 ( 1 % ) , while platelet derived growth factor receptor-α ( PDGFRA ) mutations ( 10 % ) , which are less common than @GENE$ mutations , occur mostly in exons 18 ( 6 % ) , 12 ( 0.7 % ) , or 14 ( 0.1 % ) . Mutational analysis is helpful in detecting the development of secondary mutations in tumors that are responding poorly to tyrosine kinase inhibitors and in identifying the PDGFRA exon 18 codon @VARIANT$ missense mutation , which is associated with a good prognosis , but conversely confers resistance to imatinib. , Exon 9 is reported to benefit from a high dose ( 800 mg/day ) of imatinib in some studies .", "label": "None"}
{"id": "23937717", "sentence": "Two @DRUG$ resistance NSCLC cell lines A549 ( EGFR wt ) and H1975 ( @GENE$ L858R + @VARIANT$ ) were used .", "label": "resistance or non-response"}
{"id": "21333004", "sentence": "Based on these observations , we speculated that other unknown factors affect @DRUG$ sensitivity in vivo rather than alteration of the binding affinity . So far , cells with the @VARIANT$ mutated @GENE$ have been reported to have two characteristics .", "label": "sensitivity"}
{"id": "25278773", "sentence": "These second-generation EGFR inhibitors have also been shown to drive drug resistance through the acquisition of @VARIANT$ in both preclinical and clinical settings , suggesting low potency against T790M. , As a potential solution , afatinib was combined with the EGFR antibody @DRUG$ in a Phase IIB study , which demonstrated an impressive response rate of 32 % in patients with @GENE$ mutant lung cancers resistant to first-generation EGFR inhibitors .", "label": "response"}
{"id": "22034911", "sentence": "In this study , we have used an accelerated mutagenesis strategy to identify an extensive set of mutations in @GENE$ that can confer resistance to @DRUG$ . Alterations at 16 different amino acids were observed , with three of them , @VARIANT$ , S1206R and G1269S , rendering cells completely insensitive in mouse xenograft studies .", "label": "resistance"}
{"id": "21980452", "sentence": "Profile shows A280 of the wild type ( solid ) or @VARIANT$ mutant ( dashed ) form on the ordinate and cumulative elution volume on the abscissa . V0 indicates void volume of the Superose 12 column ( 7.9 ml ) ; numbers indicate elution of standard proteins β-amylase ( 200 kDa ; 11.2 ml ) , @DRUG$ dehydrogenase ( 150 kDa ; 11.8 ml ) , BSA ( 66 kDa ; 12.4 ml ) and @GENE$ 29 kDa ; 14.3 ml ) .", "label": "None"}
{"id": "24121633", "sentence": "Based on our data , we hypothesized that PRR of hnRNP L binds to PTB and cooperatively suppresses inclusion of exon @VARIANT$ . We thus examined the role of PRR of hnRNP L on the interaction with PTB . @DRUG$ tagged hnRNP L ( His-L ) , its PRR deleted variant ( His-L-ΔPRR ) , histidine tagged hnRNP LL ( His-LL ) , and its PRR inserted variant ( @GENE$ ) were expressed in SH-SY5Y cells , and they were immunoprecipitated with anti-histidine antibody in the presence of RNase .", "label": "None"}
{"id": "23423768", "sentence": "( A ) Structures of two approved EGFR TKIs , gefitinib and @DRUG$ , used in the treatment of NSCLC . ( B ) Ribbon diagram of wild-type human EGFR ( @GENE$ code 2ITY ) , illustrating binding of gefitinib to the active site of the kinase . The magenta ball-stick ( located just above the gefitinib molecule in the active site ) indicates the gatekeeper residue ( threonine790 ) that is commonly mutated to methionine ( @VARIANT$ ) , resulting in reduced inhibitor binding and drug resistance .", "label": "None"}
{"id": "24624361", "sentence": "Our unpublished data show that Dinaciclib exposure results in downregulation of BRCA1 and BRCA2 and sensitized cyclin E1-dependent ovarian cancer cells to @DRUG$ . Hence , Dinaciclib may have a dual effect on BRCA1 and BRCA2 by causing @VARIANT$ mediated transcriptional downregulation and inhibiting CDK1/2 mediated activation of the BRCA proteins ( Figure A ) .", "label": "None"}
{"id": "25278773", "sentence": "There were five ( 8.1 % ) patients who had RECIST partial response , and two patients with secondary @VARIANT$ mutations ( L858R T790M , and deletion in exon 19 T790M ) achieved disease stabilization for 9 months and 1 month , respectively . Afatinib in squamous NSCLC : LUX-Lung 8 study In view of the antitumor activity observed in EGFR-wild-type patients with first-generation @GENE$ inhibitors , coupled with evidence of benefit with other irreversible pan-HER inhibitors , this study was initiated to assess the activity of afatinib versus @DRUG$ in squamous subtype NSCLC after the failure of at least one prior platinum based chemotherapy ( NCT01523587 ; ) .", "label": "resistance or non-response"}
{"id": "24004697", "sentence": "More importantly , we found a significantly higher inhibition effect in @VARIANT$ cells treated with PPP2R5C-siRNA799 , and the inhibition effect in 32D-Bcr-Abl T315I cells , which have a T315I Abl mutation , was similar to that of @GENE$ WT cells . Such effects are particularly important for the targeted therapy of imatinib-resistant CML cells that either lack an Abl mutation and have primary and @DRUG$ induced resistance or those with an Abl T315I mutation , which resist new-generation TKIs .", "label": "None"}
{"id": "24982846", "sentence": "@DRUG$ EGFR EGFR exon 19 deletion or exon 21 substitution ( @VARIANT$ ) mutation positive Indications and usage , dosage and administration , adverse reactions , clinical pharmacology , clinical studies , patient counseling information Anastrozole ESR1 , PGR Hormone receptor positive Indications and usage , clinical pharmacology , clinical studies Arsenic trioxide PML/RARα @GENE$ [ t ( 15 ; 17 ) ] gene expression positive Boxed warning , clinical pharmacology , indications and usage , warnings", "label": "None"}
{"id": "24982846", "sentence": "Imatinib @GENE$ c-KIT @VARIANT$ mutation negative Indications and usage , dosage and administration clinical pharmacology , clinical studies BCR/ABL1 Philadelphia chromosome [ t ( 9 ; 22 ) ] positive PDGFRβ PDGFR gene rearrangement positive FIP1L1/PDGFRα FIP1L1/PDGFRα fusion kinase ( or CHIC2 deletion ) positive Indications and usage , dosage and administration , clinical studies Irinotecan UGT1A1 UGT1A1*28 allele carriers Dosage and administration , warnings , clinical pharmacology @DRUG$ ERBB2 HER2 protein overexpression positive Indications and usage , clinical pharmacology , patient counseling information", "label": "None"}
{"id": "23866929", "sentence": "Furthermore , a high response rate ( 60 to 90 % ) to treatment with EGFR-TKIs has been observed in patients harboring mutations in exons 18 to 21 of the tyrosine kinase domain of EGFR , with exon 19 deletions and exon 21 @VARIANT$ point mutations comprising about 90 % of all mutations [ , ] . Although the mechanism of lethal interstitial pneumonia as a side effect of EGFR-TKI is still unknown , EGFR-TKI can be striking in cancer reduction and quality of life improvement in patients with advanced NSCLC harboring EGFR gene mutations . Currently , EGFR-TKI is considered third-line chemotherapy for patients with inoperable and recurrent NSCLC after first-line platinum based combination chemotherapy and second-line chemotherapy with @DRUG$ ; however , in future the combination of cytotoxic agents and @GENE$ may become first- or second-line standard chemotherapy .", "label": "None"}
{"id": "22994622", "sentence": "Therefore , the low KRAS mutation frequency of HNSCC may cause difficulty in predicting the effect of @DRUG$ and other EGFR inhibitors . We analyzed exon 15 of BRAF to search for a @VARIANT$ substitution , the most common activating mutation of @GENE$ , which is observed at high frequencies in various cancers [ ] .", "label": "resistance or non-response"}
{"id": "24920920", "sentence": "In 40 patients harboring L858R , five revealed complex mutations , including two with @VARIANT$ . In 61 patients with @GENE$ TKI as first-line therapy , 46 received @DRUG$ , 13 received erlotinib , and two received afatinib .", "label": "resistance or non-response"}
{"id": "24294007", "sentence": "Although a retrospective study and the PICCOLO ( Panitumumab , Irinotecan and Ciclosporin in Colorectal Cancer Therapy ) trial have demonstrated a reduced response to cetuximab and @DRUG$ for patients with NRAS mutations , , further work is required to demonstrate the predictive capacity of these mutations . The @GENE$ an effector in the MAPK signaling pathway , downstream of K-Ras . Mutations in the proto-oncogene BRAF are present in 5 % –10 % of the metastatic CRC population and are also mutually exclusive of KRAS mutations . BRAF @VARIANT$ is the most common of all BRAF mutations ( present in 90 % of cases ) , and is enriched in a subset of patients who are female , greater than 70 years of age , with KRAS WT right sided colon cancer .", "label": "resistance or non-response"}
{"id": "23992330", "sentence": "In the colorectal cancer setting , preclinical in vitro models of resistance to the anti-EGFR mAbs cetuximab and @DRUG$ include cell lines showing mutations of the K-Ras gene , most frequently in codon 12 of exon 2 , such as SW480 , LS174T , HCT116 , LoVo cells . These mutations produce a single amino acid change resulting in mutant Ras proteins that are insensitive to GAP function and constitutively active , with consequent activation of the Ras/MAPK signaling [ ] . Furthermore , several colorectal cancer cell lines ( VAC0432 , SNU-C5 , HT29 , KM20 , WiDr ) are considered valuable models of resistance to the @GENE$ @VARIANT$ ) inhibitor vemurafenib [ ] because of the high levels of EGFR expression .", "label": "resistance or non-response"}
{"id": "23569389", "sentence": "Dasatinib is active against at least 100 of the BCR-ABL1 mutations known to confer resistance to @DRUG$ that have been tested to date , ( including many in the p-loop region ) , except for the @VARIANT$ mutation and a few other mutations ( V299L , F317L/V , and T315A ) . Dasatinib is able to block downstream intracellular signaling pathways activated by BCR-ABL1 in vitro , including signal transducer and activator of transcription 5 ( Stat5 ) , with downregulation of Stat5 target gene expression and the @GENE$ , Notably , dasatinib is not a substrate of multidrug resistance protein-1 , an efflux protein expressed on normal and leukemic hematopoietic stem cells .", "label": "None"}
{"id": "15737014", "sentence": "To our knowledge , no NSCLC patient who initially responded to but then progressed on either @DRUG$ or erlotinib has yet been treated with lapatinib . In some of the patient specimens analyzed , the actual sequencing peaks demonstrating the @VARIANT$ mutation were smaller than originally anticipated . These results differ from those of acquired resistance mutation in CML [ ] , GIST [ , ] , and @GENE$ [ ] .", "label": "None"}
{"id": "23055691", "sentence": "While @VARIANT$ is found in about half of patients with acquired resistance to @DRUG$ and gefitinib , the other mechanism of resistance – MET amplification – makes up about 5 % –10 % of these patients . There is a significant overlap of these two mechanisms , as about half of the patients with MET amplification also had the T790M mutation. , It is theorized that MET activates an AKT mediated signaling pathway that bypasses the inhibited @GENE$ , a process dubbed “bypass track activation.”", "label": "resistance or non-response"}
{"id": "22815900", "sentence": "The presence of activating @GENE$ mutations is closely associated with a more favorable outcome following treatment with EGFR targeted drugs . In our present study , erlotinib-resistant cell lines were established ; PC9/ER1 from PC9 cells harboring delE746-A750 mutation , and 11–18/ER1-7 and 11–18/ER2-1 from 11–18 cells harboring @VARIANT$ mutation .", "label": "sensitivity"}
{"id": "22363766", "sentence": "@GENE$ TKIs ( such as @DRUG$ or gefitinib ) are selective inhibitors of EGFR 's kinase domain that work by competing with ATP for binding at the ATP binding site , thereby preventing autophosphorylation and activation . The @VARIANT$ mutation affects the gatekeeper residue in the catalytic kinase domain and confers drug resistance by increasing EGFR 's affinity for ATP – thus reducing the potency of the ATP-competitive kinase inhibitors .", "label": "resistance or non-response"}
{"id": "22970367", "sentence": "The data suggest that low BRCA1 level may neutralize the negative effects of the EGFR @VARIANT$ mutation on @DRUG$ sensitivity and that high @GENE$ expression may lead to de novo EGFR TKI resistance potentially through increased DNA damage repair capacity [ ] .", "label": "None"}
{"id": "24789720", "sentence": "T790M mutation in EGFR gene seems to be one of the most important genetic abnormalities involving the resistance for reversible epidermal growth factor receptor tyrosine kinases inhibitors ( @GENE$ ) —erlotinib and @DRUG$ in NSCLC patients [ – ] . T790M mutation is detected with highest prevalence in patients with common activating mutations of EGFR gene ( @VARIANT$ in exon 21 and deletions in exon 19 ) after long-term and initially effective treatment with EGFR-TKIs .", "label": "sensitivity"}
{"id": "24876815", "sentence": "Analyses were also performed for other polymorphisms in the EGFR gene : G216T and @VARIANT$ , and in the EGF gene : A61G . Graziano et al. demonstrated the presence of the short variant of the @GENE$ gene intron-1 and the G allele in codon 61 of the EGF gene ( higher EGF production ) to be a favourable predictive factor for cetuximab-irinotecan therapy .", "label": "None"}
{"id": "19707322", "sentence": "Nilotinib is approximately 30-fold more sensitive than @DRUG$ in the killing of @GENE$ dependent cells derived from patients with CML ( K562 and Ku-812F cells ) and cell lines ( 32D and baF3 ) , and it is active against 32/33 imatinib-resistant cell lines with BCR-ABL mutations . The sensitivity of Bcr-Abl mutants to AMN107 can be summarized into 4 categories : high ( IC50 ≤ 70 nmol/L : M244V , G250E , Q252H , F3llL , F317L , M351T , V379I , L387M , H396P , H396R ) , medium ( IC50 ≤ 200 nmol/L : @VARIANT$ , E255K , F359V ) , low ( IC50 ≤ 450 nmol/L : Y253H , E255V ) , and insensitive ( IC50 & gt ; 2 μmol/L : T315I ) ( ) ( ) .", "label": "None"}
{"id": "23818899", "sentence": "EGFR KRAS ( mutation ) Colorectal Cancer ( expressing metastatic colorectal carcinoma , EGFR ) **Therascreen KRAS Test ( Qiagen , Corporate Headquarters , Nederland 's ) **Erbitux , cetuximab ( ImClone , ImClone Systems , NJ ) **Vectibix , panitumumab ( Amgen , Amgen Inc , . CA ) [ , , ] BRAF @VARIANT$ ( mutation ) Melanoma ( metastatic melanoma with BRAFV600E mutation ) **Cobas 4800 @GENE$ V600 Mutation Test ( Panagene , Corporate Headquarters , Korea ) **Zelboraf , vemurafenib ( Genentech/Roche ) [ , ]", "label": "resistance or non-response"}
{"id": "21333004", "sentence": "Overexpression of wild type EGFR induced high and sustained phosphorylation of EGFR , Shc , MEK ( mitogen activated protein kinase kinase ) and ERK ( extracellular signal regulated kinase ) , while the @VARIANT$ mutation reduced these response levels . In addition , H1299L858R , which is supposed to be more sensitive to gefitinib than @GENE$ , was effectively inhibited by @DRUG$ administration at the downstream part of the signaling pathway ( MEK and ERK ) compared with H1299EGFR-WT , but , surprisingly , not at the upstream part of the pathway ( EGFR and Shc ) .", "label": "sensitivity"}
{"id": "23320171", "sentence": "Primary results from the EMILIA study , a randomized trial comparing @DRUG$ DM-1 to lapatinib and capecitabine , have shown that Trastuzumab DM-1 significantly improved progression-free survival in patients with metastatic HER2 positive breast cancer . Further research is looking into inhibiting other targets such as mTOR , @VARIANT$ , or @GENE$ pathways .", "label": "None"}
{"id": "25193854", "sentence": "To overcome the acquired resistance to IM , new tyrosine kinase inhibitors ( TKI ) such as nilotinib , dasatinib and INNO-406 have been developed and are effective against most mutations but not the @VARIANT$ mutation [ - ] . Thus , novel strategies to overcome IM resistance are desperately needed . To this end , @DRUG$ has been established as a third generation TKI , which suggests that inhibiting @GENE$ expression is a promising approach [ ] .", "label": "response"}
{"id": "24348666", "sentence": "It was initially proposed that the T790M mutation might prevent the proper binding of tyrosine kinase inhibitors via steric hindrance , similar to the corresponding gatekeeper mutations in BCR-ABL ( T315I ) and @GENE$ ( @VARIANT$ ) that confer resistance to imatinib ( Gleevec ) in chronic myelogenous leukemia and in patients with gastrointestinal stromal tumors . Interestingly , it was discovered that the T790M mutation does not confer resistance to @DRUG$ and erlotinib by preventing their binding as originally thought .", "label": "None"}
{"id": "24278442", "sentence": "For example , detecting the @VARIANT$ mutation in blood samples would be useful for patient selection for treatment with new EGFR-TKIs for lung cancers that are resistant to @DRUG$ and erlotinib [ ] . Recent two studies suggest other possibilities of ctDNA analysis . Dawson et al. followed the dynamics of ctDNA in metastatic breast cancer patients using mutations in @GENE$ and/or PIK3CA , and found its merit for monitoring disease progression [ ] .", "label": "None"}
{"id": "24004697", "sentence": "The proliferation inhibition effect of PPP2R5C-siRNAs on the imatinib-sensitive and imatinib-resistant cell lines . A : K562 and @VARIANT$ cells treated with PPP2R5C-siRNA799 , B : 32D-Bcr-Abl WT and @GENE$ T315I cells treated with PPP2R5C-siRNA799 , C : K562 and K562R cells treated with PPP2R5C-siRNA991 , D : 32D-Bcr-Abl WT and 32D-Bcr-Abl T315I cells treated with PPP2R5C-siRNA991 .", "label": "None"}
{"id": "24155950", "sentence": "Murine Baf3 Bcr-Abl and @GENE$ Bcr-Abl @VARIANT$ cells were plated in 75cm2 flasks ( 4 x 106 cells/35 ml/flask ) and treated with 0.5 or 1 µM imatinib . For nilotinib and dasatinib treatments , the cells were plated in 25cm2 flasks ( 2 x 106 cells/10 ml/flask ) and treated with 0.125 µM or 0.5 µM nilotinib and 0.056 µM or 0.112 µM @DRUG$ for 48h .", "label": "None"}
{"id": "25429239", "sentence": "It inhibits both @VARIANT$ in @GENE$ NSCLC and the T790M in EGFR mutants . Phase I/II data for AP26113 have demonstrated efficacy in both @DRUG$ naive and resistant patients .", "label": "resistance"}
{"id": "24523596", "sentence": "Several studies have reported renal failure and tumor lysis syndrome during TKI based molecular targeted therapies , including with sorafenib for hepatocellular carcinoma , with imatinib for chronic myelogenous leukemia , and with flavopiridol for chronic lymphocytic leukemia.– Because the @VARIANT$ variant of ABCG2/BCRP corresponding to SNP 421C&gt ; A reduces uric acid transport and those TKIs are substrates/inhibitors of ABCG2/BCRP , TKI therapy in patients with the SNP 421C&gt ; A ( Q141K ) may be at higher risk of tumor lysis syndrome . A defect in the pharmacological interaction has been suggested between sunitinib and another ABCG2/BCRP germ-line mutant allele , 1291T & gt ; C. Remarkably , @DRUG$ reversed wild-type ABCG2/BCRP mediated drug resistance and competitively inhibited @GENE$ mediated estrone 3-sulfate transport and the binding of 125I-iodoarylazidoprazosin to ABCG2/BCRP .", "label": "None"}
{"id": "19876398", "sentence": "The capacity of ABL/BCR to autonomously induce leukemia suggests that the presence of p40ABL/BCR or p96ABL/BCR contributes to the maintenance of a leukemic subpopulation upon inhibition of @GENE$ by ATP-analogues such as @DRUG$ , Dasatinib or Nilotinib , a scenario of particular importance in Ph+ ALL . One could speculate that the presence of ABL/BCR supports the proliferation of cells harboring BCR/ABL mutants with lower kinase activity , such as the @VARIANT$ , which boasts nearly complete resistance to small molecules – .", "label": "None"}
{"id": "24523596", "sentence": "Rudin et al , Lemos et al , van Erp et al 1291T & gt ; C F431L TMD Insensitive to @DRUG$ mediated inhibition . Kawahara et al @GENE$ ; G No change TMD 1465T & gt ; C F489L TMD 1768A&gt ; T @VARIANT$ TMD 1858G&gt;A D620N TMD 2237G&gt ; T – 2393G&gt ; T –", "label": "None"}
{"id": "18937829", "sentence": "Control patients 18 f 72 Rectum 5FU 1 1 0 - 20 0 19 f 54 Gastric 5FU-FA-P 2 1 0 c.1679T & gt ; G , I560S_21 0 20 m 59 Pancreas 5FU-FA-P 0 1 0 c.85T & gt ; C , @VARIANT$ ; c.1627A&gt ; G , I543V ( H ) 20 0 21 m 62 Colon 5FU-FA-P 0 1 0 c.85T & gt ; C , C29R ( H ) ; c.496A&gt ; G , M166V , c.1236G&gt;A , E412E 19 0 22 f 64 Colon 5FU-FA 0 0 0 c.85T & gt ; C , C29R ; c.1627A&gt ; G , I543V 20 0 23 m 63 Oesophagus 5FU-P_1 0 0 - 20 0 24 f 69 Colon 5FU-FA 0 1 0 c.85T & gt ; C , C29R ( H ) ; c.496A&gt ; G , M166V ; c.2194G&gt;A , V732I 20 0 25 m 59 Gastric 5FU-FA_1 1 0 c.85T & gt ; C , C29R ; c.1627A&gt ; G , I543V ; 1896T & gt ; C , F632F 21 0 26 m 59 Colon @GENE$ 1 1 0 c.85T & gt ; C , C29R ( H ) ; c.496A&gt ; G , M166V ; c.1627A&gt ; G , I543V 20 0 27 m 62 Gastric E-CAPE-P_2_1 2 c.85T & gt ; C , C29R ( H ) ; c.496A&gt ; G , M166V ; c.1236G&gt;A , E412E c.1627A&gt ; G , I543V 30 0 Abbreviations : FA , folinic acid ; CAPE , capecitabine ; P , platinum compound ; E , @DRUG$ ; C , cyclophosphamide ; H , homozygous carrier a adenocarcinoma of unknown origin", "label": "None"}
{"id": "23329883", "sentence": "There was no significant difference in the levels of TG , HDL-C , ApoA1 , ApoB , and the ratio of ApoA1 to ApoB between AA and AG genotypes in the both groups ( @GENE$ 0.05 for all ) . Interactions between genotypes and alcohol consumption on serum lipid parameters The interactions between genotypes of the PCSK9 @VARIANT$ and @DRUG$ consumption on serum TC and LDL-C levels are also shown in Table .", "label": "None"}
{"id": "23994953", "sentence": "NSCLC tumors carrying @GENE$ activating mutations ( e.g. , exon 19 deletions or @VARIANT$ ) respond preferentially to the EGFR TKIs gefitinib and @DRUG$ .", "label": "sensitivity"}
{"id": "24964744", "sentence": "The parental MCF10a cell line showed greater resistance to @DRUG$ than those with mutations in EGFR , KRAS , PI3K , BRAF and AKT ( Figure ) . Greatest sensitivity was seen within the PI3K mutated cells where IndexSUM values decreased from a relatively resistant index of 423 to 120 and 64 for the H1407R and @VARIANT$ mutations of @GENE$ respectively .", "label": "None"}
{"id": "23994953", "sentence": "NSCLC tumors carrying EGFR activating mutations ( e.g. , exon 19 deletions or @VARIANT$ ) respond preferentially to the @GENE$ TKIs @DRUG$ and erlotinib .", "label": "sensitivity"}
{"id": "25562798", "sentence": "The mechanisms of acquired resistance to crizotinib are only just coming to light but , analogous to acquired resistance to EGFR inhibitors , secondary mutations in ALK that render the @GENE$ kinase resistant to inhibition by @DRUG$ have been identified [ , , ] . These mutations including @VARIANT$ in the ALK kinase domain may be susceptible to inhibition with novel ALK inhibitors e.g. , LDK378 , AP26113 , or AF802 .", "label": "resistance"}
{"id": "20102612", "sentence": "For the @VARIANT$ cell line , medium was supplemented with 0,6 μg/ml @GENE$ . 9-cis-RA and BMS493 were dissolved in @DRUG$ and used at 1 × 10-6 M unless otherwise indicated .", "label": "None"}
{"id": "21712828", "sentence": "Consistent with this hypothesis , in a recent meta-analysis of cetuximab clinical trial data , clearly demonstrated that patients with colorectal tumours with a @VARIANT$ mutation were significantly more likely to respond to @DRUG$ treatment than other @GENE$ mutant tumours and survived longer .", "label": "resistance or non-response"}
{"id": "25525597", "sentence": "Another research by Mancuso et al. , also about the effects of @DRUG$ in @GENE$ ( @VARIANT$ ) ALS mice , showed that the protective effects of resveratrol were associated with increased expression and activation of sirtuin 1 and AMPK in the ventral spinal cord .", "label": "None"}
{"id": "23414419", "sentence": "Our findings are in accordance with a prior report by Carlson and colleagues , who demonstrated that @DRUG$ causes cell cytotoxicity by G1-S phase arrest in MDA-MB-468 breast carcinoma cells [ ] . RB protein , a tumor suppressor that blocks @VARIANT$ @GENE$ transcription of E2F-responsive genes involved in cell cycle progression from G1 to S phase .", "label": "None"}
{"id": "24729716", "sentence": "The presence of mutations in the kinase domain of @GENE$ in non-small cell lung cancer ( NSCLC ) patients has been regarded as a predictive marker of good response to tyrosine kinase inhibitors ( TKIs ) , such as gefitinib and @DRUG$ . Nearly 90 % of these mutations occur as either multinucleotide in-frame deletions in exon 19 or as single missense mutations that result in substitution of arginine for leucine at position 858 ( @VARIANT$ ) in exon 21 .", "label": "sensitivity"}
{"id": "PMC3990302", "sentence": "@DRUG$ 250 mg/m2 IV was given on day -3 followed by ONT-10 at the cohort-specific dose ( 250 µg , 500 µg or 1000 µg ) subcutaneously day 1 and then @VARIANT$ for 4 total doses or QW for 8 total doses in a 3+3 dose escalation design . Immune response was assessed by serum titers of MUC1-specific antibodies using M40Tn6 ELISA and by MUC1-specific ELISPOT for @GENE$", "label": "None"}
{"id": "22569033", "sentence": "Heinrich and associates reported on the effect of crenolanib on phosphorylation of the imatinib-resistant @VARIANT$ @GENE$ activating mutation [ ] .", "label": "resistance or non-response"}
{"id": "23986642", "sentence": "While the first and second-generation TKIs have demonstrated improved outcomes in patients with CML and Ph+ ALL , resistance still occurs in a subset of patients who harbor @GENE$ mutations , particularly the @VARIANT$ mutant . Until the recent approval of ponatinib ( Iclusig® , ARIAD Pharmaceuticals , Cambridge , MA , USA ) , there were no approved therapies for patients who had developed resistance , refractoriness , or intolerance to commercially available TKIs .", "label": "None"}
{"id": "24212832", "sentence": "This is in keeping with an earlier study by Di Nicolantonio and colleagues [ ] , where the response to panitumumab or cetuximab was found to be impeded by the presence of BRAF @VARIANT$ mutation and restored ( in a cellular model of CRC cells ) by BRAF inhibitor sorafenib [ ] . They suggested that this experimental observation should encourage conceiving clinical trials using multiple therapies with EGFR and @GENE$ inhibitors , considering that cetuximab , panitumumab , and sorafenib are already approved for clinical use . Standard neoadjuvant chemotherapy , using @DRUG$ or oxaliplatin did not seem to be affected by KRAS/BRAF mutations [ ] .", "label": "None"}
{"id": "24114583", "sentence": "Another second-generation irreversible @GENE$ TKI , dacomitinib , demonstrated preclinical efficacy in NSCLC tumours harbouring the @VARIANT$ gatekeeper mutation , , which is present in ∼50 % of NSCLCs that have acquired resistance to erlotinib or @DRUG$ , .", "label": "resistance or non-response"}
{"id": "24348666", "sentence": "To test this possibility , two types of gefitinib-sensitive cells ( PC9 cells that endogenously express EGFR deletion mutant in exon19 of EGFR gene and HEK293T cells that exogenously express @GENE$ @VARIANT$ mutant ) were transfected with an expression vector encoding the oncogenic K-Ras G12V mutant .", "label": "sensitivity"}
{"id": "23388413", "sentence": "This @GENE$ mutation is known to be related to diverse diseases and to elevate the risk of jaundice and gallstones [ ] . Because treatment with several anti-cancer drugs ( such as @DRUG$ hydrochloride ) can cause bone marrow suppression and severe diarrhea in individuals with the @VARIANT$ polymorphism , screening for polymorphisms in this gene prior to starting such treatments is authorized .", "label": "None"}
{"id": "25580268", "sentence": "A randomized phase II study of WBRT with or without @DRUG$ in patients with @GENE$ breast cancer with brain metastases is ongoing ( NCT01622868 ) . Inhibitors targeting BRAF in melanoma Activating BRAF mutations that result in constitutive activation of the mitogen activated protein kinase pathway affect approximately half of patients with melanoma , and more than 95 % of these are the @VARIANT$ mutation ( substitution of valine by glutamic acid at the 600th amino acid position ) [ ] .", "label": "None"}
{"id": "19238210", "sentence": "The resistant cell line category was the largest and included two mEGFR cell lines , one having the secondary @VARIANT$ mutation and the other having homozygous deletion of PTEN gene . The remaining resistant lines included all of the wild type lines and all lines having KRAS , BRAF , HER2 , HER4 and PIK3CA mutations . Using univariate tests , we analyzed the association between @DRUG$ sensitivity and mutational status or CNGs of the various EGFR pathway genes and found a significant correlation between gefitinib sensitivity with EGFR mutation ( p = 0.002 ) and @GENE$ copy number gains ( p = 0.001 ) .", "label": "resistance or non-response"}
{"id": "23817662", "sentence": "Further studies of @DRUG$ revealed that this 4-anilinoquinazoline inhibitor , structurally similar to erlotinib , binds the EGFR c.2573T & gt ; G ( L858R ) mutant with a 20-fold higher affinity compared to the wild-type enzyme . Both mutations , the activating EGFR c.2573T & gt ; G ( L858R ) and the inhibiting EGFR @GENE$ ; T ( @VARIANT$ ) were found in our cytological assessment .", "label": "None"}
{"id": "23927433", "sentence": "Infiltrate of mature lymphoid cells ( hematoxylin & amp ; eosin , H/E ) , which stained for CD20 ( B cell marker ) , DBA44 and @VARIANT$ @GENE$ ( HCL markers ) . Histology and immunohistology were performed according to standard diagnostic procedures . The severely neutropenic patient was supported with both G-CSF and Epo and underwent ambulatory chemotherapy with the purine analog 2-CDA ( 2-Chlorodeoxyadenosine , leustatin , @DRUG$ ) according to a schedule of 0.1 mg/Kg IV once per week for 4 to 6 weeks .", "label": "None"}
{"id": "22034911", "sentence": "However , the ability of @DRUG$ to inhibit @GENE$ phosphorylation was substantially reduced in all mutants tested , with IC50s & gt ; 1000 nm for @VARIANT$ and G1269S ( ) .", "label": "resistance"}
{"id": "22751098", "sentence": "To test this hypothesis and to clinically validate our preclinical findings , we measured the expression of AXL by IHC ( immunohistochemistry ) in 35 matched @GENE$ NSCLC specimens obtained from patients both prior to treatment with the EGFR TKIs erlotinib or @DRUG$ and upon the development of EGFR TKI acquired resistance . In cases where enough material was available for additional studies , we also examined the specimens for GAS6 and vimentin ( as a marker for EMT ) expression by IHC ( scoring system shown in ) , EGFR @VARIANT$ by sequencing , and MET amplification by FISH .", "label": "resistance or non-response"}
{"id": "25505694", "sentence": "Although cetuximab-afatinib combination showed promising results , current data do not justify its use outside clinical trials . Targeting a specific alteration of the @GENE$ downstreamingsignalling Recently , investigators have identified covalent pyrimidine EGFR inhibitors , which are 30–100 fold more potent than quinazoline based EGFR inhibitors against EGFR @VARIANT$ cells , and up to 100 fold less potent against wild type EGFR cells , as CO-1686 and AP26113 [ ] .", "label": "response"}
{"id": "19687189", "sentence": "Antrodia camphorata solid-state cultured mycelium ( AC-SS , 1 μg ml−1 ) showed adjuvant anti-proliferative effects with cisplatin ( 10 μM ) or mitomycin ( 10 μM ) in hepatoma cell lines C3A and PLC/PRF/5 cells ( in vitro ) and , on xenografted cells in tumor implanted nude mice ( in vivo ) . Furthermore , AC-SS showed its adjuvant effects through the inhibition of MDR gene expressions and the pathway of COX-2 dependent inhibition of AKT phosphorylation [ ] . In terms of the very recent literature , Lu et al. [ ] noted that @DRUG$ extract from wild fruiting bodies of A. camphorata ( EEAC ) dose-dependently induced human premyelocytic leukemia HL 60 cells apoptosis via histone hypoacetylation , upregulation of @GENE$ and downregulation of histone acetyltransferase activities including GCN 5 , CBP and PCAF .", "label": "None"}
{"id": "19920910", "sentence": "The pattern of resistance to nilotinib and dasatinib differed ; those with greatest resistance to nilotinib ( Y253H and E255V ) were susceptible to @DRUG$ . @VARIANT$ remained resistant to all the three drugs . In vivo experiments with CML xenografts in mice demonstrated that nilotinib treatment , compared with treatment with vehicle , improved survival of mice infused with either wild type @GENE$ or the imatinib-resistant Bcr-Abl mutant ( E255V ) ( ; ) .", "label": "None"}
{"id": "22970367", "sentence": "The data suggest that low BRCA1 level may neutralize the negative effects of the @GENE$ T790M mutation on @DRUG$ sensitivity and that high BRCA1 expression may lead to de novo EGFR TKI resistance potentially through increased DNA damage repair capacity [ ] . In addition to EGFR T790M , primary EGFR TKI resistance may also be due to other secondary mutations in EGFR ( e.g. , D761Y ) that occur in cis with an activating EGFR kinase domain mutation ( e.g. , @VARIANT$ ) [ ] .", "label": "sensitivity"}
{"id": "25091415", "sentence": "As in , the histogram plot shows T790 mutant exhibited a higher average distance between M793 and the drug , though the G719 mutation caused @DRUG$ to move closer to the binding site . This result proves that the T790M secondary mutation effectively restores the nucleotide binding property of the @VARIANT$ mutant as observed for the L858R mutant . To identify the specific structural change in the binding pocket that resulted in the observed ligand movements , we calculated time dependent distances among the @GENE$ pharmacophore residues in the hydrophobic region ( L718 and G796 ) .", "label": "sensitivity"}
{"id": "23419122", "sentence": "The studies that established the relationship between mutations in the @GENE$ gene and response to the small molecule EGFR TKIs @DRUG$ and erlotinib were done using analysis of DNA extracted from the tumor [ ] . The recent availability of antibodies that are specific for the mutations most clearly associated with response to EGFR TKIs , @VARIANT$ and E746_A750del , create the opportunity to exploit an alternative method to evaluate NSCLC for EGFR mutations to aid decisions with regard to EGFR TKI therapy [ ] .", "label": "sensitivity"}
{"id": "25405807", "sentence": "Inhibition of @GENE$ activity by EGFR tyrosine kinase inhibitors ( EGFR-TKIs ) , such as gefitinib and @DRUG$ , can result in improved response and prolonged progression-free survival ( PFS ) in selected non-small cell lung cancer ( NSCLC ) patients harboring sensitizing EGFR mutations , especially the exon 19del and exon 21 @VARIANT$ mutations – .", "label": "sensitivity"}
{"id": "19551155", "sentence": "Cdk4 associated with its @DRUG$ cyclin D catalyzes phosphorylation of retinoblastoma family proteins ( pRb ) . Nuclear proteins pRb exhibit numerous threonine or serine residues as phosphorylation sites [ , ] . pRb interact as pocket proteins by binding and inhibiting critical regulatory proteins , including transcription factors of @VARIANT$ family [ ] .", "label": "None"}
{"id": "22933967", "sentence": "In our retrospective study , 26.7 % of patients , all with @GENE$ wild-type tumours , who had previously unresectable liver-only metastases , underwent surgical resection after systemic therapy , with R0 resection achieved in 38 patients ( 21.6 % ) ; one of those was patient with the BRAF @VARIANT$ mutation . Although it is difficult to make any comparison , because our patients were not selected according to specific systemic therapy , these results are comparable with those reported in previous studies claiming that 19 to 23 % patients treated with bevacizumab- and irinotecan based chemotherapy and with previously unresectable liver-only metastases underwent resection.– In a recently published clinical study BOXER , where the patients with unresectable liver-only metastases were treated with oxaliplatin , capecitabine and bevacizumab , R0 resection was achieved in 40 % of patients .", "label": "None"}
{"id": "16187797", "sentence": "Calculated IC50 values for @DRUG$ , erlotinib , and CL-387,785 against D770_N771insNPG were 2.6 μM , 2.5 μM , and 0.2 μM , respectively . CL-387,785 had an even greater effect on colony formation by cells expressing @VARIANT$ @GENE$ , completely inhibiting transformation at 0.003 μM ( unpublished data ) .", "label": "sensitivity"}
{"id": "21445332", "sentence": "At 20 min in the @GENE$ @DRUG$ activity assay , no C4d was detected in the @VARIANT$ lane , but an easily discernable band in wild-type MCP .", "label": "None"}
{"id": "23606169", "sentence": "Because mutations in the KRAS gene result in activation of the epidermal growth factor receptor (EGFR) signaling pathway , only metastatic colorectal cancer patients with wild-type KRAS tumors qualify for anti-EGFR targeted therapies with @DRUG$ or panitumumab [ ] . Also , a clinical trial with the BRAF inhibitor ( PLX4032 ) demonstrated antitumor activity in tumors with the BRAF @VARIANT$ mutation and confirmed that V600E @GENE$ is a valid therapeutic target in human cancer [ ] .", "label": "resistance or non-response"}
{"id": "24894453", "sentence": "A and B expressing G719S ( C ) , and @VARIANT$ ( D ) mutants with or/and without dimerization impairing mutations ( L704N or I941R ) in the absence or presence of EGF treatment for 15 minutes ( 25 ng/ml ) were subjected to immunoblotting with antibodies against phospho-tyrosine ( 4G10 ) and EGFR . In summary , our findings suggest that @GENE$ mutation may underlie at least some cases of @DRUG$ responsiveness in colorectal carcinoma .", "label": "sensitivity"}
{"id": "23566546", "sentence": "Case Histrogical type @GENE$ mutation status Brinkman index Treatment agent Response IL-8 ( ng/mL ) IL-10 ( ng/mL ) RANTES ( pg/ml ) 1 Ad Ex21 @VARIANT$ 900 gefitinib PR 5.79 1.67 2 2 Ad Ex21 L858R 0 erlotinib PR_3.33 94.2 1.41 3 Ad Ex19 del 0 erlotinib PR 4.09 126 2.13 4 Ad Ex21 L858R 0 @DRUG$ PR_3.92 18.1 1.85 5 Ad Ex21 L858R + Ex19 del 370 erlotinib PR 21.9 1.23 2.11 6 Ad Ex19 del 0 erlotinib PR 7.05 1.37 2.56 7 Ad Ex19 del 0 gefitinib PR 4.82 1.59 2.02 8 Ad Ex21 L858R 1640 gefitinib PR 54.9 2.7 2.38 9 Ad negative 400 erlotinib SD 34.9 3.39 3.66 10 Ad negative 0 erlotinib SD 27.1 4.94 2.25 11 Ad unknown 1800 erlotinib SD NE NE NE 12 Sq Ex19 del 3840 gefitinib SD 12.6 1.1 1.98 13 Ad Ex19 del 30 erlotinib SD 5.27 0.69 2.66 14 Ad Ex19 del 0 erlotinib SD 10.5 0.85 2.5 15 Ad unknown 300 erlotinib SD 7.69 2.61 1.7 16 La negative 2080 erlotinib SD NE NE NE 17 Sq Ex21 L858R 750 erlotinib SD 11.6 56.3 3.06 18 Ad unknown 600 erlotinib SD 13.7 1.1 2.82 19 Ad Ex21 L858R 0 erlotinib SD 20.6 11.6 0.783 20 Ad Ex19 del 0 erlotinib SD 14.8 2.07 2.02 21 Ad Ex21 L858R + Ex19 del 0 gefitinib SD 3.04 1.3 1.76 22 Ad Ex19 del 200 gefitinib SD 10.9 1.59 1.91 23 Sq unknown 1560 erlotinib PD NE NE NE 24 Ad negative 1080 erlotinib PD 25.2 8.15 1.57 25 Ad unknown 0 erlotinib PD NE NE NE 26 Ad Ex18 G719A 2000 erlotinib PD 11.6 4.48 3.12 27 Ad unknown 1410 erlotinib PD NE NE NE 28 Ad Ex19 del 1000 gefitinib PD 9.44 2.25 2.89 29 Ad negative 1100 erlotinib PD 56.3 5.63 2.16 30 Ad negative 2000 erlotinib PD 15.6 0.85 0.292 31 Ad negative 825 erlotinib PD 8.27 1.59 2.13 32 Ad Ex21 L858R 0 erlotinib PD 5.34 7.05 1.7 33 Ad negative 1680 erlotinib PD 57.7 1.63 2.06", "label": "sensitivity"}
{"id": "25309870", "sentence": "The treatment effect of @DRUG$ was more pronounced when comparing progression-free survival in the pre defined subgroup of patients with the common Del-19 or Point 21 @VARIANT$ @GENE$ mutations .", "label": "sensitivity"}
{"id": "19452042", "sentence": "Several researchers have identified somatic mutations in the @GENE$ gene and have discovered that these mutations were associated with a higher likelihood of clinical response to treatment with gefitinib and @DRUG$ [ - , ] . EGFR gene mutations were most frequently detected in a subpopulation of NSCLC patients with characteristics associated with a better treatment outcome : female sex , non smokers patients , Asian origin , adenocarcinoma histology . The more common EGFR mutations are an in frame deletion in exon 19 around codons 746 to 750 and a missense mutation leading to leucine to arginine substitution at codon 858 ( @VARIANT$ ) in exon 21 [ ] .", "label": "sensitivity"}
{"id": "24465628", "sentence": "Cover glasses pretreated with acetone , absolute @DRUG$ and 0.1 M @GENE$ in turn were coated and used for immunofluorescence assay . Every three days , half of the mediums were replaced by fresh ones . For nucleoside analogues toxicity experiment , 25 µM @VARIANT$ , 50 µM AZT , 25 µM 3TC , or 25 µM DDI were tested to be the appropriated mtDNA toxicity concentrations which did not inhibit neuron growth by PI and Calcein-AM uptake test and were kept in the cultural medium for seven days respectively .", "label": "None"}
{"id": "18611285", "sentence": "In breast cancer cell line studies , @GENE$ activation markedly increased resistance to microtubule directed agents as well as @DRUG$ and tamoxifen treatment [ , ] . Furthermore , the @VARIANT$ was shown to alter the sensitivity to an allosteric kinase inhibitor but not to ATP competitive inhibitors .", "label": "None"}
{"id": "19920910", "sentence": "Corresponding experiments with mutant @GENE$ kinase domains revealed that a 20-fold improved potency of nilotinib compared with imatinib is also seen with the imatinib-resistant mutants . The mutants , other than @VARIANT$ , that were least responsive to nilotinib in all three cellular assays were Y253H and E255V . The pattern of resistance to nilotinib and @DRUG$ differed ; those with greatest resistance to nilotinib ( Y253H and E255V ) were susceptible to dasatinib .", "label": "None"}
{"id": "23527257", "sentence": "In the erlotinib-resistant cells from PC9 established by Tabara et al , constitutive PI3K/Akt activation was effectively inhibited by afatinib . Moreover , HER2 overexpression and amplification were reported recently to be a potential mechanism of acquired resistance to @GENE$ inhibition in EGFR mutant lung cancers that lack the second-site EGFR @VARIANT$ mutation .", "label": "resistance or non-response"}
{"id": "23983709", "sentence": "Tumor genetic evaluation showed the presence of the @GENE$ @VARIANT$ mutation . She underwent right hemicolectomy , subsequent systemic neoadjuvant chemotherapy with oxaliplatin and @DRUG$ ( XELOX regimen ) for 4 cycles with significant shrinkage of liver nodules and , in February 2009 , resection of hepatic metastases .", "label": "sensitivity"}
{"id": "23864840", "sentence": "Another approach for @VARIANT$ mediated resistance is the dual inhibition of EGFR with afatinib and cetuximab , an @GENE$ blocking antibody resembling the synergistic combination of lapatinib and @DRUG$ in ErbB2 positive breast cancer .", "label": "None"}
{"id": "23674887", "sentence": "Preclinical activity of bosutinib has been reported against most IM-resistant mutants of BCR-ABL with the exception of @VARIANT$ and V299L. , In clinical studies , the impact of preexisting @GENE$ mutations on bosutinib efficacy was evaluated in patients pretreated with IM only ( n = 115 ) or with IM followed by @DRUG$ and/or dasatinib ( n = 39 ) .", "label": "None"}
{"id": "23874486", "sentence": "In a multivariate analysis , patients with G13D mutation tumors treated with @DRUG$ had longer overall survival ( median , 7.6 months vs 5.7 months ) and longer progression-free survival ( median , 4.0 months vs 1.9 months ) than other @GENE$ mutant tumors . Several meta-analysis also got similar results , . Other than that , a pooled analysis of three trials showed that specific mutation in KRAS codon 12 also had different impact on treatment efficacy in colorectal cancer patients and tumor bearing a KRAS @VARIANT$ mutation showed a strong trend to a more favorable outcome comparing to other codon 12 mutations .", "label": "sensitivity"}
{"id": "23527257", "sentence": "The cell line H1975 has a sensitizing L858R kinase domain mutation in exon 21 , and a second @VARIANT$ in exon 20 , in cis , in the @GENE$ kinase domain , rendering them resistant to the reversible TKIs gefitinib and @DRUG$ .", "label": "resistance or non-response"}
{"id": "21192840", "sentence": "Tumor type @GENE$ mutation EGFR expression changes EGFR targeting agents ( FDA approved for clinical use ) Resistance mechanisms Non-small cell lung cancer Kinase domain deletions ( exon 19 ) , point mutations ( exon 21 ) Gene amplification Erlotinib , @DRUG$ @VARIANT$ gatekeeper mutation ( 50 % ) , , elevated c-Met/HGF expression ( 20 % ) –", "label": "resistance or non-response"}
{"id": "23476798", "sentence": "The conclusion was that trametinib improved PFS and OS in patients with @GENE$ V600E mutation or @VARIANT$ [ ] . Other drugs are currently under investigation in combination with chemotherapy such as Lenvatinib , Pazopanib , Dabrafenib , @DRUG$ , Everolimus , Bevacizumab , and so forth [ , ] .", "label": "None"}
{"id": "22773931", "sentence": "A1AT , @VARIANT$ , SOD2 , and CaM proteins were probed for by means of Western blot to verify their presence in a normal breast and different stages of cancer tissue samples ( Figure ) . Cancer tissues that are ER- and PR- ( @DRUG$ receptor negative ) are those cancers that are not affected by anti-hormonal drugs and were proven to be more aggressive than ER+ PR+ breast cancer - , .", "label": "None"}
{"id": "24894453", "sentence": "The results are indicated as mean +/- SD of sextuplicate wells and are representative of three independent experiments ( B and C ) @DRUG$ is effective against SW48 ( @GENE$ @VARIANT$ mutant ) -induced tumors but not HCT8 ( KRAS G13D mutant ) induced-tumors in xenografted mice .", "label": "sensitivity"}
{"id": "25212966", "sentence": "These were defined by estrogen receptor (ER) , @DRUG$ receptor (PR) and human epidermal growth factor receptor 2 ( HER2 ) expression as luminal A ( ER + and/or PR+ , HER2− ) , luminal B ( ER + and/or PR+ , @GENE$ ) , triple negative ( ER− , PR− , HER2− ) and HER2 type ( ER− , PR− , HER2+ ) [ , ] . All four subtypes were present in the cohort of the eighty-eight analyzed patients , and metastasis-free survival significantly differed by subtype ( Additional file : Figure @VARIANT$ ) .", "label": "None"}
{"id": "22536370", "sentence": "Tumors that harbor BRAF V600E mutations display high radiographic response rates to mutant-specific inhibitors such as PLX4032/RG7204/vemurafinib ( Plexxikon/Roche ) , and GSK2118436 ( GlaxoSmithKline ) , while patients whose tumors have certain KIT mutations ( @VARIANT$ , K642E , V559A ) have disease sensitive to the @GENE$ inhibitor , @DRUG$ ( ) , , , , , , , , .", "label": "resistance or non-response"}
{"id": "23299535", "sentence": "A similar theme exists in NSCLCs with a mutation in the @GENE$ – secondary mutations confer insensitivity to the EGFR tyrosine kinase inhibitor ( EGFR-TKI ) gefitinib , and have been identified in patients with clinical resistance to @DRUG$ , but also in untreated patients ( ) . analysed NSCLC samples for one such mutation in EGFR , the @VARIANT$ mutation , from treatment-naïve patients , and from patients before and during treatment with EGFR-TKIs .", "label": "resistance or non-response"}
{"id": "23209813", "sentence": "10.1371/journal.pone.0050701.g001Knocking down KRAS expression in KRAS-mutant ( @VARIANT$ ) CRC cells confers oxaliplatin resistance and ERCC1 upregulation . ( A ) @GENE$ DLD-1G13D cells were more resistant to oxaliplatin , but have the same sensitivity to irinotecan , 5FU , and @DRUG$ than parental DLD-1G13D cells , as demonstrated by MTT assay .", "label": "None"}
{"id": "25033171", "sentence": "Awad has supposed that the solvent front mutation @VARIANT$ may hinder the drug binding to the mutated ROS1 , which seems possible when a small amino acid was replaced by a larger one . Alternatively , it seems that the up-moved P-loop region in @GENE$ could attribute to the crizotinib resistance by attenuating the interactions between the drug and the enlarged binding pocket , which has also been observed in the C1156Y induced @DRUG$ resistance in the ALK tyrosine kinase .", "label": "resistance"}
{"id": "21931712", "sentence": "EGFR was found to harbor mutations in close to 10 % of cases , and @GENE$ inhibitors such as @DRUG$ could be tested in this subset of cancers . In lung cancer , these inhibitors are used to treat cancers that harbor exon 20 variants , codon 719 variants , and @VARIANT$ substitutions in addition to other types of EGFR mutations , .", "label": "sensitivity"}
{"id": "24276379", "sentence": "It has even been observed that cells that have been induced to become cetuximab-resistant by continuously exposing them to @DRUG$ have acquired either @GENE$ G12V or K-Ras @VARIANT$ mutations [ ] .", "label": "resistance or non-response"}
{"id": "25110867", "sentence": "Moreover , dacomitinib showed significant effects in vitro and in vivo against NCI-H1975 cells containing the EGFR @VARIANT$ , T790M mutation . These preclinical models suggest that dacomitinib may be quite effective against lung cancer that becomes resistant to gefitinib or @DRUG$ via acquisition of a T790M mutation in @GENE$ [ ] .", "label": "sensitivity"}
{"id": "25562700", "sentence": "Molecule Target Biomarker Indication vemurafenib BRAF kinase BRAF @VARIANT$ mutant melanoma vandetanib VEGFR , EGFR , RETR not included on the label thyroid cancer @DRUG$ CYP 17A1 not included on the label prostate cancer ipilimumab CTLA-4 not included on the label melanoma brentuximab vedotin CD30 ( ACD technology ) not included on the label lymphoma crizotinib ALK @GENE$ fusion protein lung cancer", "label": "None"}
{"id": "24416052", "sentence": "Further , they represented a SQCLC patient with a wild type EGFR who showed radiological response after treatment with both dasatinib and @DRUG$ in their clinical trial . The patient was confirmed to have a new mutation ( @VARIANT$ ) in the @GENE$ kinase domain .", "label": "response"}
{"id": "24337632", "sentence": "Cells were transiently transfected with pBabe puroL Akt @VARIANT$ T308A S473A ( ΔN-AKT ) plasmid ( kindly provided by Aykut Uren ) for 48 h . They were then treated with 10 μM @DRUG$ , 5 and 10 μM doxorubicin and/or 25 μM LY294002 for both 24 and 48 h before staining with @GENE$ Cells were analyzed by flow cytometry ( FACSCalibur ; BD Biosciences ) and results were analyzed by BD CellQuestPro .", "label": "None"}
{"id": "19669220", "sentence": "@DRUG$ , to which @GENE$ @VARIANT$ is sensitive , may have a role in the therapy of these cases as evidenced by in vitro data as well as its in vivo activity of this drug in recent reports of SM , including a patient with SM-AML [ – ] .", "label": "response"}
{"id": "23109866", "sentence": "The second-generation TKIs may overcome resistance to the treatment of erlotinib or gefitinib via the @VARIANT$ gatekeeper mutation . However , this activity needs to be further validated since it has also been reported that @DRUG$ , a second-generation TKI , was not qualitatively superior in preventing the acquired resistance [ ] . Several irreversible EGFR inhibitors blocked multiple @GENE$ family members , interrupting the cooperative signal pathway among EGFR members and resulted in a more complete blockage .", "label": "response"}
{"id": "19513066", "sentence": "( B ) Srcein lysates of MDA-MB-231 , MCF7 , and @VARIANT$ cells treated for 2 h were immunoblotted as indicated for pSrc-Y416 , stripped and reprobed for total Prot . ( C ) Cells were treated for 48 h with DMSO , 100 nM dasatinib , 100 nM @DRUG$ , or 100 nM of each drug . Whole lysates were immunoblotted for @GENE$ , p21WAF1 , and GAPDH .", "label": "None"}
{"id": "24958351", "sentence": "PI3K mutation and/or loss of PTEN have been shown to contribute to maintained activation of AKT and are associated with innate resistance to @DRUG$ [ ] and lapatinib [ ] . In our study , SKBR3-L cells exhibit a dramatic decrease in p-AKT compared to parental cells , suggesting a decreased dependence on the @VARIANT$ pathway for growth and survival , and no alteration in PTEN levels was observed . A decrease in @GENE$ was also observed indicating that numerous alterations in protein phosphorylation/kinase signaling pathways are occurring simultaneously in SKBR3-L cells .", "label": "None"}
{"id": "15737014", "sentence": "To determine how the @VARIANT$ mutation would affect EGFR proteins already containing mutations associated with sensitivity to EGFR tyrosine kinase inhibitors , we introduced the specific mutation into @GENE$ cDNAs that encoded the exon 21 and 19 mutations found in patients 1 and 2 , respectively . Various lysates from cells that were serum starved and pre treated with @DRUG$ or erlotinib were analyzed by immunoblotting .", "label": "resistance or non-response"}
{"id": "23994953", "sentence": "@VARIANT$ mutation reviewed in . The second well-known mechanism of gefitinib/erlotinib resistance is the MET receptor tyrosine kinase ( RTK ) gene amplification . MET creates a bypass signaling track that activates AKT through HER3 mediated activation of @GENE$ in the presence of EGFR TKIs .", "label": "None"}
{"id": "25429239", "sentence": "Alectinib ( CH5424802 ) is a potent , selective inhibitor of ALK that also potently inhibits the activity of ALK containing the @VARIANT$ gatekeeper mutation. , This compound is also known to work in patients with central nervous system metastasis as it crosses the blood–brain barrier . Ceritinib ( LDK378 ) is a second-generation ALK inhibitor that was granted an accelerated approval by FDA in April 2014 for treatment of patients with @GENE$ metastatic NSCLC following treatment with @DRUG$ .", "label": "resistance"}
{"id": "24876815", "sentence": "Pentheroudakis et al. identified no correlations between mutations in the PI3KCA gene and the efficacy of chemotherapy combined with @DRUG$ . An attempt can be made at explaining divergences in results as attributable to differences in the extent of @GENE$ activation induced by mutations in exons 9 and 20 of the PI3KCA gene [ ] . De Roock et al. argue that the main factor responsible for the excessive activity of phosphatidylinositol kinase is @VARIANT$ substitution .", "label": "None"}
{"id": "24672248", "sentence": "KIT is a type III receptor tyrosine kinase that initiates multiple downstream signaling pathways , such as the PI3K/AKT and @GENE$ pathways . KIT gene mutations are mainly found in melanomas , and @DRUG$ is an effective inhibitor of this oncogene . Here , we observed mutations @VARIANT$ and V559A , which are the most common KIT mutation types .", "label": "None"}
{"id": "25278773", "sentence": "One of the most critical mechanisms for acquired resistance is the gatekeeper EGFR @VARIANT$ missense mutation , which is found in approximately 49 % –63 % of patients who have developed resistance to EGFR inhibitors. , Preliminary studies also indicate that the T790M mutation may play a crucial role in primary resistance to first-generation EGFR inhibitors because of clonal evolution in tumor cells with preexisting T790M mutations . Different strategies have been pursued in the management of progressive disease after treatment with first-generation @GENE$ TKIs , including monotherapies such as dasatinib and neratinib , as well as the rational combinations of cetuximab plus erlotinib and of erlotinib/gefitinib plus everolimus .", "label": "resistance or non-response"}
{"id": "20300583", "sentence": "20 of 21 patients show concordance of the KRAS ( exon 2 , Gly 12/13 ) and @GENE$ ( exon 15 , @VARIANT$ ) mutation status between samples of primary CRCs and/or corresponding metastases before and after combined @DRUG$ therapy .", "label": "resistance or non-response"}
{"id": "23963283", "sentence": "@VARIANT$ and MET amplification account for approximately 60–70 % of all known causes of acquired resistance to @DRUG$ or erlotinib ; these amplifications are not mutually exclusive and can be detected in the same resistant tumor or may occur independently in different metastatic sites in the same patient . Consequently , ongoing research has been focused on identifying the molecular mechanisms accounting for the 30–40 % of @GENE$ TKI-resistant , EGFR-mutant tumors that do not carry EGFR mutations or MET amplification .", "label": "resistance or non-response"}
{"id": "20972475", "sentence": "Also available is a second assay , the @GENE$ ( @VARIANT$ Sequencing ) ( V6S ) , which uses sequencing to detect the BRAF p.Val600Glu sequence variant . Public Health Importance Available evidence indicates that the clinical benefit from treatment with EGFR monoclonal antibody inhibitors cetuximab and @DRUG$ is limited to a subgroup of only 10 % to 30 % of CRC patients .", "label": "resistance or non-response"}
{"id": "23493838", "sentence": "These results were recently confirmed in a larger Phase II study including 449 mostly heavily pretreated chronic phase , accelerated phase , and blast crisis CML patients , as well as patients with Philadelphia positive acute lymphoblastic leukemia with and without the @VARIANT$ mutation . A decreased incidence of progression to accelerated phase or blast crisis has been reported for bosutinib , dasatinib , and nilotinib when compared with @DRUG$ in upfront therapy , even though these differences have only been reported to be statistically significant in the case of nilotinib to date . Deep and early molecular remissions due to improved @GENE$ binding are assumed to play a major role .", "label": "None"}
{"id": "19949544", "sentence": "The @VARIANT$ mutation is most common ( comprising 50 % of mutations ) . KIT gene amplification also occurs [ , ] . @GENE$ mutations are mutually exclusive with BRAF and NRAS , and may identify a subset of melanoma that preferentially respond to the KIT inhibitors such as @DRUG$ ( Gleevec ) [ , ] or sorafenib [ , ] .", "label": "resistance or non-response"}
{"id": "24658650", "sentence": "Downstream effects of @VARIANT$ inhibition resulted in down regulation of proteins that are targets for clinically useful chemotherapeutic drugs , including methotrexate ( MTX , inhibitor of DHFR ) , the 5-fluoropyrimidines and pemetrexed ( inhibitors of TS ) and @DRUG$ ( inhibitor of RR ) .", "label": "None"}
{"id": "22997594", "sentence": "@DRUG$ demonstrates significant inhibitory activity against WT @GENE$ as well as juxtamembrane domain mutant KIT [ , ] . This activity has been proven in patients negative for @VARIANT$ KIT [ ] .", "label": "response"}
{"id": "25368674", "sentence": "Drug concentrations were as follows ; Gefitinib 1um , EMD 121463 1uM and Cetuximab 200ug/ml in MDA-MB-468 , Gefitinib 1um , EMD 121463 5uM and Cetuximab 200ug/ml in HCC 1395 , Gefitinib 5um , EMD 121463 2uM and @DRUG$ 200ug/ml in @VARIANT$ . Evaluation of receptors and downstream pathways after different treatments in TNBC cell lines and T47D . Treated cells were starved with RPMI 1640 medium overnight and next morning , they were stimulated with @GENE$ 20ng/mL and/or recombinant human HGF 75ng/mL for 10 minutes before cell lysis .", "label": "None"}
{"id": "25285017", "sentence": "Although more than 188 EGFR mutations have been identified , 85 % of TKI-sensitive clinical cases harbor only two major mutations : in-frame deletions of exon 19 ( 45 % –50 % ) and a point mutation @VARIANT$ in exon 21 ( 40 % –45 % ; ) . In addition , deletion mutation in exon 19 seems to have a better response to @DRUG$ and erlotinib than mutations at other sites. , Variations in the expression of enzymes associated with EGFR signaling may also account for diverse responses to @GENE$ inhibition .", "label": "sensitivity"}
{"id": "21995722", "sentence": "Our biological model of sensitive and resistant cells consisted of two NSCLC cell lines , HCC827 and H1975 , with different sensitivities to the @GENE$ inhibitor erlotinib. ( ) The HCC827 cell line harbors a mutation in the EGFR tyrosine kinase domain ( E746–A750 ) that renders these cells sensitive to EGFR TKI therapies , whereas the H1975 cells harbor both the L858R and @VARIANT$ mutations and are resistant to EGFR TKIs .", "label": "resistance or non-response"}
{"id": "15737014", "sentence": "To determine how the @VARIANT$ mutation would affect EGFR proteins already containing mutations associated with sensitivity to EGFR tyrosine kinase inhibitors , we introduced the specific mutation into EGFR cDNAs that encoded the exon 21 and 19 mutations found in patients 1 and 2 , respectively . Various lysates from cells that were serum starved and pre treated with @DRUG$ or erlotinib were analyzed by immunoblotting . Amounts of total @GENE$ ( t-EGFR ) were determined using an anti-EGFR monoclonal antibody , and actin served as an indicator of relative levels of protein per sample .", "label": "resistance or non-response"}
{"id": "25580271", "sentence": "A randomized phase II trial compared @DRUG$ to erlotinib plus bevacizumab in patients with activating @GENE$ mutations ( defined as exon 19 deletion and exon 21 @VARIANT$ point mutations ) and advanced stage NSCLC ( n = 152 ) [ ] .", "label": "sensitivity"}
{"id": "24348666", "sentence": "Sasaki et al. reported that cells derived from pleural effusions of patients with EML4-ALK lung cancer who developed acquired resistance to @DRUG$ displayed the gatekeeper @VARIANT$ mutation and high levels of expression of EGFR ligands ( EGF and @GENE$ ) .", "label": "None"}
{"id": "25562700", "sentence": "Molecule Target Biomarker Indication vemurafenib BRAF kinase BRAF @VARIANT$ mutant melanoma vandetanib VEGFR , @GENE$ , RETR not included on the label thyroid cancer @DRUG$ CYP 17A1 not included on the label prostate cancer ipilimumab CTLA-4 not included on the label melanoma brentuximab vedotin CD30 ( ACD technology ) not included on the label lymphoma crizotinib ALK ALK-EML4 fusion protein lung cancer", "label": "None"}
{"id": "24501009", "sentence": "Strategies to improve EGFR inhibition in EGFR @VARIANT$ cancers include the combination of irreversible EGFR inhibitors with the EGFR‐directed antibody cetuximab ( as reported for afatinib plus @DRUG$ ) 19 ; the development of more potent and specific inhibitors of @GENE$ T790M20,21 ; and the use of intermittent but high doses of existing irreversible EGFR inhibitors .", "label": "response"}
{"id": "24894453", "sentence": "To test whether G719S and @VARIANT$ EGFR mutants are cetuximab-sensitive in vitro , we ectopically expressed these mutants in Ba/F3 cells , rendering these cells IL-3 independent but dependent on exogenous oncogenic @GENE$ signaling [ ] .", "label": "sensitivity"}
{"id": "24832599", "sentence": "In spite of recent improvements in NSCLC management , such as the use of targeted therapy including @DRUG$ and erlotinib , which have led to improved progression-free survival and quality of life in NSCLC patients with an activating EGFR mutation , progression or metastasis because of resistance to targeted therapy remains a major clinical problem . Apart from @VARIANT$ and c-MET amplification , a recent study has reported that Axl kinase is upregulated in humans with acquired resistance to EGFR-TKI . Axl may drive cancer cell growth through activation of multiple pathways , such as @GENE$ , AKT and NF-κB , and Axl mediated EGFR-TKI acquired resistance may occur during EMT ; however , Axl mediated molecular alterations in TKI-resistant NSCLC are largely unknown .", "label": "None"}
{"id": "25562798", "sentence": "This shows how vemurafenib can be beneficial for tumors of one molecular phenotype ( @VARIANT$ mutant ) but potentially adverse for another ( HRAS/NRAS mutant ) . Molecular therapeutics in melanoma are not just restricted to treatments directed at the MAPK pathway . In a recent Phase II study of 43 patients with metastatic melanoma with @GENE$ aberrations ( mutation or amplification ) treated with @DRUG$ an overall response rate of 23.3 % was observed [ ] .", "label": "None"}
{"id": "22655263", "sentence": "When tested in Ba/F3 cells driven by @GENE$ mutants identified in crizotinib relapsed patients , NMS-E628 is circa fivefold more potent than @DRUG$ in inhibiting the proliferation of @VARIANT$ ALK and C1156Y ALK-driven-cells in vitro and in vivo ( Ardini et al. , ) .", "label": "resistance"}
{"id": "17177598", "sentence": "However , @DRUG$ did induce dose dependent cell death in @GENE$ subclones expressing the EGFR ectodomain mutants ( missense and vIII truncation ) or EGFR kinase domain mutants ( @VARIANT$ and L861Q ) ( A ) .", "label": "None"}
{"id": "25364578", "sentence": "Studies of ALK rearranged lung cancers with acquired resistance to @DRUG$ have identified ALK fusion gene amplification and secondary @GENE$ TK domain mutations ( @VARIANT$ and G1269A ) in about one third of cases .", "label": "resistance"}
{"id": "15737014", "sentence": "To determine how the @VARIANT$ mutation would affect EGFR proteins already containing mutations associated with sensitivity to EGFR tyrosine kinase inhibitors , we introduced the specific mutation into EGFR cDNAs that encoded the exon 21 and 19 mutations found in patients 1 and 2 , respectively . Various lysates from cells that were serum starved and pre treated with @DRUG$ or erlotinib were analyzed by immunoblotting . Amounts of total EGFR ( @GENE$ ) were determined using an anti-EGFR monoclonal antibody , and actin served as an indicator of relative levels of protein per sample .", "label": "resistance or non-response"}
{"id": "23423768", "sentence": "All @GENE$ mutated patients treated with @DRUG$ or erlotinib invariably develop acquired resistance to this kind of therapy , ( Figure ) . The most common and first identified mutation is the threonine-790 to methionine ( @VARIANT$ ) point mutation in exon 20 which represents approximately 50 % of all acquired resistance in NSCLC .", "label": "resistance or non-response"}
{"id": "22558197", "sentence": "Arresting @VARIANT$ tau expressing SH-SY5Y cells with either mitomycin C ( mito C ) or @DRUG$ RA ) , which causes a cytoplasmic accumulation of SFPQ in P301L tau expressing cells and not , untransfected controls , rules out a direct role for mitosis in the altered localization of SFPQ . In addition , neurons are post-mitotic so the cytoplasmic localization found by us for SFPQ in AD and @GENE$ brains can not be due to mitosis .", "label": "None"}
{"id": "24256696", "sentence": "In mammals , mTOR associates with mammalian lethal with SEC13 protein 8 ( mLST8 ) , @GENE$ AKT substrate of 40 kDa ( AKT1S1 ) and regulatory associated protein of mTOR ( RAPTOR ) to form the rapamycin-sensitive mTOR complex 1 (mTORC1) . The mTORC1 activates protein synthesis through modulation of the 40S ribosomal protein S6 kinase ( @VARIANT$ ) and the translational initiation factor eIF-4E binding protein 1 ( 4E-BP1 ) . mTORC1 is acutely sensitive to inhibition by Sirolimus/Everolimus .", "label": "None"}
{"id": "23606169", "sentence": "These samples were found not to carry mutations in KRAS codons 12 and 13 ; however , the patients , after @DRUG$ treatment and a short remission ( 2 months ) , had new metastasis . Finally , three additional controls were added to our study : the HT29 cell line was included as an internal control for the @VARIANT$ BRAF mutation and KRAS WT . Then two KRAS controls ( Ctrl 8 with the G12D mutation and @GENE$ 9 with the G13D mutation found previously by the TheraScreen® : K-RAS Mutation Kit for the detection of seven mutations ( by DxS Diagnostic Innovations ) [ ] .", "label": "None"}
{"id": "17551677", "sentence": "Mutations in the @GENE$ TK domain are found mostly in subjects who respond to @DRUG$ , as reported in the first three studies conducted in 2004 [ – ] . The same mutations are more frequent in women , in adenocarcinoma , in non-smokers and in Japanese subjects , all with a statistical significance [ ] . These were clustered in exons 18 , 19 and 21 and were either small in-frame deletion ( 746–750 , adjacent to K745 : ELREA aminoacids ) or heterozygous missense mutations ( mainly @VARIANT$ adjacent to the DFG motif in the COOH-terminal lobe in the activation loop of the kinase ) around the ATP binding pocket .", "label": "sensitivity"}
{"id": "25462529", "sentence": "Residue D167 of IN was mutated in this study because it is well conserved in HIV and it is embedded within a short stretch of amino acids ( 161–173 ) with nuclear localization signal properties and important for IN–p75/LEDGF interaction. , , We initially chose @DRUG$ to replace a polar acid residue by a polar basic/neutral one with the purpose to induce a mild phenotype with an integration rate between WT and Q168A vectors . Integrase mutations D167A and @VARIANT$ induced opposite effect on single round infectivity of HIV with D167A increasing it to 140 % while D167K reduced it to 5 % of WT indicating a critical role played by this residue in the processing of the @GENE$ .", "label": "None"}
{"id": "17565683", "sentence": "Histology Immunohistochemistry Mutations @GENE$ CD34 S100 SMA Desmin Gene Site 15 Spindle Positive + - - - C-kit Exon11 , MS 16 Spindle Positive + - - - C-kit Exon11 , IFD 17 Spindle Positive + - - - C-kit Exon11 , MS 18 Spindle Positive + - - - C-kit Exon11 , MS 19 Spindle Positive + - Weak - C-kit Exon11 , IFD 22 Myxoid epithelioid Weak + - + - PDGFRA Exon18 del @VARIANT$ 23 Epithelioid Weak - - - - PDGFRA Exon18 DIMH842-845 26 Epithelioid Weak + NA NA NA PDGFRA Exon18 28 Myxoid epithelioid Weak + - - - PDGFRA Exon12 , V561D MS : miss sense , IFD : in-frame deletion , NA : not available Because of possible relapse even after complete resection of omental GISTs [ - ] and the objective response rate of 67 % of @DRUG$ to the mutation in PDGFRA exon 12 [ ] , our patient received daily oral administration of 300 mg Glevec® , ( we applied 15 % reduced dose , referring to a report by Cormier , et al. after took account of a smaller average of Japanese build than American ) [ , ] .", "label": "None"}
{"id": "24675568", "sentence": "Kim et al. demonstrated a role for the IL-6R/JAK1/STAT3 signaling pathway , leading to STAT3 activation , in de novo resistance to irreversible EGFR-TKIs , such as @DRUG$ , in NSCLC cells with @GENE$ @VARIANT$ [ ] .", "label": "response"}
{"id": "24876821", "sentence": "The other one was a 2-year-old boy at diagnosis , with AML FAB @VARIANT$ , delayed CR1 ( HR ) , early CNS relapse , and a good response to one Flag course and CNS radiotherapy . The third one was a 15-year-old boy with HR AML @GENE$ positive ( FAB data missing ) , late marrow relapse , and remission entry after IdaFlag plus @DRUG$ .", "label": "None"}
{"id": "25071018", "sentence": "The @VARIANT$ mutant mimics the open conformation of SHP-1 and dN1 is the deletion of N-SH2 domain of SHP-1 , and both serve as constitutive activators . @DRUG$ potently relieved the autoinhibition of SHP-1 and contributed to growth inhibition ( A ) Left : Modeled docking of regorafenib into the N-SH2 site of SHP-1 ( pdb code : 3PS5 ) . The N-SH2 domain was in gold , the C-SH2 domain was in marine , the @GENE$ domain was in hot pink , and the linkers between them were in gray .", "label": "None"}
{"id": "24967401", "sentence": "It could be that the simultaneous silencing of PI3KCA and @GENE$ leads to a greater activation of Ras/Raf/MAPK pathway , but this phenomenon needs to be clarified . @VARIANT$ cells are less sensitive to BCNU and @DRUG$ than U87-MG cells [ ] .", "label": "None"}
{"id": "23935640", "sentence": "Ponatinib and imatinib mechanisms of binding to @GENE$ are comparable except for the presence of @DRUG$ 's characteristic carbon-carbon triple bond , between the methylphenyl and purine groups , which allows it to bind to the @VARIANT$ mutation without steric interference [ , ] .", "label": "response"}
{"id": "24387695", "sentence": "Minor responses were demonstrated in 2 patients with neuroendocrine pancreatic cancers and 1 patient with pancreatic adenocarcinoma and PTEN loss ( in addition to KRAS @VARIANT$ mutation ) . In preclinical models , MK-2206 enhanced the activity of conventional cytotoxics and other molecularly targeted therapies [ ] . In vitro , MK-2206 demonstrated synergy with both @DRUG$ and lapatinib in inhibiting proliferation and inducing apoptosis of non-small cell lung ( NSCLC ) cell lines , including those that were @GENE$ mutant , and breast cancer cell lines .", "label": "None"}
{"id": "20444688", "sentence": "In the native enzyme structures ( @GENE$ , WT2 , @VARIANT$ , and D622Nx-H2H3 ) the hydrophobic pocket ( green ) is preformed for recognizing a proline , the catalytic residues Ser538 and D622/N622 are kept in an inactive conformation by H-bonding with Arg624 , and the catalytic residue His657 is disordered . Addition of the inhibitor zPP ( yellow ) to preformed native crystals induces interdomain closure and brings residue Asp150 of the β-propeller domain into the active site to capture Arg624 in an orientation that allows it to H-bond the main chain carbonyl oxygen of the inhibitor ( D622N-zPP ) . Upon further interdomain closure ( WT-zPP ) , the catalytic @DRUG$ on the flexible loop ( green ) becomes fully ordered and forms the catalytic triad that is required for catalysis .", "label": "None"}
{"id": "24294007", "sentence": "Mutations in the proto-oncogene BRAF are present in 5 % –10 % of the metastatic CRC population and are also mutually exclusive of KRAS mutations . BRAF @VARIANT$ is the most common of all BRAF mutations ( present in 90 % of cases ) , and is enriched in a subset of patients who are female , greater than 70 years of age , with KRAS WT right sided colon cancer . This mutation leads to constitutive activation of B-Raf by mimicking a tyrosine-kinase phosphorylation . Emerging evidence from the CRYSTAL , OPUS , and PICCOLO trials supports the use of @GENE$ mutations as negative predictors of response to such EGFR inhibitors as cetuximab and panitumumab. , , Objective response rates are significantly higher in the WT group , from 17 % to 47 % compared to 0 % –8 % in the BRAF mutant group .", "label": "resistance or non-response"}
{"id": "21687596", "sentence": "In the PF2341066-resistant cell line , the @GENE$ signal pathways were activated . Resistance was suppressed by the combined application of PF2341066 and @DRUG$ . MET gene amplification and HGF overexpression often overlap with @VARIANT$ mutations .", "label": "resistance or non-response"}
{"id": "24348666", "sentence": "It was initially proposed that the T790M mutation might prevent the proper binding of tyrosine kinase inhibitors via steric hindrance , similar to the corresponding gatekeeper mutations in BCR-ABL ( @VARIANT$ ) and @GENE$ ( T670I ) that confer resistance to @DRUG$ ( Gleevec ) in chronic myelogenous leukemia and in patients with gastrointestinal stromal tumors .", "label": "None"}
{"id": "22714415", "sentence": "In a study by De Roock et al. , a pooled data set of 579 mCRC patients across various clinical trials treated with @DRUG$ plus/minus chemotherapy demonstrated that overall and progression-free survival was significantly longer in patients with @VARIANT$ @GENE$ mutant tumors .", "label": "resistance or non-response"}
{"id": "23082072", "sentence": "Further , patients with nonsmall cell lung cancer who initially responded to erlotinib or gefitinib therapy showed progression after a median of 12–13 months. , After patients developed acquired resistance confirmed on medical imaging , continuing use of @DRUG$ or gefitinib would lead to a surge in the rate of @GENE$ @VARIANT$ mutation which , in vitro , conferred resistance to treatment with erlotinib and gefitinib .", "label": "resistance or non-response"}
{"id": "23099808", "sentence": "Acquired clinical resistance to @GENE$ was also documented in lung cancer patients , who had an EGFR mutation in exon 20 ( @VARIANT$ ) ( ) . Therefore , in this study , we first examined the effects of @DRUG$ or erlotinib on cell proliferation of the cell lines including those originated from lung adenocarcinoma ( LADCA ) .", "label": "resistance or non-response"}
{"id": "23584600", "sentence": "Rarer mutations include c.1798_1799delinsAG p.Val600Arg ( @VARIANT$ ) , c.1801A &gt ; G p.Lys601Glu ( K601E ) and c.1799_1800delinsAA p.Val600Glu ( V600E2 ) . BRAF mutation results in hyperactivation of the MAPK signalling pathway , causing deregulation of cell proliferation and oncogenesis without the requirement for Ras activation . Braf is the most potent of the Raf proteins to activate the downstream signalling cascade , hence mutant @GENE$ was identified as a novel target for kinase inhibitors such as vemurafenib ( PLX4032/RG7204 ) and dabrafenib .", "label": "None"}
{"id": "25054154", "sentence": "Residual interactions in the protein-drug interface was analyzed by Ligplot ( a ) Native ( b ) Mutant F1174L ( c ) Mutant @VARIANT$ . Analysis of RMSD , RMSF , Rg , and SASA of native and mutant @GENE$ complex at 20000 ps. ( a ) Time evolution of backbone RMSDs of the native and mutant structures .", "label": "sensitivity"}
{"id": "25536104", "sentence": "In our cases with ERBB2 mutation , IHC expression of ERBB2 was not detectable in our study ; one of the ERBB2 mutations was in the kinase domain ( @VARIANT$ ) while 3 involved the extracellular domain ( S310F ) . Based on the current knowledge of @GENE$ biology , @DRUG$ or lapatinib therapy may be value in the extracellular domain mutations but could be of limited clinical benefit for kinase domain mutations and no response to either agents was noted in our cases .", "label": "sensitivity"}
{"id": "21333004", "sentence": "To obtain a logical understanding of the @DRUG$ sensitivity associated with @VARIANT$ mutation , the mathematical analysis of the @GENE$ signaling pathway should be more preferable rather than sole experimental representations .", "label": "sensitivity"}
{"id": "22909314", "sentence": "HC Stain 1 Actin , muscle specific 26 CK17 51 Myogenin 1 Alcian blue- PAS 2 AE1/AE3 27 CK19 52 Napsin A 2 Argentaffin 3 AFP 28 CK5/6 53 NSE 3 Argyrophil 4 hCG 29 Pancytokeratin 54 OCT-4 4 Colloidal iron stain 5 CA-125 30 Desmin 55 @VARIANT$ 5 Elastic , Verhoeff’s 6 Calcitonin 31 E-cadherin 56 p53 6 Mucicarmine 7 Caldesmon 32 EMA 57 p63 7 PAS 8 Calretinin 33 Estrogen Receptor 58 PAX-2 8 PASD 9 CAM 5.2 34 GCDFP-15 59 PAX5 9 PTAH 10 CD10 35 @GENE$ 60 PAX-8 10 Reticulum , Gomori’s 11 CD117 36 Glypican-3 61 PLAP 11 Trichrome , Masson’s 12 CD138 37 Hep-Par1 62 @DRUG$ Receptor 13 CD20 38 HMB 45 63 Prostate Specific Antigen 14 CD3_39 HMW Keratin 64 RCC 15 CD30 40 HNF-1 65 S-100 16 CD34 41 Inhibin 66 Synaptophysin 17 CD43 42 CK , Oscar 67 Thrombomodulin 18 CD45RO 43 Leucocyte Common Antigen 68 Thyroglobulin 19 CD56 44 Mammaglobin 69 TTF1 20 CD99 45 Melan-A 70 Uroplakin 21 CDX2 46 MOC-31 71 Villin 22 CEA-polyclonal 47 MUC 1 72 Vimentin 23 Chromogranin 48 MUC 2 73 WT-1 24 CK 20 49 MUC5AC 25 CK 7 50 Myeloperoxidase", "label": "None"}
{"id": "23493883", "sentence": "The most promising drug thus far has been @DRUG$ ( BIBW2992 ; Boehringer-Ingelheim Pharma , Ingelheim , Germany ) , , an ErbB family blocker with reported in vitro and in vivo activity against @GENE$ mutant tumors harboring exon 19 deletions , exon 21 @VARIANT$ mutations and the exon 20 T790M “resistance” mutations .", "label": "sensitivity"}
{"id": "23874486", "sentence": "Therefore , we tended to believe that patients’ response to therapy mainly contributed to @DRUG$ . Although there were studies proved that patients with @GENE$ @VARIANT$ mutation showed a strong trend to a more favorable outcome comparing to codon 12 mutations , we failed to observe this in our study potentially because of the limited number patients of this study .", "label": "resistance or non-response"}
{"id": "24025253", "sentence": "Off-label use of cetuximab plus sorafenib and @DRUG$ plus regorafenib to personalize therapy for a patient with @VARIANT$ @GENE$ metastatic colon cancer", "label": "resistance or non-response"}
{"id": "20102612", "sentence": "@DRUG$ mitigates the apoptosis induced by chemotherapeutic agents in @VARIANT$ and ZR-75-1 cells , while it is able to increase apoptosis by these compounds in H3396 cells where retinoic acid does not induce cIAP2 expression . Many antiapoptotic proteins , such as Bcl-2 , Mcl-1 and Bcl-XL , have been shown to inhibit chemotherapeutic agent induced apoptosis in diverse cell system models including hematopoietic and neuroblastoma cells . Additionally , it has been shown that the activation of genes encoding @GENE$ and IAP proteins by NF-κB serves to block apoptosis promoted by different insults including chemotherapy induced apoptosis in different cell types [ , ,, ] .", "label": "None"}
{"id": "22970367", "sentence": "L747S is thought to shift the equilibrium towards the active conformation of the receptor , while @VARIANT$ may affect the catalytic cleft of the receptor . Both T854 and D761 were identified in laboratory models of @DRUG$ resistance in addition to clinical samples [ ] . 3.2 . @GENE$ Amplification", "label": "None"}
{"id": "24419415", "sentence": "Our group has undertaken a randomized phase 3 trial to compare gefitinib plus carboplatin plus @DRUG$ with gefitinib monotherapy for patients with NSCLC with an exon 19 deletion or an L858R , @VARIANT$ , or L861Q @GENE$ mutation ( NEJ009 ; University Hospital Medical Information Network Clinical Trials Registry [ UMIN-CTR ] number , UMIN000006340 ) .", "label": "None"}
{"id": "22331137", "sentence": "Pretreatment of animals with DL-propargylglycine (PAG) , a @GENE$ inhibitor , reduced the formation of tissue @VARIANT$ and inflammation induced by lipopolysaccharide , decreased the activity of hepatic myeloperoxidase ( a marker for neutrophil infiltration ) and the tissue damage ( ) . In a recent study from our laboratory , we observed that treatment with PAG reduced the renal damage induced by @DRUG$ injection ( ) .", "label": "None"}
{"id": "21188109", "sentence": "Cyclin D1 , in association with cyclin dependent kinase-4 and -6 , induces the cell to enter the S phase by phosphorylating the retinoblastoma tumor suppressing protein , which binds to transcription factors , including @VARIANT$ . In addition to the overexpression of cyclin D1 , other genes that overexpress in MCL , such as VEGF and Raf-1 , represent further possible targets for mTOR inhibitors . Indeed , a constitutive activation of Akt and mTOR pathways either in MCL cell lines ( Granta 519 , Jeko-1 , and SP-53 ) or in primary cultures from 30 % of MCL patients has been reported. , Moreover , mTOR inhibitors in MCL could synergize with other “canonical” agents , such as vincristine , doxorubicin , bortezomib , and @DRUG$ , with resulting inhibition of Raf-1 , MAPK , and mTOR . ,", "label": "None"}
{"id": "24349829", "sentence": "As would be predicted from the prior studies cited above , miR-7 blunted @GENE$ signaling and reversed the radio-resistance . Correspondingly , direct injection of a liposome encapsulated miR-7 plasmid into established EGFR-TKI sensitive and resistant tumors bearing the @VARIANT$ EGFR mutant resulted in significant tumor regression in conjunction with repression of EGFR , RAF-1 and IRS-1 expression . In head and neck cancer , miR-7 functioned in a synergistic manner with @DRUG$ to render FaDu Erlotinib-resistant cells susceptible to the growth inhibitory activities of the drug .", "label": "None"}
{"id": "23320171", "sentence": "Primary results from the EMILIA study , a randomized trial comparing Trastuzumab DM-1 to lapatinib and @DRUG$ , have shown that Trastuzumab @GENE$ significantly improved progression-free survival in patients with metastatic HER2 positive breast cancer . Further research is looking into inhibiting other targets such as mTOR , @VARIANT$ , or AKT pathways .", "label": "None"}
{"id": "24276379", "sentence": "The H1047R , @VARIANT$ and E545K mutations , all detected in colorectal cancers , code for mutant proteins with higher lipid kinase activity than the wild-type protein [ , ] . These mutations result in @GENE$ activation and cellular transformation [ ] . In a clinical study involving 110 patients , none of the patients with the abovementioned PIK3CA gene mutations respond to panitumumab or @DRUG$ [ ] .", "label": "None"}
{"id": "25562700", "sentence": "Molecule Target Biomarker Indication vemurafenib BRAF kinase BRAF @VARIANT$ mutant melanoma vandetanib VEGFR , EGFR , RETR not included on the label thyroid cancer abiraterone CYP 17A1 not included on the label prostate cancer ipilimumab CTLA-4 not included on the label melanoma brentuximab vedotin CD30 ( ACD technology ) not included on the label lymphoma @DRUG$ ALK ALK-EML4 fusion protein lung cancer BRAF : Serine/threonine-protein kinase B-Raf ; VEGFR : Vascular endothelial growth factor receptor ; EGFR : epidermal growth factor receptor ; RETR : RET proto-oncogen receptor ; CYP 17A1 : cytochrome P450 17A1 ; CTLA-4 : Cytotoxic T-Lymphocyte Antigen 4 ; CD30 : Cluster of Differentiation 30 ; @GENE$ : Antibody Conjugated Drug ; ALK-EML4 : anaplastic lymphoma kinase (ALK) ; echinoderm microtubule associated protein-like 4 ( EML4 ) fusion .", "label": "None"}
{"id": "22720269", "sentence": "The group also demonstrated that HER2 positive breast cancer cell lines with activating @GENE$ mutations ( @VARIANT$ and H1047R ) are more resistant to @DRUG$ than are HER2 positive cell lines without those mutations ( Berns et al. , ; Kataoka et al. , ) .", "label": "None"}
{"id": "23238683", "sentence": "We first investigated the effect of these ITKs on the viability of murine Ba/F3 cells , carrying wild type ( WT ) BCR-ABL , @VARIANT$ or G250E-BCR-ABL mutation . As shown in Figure , BaF3 cells expressing native BCR-ABL were highly sensitive to imatinib , dasatinib and @DRUG$ , whereas @GENE$ and BaF3-G250E-BCR-ABL cells were resistant to both imatinib and dasatinib .", "label": "response"}
{"id": "22038681", "sentence": "Preliminary results from an ongoing phase 1 dose-escalation study of the multikinase , @GENE$ inhibitor ponatinib ( AP24534 ) showed antileukemic activity in patients with refractory CML , including patients with the @VARIANT$ mutation . Phase 1 and 2 trials of ponatinib are ongoing in patients with refractory CML and acute lymphoblastic leukemia . Danusertib ( PHA-739358 ) is a multikinase aurora inhibitor with in vitro activity against wild-type ABL and ABL/T315I ; preliminary results from an ongoing phase 1 dose-escalation study indicate antileukemic activity in patients with AP or BC who failed imatinib and/or nilotinib or @DRUG$ .", "label": "None"}
{"id": "24349829", "sentence": "Correspondingly , direct injection of a liposome encapsulated miR-7 plasmid into established EGFR-TKI sensitive and resistant tumors bearing the @VARIANT$ EGFR mutant resulted in significant tumor regression in conjunction with repression of EGFR , @GENE$ and IRS-1 expression . In head and neck cancer , miR-7 functioned in a synergistic manner with @DRUG$ to render FaDu Erlotinib-resistant cells susceptible to the growth inhibitory activities of the drug .", "label": "None"}
{"id": "22423251", "sentence": "Within the past few months , two targeted treatments have been approved by the U.S. Food and Drug Administration ( FDA ) : vemurafenib ( RO5185426 , PLX4032 ) for the treatment of people with BRAF @VARIANT$ mutation positive metastatic malignant melanoma and @DRUG$ ( PF-02341066 ) for the treatment of advanced @GENE$ non-small cell lung cancer ( NSCLC ) .", "label": "None"}
{"id": "24811491", "sentence": "Acquired resistance EGFR mutations Mutations in the EC domain ( @VARIANT$ ) and in the kinase domain ( codons 714 and 794 ) of @GENE$ found in patients Panitumumab remained active in a patient with S492R mutation , which abrogated @DRUG$ binding .", "label": "resistance"}
{"id": "24312144", "sentence": "Sequist et al that studied neratinib to overcome @VARIANT$ resistance mutation reported responses in G719X @GENE$ mutation , supporting the need of genetic information on trials of targeted agents . According to Ramalingam et al , dacomitinib demonstrated significantly improved PFS versus erlotinib , with acceptable toxicity . Moreover , cetuximab ( marketed as Erbitux® ; Dako , Copenhagen , Denmark ) is a 152 kDa chimeric monoclonal antibody of the immunoglobulin G1 subclass produced in mammalian cell culture by mouse myeloma cells .", "label": "response"}
{"id": "25562798", "sentence": "This shows how vemurafenib can be beneficial for tumors of one molecular phenotype ( @VARIANT$ mutant ) but potentially adverse for another ( HRAS/NRAS mutant ) . Molecular therapeutics in melanoma are not just restricted to treatments directed at the @GENE$ pathway . In a recent Phase II study of 43 patients with metastatic melanoma with KIT aberrations ( mutation or amplification ) treated with @DRUG$ an overall response rate of 23.3 % was observed [ ] .", "label": "None"}
{"id": "22792530", "sentence": "In this study , SW480 and HCT116 cells were more resistant to apoptosis when treated with regimens containing @DRUG$ than when treated with regimens containing bevacizumab . This finding is related to the fact that both cell lines harbor a @GENE$ mutation , with SW480 and HCT116 cells expressing G12V and @VARIANT$ KRAS mutants , respectively .", "label": "resistance or non-response"}
{"id": "23566546", "sentence": "Case Histrogical type @GENE$ mutation status Brinkman index Treatment agent Response IL-8 ( ng/mL ) IL-10 ( ng/mL ) RANTES ( pg/ml ) 1 Ad Ex21 @VARIANT$ 900 gefitinib PR 5.79 1.67 2 2 Ad Ex21 L858R 0 erlotinib PR_3.33 94.2 1.41 3 Ad Ex19 del 0 erlotinib PR 4.09 126 2.13 4 Ad Ex21 L858R 0 gefitinib PR_3.92 18.1 1.85 5 Ad Ex21 L858R + Ex19 del 370 erlotinib PR 21.9 1.23 2.11 6 Ad Ex19 del 0 erlotinib PR 7.05 1.37 2.56 7 Ad Ex19 del 0 @DRUG$ PR 4.82 1.59 2.02 8 Ad Ex21 L858R 1640 gefitinib PR 54.9 2.7 2.38 9 Ad negative 400 erlotinib SD 34.9 3.39 3.66 10 Ad negative 0 erlotinib SD 27.1 4.94 2.25 11 Ad unknown 1800 erlotinib SD NE NE NE 12 Sq Ex19 del 3840 gefitinib SD 12.6 1.1 1.98 13 Ad Ex19 del 30 erlotinib SD 5.27 0.69 2.66 14 Ad Ex19 del 0 erlotinib SD 10.5 0.85 2.5 15 Ad unknown 300 erlotinib SD 7.69 2.61 1.7 16 La negative 2080 erlotinib SD NE NE NE 17 Sq Ex21 L858R 750 erlotinib SD 11.6 56.3 3.06 18 Ad unknown 600 erlotinib SD 13.7 1.1 2.82 19 Ad Ex21 L858R 0 erlotinib SD 20.6 11.6 0.783 20 Ad Ex19 del 0 erlotinib SD 14.8 2.07 2.02 21 Ad Ex21 L858R + Ex19 del 0 gefitinib SD 3.04 1.3 1.76 22 Ad Ex19 del 200 gefitinib SD 10.9 1.59 1.91 23 Sq unknown 1560 erlotinib PD NE NE NE 24 Ad negative 1080 erlotinib PD 25.2 8.15 1.57 25 Ad unknown 0 erlotinib PD NE NE NE 26 Ad Ex18 G719A 2000 erlotinib PD 11.6 4.48 3.12 27 Ad unknown 1410 erlotinib PD NE NE NE 28 Ad Ex19 del 1000 gefitinib PD 9.44 2.25 2.89 29 Ad negative 1100 erlotinib PD 56.3 5.63 2.16 30 Ad negative 2000 erlotinib PD 15.6 0.85 0.292 31 Ad negative 825 erlotinib PD 8.27 1.59 2.13 32 Ad Ex21 L858R 0 erlotinib PD 5.34 7.05 1.7 33 Ad negative 1680 erlotinib PD 57.7 1.63 2.06", "label": "sensitivity"}
{"id": "25465236", "sentence": "( C ) EGFR T790M mutant does not resemble pEGFR unlike the EGFR L858R mutant shown in B. ( D–F ) increased inhibition potency for @DRUG$ against EGFR L858R mutant compared to @GENE$ WT protein and subsequent decrease in potency for Erlotinib against EGFR L858R + E884K double mutant . ( G–I ) increased inhibition potency for Gefitinib against EGFR L858R mutant compared to EGFR WT protein and subsequent further increase in potency for Gefitinib against EGFR L858R + E884K double mutant . ( J ) EGFR @VARIANT$ activated more than T790M but less than L858R .", "label": "None"}
{"id": "22060015", "sentence": "B ) Representative flow cytometric analysis of CD107A of @DRUG$ treated and untreated @VARIANT$ glioma cells ( solid filled , @GENE$ specific T cells alone ; dashed line , NY-ESO-1 specific T cells co-cultured with untreated T98G glioma cells ; solid line , NY-ESO-1 specific T cells co-cultured with decitabine treated T98G glioma cells ) .", "label": "None"}
{"id": "20694077", "sentence": "However , the T315I mutant remained resistant to nilotinib at concentrations & lt ; 10 μM. , @DRUG$ also potently inhibited tyrosine autophosphorylation of the E255K , @VARIANT$ , F317L , M351T , and F486S Bcr-Abl mutants , and these effects were not associated with decreases in Abl or @GENE$ protein levels .", "label": "None"}
{"id": "21814611", "sentence": "In this case , because HBeAg was detected and HBV DNA was still high 3 months after administration of clevudin , it should be clarified that the mutations in the overlapping frame gene regions , S codon L213I ( P codons P221T and @VARIANT$ ) , may be associated with escape mutation as well as drug resistance . An interesting point of this case concerns the sustained HCV suppression , which occurred even with insufficient treatment of @DRUG$ .", "label": "None"}
{"id": "23843700", "sentence": "Therefore , Phase II trials were conducted with @DRUG$ in patients with acral or mucosal melanoma or melanomas on chronically sun damaged skin that harbored @GENE$ mutations or amplifications . Response rates of 16 % –23 % with a small number of complete long-term responses have been seen , with no difference in response rates between the various melanoma subtypes.– Notably , the same KIT mutations ( K642E and N822K ) that have shown response to treatment in gastrointestinal stromal tumors also show response in the treatment of melanoma . Meanwhile , resistance to specific KIT mutations ( V654A and @VARIANT$ ) are observed in both gastrointestinal stromal tumors and melanoma .", "label": "response"}
{"id": "25382104", "sentence": "As shown in , DB07107 and DB06977 showed better docking scores than existing drugs while others showed results comparable to those of marketed drugs like @DRUG$ , bosutinib , bafetinib , dasatinib , nilotinib and imatinib . In the case of DB06977 , although one H_bond is missing ( Met318 ) with the wild-type of @GENE$ complex compared to @VARIANT$ mutant type , it still exhibits a favorable binding score of −10.94 kcal/mol .", "label": "response"}
{"id": "24590311", "sentence": "Pretreatment with carfilzomib followed by addition of imatinib resulted in a significant reduction in viability in @GENE$ @VARIANT$ , Ba/F3 M351T , LAMA84R and KCL22R ( P⩽0.04 ) . ( c ) Western blot analysis of phosphorylated-CRKL in imatinib-sensitive and -resistant cell lines following exposure to carfilzomib , imatinib or a combination of carfilzomib at t=0 , followed by imatinib at t=24 ; whole cell lysates were prepared 48 h after exposure to the first drug . ( d ) CML CD34+ cells ( n=3 ) were cultured in the presence of carfilzomib , imatinib , nilotinib or a combination of carfilzomib plus imatinib/nilotinib either simultaneously or carfilzomib at t=0 , followed by imatinib/nilotinib at t=24 ; after 48 h , cells were transferred to LTC-IC assays .", "label": "None"}
{"id": "24141978", "sentence": "Genetic mutations of some common oncogenes associated with @GENE$ pathway , e.g . KRAS , BRAF ( @VARIANT$ ) , c-MET , EGFR , AKT and PI3KC have also been investigated in these models by hot-spot mutation sequencing . Therefore , the non-response of GC xenografts to @DRUG$ apparently can not be simply attributed to these oncogene mutations .", "label": "None"}
{"id": "16187797", "sentence": "Insertion mutant autophosphorylation is less sensitive to inhibition by gefitinib than that of @VARIANT$ , but CL-387,785 is more effective than gefitinib at inhibiting insertion mutant ( and L858R ) autophosphorylation . Discussion Treatment with the EGFR inhibitors gefitinib and @DRUG$ has led to dramatic responses in many lung cancer patients , predominantly for those cancers in which @GENE$ mutations can be detected .", "label": "sensitivity"}
{"id": "25505694", "sentence": "As expected , patients were mainly East Asian , never-smokers and women ; EGFR mutations were predominantly exon 19 deletions and @VARIANT$ point mutations . The PFS assessed by independent review ( primary endpoint ) has been significantly prolonged in the @DRUG$ arm compared to chemotherapy arm , with median PFS of 11.1 and 6.9 months , and 13.6 versus 6.9 months in patients with classical ( exon 19 deletion or exon 21 ) @GENE$ mutations .", "label": "sensitivity"}
{"id": "19758442", "sentence": "The regions responsible for interaction with A3G ( red ) and @VARIANT$ ( blue ) are discontinuous . They overlap but are not identical . The region important for interaction with the @GENE$ ubiquitin ligase complex is marked in green and includes a conserved histidine-cysteine-cysteine-histidine motif and a suppressor of cytokine signaling Box domain .", "label": "None"}
{"id": "24789720", "sentence": "Mechanism of achieving resistance to @DRUG$ and gefitinib remains unclear . The recent reports confirmed , that T790M substitution could be detected in @GENE$ naïve patients independently of other EGFR gene mutations ( predominantly @VARIANT$ substitution and deletions in exon 19 ) .", "label": "sensitivity"}
{"id": "25405807", "sentence": "Inhibition of @GENE$ activity by EGFR tyrosine kinase inhibitors ( EGFR-TKIs ) , such as gefitinib and @DRUG$ , can result in improved response and prolonged progression-free survival ( PFS ) in selected non-small cell lung cancer ( NSCLC ) patients harboring sensitizing EGFR mutations , especially the exon 19del and exon 21 L858R mutations – . Unfortunately , almost all patients will ultimately develop resistance to EGFR-TKI , in whom more than 50 % cases were detected harboring the EGFR @VARIANT$ mutation in tumor specimens after EGFR-TKI , .", "label": "resistance or non-response"}
{"id": "24939055", "sentence": "Although irreversible EGFR-TKIs , including BIBW2992 , have been developed to overcome @VARIANT$ mediated resistance to gefitinib [ ] , recent clinical trials have failed to show that monotherapy with irreversible @GENE$ has benefits in patients with NSCLC refractory to @DRUG$ [ ] .", "label": "resistance or non-response"}
{"id": "24523596", "sentence": "Recently , genome-wide screening for the genetic determinants of gout found that an SNP of ABCG2/BCRP ( @VARIANT$ ) is associated with high uric acid levels , and demonstrated that uric acid is a natural substrate of ABCG2/BCRP. , ABCG2/BCRP also appears to play a protective role against xenobiotics and their metabolites. , The typical ABCG2/BCRP substrates , @DRUG$ and SN-38 , are detoxified by glucuronidation with uridine-diphosphate–glucuronyltransferase , and @GENE$ can extrude SN-38–glucuronide .", "label": "None"}
{"id": "24009732", "sentence": "Targeted therapy to inhibit the oncogene FIP1L1-PDGFRα has met with some success : the first-generation tyrosine kinase inhibitor ( TKI ) @DRUG$ has been reported to be effective to @GENE$ , but imatinib-resistant mutations emerged . Several mutations in the kinase domains such as @VARIANT$ , T674I , S601P and L629P , have been demonstrated to be responsible for the drug-resistance .", "label": "None"}
{"id": "25562700", "sentence": "Molecule Target Biomarker Indication vemurafenib BRAF kinase BRAF @VARIANT$ mutant melanoma vandetanib VEGFR , EGFR , RETR not included on the label thyroid cancer abiraterone CYP 17A1 not included on the label prostate cancer @DRUG$ CTLA-4 not included on the label melanoma brentuximab vedotin CD30 ( ACD technology ) not included on the label lymphoma crizotinib ALK ALK-EML4 fusion protein lung cancer BRAF : Serine/threonine-protein kinase B-Raf ; VEGFR : Vascular endothelial growth factor receptor ; EGFR : epidermal growth factor receptor ; RETR : RET proto-oncogen receptor ; CYP 17A1 : cytochrome P450 17A1 ; CTLA-4 : Cytotoxic @GENE$ ; CD30 : Cluster of Differentiation 30 ; ADC : Antibody Conjugated Drug ; ALK-EML4 : anaplastic lymphoma kinase (ALK) ; echinoderm microtubule associated protein-like 4 ( EML4 ) fusion .", "label": "None"}
{"id": "24964744", "sentence": "MCF10a cells containing the @GENE$ mutation H1047R showed little sensitivity to single agent sirolimus , and in combination with EGFR inhibitors were still seen to be more resistant than their parental counterpart , and were more resistant than MCF10a cells containing the PIK3CA @VARIANT$ mutation . Chou and Talalay combination indices for each cell line examined Gefitinib + ZSTK474 Erlotinib + ZSTK474 Gefitinib + Rapamycin Erlotinib + Rapamycin @DRUG$ + ZSTK474 Erlotinib + ZSTK474 Gefitinib + Rapamycin Erlotinib + Rapamycin", "label": "resistance or non-response"}
{"id": "17931419", "sentence": "H1975 cells , which also contain a second mutation ( @VARIANT$ ) linked to gefitinib resistance [ ] , responded poorly to either agent . Dose- and time dependent responses of wild-type @GENE$ and tyrosine kinase domain mutated EGFR cells to @DRUG$ and gefitinib treatment .", "label": "response"}
{"id": "18822137", "sentence": "In contrast , it only sensitizes MDA-MB-452 and @VARIANT$ cells , which have low IAPs expression , to TRAIL or @DRUG$ . Recently , it has been described that compounds that mimic Smac/DIABLO induce the activation of the @GENE$ pathway eliciting TNF-α dependent apoptosis via caspase-8 activation [ ] .", "label": "None"}
{"id": "11237392", "sentence": "We chose 2 inhibitors which would affect all pathways downstream of Ras ( simvastatin and @DRUG$ ) and a third inhibitor which should primarily affect the @GENE$ pathway by depleting Raf ( 17-AAG ) . Whereas the spectrum of NIH 3T3 cells was not affected by treatment , @VARIANT$ cells showed a drop in PC levels after treatment .", "label": "None"}
{"id": "24729716", "sentence": "Considering the extremely low prevalence of primary EGFR @VARIANT$ mutation in NSCLC patients , screening of this mutation in a large cohort is necessary to define the clinicopathological features and molecular correlations . @DRUG$ sensitizing @GENE$ mutations , such as L858R and exon 19 in-frame deletions , selectively activate antiapoptosis signaling pathways .", "label": "resistance or non-response"}
{"id": "19758442", "sentence": "The regions responsible for interaction with A3G ( red ) and @VARIANT$ ( blue ) are discontinuous . They overlap but are not identical . The region important for interaction with the @GENE$ ubiquitin ligase complex is marked in green and includes a conserved histidine-cysteine-cysteine-histidine motif and a suppressor of cytokine signaling Box domain .", "label": "None"}
{"id": "24516334", "sentence": "@DRUG$ is a powerful @GENE$ TKI and is promising for patients with CML or Ph+ acute lymphoblastic leukemia who fail imatinib , dasatinib , and nilotinib . It is also active against @VARIANT$ and other imatinib-resistant mutants .", "label": "response"}
{"id": "23606169", "sentence": "Because mutations in the KRAS gene result in activation of the epidermal growth factor receptor (EGFR) signaling pathway , only metastatic colorectal cancer patients with wild-type KRAS tumors qualify for anti-EGFR targeted therapies with cetuximab or @DRUG$ [ ] . Also , a clinical trial with the BRAF inhibitor ( PLX4032 ) demonstrated antitumor activity in tumors with the BRAF @VARIANT$ mutation and confirmed that V600E @GENE$ is a valid therapeutic target in human cancer [ ] .", "label": "resistance or non-response"}
{"id": "25376241", "sentence": "To determine whether the wild-type and @VARIANT$ β-catenin proteins differed in terms of transcription @DRUG$ activity , we conducted a assay in which we cotransfected the wild-type or C429S β-catenin cDNA with the canonical @GENE$ TOP-FLASH reporter plasmid into HEK293 cells , which have been popularly used in TOPFLASH assays .", "label": "None"}
{"id": "21034468", "sentence": "MCF7ErbB2 cells were treated with @DRUG$ ( 0 or 400 mg/dl ) with/without @VARIANT$ ( 10 , 20 or 40 μM ) for 48 h. Cells were seeded on fibronectin coated culture wells for 3 h . A : Cell lysates were collected and analyzed for the phosphorylation/expression of JNKs with immunoblotting . B : Cell lysates were IP with an anti-JNK antibody and IB with either an @GENE$ or anti-JNK antibody .", "label": "None"}
{"id": "22343623", "sentence": "However , patients with wild-type @GENE$ and acquired mutation in EGFR @VARIANT$ are eventually resistant to treatment with @DRUG$ .", "label": "resistance or non-response"}
{"id": "24811491", "sentence": "Acquired resistance @GENE$ mutations Mutations in the EC domain ( @VARIANT$ ) and in the kinase domain ( codons 714 and 794 ) of EGFR found in patients Panitumumab remained active in a patient with S492R mutation , which abrogated @DRUG$ binding .", "label": "resistance"}
{"id": "22101934", "sentence": "Given their resistance to lapatinib and @DRUG$ , there appears to be little rationale for the use of these agents in non-small cell lung cancer containing L858R and Δ746–750 @GENE$ mutations whereas erlotinib’s clinical benefit in these cases is readily understood . Furthermore , targeting cancers with these oncogenic mutations with MIG6 peptidomimetics appears to be a challenging proposition since competition for this dimer interface will be difficult . In future experiments with tEGFRs , it will be interesting to determine the effects of the gatekeeper @VARIANT$ drug resistance mutation on the relative activation and inhibitor sensitivities of these enzymes .", "label": "response"}
{"id": "23937717", "sentence": "The functional relevance of restoration of NKG2D–NKG2DL interaction by gefitinib was demonstrated by the enhanced cytotoxicity , degranulation and IFN-γ production of NK cells in response to lung cancer cells with @GENE$ L858R + @VARIANT$ resistance mutation . Recently , immune system has been demonstrated to contribute substantially to the antitumor effects of small molecule inhibitors . Through the inhibition of IDO , @DRUG$ potentiates antitumor T cell responses in gastrointestinal stromal tumor [ ] .", "label": "None"}
{"id": "23569464", "sentence": "However , co-administration of 10 µM @VARIANT$ exhibited a synergistic effect with chemotherapy agents docetaxel , @DRUG$ and cyclophosphamide increasing their cytotoxicity against MDA-MB-361 cells by almost 2-fold , 3-fold and 10-fold , respectively .", "label": "None"}
{"id": "22662154", "sentence": "Group Cell line Mutational status Copy number alterations IC50 ( nM ) PIK3CA PTEN ( mutated exons ) K-Ras PIK3CA PTEN K-Ras BEZ235 @DRUG$ C HEC-1B Mut ( G1049R ) wild type Mut ( G12D ) Gain nl nl 220 200 HHUA Mut ( R88Q ) Mut 5 ( F ) , 8 ( F ) Mut ( @VARIANT$ ) nl nl nl 250 & gt ; 1000", "label": "None"}
{"id": "23348520", "sentence": "Indeed , in non-small cell lung cancers treated with gefitinib or @DRUG$ , sensitive patients have the @GENE$ @VARIANT$ mutation in only a few cells , whereas resistant patients exhibit EGFR T790M in the majority of the tumour cells ( ; ) .", "label": "resistance or non-response"}
{"id": "23861935", "sentence": "The latter binds the @GENE$ to mediate HASMC contraction . Unlike our data showing a decreased expression of CysLT1R in response to Pam3CSK4 , poly ( I:C ) , LPS , @DRUG$ and iE-DAP , Morishima et al. have recently shown that poly ( I:C ) decreased the muscarinic acetylcholine receptor @VARIANT$ and increased M3R expression without affecting histamine receptor H1R or CysLT1R , which correlated to intracellular calcium mobilization .", "label": "None"}
{"id": "24466541", "sentence": "Similarly , our case demonstrated BRAF @VARIANT$ mutation , wild-type KRAS and no evidence of microsatellite instability on immunohistochemical workup . However , we did not assess our case for CpG island methylation status . From the therapeutic standpoint , wild-type KRAS status would imply tumor responsiveness to novel biological molecules such as @DRUG$ or anti-epidermal growth factor receptor (EGFR) compounds ; however , a @GENE$ mutation and rhabdoid morphology would signify the opposite : a poor response to conventional and novel chemotherapy regimens and a likely refractory disease with relapses .", "label": "sensitivity"}
{"id": "23788917", "sentence": "The T790M mutation leads to a substitution of threonine to methionine in the catalytic centre of @GENE$ tyrosine kinase , which is located in the binding pocket of TKI and ATP . Substitution of threonine at codon 790 into larger methionine probably results in blocking of the binding sites of erlotinib and @DRUG$ aromatic residues with their point of action . In vitro studies demonstrated that the effective concentration of erlotinib in tumour cells harbouring both the L858R and @VARIANT$ mutations has to be 300 times higher to induce apoptosis than in cells only with an activating mutation in codon 858 [ , ] .", "label": "resistance or non-response"}
{"id": "24155950", "sentence": "Additionally , we have used the Baf3 Bcr-Abl @VARIANT$ cell line , derived from @GENE$ ( an immortalized murine pro-B cell line ) , which is also resistant to 1μM imatinib and at least partially resistant to dasatinib and @DRUG$ treatments ( -6 ) .", "label": "None"}
{"id": "24419415", "sentence": "Retrospective studies and case reports suggest that some uncommon mutations are associated with sensitivity to EGFR-TKIs.– These mutations include @VARIANT$ in exon 18 , which accounts for approximately 3 % of EGFR mutations , and L861Q in exon 21 , which represents approximately 2 % of EGFR mutations . However , these uncommon EGFR mutations have not been clearly shown to be predictive markers for the efficacy of EGFR-TKIs because of their low frequency . To investigate the efficacy of gefitinib in patients with uncommon mutations , we conducted a post-hoc analysis of the NEJ002 , which compared @DRUG$ and carboplatin-paclitaxel as first-line therapies for advanced NSCLC with activating @GENE$ mutations .", "label": "None"}
{"id": "23776354", "sentence": "In short , almost all GIST with exon 11 mutations responded to imatinib , patients with exon 9 mutations should receive a 800 mg daily dose of @DRUG$ , and @VARIANT$ @GENE$ mutation is predictive of primary resistance .", "label": "resistance or non-response"}
{"id": "24071646", "sentence": "Besides , we transfected PI3K mutation plasmid-PIK3CA ( @VARIANT$ ) into A549 and Calu1 cells . As shown in , atorvastatin could also enhance the gefitinib efficacy in these transfected cells , confirming that atorvastatin can sensitize NSCLC cells to @DRUG$ in the presence of comutant @GENE$ .", "label": "resistance or non-response"}
{"id": "24523596", "sentence": "Δ-235A −113A&gt ; G −29A&gt ; G @GENE$ @VARIANT$ N-terminal 114T & gt ; C No change N-terminal 151G&gt ; T G51C N-terminal 369C&gt ; T No change NBD 376C&gt ; T Q126stop NBD 421C&gt ; A Q141K NBD Increased bioavailability of @DRUG$ and lactone form of 9-aminocamptotecin .", "label": "None"}
{"id": "24928511", "sentence": "More than 50 % of lung adenocarcinomas (LAD) from East Asian non-smokers harbor EGFR mutations , and these tumors have been termed oncogene addicted to reflect their dependence on EGFR mediated pro-survival signaling and their high susceptibility to apoptosis induced by EGFR-TKIs ( e.g. gefitinib and @DRUG$ ) ( ) . The most frequently occurring mutations in the EGFR gene ( in-frame deletion in exon 19 at codons 746–750 or a single-base substitution @VARIANT$ in exon 21 ) predict an improved clinical response to first-line oral EGFR-TKIs compared with standard platinum based chemotherapy in patients with advanced non-small-cell lung carcinoma ( NSCLC ) ( , ) . There is accumulating evidence that genetic mutations in cancer-driver genes , tumor suppressors , and amplified oncogenes are linked to specific alterations in metabolic activity in cancer cells , involving proteins such as isocitrate dehydrogenase (IDH) , fumarate hydratase (FH) , @GENE$ , K-RAS , and BRAF ( ) .", "label": "None"}
{"id": "23606169", "sentence": "Also , a clinical trial with the @GENE$ inhibitor ( @DRUG$ ) demonstrated antitumor activity in tumors with the BRAF @VARIANT$ mutation and confirmed that V600E BRAF is a valid therapeutic target in human cancer [ ] .", "label": "None"}
{"id": "17973572", "sentence": "Transient transfection experiments utilizing COS-7 cells demonstrated that auto-phosphorylation of the original L858R @GENE$ was inhibited by lower concentrations of @DRUG$ or erlotinib than the L858R-L747S or L858R-T790M constructs ( A ) . CL-387,785 partially overcame the observed inhibition ( B ) . To prove the functional significance of the @VARIANT$ mutation , we generated Ba/F3 cell lines stably expressing mutant EGFR constructs [ ] .", "label": "None"}
{"id": "24555578", "sentence": "Repeat cytology of her right pleural fluid showed adenocarcinoma with an @GENE$ exon 19 deletion and a second mutation of @VARIANT$ associated with EGFR-TKI resistance . We introduced cytotoxic chemotherapy . After five cycles of @DRUG$ pemetrexed , a relapse in her right pleural effusion was noted ( Figure c ) .", "label": "None"}
{"id": "24155950", "sentence": "C. @GENE$ Bcr-Abl and Baf3 Bcr-Abl @VARIANT$ cell lines were treated with 7nM @DRUG$ and 7nM paclitaxel for 48h , followed by detection of the total levels and phosphorylation of Bcr-Abl .", "label": "None"}
{"id": "25222496", "sentence": "However , an in vitro study showed that the growth of NSCLC cell lines harboring exon 19 deletion or @VARIANT$ mutation were almost equally inhibited by equivalent concentrations of @DRUG$ , and the degree of @GENE$ phosphorylation .", "label": "sensitivity"}
{"id": "22140458", "sentence": "The second generation @GENE$ inhibitors dasatinib and nilotinib are effective in most CML patients following failure of @DRUG$ therapy . However , one potential limitation of these therapies is that their increased potency may be associated with additional side-effects . In addition , none of these inhibitors have demonstrated significant activity against cells harboring the @VARIANT$ resistance mutation .", "label": "None"}
{"id": "21980499", "sentence": "Of these two candidate variants , the A218G in @GENE$ changes a histidine ( H ) to arginine ( R ) at position 73 ( @VARIANT$ ) and disrupted a string of histidine repeats in exon 1 , while the 9-base insertion c.82insACAGCGCCC ( referred as INS allele ) in exon 1 of HOXB1 introduces into the amino acid sequence the tripeptide histidine-serine-alanine ( H-S-A ) .", "label": "None"}
{"id": "22428003", "sentence": "On the other hand , others have suggested a dynamic hypothesis in which the @VARIANT$ substitution interrupts a “network of coupled promoting vibrations” that are required for DHFR catalysis , . Indeed , our work showed that the active site of DHFR is dynamically coupled to G121 . When @DRUG$ @GENE$ to the DHFR holoenzyme forming the ternary E : NADPH : MTX complex , G121 becomes more flexible on the ps-ns timescale and chemical exchange on the µs-ms timescale is quenched .", "label": "None"}
{"id": "20234366", "sentence": "Although other mutationally activated protein kinases downstream of EGFR are being evaluated as potential biomarkers of resistance to @DRUG$ , so far none of them has sufficient supporting evidence to be routinely used in clinical practice . The @VARIANT$ @GENE$ mutation is present in ∼5–10 % of CRC patients and is mutually exclusive with KRAS mutations .", "label": "resistance or non-response"}
{"id": "24790411", "sentence": "@DRUG$ and gefitinib belong to the first generation of TKIs and have reversible binding features . The principal predictive factor for response to such drugs is the presence of somatic “activating” mutations in the EGFR gene that cause an aberrant and constitutive activation of the receptor at the membrane level , resulting in a growth advantage of tumor cells through the activation of @GENE$ , PI3K/Akt , and STAT signaling pathways . In about 50 % of cases , a secondary mutation ( @VARIANT$ ) is supposed to be responsible for resistance. , Other mechanisms involve MET gene amplification ( 5 % –20 % ) ,", "label": "None"}
{"id": "22655263", "sentence": "The @VARIANT$ gatekeeper mutation and the C1156Y and L1152R mutants were identified in the relapsed NSCLC cases , and the F1174L mutation in the relapsed IMT ( Choi et al. , ; Sasaki et al. , , ) . The mechanisms underlying decreased activity of @DRUG$ on these secondary @GENE$ mutants were investigated by structural and biochemical analyses , together with cellular data generated in engineered in vitro models .", "label": "resistance"}
{"id": "24348666", "sentence": "Although the resistant cell line @GENE$ does not have the EGFR @VARIANT$ mutation , it was found to have MET amplification . MET is a receptor tyrosine kinase that binds to hepatocyte growth factor (HGF) and is associated with the development of various human cancers . Therefore , EGFR-TKIs fail to inhibit the PI3K/Akt pathway dependent growth signal because the constitutive phosphorylation of HER3 by MET occurs independent of EGFR activation , which causes the cells to acquire resistance to @DRUG$ .", "label": "None"}
{"id": "19758442", "sentence": "The regions responsible for interaction with @VARIANT$ ( red ) and A3F ( blue ) are discontinuous . They overlap but are not identical . The region important for interaction with the Cul5 @GENE$ marked in green and includes a conserved histidine-cysteine-cysteine-histidine motif and a suppressor of cytokine signaling Box domain .", "label": "None"}
{"id": "24495353", "sentence": "Rank Entrez ID Gene symbol Entrez ID Gene symbol Entrez ID Gene symbol 1 28978 TMEM14A 79776 ZFHX4 1727 CYB5R3 2 1843 DUSP1 4701 NDUFA7 7083 TK1 3 51022 GLRX2 715 @VARIANT$ 1292 COL6A2 4 1434 CSE1L 79818 ZNF552 857 CAV1 5 8522 GAS7 4046 LSP1 5437 POLR2H 6 51668 HSPB11 1727 CYB5R3 9833 MELK 7 10456 HAX1 357 SHROOM2 54861 SNRK 8 9902 MRC2 283298 OLFML1 4830 NME1 9 4706 NDUFAB1 23179 RGL1 231 AKR1B1 10 23560 GTPBP4 1809 DPYSL3 10418 SPON1 11 79633 FAT4 857 CAV1 2350 FOLR2 12 10418 SPON1 274 BIN1 10979 FERMT2 13 471 ATIC 79833 GEMIN6 11096 ADAMTS5 14 6403 SELP 11222 MRPL3 4638 MYLK 15 23421 ITGB3BP 23244 PDS5A 9448 MAP4K4 16 23452 ANGPTL2 6241 RRM2 54922 RASIP1 17 54861 SNRK 1289 COL5A1 6934 TCF7L2 18 2034 EPAS1 8434 RECK 4072 EPCAM 19 30008 EFEMP2 429 ASCL1 4701 NDUFA7 20 25999 CLIP3 3426 CFI 404672 GTF2H5 21 4311 MME 332 BIRC5 6241 RRM2 22 4747 NEFL 2 A2M 2192 @GENE$ 23 1809 DPYSL3 10730 YME1L1 25959 KANK2 24 28998 MRPL13 11130 ZWINT 55651 NHP2 25 25959 KANK2 1292 COL6A2 5050 PAFAH1B3 Lists of the top 25 of most influential genes in influence networks based on coexpression among genes in ER + breast tumors before , during , and after a course of neoadjuvant treatment with the drug @DRUG$ .", "label": "None"}
{"id": "24586842", "sentence": "Successful examples of this include the co-development ( and co-approval ) of the @GENE$ inhibitor vemurafenib and its companion diagnostic BRAF @VARIANT$ mutation assay for BRAF-mutant metastatic melanoma , and the ALK inhibitor crizotinib and its companion diagnostic ALK fusion gene test in advanced ALK-fusion positive non-small cell lung cancer ( NSCLC ) patients. , , However , in some cases , predictive biomarkers for a targeted therapy are not recognized until after the drug is first approved . As an example , the anti-EGFR antibody @DRUG$ was first approved in the US for the treatment of metastatic colorectal cancer in 2004 .", "label": "resistance or non-response"}
{"id": "23493883", "sentence": "Combinations of therapy such as cetuximab plus erlotinib and @DRUG$ plus everolimus have also been tried . The most promising drug thus far has been afatinib ( BIBW2992 ; Boehringer-Ingelheim Pharma , Ingelheim , Germany ) , , an @GENE$ family blocker with reported in vitro and in vivo activity against EGFR mutant tumors harboring exon 19 deletions , exon 21 L858R mutations and the exon 20 @VARIANT$ “resistance” mutations .", "label": "resistance or non-response"}
{"id": "25364578", "sentence": "Y845 ( pY845 ) phosphorylation stabilizes the activation loop , maintains the enzyme in an active state , and regulates @GENE$ activity . Surprisingly , the EGFR @VARIANT$ mutation leads to decreased ability to activate ERK compared to WT EGFR which correlates with decreased EGFR internalization , reduced phosphorylation of SHP2 , hyperactivity of STAT3 and reduced sensitivity to @DRUG$ .", "label": "None"}
{"id": "23234355", "sentence": "The combination of a TKI and a mAb was explored as a potential strategy to overcome acquired resistance to first-generation @GENE$ . Kim and colleagues demonstrated that the combination of lapatinib with @DRUG$ overcame gefitinib resistance due to the secondary @VARIANT$ mutation in NSCLC by inducing enhanced cytotoxicity both in vitro and in vivo [ ] .", "label": "response"}
{"id": "24999473", "sentence": "Deletion in exon 19 , which removes the conserved sequence LREA , and a single point mutation in exon 21 , which leads to the substitution of arginine for leucine at position 858 ( @VARIANT$ ) , are the most clinically relevant and extensively studied drug-sensitive mutations [ ] . Studies have shown that these mutations preferentially bind to first generation @GENE$ , gefitinib and @DRUG$ [ , ] .", "label": "sensitivity"}
{"id": "23238683", "sentence": "As shown in Figure , BaF3 cells expressing native BCR-ABL were highly sensitive to @DRUG$ , dasatinib and ponatinib , whereas @GENE$ and BaF3-G250E-BCR-ABL cells were resistant to both imatinib and dasatinib . By contrast , ponatinib induced loss of cell viability in BaF3 cells carrying the T315I or @VARIANT$ mutation , in agreement with previous results from the literature [ , ] .", "label": "None"}
{"id": "23824671", "sentence": "@GENE$ mutations in codons 12 and 13 , which predict the efficacy of @DRUG$ treatment , were not detected in Caco-2 and WiDR . In contrast , the codon @VARIANT$ mutation was detected in SW480 and HCT116 .", "label": "resistance or non-response"}
{"id": "15737014", "sentence": "In tumors from patients not treated with either gefitinib or @DRUG$ , the 2369 C→T mutation ( @VARIANT$ ) appears to be extremely rare . We have not identified this mutation in 155 tumors ( see above ) , and among nearly 1,300 lung cancers in which analysis of @GENE$ exons 18 to 21 has been performed [ , ,, , , ] , only one tumor ( which also harbored an L858R mutation ) was reported to contain the T790M mutation .", "label": "resistance or non-response"}
{"id": "25563355", "sentence": "In pre-clinical studies , neratinib inhibited the growth of NCI-H1975 bronchoalveolar cancer cells harboring both substitution of arginine for leucine at position 858 ( @VARIANT$ ) and T790M and cell lines harboring the HER2 mutation [ ] . A phase I study of the advanced stage of solid tumors showed that the maximum tolerated dose ( MTD ) of neratinib was 320 mg once daily [ ] . An open-label , single-agent , phase II study revealed only a 3 % RR in patients with an @GENE$ mutation who had been treated with gefitinib or @DRUG$ for more than 12 weeks .", "label": "sensitivity"}
{"id": "24441171", "sentence": "RNA was isolated at different time points ( min ) after adding @DRUG$ shown below the bars . The isolated total RNA ( 0.1 μg ) was probed for H2B , @VARIANT$ , and @GENE$ mRNA by RT-PCR .", "label": "None"}
{"id": "24387717", "sentence": "Notably , the @VARIANT$ @GENE$ mutation does not respond to any approved TKI in vitro or clinically , except @DRUG$ which was approved by US FDA more recently [ ] .", "label": "None"}
{"id": "24252457", "sentence": "Resistance due to @VARIANT$ can potentially overcome by second generation irreversible EGFR TKIs , which appear to be well tolerated in early clinical studies [ ] . Although did not demonstrated an overall survival benefit , Afatinib , an irreversible @GENE$ , Her-2 , and ErbB4 blocker has led to significant PFS in patients who progressed after a 12 week course of @DRUG$ or Erlotinib when compared to placebo in a phase 2b/3 trial [ ] .", "label": "resistance or non-response"}
{"id": "24422746", "sentence": "Furthermore , EGFR mutations in PSCCE are rare but do exist , especially gefitinib associated mutations such as @VARIANT$ , therefore @DRUG$ based gene targeted therapy at @GENE$ but not KRAS and PIK3CA genes , probably should be included in this carcinoma treatment regimens for patients harboring L858R mutation .", "label": "sensitivity"}
{"id": "17177598", "sentence": "However , @DRUG$ did induce dose dependent cell death in @GENE$ subclones expressing the EGFR ectodomain mutants ( missense and vIII truncation ) or EGFR kinase domain mutants ( @VARIANT$ and L861Q ) ( A ) .", "label": "None"}
{"id": "24212786", "sentence": "The EGFR mutations are distributed throughout the kinase domain , but a deletion in exon 19 and the point mutation @VARIANT$ in exon 21 account for approximately 90 % , which confer a greater response to @DRUG$ treatment , compared with other types of @GENE$ mutations .", "label": "sensitivity"}
{"id": "25465236", "sentence": "( C ) EGFR @VARIANT$ mutant does not resemble pEGFR unlike the EGFR L858R mutant shown in B. ( D–F ) increased inhibition potency for Erlotinib against EGFR L858R mutant compared to @GENE$ WT protein and subsequent decrease in potency for @DRUG$ against EGFR L858R + E884K double mutant .", "label": "resistance or non-response"}
{"id": "15737014", "sentence": "The EGFR T790M mutation , in conjunction with either wild-type EGFR or the drug-sensitive @VARIANT$ EGFR mutant , prevents inhibition of tyrosine phosphorylation ( A ) or p-EGFR ( B ) by gefitinib . Analogously , the T790M mutation , in conjunction with the drug-responsive del L747–E749 ; A750P @GENE$ mutant , prevents inhibition of p-EGFR by @DRUG$ ( C ) .", "label": "sensitivity"}
{"id": "21333004", "sentence": "In this study , we used experimental and computational approaches to investigate regulatory mechanisms that distinguish cell-specific @DRUG$ sensitivity in H1299 human NSCLC cell lines . We have modified the existing kinetic model of the EGFR signaling pathway and built new models for H1299 wild type ( H1299WT ) , H1299 with overexpressed wild type EGFR ( @GENE$ ) , and H1299 overexpressing the EGFR with @VARIANT$ mutation ( H1299L858R ) .", "label": "sensitivity"}
{"id": "25563355", "sentence": "However , it was demonstrated recently that @VARIANT$ increased the affinity of ATP to the @GENE$ tyrosine kinase domain ; thus , it decreased the binding of gefitinib and @DRUG$ , because they are ATP-competitive agents [ ] .", "label": "resistance or non-response"}
{"id": "24634705", "sentence": "The @VARIANT$ mutation is hypothesized to induce steric interference of @DRUG$ binding similar to those in BCR-ABL and EGFR [ , ] . An in vitro model of EML4-ALK with the L1196M mutation showed that the cells were still dependent on @GENE$ mediated signaling for tumor maintenance but are resistant to ALK inhibition [ , ] .", "label": "resistance"}
{"id": "17877814", "sentence": "Recent structural analyses indicate that enhanced activity of @GENE$ mutants may derive form the disruption of autoinhibitory interactions that suppress EGFR basal activity [ , ] . Our data suggest that exon 20 insertions may disrupt these interactions to a greater extent than the @VARIANT$ point mutation . On the other hand , our functional analysis indicates that the uncommon exon 21 mutation P848L is not a kinase activating mutation and does not confer increased sensitivity to @DRUG$ .", "label": "resistance or non-response"}
{"id": "24939055", "sentence": "Gatekeeper mutations , the @VARIANT$ mutation in @GENE$ associated with resistance to @DRUG$ [ ] , are common mechanisms by which tumor cells acquire resistance to molecularly targeted drugs .", "label": "resistance or non-response"}
{"id": "17973572", "sentence": "Based on the data obtained from lung cancer cell lines , we further explored the mechanisms by which @VARIANT$ and L747S resistant mutations affect BIM up-regulation and apoptosis . @DRUG$ effectively induced apoptosis in Ba/F3-L858R cells , whereas Ba/F3-L858R-L747S cells were intermediately resistant and @GENE$ completely resistant ( A , top ) .", "label": "None"}
{"id": "23994953", "sentence": "@VARIANT$ mutation reviewed in . The second well-known mechanism of gefitinib/erlotinib resistance is the MET receptor tyrosine kinase ( RTK ) gene amplification . MET creates a bypass signaling track that activates AKT through @GENE$ mediated activation of PI3K in the presence of EGFR TKIs .", "label": "None"}
{"id": "25100284", "sentence": "Exon 19 deletions and @VARIANT$ mutations have shown similar in vitro sensitivity to @DRUG$ [ ] ; however , erlotinib and gefitinib have shown different clinical efficacy depending on whether exon 19 deletions and L858R mutations are present [ , ] . Despite these differences , both drugs have efficacy in patients with both of these mutations and these differences would not influence treatment selection . As the number of clinical trials evaluating @GENE$ TKIs continues to increase , the number of patients eligible for pooled analyses such as this one will increase .", "label": "sensitivity"}
{"id": "22738201", "sentence": "@VARIANT$ is present as a minor clone in NSCLC [ , ] and may be selected for during therapy [ ] . This mutation has been shown to prevent the activation of BIM in response to @DRUG$ but can be overcome by an irreversible inhibitor of EGFR [ ] . Other critical resistance mechanisms have been identified to be linked to the inhibition of EGFRMUT and include @GENE$ amplification [ - ] , PTEN loss [ ] , HER2 kinase domain [ ] or PIK3CA , and transformation to small cell lung cancer [ ] .", "label": "None"}
{"id": "21873989", "sentence": "GIST-T1R cells were generated by chronic , intermittent culture with @DRUG$ , which resulted in the acquisition of an exon 13 mutation at @GENE$ @VARIANT$ .", "label": "resistance"}
{"id": "23776354", "sentence": ", Concerning @GENE$ mutations , concordant in vitro data and clinical results support that the @VARIANT$ substitution and other mutations within the kinase domain activation loop ( exon 18 ) are predictive of primary resistance to @DRUG$ , whereas it is efficient in cases of juxtamembrane domain mutations. , ,", "label": "resistance or non-response"}
{"id": "25222836", "sentence": "@GENE$ TKi EGFR TK domain Resistance mutation , e.g. @VARIANT$ ● @DRUG$", "label": "resistance or non-response"}
{"id": "25580271", "sentence": "Two phase III trials compared @DRUG$ to a platinum-doublet in patients with advanced @GENE$ mutant NSCLC , and a combined analysis for overall survival was presented at ASCO , as well as subset analyses based on EGFR mutation subtype ( exon 19 deletion and exon 21 @VARIANT$ point mutation ) [ ] .", "label": "sensitivity"}
{"id": "23992330", "sentence": "In addition , they showed that two dominant activating mutations in the PI3K catalytic , alpha polypeptide ( @GENE$ ) , E545K and H1047R , which are prevalent in breast cancer , also confer resistance to lapatinib [ ] . Conversely , Li et al. infected cells with lentiviruses expressing either wild-type kinases ( Src , Fyn Lyn , EGFR and others ) or kinase alleles with gatekeeper mutations . Through this approach , they showed that Src Family Kinases (SFKs) , as well as EGFR , are relevant targets for the Src inhibitor dasatinib and that acquired @VARIANT$ mutations render cells resistant not only to @DRUG$ and gefitinib , but also to dasatinib [ ] .", "label": "None"}
{"id": "25033171", "sentence": "As shown in , the separation PMF in @GENE$ was much lower than that in WT-ROS1 , suggesting that serious @DRUG$ resistance could be induced by the mutation @VARIANT$ in the ROS1 tyrosine kinase .", "label": "resistance"}
{"id": "22132735", "sentence": "EGFR gene mutations indicate sensitivity to gefitinib , and it was demonstrated that about 85 % of patients with NSCLC who obtained benefit from @DRUG$ treatment were found to have mutations in exons 18 to 21 of the tyrosine kinase domain of the EGFR gene [ - ] . EGFR mutations in exon 19 ( short in-frame deletions ) or 21 @VARIANT$ ( point mutation ) affect the adenosine triphosphate ( ATP ) pocket of the tyrosine kinase domain leading to the activation of 4-anilinoquinazoline compounds , which function to compete with ATP [ ] . Anti-EGFR therapy can consequently lead to the downregulation of downstream signaling cascades , such as the PI3K/Akt , @GENE$ , MAPK , and STAT pathways , responsible for cell proliferation and survival , resulting in the inhibition of cell proliferation and induction of cell apoptosis , respectively .", "label": "None"}
{"id": "21444946", "sentence": "It has been shown that exon 19 deletions are more sensitive to @DRUG$ inhibition than the @VARIANT$ mutation , a finding demonstrated by kinetic analysis [ ] and also confirmed in clinical studies [ - ] . On the other hand , cetuximab is not as potent as EGFR TKIs in tumors with exon 19 deletion or L858R @GENE$ mutations [ ] .", "label": "sensitivity"}
{"id": "22363766", "sentence": "Preclinical data have demonstrated that @DRUG$ is a potent irreversible inhibitor of @GENE$ receptors including the @VARIANT$ variant .", "label": "response"}
{"id": "17927446", "sentence": "Lungs from all EGFR-transgenic animals expressed the induced oncoprotein , as measured by immunoreactivity of lysates with antisera against the specific @VARIANT$ EGFR [ ] ( A ) . At 13 h after treatment , lung tissues from control treated animals expressed high levels of phosphorylated @GENE$ , while EGFR phosphorylation was abolished in lungs from @DRUG$ treated mice .", "label": "sensitivity"}
{"id": "23520442", "sentence": "Sequist et al performed a longitudinal analysis of genetic and phenotypic changes in 37 patients with erlotinib-resistant NSCLCs carrying @GENE$ mutations . Using serial biopsies , the authors reported that @VARIANT$ and PIK3CA ( phosphoinositide-3-kinase catalytic , alpha polypeptide ) mutation were lost in the absence of continued selective pressure from EGFR inhibitors .", "label": "resistance or non-response"}
{"id": "24621983", "sentence": "Intracellular accumulation of Rhodamine123 ( 5 μM ) in presence ( 0.1 and 0.2 μM ) or absence of ABCB1 inhibitor ( LY335979 ) ( N = 6 ) in ( A) CTL HEK293 , CTL HEKpcDNA3.1 , HEK1199G and HEK1199A and ( B ) CTL K562 , CTL K562pcDNA3.1 , K5621199G and @VARIANT$ . * compared without inhibitor *p & lt ; 0.05 **p & lt ; 0.01 ***p & lt ; 0.001 , # compared to CTL pcDNA3.1 # p & lt ; 0.05 # # p & lt ; 0.01 # # # p & lt ; 0.001 . Impact of @GENE$ 1199G&gt;A polymorphism on the cytostatic effects of @DRUG$ and vinblastine", "label": "None"}
{"id": "24928511", "sentence": "More than 50 % of lung adenocarcinomas (LAD) from East Asian non-smokers harbor EGFR mutations , and these tumors have been termed oncogene addicted to reflect their dependence on EGFR mediated pro-survival signaling and their high susceptibility to apoptosis induced by @GENE$ ( e.g. gefitinib and @DRUG$ ) ( ) . The most frequently occurring mutations in the EGFR gene ( in-frame deletion in exon 19 at codons 746–750 or a single-base substitution @VARIANT$ in exon 21 ) predict an improved clinical response to first-line oral EGFR-TKIs compared with standard platinum based chemotherapy in patients with advanced non-small-cell lung carcinoma ( NSCLC ) ( , ) .", "label": "sensitivity"}
{"id": "19687189", "sentence": "Antrodia camphorata solid-state cultured mycelium ( AC-SS , 1 μg @GENE$ ) showed adjuvant anti-proliferative effects with @DRUG$ ( 10 μM ) or mitomycin ( 10 μM ) in hepatoma cell lines C3A and PLC/PRF/5 cells ( in vitro ) and , on xenografted cells in tumor implanted nude mice ( in vivo ) .", "label": "None"}
{"id": "18794843", "sentence": "Similarly , the gatekeeper mutation @VARIANT$ in @GENE$ causes resistance to gefitinib and @DRUG$ , and has been detected in lung cancer patients before drug treatment and in the germ line of a family pedigree with several cases of lung cancer , .", "label": "resistance or non-response"}
{"id": "23493883", "sentence": "Combinations of therapy such as cetuximab plus erlotinib and @DRUG$ plus everolimus have also been tried . The most promising drug thus far has been afatinib ( BIBW2992 ; Boehringer-Ingelheim Pharma , Ingelheim , Germany ) , , an ErbB family blocker with reported in vitro and in vivo activity against @GENE$ mutant tumors harboring exon 19 deletions , exon 21 @VARIANT$ mutations and the exon 20 T790M “resistance” mutations .", "label": "sensitivity"}
{"id": "17973573", "sentence": "H1975 cells harbor two mutations ( L858R and @VARIANT$ ) in the EGFR gene . All cells were maintained in RPMI-1640 medium supplemented with 10 % heat inactivated fetal calf serum ( FCS , JRH Biosciences , Lenexa , Kansas ) . The @GENE$ inhibitor QVD-OPH ( MP Biomedicals , Aurora , Ohio ) was used at 25 μM and added to cells 30 min prior to treatment with @DRUG$ .", "label": "None"}
{"id": "25155131", "sentence": "@DRUG$ IgG ) and IgM assays for anti-cardiolipin and @GENE$ antibodies were below diagnostic values , as were anti-nuclear antibody tests . However , the patient’s serum homocysteine levels were markedly high at 70μmol/L ( normal 4μmol/L to 12μmol/L ) . The results of a test for the methyltetrahydrofolate reductase (MTHFR) gene was negative for any remarkable polymorphisms , including the @VARIANT$ mutation .", "label": "None"}
{"id": "25465236", "sentence": "( C ) EGFR @VARIANT$ mutant does not resemble pEGFR unlike the @GENE$ L858R mutant shown in B. ( D–F ) increased inhibition potency for Erlotinib against EGFR L858R mutant compared to EGFR WT protein and subsequent decrease in potency for @DRUG$ against EGFR L858R + E884K double mutant .", "label": "resistance or non-response"}
{"id": "17973572", "sentence": "After the cells were exposed to gefitinib for 24 h , Ba/F3-L858R cells were unable to proliferate while Ba/F3-L858R-L747S and @GENE$ cells continued to grow even in the presence of 1 μM @DRUG$ ( E ) . These results suggest that execution of apoptosis may be impaired by the presence of @VARIANT$ and , to a lesser extent , L747S .", "label": "None"}
{"id": "20406486", "sentence": "In fact , there was a markedly increased pErk signal in one NRAS @VARIANT$ mutated cell line ( M207 ) , an observation consistent with data from others that has been attributed to loss of negative regulatory pathways [ , ] and enhanced signaling through C-Raf [ , ] . Therefore , @DRUG$ inhibits @GENE$ pathway signaling specifically in cell lines that harbor the BRAFV600E mutation .", "label": "None"}
{"id": "25054154", "sentence": "We utilised three complexes , namely , native ( ALK-crizotinib ) , F1174L ( @GENE$ F1174L-crizotinib ) , and @VARIANT$ ( ALK R1275Q-crizotinib ) for our analysis .", "label": "sensitivity"}
{"id": "25465236", "sentence": "( C ) EGFR T790M mutant does not resemble pEGFR unlike the EGFR @VARIANT$ mutant shown in B. ( D–F ) increased inhibition potency for Erlotinib against EGFR L858R mutant compared to EGFR WT protein and subsequent decrease in potency for @DRUG$ against @GENE$ L858R + E884K double mutant .", "label": "sensitivity"}
{"id": "19920910", "sentence": "In a cell-line based mutagenesis study , the emergence of @GENE$ mutations resistant to imatinib , nilotinib and dasatinib were compared : 20 different mutations were identified with imatinib mesylate , 10 with nilotinib ( including only 1 novel mutation , @VARIANT$ ) and 9 with @DRUG$ .", "label": "None"}
{"id": "17626639", "sentence": "Tumours from four of thirty-eight patients contained a form of the exon 19 L747-A750 deletion and one tumour harboured the exon 21 @VARIANT$ point mutation . Two of the patients with exon 19 deletions were responsive to @DRUG$ and were also found to have increased @GENE$ copy number .", "label": "sensitivity"}
{"id": "20630094", "sentence": "Another known mutation at this site involves two nucleotides ( GTG to AAG ) , substituting lysine for valine ( @VARIANT$ ) ( see Table for statistics on the frequency of these mutations reported in melanoma ) . The specific @GENE$ inhibitor @DRUG$ ( Plexxikon Inc. , Berkeley , CA ) suppresses the activated oncogenic pathway by inhibiting the ERK kinase cascade .", "label": "None"}
{"id": "17877814", "sentence": "These mutations were introduced into @GENE$ and transient transfection experiments were carried out in MCF-7 cells . The kinase activity of each mutant ( autophosphorylation at Y1092 and phosphorylation of endogenous Akt ) , and its response to different concentrations of @DRUG$ were evaluated as described above . Other exon 20 and 21 mutations ( T790M , S768I and @VARIANT$ ) that have been previously tested using transfection based assays were also included in the assay for comparison .", "label": "sensitivity"}
{"id": "25122428", "sentence": "The dual inhibition of PI3K and mTOR might be advantageous over single inhibition by suppressing a @VARIANT$ feedback loop that leads to the pathway reactivation . Based on this idea , an on-going phase I study of the PI3K and @GENE$ dual inhibitor , BEZ235 , was designed for the patients with advanced solid tumors harboring PIK3CA or PTEN alteration ( NCT01195376 ) . In this study , we showed that the survival of the cisplatin-resistant SCLC cell lines was well suppressed by BEZ235 , accompanied by the suppression of S6RP phosphorylation .", "label": "None"}
{"id": "24789720", "sentence": "Mechanism of achieving resistance to @DRUG$ and gefitinib remains unclear . The recent reports confirmed , that T790M substitution could be detected in EGFR-TKIs naïve patients independently of other @GENE$ gene mutations ( predominantly @VARIANT$ substitution and deletions in exon 19 ) .", "label": "sensitivity"}
{"id": "22536370", "sentence": "Tumors that harbor BRAF V600E mutations display high radiographic response rates to mutant-specific inhibitors such as PLX4032/RG7204/vemurafinib ( Plexxikon/Roche ) , and GSK2118436 ( GlaxoSmithKline ) , while patients whose tumors have certain @GENE$ mutations ( @VARIANT$ , K642E , V559A ) have disease sensitive to the KIT inhibitor , @DRUG$ ( ) , , , , , , , , .", "label": "resistance or non-response"}
{"id": "15737014", "sentence": "@GENE$ Mutants Containing the T790M Mutation Are Resistant to Inhibition by Gefitinib or @DRUG$ 293T cells were transiently transfected with plasmids encoding wild-type ( WT ) EGFR or EGFR mutants with the following changes : T790M , @VARIANT$ , L858R + T790M , del L747–E749 ; A750P , or del L747–E749 ; A750P + T790M .", "label": "sensitivity"}
{"id": "23472154", "sentence": "Similarly , alanine was no longer differentially composed between @VARIANT$ and non-T3S sequences ; cysteine , @DRUG$ and methionine were not strikingly depleted in T3S sequences compared with non-T3S sequences ( ) . The ranks of @GENE$ conditional probabilities on each amino acid at preceding position also showed an apparent difference between T3S and non-T3S sequences ( ; marked with backward or forward arrow below the bar ) .", "label": "None"}
{"id": "24212832", "sentence": "This is in keeping with an earlier study by Di Nicolantonio and colleagues [ ] , where the response to @DRUG$ or cetuximab was found to be impeded by the presence of @GENE$ @VARIANT$ mutation and restored ( in a cellular model of CRC cells ) by BRAF inhibitor sorafenib [ ] .", "label": "resistance or non-response"}
{"id": "23227361", "sentence": "The gatekeeper mutant displayed higher affinity for ATP , providing a potential explanation for resistance to the reversible TKI @DRUG$ . In contrast , irreversible TKIs CL-387785 and WZ-4002 bound irreversibly to an active conformation of HER2 and suppressed HER2 signaling and growth in stable clones of wild-type or mutant T798M , L755P , or @VARIANT$ @GENE$ [ ] .", "label": "resistance or non-response"}
{"id": "23233201", "sentence": "Moreover , as shown in , SHP2 physically associated with PECAM-1 more prominently in cells expressing the @VARIANT$ or T315I mutant as compared with cells expressing native BCR/ABL , while these mutants had less significant effects on complex formation between SHP2 and Gab2 . We next examined the effect of @DRUG$ on tyrosine phosphorylation of PECAM-1 in @GENE$ cells expressing the T315I mutant , which is totally resistant to dasatinib as well as imatinib but sensitive to the multi-kinase inhibitor sorafenib ( , ) .", "label": "None"}
{"id": "23515752", "sentence": "H1975 cells [ TKI-resistant , EGFR exon 20 ( @VARIANT$ ) and -21 mutations ] were treated for 24 h with either dasatinib ( 200 nM ) , 17-DMAG ( 50 nM ) , belinostat ( 500 nM ) , panobinostat ( 50 nM ) or @DRUG$ ( 10 nM ) . Lysates were made , western blotted and probed with antibody against EGFR and @GENE$ ( loading control ) ( A ) .", "label": "None"}
{"id": "25054154", "sentence": "In 2010 , Choi et al. [ ] identified two secondary mutations ( @VARIANT$ and L1196M ) within the kinase domain of @GENE$ fusion protein , which confer marked @DRUG$ resistance .", "label": "resistance"}
{"id": "23817662", "sentence": "In fact , the patient with EGFR c.2573T & gt ; G ( L858R ) and @GENE$ c.2369C&gt ; T ( @VARIANT$ ) was treated with @DRUG$ and a short-term improvement was observed .", "label": "resistance or non-response"}
{"id": "24039819", "sentence": "Down-regulation of C4H , HCT , @VARIANT$ , @GENE$ or CcoA-OMT was previously reported to cause reduction of total lignin in transgenic alfalfa , Arabidopsis , and poplar – . The Log2 ( S7/S8 ) fold value of unigene annotated as F5H was lowest ( –6.25 ) ( ) . F5H , a cytochrome P450 dependent monooxygenasea , , is a key enzyme that catalyzes the hydroxylation of ferulic acid , coniferaldehyde , and coniferyl @DRUG$ , leading to sinapic acid and syringyl lignin ( S lignin ) biosynthesis .", "label": "None"}
{"id": "22815900", "sentence": "Both @DRUG$ and gefitinib show similar kinase inhibition selectivity based on quantitative analysis of small molecule-kinase interaction maps for 38 kinase inhibitors , and show therapeutic efficacy against progressive NSCLC patients – . The most common activating @GENE$ mutations are in-frame deletion in exon 19 ( delE746-A750 ) and the point mutation replacing leucine with arginine at codon 858 of exon21 ( @VARIANT$ ) – .", "label": "sensitivity"}
{"id": "23285088", "sentence": "Nilotinib markedly differs from imatinib in its interactions with the BCR-ABL protein , and is 30 times more potent than imatinib against the @GENE$ in vitro activity in several Ph+ cell lines and is active against most imatinib-resistant BCR-ABL mutations , but not against the @VARIANT$ mutant , .", "label": "None"}
{"id": "24789720", "sentence": "The new therapy methods , which could be effective in patients with @VARIANT$ mutation includes irreversible EGFR-TKIs ( afatinib , neratinib ) . In LUX-Lung 1 study in patients after failure of erlotinib or @DRUG$ treatment with afatinib led to partial responses and prolongation of progression-free survival compared to placebo to 3,3 months [ , ] . Recently the studies are conducted with combining of irreversible EGFR-TKI and monoclonal antibody against extracellular domain of @GENE$ – cetuximab .", "label": "resistance or non-response"}
{"id": "23994953", "sentence": "Prospective trials have demonstrated an impressive ~75 % response rate for patients whose tumors harbor these mutations , which occur as either multinucleotide in-frame deletions in exon 19 ( e.g. , delE746-A750 ) or as single missense mutations ( e.g. , @VARIANT$ ) . Unfortunately , the EGFR TKI-driven improvement in patient outcome is notably limited because virtually all NSCLC patients with erlotinib/gefitinib sensitizing @GENE$ mutations eventually acquire resistance after a median of 6–12 months of EGFR TKI therapy .", "label": "sensitivity"}
{"id": "22060015", "sentence": "However , @DRUG$ treated @VARIANT$ glioma cells , blocked with a Fas antagonistic antibody , showed dramatic decreases in @GENE$ expression levels compared to decitabine treated T98G glioma cells co-cultured with NY-ESO-1 specific T cells ( Figure ) .", "label": "None"}
{"id": "23994953", "sentence": "Indeed , the fact that the combination of erlotinib plus IGF-1R inhibitors ( I-OMe-AG538 or AG1024 ) fully prevents the acquired erlotinib-resistant phenotype is consistent with IGF-1R playing a major role in this process . While preparing this manuscript , Cortot et al. reported that PC-9 derived clones with acquired resistance to mutant-selective EGFR inhibitors and irreversible quinazoline EGFR inhibitors in the absence of EGFR @VARIANT$ demonstrate a significantly activated IGF-1R signaling , and pharmacological inhibition of IGF-1R restored sensitivity to @GENE$ inhibitors .", "label": "resistance or non-response"}
{"id": "22705791", "sentence": "The dimer angle of @GENE$ is rotated by 30° , in comparison to apo–Mre11cd , towards a more compact and closed conformation . In vivo characterization of Mre11 latching loop compromising mutations in S. cerevisiae ( a ) Plate survival assays by serial dilutions reveal sensitivity of latching loop targeting mutations to @DRUG$ ( CPT ) , methyl–methanesulfonate ( MMS ) and hydroxyurea ( HU ) . ( b ) Spore viability is strongly reduced in ScMre11 R76A and ScMre11 @VARIANT$ diploid strains .", "label": "None"}
{"id": "21333004", "sentence": "When RY is defined as the ratios of Y with gefitinib to Y without @DRUG$ , Figure shows RE11P/ShcP/Grb2/SOS/RY by varying the values of k3 and k8 ( Y : RasGTP , Raf1A , MEKP , MEKPP , ERKP , and ERKPP ) . The values in each panel indicate RE11P/ShcP/Grb2/SOS/RY calculated by using the values of k3 and k8 in @VARIANT$ model A and k5 and k7 in @GENE$ model .", "label": "sensitivity"}
{"id": "24594844", "sentence": "DzT overcomes TKI resistance in @GENE$ @VARIANT$ mutant cells . @DRUG$ ( 1 μmol/l ; a ) or DzT- ( 100 nmol/l ; b ) treated cells were analyzed by immunoblotting with the indicated primary antibodies listed on the left .", "label": "resistance or non-response"}
{"id": "24811491", "sentence": "The @GENE$ @VARIANT$ mutation has been described as a predictor of tumor aggressiveness in metastatic disease [ , , ] and also of low RRs to cetuximab and @DRUG$ [ , , , ] .", "label": "resistance or non-response"}
{"id": "22110503", "sentence": "In a recently concluded phase I clinical trial , the multikinase and @GENE$ inhibitor , @DRUG$ ( AP24534 ) induced a complete cytogenetic and major molecular response rates of 89 % and 78 % , respectively , in CML patients with @VARIANT$ , and most responses were maintained after 12 months of follow-up [ , ] .", "label": "response"}
{"id": "24944510", "sentence": "EGFR-TKI ( such as @DRUG$ or erlotinib ) treatment of lung-cancer harboring @GENE$ gene mutation is one of the prototypes of such therapies . Several clinical trials clearly demonstrated that progression-free survival of patients treated with EGFR-TKI therapy is significantly longer than that of those treated by conventional platinum doublet chemotherapy.– EGFR-TKI therapy dramatically changed the paradigm of lung cancer treatment . Which strategy is better in the management of advanced NSCLCs – the inhibition of mutated EGFR with TKIs ( @VARIANT$ mutation increases tyrosine kinase affinity for TKIs ) or a combined approach with cetuximab ( an anti-EGFR monoclonal antibody ) plus first-line chemotherapy – is yet to be determined .", "label": "sensitivity"}
{"id": "25050082", "sentence": "Two @GENE$ mutations ( exon 19 deletion and exon 21 @VARIANT$ substitution ) that cluster around the adenosine-5′-triphosphate binding pocket of the EGFR tyrosine kinase ( TK ) domain are highly responsive to EGFR TK inhibitors ( TKIs ) like @DRUG$ or erlotinib [ ] .", "label": "sensitivity"}
{"id": "24523596", "sentence": "Several studies have reported renal failure and tumor lysis syndrome during TKI based molecular targeted therapies , including with sorafenib for hepatocellular carcinoma , with @DRUG$ for chronic myelogenous leukemia , and with flavopiridol for chronic lymphocytic leukemia.– Because the Q141K variant of @GENE$ corresponding to SNP 421C&gt ; A reduces uric acid transport and those TKIs are substrates/inhibitors of ABCG2/BCRP , TKI therapy in patients with the SNP 421C&gt ; A ( Q141K ) may be at higher risk of tumor lysis syndrome . A defect in the pharmacological interaction has been suggested between sunitinib and another ABCG2/BCRP germ-line mutant allele , 1291T & gt ; C. Remarkably , sunitinib reversed wild-type ABCG2/BCRP mediated drug resistance and competitively inhibited ABCG2/BCRP mediated estrone 3-sulfate transport and the binding of 125I-iodoarylazidoprazosin to ABCG2/BCRP . The @VARIANT$ variant of ABCG2/BCRP , which is expressed from a germ-line mutant allele 1291T & gt ; C , was insensitive to sunitinib mediated inhibition .", "label": "None"}
{"id": "25349473", "sentence": "Response rates were similar for those with and without mutant BCR-ABL , with MCyR occurring in 56 % of all patients , 49 % of patients with native @GENE$ , 64 % for those with one mutation , 62 % for those with two or more mutations , and 74 % for those with the @VARIANT$ mutant . Though no single point mutation has shown resistance against @DRUG$ , compound mutations developed in 21 patients , mainly those in BC-CML or Ph+ALL .", "label": "response"}
{"id": "22500115", "sentence": "In thyroid cancer cell lines , it was shown to be effective in inhibiting RET/PTC1 and @GENE$ mutations in some PTCs and @VARIANT$ RET mutations in MEN2B and some sporadic MTCs . RET mutations in certain inherited forms of MTC , as in codon 804 and 806 , seem to confer resistance to vandetanib. ,", "label": "None"}
{"id": "23419122", "sentence": "Studies support that some of these activating mutations are not only reliable predictors of response to the small molecule @GENE$ tyrosine kinase inhibitors ( TKIs ) @DRUG$ and erlotinib but also prognostic factors for survival [ - ] . Among numerous TK domain mutations , 85–90 % are exon 19 E746_A750 deletions or exon 21 @VARIANT$ point mutations [ ] .", "label": "sensitivity"}
{"id": "22714415", "sentence": "Patients with @VARIANT$ @GENE$ mutant tumors and treated with cetuximab/chemotherapy regimes had overall survival and progression free survival of average 7.6 and 4.0 mo vs. 5.7 and 1.9 mo in other KRAS mutant tumor subtypes .", "label": "resistance or non-response"}
{"id": "24212777", "sentence": "This consists of BRAF mutational analysis at @VARIANT$ and MLH1 promoter methylation , both of which are associated with sporadic CRC [ , ] . At present , inhibitors of @GENE$ have been tested in vitro and the inhibitor PLX4032 has been shown to potentiate the anti-proliferative action of 5-FU therapy [ ] . At present , further in vivo studies investigating the action of the tyrosine kinase inhibitor ( BAY 43-9006 ) and @DRUG$ in the metastatic setting are being undertaken .", "label": "resistance or non-response"}
{"id": "19452042", "sentence": "Emerging data suggest that patients with NSCLC and @GENE$ exon 19 deletion have a longer survival following treatment with gefitinib or @DRUG$ compared with those with the @VARIANT$ mutation [ - ] .", "label": "sensitivity"}
{"id": "24516334", "sentence": "It is also active against @VARIANT$ and other imatinib-resistant mutants . However , not all CML patients who are refractory or intolerant to dasatinib or nilotinib are responsive to @DRUG$ . We have shown that the resistance of leukemia stem cells to imatinib does not appear to involve @GENE$ kinase domain mutations , suggesting that BCR-ABL activates some signaling pathways in a kinase independent manner in leukemia stem cells .", "label": "response"}
{"id": "24959087", "sentence": "A final mechanism of resistance in gastric cancer cell lines has been demonstrated when @GENE$ amplified SNU6838 gastric cancer cell lines were treated with the MET inhibitors PHA-665752 and PF2341066 ; a novel mutation occurred in the activation loop of MET , causing a conformal change that blocked inhibitor binding analogous to the gatekeeper mutations seen in EGFR ( T790M ) following erlotinib treatment and in ABL ( T315I ) following @DRUG$ . Although the MET @VARIANT$ mutation renders cancers insensitive to type I MET inhibitors , conformal differences between these and type II compounds may allow treatment of MET Y1230H mutant cancers or prevent the emergence of resistance due to the mutation. ,", "label": "None"}
{"id": "21444946", "sentence": "The most commonly identified mechanism of resistance is an EGFR mutation at position 790 ( @VARIANT$ ) , resulting in substitution of a threonine residue with methionine , which abrogates the ability of gefitinib or @DRUG$ to inhibit @GENE$ [ , ] .", "label": "resistance or non-response"}
{"id": "25562798", "sentence": "Although irreversible inhibitors of the EGFR such as dacomitinib or @DRUG$ inhibit @VARIANT$ in vitro their clinical activity in the setting of tumors with T790M mutations remains to be demonstrated and novel mutation specific T790M inhibitors are in clinical development . A second mechanism for resistance which is seen in 5–20 % of patients is amplification of CMET which causes resistance to EGFR TKIs by activating @GENE$ Kinase signaling through ERBB3 [ , ,, ] .", "label": "None"}
{"id": "19707313", "sentence": "Taking their in vitro activity into consideration , the following rank order of ( oncogenic ) potency is found : Y253F = @VARIANT$ & gt ; wt BCR-ABL & gt ; T315I & gt ; H396P &gt ; M351T & gt ; others . These mutations should not count in the evaluation of drug resistance and the consecutive treatment plan in the same way as clinically relevant ( oncogenic ) mutations . A number of different strategies have been proposed to treat patients with @DRUG$ resistant CML , in whom @GENE$ mutations are detected .", "label": "None"}
{"id": "23992330", "sentence": "Very recently , sophisticated GEMM models of lung cancer were used to evaluate responsiveness to combined therapy of @DRUG$ and the @GENE$ inhibitor selumetinib ( AZD6244 ) , according to a co-clinical trial effort [ ] . Co-clinical trials aim to anticipate , in suitable GEMMs , the results of concomitant human clinical trials , as well as to provide a rationale in the elaboration of clinically relevant hypotheses , useful for design of corresponding studies in human cancer [ , ] . In this model , the KRAS @VARIANT$ activating mutation was associated either to TP53 or LKB1 loss in lung epithelium , to parallel selected human NSCLC cases harboring both oncogene activation ( KRAS ) and oncosuppressor ( TP53 or LKB1 ) loss .", "label": "None"}
{"id": "23329883", "sentence": "The minor-allele frequency ( 670G ) in the @GENE$ 3.6 % in whites , 4.2 % in Hispanics , and 26.0 % in blacks . However , little is known about the interactions of PCSK9 @VARIANT$ SNP and @DRUG$ consumption on serum lipid concentrations .", "label": "None"}
{"id": "25405807", "sentence": "Inhibition of epidermal growth factor receptor (EGFR) kinase activity by @GENE$ tyrosine kinase inhibitors ( EGFR-TKIs ) , such as gefitinib and @DRUG$ , can result in improved response and prolonged progression-free survival ( PFS ) in selected non-small cell lung cancer ( NSCLC ) patients harboring sensitizing EGFR mutations , especially the exon 19del and exon 21 @VARIANT$ mutations – .", "label": "sensitivity"}
{"id": "24634705", "sentence": "The D761Y mutation is located on the α-C-helix of @GENE$ and is similar to a mutation in BCR-ABL , D276G , that is associated with acquired resistance after @DRUG$ treatment [ ] . The L747S mutation lies at the start of the β3 strand and the α-C-helix [ ] and has analogous residues in BCR-ABL ( @VARIANT$ ) and ERBB2 ( L755S or P ) that have been identified in TKI resistant disease [ ] .", "label": "None"}
{"id": "25563355", "sentence": "They also have in vitro activity against the @VARIANT$ mutation . Of the second generation @GENE$ , neratinib , dacomitinib and @DRUG$ have been getting more attention recently ( ) .", "label": "response"}
{"id": "22852012", "sentence": "Imatinib , masitinib and bafetinib are agents unable to block the kinase activity of @GENE$ @VARIANT$ , whereas midostaurin and @DRUG$ have clear inhibitory activity against KIT D816V [ , , – ] .", "label": "response"}
{"id": "20576107", "sentence": "Cell death induced by combination treatment was @GENE$ dependent as it was blocked by the caspase-inhibitor zVAD-fmk ( Additional file , Figure @VARIANT$ ) . ABT-737 thus can sensitize RCC cell lines for treatment with vinblastine , paclitaxel or @DRUG$ .", "label": "None"}
{"id": "24069582", "sentence": "Harris et al. Phase III NCT01266486 Metformin 40 Participants with locally advanced breast cancer IHC analysis of effects on phosphorylation of @VARIANT$ , 4E-BP-1 , and @GENE$ Han et al. Phase II NCT01589367 Metformin vs. placebo in letrozole and no @DRUG$ arms 208 Postmenopausal women with stage I/II ER-positive breast cancer Clinical response rate at 24 weeks and comparison with RECIST 1.1 at baseline", "label": "None"}
{"id": "25071018", "sentence": "We also observed drastically downregulated @GENE$ expression and significant inhibition of growth in regorafenib treated wild-type SHP-1 expressing cells but no significant p-STAT3Tyr705 expression either in @VARIANT$ or dN1 mutant SHP-1 transfected cells following treatment with @DRUG$ ( Figure ) .", "label": "None"}
{"id": "25465236", "sentence": "( C ) EGFR @VARIANT$ mutant does not resemble pEGFR unlike the EGFR L858R mutant shown in B. ( D–F ) increased inhibition potency for Erlotinib against EGFR L858R mutant compared to EGFR WT protein and subsequent decrease in potency for Erlotinib against EGFR L858R + E884K double mutant . ( G–I ) increased inhibition potency for Gefitinib against EGFR L858R mutant compared to @GENE$ WT protein and subsequent further increase in potency for @DRUG$ against EGFR L858R + E884K double mutant .", "label": "resistance or non-response"}
{"id": "15737014", "sentence": "EGFR Mutants Containing the T790M Mutation Are Resistant to Inhibition by Gefitinib or @DRUG$ 293T cells were transiently transfected with plasmids encoding wild-type ( WT ) EGFR or @GENE$ mutants with the following changes : T790M , @VARIANT$ , L858R + T790M , del L747–E749 ; A750P , or del L747–E749 ; A750P + T790M .", "label": "sensitivity"}
{"id": "21605429", "sentence": "The @GENE$ exon 18 D842V point mutant activates PDGFRA both in vitro and in vivo [ , ] and is also imatinib resistant in vivo and in vitro [ , , ] , whereas other mutations affecting exon 18 ( @VARIANT$ , N848K , Y849K and HDSN845-848P ) are @DRUG$ sensitive [ ] .", "label": "None"}
{"id": "17877814", "sentence": "In a subset of NSCLC patients , the presence of somatic mutations in the kinase domain of @GENE$ may predict the outcome of treatment with the EGFR TKIs @DRUG$ and gefitinib . The favorable clinical response of tumors harboring the common exon 19 deletions or the @VARIANT$ mutation correlates with the high TKI sensitivity of these EGFR mutant proteins at the molecular level .", "label": "sensitivity"}
{"id": "16173832", "sentence": "The @VARIANT$ mutation is rarely found in tumors from patients not treated with either gefitinib or @DRUG$ , and could be discovered only in progressing tumors , in addition to a primary drug-sensitive mutation in @GENE$ .", "label": "resistance or non-response"}
{"id": "24121633", "sentence": "Based on our data , we hypothesized that PRR of hnRNP L binds to PTB and cooperatively suppresses inclusion of exon @VARIANT$ . We thus examined the role of PRR of hnRNP L on the interaction with PTB . Histidine tagged hnRNP L ( His-L ) , its @GENE$ deleted variant ( His-L-ΔPRR ) , histidine tagged hnRNP LL ( His-LL ) , and its PRR inserted variant ( His-LL-PRR ) were expressed in SH-SY5Y cells , and they were immunoprecipitated with anti-histidine antibody in the presence of RNase .", "label": "None"}
{"id": "24634785", "sentence": "@DRUG$ inhibits a broader range of kinase targets than IM or nilotinib , including @GENE$ family kinases , but had no significant activity against Kit or PDGFR [ , ] . It also demonstrated activity against a number of mutations , but not T315I and @VARIANT$ [ ] .", "label": "None"}
{"id": "21687596", "sentence": "An experiment using cell lines transfected concurrently with activating mutations and a @VARIANT$ mutation also proved that resistance to @DRUG$ and erlotinib is evident when this mutation is present [ – ] . Analogous secondary mutations of the BCR-ABL gene in case of chronic myelogenous leukemia ( CML ) [ ] and the KIT gene in case of gastrointestinal stromal tumor [ ] have previously been reported as mechanisms of imatinib resistance , which is also a TKI . The structural similarity between ABL and @GENE$ tyrosine kinases is considerably high , and T315I in ABL corresponds to T790M in EGFR [ ] .", "label": "resistance or non-response"}
{"id": "23861935", "sentence": "The latter binds the @GENE$ to mediate HASMC contraction . Unlike our data showing a decreased expression of CysLT1R in response to Pam3CSK4 , poly ( I:C ) , LPS , @DRUG$ and iE-DAP , Morishima et al. have recently shown that poly ( I:C ) decreased the muscarinic acetylcholine receptor M2R and increased @VARIANT$ expression without affecting histamine receptor H1R or CysLT1R , which correlated to intracellular calcium mobilization .", "label": "None"}
{"id": "23374602", "sentence": "Regarding KRAS , the same group reported in a pooled dataset of 579 cetuximab treated CRC patients that those with codon 13 KRAS mutant tumours ( @VARIANT$ ) had better outcomes ( HR for death 0.50 ) compared to patients with other KRAS mutant tumours [ ] . Those findings stood in our Greek population cohort , as the median survival of our cetuximab treated patients seemed to de-escalate from 29–33 months for KRAS wild type to 28 months for the KRAS codon 13 mutated group , dropping to 19 months for the KRAS codon 12 mutated group . Although Peeters et al. recently failed to find a prognostic difference between codon 12 and codon 13 @GENE$ mutations in CRC patients managed with @DRUG$ in three randomised trials , another group from Germany did so for cetuximab [ , , ] .", "label": "None"}
{"id": "21445332", "sentence": "( B ) @DRUG$ activity for CFI mediated cleavage of C4b and C3b . Cell lysates containing 25 pg of MCP ( wild-type or @VARIANT$ ) were incubated with biotinylated C4b or C3b in the presence of purified human CFI in 25 mM NaCl and cleavage was assessed by Western blot .", "label": "None"}
{"id": "22933967", "sentence": "In our retrospective study , 26.7 % of patients , all with KRAS wild-type tumours , who had previously unresectable liver-only metastases , underwent surgical resection after systemic therapy , with R0 resection achieved in 38 patients ( 21.6 % ) ; one of those was patient with the @GENE$ @VARIANT$ mutation . Although it is difficult to make any comparison , because our patients were not selected according to specific systemic therapy , these results are comparable with those reported in previous studies claiming that 19 to 23 % patients treated with bevacizumab- and @DRUG$ based chemotherapy and with previously unresectable liver-only metastases underwent resection.– In a recently published clinical study BOXER , where the patients with unresectable liver-only metastases were treated with oxaliplatin , capecitabine and bevacizumab , R0 resection was achieved in 40 % of patients .", "label": "None"}
{"id": "23233201", "sentence": "Moreover , as shown in , SHP2 physically associated with PECAM-1 more prominently in cells expressing the @VARIANT$ or T315I mutant as compared with cells expressing native @GENE$ , while these mutants had less significant effects on complex formation between SHP2 and Gab2 . We next examined the effect of dasatinib on tyrosine phosphorylation of PECAM-1 in BaF3 cells expressing the T315I mutant , which is totally resistant to @DRUG$ as well as imatinib but sensitive to the multi-kinase inhibitor sorafenib ( , ) .", "label": "None"}
{"id": "19452042", "sentence": "The more common EGFR mutations are an in frame deletion in exon 19 around codons 746 to 750 and a missense mutation leading to leucine to arginine substitution at codon 858 ( @VARIANT$ ) in exon 21 [ ] . In a large number of retrospective clinical trials , it has been suggested that NSCLC patients treated with EGFR-TKIs , whose tumors are carrying sensitizing EGFR mutations achieve an improvement of survival [ - ] , although this effect has not always been demonstrated [ , - ] . Different somatic @GENE$ gene mutations may confer diverse tumor activation profiles that lead to variations in both natural history and clinical course after treatment with erlotinib or @DRUG$ .", "label": "sensitivity"}
{"id": "19238632", "sentence": "H1975 cell line was chosen because it expresses the ‘gatekeeper'-resistant @GENE$ mutation ( in-cis with @VARIANT$ ) in the receptor kinase domain hydrophobic pocket , representing a major mechanism of resistance to reversible EGFR-TKI ( erlotinib/gefitinib ) ( ; ) .", "label": "sensitivity"}
{"id": "23606169", "sentence": "In the current clinical settings , broad knowledge regarding the KRAS and @GENE$ genes has been used to personalize treatment . Because mutations in the KRAS gene result in activation of the epidermal growth factor receptor (EGFR) signaling pathway , only metastatic colorectal cancer patients with wild-type KRAS tumors qualify for anti-EGFR targeted therapies with cetuximab or @DRUG$ [ ] . Also , a clinical trial with the BRAF inhibitor ( PLX4032 ) demonstrated antitumor activity in tumors with the BRAF @VARIANT$ mutation and confirmed that V600E BRAF is a valid therapeutic target in human cancer [ ] .", "label": "resistance or non-response"}
{"id": "21681573", "sentence": "Cases Age ( yr ) Sex PS Histology EGFR gene Smoking status Previous chemotherapy regimen Previous @DRUG$ ( length of PFS ) Previous WBRT 1 59 F 3 Ad NE Never 3 Yes ( 10 months ) Yes 2 82 F 4 Ad Wild type Never 0 No @GENE$ F 3 Ad Wild type Never 1 No Yes 4 86 F 3 Ad Ex 21 ; @VARIANT$ Never 1 Yes ( 7 months ) No 5 67 F 1 Ad Ex 21 ; L858R Never 1 No No 6 72 M 0 Ad Ex 21 ; L858R Former 1 No No 7 81 M 1 Ad Ex 19 deletion Former 1 Yes ( 46 months ) Yes 8 85 F 2 Ad Ex 21 ; L858R Never 1 No Yes a 66 F 1 Ad Ex 21 ; L858R Never 3 No Yes", "label": "None"}
{"id": "20098423", "sentence": "( b ) ChIP for RNAPII , S5P and @VARIANT$ at the EGR1 and @GENE$ loci following serum stimulation with or without @DRUG$ ( 150 nM ) pre-treatment .", "label": "None"}
{"id": "22034911", "sentence": "Consistent with this , we found that the introduction of R1275Q into EML4-ALK had no negative impact on sensitivity to @DRUG$ ( IC50 47 ± 8 nm ) . As expected , the IC50 values for viability of Ba/F3 cells expressing these mutants were all above that for @GENE$ cells expressing native EML4-ALK , with IC50s ranging from 231 to 981 nm . The three most resistant mutants , L1196M , S1206R , and @VARIANT$ , all had IC50s within twofold of parental , ALK negative , Ba/F3 cells ( IC50 1176 nm ) .", "label": "None"}
{"id": "24787964", "sentence": "One of the proposed mechanisms of resistance to gefitinib and @DRUG$ is the @VARIANT$ mutation on exon 20 . As the theoretical advantage of afatinib versus the first-generation @GENE$ did not translate into progression-free survival gains , maybe the clinical relevance of possible inhibition of T790M is minimal , at least in the first-line setting , when T790M positive clones are rarely detected .", "label": "resistance or non-response"}
{"id": "24502453", "sentence": "Comparable with the experience in anti-infective drugs , multidrug-resistant @GENE$ mutations occur which preclude further use of the approved TKI . For example , patients with @VARIANT$ mutation respond only on treatment with third generation TKI @DRUG$ , which was specifically designed as a treatment option for these populations .", "label": "response"}
{"id": "19238210", "sentence": "The resistant cell line category was the largest and included two mEGFR cell lines , one having the secondary @VARIANT$ mutation and the other having homozygous deletion of PTEN gene . The remaining resistant lines included all of the wild type lines and all lines having KRAS , BRAF , HER2 , HER4 and PIK3CA mutations . Using univariate tests , we analyzed the association between gefitinib sensitivity and mutational status or CNGs of the various @GENE$ pathway genes and found a significant correlation between @DRUG$ sensitivity with EGFR mutation ( p = 0.002 ) and EGFR copy number gains ( p = 0.001 ) .", "label": "resistance or non-response"}
{"id": "25562798", "sentence": "In the case of acquired resistance to @DRUG$ and erlotinib in @GENE$ mutant tumors two major mechanisms have been identified . Firstly , a secondary mutation , the @VARIANT$ mutation within exon 20 of EGFR , is responsible for about 50 % of instances of acquired resistance [ , ] .", "label": "resistance or non-response"}
{"id": "23320171", "sentence": "Further research is looking into inhibiting other targets such as mTOR , @VARIANT$ , or @GENE$ pathways . Two randomized trials are evaluating the addition of the mTOR inhibitor , everolimus , to chemotherapy and @DRUG$ in the first-line and Trastuzumab-resistance metastatic setting .", "label": "None"}
{"id": "24920920", "sentence": "In 40 patients harboring L858R , five revealed complex mutations , including two with @VARIANT$ . In 61 patients with @GENE$ TKI as first-line therapy , 46 received gefitinib , 13 received erlotinib , and two received @DRUG$ .", "label": "response"}
{"id": "23547655", "sentence": "Furthermore , slow monophasic responders were more likely to be imatinib-resistant ( as opposed to imatinib-intolerant ) and have nilotinib-insensitive mutations ( half maximal inhibitory concentration [ IC50 ] & gt ; 150 nm ; @VARIANT$ , E255V/K , F359V/C ) [ ] in @GENE$ at baseline ( Table ) .", "label": "None"}
{"id": "22970367", "sentence": "Moreover , dual inhibition of @GENE$ with an irreversible EGFR inhibitor ( @DRUG$ ) and the EGFR neutralizing antibody cetuximab has recently shown promising activity in EGFR mutant lung cancers with acquired EGFR TKI resistance that harbor an EGFR @VARIANT$ mutation [ ] .", "label": "response"}
{"id": "24348666", "sentence": "Not only MET amplification but also the overexpression of HGF has been reported as a mechanism of @GENE$ resistance in 2008 . In cancer tissues from lung adenocarcinoma patients who showed resistance to @DRUG$ , high expression levels of HGF were observed in the lung cancer cells that did not harbor the @VARIANT$ mutation or MET amplification .", "label": "resistance or non-response"}
{"id": "21687596", "sentence": "However , the frequency of all such mutations appears to be low in comparison with the @VARIANT$ mutation and further analysis of such cases is required in the future . 2.4.2 . IGF-1R Guix et al. established gefitinib-resistant clones from a gefitinib-sensitive cell line of squamous cell lung carcinoma that amplified the wild-type @GENE$ gene ( A431 ) by exposing the cells to increasing concentrations of gefitinib [ ] .", "label": "resistance or non-response"}
{"id": "15737014", "sentence": "EGFR Mutants Containing the @VARIANT$ Mutation Are Resistant to Inhibition by @DRUG$ or Erlotinib 293T cells were transiently transfected with plasmids encoding wild-type ( WT ) @GENE$ or EGFR mutants with the following changes : T790M , L858R , L858R + T790M , del L747–E749 ; A750P , or del L747–E749 ; A750P + T790M .", "label": "resistance or non-response"}
{"id": "17973572", "sentence": "The Secondary Resistant Mutations L747S and @VARIANT$ Affect @DRUG$ Induced Apoptosis and Inhibit BIM Up-Regulation ( A ) Top : Annexin V apoptosis assay : @GENE$ cells expressing L858R (LR) , L858R-L747S # 4 ( LR-LS ) , or L858R-T790M (LR-TM) cells were grown in the absence or presence of gefitinib for 24 h .", "label": "None"}
{"id": "23843700", "sentence": "Therefore , Phase II trials were conducted with @DRUG$ in patients with acral or mucosal melanoma or melanomas on chronically sun damaged skin that harbored @GENE$ mutations or amplifications . Response rates of 16 % –23 % with a small number of complete long-term responses have been seen , with no difference in response rates between the various melanoma subtypes.– Notably , the same KIT mutations ( @VARIANT$ and N822K ) that have shown response to treatment in gastrointestinal stromal tumors also show response in the treatment of melanoma .", "label": "None"}
{"id": "24944510", "sentence": "Thus , the @VARIANT$ mutation significantly reduces drug binding and avoids reaching an efficient blood drug concentration . Many trials have studied intensification of @GENE$ inhibition through use of second-generation TKIs such as neratinib , @DRUG$ , and dacomitinib .", "label": "response"}
{"id": "23818899", "sentence": "EGFR KRAS ( mutation ) Colorectal Cancer ( expressing metastatic colorectal carcinoma , EGFR ) **Therascreen KRAS Test ( Qiagen , Corporate Headquarters , Nederland 's ) **Erbitux , @DRUG$ ( ImClone , ImClone Systems , NJ ) **Vectibix , panitumumab ( Amgen , Amgen Inc , . CA ) [ , , ] @GENE$ @VARIANT$ ( mutation ) Melanoma ( metastatic melanoma with BRAFV600E mutation ) **Cobas 4800 BRAF V600 Mutation Test ( Panagene , Corporate Headquarters , Korea ) **Zelboraf , vemurafenib ( Genentech/Roche ) [ , ]", "label": "resistance or non-response"}
{"id": "25465236", "sentence": "( G–I ) increased inhibition potency for Gefitinib against @GENE$ @VARIANT$ mutant compared to EGFR WT protein and subsequent further increase in potency for @DRUG$ against EGFR L858R + E884K double mutant .", "label": "sensitivity"}
{"id": "23817662", "sentence": "In fact , the patient with EGFR c.2573T & gt ; G ( @VARIANT$ ) and @GENE$ c.2369C&gt ; T ( T790M ) was treated with @DRUG$ and a short-term improvement was observed .", "label": "sensitivity"}
{"id": "20633291", "sentence": "Secondary imatinib-refractory mutations D816V Single mutation Activation loop @VARIANT$ Single mutation Activation loop V560D/V654A Double mutation Juxtamembrane domain/kinase domain I V560D/T670I Double mutation Juxtamembrane domain/kinase domain I Stable Transfection of CHO and @GENE$ Cells With Wild-Type and Mutant KIT", "label": "None"}
{"id": "22701429", "sentence": "@VARIANT$ decreases current amplitude which explains the LQT in the electrocardiogram , but also produces a hyperpolarizing shift of the voltage dependence of activation and tail currents , thereby explaining the additional atrial fibrillation in these patients ( Bartos et al. , ) . R5H/C produce a slowed rate of activation , a positive voltage shift of activation and/or dominant suppression of co-expressed wild type ( Franqueza et al. , ; Mohammad-Panah et al. , ; Chouabe et al. , ) . R1 , R3 , and R5 mutants all fulfill the concept of adjacent arginine replacements because there is a @GENE$ at R2 and a @DRUG$ at R4 ( Figure ) .", "label": "None"}
{"id": "16953242", "sentence": "In fact , the pleiotropic effect of BCR/ABL transformation is mostly dependent on post-translational modifications ( e.g. phosphorylation ) of signalling molecules , like those involved in the @GENE$ , PI3K/Akt and STATs pathways , which control cell growth , survival and differentiation of haematopoietic cells by modulating the expression and/or activity of downstream effectors ( ; ) ( ) . Being the deregulated BCR/ABL kinase activity the cause of CML , targeting its catalytic domain was the most rationale approach for the rational development of small molecules that inhibit ABL kinase activity . In these CML-BC patients , imatinib resistance often depends on reactivation of BCR/ABL tyrosine kinase activity via mechanisms involving BCR/ABL overexpression , gene amplification or mutations that suppress imatinib mediated kinase inhibition ( i.e. E255V and G250E ) or disrupt @DRUG$ binding ( i.e. @VARIANT$ ) ( ) .", "label": "None"}
{"id": "25275314", "sentence": "To prepare the mutants , we mutated arginines of the WT sequence inside the transformed @GENE$ model and obtained the models that contain PKA and the peptides LARASLG ( R18A ) , LRAASLG ( R19A ) , LKRASLG ( R18K ) , LRKASLG ( @VARIANT$ ) , LHRASLG ( R18H ) , and LRHASLG ( R19H ) . We also prepared the models including the shorter chain peptides RRASLG , RASLG , and LRRASL . For the mutants that contain histidine we prepared the models containing neutral histidine with the hydrogen atoms at position δ or ε ( Hδ and Hε ) , and the models containing the protonated @DRUG$ Hp ( see the next section ) .", "label": "None"}
{"id": "23788917", "sentence": "The @VARIANT$ mutation in exon 20 of the @GENE$ gene was detected for the first time in tumour cells of a patient with progression after a few months of efficacious therapy with @DRUG$ .", "label": "resistance or non-response"}
{"id": "24124608", "sentence": "In addition to upregulation of IGF1R and VEGF , frequent CN gain and increased mRNA expression of GSTT1 as well as significant overexpression of @GENE$ subfamily members were observed in wild-type/PDGFRA @VARIANT$ GISTs compared to KIT-mutant GISTs . CN gain of GSTT1 was closely associated with @DRUG$ resistance .", "label": "None"}
{"id": "23799845", "sentence": "For example , dasatinib is recommended for patients with F359V or Y253H , nilotinib for patients with F317L , and @DRUG$ for patients with @VARIANT$ . Hence , the same precautions with TKI selection apply . Mutant @GENE$ clones are often deselected upon TKI cessation or change of therapy , and may become undetectable , even by very sensitive techniques ( ; ) .", "label": "response"}
{"id": "24691136", "sentence": "The @VARIANT$ @GENE$ mutant has increased affinity for ATP , which is the primary mechanism responsible for the development of resistance to small molecule tyrosine kinase inhibitors ( TKIs ) , such as gefitinib and @DRUG$ .", "label": "resistance or non-response"}
{"id": "23788917", "sentence": "The @VARIANT$ mutation leads to a substitution of threonine to methionine in the catalytic centre of @GENE$ tyrosine kinase , which is located in the binding pocket of TKI and ATP . Substitution of threonine at codon 790 into larger methionine probably results in blocking of the binding sites of erlotinib and @DRUG$ aromatic residues with their point of action .", "label": "resistance or non-response"}
{"id": "22587422", "sentence": "In contrast , the median @GENE$ for patients without T315I had not yet been reached , and the estimated 20-month survival rate was 70 % . Table summarizes the comparison between clinical characteristics and @DRUG$ pharmacokinetics in patients with and without @VARIANT$ during dasatinib therapy .", "label": "None"}
{"id": "20500904", "sentence": "As expected , the effect of @GENE$ was abolished by @DRUG$ ( data not shown ) . Mutated EGFR or TGFα autocrine production impair the biological effects of MET targeting . A-B ) Cells , bearing the doxycycline-inducible MET shRNAs , were transduced with the mutated form of EGFR ( @VARIANT$ ) ( A ) or with the Hys tagged TGFα ( B ) .", "label": "sensitivity"}
{"id": "23493804", "sentence": "Differences have been reported between a T790M mutation that emerges after @GENE$ treatment and pretreatment T790M , suggesting that they are genetically distinct diseases . In the @DRUG$ Pan-Asia Study ( IPASS ) study , eleven treatment-naïve patients had an exon 20 @VARIANT$ mutation : four had coexisting exon 19 deletions and three had coexisting L858R mutations .", "label": "resistance or non-response"}
{"id": "25202264", "sentence": "The majority of these patients also had other coexisting @GENE$ mutations . The coexisting point mutations on exon 20 that rendered the patients resistant to @DRUG$ were G719A , V769L , W731 Stop , @VARIANT$ , L 861Q and delE749_T751insVA [ ] .", "label": "sensitivity"}
{"id": "24523596", "sentence": "Several studies have reported renal failure and tumor lysis syndrome during TKI based molecular targeted therapies , including with sorafenib for hepatocellular carcinoma , with imatinib for chronic myelogenous leukemia , and with flavopiridol for chronic lymphocytic leukemia.– Because the @VARIANT$ variant of ABCG2/BCRP corresponding to SNP 421C&gt ; A reduces uric acid transport and those TKIs are substrates/inhibitors of ABCG2/BCRP , TKI therapy in patients with the SNP 421C&gt ; A ( Q141K ) may be at higher risk of tumor lysis syndrome . A defect in the pharmacological interaction has been suggested between @DRUG$ and another @GENE$ germ-line mutant allele , 1291T & gt ; C. Remarkably , sunitinib reversed wild-type ABCG2/BCRP mediated drug resistance and competitively inhibited ABCG2/BCRP mediated estrone 3-sulfate transport and the binding of 125I-iodoarylazidoprazosin to ABCG2/BCRP .", "label": "None"}
{"id": "20387067", "sentence": "For the leukemic counterpart , we used the SKNO-1 cell line , which is GM-CSF dependent expressing homozygous @VARIANT$ KIT mutation . @DRUG$ showed significant growth reduction on long-term coculture assay , particularly in the absence of GM-CSF , suggesting that dasatinib can target @GENE$ mutation effectively .", "label": "sensitivity"}
{"id": "24724051", "sentence": "Most of these mutant @GENE$ proteins are still sensitive to the second generation ABL kinase inhibitors @DRUG$ and nilotinib . In addition , the recently approved ponatinib is active against the most common mutation that causes resistance to both first and second generation ABL TKIs , the “gatekeeper” @VARIANT$ mutation ( Table ; Figure ) .", "label": "None"}
{"id": "25486409", "sentence": "Chen et al. demonstrated that @GENE$ siRNAs strongly inhibited cell growth and induced apoptosis in H1975 cells harboring both L858R and T790M . Even knock-down of the @VARIANT$ transcript by siRNAs , when combined with @DRUG$ , was efficacious in controlling T790M-mutant , lung cancer cells .", "label": "response"}
{"id": "24155950", "sentence": "The sensitivity of K562 , K562-R , LAMA84 , LAMA84-R , Baf3 Bcr-Abl , and @GENE$ Bcr-Abl @VARIANT$ cell lines to the most used Bcr-Abl inhibitors in CML : imatinib , dasatinib ( Santa Cruz Biotechnology , CA , USA , Cat. # sc-218081 ) and nilotinib ( Santa Cruz Biotechnology , CA , USA , Cat. # sc-202245 ) was investigated by treating these cells with increasing concentrations of each drug and measuring cell death using an automated Trypan Blue exclusion method ( see ) . 10.1371/journal.pone.0077390.g001Combined treatment of @DRUG$ and paclitaxel efficiently activates caspases and induces cell death in human leukemic Bcr-Abl positive K562 and LAMA84 cell lines .", "label": "None"}
{"id": "23937717", "sentence": "The functional relevance of restoration of NKG2D–NKG2DL interaction by @DRUG$ was demonstrated by the enhanced cytotoxicity , degranulation and IFN-γ production of NK cells in response to lung cancer cells with @GENE$ @VARIANT$ + T790M resistance mutation .", "label": "sensitivity"}
{"id": "22745767", "sentence": "Since type 2 diabetes has been recognized as a @DRUG$ that can modify the course of chronic CHC infection and can be used as an independent predictor of HCC , we have compared the significant molecules in patients with @VARIANT$ and CHC . In details , we have evidenced that : i ) ghrelin and leptin levels are lower in CHC patients than in those with T2D , ii ) IL-1α , insulin and PAI-1 levels are higher in CHC patients than in those with T2D , iii ) CXCL1 , CXCL9 , β-NGF , C-peptide , GIP and adiponectin are higher only in CHC patients and iv ) HGF and glucagon are higher only @GENE$ .", "label": "None"}
{"id": "24737397", "sentence": "PRL-3 overexpression counteracted the drug sensitivity of AML cells to @DRUG$ , but the PRL-3 mutant ( @VARIANT$ ) did not ( A , B ) .", "label": "None"}
{"id": "24472312", "sentence": "Therefore , imatinib-resistant CEL remains a therapeutic challenge . There has been exciting recent advance in third-generation TKIs ( ponatinib , HG-7-85-1 and @GENE$ ) efficacious against the gatekeeper mutants [ - ] . In vitro screening assay has demonstrated that ponatinib , the first TKI effective against @VARIANT$ Bcr-Abl , is also a potent inhibitor of KIT , PDGFRα , Flt3 , Src , VEGFR and FGFR [ , , ] .", "label": "None"}
{"id": "24419415", "sentence": "Our group has undertaken a randomized phase 3 trial to compare gefitinib plus carboplatin plus @DRUG$ with gefitinib monotherapy for patients with NSCLC with an exon 19 deletion or an @VARIANT$ , G719X , or L861Q @GENE$ mutation ( NEJ009 ; University Hospital Medical Information Network Clinical Trials Registry [ UMIN-CTR ] number , UMIN000006340 ) .", "label": "None"}
{"id": "22655263", "sentence": "In vivo efficacy was described only for the L1196M gatekeeper mutation , confirming a higher potency with respect to @DRUG$ in inhibiting the in vivo growth of ALK–L1196M driven @GENE$ cells . For the @VARIANT$ mutant , activity in Ba/F3 cells was not described , but the compound was able to effectively inhibit proliferation of a neuroblastoma cell line naturally bearing the mutation .", "label": "None"}
{"id": "25277176", "sentence": "( B ) Drugs such as the 4-anilinoquinazolines gefitinib ( @DRUG$ ) [ ] and erlotinib ( Tarceva ) [ ] can inhibit the activity of @GENE$ @VARIANT$ mutant .", "label": "sensitivity"}
{"id": "15737014", "sentence": "The mutant 2369 T peak was small , possibly because @DRUG$ had been discontinued in this patient for 4 mo at the time pleural fluid tumor cells were collected ; thus , there was no selective advantage conferred upon cells bearing the @VARIANT$ mutation . To determine whether the 2369 C→T mutation was a previously overlooked @GENE$ mutation found in NSCLCs , we re-reviewed exon 20 sequence tracings derived from analysis of 96 fresh-frozen resected tumors [ ] and 59 paraffin embedded tumors [ ] , all of which were removed from patients prior to treatment with an EGFR tyrosine kinase inhibitor .", "label": "resistance or non-response"}
{"id": "25013503", "sentence": "Furthermore , the @GENE$ mutation is a predictor of @DRUG$ sensitivity in lung cancer ( , ) . Thus , early detection of the EGFR mutation rate and its associated factors in lung tumors may present an important reference to individualize clinical treatment and improve treatment implementation in lung cancer , as well as to reduce the toxicity of drugs . EGFR gene mutations , including delE746-A750 , delL747-p753inss , delL747-T75linss , delL747-S752ins , @VARIANT$ and L858R , have been identified in NSCLC patients .", "label": "resistance or non-response"}
{"id": "25013503", "sentence": "Furthermore , the @GENE$ mutation is a predictor of @DRUG$ sensitivity in lung cancer ( , ) . Thus , early detection of the EGFR mutation rate and its associated factors in lung tumors may present an important reference to individualize clinical treatment and improve treatment implementation in lung cancer , as well as to reduce the toxicity of drugs . EGFR gene mutations , including delE746-A750 , delL747-p753inss , delL747-T75linss , delL747-S752ins , T790M and @VARIANT$ , have been identified in NSCLC patients .", "label": "sensitivity"}
{"id": "21980421", "sentence": "using NAD+ or NADP+ as the @DRUG$ . The S346K and @VARIANT$ @GENE$ may have similar positively charged nucleotide binding sites because the net charges of the sites are apparently equivalent .", "label": "None"}
{"id": "23992330", "sentence": "In this model , the KRAS @VARIANT$ activating mutation was associated either to TP53 or LKB1 loss in lung epithelium , to parallel selected human NSCLC cases harboring both oncogene activation ( KRAS ) and oncosuppressor ( TP53 or LKB1 ) loss . The latter were obtained via nasal instillation of adenoviruses expressing CRE recombinase in the appropriate genetic models . The study showed that the combination therapy with selumetinib was more effective than @DRUG$ alone in @GENE$ and K-Ras/p53 mice , while K-Ras/Lkb1 mice where showing primary resistance to the combination therapy .", "label": "None"}
{"id": "17352537", "sentence": "Different P-gp variants displayed higher levels of resistance ( A893S-M89T , L662R , and R669C ) or lower levels of resistance ( A893S , @VARIANT$ , A893S-R669C , A893S-P1051A , W1108R , and W1108R-R669C ) relative to the P-gp reference ( A and B ) . The alleles varied widely in their ability to survive on high concentrations of daunorubicin and @DRUG$ . The replacement of Arg669 by Cys led to one of the most drastic gain-of-function effects on the ability of @GENE$ to confer drug resistance .", "label": "None"}
{"id": "17877814", "sentence": "In this regard , certain mutations , such as the @VARIANT$ amino acid change , have been shown to confer resistance to gefitinib and @DRUG$ [ reviewed in [ ] ] . Second-generation TKIs , which bind covalently to @GENE$ and may be active against these resistant mutants , are currently being developed .", "label": "resistance or non-response"}
{"id": "22558339", "sentence": "Wild type KRAS is now considered a pre-condition to treat CRC patients with EGFR inhibitors like Cetuximab or @DRUG$ , . Oncogenic BRAF mutations occur in up to 15 % of all human tumors , the vast majority ( & gt ; 90 % ) being c.1799 : T & gt ; A substitutions that lead to the replacement of valine with aspartic acid ( @VARIANT$ ) causing constitutive @GENE$ activation .", "label": "resistance or non-response"}
{"id": "25505694", "sentence": "The lack of efficacy could probably be related to the high concentrations of neratinib required in preclinical studies to inhibit EGFR @VARIANT$ and the limitations of clinical dosing . Dacomitinib Dacomitinib is an irreversible EGFR , @GENE$ and HER4 inhibitor with a higher kinase inhibition than gefitinib/erlotinib in both gefitinib/erlotinib-sensitive and in EGFR-T790M and HER2 mutated cell lines [ ] .", "label": "None"}
{"id": "17877814", "sentence": "In contrast , @GENE$ @VARIANT$ induced phosphorylation of endogenous Akt , which was inhibited by 10 nM of @DRUG$ , and 100 nM or higher concentrations of the drug induced fibril formation .", "label": "sensitivity"}
{"id": "21188105", "sentence": "Cells bearing the mutant @GENE$ are in general more sensitive to TKIs than cells expressing the wild-type kinase . In particular , the L858R mutant is 10- to 100-fold more sensitive to @DRUG$ and gefitinib than the wild-type kinase , ,, and significantly more sensitive than the @VARIANT$ mutant .", "label": "None"}
{"id": "20190765", "sentence": "cDNA for @VARIANT$ EGFR and L858R/T790M EGFR were provided by Dr. William Pao ( Vanderbilt University , Nashville , TN ) , ACK was provided by Dr. Nupam Mahajan ( Moffitt Cancer Center , FL ) , and Human BRK was purchased from ORIGENE ( Rockville , MD ) . Lentiviral plasmids containing WT and gatekeeper @GENE$ , FYN , LYN , LCK , ABL , DDR1 , FRK , EphB1 , EphA2 and EphA4 were generously provided by Dr. Jinyan Du and Dr. Todd Golub ( The Broad Institute , MA ) . Erlotinib was provided by OSI Pharmaceuticals ( Melville , NY ) and @DRUG$ by Bristol-Myers Squibb ( New Brunswick , NJ ) .", "label": "None"}
{"id": "25032217", "sentence": "Notably , the Evaluation of Genomic Applications in Practice and Prevention ( EGAPP ) Working Group ( EWG ) found insufficient evidence to recommend or discourage testing for mutations in @GENE$ @VARIANT$ , NRAS , or PIK3CA and/or loss of PTEN or AKT protein . Therefore , the EWG discourages the use of these tests for deciding whether to introduce anti-EGFR therapy with cetuximab or @DRUG$ until more evidence supports improved clinical outcomes [ ] .", "label": "resistance or non-response"}
{"id": "21333004", "sentence": "The values in each panel indicate RE11P/ShcP/Grb2/SOS/RY calculated by using the values of k3 and k8 in @VARIANT$ model A and k5 and k7 in @GENE$ model . Based on this analysis , we found high @DRUG$ sensitivity in MEKPP , ERKP , and ERKPP .", "label": "sensitivity"}
{"id": "22738201", "sentence": "@VARIANT$ is present as a minor clone in NSCLC [ , ] and may be selected for during therapy [ ] . This mutation has been shown to prevent the activation of BIM in response to @DRUG$ but can be overcome by an irreversible inhibitor of @GENE$ [ ] .", "label": "resistance or non-response"}
{"id": "23579627", "sentence": "This findings show that EGFR @VARIANT$ is a common resistance mechanism to both reversible , and when amplified , the irreversible EGFR inhibitors . In our case , the response duration of irreversible EGFR inhibitor was 11 months which was unusually longer than those of initial @DRUG$ ( for 4 months ) and second round gefitinib ( for 6 months ) treatments . Recently an alternative approach is to develop novel strategies , instead of irreversible EGFR inhibitors , to inhibit EGFR and/or EGFR signaling , including the use of inhibitors of HSP90 and/or EGFR downstream signaling ( such as phosphatidylinositol 3-kinase and @GENE$ inhibitors ) as these resistant cancers still remain dependent on EGFR signaling for their growth .", "label": "None"}
{"id": "18577988", "sentence": "Interestingly , four EGFR FISH+ patients with @GENE$ mutations ( G12V in one case , @VARIANT$ in another one , G13D in the remaining two cases ) responded to @DRUG$ therapy .", "label": "sensitivity"}
{"id": "25580271", "sentence": "Two phase III trials compared afatinib to a platinum-doublet in patients with advanced EGFR mutant NSCLC , and a combined analysis for overall survival was presented at ASCO , as well as subset analyses based on EGFR mutation subtype ( exon 19 deletion and exon 21 @VARIANT$ point mutation ) [ ] . In subgroup analysis based on EGFR mutation type the benefit appeared to be limited to patients with exon 19 mutations . When cross-over to EGFR tyrosine kinase inhibitor therapy was examined , 75 % of patients who received cisplatin and pemetrexed received an EGFR tyrosine kinase inhibitor and 56 % of patients who received cisplatin and @DRUG$ received an @GENE$ tyrosine kinase inhibitor .", "label": "None"}
{"id": "19055788", "sentence": "Significantly , our recent studies in an additional ER-positive , E-cadherin positive breast cancer cell model ( @VARIANT$ cells ) also demonstrate that similar pro-invasive effects can be elicited by @DRUG$ following suppression of @GENE$ ; importantly , this is also accompanied by an increase in Src activity [ see Additional data file ] thus suggesting that these events are not specific to MCF-7 cells , but may represent a generic effect in such breast cancer subtypes .", "label": "None"}
{"id": "19893626", "sentence": "The second-generation BCR-ABL inhibitors , dasatinib and nilotinib , can circumvent most mutations that confer resistance to imatinib ; the @VARIANT$ mutation , however , causes resistance to all @GENE$ kinase inhibitors developed so far . Similarly , the T790M point mutation in the epidermal growth factor receptor (EGFR) confers resistance to the EGFR tyrosine kinase inhibitors gefitinib and @DRUG$ , which are used to treat non-small cell lung cancer .", "label": "None"}
{"id": "24255704", "sentence": "Somatic mutation of EGFR defines a specific subclass of lung adenocarcinomas with sensitivity to treatment with the @GENE$ inhibitors gefitinib or @DRUG$ [ - ] . The two major classes of EGFR mutations are an @VARIANT$ point mutation and small , in-frame deletions in exon 19 ; both types of mutation enhance the activity and oncogenicity of EGFR compared to the wild-type protein [ ] .", "label": "sensitivity"}
{"id": "21165163", "sentence": "Median PFS and OS for the 217 patients who received erlotinib were 14 and 27 months , patients with @VARIANT$ had longer PFS than patients with exon 19 deletions and outcomes did not seem to differ whether @DRUG$ was given in the first or second-line setting . A combined survival analysis ( I-CAMP ) of seven prospective Japanese trials of 148 patients with @GENE$ mutations who received gefitinib demonstrated a response rate of 76.4 % , median PFS of 9.7 months and overall survival of 24.3 months [ ] .", "label": "sensitivity"}
{"id": "24124608", "sentence": "In addition to upregulation of IGF1R and VEGF , frequent CN gain and increased mRNA expression of GSTT1 as well as significant overexpression of @GENE$ subfamily members were observed in wild-type/PDGFRA @VARIANT$ GISTs compared to KIT-mutant GISTs . CN gain of GSTT1 was closely associated with @DRUG$ resistance .", "label": "None"}
{"id": "21188105", "sentence": "At least 10 other activating mutations ( less common single amino acid substitutions such as @VARIANT$ , L747S , and T854A ) have been reported within the kinase domain and the novel E884K mutation has been associated with resistance to gefitinib and @DRUG$ . Balak et al noted that given the proportion of patients with acquired resistance , whose tumors contain T790M , malignant cells remain dependent on mutant @GENE$ for survival in at least half of patients .", "label": "None"}
{"id": "22489192", "sentence": "NSCLC patients harboring exon 19 deletion or exon 21 @VARIANT$ somatic mutations experience significant tumor regression when prescribed the reversible small molecular tyrosine kinase inhibitors ( TKIs ) such as gefitinib and @DRUG$ . Discovery of @GENE$ which is based on the novel understanding of biological mechanisms underlying lung cancer development is a breakthrough in the therapeutic strategy of thoracic oncology .", "label": "sensitivity"}
{"id": "25090459", "sentence": "Furthermore , although KRAS mutations are typically associated with non-responsiveness to anti-EGFR antibodies , recent data indicate that KRAS @VARIANT$ mutations may be a positive predictor of cetuximab response . Mutations within the PIK3CA gene , which is an important regulator of PI3K signaling , are also present in some CRC tumors that can co-occur with KRAS or BRAF mutations , , thus suggesting their possible influence on responsiveness to targeted therapeutics such as @GENE$ antibodies but a clear demonstration of such a correlation is lacking , . From the studies outlined above and given that a large proportion of CRC patients with KRAS WT tumors do not respond to cetuximab or @DRUG$ , it is clear that a simple mutational analysis is insufficient to predict responsiveness to such therapeutics .", "label": "None"}
{"id": "24634705", "sentence": "@GENE$ Secondary Mutations Similar to other tyrosine kinase inhibitors , patients treated with @DRUG$ eventually develop resistance and mutations that lead to resistance have been reported [ , ] . In one report , the patient developed two de novo mutations within the kinase domain of EML4-ALK , @VARIANT$ and L1196M [ ] .", "label": "resistance"}
{"id": "22655263", "sentence": "In vivo efficacy was described only for the L1196M gatekeeper mutation , confirming a higher potency with respect to @DRUG$ in inhibiting the in vivo growth of ALK–L1196M driven @GENE$ cells . For the @VARIANT$ mutant , activity in Ba/F3 cells was not described , but the compound was able to effectively inhibit proliferation of a neuroblastoma cell line naturally bearing the mutation .", "label": "None"}
{"id": "23493838", "sentence": "A complete hematological response and a major cytogenetic response were observed broadly across the @GENE$ mutants , including individuals harboring the dasatinib-resistant F317L , the nilotinib-resistant Y253H , and F359C/I/V mutations , but not T315I . Nine individuals developed new mutations in the course of bosutinib treatment ( @VARIANT$ , n = 4 ; L248V , n = 2 ; T315I , n = 2 ; F359C , n = 1 ; G250E , n = 1 ) and eight of these individuals discontinued bosutinib because of progressive disease or unsatisfactory response .", "label": "None"}
{"id": "20657741", "sentence": "Rapamycin and rapalogs ( everolimus , @DRUG$ ) can slow the proliferation of cancer cell lines and have achieved some success in specific malignancies [ , ] . Unfortunately , however , their overall efficacy as cancer therapeutics has been limited . The major drawbacks of rapalogs are : 1 ) @VARIANT$ is exquisitely inhibited , yet the control of 4EBP and mRNA translation is far less sensitive [ , ] ; 2 ) TORC2 activity is not acutely blocked ( though it can be suppressed upon sustained exposure [ ] ) ; 3 ) the loss of a feedback inhibition pathway mediated by S6K results in amplified PI3K signaling , with potential to amplify RAS , @GENE$ , and TORC2 itself [ - ] .", "label": "None"}
{"id": "24416053", "sentence": "The tolerance mechanism of those mutations resembles that of @DRUG$ used in recombination of BCR-ABL rather than @VARIANT$ mutation which is the tolerance mechanism of EGFR-TKI . Mutation was observed in 20 % to 40 % of patients , and the amplification of @GENE$ gene was detected in 5 % to 20 % of patients in case of resistance to ALK inhibitors .", "label": "None"}
{"id": "24789720", "sentence": "@VARIANT$ mutation in EGFR gene seems to be one of the most important genetic abnormalities involving the resistance for reversible @GENE$ kinases inhibitors ( EGFR-TKI ) —erlotinib and gefitinib in NSCLC patients [ – ] .", "label": "resistance or non-response"}
{"id": "25162713", "sentence": "Many evidences showed that patients with advanced lung adenocarcinomas harbor EGFR mutations , @VARIANT$ missense mutations at exon 21 or deletions in exon 19 were more sensitive to the @GENE$ erlotinib or @DRUG$ , , .", "label": "sensitivity"}
{"id": "24894453", "sentence": "In order to further examine the efficacy of @DRUG$ , we expanded our studies by generating xenograft mouse models with either SW48 or HCT8 colon cancer cells , which harbor either EGFR G719S or @GENE$ @VARIANT$ mutation , respectively .", "label": "resistance or non-response"}
{"id": "23238683", "sentence": "In BaF3-WT-BCR-ABL and @VARIANT$ cells , @DRUG$ efficiently inhibited @GENE$ phosphorylation , but dephosphorylation of CRLK necessitated higher doses of ponatinib ( Figure ) .", "label": "response"}
{"id": "23788917", "sentence": "In case of occurrence of both @VARIANT$ and T790M mutations , the concentration of @DRUG$ should be three times higher in order to achieve a therapeutic effect . Analysis of the @GENE$ structure in patients harbouring the T854A mutation suggests the presence of an additional side chain , localised near the EGFR TKI binding site [ ] .", "label": "sensitivity"}
{"id": "23702846", "sentence": "In the cell proliferation and malignancy of MCF7 and SUM149 breast cancer cells , Src dependent ( i.e. , dasatinib-sensitive ) Y845 phosphorylation ( i.e. , @VARIANT$ mutation-sensitive ) signaling was shown to require the activity of p38 MAPK , but not the activity of the EGFR/kinase ERK/MAPK , as well as Akt [ ] . ROS that are produced by colchicine and nocodazole , both of which disrupt microtubules , have also been reported to promote Y845 phosphorylation in vascular smooth muscle cells , R22 , by which ERK/MAPK signaling is triggered to activate @GENE$ PAI-1 ) expression [ ] .", "label": "None"}
{"id": "25376241", "sentence": "As morphologically distinctive differences in the Wolffian ducts appeared , specifically excessive branching in males and simple @GENE$ in females , the hyperplastic defects in the Wolffian ducts may occur after sex determination . The transcription @DRUG$ activities of the wild-type and @VARIANT$ β-catenin proteins were almost equivalent", "label": "None"}
{"id": "17973572", "sentence": "Transient transfection experiments utilizing COS-7 cells demonstrated that auto-phosphorylation of the original @VARIANT$ EGFR was inhibited by lower concentrations of gefitinib or @DRUG$ than the L858R-L747S or L858R-T790M constructs ( A ) . CL-387,785 partially overcame the observed inhibition ( B ) . To prove the functional significance of the L747S mutation , we generated @GENE$ cell lines stably expressing mutant EGFR constructs [ ] .", "label": "None"}
{"id": "22034911", "sentence": "( B) PK/PD analysis after treating tumor bearing mice with a single dose of vehicle ( V , for 6 h ) or 200 mg/kg @DRUG$ . In pharmacodynamic studies ( ) , xenografts expressing native @GENE$ exhibited a 60–70 % inhibition in p-ALK levels at 6 h postdose , with more pronounced inhibition at 24 h . By contrast , p-ALK levels were reduced by approximately 25–35 % at 6 h in tumors expressing @VARIANT$ or S1206R , with a partial recovery at 24 h .", "label": "resistance"}
{"id": "24931142", "sentence": "He was next treated with capecitabine and progressed after 1.8 months , then treated on a clinical trial with @DRUG$ for 49.3 months and then with sorafenib , but progressed after 1.7 months . NGS performed on a tumor sample from the liver resection obtained at the time of diagnosis revealed mTOR mutation @VARIANT$ and FLT3 mutation splice site 1418+2A&gt ; G ( Figure ) . mTOR acts downstream of multiple pathways , including the @GENE$ pathway ( Figure ) .", "label": "None"}
{"id": "23493883", "sentence": "Some data suggest that patients with EGFR exon 19 deletions are more susceptible to the activity of reversible EGFR-TKIs compared to those with the exon 21 @VARIANT$ mutation. , Further studies then compared first-generation @GENE$ ( erlotinib and @DRUG$ ) to chemotherapy in patients with EGFR activating mutations in advanced NSCLC .", "label": "sensitivity"}
{"id": "21687596", "sentence": "A recent analysis showed that T790M mutations do not considerably affect the binding affinity between @GENE$ and EGFR-TKIs but instead increase the binding affinity between EGFR and ATP , causing a relative decrease in binding with EGFR-TKIs [ ] . The authors reported that increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance . An experiment using cell lines transfected concurrently with activating mutations and a @VARIANT$ mutation also proved that resistance to @DRUG$ and erlotinib is evident when this mutation is present [ – ] .", "label": "resistance or non-response"}
{"id": "24612546", "sentence": "A number of small-molecule tyrosine kinase inhibitors ( TKIs ) ( e.g. , @DRUG$ , erlotinib , lapatinib ) and antibodies ( eg , trastuzumab , cetuximab , panitumumab ) targeting the erbB family have been developed to treat breast , colorectal , lung , gastric and head and neck squamous cell cancers [ ] . Despite the improvements achieved in patients treated with reversible inhibitors of @GENE$ or EGFR and HER2 , primary and acquired resistances to these agents remain a clinical challenge . This is exemplified by the development of resistance to EGFR tyrosine kinase inhibitor ( TKI ) , through emergence of a secondary @VARIANT$ EGFR mutation in non-small-cell lung carcinoma ( NSCLC ) [ ] , which occurs in 50 % of the patients with lung adenocarcinoma [ ] .", "label": "resistance or non-response"}
{"id": "24789720", "sentence": "The role of @VARIANT$ mutation , particularly its presence in patients before @GENE$ treatment is still controversial being a subject of intensive discussions . Mechanism of achieving resistance to erlotinib and @DRUG$ remains unclear .", "label": "resistance or non-response"}
{"id": "23566546", "sentence": "Case Histrogical type @GENE$ mutation status Brinkman index Treatment agent Response IL-8 ( ng/mL ) IL-10 ( ng/mL ) RANTES ( pg/ml ) 1 Ad Ex21 @VARIANT$ 900 gefitinib PR 5.79 1.67 2 2 Ad Ex21 L858R 0 erlotinib PR_3.33 94.2 1.41 3 Ad Ex19 del 0 erlotinib PR 4.09 126 2.13 4 Ad Ex21 L858R 0 gefitinib PR_3.92 18.1 1.85 5 Ad Ex21 L858R + Ex19 del 370 @DRUG$ PR 21.9 1.23 2.11 6 Ad Ex19 del 0 erlotinib PR 7.05 1.37 2.56 7 Ad Ex19 del 0 gefitinib PR 4.82 1.59 2.02 8 Ad Ex21 L858R 1640 gefitinib PR 54.9 2.7 2.38 9 Ad negative 400 erlotinib SD 34.9 3.39 3.66 10 Ad negative 0 erlotinib SD 27.1 4.94 2.25 11 Ad unknown 1800 erlotinib SD NE NE NE 12 Sq Ex19 del 3840 gefitinib SD 12.6 1.1 1.98 13 Ad Ex19 del 30 erlotinib SD 5.27 0.69 2.66 14 Ad Ex19 del 0 erlotinib SD 10.5 0.85 2.5 15 Ad unknown 300 erlotinib SD 7.69 2.61 1.7 16 La negative 2080 erlotinib SD NE NE NE 17 Sq Ex21 L858R 750 erlotinib SD 11.6 56.3 3.06 18 Ad unknown 600 erlotinib SD 13.7 1.1 2.82 19 Ad Ex21 L858R 0 erlotinib SD 20.6 11.6 0.783 20 Ad Ex19 del 0 erlotinib SD 14.8 2.07 2.02 21 Ad Ex21 L858R + Ex19 del 0 gefitinib SD 3.04 1.3 1.76 22 Ad Ex19 del 200 gefitinib SD 10.9 1.59 1.91 23 Sq unknown 1560 erlotinib PD NE NE NE 24 Ad negative 1080 erlotinib PD 25.2 8.15 1.57 25 Ad unknown 0 erlotinib PD NE NE NE 26 Ad Ex18 G719A 2000 erlotinib PD 11.6 4.48 3.12 27 Ad unknown 1410 erlotinib PD NE NE NE 28 Ad Ex19 del 1000 gefitinib PD 9.44 2.25 2.89 29 Ad negative 1100 erlotinib PD 56.3 5.63 2.16 30 Ad negative 2000 erlotinib PD 15.6 0.85 0.292 31 Ad negative 825 erlotinib PD 8.27 1.59 2.13 32 Ad Ex21 L858R 0 erlotinib PD 5.34 7.05 1.7 33 Ad negative 1680 erlotinib PD 57.7 1.63 2.06", "label": "sensitivity"}
{"id": "12569391", "sentence": "Our studies with serum-free media showed that the presence of CD26/DPPIV was still associated with enhanced sensitivity to @DRUG$ and etoposide , by influencing the key components of @GENE$ following drug treatment .", "label": "None"}
{"id": "23994953", "sentence": "More recently , Chang et al. confirmed that in the absence of the common second-site EGFR mutation @VARIANT$ or MET amplification , acquired resistance to @DRUG$ occurs in @GENE$ mutated PC9 cells that have undergone EMT .", "label": "resistance or non-response"}
{"id": "25277176", "sentence": "( B ) Drugs such as the 4-anilinoquinazolines gefitinib ( @DRUG$ ) [ ] and erlotinib ( Tarceva ) [ ] can inhibit the activity of EGFR @VARIANT$ mutant . ( C ) However , tumors develop resistance , in this case one possibility is through overexpression of @GENE$ [ ] .", "label": "None"}
{"id": "16187797", "sentence": "Although exon 20 mutations were not widely reported at first , recently five large-scale studies that sequenced @GENE$ exons 18 through 21 reported a total of 18 exon 20 insertions out of 350 EGFR mutations identified in 1,108 non-small-cell lung cancers [ – ] . Patients who responded to @DRUG$ and subsequently relapsed were found to have @VARIANT$ secondary mutations , also in exon 20 [ , ] .", "label": "resistance or non-response"}
{"id": "23493883", "sentence": "Inhibition of @GENE$ cell lines by afatinib compared to @DRUG$ as shown by EC50 values Wild-type L858R mutation L858R + @VARIANT$", "label": "resistance or non-response"}
{"id": "22970367", "sentence": "Intriguingly , low expression of the NFκB inhibitor IκB was predictive of a poor clinical outcome in patients treated with @DRUG$ without a @VARIANT$ mutation . Importantly , IκB status was not predictive of outcomes in @GENE$ mutant lung cancer patients treated with surgery or chemotherapy , indicating NFκB signaling is specific biomarker of EGFR TKI response in this patient population [ , ] ( ) .", "label": "resistance or non-response"}
{"id": "24457960", "sentence": "Indeed , a Par-4 cleaved form was previously reported in human cells during Fas- or @DRUG$ induced apoptosis. , Thus , phosphorylation by CK2 on residues S124 and S223 results in loss of rat Par-4 proapoptotic properties and prevents the generation of the caspase mediated cleaved form of @GENE$ . We then examined whether Par-4 cleavage was regulated by phosphorylation of S124 by CK2 . We first performed an in vitro caspase assay using purified wild-type Par-4 or its mutants ( S124A , S124D , S223A , @VARIANT$ , S124A , S223A or S124D/S223D ) in the presence of recombinant caspases .", "label": "None"}
{"id": "20003272", "sentence": "For phosphorylated @VARIANT$ .X immunostaining one coverslip per cell type was incubated with 2 μg/ml @DRUG$ ( Doxo ) for 7 hours in order to have a positive control .", "label": "None"}
{"id": "24167634", "sentence": "These data support the role of @GENE$ in cell motility and invasiveness and suggest the importance of EGFR-TKIs maintenance treatment after tumor progression . Of note , the continuous exposure of H1975 cells , carrying the @VARIANT$ mutation , to @DRUG$ did not modify their migratory phenotype , possibly because of the low affinity of the mutated receptor for this drug .", "label": "resistance or non-response"}
{"id": "22384259", "sentence": "The hetero atoms ( crystallographic waters and @DRUG$ , CIT ) were removed from the structure before simulation . WT-ANG has three disulfide bonds Cys26–Cys81 , Cys39–Cys91 and Cys57–Cys107 which were processed according to AMBER protocols . To model the starting structures of mutants K17I , @VARIANT$ , P112L , L35P , K60E and V113I for which crystal structures do not exist , we mutated the corresponding residues in silico by replacing the target residues with the desired amino acids , keeping the secondary structures intact .", "label": "None"}
{"id": "23579627", "sentence": "This findings show that EGFR @VARIANT$ is a common resistance mechanism to both reversible , and when amplified , the irreversible EGFR inhibitors . In our case , the response duration of irreversible EGFR inhibitor was 11 months which was unusually longer than those of initial @DRUG$ ( for 4 months ) and second round gefitinib ( for 6 months ) treatments . Recently an alternative approach is to develop novel strategies , instead of irreversible EGFR inhibitors , to inhibit EGFR and/or EGFR signaling , including the use of inhibitors of @GENE$ and/or EGFR downstream signaling ( such as phosphatidylinositol 3-kinase and MEK inhibitors ) as these resistant cancers still remain dependent on EGFR signaling for their growth .", "label": "None"}
{"id": "20482842", "sentence": "Human CML cell lines ( KBM5 , KBM5-T315I and K562 ) , and a pair of murine myeloid cells 32D stably transfected with either the wild-type or @VARIANT$ human @GENE$ were exposed to escalating concentrations of pristimerin for 72 h , followed by the MTS assay . Cell viability of all 5 lines of CML cells was inhibited , with IC50 values of 199 nM , 135 nM , 450 nM , 242 nM and 387 nM , respectively ( Figure ) . These data suggest similar sensitivities of imatinib-sensitive and imatinib-resistant CML cells to pristimerin .", "label": "None"}
{"id": "22123319", "sentence": "In a melanoma study of 21 patients who received a sufficiently high dose of vemurafenib , 5 without the @VARIANT$ BRAF mutation did not respond to the drug ; however , of 16 patients with the mutation , 9 responded to vemurafenib and 7 did not [ ] . In a phase II study of @DRUG$ for advanced melanoma , a substantial proportion of patients with tumors characterized by mutation or amplification of @GENE$ responded to the drug whereas it had limited activity in a nonselected population of melanoma patients [ ] .", "label": "None"}
{"id": "25538894", "sentence": "For neratinib , a phase II trial showed disappointing results ( ) and the dacomitinib data showed possible benefit in patients with @DRUG$ resistance ( ) , but further investigations are necessary . In preclinical studies , third-generation EGFR inhibitors ( WZ4002 and CO-1686 ) showed hopeful results , with activity against @VARIANT$ mutations and sparing wild-type @GENE$ ( – ) .", "label": "resistance or non-response"}
{"id": "22185378", "sentence": "In contrast , we have demonstrated that the combination of @DRUG$ and PD153035 ( a specific EGFR TKI ) proved to be antagonistic in @VARIANT$ cell line , with no reduction in proliferation and EGFR , HER2 , AKT and @GENE$ phosphorylation status when compared to either drug alone [ ] .", "label": "None"}
{"id": "25364578", "sentence": "Lazzara and colleagues found that SHP2 Y542 phosphorylation was not induced in response to @GENE$ in the H3255 cells , which harbor the missense @VARIANT$ exon 21 mutation , suggesting that SHP2 activity may be less efficiently promoted by EGFR L858R and the STAT3 pathway may be more active . The main problem is that STAT3 activation is not abrogated by single EGFR TKI treatment with gefitinib , erlotinib , @DRUG$ or dacomitinib , - .", "label": "None"}
{"id": "21333004", "sentence": "Overexpression of wild type EGFR induced high and sustained phosphorylation of EGFR , Shc , MEK ( mitogen activated protein kinase kinase ) and ERK ( extracellular signal regulated kinase ) , while the @VARIANT$ mutation reduced these response levels . In addition , H1299L858R , which is supposed to be more sensitive to @DRUG$ than H1299EGFR-WT , was effectively inhibited by gefitinib administration at the downstream part of the signaling pathway ( MEK and ERK ) compared with H1299EGFR-WT , but , surprisingly , not at the upstream part of the pathway ( @GENE$ and Shc ) .", "label": "sensitivity"}
{"id": "23864840", "sentence": "Another approach for @VARIANT$ mediated resistance is the dual inhibition of @GENE$ with afatinib and cetuximab , an EGFR blocking antibody resembling the synergistic combination of @DRUG$ and trastuzumab in ErbB2 positive breast cancer .", "label": "None"}
{"id": "23566546", "sentence": "Case Histrogical type EGFR mutation status Brinkman index Treatment agent Response IL-8 ( ng/mL ) @GENE$ ( ng/mL ) RANTES ( pg/ml ) 1 Ad Ex21 @VARIANT$ 900 gefitinib PR 5.79 1.67 2 2 Ad Ex21 L858R 0 erlotinib PR_3.33 94.2 1.41 3 Ad Ex19 del 0 erlotinib PR 4.09 126 2.13 4 Ad Ex21 L858R 0 gefitinib PR_3.92 18.1 1.85 5 Ad Ex21 L858R + Ex19 del 370 erlotinib PR 21.9 1.23 2.11 6 Ad Ex19 del 0 erlotinib PR 7.05 1.37 2.56 7 Ad Ex19 del 0 gefitinib PR 4.82 1.59 2.02 8 Ad Ex21 L858R 1640 gefitinib PR 54.9 2.7 2.38 9 Ad negative 400 erlotinib SD 34.9 3.39 3.66 10 Ad negative 0 erlotinib SD 27.1 4.94 2.25 11 Ad unknown 1800 erlotinib SD NE NE NE 12 Sq Ex19 del 3840 gefitinib SD 12.6 1.1 1.98 13 Ad Ex19 del 30 erlotinib SD 5.27 0.69 2.66 14 Ad Ex19 del 0 erlotinib SD 10.5 0.85 2.5 15 Ad unknown 300 erlotinib SD 7.69 2.61 1.7 16 La negative 2080 erlotinib SD NE NE NE 17 Sq Ex21 L858R 750 @DRUG$ SD 11.6 56.3 3.06 18 Ad unknown 600 erlotinib SD 13.7 1.1 2.82 19 Ad Ex21 L858R 0 erlotinib SD 20.6 11.6 0.783 20 Ad Ex19 del 0 erlotinib SD 14.8 2.07 2.02 21 Ad Ex21 L858R + Ex19 del 0 gefitinib SD 3.04 1.3 1.76 22 Ad Ex19 del 200 gefitinib SD 10.9 1.59 1.91 23 Sq unknown 1560 erlotinib PD NE NE NE 24 Ad negative 1080 erlotinib PD 25.2 8.15 1.57 25 Ad unknown 0 erlotinib PD NE NE NE 26 Ad Ex18 G719A 2000 erlotinib PD 11.6 4.48 3.12 27 Ad unknown 1410 erlotinib PD NE NE NE 28 Ad Ex19 del 1000 gefitinib PD 9.44 2.25 2.89 29 Ad negative 1100 erlotinib PD 56.3 5.63 2.16 30 Ad negative 2000 erlotinib PD 15.6 0.85 0.292 31 Ad negative 825 erlotinib PD 8.27 1.59 2.13 32 Ad Ex21 L858R 0 erlotinib PD 5.34 7.05 1.7 33 Ad negative 1680 erlotinib PD 57.7 1.63 2.06", "label": "None"}
{"id": "25405807", "sentence": "Inhibition of epidermal growth factor receptor (EGFR) kinase activity by EGFR tyrosine kinase inhibitors ( @GENE$ ) , such as @DRUG$ and erlotinib , can result in improved response and prolonged progression-free survival ( PFS ) in selected non-small cell lung cancer ( NSCLC ) patients harboring sensitizing EGFR mutations , especially the exon 19del and exon 21 L858R mutations – . Unfortunately , almost all patients will ultimately develop resistance to EGFR-TKI , in whom more than 50 % cases were detected harboring the EGFR @VARIANT$ mutation in tumor specimens after EGFR-TKI , .", "label": "resistance or non-response"}
{"id": "24523596", "sentence": "@VARIANT$ in 88.6/D800-B TMD Increased rhodamine 123 efflux , resistant to mitoxantrone/anthracyclin , and decrease of @DRUG$ transport . Honjo et al , Allen et al , Volk and Schneider , and Wang et al Abbreviations : ABC , adenine-triphosphate binding cassette ; @GENE$ , breast cancer resistance protein ; NBD , nucleotide binding domain ; TMD , transmembrane domain .", "label": "None"}
{"id": "25505694", "sentence": "The study showed that , among the 5 tumor samples collected at the time of XL647 failure , only one harbored the @VARIANT$ mutation and that three patients treated with second line @DRUG$ derived additional long-term benefit from the @GENE$ TKI [ ] .", "label": "resistance or non-response"}
{"id": "25532027", "sentence": "In particular , epidermal growth factor receptor-tyrosine kinase inhibitors ( EGFR-TKIs ) , such as @DRUG$ and erlotinib , demonstrated marked clinical activity against NSCLC harboring an activating @GENE$ mutation ( – ) . Additionally , some reports suggest that the EGFR @VARIANT$ mutation may not be rare and may exist in a small population of in tumor cells before TKI treatment ( – ) .", "label": "resistance or non-response"}
{"id": "23864840", "sentence": "However , acquired resistance to EGFR-TKIs is inevitable due to various mechanisms , such as @VARIANT$ , c-Met amplification , activation of alternative pathways ( IGF-1 , HGF , PI3CA , AXL [ ] ) , transformation to mesenchymal cells [ ] or small cell features [ ] , and tumor heterogeneity [ ] . A randomized trial comparing the irreversible @GENE$ blocker @DRUG$ versus placebo in patients with NSCLC after prior EGFR-TKI exposure failed to prove a benefit of overall survival [ ] .", "label": "response"}
{"id": "PMC4001129", "sentence": "Introduction : @GENE$ kinase inhibitors ( TKIs ) such as @DRUG$ are one of gold standard treatment options for non-small-cell lung cancer ( NSCLC ) patients , which eventually fail due to the acquired resistance and relapse because of the development of secondary activating mutations such as @VARIANT$ in EGFR .", "label": "resistance or non-response"}
{"id": "15737014", "sentence": "Analogously , the @VARIANT$ mutation , in conjunction with the drug-responsive del L747–E749 ; A750P @GENE$ mutant , prevents inhibition of p-EGFR by @DRUG$ ( C ) .", "label": "resistance or non-response"}
{"id": "24590311", "sentence": "Pretreatment with carfilzomib followed by addition of @DRUG$ resulted in a significant reduction in viability in Ba/F3 T315I , @GENE$ @VARIANT$ , LAMA84R and KCL22R ( P⩽0.04 ) .", "label": "None"}
{"id": "20404937", "sentence": "The R26R-RERT or R26R-EYFP-RERT mice lines were used for clonal analysis ; these are crosses between lines carrying the @VARIANT$ or R26R-EYFP reporter and RERTn transgenes . Labelled cells are produced by the activity of CreERT2 , an inducible recombinase activated by 4-hydroxy-tamoxifen ( TM ) . Ubiquitous CreERT2 expression is provided by a knock-in insertion of the CreERT2 cDNA into the 3′ UTR of the @GENE$ , which yields viable homozygotes with no obvious phenotype .", "label": "None"}
{"id": "19920910", "sentence": "Although these studies do not consistently identify the same drug-resistant @GENE$ point mutations for individual drugs , it is clear that all 3 compounds display different mutagenicity profiles . The patterns of mutations occurring in patients with all phase CML treated sequentially with @DRUG$ , and 1 or 2 second-generation TKIs after imatinib failure were investigated ( ) . Response rates were similar for patients with and without mutations , regardless of mutation site except for @VARIANT$ .", "label": "None"}
{"id": "21206909", "sentence": "Approximately 40 % of patients with mucosal melanoma have c-kit aberrations in exons 11 , 13 , and 17 , and clinical responses , including CR 's , were seen in these patients after treatment with @DRUG$ , , , . Notably , a recent case report documented a PR in a patient with the @VARIANT$ mutation in exon 17 of @GENE$ who was treated with sorafenib .", "label": "response"}
{"id": "23874486", "sentence": "Patients carrying @GENE$ @VARIANT$ mutation could still benefit from @DRUG$ treatment .", "label": "resistance or non-response"}
{"id": "22714415", "sentence": "This year at ASCO , Tejpar et al. further supported this finding by presenting retrospective analyses of two large phase III multicenter trials ( CRYSTAL and OPUS ) representing 83 patients with @VARIANT$ KRAS mutant mCRC tumors who had longer overall survival and progression free survival on average post @DRUG$ treatment then other @GENE$ mutant subtypes .", "label": "resistance or non-response"}
{"id": "24386407", "sentence": "Recent clinical trials have shown that progression-free survival ( PFS ) in patients with EGFR mutant lung cancer is prolonged by treatment with a reversible @GENE$ and the irreversible EGFR-TKI @DRUG$ , which was designed to covalently bind to EGFR [ - ] . Nevertheless , almost all responders relapse after acquiring resistance to these EGFR-TKIs [ , ] . Among the mechanisms by which cancer cells become resistant to reversible EGFR-TKIs are 1 ) gatekeeper mutations in EGFR , such as the @VARIANT$ second mutation [ , ] ; 2 ) activation of bypass signaling caused by Met amplification [ ] , hepatocyte growth factor (HGF) overexpression [ ] , or Gas6-Axl activation [ ] ; 3 ) activation of downstream molecules ( PTEN loss or PIK3CA mutation ) [ , ] ; 4 ) small-cell lung cancer transformation [ ] ; and 5 ) epithelial-to-mesenchymal transition [ ] .", "label": "response"}
{"id": "23963283", "sentence": "@GENE$ @VARIANT$ and MET amplification account for approximately 60–70 % of all known causes of acquired resistance to gefitinib or @DRUG$ ; these amplifications are not mutually exclusive and can be detected in the same resistant tumor or may occur independently in different metastatic sites in the same patient .", "label": "resistance or non-response"}
{"id": "25563222", "sentence": "Zelboraf ( vemurafenib ) —non-small cell lung cancer Cobas @GENE$ @VARIANT$ Yes Part D @DRUG$ ( crizotinib ) —melanoma ALK Yes Part D", "label": "None"}
{"id": "24187524", "sentence": "Indeed , there are three currently approved antibodies in clinical use : herceptin ( an anti-HER2 approved to treat breast cancer overexpressing HER2 ) , cetuximab , and panitumumab ( @GENE$ approved for treating metastatic colorectal cancer ) [ ] . Furthermore , there are three small-molecule inhibitors of the tyrosine kinase domain ( TKIs ) that interfere with the binding of ATP , also approved to treat non-small cell lung cancer ( i.e. , @DRUG$ , erlotinib , and lapatinib ) [ ] . These therapeutic molecules are limited by the development of resistance mutations such as @VARIANT$ in EGFR , which necessitates the screening of new inhibitors .", "label": "resistance or non-response"}
{"id": "20694077", "sentence": "However , the T315I mutant remained resistant to nilotinib at concentrations & lt ; 10 μM. , Nilotinib also potently inhibited tyrosine autophosphorylation of the E255K , E255V , F317L , @VARIANT$ , and F486S Bcr-Abl mutants , and these effects were not associated with decreases in Abl or Bcr-Abl protein levels . Overall , these results supported the conclusion that many imatinib-resistant Bcr-Abl mutants were relatively or absolutely more sensitive to nilotinib . Nilotinib also inhibits to a lesser extent platelet derived growth factor receptor ( PDGFR-alpha ) and @GENE$ , as well as c-kit dependent cell proliferation .", "label": "None"}
{"id": "25091415", "sentence": "Therefore , to elucidate the structural and dynamic consequences of the DM on the catalytic domain of @GENE$ and its affinity toward gefitinib , we performed molecular dynamic simulations ( 50 ns ) of the wild type ( WT ) -EGFR and three oncogenic mutants : @VARIANT$ , T790M , and DM in complex with @DRUG$ .", "label": "sensitivity"}
{"id": "22034911", "sentence": "Consistent with this , we found that the introduction of R1275Q into EML4-ALK had no negative impact on sensitivity to @DRUG$ ( IC50 47 ± 8 nm ) . As expected , the IC50 values for viability of @GENE$ cells expressing these mutants were all above that for Ba/F3 cells expressing native EML4-ALK , with IC50s ranging from 231 to 981 nm . The three most resistant mutants , @VARIANT$ , S1206R , and G1269S , all had IC50s within twofold of parental , ALK negative , Ba/F3 cells ( IC50 1176 nm ) .", "label": "None"}
{"id": "23515752", "sentence": "H1975 cells ( @VARIANT$ ) were treated with 17-DMAG ( 50 nM ) and @DRUG$ ( 500 nM ) for 24 h. Cells were harvested , lysates made , subjected to Western blotting and probed with antibody against p-Akt ( Ser473 ) , @GENE$ and GAPDH ( loading control ) ( B ) .", "label": "None"}
{"id": "23994953", "sentence": "@VARIANT$ and MET amplification , which can be detected in up to 20 % of @GENE$ NSCLCs secondarily refractory to EGFR TKIs , account for approximately 60–70 % of all known causes of acquired resistance to gefitinib/erlotinib .", "label": "resistance or non-response"}
{"id": "22693611", "sentence": "Here , @DRUG$ and siNucleolin reduced COUP-TFII induced @GENE$ expression in MCF-7 and @VARIANT$ cells and cotransfection with nucleolin reduced AS1411-inhibition .", "label": "None"}
{"id": "22714415", "sentence": "This year at ASCO , Tejpar et al. further supported this finding by presenting retrospective analyses of two large phase III multicenter trials ( CRYSTAL and OPUS ) representing 83 patients with @VARIANT$ KRAS mutant mCRC tumors who had longer overall survival and progression free survival on average post @DRUG$ treatment then other KRAS mutant subtypes . Overall , these data suggest that @GENE$ mAbs should still be considered as treatment options for patients with a G13D KRAS mutation , and that stratification of different KRAS mutant subtypes should now be documented .", "label": "None"}
{"id": "24069582", "sentence": "Harris et al. Phase III NCT01266486 Metformin 40 Participants with locally advanced breast cancer IHC analysis of effects on phosphorylation of @VARIANT$ , @GENE$ , and AMPK Han et al. Phase II NCT01589367 Metformin vs. placebo in letrozole and no @DRUG$ arms 208 Postmenopausal women with stage I/II ER-positive breast cancer Clinical response rate at 24 weeks and comparison with RECIST 1.1 at baseline", "label": "None"}
{"id": "24676216", "sentence": "Furthermore , we performed highly sensitive deep sequencing for mutations in KRAS ( exon 2 ) , PIK3CA ( exons 9 and 20 ) , @GENE$ ( @VARIANT$ ) , and EGFR ( S492R mutation in patients who received @DRUG$ ) .", "label": "resistance or non-response"}
{"id": "22209766", "sentence": "On the other hand , erlotinib could not inhibit EGFR phosphorylation in H1975 cells because the @VARIANT$ mutation in @GENE$ causes a conformation change at the ATP binding pocket , thus decreasing the affinity between @DRUG$ and EGFR .", "label": "resistance or non-response"}
{"id": "22481926", "sentence": "A clinical trial is currently underway to study the efficacy of liposomal adenoviral @VARIANT$ , which interferes with NFKB signaling , in combination with @DRUG$ in patients with recurrent ovarian cancer . The use of poly ( ADP-ribose ) polymerase ( PARP ) inhibitors in ovarian cancer is being evaluated in various preclinical , and clinical studies . By interfering with PARP single-strand DNA repair activity , this strategy is aimed at increasing the cytotoxicity associated with DNA damage induced by chemotherapy and takes advantage of the fact that loss of function of @GENE$ genes , which are also involved in DNA strand breaks repair , is a common feature of this type of cancer [ ] .", "label": "None"}
{"id": "21712828", "sentence": "Consistent with this hypothesis , in a recent meta-analysis of @DRUG$ clinical trial data , clearly demonstrated that patients with colorectal tumours with a @VARIANT$ mutation were significantly more likely to respond to cetuximab treatment than other @GENE$ mutant tumours and survived longer .", "label": "resistance or non-response"}
{"id": "18665217", "sentence": "The transfected plasmids were as follows : Gα13 @VARIANT$ , Gα13 Q226L/D294N , RhoA T19 and RhoA G14V , @GENE$ or dominant negative p85α ( Δp85α ) . These constructs were obtained from the Guthrie cDNA Resource Center ( www.cdna.org ) . Plasmids for CMV human @DRUG$ receptor A ( hPR-A , # 95 ) and B ( hPR-A , # 90 ) were provided by Dean P. Edwards ( Baylor college of medicine , USA ) .", "label": "None"}
{"id": "21034468", "sentence": "MCF7ErbB2 cells were pretreated with ethanol with/without @VARIANT$ for 48 hours , then the cells were seeded on fibronectin precoated plates and allowed to attach for 1 hour in the presence/absence of @DRUG$ and/or C3G .", "label": "None"}
{"id": "15737014", "sentence": "These results suggest that the @VARIANT$ mutation may impair the ability of @DRUG$ or erlotinib to inhibit EGFR tyrosine kinase activity , even in @GENE$ mutants ( i.e. , L858R or an exon 19 deletion ) that are clinically associated with drug sensitivity .", "label": "resistance or non-response"}
{"id": "24523596", "sentence": "Recently , genome-wide screening for the genetic determinants of gout found that an SNP of ABCG2/BCRP ( @VARIANT$ ) is associated with high uric acid levels , and demonstrated that uric acid is a natural substrate of ABCG2/BCRP. , ABCG2/BCRP also appears to play a protective role against xenobiotics and their metabolites. , The typical @GENE$ substrates , @DRUG$ and SN-38 , are detoxified by glucuronidation with uridine-diphosphate–glucuronyltransferase , and ABCG2/BCRP can extrude SN-38–glucuronide .", "label": "None"}
{"id": "17973572", "sentence": "A parallel situation is seen with gastrointestinal stromal tumor ( GIST ) , in which activating mutations of the receptor tyrosine kinases @GENE$ or PDGFRA ( platelet derived growth factor receptor , alpha polypeptide ) contribute to the disease , and again @DRUG$ is an effective treatment option improving patient survival [ ] . A similar clinical benefit is observed in patients with lung cancers harboring the two most common EGFR activating mutations , @VARIANT$ and exon 19 deletions [ – , ] .", "label": "None"}
{"id": "23515890", "sentence": "RNA ( siRNA ) -mediated depletion of NRAS in two melanoma cell lines ( 224 and BL , which harbor a @VARIANT$ NRAS mutation ) inhibits proliferation and renders cells more sensitive to chemotherapy ( Eskandarpour et al. , ) . A single-agent , single-arm phase II trial conducted with metastatic melanoma patients investigated Farnesyltransferase inhibitors (FTI’s) which block farnesylation , the key activating post-translational modification of @GENE$ ( Sebti , ) . The outcome of this trial using the FTI Tipifarnib ( otherwise known as @DRUG$ ) , showed a low response in the first 14 patients which led to early closure of the trial ( Gajewski et al. , ) .", "label": "None"}
{"id": "25429239", "sentence": "It inhibits both L1196M in ALK+ NSCLC and the @VARIANT$ in EGFR mutants . Phase I/II data for AP26113 have demonstrated efficacy in both @DRUG$ naive and resistant patients . It also has the ability to cross the blood–brain barrier and is active in @GENE$ brain metastasis .", "label": "None"}
{"id": "24876815", "sentence": "@GENE$ et al. , investigating a group of 246 patients with CRC to determine polymorphism @VARIANT$ ( 818A &gt ; C ) and the efficacy of cetuximab , found that the C allele was an unfavourable predictive factor for @DRUG$ treatment .", "label": "None"}
{"id": "23937717", "sentence": "Though @DRUG$ can also restore NKG2D ligands and NKG2D interaction , and inhibit stat3 expression , we did not find significant improvement on NK cells cytotoxicity to A549 cells with wild type EGFR , while there was significant enhancement to H1975 cells with @GENE$ L858R + @VARIANT$ resistance mutations .", "label": "resistance or non-response"}
{"id": "18454182", "sentence": "One special group of patients , those harbouring a T315I mutation in the @GENE$ kinase domain , warrants further discussion . The @VARIANT$ mutation has been shown to mediate resistance to all three tkis ( @DRUG$ , dasatinib , nilotinib ) , and therefore patients with this particular mutation should be evaluated for an allogeneic hsct or offered experimental therapy if transplantation is not a suitable option .", "label": "None"}
{"id": "24574860", "sentence": "@GENE$ producing hepatoma family of receptors Whether this strategy can overcome the oncogenic effect of the recurrent somatic @VARIANT$ mutation in the first fibronectin Type III domain of EphA2 reported in 7 % of squamous cell lung carcinomas ( SQCLC ) is unknown . This mutation promotes cell survival and metastasis through activation of p130Cas which appears to be responsive to mTOR inhibition. [ ] In comparison , several kinase domain mutations in EPHA3 result in diminished phosphorylation of the EPHA3 receptor , which functionally attenuates the tumor-suppressive effects of wild-type EPHA3 through regulation of AKT activity. [ ] Various multikinase inhibitors currently in clinical use potently target Eph receptors , such as dasatinib and @DRUG$ .", "label": "None"}
{"id": "20972475", "sentence": "Also available is a second assay , the @GENE$ ( V600E Sequencing ) ( @VARIANT$ ) , which uses sequencing to detect the BRAF p.Val600Glu sequence variant . Public Health Importance Available evidence indicates that the clinical benefit from treatment with EGFR monoclonal antibody inhibitors @DRUG$ and panitumumab is limited to a subgroup of only 10 % to 30 % of CRC patients .", "label": "None"}
{"id": "15736989", "sentence": "For example , @DRUG$ is effective in treatment of chronic myelomonocytic leukemia with gene rearrangements that constitutively activate PDGFRB [ ] , of hypereosinophilic syndrome with activating mutations in PDGFRA [ ] , and of gastrointestinal stromal cell tumors associated with activating mutations in KIT [ ] ( all reviewed in [ ] ) . More recently , this paradigm has been extended to treatment of non-small cell lung cancer ( NSCLC ) . Several mutations have been identified in the context of epidermal growth factor receptor (EGFR) in patients with NSCLC that are associated with clinical response to the small-molecule @GENE$ inhibitors gefitinib ( Iressa ) or erlotinib ( Tarceva ) [ , , ] , including in-frame deletions such as del L747–E749 ; @VARIANT$ in exon 19 , or L858R in exon 21 .", "label": "None"}
{"id": "21687596", "sentence": "A recent analysis showed that T790M mutations do not considerably affect the binding affinity between EGFR and @GENE$ but instead increase the binding affinity between EGFR and ATP , causing a relative decrease in binding with EGFR-TKIs [ ] . The authors reported that increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance . An experiment using cell lines transfected concurrently with activating mutations and a @VARIANT$ mutation also proved that resistance to gefitinib and @DRUG$ is evident when this mutation is present [ – ] .", "label": "resistance or non-response"}
{"id": "25462529", "sentence": "The fact that D167A or K substitutions do not reduce IN enzymatic activity , but slightly affect RT and interaction with p75/LEDGF , points to a change in @GENE$ processing due to a modified trend of interactions between IN monomers , between IN and RT , or between IN and a cellular factor such as p75/LEDGF . @DRUG$ is a versatile amino acid that can assume positive charge , but remains usually neutral at physiological pH . In fact , this mutation affects later time points of our analysis with vector @VARIANT$ still integrating between 48 and 72 hours following transduction .", "label": "None"}
{"id": "23976869", "sentence": "Dasatinib is a dual SRC/ABL1 inhibitor that also inhibits PDGFRs and FIP1L1-PDGFRA fusion but has no effect on imatinib-resistant @GENE$ T674I and @VARIANT$ mutants .", "label": "resistance or non-response"}
{"id": "17931419", "sentence": "In this study , we used a group of cancer cell lines with either overexpressed or tyrosine kinase domain mutated ( ΔE746-A750 or @VARIANT$ ) EGFR to assess their responsiveness to @DRUG$ and gefitinib treatment and to evaluate HIF-1α as novel molecular marker for the therapeutic responses of the cancer cells to @GENE$ targeted therapy .", "label": "None"}
{"id": "21445332", "sentence": "While binding to @GENE$ was similar to wild-type MCP , the mutant showed an approximately 50 % decrease in C4b binding ( p & lt ; 0.001 ) compared to wild-type MCP . Given the lower binding to C4b , we suspected that the @VARIANT$ mutant form of MCP would have a decreased capacity to serve as a @DRUG$ for CFI mediated cleavage of C4b .", "label": "None"}
{"id": "15736989", "sentence": "Several mutations have been identified in the context of @GENE$ patients with NSCLC that are associated with clinical response to the small-molecule EGFR inhibitors @DRUG$ ( Iressa ) or erlotinib ( Tarceva ) [ , , ] , including in-frame deletions such as del L747–E749 ; A750P in exon 19 , or @VARIANT$ in exon 21 .", "label": "sensitivity"}
{"id": "24419415", "sentence": "Recent studies suggest that NSCLC patients with uncommon EGFR mutations are less responsive to EGFR-TKIs compared with patients with L858R and exon 19 deletions.– However , the efficacy of @GENE$ in NSCLC patients with uncommon mutations has not been fully elucidated . We conducted a post-hoc analysis of the NEJ002 study to evaluate the effectiveness of @DRUG$ against NSCLC with G719X or @VARIANT$ .", "label": "None"}
{"id": "19920910", "sentence": "In a cell-line based mutagenesis study , the emergence of @GENE$ mutations resistant to imatinib , nilotinib and dasatinib were compared : 20 different mutations were identified with imatinib mesylate , 10 with nilotinib ( including only 1 novel mutation , E292V ) and 9 with @DRUG$ . In contrast to imatinib mesylate , mutations recovered in the presence of 50 nM nilotinib were limited to L248V , G250E , Y253H , E255K ( p-loop ) , T315I , @VARIANT$ , L384M and L387F .", "label": "None"}
{"id": "23852704", "sentence": "Thus , in two trials , administration of cetuximab to patients with this mutation was associated with a significantly better outcome than that seen in patients with other types of K-RAS mutations. , Indeed , patients with the @VARIANT$ mutation appeared to benefit to approximately the same extent as patients with @GENE$ wild-type tumors from the addition of @DRUG$ to first-line chemotherapy .", "label": "resistance or non-response"}
{"id": "25465236", "sentence": "( C ) @GENE$ T790M mutant does not resemble pEGFR unlike the EGFR L858R mutant shown in B. ( D–F ) increased inhibition potency for @DRUG$ against EGFR L858R mutant compared to EGFR WT protein and subsequent decrease in potency for Erlotinib against EGFR L858R + E884K double mutant . ( G–I ) increased inhibition potency for Gefitinib against EGFR L858R mutant compared to EGFR WT protein and subsequent further increase in potency for Gefitinib against EGFR L858R + E884K double mutant . ( J ) EGFR @VARIANT$ activated more than T790M but less than L858R .", "label": "None"}
{"id": "24594844", "sentence": "cDzT specifically degraded EGFR @VARIANT$ mRNA and decreased EGFR protein levels , whereas @DRUG$ inhibited autophosphorylation of @GENE$ without affecting EGFR protein level .", "label": "response"}
{"id": "21333004", "sentence": "According to recent reports , the sensitivity to kinase inhibition reflects intrinsic differences in the binding affinity of the EGFR mutants such as L858R , @VARIANT$ , and exon19 deletions [ , - ] . Yun et al [ ] showed that gefitinib directly binds more tightly to the L858R mutant than to the wild type @GENE$ in vitro , while Fabian et al [ ] indicated that EGFR with @DRUG$ sensitive mutations does not differ from wild type EGFR in terms of gefitinib binding affinity .", "label": "sensitivity"}
{"id": "21915126", "sentence": "Therefore , CPT-11 and gefitinib should have a synergistic beneficial effect in NSCLC patients with acquired resistance to @DRUG$ . The mechanistic reasons behind the resistance to EGFR TKI are different , probably involving @VARIANT$ secondary mutation and @GENE$ amplification .", "label": "None"}
{"id": "23099808", "sentence": "Acquired clinical resistance to EGFR-TKI was also documented in lung cancer patients , who had an EGFR mutation in exon 20 ( @VARIANT$ ) ( ) . Therefore , in this study , we first examined the effects of gefitinib or @DRUG$ on cell proliferation of the cell lines including those originated from lung adenocarcinoma ( LADCA ) . We then evaluated gene profiles of EGFR-TKI-sensitive cells using a microarray analysis in order to further characterise the possible differential mRNA expression patterns among @GENE$ cells .", "label": "resistance or non-response"}
{"id": "25222496", "sentence": "Another seven studies ( clinical trials or retrospective studies ) , , , , , , involving 549 advanced NSCLC patients receiving first-line @GENE$ ( @DRUG$ or erlotinib ) presented direct comparison of exon 19 deletion and @VARIANT$ mutation for PFS .", "label": "sensitivity"}
{"id": "24811491", "sentence": "Acquired resistance EGFR mutations Mutations in the EC domain ( @VARIANT$ ) and in the kinase domain ( codons 714 and 794 ) of EGFR found in patients @DRUG$ remained active in a patient with S492R mutation , which abrogated cetuximab binding . RAS/BRAF activation CRC cell lines with acquired KRAS/BRAF point mutations and/or KRAS amplification and one patient derived xenograft Combination of cetuximab with pimasertib ( @GENE$ inhibitor ) induced moderate tumor shrinkage in vivo .", "label": "None"}
{"id": "22997594", "sentence": "It is now well established that Imatinib does not have direct effect on the @VARIANT$ KIT mutation , but it may affect other sporadic mutations [ , , ] . @DRUG$ demonstrates significant inhibitory activity against WT KIT as well as juxtamembrane domain mutant @GENE$ [ , ] .", "label": "response"}
{"id": "23632482", "sentence": "In contrast , no significant changes in the phosphorylation of CENP-A were observed in tumour tissues from mice treated with paclitaxel , suggesting that 212Pb-TCMC-trastuzumab may interfere with the affinity of BubR1 for kinetocores , thus perturbing the mitotic spindle checkpoint induced by paclitaxel . @VARIANT$ is involved in DNA replication , DNA repair and mitosis , suggesting E2F affects cell cycle progression both at S-phase and during mitosis .", "label": "None"}
{"id": "25083769", "sentence": "In lung cancers , ALK mutations appear to develop during clinical treatment with crizotinib and their generation probably renders EML4-ALK resistant not only to @DRUG$ but also to other @GENE$ inhibitors . In our series , no ALK @VARIANT$ mutation was observed .", "label": "None"}
{"id": "20633291", "sentence": "Viability experiments were performed once and representative curves are shown ( @VARIANT$ was not evaluated because @GENE$ cells expressing this mutant could not be established ) . Similarly , motesanib inhibited autophosphorylation of the imatinib-resistant activation loop mutant Y823 D ( IC50 = 64 nM ) more potently than @DRUG$ ( IC50 & gt ; 3000 nM ) ( Table : Figure ) .", "label": "None"}
{"id": "23320171", "sentence": "Further research is looking into inhibiting other targets such as mTOR , @VARIANT$ , or @GENE$ pathways . Two randomized trials are evaluating the addition of the mTOR inhibitor , everolimus , to chemotherapy and @DRUG$ in the first-line and Trastuzumab-resistance metastatic setting .", "label": "None"}
{"id": "15737014", "sentence": "Consistent with this , the T790M mutation has been shown not to abrogate the catalytic activity of wild-type @GENE$ [ ] . The T790M mutation could also affect the kinase activity or alter the substrate specificity of mutant EGFRs , such that a proliferative advantage would be conferred upon cells bearing the mutation . Consistent with this , the H1975 NSCLC cell line reported here to contain both @VARIANT$ and L858R did not to our knowledge undergo any prior treatment with gefitinib or @DRUG$ ; the doubly mutated cells must have become dominant over time through multiple passages in vitro .", "label": "resistance or non-response"}
{"id": "16187797", "sentence": "Transformation by cells expressing the @VARIANT$ @GENE$ was inhibited by 0.1 μM @DRUG$ or erlotinib , whereas transformation by cells expressing the insertion mutant was resistant to low concentrations of these inhibitors .", "label": "sensitivity"}
{"id": "19707322", "sentence": "The sensitivity of Bcr-Abl mutants to @DRUG$ can be summarized into 4 categories : high ( IC50 ≤ 70 nmol/L : M244V , G250E , Q252H , F3llL , F317L , M351T , V379I , L387M , H396P , H396R ) , medium ( IC50 ≤ 200 nmol/L : Y253F , @VARIANT$ , F359V ) , low ( IC50 ≤ 450 nmol/L : Y253H , E255V ) , and insensitive ( IC50 & gt ; 2 μmol/L : T315I ) ( ) ( ) .", "label": "None"}
{"id": "25054154", "sentence": "We utilised three complexes , namely , native ( @GENE$ ) , @VARIANT$ ( ALK F1174L-crizotinib ) , and R1275Q ( ALK R1275Q-crizotinib ) for our analysis .", "label": "resistance"}
{"id": "19738166", "sentence": "Di Nicolantonio et al. ( ) also demonstrated that introduction of the @GENE$ @VARIANT$ allele could confer resistance to either @DRUG$ or panitumumab in wild-type BRAF colorectal cancer cells .", "label": "resistance or non-response"}
{"id": "25033171", "sentence": "As shown in , the separation PMF in G2032R-ROS1 was much lower than that in WT-ROS1 , suggesting that serious @DRUG$ resistance could be induced by the mutation @VARIANT$ in the @GENE$ tyrosine kinase .", "label": "resistance"}
{"id": "21182469", "sentence": "cAMP ( cyclic adenosine monophosphate ) , cGMP ( cyclic guanosine monophosphate ) , LTC4 ( leukotriene C4 ) , DNP-SG ( S- ( 2,4-dinitrophenyl ) -glutathione ) , E13S ( estrone 3-sulfate ) , DHEAS ( dehydroepiandrosterone 3-sulfate ) , and E217βG ( estradiol 17-β-D-glucuronide ) . ( B ) Anticancer drugs that are transported by ABCC11 . MTA ( pemetrexed ) , MTX , ( @DRUG$ ) , @GENE$ ( Cytosine arabinoside ) , PMEA ( 9’- ( 2’-phosphonyl-methoxyethyl ) adenine ) are substrate for ABCC11 .", "label": "None"}
{"id": "24501009", "sentence": "The remaining members of the HER family comprise HER2 and HER4 tyrosine kinases , and the kinase‐null @GENE$ .1 HER family members act together via hetero‐ and homodimerization to enable downstream signaling pathways modulating a range of cellular activities , including growth , proliferation , differentiation , and migration . In contrast to patients with EGFR‐mutation‐positive tumors , patients with KRAS‐mutant NSCLC are unlikely to respond to @DRUG$ or erlotinib and do not have an improved progression‐free survival ( PFS ) compared with those who have placebo following erlotinib therapy . Dacomitinib ( PF‐00299804 ) is a potent , irreversible , oral small‐molecule inhibitor of HER1/EGFR , HER2 , and HER4 tyrosine kinases with antitumor activity in both gefitinib‐sensitive and gefitinib‐resistant , including EGFR @VARIANT$ , preclinical NSCLC models .", "label": "None"}
{"id": "24971022", "sentence": "@DRUG$ Humanized IgG monoclonal antibody Overcoming @GENE$ suppression to enhance the immune response against tumors Vemurafenib , dabrafenib Synthetic small molecules Binding to the ATP binding site of BRAF ( @VARIANT$ ) kinase with inhibition of downstream pathway", "label": "None"}
{"id": "22436374", "sentence": "H1650 and HCC827 have an in-frame deletion in the @GENE$ tyrosine kinase domain ( EGFR tyrosine kinase domainΔE746-A750 , exon 19 ) . H1650 cells have also a deletion of the 3 ' part of exon 8 and the entire exon 9 of PTEN , which causes loss of the protein [ ] and in addition express the insulin-like growth factor receptor ( IGF1R ) [ ] . The cell line H1975 has a sensitizing L858R kinase domain mutation in exon 21 , but also a second mutation ( @VARIANT$ , in cis , in the kinase domain ) rendering them resistant to the reversible TKIs gefitinib and @DRUG$ [ ] .", "label": "resistance or non-response"}
{"id": "18695135", "sentence": "@DRUG$ drinker No 1.00 ( referent ) 1.00 ( referent ) 1.00 ( referent ) 1.00 ( referent ) @GENE$ .77 ( 1.92 to 4.00 ) & lt ; .001 1.51 ( 1.01 to 2.26 ) .044 2.94 ( 1.95 to 4.43 ) & lt ; .001 1.30 ( 0.83 to 2.05 ) .25 HBV genotype B 1.00 ( referent ) 1.00 ( referent ) 1.00 ( referent ) 1.00 ( referent ) C 2.59 ( 1.88 to 3.57 ) & lt ; .001 2.35 ( 1.68 to 3.30 ) & lt ; .001 2.63 ( 1.83 to 3.77 ) & lt ; .001 1.76 ( 1.19 to 2.61 ) .005 B and C 0.53 ( 0.13 to 2.16 ) .38 0.65 ( 0.16 to 2.66 ) .55 0.35 ( 0.05 to 2.55 ) .30 0.33 ( 0.04 to 2.40 ) .27 Precore 1896 Wild type 1.00 ( referent ) 1.00 ( referent ) @VARIANT$ 0.28 ( 0.18 to 0.44 ) & lt ; .001 0.34 ( 0.21 to 0.57 ) & lt ; .001 Mixed type 1.30 ( 0.82 to 2.06 ) .27 1.18 ( 0.71 to 1.96 ) .52", "label": "None"}
{"id": "24276379", "sentence": "In a clinical study involving 110 patients , none of the patients with the abovementioned @GENE$ gene mutations respond to @DRUG$ or cetuximab [ ] . In another study that included 370 wild-type K-Ras patients , patients with mutant PIK3CA , particularly @VARIANT$ , had a significantly lower response rate than patients with wild-type PIK3CA [ ] .", "label": "resistance or non-response"}
{"id": "24121633", "sentence": "Based on our data , we hypothesized that PRR of hnRNP L binds to PTB and cooperatively suppresses inclusion of exon @VARIANT$ . We thus examined the role of PRR of hnRNP L on the interaction with PTB . Histidine tagged hnRNP L ( His-L ) , its @GENE$ deleted variant ( His-L-ΔPRR ) , @DRUG$ tagged hnRNP LL ( His-LL ) , and its PRR inserted variant ( His-LL-PRR ) were expressed in SH-SY5Y cells , and they were immunoprecipitated with anti-histidine antibody in the presence of RNase .", "label": "None"}
{"id": "24665456", "sentence": "Ponatinib is a potent @GENE$ inhibitor with activity against the @VARIANT$ mutation. [ ] However on October 31 , 2013 , the Food and Drug Administration asked the manufacturer of the leukemia chemotherapy drug @DRUG$ hydrochloride to suspend marketing and sales of this drug because of the risk of life threatening blood clots and severe narrowing of blood vessels .", "label": "response"}
{"id": "23579627", "sentence": "Although EGFR gene mutation analysis by direct sequencing on initial bronchoscopic lung biopsy specimen revealed wild-type EGFR , rebiopsy specimen by the PNA clamping method after failure of irreversible EGFR inhibitor therapy revealed L858R/L861Q and @VARIANT$ mutations . Because of repeated favorable responses to initial @DRUG$ and second round gefitinib , we suggest that the result of the initial @GENE$ mutation test was a false negative due to insufficient specimen .", "label": "resistance or non-response"}
{"id": "15737014", "sentence": "The @GENE$ @VARIANT$ mutation , in conjunction with either wild-type EGFR or the drug-sensitive L858R EGFR mutant , prevents inhibition of tyrosine phosphorylation ( A ) or p-EGFR ( B ) by @DRUG$ .", "label": "resistance or non-response"}
{"id": "23674887", "sentence": "Bosutinib effectively targets most IM-resistance conferring @GENE$ mutations , with the exception of the highly resistant T315I ( resistant to IM , @DRUG$ , nilotinib , and bosutinib ) and @VARIANT$ mutations ( resistant to dasatinib and bosutinib ) .", "label": "None"}
{"id": "23921604", "sentence": "These results suggest that acquired resistance to adjuvant @DRUG$ was infrequent , especially since both arms included patients with mutations known to be less sensitive or resistant to imatinib ( e.g. , platelet derived growth factor receptor alpha @GENE$ ] @VARIANT$ ) [ ] .", "label": "resistance or non-response"}
{"id": "15737014", "sentence": "The EGFR @VARIANT$ mutation , in conjunction with either wild-type @GENE$ or the drug-sensitive L858R EGFR mutant , prevents inhibition of tyrosine phosphorylation ( A ) or p-EGFR ( B ) by @DRUG$ .", "label": "resistance or non-response"}
{"id": "24294007", "sentence": "Recent data have suggested that tumors with specific KRAS mutations , especially the glycine-to-aspartate mutation in codon 13 ( @VARIANT$ ) mutation , may be sensitive to @DRUG$ or panitumumab .", "label": "None"}
{"id": "24624361", "sentence": "Our unpublished data show that Dinaciclib exposure results in downregulation of BRCA1 and BRCA2 and sensitized cyclin E1-dependent ovarian cancer cells to @DRUG$ . Hence , Dinaciclib may have a dual effect on BRCA1 and BRCA2 by causing @VARIANT$ mediated transcriptional downregulation and inhibiting CDK1/2 mediated activation of the @GENE$ proteins ( Figure A ) .", "label": "None"}
{"id": "21333004", "sentence": "Therefore , Mig6 could be one of the critical factors to explain @DRUG$ sensitivity at cellular level . We constructed the model by referring to the earlier studies on Mig6 functions [ - ] . However , the model could be modified and improved when novel mechanism of Mig6 in the regulation of @GENE$ or new regulators associated with the EGFR @VARIANT$ mutation are identified by further studies .", "label": "sensitivity"}
{"id": "24931142", "sentence": "NGS performed on a tumor sample from the chest wall biopsy obtained at the time of diagnosis revealed PIK3CA mutation H1047R , @GENE$ mutation S37C , and protein tyrosine phosphatase delta ( PTPRD ) mutation S1845fs*2 ( Figure ) . At the time of referral to the CCTT the patient had metastatic disease to the mediastinum , bones , and liver and subsequently received experimental therapy with a mTOR inhibitor sirolimus ( 4 mg orally daily ) in combination with a histone deacetylase inhibitor (HDAC) @DRUG$ ( 300 mg orally daily ) , which was matching a molecular abnormality in the PI3K/AKT/mTOR pathway ( PIK3CA @VARIANT$ mutation ) and attained 15 % shrinkage per RECIST .", "label": "None"}
{"id": "25465236", "sentence": "( G–I ) increased inhibition potency for @DRUG$ against EGFR @VARIANT$ mutant compared to EGFR WT protein and subsequent further increase in potency for Gefitinib against @GENE$ L858R + E884K double mutant .", "label": "sensitivity"}
{"id": "24956168", "sentence": "@GENE$ mutations are present at around 3 % in lung cancer and the R248C mutation is known to drive tumour formation in xenograft models which were inhibited by multi-kinase inhibitor @DRUG$ . One sample with a KRAS mutation showed a concomitant mutation with an EGFR @VARIANT$ mutation .", "label": "None"}
{"id": "24971999", "sentence": "DNA sequence at the site of putative gefitinib-responsive mutations in the @GENE$ gene of PC-3 cells . DNA sequences of the EGFR gene around the E746-A750 deletion ( A ) and around the mutations @VARIANT$ ( B ) , D761Y ( C ) and L858R ( D ) in non-small-cell lung cancer cells were determined in PC-3 cells .", "label": "resistance or non-response"}
{"id": "25061320", "sentence": "Exon 19 deletion mutation and a mutation in exon 21 ( @VARIANT$ ) are the two main types of EGFR mutation . Riely et al found that patients with the EGFR exon 19 mutation had a longer median survival time than those with the @GENE$ exon 21 mutation after receiving gefitinib or @DRUG$ ( 34 versus 8 months , respectively ; P=0.01 , log-rank ) .", "label": "sensitivity"}
{"id": "22132735", "sentence": "@GENE$ gene mutations indicate sensitivity to @DRUG$ , and it was demonstrated that about 85 % of patients with NSCLC who obtained benefit from gefitinib treatment were found to have mutations in exons 18 to 21 of the tyrosine kinase domain of the EGFR gene [ - ] . EGFR mutations in exon 19 ( short in-frame deletions ) or 21 @VARIANT$ ( point mutation ) affect the adenosine triphosphate ( ATP ) pocket of the tyrosine kinase domain leading to the activation of 4-anilinoquinazoline compounds , which function to compete with ATP [ ] .", "label": "sensitivity"}
{"id": "21165163", "sentence": "E.g. one study of CTCs from lung cancer patients was able to identify @GENE$ @VARIANT$ in CTCs of some patients and progression-free survival was shorter as one might expect in patients with than without T790M on @DRUG$ [ ] .", "label": "resistance or non-response"}
{"id": "24197907", "sentence": "Six ( 5 % ) tumor samples harbored EGFR mutations : four exon 19 deletions and two @VARIANT$ mutations in exon 21 . The presence of @GENE$ mutations was not associated with outcome . At the time of data collection , one of the six patients had received @DRUG$ as second-line treatment for more than one month and another had received erlotinib as second-line treatment for three weeks .", "label": "sensitivity"}
{"id": "19920925", "sentence": "Other protein kinase targets of nilotinib include TEL-PDGFR β , FIP1L1-PDGFR α and @VARIANT$ mutated KIT .– @DRUG$ , therefore , may have a place in the treatment of idiopathic @GENE$ chronic myelomonocytic leukemia ( CMML ) and systemic mastocytosis ( SM ) .", "label": "None"}
{"id": "25278773", "sentence": "There were five ( 8.1 % ) patients who had RECIST partial response , and two patients with secondary @VARIANT$ mutations ( L858R T790M , and deletion in exon 19 T790M ) achieved disease stabilization for 9 months and 1 month , respectively . Afatinib in squamous NSCLC : LUX-Lung 8 study In view of the antitumor activity observed in @GENE$ patients with first-generation EGFR inhibitors , coupled with evidence of benefit with other irreversible pan-HER inhibitors , this study was initiated to assess the activity of afatinib versus @DRUG$ in squamous subtype NSCLC after the failure of at least one prior platinum based chemotherapy ( NCT01523587 ; ) .", "label": "resistance or non-response"}
{"id": "23580227", "sentence": "To determine whether @VARIANT$ and Genistein can sensitize endometrial cancer , Ishikawa and HEC1A cells were grown in presence of I3C , @DRUG$ and @GENE$ for 24 hr. I3C and Genistein did not show significant cell death alone or in combination .", "label": "None"}
{"id": "24643470", "sentence": "@DRUG$ also shows activity against cancers resistant to first-generation EGFR inhibitors due to certain activating @GENE$ mutations , secondary EGFR mutations such as @VARIANT$ or tumours expressing other ErbB family receptors activated by drug induced reprogramming of signalling pathways .", "label": "response"}
{"id": "24932685", "sentence": "@VARIANT$ and S1B of ) , while HEY-T30 does not have a mutation in β-tubulin . @GENE$ proliferated similarly in Taxol-free media or media containing low concentrations of Taxol ( ≤30 nM ) ( ) .", "label": "None"}
{"id": "21623355", "sentence": "These include already known entry factors used by pathogens such as the entry receptor for diphtheria toxin ( HBEGF ) , the reovirus receptor ( @VARIANT$ ) and an enzyme involved in carbohydrate synthesis required for ricin entry ( MGAT2 ) . It also includes downstream effectors of kinases for example @GENE$ in a screen with a Chk1 inhibitor or PTPN1 and PTPN12 identified by BCR-ABL inhibition using imatinib . Strong resistance against @DRUG$ was observed in cells containing mutations in deoxycytidine kinase (DCK) , the rate limiting kinase for activation of several nucleoside analogs .", "label": "None"}
{"id": "25364578", "sentence": "Studies of ALK rearranged lung cancers with acquired resistance to @DRUG$ have identified ALK fusion gene amplification and secondary @GENE$ TK domain mutations ( L1196M and @VARIANT$ ) in about one third of cases .", "label": "resistance"}
{"id": "15737014", "sentence": "The EGFR @VARIANT$ mutation , in conjunction with either wild-type EGFR or the drug-sensitive L858R @GENE$ mutant , prevents inhibition of tyrosine phosphorylation ( A ) or p-EGFR ( B ) by @DRUG$ .", "label": "resistance or non-response"}
{"id": "24052618", "sentence": "In vitro NSCLC cell lines selected for resistance to @DRUG$ also show amplification of the @GENE$ fusion gene as well as kinase domain mutations such as @VARIANT$ ( ) .", "label": "resistance"}
{"id": "23423768", "sentence": "Neratinib ( @GENE$ ) , one of the three agents investigated , has n't shown good RR when tested on patients with known @VARIANT$ mutation , therefore further development of this drug in lung cancer has been halted . @DRUG$ ( BIBW2992 ) is being investigated as part of the LUX-Lung program which aims to evaluate the use of TKI in second- or third-line treatment in patients who have acquired resistance to gefitinib or erlotinib ( LUX-Lung 1 , 4 and 5 ) as well as the use of TKIs as a first-line treatment in patients with EGFR activating mutations ( LUX-Lung 2 , 3 and 6 ) .", "label": "None"}
{"id": "21448591", "sentence": "Recently , a functional Aurora kinase A mutation ( @VARIANT$ ) that renders the kinase impervious to @GENE$ and @DRUG$ inhibition has been reported [ ] and points to a mechanism of resistance independent from levels of expression .", "label": "None"}
{"id": "17973572", "sentence": "To prove the functional significance of the @VARIANT$ mutation , we generated Ba/F3 cell lines stably expressing mutant EGFR constructs [ ] . These cell lines , including L858R-L747S , proliferated in the absence of IL3 . @GENE$ cells were extremely sensitive to @DRUG$ ( D ) , whereas Ba/F3-L858R-T790M cells were highly resistant up to 1 μM gefitinib .", "label": "None"}
{"id": "23329883", "sentence": "The results of the present study show that the levels of TG , HDL-C , ApoA1 , and the ratio of ApoA1 to @GENE$ were higher in drinkers than in non-drinkers , whereas the levels of TC , LDL-C and ApoB were lower in drinkers than in non-drinkers . The subjects with AA genotype of PCSK9 E670G had lower serum TC and LDL-C levels in drinkers than in non-drinkers . The interactions between PCSK9 @VARIANT$ genotypes and @DRUG$ consumption on serum TC and LDL-C levels were also detected by using a factorial design covariance analysis after controlling for potential confounders .", "label": "None"}
{"id": "23029123", "sentence": "The importance of D2 receptor involvement in @DRUG$ actions on @GENE$ production and cell proliferation is evident in the experiment where ethanol actions on lactotropes ' function were evaluated in clonal cell lines expressing various levels of D2 receptor isoforms . It was found that V cells , which lacked functional D2 receptors and had high basal levels of PRL , showed a significant reduction in PRL production following D2S and @VARIANT$ receptor transfection .", "label": "None"}
{"id": "23976869", "sentence": "Relapse in one patient was associated with the detection of the @VARIANT$ mutation in @GENE$ that confers resistance to @DRUG$ .", "label": "resistance"}
{"id": "24894453", "sentence": "Furthermore , these results are consistent with our model that @GENE$ variants that are dependent on dimerization can be inhibited by @DRUG$ . Dimerization disruption has effects on the transforming activity of G719S and @VARIANT$ EGFR proteins .", "label": "sensitivity"}
{"id": "23963283", "sentence": "The most common lesion is the so-called “gatekeeper mutation” , which involves a substitution of methionine for threonine at position 790 ( @VARIANT$ ) . The second well-known mechanism of resistance to @DRUG$ or erlotinib is the amplification of the MET receptor tyrosine kinase ( RTK ) gene , which activates downstream intracellular signaling independently of @GENE$ .", "label": "resistance or non-response"}
{"id": "23986642", "sentence": "This trial provided valuable evidence of ponatinib’s direct kinase inhibiting activity in patients with a variety of BCR-ABL mutations , including the @VARIANT$ mutant , leading to further evaluation of its effects . Preclinical @DRUG$ has been observed to achieve marked reductions in levels of phosphorylated BCR-ABL and CrkL within 6 hours of administration in a mouse model injected with T315I-variant BCR-ABL expressing @GENE$ cells .", "label": "None"}
{"id": "24065096", "sentence": "Evaluating methylation status of 14-3-3 sigma of serum DNA in pretreatment condition and for @VARIANT$ in pleural lavage are considered for survival . Hypermethylation of RASSF1A , p14 ( ARF ) and APC are useful prognostic markers in patients receiving gemcitabine , and testing plasma DNA for K-RAS mutation is helpful in monitoring NSCLC patients receiving @DRUG$ and carboplatin [ – ] . Furthermore , detection of @GENE$ using plasma DNA is essential to determine appropriate lung cancer treatment and monitoring [ ] .", "label": "None"}
{"id": "24497964", "sentence": "Thirty-eight patients ( 90 % ) had adenocarcinoma , 34 ( 81 % ) had a good performance status ( Eastern Cooperative Oncology Group 0 ) , and 15 ( 36 % ) received @DRUG$ as first-line chemotherapy . With regard to the type of EGFR mutation , 8 patients ( 19 % ) had deletions in exon 19 , 13 ( 31 % ) had the @VARIANT$ missense mutation in exon 21 , and 21 ( 50 % ) had the wild-type @GENE$ .", "label": "sensitivity"}
{"id": "23493838", "sentence": "A complete hematological response and a major cytogenetic response were observed broadly across the @GENE$ mutants , including individuals harboring the dasatinib-resistant F317L , the nilotinib-resistant Y253H , and F359C/I/V mutations , but not T315I . Nine individuals developed new mutations in the course of bosutinib treatment ( V299L , n = 4 ; @VARIANT$ , n = 2 ; T315I , n = 2 ; F359C , n = 1 ; G250E , n = 1 ) and eight of these individuals discontinued @DRUG$ because of progressive disease or unsatisfactory response .", "label": "None"}
{"id": "24121633", "sentence": "Based on our data , we hypothesized that PRR of hnRNP L binds to PTB and cooperatively suppresses inclusion of exon @VARIANT$ . We thus examined the role of PRR of hnRNP L on the interaction with PTB . Histidine tagged hnRNP L ( His-L ) , its @GENE$ deleted variant ( His-L-ΔPRR ) , @DRUG$ tagged hnRNP LL ( His-LL ) , and its PRR inserted variant ( His-LL-PRR ) were expressed in SH-SY5Y cells , and they were immunoprecipitated with anti-histidine antibody in the presence of RNase .", "label": "None"}
{"id": "23292247", "sentence": "The T47D cells were grown in RPMI-1640 medium ( Invitrogen , Carlsbad , CA , USA ) supplemented with 10 % fetal bovine serum ( Invitrogen ) and penicillin ( 100 U/ml ) /streptomycin ( 100 μg/ml ) ( Invitrogen ) at 37°C in a 5 % @GENE$ atmosphere . The @VARIANT$ cells were exposed for 48 h to 100 mM alcohol and 10 μM U0126 ( MEK1/2 inhibitor ) , and the medium with @DRUG$ was changed every 24 h .", "label": "None"}
{"id": "22655263", "sentence": "Additionally , AP26113 was evaluated on the crizotinib resistant gatekeeper mutant @VARIANT$ both in vitro and in vivo and appeared to be able to overcome resistance to @DRUG$ . Ki determination demonstrated a very similar biochemical potency on wild-type ALK and the L1196M ALK mutant ( 0.09 and 0.08 nM respectively ) , with both cellular and in vivo data ( using engineered Ba/F3 cells ) indicating that growth of @GENE$ mutant driven-cells is inhibited at similar , albeit slightly higher , doses which inhibit cells harboring wild-type ALK ( Katayama et al. , ) .", "label": "resistance"}
{"id": "23994953", "sentence": "Our data appear to support a previously unrecognized scenario in which , in the presence of @DRUG$ sensitizing EGFR mutations ( delE746-A750 , @VARIANT$ ) , an aberrant/incomplete epithelial differentiation might determine the intrinsic ability of @GENE$ mutant-NSCLC cells to rapidly shift toward the erlotinib-refractory mesenchymal end of the epithelial-mesenchymal spectrum .", "label": "sensitivity"}
{"id": "23566546", "sentence": "Case Histrogical type @GENE$ mutation status Brinkman index Treatment agent Response IL-8 ( ng/mL ) IL-10 ( ng/mL ) RANTES ( pg/ml ) 1 Ad Ex21 @VARIANT$ 900 gefitinib PR 5.79 1.67 2 2 Ad Ex21 L858R 0 erlotinib PR_3.33 94.2 1.41 3 Ad Ex19 del 0 erlotinib PR 4.09 126 2.13 4 Ad Ex21 L858R 0 gefitinib PR_3.92 18.1 1.85 5 Ad Ex21 L858R + Ex19 del 370 erlotinib PR 21.9 1.23 2.11 6 Ad Ex19 del 0 erlotinib PR 7.05 1.37 2.56 7 Ad Ex19 del 0 gefitinib PR 4.82 1.59 2.02 8 Ad Ex21 L858R 1640 gefitinib PR 54.9 2.7 2.38 9 Ad negative 400 erlotinib SD 34.9 3.39 3.66 10 Ad negative 0 erlotinib SD 27.1 4.94 2.25 11 Ad unknown 1800 erlotinib SD NE NE NE 12 Sq Ex19 del 3840 gefitinib SD 12.6 1.1 1.98 13 Ad Ex19 del 30 erlotinib SD 5.27 0.69 2.66 14 Ad Ex19 del 0 erlotinib SD 10.5 0.85 2.5 15 Ad unknown 300 erlotinib SD 7.69 2.61 1.7 16 La negative 2080 erlotinib SD NE NE NE 17 Sq Ex21 L858R 750 @DRUG$ SD 11.6 56.3 3.06 18 Ad unknown 600 erlotinib SD 13.7 1.1 2.82 19 Ad Ex21 L858R 0 erlotinib SD 20.6 11.6 0.783 20 Ad Ex19 del 0 erlotinib SD 14.8 2.07 2.02 21 Ad Ex21 L858R + Ex19 del 0 gefitinib SD 3.04 1.3 1.76 22 Ad Ex19 del 200 gefitinib SD 10.9 1.59 1.91 23 Sq unknown 1560 erlotinib PD NE NE NE 24 Ad negative 1080 erlotinib PD 25.2 8.15 1.57 25 Ad unknown 0 erlotinib PD NE NE NE 26 Ad Ex18 G719A 2000 erlotinib PD 11.6 4.48 3.12 27 Ad unknown 1410 erlotinib PD NE NE NE 28 Ad Ex19 del 1000 gefitinib PD 9.44 2.25 2.89 29 Ad negative 1100 erlotinib PD 56.3 5.63 2.16 30 Ad negative 2000 erlotinib PD 15.6 0.85 0.292 31 Ad negative 825 erlotinib PD 8.27 1.59 2.13 32 Ad Ex21 L858R 0 erlotinib PD 5.34 7.05 1.7 33 Ad negative 1680 erlotinib PD 57.7 1.63 2.06", "label": "sensitivity"}
{"id": "25405807", "sentence": "Inhibition of epidermal growth factor receptor (EGFR) kinase activity by @GENE$ tyrosine kinase inhibitors ( EGFR-TKIs ) , such as @DRUG$ and erlotinib , can result in improved response and prolonged progression-free survival ( PFS ) in selected non-small cell lung cancer ( NSCLC ) patients harboring sensitizing EGFR mutations , especially the exon 19del and exon 21 L858R mutations – . Unfortunately , almost all patients will ultimately develop resistance to EGFR-TKI , in whom more than 50 % cases were detected harboring the EGFR @VARIANT$ mutation in tumor specimens after EGFR-TKI , .", "label": "resistance or non-response"}
{"id": "25405807", "sentence": "Inhibition of @GENE$ activity by EGFR tyrosine kinase inhibitors ( EGFR-TKIs ) , such as @DRUG$ and erlotinib , can result in improved response and prolonged progression-free survival ( PFS ) in selected non-small cell lung cancer ( NSCLC ) patients harboring sensitizing EGFR mutations , especially the exon 19del and exon 21 @VARIANT$ mutations – .", "label": "sensitivity"}
{"id": "25120654", "sentence": "@GENE$ mutation was positive according to the amplification-refractory mutation system method . ( A ) L858R point mutation prior to the use of @DRUG$ , and ( B ) L858R and @VARIANT$ point mutations following treatment with gefitinib .", "label": "resistance or non-response"}
{"id": "25465236", "sentence": "On the other hand , the increased inhibition potency for @DRUG$ against EGFR @VARIANT$ mutant ( compared to EGFR WT protein ) and subsequent further increase in potency for Gefitinib against the @GENE$ L858R + E884K double mutant correlates well with the increased global connectivity of the hub residues in the mutants ( – wild type , – L858R , – L858R + E884K ) .", "label": "sensitivity"}
{"id": "24944510", "sentence": "@GENE$ ( such as @DRUG$ or erlotinib ) treatment of lung-cancer harboring EGFR gene mutation is one of the prototypes of such therapies . Several clinical trials clearly demonstrated that progression-free survival of patients treated with EGFR-TKI therapy is significantly longer than that of those treated by conventional platinum doublet chemotherapy.– EGFR-TKI therapy dramatically changed the paradigm of lung cancer treatment . Which strategy is better in the management of advanced NSCLCs – the inhibition of mutated EGFR with TKIs ( @VARIANT$ mutation increases tyrosine kinase affinity for TKIs ) or a combined approach with cetuximab ( an anti-EGFR monoclonal antibody ) plus first-line chemotherapy – is yet to be determined .", "label": "sensitivity"}
{"id": "23145123", "sentence": "First , we generated the PC9-ER cell line by culturing PC9 lung cancer cells , which express the transforming @GENE$ delE745-A750 allele , in the presence of escalating doses of the EGFR inhibitor @DRUG$ ( ) . Screening of a cDNA library generated from PC9-ER in Ba/F3 cells resulted in multiple full-length clones that harbored EGFR with both delE745-A750 and @VARIANT$ ( ) and were sensitive to the mutant-selective EGFR inhibitor WZ4002 ( LD99 & lt ; 1 µM ) .", "label": "resistance or non-response"}
{"id": "24709958", "sentence": "This phenomenon was initially observed in Imatinib-resistant CML and GIST , where the respective targets , @GENE$ and c-Kit acquired a mutation in a “gatekeeper” residue of the ATP binding pocket [ , ] . Likewise , the @VARIANT$ mutation in the EGFR gene rose after chronic exposure to Gefitinib in NSCLC , conferring resistance to this inhibitor [ ] .", "label": "None"}
{"id": "25562700", "sentence": "Molecule Target Biomarker Indication vemurafenib BRAF kinase BRAF @VARIANT$ mutant melanoma vandetanib VEGFR , EGFR , RETR not included on the label thyroid cancer abiraterone CYP 17A1 not included on the label prostate cancer ipilimumab CTLA-4 not included on the label melanoma brentuximab vedotin CD30 ( ACD technology ) not included on the label lymphoma @DRUG$ ALK ALK-EML4 fusion protein lung cancer BRAF : Serine/threonine-protein kinase B-Raf ; VEGFR : Vascular endothelial growth factor receptor ; EGFR : epidermal growth factor receptor ; RETR : @GENE$ proto-oncogen receptor ; CYP 17A1 : cytochrome P450 17A1 ; CTLA-4 : Cytotoxic T-Lymphocyte Antigen 4 ; CD30 : Cluster of Differentiation 30 ; ADC : Antibody Conjugated Drug ; ALK-EML4 : anaplastic lymphoma kinase (ALK) ; echinoderm microtubule associated protein-like 4 ( EML4 ) fusion .", "label": "None"}
{"id": "23976869", "sentence": "Dasatinib is a dual SRC/ABL1 inhibitor that also inhibits PDGFRs and @GENE$ fusion but has no effect on imatinib-resistant FIP1L1-PDGFRA T674I and @VARIANT$ mutants .", "label": "resistance or non-response"}
{"id": "24349829", "sentence": "As would be predicted from the prior studies cited above , miR-7 blunted @GENE$ signaling and reversed the radio-resistance . Correspondingly , direct injection of a liposome encapsulated miR-7 plasmid into established EGFR-TKI sensitive and resistant tumors bearing the @VARIANT$ EGFR mutant resulted in significant tumor regression in conjunction with repression of EGFR , RAF-1 and IRS-1 expression . In head and neck cancer , miR-7 functioned in a synergistic manner with erlotinib to render FaDu Erlotinib-resistant cells susceptible to the growth inhibitory activities of the drug .", "label": "None"}
{"id": "24348666", "sentence": "To test this possibility , two types of gefitinib-sensitive cells ( PC9 cells that endogenously express EGFR deletion mutant in exon19 of @GENE$ gene and HEK293T cells that exogenously express EGFR L858R mutant ) were transfected with an expression vector encoding the oncogenic K-Ras @VARIANT$ mutant .", "label": "None"}
{"id": "25505733", "sentence": "Activating mutations are significantly associated with response to @GENE$ TKIs , with erlotinib , gefitinib , and @DRUG$ established as initial standard therapy . However , resistance mutations have been identified , such as @VARIANT$ in exon 20 .", "label": "response"}
{"id": "25435999", "sentence": "@GENE$ mutation analysis Mutations conferring @DRUG$ resistance were detected using allele-specific oligonucleotide polymerase chain reaction ( ASO-PCR ) . The primer sequences for @VARIANT$ were as follows : Forward , 5′-GCC CCC CTT CTA TAT CAT CAC-3′ for normal PCR ; forward , 5′-GCC CCC CTT CTA TAT CAT CAT-3′ for ASO-PCR ; and reverse , 5′-GGA TGA AGT TTT TCT TCT CCA-3′ .", "label": "None"}
{"id": "25414829", "sentence": "The first example of a clinically relevant NSCLC driver oncogene was the identification of somatic mutations in the @GENE$ ( – ) .Common EGFR alterations ( the @VARIANT$ point mutation and exon 19 deletions ) are present in 10–30 % of patients with NSCLC and confer sensitivity to @DRUG$ , erlotinib , and afatinib .", "label": "sensitivity"}
{"id": "25505694", "sentence": "@DRUG$ is an orally , irreversible @GENE$ , HER2 and HER4 inhibitor , showing preclinical activity against cancer cells harboring common activating EGFR mutations and the @VARIANT$ mutation , albeit with a lower potency [ ] .", "label": "response"}
{"id": "25099740", "sentence": "Cetuximab-resistant PIK3CA and RAS cells isolated from control treated tumors in panel E were processed in parallel Cal27 cells infected with lentiviruses encoding @GENE$ @VARIANT$ or RAS G12V mutations .", "label": "resistance or non-response"}
{"id": "20234366", "sentence": "Such a low percentage compared with that in previous reports is probably due to the fact that after Health Authorities approval to limit the use of anti-EGFR moAb to @GENE$ wild-type mCRC patients , KRAS mutant cases have not received @DRUG$ based therapy at our Institution . KRAS mutations were as follows : @VARIANT$ in five patients ; G12D in three patients ; G12V in three patients ; and G12A in one patient .", "label": "resistance or non-response"}
{"id": "24885169", "sentence": "In addition , the presence of common activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene ( exon 19 deletion and exon 21 @VARIANT$ mutation ) confers strong sensitivity to @DRUG$ and erlotinib , which are selective tyrosine kinase inhibitors of @GENE$ [ , ] .", "label": "sensitivity"}
{"id": "23555954", "sentence": "The cell line H1975 has a sensitizing L858R kinase domain mutation in exon 21 , but also a second mutation ( @VARIANT$ , in cis , in the kinase domain ) rendering them resistant to the reversible TKIs @DRUG$ and erlotinib . miR-146a was expressed in all the five cell lines studied , with the similar magnitude , independent of the genomic status of the @GENE$ .", "label": "resistance or non-response"}
{"id": "25486409", "sentence": "As the second-generation , irreversible EGFR-TKIs , such as @DRUG$ and dacomitinib , failed to overcome the resistance caused by @VARIANT$ , , other measures , such as EGFR dual targeting with cetuximab and afatinib and third-geneneration , mutant-selective @GENE$ – are being actively evaluated .", "label": "response"}
{"id": "25243124", "sentence": "Adsorbents were subsequently sputter coated with gold ( @VARIANT$ ES , Quorum Technologies ) . Cellulose based adsorbents were incubated overnight with 2.5 vol % glutaraldehyde , rinsed with dH2O , and dehydrated with increasing concentrations of @DRUG$ ( 30 to 100 vol % ) before sputter coating . Adsorption of @GENE$ to the different polymers was studied in batch experiments using adsorbent-to-plasma ratios of 1 , 5 , and 10 vol % .", "label": "None"}
{"id": "24009732", "sentence": "B , EOL-1 cells and BaF3 cells expressing WT or @VARIANT$ FIP1L1-PDGFRα were treated with DCC-2036 for indicated durations with different concentrations ( 6 nM for EOL-1 cells , 400 nM for BaF3 cells ) , the phosphorylated and total levels of indicated proteins were analyzed by immunoblotting . C , @GENE$ cells were exposed to the indicated concentrations of DCC-2036 , @DRUG$ or sorafenib for 36 h , the phosphorylated PDGFRα and total PDGFRα were analyzed by immunoblotting .", "label": "None"}
{"id": "22912935", "sentence": "Independent associations between folate intake , @DRUG$ consumption , and @GENE$ @VARIANT$ genotype and risk of prostate cancer were estimated using unconditional logistic regression , with age included in all models .", "label": "None"}
{"id": "21108851", "sentence": "Ponatinib ( @DRUG$ ) is a multitargeted BCR-ABL/SRC kinase inhibitor with potent in vitro activity against all tested mutants of @GENE$ including @VARIANT$ , and clinical activity has been reported in patients with a T315I mutation [ - ] .", "label": "response"}
{"id": "25383622", "sentence": "Histamine , produced from @DRUG$ through the action of histidine decarboxylase and stored in mast cells and basophils in the nasal mucosa , plays an important role in the immunoregulation of allergic inflammation . There are 4 subtypes of histamine receptors , including @GENE$ H2R , H3R and @VARIANT$ .", "label": "None"}
{"id": "23209813", "sentence": "Human CRC cell lines COLO320DM ( @GENE$ ) , DLD-1G13D ( KRAS @VARIANT$ mutation ) , and SW480G12V ( KRAS G12V mutation ) were all obtained from American Type Culture Collection . Cells were all maintained in RPMI-1640 containing 10 % fetal bovine serum , 2 mmol/L of L-glutamine ( Life Technologies , Carlsbad , CA , USA ) , and PSA ( 10,000 units/ml of penicillin , 10 mg/ml of streptomycin , and 25 µg/ml amphotericin B ; Biological Industries , Kibbutz Beit Haemek , Israel ) and cultured at 37°C in a humidified incubator containing 5 % CO2 . Oxaliplatin ( Eloxatin® injection 5 mg/ml ) was obtained from Sanofi-Aventis Co. , Ltd. ( Taipei , Taiwan ) .", "label": "None"}
{"id": "23696715", "sentence": "Similar results were found in another clinical trial with @DRUG$ at the same doses . Of the 15 patients with disseminated MTC treated for up to 12 months , four patients had SD over 24 months . A recent study compared the effect of four TKIs ( axitinib , sunitinib , vandetanib , and XL184 ) on cell proliferation , @GENE$ autophosphorylation , and extracellular signal regulated kinase activation in three cell lines : MZ-CRC-1 ( M918T RET mutation ) , MTC-TT ( @VARIANT$ RET mutation ) , and TPC-1 ( RET/PTC-1 rearrangement ) cells .", "label": "None"}
{"id": "22132735", "sentence": "EGFR gene mutations indicate sensitivity to @DRUG$ , and it was demonstrated that about 85 % of patients with NSCLC who obtained benefit from gefitinib treatment were found to have mutations in exons 18 to 21 of the tyrosine kinase domain of the @GENE$ gene [ - ] . EGFR mutations in exon 19 ( short in-frame deletions ) or 21 @VARIANT$ ( point mutation ) affect the adenosine triphosphate ( ATP ) pocket of the tyrosine kinase domain leading to the activation of 4-anilinoquinazoline compounds , which function to compete with ATP [ ] .", "label": "sensitivity"}
{"id": "24860780", "sentence": "Examples of FDA approved kitted CDxs are the Roche COBAS 4800 test for BRAF @VARIANT$ mutation detection as a @GENE$ for vemurafenib ( Zelboraf ) and the Abbott Vysis ALK Break Apart FISH Probe test to identify ALK positive NSCLC patients for Pfizer’s approved NSCLC therapy @DRUG$ ( Crizotinib ) ( , , , ) .", "label": "None"}
{"id": "25465236", "sentence": "Clinically observed @GENE$ kinase mutations that sensitize patients differentially to the inactive ( non phosphorylated ) EGFR kinase inhibitors Gefitinib and @DRUG$ were analyzed . The oncogenic EGFR @VARIANT$ mutation is one of the most common non small cell lung cancer ( NSCLC ) somatic mutations , observed from sequencing of both solid tumor biopsies and circulating tumor cells ( CTCs ) .", "label": "sensitivity"}
{"id": "25146448", "sentence": "MTNR1B , located on human chromosome 11q21–22 , is a member of the @GENE$ , and one of the functional and high-affinity @DRUG$ membrane receptors . MTNR1B is expressed in human and rodent pancreatic islets . Studies have shown that MTNR1B is a novel candidate gene for @VARIANT$ .", "label": "None"}
{"id": "23864840", "sentence": "The ability of irreversible pan-HER inhibitors such as afatinib and dacomitinib to overcome @VARIANT$ mediated resistance to @DRUG$ has been demonstrated in some preclinical studies ; therefore , they are being actively investigated . Dacomitinib showed a better response rate and prolonged response duration compared to erlotinib in patients without prior @GENE$ targeted therapy [ ] .", "label": "resistance or non-response"}
{"id": "21285991", "sentence": "Using a representative cohort of 229 sporadic CRCs , we identified the BRAF @VARIANT$ mutation as an independent prognostic factor for survival in patients with advanced and recurrent CRC . The presence of the @GENE$ mutation is associated with a significantly higher risk of dying of cancer related causes , independently of other factors such as age , gender , PS , KRAS status , pathological finding , number of metastasis and metastatic sites , in agreement with other recent studies ( ; ; ; ) . However , our study focused on the advanced and recurrent group who received systemic chemotherapy , including fluoropyrimidines , in combination with oxaliplatin , irinotecan , @DRUG$ and anti-EGFR antibody in several lines .", "label": "sensitivity"}
{"id": "23976869", "sentence": "@DRUG$ has a potent activity towards @GENE$ , as well as numerous imatinib-resistant BCR-ABL1 kinase domain mutants , including the @VARIANT$ mutation .", "label": "None"}
{"id": "19707322", "sentence": "Nilotinib is approximately 30-fold more sensitive than @DRUG$ in the killing of BCR-ABL dependent cells derived from patients with CML ( K562 and Ku-812F cells ) and cell lines ( 32D and baF3 ) , and it is active against 32/33 imatinib-resistant cell lines with BCR-ABL mutations . The sensitivity of @GENE$ mutants to AMN107 can be summarized into 4 categories : high ( IC50 ≤ 70 nmol/L : @VARIANT$ , G250E , Q252H , F3llL , F317L , M351T , V379I , L387M , H396P , H396R ) , medium ( IC50 ≤ 200 nmol/L : Y253F , E255K , F359V ) , low ( IC50 ≤ 450 nmol/L : Y253H , E255V ) , and insensitive ( IC50 & gt ; 2 μmol/L : T315I ) ( ) ( ) .", "label": "None"}
{"id": "25100284", "sentence": "Afatinib and icotinib were not included in the pooled analysis calculations , but studies were identified that included 129 @DRUG$ treated patients ( US and Taiwanese ) and 29 icotinib treated patients ( all Chinese ) . In studies where mutation types were reported individually the most common @GENE$ mutations were exon 19 deletions ( 53 % ) and @VARIANT$ mutations ( 38 % ) .", "label": "sensitivity"}
{"id": "21995722", "sentence": "In this paper , we utilized mathematical modeling in conjunction with quantitative in vitro experiments to identify optimal combination treatment strategies using @DRUG$ and paclitaxel to prevent or delay resistance to treatment in NSCLC cells . We used an integrative approach to investigate the evolutionary dynamics of a tumor , which are determined by the composition of , and interactions between , sensitive and resistant cells in the presence of treatment . Although several mechanisms of resistance to @GENE$ TKIs ( e.g. , MET amplification ) have been identified , we focused on addressing the penetrance of preexisting @VARIANT$ harboring resistant cells in NSCLC since this mechanism of resistance remains a major clinical problem .", "label": "resistance or non-response"}
{"id": "21197464", "sentence": "Schematic representation of the signal pathways of @DRUG$ (RA-) induced ( RA-induced ) differentiation of mouse embryonic carcinoma F9 cells . At the undifferentiation stage of F9 cells , HDAC3 , @GENE$ , and JDP2 were recruited on the DRE ( differentiation response element ) in the promoter region of the c-jun gene to induce the heterochromatin . Ac , acetylated residues ; K , lysine residues of histone; @VARIANT$ , lysine residues of histone H3; H4K8 , lysine residue at position 8 of histone H4 ; H4K16 , lysine residue at position 16 of histone H4 ; X1 = ATF-2 , ATF-7 .", "label": "None"}
{"id": "15737014", "sentence": "To determine how the @VARIANT$ mutation would affect @GENE$ proteins already containing mutations associated with sensitivity to EGFR tyrosine kinase inhibitors , we introduced the specific mutation into EGFR cDNAs that encoded the exon 21 and 19 mutations found in patients 1 and 2 , respectively . Various lysates from cells that were serum starved and pre treated with @DRUG$ or erlotinib were analyzed by immunoblotting .", "label": "resistance or non-response"}
{"id": "21188126", "sentence": "This @VARIANT$ allele mutation occurs in approximately 10 % of colorectal cancer patients . It is associated with microsatellite instability and poor survival of colon cancer patients. , BRAF mutations in colorectal cancer cause resistance to EGFR targeted therapy with shorter PFS and OS compared to nonmutated patients . Remarkably , treatment with the @GENE$ sorafenib in in vitro experiments restored sensitivity to @DRUG$ in colon cancer cells .", "label": "resistance or non-response"}
{"id": "25061320", "sentence": "Exon 19 deletion mutation and a mutation in exon 21 ( @VARIANT$ ) are the two main types of EGFR mutation . Riely et al found that patients with the @GENE$ exon 19 mutation had a longer median survival time than those with the EGFR exon 21 mutation after receiving gefitinib or @DRUG$ ( 34 versus 8 months , respectively ; P=0.01 , log-rank ) .", "label": "sensitivity"}
{"id": "25382104", "sentence": "Ponatinib is the only available drug that is designed to overcome @VARIANT$ gatekeeper mutation and is efficient in inhibiting the mutant @GENE$ Ponatinib exhibits triple carbon-carbon ( ethynyl linkage ) bond between the methyl phenyl and purine groups . It holds the Isoleucine side chain without steric interference and without any loss of hydrogen bond ( H_bond ) . It also showed similar binding pattern ( DFG-out ) as imatinib and @DRUG$ which interacts with Met318 , Asp381 and the side chain of Glu286 .", "label": "None"}
{"id": "23937717", "sentence": "We also found @DRUG$ or NK cells could enhance MHC-I expression , which impairs the recognization of NK cells , in lung tumor cells with wild type EGFR , while not in those with @GENE$ @VARIANT$ + T790M .", "label": "sensitivity"}
{"id": "23569389", "sentence": "Baseline @GENE$ mutation data were available for 95 % of patients . Very high @DRUG$ resistance mutations ( M244V , G250E , Y253H , @VARIANT$ , E255V , T315I , F359V , H396R ) were associated with the lowest response rates to dasatinib .", "label": "None"}
{"id": "17877814", "sentence": "These mutations were introduced into @GENE$ and transient transfection experiments were carried out in MCF-7 cells . The kinase activity of each mutant ( autophosphorylation at Y1092 and phosphorylation of endogenous Akt ) , and its response to different concentrations of @DRUG$ were evaluated as described above . Other exon 20 and 21 mutations ( @VARIANT$ , S768I and L858R ) that have been previously tested using transfection based assays were also included in the assay for comparison .", "label": "resistance or non-response"}
{"id": "24672248", "sentence": "V559I is considered to confer resistance to @DRUG$ , whereas @VARIANT$ reportedly confers sensitivity to imatinib. , @GENE$ belongs to the type III tyrosine kinase family .", "label": "None"}
{"id": "24260231", "sentence": "As shown in , sorafenib much more significantly enhanced @DRUG$ induced apoptosis of BaF3 cells when they were driven by the @VARIANT$ mutant as compared with when cultured with IL-3 , which correlated with its inhibitory activity on Chk1 activation as well as on phosphorylation of the @GENE$ substrate STAT5 and GSK3 .", "label": "None"}
{"id": "22655263", "sentence": "Additionally , AP26113 was evaluated on the crizotinib resistant gatekeeper mutant @VARIANT$ both in vitro and in vivo and appeared to be able to overcome resistance to @DRUG$ . Ki determination demonstrated a very similar biochemical potency on wild-type ALK and the L1196M ALK mutant ( 0.09 and 0.08 nM respectively ) , with both cellular and in vivo data ( using engineered @GENE$ cells ) indicating that growth of ALK–L1196M mutant driven-cells is inhibited at similar , albeit slightly higher , doses which inhibit cells harboring wild-type ALK ( Katayama et al. , ) .", "label": "None"}
{"id": "24790411", "sentence": "Erlotinib and @DRUG$ belong to the first generation of TKIs and have reversible binding features . The principal predictive factor for response to such drugs is the presence of somatic “activating” mutations in the EGFR gene that cause an aberrant and constitutive activation of the receptor at the membrane level , resulting in a growth advantage of tumor cells through the activation of @GENE$ , PI3K/Akt , and STAT signaling pathways . In about 50 % of cases , a secondary mutation ( @VARIANT$ ) is supposed to be responsible for resistance. , Other mechanisms involve MET gene amplification ( 5 % –20 % ) ,", "label": "None"}
{"id": "24876815", "sentence": "The cause of refractoriness has been identified in ca. 15 % of mCRC patients as mutations in the BRAF gene , primarily @VARIANT$ substitution . Raf family proteins are downstream of Ras proteins in the signal transduction pathway originating at @GENE$ . It comes as no surprise , then , that activating mutations in the BRAF gene occurring in cancer cells have a similar clinical effect to KRAS gene mutations , making them refractory both to @DRUG$ and panitumumab [ , , – ] .", "label": "None"}
{"id": "25202264", "sentence": "In the Taiwanese population , the treatment response to @DRUG$ was found to be 25 % , which was much lower when compared to exon 19 and @VARIANT$ mutations . The majority of these patients also had other coexisting @GENE$ mutations .", "label": "sensitivity"}
{"id": "24789720", "sentence": "The new therapy methods , which could be effective in patients with @VARIANT$ mutation includes irreversible EGFR-TKIs ( afatinib , neratinib ) . In LUX-Lung 1 study in patients after failure of erlotinib or gefitinib treatment with afatinib led to partial responses and prolongation of progression-free survival compared to placebo to 3,3 months [ , ] . Recently the studies are conducted with combining of irreversible EGFR-TKI and monoclonal antibody against extracellular domain of @GENE$ – @DRUG$ .", "label": "response"}
{"id": "20482850", "sentence": "CDKN1A @GENE$ [ ] Pim-1 kinase dependent phosphorylation of p21Cip1/WAF1 ( CDKN1A ) influences subcellular localization of p21 CDKN1B NUP50 [ ] NUP50 protein is required for degradation of CDKN1B protein , which is important in cell cycle regulation E2F1 TRRAP [ ] TRRAP is required as a @DRUG$ for @VARIANT$ transcriptional activation", "label": "None"}
{"id": "23864840", "sentence": "After re-introduction of gefitinib , 25 % achieved partial remission and 75 % showed @GENE$ . A different response to the same EGFR-TKI regimen after a drug holiday can be explained with tumor heterogeneity . In a retrospective analysis of an erlotinib retrial , Becker et al. [ ] reported five cases of the @VARIANT$ mutation and exon 19 deletions in rebiopsy specimens taken before the retrial of @DRUG$ .", "label": "None"}
{"id": "23994953", "sentence": "@VARIANT$ and MET amplification , which can be detected in up to 20 % of EGFR NSCLCs secondarily refractory to @GENE$ TKIs , account for approximately 60–70 % of all known causes of acquired resistance to gefitinib/erlotinib .", "label": "resistance or non-response"}
{"id": "23493804", "sentence": "EGFR–TKIs such as gefitinib or @DRUG$ attain a response rate of approximately 70 % and progression-free survival of 9–13 months , although subgroups of patients experience long lasting remission. , Use of EGFR–TKIs as a first-line treatment in patients with advanced NSCLC harboring @GENE$ mutations improved progression-free survival with acceptable toxicity , compared with standard chemotherapy . EGFR–TKIs are currently considered a standard first-line treatment for this disease entity.– However , these tumors eventually develop resistance to EGFR–TKIs , possibly as a result of a secondary threonine–methionine substitution mutation at position 790 in exon 20 ( @VARIANT$ ) , MET amplification , or hepatocyte growth factor overexpression in relapsed tumors .", "label": "resistance or non-response"}
{"id": "25033171", "sentence": "Alternatively , it seems that the up-moved P-loop region in G2032R-ROS1 could attribute to the @DRUG$ resistance by attenuating the interactions between the drug and the enlarged binding pocket , which has also been observed in the @VARIANT$ induced crizotinib resistance in the @GENE$ tyrosine kinase .", "label": "resistance"}
{"id": "25091415", "sentence": "Therefore , to elucidate the structural and dynamic consequences of the DM on the catalytic domain of EGFR and its affinity toward gefitinib , we performed molecular dynamic simulations ( 50 ns ) of the wild type ( WT ) @GENE$ and three oncogenic mutants : G719S , @VARIANT$ , and DM in complex with @DRUG$ .", "label": "resistance or non-response"}
{"id": "15737014", "sentence": "Similar results were obtained using erlotinib against wild-type and del E747–L747 ; @VARIANT$ EGFRs in comparison to the corresponding mutants containing the T790M mutation ( C ) . These results suggest that the T790M mutation may impair the ability of @DRUG$ or erlotinib to inhibit EGFR tyrosine kinase activity , even in @GENE$ mutants ( i.e. , L858R or an exon 19 deletion ) that are clinically associated with drug sensitivity .", "label": "None"}
{"id": "22209766", "sentence": "On the other hand , erlotinib could not inhibit @GENE$ phosphorylation in H1975 cells because the @VARIANT$ mutation in EGFR causes a conformation change at the ATP binding pocket , thus decreasing the affinity between @DRUG$ and EGFR .", "label": "resistance or non-response"}
{"id": "22272226", "sentence": "@VARIANT$ or leiomyoma cells treated with RU486 for 1 hour were fixed with 1 % formaldehyde for 15 min and quenched with 0.125 M glycine . Chromatin was isolated by adding lysis buffer , followed by disruption with a Dounce homogenizer . Lysates were sonicated and the DNA sheared to an average length of 300–500 bp. Genomic DNA was prepared by treating aliquots of chromatin with @GENE$ , proteinase K and heat for de-crosslinking , followed by @DRUG$ precipitation .", "label": "None"}
{"id": "22933967", "sentence": "In our retrospective study , 26.7 % of patients , all with KRAS wild-type tumours , who had previously unresectable liver-only metastases , underwent surgical resection after systemic therapy , with R0 resection achieved in 38 patients ( 21.6 % ) ; one of those was patient with the @GENE$ @VARIANT$ mutation . Although it is difficult to make any comparison , because our patients were not selected according to specific systemic therapy , these results are comparable with those reported in previous studies claiming that 19 to 23 % patients treated with bevacizumab- and irinotecan based chemotherapy and with previously unresectable liver-only metastases underwent resection.– In a recently published clinical study BOXER , where the patients with unresectable liver-only metastases were treated with oxaliplatin , @DRUG$ and bevacizumab , R0 resection was achieved in 40 % of patients .", "label": "sensitivity"}
{"id": "24092989", "sentence": "Another critical serine-threonine protein kinase involved in the @GENE$ pathway that has been targeted to block its constitutive kinase activation is BRAF . , BRAF mutation ( V600E ) is reported in 24 % of papillary derived ATC . Preclinical and clinical studies investigating combination therapy with agents such as selective ( PLX4032 ) and potent ( @DRUG$ ARQ 736 ) small-molecule BRAF inhibitors , and MAP/ERK kinase inhibitors ( AZD6244 ) hold great promise in the treatment of BRAF ( @VARIANT$ ) ATC . , ,", "label": "None"}
{"id": "15737014", "sentence": "The EGFR T790M mutation , in conjunction with either wild-type EGFR or the drug-sensitive @VARIANT$ @GENE$ mutant , prevents inhibition of tyrosine phosphorylation ( A ) or p-EGFR ( B ) by @DRUG$ .", "label": "sensitivity"}
{"id": "25562798", "sentence": "Firstly , a secondary mutation , the @VARIANT$ mutation within exon 20 of EGFR , is responsible for about 50 % of instances of acquired resistance [ , ] . This mutation increases the affinity of the EGFR for ATP approximately 10-fold and allows ATP to competitively displace gefitinib and @DRUG$ from @GENE$ [ ] .", "label": "resistance or non-response"}
{"id": "24964744", "sentence": "MCF10a cells containing the PI3K mutation H1047R showed little sensitivity to single agent sirolimus , and in combination with EGFR inhibitors were still seen to be more resistant than their parental counterpart , and were more resistant than MCF10a cells containing the @GENE$ @VARIANT$ mutation . Chou and Talalay combination indices for each cell line examined Gefitinib + ZSTK474 Erlotinib + ZSTK474 @DRUG$ + Rapamycin Erlotinib + Rapamycin Gefitinib + ZSTK474 Erlotinib + ZSTK474 Gefitinib + Rapamycin Erlotinib + Rapamycin", "label": "resistance or non-response"}
{"id": "24263064", "sentence": "As in our study , iTARGET and EURTAC reported generally mild to moderate AEs ( rash and diarrhoea ) , although 13 % of patients ( 11 out of 84 ) in EURTAC did experience grade-3/4 rash with @DRUG$ ( there were no grade-3/4 rash events with gefitinib reported in our study ) . Mutation subtype analysis results in iTARGET and EURTAC were also similar to our study , with exon 19 deletions and @VARIANT$ the most common mutation subtypes detected . Consistent with the mechanism of action of @GENE$ TKIs , rash and diarrhoea were the most commonly reported AEs .", "label": "sensitivity"}
{"id": "22879989", "sentence": "Cells were fixed with 70 % @DRUG$ ( 30 min at 4°C ) , stained with propidium iodide ( 50 µg/mL ) containing 20 µg/mL of @GENE$ ( 30 min at room temperature ) , and were subsequently analyzed by flow cytometric analysis using a FACS Canto™ II ( Becton Dickinson ) . The fractions of the cells in the G0–G1 , S , and G2–M phases were analyzed using Flow Jo software ( Tree Star , Ashland , OR ) .", "label": "None"}
{"id": "19384426", "sentence": "Expression of these mutant p110α isoforms also confered increased resistance to @DRUG$ and induced abnormal mammary acinar morphogenesis in three-dimensional basement membrane cultures [ ] . Another study compared the biochemical activity and transforming potential of mutant forms of p110α and p110β in a human mammary epithelial cell system [ ] . The two most common tumor derived alleles of p110α ( @VARIANT$ and E545K ) potently activated @GENE$ signaling [ ] .", "label": "None"}
{"id": "24502453", "sentence": "Ponatinib2 Iclusig® Ariad @GENE$ Patients with CML for which Imatinib , Nilotinib , and Dasatinib are not appropriate ( or patients carrying a @VARIANT$ single-point-mutation ) 1st July 2013 CML , ALL", "label": "response"}
{"id": "17325698", "sentence": "However , @GENE$ mutations was not a significant prognostic factor in an initial two large retrospective studies in surgically treated patients without @DRUG$ treatment ( ; ) , although reported that patients with exon 19 deletion have significantly shorter survival than those with @VARIANT$ , but this is not confirmed by other investigators so far .", "label": "sensitivity"}
{"id": "23737971", "sentence": "@GENE$ specificity of the interaction with Mint1 . prey plasmid bait plasmid his3 β -gal pP6 Mint1 ( aa 438–769 ) pAS Rab6A Q72L +++ +++ pAS Rab6A‘ Q72L +++ +++ pAS Rab6B Q72L +++ +++ pAS Rab1A wt − − pAS Rab1B wt − − pAS Rab1B Q67L − − pAS Rab2 wt − − pAS Rab2 Q65L − − pAS Rab3A wtΔC − − pAS Rab11A wt − − pAS Rab33B wt − − pAS Rab33B Q92L − − pAS Rab33B T47N_−_− pAS RhoA wt − − pAS H-Ras wt ΔC − − pAS Ypt6p wt − − pAS Ypt6p Q69L − − pAS Ypt1 wt − − After co-transformation , Y190 strains were cultivated in synthetic media lacking leucine , tryptophan and @DRUG$ , supplemented with 30 mM 3 AT ( his3 ) .", "label": "None"}
{"id": "24516334", "sentence": "For example , three BCR-ABL mutations ( @VARIANT$ , Y253H , and F317L ) have a predicted role in abrogating binding of imatinib to BCR-ABL in resistant patients . The second-generation BCR-ABL kinase inhibitor , @DRUG$ , binds to @GENE$ with less stringent conformational requirements and was shown to be effective in inhibition of imatinib-resistant mutants .", "label": "None"}
{"id": "17973572", "sentence": "To prove the functional significance of the @VARIANT$ mutation , we generated Ba/F3 cell lines stably expressing mutant EGFR constructs [ ] . These cell lines , including L858R-L747S , proliferated in the absence of IL3 . @GENE$ cells were extremely sensitive to @DRUG$ ( D ) , whereas Ba/F3-L858R-T790M cells were highly resistant up to 1 μM gefitinib .", "label": "None"}
{"id": "24876815", "sentence": "In the study by Pentheroudakis et al. , patients with a mutation in codon 12 of the KRAS gene who received chemotherapy combined with @DRUG$ had a median overall survival of 19 months , whereas patients with other KRAS mutations and KRAS-wild type gene subjects treated with the same modality had a considerably longer median survival of nearly 30 months [ – ] . Furthermore , there are many reports on patients with the wild-type KRAS gene who are refractory to anti-EGFR treatment . The cause of refractoriness has been identified in ca. 15 % of mCRC patients as mutations in the @GENE$ gene , primarily @VARIANT$ substitution .", "label": "resistance or non-response"}
{"id": "23029123", "sentence": "The importance of D2 receptor involvement in @DRUG$ actions on PRL production and cell proliferation is evident in the experiment where ethanol actions on lactotropes ' function were evaluated in clonal cell lines expressing various levels of D2 receptor isoforms . It was found that V cells , which lacked functional D2 receptors and had high basal levels of PRL , showed a significant reduction in PRL production following D2S and @VARIANT$ receptor transfection . As described by an extended allosteric ternary complex model of @GENE$ , receptors spontaneously isomerize between active and inactive conformations , so receptors can modulate signaling pathways in the absence of an agonist .", "label": "None"}
{"id": "23493883", "sentence": "Combinations of therapy such as cetuximab plus erlotinib and @DRUG$ plus everolimus have also been tried . The most promising drug thus far has been afatinib ( BIBW2992 ; Boehringer-Ingelheim Pharma , Ingelheim , Germany ) , , an @GENE$ family blocker with reported in vitro and in vivo activity against EGFR mutant tumors harboring exon 19 deletions , exon 21 @VARIANT$ mutations and the exon 20 T790M “resistance” mutations .", "label": "sensitivity"}
{"id": "21613978", "sentence": "Left : HEK cells expressing a fusion protein of the catalytic domain of Raf-1 with oestrogen receptor binding domain show no feedback regulation @GENE$ inhibition when stimulated with @DRUG$ ( 4OHT ) , but show feedback regulation when stimulated with FGF . Right : CaCo2 cells expressing B-Raf @VARIANT$ show no feedback post-Mek inhibition , while cells with control constructs show strong feedback regulation .", "label": "None"}
{"id": "22928112", "sentence": "The heterogeneity of B-RAF mutations observed in lung cancer makes the use of @DRUG$ ( the promising small molecule B-RAF kinase inhibitor designed to target the @VARIANT$ mutation ) less desirable [ ] . In addition to the complexities associated with the precise mutation-specific actions of this new drug , resistance can develop to the inhibitor . Various studies have identified mechanisms for acquired resistance in melanoma to mutations in upstream regulators of the ERK pathway including NRAS , @GENE$ , PDGF , and IGF-1 receptor tyrosine kinases [ – ] .", "label": "None"}
{"id": "23662119", "sentence": "Similarly , we also found that GTE could increase the chemotherapeutic efficacy of anticancer drugs against other HER2 overexpressing cancer cell lines , for example , MDA-MB-453/HER2 ( Supplementary Figures @VARIANT$ and S3B ) . These findings suggest that GTE can chemosensitize HER2 overexpressing cancer cells to anticancer drugs ( e.g. , taxol and @DRUG$ ) .", "label": "None"}
{"id": "23691449", "sentence": "Some of the molecular mechanisms of acquired resistance include T790M second mutation , mesenchymal epithelial transition factor ( MET ) amplification , ATP binding cassette (ABC)-G2 transporter ( ABCG2 ) and hepatocyte growth factor (HGF) overexpression , insulin-like growth factor (IGF) binding protein-3 ( @GENE$ ) downregulation , as well as ERBB3 activation . T790M mutation The @VARIANT$ second mutation accounts for half of all resistances to gefitinib and @DRUG$ [ ] .", "label": "None"}
{"id": "24244732", "sentence": "Alcohol sensitivity phenotypes of single point mutations in unc-18 We recently demonstrated that a single point mutation ( @VARIANT$ ) in Munc18 acts biochemically by reducing binding to the assembled SNARE complex and that the orthologous mutation in C. elegans unc-18 ( D214N ) reduces sensitivity to both low and high concentrations of exogenous @DRUG$ [ ] . Previously , we have biochemically characterised other point mutations in Munc18 that affect binding to other proteins including R39C ( inhibits binding to closed-conformation syntaxin ) [ , ] , P242S ( inhibits binding to Mint proteins ) [ ] and E466K ( enhances binding to @GENE$ ) [ ] .", "label": "None"}
{"id": "24650752", "sentence": "The level of @GENE$ transcription gradually decreased from baseline , with a 1-log reduction at 6 months and a 2-log reduction at 12 months . Our findings are consistent with these observations and suggest that nilotinib is highly active in patients with imatinib-resistant or -intolerant CML-CP/AP . We detected 5 BCR-ABL mutations ( M244V , F317L , N358D , @VARIANT$ , and E459K ) in 6 patients at baseline screening .", "label": "None"}
{"id": "23029355", "sentence": "Given that several aspects of @DRUG$ ( P4 ) signaling are differentially influenced by PR isoforms , PRA/PRB ratio should be considered as an important determinant of functional consequences of P4 signaling . We have recently reported a major role of p38 and @GENE$ mitogen activated protein kinases ( MAPKs ) in regulating PRA/PRB expression ratio at post-translational level that might influence P4 signaling in PR expressing cells . Most of previous studies – on transcriptional regulation by PR isoforms were conducted in @VARIANT$ cells ( ER+ ) expressing either PRA or PRB where PR homodimers are the only molecular species or in separate cell lines expressing each PR isoform .", "label": "None"}
{"id": "23696715", "sentence": "A recent study compared the effect of four TKIs ( axitinib , sunitinib , @DRUG$ , and XL184 ) on cell proliferation , RET autophosphorylation , and extracellular signal regulated kinase activation in three cell lines : MZ-CRC-1 ( M918T RET mutation ) , MTC-TT ( @VARIANT$ RET mutation ) , and TPC-1 ( @GENE$ rearrangement ) cells .", "label": "response"}
{"id": "22662154", "sentence": "Group Cell line Mutational status Copy number alterations IC50 ( nM ) PIK3CA PTEN ( mutated exons ) K-Ras PIK3CA PTEN K-Ras BEZ235 @DRUG$ C HEC-1B Mut ( G1049R ) wild type Mut ( G12D ) Gain nl nl 220 200 HHUA Mut ( R88Q ) Mut 5 ( F ) , 8 ( F ) @GENE$ ( @VARIANT$ ) nl nl nl 250 & gt ; 1000", "label": "None"}
{"id": "23186157", "sentence": "Levels of pSTAT5α were also marginally reduced when GNF-2 was applied in the presence of Imatinib , Nilotinib ( Figure ) and significantly reduced in the presence of @DRUG$ ( Figure ) . Cooperation between GNF-2 and AKIs in inhibition phosphorylation of Bcr-Abl and STAT5α . @GENE$ , a laboratory model of Ph + cells carrying native Bcr-Abl ( A and B ) , @VARIANT$ mutated Bcr-Abl ( C ) and SupB15 , a patient derived Ph+ ALL cell line ( D-E ) were treated with various concentrations of GNF-2 in the presence of AKIs , as indicated in each figure .", "label": "None"}
{"id": "17973573", "sentence": "H1975 cells harbor two mutations ( @VARIANT$ and T790M ) in the EGFR gene . All cells were maintained in RPMI-1640 medium supplemented with 10 % heat inactivated fetal calf serum ( FCS , JRH Biosciences , Lenexa , Kansas ) . The @GENE$ inhibitor QVD-OPH ( MP Biomedicals , Aurora , Ohio ) was used at 25 μM and added to cells 30 min prior to treatment with @DRUG$ .", "label": "None"}
{"id": "24472312", "sentence": "Our molecular docking analysis revealed that @DRUG$ could target native or T674I FIP1L1-PDGFRα in the DFG-out ( inactive ) binding mode , similar to ponatinib docking in @VARIANT$ @GENE$ .", "label": "response"}
{"id": "23817662", "sentence": "In fact , the patient with EGFR c.2573T & gt ; G ( L858R ) and EGFR @GENE$ ; T ( @VARIANT$ ) was treated with @DRUG$ and a short-term improvement was observed .", "label": "None"}
{"id": "22960745", "sentence": "Only one sample had a KRAS codon 61 mutation , and there were no exon 19 deletions or @VARIANT$ mutations in EGFR . However , amplifications of EGFR were found in 7 % of cases as were two instances of the L861Q @GENE$ mutation , which confers sensitivity to @DRUG$ and gefitinib .", "label": "sensitivity"}
{"id": "24594844", "sentence": "Combined treatment of cDzT and @DRUG$ exerts a synergistic inhibitory effect on cell viability in cells harboring @GENE$ @VARIANT$ mutants .", "label": "response"}
{"id": "25429239", "sentence": "Other amino acid substitutions observed include @VARIANT$ , G1202R , and S1206Y substitutions , as well as a 1151 threonine insertion . Another described resistance mechanism involves amplification of the @GENE$ fusion gene and activation of other bypass mechanisms.– KIT gene amplification and EGFR activation have also been reported as mechanisms of acquired @DRUG$ resistance. , ,", "label": "resistance"}
{"id": "24292070", "sentence": "To verify that these pronounced frequency shifts of the probe report on the loss of the hydrogen bond to W1 , we solved x-ray structures of @DRUG$ bound to @GENE$ bearing mutations at either T338 or A403 . Methionine is the most common gatekeeper residue in human kinases , but the @VARIANT$ mutant of Src yielded small crystals that diffracted x-rays poorly .", "label": "None"}
{"id": "20672050", "sentence": "Emerging data suggest that patients with NSCLC and EGFR exon 19 deletion have a longer survival following treatment with gefitinib or erlotinib compared with those with @VARIANT$ mutation [ – ] . Recently , IPASS study showed that , in the subgroup of 261 patients who were positive for the EGFR mutation , PFS was significantly longer among those receiving gefitinib that than among those receiving carboplatin-paclitaxel as first-line treatment ( P & lt ; .001 ) [ ] . Several retrospective analyses of clinical trials have failed to demonstrate the correlation between EGFR IHC status and response , @GENE$ and OS in NSCLC patients treated with gefitinib or erlotinib [ – ] .", "label": "None"}
{"id": "15736989", "sentence": "Structural Models of @GENE$ Showing the @VARIANT$ Resistance Mutation ( A ) Space filling representation of the wild-type kinase active site ( cyan ) with the viewer looking down the vertical axis . The structure above the plane of the figure is omitted for clarity . The threonine 790 side chain is green , and @DRUG$ 's molecular surface is shown as a yellow net .", "label": "resistance or non-response"}
{"id": "24987354", "sentence": "Multikinase small molecule inhibitors such as sorafenib and @DRUG$ can be used per recent NCCN guidelines ( Version 2.2013 ) , but prospective clinical trials have not yet demonstrated a distinct molecular subgroup of PTC patients that derives large benefit from such targeted therapies [ ] . BRAF @VARIANT$ is present in approximately 45 % of all PTC [ ] , with alterations of CTNNB1 , HRAS , @GENE$ , KRAS , NRAS , PIK3CA and TP53 being less common .", "label": "None"}
{"id": "25349473", "sentence": "For the 30 mg/day dose , the half-life was 22 hours ; and the trough blood concentration was above 40 nM , which is the minimal concentration thought to be required to prevent the emergence of @GENE$ mutants resistant to @DRUG$ . Further , all 12 patients with CP-CML and the @VARIANT$ mutation had a complete hematologic response , and 8/12 ( 67 % ) had a MMR .", "label": "response"}
{"id": "23994953", "sentence": "Our data appear to support a previously unrecognized scenario in which , in the presence of erlotinib sensitizing EGFR mutations ( delE746-A750 , @VARIANT$ ) , an aberrant/incomplete epithelial differentiation might determine the intrinsic ability of @GENE$ mutant-NSCLC cells to rapidly shift toward the erlotinib-refractory mesenchymal end of the epithelial-mesenchymal spectrum .", "label": "sensitivity"}
{"id": "25462529", "sentence": "Residue D167 of IN was mutated in this study because it is well conserved in HIV and it is embedded within a short stretch of amino acids ( 161–173 ) with nuclear localization signal properties and important for IN–p75/LEDGF interaction. , , We initially chose @DRUG$ to replace a polar acid residue by a polar basic/neutral one with the purpose to induce a mild phenotype with an integration rate between WT and Q168A vectors . Integrase mutations @VARIANT$ and D167K induced opposite effect on single round infectivity of HIV with D167A increasing it to 140 % while D167K reduced it to 5 % of WT indicating a critical role played by this residue in the processing of the @GENE$ .", "label": "None"}
{"id": "25382104", "sentence": "Results showed that @DRUG$ has the highest binding affinity towards the @VARIANT$ mutant @GENE$ with a docking score of −11.050 kcal/mol while bosutinib , bafetinib , dasatinib , nilotinib and imatinib showed −5.513 kcal/mol , −4.689 kcal/mol , −4.702 kcal/mol , −3.772 kcal/mol , −3.593 kcal/mol and −3.78 kcal/mol , respectively ( ) .", "label": "response"}
{"id": "22740817", "sentence": "Whether the survival difference between BRAF WT and mutant patients is only due to the fact that @GENE$ mutational status has prognostic value or if BRAF mutational status may also be predictive for a combination treatment with @DRUG$ and temozolomide can not be concluded definitively from our data set , but should be prospectively studied . If the 2 most frequent BRAF mutations , @VARIANT$ and V600K , are the alterations with predictive value in melanoma patients , techniques identical or similar to method 1 described in this paper may be the detection system of choice .", "label": "sensitivity"}
{"id": "24294007", "sentence": "Although a retrospective study and the PICCOLO ( Panitumumab , Irinotecan and Ciclosporin in Colorectal Cancer Therapy ) trial have demonstrated a reduced response to cetuximab and @DRUG$ for patients with NRAS mutations , , further work is required to demonstrate the predictive capacity of these mutations . The serine/threonine-protein kinase B-Raf is an effector in the @GENE$ signaling pathway , downstream of K-Ras . Mutations in the proto-oncogene BRAF are present in 5 % –10 % of the metastatic CRC population and are also mutually exclusive of KRAS mutations . BRAF @VARIANT$ is the most common of all BRAF mutations ( present in 90 % of cases ) , and is enriched in a subset of patients who are female , greater than 70 years of age , with KRAS WT right sided colon cancer .", "label": "None"}
{"id": "23836985", "sentence": "Jin et al also reported that the HDAC inhibitor , @DRUG$ , inhibits HDAC activity by downregulating cyclin D1 protein expression in colonic carcinoma cells in xenografted mice . In conclusion , our study confirms that valproic acid significantly suppresses growth of Kasumi-1 cell xenograft tumors in nude mice via cell cycle arrest . The antitumor activity of valproic acid is possibly attributable to its direct downregulation of cyclin D1 , CDK4/6 , and cyclin E1 expression , blockage of Rb phosphorylation , reduction of free @VARIANT$ , inhibition of HDAC activity , attenuation of histone acetylation in the p21 promoter region , upregulation of p21 expression , and induction of cell cycle arrest .", "label": "None"}
{"id": "15737014", "sentence": "We have not identified this mutation in 155 tumors ( see above ) , and among nearly 1,300 lung cancers in which analysis of @GENE$ exons 18 to 21 has been performed [ , ,, , , ] , only one tumor ( which also harbored an L858R mutation ) was reported to contain the @VARIANT$ mutation . Whether the patient from which this tumor was resected had received gefitinib or @DRUG$ is unclear , and the report did not note an association with acquired resistance to either drug [ ] .", "label": "resistance or non-response"}
{"id": "20406486", "sentence": "In fact , there was a markedly increased pErk signal in one NRAS @VARIANT$ mutated cell line ( M207 ) , an observation consistent with data from others that has been attributed to loss of negative regulatory pathways [ , ] and enhanced signaling through C-Raf [ , ] . Therefore , @DRUG$ inhibits @GENE$ pathway signaling specifically in cell lines that harbor the BRAFV600E mutation .", "label": "None"}
{"id": "24586514", "sentence": "@DRUG$ induced growth arrest and apoptosis , thus aggravating the apoptotic and cytotoxic effects of ponatinib on @GENE$ @VARIANT$ mutant cells .", "label": "None"}
{"id": "22654561", "sentence": "Verbeek and coworkers set out to compare the efficiency of four recently developed TK inhibitors , XL184 , @DRUG$ , Sunitinib and Axitinib , using three cell lines : the first derived from sporadic MTC expressing a @VARIANT$ @GENE$ mutation , the second derived from metastatic sporadic MTC expressing a M918T RET mutation .", "label": "response"}
{"id": "19547661", "sentence": "A somatic mutation ( @VARIANT$ ) in exon 15 of BRAF has been identified in multiple human cancers with a mutation rate of 66 % in malignant melanomas [ ] and at lower frequency in other human carcinomas . Recently , it was demonstrated that wildtype @GENE$ is required for the response of patients with metastatic colorectal cancer to @DRUG$ and panitumumab [ ] .", "label": "resistance or non-response"}
{"id": "PMC4041556", "sentence": "Second-generation EGFR TKIs – such as neratinib , afatinib and dacomitinib – are effective in preclinical gefitinib- and erlotinib-resistant EGFR @VARIANT$ models , but to date their delivery in @GENE$ TKI-resistant patients have shown disappointing results in the clinic .", "label": "resistance or non-response"}
{"id": "25278773", "sentence": "There were five ( 8.1 % ) patients who had RECIST partial response , and two patients with secondary T790M mutations ( @VARIANT$ T790M , and deletion in exon 19 T790M ) achieved disease stabilization for 9 months and 1 month , respectively . Afatinib in squamous NSCLC : LUX-Lung 8 study In view of the antitumor activity observed in EGFR-wild-type patients with first-generation @GENE$ inhibitors , coupled with evidence of benefit with other irreversible pan-HER inhibitors , this study was initiated to assess the activity of afatinib versus @DRUG$ in squamous subtype NSCLC after the failure of at least one prior platinum based chemotherapy ( NCT01523587 ; ) .", "label": "sensitivity"}
{"id": "17551498", "sentence": "Although this cell line was responsive to low doses of the other drugs tested , the lack of activity of xanafide in the @VARIANT$ could be , in part , due to its long doubling time . Furthermore , xanafide has proved to be more active than the taxanes , gemcitabine , vinorelbine and @DRUG$ in MCF-7 . These findings suggest a specificity of xanafide against the ER+ , @GENE$ w/t MCF-7 cell line .", "label": "None"}
{"id": "24279718", "sentence": "The EGFR mutation L862R has to our knowledge not previously been described in the literature , but given its proximity to mutations known to be sensitive to EGFR-TKI ( @VARIANT$ and L861X ) , tumor clones bearing the L862R mutation could also be potentially responsive to @GENE$ . Meanwhile , because of rapid worsening while waiting for these new molecular tests the patient received third-line pemetrexed , showing further progression in abdomen and pelvis , but still no sign of relapse in the thorax . Unfortunately , the patient rapidly deteriorated and died before being able to attempt a palliative radiation of the lymph nodes in pelvis and a fourth-line treatment with @DRUG$ .", "label": "sensitivity"}
{"id": "23963283", "sentence": "For example , Caucasian patients harboring activating mutations in the EGFR kinase domain , such as a deletion in exon 19 or @VARIANT$ , have shown significant responses to the @GENE$ tyrosine kinase inhibitor ( TKI ) @DRUG$ , including a 70 % response rate , 14-month progression-free survival , and 27-month median survival .", "label": "sensitivity"}
{"id": "25091415", "sentence": "The main hydrogen bonding between EGFR ( Met 793 ) and @DRUG$ is common for the WT and mutant models ; however , the aniline ring of gefitinib was shifted upward in DM when compared to WT @GENE$ . The dictionary of secondary structure of protein ( DSSP ) program was applied to the secondary structure of the EGFR WT and mutant models , and the resulting fluctuations were illustrated in ( A–D ) . In the @VARIANT$ mutation , minimal changes were observed in the coil region that remains near to the point mutant region .", "label": "sensitivity"}
{"id": "23864840", "sentence": "Another approach for @VARIANT$ mediated resistance is the dual inhibition of EGFR with afatinib and cetuximab , an EGFR blocking antibody resembling the synergistic combination of @DRUG$ and trastuzumab in @GENE$ positive breast cancer .", "label": "None"}
{"id": "23234355", "sentence": "The combination of a TKI and a mAb was explored as a potential strategy to overcome acquired resistance to first-generation @GENE$ . Kim and colleagues demonstrated that the combination of lapatinib with cetuximab overcame gefitinib resistance due to the secondary T790M mutation in NSCLC by inducing enhanced cytotoxicity both in vitro and in vivo [ ] . Furthermore , the association of cetuximab with @DRUG$ has been shown to be effective to overcome @VARIANT$ mediated drug resistance [ ] .", "label": "response"}
{"id": "25091415", "sentence": "Cells bearing mutant EGFR proteins show oncogenic properties but typically also exhibit enhanced sensitivity toward inhibitors than the wild-type ( WT ) @GENE$ protein . @DRUG$ , the most common TK inhibitor ( TKI ) , blocks signal transduction pathways implicated in cancers . NSCLC patients who initially respond to TKIs but eventually results in acquired drug resistance by the initiation of secondary mutation @VARIANT$ .", "label": "resistance or non-response"}
{"id": "24790411", "sentence": "The mutation @VARIANT$ is localized at codon 790 on exon 20 of EGFR and results in the change of threonine to methionine at the protein level . The amino acid change causes steric hindrance to EGFR TKIs in crystal analysis and/or increased affinity for adenosine triphosphate ( ATP ) . , Consequently , reversible EGFR TKIs can no longer bind to the receptor or can not efficiently compete for the ATP binding site . Afatinib ( @DRUG$ Boehringer-Ingelheim Pharma , Ingelheim , Germany ) is an irreversible pan-HER inhibitor that blocks all the members of the HER family with tyrosine kinase properties ( @GENE$ , HER2 , and HER4 ) .", "label": "response"}
{"id": "23493838", "sentence": "A complete hematological response and a major cytogenetic response were observed broadly across the @GENE$ mutants , including individuals harboring the dasatinib-resistant @VARIANT$ , the nilotinib-resistant Y253H , and F359C/I/V mutations , but not T315I .", "label": "None"}
{"id": "21165163", "sentence": "At least one study has demonstrated prolonged PFS with the combination of @DRUG$ with the MET TKI , ARQ197 as compared to erlotinib alone [ ] and phase III studies in the EGFR TKI-naïve setting are ongoing . Other strategies Several preclinical reports showed that other agents , such as the anti-EGFR monoclonal Ab cetuximab or @GENE$ inhibitors combined with irreversible EGFR inhibitors hold promise to overcome resistance mediated by @VARIANT$ [ ] .", "label": "None"}
{"id": "19238210", "sentence": "The resistant cell line category was the largest and included two mEGFR cell lines , one having the secondary @VARIANT$ mutation and the other having homozygous deletion of PTEN gene . The remaining resistant lines included all of the wild type lines and all lines having KRAS , BRAF , HER2 , HER4 and PIK3CA mutations . Using univariate tests , we analyzed the association between @DRUG$ sensitivity and mutational status or CNGs of the various EGFR pathway genes and found a significant correlation between gefitinib sensitivity with @GENE$ mutation ( p = 0.002 ) and EGFR copy number gains ( p = 0.001 ) .", "label": "resistance or non-response"}
{"id": "23207070", "sentence": "The most frequent EGFR mutations are deletions in exon 19 and a point mutation in codon 858 of exon 21 , known as @VARIANT$ ( T2573G ; ID : rs121434568 ) [ ] . Patients who carry these mutations in EGFR tend to have a better response to @DRUG$ , an @GENE$ , whereas patients with the wild-type genotype show a better response to conventional chemotherapy [ ] .", "label": "sensitivity"}
{"id": "25105411", "sentence": "In this study , we demonstrated that hinokitiol significantly inhibited cell proliferation in a series of lung adenocarcinoma cell lines , including @GENE$ and TKI-resistant cells , H1975 and PC9-IR , respectively . The mechanism of H1975 resistance to @DRUG$ is due to @VARIANT$ mutation , whereas that of PC9-IR , which was selected from parental PC9 cells that had been continuously exposed to increasing concentrations of gefitinib , could be associated with persistent activation of ERK pathway , .", "label": "resistance or non-response"}
{"id": "23788917", "sentence": "In vitro studies demonstrated that the effective concentration of @DRUG$ in tumour cells harbouring both the L858R and @VARIANT$ mutations has to be 300 times higher to induce apoptosis than in cells only with an activating mutation in codon 858 [ , ] . Presence of a mutation in exon 20 of the @GENE$ gene is a potential prognostic and predictive marker of EGFR TKI therapy and may play an important role in the planning of therapy .", "label": "resistance or non-response"}
{"id": "20459770", "sentence": "In NSCLC , approximately 85 % of patients who responded favourably to gefitinib or @DRUG$ , two FDA approved small-molecule EGFR-tyrosine-kinase inhibitors , were shown to have somatic mutations in the @GENE$ gene . Somatic EGFR mutations are primarily located in exons 18 through 21 around the ATP binding pocket of the tyrosine kinase domain [ - ] . The most common mutations are short deletions in exon 19 affecting the amino acid sequence LREA ( DelE746-A750 ) or a point mutation in exon 21 resulting in the amino acid change @VARIANT$ .", "label": "sensitivity"}
{"id": "24489728", "sentence": "Most of the previously reported NSCLC cells that were resistant to EGFR-TKI were established using the stepwise escalation of @GENE$ concentrations , . Specifically , @DRUG$ concentrations were increased stepwise from 1 to 100 nM when cells resumed growth kinetics that were similar to untreated parental cells . Acquired resistance by genetic alterations , such as the EGFR @VARIANT$ mutation or amplified MET , were caused by the stepwise escalation method of EGFR-TKI exposure after prolonged treatment , .", "label": "resistance or non-response"}
{"id": "22117530", "sentence": "Even though some studies have reported significant associations between these polymorphisms and clinical efficacy of rituximab [ ] , @DRUG$ [ ] or cetuximab [ , ] , data conflict regarding which alleles are linked to favorable patient outcome . In the present study , we report a significant influence of @GENE$ @VARIANT$ polymorphism on survival both in the whole population and in patients with a wt KRas tumor , with VV patients presenting a dramatically shorter survival .", "label": "None"}
{"id": "24920919", "sentence": "Consequently , inhibition of mTORC1 releases the @VARIANT$ mediated negative feedback loop , resulting in a paradoxical increase of PI3K and Akt activity . Therefore , there is legitimate concern that the efficacy of selective @GENE$ inhibitors , which include rapamycin and its analogs ( rapalogs ) , eg , @DRUG$ , is limited .", "label": "None"}
{"id": "24355041", "sentence": "Taken together , altered expression of pluripotency and differentiation genes , including increased expression of SOX2 , decreased expression of other SOX gene families , and alterations of the expression of @VARIANT$ genes and pocket protein genes , may suggest a role for cancer initiating cells/cancer stem-like cells in @DRUG$ resistance .", "label": "None"}
{"id": "24167634", "sentence": "Of note , the continuous exposure of H1975 cells , carrying the @VARIANT$ mutation , to @DRUG$ did not modify their migratory phenotype , possibly because of the low affinity of the mutated receptor for this drug . Indeed , irreversible @GENE$ such as PD168393 or BIBW2992 significantly reduced H1975 cell migration and invasion , confirming the importance of EGFR in controlling these processes .", "label": "resistance or non-response"}
{"id": "25100284", "sentence": "However , a significant PFS benefit of @DRUG$ compared with chemotherapy was reported in patients with established @GENE$ mutated-disease ( 9.5 months versus 6.3 months , respectively , HR = 0.48 , 95 % CI 0.36–0.64 P & lt ; 0.0001 ) [ ] . Obviously , clinical characteristics are not an appropriate surrogate for EGFR mutation testing . Furthermore , although common mutations , such as exon 19 deletions and @VARIANT$ mutations in exon 21 have been associated with response to EGFR TKIs , many other mutations are detected only occasionally , and correlations with response are not defined .", "label": "sensitivity"}
{"id": "25009641", "sentence": "Thus , melatonin tends to modify the expression of the enzymes involved in the local synthesis of @DRUG$ , causing it to be similar to the expression of enzymes in the mammary normal tissue . STS , sulfatase ; AROM , aromatase ; 17β-HSD1 , 17β-hydroxysteroid dehydrogenase type 1 ; EST , estrogen @GENE$ , estrone sulfate ; @VARIANT$ , estradiol sulfate .", "label": "None"}
{"id": "22719810", "sentence": "Thus , the patient began to take @DRUG$ at 250 mg/day because @GENE$ gene analysis in this patient showed a deletion mutation in exon 19 and point mutation @VARIANT$ in exon 21 by direct sequence method ( ) .", "label": "sensitivity"}
{"id": "24092472", "sentence": "These systems each incorporate an @GENE$ kinase protein ( WT , @VARIANT$ , delE746_A750 or delL747_P753insS ) and an inhibitor ( gefitinib or @DRUG$ ) .", "label": "sensitivity"}
{"id": "23515890", "sentence": "The drug resistance mutation @VARIANT$ was detected in CTCs collected from patients with @GENE$ mutations that had received tyrosine kinase inhibitors Gefitinib ( @DRUG$ ) or Erlotinib ( Tarceva ) .", "label": "resistance or non-response"}
{"id": "24348666", "sentence": "Although the resistant cell line @GENE$ does not have the EGFR @VARIANT$ mutation , it was found to have MET amplification . MET is a receptor tyrosine kinase that binds to hepatocyte growth factor (HGF) and is associated with the development of various human cancers . Therefore , EGFR-TKIs fail to inhibit the PI3K/Akt pathway dependent growth signal because the constitutive phosphorylation of HER3 by MET occurs independent of EGFR activation , which causes the cells to acquire resistance to @DRUG$ .", "label": "None"}
{"id": "23865062", "sentence": "In patients chronically infected by HCV , a significant increase in @VARIANT$ expression was seen in hepatocytes and in lymphocytes [ ] . Overexpression of APOBEC has also been observed in HCV/HBV coinfection [ ] . APOBEC3 also appears to play an important role on treatment with exogenous @DRUG$ IFNα ) in vivo .", "label": "None"}
{"id": "19672324", "sentence": "It has been shown that decreasing the expression of rat IRAS or @GENE$ in PC12 rat pheochromocytoma cells could attenuate the activation of extracellular signal regulated kinase ( ERK ) or reduce the radioligand binding to @VARIANT$ , which further supported that hIRAS or Nischarin might serve as I1R itself , or at least a functional subunit of I1R [ ] . Recently , Molderings et al. have reported that the “I1-imidazoline receptors” mediating effects of @DRUG$ and moxonidine in PC12 and the transfected HEK293 cells belonged to the S1P-receptor family , in particular , representing a mixture of sphingosine-1-phosphate (S1P)1- and S1P3-receptors and/or heterodimers of both .", "label": "None"}
{"id": "23133538", "sentence": "@GENE$ mutations are divided into two groups of drug resistant and drug sensitive mutations ( the drugs are @DRUG$ and gefitinib ) . More than 90 % of mutations are drug sensitive , 45 % of which are in exon 19 and 40–45 % occur in exon 21 . Two of the most common mutations are Δ747-P753 that arises in exon 19 and @VARIANT$ and take place in exon 21 , .", "label": "sensitivity"}
{"id": "22343623", "sentence": "In this study , we examined whether the selective KOR agonist U50 ,488H could inhibit the growth of gefitinib-sensitive and EGFR mutant ( delE746-A750 , @VARIANT$ ) NSCLC cells ( HCC827 ) and gefitinib-resistant and @GENE$ mutant ( T790M ) NSCLC cells ( H1975 ) , and investigated the signalling mechanism of the KOR mediated inhibitory effect on tumour cell growth .", "label": "sensitivity"}
{"id": "24559095", "sentence": "Downregulation of @GENE$ results in a weaker @DRUG$ response in the @VARIANT$ cell line .", "label": "None"}
{"id": "24495353", "sentence": "Rank Entrez ID Gene symbol Entrez ID Gene symbol Entrez ID Gene symbol 1 28978 TMEM14A 79776 ZFHX4 1727 CYB5R3 2 1843 DUSP1 4701 NDUFA7 7083 TK1 3 51022 GLRX2 715 C1R 1292 COL6A2 4 1434 CSE1L 79818 ZNF552 857 CAV1 5 8522 GAS7 4046 LSP1 5437 POLR2H 6 51668 HSPB11 1727 CYB5R3 9833 MELK 7 10456 HAX1 357 SHROOM2 54861 SNRK 8 9902 MRC2 283298 OLFML1 4830 NME1 9 4706 NDUFAB1 23179 RGL1 231 AKR1B1 10 23560 GTPBP4 1809 DPYSL3 10418 SPON1 11 79633 FAT4 857 CAV1 2350 FOLR2 12 10418 SPON1 274 BIN1 10979 FERMT2 13 471 ATIC 79833 GEMIN6 11096 ADAMTS5 14 6403 SELP 11222 MRPL3 4638 MYLK 15 23421 ITGB3BP 23244 PDS5A 9448 MAP4K4 16 23452 ANGPTL2 6241 RRM2 54922 RASIP1 17 54861 SNRK 1289 COL5A1 6934 TCF7L2 18 2034 EPAS1 8434 RECK 4072 EPCAM 19 30008 EFEMP2 429 ASCL1 4701 NDUFA7 20 25999 CLIP3 3426 CFI 404672 GTF2H5 21 4311 MME 332 BIRC5 6241 RRM2 22 4747 NEFL 2 @VARIANT$ 2192 FBLN1 23 1809 DPYSL3 10730 YME1L1 25959 KANK2 24 28998 MRPL13 11130 ZWINT 55651 NHP2 25 25959 KANK2 1292 @GENE$ 5050 PAFAH1B3 Lists of the top 25 of most influential genes in influence networks based on coexpression among genes in ER + breast tumors before , during , and after a course of neoadjuvant treatment with the drug @DRUG$ .", "label": "None"}
{"id": "22970367", "sentence": "Gatekeeper mutations have been found in many kinase-driven tumors that develop resistance to kinase inhibitor treatment ( e.g. , CML patients treated with @DRUG$ that develop the @VARIANT$ resistance mutation in BCR-ABL ) . Two potential mechanisms could explain how the @GENE$ T790M mutation confers EGFR TKI resistance .", "label": "None"}
{"id": "22970367", "sentence": "Moreover , dual inhibition of EGFR with an irreversible EGFR inhibitor ( afatinib ) and the EGFR neutralizing antibody @DRUG$ has recently shown promising activity in EGFR mutant lung cancers with acquired @GENE$ TKI resistance that harbor an EGFR @VARIANT$ mutation [ ] .", "label": "response"}
{"id": "25505694", "sentence": "The lack of efficacy could probably be related to the high concentrations of neratinib required in preclinical studies to inhibit EGFR @VARIANT$ and the limitations of clinical dosing . Dacomitinib Dacomitinib is an irreversible EGFR , HER2 and HER4 inhibitor with a higher kinase inhibition than gefitinib/erlotinib in both gefitinib/erlotinib-sensitive and in EGFR-T790M and @GENE$ mutated cell lines [ ] .", "label": "None"}
{"id": "23674887", "sentence": "Bosutinib effectively targets most IM-resistance conferring @GENE$ mutations , with the exception of the highly resistant T315I ( resistant to IM , dasatinib , nilotinib , and bosutinib ) and @VARIANT$ mutations ( resistant to @DRUG$ and bosutinib ) .", "label": "None"}
{"id": "24729716", "sentence": "This molecular change had been found in samples with @DRUG$ or erlotinib resistance in vivo or in vitro . c-MET amplification has also occasionally been found to coexist with @GENE$ @VARIANT$ mutation .", "label": "resistance or non-response"}
{"id": "25146448", "sentence": "MTNR1B , located on human chromosome 11q21–22 , is a member of the @GENE$ , and one of the functional and high-affinity @DRUG$ membrane receptors . MTNR1B is expressed in human and rodent pancreatic islets . Studies have shown that MTNR1B is a novel candidate gene for @VARIANT$ .", "label": "None"}
{"id": "24143235", "sentence": "A few exceptions to this observation were the BT474HR , HCC1954 and @VARIANT$ cell lines , which showed comparatively higher levels of TCF4 and beta-catenin ( & amp ; ) . Recently , expression of @GENE$ has been shown to activate WP and promoted EMT-like phenotype in trastuzumab-resistant HER2 overexpressing breast cancer cells [ ] .", "label": "None"}
{"id": "23723710", "sentence": "Garcia et al reported an association with response to @DRUG$ and a polymorphism in @GENE$ exon 20 ( 2361 G &gt ; A , @VARIANT$ ) .", "label": "None"}
{"id": "24124608", "sentence": "In addition to upregulation of IGF1R and VEGF , frequent CN gain and increased mRNA expression of GSTT1 as well as significant overexpression of @GENE$ subfamily members were observed in wild-type/PDGFRA @VARIANT$ GISTs compared to KIT-mutant GISTs . CN gain of GSTT1 was closely associated with @DRUG$ resistance .", "label": "None"}
{"id": "25221748", "sentence": "This agent is also being assessed in a phase II trial in patients with de novo resistant @VARIANT$ mutations not previously treated with EGFR-TKIs ( www.clinicaltrials.gov : NCT01854034 ) and in patients with EGFR mutations and/or EGFR-TKI resistant disease , as part of a phase II cluster study in Chinese patients evaluating five novel inhibitors of HSP90 , @GENE$ , ALK , MET , and MEK ( ) . Further , AUY922 is also being assessed in combination with @DRUG$ in patients who have previously responded to EGFR-TKIs and/or whose tumors harbor activating EGFR mutations ( www.clinicaltrials.gov : NCT01259089 ) , with results expected in the near future .", "label": "None"}
{"id": "21362200", "sentence": "( b ) Western blot showing effects of BGT226 , BKM120 and @DRUG$ on p-Akt and p-S6 in MCF7 LTED and @VARIANT$ LTED lines .", "label": "None"}
{"id": "23994953", "sentence": "@VARIANT$ mutation reviewed in . The second well-known mechanism of gefitinib/erlotinib resistance is the @GENE$ receptor tyrosine kinase ( RTK ) gene amplification .", "label": "None"}
{"id": "24236021", "sentence": "With the exception of @VARIANT$ , most @GENE$ mutations are inhibited by @DRUG$ and nilotinib .", "label": "None"}
{"id": "22500155", "sentence": "Rapid improvement of therapeutic responses using combined vemurafenib plus @DRUG$ therapy for @GENE$ @VARIANT$ mutation positive melanoma is expected .", "label": "None"}
{"id": "24386407", "sentence": "Lung cancers with mutations that activate epidermal growth factor receptor (EGFR) , including exon 19 deletions and the exon 21 @VARIANT$ point mutation , respond to the reversible EGFR-tyrosine kinase inhibitors ( @GENE$ ) @DRUG$ and erlotinib [ ] .", "label": "sensitivity"}
{"id": "19714203", "sentence": "Similarly , @GENE$ mutant could cause resistance to Gefitinib and @DRUG$ drugs in the treatment of lung cancer , . Importantly , these mutations can promote oncogenic activation , uncontrolled cell proliferation and tumorigenesis even in the absence of the selective pressure from the kinase inhibitors . An activating mutation in the activation loop of the EGFR kinase domain , @VARIANT$ ( also identified as Leu834 in a different numbering of the EGFR sequence ) is among most frequent mutations in lung cancer , amounting to more than 40 % of EGFR mutations in this cancer category – .", "label": "sensitivity"}
{"id": "25210769", "sentence": "While in the Y67H variant , the removal of the hydrogen bond between Tyr67 and Met80 weakens the heme-Met80 ligation , leading to that @GENE$ easily detaches from heme ring . The cleavage of Fe-S bond in the Y67H variant results in a channel in the heme crevice to H2O2 and substrate for peroxidation , which is a characteristic of the cardiolipin induced conformational transition in cyt c . Therefore , at pH values from 4.0 to 5.2 , two following elements may stimulate the @VARIANT$ variant with the highest peroxidase activity : 1 ) His67 acts as a distal @DRUG$ ; 2 ) vacancy generation specific for the substrate or H2O2 loading .", "label": "None"}
{"id": "15736989", "sentence": "T790M in the context of either transiently expressed wild-type @GENE$ or the mutant alleles del L474–E749 ; @VARIANT$ or L858R impairs inhibition by @DRUG$ or erlotinib as assessed by autophosphorylation .", "label": "None"}
{"id": "19384426", "sentence": "Treatment of PC-3 PTEN negative cells with rapamycin inhibited @GENE$ ( @VARIANT$ ) and increased the proliferative response of these cells to doxorubicin [ ] . Furthermore , treatment of mice bearing the PTEN negative prostate cancer xenografts with @DRUG$ , an ester of rapamycin combined with doxorubicin , inhibited the growth of the doxorubicin-resistant tumors confirming the observations in vitro [ ] .", "label": "None"}
{"id": "18974832", "sentence": "( B ) Murine BM cells transduced with unmutated BCR-ABL and single point mutation @VARIANT$ , E255K , and T315I genes were tested for the effectiveness of 1R-Chl ( 125 nM to 1000 nM ) , 1S-Chl ( 500 nM and 1000 nM ) , @DRUG$ ( 500 nM and 5000 nM ; IC50 = 260 nM for the native BCR-ABL transduced cells ) , and dasatinib ( 10 nM and 100 nM ; IC50 = 0.8 nM for the native @GENE$ transduced cells ) .", "label": "None"}
{"id": "15737014", "sentence": "To determine whether additional mutations in the @GENE$ kinase domain were associated with progression of disease in these patients , we performed direct sequencing of all of the exons ( 18 through 24 ) encoding the EGFR catalytic region in the available tumor specimens . However , careful analysis of the exon 20 sequence chromatograms in both forward and reverse directions from this patient 's lung biopsy specimen obtained after disease progression on @DRUG$ demonstrated an additional small peak at nucleotide 2369 , suggesting a C→T mutation ( A , upper panels ; ) . This nucleotide change leads to substitution of methionine for threonine at position 790 ( @VARIANT$ ) .", "label": "resistance or non-response"}
{"id": "21165163", "sentence": "At least one study has demonstrated prolonged PFS with the combination of @DRUG$ with the MET TKI , ARQ197 as compared to erlotinib alone [ ] and phase III studies in the @GENE$ TKI-naïve setting are ongoing . Other strategies Several preclinical reports showed that other agents , such as the anti-EGFR monoclonal Ab cetuximab or PI3K/mTOR inhibitors combined with irreversible EGFR inhibitors hold promise to overcome resistance mediated by @VARIANT$ [ ] .", "label": "resistance or non-response"}
{"id": "21042543", "sentence": "The only B-RAF mutation found was the @VARIANT$ substitution . The most important thing was that patients who received panitumumab or @DRUG$ but had B-RAF alteration , presented no objective response to therapy ; consequently TTP was worse for subjects bearing a mutated @GENE$ although not statistically significant probably due to the limited number of tumors carrying these mutations .", "label": "resistance or non-response"}
{"id": "25277176", "sentence": "( B ) Drugs such as the 4-anilinoquinazolines gefitinib ( Iressa ) [ ] and @DRUG$ ( Tarceva ) [ ] can inhibit the activity of @GENE$ @VARIANT$ mutant .", "label": "sensitivity"}
{"id": "23584600", "sentence": "Rarer mutations include c.1798_1799delinsAG p.Val600Arg ( V600R ) , c.1801A &gt ; G p.Lys601Glu ( @VARIANT$ ) and c.1799_1800delinsAA p.Val600Glu ( V600E2 ) . BRAF mutation results in hyperactivation of the @GENE$ signalling pathway , causing deregulation of cell proliferation and oncogenesis without the requirement for Ras activation . Braf is the most potent of the Raf proteins to activate the downstream signalling cascade , hence mutant Braf was identified as a novel target for kinase inhibitors such as vemurafenib ( PLX4032/RG7204 ) and dabrafenib .", "label": "None"}
{"id": "23579627", "sentence": "Oh et al. reported a disease control rate of 65.2 % in advanced NSCLC patients with retreatment of @DRUG$ after prior gefitinib treatment evidenced partial response or stable disease . However , as in the present case , despite repetitive responses to @GENE$ , the development of secondary resistance inevitably leads to treatment failure . Recently , several second-generation irreversible EGFR inhibitors have been developed with a specific focus on @VARIANT$ to overcome acquired resistance of EGFR-TKI .", "label": "resistance or non-response"}
{"id": "15737014", "sentence": "In tumors from patients not treated with either gefitinib or @DRUG$ , the 2369 C→T mutation ( T790M ) appears to be extremely rare . We have not identified this mutation in 155 tumors ( see above ) , and among nearly 1,300 lung cancers in which analysis of @GENE$ exons 18 to 21 has been performed [ , ,, , , ] , only one tumor ( which also harbored an @VARIANT$ mutation ) was reported to contain the T790M mutation .", "label": "sensitivity"}
{"id": "23579627", "sentence": "This findings show that EGFR @VARIANT$ is a common resistance mechanism to both reversible , and when amplified , the irreversible EGFR inhibitors . In our case , the response duration of irreversible @GENE$ inhibitor was 11 months which was unusually longer than those of initial gefitinib ( for 4 months ) and second round @DRUG$ ( for 6 months ) treatments .", "label": "resistance or non-response"}
{"id": "24244732", "sentence": "Most surprisingly , we demonstrate that the epistatic interactions between mutants of unc-18 and rab-3 are distinct depending on the phenotypic context such that the @VARIANT$ mutation acts downstream of @GENE$ in exocytosis whereas it acts upstream of Rab3 in @DRUG$ sensitivity .", "label": "None"}
{"id": "17973572", "sentence": "After the cells were exposed to @DRUG$ for 24 h , Ba/F3-L858R cells were unable to proliferate while Ba/F3-L858R-L747S and @GENE$ cells continued to grow even in the presence of 1 μM gefitinib ( E ) . These results suggest that execution of apoptosis may be impaired by the presence of T790M and , to a lesser extent , @VARIANT$ .", "label": "None"}
{"id": "18454182", "sentence": "Like @DRUG$ , nilotinib is a new , second-generation tki with structural similarity to imatinib . It has greater potency than imatinib , with activity against most imatinibresistant @GENE$ mutations , with the notable exception of the @VARIANT$ mutation , in which resistance to tki therapy is universal .", "label": "None"}
{"id": "25505694", "sentence": "The LUX-LUNG 3 study [ ] , a multicenter , randomized , open-label phase III study compared afatinib with cisplatin plus @DRUG$ in patients with lung adenocarcinoma , stage IIIb/IV harboring @GENE$ mutations [ , ] . Among the 1,269 screened patients , 345 resulted eligible and were randomized in a two-to-one fashion to afatinib 40 mg daily or chemotherapy up to a maximum of six cycles ( without any maintenance therapy ) . As expected , patients were mainly East Asian , never-smokers and women ; EGFR mutations were predominantly exon 19 deletions and @VARIANT$ point mutations .", "label": "None"}
{"id": "19238210", "sentence": "The resistant cell line category was the largest and included two mEGFR cell lines , one having the secondary @VARIANT$ mutation and the other having homozygous deletion of PTEN gene . The remaining resistant lines included all of the wild type lines and all lines having KRAS , BRAF , HER2 , HER4 and PIK3CA mutations . Using univariate tests , we analyzed the association between gefitinib sensitivity and mutational status or CNGs of the various EGFR pathway genes and found a significant correlation between @DRUG$ sensitivity with @GENE$ mutation ( p = 0.002 ) and EGFR copy number gains ( p = 0.001 ) .", "label": "resistance or non-response"}
{"id": "15696205", "sentence": "@GENE$ and KRAS Mutation Status in Lung Adenocarcinomas Sensitive or Refractory to Gefitinib or @DRUG$ Lung tumors were examined for mutations in EGFR ( exons 18–21 ) and KRAS ( exon 2 ) . In gefitinib treated patients , six EGFR mutations involved exon 19 deletions that lacked the amino acids Leu-Arg-Glu-Ala , and two were exon 21 amino acid substitutions ( @VARIANT$ ) .", "label": "sensitivity"}
{"id": "24167634", "sentence": "Of note , the continuous exposure of H1975 cells , carrying the @VARIANT$ mutation , to @DRUG$ did not modify their migratory phenotype , possibly because of the low affinity of the mutated receptor for this drug . Indeed , irreversible EGFR-TKIs such as PD168393 or BIBW2992 significantly reduced H1975 cell migration and invasion , confirming the importance of @GENE$ in controlling these processes .", "label": "resistance or non-response"}
{"id": "24466094", "sentence": "In addition , PGRMC1 has been shown to bind other CYP enzymes ( CYP3A4 , CYP21A2 , CYP7A1 , CYP2C2 and CYP2C8 ) , , with the activities of CYP2C2 and drug metabolizing P450 cytochromes ( CYP3A4 and CYP2C8 ) being modestly affected in human embryonic kidney ( @GENE$ ) and HepG2 liver cells . Furthermore , the heme binding defective mutant , PGRMC1 ( @VARIANT$ ) , reduced the survival of MDA-MB-231 breast cancer cells from @DRUG$ and camptothecin , implicating the heme binding capacity of PGRMC1 in regulating susceptibility towards chemotherapeutic agents .", "label": "None"}
{"id": "24223798", "sentence": "In particular , @GENE$ kinase inhibitors ( EGFR-TKIs ) , such as @DRUG$ and erlotinib , have been developed as a novel treatment option for patients with non–small cell lung cancers ( NSCLCs ) that possess somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene – . Prospective clinical trials of EGFR-TKI treatment in NSCLC patients with activating EGFR mutations , such as delE746-A750 ( exon 19 ) and @VARIANT$ ( exon 21 ) , have demonstrated high clinical response rates of approximately 80 % – .", "label": "sensitivity"}
{"id": "21556318", "sentence": "@VARIANT$ , E255K , and F359V were deemed less sensitive , but not inherently resistant , as was the T315I identified in three patients receiving nilotinib . Six of 16 @DRUG$ treated patients ( 38 % ) with @GENE$ mutations progressed to accelerated phase/blast crisis CML , as compared with 1/13 ( 8 % ) of nilotinib treated patients .", "label": "None"}
{"id": "20195537", "sentence": "In E. coli the corresponding substitution ( @VARIANT$ ) produces a defective @GENE$ enzyme that lacks nuclease and RecA loading activity affecting the recombination and DNA repair proficiency of cells , . 10.1371/journal.pone.0009412.g006DNA repairing proficiency of RecBK28QCD , RecBD1118A , and RecBCDK229Q enzymes of P. syringae . LCBD ( ΔrecCBD ) strains carrying the plasmid-borne mutant alleles of recB ( recBK28Q or recBD1118A ) or recD ( recD229Q ) of recCBD operon were tested for UV ( A ) and @DRUG$ @DRUG$ ( B ) sensitivity , and compared with the wild-type ( WT ) harboring the empty plasmid vector ( pGL10 ) .", "label": "None"}
{"id": "24594844", "sentence": "cDzT specifically degraded EGFR @VARIANT$ mRNA and decreased @GENE$ protein levels , whereas @DRUG$ inhibited autophosphorylation of EGFR without affecting EGFR protein level .", "label": "response"}
{"id": "21403834", "sentence": "Secondary resistance to @DRUG$ in an IMT with @GENE$ translocation ( ALK/RANBP2 ) has been recently documented in another patient . This resistance was suspected to occur via the neuroblastoma associated @VARIANT$ ALK mutation that has been well studied in neuroblastomas as a mechanism of resistance to some ALK inhibitors [ ] .", "label": "resistance"}
{"id": "24964744", "sentence": "MCF10a cells containing the @GENE$ mutation H1047R showed little sensitivity to single agent sirolimus , and in combination with EGFR inhibitors were still seen to be more resistant than their parental counterpart , and were more resistant than MCF10a cells containing the PIK3CA @VARIANT$ mutation . Chou and Talalay combination indices for each cell line examined @DRUG$ + ZSTK474 Erlotinib + ZSTK474 Gefitinib + Rapamycin Erlotinib + Rapamycin Gefitinib + ZSTK474 Erlotinib + ZSTK474 Gefitinib + Rapamycin Erlotinib + Rapamycin", "label": "resistance or non-response"}
{"id": "21687596", "sentence": "A recent analysis showed that T790M mutations do not considerably affect the binding affinity between EGFR and EGFR-TKIs but instead increase the binding affinity between @GENE$ and ATP , causing a relative decrease in binding with EGFR-TKIs [ ] . The authors reported that increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance . An experiment using cell lines transfected concurrently with activating mutations and a @VARIANT$ mutation also proved that resistance to gefitinib and @DRUG$ is evident when this mutation is present [ – ] .", "label": "resistance or non-response"}
{"id": "25562798", "sentence": "These mutations including @VARIANT$ in the ALK kinase domain may be susceptible to inhibition with novel @GENE$ inhibitors e.g. , LDK378 , AP26113 , or AF802 . However , other mechanisms of resistance including activation of alternative kinases e.g. , EGFR have also been implicated in resistance to @DRUG$ [ ] .", "label": "resistance"}
{"id": "22655263", "sentence": "LDK378 appears very efficacious in vivo , inducing complete and durable tumor regression in an @GENE$ positive NSCLC dependent model and was also described to be active in tumors bearing the @VARIANT$ mutation that confers @DRUG$ resistance ( Li et al. , ) .", "label": "resistance"}
{"id": "20102612", "sentence": "In addition , we could not detect basal occupancy of the cIAP2 promoter by p65 , RAR or RXRα , but significant occupancy of the promoter by these transcription factors was observed after exposure of T47D cells to @GENE$ . In contrast with the results obtained with the cIAP2 promoter , p65 was not recruited to the RARβ gene promoter , a well characterized @DRUG$ acid-responsive gene , where we were able to detect basal and induced recruitment of RAR and RXRα ( Fig. , middle panel ) . Whereas binding of cJUN to the cIAP2 promoter in 9-cis treated @VARIANT$ chromatin extracts was not observed ( Fig. , upper panel ) , strong occupancy of the cJUN proximal promoter , used as a positive control , was easily detected ( Fig. , lower panel ) .", "label": "None"}
{"id": "24964744", "sentence": "MCF10a cells containing the PI3K mutation H1047R showed little sensitivity to single agent sirolimus , and in combination with EGFR inhibitors were still seen to be more resistant than their parental counterpart , and were more resistant than MCF10a cells containing the @GENE$ @VARIANT$ mutation . Chou and Talalay combination indices for each cell line examined Gefitinib + ZSTK474 Erlotinib + ZSTK474 Gefitinib + Rapamycin Erlotinib + Rapamycin @DRUG$ + ZSTK474 Erlotinib + ZSTK474 Gefitinib + Rapamycin Erlotinib + Rapamycin", "label": "resistance or non-response"}
{"id": "24348666", "sentence": "However , a small percentage of cells with MET gene amplification selectively grew during the long periods under the EGFR-TKI treatment , and they became a major population , similar to the cells with the @VARIANT$ mutation . ( 1 ) Met inhibitors ( @DRUG$ , heat shock protein 90 [HSP90 ] ) The concomitant inhibition of MET and @GENE$ using the monoclonal antiboby MetMab and erlotinib proved to beefficacious in a phase II trial and early clinical trials of small-molecule inhibitors of MET given with EGFR inhibitors are now currently underway ( ) .", "label": "None"}
{"id": "23606169", "sentence": "Also , a clinical trial with the BRAF inhibitor ( @DRUG$ ) demonstrated antitumor activity in tumors with the BRAF @VARIANT$ mutation and confirmed that V600E BRAF is a valid therapeutic target in human cancer [ ] . Therefore , recent guidelines for anti-EGFR therapies has forced assessment for @GENE$ mutation in codons 12 and 13 in colorectal cancer .", "label": "None"}
{"id": "15737014", "sentence": "Since tumor specimens from three additional patients with acquired resistance to @GENE$ tyrosine kinase inhibitors did not demonstrate the @VARIANT$ mutation , this specific lesion does not account for all mechanisms of acquired resistance to @DRUG$ or erlotinib .", "label": "resistance or non-response"}
{"id": "23986642", "sentence": "These additional oncogenic kinases have been implicated in the pathogenesis of acute myeloid leukemia as well , which furthers the importance of a @GENE$ inhibitor as a treatment option . The @DRUG$ molecule is designed to interact with @VARIANT$ in a different manner than the existing kinase inhibitors .", "label": "response"}
{"id": "24348666", "sentence": "Although the resistant cell line HCG827GR does not have the EGFR @VARIANT$ mutation , it was found to have MET amplification . MET is a receptor tyrosine kinase that binds to hepatocyte growth factor (HGF) and is associated with the development of various human cancers . Therefore , EGFR-TKIs fail to inhibit the PI3K/Akt pathway dependent growth signal because the constitutive phosphorylation of HER3 by MET occurs independent of @GENE$ activation , which causes the cells to acquire resistance to @DRUG$ .", "label": "resistance or non-response"}
{"id": "23423768", "sentence": "Neratinib ( HKI-272 ) , one of the three agents investigated , has n't shown good RR when tested on patients with known @VARIANT$ mutation , therefore further development of this drug in lung cancer has been halted . Afatinib ( BIBW2992 ) is being investigated as part of the LUX-Lung program which aims to evaluate the use of TKI in second- or third-line treatment in patients who have acquired resistance to @DRUG$ or erlotinib ( LUX-Lung 1 , 4 and 5 ) as well as the use of TKIs as a first-line treatment in patients with @GENE$ activating mutations ( LUX-Lung 2 , 3 and 6 ) .", "label": "resistance or non-response"}
{"id": "23227361", "sentence": "The gatekeeper mutant displayed higher affinity for ATP , providing a potential explanation for resistance to the reversible TKI @DRUG$ . In contrast , irreversible TKIs CL-387785 and WZ-4002 bound irreversibly to an active conformation of @GENE$ and suppressed HER2 signaling and growth in stable clones of wild-type or mutant T798M , L755P , or @VARIANT$ HER2 [ ] .", "label": "resistance or non-response"}
{"id": "21299869", "sentence": "As shown in Figure , all putative ER , @GENE$ , and CREB binding sites on Trip10 promoter were enriched for H3K4me3 , but not H3K27me3 , confirming that Trip10 expression is regulated by both DNA methylation and histone modification . A comparison of endogenous Trip10 mRNA expression in these tested cell lines is correspondingly shown in Additional File : Figure @VARIANT$ . To further evaluate the role of DNA methylation , IMR-32 cells were treated with @DRUG$ ( 5-Aza ) , which appeared to suppress DNA methylation in GSTp1 and slightly decrease Trip10 DNA methylation in the first exon region ( Figure upper panel ) .", "label": "None"}
{"id": "24586514", "sentence": "( B ) K562 or @GENE$ @VARIANT$ cells were treated with @DRUG$ and/or vorinostat for 24 h , and total extracts were examined by immunoblot analysis with anti-phospho ABL , Crk-L , γH2A.X , cleaved caspase 3 , PARP , acetyl histone H4 , and tubulin antibodies .", "label": "None"}
{"id": "22034911", "sentence": "However , analogous Ba/F3 xenografts expressing @VARIANT$ , S1206R , or G1269S mutants were completely insensitive to these doses , with no statistically significant changes in tumor growth rate . @DRUG$ is not efficacious in mouse @GENE$ xenograft models expressing EML4-ALK mutants .", "label": "None"}
{"id": "25099740", "sentence": "Briefly , Cal27 cells stably expressing an activated allele of PIK3CA and RAS were generated by infection with pLESIP HA-PIK3CA H1047A or pLESIP GFP-KRAS @VARIANT$ lentiviruses . Cetuximab solution was purchased from Imclone LLC ( Bridgewater , NJ ) . Rapamcyin and @DRUG$ were from LC Laboratories ( Woburn , MA ) .", "label": "None"}
{"id": "24065105", "sentence": "As with @VARIANT$ @GENE$ , lung cancer cells that overexpress the R248Q mutant show no difference in sensitivity to @DRUG$ [ ] .", "label": "None"}
{"id": "25054154", "sentence": "This suggests that F1174L mutation affects the binding of @DRUG$ and makes the backbone more flexible to move . Furthermore , the flexibility of mutant @VARIANT$ was found to be in consistent with the native @GENE$ .", "label": "sensitivity"}
{"id": "23937717", "sentence": "Though @DRUG$ can also restore NKG2D ligands and NKG2D interaction , and inhibit stat3 expression , we did not find significant improvement on NK cells cytotoxicity to A549 cells with wild type EGFR , while there was significant enhancement to H1975 cells with @GENE$ @VARIANT$ + T790M resistance mutations .", "label": "sensitivity"}
{"id": "25405807", "sentence": "Inhibition of epidermal growth factor receptor (EGFR) kinase activity by @GENE$ tyrosine kinase inhibitors ( EGFR-TKIs ) , such as gefitinib and @DRUG$ , can result in improved response and prolonged progression-free survival ( PFS ) in selected non-small cell lung cancer ( NSCLC ) patients harboring sensitizing EGFR mutations , especially the exon 19del and exon 21 L858R mutations – . Unfortunately , almost all patients will ultimately develop resistance to EGFR-TKI , in whom more than 50 % cases were detected harboring the EGFR @VARIANT$ mutation in tumor specimens after EGFR-TKI , .", "label": "resistance or non-response"}
{"id": "24401087", "sentence": "In view of the ability of Stat6 to function as a @GENE$ in this study we tested whether Stat6 interacts with PR and influences the @DRUG$ dependent regulation of mammary cancer cell growth . Using the @VARIANT$ cell line as a model , we show that Stat6 is indeed a coactivator of PR at the p21 and p27 gene promoters .", "label": "None"}
{"id": "21188109", "sentence": "Cyclin D1 , in association with cyclin dependent kinase-4 and -6 , induces the cell to enter the S phase by phosphorylating the retinoblastoma tumor suppressing protein , which binds to transcription factors , including @VARIANT$ . In addition to the overexpression of cyclin D1 , other genes that overexpress in MCL , such as VEGF and Raf-1 , represent further possible targets for mTOR inhibitors . Indeed , a constitutive activation of @GENE$ and mTOR pathways either in MCL cell lines ( Granta 519 , Jeko-1 , and SP-53 ) or in primary cultures from 30 % of MCL patients has been reported. , Moreover , mTOR inhibitors in MCL could synergize with other “canonical” agents , such as vincristine , @DRUG$ , bortezomib , and rituximab , with resulting inhibition of Raf-1 , MAPK , and mTOR . ,", "label": "None"}
{"id": "17150109", "sentence": "As a positive control for mutation detection , we sequenced EGFR exons 18–21 in 44 adenocarcinoma of the lung and found 2 ( 5 % ) with somatic delE746-A750 mutations , previously reported to be associated with @DRUG$ responsiveness . In contrast , 2 ( 11 % ) of the 18 hepatoma had a single novel somatic @VARIANT$ ( CAT to @GENE$ ; c.2632C &gt ; T ) mutation in exon 21 of ERBB2 ( figure ) , while none of the biliary cancers were found to have somatic mutations .", "label": "None"}
{"id": "23992330", "sentence": "In addition , they showed that two dominant activating mutations in the PI3K catalytic , alpha polypeptide ( @GENE$ ) , @VARIANT$ and H1047R , which are prevalent in breast cancer , also confer resistance to lapatinib [ ] . Conversely , Li et al. infected cells with lentiviruses expressing either wild-type kinases ( Src , Fyn Lyn , EGFR and others ) or kinase alleles with gatekeeper mutations . Through this approach , they showed that Src Family Kinases (SFKs) , as well as EGFR , are relevant targets for the Src inhibitor dasatinib and that acquired T790M mutations render cells resistant not only to erlotinib and @DRUG$ , but also to dasatinib [ ] .", "label": "resistance or non-response"}
{"id": "21681573", "sentence": "A 66-year-old Japanese woman was diagnosed with advanced lung adenocarcinoma and @GENE$ mutation ( @VARIANT$ ) 3 years prior . @DRUG$ had been administered as fourth line of treatment .", "label": "sensitivity"}
{"id": "24472312", "sentence": "In contrast to imatinib , 300 nM @DRUG$ inhibited phosphorylation of @VARIANT$ @GENE$ to a similar degree as 1000 nM sorafenib ( Figure A ) .", "label": "None"}
{"id": "18544172", "sentence": "Non-responders 10 F 68 0 Folfiri , @DRUG$ , Xelox SD 17 Wild-type @VARIANT$ trisomy 11 F 74 1 LV5FU Folfiri SD 10 Gly12Val disomy 12 M 61 0 Folfirinox SD 18 Gly13Asp R521K disomy 13 F 71 0 Xelox Avastin-Xeliri SD 15 Gly12Asp disomy 14 M 59 0 LV5FU , Folfiri , Folfox SD 24 Gly12Cys R521K trisomy 15 M 71 0 Folfox , Irinotecan SD 14 Wild-type disomy 16 F 60 1 Fufol Folfiri , Folfox , Cape , LV5FU SD 17 Wild-type trisomy 17 M 65 0 Folfirinox , Folfiri SD 18 Wild-type low polysomy 18 M 66 0 Folfiri SD 17 Wild-type R521K disomy 19 F 45 0 Folfox , Xelox SD 17 Wild-type R521K NE 20 F 42 0 Folfirinox SD 21 Gly12Asp R521K trisomy 21 M 62 1 Folfox Xeliri SD 36 @GENE$ R521K disomy 22 M 58 1 Folfiri Xelox , Xeliri PD NA Gly13Asp disomy 23 M 75 1 Xelox Xeliri PD NA Wild-type trisomy 24 M 81 0 Xelox , Folfiri PD NA Gly12Val disomy 25 F 55 0 Xelox Avastin-Xeliri PD NA Gly12Asp disomy 26 M 60 1 LV5FU Folfiri , Folfiri , Folfox PD NA Wild-type NE 27 M 59 0 Folfiri , Folfiri/Folfox , Folfox PD NA Gly12Asp NE 28 F 58 1 LV5FU Folfiri , Xelox PD NA Gly12Asp disomy 29 M 51 0 Folfox , Folfiri PD NA Wild-type disomy 30 F 66 0 Folfiri , Xelox PD NA Wild-type R521K trisomy 31 F 56 0 - PD NA Wild-type disomy 32 F 78 0 Folfox , Folfiri , Cape PD NA Gly12Val disomy", "label": "None"}
{"id": "23208557", "sentence": "Cancer @GENE$ exon18 G719X Drug efficacy prediction of gefitinib and erlotinib exon19 deletion exon20 @VARIANT$ exon21 L858R KRAS codon12 , 13 Drug efficacy prediction of @DRUG$", "label": "response"}
{"id": "24790411", "sentence": "Compared to erlotinib and gefitinib , afatinib shows lower EC50 values and greater potency against wild type ( afatinib vs erlotinib vs gefitinib : 60 nM vs 110 nM vs 157 nM ) and @VARIANT$ mutated @GENE$ ( @DRUG$ vs erlotinib vs gefitinib : 0.7 nM vs 40 nM vs 5 nM ) .", "label": "sensitivity"}
{"id": "23320171", "sentence": "Primary results from the EMILIA study , a randomized trial comparing @DRUG$ DM-1 to lapatinib and capecitabine , have shown that Trastuzumab DM-1 significantly improved progression-free survival in patients with metastatic HER2 positive breast cancer . Further research is looking into inhibiting other targets such as @GENE$ , @VARIANT$ , or AKT pathways .", "label": "None"}
{"id": "23723712", "sentence": "@DRUG$ and erlotinib represent the first generation of small EGFR tyrosine kinase inhibitors ( TKIs ) that selectively target the intracellular tyrosine kinase domain of @GENE$ , blocking the downstream signaling of the receptor . The EGFR somatic mutations have emerged to be the most relevant predictor of response to these agents. , Thus , several prospective randomized trials have demonstrated that the use of EGFR TKIs in patients with advanced treatment-naive NSCLC with EGFR mutations significantly improved the objective response rate ( ORR ) and progression-free survival ( PFS ) compared with standard platinum based chemotherapy.– Unfortunately , all responders eventually develop resistance , most commonly because of the emergence of a gatekeeper mutation in the kinase domain , such as @VARIANT$ in EGFR mutated NSCLC or amplification of mesenchymal–epithelial transition factor ( c-Met ) .", "label": "resistance or non-response"}
{"id": "24594844", "sentence": "Besides , after EGF treatment , cDzT remained its suppression effect on EGFR protein expression and downstream signaling including EGFR , STAT3 , @GENE$ , and ERK ( Supplementary Figure S5 ) . Synergistic antitumor effect of combined treatment with cDzT and @DRUG$ in vitro and in vivo cDzT could be used as single agent or as part of combination therapy with second generation TKIs to increase efficacy in the treatment of NSCLCs that harbor the EGFR @VARIANT$ mutant .", "label": "None"}
{"id": "25580271", "sentence": "Two phase III trials compared afatinib to a platinum-doublet in patients with advanced EGFR mutant NSCLC , and a combined analysis for overall survival was presented at ASCO , as well as subset analyses based on EGFR mutation subtype ( exon 19 deletion and exon 21 @VARIANT$ point mutation ) [ ] . In subgroup analysis based on EGFR mutation type the benefit appeared to be limited to patients with exon 19 mutations . When cross-over to EGFR tyrosine kinase inhibitor therapy was examined , 75 % of patients who received @DRUG$ and pemetrexed received an EGFR tyrosine kinase inhibitor and 56 % of patients who received cisplatin and gemcitabine received an @GENE$ tyrosine kinase inhibitor .", "label": "None"}
{"id": "15737014", "sentence": "Using this insight , new small-molecule inhibitors have been identified that retain activity against the majority of imatinib-resistant BCR-ABL mutants [ , ] . For example , in CML , a commonly found mutation is a C→T single nucleotide change that replaces threonine with isoleucine at position 315 ( T315I ) in the ABL kinase domain [ , , ] . In GIST and @GENE$ , respectively , the analogous @VARIANT$ mutation in KIT and T674I mutation in PDGFR-alpha have been associated with acquired resistance to this drug [ , ] .", "label": "None"}
{"id": "17973572", "sentence": "Mutations in the analogous residue of @GENE$ ( L273M ) and ErbB2 ( @VARIANT$ or P) (C ) have been described in patients with imatinib-resistant chronic myelogenous leukemia ( CML ) and solid tumors including gastric , breast , and lung cancers , respectively [ – ] .", "label": "None"}
{"id": "23423768", "sentence": "The magenta ball-stick ( located just above the @DRUG$ molecule in the active site ) indicates the gatekeeper residue ( threonine790 ) that is commonly mutated to methionine ( @VARIANT$ ) , resulting in reduced inhibitor binding and drug resistance . ( C ) Simplified pathway diagram of EGFR signaling through RAS/MEK/ERK and PI3K/PDK1/AKT indicating the points of mutation/amplification in @GENE$ TKI resistance as reported by Sequist and colleagues .", "label": "resistance or non-response"}
{"id": "23818899", "sentence": "EGFR KRAS ( mutation ) Colorectal Cancer ( expressing metastatic colorectal carcinoma , EGFR ) **Therascreen KRAS Test ( Qiagen , Corporate Headquarters , Nederland 's ) **Erbitux , cetuximab ( ImClone , ImClone Systems , NJ ) **Vectibix , @DRUG$ ( Amgen , Amgen Inc , . CA ) [ , , ] BRAF @VARIANT$ ( mutation ) Melanoma ( metastatic melanoma with BRAFV600E mutation ) **Cobas 4800 @GENE$ V600 Mutation Test ( Panagene , Corporate Headquarters , Korea ) **Zelboraf , vemurafenib ( Genentech/Roche ) [ , ]", "label": "resistance or non-response"}
{"id": "22787558", "sentence": "For example , mutant animals show decreased chemotaxis to isoamyl @DRUG$ , which is sensed by AWC olfactory neurons ( ) . @GENE$ is activated within 10 sec by odorant stimuli in the AWC neurons , and the activity of the Ras-MAPK pathway in AWC is important for behavioural response to the odour . Constitutive activation of LET-60 Ras in the let-60 ( n1046gf ) mutant , which carries the @VARIANT$ mutation , also reduces olfactory responses ( ) .", "label": "None"}
{"id": "21687596", "sentence": "In the gefitinib-resistant cell line , clones with amplified @VARIANT$ mutant alleles existed in small quantities . Selective proliferation of these clones occurred on long-term exposure to PF-00299804 . The researchers suggested that although irreversible @GENE$ may be transiently effective against cancers harboring T790M mutations , clones harboring amplified EGFR T790M will rapidly emerge in vitro and in vivo through selection of pre existing EGFR T790M or high expressing clones , leading to clinical drug resistance .", "label": "resistance or non-response"}
{"id": "23696715", "sentence": "A recent study compared the effect of four TKIs ( axitinib , sunitinib , @DRUG$ , and XL184 ) on cell proliferation , RET autophosphorylation , and extracellular signal regulated kinase activation in three cell lines : MZ-CRC-1 ( M918T RET mutation ) , MTC-TT ( @VARIANT$ @GENE$ mutation ) , and TPC-1 ( RET/PTC-1 rearrangement ) cells .", "label": "response"}
{"id": "24201813", "sentence": "The increase of AEBP1 in BRAF ( @VARIANT$ ) melanoma cells with @DRUG$ resistance appears to be due to transcriptional upregulation mediated by the @GENE$ .", "label": "None"}
{"id": "16173832", "sentence": "Citation : Gow CH , Shih JY , Chang YL , Yu CJ ( 2005 ) Acquired gefitinib-resistant mutation of @GENE$ a chemonaive lung adenocarcinoma harboring gefitinib-sensitive mutation @VARIANT$ .", "label": "sensitivity"}
{"id": "21333004", "sentence": "According to recent reports , the sensitivity to kinase inhibition reflects intrinsic differences in the binding affinity of the EGFR mutants such as L858R , @VARIANT$ , and exon19 deletions [ , - ] . Yun et al [ ] showed that gefitinib directly binds more tightly to the L858R mutant than to the wild type EGFR in vitro , while Fabian et al [ ] indicated that EGFR with gefitinib sensitive mutations does not differ from wild type @GENE$ in terms of @DRUG$ binding affinity .", "label": "sensitivity"}
{"id": "25414829", "sentence": "The first example of a clinically relevant NSCLC driver oncogene was the identification of somatic mutations in the epidermal growth factor receptor (EGFR) gene ( – ) .Common @GENE$ alterations ( the @VARIANT$ point mutation and exon 19 deletions ) are present in 10–30 % of patients with NSCLC and confer sensitivity to gefitinib , erlotinib , and @DRUG$ .", "label": "sensitivity"}
{"id": "24991762", "sentence": "mTORC1 controls cell growth and translation through the phosphorylation of ribosomal protein S6 kinase @VARIANT$ and of eukaryotic translation initiation factor 4EBP1 , which regulate either the translation of ribosomal proteins or the cap dependent translation by inhibition of eukaryotic translation initiation factor 4E , respectively. , The activated mTOR pathway has been identified in several human malignancies , thus being an attractive target for anticancer therapy . @GENE$ activity is inhibited by rapalogs such as rapamycin ( sirolimus ) and associated analogs ( temsirolimus/CCI-779 , RAD001 , ridaforolimus/AP23573 ) .", "label": "None"}
{"id": "23584600", "sentence": "Rarer mutations include c.1798_1799delinsAG p.Val600Arg ( V600R ) , c.1801A &gt ; G p.Lys601Glu ( @VARIANT$ ) and c.1799_1800delinsAA p.Val600Glu ( V600E2 ) . BRAF mutation results in hyperactivation of the @GENE$ signalling pathway , causing deregulation of cell proliferation and oncogenesis without the requirement for Ras activation . Braf is the most potent of the Raf proteins to activate the downstream signalling cascade , hence mutant Braf was identified as a novel target for kinase inhibitors such as vemurafenib ( PLX4032/RG7204 ) and dabrafenib .", "label": "None"}
{"id": "22209766", "sentence": "We found that the mechanism of @DRUG$ resistance of HCC827TR3 was neither c-Met amplification nor @VARIANT$ mutation in @GENE$ ( data not shown ) .", "label": "resistance or non-response"}
{"id": "15736989", "sentence": "For example , @DRUG$ is effective in treatment of chronic myelomonocytic leukemia with gene rearrangements that constitutively activate PDGFRB [ ] , of hypereosinophilic syndrome with activating mutations in PDGFRA [ ] , and of gastrointestinal stromal cell tumors associated with activating mutations in @GENE$ [ ] ( all reviewed in [ ] ) . More recently , this paradigm has been extended to treatment of non-small cell lung cancer ( NSCLC ) . Several mutations have been identified in the context of epidermal growth factor receptor (EGFR) in patients with NSCLC that are associated with clinical response to the small-molecule EGFR inhibitors gefitinib ( Iressa ) or erlotinib ( Tarceva ) [ , , ] , including in-frame deletions such as del L747–E749 ; @VARIANT$ in exon 19 , or L858R in exon 21 .", "label": "None"}
{"id": "25031955", "sentence": "Another mutation , @VARIANT$ , has been identified in a patient with inflammatory myofibroblastic tumor and @GENE$ translocation who relapsed on @DRUG$ therapy ( Ou , 2011 ) .", "label": "resistance"}
{"id": "22970367", "sentence": "Intriguingly , low expression of the NFκB inhibitor IκB was predictive of a poor clinical outcome in patients treated with @DRUG$ without a @VARIANT$ mutation . Importantly , IκB status was not predictive of outcomes in EGFR mutant lung cancer patients treated with surgery or chemotherapy , indicating NFκB signaling is specific biomarker of @GENE$ TKI response in this patient population [ , ] ( ) .", "label": "resistance or non-response"}
{"id": "23525126", "sentence": "@GENE$ mutation analysis was positive for a @VARIANT$ mutation in codon 13 of the KRAS gene . Chemotherapy with capecitabine 1000 mg/m2 on days 1 to 14 , oxaliplatin 130 mg/m2 on day 1 , and bevacizumab 7.5 mg/kg on day 1 of a 21-day cycle was initiated , as was treatment with @DRUG$ 28 days .", "label": "None"}
{"id": "23515752", "sentence": "H1975 cells [ TKI-resistant , EGFR exon 20 ( @VARIANT$ ) and -21 mutations ] were treated for 24 h with either @DRUG$ ( 200 nM ) , 17-DMAG ( 50 nM ) , belinostat ( 500 nM ) , panobinostat ( 50 nM ) or docetaxel ( 10 nM ) . Lysates were made , western blotted and probed with antibody against EGFR and GAPDH ( loading control ) ( A ) . 17-DMAG and belinostat decreased levels of activated @GENE$ ( p-Akt ) in TKI-resistant cells .", "label": "None"}
{"id": "25514649", "sentence": "A recent report claimed that @DRUG$ IFN-α and lymphotoxin beta ( LT-β ) pathways might cause the destruction of cccDNA by certain endonucleases following deamination of the minus strand DNA by APOBEC3A @VARIANT$ and A3B .", "label": "None"}
{"id": "19216789", "sentence": "Based on this rationale , we investigated the effects of a new dual Src/Abl kinase inhibitor , AZD0530 with the aim of inhibiting both Src and @GENE$ kinases irrespective of their conformations to explore the possibility of overcoming resistance to @DRUG$ with the use of AZD0530 . Methods p185Bcr-Abl mutant constructs Bcr-Abl cDNAs harbouring @VARIANT$ , T315I , and Y253F mutations were obtained by site directed mutagenesis using a modification of Stratagene 's QuickChange site directed mutagenesis Kit protocol .", "label": "None"}
{"id": "24894453", "sentence": "Furthermore , we found that dimerization dependent L858R mutant shows a dramatic response to cetuximab , whereas tumors driven by dimerization independent mutants such as @VARIANT$ are resistant to the antibody , suggesting that there is a close correlation between dimerization dependency of lung cancer derived oncogenic mutant @GENE$ and pharmacological effects of @DRUG$ [ ] .", "label": "response"}
{"id": "23994953", "sentence": "Unfortunately , the EGFR TKI-driven improvement in patient outcome is notably limited because virtually all NSCLC patients with erlotinib/gefitinib sensitizing EGFR mutations eventually acquire resistance after a median of 6–12 months of @GENE$ TKI therapy . In approximately half of cases , the tumor cells present after disease progression contain second-site mutations that alter drug binding to the EGFR TK domain . The most common lesion ( & gt ; 90 % ) is the so-called “gatekeeper mutation , ” which involves a substitution of methionine for threonine at position 790 ( @VARIANT$ ) .", "label": "resistance or non-response"}
{"id": "17565683", "sentence": "Histology Immunohistochemistry Mutations @GENE$ CD34 S100 SMA Desmin Gene Site 15 Spindle Positive + - - - C-kit Exon11 , MS 16 Spindle Positive + - - - C-kit Exon11 , IFD 17 Spindle Positive + - - - C-kit Exon11 , MS 18 Spindle Positive + - - - C-kit Exon11 , MS 19 Spindle Positive + - Weak - C-kit Exon11 , IFD 22 Myxoid epithelioid Weak + - + - PDGFRA Exon18 del D842V 23 Epithelioid Weak - - - - PDGFRA Exon18 DIMH842-845 26 Epithelioid Weak + NA NA NA PDGFRA Exon18 28 Myxoid epithelioid Weak + - - - PDGFRA Exon12 , @VARIANT$ MS : miss sense , IFD : in-frame deletion , NA : not available Because of possible relapse even after complete resection of omental GISTs [ - ] and the objective response rate of 67 % of @DRUG$ to the mutation in PDGFRA exon 12 [ ] , our patient received daily oral administration of 300 mg Glevec® , ( we applied 15 % reduced dose , referring to a report by Cormier , et al. after took account of a smaller average of Japanese build than American ) [ , ] .", "label": "None"}
{"id": "22038681", "sentence": "Preliminary results from an ongoing phase 1 dose-escalation study of the multikinase , pan–BCR-ABL inhibitor ponatinib ( AP24534 ) showed antileukemic activity in patients with refractory CML , including patients with the @VARIANT$ mutation . Phase 1 and 2 trials of ponatinib are ongoing in patients with refractory CML and acute lymphoblastic leukemia . Danusertib ( PHA-739358 ) is a multikinase aurora inhibitor with in vitro activity against wild-type ABL and @GENE$ ; preliminary results from an ongoing phase 1 dose-escalation study indicate antileukemic activity in patients with AP or BC who failed imatinib and/or nilotinib or @DRUG$ .", "label": "None"}
{"id": "25505694", "sentence": "Overall , the study emphasize the potential role of @DRUG$ as an agent that do not necessarily select for @VARIANT$ mediated resistance and allow the sequential use of non-cross-resistant EGFR TKIs . BMS-690514 , a reversible oral inhibitor of EGFR , @GENE$ and −4 , VEGFRs-1 to −3 , showed antitumour activity in tumour xenograft models and in cell lines containing the EGFR T790M mutation , suggesting a role against erlotinib-resistant tumours [ ] .", "label": "None"}
{"id": "24495353", "sentence": "Rank Entrez ID Gene symbol Entrez ID Gene symbol Entrez ID Gene symbol 1 28978 TMEM14A 79776 ZFHX4 1727 CYB5R3 2 1843 DUSP1 4701 NDUFA7 7083 TK1 3 51022 GLRX2 715 @VARIANT$ 1292 COL6A2 4 1434 CSE1L 79818 ZNF552 857 CAV1 5 8522 GAS7 4046 LSP1 5437 POLR2H 6 51668 HSPB11 1727 CYB5R3 9833 MELK 7 10456 HAX1 357 SHROOM2 54861 SNRK 8 9902 MRC2 283298 OLFML1 4830 NME1 9 4706 NDUFAB1 23179 RGL1 231 AKR1B1 10 23560 GTPBP4 1809 DPYSL3 10418 SPON1 11 79633 FAT4 857 CAV1 2350 FOLR2 12 10418 SPON1 274 BIN1 10979 FERMT2 13 471 ATIC 79833 GEMIN6 11096 ADAMTS5 14 6403 SELP 11222 MRPL3 4638 MYLK 15 23421 ITGB3BP 23244 PDS5A 9448 MAP4K4 16 23452 ANGPTL2 6241 RRM2 54922 RASIP1 17 54861 SNRK 1289 COL5A1 6934 TCF7L2 18 2034 EPAS1 8434 RECK 4072 EPCAM 19 30008 EFEMP2 429 ASCL1 4701 NDUFA7 20 25999 CLIP3 3426 CFI 404672 GTF2H5 21 4311 MME 332 BIRC5 6241 @GENE$ 22 4747 NEFL 2 A2M 2192 FBLN1 23 1809 DPYSL3 10730 YME1L1 25959 KANK2 24 28998 MRPL13 11130 ZWINT 55651 NHP2 25 25959 KANK2 1292 COL6A2 5050 PAFAH1B3 Lists of the top 25 of most influential genes in influence networks based on coexpression among genes in ER + breast tumors before , during , and after a course of neoadjuvant treatment with the drug @DRUG$ .", "label": "None"}
{"id": "25119968", "sentence": "Nevertheless the percentage of @VARIANT$ cells which were arrested in @GENE$ of the cell cycle , after treatment with the selected , cytostatic concentrations of @DRUG$ , was comparable to the one observed in control L5 cells .", "label": "None"}
{"id": "22693611", "sentence": "C , MCF-7 and D , T47D cells were transfected with 2 µg pCMV-tag2 ( − ) or @GENE$ ( + ) for 24 h prior to 24 h treatment with EtOH , 10 µM CRO , or 10 µM AS1411 . Where indicated , cells were treated with 1 µM atRA , 100 nM 4-OHT , or 100 nM @DRUG$ @DRUG$ for 6 h. Q-PCR for RARB2 expression . Values are the average of 6 ( MCF-7 ) and 4–10 ( @VARIANT$ ) separate experiments ± SEM. * P & lt ; 0.05 versus EtOH or ** between the indicated values .", "label": "None"}
{"id": "24724051", "sentence": "A plethora of different mutations mediating imatinib-resistance have been described . Most of these mutant BCR–ABL1 proteins are still sensitive to the second generation @GENE$ kinase inhibitors dasatinib and nilotinib . In addition , the recently approved ponatinib is active against the most common mutation that causes resistance to both first and second generation ABL TKIs , the “gatekeeper” @VARIANT$ mutation ( Table ; Figure ) .", "label": "None"}
{"id": "23244248", "sentence": "Global induction of apoptosis with @DRUG$ , cycloheximide or puromycin was shown to lead to a loss of cell coupling , probably due to caspase-3 mediated degradation of Cx43 , in primary bovine lens epithelial and mouse NIH3T3 fibroblasts [ ] . Interestingly , we previously demonstrated that Stat3 inhibition in cells transformed by Src or the Large Tumor antigen of Simian Virus 40 leads to apoptosis [ , ] , possibly due to activation of the @GENE$ family , potent apoptosis inducers , by these oncogenes .", "label": "None"}
{"id": "24419415", "sentence": "Our group has undertaken a randomized phase 3 trial to compare gefitinib plus carboplatin plus pemetrexed with @DRUG$ monotherapy for patients with NSCLC with an exon 19 deletion or an L858R , G719X , or @VARIANT$ @GENE$ mutation ( NEJ009 ; University Hospital Medical Information Network Clinical Trials Registry [ UMIN-CTR ] number , UMIN000006340 ) .", "label": "None"}
{"id": "23873214", "sentence": "Under steady-state turnover conditions , H2OCbl forms at a rate of 9.5 × 10−3 min−1 in the @GENE$ : MeaB complex in the absence of nucleotides . The presence of GTP decreases @DRUG$ oxidation ~30-fold ( kobs = 3.0 × 10−4 min−1 ) . While the switch III mutant E183A protects MCM from oxidation to a similar degree as wild-type MeaB ( data not shown ) , the @VARIANT$ ( kobs = 0.9 × 10−4 min−1 ) and Q185A ( kobs = 1.7 × 10−4 min−1 ) mutants offer less protection .", "label": "None"}
{"id": "22536370", "sentence": "NRAS G12C/S/R/V/A/D G13A/V/R/D Q61E/H/L/K/P/R 10 % Acral 24 % Mucosa 15 % CSD 22 % non-CSD , Sensitive to : ( pre-clinical ) MEK +/− @GENE$ inhibition , , , MET inhibition Resistant to : BRAF inhibitors KIT @VARIANT$ V559A/D L576P K642E D816H 23 % Acral 16 % Mucosal 28 % CSD , , Sensitive to : Imatinib @DRUG$ Sunitinib Dasatinib Decreased sensitivity to : Imatinib ( D816H only ) , , , ,", "label": "None"}
{"id": "22101934", "sentence": "The cDNAs encoding human @GENE$ aa 25–1022 ( tEGFR ) with mutations L858R or Δ746–750 were transiently transfected into 2–4 L of HEK 293 GnTi− cells , and the mutant tEGFRs were purified from detergent solubilized cell extracts as previously described using the anti-EGFR Ab 528, . Addition of @DRUG$ to the cell culture media allowed for the purification of ~0.1 mg of @VARIANT$ and Δ746–750 tEGFRs per liter of cell culture .", "label": "sensitivity"}
{"id": "22220249", "sentence": "Similarly , the analysis of oncogenic signaling pathway showed that older patients have a lower probability of @VARIANT$ and PI3-kinase pathway activation , but a higher probability of @GENE$ , TNF , Src , and EPI pathway activation . Using genomic derived signatures of anthracycline-sensitivity , elderly patients presented a uniformly anthracycline resistant signature irrespective of tumor biology , while younger patients were much more likely to be sensitive to @DRUG$ .", "label": "None"}
{"id": "17973572", "sentence": "After the cells were exposed to @DRUG$ for 24 h , Ba/F3-L858R cells were unable to proliferate while @GENE$ and Ba/F3-L858R-T790M cells continued to grow even in the presence of 1 μM gefitinib ( E ) . These results suggest that execution of apoptosis may be impaired by the presence of @VARIANT$ and , to a lesser extent , L747S .", "label": "None"}
{"id": "24422746", "sentence": "Furthermore , @GENE$ mutations in PSCCE are rare but do exist , especially gefitinib associated mutations such as @VARIANT$ , therefore @DRUG$ based gene targeted therapy at EGFR but not KRAS and PIK3CA genes , probably should be included in this carcinoma treatment regimens for patients harboring L858R mutation .", "label": "sensitivity"}
{"id": "24555578", "sentence": "Repeat cytology of her right pleural fluid showed adenocarcinoma with an EGFR exon 19 deletion and a second mutation of @VARIANT$ associated with @GENE$ resistance . We introduced cytotoxic chemotherapy . After five cycles of @DRUG$ pemetrexed , a relapse in her right pleural effusion was noted ( Figure c ) .", "label": "None"}
{"id": "25347122", "sentence": "PI3K/mTOR/AKT pathway ; HSP90 NVP-BEZ235 ; 17-DMAG ( @GENE$ inhibitor ) However , in these trials , TNBC was unselected based on gene ontologies and differential gene expression profiles . In the randomized open-label phase III CALGB 40502/NCCTG @VARIANT$ , the new and expensive BC treatments , nanoparticle albumin bound nab-paclitaxel ( Abraxane ) and ixabepilone , the latter being a potent epothilone that can be effective after microtubule inhibitor resistance ( Ixempra ) , have failed to demonstrate any superior efficacy versus the standard of weekly paclitaxel in combination with bevacizumab in patients with chemotherapy naïve metastatic BC .", "label": "None"}
{"id": "17973572", "sentence": "Based on the data obtained from lung cancer cell lines , we further explored the mechanisms by which @VARIANT$ and L747S resistant mutations affect BIM up-regulation and apoptosis . @DRUG$ effectively induced apoptosis in Ba/F3-L858R cells , whereas Ba/F3-L858R-L747S cells were intermediately resistant and @GENE$ completely resistant ( A , top ) .", "label": "None"}
{"id": "25344762", "sentence": "The @GENE$ ( EGFR exon 19 deletion ) and 11–18 ( EGFR L858 ) cells were sensitive to erlotinib , with IC50 values of 0.043 ± 0.025 µmol/L and 0.067 ± 0.0065 µmol/L , respectively ( Fig. b ) . The H1975 cell ( @VARIANT$ + T790 M ) and the EGFR wild-type cells ( H157 , H460 and A549 ) were resistant to erlotinib , with IC50 values of 9.07 ± 2.11 , 20.73 ± 4.66 , 4.58 ± 2.08 , and 7.27 ± 0.69 µmol/L , respectively ( Fig. b ) . The differences in sensitivity to erlotinib between the sensitive and the resistant cells were significant ( P & lt ; 0.05 ) .Effects of erlotinib/bevacizumab on NSCLC cell lines in vitro .", "label": "None"}
{"id": "23579627", "sentence": "Although EGFR gene mutation analysis by direct sequencing on initial bronchoscopic lung biopsy specimen revealed wild-type EGFR , rebiopsy specimen by the PNA clamping method after failure of irreversible EGFR inhibitor therapy revealed L858R/L861Q and @VARIANT$ mutations . Because of repeated favorable responses to initial gefitinib and second round @DRUG$ , we suggest that the result of the initial @GENE$ mutation test was a false negative due to insufficient specimen .", "label": "resistance or non-response"}
{"id": "23208557", "sentence": "It is well known that the efficacy of targeted therapies such as @DRUG$ or erlotinib with NSCLC patients depends on the presence of @GENE$ activating mutations including in-frame deletion in exon 19 or @VARIANT$ in exon 21 [ – ] .", "label": "sensitivity"}
{"id": "24495353", "sentence": "Rank Entrez ID Gene symbol Entrez ID Gene symbol Entrez ID Gene symbol 1 28978 TMEM14A 79776 ZFHX4 1727 CYB5R3 2 1843 DUSP1 4701 NDUFA7 7083 TK1 3 51022 GLRX2 715 @VARIANT$ 1292 COL6A2 4 1434 CSE1L 79818 ZNF552 857 CAV1 5 8522 GAS7 4046 LSP1 5437 POLR2H 6 51668 HSPB11 1727 CYB5R3 9833 MELK 7 10456 HAX1 357 SHROOM2 54861 SNRK 8 9902 MRC2 283298 OLFML1 4830 NME1 9 4706 NDUFAB1 23179 RGL1 231 AKR1B1 10 23560 GTPBP4 1809 DPYSL3 10418 SPON1 11 79633 @GENE$ 857 CAV1 2350 FOLR2 12 10418 SPON1 274 BIN1 10979 FERMT2 13 471 ATIC 79833 GEMIN6 11096 ADAMTS5 14 6403 SELP 11222 MRPL3 4638 MYLK 15 23421 ITGB3BP 23244 PDS5A 9448 MAP4K4 16 23452 ANGPTL2 6241 RRM2 54922 RASIP1 17 54861 SNRK 1289 COL5A1 6934 TCF7L2 18 2034 EPAS1 8434 RECK 4072 EPCAM 19 30008 EFEMP2 429 ASCL1 4701 NDUFA7 20 25999 CLIP3 3426 CFI 404672 GTF2H5 21 4311 MME 332 BIRC5 6241 RRM2 22 4747 NEFL 2 A2M 2192 FBLN1 23 1809 DPYSL3 10730 YME1L1 25959 KANK2 24 28998 MRPL13 11130 ZWINT 55651 NHP2 25 25959 KANK2 1292 COL6A2 5050 PAFAH1B3 Lists of the top 25 of most influential genes in influence networks based on coexpression among genes in ER + breast tumors before , during , and after a course of neoadjuvant treatment with the drug @DRUG$ .", "label": "None"}
{"id": "22132735", "sentence": "EGFR gene mutations indicate sensitivity to gefitinib , and it was demonstrated that about 85 % of patients with NSCLC who obtained benefit from @DRUG$ treatment were found to have mutations in exons 18 to 21 of the tyrosine kinase domain of the @GENE$ gene [ - ] . EGFR mutations in exon 19 ( short in-frame deletions ) or 21 @VARIANT$ ( point mutation ) affect the adenosine triphosphate ( ATP ) pocket of the tyrosine kinase domain leading to the activation of 4-anilinoquinazoline compounds , which function to compete with ATP [ ] .", "label": "sensitivity"}
{"id": "23963283", "sentence": "This was the case for both primary tumors and the cells that had acquired TKI resistance via the @GENE$ @VARIANT$ mutation . This finding might open a new , unexpected therapeutic avenue for the clinical management of EMT-driven , acquired resistance to @DRUG$ .", "label": "resistance or non-response"}
{"id": "25146448", "sentence": "MTNR1B , located on human chromosome 11q21–22 , is a member of the @GENE$ , and one of the functional and high-affinity @DRUG$ membrane receptors . MTNR1B is expressed in human and rodent pancreatic islets . Studies have shown that MTNR1B is a novel candidate gene for @VARIANT$ .", "label": "None"}
{"id": "24280348", "sentence": "This type of drugs selectively bind to the ATP binding pocket of the phosphorylation sites on the @GENE$ tyrosine kinase domain , thus suppress EGFR activation and block downstream signaling pathways . @DRUG$ has shown measurable efficacy at early stage of treatment , but patients become insensitive to this drug after 6 to 9 months , which finally leads to treatment failure [ ] . Several resistance mechanisms , such as EGFR @VARIANT$ secondary mutation that leads to a higher ATP binding capacity , and MET amplification resulting in an aberrantly activated alternative pathway that bypasses the inhibited EGF receptors , had been discovered .", "label": "resistance or non-response"}
{"id": "20234366", "sentence": "KRAS mutations were as follows : @VARIANT$ in five patients ; G12D in three patients ; G12V in three patients ; and G12A in one patient . In all , 11 out of 36 @GENE$ wild-type patients ( 30 % ) responded to @DRUG$ , whereas none of the 12 patients ( 0 % ) harbouring a KRAS mutation had a partial response ( P=0.04 ) .", "label": "resistance or non-response"}
{"id": "25173530", "sentence": "Eight months after starting the treatment , when patients still responded to the @DRUG$ , authors sequenced kinase domain of @GENE$ gene and identified the @VARIANT$ mutation .", "label": "response"}
{"id": "24634705", "sentence": "The L747S mutation lies at the start of the β3 strand and the α-C-helix [ ] and has analogous residues in @GENE$ ( L237M ) and ERBB2 ( L755S or P ) that have been identified in TKI resistant disease [ ] . The occurrence of these secondary mutations spurred development of second and third generation irreversible TKIs which bind covalently to the cysteinyl-797 residue in the pocket of the EGFR-kinase domain and overcome resistance driven by the @VARIANT$ mutation [ ] . These agents show greater potency in the inhibition of kinase activity in vitro and in vivo compared to @DRUG$ and are in various stages of clinical testing [ , ] .", "label": "None"}
{"id": "21444946", "sentence": "The most commonly identified mechanism of resistance is an @GENE$ mutation at position 790 ( @VARIANT$ ) , resulting in substitution of a threonine residue with methionine , which abrogates the ability of @DRUG$ or erlotinib to inhibit EGFR [ , ] .", "label": "resistance or non-response"}
{"id": "24236082", "sentence": "Additionally , cells bearing the mutant EGFR were in general more sensitive to @GENE$ than cells expressing the wild type kinase . The @VARIANT$ mutant was 10–100 fold more sensitive to erlotinib and @DRUG$ than the wild type kinase , .", "label": "sensitivity"}
{"id": "17626639", "sentence": "The exon 20 @VARIANT$ mutation previously documented to confer resistance to @DRUG$ [ ] was not observed . The exon 20 point mutations we observed are unlikely to be artifactual as previously postulated [ ] , as similar mutations were not observed in any of the other amplicons we sequenced . @GENE$ exon 19 deletions/substitution # Sex Ethnicity Smoking Status Source Tissue Response1 I K E L R E A T S P K a.a .", "label": "resistance or non-response"}
{"id": "17973572", "sentence": "Based on the data obtained from lung cancer cell lines , we further explored the mechanisms by which @VARIANT$ and L747S resistant mutations affect BIM up-regulation and apoptosis . @DRUG$ effectively induced apoptosis in Ba/F3-L858R cells , whereas @GENE$ cells were intermediately resistant and Ba/F3-L858R-T790M completely resistant ( A , top ) .", "label": "None"}
{"id": "21915126", "sentence": "The mechanistic reasons behind the resistance to EGFR TKI are different , probably involving @VARIANT$ secondary mutation and MET amplification . Recently , some irreversible @GENE$ and MET inhibitors have shown antitumour activity in patients resistant to gefitinib or @DRUG$ in pre-clinical studies ( ; ; ; ; ) .", "label": "resistance or non-response"}
{"id": "23329883", "sentence": "There was no significant difference in the levels of TG , HDL-C , @GENE$ , ApoB , and the ratio of ApoA1 to ApoB between AA and AG genotypes in the both groups ( P &gt ; 0.05 for all ) . Interactions between genotypes and alcohol consumption on serum lipid parameters The interactions between genotypes of the PCSK9 @VARIANT$ and @DRUG$ consumption on serum TC and LDL-C levels are also shown in Table .", "label": "None"}
{"id": "16552419", "sentence": "Sixty-two of the 76 female patients with mutations were never smokers , in which 40 patients ( 65 % ) had an @VARIANT$ mutation . We examined the overall survival in relation to @GENE$ mutations in patients with adenocarcinoma who did not receive @DRUG$ treatment .", "label": "sensitivity"}
{"id": "25465236", "sentence": "The increased inhibition potency for @DRUG$ against the oncogenic EGFR @VARIANT$ mutant ( over the EGFR WT protein ) correlates with decreased global connectivity of the hub residues ( Arg-958 , Glu-884 , Gln-894 and @GENE$ ) in the mutant ( – wild type , – L858R mutant ) .", "label": "None"}
{"id": "21264348", "sentence": "A. @DRUG$ antiproliferative EC50 in the presence of 0.4 to 10 μM GNF‐5 on Ba/F3 cells expressing @VARIANT$ and E505K Bcr‐Abl. B. Inhibition of Bcr‐Abl autophosphoryl‐ation was determined by Bcr‐Abl immunoprecipitation , followed by a immunoblot for @GENE$ ( Tyr412 ) , phospho‐STAT 5 ( Tyr694 ) and total Bcr‐Abl ( antibody K‐12 ) from cell lystates obtained after treatment of T315I Bcr‐Abl expressing Ba/F3 with 10 μM of dasatinib and increasing concentrations of GNF‐5 ( 0 , 0.5 , 5 and 10 μM ) for 90 min. ( TIF )", "label": "None"}
{"id": "20498723", "sentence": "( A ) Schematic representation of dSETDB1 and dSETDB1 ( @VARIANT$ ) , which contains a single amino acid exchange mutation of @DRUG$ ( H ) to leucine ( L ) at amino acid position 775 . Rectangles mark the positions of the @GENE$ ( MBDL ) , Pre-SET domain ( Pre ) , SET-domain ( SET ) , and Post-SET domain ( Post ) .", "label": "None"}
{"id": "24811491", "sentence": "Acquired resistance EGFR mutations Mutations in the EC domain ( @VARIANT$ ) and in the kinase domain ( codons 714 and 794 ) of @GENE$ found in patients @DRUG$ remained active in a patient with S492R mutation , which abrogated cetuximab binding .", "label": "response"}
{"id": "25376241", "sentence": "As morphologically distinctive differences in the Wolffian ducts appeared , specifically excessive branching in males and simple @GENE$ in females , the hyperplastic defects in the Wolffian ducts may occur after sex determination . The transcription @DRUG$ activities of the wild-type and @VARIANT$ β-catenin proteins were almost equivalent", "label": "None"}
{"id": "21182469", "sentence": "cAMP ( cyclic adenosine monophosphate ) , cGMP ( cyclic guanosine monophosphate ) , LTC4 ( leukotriene C4 ) , DNP-SG ( S- ( 2,4-dinitrophenyl ) -glutathione ) , E13S ( estrone 3-sulfate ) , DHEAS ( @DRUG$ 3-sulfate ) , and E217βG ( estradiol 17-β-D-glucuronide ) . ( B ) Anticancer drugs that are transported by ABCC11 . MTA ( pemetrexed ) , MTX , ( methotrexate ) , @GENE$ ( Cytosine arabinoside ) , PMEA ( 9’- ( 2’-phosphonyl-methoxyethyl ) adenine ) are substrate for ABCC11 .", "label": "None"}
{"id": "21814611", "sentence": "In this case , because HBeAg was detected and HBV DNA was still high 3 months after administration of clevudin , it should be clarified that the mutations in the overlapping frame gene regions , S codon @VARIANT$ ( P codons P221T and A222T ) , may be associated with escape mutation as well as drug resistance . An interesting point of this case concerns the sustained HCV suppression , which occurred even with insufficient treatment of @DRUG$ .", "label": "None"}
{"id": "25054154", "sentence": "We utilised three complexes , namely , native ( @GENE$ ) , @VARIANT$ ( ALK F1174L-crizotinib ) , and R1275Q ( ALK R1275Q-crizotinib ) for our analysis .", "label": "resistance"}
{"id": "23875003", "sentence": "Exogenous lipoic acid equilibrates among different intracellular and extracellular compartments but can not substitute for covalently bound lipoic acid ( as the @DRUG$ of mitochondrial complexes such as pyruvate dehydrogenase and α-ketoglutarate dehydrogenase ) . This study is aimed at establishing the effects of lipoic acid , on glucose uptake , insulin signaling through the @GENE$ pathway , and synaptic plasticity on a triple transgenic mouse model of Alzheimer’s disease ( 3xTg-AD ) . This transgenic model harbors PS1 ( @VARIANT$ ) , APP ( Swe ) , and tau ( P301L ) transgenes , shows progressive development of both plaques and tangles with increasing age in a region specific manner : ~6 month-old 3xTg-AD mice show diffuse amyloid plaques in different regions but tangle pathology is established at ~12 months [ ] .", "label": "None"}
{"id": "23566546", "sentence": "Case Histrogical type @GENE$ mutation status Brinkman index Treatment agent Response IL-8 ( ng/mL ) IL-10 ( ng/mL ) RANTES ( pg/ml ) 1 Ad Ex21 @VARIANT$ 900 gefitinib PR 5.79 1.67 2 2 Ad Ex21 L858R 0 erlotinib PR_3.33 94.2 1.41 3 Ad Ex19 del 0 erlotinib PR 4.09 126 2.13 4 Ad Ex21 L858R 0 gefitinib PR_3.92 18.1 1.85 5 Ad Ex21 L858R + Ex19 del 370 erlotinib PR 21.9 1.23 2.11 6 Ad Ex19 del 0 erlotinib PR 7.05 1.37 2.56 7 Ad Ex19 del 0 gefitinib PR 4.82 1.59 2.02 8 Ad Ex21 L858R 1640 gefitinib PR 54.9 2.7 2.38 9 Ad negative 400 erlotinib SD 34.9 3.39 3.66 10 Ad negative 0 erlotinib SD 27.1 4.94 2.25 11 Ad unknown 1800 erlotinib SD NE NE NE 12 Sq Ex19 del 3840 gefitinib SD 12.6 1.1 1.98 13 Ad Ex19 del 30 erlotinib SD 5.27 0.69 2.66 14 Ad Ex19 del 0 erlotinib SD 10.5 0.85 2.5 15 Ad unknown 300 erlotinib SD 7.69 2.61 1.7 16 La negative 2080 erlotinib SD NE NE NE 17 Sq Ex21 L858R 750 erlotinib SD 11.6 56.3 3.06 18 Ad unknown 600 @DRUG$ SD 13.7 1.1 2.82 19 Ad Ex21 L858R 0 erlotinib SD 20.6 11.6 0.783 20 Ad Ex19 del 0 erlotinib SD 14.8 2.07 2.02 21 Ad Ex21 L858R + Ex19 del 0 gefitinib SD 3.04 1.3 1.76 22 Ad Ex19 del 200 gefitinib SD 10.9 1.59 1.91 23 Sq unknown 1560 erlotinib PD NE NE NE 24 Ad negative 1080 erlotinib PD 25.2 8.15 1.57 25 Ad unknown 0 erlotinib PD NE NE NE 26 Ad Ex18 G719A 2000 erlotinib PD 11.6 4.48 3.12 27 Ad unknown 1410 erlotinib PD NE NE NE 28 Ad Ex19 del 1000 gefitinib PD 9.44 2.25 2.89 29 Ad negative 1100 erlotinib PD 56.3 5.63 2.16 30 Ad negative 2000 erlotinib PD 15.6 0.85 0.292 31 Ad negative 825 erlotinib PD 8.27 1.59 2.13 32 Ad Ex21 L858R 0 erlotinib PD 5.34 7.05 1.7 33 Ad negative 1680 erlotinib PD 57.7 1.63 2.06", "label": "sensitivity"}
{"id": "23493838", "sentence": "A complete hematological response and a major cytogenetic response were observed broadly across the @GENE$ mutants , including individuals harboring the dasatinib-resistant F317L , the nilotinib-resistant @VARIANT$ , and F359C/I/V mutations , but not T315I . Nine individuals developed new mutations in the course of bosutinib treatment ( V299L , n = 4 ; L248V , n = 2 ; T315I , n = 2 ; F359C , n = 1 ; G250E , n = 1 ) and eight of these individuals discontinued @DRUG$ because of progressive disease or unsatisfactory response .", "label": "response"}
{"id": "16626260", "sentence": "Although several previous studies have suggested that tumors harboring mutations in the EGFR kinase domain were sensitive to TKIs such as gefitinib or @DRUG$ , others had reported an association between the @VARIANT$ mutation in exon 20 and the resistance to TKIs . As we learn more about the relationship between EGFR status ( including gene copy number , mutation status , and mutation type ) and drug sensitivity , decisions about treatment with TKIs for patients with non-small-cell lung cancer ( NSCLC ) become more complex . Previously , we reported @GENE$ mutational status , as well as EGFR and KRAS , in a large number of NSCLCs .", "label": "None"}
{"id": "24349829", "sentence": "Correspondingly , direct injection of a liposome encapsulated miR-7 plasmid into established EGFR-TKI sensitive and resistant tumors bearing the @VARIANT$ EGFR mutant resulted in significant tumor regression in conjunction with repression of @GENE$ , RAF-1 and IRS-1 expression . In head and neck cancer , miR-7 functioned in a synergistic manner with erlotinib to render FaDu Erlotinib-resistant cells susceptible to the growth inhibitory activities of the drug .", "label": "resistance or non-response"}
{"id": "23552733", "sentence": "The impact of trastuzumab and @DRUG$ on downstream signaling was highly different in HCC1954 cells harboring the @VARIANT$ @GENE$ gain-of-function mutation .", "label": "None"}
{"id": "24312144", "sentence": "Screening for such mutations in lung cancers identifies patients who will have a clinical responsiveness to @DRUG$ , . Since the existence of EGFR gene mutations ( exon 19 deletions or the exon 21 @VARIANT$ ) were reported as a predictive factor for sensitivity to @GENE$ , several studies based their research on this conclusion , .", "label": "sensitivity"}
{"id": "23493883", "sentence": "Inhibition of @GENE$ cell lines by afatinib compared to @DRUG$ as shown by EC50 values Wild-type @VARIANT$ mutation L858R + T790M", "label": "sensitivity"}
{"id": "PMC2557557", "sentence": "@VARIANT$ PHASE I INTRA- & INTER-PATIENT DOSE RANGING STUDY OF GEMCITABINE , @DRUG$ AND PACLITAXEL ( @GENE$ ) IN", "label": "None"}
{"id": "22343623", "sentence": "In this study , we examined whether the selective KOR agonist U50 ,488H could inhibit the growth of gefitinib-sensitive and @GENE$ mutant ( delE746-A750 , @VARIANT$ ) NSCLC cells ( HCC827 ) and gefitinib-resistant and EGFR mutant ( T790M ) NSCLC cells ( H1975 ) , and investigated the signalling mechanism of the KOR mediated inhibitory effect on tumour cell growth .", "label": "sensitivity"}
{"id": "24348666", "sentence": "Bianco et al. showed that Akt is activated independent of @GENE$ signaling in resistant cells , and reintroduction of a PTEN gene restores gefitinib induced Akt inhibition , indicating that loss of PTEN is associated with acquired resistance . Therefore , PTEN downregulation or Akt activation may be one of the mechanisms for acquired resistance to @DRUG$ . 2. Acquired resistance mechanism 1 ) Secondary @VARIANT$ mutation of the EGFR gene", "label": "resistance or non-response"}
{"id": "24523596", "sentence": "Recently , genome-wide screening for the genetic determinants of gout found that an SNP of ABCG2/BCRP ( @VARIANT$ ) is associated with high uric acid levels , and demonstrated that uric acid is a natural substrate of ABCG2/BCRP. , ABCG2/BCRP also appears to play a protective role against xenobiotics and their metabolites. , The typical ABCG2/BCRP substrates , irinotecan and SN-38 , are detoxified by glucuronidation with uridine-diphosphate–glucuronyltransferase , and ABCG2/BCRP can extrude SN-38–glucuronide . Interestingly , ABCG2/BCRP can transport another of the glucuronide conjugates , 17-β-estradiol 17- ( β-D-glucuronide ) , and the sulfated conjugates estrone-3-sulfate @DRUG$ @DRUG$ are also substrates of ABCG2/BCRP. , The apical localization of @GENE$ in the intestinal epithelium and the bile canalicular membrane also suggests the intestinal absorption and hepatobiliary excretion of ABCG2/BCRP substrates. , – ABCG2/BCRP may also play a protective role by transporting dietary carcinogens .", "label": "None"}
{"id": "24996221", "sentence": "E ) . Western blot analysis of c-caspase3 and @GENE$ also confirmed the results ( Additional file : Figure @VARIANT$ and S1B ) . However , the sensitivity of SPC-A1/DTX and H1299/DTX cells to @DRUG$ was markedly enhanced ( Figure", "label": "None"}
{"id": "23566546", "sentence": "Case Histrogical type @GENE$ mutation status Brinkman index Treatment agent Response IL-8 ( ng/mL ) IL-10 ( ng/mL ) RANTES ( pg/ml ) 1 Ad Ex21 @VARIANT$ 900 @DRUG$ PR 5.79 1.67 2 2 Ad Ex21 L858R 0 erlotinib PR_3.33 94.2 1.41 3 Ad Ex19 del 0 erlotinib PR 4.09 126 2.13 4 Ad Ex21 L858R 0 gefitinib PR_3.92 18.1 1.85 5 Ad Ex21 L858R + Ex19 del 370 erlotinib PR 21.9 1.23 2.11 6 Ad Ex19 del 0 erlotinib PR 7.05 1.37 2.56 7 Ad Ex19 del 0 gefitinib PR 4.82 1.59 2.02 8 Ad Ex21 L858R 1640 gefitinib PR 54.9 2.7 2.38 9 Ad negative 400 erlotinib SD 34.9 3.39 3.66 10 Ad negative 0 erlotinib SD 27.1 4.94 2.25 11 Ad unknown 1800 erlotinib SD NE NE NE 12 Sq Ex19 del 3840 gefitinib SD 12.6 1.1 1.98 13 Ad Ex19 del 30 erlotinib SD 5.27 0.69 2.66 14 Ad Ex19 del 0 erlotinib SD 10.5 0.85 2.5 15 Ad unknown 300 erlotinib SD 7.69 2.61 1.7 16 La negative 2080 erlotinib SD NE NE NE 17 Sq Ex21 L858R 750 erlotinib SD 11.6 56.3 3.06 18 Ad unknown 600 erlotinib SD 13.7 1.1 2.82 19 Ad Ex21 L858R 0 erlotinib SD 20.6 11.6 0.783 20 Ad Ex19 del 0 erlotinib SD 14.8 2.07 2.02 21 Ad Ex21 L858R + Ex19 del 0 gefitinib SD 3.04 1.3 1.76 22 Ad Ex19 del 200 gefitinib SD 10.9 1.59 1.91 23 Sq unknown 1560 erlotinib PD NE NE NE 24 Ad negative 1080 erlotinib PD 25.2 8.15 1.57 25 Ad unknown 0 erlotinib PD NE NE NE 26 Ad Ex18 G719A 2000 erlotinib PD 11.6 4.48 3.12 27 Ad unknown 1410 erlotinib PD NE NE NE 28 Ad Ex19 del 1000 gefitinib PD 9.44 2.25 2.89 29 Ad negative 1100 erlotinib PD 56.3 5.63 2.16 30 Ad negative 2000 erlotinib PD 15.6 0.85 0.292 31 Ad negative 825 erlotinib PD 8.27 1.59 2.13 32 Ad Ex21 L858R 0 erlotinib PD 5.34 7.05 1.7 33 Ad negative 1680 erlotinib PD 57.7 1.63 2.06", "label": "sensitivity"}
{"id": "24594844", "sentence": "The efficacy of combined treatment with cDzT and the TKI , @DRUG$ , against @GENE$ @VARIANT$ based drug resistance was evaluated in vitro and in vivo .", "label": "response"}
{"id": "21808883", "sentence": "The D2L isoform is predominant in the rat pituitary , striatum , and olfactory tubercle , whereas @VARIANT$ is more abundant in the hypothalamus.- Activation of either isoform in rat lactotrophs mediates dopamine suppression of the PRL gene . While PRL directly inhibits secretion of gonadotropins from the anterior pituitary , there is accumulating evidence that PRL also exerts a direct inhibitory effect on @GENE$ actions in the ovary . Physiological levels of PRL suppress follicle stimulating hormone ( FSH ) -induced estradiol production through a reduction in aromatase expression and PRL increases @DRUG$ production by augmenting StAR , P450scc , and 3βHSD expression in granulosa cells .", "label": "None"}
{"id": "15737014", "sentence": "The mutant 2369 T peak was small , possibly because @DRUG$ had been discontinued in this patient for 4 mo at the time pleural fluid tumor cells were collected ; thus , there was no selective advantage conferred upon cells bearing the @VARIANT$ mutation . To determine whether the 2369 C→T mutation was a previously overlooked EGFR mutation found in NSCLCs , we re-reviewed exon 20 sequence tracings derived from analysis of 96 fresh-frozen resected tumors [ ] and 59 paraffin embedded tumors [ ] , all of which were removed from patients prior to treatment with an @GENE$ tyrosine kinase inhibitor .", "label": "resistance or non-response"}
{"id": "24223798", "sentence": "All of the patients had the @GENE$ gene mutations in exon 19 ( delE746-A750 ) or exon 21 ( L858R ) , and had received or were receiving @DRUG$ or erlotinib for treatment against advanced diseases at the blood sampling . For analysis of EGFR gene mutations in exon 19 ( delE746-A750 ) or exon 21 ( L858R ) , the peptic nucleic acid locked nucleic acid ( PNA-LNA ) polymerase chain reaction ( PCR ) clamp method was adopted , using protocols described previously . The EGFR @VARIANT$ mutation was examined in cell-free DNA obtained from plasma of the patients , since no biopsy specimens for DNA analysis could be obtained because of difficult accessibility of tumors during or after EGFR-TKI-treatment .", "label": "resistance or non-response"}
{"id": "21042543", "sentence": "The only B-RAF mutation found was the @VARIANT$ substitution . The most important thing was that patients who received panitumumab or @DRUG$ but had @GENE$ alteration , presented no objective response to therapy ; consequently TTP was worse for subjects bearing a mutated B-RAF although not statistically significant probably due to the limited number of tumors carrying these mutations .", "label": "resistance or non-response"}
{"id": "23139670", "sentence": "Of note , according to our case , CBDCA + pemetrexed + bevacizumab and its maintenance chemotherapy is feasible and well tolerated for solitary breast metastasis from a lung adenocarcinoma which is resistant to @DRUG$ and possesses the secondary @VARIANT$ mutation in the @GENE$ gene .", "label": "resistance or non-response"}
{"id": "23555954", "sentence": "The cell line H1975 has a sensitizing @VARIANT$ kinase domain mutation in exon 21 , but also a second mutation ( T790M , in cis , in the kinase domain ) rendering them resistant to the reversible TKIs @DRUG$ and erlotinib . miR-146a was expressed in all the five cell lines studied , with the similar magnitude , independent of the genomic status of the @GENE$ .", "label": "sensitivity"}
{"id": "24939055", "sentence": "Although irreversible @GENE$ , including BIBW2992 , have been developed to overcome @VARIANT$ mediated resistance to gefitinib [ ] , recent clinical trials have failed to show that monotherapy with irreversible EGFR-TKIs has benefits in patients with NSCLC refractory to @DRUG$ [ ] .", "label": "resistance or non-response"}
{"id": "25105411", "sentence": "The human lung adenocarcinoma cell lines , A549 ( @GENE$ wild type ) , H1975 ( EGFR L858R/T790M , gefitinib-resistant ) , H1299 ( EGFR wild type , p53 null ) , and H3255 ( EGFR @VARIANT$ ) were purchased from American Type Culture Collection ( ATCC ; Manassas , VA , USA ) .", "label": "sensitivity"}
{"id": "25295230", "sentence": "@VARIANT$ AML PKC412 Heidel et al. ( ) 32D F691L AML @DRUG$ Smith et al. ( ) Ba/F3 AML AC220 Albers et al. ( ) @GENE$ AML ( pediatric ) Sorafenib Baker et al. ( )", "label": "None"}
{"id": "24724051", "sentence": "Irrespective of its potential use in TKI-naïve CML and Ph+ ALL patients , the impressive activity against the @VARIANT$ @GENE$ will likely make @DRUG$ a crucial second line agent for patients with this mutation .", "label": "response"}
{"id": "16255777", "sentence": "This drug was designed as a specific inhibitor of the BCR-ABL oncogene @GENE$ known to be responsible for chronic myeloid leukemia ( CML ) cells [ ] . The therapeutic effectiveness of @DRUG$ and relative absence of detrimental side-effects has made it a model for the development of an array of new therapeutic agents targeted to inhibit signal transduction enzymes , especially protein kinases . The recent discovery that 60–70 % of human melanomas have activating mutations in B-Raf ( with 80 % of these mutations caused by a single substitution @VARIANT$ ) make this protein kinase an especially promising target for inhibition [ , ] .", "label": "None"}
{"id": "24009732", "sentence": "@VARIANT$ FIP1L1-PDGFRα , analogous to T315I Bcr-Abl in CML , is also resistant to the second-generation TKIs , such as @DRUG$ . Novel agents for imatinib-resistant @GENE$ are needed .", "label": "None"}
{"id": "23992330", "sentence": "Very recently , sophisticated GEMM models of lung cancer were used to evaluate responsiveness to combined therapy of @DRUG$ and the MEK inhibitor selumetinib ( AZD6244 ) , according to a co-clinical trial effort [ ] . Co-clinical trials aim to anticipate , in suitable GEMMs , the results of concomitant human clinical trials , as well as to provide a rationale in the elaboration of clinically relevant hypotheses , useful for design of corresponding studies in human cancer [ , ] . In this model , the @GENE$ @VARIANT$ activating mutation was associated either to TP53 or LKB1 loss in lung epithelium , to parallel selected human NSCLC cases harboring both oncogene activation ( KRAS ) and oncosuppressor ( TP53 or LKB1 ) loss .", "label": "None"}
{"id": "15737014", "sentence": "Analogously , the @VARIANT$ mutation , in conjunction with the drug-responsive del L747–E749 ; A750P EGFR mutant , prevents inhibition of p-EGFR by erlotinib ( C ) . Sensitivity to @DRUG$ Differs Among NSCLC Cell Lines Containing Various Mutations in EGFR or @GENE$", "label": "None"}
{"id": "24276379", "sentence": "It has even been observed that cells that have been induced to become cetuximab-resistant by continuously exposing them to cetuximab have acquired either K-Ras G12V or @GENE$ @VARIANT$ mutations [ ] .", "label": "resistance or non-response"}
{"id": "22124674", "sentence": "Wild-type patients do not seem to benefit from adjuvant imatinib [ ] ; however , in vivo studies evaluating @DRUG$ [ ] and in vitro studies for nilotinib and dasatinib [ ] are promising . As for @GENE$ mutated GIST , PDGFRA exon 18 generally benefits from adjuvant imatinib therapy , with the exception of PDGFRA exon 18 @VARIANT$ mutated GIST [ ] .", "label": "None"}
{"id": "24348666", "sentence": "Although the resistant cell line HCG827GR does not have the EGFR @VARIANT$ mutation , it was found to have MET amplification . MET is a receptor tyrosine kinase that binds to hepatocyte growth factor (HGF) and is associated with the development of various human cancers . Therefore , @GENE$ fail to inhibit the PI3K/Akt pathway dependent growth signal because the constitutive phosphorylation of HER3 by MET occurs independent of EGFR activation , which causes the cells to acquire resistance to @DRUG$ .", "label": "resistance or non-response"}
{"id": "19707322", "sentence": "The sensitivity of @GENE$ mutants to @DRUG$ can be summarized into 4 categories : high ( IC50 ≤ 70 nmol/L : M244V , G250E , Q252H , F3llL , F317L , M351T , V379I , L387M , H396P , @VARIANT$ ) , medium ( IC50 ≤ 200 nmol/L : Y253F , E255K , F359V ) , low ( IC50 ≤ 450 nmol/L : Y253H , E255V ) , and insensitive ( IC50 & gt ; 2 μmol/L : T315I ) ( ) ( ) .", "label": "None"}
{"id": "24634705", "sentence": "The L747S mutation lies at the start of the β3 strand and the α-C-helix [ ] and has analogous residues in BCR-ABL ( L237M ) and @GENE$ ( @VARIANT$ or P ) that have been identified in TKI resistant disease [ ] . The occurrence of these secondary mutations spurred development of second and third generation irreversible TKIs which bind covalently to the cysteinyl-797 residue in the pocket of the EGFR-kinase domain and overcome resistance driven by the T790M mutation [ ] . These agents show greater potency in the inhibition of kinase activity in vitro and in vivo compared to @DRUG$ and are in various stages of clinical testing [ , ] .", "label": "None"}
{"id": "22997594", "sentence": "@DRUG$ demonstrates significant inhibitory activity against WT KIT as well as juxtamembrane domain mutant @GENE$ [ , ] . This activity has been proven in patients negative for @VARIANT$ KIT [ ] .", "label": "response"}
{"id": "24982846", "sentence": "@DRUG$ BCR/ABL1 Philadelphia chromosome [ t ( 9 ; 22 ) ] positive , @GENE$ @VARIANT$ mutation Indications and usage , warnings and precautions , adverse reactions , use in specific populations , clinical pharmacology , clinical studies", "label": "None"}
{"id": "24497964", "sentence": "To examine whether IgG titers against each of the 60 different peptides were associated with @GENE$ mutation status , their median values were compared among patients with EGFR mutations ( delE746-A750 and @VARIANT$ ) and the wild-type EGFR using the Wilcoxon rank-sum test . PFS was calculated from the date of initiation of @DRUG$ treatment until either the date of disease progression or the date of last contact .", "label": "sensitivity"}
{"id": "24369725", "sentence": "In agreement with these findings , we also observed that patients with secondary @VARIANT$ mutation showed significantly longer progression-free survival ( p = 0.009 ) . Recently , we demonstrated that increased AXL expression could contribute to erlotinib-resistance in both cell lines and an animal model . Altered AXL related signaling was also observed in approximately 20 % of patients with acquired resistance to @GENE$ , although it remains to be determined whether these patients could benefit from AXL inhibition [ ] .", "label": "resistance or non-response"}
{"id": "25170609", "sentence": "Since no significant changes in growth inhibition with concurrent inhibitors treatment were observed in MDA-MB-231 cells ( ) , drug effects on the activity of @GENE$ and PI3K signaling pathways were assessed in the remaining three cell lines : MCF-7 , T47D and SKBr3 ( ) . @DRUG$ ( 1 nM ) with or without trametinib was observed to up-regulate p-AKT and markedly reduce p-rpS6 in MCF-7 and SKBr3 cells ( ) , and reduce p-p70S6K in MCF-7 cells ( ) . For NVP-BEZ235 , increased p-AKT was observed in SKBr3 cells alone or in combination with trametinib , while GSK2126458 , with or without trametinib , reduced p-AKT in the @VARIANT$ and SKBr3 cell lines .", "label": "None"}
{"id": "24742823", "sentence": "Of note , responding patients had a @GENE$ ratio of more than 5 and both of our MET amplified patients treated with a c-MET inhibitor had a ratio inferior to this . Interestingly , a recent series showed that the level of HER-2 amplification predicted sensitivity to trastuzumab. [ ] In this study , a ratio of 4.7 was discriminative of sensitive patients , which suggests that a similar relation can be explored for MET amplification and sensitivity to c-MET inhibitors . Additionally , one of the patients receiving a c-MET inhibitor in our series had a @VARIANT$ MET variant .", "label": "None"}
{"id": "24244612", "sentence": "Mutation analysis of leukemic cells prior to and during culture demonstrated the presence of the BCR-ABL TKD gatekeeper mutation @VARIANT$ . As expected , KÖ cells were unresponsive to imatinib , @DRUG$ and nilotinib when used at clinically achievable concentrations , known to inhibit proliferation and induce cell death in non-resistant @GENE$ cells .", "label": "None"}
{"id": "24523812", "sentence": "The eligible 10 patients had stage IV NSCLC and were treated with gefitinib or @DRUG$ monotherapy for more than 6 months . They had achieved radiographic response before EGFR-TKI failure or documentation of either EGFR exon 19 deletion or an @GENE$ @VARIANT$ mutation .", "label": "sensitivity"}
{"id": "16187797", "sentence": "Transformation by cells expressing the @VARIANT$ @GENE$ was inhibited by 0.1 μM gefitinib or @DRUG$ , whereas transformation by cells expressing the insertion mutant was resistant to low concentrations of these inhibitors .", "label": "sensitivity"}
{"id": "22970367", "sentence": "The data suggest that low BRCA1 level may neutralize the negative effects of the @GENE$ T790M mutation on @DRUG$ sensitivity and that high BRCA1 expression may lead to de novo EGFR TKI resistance potentially through increased DNA damage repair capacity [ ] . In addition to EGFR T790M , primary EGFR TKI resistance may also be due to other secondary mutations in EGFR ( e.g. , @VARIANT$ ) that occur in cis with an activating EGFR kinase domain mutation ( e.g. , L858R ) [ ] .", "label": "None"}
{"id": "17973572", "sentence": "The activation loop is orange , helix αC yellow , the glycine-rich P-loop green , and the inhibitor @DRUG$ yellow . The figure was made using the program PYMOL ( http : //pymol.sourceforge.net/ ) . ( D ) Top : Dose dependent growth inhibition of Ba/F3 cells expressing EGFR @VARIANT$ @GENE$ (LR-TM) , or L858R-L747S ( LR-LS ) detected by the MTS assay .", "label": "None"}
{"id": "17177598", "sentence": "However , @DRUG$ did induce dose dependent cell death in @GENE$ subclones expressing the EGFR ectodomain mutants ( missense and vIII truncation ) or EGFR kinase domain mutants ( @VARIANT$ and L861Q ) ( A ) .", "label": "None"}
{"id": "24392141", "sentence": "In this work we designed , expressed and purified the intra-melanosomal domain of human tyrosinase , hTyrCtr , and two temperature-sensitive mutants , R422Q and @VARIANT$ , found in some patients with @GENE$ . The recombinant proteins were modified by removing the C-terminal trans-membrane domain to avoid potential protein insolubility but retain all other functional features of the enzyme which reside in the remaining N-terminal sequence . Recombinant proteins ( as hexa-histidine fusions ) were produced in whole insect T. ni and purified by IMAC and SEC as active enzymes .", "label": "None"}
{"id": "19384426", "sentence": "Another study demonstrated that Akt is activated in AML blasts and that p70 ( @VARIANT$ ) and 4EBP-1 , downstream mediators of Akt signaling , also are phosphorylated in AML blasts [ ] . In a short-term culture system , most AML patient samples showed a dose dependent decrease in survival after incubation with LY294002 [ ] . Incubation of AML blasts with @DRUG$ induced only a small decrease in survival of the cells [ ] .", "label": "None"}
{"id": "25146448", "sentence": "MTNR1B , located on human chromosome 11q21–22 , is a member of the @GENE$ , and one of the functional and high-affinity @DRUG$ membrane receptors . MTNR1B is expressed in human and rodent pancreatic islets . Studies have shown that MTNR1B is a novel candidate gene for @VARIANT$ .", "label": "None"}
{"id": "22252115", "sentence": "Adenocarcinoma of esophagogastric junction rarely presents @GENE$ mutation , especially @DRUG$ associated mutations such as @VARIANT$ , or delE746-A750 .", "label": "sensitivity"}
{"id": "24594844", "sentence": "Moreover , the cleaved form of @GENE$ was elevated in H1975TM/LR cells , indicating that chol-TEG modification did not alter the ability of DzT to specifically trigger apoptosis in EGFR T790M mutant cells . Besides , after EGF treatment , cDzT remained its suppression effect on EGFR protein expression and downstream signaling including EGFR , STAT3 , AKT , and ERK ( Supplementary Figure S5 ) . Synergistic antitumor effect of combined treatment with cDzT and @DRUG$ in vitro and in vivo cDzT could be used as single agent or as part of combination therapy with second generation TKIs to increase efficacy in the treatment of NSCLCs that harbor the EGFR @VARIANT$ mutant .", "label": "None"}
{"id": "24103790", "sentence": "Chen et al. have reported that ABCC10 transports leukotriene C4 , but not glycocholic acid , taurocholic acid , @DRUG$ , folic acid , cyclic adenosine monophosphate , or cyclic guanosine monophosphate , which are substrates for other MRP family members . However , the transport of estradiol-17β-D-glucuronide ( E217βG ) , a glucuronide conjugate and the only physical element other than leukotriene C4 to be transported by ABCC10 , is competitively inhibited by amphiphiles , such as leukotriene C4 , glycolithocholate 3-sulfate , and MK571 , as well as lipophilic compounds , such as cyclosporine A . The transfection of @GENE$ cells with the ABCC10 gene confers resistance to various chemotherapeutic drugs , including docetaxel , paclitaxel , vincristine , vinblastine , cytarabine , gemcitabine , 2′,3′-dideoxycytidine , 9- ( 2-phosphonyl methoxyethyl ) adenine ( PMEA ) , and epothilone B , .", "label": "None"}
{"id": "24675568", "sentence": "Kim et al. demonstrated a role for the IL-6R/JAK1/STAT3 signaling pathway , leading to STAT3 activation , in de novo resistance to irreversible @GENE$ , such as @DRUG$ , in NSCLC cells with EGFR @VARIANT$ [ ] .", "label": "response"}
{"id": "24832599", "sentence": "In spite of recent improvements in NSCLC management , such as the use of targeted therapy including gefitinib and @DRUG$ , which have led to improved progression-free survival and quality of life in NSCLC patients with an activating @GENE$ mutation , progression or metastasis because of resistance to targeted therapy remains a major clinical problem . Apart from @VARIANT$ and c-MET amplification , a recent study has reported that Axl kinase is upregulated in humans with acquired resistance to EGFR-TKI .", "label": "resistance or non-response"}
{"id": "15737014", "sentence": "Sequencing Chromatograms with the @VARIANT$ @GENE$ Exon 20 Mutation in Various Clinical Specimens and the NSCLC Cell Line H1975 ( A–C ) In all three patients—patient 1 ( A ) , patient 2 ( B ) , and patient 3 ( C ) —the secondary T790M mutation was observed only in lesions obtained after progression on either gefitinib or @DRUG$ .", "label": "resistance or non-response"}
{"id": "25580268", "sentence": "An ongoing phase II study of the combination of dabrafenib with SRS in @GENE$ @VARIANT$ melanoma brain metastases uses this strategy ( NCT01721603 ) . An institutional trial using lapatanib/capecitabine or trastuzumab-emtansine ( TDM-1 ) in HER 2+ breast cancer patients with one to 10 brain metastases treated with radiosurgery is in development ( Minesh Mehta and colleagues , personal communication ) .", "label": "sensitivity"}
{"id": "25309870", "sentence": "While the majority of patient tumors harbored common @GENE$ mutations ( Del-19 and Point 21 @VARIANT$ ) , approximately 10 % of patients had uncommon EGFR mutations . The primary endpoint of this trial was progression-free survival and secondary endpoints included overall survival , objective response rate , and quality of life . @DRUG$ treatment led to an increase in the objective response rate compared with chemotherapy treatment ( 56.1 vs. 22.6 % ) .", "label": "sensitivity"}
{"id": "23320171", "sentence": "Further research is looking into inhibiting other targets such as mTOR , @VARIANT$ , or @GENE$ pathways . Two randomized trials are evaluating the addition of the mTOR inhibitor , everolimus , to chemotherapy and @DRUG$ in the first-line and Trastuzumab-resistance metastatic setting .", "label": "None"}
{"id": "23986642", "sentence": "@DRUG$ inhibited native @GENE$ with an IC50 of 0.37 nM and clinically relevant BCR-ABL mutations @VARIANT$ , G252H , T253P , M351T , and H396A with IC50 values of 2.0 nM , 0.44 nM , 0.30 nM , 0.30 nM , and 0.35 nM , respectively .", "label": "response"}
{"id": "25033171", "sentence": "By using the combination of US , ABF , and Roux 's absolute binding free energy calculation scheme , we accurately characterized the one-dimensional ( 1D ) free energy profile of @DRUG$ separated from the binding sites of the WT and @VARIANT$ mutated @GENE$ to the bulk .", "label": "resistance"}
{"id": "22928112", "sentence": "A similar “gatekeeper” mutation ( T315I ) in the @GENE$ fusion kinase in chronic myelogenous leukemia cancer cells renders these leukemias resistant to the ABL kinase inhibitors gleevec and @DRUG$ , suggesting a conserved mechanism of resistance to TKIs [ ] . However , the T790 M mutation may also occur prior to treatment with erlotinib or gefitinib and therefore , may contribute to primary resistance [ ] . Several other EGFR mutations can also confer resistance to first generation TKIs such as @VARIANT$ and T854A [ , ] .", "label": "None"}
{"id": "20942962", "sentence": "Of the 8 mutations in the TK domain , 7 were novel ( W731L , E734Q , T785A , C797Y , Y801H , @VARIANT$ and E868G ) ( Figure ) . One of the mutations ( L858R ) was previously identified in non-small cell lung cancer ( NSCLC ) patients and this mutation was found to increase sensitivity to @GENE$ inhibitor , @DRUG$ .", "label": "None"}
{"id": "19920910", "sentence": "In a cell-line based mutagenesis study , the emergence of @GENE$ mutations resistant to imatinib , nilotinib and @DRUG$ were compared : 20 different mutations were identified with imatinib mesylate , 10 with nilotinib ( including only 1 novel mutation , E292V ) and 9 with dasatinib . In contrast to imatinib mesylate , mutations recovered in the presence of 50 nM nilotinib were limited to @VARIANT$ , G250E , Y253H , E255K ( p-loop ) , T315I , F359C , L384M and L387F .", "label": "None"}
{"id": "15737014", "sentence": "EGFR Mutants Containing the T790M Mutation Are Resistant to Inhibition by @DRUG$ or Erlotinib 293T cells were transiently transfected with plasmids encoding wild-type ( WT ) @GENE$ or EGFR mutants with the following changes : T790M , @VARIANT$ , L858R + T790M , del L747–E749 ; A750P , or del L747–E749 ; A750P + T790M .", "label": "sensitivity"}
{"id": "24501009", "sentence": "Strategies to improve EGFR inhibition in EGFR @VARIANT$ cancers include the combination of irreversible EGFR inhibitors with the EGFR‐directed antibody cetuximab ( as reported for afatinib plus @DRUG$ ) 19 ; the development of more potent and specific inhibitors of EGFR T790M20,21 ; and the use of intermittent but high doses of existing irreversible @GENE$ inhibitors .", "label": "response"}
{"id": "23515752", "sentence": "H1975 cells ( @VARIANT$ ) were treated with 17-DMAG ( 50 nM ) and @DRUG$ ( 500 nM ) for 24 h. Cells were harvested , lysates made , subjected to Western blotting and probed with antibody against @GENE$ ( Ser473 ) , pan-Akt and GAPDH ( loading control ) ( B ) .", "label": "None"}
{"id": "25465236", "sentence": "The subsequent decrease in potency for @DRUG$ against the oncogenic @GENE$ @VARIANT$ + E884K double mutant correlates well with the increased global connectivity of the hub residues ( – wild type , – L858R + E884K mutant ) .", "label": "sensitivity"}
{"id": "25505694", "sentence": "The firstly described and the most common event responsible for resistance is the acquisition of the @VARIANT$ missense mutation , which is found in ≈ 50 % of patients progressing after an initial response to erlotinib or @DRUG$ [ , ] . Other less frequent mechanisms include secondary mutations within EGFR [ , ] , @GENE$ amplification [ ] , HER2 amplification [ , ] , small cell histologic transformation [ ] .", "label": "None"}
{"id": "23992330", "sentence": "In fact , while cells knocked-in for the PIK3-CA alleles @VARIANT$ and E545K showed an increased response to @DRUG$ , oncogenic @GENE$ mutations conferred resistance to this agents [ ] .", "label": "None"}
{"id": "25033171", "sentence": "Energetic spectrums ( enthalpy ) were decomposed into drug-residue pairs for ( A ) wild-type @GENE$ , and ( B ) @VARIANT$ mutated ROS1 , and their corresponding structural descriptions are shown in panel D and panel E , where the P-loop region and important residues on it ( Leu18 and Val26 ) are illustrated in orange cartoon model and stick model , respectively . The mutated residue and @DRUG$ are modeled in green stick model ( Gly99 in panel D and Arg99 in panel E ) and pink stick model , respectively .", "label": "resistance"}
{"id": "19774209", "sentence": "They have been shown to successfully inhibit EGFR bearing the @VARIANT$ mutation in vitro . Conclusions @DRUG$ is the only @GENE$ targeted therapy currently approved by the FDA for use ( in combination with gemcitabine ) in the management of advanced pancreatic cancer .", "label": "resistance or non-response"}
{"id": "25379782", "sentence": "The probable substitutions showed the 20 most likely amino acids to be replaced in G. mellonella : E2D , V11I/V11T , T22A/T22V , I23L , E28D , T37N , R43K , Q44K/Q44R , D45E , N48G/N48E/N48D , F49Y , V50N , K65S , @VARIANT$ , T90I , A98P/A98Q/A98D , L101S , V106I , A120T , and V131A . We also hypothesized a tertiary structure using the EHJ79039.1 cellular retinoic acid binding protein from D. plexippus on Phyre server as a pattern . The 3D alignment between the hypothetical structure ( orange ) and 2CBR ( cellular @DRUG$ proteinein Data Bank , in blue with ATP ) Prot ( 136 AA ) from Bos taurus was made using the Phyre server and visualized with UCSF Chimera version 1.8 .", "label": "None"}
{"id": "23717811", "sentence": "It is hypothesized that signaling through redundant pathways involving the PI3-kinase (PI3K)/mammalian target of rapamycin (mTOR) , VEGF , @GENE$ , and EGFR pathways contributes to such drug resistance ( Jang and Atkins , ) . For example , colon cancers with BRAF V600E mutations do not respond to vemurafenib due to feedback activation of EGFR . Therefore , in pre-clinical studies , vemurafenib is strongly synergistic with EFGR inhibitors like @DRUG$ for colon cancers expressing BRAF @VARIANT$ mutations ( Prahallad et al. , ) .", "label": "None"}
{"id": "22098950", "sentence": "The results indicated that relative to wild-type BCRP expressing cells , the IC50 value of SN38 against @VARIANT$ expressing Flp-ln-293 cells was reduced approximately 50 % , but it was not reduced in V12M expressing cells . Interestingly , the IC50 values of SN38 , mitoxantrone , @DRUG$ , daunorubicin , and etoposide for Flp-ln-293 cells expressing other variants were significantly lower than those for cells expressing wild-type @GENE$ .", "label": "None"}
{"id": "21034468", "sentence": "More specific antioxidants , @GENE$ ( for superoxide ) plus catalase ( for hydrogen peroxide ) fail to inhibit @DRUG$ stimulated invasion and ErbB2 phosphorylation . These data suggest that although the antioxidant property may be involved , @VARIANT$ may also act through other mechanisms to regulate ErbB2 signaling and subsequent migration/invasion .", "label": "None"}
{"id": "25536104", "sentence": "In our cases with ERBB2 mutation , IHC expression of ERBB2 was not detectable in our study ; one of the ERBB2 mutations was in the kinase domain ( V777L ) while 3 involved the extracellular domain ( @VARIANT$ ) . Based on the current knowledge of @GENE$ biology , @DRUG$ or lapatinib therapy may be value in the extracellular domain mutations but could be of limited clinical benefit for kinase domain mutations and no response to either agents was noted in our cases .", "label": "sensitivity"}
{"id": "25580271", "sentence": "There are several promising agents for patients with activating EGFR mutations who experience disease progression of an EGFR tyrosine kinase inhibitor and have a @VARIANT$ resistance mutation , and multiple clinical trials will be available . Trials investigating adjuvant erlotinib in EGFR mutant NSCLC and comparing @DRUG$ to erlotinib plus bevacizumab in metastatic EGFR mutant NSCLC are ongoing . Crizotinib , when compared to platinum pemetrexed , results in a superior ORR and progression-free survival in patients with @GENE$ rearranged NSCLC , and ceritinib is a second-line option for this patient population , but patients need to be monitored closely for adverse events and the need for dose reductions .", "label": "None"}
{"id": "22809298", "sentence": "However , one patient with a @VARIANT$ mutation in exon 21 practically achieved a PR . The other with a G719S mutation in exon 18 succeeded in maintaining a long SD , which was also practically beneficial , considering that in patients with the G719X mutation the reported RR to EGFR-TKIs was approximately 56 % [ ] . Collectively , the @DRUG$ and pemetrexed combination is not only well tolerated , but also attractive in terms of antitumor efficacy , regardless of @GENE$ mutation status .", "label": "sensitivity"}
{"id": "22655263", "sentence": "Additionally , AP26113 was evaluated on the @DRUG$ resistant gatekeeper mutant @VARIANT$ both in vitro and in vivo and appeared to be able to overcome resistance to crizotinib . Ki determination demonstrated a very similar biochemical potency on wild-type ALK and the L1196M ALK mutant ( 0.09 and 0.08 nM respectively ) , with both cellular and in vivo data ( using engineered Ba/F3 cells ) indicating that growth of ALK–L1196M mutant driven-cells is inhibited at similar , albeit slightly higher , doses which inhibit cells harboring wild-type @GENE$ ( Katayama et al. , ) .", "label": "resistance"}
{"id": "24422746", "sentence": "Furthermore , EGFR mutations in PSCCE are rare but do exist , especially @DRUG$ associated mutations such as @VARIANT$ , therefore gefitinib based gene targeted therapy at @GENE$ but not KRAS and PIK3CA genes , probably should be included in this carcinoma treatment regimens for patients harboring L858R mutation .", "label": "sensitivity"}
{"id": "24375389", "sentence": "Other examples of useful biomarkers are KRAS mutation testing to predict benefit from monoclonal antibodies against EGFR , cetuximab and @DRUG$ , in metastatic colon cancer [ ] and BRAF @VARIANT$ mutation analysis in metastatic melanoma in order to predict responsiveness to @GENE$ inhibitors such as vemurafenib [ ] .", "label": "resistance or non-response"}
{"id": "23493883", "sentence": "Many drugs have been studied in patients who progressed after treatment with a reversible @GENE$ , including XL-647 , dasatinib , and neratinib , with little success . Combinations of therapy such as cetuximab plus erlotinib and @DRUG$ plus everolimus have also been tried . The most promising drug thus far has been afatinib ( BIBW2992 ; Boehringer-Ingelheim Pharma , Ingelheim , Germany ) , , an ErbB family blocker with reported in vitro and in vivo activity against EGFR mutant tumors harboring exon 19 deletions , exon 21 @VARIANT$ mutations and the exon 20 T790M “resistance” mutations .", "label": "sensitivity"}
{"id": "25382104", "sentence": "@DRUG$ is the only available drug that is designed to overcome @VARIANT$ gatekeeper mutation and is efficient in inhibiting the mutant @GENE$ Ponatinib exhibits triple carbon-carbon ( ethynyl linkage ) bond between the methyl phenyl and purine groups .", "label": "response"}
{"id": "17927446", "sentence": "In Vivo Correlation of BIM/Bim Expression and Mutant @GENE$ Activity ( A and B ) Lung tumor bearing mice that express a tetracycline-inducible @VARIANT$ mutant ( EGFRL858R ) ( A ) or an exon 19 deletion mutant ( EGFRΔL747–S752 ) ( B ) were treated with a single dose of either vehicle control or 50 mg/kg @DRUG$ intraperitoneally .", "label": "sensitivity"}
{"id": "23238683", "sentence": "In addition , we used the murine BaF3 cell line carrying either a wild-type @GENE$ protein or its @VARIANT$ and G250E mutated counterparts to decipher the mechanisms of action of this TKI . We show that @DRUG$ is highly efficient to induce cell growth inhibition and induction of apoptosis on different imatinib CML cell lines , whatever their mode of resistance .", "label": "response"}
{"id": "18937829", "sentence": "Control patients 18 f 72 Rectum 5FU 1 1 0 - 20 0 19 f 54 Gastric 5FU-FA-P 2 1 0 c.1679T & gt ; G , I560S_21 0 20 m 59 Pancreas 5FU-FA-P 0 1 0 c.85T & gt ; C , C29R ; c.1627A&gt ; G , @VARIANT$ ( H ) 20 0 21 m 62 Colon 5FU-FA-P 0 1 0 c.85T & gt ; C , C29R ( H ) ; c.496A&gt ; G , M166V , c.1236G&gt;A , E412E 19 0 22 f 64 Colon 5FU-FA 0 0 0 c.85T & gt ; C , C29R ; c.1627A&gt ; G , I543V 20 0 23 m 63 Oesophagus 5FU-P_1 0 0 - 20 0 24 f 69 Colon 5FU-FA 0 1 0 c.85T & gt ; C , C29R ( H ) ; c.496A&gt ; G , M166V ; c.2194G&gt;A , V732I 20 0 25 m 59 Gastric 5FU-FA_1 1 0 c.85T & gt ; C , C29R ; c.1627A&gt ; G , I543V ; 1896T & gt ; C , F632F 21 0 26 m 59 Colon 5FU-FA-P 1 1 0 c.85T & gt ; C , C29R ( H ) ; @GENE$ ; G , M166V ; c.1627A&gt ; G , I543V 20 0 27 m 62 Gastric E-CAPE-P_2_1 2 c.85T & gt ; C , C29R ( H ) ; c.496A&gt ; G , M166V ; c.1236G&gt;A , E412E c.1627A&gt ; G , I543V 30 0 Abbreviations : FA , @DRUG$ CAPE , capecitabine ; P , platinum compound ; E , epirubicin ; C , cyclophosphamide ; H , homozygous carrier a adenocarcinoma of unknown origin", "label": "None"}
{"id": "24944510", "sentence": "Multiple secondary mutations have already been identified in patients treated with @DRUG$ . Homologous to the gatekeeper EGFR T790M mutation is the @VARIANT$ substitution , which , unlike EGFR T790M , does not appear to confer a growth disadvantage to cells . Other secondary mutations such as G1269A , C1156Y , L1152R , and 1151Tins may affect affinity of the mutant ALK for either ATP or drug , and these differences have ramifications on the development of next-generation @GENE$ inhibitors , which have varied mutation-specific efficacy among different agents .", "label": "resistance"}
{"id": "15696205", "sentence": "In gefitinib treated patients , six EGFR mutations involved exon 19 deletions that lacked the amino acids @GENE$ , and two were exon 21 amino acid substitutions ( @VARIANT$ ) . A seventh case with an exon 19 deletion ( involving 12 nucleotides ) was detected by fluorescent capillary electrophoresis only , so exact sequence deletion information was unavailable ( see Methods ) . KRAS Exon 2 Mutations Found in Non-Small-Cell Lung Cancers Refractory to Treatment with Gefitinib or @DRUG$ a Bold indicates mutations", "label": "None"}
{"id": "18937829", "sentence": "Control patients 18 f 72 Rectum 5FU 1 1 0 - 20 0 19 f 54 Gastric @GENE$ 2 1 0 c.1679T & gt ; G , I560S_21 0 20 m 59 Pancreas 5FU-FA-P 0 1 0 c.85T & gt ; C , C29R ; c.1627A&gt ; G , @VARIANT$ ( H ) 20 0 21 m 62 Colon 5FU-FA-P 0 1 0 c.85T & gt ; C , C29R ( H ) ; c.496A&gt ; G , M166V , c.1236G&gt;A , E412E 19 0 22 f 64 Colon 5FU-FA 0 0 0 c.85T & gt ; C , C29R ; c.1627A&gt ; G , I543V 20 0 23 m 63 Oesophagus 5FU-P_1 0 0 - 20 0 24 f 69 Colon 5FU-FA 0 1 0 c.85T & gt ; C , C29R ( H ) ; c.496A&gt ; G , M166V ; c.2194G&gt;A , V732I 20 0 25 m 59 Gastric 5FU-FA_1 1 0 c.85T & gt ; C , C29R ; c.1627A&gt ; G , I543V ; 1896T & gt ; C , F632F 21 0 26 m 59 Colon 5FU-FA-P 1 1 0 c.85T & gt ; C , C29R ( H ) ; c.496A&gt ; G , M166V ; c.1627A&gt ; G , I543V 20 0 27 m 62 Gastric E-CAPE-P_2_1 2 c.85T & gt ; C , C29R ( H ) ; c.496A&gt ; G , M166V ; c.1236G&gt;A , E412E c.1627A&gt ; G , I543V 30 0 Abbreviations : FA , folinic acid ; CAPE , capecitabine ; P , platinum compound ; E , epirubicin ; C , @DRUG$ ; H , homozygous carrier a adenocarcinoma of unknown origin", "label": "None"}
{"id": "22613958", "sentence": "More than 90 % of these mutations are observed in two hotspots : in-frame deletions including amino acids at codons 747 to 749 in exon 19 , and an amino acid substitution at codon 858 ( @VARIANT$ ) in exon 21 [ - ] . These mutations are postulated to mediate oncogenic effects by altering downstream signaling and anti-apoptotic mechanisms [ - ] . Prior trials confirmed that the response rate to EGFR-TKI in NSCLC patients with EGFR mutations is approximately 70–80 % [ , , ] , and results of recent phase III trials showed that the oral @GENE$ @DRUG$ has a superior progression-free survival ( PFS ) to standard chemotherapy as the first-line therapy for NSCLC with mutated EGFR [ , ] .", "label": "sensitivity"}
{"id": "PMC3991357", "sentence": "@GENE$ kinase inhibitors ( EGFR-TKIs ) , such as gefitinib and @DRUG$ , have achieved high clinical response rates in patients with non-small cell lung cancers ( NSCLCs ) , which possess somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene . However , over time ( median of 6-12 months ) , most tumors are known to develop acquired resistance to EGFR TKIs . Currently , there have been no effective treatment options against NSCLC patients with the secondary @VARIANT$ resistance mutation , which occurs in 50 % of patients with acquired resistance to EGFR-TKIs .", "label": "resistance or non-response"}
{"id": "24244732", "sentence": "Applying the same logic of @VARIANT$ and syntaxin , this would imply that increased @DRUG$ sensitivity of the E465K mutation would be a consequence of increased @GENE$ binding .", "label": "None"}
{"id": "20098423", "sentence": "( b ) ChIP for RNAPII , S5P and @VARIANT$ at the EGR1 and EGR2 loci following serum stimulation with or without @DRUG$ ( 150 nM ) pre-treatment . Average data from at least three independent experiments is represented . P-TEFb associates with @GENE$ ( a ) Silver stain of CDK8 and MED1 immunoprecipitates ( IPs ) .", "label": "None"}
{"id": "15737014", "sentence": "To determine whether the 2369 C→T mutation was a previously overlooked @GENE$ mutation found in NSCLCs , we re-reviewed exon 20 sequence tracings derived from analysis of 96 fresh-frozen resected tumors [ ] and 59 paraffin embedded tumors [ ] , all of which were removed from patients prior to treatment with an EGFR tyrosine kinase inhibitor . We did not detect any evidence of the T790M mutation in these 155 tumors ( data not shown ; see ) . Collectively , our results suggest that the @VARIANT$ mutation is associated with lesions that progress while on gefitinib or @DRUG$ .", "label": "resistance or non-response"}
{"id": "23493804", "sentence": "Differences have been reported between a T790M mutation that emerges after @GENE$ treatment and pretreatment T790M , suggesting that they are genetically distinct diseases . In the @DRUG$ Pan-Asia Study ( IPASS ) study , eleven treatment-naïve patients had an exon 20 T790M mutation : four had coexisting exon 19 deletions and three had coexisting @VARIANT$ mutations .", "label": "sensitivity"}
{"id": "24236082", "sentence": "The @VARIANT$ mutant was 10–100 fold more sensitive to @DRUG$ and gefitinib than the wild type kinase , . These basic researches , randomized controlled clinical trials – and meta-analyses , thoroughly demonstrated the better treatment outcomes of the @GENE$ in mutation positive patients .", "label": "sensitivity"}
{"id": "24294007", "sentence": "However these studies were small , with only 32 and 83 patients , respectively , with the @VARIANT$ mutation . On the other hand , a number of studies have demonstrated no benefit for either @DRUG$ or panitumumab by specific @GENE$ mutations .", "label": "resistance or non-response"}
{"id": "25221748", "sentence": "In the advanced NSCLC @GENE$ resistant setting , the HSP90 small molecule inhibitor AUY922 is being evaluated as monotherapy in a phase II clinical trial vs. pemetrexed or @DRUG$ in patients with tumors with activating EGFR mutations ( www.clinicaltrials.gov : NCT016461250 ) . This agent is also being assessed in a phase II trial in patients with de novo resistant @VARIANT$ mutations not previously treated with EGFR-TKIs ( www.clinicaltrials.gov : NCT01854034 ) and in patients with EGFR mutations and/or EGFR-TKI resistant disease , as part of a phase II cluster study in Chinese patients evaluating five novel inhibitors of HSP90 , PI3K , ALK , MET , and MEK ( ) .", "label": "None"}
{"id": "24349829", "sentence": "Correspondingly , direct injection of a liposome encapsulated miR-7 plasmid into established EGFR-TKI sensitive and resistant tumors bearing the @VARIANT$ EGFR mutant resulted in significant tumor regression in conjunction with repression of EGFR , RAF-1 and IRS-1 expression . In head and neck cancer , @GENE$ functioned in a synergistic manner with @DRUG$ to render FaDu Erlotinib-resistant cells susceptible to the growth inhibitory activities of the drug .", "label": "None"}
{"id": "21687596", "sentence": "Inukai et al. hypothesized that @DRUG$ treatment may lead to the selection of @VARIANT$ mutant cells and that even a small fraction of T790M positive tumor cells at the beginning of treatment could lead to clinical gefitinib resistance because of selective proliferation of T790M mutant cells . Maheswaran et al. proved this hypothesis by analyzing circulating tumor cells using a highly sensitive method [ ] . They analyzed pretreatment tumor samples from 26 NSCLC cases with activating @GENE$ gene mutations and found low levels of T790M in 10 of these cases ( 38 % ) .", "label": "resistance or non-response"}
{"id": "15737014", "sentence": "To our knowledge , no NSCLC patient who initially responded to but then progressed on either gefitinib or erlotinib has yet been treated with @DRUG$ . In some of the patient specimens analyzed , the actual sequencing peaks demonstrating the @VARIANT$ mutation were smaller than originally anticipated . These results differ from those of acquired resistance mutation in CML [ ] , GIST [ , ] , and @GENE$ [ ] .", "label": "None"}
{"id": "24965831", "sentence": "Efforts to @GENE$ reaction intermediates lead to characterization of an important intermediate state E4 that carries four electrons stored as two [ Fe–H–Fe ] bridging hydrides and two protons bound to the sulfides on the FeMo-cofactor . The currently proposed reaction scheme that predicts the E4 state suggests that the coupling between electron and proton transfers is too tight to be discriminated . In contrast , we succeeded to identify the sequential electron and proton transfer steps on the NB-protein in the DPOR reaction , by blocking of the proton transfer step using @VARIANT$ and Chl c .", "label": "None"}
{"id": "25382104", "sentence": "The availability of 3D-structure of the target protein and the structural details of @DRUG$ and @VARIANT$ mutant BCR-ABL protein complex renders an opportunity to identify the most active drug candidate that can efficiently block the catalytic activity of @GENE$ .", "label": "response"}
{"id": "23864840", "sentence": "Another approach for @VARIANT$ mediated resistance is the dual inhibition of EGFR with afatinib and @DRUG$ , an @GENE$ blocking antibody resembling the synergistic combination of lapatinib and trastuzumab in ErbB2 positive breast cancer .", "label": "response"}
{"id": "24472312", "sentence": "These findings were similar to those observed in the complex between @DRUG$ and @VARIANT$ @GENE$ [ , ] .", "label": "response"}
{"id": "24189400", "sentence": "This included PC9GR cells as well as two cell lines ( HCC827 and HCC4006 ) that were engineered to have exon 19 deletion E746-A750 plus @VARIANT$ EGFR through retroviral mediated transduction . These results are shown in . @DRUG$ or midostaurin alone had modest effects on total @GENE$ phosphorylation across the three cell lines ; however , when combined , the two inhibitors had more pronounced effects on EGFR and downstream ERK phosphorylation .", "label": "resistance or non-response"}
{"id": "18030354", "sentence": "A 194-gene signature present in EGFR-mutant but not @GENE$ cell lines distinguishes @VARIANT$ ( P.M. [ point mutation ] ) from Δ746–750 ( deletion ) . Cells were treated with ( + ) or without ( − ) @DRUG$ .", "label": "sensitivity"}
{"id": "23994953", "sentence": "However , it should be noted that these studies were largely based on NSCLC cells expressing wild-type @GENE$ ; therefore , these studies did not mimic clinical usage of EGFR TKIs because EGFR wild-type NSCLC cells are intrinsically resistant to EGFR TKIs . In this scenario , it might appear reasonable to suggest that in addition to the presence of the @VARIANT$ mutation , immunohistochemical and/or microarray based transcriptional profiling studies dedicated to specific alterations of EMT drivers ( e.g. , SLUG ) and/or effectors ( e.g. , vimentin ) may be helpful in monitoring for @DRUG$ responders and non-responders based on the loss of biomarkers associated with epithelial status and gain of biomarkers associated with mesenchymal status .", "label": "resistance or non-response"}
{"id": "22970367", "sentence": "One of these agents , BIBW2992 ( afatinib ) , is able to target both EGFR and @GENE$ and overcome T790M-driven acquired resistance [ ] . However , in clinical studies , BIBW2992 did not prolong survival compared to placebo in NSCLC patients who have developed acquired resistance to @DRUG$ or erlotinib [ ] . Another agent in this class of next generation EGFR TKIs , PF-002999804 , inhibits all ERBB family members and has been shown to be effective against tumors harboring @VARIANT$ [ , ] .", "label": "None"}
{"id": "21799856", "sentence": "Later , we found that the TxDE ( D175A ) -toxoflavin complex could be formed by soaking a TxDE ( D175A ) crystal for about 30 min in a solution of 0.1 M HEPES , pH 7.5 , 2 M ammonium sulfate , 2 % @GENE$ , and 20 % sucrose , as well as additional 1 mM MnCl2 , 5 mM DTT , and 2 mM toxoflavin . For TxDE ( @VARIANT$ ) structure determination , the program SOLVE/RESOLVE , was used for initial phasing and density modification . The initial electron density map was sufficiently interpretable to trace all residues , except the N-terminal Met-1 and the last two @DRUG$ residues in the C-terminal His-tag .", "label": "None"}
{"id": "24790411", "sentence": "Compared to erlotinib and @DRUG$ , afatinib shows lower EC50 values and greater potency against wild type ( afatinib vs erlotinib vs gefitinib : 60 nM vs 110 nM vs 157 nM ) and @VARIANT$ mutated @GENE$ ( afatinib vs erlotinib vs gefitinib : 0.7 nM vs 40 nM vs 5 nM ) .", "label": "sensitivity"}
{"id": "24348397", "sentence": "The @GENE$ mutation @VARIANT$ , sporadic wild-type GISTs , mutations with succinate dehydrogenase or BRAF mutated GISTs are unlikely to respond to @DRUG$ [ ] .", "label": "resistance or non-response"}
{"id": "22792530", "sentence": "In this study , SW480 and HCT116 cells were more resistant to apoptosis when treated with regimens containing @DRUG$ than when treated with regimens containing bevacizumab . This finding is related to the fact that both cell lines harbor a KRAS mutation , with SW480 and HCT116 cells expressing G12V and @VARIANT$ @GENE$ mutants , respectively .", "label": "resistance or non-response"}
{"id": "24349829", "sentence": "Correspondingly , direct injection of a liposome encapsulated miR-7 plasmid into established @GENE$ sensitive and resistant tumors bearing the @VARIANT$ EGFR mutant resulted in significant tumor regression in conjunction with repression of EGFR , RAF-1 and IRS-1 expression . In head and neck cancer , miR-7 functioned in a synergistic manner with @DRUG$ to render FaDu Erlotinib-resistant cells susceptible to the growth inhibitory activities of the drug .", "label": "resistance or non-response"}
{"id": "15737014", "sentence": "We have not identified this mutation in 155 tumors ( see above ) , and among nearly 1,300 lung cancers in which analysis of @GENE$ exons 18 to 21 has been performed [ , ,, , , ] , only one tumor ( which also harbored an @VARIANT$ mutation ) was reported to contain the T790M mutation . Whether the patient from which this tumor was resected had received gefitinib or @DRUG$ is unclear , and the report did not note an association with acquired resistance to either drug [ ] .", "label": "sensitivity"}
{"id": "19707322", "sentence": "Nilotinib is approximately 30-fold more sensitive than imatinib in the killing of @GENE$ dependent cells derived from patients with CML ( K562 and Ku-812F cells ) and cell lines ( 32D and baF3 ) , and it is active against 32/33 imatinib-resistant cell lines with BCR-ABL mutations . The sensitivity of Bcr-Abl mutants to AMN107 can be summarized into 4 categories : high ( IC50 ≤ 70 nmol/L : M244V , G250E , Q252H , F3llL , F317L , @VARIANT$ , V379I , L387M , H396P , H396R ) , medium ( IC50 ≤ 200 nmol/L : Y253F , E255K , F359V ) , low ( IC50 ≤ 450 nmol/L : Y253H , E255V ) , and insensitive ( IC50 & gt ; 2 μmol/L : T315I ) ( ) ( ) .", "label": "None"}
{"id": "23755371", "sentence": "For example , @DRUG$ , an antibody that blocks a T-cell function regulating surface receptor ( CTLA-4 ) , was approved by the Food & amp ; Drug Administration ( FDA ) for treatment of metastatic melanoma ( Hodi et al. , ) ; Adoptive cell transfer ( ACT ) therapy that utilizes T cells expressing transgenic T cell receptor ( TCR ) or chimeric antigen receptor ( CAR ) has demonstrated high objective response rate ( & gt ; 40 % ) in Phase II clinical trials ( Rosenberg , ) . The newly approved small molecule drug , vemurafenib , or PLX 4032 , that targets @GENE$ oncogenic mutation ( @VARIANT$ ) , has been found to induce T-cell mediated antitumor response ( Sosman et al. , ; Liu et al. , ) .", "label": "None"}
{"id": "23986642", "sentence": "In patients receiving 8 mg of @DRUG$ , a reduction of 50 % or more in CrkL phosphorylation was observed in four of six patients ( 67 % ) . At doses of 15 mg or more , 32 of 34 patients ( 94 % ) had a reduction of 50 % or more in p CrkL , and this included eight of ten patients ( 80 % ) with the @VARIANT$ mutation . This trial provided valuable evidence of ponatinib’s direct kinase inhibiting activity in patients with a variety of @GENE$ mutations , including the T315I mutant , leading to further evaluation of its effects .", "label": "response"}
{"id": "25562798", "sentence": "The mechanisms of acquired resistance to @DRUG$ are only just coming to light but , analogous to acquired resistance to EGFR inhibitors , secondary mutations in ALK that render the @GENE$ kinase resistant to inhibition by crizotinib have been identified [ , , ] . These mutations including @VARIANT$ in the ALK kinase domain may be susceptible to inhibition with novel ALK inhibitors e.g. , LDK378 , AP26113 , or AF802 .", "label": "resistance"}
{"id": "23788881", "sentence": "Among CML patients , 19 had advanced disease , 16 were resistant to @DRUG$ , and 6 had @GENE$ domain mutations ( @VARIANT$ , E255K , Y253H , M351T and 2 with F317L ) .", "label": "None"}
{"id": "24944510", "sentence": "The reversible dual @GENE$ inhibitor AP26113 is a more potent ALK inhibitor than crizotinib and demonstrates preclinical activity against various secondary mutations resistant to @DRUG$ , including L1196 and @VARIANT$ .", "label": "resistance"}
{"id": "23493804", "sentence": "EGFR–TKIs such as @DRUG$ or erlotinib attain a response rate of approximately 70 % and progression-free survival of 9–13 months , although subgroups of patients experience long lasting remission. , Use of EGFR–TKIs as a first-line treatment in patients with advanced NSCLC harboring EGFR mutations improved progression-free survival with acceptable toxicity , compared with standard chemotherapy . EGFR–TKIs are currently considered a standard first-line treatment for this disease entity.– However , these tumors eventually develop resistance to EGFR–TKIs , possibly as a result of a secondary threonine–methionine substitution mutation at position 790 in exon 20 ( @VARIANT$ ) , MET amplification , or @GENE$ in relapsed tumors .", "label": "None"}
{"id": "23407898", "sentence": "For such patients , irreversible @GENE$ TKIs hold a lot of promise . The irreversible TKI @DRUG$ afatinib ) is currently being investigated in advanced clinical trials ( Yap et al. , ; Murakami et al. , ) . Another novel irreversible pan-HER inhibitor HM781-36B has recently shown promise in the inhibition of EGFR , HER2 , and HER4 as well as against the gatekeeper mutation – EGFR @VARIANT$ that is responsible for acquired drug resistance in lung cancer patients ( Cha et al. , ) .", "label": "response"}
{"id": "23888935", "sentence": "Ponatinib is a novel , synthetic , orally active , potent pan–BCR-ABL inhibitor and multi targeted TKI that was discovered using a computational and structure based drug design approach.– @DRUG$ was specifically designed to inhibit native @GENE$ and mutant forms that can arise during treatment with other TKIs and cause resistance , including the @VARIANT$ gatekeeper mutant .", "label": "response"}
{"id": "23606169", "sentence": "Likewise , codon 61 has been included in many diagnostic tests because the KRAS mutation in codon 61 predicts resistance to cetuximab plus irinotecan in @GENE$ codon 12 and 13 wild-type metastatic colorectal cancer [ ] . Moreover , the presence of the @VARIANT$ mutation in the BRAF gene is more and more frequently taken into consideration before patient targeted therapy qualification , because wild-type BRAF is required for a response to @DRUG$ or cetuximab [ , ] .", "label": "None"}
{"id": "25580271", "sentence": "When cross-over to EGFR tyrosine kinase inhibitor therapy was examined , 75 % of patients who received @DRUG$ and pemetrexed received an EGFR tyrosine kinase inhibitor and 56 % of patients who received cisplatin and gemcitabine received an @GENE$ tyrosine kinase inhibitor . The rate of second-line EGFR tyrosine kinase inhibitors in countries with insurance coverage was 91 % and without insurance coverage was 52 % . Overall survival of patients with common EGFR mutations ( defined as exon 19 deletion and exon 21 @VARIANT$ point mutation ) in LUX-3 , LUX-6 , and combined cohorts [ ]", "label": "None"}
{"id": "24612546", "sentence": "A secondary mutation of @VARIANT$ in @GENE$ exon 20 was confirmed after progression on 15-month @DRUG$ treatment with subsequent lung wedge resection .", "label": "resistance or non-response"}
{"id": "23705826", "sentence": "The @GENE$ fusion positive acute monocytic leukemia cell line MOLM-14 harbors a heterozygous FLT3 ITD mutation [ ] . The T-lymphoblastic cell line Jurkat and the CML blast crisis cell line K562 were obtained from the Deutsche Sammlung für Mikroorganismen und Zellkulturen ( DSMZ , Braunschweig , Germany ) . The human mast cell leukemia cell line HMC1.1 , harboring an imatinib-sensitive KIT V560G mutation [ ] , and the sister cell line HMC1.2 , harboring an additional imatinib-insensitive KIT @VARIANT$ mutation [ ] were provided by Prof. Heinrich , OHSU , Oregon .", "label": "None"}
{"id": "23527257", "sentence": "The cell line H1975 has a sensitizing @VARIANT$ kinase domain mutation in exon 21 , and a second T790M in exon 20 , in cis , in the @GENE$ kinase domain , rendering them resistant to the reversible TKIs gefitinib and @DRUG$ .", "label": "sensitivity"}
{"id": "25532027", "sentence": "In particular , epidermal growth factor receptor-tyrosine kinase inhibitors ( @GENE$ ) , such as gefitinib and @DRUG$ , demonstrated marked clinical activity against NSCLC harboring an activating EGFR mutation ( – ) . Additionally , some reports suggest that the EGFR @VARIANT$ mutation may not be rare and may exist in a small population of in tumor cells before TKI treatment ( – ) .", "label": "resistance or non-response"}
{"id": "19920910", "sentence": "In a cell-line based mutagenesis study , the emergence of @GENE$ mutations resistant to imatinib , nilotinib and dasatinib were compared : 20 different mutations were identified with imatinib mesylate , 10 with nilotinib ( including only 1 novel mutation , E292V ) and 9 with @DRUG$ . In contrast to imatinib mesylate , mutations recovered in the presence of 50 nM nilotinib were limited to L248V , G250E , Y253H , E255K ( p-loop ) , T315I , F359C , L384M and @VARIANT$ .", "label": "None"}
{"id": "25100284", "sentence": "@DRUG$ Yang et al. [ ] Ph II ; randomized , single-arm n = 129 ; Taiwanese and US ; chemo-naïve , or one previous line of chemotherapy ; exon 19 deletion ( n = 52 ) ; @VARIANT$ ( n = 54 ) ; other ( n = 23 ) Afatinib 40 mg or 50 mg/day PFS : 14 months Icotinib Ren et al. [ ] @GENE$ single-arm n = 7 : Chinese ; previously treated ; exon 19 deletion ( n = 3 ) ; L858R ( n = 4 ) Icotinib ( varied dose and schedule ) PFS : 141 days ( 4.6 months ) Sun et al. [ ] Ph III ; randomized comparison with gefitinib ( ICOGEN ) n = 27 : Chinese ; previously treated ; EGFR mutation Icotinib 125 mg three times/day PFS : 198 days ( 6.5 months )", "label": "None"}
{"id": "24071646", "sentence": "Besides , we transfected PI3K mutation plasmid-PIK3CA ( @VARIANT$ ) into A549 and Calu1 cells . As shown in , atorvastatin could also enhance the @DRUG$ efficacy in these transfected cells , confirming that atorvastatin can sensitize NSCLC cells to gefitinib in the presence of comutant @GENE$ .", "label": "resistance or non-response"}
{"id": "25247240", "sentence": "It was not only found that 5-FU-resistant cells expressed significant higher levels of miR-34a , but also that the introduction of miR-34a into resistant cells significantly inhibited cell growth and induced a considerable attenuation of 5-FU-resistance , which was accompanied by reduced expression of SIRT1 and @VARIANT$ family proteins . These findings suggest that the resistance to 5-FU in DLD-1 cells was at least in part mediated by @GENE$ cascade . Furthermore , also @DRUG$ resistance resulted overcome by miR-34a over-expression and SIRT1 knockdown in hormone-refractory PC3 , as demonstrated by Kojima et al .", "label": "None"}
{"id": "24349829", "sentence": "Correspondingly , direct injection of a liposome encapsulated miR-7 plasmid into established EGFR-TKI sensitive and resistant tumors bearing the @VARIANT$ EGFR mutant resulted in significant tumor regression in conjunction with repression of EGFR , RAF-1 and IRS-1 expression . In head and neck cancer , miR-7 functioned in a synergistic manner with @DRUG$ to render FaDu Erlotinib-resistant cells susceptible to the growth inhibitory activities of the drug . Interestingly , expression profiling analysis suggested that the downregulation of @GENE$ and EGFR and its ligand TGF-α by miR-7 was a possible mechanism by which miR-7 orchestrates the inhibition of EGFR signaling at multiple levels115 .", "label": "None"}
{"id": "22970367", "sentence": "Second-generation irreversible EGFR inhibitors , which bind irreversibly in the ATP binding pocket of EGFR through a covalent bond at C797 , were shown to be more potent inhibitors of the second-site @VARIANT$ mutation than erlotinib or gefitinib in pre-clinical models [ , ] ( ) . These inhibitors are currently under clinical trials in patients with acquired resistance . One of these agents , BIBW2992 ( @DRUG$ ) , is able to target both EGFR and @GENE$ and overcome T790M-driven acquired resistance [ ] .", "label": "None"}
{"id": "25105411", "sentence": "In this study , we demonstrated that hinokitiol significantly inhibited cell proliferation in a series of lung adenocarcinoma cell lines , including @GENE$ and TKI-resistant cells , H1975 and PC9-IR , respectively . The mechanism of H1975 resistance to gefitinib is due to @VARIANT$ mutation , whereas that of PC9-IR , which was selected from parental PC9 cells that had been continuously exposed to increasing concentrations of @DRUG$ , could be associated with persistent activation of ERK pathway , .", "label": "resistance or non-response"}
{"id": "24385803", "sentence": "Sometimes the entire treatment strategy of CML has to be changed because of the presence of the @GENE$ domain mutation . For instance , @VARIANT$ is a unique mutation making the CML patient irresponsive to most TKIs ( excluding @DRUG$ ) and leads allografting to become an option in the case [ ] .", "label": "response"}
{"id": "24278035", "sentence": "To test whether functional interactions between NF1 and ALK exist in human cells , we used the SK-SY5Y and Kelly neuroblastoma cells , both of which harbor constitutively active @VARIANT$ ALK alleles , and both of which are highly sensitive to pharmacological ALK inhibition . Compatible with a role for NF1 as a negative regulator of mitogenic @GENE$ signals , qRT-PCR verified NF1 knockdown with two shRNA retroviral vectors increased the resistance of both lines to ALK inhibitors NVP-TAE684 and @DRUG$ ( and ) .", "label": "resistance"}
{"id": "24879454", "sentence": "These include the use of second generation TKIs in case of therapeutic failure or intolerance , e.g. , Dasatinib , @DRUG$ , Bosutinib and Ponatinib , the latter particularly used in case of a secondary resistance by @VARIANT$ mutation [ ] ( ) . 3.2 . @GENE$", "label": "None"}
{"id": "24167634", "sentence": "Novel strategies under investigation include the continuation beyond progression of @GENE$ combined with chemotherapy , the re-challenge with TKIs after second-line chemotherapy , the use of irreversible TKIs or the combination with novel agents targeting different molecular pathways . Further preclinical studies to describe molecular mechanisms and potential markers of drug activity are also warranted . Therefore , in this study we explored the retained antitumor activity of @DRUG$ in resistant HCC827-GR5 and NCI-H1975 NSCLC cells , carrying MET amplification and @VARIANT$ mutation , respectively .", "label": "resistance or non-response"}
{"id": "22081024", "sentence": "Importantly , expression of kinase dead ( @VARIANT$ ) , phospho-mimetic S338D or WT CRAF rescued this mitotic defect , whereas a non-phosphorylatable ( S338A ) CRAF mutant , failed to do so ( and ) , even though this mutant maintains kinase activity and can dimerize with BRAF ( data not shown ) . Moreover , in cells treated with the microtubule stabilizing agent paclitaxel , CRAF remained localized to the mitotic spindle suggesting that KG5 and @DRUG$ arrest cells at pro-metaphase via distinct mechanisms ( ) . Previous studies have revealed that CRAF and BRAF can form heterodimers and that @GENE$ can play a role in mitosis– .", "label": "None"}
{"id": "22815900", "sentence": "D , Comparison of DNA sequences of 15 bases responsible for the @VARIANT$ mutation in the EGFR gene exon 21 in 11–18 , 11–18/GEF10-1 , and 11–18/GEF20-1 cells . E , Comparison of gene copy of wild-type and mutant @GENE$ between 11–18 cells and gefitinib-resistant counterparts by PLACE-SSCP .", "label": "sensitivity"}
{"id": "22844452", "sentence": "A similar phenomenon has recently been described for the acquired resistance to @GENE$ kinase inhibitors in non-small-cell lung cancers . Sensitive detection methods have identified a proportion of tyrosin- kinase- naive tumors that carry @VARIANT$ , a resistant tumor cell clones that may be selected during the exposure to gefitinib or @DRUG$ .", "label": "resistance or non-response"}
{"id": "15737014", "sentence": "To determine how the @VARIANT$ mutation would affect EGFR proteins already containing mutations associated with sensitivity to @GENE$ tyrosine kinase inhibitors , we introduced the specific mutation into EGFR cDNAs that encoded the exon 21 and 19 mutations found in patients 1 and 2 , respectively . Various lysates from cells that were serum starved and pre treated with @DRUG$ or erlotinib were analyzed by immunoblotting .", "label": "resistance or non-response"}
{"id": "24212832", "sentence": "This is in keeping with an earlier study by Di Nicolantonio and colleagues [ ] , where the response to panitumumab or cetuximab was found to be impeded by the presence of BRAF @VARIANT$ mutation and restored ( in a cellular model of CRC cells ) by BRAF inhibitor sorafenib [ ] . They suggested that this experimental observation should encourage conceiving clinical trials using multiple therapies with EGFR and @GENE$ inhibitors , considering that cetuximab , panitumumab , and sorafenib are already approved for clinical use . Standard neoadjuvant chemotherapy , using @DRUG$ or oxaliplatin did not seem to be affected by KRAS/BRAF mutations [ ] .", "label": "None"}
{"id": "23788917", "sentence": "These patients were treated with @DRUG$ or gefitinib . Activating mutations in @GENE$ were detected in cells obtained from primary tumour , circulating tumour cells in peripheral blood ( consistency of results – 92 % ) and in free circulating DNA ( consistency of results – 33 % ) . The authors also investigated presence of the @VARIANT$ mutation in similar samples , and they detected cells harbouring that mutation in 10 patients ( n = 26 ; 38.5 % ) .", "label": "resistance or non-response"}
{"id": "24523596", "sentence": "Several studies have reported renal failure and tumor lysis syndrome during TKI based molecular targeted therapies , including with sorafenib for hepatocellular carcinoma , with imatinib for chronic myelogenous leukemia , and with @DRUG$ for chronic lymphocytic leukemia.– Because the Q141K variant of ABCG2/BCRP corresponding to SNP 421C&gt ; A reduces uric acid transport and those TKIs are substrates/inhibitors of @GENE$ , TKI therapy in patients with the SNP 421C&gt ; A ( Q141K ) may be at higher risk of tumor lysis syndrome . A defect in the pharmacological interaction has been suggested between sunitinib and another ABCG2/BCRP germ-line mutant allele , 1291T & gt ; C. Remarkably , sunitinib reversed wild-type ABCG2/BCRP mediated drug resistance and competitively inhibited ABCG2/BCRP mediated estrone 3-sulfate transport and the binding of 125I-iodoarylazidoprazosin to ABCG2/BCRP . The @VARIANT$ variant of ABCG2/BCRP , which is expressed from a germ-line mutant allele 1291T & gt ; C , was insensitive to sunitinib mediated inhibition .", "label": "None"}
{"id": "23520446", "sentence": "Approximately 50 % of EGFR mutations consist of deletions in exon 19 , whereas 35–45 % consist of the @VARIANT$ mutation and 5 % consist of insertions in exon 20 or the L861Q mutation – . Gefitinib ( @DRUG$ ) and Erlotinib ( Tarceva ) are @GENE$ inhibitors that are used clinically for the treatment of advanced NSCLC , primarily that with EGFR mutations in the tyrosine kinase domains – .", "label": "sensitivity"}
{"id": "23936861", "sentence": "XL647 has also showed to be active against cells containing the @VARIANT$ mutation , which have been associated with emerging resistance to first-generation @GENE$ TKIs such as gefitinib or @DRUG$ [ ] .", "label": "resistance or non-response"}
{"id": "23566546", "sentence": "Case Histrogical type EGFR mutation status Brinkman index Treatment agent Response IL-8 ( ng/mL ) IL-10 ( ng/mL ) RANTES ( pg/ml ) 1 Ad Ex21 @VARIANT$ 900 gefitinib PR 5.79 1.67 2 2 Ad Ex21 L858R 0 erlotinib PR_3.33 94.2 1.41 3 Ad Ex19 del 0 erlotinib PR 4.09 126 2.13 4 Ad Ex21 L858R 0 gefitinib @GENE$ 18.1 1.85 5 Ad Ex21 L858R + Ex19 del 370 erlotinib PR 21.9 1.23 2.11 6 Ad Ex19 del 0 erlotinib PR 7.05 1.37 2.56 7 Ad Ex19 del 0 gefitinib PR 4.82 1.59 2.02 8 Ad Ex21 L858R 1640 gefitinib PR 54.9 2.7 2.38 9 Ad negative 400 erlotinib SD 34.9 3.39 3.66 10 Ad negative 0 erlotinib SD 27.1 4.94 2.25 11 Ad unknown 1800 erlotinib SD NE NE NE 12 Sq Ex19 del 3840 gefitinib SD 12.6 1.1 1.98 13 Ad Ex19 del 30 erlotinib SD 5.27 0.69 2.66 14 Ad Ex19 del 0 erlotinib SD 10.5 0.85 2.5 15 Ad unknown 300 erlotinib SD 7.69 2.61 1.7 16 La negative 2080 erlotinib SD NE NE NE 17 Sq Ex21 L858R 750 erlotinib SD 11.6 56.3 3.06 18 Ad unknown 600 erlotinib SD 13.7 1.1 2.82 19 Ad Ex21 L858R 0 erlotinib SD 20.6 11.6 0.783 20 Ad Ex19 del 0 erlotinib SD 14.8 2.07 2.02 21 Ad Ex21 L858R + Ex19 del 0 gefitinib SD 3.04 1.3 1.76 22 Ad Ex19 del 200 gefitinib SD 10.9 1.59 1.91 23 Sq unknown 1560 erlotinib PD NE NE NE 24 Ad negative 1080 erlotinib PD 25.2 8.15 1.57 25 Ad unknown 0 erlotinib PD NE NE NE 26 Ad Ex18 G719A 2000 erlotinib PD 11.6 4.48 3.12 27 Ad unknown 1410 erlotinib PD NE NE NE 28 Ad Ex19 del 1000 gefitinib PD 9.44 2.25 2.89 29 Ad negative 1100 erlotinib PD 56.3 5.63 2.16 30 Ad negative 2000 @DRUG$ PD 15.6 0.85 0.292 31 Ad negative 825 erlotinib PD 8.27 1.59 2.13 32 Ad Ex21 L858R 0 erlotinib PD 5.34 7.05 1.7 33 Ad negative 1680 erlotinib PD 57.7 1.63 2.06", "label": "None"}
{"id": "21818254", "sentence": "ZF-TF infected MCF7 and @VARIANT$ cells , and corresponding control cells were seeded @GENE$ 2×103 cells per 96-well plate and grown at 37°C in a humidified incubator containing 5 % CO2 in the presence of puromycin ( 0.4 micrograms/ml ) only and puromycin plus 100 nM @DRUG$ for 10–15 days .", "label": "None"}
{"id": "23493804", "sentence": "Three out of five patients with @VARIANT$ mutations who received @DRUG$ attained a partial response ( all three responders also had exon 19 deletions ) . Thus , @GENE$ are suitable for NSCLC with a T790M mutation that coexists with activating mutations , such as exon 19 deletions or exon 21 point mutation .", "label": "resistance or non-response"}
{"id": "23696715", "sentence": "A recent study compared the effect of four TKIs ( axitinib , sunitinib , @DRUG$ , and XL184 ) on cell proliferation , @GENE$ autophosphorylation , and extracellular signal regulated kinase activation in three cell lines : MZ-CRC-1 ( M918T RET mutation ) , MTC-TT ( @VARIANT$ RET mutation ) , and TPC-1 ( RET/PTC-1 rearrangement ) cells .", "label": "response"}
{"id": "21687596", "sentence": "However , the frequency of all such mutations appears to be low in comparison with the @VARIANT$ mutation and further analysis of such cases is required in the future . 2.4.2 . IGF-1R Guix et al. established gefitinib-resistant clones from a gefitinib-sensitive cell line of squamous cell lung carcinoma that amplified the wild-type @GENE$ gene ( A431 ) by exposing the cells to increasing concentrations of @DRUG$ [ ] .", "label": "resistance or non-response"}
{"id": "20300583", "sentence": "In the one case of discordance between KRAS mutation status before and after combined @DRUG$ therapy ( case # 4 ) , a mutated @GENE$ gene ( Exon 2 @VARIANT$ ) was found in the primary CRC , while no KRAS mutation was observed in a liver metastasis sample obtained after combined cetuximab therapy ( ) .", "label": "sensitivity"}
{"id": "25539768", "sentence": "In the combination of erlotinib and @DRUG$ , erlotinib is an @GENE$ , typically used in non-small-cell lung cancer . However , the acquired @VARIANT$ mutation of EGFR leads to erlotinib resistance .", "label": "response"}
{"id": "19102745", "sentence": "This final @DRUG$ level ( 1600 μmole gDW-1 ) represents an increase between 10- and more than 1000-fold with respect to previous reports [ , , ] . The expression analysis of this response shows that both elicitors stimulated the expression of PAL , @VARIANT$ , 4CL and STS independently of the anthocyanins/isoflavonoids ( CHS ) and lignins ( @GENE$ ) pathways and therefore both induce stilbene biosynthetic genes in a highly specific way , in agreement to results reported by Saigne-Soulard et al. [ ] .", "label": "None"}
{"id": "25221748", "sentence": "This agent is also being assessed in a phase II trial in patients with de novo resistant @VARIANT$ mutations not previously treated with EGFR-TKIs ( www.clinicaltrials.gov : NCT01854034 ) and in patients with EGFR mutations and/or EGFR-TKI resistant disease , as part of a phase II cluster study in Chinese patients evaluating five novel inhibitors of HSP90 , PI3K , ALK , MET , and @GENE$ ( ) . Further , AUY922 is also being assessed in combination with @DRUG$ in patients who have previously responded to EGFR-TKIs and/or whose tumors harbor activating EGFR mutations ( www.clinicaltrials.gov : NCT01259089 ) , with results expected in the near future .", "label": "None"}
{"id": "23493883", "sentence": "Combinations of therapy such as cetuximab plus @DRUG$ and gefitinib plus everolimus have also been tried . The most promising drug thus far has been afatinib ( BIBW2992 ; Boehringer-Ingelheim Pharma , Ingelheim , Germany ) , , an @GENE$ family blocker with reported in vitro and in vivo activity against EGFR mutant tumors harboring exon 19 deletions , exon 21 L858R mutations and the exon 20 @VARIANT$ “resistance” mutations .", "label": "resistance or non-response"}
{"id": "21192840", "sentence": "The kinase domain mutations documented in non-small cell lung cancer ( NSCLC ) and deletion mutations found in glioblastoma ( GBM ) are detailed , with the most frequent alterations ( @VARIANT$ and ΔEGFR/EGFRvlll respectively ) shown in bold , . The T790M “gatekeeper mutation” is associated with acquired resistance to @DRUG$ in NSCLC ( see text for details and further references ) . @GENE$ is expressed at elevated levels in many solid tumors , most often as a result of focal gene amplification or genomic copy number gain– .", "label": "sensitivity"}
{"id": "24451154", "sentence": "We first compared BT474 and SKBR3 cells ( without endogenous hotspot mutations ) infected with wild-type , E545K or @VARIANT$ p110α retroviral constructs . As expected , IC50 data for inhibition of HER2 by @DRUG$ were similar between wild-type and @GENE$ mutant expressing cells ( Figure B ) .", "label": "None"}
{"id": "19920910", "sentence": "In vivo experiments with CML xenografts in mice demonstrated that nilotinib treatment , compared with treatment with vehicle , improved survival of mice infused with either wild type @GENE$ or the imatinib-resistant Bcr-Abl mutant ( @VARIANT$ ) ( ; ) .", "label": "None"}
{"id": "23484125", "sentence": "Additionally , we have shown that the preinfection of mice with T. crassiceps can reduce the incidence of @VARIANT$ induced by @DRUG$ (STZ) up to 50 % , mainly by lowering blood glucose levels to below 200 mg/dL , leukocyte infiltration into the pancreas and , in consequence , the degree of insulitis . Such effects last for at least 6 weeks after induction of T1D . These protective effects were associated with high systemic levels of @GENE$ , a reduction in TNF-α circulating levels , and the induction of AAM populations ; however , analysis of the spleens did not show increased populations of Treg cells [ ] .", "label": "None"}
{"id": "24964744", "sentence": "The parental MCF10a cell line showed greater resistance to @DRUG$ than those with mutations in EGFR , KRAS , @GENE$ , BRAF and AKT ( Figure ) . Greatest sensitivity was seen within the PI3K mutated cells where IndexSUM values decreased from a relatively resistant index of 423 to 120 and 64 for the H1407R and @VARIANT$ mutations of PI3KCA respectively .", "label": "resistance or non-response"}
{"id": "24223798", "sentence": "In particular , epidermal growth factor receptor tyrosine kinase inhibitors ( @GENE$ ) , such as gefitinib and @DRUG$ , have been developed as a novel treatment option for patients with non–small cell lung cancers ( NSCLCs ) that possess somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene – . Prospective clinical trials of EGFR-TKI treatment in NSCLC patients with activating EGFR mutations , such as delE746-A750 ( exon 19 ) and @VARIANT$ ( exon 21 ) , have demonstrated high clinical response rates of approximately 80 % – .", "label": "sensitivity"}
{"id": "24523596", "sentence": "Several studies have reported renal failure and tumor lysis syndrome during TKI based molecular targeted therapies , including with sorafenib for hepatocellular carcinoma , with imatinib for chronic myelogenous leukemia , and with @DRUG$ for chronic lymphocytic leukemia.– Because the @VARIANT$ variant of @GENE$ corresponding to SNP 421C&gt ; A reduces uric acid transport and those TKIs are substrates/inhibitors of ABCG2/BCRP , TKI therapy in patients with the SNP 421C&gt ; A ( Q141K ) may be at higher risk of tumor lysis syndrome .", "label": "None"}
{"id": "19680652", "sentence": "@GENE$ mutation tests were available in four patients , in whom three of them were positive for point mutation in exon 21 ( @VARIANT$ and L861Q ) and one was negative . At the time of initiation of gefitinib treatment , most of the patients were in good performance status ( & gt ; 90 % in ECOG 0 or 1 ) . Gefitinib was prescribed at standard dosage of 250 mg daily and @DRUG$ at 150 mg daily .", "label": "sensitivity"}
{"id": "25033171", "sentence": "Awad has supposed that the solvent front mutation @VARIANT$ may hinder the drug binding to the mutated ROS1 , which seems possible when a small amino acid was replaced by a larger one . Alternatively , it seems that the up-moved P-loop region in @GENE$ could attribute to the @DRUG$ resistance by attenuating the interactions between the drug and the enlarged binding pocket , which has also been observed in the C1156Y induced crizotinib resistance in the ALK tyrosine kinase .", "label": "resistance"}
{"id": "24386407", "sentence": "Taken together , these findings indicated that the Met inhibitor crizotinib plus a new generation @GENE$ , either @DRUG$ or WZ4002 , circumvented resistance to HGF in an autocrine manner , in the presence or absence of the EGFR @VARIANT$ mutation or Met gene amplification .", "label": "response"}
{"id": "24789720", "sentence": "The role of @VARIANT$ mutation , particularly its presence in patients before EGFR-TKIs treatment is still controversial being a subject of intensive discussions . Mechanism of achieving resistance to erlotinib and @DRUG$ remains unclear . The recent reports confirmed , that T790M substitution could be detected in @GENE$ naïve patients independently of other EGFR gene mutations ( predominantly L858R substitution and deletions in exon 19 ) .", "label": "resistance or non-response"}
{"id": "25435999", "sentence": "Mutations conferring @DRUG$ resistance were detected using allele-specific oligonucleotide polymerase chain reaction ( ASO-PCR ) . The primer sequences for @VARIANT$ were as follows : Forward , 5′-GCC CCC CTT CTA TAT CAT CAC-3′ for normal PCR ; forward , 5′-GCC CCC CTT CTA TAT CAT @GENE$ for ASO-PCR ; and reverse , 5′-GGA TGA AGT TTT TCT TCT CCA-3′ .", "label": "None"}
{"id": "17551677", "sentence": "Finally , a recent study shows not only that @GENE$ mutations are statistically associated with Asian ethnicity and never-smoker status , but also that patients with EGFR exon 19 deletions have significantly longer median survival than patients with EGFR @VARIANT$ mutation ( 34 vs. 8 months , p=0.01 ) after treatment with @DRUG$ or erlotinib [ ] .", "label": "sensitivity"}
{"id": "24689036", "sentence": "However , treatment of PC3 cells with SMA-Ral 5 and 10 μM potentiated G0/G1 arrest and increased the percentage of cells by 15 and 20 % in G1/G0 phase with a concomitant reduction of S-phase ( −5 and 7 % ) and @VARIANT$ phase ( −10 and 13 % ) , respectively ( ) . In DU145 cells , free @DRUG$ treatments did not affect the cell cycle progression at the concentrations here used ( ) . SMA-Ral treatment slightly increased the number of cells in G0/G1 phase of the cell cycle by 4 and 7 % for @GENE$ concentration of 5 and 10 μM , respectively ( ) .", "label": "None"}
{"id": "25100284", "sentence": "Afatinib Yang et al. [ ] Ph II ; randomized , single-arm n = 129 ; Taiwanese and US ; chemo-naïve , or one previous line of chemotherapy ; exon 19 deletion ( n = 52 ) ; @VARIANT$ ( n = 54 ) ; other ( n = 23 ) @DRUG$ 40 mg or 50 mg/day PFS : 14 months Icotinib Ren et al. [ ] Ph I ; single-arm n = 7 : Chinese ; previously treated ; exon 19 deletion ( n = 3 ) ; L858R ( n = 4 ) Icotinib ( varied dose and schedule ) PFS : 141 days ( 4.6 months ) Sun et al. [ ] Ph III ; randomized comparison with gefitinib ( ICOGEN ) n = 27 : Chinese ; previously treated ; @GENE$ mutation Icotinib 125 mg three times/day PFS : 198 days ( 6.5 months )", "label": "sensitivity"}
{"id": "17973572", "sentence": "After the cells were exposed to gefitinib for 24 h , Ba/F3-L858R cells were unable to proliferate while @GENE$ and Ba/F3-L858R-T790M cells continued to grow even in the presence of 1 μM @DRUG$ ( E ) . These results suggest that execution of apoptosis may be impaired by the presence of @VARIANT$ and , to a lesser extent , L747S .", "label": "None"}
{"id": "24523596", "sentence": "Several studies have reported renal failure and tumor lysis syndrome during TKI based molecular targeted therapies , including with sorafenib for hepatocellular carcinoma , with imatinib for chronic myelogenous leukemia , and with flavopiridol for chronic lymphocytic leukemia.– Because the @VARIANT$ variant of ABCG2/BCRP corresponding to SNP 421C&gt ; A reduces uric acid transport and those TKIs are substrates/inhibitors of ABCG2/BCRP , TKI therapy in patients with the SNP 421C&gt ; A ( Q141K ) may be at higher risk of tumor lysis syndrome . A defect in the pharmacological interaction has been suggested between sunitinib and another ABCG2/BCRP germ-line mutant allele , 1291T & gt ; C. Remarkably , @DRUG$ reversed wild-type ABCG2/BCRP mediated drug resistance and competitively inhibited ABCG2/BCRP mediated estrone 3-sulfate transport and the binding of 125I-iodoarylazidoprazosin to @GENE$ .", "label": "None"}
{"id": "24894453", "sentence": "Although high-level expression of EGFR ligands and/or increased @GENE$ gene copy numbers may be predictive markers for antitumor response by cetuximab in colon cancer [ - ] , and patients with RAS driven cancers are known not to benefit from cetuximab treatment , a clear molecular explanation of cancer response to @DRUG$ has remained elusive . Genomic studies identify @VARIANT$ mutant in colorectal carcinomas", "label": "sensitivity"}
{"id": "22960745", "sentence": "Only one sample had a KRAS codon 61 mutation , and there were no exon 19 deletions or @VARIANT$ mutations in EGFR . However , amplifications of @GENE$ were found in 7 % of cases as were two instances of the L861Q EGFR mutation , which confers sensitivity to erlotinib and @DRUG$ .", "label": "sensitivity"}
{"id": "24052078", "sentence": "In addition , previous reports showed the presence of signaling cross-activation between MET and EGFR in both A549 and H1975 cells , and both the @VARIANT$ mutation of EGFR and c-Met amplification are known mechanisms of acquired gefitinib ( TKI ) resistance in lung cancer . As c-Met has a critical role in NSCLC , co-treatment with a c-Met inhibitor plus a reversible or irreversible EGFR kinase inhibitor ( i.e. , to achieve dual c-Met /EGFR inhibition ) may represent an alternative strategy to circumvent @GENE$ mediated resistance in lung cancer . Here , we report for the first time that erlotinib/MPT0E028 co-treatment inhibits HER-2 , IGF-IR , and c-Met in erlotinib-resistant lung cancer cells .", "label": "resistance or non-response"}
{"id": "19893626", "sentence": "The second-generation BCR-ABL inhibitors , dasatinib and nilotinib , can circumvent most mutations that confer resistance to imatinib ; the @VARIANT$ mutation , however , causes resistance to all BCR-ABL kinase inhibitors developed so far . Similarly , the T790M point mutation in the epidermal growth factor receptor (EGFR) confers resistance to the @GENE$ tyrosine kinase inhibitors gefitinib and @DRUG$ , which are used to treat non-small cell lung cancer .", "label": "None"}
{"id": "15737014", "sentence": "Using this insight , new small-molecule inhibitors have been identified that retain activity against the majority of imatinib-resistant BCR-ABL mutants [ , ] . For example , in CML , a commonly found mutation is a C→T single nucleotide change that replaces threonine with isoleucine at position 315 ( T315I ) in the ABL kinase domain [ , , ] . In GIST and @GENE$ , respectively , the analogous T670I mutation in KIT and @VARIANT$ mutation in PDGFR-alpha have been associated with acquired resistance to this drug [ , ] .", "label": "None"}
{"id": "25296354", "sentence": "EGFR TKIs ( gefitinib , @DRUG$ , and afatinib ) lead to responses in most patients with advanced NSCLCs harboring sensitizing @GENE$ activating mutations when given as first or further lines of treatment . It is important to note that the most predominant somatic mutations that were included in these trials were EGFR exon 19 deletions ( the most common is delE746_A750 ) and @VARIANT$ ; therefore , all current genomic based approvals for EGFR TKIs are limited to tumors with the aforementioned classic mutations .", "label": "sensitivity"}
{"id": "23805327", "sentence": "Screening patients for low level @VARIANT$ @GENE$ mutations prior to administering @DRUG$ treatment may be useful for assessing the possibility of disease relapse .", "label": "resistance or non-response"}
{"id": "24501009", "sentence": "Three of the 4 patients with @VARIANT$ status ascertained from an archival biopsy initiated dacomitinib more than 90 days after discontinuing from @DRUG$ . Patients previously treated with investigational @GENE$ therapies were eligible to participate in the study and did not represent protocol deviations , provided the study sponsor provided written agreement .", "label": "resistance or non-response"}
{"id": "22655263", "sentence": "X-296/X-396 ( Xcovery ) are aminopyridazine based @GENE$ kinase inhibitors which display good anti-tumor activity in vitro and in vivo on different ALK dependent tumor models . X-396 was also evaluated on @VARIANT$ and C1156Y mutations and data suggest that it can potentially overcome at least these @DRUG$ resistance mutations .", "label": "resistance"}
{"id": "19707322", "sentence": "Nilotinib is approximately 30-fold more sensitive than imatinib in the killing of BCR-ABL dependent cells derived from patients with CML ( K562 and Ku-812F cells ) and cell lines ( 32D and baF3 ) , and it is active against 32/33 imatinib-resistant cell lines with BCR-ABL mutations . The sensitivity of @GENE$ mutants to AMN107 can be summarized into 4 categories : high ( IC50 ≤ 70 nmol/L : M244V , G250E , Q252H , F3llL , F317L , M351T , V379I , L387M , H396P , H396R ) , medium ( IC50 ≤ 200 nmol/L : Y253F , @VARIANT$ , F359V ) , low ( IC50 ≤ 450 nmol/L : Y253H , E255V ) , and insensitive ( IC50 & gt ; 2 μmol/L : T315I ) ( ) ( ) .", "label": "None"}
{"id": "24052078", "sentence": "In addition , previous reports showed the presence of signaling cross-activation between MET and EGFR in both A549 and H1975 cells , and both the @VARIANT$ mutation of EGFR and c-Met amplification are known mechanisms of acquired gefitinib ( TKI ) resistance in lung cancer . As c-Met has a critical role in NSCLC , co-treatment with a c-Met inhibitor plus a reversible or irreversible @GENE$ kinase inhibitor ( i.e. , to achieve dual c-Met /EGFR inhibition ) may represent an alternative strategy to circumvent T790M-EGFR mediated resistance in lung cancer . Here , we report for the first time that erlotinib/MPT0E028 co-treatment inhibits HER-2 , IGF-IR , and c-Met in erlotinib-resistant lung cancer cells .", "label": "resistance or non-response"}
{"id": "23937717", "sentence": "We postulate that the attenuation of inhibitory effect of tumor cells on NK cells may partially attributed to the stat3 inhibition by @DRUG$ . In our present study , we also find that high purity NK cells increase autophagy in A549 cancer cells with wide type EGFR , while not in H1975 cells with @GENE$ L858R + @VARIANT$ .", "label": "resistance or non-response"}
{"id": "23951354", "sentence": "Yeast two-hybrid interaction tests between XopAC or its mutant allele @VARIANT$ as bait and full-length PIX1 , PIX7 , @GENE$ , PBL2 or BIK1 as prey . P53 was used as specificity control for the prey . Ten-fold serial dilutions of yeast transformants were spotted from left to right on minimal medium ( -WL ) and minimal medium without histidine ( -WLH ) or @DRUG$ and adenine ( -WLHA ) which were used to visualize prey/bait interaction .", "label": "None"}
{"id": "18974847", "sentence": "injection of @VARIANT$ mice with K1735-M1 and of C57/BL6 mice with B16-F1 melanoma cells , at which time the treatment was initiated . Intratumoral injections of @GENE$ conjugate ( 300 ng paclitaxel ) on five consecutive days resulted in a consistent measurable difference in tumor size between the control and AMF/PGI-paclitaxel treated animals in both K1735-M1 and B16-F1 models ( ) .", "label": "None"}
{"id": "23788917", "sentence": "Unfortunately , more than half of patients with MET gene amplification also presented the @VARIANT$ mutation in the EGFR gene . Despite the lack of unequivocal efficacy , simultaneous inhibition of c-MET and EGFR function seems to be an attractive alternative therapeutic option in resistance to reversible EGFR TKI . There are ongoing second and third phase trials of the c-MET inhibitors tivantinib and PF-2341066 , used together with @DRUG$ in patients previously untreated with @GENE$ TKI or in case of progression after successful monotherapy with erlotinib [ , – ] .", "label": "resistance or non-response"}
{"id": "23606169", "sentence": "Because mutations in the KRAS gene result in activation of the epidermal growth factor receptor (EGFR) signaling pathway , only metastatic colorectal cancer patients with wild-type KRAS tumors qualify for anti-EGFR targeted therapies with @DRUG$ or panitumumab [ ] . Also , a clinical trial with the @GENE$ inhibitor ( PLX4032 ) demonstrated antitumor activity in tumors with the BRAF @VARIANT$ mutation and confirmed that V600E BRAF is a valid therapeutic target in human cancer [ ] .", "label": "resistance or non-response"}
{"id": "24303221", "sentence": "Interestingly , studies on different lung cancer cell lines suggested that NCI-H292 , a pulmonary MEC cell line that has wild-type @GENE$ , is more sensitive to @DRUG$ than other wild-type EGFR non-small cell lung cancer cell lines [ ] . O'Neill analyzed the data from multiple studies and raised the interesting question that different ethnic populations may have different EGFR mutations in their pulmonary MEC tumors [ ] . Per review of the literature , 48 pulmonary MEC tumors were tested for EGFR mutations , and nine tumors ( 19 % ) tested positive for mutations including two reports of L858R mutations , five @VARIANT$ mutations , one I760I mutation , and one exon 19 deletion .", "label": "None"}
{"id": "25027595", "sentence": "The interaction between TM4SF5 and EGFR is observed by a co-immunoprecipitation approach using NSCLC expressing TM4SF5 , where the interaction is positively correlated with the @DRUG$ resistance even without @GENE$ mutation ( e.g. , @VARIANT$ ) following TM4SF5 overexpression .", "label": "resistance or non-response"}
{"id": "24790411", "sentence": "@DRUG$ and gefitinib belong to the first generation of TKIs and have reversible binding features . The principal predictive factor for response to such drugs is the presence of somatic “activating” mutations in the EGFR gene that cause an aberrant and constitutive activation of the receptor at the membrane level , resulting in a growth advantage of tumor cells through the activation of Ras/MAPK , @GENE$ , and STAT signaling pathways . In about 50 % of cases , a secondary mutation ( @VARIANT$ ) is supposed to be responsible for resistance. , Other mechanisms involve MET gene amplification ( 5 % –20 % ) ,", "label": "None"}
{"id": "24187524", "sentence": "Furthermore , there are three small-molecule inhibitors of the tyrosine kinase domain ( TKIs ) that interfere with the binding of ATP , also approved to treat non-small cell lung cancer ( i.e. , gefitinib , @DRUG$ , and lapatinib ) [ ] . These therapeutic molecules are limited by the development of resistance mutations such as @VARIANT$ in @GENE$ , which necessitates the screening of new inhibitors .", "label": "resistance or non-response"}
{"id": "24201813", "sentence": "To identify novel mechanism ( s ) of resistance to @GENE$ inhibition , we generated PLX4032-resistant cell lines by chronic exposure of a BRAF ( @VARIANT$ ) -positive melanoma cell line to @DRUG$ .", "label": "None"}
{"id": "23937717", "sentence": "Though @DRUG$ can also restore NKG2D ligands and NKG2D interaction , and inhibit stat3 expression , we did not find significant improvement on NK cells cytotoxicity to A549 cells with wild type @GENE$ , while there was significant enhancement to H1975 cells with EGFR @VARIANT$ + T790M resistance mutations .", "label": "sensitivity"}
{"id": "23606169", "sentence": "SSCP analysis indicated KRAS WT status , which qualified her ( the patient ) for concomitant targeted therapy ( cetuximab : first dose , 400 mg/m2 ; subsequent doses , 250 mg/m2 ) and chemotherapy ( 5-fluorouracil 400 mg/m2 bolus and then 600 mg/m2 over 22 h for day 1 ; @DRUG$ 200 mg/m2 before 5-fluorouracil ) . After 4 months of treatment , stabilization of the metastatic lesions within the pelvis was observed , but two new metastatic lesions within the skin layers had occurred . Fine needle aspiration of the new metastatic lesions indicated adenocarcinomas , which were tested for KRAS and @VARIANT$ @GENE$ mutation using the real-time PCR method ( KRBR-RT50 , Entrogen ) .", "label": "None"}
{"id": "24638075", "sentence": "A number of effective @GENE$ therapeutic compounds against NSCLC , with EGFR activating mutations ( exon 19 deletions and @VARIANT$ point mutations ) , have been developed and approved for clinical use . These include both small molecule ( i.e. @DRUG$ and Gefitinib ) and antibody ( i.e. Cetuximab and Panitumumab ) inhibitors .", "label": "sensitivity"}
{"id": "16187797", "sentence": "Calculated IC50 values for gefitinib , @DRUG$ , and CL-387,785 against D770_N771insNPG were 2.6 μM , 2.5 μM , and 0.2 μM , respectively . CL-387,785 had an even greater effect on colony formation by cells expressing @VARIANT$ @GENE$ , completely inhibiting transformation at 0.003 μM ( unpublished data ) .", "label": "sensitivity"}
{"id": "15737014", "sentence": "Analogously , the @VARIANT$ mutation , in conjunction with the drug-responsive del L747–E749 ; A750P EGFR mutant , prevents inhibition of p-EGFR by erlotinib ( C ) . Sensitivity to @DRUG$ Differs Among NSCLC Cell Lines Containing Various Mutations in @GENE$ or KRAS", "label": "resistance or non-response"}
{"id": "24204234", "sentence": "In 75 % of the cases where there is a confident binding partner on the same binding site , the binding affinity is higher in the EBM proteins than in the target , as shown by the binding free-energy calculated by @DRUG$ and X-score . Two typical examples were shown in : for @GENE$ , a new binding pocket was formed by the mutation of three key residues in the active site , which improved the binding pocket shape and hydrogen bonding network with the ligand ; for PZAase , although the overall sequence identity is only 39 % , the triad , cis-peptide and metal ion binding residues at the active site are well conserved on the designed sequence . Nevertheless , one of the two competing binding sites ( the one with sulfate ion ) was eliminated by the mutation of @VARIANT$ in which one aromatic hydrophilic residue is replaced by a hydrophobic residue .", "label": "None"}
{"id": "22792530", "sentence": "This finding is related to the fact that both cell lines harbor a KRAS mutation , with SW480 and HCT116 cells expressing G12V and @VARIANT$ KRAS mutants , respectively . The finding that @GENE$ mutations are associated with resistance to @DRUG$ , reported here , is consistent with the results of previous clinical studies [ ] .", "label": "resistance or non-response"}
{"id": "24959087", "sentence": "Further evidence of the efficacy of combination therapy in overcoming resistance is demonstrated by NSCLC cell lines resistant to erlotinib and the MET inhibitor SU11274 , which display upregulation of both mTOR ( mammalian target of rapamycin ) and Wnt pathway components and restoration of sensitivity to @GENE$ inhibition by the addition of @DRUG$ . A final mechanism of resistance in gastric cancer cell lines has been demonstrated when MET amplified SNU6838 gastric cancer cell lines were treated with the MET inhibitors PHA-665752 and PF2341066 ; a novel mutation occurred in the activation loop of MET , causing a conformal change that blocked inhibitor binding analogous to the gatekeeper mutations seen in EGFR ( T790M ) following erlotinib treatment and in ABL ( T315I ) following imatinib . Although the MET @VARIANT$ mutation renders cancers insensitive to type I MET inhibitors , conformal differences between these and type II compounds may allow treatment of MET Y1230H mutant cancers or prevent the emergence of resistance due to the mutation. ,", "label": "None"}
{"id": "15737014", "sentence": "This study revealed that the quinazoline rings of erlotinib and lapatinib interact differently with the EGFR kinase domain , suggesting that while the @VARIANT$ mutation may affect inhibition by @DRUG$ and gefitinib , it may not affect inhibition of @GENE$ by compounds similar to lapatinib .", "label": "resistance or non-response"}
{"id": "24959087", "sentence": "A final mechanism of resistance in gastric cancer cell lines has been demonstrated when MET amplified SNU6838 gastric cancer cell lines were treated with the MET inhibitors PHA-665752 and PF2341066 ; a novel mutation occurred in the activation loop of MET , causing a conformal change that blocked inhibitor binding analogous to the gatekeeper mutations seen in @GENE$ ( @VARIANT$ ) following erlotinib treatment and in ABL ( T315I ) following @DRUG$ .", "label": "None"}
{"id": "23099808", "sentence": "Acquired clinical resistance to @GENE$ was also documented in lung cancer patients , who had an EGFR mutation in exon 20 ( @VARIANT$ ) ( ) . Therefore , in this study , we first examined the effects of gefitinib or @DRUG$ on cell proliferation of the cell lines including those originated from lung adenocarcinoma ( LADCA ) .", "label": "resistance or non-response"}
{"id": "23788917", "sentence": "In case of occurrence of both L858R and @VARIANT$ mutations , the concentration of @DRUG$ should be three times higher in order to achieve a therapeutic effect . Analysis of the EGFR structure in patients harbouring the T854A mutation suggests the presence of an additional side chain , localised near the @GENE$ TKI binding site [ ] .", "label": "resistance or non-response"}
{"id": "24855380", "sentence": "These drugs inhibit @GENE$ , and interestingly , they have also been demonstrated to be active in GIST harboring mutations predictive of resistance to @DRUG$ , such as mutations in exons 13 and 14 . Two cases of c-KIT mutated thymic cancers responsive to sorafenib have been reported : in one case , a patient with the missense mutation @VARIANT$ in exon 17 had a partial response lasting more than 15 months , while in the other case , stable disease was achieved in the presence of exon 11 deletion. ,", "label": "None"}
{"id": "23527257", "sentence": "When @VARIANT$ and c-MET siRNAs were combined , the cooperative effect was less potent . The dual targeting of @GENE$ and c-MET was then verified using TKIs ( gefitinib , @DRUG$ and afatinib plus su11274 ) .", "label": "resistance or non-response"}
{"id": "24634785", "sentence": "However there are still some @GENE$ mutations that confer resistance to @DRUG$ , including F317L , V299L , and @VARIANT$ [ ] .", "label": "None"}
{"id": "21042543", "sentence": "The @VARIANT$ B-RAF mutation appears in 4 % –15 % of CRC.– The possible relationship between of B-RAF mutational status and response to treatment with @DRUG$ in 48 patients with mCRC was investigated by Benvenuti et al . @GENE$ mutations were detected in 12,5 % tumors and they were mutually exclusive with K-RAS alterations .", "label": "resistance or non-response"}
{"id": "24789720", "sentence": "The possibility of detection of @VARIANT$ mutation in @GENE$ naive patients forces to expand the diagnostics of EGFR gene status during qualification for erlotinib or @DRUG$ treatment and to consider the new therapy modalities in carriers of this mutation .", "label": "resistance or non-response"}
{"id": "24810093", "sentence": "In a cohort of 309 patients from the Australian Ovarian Cancer Study ( AOCS ) , we found three common single nucleotide polymorphisms ( SNPs ) in @GENE$ ( C1236T ( rs1128503 ) , G2677T/A ( rs2032582 ) and @VARIANT$ ( rs1045642 ) ) were associated with significant differences in progression-free survival ( PFS ) for the subgroup of women with ≤ 1 cm residual disease who received @DRUG$ and carboplatin first-line chemotherapy .", "label": "None"}
{"id": "23866929", "sentence": "The entry of tyrosine kinase inhibitors ( TKIs ) gefitinib ( Iressa® , AstraZeneca , Wilmington , Delaware ) and erlotinib ( Tarceva® , Genentech , South San Francisco , California ) , which target epidermal growth factor receptor (EGFR) , is one of the most recent , gratifying events in the treatment of advanced non-small-cell lung cancer ( NSCLC ) . Clinical trials have revealed significant variability in response to EGFR-TKIs , and patient characteristics such as sex , dominantly female , East Asian ethnicity , non smoking history , and @GENE$ have been associated with an increased likelihood of EGFR-TKI effectiveness [ - ] . Furthermore , a high response rate ( 60 to 90 % ) to treatment with EGFR-TKIs has been observed in patients harboring mutations in exons 18 to 21 of the tyrosine kinase domain of EGFR , with exon 19 deletions and exon 21 @VARIANT$ point mutations comprising about 90 % of all mutations [ , ] .", "label": "None"}
{"id": "20948870", "sentence": "No changes in JAK2 @VARIANT$ allele burden were observed [ ] . Similar results ( 33 % for hepatosplenomegaly and 38 % for transfusion dependent anemia ) were reported in a phase II trial with @DRUG$ , a @GENE$ inhibitor [ ] .", "label": "None"}
{"id": "20694077", "sentence": "However , the @VARIANT$ mutant remained resistant to nilotinib at concentrations & lt ; 10 μM. , Nilotinib also potently inhibited tyrosine autophosphorylation of the E255K , E255V , F317L , M351T , and F486S Bcr-Abl mutants , and these effects were not associated with decreases in Abl or @GENE$ protein levels . Overall , these results supported the conclusion that many imatinib-resistant Bcr-Abl mutants were relatively or absolutely more sensitive to nilotinib .", "label": "None"}
{"id": "23610714", "sentence": "Mutational analysis is helpful in detecting the development of secondary mutations in tumors that are responding poorly to tyrosine kinase inhibitors and in identifying the @GENE$ exon 18 codon @VARIANT$ missense mutation , which is associated with a good prognosis , but conversely confers resistance to imatinib. , Exon 9 is reported to benefit from a high dose ( 800 mg/day ) of imatinib in some studies .", "label": "resistance or non-response"}
{"id": "21605429", "sentence": "The PDGFRA exon 18 @VARIANT$ point mutant activates @GENE$ both in vitro and in vivo [ , ] and is also imatinib resistant in vivo and in vitro [ , , ] , whereas other mutations affecting exon 18 ( D846Y , N848K , Y849K and HDSN845-848P ) are @DRUG$ sensitive [ ] .", "label": "resistance or non-response"}
{"id": "15123883", "sentence": "A full-length cDNA clone corresponding to the @GENE$ [ ] was isolated and subcloned into pALTER ( Promega , Madison , Wi ) . @VARIANT$ affects pH and channel conductance Before generating SHAM mutants , we tested wild-type ( WT ) 5-HT3R for any pH sensitivity , as we will be using protons for probing the introduced @DRUG$ sites in the M2 region .", "label": "None"}
{"id": "21264348", "sentence": "Later generation inhibitors such as nilotinib , dasatinib and @DRUG$ overcome some of the resistance created by the majority of the mutations . Both dasatinib and nilotinib exhibit higher binding affinity for the ATP-site and can overcome all but the @VARIANT$ gatekeeper mutation , . In addition , other new ATP-competitive inhibitors capable of inhibiting T315I @GENE$ have been reported in conjunction with co-crystal structures : PPY-A , SGX393 , and PHA-739358 , AP24163 , DSA series compounds , HG-7-85-01 and AP24534 ; see also .", "label": "None"}
{"id": "24276379", "sentence": "In a clinical study involving 110 patients , none of the patients with the abovementioned @GENE$ gene mutations respond to panitumumab or @DRUG$ [ ] . In another study that included 370 wild-type K-Ras patients , patients with mutant PIK3CA , particularly @VARIANT$ , had a significantly lower response rate than patients with wild-type PIK3CA [ ] .", "label": "resistance or non-response"}
{"id": "24036898", "sentence": "Trastuzumab and @DRUG$ were provided by Chugai Pharmaceutical Co. ( Tokyo , Japan ) . Rabbit polyclonal antibodies ( Abs ) against ubiquitin and actin ( Santa Cruz Biotechnology , Santa Cruz , CA ) , @GENE$ , phospho-Erk , and Erk ( Cell Signaling Technology , Danvers , MA ) , and CD31 and Ki67 ( Abcam , Cambridge , England ) were used . Mouse monoclonal Abs against CD16 ( 3G8 ) and CD54 ( HCD54 ) ( BioLegend , San Diego , CA ) and CD11a ( Ancell , North Bayport , MN ) , rabbit monoclonal Abs against HER2 ( D8F12 ) , phospho-HER2 ( 6B12 ) and phospho-Akt ( @VARIANT$ ) ( Cell Signaling Technology ) , and rat monoclonal Ab against CD18 ( YFC118.3 ) ( Chemicon International , Temecula , CA ) are also commercially available .", "label": "None"}
{"id": "23566546", "sentence": "Case Histrogical type EGFR mutation status Brinkman index Treatment agent Response @GENE$ ( ng/mL ) IL-10 ( ng/mL ) RANTES ( pg/ml ) 1 Ad Ex21 L858R 900 gefitinib PR 5.79 1.67 2 2 Ad Ex21 L858R 0 erlotinib PR_3.33 94.2 1.41 3 Ad Ex19 del 0 erlotinib PR 4.09 126 2.13 4 Ad Ex21 L858R 0 gefitinib PR_3.92 18.1 1.85 5 Ad Ex21 L858R + Ex19 del 370 erlotinib PR 21.9 1.23 2.11 6 Ad Ex19 del 0 erlotinib PR 7.05 1.37 2.56 7 Ad Ex19 del 0 gefitinib PR 4.82 1.59 2.02 8 Ad Ex21 L858R 1640 gefitinib PR 54.9 2.7 2.38 9 Ad negative 400 erlotinib SD 34.9 3.39 3.66 10 Ad negative 0 erlotinib SD 27.1 4.94 2.25 11 Ad unknown 1800 erlotinib SD NE NE NE 12 Sq Ex19 del 3840 gefitinib SD 12.6 1.1 1.98 13 Ad Ex19 del 30 erlotinib SD 5.27 0.69 2.66 14 Ad Ex19 del 0 erlotinib SD 10.5 0.85 2.5 15 Ad unknown 300 erlotinib SD 7.69 2.61 1.7 16 La negative 2080 erlotinib SD NE NE NE 17 Sq Ex21 L858R 750 erlotinib SD 11.6 56.3 3.06 18 Ad unknown 600 erlotinib SD 13.7 1.1 2.82 19 Ad Ex21 L858R 0 erlotinib SD 20.6 11.6 0.783 20 Ad Ex19 del 0 erlotinib SD 14.8 2.07 2.02 21 Ad Ex21 L858R + Ex19 del 0 gefitinib SD 3.04 1.3 1.76 22 Ad Ex19 del 200 gefitinib SD 10.9 1.59 1.91 23 Sq unknown 1560 erlotinib PD NE NE NE 24 Ad negative 1080 erlotinib PD 25.2 8.15 1.57 25 Ad unknown 0 erlotinib PD NE NE NE 26 Ad Ex18 @VARIANT$ 2000 @DRUG$ PD 11.6 4.48 3.12 27 Ad unknown 1410 erlotinib PD NE NE NE 28 Ad Ex19 del 1000 gefitinib PD 9.44 2.25 2.89 29 Ad negative 1100 erlotinib PD 56.3 5.63 2.16 30 Ad negative 2000 erlotinib PD 15.6 0.85 0.292 31 Ad negative 825 erlotinib PD 8.27 1.59 2.13 32 Ad Ex21 L858R 0 erlotinib PD 5.34 7.05 1.7 33 Ad negative 1680 erlotinib PD 57.7 1.63 2.06", "label": "None"}
{"id": "15737014", "sentence": "Collectively , these findings imply that the exon 20 T790M mutation was present on the same allele as the exon 21 @VARIANT$ mutation , and that a subclone of cells harboring these mutations emerged during drug treatment . In patient 2 , the tumor-rich sample obtained prior to treatment with @DRUG$ did not contain any additional mutations in the exons encoding the @GENE$ tyrosine kinase domain ( B , upper panels ; ) .", "label": "sensitivity"}
{"id": "23186157", "sentence": "Mutations of three residues near the mouth of the myristate binding site ( C464Y , P465S and @VARIANT$ ) were reported to cause resistance to the binding of GNF-2 , presumably for steric reasons . The myristate-binding-site mutant , E505K , was inhibited by Imatinib and Nilotinib , but not by GNF-2 , arguing that GNF-2 targets the myristoyl pocket [ ] . In this report we showed that GNF-2 cooperated with the Abl kinase inhibitors (AKIs) , Imatinib , Nilotinib and @DRUG$ , in inhibiting clonigenicity of Bcr-Abl T315I transformed @GENE$ cells .", "label": "None"}
{"id": "21814597", "sentence": "The most common PDGFRA mutation , @VARIANT$ in exon 18 , is resistant to imatinib. , , In contrast , the substitution V561D in exon 12 results in an isoform of @GENE$ that is highly sensitive to imatinib. , Lasota et al. and Heinrich et al. reported @DRUG$ sensitivities for a deletion/substitution ( SPDGHE566-571R ) and an in-frame insertion mutation ( ER561-562 ) in exon 12 .", "label": "resistance or non-response"}
{"id": "21264348", "sentence": "A. Dasatinib antiproliferative EC50 in the presence of 0.4 to 10 μM GNF‐5 on Ba/F3 cells expressing T315I and @VARIANT$ Bcr‐Abl. B. Inhibition of Bcr‐Abl autophosphoryl‐ation was determined by Bcr‐Abl immunoprecipitation , followed by a immunoblot for phospho‐Tyr ( Tyr412 ) , phospho‐STAT 5 ( @GENE$ ) and total Bcr‐Abl ( antibody K‐12 ) from cell lystates obtained after treatment of T315I Bcr‐Abl expressing Ba/F3 with 10 μM of dasatinib and increasing concentrations of GNF‐5 ( 0 , 0.5 , 5 and 10 μM ) for 90 min. ( TIF )", "label": "None"}
{"id": "25486409", "sentence": "To investigate whether CX-4945 can inhibit the growth of lung cancer cells with @VARIANT$ mediated resistance to @GENE$ , cells were treated with CX-4945 in a dose dependent manner . As shown in , CX-4945 treatment did not show a significant growth inhibition in gefitinib/erlotinib-resistant cells .", "label": "resistance or non-response"}
{"id": "18060053", "sentence": "The pRb family of proteins inhibit the G1 to S phase transition by sequestering the @VARIANT$ family of transcription factors . The MCF-7 cell-line is the most widely studied model of estrogen dependent and antiestrogen sensitive human breast cancers . MCF-7 cells were derived from a human tumor , they are ER positive ( ER+ ) , and their proliferation is stimulated by @DRUG$ and inhibited by antiestrogens in vivo and in vitro .", "label": "None"}
{"id": "23788917", "sentence": "That point mutation is caused by a single nucleotide substitution ( @GENE$ T ) at position 2369 ( codon 790 ) in exon 20 of the EGFR gene . The @VARIANT$ mutation leads to a substitution of threonine to methionine in the catalytic centre of EGFR tyrosine kinase , which is located in the binding pocket of TKI and ATP . Substitution of threonine at codon 790 into larger methionine probably results in blocking of the binding sites of @DRUG$ and gefitinib aromatic residues with their point of action .", "label": "None"}
{"id": "23522120", "sentence": "She was referred to the medical genetics service and a deleterious missense @GENE$ mutation , c.5521A&gt ; C , @VARIANT$ , situated in the highly conserved BRCT domain of BRCA1 [ ] was identified and found to be segregating with breast and ovarian cancer in her family ( Figure ) . Despite further chemotherapy including adjuvant carboplatin-paclitaxel , @DRUG$ consolidation , and cisplatin with gemcitabine , liposomal doxorubicin , topotecan , and thalidomide ( all of which resulted in short lived partial responses ) , the patient died of recurrent disease in August 2007 .", "label": "None"}
{"id": "24107858", "sentence": "They described a 3.5-fold greater mean increase in log transformed PC20 for methacholine in asthmatic children with @GENE$ variants compared to those homozygous for @DRUG$ 33 TBX21 rs2240017 after 4 years of treatment with ICS . However , the allele frequency of the minor allele @VARIANT$ was only 4.5 % and no minor homozygotes were detected .", "label": "None"}
{"id": "PMC4053234", "sentence": "For example , @DRUG$ resistance in patients with @GENE$ mutant non-small cell lung cancers has been shown to be mediated in some cases by the selection of cancer cells harboring the EGFR ( @VARIANT$ ) gatekeeper mutation and/or MET gene amplification [ ] .", "label": "resistance or non-response"}
{"id": "23818899", "sentence": "EGFR KRAS ( mutation ) Colorectal Cancer ( expressing metastatic colorectal carcinoma , EGFR ) **Therascreen KRAS Test ( Qiagen , Corporate Headquarters , Nederland 's ) **Erbitux , cetuximab ( ImClone , ImClone Systems , NJ ) **Vectibix , panitumumab ( Amgen , Amgen Inc , . CA ) [ , , ] @GENE$ @VARIANT$ ( mutation ) Melanoma ( metastatic melanoma with BRAFV600E mutation ) **Cobas 4800 BRAF V600 Mutation Test ( Panagene , Corporate Headquarters , Korea ) **Zelboraf , vemurafenib ( Genentech/Roche ) [ , ]", "label": "resistance or non-response"}
{"id": "23801357", "sentence": "@DRUG$ ( AP24534 ) is a novel pan–BCR-ABL inhibitor developed using a computational and structure based approach.– It was designed to bind to and inhibit native @GENE$ and BCR-ABL mutants that can arise during treatment with other TKIs and cause resistance , including the @VARIANT$ mutant .", "label": "response"}
{"id": "24348666", "sentence": "The concomitant inhibition of MET and EGFR using the monoclonal antiboby MetMab and @DRUG$ proved to beefficacious in a phase II trial and early clinical trials of small-molecule inhibitors of MET given with EGFR inhibitors are now currently underway ( ) . The combination of crizotinib ( dual c-MET/anaplastic lymphoma kinase @GENE$ ] inhibitor ) ( ) and dacomitinib , although in early phase , is particularly interesting since one of its components , dacomitinib , was designed to address the acquired resistance by the @VARIANT$ secondary mutation in EGFR .", "label": "None"}
{"id": "24576347", "sentence": "They should also help to clarify whether response to @DRUG$ is dependent on the stage of the disease . The mutation found in our patients ( p.T139M ) was described previously as a cause of MPS IIIA in a patient from the UK but no clinical description was reported [ ] . Here we show that the @VARIANT$ mutation in @GENE$ can cause a severe phenotype and does occur in the Arab population of Israel .", "label": "None"}
{"id": "21687596", "sentence": "The authors established gefitinib-resistant clones from a sensitive cell line with @GENE$ exon 19 deletion mutations ( HCC827 ) by exposing the cells to increasing concentrations of gefitinib . In these resistant cells , @VARIANT$ mutations were not observed but MET gene amplification occurred .", "label": "resistance or non-response"}
{"id": "24634705", "sentence": "The D761Y mutation is located on the α-C-helix of EGFR and is similar to a mutation in @GENE$ , D276G , that is associated with acquired resistance after @DRUG$ treatment [ ] . The L747S mutation lies at the start of the β3 strand and the α-C-helix [ ] and has analogous residues in BCR-ABL ( @VARIANT$ ) and ERBB2 ( L755S or P ) that have been identified in TKI resistant disease [ ] .", "label": "None"}
{"id": "20300583", "sentence": "In the one case of discordance between @GENE$ mutation status before and after combined cetuximab therapy ( case # 4 ) , a mutated KRAS gene ( Exon 2 @VARIANT$ ) was found in the primary CRC , while no KRAS mutation was observed in a liver metastasis sample obtained after combined @DRUG$ therapy ( ) .", "label": "sensitivity"}
{"id": "25336973", "sentence": "On the contrary , the mutation @VARIANT$ in exon 2 has been associated with better response to @GENE$ antibodies than other KRAS mutations , but the data are mixed. , In addition to the exon 2 KRAS mutation , other mutations such as KRAS mutation exons 3–4 and NRAS mutation exons 2–4 have also emerged to be clinically relevant biomarkers of a lack of response to EGFR antibodies . For example , treating RAS-mutant tumor patients with @DRUG$ may even have a detrimental effect on survival as shown in the Panitumumab Randomized Trial in Combination With Chemotherapy for Metastatic CRC to Determine Efficacy ( PRIME ) study , where patients were randomized to first-line chemotherapy with or without panitumumab .", "label": "None"}
{"id": "23805327", "sentence": "This method has recently been adapted for the detection of @VARIANT$ @GENE$ mutation in gefitinib-refractory disease by the use of the PNA “clamp” to inhibit the amplification of wild type DNA , .", "label": "resistance or non-response"}
{"id": "23937717", "sentence": "We postulate that the attenuation of inhibitory effect of tumor cells on NK cells may partially attributed to the stat3 inhibition by @DRUG$ . In our present study , we also find that high purity NK cells increase autophagy in A549 cancer cells with wide type @GENE$ , while not in H1975 cells with EGFR L858R + @VARIANT$ .", "label": "resistance or non-response"}
{"id": "23723712", "sentence": "Gefitinib and @DRUG$ represent the first generation of small @GENE$ tyrosine kinase inhibitors ( TKIs ) that selectively target the intracellular tyrosine kinase domain of EGFR , blocking the downstream signaling of the receptor . The EGFR somatic mutations have emerged to be the most relevant predictor of response to these agents. , Thus , several prospective randomized trials have demonstrated that the use of EGFR TKIs in patients with advanced treatment-naive NSCLC with EGFR mutations significantly improved the objective response rate ( ORR ) and progression-free survival ( PFS ) compared with standard platinum based chemotherapy.– Unfortunately , all responders eventually develop resistance , most commonly because of the emergence of a gatekeeper mutation in the kinase domain , such as @VARIANT$ in EGFR mutated NSCLC or amplification of mesenchymal–epithelial transition factor ( c-Met ) .", "label": "resistance or non-response"}
{"id": "22690222", "sentence": "Further testing revealed the presence of a @GENE$ ( @VARIANT$ ) mutation . Her prior medications of aspirin 81 mg daily and @DRUG$ 1000 mg twice daily were restarted .", "label": "None"}
{"id": "24155950", "sentence": "Murine Baf3 Bcr-Abl and @GENE$ Bcr-Abl @VARIANT$ cells were plated in 75cm2 flasks ( 4 x 106 cells/35 ml/flask ) and treated with 0.5 or 1 µM imatinib . For @DRUG$ and dasatinib treatments , the cells were plated in 25cm2 flasks ( 2 x 106 cells/10 ml/flask ) and treated with 0.125 µM or 0.5 µM nilotinib and 0.056 µM or 0.112 µM dasatinib for 48h .", "label": "None"}
{"id": "24298448", "sentence": "Vemurafenib ( @DRUG$ ) and dabrafenib ( GSK2118436 ) are approved for treatment of unresectable or metastatic melanoma ( Food and Drug Administration ) and vemurafenib is also approved by the European commission/European Medicines Agency . Both selectively inhibit the BRAF V600 mutated form of BRAF , inhibit phosphorylation of ERK , and have high clinical response rates in melanoma patients ( Figure C ) ( , ) . It has been noted already in xenografts from BRAF @VARIANT$ mutant colorectal cancer cell lines that tumor growth inhibition was most efficient when vemurafenib was combined with EGRF or @GENE$ inhibitors and/or chemotherapeutic agents ( ) .", "label": "None"}
{"id": "22481926", "sentence": "A clinical trial is currently underway to study the efficacy of liposomal adenoviral @VARIANT$ , which interferes with NFKB signaling , in combination with @DRUG$ in patients with recurrent ovarian cancer . The use of poly ( ADP-ribose ) polymerase ( @GENE$ ) inhibitors in ovarian cancer is being evaluated in various preclinical , and clinical studies .", "label": "None"}
{"id": "22779020", "sentence": "@DRUG$ was administered after palliative radiotherapy to the lumbar vertebrae , resulting in continued response for 5 years without any clinical symptom . Later tumor analysis revealed arginine-for-leucine substitution at amino acid 858 ( @VARIANT$ ) in the @GENE$ kinase domain .", "label": "sensitivity"}
{"id": "24348666", "sentence": "It was initially proposed that the T790M mutation might prevent the proper binding of tyrosine kinase inhibitors via steric hindrance , similar to the corresponding gatekeeper mutations in BCR-ABL ( @VARIANT$ ) and KIT ( T670I ) that confer resistance to imatinib ( @DRUG$ ) in chronic myelogenous leukemia and in patients with gastrointestinal stromal tumors . Interestingly , it was discovered that the T790M mutation does not confer resistance to gefitinib and erlotinib by preventing their binding as originally thought . Instead , the T790M mutation induces resistance by increasing the binding affinity of ATP by one order of magnitude , which is near the affinity for wild-type @GENE$ , thus enabling ATP to compete effectively with the kinase inhibitors .", "label": "None"}
{"id": "22870311", "sentence": "Patients with @GENE$ mutations have shown a positive response to therapy with @DRUG$ , although many of these patients relapse later , frequently due to a secondary EGFR mutation , @VARIANT$ .", "label": "resistance or non-response"}
{"id": "22123319", "sentence": "In a melanoma study of 21 patients who received a sufficiently high dose of vemurafenib , 5 without the @VARIANT$ BRAF mutation did not respond to the drug ; however , of 16 patients with the mutation , 9 responded to vemurafenib and 7 did not [ ] . In a phase II study of imatinib for advanced melanoma , a substantial proportion of patients with tumors characterized by mutation or amplification of KIT responded to the drug whereas it had limited activity in a nonselected population of melanoma patients [ ] . Results of the CRYSTAL trial indicate that the clinical activity of cetuximab against metastatic colorectal cancer is enhanced in patients with wild-type @GENE$ compared with individuals having KRAS mutations , none of whom benefited from @DRUG$ treatment [ ] .", "label": "None"}
{"id": "24304820", "sentence": "Montagut et al. reported an acquired @GENE$ ectodomain mutation ( @VARIANT$ ) that prevented cetuximab binding , thus conferring resistance to this drug . The cells with this mutation , however , retained binding to @DRUG$ , which inhibited their growth .", "label": "response"}
{"id": "25364578", "sentence": "Lazzara and colleagues found that SHP2 Y542 phosphorylation was not induced in response to EGF in the H3255 cells , which harbor the missense @VARIANT$ exon 21 mutation , suggesting that SHP2 activity may be less efficiently promoted by EGFR L858R and the STAT3 pathway may be more active . The main problem is that STAT3 activation is not abrogated by single @GENE$ TKI treatment with @DRUG$ , erlotinib , afatinib or dacomitinib , - .", "label": "sensitivity"}
{"id": "15737014", "sentence": "Since tumor specimens from three additional patients with acquired resistance to @GENE$ tyrosine kinase inhibitors did not demonstrate the @VARIANT$ mutation , this specific lesion does not account for all mechanisms of acquired resistance to gefitinib or @DRUG$ .", "label": "resistance or non-response"}
{"id": "23847684", "sentence": "But 8 TFs , including @VARIANT$ transcription factor 4 , p107/p130 binding ( E2F4 ) , regulatory factor X , 3 ( RFX3 ) , estrogen receptor 1 (ESR1) , SMAD family member 2 (SMAD2) , spleen focus forming virus ( SFFV ) proviral integration oncogene ( SPI1 ) , SP3 , nuclear transcription factor Y , alpha ( NFYA ) , and MYC , regulated their target genes independently . And we also found 3 regulationships between TFs : retinoic acid receptor , alpha ( RARA ) , retinoic acid receptor , beta ( RARB ) , and retinoic acid receptor , gamma ( RARG ) , 3 @DRUG$ subtypes [ ] . Regulation network of osteosarcoma The triangle denotes the @GENE$ the circle denotes target genes .", "label": "None"}
{"id": "23497317", "sentence": "Cell lines harboring a mutant KIT , FLT3 or @GENE$ were sequence confirmed . The gastrointestinal stromal tumor cell lines GIST822 , harboring a KIT exon 13 mutation ( K642E ) , and GIST48 , harboring an imatinib-sensitive @VARIANT$ mutation plus a secondary imatinib-insensitive activation loop mutation ( D820A ) were generously provided by Dr. Kopp ( University of Tübingen ) [ , ] .", "label": "None"}
{"id": "23994953", "sentence": "Our data appear to support a previously unrecognized scenario in which , in the presence of erlotinib sensitizing @GENE$ mutations ( delE746-A750 , @VARIANT$ ) , an aberrant/incomplete epithelial differentiation might determine the intrinsic ability of EGFR mutant-NSCLC cells to rapidly shift toward the erlotinib-refractory mesenchymal end of the epithelial-mesenchymal spectrum .", "label": "sensitivity"}
{"id": "24303221", "sentence": "Interestingly , studies on different lung cancer cell lines suggested that NCI-H292 , a pulmonary MEC cell line that has wild-type EGFR , is more sensitive to @DRUG$ than other wild-type @GENE$ non-small cell lung cancer cell lines [ ] . O'Neill analyzed the data from multiple studies and raised the interesting question that different ethnic populations may have different EGFR mutations in their pulmonary MEC tumors [ ] . Per review of the literature , 48 pulmonary MEC tumors were tested for EGFR mutations , and nine tumors ( 19 % ) tested positive for mutations including two reports of L858R mutations , five @VARIANT$ mutations , one I760I mutation , and one exon 19 deletion .", "label": "None"}
{"id": "21556318", "sentence": "Cortes et al reported that one patient who had never achieved a major molecular remission developed a @VARIANT$ mutation after 8 months on frontline nilotinib therapy . Two further patients in this study discontinued nilotinib due to intolerance and later progressed to blast crisis , one of whom developed a F359C mutation . Although BCR–ABL mutations are still being identified despite nilotinib use in frontline therapy , accounting for the number of patients receiving this therapy and comparing @DRUG$ data , it does not appear that the use of nilotinib is associated with an increased risk of inducing @GENE$ mutations .", "label": "None"}
{"id": "25364578", "sentence": "Afatinib exhibits superior anticancer activity in lung cancer patients harboring gefitinib/erlotinib-resistant mutant @GENE$ ( including @VARIANT$ , exon 20 insertion , and T790M/L858R double mutation ) .", "label": "resistance or non-response"}
{"id": "21687596", "sentence": "In the gefitinib-resistant cell line , clones with amplified @VARIANT$ mutant alleles existed in small quantities . Selective proliferation of these clones occurred on long-term exposure to PF-00299804 . The researchers suggested that although irreversible EGFR-TKI may be transiently effective against cancers harboring T790M mutations , clones harboring amplified @GENE$ T790M will rapidly emerge in vitro and in vivo through selection of pre existing EGFR T790M or high expressing clones , leading to clinical drug resistance .", "label": "resistance or non-response"}
{"id": "24339985", "sentence": "@VARIANT$ is located in the @GENE$ domain [ ] , which may play a role in protein folding [ ] . Although the substitution of arginine with @DRUG$ would not dramatically affect the protein polarity , the newly added guanidine group may affect the protein stability by modifying the folding structure of LRRK2 .", "label": "None"}
{"id": "24885169", "sentence": "For example , large phase III clinical trials have demonstrated that ADC is a strong predictive factor for improved outcome following treatment with the combination of pemetrexed with @DRUG$ compared with SQC [ ] . In addition , the presence of common activating mutations in the tyrosine kinase domain of the @GENE$ ( exon 19 deletion and exon 21 @VARIANT$ mutation ) confers strong sensitivity to gefitinib and erlotinib , which are selective tyrosine kinase inhibitors of EGFR [ , ] .", "label": "None"}
{"id": "23238683", "sentence": "@DRUG$ is a multi targeted kinase inhibitor that exhibits high activity against the @VARIANT$ mutation but also other @GENE$ kinase mutants in vitro [ , ] .", "label": "response"}
{"id": "19949544", "sentence": "The @VARIANT$ mutation is most common ( comprising 50 % of mutations ) . KIT gene amplification also occurs [ , ] . KIT mutations are mutually exclusive with BRAF and NRAS , and may identify a subset of melanoma that preferentially respond to the @GENE$ inhibitors such as imatinib ( @DRUG$ ) [ , ] or sorafenib [ , ] .", "label": "resistance or non-response"}
{"id": "23963283", "sentence": "@VARIANT$ and MET amplification account for approximately 60–70 % of all known causes of acquired resistance to @DRUG$ or erlotinib ; these amplifications are not mutually exclusive and can be detected in the same resistant tumor or may occur independently in different metastatic sites in the same patient . Consequently , ongoing research has been focused on identifying the molecular mechanisms accounting for the 30–40 % of EGFR TKI-resistant , @GENE$ tumors that do not carry EGFR mutations or MET amplification .", "label": "resistance or non-response"}
{"id": "17973572", "sentence": "@GENE$ cells expressing @VARIANT$ (LR) , L858R-L747S # 4 ( LR-LS ) , or L858R-T790M (LR-TM) were plated in 24-well plates at a density of 1 × 105/well and treated with 0.1 % DMSO ( control ) or @DRUG$ for 24 h .", "label": "None"}
{"id": "21605429", "sentence": "The @GENE$ exon 18 D842V point mutant activates PDGFRA both in vitro and in vivo [ , ] and is also imatinib resistant in vivo and in vitro [ , , ] , whereas other mutations affecting exon 18 ( D846Y , @VARIANT$ , Y849K and HDSN845-848P ) are @DRUG$ sensitive [ ] .", "label": "None"}
{"id": "24594844", "sentence": "Tumor sections from the combined treatment group exhibited lower levels of EGFR @VARIANT$ expression accompanied by higher caspase-3 protein expression levels compared with sections from the control group ( , middle and lower panel ) . Tumor tissues were also evaluated for EGFR expression and downstream signaling . The results showed that the combination of cDzT and @DRUG$ further suppressed total @GENE$ expression , the phosphorylation of EGFR in tumor tissues , and the levels of the phosphorylated forms of STAT3 , AKT , and ERK compared with the control group ( ) .", "label": "sensitivity"}
{"id": "23579627", "sentence": "An @GENE$ mutation test with this specimen using the peptide nucleic acid ( PNA ) clamping method , revealed two mutations in exon 21 ( L858R/L861Q ) and exon 20 ( @VARIANT$ ) ( ) . With the progressive disease , sixth-line @DRUG$ chemotherapy was started beginning in April 2012 .", "label": "None"}
{"id": "24141978", "sentence": "Genetic mutations of some common oncogenes associated with EGFR pathway , e.g . KRAS , BRAF ( @VARIANT$ ) , c-MET , @GENE$ , AKT and PI3KC have also been investigated in these models by hot-spot mutation sequencing . Therefore , the non-response of GC xenografts to @DRUG$ apparently can not be simply attributed to these oncogene mutations .", "label": "None"}
{"id": "25360523", "sentence": "@GENE$ binding specificity of LRRK2-N . bait plasmid prey plasmid QDO+X-α-gal+aureobasidin A pAS2-1-Rab32 wt pACT2-LRRK2-N_+ pAS2-1-Rab38 wt + pAS2-1-Rab1B Q67L − pAS2-1-Rab1B @VARIANT$ − pAS2-1-Rab11A wt − pAS2-1-Rab5A wt − pAS2-1-Rab6A Q72L − pAS2-1-Rab6A Q72R − pAS2-1-Rab7ΔC − pAS2-1-tau − After co-transformation of the yeast strain Gold with the indicated plasmids , cells were grown on synthetic media lacking adenine and @DRUG$ supplemented with 125 ng/ml aureobasidin and 40 µg/ml X-α-gal .", "label": "None"}
{"id": "25278773", "sentence": "These second-generation @GENE$ inhibitors have also been shown to drive drug resistance through the acquisition of @VARIANT$ in both preclinical and clinical settings , suggesting low potency against T790M. , As a potential solution , afatinib was combined with the EGFR antibody @DRUG$ in a Phase IIB study , which demonstrated an impressive response rate of 32 % in patients with EGFR mutant lung cancers resistant to first-generation EGFR inhibitors .", "label": "response"}
{"id": "20459863", "sentence": "Clinical responsiveness to gefitinib and @DRUG$ in NSCLC have been shown to correlate with somatic mutations in the @GENE$ gene , which result in increased sensitivity to inhibition of growth by the drugs [ , - ] . EGFR mutations have been found more frequently in non smoking East Asian women with adenocarcinoma with bronchioalvelar features [ , - ] . A protocol based on mutant enriched PCR followed by primer extension of the PCR products was used to detect EGFR @VARIANT$ mutation in NSCLC [ ] .", "label": "resistance or non-response"}
{"id": "24124361", "sentence": "For example , patients with @GENE$ , most frequently exon 19 deletions and exon 21 point mutation @VARIANT$ may respond to EGFR–TKI , like @DRUG$ or erlotinib .", "label": "sensitivity"}
{"id": "23992330", "sentence": "Briefly , they demonstrated the different effects of the G12 and G13 K-Ras alleles on response to @DRUG$ and found a significant association between the presence of a G13D mutation and survival benefit after cetuximab treatment in metastatic colorectal cancer patients [ ] . Moreover , a paper by Di Nicolantonio et al. demonstrated the different role of @GENE$ and K-Ras mutations in the response to the mammalian Target Of Rapamycin (mTOR) inhibitor everolimus . In fact , while cells knocked-in for the PIK3-CA alleles @VARIANT$ and E545K showed an increased response to everolimus , oncogenic K-Ras mutations conferred resistance to this agents [ ] .", "label": "resistance or non-response"}
{"id": "18030354", "sentence": "A 194-gene signature present in @GENE$ but not EGFR–wild-type cell lines distinguishes @VARIANT$ ( P.M. [ point mutation ] ) from Δ746–750 ( deletion ) . Cells were treated with ( + ) or without ( − ) @DRUG$ .", "label": "sensitivity"}
{"id": "24155950", "sentence": "Our results show that bortezomib and paclitaxel combined treatment is able to target the TKIs-resistant cell lines with the @VARIANT$ mutation in Bcr-Abl . Bortezomib in combination with the PLK1 inhibitor BI 2536 induces a significant downregulation of the total levels and phosphorylation of @GENE$ , a decrease of downstream phosphorylated STAT5 and caspase dependent cell death in imatinib- , dasatinib- and nilotinib-resistant and -sensitive K562 cell lines", "label": "None"}
{"id": "24924344", "sentence": "@DRUG$ rs562 ( C/T ) Chr3 : 183637845 ABCC5 ( UTR3 ) 0.049494 0.392 rs3749445 ( A/G ) Chr3 : 183638506 ABCC5 ( UTR3 ) 0.044895 0.410 rs2292998 ( C/T ) Chr3 : 183663833 ABCC5 ( intronic ) 0.039882 0.277 rs1016752 ( C/G ) Chr3 : 183665062 ABCC5 ( intronic ) 0.039781 0.232 rs4148585 ( C/T ) Chr3 : 183670642 ABCC5 ( intronic ) 0.039781 0.283 rs6443924 ( A/G ) Chr3 : 183679532 ABCC5 ( intronic ) 0.039781 0.279 rs4148579 ( A/G ) Chr3 : 183685249 ABCC5 ( intronic ) 0.039781 0.279 rs939336 ( A/G =&gt ; @VARIANT$ ) Chr3 : 183685534 ABCC5 ( exonic ) 0.039781 0.279 rs1132776 ( C/T = & gt ; A395A ) Chr3 : 183696402 ABCC5 ( exonic ) 0.044895 0.289 rs2313212 ( C/T ) Chr3 : 183700928 ABCC5 ( intronic ) 0.039781 0.279 rs4148575 ( C/T ) @GENE$ : 183702275 ABCC5 ( UTR3 ) 0.044895 0.289 rs1846692 ( C/T ) Chr16 : 56671696 MT1A ( near - gene 5 ) 0.049494 0.360 rs35346959 ( A/G ) Chr16 : 56671867 MT1A ( near- gene 5 ) 0.044895 0.137 rs9922957 ( C/G ) Chr16 : 56672380 MT1A ( near - gene 5 ) 0.039781 0.185 rs9922409 ( A/G ) Chr16 : 56672400 MT1A ( near - gene 5 ) 0.04532 0.103 rs7190725 ( G/T ) Chr16 : 56673290 MT1A ( intronic ) 0.044895 0.170 rs8052394 ( A/G =&gt ; K51R ) Chr16 : 56673828 MT1A ( missense ) 0.044895 0.152 rs1800566 ( C/T = & gt ; P187S ) chr16 : 69745145 NQO1 ( exonic ) 0.039781 0.258 rs689455 ( A/C ) Chr16 : 69761661 NQO1 ( near- gene 5 ) 0.039781 0.242", "label": "None"}
{"id": "21814597", "sentence": "The most common PDGFRA mutation , @VARIANT$ in exon 18 , is resistant to imatinib. , , In contrast , the substitution V561D in exon 12 results in an isoform of @GENE$ that is highly sensitive to imatinib. , Lasota et al. and Heinrich et al. reported imatinib sensitivities for a deletion/substitution ( SPDGHE566-571R ) and an in-frame insertion mutation ( ER561-562 ) in exon 12 .", "label": "resistance or non-response"}
{"id": "17973572", "sentence": "It is possible to conceive that an increase in the clinical doses of gefitinib or switching to @DRUG$ , which is given at its maximal tolerated dose [ ] , may lead to beneficial clinical effects , possibly by increasing BIM expression , in patients with EGFR mutations who acquired L747S after exposure to gefitinib . The data presented here indicate that BIM is both a marker and an effector of TKI induced apoptosis in EGFR-mutant NSCLC cells . Furthermore , we identified a novel acquired EGFR secondary mutation , L747S , and showed that both the L747S and the common T790M in @GENE$ to an activating EGFR mutation ( either @VARIANT$ or an exon 19 deletion ) cause resistance to EGFR TKI induced apoptosis and attenuate the up-regulation of BIM .", "label": "None"}
{"id": "22192458", "sentence": "Inhibition of @GENE$ activity in NB cell lines has already been approached by using specific small molecule ALK inhibitors , such as @DRUG$ [ ] , NVP-TAE684 [ ] and CEP14083/CEP14513 [ ] , and more recently by RNA interference molecules [ ] . Particularly , NB cells harboring either @VARIANT$ mutation or ALK amplification showed sensitivity to PF-02341066 and these results were also confirmed in xenografts ( Wood AC et al. , ASCO Annual Meeting , 2009 ) .", "label": "sensitivity"}
{"id": "21445332", "sentence": "Our results define the functional defect in @VARIANT$ and identify the initial disease related mutation in MCP that results exclusively in impaired ability to bind C4b and mediate C4b @DRUG$ activity .", "label": "None"}
{"id": "22655263", "sentence": "Ki determination demonstrated a very similar biochemical potency on wild-type ALK and the @VARIANT$ ALK mutant ( 0.09 and 0.08 nM respectively ) , with both cellular and in vivo data ( using engineered @GENE$ cells ) indicating that growth of ALK–L1196M mutant driven-cells is inhibited at similar , albeit slightly higher , doses which inhibit cells harboring wild-type ALK ( Katayama et al. , ) . AP26113 was also described to be active on a series of in vitro induced crizotinib resistant mutations , which however have not been observed to date in clinical cases of acquired @DRUG$ resistance ( Zhang et al. , ) .", "label": "None"}
{"id": "24884501", "sentence": "The mutational frequencies of the 195 KRAS mutations in the NORDIC VII cohort were ; G12A ( 9.7 % ) , G12R ( 1.5 % ) , G12D ( 35.4 % ) , G12C ( 9.7 % ) , G12S ( 6.2 % ) , G12V ( 15.4 % ) , and @VARIANT$ ( 22.1 % ) . Cetuximab did not add significant benefit to Nordic FLOX and @GENE$ mutation was not predictive for @DRUG$ effect .", "label": "resistance or non-response"}
{"id": "25054154", "sentence": "Comparing the binding free energy of @GENE$ to the drug , mutant F1174L exhibited the weakest interaction with the energy value of −7.34 Kcal/mol when compared to the mutant @VARIANT$ ( −8.07 Kcal/mol ) and native complex ( −9.21 Kcal/mol ) , respectively . Detailed analysis showed that the @DRUG$ acquired an altered mode of binding in both the mutant complexes .", "label": "sensitivity"}
{"id": "25431951", "sentence": "For instance , one @GENE$ patient in blast crisis harboring @VARIANT$ FIP1L1-PDGFRα showed a short response , followed by a rapid emergence of pan-resistance D842V mutation in FIP1L1-PDGFRα . In addition , mutations such as S601P [ ] , L629P [ ] were reported to be associated with primary resistance to @DRUG$ in FIP1L1-PDGFRα positive patient .", "label": "None"}
{"id": "23606169", "sentence": "Moreover , the presence of the @VARIANT$ mutation in the BRAF gene is more and more frequently taken into consideration before patient targeted therapy qualification , because wild-type @GENE$ is required for a response to panitumumab or @DRUG$ [ , ] .", "label": "resistance or non-response"}
{"id": "23493838", "sentence": "Transformation to accelerated phase CML occurred in four third-line patients ( dasatinib-resistant , n = 3 ; nilotinib-resistant , n = 1 ) and one fourth-line patient . Response rates were analyzed with respect to the mutational status of @GENE$ . The most frequent BCR-ABL mutations at baseline were F317L , T315I , G250E , and @VARIANT$ .", "label": "None"}
{"id": "23986642", "sentence": "In patients receiving 8 mg of @DRUG$ , a reduction of 50 % or more in CrkL phosphorylation was observed in four of six patients ( 67 % ) . At doses of 15 mg or more , 32 of 34 patients ( 94 % ) had a reduction of 50 % or more in p CrkL , and this included eight of ten patients ( 80 % ) with the @VARIANT$ mutation . This trial provided valuable evidence of ponatinib’s direct kinase inhibiting activity in patients with a variety of @GENE$ mutations , including the T315I mutant , leading to further evaluation of its effects .", "label": "None"}
{"id": "23579627", "sentence": "This findings show that EGFR @VARIANT$ is a common resistance mechanism to both reversible , and when amplified , the irreversible EGFR inhibitors . In our case , the response duration of irreversible EGFR inhibitor was 11 months which was unusually longer than those of initial gefitinib ( for 4 months ) and second round @DRUG$ ( for 6 months ) treatments . Recently an alternative approach is to develop novel strategies , instead of irreversible EGFR inhibitors , to inhibit EGFR and/or EGFR signaling , including the use of inhibitors of HSP90 and/or EGFR downstream signaling ( such as phosphatidylinositol 3-kinase and @GENE$ inhibitors ) as these resistant cancers still remain dependent on EGFR signaling for their growth .", "label": "None"}
{"id": "24349829", "sentence": "Correspondingly , direct injection of a liposome encapsulated miR-7 plasmid into established EGFR-TKI sensitive and resistant tumors bearing the @VARIANT$ EGFR mutant resulted in significant tumor regression in conjunction with repression of EGFR , RAF-1 and IRS-1 expression . In head and neck cancer , miR-7 functioned in a synergistic manner with erlotinib to render FaDu Erlotinib-resistant cells susceptible to the growth inhibitory activities of the drug . Interestingly , expression profiling analysis suggested that the downregulation of RAF-1 and @GENE$ and its ligand TGF-α by miR-7 was a possible mechanism by which miR-7 orchestrates the inhibition of EGFR signaling at multiple levels115 .", "label": "resistance or non-response"}
{"id": "24920926", "sentence": "On performing rebiopsies in 155 patients with lung adenocarcinoma after development of acquired resistance to EGFR TKIs , Yu et al showed that 63 % of patients had @VARIANT$ mutation , 13 % had @GENE$ amplification , 5 % had MET amplification , and 3 % had small cell transformation . There is no standard treatment after failure of @DRUG$ .", "label": "None"}
{"id": "25465236", "sentence": "( G–I ) increased inhibition potency for Gefitinib against EGFR @VARIANT$ mutant compared to @GENE$ WT protein and subsequent further increase in potency for @DRUG$ against EGFR L858R + E884K double mutant .", "label": "sensitivity"}
{"id": "23149688", "sentence": "All relevant phosphopeptides detected by shotgun phosphoproteomics are listed , as well as the corresponding phosphorylation sites and the fold-changes between @DRUG$ and glucose , with a negative value indicating higher abundance in glucose . Phosphosite-deficient mutants were constructed through site directed mutagenesis by replacing serine by alanine . ( B ) Evidence for increased @GENE$ in the Pda1 [ @VARIANT$ ] mutant .", "label": "None"}
{"id": "23610714", "sentence": "KIT mutations observed in patients with metastatic tumors are most frequently observed in exons 11 ( 67 % ) , 9 ( 10 % ) , 13 ( 1 % ) , or 17 ( 1 % ) , while platelet derived growth factor receptor-α ( PDGFRA ) mutations ( 10 % ) , which are less common than @GENE$ mutations , occur mostly in exons 18 ( 6 % ) , 12 ( 0.7 % ) , or 14 ( 0.1 % ) . Mutational analysis is helpful in detecting the development of secondary mutations in tumors that are responding poorly to tyrosine kinase inhibitors and in identifying the PDGFRA exon 18 codon @VARIANT$ missense mutation , which is associated with a good prognosis , but conversely confers resistance to imatinib. , Exon 9 is reported to benefit from a high dose ( 800 mg/day ) of @DRUG$ in some studies .", "label": "None"}
{"id": "20485284", "sentence": "In accordance with previous reports ( ; ) , we found that @GENE$ mutation predicted resistance to @DRUG$ treatment in the subpopulation of patients that have received this kind of therapy . Furthermore , the prognostic impact of BRAF mutation remains significant not only in the whole of the study but also in the subpopulation of patients that have not received an anti-EGFR moAbs . In summary , BRAF @VARIANT$ mutations , which are correlated with MSI-H status and cyclin D1 overexpression , characterise a subgroup of patients with poor prognosis .", "label": "resistance or non-response"}
{"id": "19758442", "sentence": "The region important for interaction with the Cul5 ubiquitin ligase complex is marked in green and includes a conserved histidine-cysteine-cysteine-histidine motif and a @GENE$ domain . The scale at the bottom indicates amino acid positions . The structural determination of full-length @VARIANT$ has so far been unsuccessful .", "label": "None"}
{"id": "24594844", "sentence": "However , the phosphorylation level of EGFR in @GENE$ @VARIANT$ mutant cells ( H1975TM/LR ) was not suppressed by @DRUG$ treatment .", "label": "resistance or non-response"}
{"id": "21716602", "sentence": "While in healthy tissues , BRCA proteins may compensate for the @GENE$ inhibition of single stranded DNA break repair , such buffering is lost in BRCA mutated tumors . Other examples of addiction dependent on tumor suppressor genes are the loss of PTEN and pRB , which lead to the stimulation of PI3K/mTOR ( Neshat et al. , ) and E2F ( Sellers and Kaelin , ) , respectively . Those defects consequently render tumor cells particularly sensitive to mTOR inhibitors and @DRUG$ ( which inhibits @VARIANT$ activated topoisomerase II ) .", "label": "None"}
{"id": "22076124", "sentence": "L1196M represents a mutation of the “gatekeeper” residue , similar to the @VARIANT$ gefitinib-resistance mutations observed in @GENE$ , and T315I mutations in ABL . Mutations in the gatekeeper site are thought to increase the affinity for ATP significantly , outcompeting the effects of ATP competitive inhibitors [ ] .", "label": "resistance or non-response"}
{"id": "23788917", "sentence": "Appearance of the most frequent activating mutation – deletion of 15 nucleotides in codons 746-750 in exon 19 and the @VARIANT$ substitution in exon 21 of the EGFR gene – is associated with permanent stimulation of the receptor , but they also lead to an increase in both efficiency of reversible EGFR TKI and effectiveness of radiotherapy . Activating mutations of the EGFR gene have been reported in only about 10 % of Caucasians patients with NSCLC , more often in non-smokers , women , and patients with adenocarcinoma . Therefore , the first studies on the efficacy of @DRUG$ and gefitinib in second-line treatment ( BR.21 , ISEL , INTEREST ) have shown that an objective response to @GENE$ TKI treatment occurs in less than 10 % of patients in the general population [ – ] .", "label": "sensitivity"}
{"id": "22970367", "sentence": "Moreover , dual inhibition of EGFR with an irreversible EGFR inhibitor ( afatinib ) and the EGFR neutralizing antibody @DRUG$ has recently shown promising activity in EGFR mutant lung cancers with acquired EGFR TKI resistance that harbor an @GENE$ @VARIANT$ mutation [ ] .", "label": "response"}
{"id": "23356214", "sentence": "In 2009 , the FDA updated the product labels for cetuximab and @DRUG$ , indicating that patients with CRC tumours harbouring @GENE$ mutations were unlikely to derive benefit from these therapies . However , these guidelines may have to be re-visited , as it has been shown ( in one study ) that patients with a @VARIANT$ mutation showed improved survival compared to patients with other mutations , indicating that this patient group may respond to therapy [ ] .", "label": "None"}
{"id": "23569389", "sentence": "Baseline @GENE$ mutation data were available for 95 % of patients . Very high imatinib resistance mutations ( @VARIANT$ , G250E , Y253H , E255K , E255V , T315I , F359V , H396R ) were associated with the lowest response rates to @DRUG$ .", "label": "None"}
{"id": "23566546", "sentence": "Case Histrogical type EGFR mutation status Brinkman index Treatment agent Response IL-8 ( ng/mL ) IL-10 ( ng/mL ) RANTES ( pg/ml ) 1 Ad Ex21 L858R 900 gefitinib PR 5.79 1.67 2 2 Ad Ex21 L858R 0 erlotinib PR_3.33 94.2 1.41 3 Ad Ex19 del 0 erlotinib PR 4.09 126 2.13 4 Ad Ex21 L858R 0 gefitinib @GENE$ 18.1 1.85 5 Ad Ex21 L858R + Ex19 del 370 erlotinib PR 21.9 1.23 2.11 6 Ad Ex19 del 0 erlotinib PR 7.05 1.37 2.56 7 Ad Ex19 del 0 gefitinib PR 4.82 1.59 2.02 8 Ad Ex21 L858R 1640 gefitinib PR 54.9 2.7 2.38 9 Ad negative 400 erlotinib SD 34.9 3.39 3.66 10 Ad negative 0 erlotinib SD 27.1 4.94 2.25 11 Ad unknown 1800 erlotinib SD NE NE NE 12 Sq Ex19 del 3840 gefitinib SD 12.6 1.1 1.98 13 Ad Ex19 del 30 erlotinib SD 5.27 0.69 2.66 14 Ad Ex19 del 0 erlotinib SD 10.5 0.85 2.5 15 Ad unknown 300 erlotinib SD 7.69 2.61 1.7 16 La negative 2080 erlotinib SD NE NE NE 17 Sq Ex21 L858R 750 erlotinib SD 11.6 56.3 3.06 18 Ad unknown 600 erlotinib SD 13.7 1.1 2.82 19 Ad Ex21 L858R 0 erlotinib SD 20.6 11.6 0.783 20 Ad Ex19 del 0 @DRUG$ SD 14.8 2.07 2.02 21 Ad Ex21 L858R + Ex19 del 0 gefitinib SD 3.04 1.3 1.76 22 Ad Ex19 del 200 gefitinib SD 10.9 1.59 1.91 23 Sq unknown 1560 erlotinib PD NE NE NE 24 Ad negative 1080 erlotinib PD 25.2 8.15 1.57 25 Ad unknown 0 erlotinib PD NE NE NE 26 Ad Ex18 @VARIANT$ 2000 erlotinib PD 11.6 4.48 3.12 27 Ad unknown 1410 erlotinib PD NE NE NE 28 Ad Ex19 del 1000 gefitinib PD 9.44 2.25 2.89 29 Ad negative 1100 erlotinib PD 56.3 5.63 2.16 30 Ad negative 2000 erlotinib PD 15.6 0.85 0.292 31 Ad negative 825 erlotinib PD 8.27 1.59 2.13 32 Ad Ex21 L858R 0 erlotinib PD 5.34 7.05 1.7 33 Ad negative 1680 erlotinib PD 57.7 1.63 2.06", "label": "None"}
{"id": "22489192", "sentence": "Somatic mutations in exon 19 and exon 21 encoding the @GENE$ TKs domain are found in about 10 % of non-small cell lung cancer ( NSCLC ) in the United States , with 78.8 % frequency in the Chinese populations with lung adenocarcinoma [ ] . NSCLC patients harboring exon 19 deletion or exon 21 @VARIANT$ somatic mutations experience significant tumor regression when prescribed the reversible small molecular tyrosine kinase inhibitors ( TKIs ) such as gefitinib and @DRUG$ .", "label": "sensitivity"}
{"id": "17551678", "sentence": "The relation of @DRUG$ treatment and @GENE$ mutation is explored by Jones et al. in 9 PV patients for whom pre-treatment samples were available [ ] . There are two cases that achieved complete haematologic remission and a 2–3-fold reduction in the percentage of @VARIANT$ alleles .", "label": "None"}
{"id": "21333004", "sentence": "The inhibitory effects of Mig6 and @DRUG$ are indicated by red lines . E11 : EGFR homodimer ; ShcP : free phosphorylated Shc ; E11P : phosphorylated EGFR homodimer ; Raf1A : activated Raf1 ; MEKP : singly phosphorylated MEK ; MEKPP : doubly phosphorylated MEK ; ERKP : singly phosphorylated ERK ; ERKPP : doubly phosphorylated @GENE$ . To investigate cell-specific EGFR signaling dynamics , we constructed an H1299WT model ( WT model ) , an H1299EGFR-WT model ( EGFR-WT model ) , and two alternate H1299L858R models ( @VARIANT$ model A with Mig6 overexpression and L858R model B with Cbl overexpression ) .", "label": "None"}
{"id": "23423768", "sentence": "The magenta ball-stick ( located just above the @DRUG$ molecule in the active site ) indicates the gatekeeper residue ( threonine790 ) that is commonly mutated to methionine ( @VARIANT$ ) , resulting in reduced inhibitor binding and drug resistance . ( C ) Simplified pathway diagram of EGFR signaling through RAS/MEK/ERK and @GENE$ indicating the points of mutation/amplification in EGFR TKI resistance as reported by Sequist and colleagues .", "label": "None"}
{"id": "24348666", "sentence": "Specifically , a leucine to methionine mutation at position 1196 ( @VARIANT$ ) and a cysteine to tyrosine mutation at position 1156 ( C1156Y ) were found . With regard to resistance due to ligands , EGFR ligands ( epidermal growth factor , @GENE$ , HB-EGF , and transforming growth factor-α ) are reported to induce @DRUG$ resistance .", "label": "None"}
{"id": "24419415", "sentence": "We retrospectively analyzed the data of 225 patients who received @DRUG$ treatment at any point in the NEJ002 study . The eligibility criteria of the NEJ002 study included the presence of advanced NSCLC harboring an @GENE$ mutation ( exon 19 deletion or L858R , @VARIANT$ , or L861Q point mutation ) without the resistant EGFR mutation T790M ( identified using the peptide nucleic acid–locked nucleic acid polymerase chain reaction clamp method ) , no history of chemotherapy , an age of 75 years or younger , a performance status of 0 to 1 , and appropriate organ function. , Patients provided a written informed consent .", "label": "None"}
{"id": "25333255", "sentence": "In addition , bosutinib ( SKI-606 ) was developed , a second line inhibitor which has the broadest target spectrum inhibiting SRC , ABL and TEC , as well as serine kinases CAMK2G and STE20 , but @DRUG$ does not target PDGFR and KIT [ , ] . Finally , the third line inhibitor ponatinib has been developed and shown to exhibit substantial efficacy in patients with CML in whom the polyresistant BCR-ABL1 @VARIANT$ mutation is expressed in leukemic cells [ ] . @GENE$ enhances resistance to therapy", "label": "None"}
{"id": "17973572", "sentence": "Transient transfection experiments utilizing COS-7 cells demonstrated that auto-phosphorylation of the original L858R EGFR was inhibited by lower concentrations of @DRUG$ or erlotinib than the L858R-L747S or L858R-T790M constructs ( A ) . CL-387,785 partially overcame the observed inhibition ( B ) . To prove the functional significance of the @VARIANT$ mutation , we generated @GENE$ cell lines stably expressing mutant EGFR constructs [ ] .", "label": "None"}
{"id": "20190765", "sentence": "A . PC9 cells expressing either @VARIANT$ @GENE$ or L858R/T790M EGFR were exposed to indicated concentrations of dasatinib ( D ) or @DRUG$ ( E ) for 120 hr and cell viability was accessed .", "label": "sensitivity"}
{"id": "15737014", "sentence": "In GIST and @GENE$ , respectively , the analogous @VARIANT$ mutation in KIT and T674I mutation in PDGFR-alpha have been associated with acquired resistance to this drug [ , ] . To determine whether lung cancers that acquire clinical resistance to either @DRUG$ or erlotinib display additional mutations in the EGFR kinase domain , we have examined the status of EGFR exons 18 to 24 in tumors from five patients who initially responded but subsequently progressed while on these drugs .", "label": "None"}
{"id": "22192458", "sentence": "Inhibition of ALK activity in NB cell lines has already been approached by using specific small molecule @GENE$ inhibitors , such as @DRUG$ [ ] , NVP-TAE684 [ ] and CEP14083/CEP14513 [ ] , and more recently by RNA interference molecules [ ] . Particularly , NB cells harboring either R1275Q mutation or ALK amplification showed sensitivity to PF-02341066 and these results were also confirmed in xenografts ( Wood AC et al. , ASCO Annual Meeting , 2009 ) . However , NB cell lines with both @VARIANT$ ALK mutations and wild type ALK were more resistant .", "label": "resistance"}
{"id": "22132735", "sentence": "EGFR gene mutations indicate sensitivity to gefitinib , and it was demonstrated that about 85 % of patients with NSCLC who obtained benefit from @DRUG$ treatment were found to have mutations in exons 18 to 21 of the tyrosine kinase domain of the EGFR gene [ - ] . EGFR mutations in exon 19 ( short in-frame deletions ) or 21 @VARIANT$ ( point mutation ) affect the adenosine triphosphate ( ATP ) pocket of the tyrosine kinase domain leading to the activation of 4-anilinoquinazoline compounds , which function to compete with ATP [ ] . Anti-EGFR therapy can consequently lead to the downregulation of downstream signaling cascades , such as the PI3K/Akt , @GENE$ , MAPK , and STAT pathways , responsible for cell proliferation and survival , resulting in the inhibition of cell proliferation and induction of cell apoptosis , respectively .", "label": "None"}
{"id": "22889873", "sentence": "MM-121 effects were also assessed in a mouse model of lung cancer caused by doxycycline induced over-expression of a double mutant @GENE$ T790M-L858R . This model mimics resistance to TKIs that develops in patients following the secondary mutation @VARIANT$ and is characterized by increased heregulin expression and phosphorylation of ErbB3 . MM-121 , which is cross-reactive to the mouse homologue , was poorly active when administered as monotherapy , but exterted strong tumor growth inhibitory effect when given in combination with @DRUG$ [ ] .", "label": "response"}
{"id": "21814611", "sentence": "In this case , because HBeAg was detected and HBV DNA was still high 3 months after administration of clevudin , it should be clarified that the mutations in the overlapping frame gene regions , S codon L213I ( P codons @VARIANT$ and A222T ) , may be associated with escape mutation as well as drug resistance . An interesting point of this case concerns the sustained HCV suppression , which occurred even with insufficient treatment of @DRUG$ .", "label": "None"}
{"id": "23493883", "sentence": "Many drugs have been studied in patients who progressed after treatment with a reversible @GENE$ , including XL-647 , @DRUG$ , and neratinib , with little success . Combinations of therapy such as cetuximab plus erlotinib and gefitinib plus everolimus have also been tried . The most promising drug thus far has been afatinib ( BIBW2992 ; Boehringer-Ingelheim Pharma , Ingelheim , Germany ) , , an ErbB family blocker with reported in vitro and in vivo activity against EGFR mutant tumors harboring exon 19 deletions , exon 21 L858R mutations and the exon 20 @VARIANT$ “resistance” mutations .", "label": "None"}
{"id": "23994953", "sentence": "Somatic mutations in exons encoding the tyrosine kinase ( TK ) domain of the @GENE$ positively associated with increased sensitivity of non-small cell lung cancer ( NSCLC ) patients to the selective EGFR TK inhibitors ( TKIs ) gefitinib ( Iressa™ ) and @DRUG$ ( Tarceva™ ) . Prospective trials have demonstrated an impressive ~75 % response rate for patients whose tumors harbor these mutations , which occur as either multinucleotide in-frame deletions in exon 19 ( e.g. , delE746-A750 ) or as single missense mutations ( e.g. , @VARIANT$ ) .", "label": "sensitivity"}
{"id": "23493883", "sentence": "Many drugs have been studied in patients who progressed after treatment with a reversible @GENE$ , including XL-647 , dasatinib , and neratinib , with little success . Combinations of therapy such as cetuximab plus @DRUG$ and gefitinib plus everolimus have also been tried . The most promising drug thus far has been afatinib ( BIBW2992 ; Boehringer-Ingelheim Pharma , Ingelheim , Germany ) , , an ErbB family blocker with reported in vitro and in vivo activity against EGFR mutant tumors harboring exon 19 deletions , exon 21 L858R mutations and the exon 20 @VARIANT$ “resistance” mutations .", "label": "resistance or non-response"}
{"id": "23741498", "sentence": "To investigate if the co-treatment with both @VARIANT$ and A3AR agonists determined an even further inhibition of IL-6 as an example of inflammatory @GENE$ we incubated T/C-28a2 or hFOB 1.19 cells with CGS 21680 ( 100 nM ) and Cl-IB-MECA ( 100 nM ) .", "label": "None"}
{"id": "23407898", "sentence": "The irreversible TKI @DRUG$ afatinib ) is currently being investigated in advanced clinical trials ( Yap et al. , ; Murakami et al. , ) . Another novel irreversible pan-HER inhibitor HM781-36B has recently shown promise in the inhibition of EGFR , @GENE$ , and HER4 as well as against the gatekeeper mutation – EGFR @VARIANT$ that is responsible for acquired drug resistance in lung cancer patients ( Cha et al. , ) .", "label": "None"}
{"id": "24349829", "sentence": "As would be predicted from the prior studies cited above , miR-7 blunted @GENE$ signaling and reversed the radio-resistance . Correspondingly , direct injection of a liposome encapsulated miR-7 plasmid into established EGFR-TKI sensitive and resistant tumors bearing the @VARIANT$ EGFR mutant resulted in significant tumor regression in conjunction with repression of EGFR , RAF-1 and IRS-1 expression . In head and neck cancer , miR-7 functioned in a synergistic manner with erlotinib to render FaDu Erlotinib-resistant cells susceptible to the growth inhibitory activities of the drug .", "label": "None"}
{"id": "23710459", "sentence": "Finally , Shin and coworkers engineered the S. cerevisiae strain ( W303-1A ) with four heterologous genes , the PAL gene from Rhodosporidium toruloides , the @VARIANT$ and the 4CL1 genes from A. thaliana , and the STS gene from Arachis hypogea [ ] . Overexpression of the @GENE$ carboxylase ( ACC1 ) gene for increasing the pool of malonyl-CoA resulted in an engineered strain termed W303-1A/ACC1 harboring the p425PAL , p423C4H , and pESCTRP4CL1-STS plasmids capable of synthesizing 5.8 mg/L @DRUG$ upon feeding with 12 mM tyrosine in YP medium containing 2 % galactose .", "label": "None"}
{"id": "16552419", "sentence": "Seven of nine cases with mutated types showed high sensitivity to @DRUG$ , and the patients with @GENE$ mutations had a more favourable prognosis than those with wild type after gefitinib treatment ( P=0.033 ) ( ) . In conclusion , our established methods are thus considered to be very useful for identifying a deletion of exon 19 and a point mutation ( @VARIANT$ ) of exon 21 of the EGFR gene as a screening .", "label": "sensitivity"}
{"id": "25405807", "sentence": "Inhibition of epidermal growth factor receptor (EGFR) kinase activity by EGFR tyrosine kinase inhibitors ( @GENE$ ) , such as gefitinib and @DRUG$ , can result in improved response and prolonged progression-free survival ( PFS ) in selected non-small cell lung cancer ( NSCLC ) patients harboring sensitizing EGFR mutations , especially the exon 19del and exon 21 @VARIANT$ mutations – .", "label": "sensitivity"}
{"id": "22436374", "sentence": "H1650 and HCC827 have an in-frame deletion in the @GENE$ tyrosine kinase domain ( EGFR tyrosine kinase domainΔE746-A750 , exon 19 ) . H1650 cells have also a deletion of the 3 ' part of exon 8 and the entire exon 9 of PTEN , which causes loss of the protein [ ] and in addition express the insulin-like growth factor receptor ( IGF1R ) [ ] . The cell line H1975 has a sensitizing @VARIANT$ kinase domain mutation in exon 21 , but also a second mutation ( T790M , in cis , in the kinase domain ) rendering them resistant to the reversible TKIs @DRUG$ and erlotinib [ ] .", "label": "sensitivity"}
{"id": "22655263", "sentence": "When tested in Ba/F3 cells driven by ALK mutants identified in crizotinib relapsed patients , NMS-E628 is circa fivefold more potent than @DRUG$ in inhibiting the proliferation of @VARIANT$ @GENE$ and C1156Y ALK-driven-cells in vitro and in vivo ( Ardini et al. , ) .", "label": "resistance"}
{"id": "22249430", "sentence": "Antitumor effects were shown against tumors with @GENE$ activating mutations , found in 30–50 % of Asian patients with lung cancer [ ] , and also against tumors with @VARIANT$ , a mutation detected in the tumors of approximately 50 % of patients with lung adenocarcinoma who develop acquired resistance to @DRUG$ or erlotinib [ – ] .", "label": "resistance or non-response"}
{"id": "25465236", "sentence": "( C ) EGFR T790M mutant does not resemble pEGFR unlike the EGFR @VARIANT$ mutant shown in B. ( D–F ) increased inhibition potency for @DRUG$ against EGFR L858R mutant compared to EGFR WT protein and subsequent decrease in potency for Erlotinib against @GENE$ L858R + E884K double mutant .", "label": "sensitivity"}
{"id": "24236082", "sentence": "Additionally , cells bearing the mutant @GENE$ were in general more sensitive to EGFR–TKIs than cells expressing the wild type kinase . The @VARIANT$ mutant was 10–100 fold more sensitive to @DRUG$ and gefitinib than the wild type kinase , .", "label": "sensitivity"}
{"id": "23082072", "sentence": "However , in patients with acquired resistance , tumor cells bearing EGFR @VARIANT$ represented a minority of cells , and as such , part of the tumor may remain responsive to erlotinib or gefitinib. , The other signal pathway related @GENE$ followed the same principles .", "label": "resistance or non-response"}
{"id": "25122428", "sentence": "The dual inhibition of PI3K and mTOR might be advantageous over single inhibition by suppressing a @VARIANT$ feedback loop that leads to the pathway reactivation . Based on this idea , an on-going phase I study of the @GENE$ and mTORC1/2 dual inhibitor , BEZ235 , was designed for the patients with advanced solid tumors harboring PIK3CA or PTEN alteration ( NCT01195376 ) . In this study , we showed that the survival of the cisplatin-resistant SCLC cell lines was well suppressed by BEZ235 , accompanied by the suppression of S6RP phosphorylation .", "label": "None"}
{"id": "22970367", "sentence": "The data suggest that low BRCA1 level may neutralize the negative effects of the EGFR T790M mutation on @DRUG$ sensitivity and that high @GENE$ expression may lead to de novo EGFR TKI resistance potentially through increased DNA damage repair capacity [ ] . In addition to EGFR T790M , primary EGFR TKI resistance may also be due to other secondary mutations in EGFR ( e.g. , @VARIANT$ ) that occur in cis with an activating EGFR kinase domain mutation ( e.g. , L858R ) [ ] .", "label": "None"}
{"id": "16987420", "sentence": "Also , centrosome amplification induced by a transient G1/S arrest because of the presence of @DRUG$ , generated aneuploidy both in human and MEFs with pRb dysfunction [ ] . However , it is still controversial whether p53 loss/inactivation plays a direct role in centrosome amplification [ ] and chromosome instability [ ] . Indeed , recently it has been reported that p53 deficient cells need cyclin E over-expression , a target of @VARIANT$ @GENE$ induce chromosome instability and centrosome amplification [ ] .", "label": "None"}
{"id": "23874486", "sentence": "We didn’t observe that patients with @GENE$ @VARIANT$ mutation had better response rate ( ) . 10.1371/journal.pone.0068022.t002Patients’ characteristics of the 35 patients receiving @DRUG$ .", "label": "resistance or non-response"}
{"id": "25054154", "sentence": "This suggests that @VARIANT$ mutation affects the binding of @DRUG$ and makes the backbone more flexible to move . Furthermore , the flexibility of mutant R1275Q was found to be in consistent with the native @GENE$ .", "label": "resistance"}
{"id": "23493883", "sentence": "The most promising drug thus far has been @DRUG$ ( BIBW2992 ; Boehringer-Ingelheim Pharma , Ingelheim , Germany ) , , an ErbB family blocker with reported in vitro and in vivo activity against @GENE$ mutant tumors harboring exon 19 deletions , exon 21 L858R mutations and the exon 20 @VARIANT$ “resistance” mutations .", "label": "response"}
{"id": "23674887", "sentence": "When patients with @VARIANT$ at baseline were excluded from the second-line setting , response rates for the remaining patients with ≥1 mutation were 93 % for @GENE$ and 62 % for MCyR . Efficacy of @DRUG$ in CML patients without resistance conferring mutations at baseline", "label": "None"}
{"id": "17973572", "sentence": "To prove the functional significance of the @VARIANT$ mutation , we generated Ba/F3 cell lines stably expressing mutant EGFR constructs [ ] . These cell lines , including L858R-L747S , proliferated in the absence of IL3 . Ba/F3-L858R cells were extremely sensitive to @DRUG$ ( D ) , whereas @GENE$ cells were highly resistant up to 1 μM gefitinib .", "label": "None"}
{"id": "23049365", "sentence": "@DRUG$ ( AP24534 ) was developed to interact with the inactive @GENE$ conformation at multiple sites and with the @VARIANT$ mutation , providing high affinity and efficacy .", "label": "response"}
{"id": "22586484", "sentence": "It has been reported that the use of @DRUG$ was associated with longer overall and progression-free survival among patients with chemotherapy-refractory colorectal cancer with @VARIANT$ mutated tumors than patients with other @GENE$ mutated tumors .", "label": "resistance or non-response"}
{"id": "25033171", "sentence": "Therefore , by using the advanced metadynamics techniques , namely , well tempered metadynamics and funnel metadynamics , we explored the free energy surfaces of the @DRUG$ unbinding from WT and @VARIANT$ mutated @GENE$ tyrosine kinase , which were designed to move against the ligand-receptor distance and P-loop conformational change ( open or close ) as described in the previous studies , .", "label": "resistance"}
{"id": "23320171", "sentence": "Further research is looking into inhibiting other targets such as mTOR , @VARIANT$ , or AKT pathways . Two randomized trials are evaluating the addition of the @GENE$ inhibitor , everolimus , to chemotherapy and Trastuzumab in the first-line and Trastuzumab-resistance metastatic setting .", "label": "None"}
{"id": "23606169", "sentence": "Because mutations in the KRAS gene result in activation of the epidermal growth factor receptor (EGFR) signaling pathway , only metastatic colorectal cancer patients with wild-type KRAS tumors qualify for anti-EGFR targeted therapies with cetuximab or @DRUG$ [ ] . Also , a clinical trial with the BRAF inhibitor ( PLX4032 ) demonstrated antitumor activity in tumors with the @GENE$ @VARIANT$ mutation and confirmed that V600E BRAF is a valid therapeutic target in human cancer [ ] .", "label": "resistance or non-response"}
{"id": "25562798", "sentence": "In the case of acquired resistance to gefitinib and @DRUG$ in @GENE$ mutant tumors two major mechanisms have been identified . Firstly , a secondary mutation , the @VARIANT$ mutation within exon 20 of EGFR , is responsible for about 50 % of instances of acquired resistance [ , ] .", "label": "resistance or non-response"}
{"id": "23515890", "sentence": "Of the melanoma patients treated with @DRUG$ , 11 % had mutations in KIT [ other patients presented with mutations in BRAF ( 23 % ) , NRAS ( 14 % ) , or @GENE$ ( 0 % ) ] . Patients positive for KIT mutations ( n = 4 ; exon 11 ; W557G , @VARIANT$ , or L576P ) showed varied responses to the treatment .", "label": "None"}
{"id": "23888935", "sentence": "Ponatinib is a novel , synthetic , orally active , potent @GENE$ inhibitor and multi targeted TKI that was discovered using a computational and structure based drug design approach.– @DRUG$ was specifically designed to inhibit native BCR-ABL and mutant forms that can arise during treatment with other TKIs and cause resistance , including the @VARIANT$ gatekeeper mutant .", "label": "response"}
{"id": "19949544", "sentence": "The @VARIANT$ mutation is most common ( comprising 50 % of mutations ) . KIT gene amplification also occurs [ , ] . KIT mutations are mutually exclusive with @GENE$ and NRAS , and may identify a subset of melanoma that preferentially respond to the KIT inhibitors such as @DRUG$ ( Gleevec ) [ , ] or sorafenib [ , ] .", "label": "None"}
{"id": "23606169", "sentence": "Because mutations in the KRAS gene result in activation of the epidermal growth factor receptor (EGFR) signaling pathway , only metastatic colorectal cancer patients with wild-type KRAS tumors qualify for @GENE$ targeted therapies with @DRUG$ or panitumumab [ ] . Also , a clinical trial with the BRAF inhibitor ( PLX4032 ) demonstrated antitumor activity in tumors with the BRAF @VARIANT$ mutation and confirmed that V600E BRAF is a valid therapeutic target in human cancer [ ] .", "label": "None"}
{"id": "23238683", "sentence": "As shown in Figure , BaF3 cells expressing native BCR-ABL were highly sensitive to imatinib , dasatinib and ponatinib , whereas @GENE$ and BaF3-G250E-BCR-ABL cells were resistant to both imatinib and @DRUG$ . By contrast , ponatinib induced loss of cell viability in BaF3 cells carrying the T315I or @VARIANT$ mutation , in agreement with previous results from the literature [ , ] .", "label": "None"}
{"id": "24955213", "sentence": "@VARIANT$ EML-ALKpm A mutation-specific strong H-bond pulls @DRUG$ out of the position found in the non-crizotinib resistant EML-ALK fusion gene [ , ] 1151Tins Thr insertion is predicted to alter ATP binding to ALK [ ] ALK Copy Number Gain Two cases ; one with and one without an ALK mutation , 4-5-fold increased expression [ ] EGFR Alterations L585R mutation in one case , other cases often show in EGFR and @GENE$ amplification [ , , ]", "label": "None"}
{"id": "24155950", "sentence": "The sensitivity of K562 , K562-R , LAMA84 , LAMA84-R , @GENE$ Bcr-Abl , and Baf3 Bcr-Abl @VARIANT$ cell lines to the most used Bcr-Abl inhibitors in CML : imatinib , dasatinib ( Santa Cruz Biotechnology , CA , USA , Cat. # sc-218081 ) and @DRUG$ ( Santa Cruz Biotechnology , CA , USA , Cat. # sc-202245 ) was investigated by treating these cells with increasing concentrations of each drug and measuring cell death using an automated Trypan Blue exclusion method ( see ) .", "label": "None"}
{"id": "25505694", "sentence": "@DRUG$ is an orally , irreversible EGFR , HER2 and HER4 inhibitor , showing preclinical activity against cancer cells harboring common activating @GENE$ mutations and the @VARIANT$ mutation , albeit with a lower potency [ ] .", "label": "response"}
{"id": "24501009", "sentence": "The remaining members of the HER family comprise HER2 and HER4 tyrosine kinases , and the kinase‐null @GENE$ .1 HER family members act together via hetero‐ and homodimerization to enable downstream signaling pathways modulating a range of cellular activities , including growth , proliferation , differentiation , and migration . In contrast to patients with EGFR‐mutation‐positive tumors , patients with KRAS‐mutant NSCLC are unlikely to respond to gefitinib or @DRUG$ and do not have an improved progression‐free survival ( PFS ) compared with those who have placebo following erlotinib therapy . Dacomitinib ( PF‐00299804 ) is a potent , irreversible , oral small‐molecule inhibitor of HER1/EGFR , HER2 , and HER4 tyrosine kinases with antitumor activity in both gefitinib‐sensitive and gefitinib‐resistant , including EGFR @VARIANT$ , preclinical NSCLC models .", "label": "None"}
{"id": "23937717", "sentence": "@DRUG$ enhanced cytotoxicity of NK cells in human lung cancer cells with @GENE$ L858R + @VARIANT$ mutation", "label": "resistance or non-response"}
{"id": "24634705", "sentence": "Similar to other tyrosine kinase inhibitors , patients treated with @DRUG$ eventually develop resistance and mutations that lead to resistance have been reported [ , ] . In one report , the patient developed two de novo mutations within the kinase domain of @GENE$ , @VARIANT$ and L1196M [ ] .", "label": "resistance"}
{"id": "23569389", "sentence": "No differences in overall response rate were observed in patients with @GENE$ mutations at baseline , in particular for p-loop mutations . A subanalysis was conducted by Branford et al on the emergence of new detectable mutations in 479 patients treated with dasatinib after @DRUG$ failure , and development of new mutations , including T315A , F317L , and @VARIANT$ , was rare ( 13 % ) .", "label": "None"}
{"id": "16187797", "sentence": "Tumors from patients with clinical responses to the EGFR inhibitors gefitinib or @DRUG$ have been shown to contain @GENE$ deletion mutations or substitution mutations [ , ,, ] , but no exon 20 insertion mutations have been reported in this group of clinical responders . Although exon 20 mutations were not widely reported at first , recently five large-scale studies that sequenced EGFR exons 18 through 21 reported a total of 18 exon 20 insertions out of 350 EGFR mutations identified in 1,108 non-small-cell lung cancers [ – ] . Patients who responded to gefitinib and subsequently relapsed were found to have @VARIANT$ secondary mutations , also in exon 20 [ , ] .", "label": "resistance or non-response"}
{"id": "22935382", "sentence": "To explore potential @DRUG$ resistance mechanisms in model EC039 , we screened for mutations in a panel of genes ( EGFR , @GENE$ , B-raf and PIK3CA ) across all 5 PDECX models and their corresponding patient EC tissues . Screened gene locations included ; exons 18 , 19 , 20 , 21 of EGFR gene , exons 2 and 3 of K-ras gene , exons 11 and 15 of B-raf gene , and exons 9 and 20 of PI3KCA gene . Interestingly , PIK3CA @VARIANT$ ( E542K ) mutation was identified within exon 9 of the PIK3CA gene helical domain in both EC039 model and the corresponding patient’s EC tissue .", "label": "None"}
{"id": "22117530", "sentence": "Even though some studies have reported significant associations between these polymorphisms and clinical efficacy of rituximab [ ] , trastuzumab [ ] or @DRUG$ [ , ] , data conflict regarding which alleles are linked to favorable patient outcome . In the present study , we report a significant influence of @GENE$ @VARIANT$ polymorphism on survival both in the whole population and in patients with a wt KRas tumor , with VV patients presenting a dramatically shorter survival .", "label": "None"}
{"id": "15737014", "sentence": "To determine how the @VARIANT$ mutation would affect EGFR proteins already containing mutations associated with sensitivity to @GENE$ tyrosine kinase inhibitors , we introduced the specific mutation into EGFR cDNAs that encoded the exon 21 and 19 mutations found in patients 1 and 2 , respectively . Various lysates from cells that were serum starved and pre treated with gefitinib or @DRUG$ were analyzed by immunoblotting .", "label": "resistance or non-response"}
{"id": "22536370", "sentence": "NRAS @GENE$ % Acral 24 % Mucosa 15 % CSD 22 % non-CSD , Sensitive to : ( pre-clinical ) MEK +/− PI3K inhibition , , , MET inhibition Resistant to : BRAF inhibitors KIT @VARIANT$ V559A/D L576P K642E D816H 23 % Acral 16 % Mucosal 28 % CSD , , Sensitive to : Imatinib Nilotinib @DRUG$ Dasatinib Decreased sensitivity to : Imatinib ( D816H only ) , , , ,", "label": "None"}
{"id": "23994953", "sentence": "However , it should be noted that these studies were largely based on NSCLC cells expressing wild-type EGFR ; therefore , these studies did not mimic clinical usage of @GENE$ TKIs because EGFR wild-type NSCLC cells are intrinsically resistant to EGFR TKIs . In this scenario , it might appear reasonable to suggest that in addition to the presence of the @VARIANT$ mutation , immunohistochemical and/or microarray based transcriptional profiling studies dedicated to specific alterations of EMT drivers ( e.g. , SLUG ) and/or effectors ( e.g. , vimentin ) may be helpful in monitoring for @DRUG$ responders and non-responders based on the loss of biomarkers associated with epithelial status and gain of biomarkers associated with mesenchymal status .", "label": "resistance or non-response"}
{"id": "22343623", "sentence": "However , patients with wild-type EGFR and acquired mutation in @GENE$ @VARIANT$ are eventually resistant to treatment with @DRUG$ .", "label": "resistance or non-response"}
{"id": "23515890", "sentence": "The drug resistance mutation @VARIANT$ was detected in CTCs collected from patients with @GENE$ mutations that had received tyrosine kinase inhibitors Gefitinib ( Iressa ) or Erlotinib ( @DRUG$ ) .", "label": "resistance or non-response"}
{"id": "25347122", "sentence": "@GENE$ pathway ; HSP90 NVP-BEZ235 ; 17-DMAG ( HSP90 inhibitor ) However , in these trials , TNBC was unselected based on gene ontologies and differential gene expression profiles . In the randomized open-label phase III CALGB 40502/NCCTG @VARIANT$ , the new and expensive BC treatments , nanoparticle albumin bound nab-paclitaxel ( Abraxane ) and ixabepilone , the latter being a potent epothilone that can be effective after microtubule inhibitor resistance ( Ixempra ) , have failed to demonstrate any superior efficacy versus the standard of weekly paclitaxel in combination with @DRUG$ in patients with chemotherapy naïve metastatic BC .", "label": "None"}
{"id": "23552882", "sentence": "For example , HCC827 cells undergo @GENE$ amplification and AXL induction upon adaption to gefitinib , , , and PC9 cells acquire the @VARIANT$ mutation in EGFR that confers resistance to @DRUG$ and gefitinib .", "label": "None"}
{"id": "25429239", "sentence": "Other amino acid substitutions observed include @VARIANT$ , G1202R , and S1206Y substitutions , as well as a 1151 threonine insertion . Another described resistance mechanism involves amplification of the ALK fusion gene and activation of other bypass mechanisms.– @GENE$ gene amplification and EGFR activation have also been reported as mechanisms of acquired @DRUG$ resistance. , ,", "label": "None"}
{"id": "17877814", "sentence": "No fibrils were observed in the case of @GENE$ @VARIANT$ or Ins774HV at any of the @DRUG$ concentrations tested .", "label": "resistance or non-response"}
{"id": "17973572", "sentence": "Based on the data obtained from lung cancer cell lines , we further explored the mechanisms by which @VARIANT$ and L747S resistant mutations affect BIM up-regulation and apoptosis . @DRUG$ effectively induced apoptosis in @GENE$ cells , whereas Ba/F3-L858R-L747S cells were intermediately resistant and Ba/F3-L858R-T790M completely resistant ( A , top ) .", "label": "None"}
{"id": "23210897", "sentence": "E2F1 belongs to the @VARIANT$ family of transcription factors , and plays an important role in cell cycle progression and apoptosis [ ] . Besides cell cycle regulation , E2F1 participates in DNA damage response and functions as a checkpoint control [ ] . Increased E2F1 protein level associated with DNA damage and repair is observed in NSCLC cells after exposure to @DRUG$ [ ] .", "label": "None"}
{"id": "22655263", "sentence": "The mechanisms underlying decreased activity of @DRUG$ on these secondary @GENE$ mutants were investigated by structural and biochemical analyses , together with cellular data generated in engineered in vitro models . For the L1196M , @VARIANT$ , and L1152R mutants , it appears that binding of the inhibitor to ALK may be negatively affected by steric hindrance or conformational changes in the enzyme .", "label": "resistance"}
{"id": "24523812", "sentence": "The eligible 10 patients had stage IV NSCLC and were treated with gefitinib or @DRUG$ monotherapy for more than 6 months . They had achieved radiographic response before EGFR-TKI failure or documentation of either @GENE$ exon 19 deletion or an EGFR @VARIANT$ mutation .", "label": "sensitivity"}
{"id": "24137394", "sentence": "The patient was first administered @DRUG$ and maintained a good response for one year , according to the literature data ( 14 months ) ( ) . The patient then presented with a peritoneal progression and a second biopsy was planned to rule out acquired resistant @GENE$ mutations . A double mutation was detected , consisting of an activating mutation ( exon 19 deletion ) and an acquired resistance mutation ( exon 20 @VARIANT$ ) .", "label": "resistance or non-response"}
{"id": "24071646", "sentence": "Atorvastatin could still enhance gefitinib efficacy in H460 cells ( @DRUG$ treatment versus 1 or 5 μM atorvastatin+gefitinib treatment , IC50=16.4 versus 4.06 or 1 μM ) . Besides , we transfected PI3K mutation @GENE$ ( @VARIANT$ ) into A549 and Calu1 cells .", "label": "resistance or non-response"}
{"id": "24004697", "sentence": "The proliferation inhibition effect of PPP2R5C-siRNAs on the imatinib-sensitive and imatinib-resistant cell lines . A : K562 and K562R cells treated with PPP2R5C-siRNA799 , B : 32D-Bcr-Abl WT and 32D-Bcr-Abl @VARIANT$ cells treated with PPP2R5C-siRNA799 , C : K562 and K562R cells treated with PPP2R5C-siRNA991 , D : @GENE$ WT and 32D-Bcr-Abl T315I cells treated with PPP2R5C-siRNA991 .", "label": "None"}
{"id": "22436374", "sentence": "H1650 and HCC827 have an in-frame deletion in the EGFR tyrosine kinase domain ( @GENE$ tyrosine kinase domainΔE746-A750 , exon 19 ) . H1650 cells have also a deletion of the 3 ' part of exon 8 and the entire exon 9 of PTEN , which causes loss of the protein [ ] and in addition express the insulin-like growth factor receptor ( IGF1R ) [ ] . The cell line H1975 has a sensitizing @VARIANT$ kinase domain mutation in exon 21 , but also a second mutation ( T790M , in cis , in the kinase domain ) rendering them resistant to the reversible TKIs gefitinib and @DRUG$ [ ] .", "label": "sensitivity"}
{"id": "25364578", "sentence": "Lazzara and colleagues found that SHP2 Y542 phosphorylation was not induced in response to @GENE$ in the H3255 cells , which harbor the missense @VARIANT$ exon 21 mutation , suggesting that SHP2 activity may be less efficiently promoted by EGFR L858R and the STAT3 pathway may be more active . The main problem is that STAT3 activation is not abrogated by single EGFR TKI treatment with @DRUG$ , erlotinib , afatinib or dacomitinib , - .", "label": "None"}
{"id": "20588273", "sentence": "@GENE$ exon 18 mutations ( @VARIANT$ ) , which affect the activation loop of the PDGFRα kinase , are biochemically less sensitive to @DRUG$ than the more common KIT exon 11 mutations .", "label": "resistance or non-response"}
{"id": "24988429", "sentence": "For example , Thomae et al reported that a naturally occurring mutation in the dimerization motif of SULT2A1 ( @VARIANT$ ) resulted in monomeric protein with similar capacity to metabolize @DRUG$ as the wild-type protein . However , Cook et al showed using a fusion protein of maltose binding protein and SULT2A1 that the monomeric form of the enzyme did not exhibit the typical substrate inhibition seen with the dimeric form . Similarly , human @GENE$ , which is a homodimer , exhibits strong substrate inhibition while murine SULT1E1 , which is a monomer , does not .", "label": "None"}
{"id": "23963283", "sentence": "@VARIANT$ and MET amplification account for approximately 60–70 % of all known causes of acquired resistance to gefitinib or @DRUG$ ; these amplifications are not mutually exclusive and can be detected in the same resistant tumor or may occur independently in different metastatic sites in the same patient . Consequently , ongoing research has been focused on identifying the molecular mechanisms accounting for the 30–40 % of @GENE$ TKI-resistant , EGFR-mutant tumors that do not carry EGFR mutations or MET amplification .", "label": "resistance or non-response"}
{"id": "23208557", "sentence": "Cancer @GENE$ exon18 G719X Drug efficacy prediction of gefitinib and @DRUG$ exon19 deletion exon20 @VARIANT$ exon21 L858R", "label": "resistance or non-response"}
{"id": "23207070", "sentence": "Patients who carry these mutations in EGFR tend to have a better response to @DRUG$ , an @GENE$ , whereas patients with the wild-type genotype show a better response to conventional chemotherapy [ ] . This could be explained by the fact that the mutated receptor possess a greater affinity to the drug in comparison with ATP , and therefore can not initiate the phosphorylation cascade downstream through the signaling pathways that lead to proliferation and cell survival . However , about 50 % of lung cancer patients treated with EGFR-TKI acquire a secondary mutation that confers drug resistance , the @VARIANT$ ( C2369G ; ID : rs121434569 ) , located in exon 21 of the gene , which reduces the affinity of the ATP binding site for the drug [ ] .", "label": "resistance or non-response"}
{"id": "24790411", "sentence": "Patients with exon 20 insertions and de novo @VARIANT$ should best be treated with chemotherapy or included in clinical trials with novel agents . @DRUG$ also showed some activity in patients with @GENE$ mutations who are resistant to both chemotherapy and reversible TKIs , but the study that sought to address this question has several biases that reduce the strength of its results .", "label": "response"}
{"id": "25505694", "sentence": "Among the 1,269 screened patients , 345 resulted eligible and were randomized in a two-to-one fashion to @DRUG$ 40 mg daily or chemotherapy up to a maximum of six cycles ( without any maintenance therapy ) . As expected , patients were mainly East Asian , never-smokers and women ; @GENE$ mutations were predominantly exon 19 deletions and @VARIANT$ point mutations .", "label": "sensitivity"}
{"id": "22970367", "sentence": "Moreover , dual inhibition of EGFR with an irreversible EGFR inhibitor ( afatinib ) and the EGFR neutralizing antibody @DRUG$ has recently shown promising activity in @GENE$ mutant lung cancers with acquired EGFR TKI resistance that harbor an EGFR @VARIANT$ mutation [ ] .", "label": "response"}
{"id": "24501009", "sentence": "Six patients had @GENE$ @VARIANT$ resistance mutation identified after treatment with @DRUG$ ( Supporting Table ; see online supporting information ) .", "label": "resistance or non-response"}
{"id": "22970367", "sentence": "Similar to the @GENE$ @VARIANT$ mutation , alteration of the drug contact residue T854 to a smaller hydrophobic alanine may increase the size of the selectivity pocket and negatively impact @DRUG$ binding .", "label": "resistance or non-response"}
{"id": "25364578", "sentence": "Surprisingly , the EGFR @VARIANT$ mutation leads to decreased ability to activate ERK compared to WT @GENE$ which correlates with decreased EGFR internalization , reduced phosphorylation of SHP2 , hyperactivity of STAT3 and reduced sensitivity to @DRUG$ .", "label": "sensitivity"}
{"id": "17973572", "sentence": "Based on the data obtained from lung cancer cell lines , we further explored the mechanisms by which @VARIANT$ and L747S resistant mutations affect BIM up-regulation and apoptosis . @DRUG$ effectively induced apoptosis in Ba/F3-L858R cells , whereas Ba/F3-L858R-L747S cells were intermediately resistant and @GENE$ completely resistant ( A , top ) .", "label": "None"}
{"id": "19893626", "sentence": "The second-generation BCR-ABL inhibitors , dasatinib and nilotinib , can circumvent most mutations that confer resistance to imatinib ; the @VARIANT$ mutation , however , causes resistance to all @GENE$ kinase inhibitors developed so far . Similarly , the T790M point mutation in the epidermal growth factor receptor (EGFR) confers resistance to the EGFR tyrosine kinase inhibitors gefitinib and @DRUG$ , which are used to treat non-small cell lung cancer .", "label": "None"}
{"id": "23946814", "sentence": "Splenocytes were prepared and cultured in 24-well plates for 48 h , then the cells were washed and fixed in 70 % @DRUG$ overnight at 4°C . The cells were washed with PBS and 500 μl @GENE$ ( 30 μl/ug ) was added into Eppendorf tubes for 30 min . The lymphocyte proliferation rate ( % ) was calculated as follows : proliferation rate ( % ) = [ ( S + @VARIANT$ ) / ( G0/1 + S + G2M ) ] × 100 .", "label": "None"}
{"id": "22363766", "sentence": "The @VARIANT$ mutation accounts for approximately 50 % of cases in which acquired resistance to erlotinib or @DRUG$ occurs , , . A small percentage of patients may carry the mutation prior to @GENE$ TKI treatment .", "label": "resistance or non-response"}
{"id": "23566546", "sentence": "Case Histrogical type @GENE$ mutation status Brinkman index Treatment agent Response IL-8 ( ng/mL ) IL-10 ( ng/mL ) RANTES ( pg/ml ) 1 Ad Ex21 @VARIANT$ 900 gefitinib PR 5.79 1.67 2 2 Ad Ex21 L858R 0 erlotinib PR_3.33 94.2 1.41 3 Ad Ex19 del 0 erlotinib PR 4.09 126 2.13 4 Ad Ex21 L858R 0 gefitinib PR_3.92 18.1 1.85 5 Ad Ex21 L858R + Ex19 del 370 erlotinib PR 21.9 1.23 2.11 6 Ad Ex19 del 0 erlotinib PR 7.05 1.37 2.56 7 Ad Ex19 del 0 gefitinib PR 4.82 1.59 2.02 8 Ad Ex21 L858R 1640 gefitinib PR 54.9 2.7 2.38 9 Ad negative 400 erlotinib SD 34.9 3.39 3.66 10 Ad negative 0 erlotinib SD 27.1 4.94 2.25 11 Ad unknown 1800 erlotinib SD NE NE NE 12 Sq Ex19 del 3840 gefitinib SD 12.6 1.1 1.98 13 Ad Ex19 del 30 erlotinib SD 5.27 0.69 2.66 14 Ad Ex19 del 0 erlotinib SD 10.5 0.85 2.5 15 Ad unknown 300 erlotinib SD 7.69 2.61 1.7 16 La negative 2080 erlotinib SD NE NE NE 17 Sq Ex21 L858R 750 erlotinib SD 11.6 56.3 3.06 18 Ad unknown 600 erlotinib SD 13.7 1.1 2.82 19 Ad Ex21 L858R 0 erlotinib SD 20.6 11.6 0.783 20 Ad Ex19 del 0 erlotinib SD 14.8 2.07 2.02 21 Ad Ex21 L858R + Ex19 del 0 gefitinib SD 3.04 1.3 1.76 22 Ad Ex19 del 200 gefitinib SD 10.9 1.59 1.91 23 Sq unknown 1560 erlotinib PD NE NE NE 24 Ad negative 1080 erlotinib PD 25.2 8.15 1.57 25 Ad unknown 0 @DRUG$ PD NE NE NE 26 Ad Ex18 G719A 2000 erlotinib PD 11.6 4.48 3.12 27 Ad unknown 1410 erlotinib PD NE NE NE 28 Ad Ex19 del 1000 gefitinib PD 9.44 2.25 2.89 29 Ad negative 1100 erlotinib PD 56.3 5.63 2.16 30 Ad negative 2000 erlotinib PD 15.6 0.85 0.292 31 Ad negative 825 erlotinib PD 8.27 1.59 2.13 32 Ad Ex21 L858R 0 erlotinib PD 5.34 7.05 1.7 33 Ad negative 1680 erlotinib PD 57.7 1.63 2.06", "label": "sensitivity"}
{"id": "25465236", "sentence": "( C ) EGFR @VARIANT$ mutant does not resemble pEGFR unlike the EGFR L858R mutant shown in B. ( D–F ) increased inhibition potency for Erlotinib against EGFR L858R mutant compared to EGFR WT protein and subsequent decrease in potency for Erlotinib against EGFR L858R + E884K double mutant . ( G–I ) increased inhibition potency for @DRUG$ against EGFR L858R mutant compared to EGFR WT protein and subsequent further increase in potency for Gefitinib against @GENE$ L858R + E884K double mutant .", "label": "resistance or non-response"}
{"id": "23238683", "sentence": "In addition , the IC50 values for @DRUG$ were 0.5 to 30nM in parental cells and 30 to more than 300nM in resistant cells . As a whole our findings confirmed the efficacy of ponatinib on the @VARIANT$ mutation , but also highlighted the notion that ponatinib is effective on all types of imatinib-resistant CML cells , whatever their mode of resistance . Importantly , the IC50 values obtained for ponatinib in the present study for BaF3-WT-BCR-ABL , @GENE$ and BaF3-G250E-BCR-ABL ( 1nM , 8nM and 8nM respectively ) were very similar to the one reported previously by O’ Hare et al. ( 0.5 , 11 and 4.1nM respectively ) [ ] .", "label": "None"}
{"id": "22043994", "sentence": "The effect of @GENE$ @VARIANT$ mutation on cetuximab or @DRUG$ response was also assessed using cellular models of CRC .", "label": "resistance or non-response"}
{"id": "24643470", "sentence": "@DRUG$ also shows activity against cancers resistant to first-generation EGFR inhibitors due to certain activating EGFR mutations , secondary EGFR mutations such as @VARIANT$ or tumours expressing other @GENE$ family receptors activated by drug induced reprogramming of signalling pathways .", "label": "response"}
{"id": "23965851", "sentence": "The @GENE$ ( HER1 ) -Tyrosine Kinase Inhibitor ( TKI ) gefitinib ( ZD1839 ; @DRUG$ ) was kindly provided by AstraZeneca ( AstraZeneca PLC Headquarters , 15 Stanhope Gate , @VARIANT$ 1 LN , London , UK ) .", "label": "None"}
{"id": "24789720", "sentence": "The role of T790M mutation , particularly its presence in patients before @GENE$ treatment is still controversial being a subject of intensive discussions . Mechanism of achieving resistance to @DRUG$ and gefitinib remains unclear . The recent reports confirmed , that @VARIANT$ substitution could be detected in EGFR-TKIs naïve patients independently of other EGFR gene mutations ( predominantly L858R substitution and deletions in exon 19 ) .", "label": "resistance or non-response"}
{"id": "24724051", "sentence": "CDKN2A/B is rarely deleted in ALL with translocations of @VARIANT$ [E2A–PBX1 in t ( 1 ; 19 ) ( q23 ; p13 ) and @GENE$ in t ( 17 ; 19 ) ( q21–22 ; p13 ) ALL ] ( ) . Introduction of p190BCR–ABL1 into Arf -null murine bone marrow decreases the latency and increases resistance to @DRUG$ in the lymphoid malignancy that develops in recipient mice .", "label": "None"}
{"id": "22233865", "sentence": "Aire , @GENE$ CB-SCs , cord blood stem cells ; IgG , @DRUG$ PCR , polymerase chain reaction ; PHA , phytohaemagglutinin ; siRNA , small interfering RNA ; @VARIANT$ , type 1 diabetes ; Tregs , regulatory T cells .", "label": "None"}
{"id": "18030354", "sentence": "To identify gene expression changes that preceded , and possibly contributed to , the biologic effects of @GENE$ TKI treatment on EGFR-mutant NSCLC cells , the cells were subjected to short-term treatment with @DRUG$ . As a negative control in this experiment , we used the TKI-resistant H1975 cells , which have a @VARIANT$ mutation that blocks binding to the EGFR TKI .", "label": "resistance or non-response"}
{"id": "23579627", "sentence": "Although we could not perform an EGFR mutation test at the time of progression after @DRUG$ retreatment , the patient had another partial response with irreversible EGFR inhibitor , which is believed to overcome secondary resistance to reversible @GENE$ related with @VARIANT$ mutation .", "label": "resistance or non-response"}
{"id": "25277177", "sentence": "The wild-type @GENE$ , EGFRvIII , and H-Ras ( @VARIANT$ ) constructs were generously provided by Dr. Frank Furnari ( University of California , San Diego ) . Retrovirus packaging and infection were performed as previously described [ ] and stably infected cells were generated by selection with puromycin ( 1 μg/ml ) for 5 days , G418 ( 600 μg/ml ) for 2 weeks , or Hygromycin ( 100 μg/ml ) for 2 weeks prior to the subsequent experiments . @DRUG$ was purchased from SelleckChem and used at 10 μM .", "label": "None"}
{"id": "22952984", "sentence": "Lipid skin surface mantel represents the first-line protective barrier between solar UV and viable human skin structures : it directly and very effectively absorbs UVB and UVA rays , , inhibits free radical-driven lipid peroxidation ( α-tocopherol and @GENE$ – , and scavenges reactive oxygen species such as singlet oxygen ( squalene ) . Indeed , SqPx was shown to induce melanocyte dendricity and melanogenesis and IL-6 release from HaCaT . Nuclear translocation of UVB induced EGFR in primary human keratinocytes was mediated by 4-HNE , , and a UVB-like cytokine pattern was observed upon keratinocyte exposure to 9-HODA through UVB-like expression of @VARIANT$ receptor .", "label": "None"}
{"id": "25565776", "sentence": "It has been recognized that coffee ( Coff ) , caffeine ( Caff ) ( 1,3,7-trimethylxanthine or 3,7-dihydro-1,3,7-trimethyl-1H-purine-2,6-dione ) ( ) , and @DRUG$ (Mel) ( N-acetyl-5-methoxytryptamine ) possess a variety of pharmacological activities , including antioxidative , antiapoptotic , antiautophagic , and neuroprotective effects . Caff is the most widely consumed psychoactive substance and acts as an antagonist of @GENE$ @VARIANT$ receptors ( A2ARs ) at nontoxic doses .", "label": "None"}
{"id": "19893626", "sentence": "The second-generation BCR-ABL inhibitors , @DRUG$ and nilotinib , can circumvent most mutations that confer resistance to imatinib ; the T315I mutation , however , causes resistance to all @GENE$ kinase inhibitors developed so far . Similarly , the @VARIANT$ point mutation in the epidermal growth factor receptor (EGFR) confers resistance to the EGFR tyrosine kinase inhibitors gefitinib and erlotinib , which are used to treat non-small cell lung cancer .", "label": "None"}
{"id": "24419415", "sentence": "In contrast to other phase 3 trials investigating EGFR-TKIs for patients with common EGFR mutations of exon 19 deletion and L858R , the NEJ002 is the only study that included uncommon EGFR mutations of G719X and @VARIANT$ . This study showed that the PFS and OS tended to be shorter among patients treated with first-line gefitinib compared with PFS and OS among those treated with first-line carboplatin-paclitaxel in the uncommon @GENE$ mutation group ( supplementary Table S2 , Supplemental Digital Content 1 , http : //links.lww.com/JTO/A494 ) .", "label": "None"}
{"id": "22586398", "sentence": "In addition , no support was found for interactions between adenosine A1 and A2AR , or A1 and @GENE$ , suggesting this reduction in @DRUG$ self-administration and alcohol seeking behavior was specific to a functional interaction between @VARIANT$ and mGlu5 receptors ( Adams et al. , , ) .", "label": "None"}
{"id": "17931419", "sentence": "In this study , we used a group of cancer cell lines with either overexpressed or tyrosine kinase domain mutated ( ΔE746-A750 or @VARIANT$ ) EGFR to assess their responsiveness to cetuximab and @DRUG$ treatment and to evaluate HIF-1α as novel molecular marker for the therapeutic responses of the cancer cells to @GENE$ targeted therapy .", "label": "sensitivity"}
{"id": "22679366", "sentence": "@VARIANT$ cells were maintained in vitro and injected intravenously ( 1 × 105 cells/100 μL phosphate buffered saline ) into the mice , to obtain an aggressive metastatic leukemia model . The mice were then divided into five groups of ten animals each and treated on days 4 , 8 , 12 , 16 , and 20 with the following formulations : saline solution ( NaCl 0.9 % w/v ) as a control , Ara-C 100 mg/kg , Sq-Ara-C nanomedicine ( 50 mg/kg equivalent of Ara-C ) , pure squalene nanosystems ( drug absent ) , and a physical mixture of squalene nanosystems and @DRUG$ 100 mg/kg .", "label": "None"}
{"id": "23377281", "sentence": "NT5C2 is a ubiquitous enzyme responsible for the final dephosphorylation of 6-hydroxypurine nucleotide monophosphates such as @GENE$ , dIMP , GMP , dGMP and XMP before they can be exported out of the cell , . In addition , and most notably , NT5C2 can also dephosphorylate and inactivate 6-thioinositol monophosphate and 6-thioguanosine monophosphate which mediate the cytotoxic effects of @DRUG$ ( 6-MP ) and 6-thioguanine ( 6-TG ) , two nucleoside analogs commonly used in the treatment of ALL . Strikingly , 13 of these samples harbored the same NT5C2 R367Q mutation , 4 cases showed a recurrent NT5C2 R238W mutation and 2 samples harbored a @VARIANT$ single amino acid substitution ( and ) .", "label": "None"}
{"id": "21681573", "sentence": "Cases Age ( yr ) Sex PS Histology @GENE$ gene Smoking status Previous chemotherapy regimen Previous @DRUG$ ( length of PFS ) Previous WBRT 1 59 F 3 Ad NE Never 3 Yes ( 10 months ) Yes 2 82 F 4 Ad Wild type Never 0 No No 3 70 F 3 Ad Wild type Never 1 No Yes 4 86 F 3 Ad Ex 21 ; @VARIANT$ Never 1 Yes ( 7 months ) No 5 67 F 1 Ad Ex 21 ; L858R Never 1 No No 6 72 M 0 Ad Ex 21 ; L858R Former 1 No No 7 81 M 1 Ad Ex 19 deletion Former 1 Yes ( 46 months ) Yes 8 85 F 2 Ad Ex 21 ; L858R Never 1 No Yes a 66 F 1 Ad Ex 21 ; L858R Never 3 No Yes", "label": "sensitivity"}
{"id": "15737014", "sentence": "To our knowledge , no NSCLC patient who initially responded to but then progressed on either gefitinib or @DRUG$ has yet been treated with lapatinib . In some of the patient specimens analyzed , the actual sequencing peaks demonstrating the @VARIANT$ mutation were smaller than originally anticipated . These results differ from those of acquired resistance mutation in CML [ ] , GIST [ , ] , and @GENE$ [ ] .", "label": "None"}
{"id": "25580271", "sentence": "There are several promising agents for patients with activating EGFR mutations who experience disease progression of an EGFR tyrosine kinase inhibitor and have a @VARIANT$ resistance mutation , and multiple clinical trials will be available . Trials investigating adjuvant erlotinib in @GENE$ mutant NSCLC and comparing @DRUG$ to erlotinib plus bevacizumab in metastatic EGFR mutant NSCLC are ongoing .", "label": "resistance or non-response"}
{"id": "19547661", "sentence": "BRAF ( v-raf murine sarcoma viral oncogene homolog B1 ) , a serine/threonine kinase , is the downstream effector of @GENE$ in the RAS-RAF-MAPK signaling pathway . A somatic mutation ( @VARIANT$ ) in exon 15 of BRAF has been identified in multiple human cancers with a mutation rate of 66 % in malignant melanomas [ ] and at lower frequency in other human carcinomas . Recently , it was demonstrated that wildtype BRAF is required for the response of patients with metastatic colorectal cancer to @DRUG$ and panitumumab [ ] .", "label": "None"}
{"id": "24223798", "sentence": "In particular , epidermal growth factor receptor tyrosine kinase inhibitors ( EGFR-TKIs ) , such as @DRUG$ and erlotinib , have been developed as a novel treatment option for patients with non–small cell lung cancers ( NSCLCs ) that possess somatic mutations in the tyrosine kinase domain of the @GENE$ – . Prospective clinical trials of EGFR-TKI treatment in NSCLC patients with activating EGFR mutations , such as delE746-A750 ( exon 19 ) and @VARIANT$ ( exon 21 ) , have demonstrated high clinical response rates of approximately 80 % – .", "label": "sensitivity"}
{"id": "24724051", "sentence": "Targeting the @VARIANT$ mutation : @DRUG$ Dasatinib and nilotinib are effective against the vast majority of reported @GENE$ TKD mutants with one crucial exception : the T315I mutation .", "label": "response"}
{"id": "23630663", "sentence": "However , three of four patients harboring the rare EGFR mutation @VARIANT$ ( X indicates substitution of glycine by either serine , cysteine , or alanine ) were found to respond to neratinib ( Sequist et al. , ) . Strikingly , neratinib showed promising activity in ERBB2 overexpressing breast cancers and could potentially be approved as a first-line therapy in locally advanced or metastatic ERBB2 overexpressing breast cancers ( Chow et al. , ; Limentani et al. , ; Burstein et al. , ; Awada et al. , ) . Preclinical activity for @DRUG$ ( BIBW2992 ) , a second irreversible inhibitor of EGFR and ERBB2 , was demonstrated in @GENE$ cells expressing an ERBB2-mutant with an insertional mutation at codon 776 and in transgenic lung cancer models ( Li et al. , ) .", "label": "None"}
{"id": "24551227", "sentence": "As cellular proliferation exhibited normal doubling rates under IC90 selection , the resistant cells were plated at a low dilution ( HCC827res ) or high dilution to create near-pure , @DRUG$ resistant clones ( HCC827res- # 5,6 and 7 ) . To study effects in hepatocellular carcinoma ( HCC ) cells , Hep3B , Huh7 , @VARIANT$ and HepG2 were used .", "label": "None"}
{"id": "24964744", "sentence": "Cells with PIK3CA mutations H1047R and @VARIANT$ showed greatest single agent sensitivity to the @GENE$ inhibitor . Interestingly , cells with these mutations also showed greater sensitivity to @DRUG$ and erlotinib than cells with the EGFR mutation ( exon 19 deletion ) , which are associated with sensitivity to EGFR inhibitors in NSCLC .", "label": "None"}
{"id": "23569389", "sentence": "Baseline @GENE$ mutation data were available for 95 % of patients . Very high @DRUG$ resistance mutations ( M244V , G250E , Y253H , @VARIANT$ , E255V , T315I , F359V , H396R ) were associated with the lowest response rates to dasatinib .", "label": "None"}
{"id": "22034911", "sentence": "However , analogous Ba/F3 xenografts expressing L1196M , @VARIANT$ , or G1269S mutants were completely insensitive to these doses , with no statistically significant changes in tumor growth rate . @DRUG$ is not efficacious in mouse @GENE$ xenograft models expressing EML4-ALK mutants .", "label": "None"}
{"id": "21897848", "sentence": "Arachidonic acid also plays an important role in STX3 action , highlighting the impact of metabolism as a potential @DRUG$ fundamental to neurometabolism , and therefore brain function . In HAB vs. LAB mice , expression differences in Stx3 have been identified , again pointing to basic differences in neuronal function between the two mouse lines ( as also demonstrated here by Syt4 , Pdhb and Slc25a17 ) , which have the potential to cause the observed phenotypic differences . @GENE$ encodes a nucleotide metabolizing ecto-enzyme , a class of enzymes that regulate the availability of extracellular nucleotides , and therefore control signaling through purinoceptors such as the @VARIANT$ ion channels .", "label": "None"}
{"id": "24498038", "sentence": "Abbreviations : @VARIANT$ , glycated hemoglobin ; HOMA-IR , HOMA-insulin resistance ; HDL , high density @GENE$ , SGOT , serum glutamic oxalacetic transaminase ; SGPT , Serum glutamic pyruvic transaminase ; Free T4 , free thyroxine ; TSH , @DRUG$ SHBG , sex hormone binding globulin ; LepRs , leptin receptor soluble fraction ; N.D. , not detected .", "label": "None"}
{"id": "17877814", "sentence": "In this regard , certain mutations , such as the @VARIANT$ amino acid change , have been shown to confer resistance to @DRUG$ and erlotinib [ reviewed in [ ] ] . Second-generation TKIs , which bind covalently to @GENE$ and may be active against these resistant mutants , are currently being developed .", "label": "resistance or non-response"}
{"id": "15737014", "sentence": "To determine whether the 2369 C→T mutation was a previously overlooked EGFR mutation found in NSCLCs , we re-reviewed exon 20 sequence tracings derived from analysis of 96 fresh-frozen resected tumors [ ] and 59 paraffin embedded tumors [ ] , all of which were removed from patients prior to treatment with an @GENE$ tyrosine kinase inhibitor . We did not detect any evidence of the T790M mutation in these 155 tumors ( data not shown ; see ) . Collectively , our results suggest that the @VARIANT$ mutation is associated with lesions that progress while on gefitinib or @DRUG$ .", "label": "resistance or non-response"}
{"id": "25536104", "sentence": "In our cases with ERBB2 mutation , IHC expression of ERBB2 was not detectable in our study ; one of the ERBB2 mutations was in the kinase domain ( V777L ) while 3 involved the extracellular domain ( @VARIANT$ ) . Based on the current knowledge of @GENE$ biology , trastuzumab or @DRUG$ therapy may be value in the extracellular domain mutations but could be of limited clinical benefit for kinase domain mutations and no response to either agents was noted in our cases .", "label": "sensitivity"}
{"id": "24789720", "sentence": "@VARIANT$ mutation in @GENE$ gene seems to be one of the most important genetic abnormalities involving the resistance for reversible epidermal growth factor receptor tyrosine kinases inhibitors ( EGFR-TKI ) —erlotinib and gefitinib in NSCLC patients [ – ] .", "label": "resistance or non-response"}
{"id": "24276125", "sentence": "In a phase III open-label clinical trial ( METRIC ) [ ] trametinib was shown to significantly improve rates of progression-free and overall survival compared with chemotherapy with dacarbazine or @DRUG$ ( 6 month overall survival of 81 % and 67 % respectively , patient crossover included , p = 0.01 ) , in patients with @VARIANT$ or V600K BRAF mutation positive metastatic melanoma . Treatment with combined BRAF and @GENE$ inhibition in V600 BRAF mutation positive metastatic melanoma has been evaluated in phase I and II clinical trials [ ] .", "label": "None"}
{"id": "17973572", "sentence": "Our data indicate that the intrinsic mitochondrial pathway is involved in @DRUG$ induced cell death and that the up-regulation of the proapoptotic polypeptide BIM was consistently seen during TKI induced apoptosis . In addition , sustained activation of EGFR , @GENE$ , and/or ERK caused by the @VARIANT$ and L747S resistant mutations delayed BIM up-regulation and apoptosis .", "label": "None"}
{"id": "25278773", "sentence": "For example , the combination trial of @DRUG$ and afatinib has shown promising results , with an overall response rate of 29 % and a median duration of response of 5.7 months in patients with advanced lung adenocarcinoma and acquired resistance to erlotinib/gefitinib . Importantly , this combination conferred robust and durable clinical responses irrespective of @VARIANT$ status ( T790M positive , 32 % , versus T790M negative , 25 % ; P=0.341 ) , as well as an acceptable safety profile . More recently , third-generation EGFR mutation-specific inhibitors have shown potential in circumventing toxicities related to wild-type @GENE$ and overcoming resistance resulting from the acquired T790M mutation .", "label": "response"}
{"id": "24789720", "sentence": "The role of @VARIANT$ mutation , particularly its presence in patients before EGFR-TKIs treatment is still controversial being a subject of intensive discussions . Mechanism of achieving resistance to @DRUG$ and gefitinib remains unclear . The recent reports confirmed , that T790M substitution could be detected in EGFR-TKIs naïve patients independently of other @GENE$ gene mutations ( predominantly L858R substitution and deletions in exon 19 ) .", "label": "resistance or non-response"}
{"id": "23552882", "sentence": "For example , HCC827 cells undergo MET amplification and AXL induction upon adaption to gefitinib , , , and PC9 cells acquire the T790M mutation in @GENE$ that confers resistance to @DRUG$ and gefitinib . In addition , studies with TKI-resistant tumor specimens suggest alternative mechanisms that remain to be defined . In addition , H1975 cells , which express EGFR bearing the activating @VARIANT$ mutation and the T790M gate-keeper mutation , were selected for resistance to the irreversible EGFR inhibitor , BIBW2992 .", "label": "sensitivity"}
{"id": "23566546", "sentence": "Case Histrogical type EGFR mutation status Brinkman index Treatment agent Response IL-8 ( ng/mL ) @GENE$ ( ng/mL ) RANTES ( pg/ml ) 1 Ad Ex21 @VARIANT$ 900 gefitinib PR 5.79 1.67 2 2 Ad Ex21 L858R 0 erlotinib PR_3.33 94.2 1.41 3 Ad Ex19 del 0 erlotinib PR 4.09 126 2.13 4 Ad Ex21 L858R 0 gefitinib PR_3.92 18.1 1.85 5 Ad Ex21 L858R + Ex19 del 370 erlotinib PR 21.9 1.23 2.11 6 Ad Ex19 del 0 erlotinib PR 7.05 1.37 2.56 7 Ad Ex19 del 0 gefitinib PR 4.82 1.59 2.02 8 Ad Ex21 L858R 1640 gefitinib PR 54.9 2.7 2.38 9 Ad negative 400 erlotinib SD 34.9 3.39 3.66 10 Ad negative 0 erlotinib SD 27.1 4.94 2.25 11 Ad unknown 1800 erlotinib SD NE NE NE 12 Sq Ex19 del 3840 gefitinib SD 12.6 1.1 1.98 13 Ad Ex19 del 30 erlotinib SD 5.27 0.69 2.66 14 Ad Ex19 del 0 erlotinib SD 10.5 0.85 2.5 15 Ad unknown 300 erlotinib SD 7.69 2.61 1.7 16 La negative 2080 erlotinib SD NE NE NE 17 Sq Ex21 L858R 750 erlotinib SD 11.6 56.3 3.06 18 Ad unknown 600 erlotinib SD 13.7 1.1 2.82 19 Ad Ex21 L858R 0 erlotinib SD 20.6 11.6 0.783 20 Ad Ex19 del 0 erlotinib SD 14.8 2.07 2.02 21 Ad Ex21 L858R + Ex19 del 0 gefitinib SD 3.04 1.3 1.76 22 Ad Ex19 del 200 gefitinib SD 10.9 1.59 1.91 23 Sq unknown 1560 erlotinib PD NE NE NE 24 Ad negative 1080 erlotinib PD 25.2 8.15 1.57 25 Ad unknown 0 erlotinib PD NE NE NE 26 Ad Ex18 G719A 2000 erlotinib PD 11.6 4.48 3.12 27 Ad unknown 1410 @DRUG$ PD NE NE NE 28 Ad Ex19 del 1000 gefitinib PD 9.44 2.25 2.89 29 Ad negative 1100 erlotinib PD 56.3 5.63 2.16 30 Ad negative 2000 erlotinib PD 15.6 0.85 0.292 31 Ad negative 825 erlotinib PD 8.27 1.59 2.13 32 Ad Ex21 L858R 0 erlotinib PD 5.34 7.05 1.7 33 Ad negative 1680 erlotinib PD 57.7 1.63 2.06", "label": "None"}
{"id": "PMC4125961", "sentence": "Analysis of the cell-free tumor DNA samples at PD in patient 1 and 2 showed the presence of the KRAS mutation G12V while in patient 3 the @VARIANT$ mutation was detected . Interestingly , pre-cetuximab cell-free tumor DNA was positive for @GENE$ mutant alleles for patients 2 and 3 , but was not sufficient to test the mutational status of KRAS in patient 1 .", "label": "sensitivity"}
{"id": "23690929", "sentence": "Both HGF and @VARIANT$ gatekeeper mutations are frequently detected in EGFR-TKI resistant tumors , where they contribute to resistance . Therefore , these observations illustrate the necessity of clinical trials with mTOR inhibitors in @GENE$ mutant lung cancer patients who become refractory to gefitinib and @DRUG$ .", "label": "resistance or non-response"}
{"id": "21738687", "sentence": "Most potent LRRK2 inhibitors ( @VARIANT$ , IN-1 and @DRUG$ ) induced a severe reduction of CD14 ( A ) and @GENE$ by monocytes meanwhile less potent inhibitors ( H1152 and Y27632 ) had no effect .", "label": "None"}
{"id": "15737014", "sentence": "EGFR Mutants Containing the T790M Mutation Are Resistant to Inhibition by Gefitinib or @DRUG$ 293T cells were transiently transfected with plasmids encoding wild-type ( WT ) @GENE$ or EGFR mutants with the following changes : T790M , @VARIANT$ , L858R + T790M , del L747–E749 ; A750P , or del L747–E749 ; A750P + T790M .", "label": "sensitivity"}
{"id": "21197464", "sentence": "Schematic representation of the signal pathways of @DRUG$ @GENE$ differentiation of mouse embryonic carcinoma F9 cells . At the undifferentiation stage of F9 cells , HDAC3 , NcoR/SMART , and JDP2 were recruited on the DRE ( differentiation response element ) in the promoter region of the c-jun gene to induce the heterochromatin . Ac , acetylated residues ; K , lysine residues of histone; @VARIANT$ , lysine residues of histone H3; H4K8 , lysine residue at position 8 of histone H4 ; H4K16 , lysine residue at position 16 of histone H4 ; X1 = ATF-2 , ATF-7 .", "label": "None"}
{"id": "22034911", "sentence": "Consistent with this , we found that the introduction of R1275Q into EML4-ALK had no negative impact on sensitivity to @DRUG$ ( IC50 47 ± 8 nm ) . As expected , the IC50 values for viability of Ba/F3 cells expressing these mutants were all above that for @GENE$ cells expressing native EML4-ALK , with IC50s ranging from 231 to 981 nm . The three most resistant mutants , L1196M , S1206R , and @VARIANT$ , all had IC50s within twofold of parental , ALK negative , Ba/F3 cells ( IC50 1176 nm ) .", "label": "None"}
{"id": "19654571", "sentence": "Antibody dependent cellular cytotoxicity activity is another important anticancer mechanism induced by cetuximab in various cell lines ( ; ) and this MAb effectively induced ADCC in A431 and Caski cells , whereas no ADCC was observed in the @VARIANT$ cell line . Based on these findings we conclude that cell surface EGFR expression is very relevant for cetuximab induction of ADCC , but not as much for inhibiting VEGF secretion and cell proliferation , demonstrating that cetuximab can modulate multiple crucial pathways of CC cell lines in different ways . In summary , our data suggested that the combination of cetuximab with cisplatin/ RxT , @DRUG$ or with @GENE$ inhibitors could be useful for CC treatment , independently of EGFR expression status .", "label": "None"}
{"id": "24348666", "sentence": "Moreover , in all the 4 cases with @GENE$ amplification , a higher expression of HGF was observed after @DRUG$ treatment than before treatment . These results indicate that HGF accelerates the expansion of the tumor cells with MET amplification . The cells with MET amplification as the @VARIANT$ mutation was present in a small proportion of the tumor cells before EGFR-TKI treatment and became dominant during treatment with EGFR-TKIs , suggesting that HGF may play an important role in this process .", "label": "None"}
{"id": "23579627", "sentence": "This findings show that EGFR @VARIANT$ is a common resistance mechanism to both reversible , and when amplified , the irreversible EGFR inhibitors . In our case , the response duration of irreversible @GENE$ inhibitor was 11 months which was unusually longer than those of initial @DRUG$ ( for 4 months ) and second round gefitinib ( for 6 months ) treatments .", "label": "resistance or non-response"}
{"id": "23493838", "sentence": "A complete hematological response and a major cytogenetic response were observed broadly across the BCR-ABL mutants , including individuals harboring the dasatinib-resistant F317L , the nilotinib-resistant Y253H , and @GENE$ mutations , but not T315I . Nine individuals developed new mutations in the course of @DRUG$ treatment ( V299L , n = 4 ; L248V , n = 2 ; @VARIANT$ , n = 2 ; F359C , n = 1 ; G250E , n = 1 ) and eight of these individuals discontinued bosutinib because of progressive disease or unsatisfactory response .", "label": "None"}
{"id": "22655263", "sentence": "Additionally , AP26113 was evaluated on the @DRUG$ resistant gatekeeper mutant @VARIANT$ both in vitro and in vivo and appeared to be able to overcome resistance to crizotinib . Ki determination demonstrated a very similar biochemical potency on wild-type @GENE$ and the L1196M ALK mutant ( 0.09 and 0.08 nM respectively ) , with both cellular and in vivo data ( using engineered Ba/F3 cells ) indicating that growth of ALK–L1196M mutant driven-cells is inhibited at similar , albeit slightly higher , doses which inhibit cells harboring wild-type ALK ( Katayama et al. , ) .", "label": "resistance"}
{"id": "25203004", "sentence": "The two most common genetic mutations are the in-frame deletion in exon 19 ( E746-A750 ) and the substitution of leucine 858 by arginine in the exon 21 ( @VARIANT$ ) . These two mutations constitute about 90 % of all mutations and are known as the “classical” mutations . These two EGFR-specific mutations are strong predictors of the response to small-molecule @GENE$ kinase inhibitors such as gefitinib , and @DRUG$ .", "label": "sensitivity"}
{"id": "24944510", "sentence": "The reversible dual ALK/EGFR inhibitor AP26113 is a more potent @GENE$ inhibitor than crizotinib and demonstrates preclinical activity against various secondary mutations resistant to @DRUG$ , including L1196 and @VARIANT$ .", "label": "resistance"}
{"id": "23864840", "sentence": "However , acquired resistance to EGFR-TKIs is inevitable due to various mechanisms , such as @VARIANT$ , c-Met amplification , activation of alternative pathways ( IGF-1 , HGF , PI3CA , AXL [ ] ) , transformation to mesenchymal cells [ ] or small cell features [ ] , and tumor heterogeneity [ ] . A randomized trial comparing the irreversible ErbB-family blocker @DRUG$ versus placebo in patients with NSCLC after prior @GENE$ exposure failed to prove a benefit of overall survival [ ] .", "label": "response"}
{"id": "21687501", "sentence": "Consistently HTR3A rs1062613 ( @VARIANT$ ) and two polymorphisms in HTR3B ( −100 −102 AAG deletion variant and rs1176744 ) have been found to be associated with chemotherapy and @DRUG$ treatment induced vomiting and nausea ( Tremblay et al. , ; Kato et al. , ; Sugai et al. , ; Tanaka et al. , ) . 5-HT6 receptor The 5-HT6 receptor is a @GENE$ is expressed almost exclusively in the brain .", "label": "None"}
{"id": "25054154", "sentence": "We utilised three complexes , namely , native ( @GENE$ ) , F1174L ( ALK F1174L-crizotinib ) , and @VARIANT$ ( ALK R1275Q-crizotinib ) for our analysis .", "label": "sensitivity"}
{"id": "25562798", "sentence": "The mechanisms of acquired resistance to crizotinib are only just coming to light but , analogous to acquired resistance to EGFR inhibitors , secondary mutations in @GENE$ that render the ALK kinase resistant to inhibition by @DRUG$ have been identified [ , , ] . These mutations including @VARIANT$ in the ALK kinase domain may be susceptible to inhibition with novel ALK inhibitors e.g. , LDK378 , AP26113 , or AF802 .", "label": "resistance"}
{"id": "23099808", "sentence": "Acquired clinical resistance to EGFR-TKI was also documented in lung cancer patients , who had an @GENE$ mutation in exon 20 ( @VARIANT$ ) ( ) . Therefore , in this study , we first examined the effects of gefitinib or @DRUG$ on cell proliferation of the cell lines including those originated from lung adenocarcinoma ( LADCA ) .", "label": "resistance or non-response"}
{"id": "21333004", "sentence": "According to recent reports , the sensitivity to kinase inhibition reflects intrinsic differences in the binding affinity of the EGFR mutants such as L858R , @VARIANT$ , and exon19 deletions [ , - ] . Yun et al [ ] showed that @DRUG$ directly binds more tightly to the L858R mutant than to the wild type EGFR in vitro , while Fabian et al [ ] indicated that @GENE$ with gefitinib sensitive mutations does not differ from wild type EGFR in terms of gefitinib binding affinity .", "label": "sensitivity"}
{"id": "24092989", "sentence": "Another critical serine-threonine protein kinase involved in the @GENE$ pathway that has been targeted to block its constitutive kinase activation is BRAF . , BRAF mutation ( V600E ) is reported in 24 % of papillary derived ATC . Preclinical and clinical studies investigating combination therapy with agents such as selective ( @DRUG$ ) and potent ( BAY 73-4506 and ARQ 736 ) small-molecule BRAF inhibitors , and MAP/ERK kinase inhibitors ( AZD6244 ) hold great promise in the treatment of BRAF ( @VARIANT$ ) ATC . , ,", "label": "None"}
{"id": "17973572", "sentence": "After the cells were exposed to gefitinib for 24 h , Ba/F3-L858R cells were unable to proliferate while @GENE$ and Ba/F3-L858R-T790M cells continued to grow even in the presence of 1 μM @DRUG$ ( E ) . These results suggest that execution of apoptosis may be impaired by the presence of T790M and , to a lesser extent , @VARIANT$ .", "label": "None"}
{"id": "25382104", "sentence": "Results showed that ponatinib has the highest binding affinity towards the @VARIANT$ mutant @GENE$ with a docking score of −11.050 kcal/mol while bosutinib , bafetinib , dasatinib , nilotinib and @DRUG$ showed −5.513 kcal/mol , −4.689 kcal/mol , −4.702 kcal/mol , −3.772 kcal/mol , −3.593 kcal/mol and −3.78 kcal/mol , respectively ( ) .", "label": "None"}
{"id": "25562798", "sentence": "Less frequent activating mutations including @VARIANT$ in exon 18 and L861Q in exon 21 have also been described . Prospective studies of @GENE$ TKIs in patients with EGFR mutations have consistently identified high response rates and prolonged progression free survival . The Spanish Lung Cancer Group screened 2105 patients , to identify 350 patients ( 15 % ) with exon 19 deletions and L858R of whom 250 patients went on to receive @DRUG$ in the first or second-line setting .", "label": "None"}
{"id": "17352537", "sentence": "The cloned cDNA carried the @VARIANT$ SNP of ABCB1 , and therefore site directed mutagenesis was used to restore it to the most common allele , referred to as the ABCB1 reference allele in the Pharmacogenetics of Membrane Transporters dataset ( pJR2703 ) ( http : //pharmacogenetics.ucsf.edu or http : //www.pharmgkb.org ) . Cells expressing the ABCB1 reference cDNA from the multicopy plasmid in the pdr5 snq2 yor1 strain showed highly increased resistance towards @DRUG$ and doxorubicin relative to that of the pdr5 snq2 yor1 strain ( B ) . Thus the @GENE$ reference was functionally expressed in these yeast cells .", "label": "None"}
{"id": "25309870", "sentence": "This phase III trial randomized 345 patients with NSCLC in the first-line setting who had @GENE$ mutation positive tumors to receive either @DRUG$ or cisplatin/pemetrexed . For this study , all EGFR mutations from codons 18–21 were analyzed . While the majority of patient tumors harbored common EGFR mutations ( Del-19 and Point 21 @VARIANT$ ) , approximately 10 % of patients had uncommon EGFR mutations .", "label": "sensitivity"}
{"id": "19277036", "sentence": "The @GENE$ @VARIANT$ polymorphism was studied in Caco-2 and WiDr HF- and LF-adapted cells as well as in MCF-7/MR. All cell lines displayed the wild-type genotype ( CC ) ( data not shown ) . Discussion Caco-2 LF/LV cells , but not Caco-2 LF/FA , showed 1.8-fold resistance to @DRUG$ compared with the HF cells .", "label": "None"}
{"id": "22101934", "sentence": "@DRUG$ is particularly effective in cancers in which the @GENE$ kinase domain contains activating mutations , the two most common of which are Δ746–750 and L858R– .", "label": "sensitivity"}
{"id": "21333004", "sentence": "The inhibitory effects of Mig6 and @DRUG$ are indicated by red lines . E11 : @GENE$ homodimer ; ShcP : free phosphorylated Shc ; E11P : phosphorylated EGFR homodimer ; Raf1A : activated Raf1 ; MEKP : singly phosphorylated MEK ; MEKPP : doubly phosphorylated MEK ; ERKP : singly phosphorylated ERK ; ERKPP : doubly phosphorylated ERK . To investigate cell-specific EGFR signaling dynamics , we constructed an H1299WT model ( WT model ) , an H1299EGFR-WT model ( EGFR-WT model ) , and two alternate H1299L858R models ( @VARIANT$ model A with Mig6 overexpression and L858R model B with Cbl overexpression ) .", "label": "sensitivity"}
{"id": "24587218", "sentence": "Hence we hypothesized that the constitutive activation of the EGFR/RAS/BRAF pathway could be responsible for the lack of sensitivity of FO-1 cells to @GENE$ and therefore treated them with both NAC and @DRUG$ , a specific inhibitor of BRAF @VARIANT$ .", "label": "None"}
{"id": "21687596", "sentence": "However , the frequency of all such mutations appears to be low in comparison with the @VARIANT$ mutation and further analysis of such cases is required in the future . 2.4.2 . IGF-1R Guix et al. established gefitinib-resistant clones from a gefitinib-sensitive cell line of squamous cell lung carcinoma that amplified the wild-type @GENE$ gene ( A431 ) by exposing the cells to increasing concentrations of gefitinib [ ] .", "label": "resistance or non-response"}
{"id": "24982846", "sentence": "@DRUG$ ESR1 Estrogen receptor positive Indications and usage , clinical pharmacology , clinical studies , patient counseling information Ibritumomab tiuxetan MS4A1 CD20 positive Indications and usage , clinical pharmacology , description Imatinib KIT c-KIT @VARIANT$ mutation negative Indications and usage , dosage and administration clinical pharmacology , clinical studies BCR/ABL1 Philadelphia chromosome [ t ( 9 ; 22 ) ] positive PDGFRβ PDGFR gene rearrangement positive FIP1L1/PDGFRα @GENE$ fusion kinase ( or CHIC2 deletion ) positive Indications and usage , dosage and administration , clinical studies", "label": "None"}
{"id": "21188105", "sentence": "Median OS was 27 months and the multivariate analysis found that @GENE$ male sex , the presence of the @VARIANT$ mutation , brain metastases , and bronchioloalveolar adenocarcinoma were associated with poor prognosis . Until now , there have been no published randomized trials of EGFR TKIs vs chemotherapy as first-line therapy for NSCLC patients from Western countries ; however , 2 integrative studies of phase II trials support the findings of the SLCG and promote the role of @DRUG$ as first-line therapy for patients with NSCLC carrying EGFR mutations .", "label": "None"}
{"id": "23527257", "sentence": "When @VARIANT$ and c-MET siRNAs were combined , the cooperative effect was less potent . The dual targeting of @GENE$ and c-MET was then verified using TKIs ( gefitinib , erlotinib and @DRUG$ plus su11274 ) .", "label": "response"}
{"id": "24787964", "sentence": "Preclinical studies have shown superior activity of afatinib over first-generation TKIs , mainly due to ( 1 ) irreversible binding , which confers stronger binding affinity and potency , ( 2 ) ability to circumvent first-generation TKI resistance mechanism @VARIANT$ mutation in exon 20 , and ( 3 ) effectiveness against multiple HER-endothelial growth factor receptors . Recently , TKIs have been investigated in eight phase 3 trials as first-line treatment in patients with advanced NSCLC harboring @GENE$ activating mutations , in comparison with platinum based chemotherapy doublets : @DRUG$ trials IPASS , , West Japan , North-East Japan , , and First-SIGNAL ; erlotinib trials OPTIMAL , and EURTAC ; and afatinib trials LUX-Lung 3 and LUX-Lung 6 .", "label": "resistance or non-response"}
{"id": "23976869", "sentence": "Treatment of two patients resistant to @DRUG$ with nilotinib was successful. , Another patient intolerant to imatinib responded to nilotinib and dasatinib. , The sensitivity of the @VARIANT$ mutation to second generation TKIs has been a matter of debate . Vo n Bubnoff et al reported that nilotinib suppresses the growth of @GENE$ cells transfected with the T674I FIP1L1-PDGFRA mutant .", "label": "None"}
{"id": "20385023", "sentence": "According to a compendium of studies that include 1170 patients , more than 70 % of NSCLCs with EGFR mutations respond to EGFR-TKIs , whereas only 10 % of tumors without @GENE$ mutations do so . Unfortunately , upon treatment of these patients with gefitinib and @DRUG$ , two major mechanisms of resistance have been observed . The first is the appearance of a `` resistance '' point mutation in the kinase domain ( @VARIANT$ ) , observed in 50 % of the gefitinib-resistant patients [ ] .", "label": "resistance or non-response"}
{"id": "21264348", "sentence": "B. Synergistic inhibition of @GENE$ T315I transformed Ba/F3 cells . Dose and effect curve of GNF-5 , dasatinib and the combination of GNF-5 and @DRUG$ ( 1∶1 ratio ) on Bcr-Abl @VARIANT$ transformed cells .", "label": "None"}
{"id": "21785682", "sentence": "Most of the mutations are in frame deletions in exon 19 and a point mutation in exon 21 ( @VARIANT$ ) [ ] . A deletion between codons 746 and 750 accounts for 65–75.5 % of the deletions in exon 19 [ ] . @DRUG$ and gefitinib are compounds that reversibly inhibit the tyrosine kinase activity of @GENE$ and have been employed in the treatment of patients with NSCLC .", "label": "sensitivity"}
{"id": "20190765", "sentence": "B PC9 cells expressing either @VARIANT$ EGFR ( left panel ) or L858R/T790M @GENE$ ( right panel ) were exposed to indicated concentrations of @DRUG$ ( E ) or dasatinib ( D ) for 24 hr. Protein lysates were transferred to membranes and probed with indicated antibodies .", "label": "sensitivity"}
{"id": "23055691", "sentence": "In adenocarcinoma tumor samples from never smokers , a Memorial Sloan Kettering group similarly identified @GENE$ mutations that were associated with sensitivity to gefitinib and @DRUG$ . These EGFR mutations activate the EGFR signaling pathway that promotes survival , and commonly include exon 19 deletions or the @VARIANT$ point mutation on exon 21 .", "label": "sensitivity"}
{"id": "24982846", "sentence": "@DRUG$ ALK ALK gene rearrangement positive Indications and usage , dosage and administration , drug interactions , warnings and precautions , adverse reactions , clinical pharmacology , clinical studies Dabrafenib BRAF @GENE$ V600E mutation positive Indications and usage , dosage and administration , warnings and precautions , clinical pharmacology , clinical studies , patient counseling information G6PD G6PD deficient Warnings and precautions , adverse reactions , patient counseling information Dasatinib BCR/ABL1 Philadelphia chromosome [ t ( 9 ; 22 ) ] positive ; @VARIANT$ mutation posit Indications and usage , clinical studies , patient counseling information", "label": "None"}
{"id": "24987354", "sentence": "Multikinase small molecule inhibitors such as sorafenib and @DRUG$ can be used per recent NCCN guidelines ( Version 2.2013 ) , but prospective clinical trials have not yet demonstrated a distinct molecular subgroup of PTC patients that derives large benefit from such targeted therapies [ ] . BRAF @VARIANT$ is present in approximately 45 % of all PTC [ ] , with alterations of CTNNB1 , HRAS , IDH1 , KRAS , NRAS , @GENE$ and TP53 being less common .", "label": "None"}
{"id": "25033171", "sentence": "Similar behavior of @DRUG$ was found in the @VARIANT$ mutated @GENE$ tyrosine kinase .", "label": "resistance"}
{"id": "17973572", "sentence": "The activation loop is orange , helix αC yellow , the glycine-rich P-loop green , and the inhibitor @DRUG$ yellow . The figure was made using the program PYMOL ( http : //pymol.sourceforge.net/ ) . ( D ) Top : Dose dependent growth inhibition of @GENE$ cells expressing EGFR @VARIANT$ (LR) , L858R-T790M (LR-TM) , or L858R-L747S ( LR-LS ) detected by the MTS assay .", "label": "None"}
{"id": "24924344", "sentence": "@DRUG$ rs562 ( C/T ) Chr3 : 183637845 ABCC5 ( UTR3 ) 0.049494 0.392 rs3749445 ( A/G ) Chr3 : 183638506 ABCC5 ( UTR3 ) 0.044895 0.410 rs2292998 ( C/T ) Chr3 : 183663833 ABCC5 ( intronic ) 0.039882 0.277 rs1016752 ( C/G ) Chr3 : 183665062 ABCC5 ( intronic ) 0.039781 0.232 rs4148585 ( C/T ) Chr3 : 183670642 ABCC5 ( intronic ) 0.039781 0.283 rs6443924 ( A/G ) Chr3 : 183679532 ABCC5 ( intronic ) 0.039781 0.279 rs4148579 ( A/G ) Chr3 : 183685249 ABCC5 ( intronic ) 0.039781 0.279 rs939336 ( A/G =&gt ; C594C ) Chr3 : 183685534 ABCC5 ( exonic ) 0.039781 0.279 rs1132776 ( C/T = & gt ; A395A ) Chr3 : 183696402 ABCC5 ( exonic ) 0.044895 0.289 rs2313212 ( C/T ) Chr3 : 183700928 ABCC5 ( intronic ) 0.039781 0.279 rs4148575 ( C/T ) @GENE$ : 183702275 ABCC5 ( UTR3 ) 0.044895 0.289 rs1846692 ( C/T ) Chr16 : 56671696 MT1A ( near - gene 5 ) 0.049494 0.360 rs35346959 ( A/G ) Chr16 : 56671867 MT1A ( near- gene 5 ) 0.044895 0.137 rs9922957 ( C/G ) Chr16 : 56672380 MT1A ( near - gene 5 ) 0.039781 0.185 rs9922409 ( A/G ) Chr16 : 56672400 MT1A ( near - gene 5 ) 0.04532 0.103 rs7190725 ( G/T ) Chr16 : 56673290 MT1A ( intronic ) 0.044895 0.170 rs8052394 ( A/G =&gt ; K51R ) Chr16 : 56673828 MT1A ( missense ) 0.044895 0.152 rs1800566 ( C/T = & gt ; @VARIANT$ ) chr16 : 69745145 NQO1 ( exonic ) 0.039781 0.258 rs689455 ( A/C ) Chr16 : 69761661 NQO1 ( near- gene 5 ) 0.039781 0.242", "label": "None"}
{"id": "24348666", "sentence": "Specifically , a leucine to methionine mutation at position 1196 ( L1196M ) and a cysteine to tyrosine mutation at position 1156 ( @VARIANT$ ) were found . With regard to resistance due to ligands , EGFR ligands ( epidermal growth factor , @GENE$ , HB-EGF , and transforming growth factor-α ) are reported to induce @DRUG$ resistance .", "label": "None"}
{"id": "24523596", "sentence": "Several studies have reported renal failure and tumor lysis syndrome during TKI based molecular targeted therapies , including with sorafenib for hepatocellular carcinoma , with @DRUG$ for chronic myelogenous leukemia , and with flavopiridol for chronic lymphocytic leukemia.– Because the @VARIANT$ variant of @GENE$ corresponding to SNP 421C&gt ; A reduces uric acid transport and those TKIs are substrates/inhibitors of ABCG2/BCRP , TKI therapy in patients with the SNP 421C&gt ; A ( Q141K ) may be at higher risk of tumor lysis syndrome .", "label": "None"}
{"id": "15737014", "sentence": "This study revealed that the quinazoline rings of @DRUG$ and lapatinib interact differently with the @GENE$ kinase domain , suggesting that while the @VARIANT$ mutation may affect inhibition by erlotinib and gefitinib , it may not affect inhibition of EGFR by compounds similar to lapatinib .", "label": "resistance or non-response"}
{"id": "24502453", "sentence": "Ponatinib2 Iclusig® Ariad @GENE$ Patients with CML for which Imatinib , Nilotinib , and @DRUG$ are not appropriate ( or patients carrying a @VARIANT$ single-point-mutation ) 1st July 2013 CML , ALL", "label": "None"}
{"id": "21192840", "sentence": "The @VARIANT$ “gatekeeper mutation” is associated with acquired resistance to @DRUG$ in NSCLC ( see text for details and further references ) . @GENE$ is expressed at elevated levels in many solid tumors , most often as a result of focal gene amplification or genomic copy number gain– .", "label": "resistance or non-response"}
{"id": "23994953", "sentence": "Unfortunately , the EGFR TKI-driven improvement in patient outcome is notably limited because virtually all NSCLC patients with erlotinib/gefitinib sensitizing @GENE$ mutations eventually acquire resistance after a median of 6–12 months of EGFR TKI therapy . In approximately half of cases , the tumor cells present after disease progression contain second-site mutations that alter drug binding to the EGFR TK domain . The most common lesion ( & gt ; 90 % ) is the so-called “gatekeeper mutation , ” which involves a substitution of methionine for threonine at position 790 ( @VARIANT$ ) .", "label": "resistance or non-response"}
{"id": "23667368", "sentence": "The PNA clamping method exhibits high sensitivity compared with direct sequencing , and clinical outcomes are not significantly different between groups harboring EGFR mutations detected by direct sequencing or PNA mediated PCR clamping.- Highly sensitive methods can also be useful for detection of EGFR mutations associated with acquired resistance , such as @VARIANT$ . TURNAROUND TIME @DRUG$ is approved as a first-line treatment for advanced NSCLC harboring @GENE$ mutations .", "label": "resistance or non-response"}
{"id": "23606169", "sentence": "Because mutations in the @GENE$ gene result in activation of the epidermal growth factor receptor (EGFR) signaling pathway , only metastatic colorectal cancer patients with wild-type KRAS tumors qualify for anti-EGFR targeted therapies with @DRUG$ or panitumumab [ ] . Also , a clinical trial with the BRAF inhibitor ( PLX4032 ) demonstrated antitumor activity in tumors with the BRAF @VARIANT$ mutation and confirmed that V600E BRAF is a valid therapeutic target in human cancer [ ] .", "label": "None"}
{"id": "25268703", "sentence": "BRCA1 promoter also has @VARIANT$ binding sites to bring about transcriptional regulation . With these in mind , the abundances of E2F1 association with @GENE$ and p73 promoters in tumors exposed to Pac/212Pb-trastuzumab were evaluated using the ChIP assay .", "label": "None"}
{"id": "19503843", "sentence": "In the superfamily of phosphotransferases , the conserved residues that form a corresponding motif ( DXG in actin , GTG in hexokinase/glycerol kinase , and @GENE$ in acetate and propionate kinases ) are observed to be present in binding to a- and b-phosphate groups of the nucleotide . We used site directed mutagenesis to construct two mutants ( see ) : one in which the @DRUG$ at position H247 was changed to a glutamine ( @VARIANT$ ) , and the other in which the glycine at position G392 was changed to alanine ( G392A ) .", "label": "None"}
{"id": "23493883", "sentence": "Combinations of therapy such as cetuximab plus @DRUG$ and gefitinib plus everolimus have also been tried . The most promising drug thus far has been afatinib ( BIBW2992 ; Boehringer-Ingelheim Pharma , Ingelheim , Germany ) , , an ErbB family blocker with reported in vitro and in vivo activity against @GENE$ mutant tumors harboring exon 19 deletions , exon 21 L858R mutations and the exon 20 @VARIANT$ “resistance” mutations .", "label": "resistance or non-response"}
{"id": "15736989", "sentence": "@VARIANT$ in the context of either transiently expressed wild-type @GENE$ or the mutant alleles del L474–E749 ; A750P or L858R impairs inhibition by gefitinib or @DRUG$ as assessed by autophosphorylation .", "label": "resistance or non-response"}
{"id": "15737014", "sentence": "Sequencing Chromatograms with the T790M EGFR Exon 20 Mutation in Various Clinical Specimens and the NSCLC Cell Line H1975 ( A–C ) In all three patients—patient 1 ( A ) , patient 2 ( B ) , and patient 3 ( C ) —the secondary T790M mutation was observed only in lesions obtained after progression on either gefitinib or @DRUG$ . ( D ) Cell line H1975 contains both an exon 21 @VARIANT$ mutation ( upper panel ) and the exon 20 T790M mutation ( lower panel ) . The asterisks indicate a common SNP ( A or G ) at nucleotide 2361 ; the arrows indicate the mutation at nucleotide 2369 ( C→T ) , which leads to substitution of methonine ( @GENE$ ) for threonine ( ACG ) at position 790 .", "label": "None"}
{"id": "23702846", "sentence": "In the cell proliferation and malignancy of MCF7 and SUM149 breast cancer cells , Src dependent ( i.e. , dasatinib-sensitive ) Y845 phosphorylation ( i.e. , @VARIANT$ mutation-sensitive ) signaling was shown to require the activity of p38 MAPK , but not the activity of the @GENE$ ERK/MAPK , as well as Akt [ ] .", "label": "None"}
{"id": "25360523", "sentence": "@GENE$ binding specificity of LRRK2-N . bait plasmid prey plasmid QDO+X-α-gal+aureobasidin A pAS2-1-Rab32 wt pACT2-LRRK2-N_+ pAS2-1-Rab38 wt + pAS2-1-Rab1B Q67L − pAS2-1-Rab1B Q67R − pAS2-1-Rab11A wt − pAS2-1-Rab5A wt − pAS2-1-Rab6A Q72L − pAS2-1-Rab6A Q72R − pAS2-1-Rab7ΔC − pAS2-1-tau − After co-transformation of the yeast strain Gold with the indicated plasmids , cells were grown on synthetic media lacking adenine and @DRUG$ supplemented with 125 ng/ml aureobasidin and 40 µg/ml X-α-gal .", "label": "None"}
{"id": "23836985", "sentence": "Jin et al also reported that the HDAC inhibitor , @DRUG$ , inhibits HDAC activity by downregulating cyclin D1 protein expression in colonic carcinoma cells in xenografted mice . In conclusion , our study confirms that valproic acid significantly suppresses growth of Kasumi-1 cell xenograft tumors in nude mice via cell cycle arrest . The antitumor activity of valproic acid is possibly attributable to its direct downregulation of cyclin D1 , CDK4/6 , and cyclin E1 expression , blockage of Rb phosphorylation , reduction of free @VARIANT$ , inhibition of HDAC activity , attenuation of histone acetylation in the p21 promoter region , upregulation of p21 expression , and induction of cell cycle arrest .", "label": "None"}
{"id": "25328408", "sentence": "YY1 activates transcription in the presence of @VARIANT$ , a protein that activates the AAV P5 promoter ; however , the role of YY1 is reversed when E1A is absent , converting to a transcriptional repressor . Furthermore , YY1 can also regulate targets independently of its DNA binding ability by mediating protein posttranslational modifications and acting as a transcriptional @DRUG$ . YY1 modulates posttranslational modification by interacting with proteins that mediate posttranslational modifications , such as histone deacetylases , @GENE$ , Ezh2 , and Ezh1 .", "label": "None"}
{"id": "25465236", "sentence": "( C ) EGFR @VARIANT$ mutant does not resemble pEGFR unlike the EGFR L858R mutant shown in B. ( D–F ) increased inhibition potency for @DRUG$ against @GENE$ L858R mutant compared to EGFR WT protein and subsequent decrease in potency for Erlotinib against EGFR L858R + E884K double mutant .", "label": "resistance or non-response"}
{"id": "24958351", "sentence": "PI3K mutation and/or loss of PTEN have been shown to contribute to maintained activation of @GENE$ and are associated with innate resistance to trastuzumab [ ] and @DRUG$ [ ] . In our study , SKBR3-L cells exhibit a dramatic decrease in p-AKT compared to parental cells , suggesting a decreased dependence on the @VARIANT$ pathway for growth and survival , and no alteration in PTEN levels was observed .", "label": "None"}
{"id": "24349829", "sentence": "While the @VARIANT$ mutation represents a direct mechanism for drug resistance that occurs at the level of drug accessibility to the target , there are a number of indirect mechanisms that involve the increased expression or activation of alternative growth factor receptors to maintain signal flux , despite EGFR inhibition . Perhaps the best characterized of these is the amplification of the Met receptor and/or elevated levels of its ligand HGF . In @DRUG$ resistant NSCLC cell lines , Met drives ErbB3 dependent activation of the @GENE$ pathway .", "label": "None"}
{"id": "10993652", "sentence": "@VARIANT$ proteins in cell growth control and apoptosis . Proc Natl Acad Sci USA 94 : 7245-7250 Del Bino G and Darzynkiewicz Z ( 1991 ) @DRUG$ , tenioside , or 4- ( 9-acridinylamino ) -3-methanesulfon-m-anisidide , but not mitoxantrone or doxorubicin , induces degradation of nuclear DNA in the S phase of HL-60 cells .", "label": "None"}
{"id": "24419415", "sentence": "The clinical efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors ( EGFR-TKIs ) , such as gefitinib and @DRUG$ , has been demonstrated in non–small-cell lung cancer ( NSCLC ) patients in whom standard chemotherapy has failed. , Further studies have revealed that the presence of activating mutations in the EGFR kinase domain is strongly associated with the therapeutic efficacy of @GENE$ , Randomized phase 3 trials have demonstrated that EGFR-TKIs significantly improve median progression-free survival ( PFS ) compared with platinum-doublet therapy in EGFR mutated patients.– However , not all mutations in the EGFR kinase domain are responsive to EGFR-TKI treatment . These phase 3 trials have shown that EGFR-TKIs are effective for patients with common EGFR mutations , such as an exon 19 deletion or the @VARIANT$ point mutation , which account for more than 90 % of EGFR mutations .", "label": "sensitivity"}
{"id": "23986642", "sentence": "@DRUG$ inhibits kinase targets including BCR-ABL , @GENE$ , and c-Kit , but not the Src family kinases . While the first and second-generation TKIs have demonstrated improved outcomes in patients with CML and Ph+ ALL , resistance still occurs in a subset of patients who harbor BCR-ABL mutations , particularly the @VARIANT$ mutant .", "label": "None"}
{"id": "25275314", "sentence": "shows that the side chain groups of the mutated residues Lys and the protonated @DRUG$ at position 19 of the WT substrate ( in mutants R19K and R19Hp ) also form HB interactions with the side chain carboxylate group of the PKA residue Glu170 , while the mutated residue histidine δ at the same position 19 ( in mutant R19Hδ ) also forms an HB interaction with the side chain carboxylate group of the @GENE$ residue Glu203 ( ) .", "label": "None"}
{"id": "23864840", "sentence": "After re-introduction of @DRUG$ , 25 % achieved partial remission and 75 % showed DCR . A different response to the same @GENE$ regimen after a drug holiday can be explained with tumor heterogeneity . In a retrospective analysis of an erlotinib retrial , Becker et al. [ ] reported five cases of the @VARIANT$ mutation and exon 19 deletions in rebiopsy specimens taken before the retrial of erlotinib .", "label": "resistance or non-response"}
{"id": "21681573", "sentence": "In addition to these patients , we investigated the plasma and @GENE$ concentrations of four other NSCLC patients with CNS metastases ( cases 5–8 ) ( Table ) .Patient characteristics Cases Age ( yr ) Sex PS Histology EGFR gene Smoking status Previous chemotherapy regimen Previous @DRUG$ ( length of PFS ) Previous WBRT 1 59 F 3 Ad NE Never 3 Yes ( 10 months ) Yes 2 82 F 4 Ad Wild type Never 0 No No 3 70 F 3 Ad Wild type Never 1 No Yes 4 86 F 3 Ad Ex 21 ; @VARIANT$ Never 1 Yes ( 7 months ) No 5 67 F 1 Ad Ex 21 ; L858R Never 1 No No 6 72 M 0 Ad Ex 21 ; L858R Former 1 No No 7 81 M 1 Ad Ex 19 deletion Former 1 Yes ( 46 months ) Yes 8 85 F 2 Ad Ex 21 ; L858R Never 1 No Yes a 66 F 1 Ad Ex 21 ; L858R Never 3 No Yes", "label": "None"}
{"id": "22970367", "sentence": "The data suggest that low @GENE$ level may neutralize the negative effects of the EGFR T790M mutation on @DRUG$ sensitivity and that high BRCA1 expression may lead to de novo EGFR TKI resistance potentially through increased DNA damage repair capacity [ ] . In addition to EGFR T790M , primary EGFR TKI resistance may also be due to other secondary mutations in EGFR ( e.g. , D761Y ) that occur in cis with an activating EGFR kinase domain mutation ( e.g. , @VARIANT$ ) [ ] .", "label": "None"}
{"id": "23009336", "sentence": "A secondary point mutation in exon 20 of @GENE$ ( @VARIANT$ ) is associated with acquired resistance to gefitinib or @DRUG$ , but this can be overcome by the irreversible EGFR-tyrosine kinase inhibitor BIBW2992 ( BIBW ) .", "label": "resistance or non-response"}
{"id": "24523596", "sentence": "@DRUG$ @GENE$ with mutations , including @VARIANT$ + + Sen et al", "label": "None"}
{"id": "23732709", "sentence": "JTE013 blocked @VARIANT$ induced Akt activation in both cell lines , supporting the findings using AC expression to drive increased S1P signaling . AC promotes chemotherapy resistance , but confers sensitivity to @GENE$ inhibition Cytotoxic chemotherapy depends , in part , on ceramide accumulation to cause cell death. , , PPC1 cells were subjected to a wide dose range of the cytotoxic chemotherapeutic agents @DRUG$ , Gemcitabine and 5′-Fluorouracil .", "label": "None"}
{"id": "24523596", "sentence": "Recently , genome-wide screening for the genetic determinants of gout found that an SNP of ABCG2/BCRP ( @VARIANT$ ) is associated with high uric acid levels , and demonstrated that uric acid is a natural substrate of ABCG2/BCRP. , ABCG2/BCRP also appears to play a protective role against xenobiotics and their metabolites. , The typical ABCG2/BCRP substrates , irinotecan and SN-38 , are detoxified by glucuronidation with uridine-diphosphate–glucuronyltransferase , and ABCG2/BCRP can extrude SN-38–glucuronide . Interestingly , ABCG2/BCRP can transport another of the glucuronide conjugates , 17-β-estradiol 17- ( β-D-glucuronide ) , and the sulfated conjugates estrone-3-sulfate @DRUG$ @DRUG$ are also substrates of ABCG2/BCRP. , The apical localization of @GENE$ in the intestinal epithelium and the bile canalicular membrane also suggests the intestinal absorption and hepatobiliary excretion of ABCG2/BCRP substrates. , – ABCG2/BCRP may also play a protective role by transporting dietary carcinogens .", "label": "None"}
{"id": "22076124", "sentence": "L1196M represents a mutation of the “gatekeeper” residue , similar to the T790M gefitinib-resistance mutations observed in EGFR , and @VARIANT$ mutations in @GENE$ . Mutations in the gatekeeper site are thought to increase the affinity for ATP significantly , outcompeting the effects of ATP competitive inhibitors [ ] . The effect of the C1156Y mutation is unclear , although it may have an indirect effect on @DRUG$ binding , and further studies will be required to establish its mechanism .", "label": "None"}
{"id": "22558339", "sentence": "Wild type KRAS is now considered a pre-condition to treat CRC patients with EGFR inhibitors like @DRUG$ or Panitumumab , . Oncogenic @GENE$ mutations occur in up to 15 % of all human tumors , the vast majority ( & gt ; 90 % ) being c.1799 : T & gt ; A substitutions that lead to the replacement of valine with aspartic acid ( @VARIANT$ ) causing constitutive BRAF activation .", "label": "resistance or non-response"}
{"id": "24375389", "sentence": "Other examples of useful biomarkers are @GENE$ mutation testing to predict benefit from monoclonal antibodies against EGFR , @DRUG$ and panitumumab , in metastatic colon cancer [ ] and BRAF @VARIANT$ mutation analysis in metastatic melanoma in order to predict responsiveness to BRAF inhibitors such as vemurafenib [ ] .", "label": "None"}
{"id": "21687596", "sentence": "Analogous secondary mutations of the BCR-ABL gene in case of chronic myelogenous leukemia ( CML ) [ ] and the @GENE$ gene in case of gastrointestinal stromal tumor [ ] have previously been reported as mechanisms of @DRUG$ resistance , which is also a TKI . The structural similarity between ABL and EGFR tyrosine kinases is considerably high , and @VARIANT$ in ABL corresponds to T790M in EGFR [ ] .", "label": "None"}
{"id": "25532027", "sentence": "In particular , epidermal growth factor receptor-tyrosine kinase inhibitors ( EGFR-TKIs ) , such as gefitinib and @DRUG$ , demonstrated marked clinical activity against NSCLC harboring an activating @GENE$ mutation ( – ) . Additionally , some reports suggest that the EGFR @VARIANT$ mutation may not be rare and may exist in a small population of in tumor cells before TKI treatment ( – ) .", "label": "resistance or non-response"}
{"id": "22992338", "sentence": "Preclinical data suggest that amplification of the MET proto-oncogene may play a role in acquired resistance to @GENE$ TKIs through the PI3K pathway . MET amplification has been detected in lung cancer cell lines that have acquired resistance to @DRUG$ . Current evidence implies that MET amplification occurs independently of @VARIANT$ and it has been proposed that concurrent inhibition of both may further improve clinical outcomes .", "label": "resistance or non-response"}
{"id": "21264348", "sentence": "A. @DRUG$ antiproliferative EC50 in the presence of 0.4 to 10 μM GNF‐5 on Ba/F3 cells expressing @VARIANT$ and E505K Bcr‐Abl. B. Inhibition of Bcr‐Abl autophosphoryl‐ation was determined by Bcr‐Abl immunoprecipitation , followed by a immunoblot for phospho‐Tyr ( Tyr412 ) , phospho‐STAT 5 ( Tyr694 ) and total Bcr‐Abl ( antibody K‐12 ) from cell lystates obtained after treatment of T315I Bcr‐Abl expressing @GENE$ with 10 μM of dasatinib and increasing concentrations of GNF‐5 ( 0 , 0.5 , 5 and 10 μM ) for 90 min. ( TIF )", "label": "None"}
{"id": "23419122", "sentence": "The studies that established the relationship between mutations in the EGFR gene and response to the small molecule @GENE$ TKIs @DRUG$ and erlotinib were done using analysis of DNA extracted from the tumor [ ] . The recent availability of antibodies that are specific for the mutations most clearly associated with response to EGFR TKIs , @VARIANT$ and E746_A750del , create the opportunity to exploit an alternative method to evaluate NSCLC for EGFR mutations to aid decisions with regard to EGFR TKI therapy [ ] .", "label": "sensitivity"}
{"id": "24155950", "sentence": "In conclusion , the combination of bortezomib and mitotic inhibitors such as @DRUG$ , docetaxel , vincristine or BI 2536 is an effective strategy for targeting of both TKIs -resistant and -sensitive Bcr-Abl positive leukemic cells . These regimens are able to inhibit Bcr-Abl activity and its downstream signaling , and to activate @GENE$ dependent cell death . In addition , these regimens are able to overcome the resistance to imatinib , dasatinib and nilotinib , brought about by Bcr-Abl protein overexpression or Bcr-Abl mutations ( including @VARIANT$ ) , making them attractive potential therapies for Bcr-Abl positive leukemias such as CML , especially for those resistant to current treatments .", "label": "None"}
{"id": "24583601", "sentence": "First generation mammospheres from 226L , @VARIANT$ cells and one of the ascites samples were dissociated and re-plated into a mammosphere assay in the absence of secondary treatment to assess the effects of first generation treatment on stem cell self-renewal ( Figure ) . For the ascites sample , first generation cells treated with SDF-1 alone showed an increase in self-renewal . This was reduced when @DRUG$ was added in combination with @GENE$ , while AMD3100 treatment alone had no effect .", "label": "None"}
{"id": "23788917", "sentence": "In case of occurrence of both L858R and T790M mutations , the concentration of @DRUG$ should be three times higher in order to achieve a therapeutic effect . Analysis of the EGFR structure in patients harbouring the T854A mutation suggests the presence of an additional side chain , localised near the @GENE$ TKI binding site [ ] . The role of rare mutations in exon 20 such as S768I and @VARIANT$ in development of acquired resistance to EGFR TKI is still unknown .", "label": "None"}
{"id": "24790411", "sentence": "Compared to @DRUG$ and gefitinib , afatinib shows lower EC50 values and greater potency against wild type ( afatinib vs erlotinib vs gefitinib : 60 nM vs 110 nM vs 157 nM ) and @VARIANT$ mutated @GENE$ ( afatinib vs erlotinib vs gefitinib : 0.7 nM vs 40 nM vs 5 nM ) .", "label": "sensitivity"}
{"id": "23776375", "sentence": "Mutations of the PIK3CA gene are observed in 16 % –40 % of female breast cancers and in about 18 % of male breast cancers. , –PIK3CA mutations are associated with a positive estrogen receptor and @DRUG$ receptor status , nodal involvement , and high histological grade , suggesting that they could be strong prognostic factors in breast cancer.– The great majority ( 85 % ) of @GENE$ mutations are in exons 9 and 20 , encoding the helical and kinase domains , respectively . The majority of mutations are located in two hot spot regions , including the central helical domain and the COOH terminal kinase domain . The three most common hot spot mutations lead to amino acid changes in the helical domain ( @VARIANT$ and E545K ) and in the kinase domain ( H1047R ) .", "label": "None"}
{"id": "24279718", "sentence": "Indeed , even if the co-existence of KRAS and EGFR mutations could be interpreted as double mutation occurring in the crizotinib-resistant tumor cells , the possibility of different tumor clones with activation of EGFR and @GENE$ signaling as different mechanisms of crizotinib-resistance appeared to be an alternative , perhaps more likely explanation . Furthermore , the identified @VARIANT$ EGFR mutation , although not reported before , was located near mutations known to be sensitive to EGFR-TKI , such as L858R and L861X .", "label": "None"}
{"id": "24494026", "sentence": "In HPV positive cells , HDAC binds to E7 preventing HDAC binding to @VARIANT$ promoter , leading to upregulation of E2F and increase proliferation . Tricostatin A , a HDAC inhibitor , can compete with E6 for p53 binding , resulting in p53 hyperacetylation and increased apoptosis , and clinical trials in combination with chemoradiation are ongoing , . @DRUG$ , another histone deacetylase inhibitor , is under evaluation in respiratory papillomatosis , a disease related to HPV virus other than 16 and 18 .", "label": "None"}
{"id": "25465236", "sentence": "( C ) EGFR T790M mutant does not resemble pEGFR unlike the EGFR @VARIANT$ mutant shown in B. ( D–F ) increased inhibition potency for Erlotinib against @GENE$ L858R mutant compared to EGFR WT protein and subsequent decrease in potency for @DRUG$ against EGFR L858R + E884K double mutant .", "label": "sensitivity"}
{"id": "24349229", "sentence": "For example , the @VARIANT$ mutation , termed the ‘gatekeeper’ mutation , reduces the ability of EGFR inhibitors to outcompete ATP binding to EGFR . This mutation ( along with other far less frequent resistance associated mutations ) is found in cell line models of resistance and in approximately 50 % of patients who develop acquired resistance to EGFR inhibitor therapy , , . The analogous gatekeeper position on @GENE$ , L1196 , is similarly found to be mutated in ALK fusion positive lung cancer at the time of resistance to @DRUG$ and in resistant cell line models , as are several other amino acids for which mutation also reduces the ability of the drug to inhibit the kinase , , , , .", "label": "None"}
{"id": "24724051", "sentence": "Location of the @GENE$ tyrosine kinase domain mutations listed in Table . The @VARIANT$ mutation , which causes resistance against imatinib , @DRUG$ , and nilotinib is depicted in red .", "label": "None"}
{"id": "17973572", "sentence": "After the cells were exposed to @DRUG$ for 24 h , @GENE$ cells were unable to proliferate while Ba/F3-L858R-L747S and Ba/F3-L858R-T790M cells continued to grow even in the presence of 1 μM gefitinib ( E ) . These results suggest that execution of apoptosis may be impaired by the presence of T790M and , to a lesser extent , @VARIANT$ .", "label": "None"}
{"id": "22997553", "sentence": "The water was replaced every 12 h with freshly prepared @DRUG$ and spNO . Plasmid and primers pcDNA-eNOS S1179A ( Plasmid # 22485 ) , @GENE$ @VARIANT$ ( Plasmid # 22484 ) , pcDNA-eNOS GFP ( Plasmid # 22444 ) , constructs were purchased from Addgene deposited by Prof.William Sessa 's Lab .", "label": "None"}
{"id": "23852704", "sentence": "Thus , in two trials , administration of @DRUG$ to patients with this mutation was associated with a significantly better outcome than that seen in patients with other types of K-RAS mutations. , Indeed , patients with the @VARIANT$ mutation appeared to benefit to approximately the same extent as patients with K-RAS wild-type tumors from the addition of cetuximab to first-line chemotherapy .", "label": "None"}
{"id": "23994953", "sentence": "Using the erlotinib-sensitive EGFR mutant NSCLC cell line HCC4006 harboring the delL747-E749 , A750P mutation in EGFR exon 19 , Suda et al. established that mesenchymal status , not a specific oncogenic activated protein , could sufficiently promote loss of EGFR dependence to confer resistance to erlotinib . More recently , Chang et al. confirmed that in the absence of the common second-site EGFR mutation @VARIANT$ or MET amplification , acquired resistance to gefitinib occurs in EGFR mutated PC9 cells that have undergone EMT . In agreement with the above mentioned pro-survival role of EMT TFs , the authors observed that @GENE$ overexpression efficiently protected PC9 cells from gefitinib induced apoptosis ; accordingly , specific knockdown of SLUG can reverse secondary resistance to gefitinib .", "label": "None"}
{"id": "22216257", "sentence": "Dietary vitamin D3 restriction ( 0.025 IU/g feed ) decreases @GENE$ and motor performance , improves early disease severity and delays disease onset compared to a diet with adequate vitamin D3 ( 1 IU/g feed ) in the high-copy @VARIANT$ mouse model of ALS . We hypothesize that the attenuation of early disease severity and the delay in disease onset may have been due to a transient compensatory increase in @DRUG$ under conditions of decreasing calcidiol concentrations , whereas the reduced functional performance may be due to changes in intramuscular calcium regulation and a decrease in contractile protein synthesis .", "label": "None"}
{"id": "23407898", "sentence": "The irreversible TKI @DRUG$ afatinib ) is currently being investigated in advanced clinical trials ( Yap et al. , ; Murakami et al. , ) . Another novel irreversible pan-HER inhibitor HM781-36B has recently shown promise in the inhibition of @GENE$ , HER2 , and HER4 as well as against the gatekeeper mutation – EGFR @VARIANT$ that is responsible for acquired drug resistance in lung cancer patients ( Cha et al. , ) .", "label": "response"}
{"id": "20387067", "sentence": "For the leukemic counterpart , we used the SKNO-1 cell line , which is GM-CSF dependent expressing homozygous @VARIANT$ KIT mutation . Dasatinib showed significant growth reduction on long-term coculture assay , particularly in the absence of GM-CSF , suggesting that @DRUG$ can target @GENE$ mutation effectively .", "label": "sensitivity"}
{"id": "23029123", "sentence": "The importance of D2 receptor involvement in ethanol actions on PRL production and cell proliferation is evident in the experiment where @DRUG$ actions on lactotropes ' function were evaluated in clonal cell lines expressing various levels of D2 receptor isoforms . It was found that V cells , which lacked functional D2 receptors and had high basal levels of PRL , showed a significant reduction in PRL production following @VARIANT$ and D2L receptor transfection . As described by an extended allosteric ternary complex model of @GENE$ , receptors spontaneously isomerize between active and inactive conformations , so receptors can modulate signaling pathways in the absence of an agonist .", "label": "None"}
{"id": "24466151", "sentence": "For G6P utilising enzymes ( G6PD +6PGD+H6PD ) reaction mixtures contained 25 mM @GENE$ ( pH 7.4 ) , 5 mM MgCl2 , 5 mM G6P ( Merck ) and 0.5 mM NADP+ ( Roche ) . H6PD activity was determined using 2-deoxyglucose-6-phosphate ( dG6P ) . The combined contribution of G6PD +6PGD+H6PD was assessed using fructose-6-phosphate ( F6P ) , whereby phosphoglucose isomerase initially converts F6P to @VARIANT$ .", "label": "None"}
{"id": "24790411", "sentence": "Indeed , a recent preclinical study shows how in the presence of acquired MET amplification and HGF overexpression , @DRUG$ monotherapy is unable to inhibit the growth of cells that were originally sensitive to first-generation @GENE$ TKIs . Eight patients enrolled in the study were known to harbor a @VARIANT$ mutation on archival tissue collected at diagnosis , but authors provided no information on the outcome of these patients .", "label": "response"}
{"id": "25074928", "sentence": "Because stress-inducible Atf3 is a dual-face @GENE$ activates or represses gene expression ( ) , it may initially develop a compensatory or adaptive response for the acute oxidative stress or endoplasmic reticulum stress . Furthermore , we have identified a noncoding variant in the Atf3 gene as a novel predisposing factor to @VARIANT$ after controlling for @DRUG$ consumption in T2D groups ( data not shown ) .", "label": "None"}
{"id": "25580271", "sentence": "Most patients with @GENE$ mutant NSCLC receive an EGFR tyrosine kinase inhibitor ( e.g. @DRUG$ , erlotinib , or afatinib ) as first-line therapy , and unfortunately most patients experience disease progression after approximately 10–15 months of treatment . The most common mechanism of resistance is an EGFR exon 20 @VARIANT$ mutation , which is detected in approximately 50–60 % of tumor samples when a biopsy is performed after disease progression on EGFR tyrosine kinase inhibitors [ , ] .", "label": "resistance or non-response"}
{"id": "24419415", "sentence": "Cells expressing G719X were less resistant to erlotinib than gefitinib in vitro ; however , @VARIANT$ was resistant to both erlotinib and @DRUG$ . In contrast to erlotinib , irreversible TKIs inhibited the growth of cells with G719X or L861Q at a lower concentration than those with wild-type @GENE$ .", "label": "None"}
{"id": "25031955", "sentence": "In this patient who developed resistance to @DRUG$ after 5 months of treatment , molecular analyses showed the tumor had two acquired mutations within the kinase domain of @GENE$ , C1156Y , and the gatekeeper mutation @VARIANT$ ( Katayama et al. , 2011 ) .", "label": "resistance"}
{"id": "25054154", "sentence": "Overall RMSD curve of native type and mutant @GENE$ @DRUG$ at 20 ns . Three independent simulations of each Protein-crizotinib complex . Time evolution of backbone RMSD is shown as a function of time for A ) native type , B ) F1174L and C ) @VARIANT$ .", "label": "sensitivity"}
{"id": "23829771", "sentence": "@VARIANT$ also can activate @GENE$ which upregulates the stability of the p53 protein [ ] . p53 inhibits the translation of the CDK4 protein [ ] forming a feedback loop . Some of the feedback mechanisms identified in this analysis can potentially explain the observed @DRUG$ resistance in HCC1954 cells .", "label": "None"}
{"id": "PMC4041556", "sentence": "Second-generation EGFR TKIs – such as neratinib , afatinib and dacomitinib – are effective in preclinical gefitinib- and erlotinib-resistant EGFR @VARIANT$ models , but to date their delivery in EGFR TKI-resistant patients have shown disappointing results in the clinic . Combination of afatinib with cetuximab in EGFR TKI-resistant patients resulted in a 30 % response rate and 75 % disease control rate , with significant gastrointestinal toxicity . Other mechanisms of resistance include MET amplification , with no commercially available inhibitor , HER2 amplification potentially amenable to treatment with @GENE$ monoclonal antibodies or histological transformation to small-cell lung cancer , which requires cytotoxic chemotherapy .", "label": "None"}
{"id": "24256696", "sentence": "In mammals , mTOR associates with mammalian lethal with SEC13 protein 8 ( mLST8 ) , @GENE$ AKT substrate of 40 kDa ( AKT1S1 ) and regulatory associated protein of mTOR ( RAPTOR ) to form the rapamycin-sensitive mTOR complex 1 (mTORC1) . The mTORC1 activates protein synthesis through modulation of the 40S ribosomal protein S6 kinase ( @VARIANT$ ) and the translational initiation factor eIF-4E binding protein 1 ( 4E-BP1 ) . mTORC1 is acutely sensitive to inhibition by Sirolimus/Everolimus .", "label": "None"}
{"id": "21494688", "sentence": "The mechanism of response to the IGFR and mTOR combination may be similar to that in patient 1 , that is , through Akt and mTOR suppression that occurs with chronic @DRUG$ exposure , . However , other pathways are operative in this patient 's tumor , including Ras/Raf /ERK and STAT3 ( ) .The relative overexpression of CD99 in this patient is consistent with activation of this pathway ( not shown ) . In addition , p-Akt and @VARIANT$ are not downregulated by combined @GENE$ and mTOR inhibition , perhaps due to Ras/Raf/ERK activation .", "label": "None"}
{"id": "22997553", "sentence": "The pectoral fins abnormalities are presented in scrambled vector control , GFP alone and @GENE$ GFP electroporated fishes ( E–H ) . Zebrafish eggs electroporated with @VARIANT$ were treated with NO specific dye , DAR-4M-AM . The NO production in @DRUG$ treated or untreated fishes were visualized with the fluorescence microscope .", "label": "None"}
{"id": "21747723", "sentence": "The demonstration that @DRUG$ ( Imatinib mesylate ) , an Abl tyrosine kinase inhibitor licensed for the treatment of several cancer forms [ ] , is a poxvirus blocker [ ] and the repurposing of the @GENE$ kinase inhibitor U0126 to block the Raf/MEK/ERK cascade for influenza virus inhibition [ , ] serve as cases in point . While the former originated from the insight that efficient vaccinia virus spread requires phosphorylation of the viral @VARIANT$ protein by Abl and Src family tyrosine kinases [ , ] , the latter was triggered by the observation that influenza virus infection induces the activation of MAPK family members [ , ] .", "label": "None"}
{"id": "21197464", "sentence": "Schematic representation of the signal pathways of @DRUG$ (RA-) induced ( RA-induced ) differentiation of mouse embryonic carcinoma F9 cells . At the undifferentiation stage of F9 cells , HDAC3 , NcoR/SMART , and JDP2 were recruited on the DRE ( differentiation response element ) in the promoter region of the c-jun gene to induce the heterochromatin . Ac , acetylated residues ; K , lysine residues of histone; @VARIANT$ , lysine residues of histone H3; H4K8 , lysine residue at position 8 of histone H4 ; H4K16 , lysine residue at position 16 of @GENE$ X1 = ATF-2 , ATF-7 .", "label": "None"}
{"id": "19547661", "sentence": "Recently , it was demonstrated that wildtype @GENE$ is required for the response of patients with metastatic colorectal cancer to cetuximab and @DRUG$ [ ] . The aim of this study was to determine the BRAF @VARIANT$ mutation frequency in a large cohort of SGCs of the main histopathological types and to design an allele-specific PCR as an effective screening method .", "label": "resistance or non-response"}
{"id": "25031876", "sentence": "However , the efficacy of @DRUG$ in CNS disease remains uncertain , particularly since it has poor CNS penetrance ( @GENE$ : plasma ratio of 0.033 after IV administration ) and has a slow onset of action [ ] . Similarly , recently a case series reported excellent responses to treatment with vemurafenib in patients who possess the BRAF @VARIANT$ mutation [ ] , but unfortunately vemurafenib also does not cross the blood-brain barrier [ ] .", "label": "None"}
{"id": "21556318", "sentence": "Y253H , E255K , and F359V were deemed less sensitive , but not inherently resistant , as was the @VARIANT$ identified in three patients receiving nilotinib . Six of 16 @DRUG$ treated patients ( 38 % ) with @GENE$ mutations progressed to accelerated phase/blast crisis CML , as compared with 1/13 ( 8 % ) of nilotinib treated patients .", "label": "None"}
{"id": "19920910", "sentence": "The pattern of resistance to nilotinib and dasatinib differed ; those with greatest resistance to nilotinib ( Y253H and E255V ) were susceptible to @DRUG$ . @VARIANT$ remained resistant to all the three drugs . In vivo experiments with CML xenografts in mice demonstrated that nilotinib treatment , compared with treatment with vehicle , improved survival of mice infused with either wild type @GENE$ or the imatinib-resistant Bcr-Abl mutant ( E255V ) ( ; ) .", "label": "None"}
{"id": "22855636", "sentence": "Some @GENE$ mutant GISTs show at least partial response to @DRUG$ ; however , the most common PDGFRA mutation in GISTs ( @VARIANT$ ) confers a complete resistance to the drug. , In KIT mutant GISTs , a mutation in exon 11 was associated with a higher response rate ( 67 % –83 % ) than a mutation in exon 9 ( 35 % –48 % ) .", "label": "resistance or non-response"}
{"id": "23994953", "sentence": "Using the erlotinib-sensitive EGFR mutant NSCLC cell line HCC4006 harboring the delL747-E749 , A750P mutation in EGFR exon 19 , Suda et al. established that mesenchymal status , not a specific oncogenic activated protein , could sufficiently promote loss of EGFR dependence to confer resistance to @DRUG$ . More recently , Chang et al. confirmed that in the absence of the common second-site EGFR mutation @VARIANT$ or MET amplification , acquired resistance to gefitinib occurs in EGFR mutated PC9 cells that have undergone EMT . In agreement with the above mentioned pro-survival role of EMT TFs , the authors observed that SLUG overexpression efficiently protected PC9 cells from gefitinib induced apoptosis ; accordingly , specific knockdown of @GENE$ can reverse secondary resistance to gefitinib .", "label": "None"}
{"id": "16552419", "sentence": "Seven of nine cases with mutated types showed high sensitivity to gefitinib , and the patients with @GENE$ mutations had a more favourable prognosis than those with wild type after @DRUG$ treatment ( P=0.033 ) ( ) . In conclusion , our established methods are thus considered to be very useful for identifying a deletion of exon 19 and a point mutation ( @VARIANT$ ) of exon 21 of the EGFR gene as a screening .", "label": "sensitivity"}
{"id": "24894453", "sentence": "Although high-level expression of @GENE$ ligands and/or increased EGFR gene copy numbers may be predictive markers for antitumor response by cetuximab in colon cancer [ - ] , and patients with RAS driven cancers are known not to benefit from @DRUG$ treatment , a clear molecular explanation of cancer response to cetuximab has remained elusive . Genomic studies identify @VARIANT$ mutant in colorectal carcinomas", "label": "sensitivity"}
{"id": "24789720", "sentence": "The role of T790M mutation , particularly its presence in patients before @GENE$ treatment is still controversial being a subject of intensive discussions . Mechanism of achieving resistance to @DRUG$ and gefitinib remains unclear . The recent reports confirmed , that T790M substitution could be detected in EGFR-TKIs naïve patients independently of other EGFR gene mutations ( predominantly @VARIANT$ substitution and deletions in exon 19 ) .", "label": "sensitivity"}
{"id": "25382104", "sentence": "Despite @DRUG$ 's clinical success , resistance due to mutations and side effects are still a limitation of this drug . To overcome resistance , second generation TKI 's inhibitors , nilotinib and dasatinib were developed . However , neither compound effectively inhibits @VARIANT$ mutant @GENE$ , which constitutes 20 % of all BCR-ABL mutations .", "label": "None"}
{"id": "23788917", "sentence": "The @VARIANT$ mutation leads to a substitution of threonine to methionine in the catalytic centre of @GENE$ tyrosine kinase , which is located in the binding pocket of TKI and ATP . Substitution of threonine at codon 790 into larger methionine probably results in blocking of the binding sites of @DRUG$ and gefitinib aromatic residues with their point of action .", "label": "resistance or non-response"}
{"id": "25372287", "sentence": "In preclinical studies , cell lines harboring the @VARIANT$ mutation were resistant to @DRUG$ , but were sensitive to irreversible @GENE$ inhibitor , neratinib .", "label": "sensitivity"}
{"id": "24594844", "sentence": "We also demonstrated that cDzT and @DRUG$ functioned in a synergistic manner against EGFR signaling pathways to suppress the growth of @GENE$ @VARIANT$ harboring NSCLC cells .", "label": "response"}
{"id": "22714415", "sentence": "In a study by De Roock et al. , a pooled data set of 579 mCRC patients across various clinical trials treated with @DRUG$ plus/minus chemotherapy demonstrated that overall and progression-free survival was significantly longer in patients with @VARIANT$ KRAS mutant tumors .", "label": "None"}
{"id": "23840353", "sentence": "When either of the MYB proteins was heterologously expressed in tobacco , the vascular tissue lignin content was markedly reduced , and transcript abundance of the genes encoding 4-coumarate : @GENE$ ligase ( 4CL1 ) , cinnamate-4-hydroxylase ( @VARIANT$ ) and cinnamyl @DRUG$ dehydrogenase ( CAD ) was reduced .", "label": "None"}
{"id": "24594844", "sentence": "cDzT remains its suppression effect on EGFR @VARIANT$ expression and downstream signaling after @GENE$ treatment in H1975TM/LR . Click here for additional data file . Combined treatment of cDzT and @DRUG$ significantly suppresses the phosphorylation of STAT3 , AKT , and ERK in CL97TM/GA cells .", "label": "None"}
{"id": "24501009", "sentence": "In contrast to patients with @GENE$ tumors , patients with KRAS‐mutant NSCLC are unlikely to respond to @DRUG$ or erlotinib and do not have an improved progression‐free survival ( PFS ) compared with those who have placebo following erlotinib therapy . Dacomitinib ( PF‐00299804 ) is a potent , irreversible , oral small‐molecule inhibitor of HER1/EGFR , HER2 , and HER4 tyrosine kinases with antitumor activity in both gefitinib‐sensitive and gefitinib‐resistant , including EGFR @VARIANT$ , preclinical NSCLC models .", "label": "resistance or non-response"}
{"id": "23569389", "sentence": "No differences in overall response rate were observed in patients with @GENE$ mutations at baseline , in particular for p-loop mutations . A subanalysis was conducted by Branford et al on the emergence of new detectable mutations in 479 patients treated with dasatinib after @DRUG$ failure , and development of new mutations , including T315A , F317L , and @VARIANT$ , was rare ( 13 % ) .", "label": "None"}
{"id": "24252457", "sentence": "Resistance due to @VARIANT$ can potentially overcome by second generation irreversible EGFR TKIs , which appear to be well tolerated in early clinical studies [ ] . Although did not demonstrated an overall survival benefit , @DRUG$ , an irreversible @GENE$ , Her-2 , and ErbB4 blocker has led to significant PFS in patients who progressed after a 12 week course of Gefitinib or Erlotinib when compared to placebo in a phase 2b/3 trial [ ] .", "label": "response"}
{"id": "24876815", "sentence": "Analyses were also performed for other polymorphisms in the EGFR gene : G216T and @VARIANT$ , and in the EGF gene : A61G . Graziano et al. demonstrated the presence of the short variant of the EGFR gene intron-1 and the G allele in codon 61 of the @GENE$ gene ( higher EGF production ) to be a favourable predictive factor for cetuximab-irinotecan therapy .", "label": "None"}
{"id": "24244732", "sentence": "Lof rab-3 worms are resistant to the effects of depressive concentrations of exogenous @DRUG$ [ ] . The @VARIANT$ mutation of Munc18 increases the interaction between Munc18 and Rab3 [ ] without affecting binding to @GENE$ or Mint proteins [ ] .", "label": "None"}
{"id": "22569033", "sentence": "Crenolanib was effective in blocking the activity of single or compound @GENE$ @VARIANT$ mutant kinases . In contrast , @DRUG$ had no significant activity against these same mutant kinases .", "label": "resistance or non-response"}
{"id": "24312144", "sentence": "@DRUG$ has shown activity in the treatment of patients with advanced lung adenocarcinoma with @GENE$ mutations , especially in patients with deletion 19 or @VARIANT$ mutations .", "label": "sensitivity"}
{"id": "24789720", "sentence": "T790M mutation in EGFR gene seems to be one of the most important genetic abnormalities involving the resistance for reversible @GENE$ kinases inhibitors ( EGFR-TKI ) —erlotinib and @DRUG$ in NSCLC patients [ – ] . T790M mutation is detected with highest prevalence in patients with common activating mutations of EGFR gene ( @VARIANT$ in exon 21 and deletions in exon 19 ) after long-term and initially effective treatment with EGFR-TKIs .", "label": "sensitivity"}
{"id": "22433462", "sentence": "Two small molecule EGFR tyrosine kinase inhibitors ( @GENE$ ) , gefitinib ( @DRUG$ , AstraZeneca International ) and erlotinib ( Tarveca , OSI Pharmaceuticals ) have been evaluated in patients with NSCLC [ , ] . These ATP competitive , reversible EGFR-TKIs have been effective only in a small subset of NSCLC patients bearing somatic mutations ( deletions in exon 19 and the @VARIANT$ mutation ) in the kinase domain of EGFR [ ] .", "label": "sensitivity"}
{"id": "22569033", "sentence": "Mutant PDGFRα isoforms were expressed by transient transfection of Chinese hamster ovary cells and these transfected cells were treated with various concentrations of crenolanib or @DRUG$ . Crenolanib was effective in blocking the activity of single or compound @GENE$ @VARIANT$ mutant kinases .", "label": "resistance or non-response"}
{"id": "24212955", "sentence": "In pediatric low-grade glioma , consisting of pilocytic astrocytoma and fibrillary astrocytoma , chromosome 7q34 rearrangements result in an in-frame KIAA1549 : @GENE$ fusion gene that possesses constitutive BRAF kinase activity resembling oncogenic BRAF ( @VARIANT$ ) [ ] . In contrast , RAF mutations or rearrangements are rare in malignant gliomas in adults . A phase I/II clinical trial is currently underway for recurrent GBM with combined Raf and mTOR inhibiters , Sorafenib ( NexavarR , Bayer , and Onyx , Emeryville , CA , USA ) and @DRUG$ ( CCI-779 ) ( NCT00335764 ) .", "label": "None"}
{"id": "19707354", "sentence": "Two novel kinase inhibitors , dasatinib ( Sprycel™ ; Bristol-Myers Squibb ) and @DRUG$ ( Tasigna™ ; Novartis ) , have shown promising clinical activity in some imatinib-refractory patients and both have recently earned FDA approval . Unfortunately , patients with the @VARIANT$ @GENE$ mutation do not respond to these new drugs ( ; ) .", "label": "None"}
{"id": "22343623", "sentence": "In this study , we examined whether the selective KOR agonist U50 ,488H could inhibit the growth of gefitinib-sensitive and EGFR mutant ( delE746-A750 , L858R ) NSCLC cells ( HCC827 ) and gefitinib-resistant and @GENE$ mutant ( @VARIANT$ ) NSCLC cells ( H1975 ) , and investigated the signalling mechanism of the KOR mediated inhibitory effect on tumour cell growth .", "label": "resistance or non-response"}
{"id": "23976869", "sentence": "@DRUG$ has a potent activity towards @GENE$ , as well as numerous imatinib-resistant BCR-ABL1 kinase domain mutants , including the @VARIANT$ mutation .", "label": "response"}
{"id": "19654571", "sentence": "Indeed , it markedly reduced EGF induced ERK1/2 phosphorylation in A431 cells , but in Caski and @VARIANT$ cells the reduction was more modest ( 60 and 20 % inhibition , respectively ; ) , suggesting that persistent signalling through these pathways led to increased survival of Caski and C33A cells , when compared to A431 cells in the presence of cetuximab . Cetuximab combined with @DRUG$ synergistically reduces cell proliferation and activation of downstream signalling pathways in CC cells We speculated that cells expressing higher @GENE$ ratios , such as A431 cells , rely more on EGFR signalling for MAPK pathway activation and cell proliferation , whereas cells with a lower EGFR/HER2 ratio , such as C33A cells , depend more on EGFR/HER2 heterodimer signalling .", "label": "None"}
{"id": "24612546", "sentence": "A number of small-molecule tyrosine kinase inhibitors ( TKIs ) ( e.g. , gefitinib , erlotinib , lapatinib ) and antibodies ( eg , trastuzumab , @DRUG$ , panitumumab ) targeting the erbB family have been developed to treat breast , colorectal , lung , gastric and head and neck squamous cell cancers [ ] . Despite the improvements achieved in patients treated with reversible inhibitors of EGFR or @GENE$ and HER2 , primary and acquired resistances to these agents remain a clinical challenge . This is exemplified by the development of resistance to EGFR tyrosine kinase inhibitor ( TKI ) , through emergence of a secondary @VARIANT$ EGFR mutation in non-small-cell lung carcinoma ( NSCLC ) [ ] , which occurs in 50 % of the patients with lung adenocarcinoma [ ] .", "label": "response"}
{"id": "17877814", "sentence": "Akt phosphorylation was readily detected in cells transfected with S768I , @GENE$ or Ins774HV , but not in cells expressing @VARIANT$ ( Figure ) . The phosphorylation of Akt induced by S768I was abrogated by 100 nM @DRUG$ , and fibril formation was noted upon treatment with 1 μM or higher concentration of the drug .", "label": "None"}
{"id": "25222836", "sentence": "EGFR TKi @GENE$ TK domain Resistance mutation , e.g. @VARIANT$ ● @DRUG$", "label": "resistance or non-response"}
{"id": "24349829", "sentence": "As would be predicted from the prior studies cited above , miR-7 blunted @GENE$ signaling and reversed the radio-resistance . Correspondingly , direct injection of a liposome encapsulated miR-7 plasmid into established EGFR-TKI sensitive and resistant tumors bearing the @VARIANT$ EGFR mutant resulted in significant tumor regression in conjunction with repression of EGFR , RAF-1 and IRS-1 expression . In head and neck cancer , miR-7 functioned in a synergistic manner with erlotinib to render FaDu Erlotinib-resistant cells susceptible to the growth inhibitory activities of the drug .", "label": "None"}
{"id": "21333004", "sentence": "The combination of Mig6 and @DRUG$ has a synergistic effect in inhibiting @GENE$ signaling The only difference between the EGFR-WT model and the @VARIANT$ model A is in the negative EGFR regulation produced by Mig6 , therefore , which can be experimentally verified by overexpressing Mig6 .", "label": "sensitivity"}
{"id": "23936861", "sentence": "XL647 has also showed to be active against cells containing the @VARIANT$ mutation , which have been associated with emerging resistance to first-generation @GENE$ TKIs such as @DRUG$ or erlotinib [ ] .", "label": "resistance or non-response"}
{"id": "23994953", "sentence": "Using the erlotinib-sensitive EGFR mutant NSCLC cell line HCC4006 harboring the delL747-E749 , @VARIANT$ mutation in EGFR exon 19 , Suda et al. established that mesenchymal status , not a specific oncogenic activated protein , could sufficiently promote loss of EGFR dependence to confer resistance to erlotinib . More recently , Chang et al. confirmed that in the absence of the common second-site EGFR mutation T790M or MET amplification , acquired resistance to @DRUG$ occurs in @GENE$ mutated PC9 cells that have undergone EMT .", "label": "None"}
{"id": "24004697", "sentence": "A : K562 and K562R cells treated with PPP2R5C-siRNA799 , B : 32D-Bcr-Abl WT and @GENE$ T315I cells treated with PPP2R5C-siRNA799 , C : K562 and K562R cells treated with PPP2R5C-siRNA991 , D : 32D-Bcr-Abl WT and 32D-Bcr-Abl T315I cells treated with PPP2R5C-siRNA991 . The apoptosis induction effect of PPP2R5C-siRNAs on imatinib-sensitive and imatinib-resistant cell lines . A : K562 and @VARIANT$ cells treated with PPP2R5C-siRNA799 , B : 32D-Bcr-Abl WT and 32D-Bcr-Abl T315I cells treated with PPP2R5C-siRNA799 , C : K562 and K562R cells treated with PPP2R5C-siRNA991 , D : 32D-Bcr-Abl WT and 32D-Bcr-Abl T315I cells treated with PPP2R5C-siRNA991 .", "label": "None"}
{"id": "23029123", "sentence": "In addition , significant constitutive activity of recombinant @VARIANT$ receptors expressed in mammalian cells has been described previously . Hence , the ligand independent changes in hormone production were due to constitutively activated D2 receptors in transfected cells . V cells that lacked functional D2 receptors did not respond to @DRUG$ in respect to @GENE$ production .", "label": "None"}
{"id": "20234366", "sentence": "Such a low percentage compared with that in previous reports is probably due to the fact that after Health Authorities approval to limit the use of anti-EGFR moAb to @GENE$ wild-type mCRC patients , KRAS mutant cases have not received @DRUG$ based therapy at our Institution . KRAS mutations were as follows : G13D in five patients ; @VARIANT$ in three patients ; G12V in three patients ; and G12A in one patient .", "label": "sensitivity"}
{"id": "23937717", "sentence": "@DRUG$ enhanced cytotoxicity of NK cells in human lung cancer cells with @GENE$ @VARIANT$ + T790M mutation", "label": "sensitivity"}
{"id": "25364578", "sentence": "Surprisingly , the @GENE$ @VARIANT$ mutation leads to decreased ability to activate ERK compared to WT EGFR which correlates with decreased EGFR internalization , reduced phosphorylation of SHP2 , hyperactivity of STAT3 and reduced sensitivity to @DRUG$ .", "label": "sensitivity"}
{"id": "21445332", "sentence": "Given the lower binding to C4b , we suspected that the @VARIANT$ mutant form of @GENE$ would have a decreased capacity to serve as a @DRUG$ for CFI mediated cleavage of C4b .", "label": "None"}
{"id": "23632482", "sentence": "In contrast , no significant changes in the phosphorylation of CENP-A were observed in tumour tissues from mice treated with paclitaxel , suggesting that 212Pb-TCMC-trastuzumab may interfere with the affinity of BubR1 for kinetocores , thus perturbing the mitotic spindle checkpoint induced by @DRUG$ . @VARIANT$ is involved in DNA replication , DNA repair and mitosis , suggesting E2F affects cell cycle progression both at S-phase and during mitosis . To investigate whether these transcription factors may mediate a decrease of BubR1 expression by recruitment of @GENE$ E2Fs to the BubR1 proximal promoter region , the binding of E2F1 and E2F4 to the proximal BubR1 promoter was evaluated using a ChIP assay .", "label": "None"}
{"id": "25114510", "sentence": "Furthermore , @DRUG$ , an irreversible EGFR-TKI , can also be used , and this novel drug seems to have a significant effect on NSCLCs harboring an @GENE$ exon 19 deletion . Thus , clinicians should use each of these drugs in appropriate settings . Acquired resistance , including EGFR secondary mutations ( @VARIANT$ and other rare mutations ) , MET gene amplification , PTEN gene downregulation , high-level hepatocyte growth factor expression , epithelial–mesenchymal transition , and conversion to small cell lung cancer , – continues to restrict the durable long-term outcomes of erlotinib .", "label": "response"}
{"id": "24348666", "sentence": "It was initially proposed that the T790M mutation might prevent the proper binding of tyrosine kinase inhibitors via steric hindrance , similar to the corresponding gatekeeper mutations in @GENE$ ( @VARIANT$ ) and KIT ( T670I ) that confer resistance to imatinib ( @DRUG$ ) in chronic myelogenous leukemia and in patients with gastrointestinal stromal tumors .", "label": "None"}
{"id": "21197464", "sentence": "Schematic representation of the signal pathways of @DRUG$ (RA-) induced ( RA-induced ) differentiation of mouse embryonic carcinoma F9 cells . At the undifferentiation stage of F9 cells , HDAC3 , NcoR/SMART , and JDP2 were recruited on the DRE ( differentiation response element ) in the promoter region of the c-jun gene to induce the heterochromatin . Ac , acetylated residues ; K , lysine residues of histone; @VARIANT$ , lysine residues of @GENE$ lysine residue at position 8 of histone H4 ; H4K16 , lysine residue at position 16 of histone H4 ; X1 = ATF-2 , ATF-7 .", "label": "None"}
{"id": "24982846", "sentence": "Dasatinib BCR/ABL1 Philadelphia chromosome [ t ( 9 ; 22 ) ] positive ; @VARIANT$ mutation posit Indications and usage , clinical studies , patient counseling information Denileukin diftitox IL2RA CD25 antigen positive Indications and usage , warnings and precautions , clinical studies @DRUG$ EGFR EGFR protein expression positive @GENE$ exon 19 deletion or exon 21 substitution ( L858R ) positive Clinical pharmacology Indications and usage , dosage and administration , clinical pharmacology , clinical studies", "label": "None"}
{"id": "23836985", "sentence": "The supernatant was divided into two portions ( one with 5 μg of @VARIANT$ antibody , the other with 4 μg of @DRUG$ G as the negative control ) , and followed by mild shaking overnight at 4°C .", "label": "None"}
{"id": "24244732", "sentence": "Most surprisingly , we demonstrate that the epistatic interactions between mutants of unc-18 and rab-3 are distinct depending on the phenotypic context such that the @VARIANT$ mutation acts downstream of @GENE$ in exocytosis whereas it acts upstream of Rab3 in @DRUG$ sensitivity .", "label": "None"}
{"id": "24416052", "sentence": "The mutations of @GENE$ are activating mutations , and the activation was inhibited by treatment with dasatinib , a multi-kinase inhibitor . Further , they represented a SQCLC patient with a wild type EGFR who showed radiological response after treatment with both dasatinib and @DRUG$ in their clinical trial . The patient was confirmed to have a new mutation ( @VARIANT$ ) in the DDR2 kinase domain .", "label": "response"}
{"id": "23992330", "sentence": "The @VARIANT$ mutation in EGFR is structurally analogous to drug resistance mutations in other kinases such as BCR-ABL ( T315I ) , c-KIT ( T670I ) and platelet derived growth factor receptor-α ( PDGFRα ) ( T674I ) [ ] . Furthermore , acquired resistance may be mediated by activation of redundant signaling pathways able to bypass the blockade of single proteins involved in cancer cells proliferation , survival , or migration . Having again the EGFR inhibitors as a paradigm , this is the case of K-Ras mutations leading to constitutive activation of the @GENE$ signaling pathway and mediating both intrinsic or acquired resistance to the anti-EGFR mAb @DRUG$ in colorectal cancers [ ] .", "label": "None"}
{"id": "19955662", "sentence": "@GENE$ has also been shown to signal synergistically with EGFR as part of a broad signaling network that cooperatively drives activation of these downstream pathways. [ ] Indeed , concomitant inhibition of MET and EGFR in erlotinib-resistant cells harboring the @VARIANT$ mutation significantly increases lung cancer cytotoxicity above MET targeted therapy alone in both in vitro and in vivo settings. [ ] Inhibition of PKCß with enzastaurin has been recently studied in thoracic malignancies . Our previous work has demonstrated the in vitro effect of enzastaurin against malignant pleural mesothelioma , [ ] and its synergistic activity when combined with @DRUG$ .", "label": "None"}
{"id": "21605429", "sentence": "The PDGFRA exon 18 @VARIANT$ point mutant activates @GENE$ both in vitro and in vivo [ , ] and is also @DRUG$ resistant in vivo and in vitro [ , , ] , whereas other mutations affecting exon 18 ( D846Y , N848K , Y849K and HDSN845-848P ) are imatinib sensitive [ ] .", "label": "resistance or non-response"}
{"id": "17877814", "sentence": "Several uncommon @GENE$ mutants identified in the course of this analysis were tested using the YFP-EGFR-ICD assay . Mutations in exon 20 , most notably @VARIANT$ , are usually associated with resistance to gefitinib and @DRUG$ [ reviewed in [ ] ] .", "label": "resistance or non-response"}
{"id": "25562798", "sentence": "Prospective studies of EGFR TKIs in patients with @GENE$ mutations have consistently identified high response rates and prolonged progression free survival . The Spanish Lung Cancer Group screened 2105 patients , to identify 350 patients ( 15 % ) with exon 19 deletions and @VARIANT$ of whom 250 patients went on to receive @DRUG$ in the first or second-line setting .", "label": "sensitivity"}
{"id": "20234366", "sentence": "KRAS mutations were as follows : G13D in five patients ; @VARIANT$ in three patients ; G12V in three patients ; and G12A in one patient . In all , 11 out of 36 KRAS wild-type patients ( 30 % ) responded to @DRUG$ , whereas none of the 12 patients ( 0 % ) harbouring a @GENE$ mutation had a partial response ( P=0.04 ) .", "label": "sensitivity"}
{"id": "24121633", "sentence": "Based on our data , we hypothesized that PRR of hnRNP L binds to PTB and cooperatively suppresses inclusion of exon @VARIANT$ . We thus examined the role of PRR of hnRNP L on the interaction with PTB . Histidine tagged hnRNP L ( His-L ) , its PRR deleted variant ( His-L-ΔPRR ) , histidine tagged hnRNP LL ( His-LL ) , and its @GENE$ inserted variant ( His-LL-PRR ) were expressed in SH-SY5Y cells , and they were immunoprecipitated with anti-histidine antibody in the presence of RNase .", "label": "None"}
{"id": "25486409", "sentence": "Second generation EGFR-TKIs , such as BIBW2992 ( @DRUG$ ) and PF00299804 ( dacomitinib ) , have been recommended in order to overcome the @VARIANT$ mediated resistance considering that these potent , irreversible @GENE$ no longer compete with ATP once they have become covalently bound to the kinase domain , .", "label": "response"}
{"id": "23566546", "sentence": "Case Histrogical type @GENE$ mutation status Brinkman index Treatment agent Response IL-8 ( ng/mL ) IL-10 ( ng/mL ) RANTES ( pg/ml ) 1 Ad Ex21 @VARIANT$ 900 gefitinib PR 5.79 1.67 2 2 Ad Ex21 L858R 0 erlotinib PR_3.33 94.2 1.41 3 Ad Ex19 del 0 erlotinib PR 4.09 126 2.13 4 Ad Ex21 L858R 0 gefitinib PR_3.92 18.1 1.85 5 Ad Ex21 L858R + Ex19 del 370 erlotinib PR 21.9 1.23 2.11 6 Ad Ex19 del 0 erlotinib PR 7.05 1.37 2.56 7 Ad Ex19 del 0 gefitinib PR 4.82 1.59 2.02 8 Ad Ex21 L858R 1640 gefitinib PR 54.9 2.7 2.38 9 Ad negative 400 erlotinib SD 34.9 3.39 3.66 10 Ad negative 0 erlotinib SD 27.1 4.94 2.25 11 Ad unknown 1800 erlotinib SD NE NE NE 12 Sq Ex19 del 3840 gefitinib SD 12.6 1.1 1.98 13 Ad Ex19 del 30 erlotinib SD 5.27 0.69 2.66 14 Ad Ex19 del 0 erlotinib SD 10.5 0.85 2.5 15 Ad unknown 300 erlotinib SD 7.69 2.61 1.7 16 La negative 2080 erlotinib SD NE NE NE 17 Sq Ex21 L858R 750 erlotinib SD 11.6 56.3 3.06 18 Ad unknown 600 erlotinib SD 13.7 1.1 2.82 19 Ad Ex21 L858R 0 erlotinib SD 20.6 11.6 0.783 20 Ad Ex19 del 0 erlotinib SD 14.8 2.07 2.02 21 Ad Ex21 L858R + Ex19 del 0 gefitinib SD 3.04 1.3 1.76 22 Ad Ex19 del 200 gefitinib SD 10.9 1.59 1.91 23 Sq unknown 1560 erlotinib PD NE NE NE 24 Ad negative 1080 erlotinib PD 25.2 8.15 1.57 25 Ad unknown 0 erlotinib PD NE NE NE 26 Ad Ex18 G719A 2000 erlotinib PD 11.6 4.48 3.12 27 Ad unknown 1410 erlotinib PD NE NE NE 28 Ad Ex19 del 1000 gefitinib PD 9.44 2.25 2.89 29 Ad negative 1100 erlotinib PD 56.3 5.63 2.16 30 Ad negative 2000 erlotinib PD 15.6 0.85 0.292 31 Ad negative 825 erlotinib PD 8.27 1.59 2.13 32 Ad Ex21 L858R 0 @DRUG$ PD 5.34 7.05 1.7 33 Ad negative 1680 erlotinib PD 57.7 1.63 2.06", "label": "sensitivity"}
{"id": "21687596", "sentence": "Ercan et al. established a resistant cell line for an irreversible EGFR-TKI by subjecting a reversible @GENE$ resistant cell line with a @VARIANT$ mutation ( established by long-term exposure of exon 19 deletion mutant PC9 cells to @DRUG$ ) to long-term exposure to PF-00299804 [ ] .", "label": "resistance or non-response"}
{"id": "20234366", "sentence": "It is worth noting that the presence of @GENE$ @VARIANT$ mutations was associated with MKP-1 overexpression in all the cases , although the number of patients was insufficient to achieve a significant correlation . Collectively , our results suggest a role for MKP-1 in predicting failure to respond to @DRUG$ based chemotherapy in KRAS wild-type CRC patients .", "label": "resistance or non-response"}
{"id": "22876876", "sentence": "First , numbers are low in particular in the cetuximab group and secondly addition of @DRUG$ was not randomized for . There seems to be a selection of patients with good performance status and good prognosis who received third line therapy compared to those who did not . Therefore , we can not draw definite conclusions from our analysis whether anti-EGFR antibodies are effective in patients with @GENE$ @VARIANT$ mutations or not .", "label": "resistance or non-response"}
{"id": "25431951", "sentence": "A single 25-mg/kg oral administration of S116836 in rats generated a maximal plasma concentration of 6205.0±731.4 ( Table ) , which may be sufficient to kill imatinib-resistant cells harboring gate-keeper mutant T674I PDGFRα , T315I BCR-ABL and @VARIANT$ @GENE$ .", "label": "None"}
{"id": "23861958", "sentence": "The most common ALK2 FOP mutation is a change of guanine ( G ) into adenine ( A ) causing an arginine to @DRUG$ substitution ( @VARIANT$ ) in the ALK2 GS domain . Due to this mutation , the FOP ALK2 shows a lower binding affinity for its negative regulator FKBP12 , which results in elevated @GENE$ signaling in cells , both in the presence and absence of exogenous BMP ligands , , .", "label": "None"}
{"id": "19707322", "sentence": "Nilotinib is approximately 30-fold more sensitive than @DRUG$ in the killing of BCR-ABL dependent cells derived from patients with CML ( K562 and Ku-812F cells ) and cell lines ( 32D and baF3 ) , and it is active against 32/33 imatinib-resistant cell lines with BCR-ABL mutations . The sensitivity of @GENE$ mutants to AMN107 can be summarized into 4 categories : high ( IC50 ≤ 70 nmol/L : M244V , G250E , Q252H , F3llL , F317L , M351T , V379I , L387M , H396P , @VARIANT$ ) , medium ( IC50 ≤ 200 nmol/L : Y253F , E255K , F359V ) , low ( IC50 ≤ 450 nmol/L : Y253H , E255V ) , and insensitive ( IC50 & gt ; 2 μmol/L : T315I ) ( ) ( ) .", "label": "None"}
{"id": "25505694", "sentence": "The lack of efficacy could probably be related to the high concentrations of neratinib required in preclinical studies to inhibit EGFR @VARIANT$ and the limitations of clinical dosing . Dacomitinib Dacomitinib is an irreversible EGFR , @GENE$ and HER4 inhibitor with a higher kinase inhibition than gefitinib/erlotinib in both gefitinib/erlotinib-sensitive and in EGFR-T790M and HER2 mutated cell lines [ ] .", "label": "None"}
{"id": "25054154", "sentence": "@VARIANT$ −8.07 M 1199 3.01 L 1122 , A1148 , Q 1197 , L 1196 , Q 1197 L 1198 , A 1200 , G 1202 , L 1256 , R 1253 , D 1203 , N 1254 , D 1270 , L 1150 . Docking results of @GENE$ with @DRUG$ using Patchdock .", "label": "sensitivity"}
{"id": "23994953", "sentence": "Intense research efforts over the past few years have identified two major mechanisms of acquired resistance to gefitinib/erlotinib : secondary resistance mutations ( e.g. , @VARIANT$ ) and “oncogene kinase switch” systems ( e.g. , @GENE$ amplification and AXL activation ) .", "label": "None"}
{"id": "24855380", "sentence": "In conclusion , this report suggests that patients with thymic carcinoma harboring the missense mutation @VARIANT$ in exon 13 of the @GENE$ gene can be resistant to imatinib and may obtain a tumor response when treated with sorafenib , possibly related to the antiangiogenic activity of @DRUG$ .", "label": "None"}
{"id": "24489728", "sentence": "Specifically , @DRUG$ concentrations were increased stepwise from 1 to 100 nM when cells resumed growth kinetics that were similar to untreated parental cells . Acquired resistance by genetic alterations , such as the @GENE$ @VARIANT$ mutation or amplified MET , were caused by the stepwise escalation method of EGFR-TKI exposure after prolonged treatment , .", "label": "resistance or non-response"}
{"id": "15737014", "sentence": "For example , in CML , a commonly found mutation is a C→T single nucleotide change that replaces threonine with isoleucine at position 315 ( @VARIANT$ ) in the ABL kinase domain [ , , ] . In GIST and @GENE$ , respectively , the analogous T670I mutation in KIT and T674I mutation in PDGFR-alpha have been associated with acquired resistance to this drug [ , ] . To determine whether lung cancers that acquire clinical resistance to either @DRUG$ or erlotinib display additional mutations in the EGFR kinase domain , we have examined the status of EGFR exons 18 to 24 in tumors from five patients who initially responded but subsequently progressed while on these drugs .", "label": "None"}
{"id": "23691449", "sentence": "However , the @VARIANT$ mutation may exist in only a small fraction of tumor cells before drug treatment , and the tumor cells harboring this mutation may be enriched over time during treatment with @DRUG$ or erlotinib [ ] . @GENE$ amplification", "label": "None"}
{"id": "24964744", "sentence": "MCF10a cells containing the PI3K mutation H1047R showed little sensitivity to single agent sirolimus , and in combination with EGFR inhibitors were still seen to be more resistant than their parental counterpart , and were more resistant than MCF10a cells containing the @GENE$ @VARIANT$ mutation . Chou and Talalay combination indices for each cell line examined Gefitinib + ZSTK474 Erlotinib + ZSTK474 Gefitinib + Rapamycin Erlotinib + Rapamycin Gefitinib + ZSTK474 Erlotinib + ZSTK474 @DRUG$ + Rapamycin Erlotinib + Rapamycin", "label": "resistance or non-response"}
{"id": "23934621", "sentence": "The VPT and the PPT were performed 1.5 and 1.75 hours after the @DRUG$ administration , respectively . Pharmacogenetic Analyses An exploratory post hoc PGx analysis was carried out to examine the effect of the @GENE$ @VARIANT$ polymorphism on the PD effects of GSK1521498 .", "label": "None"}
{"id": "25465236", "sentence": "( C ) @GENE$ @VARIANT$ mutant does not resemble pEGFR unlike the EGFR L858R mutant shown in B. ( D–F ) increased inhibition potency for @DRUG$ against EGFR L858R mutant compared to EGFR WT protein and subsequent decrease in potency for Erlotinib against EGFR L858R + E884K double mutant .", "label": "resistance or non-response"}
{"id": "23459666", "sentence": "By adding @DRUG$ for EGFR inhibition to a standard regimen of vemurafenib , a significant antitumor response was shown in vitro and in vivo . While there are no reported results of this combination therapy in adult patients , the laboratory results are promising and may offer another option for late stage CRC patients with wild-type KRAS and the @GENE$ ( @VARIANT$ ) mutation .", "label": "resistance or non-response"}
{"id": "25278773", "sentence": "One of the most critical mechanisms for acquired resistance is the gatekeeper EGFR @VARIANT$ missense mutation , which is found in approximately 49 % –63 % of patients who have developed resistance to EGFR inhibitors. , Preliminary studies also indicate that the T790M mutation may play a crucial role in primary resistance to first-generation EGFR inhibitors because of clonal evolution in tumor cells with preexisting T790M mutations . Different strategies have been pursued in the management of progressive disease after treatment with first-generation @GENE$ TKIs , including monotherapies such as dasatinib and neratinib , as well as the rational combinations of cetuximab plus @DRUG$ and of erlotinib/gefitinib plus everolimus .", "label": "resistance or non-response"}
{"id": "23613955", "sentence": "Moreover , interference BCR/ABL expression with @GENE$ restored the sensitivity to imatinib in cells expressing the imatinib-resistant BCR/ABL kinase domain mutant @VARIANT$ .", "label": "None"}
{"id": "24386407", "sentence": "Taken together , these findings indicated that the Met inhibitor crizotinib plus a new generation EGFR-TKI , either @DRUG$ or WZ4002 , circumvented resistance to HGF in an autocrine manner , in the presence or absence of the EGFR @VARIANT$ mutation or @GENE$ gene amplification .", "label": "None"}
{"id": "24385403", "sentence": "Moreover , in approximately 20 % of cases , the MET gene amplification , independent of the mutation @VARIANT$ in the EGFR gene , may be a potential cause of drug resistance . This may generate acquired resistance via the activation of the ERBB signaling pathway . Studies employing the @DRUG$ molecules ( inhibitors of @GENE$ kinase ) and small interfering RNA ( siRNA ) preventing MET expression demonstrated that in the H820 cell line , ERBB signaling is highly dependent on the activity of MET .", "label": "None"}
{"id": "24967705", "sentence": "The second generation tyrosine kinase inhibitors nilotinib and dasatinib show much more potent activity against @GENE$ and most mutants , but some kinase domain mutations , especially T315I , are still resistant to these drugs – . Although TKIs such as @DRUG$ , with activity against the @VARIANT$ mutation , have been developed , their application to CML therapy has been limited by concerns regarding toxicity .", "label": "response"}
{"id": "23994953", "sentence": "@VARIANT$ mutation reviewed in . The second well-known mechanism of gefitinib/erlotinib resistance is the MET receptor tyrosine kinase ( RTK ) gene amplification . MET creates a bypass signaling track that activates @GENE$ through HER3 mediated activation of PI3K in the presence of EGFR TKIs .", "label": "None"}
{"id": "25563355", "sentence": "However , it was demonstrated recently that @VARIANT$ increased the affinity of ATP to the EGFR tyrosine kinase domain ; thus , it decreased the binding of @DRUG$ and erlotinib , because they are ATP-competitive agents [ ] . Other acquired resistance mechanisms , such as small cell transformation , MET amplification , epithelial-mesenchymal transition and @GENE$ mutation , were found in small series of patients [ , ,, ] .", "label": "None"}
{"id": "24634705", "sentence": "The D761Y mutation is located on the α-C-helix of EGFR and is similar to a mutation in @GENE$ , D276G , that is associated with acquired resistance after @DRUG$ treatment [ ] . The L747S mutation lies at the start of the β3 strand and the α-C-helix [ ] and has analogous residues in BCR-ABL ( L237M ) and ERBB2 ( @VARIANT$ or P ) that have been identified in TKI resistant disease [ ] .", "label": "None"}
{"id": "24876815", "sentence": "Analyses were also performed for other polymorphisms in the EGFR gene : G216T and G497A , and in the EGF gene : @VARIANT$ . Graziano et al. demonstrated the presence of the short variant of the EGFR gene intron-1 and the G allele in codon 61 of the EGF gene ( higher @GENE$ production ) to be a favourable predictive factor for cetuximab-irinotecan therapy .", "label": "None"}
{"id": "22970367", "sentence": "The data suggest that low BRCA1 level may neutralize the negative effects of the EGFR @VARIANT$ mutation on @DRUG$ sensitivity and that high BRCA1 expression may lead to de novo @GENE$ TKI resistance potentially through increased DNA damage repair capacity [ ] .", "label": "resistance or non-response"}
{"id": "25254214", "sentence": "@DRUG$ miR-221 , miR-222 Down Targets ARH1 Prostate [ ] miR-151 Down miRNA inhibition suppresses cell migration and invasion ; targets N4BP1 , CASZ1 , IL1RAPL1 , SOX17 , and @GENE$ Prostate [ ] miR-23b-3p Down Targets PTEN ; miRNA inhibition induces apoptosis and inhibits invasion Renal [ ] miR-1260b Down Targets sFRP1 , Dkk2 and , Smad4 ; induces cell proliferation and invasion ; inhibits apoptosis Renal ; Prostate [ , ] miR-223 Down Upregulates Fbw7 ; miRNA inhibition suppresses cell growth and induces apoptosis Pancreatic [ ] miR-27a Down Upregulates ZBTB10 and Sprouty2 ; miRNA inhibition suppresses cell growth , migration , and invasion and induces apoptosis Melanoma ; Ovarian ; Pancreatic [ – ] EGCG miR-98-5p Down miRNA inhibition enhances cisplatin induced apoptosis and increases p53 expression Lung [ ] @VARIANT$ miR-21 Down Downregulates PTEN , PDCD4 , and RECK Lung ; Pancreatic [ , ] miR-221 Down Upregulates PTEN , p27kip1 , p57kip2 , and PUMA ; increases cell proliferation Pancreatic [ ]", "label": "None"}
{"id": "24586514", "sentence": "Thus , vorinostat may inhibit the growth of BCR-ABL positive cells by changing @GENE$ conformation via acetylation and inhibition of the chaperone protein HSP90 . Phosphorylated γH2A.X is associated with early DNA damage and repair processes that occur in response to double-strand breaks in eukaryotic cells . Vorinostat induced growth arrest and apoptosis , thus aggravating the apoptotic and cytotoxic effects of @DRUG$ on Ba/F3 @VARIANT$ mutant cells .", "label": "response"}
{"id": "23696715", "sentence": "Meanwhile , it is important to emphasize that preclinical studies have evidenced that RET activating mutations at codon 804 ( V804L , @VARIANT$ ) cause resistance to some TKIs , such as vandetanib . Cabozantinib ( XL184 ) @DRUG$ is a potent inhibitor of @GENE$ , VEGFR-2 , and RET .", "label": "None"}
{"id": "24419415", "sentence": "It may be beneficial to evaluate @DRUG$ as a treatment for NSCLCs with @VARIANT$ and irreversible @GENE$ as treatments for NSCLCs with G719X and L861Q .", "label": "None"}
{"id": "24894453", "sentence": "C ) . Taken together , we found that @VARIANT$ and G724S mutants are oncogenic in the absence of ligand stimulation and effectively respond to @DRUG$ in vivo and in vitro . Asymmetric dimerization is required for oncogenic activity of G719S and G724S mutant Recently , we reported that a subset of lung cancer derived oncogenic @GENE$ mutants such as L858R require asymmetric dimerization for biochemical activation and oncogenic transforming activity , meaning that their oncogenic ability depend on formation of an EGFR homodimer in which two distinct regions of the two molecule dimerize [ ] .", "label": "sensitivity"}
{"id": "23209813", "sentence": "10.1371/journal.pone.0050701.g002Knocking down KRAS expression in other KRAS-mutant subtype ( @VARIANT$ ) CRC cells results in oxaliplatin resistance and ERCC1 upregulation . ( A ) @GENE$ SW480G12V cells were more resistant to oxaliplatin , but have the same sensitivity to irinotecan , 5FU , and @DRUG$ than parental SW480G12V cells , as demonstrated by MTT assay .", "label": "None"}
{"id": "22714415", "sentence": "Patients with @VARIANT$ KRAS mutant tumors and treated with cetuximab/chemotherapy regimes had overall survival and progression free survival of average 7.6 and 4.0 mo vs. 5.7 and 1.9 mo in other @GENE$ mutant tumor subtypes .", "label": "resistance or non-response"}
{"id": "PMC4053234", "sentence": "For example , @DRUG$ resistance in patients with EGFR mutant non-small cell lung cancers has been shown to be mediated in some cases by the selection of cancer cells harboring the @GENE$ ( @VARIANT$ ) gatekeeper mutation and/or MET gene amplification [ ] .", "label": "resistance or non-response"}
{"id": "23139670", "sentence": "In our case , a biopsy ( ‘re-biopsy’ ) revealed the @VARIANT$ mutation in the EGFR gene , which was widely known as a second mutation resistant to @GENE$ TKIs , such as @DRUG$ and erlotinib .", "label": "resistance or non-response"}
{"id": "24495353", "sentence": "Rank Entrez ID Gene symbol Entrez ID Gene symbol Entrez ID Gene symbol 1 28978 TMEM14A 79776 ZFHX4 1727 CYB5R3 2 1843 DUSP1 4701 NDUFA7 7083 TK1 3 51022 GLRX2 715 @VARIANT$ 1292 COL6A2 4 1434 CSE1L 79818 ZNF552 857 CAV1 5 8522 GAS7 4046 LSP1 5437 POLR2H 6 51668 HSPB11 1727 @GENE$ 9833 MELK 7 10456 HAX1 357 SHROOM2 54861 SNRK 8 9902 MRC2 283298 OLFML1 4830 NME1 9 4706 NDUFAB1 23179 RGL1 231 AKR1B1 10 23560 GTPBP4 1809 DPYSL3 10418 SPON1 11 79633 FAT4 857 CAV1 2350 FOLR2 12 10418 SPON1 274 BIN1 10979 FERMT2 13 471 ATIC 79833 GEMIN6 11096 ADAMTS5 14 6403 SELP 11222 MRPL3 4638 MYLK 15 23421 ITGB3BP 23244 PDS5A 9448 MAP4K4 16 23452 ANGPTL2 6241 RRM2 54922 RASIP1 17 54861 SNRK 1289 COL5A1 6934 TCF7L2 18 2034 EPAS1 8434 RECK 4072 EPCAM 19 30008 EFEMP2 429 ASCL1 4701 NDUFA7 20 25999 CLIP3 3426 CFI 404672 GTF2H5 21 4311 MME 332 BIRC5 6241 RRM2 22 4747 NEFL 2 A2M 2192 FBLN1 23 1809 DPYSL3 10730 YME1L1 25959 KANK2 24 28998 MRPL13 11130 ZWINT 55651 NHP2 25 25959 KANK2 1292 COL6A2 5050 PAFAH1B3 Lists of the top 25 of most influential genes in influence networks based on coexpression among genes in ER + breast tumors before , during , and after a course of neoadjuvant treatment with the drug @DRUG$ .", "label": "None"}
{"id": "24367680", "sentence": "Since 1/1/2007 until 31/12/2012 , we prospectively analyzed for @GENE$ @VARIANT$ all patients with newly diagnosed mCRC at the Department of Medical Oncology , University Hospital of Heraklion ( Crete , Greece ) . Five hundred and four consecutive patients , with histologically confirmed mCRC and available tumor material for molecular analysis , who were treated with at least one cycle of systemic chemotherapy with or without the addition of bevacizumab , cetuximab or @DRUG$ were enrolled .", "label": "resistance or non-response"}
{"id": "23348520", "sentence": "Indeed , in non-small cell lung cancers treated with gefitinib or erlotinib , sensitive patients have the EGFR @VARIANT$ mutation in only a few cells , whereas resistant patients exhibit EGFR T790M in the majority of the tumour cells ( ; ) . In conclusion , our results , which deserve a confirmation in larger ( not only retrospective ) studies , revealed that the response to anti-EGFR MoAbs may be influenced by the HER2 gene copy number status ( as detected by FISH ) in KRAS wt mCRC patients . The presence of HER2 gene amplification throughout the tumour ( HER2-all-A patients ) is associated not only with resistance to @DRUG$ and panitumumab but may also identify patients who could benefit from specific anti-HER2 drugs ( i.e. , trastuzumab ) or from combined @GENE$ targeted agents ( i.e. , lapatinib ) ( ) .", "label": "response"}
{"id": "19687189", "sentence": "Antrodia camphorata solid-state cultured mycelium ( AC-SS , 1 μg ml−1 ) showed adjuvant anti-proliferative effects with cisplatin ( 10 μM ) or mitomycin ( 10 μM ) in hepatoma cell lines C3A and PLC/PRF/5 cells ( in vitro ) and , on xenografted cells in tumor implanted nude mice ( in vivo ) . Furthermore , AC-SS showed its adjuvant effects through the inhibition of MDR gene expressions and the pathway of @GENE$ dependent inhibition of AKT phosphorylation [ ] . In terms of the very recent literature , Lu et al. [ ] noted that @DRUG$ extract from wild fruiting bodies of A. camphorata ( EEAC ) dose-dependently induced human premyelocytic leukemia HL 60 cells apoptosis via histone hypoacetylation , upregulation of histone deacetyltransferase 1 (HDAC 1) , and downregulation of histone acetyltransferase activities including GCN 5 , CBP and PCAF .", "label": "None"}
{"id": "17973572", "sentence": "After the cells were exposed to gefitinib for 24 h , Ba/F3-L858R cells were unable to proliferate while @GENE$ and Ba/F3-L858R-T790M cells continued to grow even in the presence of 1 μM @DRUG$ ( E ) . These results suggest that execution of apoptosis may be impaired by the presence of T790M and , to a lesser extent , @VARIANT$ .", "label": "None"}
{"id": "24004697", "sentence": "A : K562 and K562R cells treated with PPP2R5C-siRNA799 , B : 32D-Bcr-Abl WT and @GENE$ T315I cells treated with PPP2R5C-siRNA799 , C : K562 and K562R cells treated with PPP2R5C-siRNA991 , D : 32D-Bcr-Abl WT and 32D-Bcr-Abl T315I cells treated with PPP2R5C-siRNA991 . The apoptosis induction effect of PPP2R5C-siRNAs on imatinib-sensitive and imatinib-resistant cell lines . A : K562 and K562R cells treated with PPP2R5C-siRNA799 , B : 32D-Bcr-Abl WT and 32D-Bcr-Abl @VARIANT$ cells treated with PPP2R5C-siRNA799 , C : K562 and K562R cells treated with PPP2R5C-siRNA991 , D : 32D-Bcr-Abl WT and 32D-Bcr-Abl T315I cells treated with PPP2R5C-siRNA991 .", "label": "None"}
{"id": "25505694", "sentence": "BMS-690514 , a reversible oral inhibitor of EGFR , @GENE$ and −4 , VEGFRs-1 to −3 , showed antitumour activity in tumour xenograft models and in cell lines containing the EGFR @VARIANT$ mutation , suggesting a role against erlotinib-resistant tumours [ ] .", "label": "None"}
{"id": "23085539", "sentence": "OSI-027 has been shown to inhibit the growth of imatinib-resistant CML cells which contain the BCR-ABL @VARIANT$ mutation that are resistant to all @GENE$ inhibitors [ ] .", "label": "None"}
{"id": "24349829", "sentence": "While the @VARIANT$ mutation represents a direct mechanism for drug resistance that occurs at the level of drug accessibility to the target , there are a number of indirect mechanisms that involve the increased expression or activation of alternative growth factor receptors to maintain signal flux , despite EGFR inhibition . Perhaps the best characterized of these is the amplification of the Met receptor and/or elevated levels of its ligand HGF . In @DRUG$ resistant NSCLC cell lines , Met drives ErbB3 dependent activation of the @GENE$ pathway .", "label": "None"}
{"id": "23029123", "sentence": "The importance of D2 receptor involvement in ethanol actions on PRL production and cell proliferation is evident in the experiment where @DRUG$ actions on lactotropes ' function were evaluated in clonal cell lines expressing various levels of D2 receptor isoforms . It was found that V cells , which lacked functional D2 receptors and had high basal levels of PRL , showed a significant reduction in PRL production following @VARIANT$ and D2L receptor transfection . As described by an extended allosteric ternary complex model of @GENE$ , receptors spontaneously isomerize between active and inactive conformations , so receptors can modulate signaling pathways in the absence of an agonist .", "label": "None"}
{"id": "23493838", "sentence": "In addition , a complete molecular response ( defined as undetectable @GENE$ , with a reverse transcriptase polymerase chain reaction sensitivity of ≥5 logs ) was reported for 49 % and 61 % of imatinib-resistant or imatinib-intolerant patients with complete cytogenetic response , respectively . Hematological and cytogenetic responses were examined in a subgroup of patients with known BCR-ABL mutations at the study baseline ( n = 115 ) . Remarkably , similar responses were observed across all BCR-ABL mutations when compared with wild-type BCR-ABL , with the exception of the highly resistant @VARIANT$ mutation .", "label": "None"}
{"id": "23566546", "sentence": "Case Histrogical type @GENE$ mutation status Brinkman index Treatment agent Response IL-8 ( ng/mL ) IL-10 ( ng/mL ) RANTES ( pg/ml ) 1 Ad Ex21 @VARIANT$ 900 gefitinib PR 5.79 1.67 2 2 Ad Ex21 L858R 0 erlotinib PR_3.33 94.2 1.41 3 Ad Ex19 del 0 erlotinib PR 4.09 126 2.13 4 Ad Ex21 L858R 0 gefitinib PR_3.92 18.1 1.85 5 Ad Ex21 L858R + Ex19 del 370 erlotinib PR 21.9 1.23 2.11 6 Ad Ex19 del 0 erlotinib PR 7.05 1.37 2.56 7 Ad Ex19 del 0 gefitinib PR 4.82 1.59 2.02 8 Ad Ex21 L858R 1640 gefitinib PR 54.9 2.7 2.38 9 Ad negative 400 erlotinib SD 34.9 3.39 3.66 10 Ad negative 0 @DRUG$ SD 27.1 4.94 2.25 11 Ad unknown 1800 erlotinib SD NE NE NE 12 Sq Ex19 del 3840 gefitinib SD 12.6 1.1 1.98 13 Ad Ex19 del 30 erlotinib SD 5.27 0.69 2.66 14 Ad Ex19 del 0 erlotinib SD 10.5 0.85 2.5 15 Ad unknown 300 erlotinib SD 7.69 2.61 1.7 16 La negative 2080 erlotinib SD NE NE NE 17 Sq Ex21 L858R 750 erlotinib SD 11.6 56.3 3.06 18 Ad unknown 600 erlotinib SD 13.7 1.1 2.82 19 Ad Ex21 L858R 0 erlotinib SD 20.6 11.6 0.783 20 Ad Ex19 del 0 erlotinib SD 14.8 2.07 2.02 21 Ad Ex21 L858R + Ex19 del 0 gefitinib SD 3.04 1.3 1.76 22 Ad Ex19 del 200 gefitinib SD 10.9 1.59 1.91 23 Sq unknown 1560 erlotinib PD NE NE NE 24 Ad negative 1080 erlotinib PD 25.2 8.15 1.57 25 Ad unknown 0 erlotinib PD NE NE NE 26 Ad Ex18 G719A 2000 erlotinib PD 11.6 4.48 3.12 27 Ad unknown 1410 erlotinib PD NE NE NE 28 Ad Ex19 del 1000 gefitinib PD 9.44 2.25 2.89 29 Ad negative 1100 erlotinib PD 56.3 5.63 2.16 30 Ad negative 2000 erlotinib PD 15.6 0.85 0.292 31 Ad negative 825 erlotinib PD 8.27 1.59 2.13 32 Ad Ex21 L858R 0 erlotinib PD 5.34 7.05 1.7 33 Ad negative 1680 erlotinib PD 57.7 1.63 2.06", "label": "sensitivity"}
{"id": "25364419", "sentence": "@GENE$ fusion was identified to be negative by reverse transcription-polymerase chain reaction analysis and no c-kit @VARIANT$ mutation was detected . Following the above mentioned assessments , the diagnosis of ABL was determined . Induction therapy with @DRUG$ ( 45 mg/m2 daily ) intravenously for three days and cytarabine ( 100 mg/m2 daily ) intravenously via continuous infusion for seven days was initiated at the First Affiliated Hospital of Chongqing Medical University ( Chongqing , China ) on day 13 .", "label": "None"}
{"id": "24244612", "sentence": "Mutation analysis of leukemic cells prior to and during culture demonstrated the presence of the BCR-ABL TKD gatekeeper mutation @VARIANT$ . As expected , KÖ cells were unresponsive to imatinib , dasatinib and @DRUG$ when used at clinically achievable concentrations , known to inhibit proliferation and induce cell death in non-resistant @GENE$ cells .", "label": "None"}
{"id": "23935640", "sentence": "Ponatinib ( AP24534 ) is an orally administered TKI designed to inhibit @GENE$ with mutations , especially T315I , which confers resistance to other TKI such as imatinib , dasatinib , @DRUG$ , and bosutinib ( reviewed in [ , ] ) . Ponatinib inhibits both native and mutated BCR-ABL including M244V , @VARIANT$ , Q252H , Y253F/H , E255 K/V , F317L , M351T , and F359V [ , ] .", "label": "None"}
{"id": "24244732", "sentence": "The results of these mutations in the lof rab-3 genetic background , however , argue against the simple interpretation that the effects are solely the result of the same @GENE$ interaction . For the stimulatory @DRUG$ phenotype , the effects of @VARIANT$ or E465K mutations were blocked .", "label": "None"}
{"id": "21573178", "sentence": "For example , we detected the @DRUG$ resistance mutation , @VARIANT$ , in tumor sample 10 ( 80 % tumor cell content ) obtained at the time of relapse ( Supplementary ) and this sample also harbored the L747_S752del_P753S deletion initially detected by dideoxy sequencing ( and ) . We further found a previously undetected G12A substitution in exon 2 of KRAS in sample 11 ( 50 % tumor cell content , Supplementary ) and confirmed this mutation by subcloning of KRAS exon 2 amplicons and subsequent dideoxy sequencing ( data not shown ) . @GENE$ exon 19 pyrograms of sample 27 ( 40 % tumor cells ) and of sample 05 ( 50 % tumor cells ) exhibited fluorescence signals indicative for the presence of mutations that were significantly above the level of experimental noise ( and Supplementary ) .", "label": "resistance or non-response"}
{"id": "25215536", "sentence": "Though the exon 19 deletions and @VARIANT$ account for the majority of EGFR mutations , patients harboring other uncommon mutations could also benefit from EGFR-TKIs therapy . Yang et al. has suggested that the absence of an EGFR mutation , as determined by methods that only detect known mutations , should not be used as an exclusion criterion for the EGFR-TKIs therapy . In the present study , 5 of 9 @DRUG$ responders ( 55.6 % ) , who had @GENE$ tumors by MtS methods , were found to possess EGFR mutations by DS .", "label": "sensitivity"}
{"id": "23566546", "sentence": "Case Histrogical type EGFR mutation status Brinkman index Treatment agent Response @GENE$ ( ng/mL ) IL-10 ( ng/mL ) RANTES ( pg/ml ) 1 Ad Ex21 @VARIANT$ 900 gefitinib PR 5.79 1.67 2 2 Ad Ex21 L858R 0 erlotinib PR_3.33 94.2 1.41 3 Ad Ex19 del 0 erlotinib PR 4.09 126 2.13 4 Ad Ex21 L858R 0 gefitinib PR_3.92 18.1 1.85 5 Ad Ex21 L858R + Ex19 del 370 erlotinib PR 21.9 1.23 2.11 6 Ad Ex19 del 0 erlotinib PR 7.05 1.37 2.56 7 Ad Ex19 del 0 gefitinib PR 4.82 1.59 2.02 8 Ad Ex21 L858R 1640 gefitinib PR 54.9 2.7 2.38 9 Ad negative 400 erlotinib SD 34.9 3.39 3.66 10 Ad negative 0 erlotinib SD 27.1 4.94 2.25 11 Ad unknown 1800 erlotinib SD NE NE NE 12 Sq Ex19 del 3840 gefitinib SD 12.6 1.1 1.98 13 Ad Ex19 del 30 erlotinib SD 5.27 0.69 2.66 14 Ad Ex19 del 0 erlotinib SD 10.5 0.85 2.5 15 Ad unknown 300 erlotinib SD 7.69 2.61 1.7 16 La negative 2080 erlotinib SD NE NE NE 17 Sq Ex21 L858R 750 erlotinib SD 11.6 56.3 3.06 18 Ad unknown 600 erlotinib SD 13.7 1.1 2.82 19 Ad Ex21 L858R 0 erlotinib SD 20.6 11.6 0.783 20 Ad Ex19 del 0 erlotinib SD 14.8 2.07 2.02 21 Ad Ex21 L858R + Ex19 del 0 gefitinib SD 3.04 1.3 1.76 22 Ad Ex19 del 200 gefitinib SD 10.9 1.59 1.91 23 Sq unknown 1560 erlotinib PD NE NE NE 24 Ad negative 1080 erlotinib PD 25.2 8.15 1.57 25 Ad unknown 0 erlotinib PD NE NE NE 26 Ad Ex18 G719A 2000 erlotinib PD 11.6 4.48 3.12 27 Ad unknown 1410 erlotinib PD NE NE NE 28 Ad Ex19 del 1000 gefitinib PD 9.44 2.25 2.89 29 Ad negative 1100 erlotinib PD 56.3 5.63 2.16 30 Ad negative 2000 @DRUG$ PD 15.6 0.85 0.292 31 Ad negative 825 erlotinib PD 8.27 1.59 2.13 32 Ad Ex21 L858R 0 erlotinib PD 5.34 7.05 1.7 33 Ad negative 1680 erlotinib PD 57.7 1.63 2.06", "label": "None"}
{"id": "23185274", "sentence": "We found a @DRUG$ mimetic , N- ( 2-bromo-5- ( trifluoromethyl ) phenyl ) -6-methoxy-7- ( 3- ( piperidin-1-yl ) propoxy ) quinazolin-4-amine ( hereafter , V1801 ) , moderately inhibited @GENE$ kinase activity but significantly suppressed cell proliferation and induced apoptosis in @VARIANT$ EGFR harboring non-small cell lung cancer ( NSCLC ) cells in vitro and in vivo .", "label": "resistance or non-response"}
{"id": "18030354", "sentence": "Of the five EGFR-mutant cell lines , three had exon 19 deletion mutations ( Δ746–750 ) ( HCC827 , HCC2279 , H4006 ) , one had an exon 21 point mutation ( @VARIANT$ ) ( H3255 ) , and one had L858R in combination with the T790M gatekeeper mutation that confers resistance to EGFR TKIs ( H1975 ) . Of the three EGFR-wild-type cell lines , one had a somatic mutation in N-ras ( H1299 ) , and one had a K-ras mutation ( H460 ) . RNA was extracted and prepared from cells after they had been cultured for 2 h at 70 % confluence in the presence or absence of the @GENE$ TKI @DRUG$ ( 1.0 µM ) .", "label": "sensitivity"}
{"id": "15696205", "sentence": "In gefitinib treated patients , six @GENE$ mutations involved exon 19 deletions that lacked the amino acids Leu-Arg-Glu-Ala , and two were exon 21 amino acid substitutions ( @VARIANT$ ) . A seventh case with an exon 19 deletion ( involving 12 nucleotides ) was detected by fluorescent capillary electrophoresis only , so exact sequence deletion information was unavailable ( see Methods ) . KRAS Exon 2 Mutations Found in Non-Small-Cell Lung Cancers Refractory to Treatment with Gefitinib or @DRUG$ a Bold indicates mutations", "label": "sensitivity"}
{"id": "24959087", "sentence": "A final mechanism of resistance in gastric cancer cell lines has been demonstrated when MET amplified SNU6838 gastric cancer cell lines were treated with the MET inhibitors PHA-665752 and PF2341066 ; a novel mutation occurred in the activation loop of MET , causing a conformal change that blocked inhibitor binding analogous to the gatekeeper mutations seen in EGFR ( T790M ) following erlotinib treatment and in @GENE$ ( T315I ) following @DRUG$ . Although the MET @VARIANT$ mutation renders cancers insensitive to type I MET inhibitors , conformal differences between these and type II compounds may allow treatment of MET Y1230H mutant cancers or prevent the emergence of resistance due to the mutation. ,", "label": "None"}
{"id": "15736989", "sentence": "Several mutations have been identified in the context of @GENE$ patients with NSCLC that are associated with clinical response to the small-molecule EGFR inhibitors gefitinib ( Iressa ) or erlotinib ( @DRUG$ ) [ , , ] , including in-frame deletions such as del L747–E749 ; A750P in exon 19 , or @VARIANT$ in exon 21 .", "label": "sensitivity"}
{"id": "24944510", "sentence": "Poziotinib ( also known as HM781-36B ) , a new potent irreversible inhibitor of EGFR , HER2 , HER4 , and transient erythroblastopenia of childhood family of kinases inhibitor ( BTK , BLK , and @GENE$ ) , demonstrated preclinical efficacy against @VARIANT$ mutant at eightfold lower doses compared to afatinib . A different approach in addressing EGFR-TKI resistance involves the use of combination regimens . Therefore , the combination of erlotinib with cetuximab , and the combination of @DRUG$ with MM-121 ( a fully human mAb that targets HER3 ) , in patients with acquired resistance to EGFR-TKIs did not show sufficient clinical activity for further investigation in this population .", "label": "None"}
{"id": "25364578", "sentence": "On the basis of this study , in May 2013 the U.S Food and Drug Administration ( FDA ) approved erlotinib for use in patients with lung cancers harboring EGFR exon 19 deletions and EGFR @VARIANT$ substitutions . Whereas reversible EGFR TKIs compete with ATP in the kinase domain of EGFR , 2nd generation EGFR TKIs , also compete for ATP binding but then covalently bind at the edge of the ATP binding cleft on Cys773 of EGFR via the Michael mechanism ( addition of nucleophile to an α , β unsaturated carbonyl ) . Currently there are two lead 2nd generation @GENE$ TKI candidates , afatinib and dacomitinib , that are active against EGFR mutations with acquired resistance to erlotinib or @DRUG$ .", "label": "sensitivity"}
{"id": "22970367", "sentence": "In pretreated patients harboring a @VARIANT$ mutation , low expression of @GENE$ mRNA is correlated with a prolonged progression-free survival to @DRUG$ treatment .", "label": "None"}
{"id": "23801357", "sentence": "Ponatinib ( @DRUG$ ) is a novel pan–BCR-ABL inhibitor developed using a computational and structure based approach.– It was designed to bind to and inhibit native @GENE$ and BCR-ABL mutants that can arise during treatment with other TKIs and cause resistance , including the @VARIANT$ mutant .", "label": "None"}
{"id": "19758442", "sentence": "The regions responsible for interaction with A3G ( red ) and @VARIANT$ ( blue ) are discontinuous . They overlap but are not identical . The region important for interaction with the Cul5 @GENE$ marked in green and includes a conserved histidine-cysteine-cysteine-histidine motif and a suppressor of cytokine signaling Box domain .", "label": "None"}
{"id": "23533466", "sentence": "H1975 cancer cell line with mutations in EGFR exons 21 ( @VARIANT$ ) and 20 ( T790M ) was refractory to reversible @GENE$ , gefitinib , and erlotinib [ ] , but was sensitive to irreversible EGFR-TKIs , such as BIBW2992 ( @DRUG$ ) .", "label": "sensitivity"}
{"id": "21884621", "sentence": "Tyrosine kinase inhibitors ( TKIs ) targeting the @GENE$ such as gefitinib and @DRUG$ , have shown remarkable activity in the patients with NSCLC , and particularly these TKIs are more effective to NSCLC with EGFR mutations in 19 exon ( in-frame deletions ) and exon 21 ( @VARIANT$ point mutation ) , which are found to be more prevalent in Asian patients [ , ] .", "label": "sensitivity"}
{"id": "25568936", "sentence": "For example , many receptor tyrosine kinases , such as EGFR , HER2 , @GENE$ , or FGFR , undergo internalization upon ligand binding . Moreover , interactions between @DRUG$ and MYO2 or MYH9 have been described , and a MYH9 inhibitor synergizes with EGFR inhibitors to induce apoptosis in cells carrying the drug-resistant mutation @VARIANT$ .", "label": "None"}
{"id": "24069582", "sentence": "Harris et al. Phase III NCT01266486 Metformin 40 Participants with locally advanced breast cancer IHC analysis of effects on phosphorylation of @VARIANT$ , 4E-BP-1 , and @GENE$ Han et al. Phase II NCT01589367 Metformin vs. placebo in letrozole and no @DRUG$ arms 208 Postmenopausal women with stage I/II ER-positive breast cancer Clinical response rate at 24 weeks and comparison with RECIST 1.1 at baseline", "label": "None"}
{"id": "23986642", "sentence": "This is reflected by the inhibition of in vitro tyrosine kinase activity of ABL and @VARIANT$ mutant ABL with a half maximal inhibitory concentration ( IC50 ) of 0.4 nM and 2.0 nM , respectively . @DRUG$ also inhibits the in vitro activity of additional oncogenic kinases with IC50 between 0.1 nM and 20 nM , including members of the vascular endothelial growth factor receptor ( VEGFR ) , PDGFR , fibroblast growth factor receptor (FGFR) , ephrin receptor , Src family kinases , c-Kit , RET , TIE2 , and FLT3 . These additional oncogenic kinases have been implicated in the pathogenesis of acute myeloid leukemia as well , which furthers the importance of a @GENE$ inhibitor as a treatment option .", "label": "response"}
{"id": "25364260", "sentence": "Other studies reported that the expressions of Mus81 in different tumor cells correlated well with their sensitivity to @DRUG$ ; also , Mus81 expression was increased in 5-FU-resistant pancreatic cancer cells. , Therefore , a targeting agent that is specific to @GENE$ is potentially a promising method for chemosensitivity improvement , especially in Mus81 positive breast carcinoma . The present study aimed to examine the effect of Mus81 on the chemosensitivity to 5-FU of MCF-7 and @VARIANT$ cells .", "label": "None"}
{"id": "24501009", "sentence": "Strategies to improve EGFR inhibition in EGFR @VARIANT$ cancers include the combination of irreversible EGFR inhibitors with the @GENE$ antibody cetuximab ( as reported for afatinib plus @DRUG$ ) 19 ; the development of more potent and specific inhibitors of EGFR T790M20,21 ; and the use of intermittent but high doses of existing irreversible EGFR inhibitors .", "label": "response"}
{"id": "22613958", "sentence": "More than 90 % of these mutations are observed in two hotspots : in-frame deletions including amino acids at codons 747 to 749 in exon 19 , and an amino acid substitution at codon 858 ( @VARIANT$ ) in exon 21 [ - ] . These mutations are postulated to mediate oncogenic effects by altering downstream signaling and anti-apoptotic mechanisms [ - ] . Prior trials confirmed that the response rate to @GENE$ in NSCLC patients with EGFR mutations is approximately 70–80 % [ , , ] , and results of recent phase III trials showed that the oral EGFR-TKI @DRUG$ has a superior progression-free survival ( PFS ) to standard chemotherapy as the first-line therapy for NSCLC with mutated EGFR [ , ] .", "label": "sensitivity"}
{"id": "24092989", "sentence": "The antitumoral activity is increased with the association of @DRUG$ . Another critical serine-threonine protein kinase involved in the @GENE$ pathway that has been targeted to block its constitutive kinase activation is BRAF . , BRAF mutation ( @VARIANT$ ) is reported in 24 % of papillary derived ATC .", "label": "None"}
{"id": "23238683", "sentence": "Surprisingly , the effect of @DRUG$ was less pronounced on @GENE$ cells . As expected , Imatinib failed to inhibit BCR-ABL and CRKL phosphorylation in BaF3 cells carrying mutated BCR-ABL . We have previously reported that @VARIANT$ cells exhibited constitutive activation of ERK1/2 as a mechanism of resistance to this TKI [ , ] .", "label": "None"}
{"id": "21333004", "sentence": "In this study , we used experimental and computational approaches to investigate regulatory mechanisms that distinguish cell-specific @DRUG$ sensitivity in H1299 human NSCLC cell lines . We have modified the existing kinetic model of the EGFR signaling pathway and built new models for H1299 wild type ( H1299WT ) , H1299 with overexpressed wild type @GENE$ ( H1299EGFR-WT ) , and H1299 overexpressing the EGFR with @VARIANT$ mutation ( H1299L858R ) .", "label": "sensitivity"}
{"id": "23630663", "sentence": "In vitro analyses identified three point mutations , L755S , @VARIANT$ , and T798M to confer resistance to lapatinib ( Kancha et al. , ) . Threonine 798 is the ERBB2 “gatekeeper” residue that is located at the periphery of the nucleotide binding site of @GENE$ kinase ( Aertgeerts et al. , ) , and regulates access to a deep hydrophobic pocket in the active site ( Schindler et al. , ) . This event is analogous to replacement of threonine 790 with methionine ( T790M ) in erlotinib-resistant lung adenocarcinoma .", "label": "None"}
{"id": "24419415", "sentence": "The NEJ002 study , comparing gefitinib and standard carboplatin-paclitaxel chemotherapy as the first-line treatment for patients with @GENE$ mutations , demonstrated no significant difference in OS between gefitinib and carboplatin-paclitaxel . In contrast to other phase 3 trials investigating EGFR-TKIs for patients with common EGFR mutations of exon 19 deletion and @VARIANT$ , the NEJ002 is the only study that included uncommon EGFR mutations of G719X and L861Q .", "label": "None"}
{"id": "21445332", "sentence": "Left panel : MCP @VARIANT$ has deficient @GENE$ @DRUG$ activity at 20 and 90 min .", "label": "None"}
{"id": "22382702", "sentence": "Furthermore , De Roock and colleagues recently reported that chemotherapy-refractory metastatic colorectal cancers harboring a @VARIANT$ KRAS mutation were more sensitive to treatment with the @GENE$ @DRUG$ compared to tumors with other KRAS mutations [ ] .", "label": "None"}
{"id": "21333004", "sentence": "Overexpression of wild type EGFR induced high and sustained phosphorylation of EGFR , Shc , MEK ( mitogen activated protein kinase kinase ) and ERK ( extracellular signal regulated kinase ) , while the @VARIANT$ mutation reduced these response levels . In addition , H1299L858R , which is supposed to be more sensitive to @DRUG$ than H1299EGFR-WT , was effectively inhibited by gefitinib administration at the downstream part of the signaling pathway ( @GENE$ and ERK ) compared with H1299EGFR-WT , but , surprisingly , not at the upstream part of the pathway ( EGFR and Shc ) .", "label": "None"}
{"id": "23520446", "sentence": "Approximately 50 % of EGFR mutations consist of deletions in exon 19 , whereas 35–45 % consist of the @VARIANT$ mutation and 5 % consist of insertions in exon 20 or the L861Q mutation – . Gefitinib ( @DRUG$ ) and Erlotinib ( Tarceva ) are EGFR inhibitors that are used clinically for the treatment of advanced NSCLC , primarily that with @GENE$ mutations in the tyrosine kinase domains – .", "label": "sensitivity"}
{"id": "22087096", "sentence": "To our knowledge , the most common types of EGFR mutation are an exon 19 deletion and an exon 21 @VARIANT$ mutation [ ] . In our case , an Asian female had adenocarcinoma of the lung with diffuse brain metastases and was treated with @DRUG$ therapy because of an @GENE$ exon 19 deletion .", "label": "sensitivity"}
{"id": "24956168", "sentence": "FGFR3 mutations are present at around 3 % in lung cancer and the R248C mutation is known to drive tumour formation in xenograft models which were inhibited by multi-kinase inhibitor @DRUG$ . One sample with a KRAS mutation showed a concomitant mutation with an @GENE$ @VARIANT$ mutation .", "label": "None"}
{"id": "22034911", "sentence": "Consistent with this , we found that the introduction of R1275Q into @GENE$ had no negative impact on sensitivity to @DRUG$ ( IC50 47 ± 8 nm ) . As expected , the IC50 values for viability of Ba/F3 cells expressing these mutants were all above that for Ba/F3 cells expressing native EML4-ALK , with IC50s ranging from 231 to 981 nm . The three most resistant mutants , L1196M , S1206R , and @VARIANT$ , all had IC50s within twofold of parental , ALK negative , Ba/F3 cells ( IC50 1176 nm ) .", "label": "None"}
{"id": "24758297", "sentence": "B ) Quantification of Western blot signal intensity in panel B. C ) @VARIANT$ and MCF7 cells were treated with 100 nM @DRUG$ ICI ) , an @GENE$ , for 24 hours .", "label": "None"}
{"id": "24466094", "sentence": "E ) Relative survival of HeLa cells expressing ectopic @GENE$ or CYB5D2 ( @VARIANT$ ) compared to empty vector ( EV ) control cells ( left panels ) , or shRNA control ( shCTRL ) and CYB5D2 shRNA mediated knockdown ( shCYB5D2 ) HeLa cells ( right panels ) , following treatment with either paclitaxel ( 400 ng/ml ) , cisplatin ( 400 ng/ml ) or @DRUG$ ( 10 µM ) for 24 and 48 h .", "label": "None"}
{"id": "23986642", "sentence": "This is reflected by the inhibition of in vitro tyrosine kinase activity of @GENE$ and @VARIANT$ mutant ABL with a half maximal inhibitory concentration ( IC50 ) of 0.4 nM and 2.0 nM , respectively . @DRUG$ also inhibits the in vitro activity of additional oncogenic kinases with IC50 between 0.1 nM and 20 nM , including members of the vascular endothelial growth factor receptor ( VEGFR ) , PDGFR , fibroblast growth factor receptor (FGFR) , ephrin receptor , Src family kinases , c-Kit , RET , TIE2 , and FLT3 .", "label": "response"}
{"id": "24908327", "sentence": "The patients who had a diagnosis of advanced NSCLC with stage III–IV and the patients harboring activating EGFR mutations ( either exon 19 deletion or @VARIANT$ in exon 21 ) . All patients received @GENE$ TKIs ( @DRUG$ or erlotinib ) for monotherapy , first line or otherwise .", "label": "sensitivity"}
{"id": "25333255", "sentence": "Further TKI improvement came from the higher binding affinity and selectivity than imatinib through the follow-up substance @DRUG$ ( @GENE$ ) [ ] . In addition , bosutinib ( SKI-606 ) was developed , a second line inhibitor which has the broadest target spectrum inhibiting SRC , ABL and TEC , as well as serine kinases CAMK2G and STE20 , but bosutinib does not target PDGFR and KIT [ , ] . Finally , the third line inhibitor ponatinib has been developed and shown to exhibit substantial efficacy in patients with CML in whom the polyresistant BCR-ABL1 @VARIANT$ mutation is expressed in leukemic cells [ ] .", "label": "None"}
{"id": "21915126", "sentence": "The mechanistic reasons behind the resistance to EGFR TKI are different , probably involving @VARIANT$ secondary mutation and MET amplification . Recently , some irreversible @GENE$ and MET inhibitors have shown antitumour activity in patients resistant to @DRUG$ or erlotinib in pre-clinical studies ( ; ; ; ; ) .", "label": "resistance or non-response"}
{"id": "25115383", "sentence": "@DRUG$ is an irreversible @GENE$ blocker that shows high affinity for EGFR @VARIANT$ mutation .", "label": "response"}
{"id": "24092472", "sentence": "Parts ( b ) and ( d ) present the distributions of total binding free energies of the mutants ( with WT protein included ) with two inhibitors gefitinib and @DRUG$ . The red lines and solid blue circles show the binding free energy for the WT @GENE$ and the @VARIANT$ mutant respectively .", "label": "sensitivity"}
{"id": "25562700", "sentence": "Molecule Target Biomarker Indication vemurafenib BRAF kinase BRAF @VARIANT$ mutant melanoma vandetanib VEGFR , EGFR , RETR not included on the label thyroid cancer abiraterone CYP 17A1 not included on the label prostate cancer ipilimumab CTLA-4 not included on the label melanoma brentuximab vedotin CD30 ( ACD technology ) not included on the label lymphoma @DRUG$ ALK ALK-EML4 fusion protein lung cancer BRAF : Serine/threonine-protein kinase B-Raf ; VEGFR : Vascular endothelial growth factor receptor ; EGFR : epidermal growth factor receptor ; RETR : RET proto-oncogen receptor ; CYP 17A1 : cytochrome P450 17A1 ; CTLA-4 : Cytotoxic T-Lymphocyte Antigen 4 ; CD30 : Cluster of Differentiation 30 ; ADC : Antibody Conjugated Drug ; ALK-EML4 : anaplastic lymphoma kinase (ALK) ; echinoderm @GENE$ ( EML4 ) fusion .", "label": "None"}
{"id": "22995644", "sentence": "We next tested whether @DRUG$ could induce PRL-3 protein down-regulation in @GENE$ murine hematopoietic cells engineered to express either wild-type , or the Imatinib resistant @VARIANT$ mutant P210 BCR-ABL .", "label": "None"}
{"id": "23497317", "sentence": "In addition IC50 estimates for the proapoptotic effect of quizartinib in the imatinib-sensitive GIST solid tumor cell line GIST882 , harboring a K642E mutation , and the imatinib-insensitive cell line GIST48 , harboring a @VARIANT$ mutation in addition to a D820A mutation in the tyrosine kinase domain , are provided , revealing sensitivity profiles similar to @DRUG$ . Estimated IC50s for the proapoptotic and antiproliferative effects of quizartinib in an isogenic cell model of @GENE$ cells transfected with various mutant TKs", "label": "None"}
{"id": "15737014", "sentence": "Such mutations rarely , if ever , accompany @GENE$ mutations and are associated with primary resistance to gefitinib or @DRUG$ [ ] . To evaluate the possibility that secondary KRAS mutations confer acquired resistance to these drugs , we performed mutational profiling of KRAS2 exon 2 from tumor specimens from patients 1 to 3 , as well as the three additional patients lacking evidence of the @VARIANT$ mutation .", "label": "resistance or non-response"}
{"id": "25580271", "sentence": "Most patients with EGFR mutant NSCLC receive an @GENE$ tyrosine kinase inhibitor ( e.g. @DRUG$ , erlotinib , or afatinib ) as first-line therapy , and unfortunately most patients experience disease progression after approximately 10–15 months of treatment . The most common mechanism of resistance is an EGFR exon 20 @VARIANT$ mutation , which is detected in approximately 50–60 % of tumor samples when a biopsy is performed after disease progression on EGFR tyrosine kinase inhibitors [ , ] .", "label": "resistance or non-response"}
{"id": "23864840", "sentence": "Another approach for @VARIANT$ mediated resistance is the dual inhibition of @GENE$ with @DRUG$ and cetuximab , an EGFR blocking antibody resembling the synergistic combination of lapatinib and trastuzumab in ErbB2 positive breast cancer .", "label": "response"}
{"id": "15737014", "sentence": "To determine how the @VARIANT$ mutation would affect EGFR proteins already containing mutations associated with sensitivity to EGFR tyrosine kinase inhibitors , we introduced the specific mutation into EGFR cDNAs that encoded the exon 21 and 19 mutations found in patients 1 and 2 , respectively . Various lysates from cells that were serum starved and pre treated with gefitinib or @DRUG$ were analyzed by immunoblotting . Amounts of total @GENE$ ( t-EGFR ) were determined using an anti-EGFR monoclonal antibody , and actin served as an indicator of relative levels of protein per sample .", "label": "resistance or non-response"}
{"id": "19920910", "sentence": "The pattern of resistance to nilotinib and dasatinib differed ; those with greatest resistance to nilotinib ( @VARIANT$ and E255V ) were susceptible to @DRUG$ . T315I remained resistant to all the three drugs . In vivo experiments with CML xenografts in mice demonstrated that nilotinib treatment , compared with treatment with vehicle , improved survival of mice infused with either wild type @GENE$ or the imatinib-resistant Bcr-Abl mutant ( E255V ) ( ; ) .", "label": "None"}
{"id": "23792636", "sentence": "Since BCL-2 and the mitochondria play an important role in sensitivity to cisplatin , , we determined if the various @GENE$ mutants exhibited a differential response to @DRUG$ . Compared with control , HEK-293 cells overexpressing PXN mutations A127T and @VARIANT$ were found to be more sensitive .", "label": "None"}
{"id": "25465236", "sentence": "( C ) @GENE$ T790M mutant does not resemble pEGFR unlike the EGFR @VARIANT$ mutant shown in B. ( D–F ) increased inhibition potency for @DRUG$ against EGFR L858R mutant compared to EGFR WT protein and subsequent decrease in potency for Erlotinib against EGFR L858R + E884K double mutant .", "label": "sensitivity"}
{"id": "24889765", "sentence": "Detailed estimates for the best fitting model are presented in Table , while only the fixed effect parameters are presented for other models specified in Table ( random effects for these models can be found in Additional file : Table @VARIANT$ ) . Model fit indices and comparison of LCS models for total weekly @DRUG$ consumption and mental health in the Whitehall II study Baseline Alcohol → ΔMCS MCS → Δalcohol Reciprocal Age and sex adjusted Fit statistics Log likelihood -146158.161 -146158.041 -146155.151 -146154.760 χ2 ( df ) 274.233 ( 12 ) 273.995 ( 11 ) 268.214 ( 11 ) 267.432 ( 10 ) RMSEA 0.059 0.061 0.061 0.064 @GENE$ 292380.321 292382.083 292376.302 292377.520 SSA BIC 292494.731 292500.068 292494.288 292499.081 CFI 0.982 0.982 0.982 0.982 TLI 0.959 0.955 0.956 0.952 Model comparison ( difference in χ2 fit ( df ) ) Versus baseline – 0.238 ( 1 ) , P = 0.63 6.019 ( 1 ) , P = 0.01 6.801 ( 2 ) , P = 0.03 Versus previous best – – – 0.782 ( 1 ) , P = 0.38", "label": "None"}
{"id": "24495353", "sentence": "Rank Entrez ID Gene symbol Entrez ID Gene symbol Entrez ID Gene symbol 1 28978 TMEM14A 79776 ZFHX4 1727 CYB5R3 2 1843 DUSP1 4701 NDUFA7 7083 TK1 3 51022 GLRX2 715 C1R 1292 COL6A2 4 1434 CSE1L 79818 ZNF552 857 CAV1 5 8522 GAS7 4046 LSP1 5437 POLR2H 6 51668 HSPB11 1727 CYB5R3 9833 MELK 7 10456 HAX1 357 SHROOM2 54861 SNRK 8 9902 MRC2 283298 OLFML1 4830 NME1 9 4706 NDUFAB1 23179 RGL1 231 AKR1B1 10 23560 GTPBP4 1809 DPYSL3 10418 SPON1 11 79633 FAT4 857 CAV1 2350 FOLR2 12 10418 SPON1 274 BIN1 10979 FERMT2 13 471 ATIC 79833 GEMIN6 11096 ADAMTS5 14 6403 @GENE$ 11222 MRPL3 4638 MYLK 15 23421 ITGB3BP 23244 PDS5A 9448 MAP4K4 16 23452 ANGPTL2 6241 RRM2 54922 RASIP1 17 54861 SNRK 1289 COL5A1 6934 TCF7L2 18 2034 EPAS1 8434 RECK 4072 EPCAM 19 30008 EFEMP2 429 ASCL1 4701 NDUFA7 20 25999 CLIP3 3426 CFI 404672 GTF2H5 21 4311 MME 332 BIRC5 6241 RRM2 22 4747 NEFL 2 @VARIANT$ 2192 FBLN1 23 1809 DPYSL3 10730 YME1L1 25959 KANK2 24 28998 MRPL13 11130 ZWINT 55651 NHP2 25 25959 KANK2 1292 COL6A2 5050 PAFAH1B3 Lists of the top 25 of most influential genes in influence networks based on coexpression among genes in ER + breast tumors before , during , and after a course of neoadjuvant treatment with the drug @DRUG$ .", "label": "None"}
{"id": "24586514", "sentence": "( D ) Ba/F3 @VARIANT$ cells were treated with @DRUG$ for 24 h , and total extracts were examined by immunoblot analysis with anti-phospho @GENE$ , anti-Crk-L , anti cleaved caspase 3 , anti-PARP , and anti-tubulin antibodies .", "label": "response"}
{"id": "23299535", "sentence": "A similar theme exists in NSCLCs with a mutation in the EGFR – secondary mutations confer insensitivity to the EGFR tyrosine kinase inhibitor ( @GENE$ ) @DRUG$ , and have been identified in patients with clinical resistance to gefitinib , but also in untreated patients ( ) . analysed NSCLC samples for one such mutation in EGFR , the @VARIANT$ mutation , from treatment-naïve patients , and from patients before and during treatment with EGFR-TKIs .", "label": "resistance or non-response"}
{"id": "24339922", "sentence": "The secondary @VARIANT$ mutation was not detected in the HCC827/GR and HCC827/ER cell lines by sequencing ( data not shown ) . To assess the inhibitory effects of @GENE$ on MET further , EGFR and their downstream signals , HCC827 , HCC827/GR and HCC827/ER cells were treated with @DRUG$ and erlotinib for 72 h .", "label": "resistance or non-response"}
{"id": "23329883", "sentence": "The results of the present study show that the levels of TG , HDL-C , ApoA1 , and the ratio of @GENE$ to ApoB were higher in drinkers than in non-drinkers , whereas the levels of TC , LDL-C and ApoB were lower in drinkers than in non-drinkers . The subjects with AA genotype of PCSK9 E670G had lower serum TC and LDL-C levels in drinkers than in non-drinkers . The interactions between PCSK9 @VARIANT$ genotypes and @DRUG$ consumption on serum TC and LDL-C levels were also detected by using a factorial design covariance analysis after controlling for potential confounders .", "label": "None"}
{"id": "25580271", "sentence": "Most patients with @GENE$ mutant NSCLC receive an EGFR tyrosine kinase inhibitor ( e.g. gefitinib , erlotinib , or @DRUG$ ) as first-line therapy , and unfortunately most patients experience disease progression after approximately 10–15 months of treatment . The most common mechanism of resistance is an EGFR exon 20 @VARIANT$ mutation , which is detected in approximately 50–60 % of tumor samples when a biopsy is performed after disease progression on EGFR tyrosine kinase inhibitors [ , ] .", "label": "response"}
{"id": "20195537", "sentence": "In E. coli the corresponding substitution ( @VARIANT$ ) produces a defective RecBD1080ACD enzyme that lacks nuclease and @GENE$ loading activity affecting the recombination and DNA repair proficiency of cells , . 10.1371/journal.pone.0009412.g006DNA repairing proficiency of RecBK28QCD , RecBD1118A , and RecBCDK229Q enzymes of P. syringae . LCBD ( ΔrecCBD ) strains carrying the plasmid-borne mutant alleles of recB ( recBK28Q or recBD1118A ) or recD ( recD229Q ) of recCBD operon were tested for UV ( A ) and @DRUG$ @DRUG$ ( B ) sensitivity , and compared with the wild-type ( WT ) harboring the empty plasmid vector ( pGL10 ) .", "label": "None"}
{"id": "25053989", "sentence": "( B) PI3K and @GENE$ pathway markers were assessed after 21 days of treatment . Five tumors are represented in each group . ( C ) SW48 @VARIANT$ resistant ( clone 10A ) tumor bearing mice were treated orally and daily with vehicle ( 0.5 % methylcellulose , 0.2 % tween-80 + 7.5 % captisol ) , 75 mg/kg GDC-0941 , 25 mg/kg @DRUG$ , or GDC-0941 and erlotinib in combination .", "label": "None"}
{"id": "16626260", "sentence": "Although several previous studies have suggested that tumors harboring mutations in the EGFR kinase domain were sensitive to TKIs such as gefitinib or @DRUG$ , others had reported an association between the @VARIANT$ mutation in exon 20 and the resistance to TKIs . As we learn more about the relationship between EGFR status ( including gene copy number , mutation status , and mutation type ) and drug sensitivity , decisions about treatment with TKIs for patients with non-small-cell lung cancer ( NSCLC ) become more complex . Previously , we reported HER2 mutational status , as well as EGFR and @GENE$ , in a large number of NSCLCs .", "label": "None"}
{"id": "24212777", "sentence": "Most B-Raf mutations involve the @VARIANT$ amino acid substitution , resulting in constitutive activation of the @GENE$ signaling pathway . They are mutually exclusive of KRAS mutations and are thus a candidate for an independent biomarker for CRC [ ] . Studies on WT-KRAS tumors treated by either a combination of chemotherapy and @DRUG$ or cetuximab alone have shown that progression free survival ( PFS ) and OS were significantly better among patient without mutated BRAF ( WT-BRAF ) [ ] .", "label": "None"}
{"id": "25120654", "sentence": "Activating mutations of the @GENE$ gene are predominantly located in exons 18–21 and & gt ; 90 % are deletions in exon 19 or the @VARIANT$ substitution in exon 21 . These activating mutations are eligible for treatment with modern TKIs , for example @DRUG$ ( – ) .", "label": "sensitivity"}
{"id": "23418490", "sentence": "At the same time , a secondary point mutation in exon 20 of EGFR ( @VARIANT$ ) is associated with acquired resistance to @GENE$ inhibitors , including @DRUG$ .", "label": "resistance or non-response"}
{"id": "25486409", "sentence": "As the second-generation , irreversible EGFR-TKIs , such as afatinib and dacomitinib , failed to overcome the resistance caused by @VARIANT$ , , other measures , such as EGFR dual targeting with @DRUG$ and afatinib and third-geneneration , mutant-selective @GENE$ – are being actively evaluated .", "label": "response"}
{"id": "23493838", "sentence": "A complete hematological response and a major cytogenetic response were observed broadly across the @GENE$ mutants , including individuals harboring the dasatinib-resistant F317L , the nilotinib-resistant Y253H , and F359C/I/V mutations , but not T315I . Nine individuals developed new mutations in the course of @DRUG$ treatment ( V299L , n = 4 ; L248V , n = 2 ; @VARIANT$ , n = 2 ; F359C , n = 1 ; G250E , n = 1 ) and eight of these individuals discontinued bosutinib because of progressive disease or unsatisfactory response .", "label": "None"}
{"id": "24419415", "sentence": "The NEJ002 study , comparing @DRUG$ and standard carboplatin-paclitaxel chemotherapy as the first-line treatment for patients with @GENE$ mutations , demonstrated no significant difference in OS between gefitinib and carboplatin-paclitaxel . In contrast to other phase 3 trials investigating EGFR-TKIs for patients with common EGFR mutations of exon 19 deletion and L858R , the NEJ002 is the only study that included uncommon EGFR mutations of G719X and @VARIANT$ .", "label": "None"}
{"id": "25502848", "sentence": "A further portion was purified for high resolution mass spectrometry by HPLC ( Atlantis C18 column ; 150 × 4.6 mm , 5 μm particles ) and a mobile phase comprising a mixture of 92 % ethanol-buffer ( 100 mM NH4OAc , pH 5.0 ) ( 85 + 15 , v/v ) and 8 % chloroform at a flow rate of 0.5 mL min−1 ( isocratic elution ) . The effluent of the HPLC was divided using a splitter ( Active splitter , @VARIANT$ , Agilent , USA ) which directed 1/5 of the flow to the @GENE$ , and the remainder to a fraction collector which collected 1.5 mL volumes .", "label": "None"}
{"id": "15737014", "sentence": "This scenario could explain the seemingly contradictory report by others who found the H1975 cell line to be highly sensitive to @DRUG$ [ ] ; our H1975 cells could represent a subclone that emerged over time . Analysis of earlier passages of H1975 cells for the @VARIANT$ mutation would be informative in this regard . Recently , new small-molecule inhibitors have been identified that retain activity against the majority of imatinib-resistant @GENE$ mutants .", "label": "None"}
{"id": "24586514", "sentence": "Using the @GENE$ @VARIANT$ xenograft model , ponatinib or @DRUG$ ( 30 and 70 mg/kg , respectively ) showed similar reduction in tumor size .", "label": "None"}
{"id": "22970367", "sentence": "Moreover , dual inhibition of EGFR with an irreversible EGFR inhibitor ( @DRUG$ ) and the @GENE$ neutralizing antibody cetuximab has recently shown promising activity in EGFR mutant lung cancers with acquired EGFR TKI resistance that harbor an EGFR @VARIANT$ mutation [ ] .", "label": "response"}
{"id": "25538894", "sentence": "The other EGFR mutations , e.g. , the @VARIANT$ mutation on exon 20 , represent less than 10 % of all mutations , and are associated with drug resistance ( ) . Treatment of patients with advanced NSCLC with EGFR mutation Both the European Society of Medical Oncology ( ESMO ) ( ) and the American College of Chest Physicians ( ACCP ) ( ) recommend first-line treatment with a TKI ( @DRUG$ or gefitinib ) in metastatic NSCLC bearing an activating @GENE$ mutation because of higher response rate , longer progression free survival ( PFS ) , and better quality of life when compared with first-line chemotherapy .", "label": "resistance or non-response"}
{"id": "22935382", "sentence": "To explore potential @DRUG$ resistance mechanisms in model EC039 , we screened for mutations in a panel of genes ( EGFR , K-ras , B-raf and @GENE$ ) across all 5 PDECX models and their corresponding patient EC tissues . Screened gene locations included ; exons 18 , 19 , 20 , 21 of EGFR gene , exons 2 and 3 of K-ras gene , exons 11 and 15 of B-raf gene , and exons 9 and 20 of PI3KCA gene . Interestingly , PIK3CA @VARIANT$ ( E542K ) mutation was identified within exon 9 of the PIK3CA gene helical domain in both EC039 model and the corresponding patient’s EC tissue .", "label": "None"}
{"id": "23566546", "sentence": "Case Histrogical type @GENE$ mutation status Brinkman index Treatment agent Response IL-8 ( ng/mL ) IL-10 ( ng/mL ) RANTES ( pg/ml ) 1 Ad Ex21 @VARIANT$ 900 gefitinib PR 5.79 1.67 2 2 Ad Ex21 L858R 0 erlotinib PR_3.33 94.2 1.41 3 Ad Ex19 del 0 erlotinib PR 4.09 126 2.13 4 Ad Ex21 L858R 0 gefitinib PR_3.92 18.1 1.85 5 Ad Ex21 L858R + Ex19 del 370 erlotinib PR 21.9 1.23 2.11 6 Ad Ex19 del 0 erlotinib PR 7.05 1.37 2.56 7 Ad Ex19 del 0 gefitinib PR 4.82 1.59 2.02 8 Ad Ex21 L858R 1640 gefitinib PR 54.9 2.7 2.38 9 Ad negative 400 erlotinib SD 34.9 3.39 3.66 10 Ad negative 0 erlotinib SD 27.1 4.94 2.25 11 Ad unknown 1800 erlotinib SD NE NE NE 12 Sq Ex19 del 3840 gefitinib SD 12.6 1.1 1.98 13 Ad Ex19 del 30 erlotinib SD 5.27 0.69 2.66 14 Ad Ex19 del 0 erlotinib SD 10.5 0.85 2.5 15 Ad unknown 300 erlotinib SD 7.69 2.61 1.7 16 La negative 2080 erlotinib SD NE NE NE 17 Sq Ex21 L858R 750 erlotinib SD 11.6 56.3 3.06 18 Ad unknown 600 erlotinib SD 13.7 1.1 2.82 19 Ad Ex21 L858R 0 erlotinib SD 20.6 11.6 0.783 20 Ad Ex19 del 0 erlotinib SD 14.8 2.07 2.02 21 Ad Ex21 L858R + Ex19 del 0 gefitinib SD 3.04 1.3 1.76 22 Ad Ex19 del 200 gefitinib SD 10.9 1.59 1.91 23 Sq unknown 1560 erlotinib PD NE NE NE 24 Ad negative 1080 erlotinib PD 25.2 8.15 1.57 25 Ad unknown 0 erlotinib PD NE NE NE 26 Ad Ex18 G719A 2000 erlotinib PD 11.6 4.48 3.12 27 Ad unknown 1410 erlotinib PD NE NE NE 28 Ad Ex19 del 1000 @DRUG$ PD 9.44 2.25 2.89 29 Ad negative 1100 erlotinib PD 56.3 5.63 2.16 30 Ad negative 2000 erlotinib PD 15.6 0.85 0.292 31 Ad negative 825 erlotinib PD 8.27 1.59 2.13 32 Ad Ex21 L858R 0 erlotinib PD 5.34 7.05 1.7 33 Ad negative 1680 erlotinib PD 57.7 1.63 2.06", "label": "sensitivity"}
{"id": "16552419", "sentence": "Although the sequence analysis of @GENE$ might be necessary for clinical trials using TKI such as gefitinib or @DRUG$ , these simple methods established in this study for detection of exon 19 deletion and exon 21 @VARIANT$ mutation are very useful for screening .", "label": "sensitivity"}
{"id": "22701522", "sentence": "Emission ratio ( emission signal at 510 nm divided by emission signal at 486 nm ) was plotted against concentration of @DRUG$ . ( B ) The same experiment as ( A ) was performed in parallel with 90 pM of SNAP-eDHFR @VARIANT$ and 2.2 nM of @GENE$ .", "label": "None"}
{"id": "25405807", "sentence": "Inhibition of epidermal growth factor receptor (EGFR) kinase activity by EGFR tyrosine kinase inhibitors ( EGFR-TKIs ) , such as gefitinib and @DRUG$ , can result in improved response and prolonged progression-free survival ( PFS ) in selected non-small cell lung cancer ( NSCLC ) patients harboring sensitizing @GENE$ mutations , especially the exon 19del and exon 21 L858R mutations – . Unfortunately , almost all patients will ultimately develop resistance to EGFR-TKI , in whom more than 50 % cases were detected harboring the EGFR @VARIANT$ mutation in tumor specimens after EGFR-TKI , .", "label": "resistance or non-response"}
{"id": "25033171", "sentence": "Therefore , the P-loop was hard to be induced during the whole binding/unbinding process of @DRUG$ , and thus , an attenuated binding state was dominated between crizotinib and binding pocket of @VARIANT$ mutated @GENE$ tyrosine kinase .", "label": "resistance"}
{"id": "23610714", "sentence": "@DRUG$ has been found to be effective not only for GIST with @GENE$ mutations but also for GIST with PDGFRA mutations and for wild-type GISTs. , However , no adjuvant treatment is recommended in GISTs with the @VARIANT$ missense mutation in the PDGFRA exon 18 , which are known to be unresponsive to imatinib and showed very favorable outcome after surgery .", "label": "None"}
{"id": "21165163", "sentence": "The @VARIANT$ mutation results in alteration of the topology of the ATP binding pocket not only interrupting the physicochemical binding of gefitinib/erlotinib , but also leading to much increased affinity of the @GENE$ protein to ATP resulting in resistance to EGFR-TKIs [ ] .", "label": "resistance or non-response"}
{"id": "25079768", "sentence": "The second-line treatment , after imatinib failure , is provided by less specific kinase inhibitors , such as sunitinib that shows potency against imatinib-resistant @GENE$ mutated in the ATP binding pocket ( V654A and @VARIANT$ ) .", "label": "resistance"}
{"id": "24715763", "sentence": "Amplification of the MYCN gene is the most common genetic aberration in neuroblastoma and has been associated with a bad prognosis. , Both ALK mutations and MYCN amplifications can occur simultaneously , predominantly with the ALK @VARIANT$ change . MYCN prevents sympathoadrenal differentiation from neuroblastic cells , some of which will transform into neuroblastoma , which is potentiated by overactivated ALK . A recent clinical trial recruited children with neuroblastoma with known or unknown @GENE$ mutations and evaluated the clinical response after treatment with @DRUG$ .", "label": "resistance"}
{"id": "24348666", "sentence": "Although the resistant cell line HCG827GR does not have the EGFR @VARIANT$ mutation , it was found to have MET amplification . MET is a receptor tyrosine kinase that binds to hepatocyte growth factor (HGF) and is associated with the development of various human cancers . Therefore , EGFR-TKIs fail to inhibit the PI3K/Akt pathway dependent growth signal because the constitutive phosphorylation of HER3 by @GENE$ occurs independent of EGFR activation , which causes the cells to acquire resistance to @DRUG$ .", "label": "None"}
{"id": "23816254", "sentence": "Due to their ability to potently inhibit @GENE$ , both afatinib and neratinib have been assessed in lung cancer that has become resistant to @DRUG$ and erlotinib due to the @VARIANT$ point mutation in the kinase domain [ , ] .", "label": "resistance or non-response"}
{"id": "24790411", "sentence": "The mutation @VARIANT$ is localized at codon 790 on exon 20 of EGFR and results in the change of threonine to methionine at the protein level . The amino acid change causes steric hindrance to EGFR TKIs in crystal analysis and/or increased affinity for adenosine triphosphate ( ATP ) . , Consequently , reversible EGFR TKIs can no longer bind to the receptor or can not efficiently compete for the ATP binding site . @DRUG$ ( BIBW 2992 ; Boehringer-Ingelheim Pharma , Ingelheim , Germany ) is an irreversible pan-HER inhibitor that blocks all the members of the HER family with tyrosine kinase properties ( @GENE$ , HER2 , and HER4 ) .", "label": "response"}
{"id": "22514283", "sentence": "There are two missense mutations identified so far in the AR segment of @GENE$ that are related to HS : H277R and @VARIANT$ ( , ) . Importantly , the His → Arg substitution involves a highly conserved @DRUG$ of the TPLH motif .", "label": "None"}
{"id": "24729716", "sentence": "The presence of mutations in the kinase domain of @GENE$ in non-small cell lung cancer ( NSCLC ) patients has been regarded as a predictive marker of good response to tyrosine kinase inhibitors ( TKIs ) , such as @DRUG$ and erlotinib . Nearly 90 % of these mutations occur as either multinucleotide in-frame deletions in exon 19 or as single missense mutations that result in substitution of arginine for leucine at position 858 ( @VARIANT$ ) in exon 21 .", "label": "sensitivity"}
{"id": "19513066", "sentence": "Although more basal @GENE$ phosphorylation was present in the @VARIANT$ cells ( compared with MDA-MB-231 cells , data not shown ) , residual phosphorylation after @DRUG$ treatment was comparable .", "label": "None"}
{"id": "25122428", "sentence": "The dual inhibition of PI3K and mTOR might be advantageous over single inhibition by suppressing a @VARIANT$ feedback loop that leads to the pathway reactivation . Based on this idea , an on-going phase I study of the PI3K and mTORC1/2 dual inhibitor , BEZ235 , was designed for the patients with advanced solid tumors harboring PIK3CA or @GENE$ alteration ( NCT01195376 ) . In this study , we showed that the survival of the cisplatin-resistant SCLC cell lines was well suppressed by BEZ235 , accompanied by the suppression of S6RP phosphorylation .", "label": "None"}
{"id": "21713039", "sentence": "@GENE$ fractions collected from CHO-K1 cells expressing the human A3R were incubated with T1-11 at the indicated concentration and 35S-GTPγS ( 0.1 nM ) for 30 min at 30°C . Relative GTPγS binding was defined as the percentage of 35S-GTPγS binding when compared with a selective agonist of the @VARIANT$ ( 2-Cl-IB-MECA , 3 µM ) .", "label": "None"}
{"id": "22350019", "sentence": "Like PH3-739358 , @DRUG$ was found to inhibit wild-type BCR-ABL and @VARIANT$ @GENE$ ( IC50 values of 110 and 4 nM , respectively ) [ ] .", "label": "None"}
{"id": "19920910", "sentence": "The pattern of resistance to nilotinib and dasatinib differed ; those with greatest resistance to nilotinib ( Y253H and @VARIANT$ ) were susceptible to @DRUG$ . T315I remained resistant to all the three drugs . In vivo experiments with CML xenografts in mice demonstrated that nilotinib treatment , compared with treatment with vehicle , improved survival of mice infused with either wild type @GENE$ or the imatinib-resistant Bcr-Abl mutant ( E255V ) ( ; ) .", "label": "None"}
{"id": "19547661", "sentence": "BRAF ( v-raf murine sarcoma viral oncogene homolog B1 ) , a @GENE$ is the downstream effector of KRAS in the RAS-RAF-MAPK signaling pathway . A somatic mutation ( @VARIANT$ ) in exon 15 of BRAF has been identified in multiple human cancers with a mutation rate of 66 % in malignant melanomas [ ] and at lower frequency in other human carcinomas . Recently , it was demonstrated that wildtype BRAF is required for the response of patients with metastatic colorectal cancer to @DRUG$ and panitumumab [ ] .", "label": "None"}
{"id": "24523812", "sentence": "The eligible 10 patients had stage IV NSCLC and were treated with gefitinib or @DRUG$ monotherapy for more than 6 months . They had achieved radiographic response before @GENE$ failure or documentation of either EGFR exon 19 deletion or an EGFR @VARIANT$ mutation .", "label": "sensitivity"}
{"id": "23569464", "sentence": "Brain metastasis is observed in approximately 10 % of breast cancer patients , and recurrence is common due to reduced efficiency of chemotherapy drugs , such as doxorubicin and carboplatin , and targeted therapy drugs , such as @DRUG$ , to cross the blood-brain barrier , . A very recent study showed that the binding of @VARIANT$ to S1PR1 in brain capillaries decreases basal @GENE$ transport activity and improves the delivery of therapeutic agents like paclitaxel to the brain .", "label": "None"}
{"id": "21192840", "sentence": "Tumor type EGFR mutation @GENE$ expression changes EGFR targeting agents ( FDA approved for clinical use ) Resistance mechanisms Non-small cell lung cancer Kinase domain deletions ( exon 19 ) , point mutations ( exon 21 ) Gene amplification Erlotinib , @DRUG$ @VARIANT$ gatekeeper mutation ( 50 % ) , , elevated c-Met/HGF expression ( 20 % ) –", "label": "resistance or non-response"}
{"id": "24987354", "sentence": "Multikinase small molecule inhibitors such as sorafenib and @DRUG$ can be used per recent NCCN guidelines ( Version 2.2013 ) , but prospective clinical trials have not yet demonstrated a distinct molecular subgroup of PTC patients that derives large benefit from such targeted therapies [ ] . BRAF @VARIANT$ is present in approximately 45 % of all PTC [ ] , with alterations of CTNNB1 , HRAS , IDH1 , KRAS , NRAS , PIK3CA and @GENE$ being less common .", "label": "None"}
{"id": "PMC4041556", "sentence": "Second-generation EGFR TKIs – such as neratinib , afatinib and dacomitinib – are effective in preclinical gefitinib- and erlotinib-resistant EGFR @VARIANT$ models , but to date their delivery in EGFR TKI-resistant patients have shown disappointing results in the clinic . Combination of afatinib with @DRUG$ in EGFR TKI-resistant patients resulted in a 30 % response rate and 75 % disease control rate , with significant gastrointestinal toxicity . Other mechanisms of resistance include MET amplification , with no commercially available inhibitor , HER2 amplification potentially amenable to treatment with @GENE$ monoclonal antibodies or histological transformation to small-cell lung cancer , which requires cytotoxic chemotherapy .", "label": "None"}
{"id": "21333004", "sentence": "The combination of @GENE$ and @DRUG$ has a synergistic effect in inhibiting EGFR signaling The only difference between the EGFR-WT model and the @VARIANT$ model A is in the negative EGFR regulation produced by Mig6 , therefore , which can be experimentally verified by overexpressing Mig6 .", "label": "None"}
{"id": "19707322", "sentence": "Nilotinib is approximately 30-fold more sensitive than @DRUG$ in the killing of BCR-ABL dependent cells derived from patients with CML ( K562 and Ku-812F cells ) and cell lines ( 32D and baF3 ) , and it is active against 32/33 imatinib-resistant cell lines with @GENE$ mutations . The sensitivity of Bcr-Abl mutants to AMN107 can be summarized into 4 categories : high ( IC50 ≤ 70 nmol/L : M244V , G250E , @VARIANT$ , F3llL , F317L , M351T , V379I , L387M , H396P , H396R ) , medium ( IC50 ≤ 200 nmol/L : Y253F , E255K , F359V ) , low ( IC50 ≤ 450 nmol/L : Y253H , E255V ) , and insensitive ( IC50 & gt ; 2 μmol/L : T315I ) ( ) ( ) .", "label": "None"}
{"id": "PMC3618654", "sentence": "Results : A total 27 , out of 49 cases were positive for @GENE$ mutation – 7/21 ( 33 % ) from north India and 20/28 ( 65 % ) from south India . The commonest mutation was del exon 19 ( 62 % ) , followed by @VARIANT$ exon 21 ( 25 % ) , G719X exon 18 ( 7 % ) and insertion exon 20 ( 3 % ) . Patients were treated either with @DRUG$ or chemotherapy .", "label": "sensitivity"}
{"id": "23238589", "sentence": "Currently , a number of agents are under investigation , including @DRUG$ ( a reversible @GENE$ inhibitor ) , DCC-2036 ( a switch-pocket inhibitor ) and homoharringtonine ( omacetaxine ) . Although no clinical studies have investigated the value of IFNα in treating patients with the @VARIANT$ mutation , two case reports have recently been published .", "label": "response"}
{"id": "23493883", "sentence": "Inhibition of @GENE$ cell lines by @DRUG$ compared to erlotinib as shown by EC50 values Wild-type @VARIANT$ mutation L858R + T790M", "label": "sensitivity"}
{"id": "24964744", "sentence": "The PIK3CA mutation @VARIANT$ still became the most sensitive phenotype , but the effect of an AKT mutation produced a slightly more resistant phenotype ( IndexSUM = 227 ) when compared with the parental line ( IndexSUM = 188 ) . However , both showed sufficient cellular inhibition to be classed as active agents in this setting with an indexSUM & lt ; 300 representing 50 % inhibition across the range of concentrations tested [ ] . Sensitivity of @DRUG$ , erlotinib , ZSTK474 and sirolimus alone and in combination on the parental MCF10a breast cancer cell line compared with isogenic clones with EGFR , KRAS and @GENE$ mutations .", "label": "resistance or non-response"}
{"id": "24241536", "sentence": "Independent of the variant/classic diagnosis , IGHV4-34 expression is associated with higher disease burden at diagnosis , poor response to single agent @DRUG$ , and shorter overall survival . HCLc was recently shown to be almost universally driven by the oncogenic activating @VARIANT$ mutation in the @GENE$ .", "label": "None"}
{"id": "21445332", "sentence": "This association also suggests that enrichment of @GENE$ ; T variants in patients with preeclampsia and aHUS is functionally important , although its mechanism is as yet undefined . Mutations in Factor H The single factor H mutation ( @VARIANT$ ) in the PROMISSE cohort was extensively investigated and not shown to have a functional defect ( normal secretion in a transfection system , normal plasma levels , and normal to increased C3b binding and @DRUG$ activity ) ( unpublished data ) .", "label": "None"}
{"id": "23817662", "sentence": "Further studies of gefitinib revealed that this 4-anilinoquinazoline inhibitor , structurally similar to @DRUG$ , binds the @GENE$ c.2573T & gt ; G ( @VARIANT$ ) mutant with a 20-fold higher affinity compared to the wild-type enzyme .", "label": "sensitivity"}
{"id": "20633291", "sentence": "Secondary imatinib-refractory mutations @VARIANT$ Single mutation Activation loop Y823D Single mutation Activation loop V560D/V654A Double mutation Juxtamembrane domain/kinase domain I V560D/T670I Double mutation Juxtamembrane domain/kinase domain I Stable Transfection of CHO and @GENE$ Cells With Wild-Type and Mutant KIT", "label": "None"}
{"id": "24276125", "sentence": "Inhibition of these dually specific threonine/tyrosine kinases leads to down-regulation of the @GENE$ signalling pathway . In a phase III open-label clinical trial ( METRIC ) [ ] trametinib was shown to significantly improve rates of progression-free and overall survival compared with chemotherapy with dacarbazine or @DRUG$ ( 6 month overall survival of 81 % and 67 % respectively , patient crossover included , p = 0.01 ) , in patients with V600E or @VARIANT$ BRAF mutation positive metastatic melanoma .", "label": "None"}
{"id": "23864840", "sentence": "The ability of irreversible pan-HER inhibitors such as @DRUG$ and dacomitinib to overcome @VARIANT$ mediated resistance to gefitinib has been demonstrated in some preclinical studies ; therefore , they are being actively investigated . Dacomitinib showed a better response rate and prolonged response duration compared to erlotinib in patients without prior @GENE$ targeted therapy [ ] .", "label": "response"}
{"id": "22162641", "sentence": "Moreover , addition of Hsp90 inhibitors resulted in cell death in an ALK dependent cell line , tumor regression in an EML4-ALK xenograft , and regression of lung adenocarcinoma in the @GENE$ transgenic mouse . Most importantly , Hsp90 inhibitors lead to cell death in both crizotinib-sensitive and crizotinib-resistant ALK dependent cell lines , , including NSCLC cell lines harboring the ALK @VARIANT$ gatekeeper mutation which provides another alternate pathway to overcome resistance to crizotinib .", "label": "None"}
{"id": "24894453", "sentence": "Furthermore , we found that dimerization dependent L858R mutant shows a dramatic response to @DRUG$ , whereas tumors driven by dimerization independent mutants such as @VARIANT$ are resistant to the antibody , suggesting that there is a close correlation between dimerization dependency of lung cancer derived oncogenic mutant @GENE$ and pharmacological effects of cetuximab [ ] .", "label": "response"}
{"id": "24790411", "sentence": "Notably , OS was 23.3 months for patients receiving afatinib as second-line treatment , while the number of events to calculate median OS is still insufficient in the first-line group , suggesting a potentially significant difference in survival if @DRUG$ is given as first or successive lines of treatment of @GENE$ patients . Patients were stratified by mutation type ( exon 19 deletion , @VARIANT$ , or other ) and race ( Asian or non-Asian ) .", "label": "sensitivity"}
{"id": "24294007", "sentence": "Although a retrospective study and the PICCOLO ( @DRUG$ , Irinotecan and Ciclosporin in Colorectal Cancer Therapy ) trial have demonstrated a reduced response to cetuximab and panitumumab for patients with NRAS mutations , , further work is required to demonstrate the predictive capacity of these mutations . The serine/threonine-protein kinase B-Raf is an effector in the @GENE$ signaling pathway , downstream of K-Ras . Mutations in the proto-oncogene BRAF are present in 5 % –10 % of the metastatic CRC population and are also mutually exclusive of KRAS mutations . BRAF @VARIANT$ is the most common of all BRAF mutations ( present in 90 % of cases ) , and is enriched in a subset of patients who are female , greater than 70 years of age , with KRAS WT right sided colon cancer .", "label": "None"}
{"id": "21915126", "sentence": "Therefore , CPT-11 and @DRUG$ should have a synergistic beneficial effect in NSCLC patients with acquired resistance to gefitinib . The mechanistic reasons behind the resistance to @GENE$ TKI are different , probably involving @VARIANT$ secondary mutation and MET amplification .", "label": "resistance or non-response"}
{"id": "22751098", "sentence": "Vimentin IHC staining was scored using an established , clinically validated protocoland EGFR @VARIANT$ and @GENE$ amplification were assessed by sequencing and FISH , respectively , using established assays . Scale bars indicate in ( a ) 100 µM and ( b ) 10 µM . @DRUG$ treatment response in HCC827 tumor xenografts", "label": "None"}
{"id": "16953242", "sentence": "In fact , the pleiotropic effect of BCR/ABL transformation is mostly dependent on post-translational modifications ( e.g. phosphorylation ) of signalling molecules , like those involved in the RAS/MAPK , @GENE$ and STATs pathways , which control cell growth , survival and differentiation of haematopoietic cells by modulating the expression and/or activity of downstream effectors ( ; ) ( ) . Being the deregulated BCR/ABL kinase activity the cause of CML , targeting its catalytic domain was the most rationale approach for the rational development of small molecules that inhibit ABL kinase activity . In these CML-BC patients , imatinib resistance often depends on reactivation of BCR/ABL tyrosine kinase activity via mechanisms involving BCR/ABL overexpression , gene amplification or mutations that suppress @DRUG$ mediated kinase inhibition ( i.e. E255V and @VARIANT$ ) or disrupt imatinib binding ( i.e. T315I ) ( ) .", "label": "None"}
{"id": "24928511", "sentence": "More than 50 % of lung adenocarcinomas (LAD) from East Asian non-smokers harbor @GENE$ mutations , and these tumors have been termed oncogene addicted to reflect their dependence on EGFR mediated pro-survival signaling and their high susceptibility to apoptosis induced by EGFR-TKIs ( e.g. gefitinib and @DRUG$ ) ( ) . The most frequently occurring mutations in the EGFR gene ( in-frame deletion in exon 19 at codons 746–750 or a single-base substitution @VARIANT$ in exon 21 ) predict an improved clinical response to first-line oral EGFR-TKIs compared with standard platinum based chemotherapy in patients with advanced non-small-cell lung carcinoma ( NSCLC ) ( , ) .", "label": "sensitivity"}
{"id": "23423768", "sentence": "This has been reported by several prospective trials of @DRUG$ and erlotinib in @GENE$ mutated NSCLC , which showed RRs exceeding 70 % in tumors with exon 19 deletions or the @VARIANT$ mutation , with PFS intervals of 6-14 months and OS times beyond 20-24 months- .", "label": "sensitivity"}
{"id": "23963283", "sentence": "@VARIANT$ and MET amplification account for approximately 60–70 % of all known causes of acquired resistance to gefitinib or @DRUG$ ; these amplifications are not mutually exclusive and can be detected in the same resistant tumor or may occur independently in different metastatic sites in the same patient . Consequently , ongoing research has been focused on identifying the molecular mechanisms accounting for the 30–40 % of EGFR TKI-resistant , EGFR-mutant tumors that do not carry @GENE$ mutations or MET amplification .", "label": "resistance or non-response"}
{"id": "24982846", "sentence": "@DRUG$ @GENE$ Philadelphia chromosome [ t ( 9 ; 22 ) ] positive ; T315I mutation posit Indications and usage , clinical studies , patient counseling information Denileukin diftitox IL2RA CD25 antigen positive Indications and usage , warnings and precautions , clinical studies Erlotinib EGFR EGFR protein expression positive EGFR exon 19 deletion or exon 21 substitution ( @VARIANT$ ) positive Clinical pharmacology Indications and usage , dosage and administration , clinical pharmacology , clinical studies", "label": "None"}
{"id": "24947048", "sentence": "The @VARIANT$ mutation was detected only twice in CTCs captured from nine blood samples : one week after bone marrow biopsy , with 10/20 EpCAM captured cells having the mutation , and six weeks after bone marrow biopsy , with 2/7 EpCAM captured cells having the mutation . Drug treatments are noted ( @GENE$ = @DRUG$ , an mTOR inhibitor ) .", "label": "None"}
{"id": "23374602", "sentence": "Regarding KRAS , the same group reported in a pooled dataset of 579 @DRUG$ treated CRC patients that those with codon 13 KRAS mutant tumours ( @VARIANT$ ) had better outcomes ( HR for death 0.50 ) compared to patients with other @GENE$ mutant tumours [ ] .", "label": "resistance or non-response"}
{"id": "22132735", "sentence": "@GENE$ gene mutations indicate sensitivity to gefitinib , and it was demonstrated that about 85 % of patients with NSCLC who obtained benefit from @DRUG$ treatment were found to have mutations in exons 18 to 21 of the tyrosine kinase domain of the EGFR gene [ - ] . EGFR mutations in exon 19 ( short in-frame deletions ) or 21 @VARIANT$ ( point mutation ) affect the adenosine triphosphate ( ATP ) pocket of the tyrosine kinase domain leading to the activation of 4-anilinoquinazoline compounds , which function to compete with ATP [ ] .", "label": "sensitivity"}
{"id": "17106442", "sentence": "The response rate in the 23 patients treated by @DRUG$ after chemotherapy was 74 % ( 95 % CI : 56–92 % ) . When patients were stratified by @GENE$ mutation types , response rates were 75 % ( 15 out of 20 patients ) for exon 19 deletions , and 86 % ( six out of seven patients ) for @VARIANT$ .", "label": "sensitivity"}
{"id": "23824671", "sentence": "Third , Montagut et al. reported that @GENE$ @VARIANT$ ectodomain mutation prevents @DRUG$ binding and confers resistance to cetuximab .", "label": "resistance"}
{"id": "23566546", "sentence": "Case Histrogical type @GENE$ mutation status Brinkman index Treatment agent Response IL-8 ( ng/mL ) IL-10 ( ng/mL ) RANTES ( pg/ml ) 1 Ad Ex21 @VARIANT$ 900 gefitinib PR 5.79 1.67 2 2 Ad Ex21 L858R 0 erlotinib PR_3.33 94.2 1.41 3 Ad Ex19 del 0 erlotinib PR 4.09 126 2.13 4 Ad Ex21 L858R 0 gefitinib PR_3.92 18.1 1.85 5 Ad Ex21 L858R + Ex19 del 370 erlotinib PR 21.9 1.23 2.11 6 Ad Ex19 del 0 erlotinib PR 7.05 1.37 2.56 7 Ad Ex19 del 0 gefitinib PR 4.82 1.59 2.02 8 Ad Ex21 L858R 1640 gefitinib PR 54.9 2.7 2.38 9 Ad negative 400 erlotinib SD 34.9 3.39 3.66 10 Ad negative 0 erlotinib SD 27.1 4.94 2.25 11 Ad unknown 1800 erlotinib SD NE NE NE 12 Sq Ex19 del 3840 gefitinib SD 12.6 1.1 1.98 13 Ad Ex19 del 30 erlotinib SD 5.27 0.69 2.66 14 Ad Ex19 del 0 erlotinib SD 10.5 0.85 2.5 15 Ad unknown 300 erlotinib SD 7.69 2.61 1.7 16 La negative 2080 erlotinib SD NE NE NE 17 Sq Ex21 L858R 750 erlotinib SD 11.6 56.3 3.06 18 Ad unknown 600 erlotinib SD 13.7 1.1 2.82 19 Ad Ex21 L858R 0 erlotinib SD 20.6 11.6 0.783 20 Ad Ex19 del 0 @DRUG$ SD 14.8 2.07 2.02 21 Ad Ex21 L858R + Ex19 del 0 gefitinib SD 3.04 1.3 1.76 22 Ad Ex19 del 200 gefitinib SD 10.9 1.59 1.91 23 Sq unknown 1560 erlotinib PD NE NE NE 24 Ad negative 1080 erlotinib PD 25.2 8.15 1.57 25 Ad unknown 0 erlotinib PD NE NE NE 26 Ad Ex18 G719A 2000 erlotinib PD 11.6 4.48 3.12 27 Ad unknown 1410 erlotinib PD NE NE NE 28 Ad Ex19 del 1000 gefitinib PD 9.44 2.25 2.89 29 Ad negative 1100 erlotinib PD 56.3 5.63 2.16 30 Ad negative 2000 erlotinib PD 15.6 0.85 0.292 31 Ad negative 825 erlotinib PD 8.27 1.59 2.13 32 Ad Ex21 L858R 0 erlotinib PD 5.34 7.05 1.7 33 Ad negative 1680 erlotinib PD 57.7 1.63 2.06", "label": "sensitivity"}
{"id": "19707322", "sentence": "Nilotinib is approximately 30-fold more sensitive than imatinib in the killing of BCR-ABL dependent cells derived from patients with CML ( K562 and Ku-812F cells ) and cell lines ( 32D and baF3 ) , and it is active against 32/33 imatinib-resistant cell lines with @GENE$ mutations . The sensitivity of Bcr-Abl mutants to AMN107 can be summarized into 4 categories : high ( IC50 ≤ 70 nmol/L : M244V , G250E , Q252H , F3llL , F317L , M351T , V379I , L387M , H396P , H396R ) , medium ( IC50 ≤ 200 nmol/L : @VARIANT$ , E255K , F359V ) , low ( IC50 ≤ 450 nmol/L : Y253H , E255V ) , and insensitive ( IC50 & gt ; 2 μmol/L : T315I ) ( ) ( ) .", "label": "None"}
{"id": "24155950", "sentence": "Our results show that bortezomib and paclitaxel combined treatment is able to target the TKIs-resistant cell lines with the @VARIANT$ mutation in Bcr-Abl . Bortezomib in combination with the PLK1 inhibitor BI 2536 induces a significant downregulation of the total levels and phosphorylation of Bcr-Abl , a decrease of downstream phosphorylated @GENE$ and caspase dependent cell death in imatinib- , dasatinib- and nilotinib-resistant and -sensitive K562 cell lines", "label": "None"}
{"id": "23610714", "sentence": "@DRUG$ has been found to be effective not only for GIST with C-KIT mutations but also for GIST with PDGFRA mutations and for wild-type GISTs. , However , no adjuvant treatment is recommended in GISTs with the @VARIANT$ missense mutation in the @GENE$ exon 18 , which are known to be unresponsive to imatinib and showed very favorable outcome after surgery .", "label": "resistance or non-response"}
{"id": "25146448", "sentence": "MTNR1B , located on human chromosome 11q21–22 , is a member of the @GENE$ , and one of the functional and high-affinity @DRUG$ membrane receptors . MTNR1B is expressed in human and rodent pancreatic islets . Studies have shown that MTNR1B is a novel candidate gene for @VARIANT$ .", "label": "None"}
{"id": "20098423", "sentence": "( b ) ChIP for RNAPII , @VARIANT$ and S2P at the EGR1 and EGR2 loci following serum stimulation with or without @DRUG$ ( 150 nM ) pre-treatment . Average data from at least three independent experiments is represented . P-TEFb associates with @GENE$ ( a ) Silver stain of CDK8 and MED1 immunoprecipitates ( IPs ) .", "label": "None"}
{"id": "15736989", "sentence": "For example , imatinib is effective in treatment of chronic myelomonocytic leukemia with gene rearrangements that constitutively activate PDGFRB [ ] , of hypereosinophilic syndrome with activating mutations in @GENE$ [ ] , and of gastrointestinal stromal cell tumors associated with activating mutations in KIT [ ] ( all reviewed in [ ] ) . More recently , this paradigm has been extended to treatment of non-small cell lung cancer ( NSCLC ) . Several mutations have been identified in the context of epidermal growth factor receptor (EGFR) in patients with NSCLC that are associated with clinical response to the small-molecule EGFR inhibitors @DRUG$ ( Iressa ) or erlotinib ( Tarceva ) [ , , ] , including in-frame deletions such as del L747–E749 ; @VARIANT$ in exon 19 , or L858R in exon 21 .", "label": "None"}
{"id": "15737014", "sentence": "Using this insight , new small-molecule inhibitors have been identified that retain activity against the majority of imatinib-resistant @GENE$ mutants [ , ] . For example , in CML , a commonly found mutation is a C→T single nucleotide change that replaces threonine with isoleucine at position 315 ( @VARIANT$ ) in the ABL kinase domain [ , , ] .", "label": "None"}
{"id": "16933962", "sentence": "The DNA in the water phase was subsequently @DRUG$ precipitated . After centrifugation , the pellet was resuspended in 200 μl of 10 mM Tris-HCl and 10 mM EDTA ( pH 8.0 ) , and frozen at −20 °C until further analysis . The factor V Leiden mutation ( G1691A ) and the @GENE$ mutation ( @VARIANT$ ) were simultaneously detected by duplex polymerase chain reaction [ , ] .", "label": "None"}
{"id": "24638075", "sentence": "A number of effective @GENE$ therapeutic compounds against NSCLC , with EGFR activating mutations ( exon 19 deletions and @VARIANT$ point mutations ) , have been developed and approved for clinical use . These include both small molecule ( i.e. Erlotinib and @DRUG$ ) and antibody ( i.e. Cetuximab and Panitumumab ) inhibitors .", "label": "sensitivity"}
{"id": "22705791", "sentence": "We also analyzed ScMre11 @GENE$ at the latching loop ( Asp118 in S. pombe , ) , mutated in human NBSLD ( human Mre11 D113G ) . We utilized a plate survival assay to monitor the consequences of the above mutations in response to various genotoxic agents . mre11–R76A cells are as sensitive as mre11Δ cells to methyl methanesulfonate ( MMS ) , @DRUG$ ( HU ) and the Topoisomerase 1 inhibitor camptothecin ( CPT ) , whereas the conservative @VARIANT$ mutation causes no detectable hypersensitivity phenotype ( ) .", "label": "None"}
{"id": "15737014", "sentence": "Using this insight , new small-molecule inhibitors have been identified that retain activity against the majority of imatinib-resistant @GENE$ mutants [ , ] . For example , in CML , a commonly found mutation is a C→T single nucleotide change that replaces threonine with isoleucine at position 315 ( T315I ) in the ABL kinase domain [ , , ] . In GIST and HES , respectively , the analogous T670I mutation in KIT and @VARIANT$ mutation in PDGFR-alpha have been associated with acquired resistance to this drug [ , ] .", "label": "None"}
{"id": "24586514", "sentence": "We confirmed that @DRUG$ was effective against @GENE$ wild-type and @VARIANT$ mutant cells at low concentrations by cell proliferation and immunoblot assays .", "label": "response"}
{"id": "21042543", "sentence": "A thymine to adenine transversion mutation results in the substitution of valine with glutamate ( V600E ) and converts B-RAF into a dominant transforming protein that causes the constitutive activation of the @GENE$ pathway independently of RAS . The @VARIANT$ B-RAF mutation appears in 4 % –15 % of CRC.– The possible relationship between of B-RAF mutational status and response to treatment with @DRUG$ in 48 patients with mCRC was investigated by Benvenuti et al . B-RAF mutations were detected in 12,5 % tumors and they were mutually exclusive with K-RAS alterations .", "label": "None"}
{"id": "23238683", "sentence": "We first investigated the effect of these ITKs on the viability of murine Ba/F3 cells , carrying wild type ( WT ) BCR-ABL , @VARIANT$ or G250E-BCR-ABL mutation . As shown in Figure , BaF3 cells expressing native BCR-ABL were highly sensitive to imatinib , dasatinib and @DRUG$ , whereas BaF3-T315I-BCR-ABL and @GENE$ cells were resistant to both imatinib and dasatinib .", "label": "response"}
{"id": "20844582", "sentence": "@GENE$ cells were cotransfected with plasmids expressing wild type ( WT ) VHL , VHL plus full length PIASy or its deletion mutant ( ΔC ) of VHL binding domain , or VHL @VARIANT$ alone . 48 h post-transfection , cell lysates treated with cycloheximide ( @DRUG$ ) for 0 , 1 , 2 and 4 hours in the presence or absence of MG132 was subjected to immunoblot as indicated .", "label": "None"}
{"id": "24419415", "sentence": "Because previous phase 3 trials that investigated @DRUG$ or irreversible TKIs for NSCLC with EGFR mutations did not include uncommon @GENE$ mutations , further clinical studies may need to be performed. , , Another possible strategy for the treatment of uncommon EGFR mutations is the combination of EGFR-TKIs and cytotoxic agents . Our group has undertaken a randomized phase 3 trial to compare gefitinib plus carboplatin plus pemetrexed with gefitinib monotherapy for patients with NSCLC with an exon 19 deletion or an @VARIANT$ , G719X , or L861Q EGFR mutation ( NEJ009 ; University Hospital Medical Information Network Clinical Trials Registry [ UMIN-CTR ] number , UMIN000006340 ) .", "label": "sensitivity"}
{"id": "25562798", "sentence": "The mechanisms of acquired resistance to @DRUG$ are only just coming to light but , analogous to acquired resistance to EGFR inhibitors , secondary mutations in @GENE$ that render the ALK kinase resistant to inhibition by crizotinib have been identified [ , , ] . These mutations including @VARIANT$ in the ALK kinase domain may be susceptible to inhibition with novel ALK inhibitors e.g. , LDK378 , AP26113 , or AF802 .", "label": "resistance"}
{"id": "24348666", "sentence": "Although the resistant cell line HCG827GR does not have the EGFR @VARIANT$ mutation , it was found to have MET amplification . MET is a receptor tyrosine kinase that binds to hepatocyte growth factor (HGF) and is associated with the development of various human cancers . Therefore , EGFR-TKIs fail to inhibit the PI3K/Akt pathway dependent growth signal because the constitutive phosphorylation of @GENE$ by MET occurs independent of EGFR activation , which causes the cells to acquire resistance to @DRUG$ .", "label": "None"}
{"id": "22101934", "sentence": "HEK293 GnTi− cells were transfected with the plasmid DNA encoding tEGFR , and cultured in the presence and absence of 50 nM @DRUG$ . ( d ) Coomassie blue stained SDS-PAGE analysis of the purified @VARIANT$ tEGFR and Δ746–750 tEGFR with either EGF or Cetuximab ( Cetux ) as ligand . Role of the asymmetric dimer interface for oncogenic @GENE$ activation ( a ) Comparison of the specific activities of L858R–EGF , L858R I706Q–EGF , and L858R V948R–EGF tEGFRs .", "label": "sensitivity"}
{"id": "15736989", "sentence": "Several mutations have been identified in the context of @GENE$ patients with NSCLC that are associated with clinical response to the small-molecule EGFR inhibitors gefitinib ( @DRUG$ ) or erlotinib ( Tarceva ) [ , , ] , including in-frame deletions such as del L747–E749 ; A750P in exon 19 , or @VARIANT$ in exon 21 .", "label": "sensitivity"}
{"id": "15737014", "sentence": "We show here , through molecular analysis of tumor material from three patients and one NSCLC cell line , as well as additional biochemical studies , that acquired clinical drug resistance to @DRUG$ or erlotinib is indeed associated with the @VARIANT$ mutation . Importantly , we find that the T790M mutation confers drug resistance not just to wild-type @GENE$ but also to mutant EGFRs associated with clinical responsiveness to EGFR tyrosine kinase inhibitors [ , , ] .", "label": "resistance or non-response"}
{"id": "25077070", "sentence": "PIK3CA Not distinctive 2-4 % Mixed reports Not distinctive ADC and SqCC Mutations in E545K AND H1047R ( most common ) , also E542K and @VARIANT$ @DRUG$ , Tensirolimus , GDC-0941 , XL-147 , Others AKT1 @GENE$ .", "label": "None"}
{"id": "23864840", "sentence": "A different response to the same @GENE$ regimen after a drug holiday can be explained with tumor heterogeneity . In a retrospective analysis of an erlotinib retrial , Becker et al. [ ] reported five cases of the @VARIANT$ mutation and exon 19 deletions in rebiopsy specimens taken before the retrial of @DRUG$ .", "label": "resistance or non-response"}
{"id": "25232318", "sentence": "Moreover , no concurrent KRAS mutations are known to exist in @GENE$ amplified patients who have responded to @DRUG$ [ , ] , but only limited molecular testing was performed on these tumors . Dual MET amplified , KRAS mutated tumors have been identified at a low frequency in the TCGA database ( February 2014 ) as 1 of 230 NSCLC harboring concurrent MET amplification and KRAS G12V and 1 of 219 stomach adenocarcinoma harboring MET amplification and KRAS @VARIANT$ .", "label": "None"}
{"id": "15737014", "sentence": "Sequencing Chromatograms with the @VARIANT$ EGFR Exon 20 Mutation in Various Clinical Specimens and the NSCLC Cell Line H1975 ( A–C ) In all three patients—patient 1 ( A ) , patient 2 ( B ) , and patient 3 ( C ) —the secondary T790M mutation was observed only in lesions obtained after progression on either gefitinib or @DRUG$ . ( D ) Cell line H1975 contains both an exon 21 L858R mutation ( upper panel ) and the exon 20 T790M mutation ( lower panel ) . The asterisks indicate a common SNP ( A or G ) at nucleotide 2361 ; the arrows indicate the mutation at nucleotide 2369 ( C→T ) , which leads to substitution of methonine ( @GENE$ ) for threonine ( ACG ) at position 790 .", "label": "None"}
{"id": "23875003", "sentence": "Exogenous lipoic acid equilibrates among different intracellular and extracellular compartments but can not substitute for covalently bound lipoic acid ( as the @DRUG$ of mitochondrial complexes such as pyruvate dehydrogenase and α-ketoglutarate dehydrogenase ) . This study is aimed at establishing the effects of lipoic acid , on glucose uptake , insulin signaling through the @GENE$ pathway , and synaptic plasticity on a triple transgenic mouse model of Alzheimer’s disease ( 3xTg-AD ) . This transgenic model harbors PS1 ( M146V ) , APP ( Swe ) , and tau ( @VARIANT$ ) transgenes , shows progressive development of both plaques and tangles with increasing age in a region specific manner : ~6 month-old 3xTg-AD mice show diffuse amyloid plaques in different regions but tangle pathology is established at ~12 months [ ] .", "label": "None"}
{"id": "25079768", "sentence": "Mutation D802V in CSF1-R is equivalent to @VARIANT$ in @GENE$ and was reported as stabilizing the active kinase domain structure to which imatinib does not bind , , as suggested by the resulting resistance to @DRUG$ .", "label": "None"}
{"id": "23818899", "sentence": "In the case of melanoma , for example , a BRAF mutation test is used to determine if a BRAF @VARIANT$ mutation exists in the patient sample , and if present , that patient will receive a customized treatment with the drug Zelboraf , which is effective only for BRAFV600E positive melanomas . Nonsmall cell lung cancer ( NSCLC ) patients carrying an @GENE$ mutation are treated with the drug @DRUG$ , which is specific for this type of mutation , whereas NSCLC patients having an EGFR mutation would receive alternative customized treatments .", "label": "None"}
{"id": "17877814", "sentence": "Images show that YFP-EGFR @VARIANT$ did not effectively induce phosphorylation of endogenous @GENE$ in MCF-7 cells , and did not relocate into fibrils upon @DRUG$ treatment .", "label": "None"}
{"id": "16173832", "sentence": "Pao et al. and Kobayashi et al. identified four cases with lung adenocarcinoma harboring pre existing mutations of @GENE$ as delL747–E749 plus A750P , delE746–A750 , or delL747–S752 , prior to the use of gefitinib or @DRUG$ [ , ] . All of them had exposure to previous systemic chemotherapies and took a small-molecule tyrosine kinase inhibitor as the second- or third-line therapy , then all acquired a second mutation @VARIANT$ in the following months after disease progression .", "label": "resistance or non-response"}
{"id": "25562798", "sentence": "Firstly , a secondary mutation , the @VARIANT$ mutation within exon 20 of EGFR , is responsible for about 50 % of instances of acquired resistance [ , ] . This mutation increases the affinity of the EGFR for ATP approximately 10-fold and allows ATP to competitively displace @DRUG$ and erlotinib from @GENE$ [ ] .", "label": "resistance or non-response"}
{"id": "19707354", "sentence": "Two novel kinase inhibitors , dasatinib ( Sprycel™ ; Bristol-Myers Squibb ) and nilotinib ( Tasigna™ ; Novartis ) , have shown promising clinical activity in some imatinib-refractory patients and both have recently earned FDA approval . Unfortunately , patients with the @VARIANT$ @GENE$ mutation do not respond to these new drugs ( ; ) .", "label": "None"}
{"id": "25563355", "sentence": "Another retrospective study reported a small group ( 14 patients ) of patients that was heavily treated and then re-treated with @DRUG$ after a median interval from the discontinuation of @GENE$ to the second episode of 9.5 months ( 3–36 months ) [ ] . The RR was 36 % ( n = 5 ) , and the disease control rate was 85.7 % ( n = 12 ) . Before beginning the re-treatment , @VARIANT$ was detected in 36 % of patients ( five of 14 ) .", "label": "resistance or non-response"}
{"id": "24348666", "sentence": "Moreover , in all the 4 cases with MET amplification , a higher expression of HGF was observed after @DRUG$ treatment than before treatment . These results indicate that HGF accelerates the expansion of the tumor cells with MET amplification . The cells with MET amplification as the @VARIANT$ mutation was present in a small proportion of the tumor cells before @GENE$ treatment and became dominant during treatment with EGFR-TKIs , suggesting that HGF may play an important role in this process .", "label": "resistance or non-response"}
{"id": "25032026", "sentence": "In murine myeloid cell lines , bosutinib demonstrated inhibition against 16 of 18 imatinib-resistant forms of @GENE$ Specifically , @DRUG$ did not inhibit @VARIANT$ and V299L mutations ( Pfizer , 2012 ) .", "label": "None"}
{"id": "23566546", "sentence": "Case Histrogical type @GENE$ mutation status Brinkman index Treatment agent Response IL-8 ( ng/mL ) IL-10 ( ng/mL ) RANTES ( pg/ml ) 1 Ad Ex21 @VARIANT$ 900 gefitinib PR 5.79 1.67 2 2 Ad Ex21 L858R 0 erlotinib PR_3.33 94.2 1.41 3 Ad Ex19 del 0 erlotinib PR 4.09 126 2.13 4 Ad Ex21 L858R 0 gefitinib PR_3.92 18.1 1.85 5 Ad Ex21 L858R + Ex19 del 370 erlotinib PR 21.9 1.23 2.11 6 Ad Ex19 del 0 erlotinib PR 7.05 1.37 2.56 7 Ad Ex19 del 0 gefitinib PR 4.82 1.59 2.02 8 Ad Ex21 L858R 1640 gefitinib PR 54.9 2.7 2.38 9 Ad negative 400 @DRUG$ SD 34.9 3.39 3.66 10 Ad negative 0 erlotinib SD 27.1 4.94 2.25 11 Ad unknown 1800 erlotinib SD NE NE NE 12 Sq Ex19 del 3840 gefitinib SD 12.6 1.1 1.98 13 Ad Ex19 del 30 erlotinib SD 5.27 0.69 2.66 14 Ad Ex19 del 0 erlotinib SD 10.5 0.85 2.5 15 Ad unknown 300 erlotinib SD 7.69 2.61 1.7 16 La negative 2080 erlotinib SD NE NE NE 17 Sq Ex21 L858R 750 erlotinib SD 11.6 56.3 3.06 18 Ad unknown 600 erlotinib SD 13.7 1.1 2.82 19 Ad Ex21 L858R 0 erlotinib SD 20.6 11.6 0.783 20 Ad Ex19 del 0 erlotinib SD 14.8 2.07 2.02 21 Ad Ex21 L858R + Ex19 del 0 gefitinib SD 3.04 1.3 1.76 22 Ad Ex19 del 200 gefitinib SD 10.9 1.59 1.91 23 Sq unknown 1560 erlotinib PD NE NE NE 24 Ad negative 1080 erlotinib PD 25.2 8.15 1.57 25 Ad unknown 0 erlotinib PD NE NE NE 26 Ad Ex18 G719A 2000 erlotinib PD 11.6 4.48 3.12 27 Ad unknown 1410 erlotinib PD NE NE NE 28 Ad Ex19 del 1000 gefitinib PD 9.44 2.25 2.89 29 Ad negative 1100 erlotinib PD 56.3 5.63 2.16 30 Ad negative 2000 erlotinib PD 15.6 0.85 0.292 31 Ad negative 825 erlotinib PD 8.27 1.59 2.13 32 Ad Ex21 L858R 0 erlotinib PD 5.34 7.05 1.7 33 Ad negative 1680 erlotinib PD 57.7 1.63 2.06", "label": "sensitivity"}
{"id": "17973572", "sentence": "To prove the functional significance of the @VARIANT$ mutation , we generated Ba/F3 cell lines stably expressing mutant EGFR constructs [ ] . These cell lines , including L858R-L747S , proliferated in the absence of IL3 . @GENE$ cells were extremely sensitive to @DRUG$ ( D ) , whereas Ba/F3-L858R-T790M cells were highly resistant up to 1 μM gefitinib .", "label": "None"}
{"id": "23503662", "sentence": "Likewise , alteration of a mCRY2 residue in the @DRUG$ pocket also compromised complex association ( @VARIANT$ , , ) . These results pinpoint the Fbxl3 C-terminal tail as a “hotspot” of the interface and suggest a possible antagonistic role of FAD in regulating Fbxl3-mCRY2 interaction . Our mutagenesis analysis also established the Fbxl3 @GENE$ subdomain as a second critical docking site for mCRY2 .", "label": "None"}
{"id": "24187524", "sentence": "Furthermore , there are three small-molecule inhibitors of the tyrosine kinase domain ( TKIs ) that interfere with the binding of ATP , also approved to treat non-small cell lung cancer ( i.e. , @DRUG$ , erlotinib , and lapatinib ) [ ] . These therapeutic molecules are limited by the development of resistance mutations such as @VARIANT$ in @GENE$ , which necessitates the screening of new inhibitors .", "label": "resistance or non-response"}
{"id": "24201813", "sentence": "To identify novel mechanism ( s ) of resistance to BRAF inhibition , we generated PLX4032-resistant cell lines by chronic exposure of a @GENE$ ( @VARIANT$ ) -positive melanoma cell line to @DRUG$ .", "label": "None"}
{"id": "25580271", "sentence": "The National Cancer Institute ( NCI ) Adjuvant Lung Cancer Enrichment Marker identification and Sequencing Trial ( ALCHEMIST ) investigating adjuvant erlotinib in patients with @GENE$ mutant NSCLC with the primary end-point of overall survival will define the role of adjuvant @DRUG$ [ ] . First-line therapy for EGFR mutant NSCLC Two phase III trials compared afatinib to a platinum-doublet in patients with advanced EGFR mutant NSCLC , and a combined analysis for overall survival was presented at ASCO , as well as subset analyses based on EGFR mutation subtype ( exon 19 deletion and exon 21 @VARIANT$ point mutation ) [ ] .", "label": "sensitivity"}
{"id": "25054154", "sentence": "We utilised three complexes , namely , native ( ALK-crizotinib ) , @VARIANT$ ( @GENE$ F1174L-crizotinib ) , and R1275Q ( ALK R1275Q-crizotinib ) for our analysis .", "label": "resistance"}
{"id": "23405260", "sentence": "Only the CAL-33 cell line exhibited a mutation in exons 9 or 20 of @GENE$ ( a heterozygous @VARIANT$ mutant ) and only UMSCC-74A exhibited a KRAS mutation ( a heterozygous G12D mutant ) . Both of these cell lines had a lower sensitivity to dacomitinib although CAL33 was somewhat responsive to @DRUG$ .", "label": "resistance or non-response"}
{"id": "22815900", "sentence": "In our present study , erlotinib-resistant cell lines were established ; PC9/ER1 from PC9 cells harboring delE746-A750 mutation , and 11–18/ER1-7 and 11–18/ER2-1 from 11–18 cells harboring @VARIANT$ mutation . Gefitinib-resistant cell lines were also established ( 11–18/GEF10-1 and 11–18/GEF20-1 ) from 11–18 cells . Gene amplification and increased copy number of the @GENE$ gene associated with the response rate to EGFR targeted drugs in NSCLC , breast cancer and colon cancer , .", "label": "sensitivity"}
{"id": "16187797", "sentence": "This compound was previously found to be active against @GENE$ containing the exon 20 point mutation @VARIANT$ , associated with resistance to @DRUG$ and erlotinib [ ] .", "label": "resistance or non-response"}
{"id": "21605429", "sentence": "@GENE$ secondary mutations are rare . The @VARIANT$ was identified in one patient with primary mutation V561D , which is known to be associated with @DRUG$ resistance [ ] .", "label": "resistance or non-response"}
{"id": "17973573", "sentence": "H1975 cells harbor two mutations ( L858R and @VARIANT$ ) in the EGFR gene . All cells were maintained in RPMI-1640 medium supplemented with 10 % heat inactivated fetal calf serum ( FCS , JRH Biosciences , Lenexa , Kansas ) . The @GENE$ inhibitor QVD-OPH ( MP Biomedicals , Aurora , Ohio ) was used at 25 μM and added to cells 30 min prior to treatment with @DRUG$ .", "label": "None"}
{"id": "24555578", "sentence": "As in that case report , our patient exhibited sensitivity to @DRUG$ in brain metastases , even though the cancer cells in the pleural effusion had acquired a resistant mutation to @GENE$ , @VARIANT$ .", "label": "resistance or non-response"}
{"id": "PMC4041556", "sentence": "Resistance mechanisms to @DRUG$ are multiple , and include ALK-dominant mechanisms such as resistance mutations and copy number gain , and ALK non-dominant mechanisms through the outgrowth of clones containing a separate activated oncogene . In contrast to the @GENE$ setting , where the @VARIANT$ mutation predominates , the spectrum of ALK resistance mutations is broad .", "label": "None"}
{"id": "20190765", "sentence": "cDNA for @VARIANT$ EGFR and L858R/T790M @GENE$ were provided by Dr. William Pao ( Vanderbilt University , Nashville , TN ) , ACK was provided by Dr. Nupam Mahajan ( Moffitt Cancer Center , FL ) , and Human BRK was purchased from ORIGENE ( Rockville , MD ) . Lentiviral plasmids containing WT and gatekeeper SRC , FYN , LYN , LCK , ABL , DDR1 , FRK , EphB1 , EphA2 and EphA4 were generously provided by Dr. Jinyan Du and Dr. Todd Golub ( The Broad Institute , MA ) . @DRUG$ was provided by OSI Pharmaceuticals ( Melville , NY ) and dasatinib by Bristol-Myers Squibb ( New Brunswick , NJ ) .", "label": "sensitivity"}
{"id": "24986269", "sentence": "Samples containing 100 ng of Arabidopsis wild type bulk genomic DNA were digested with 1 Unit of nuclease Bal 31 from New England BioLabs ( catalogue # @VARIANT$ ) at 30°C , in the presence of 1× @GENE$ 31 reaction buffer and in a final volume of 20 μL during different periods of time . The reactions were stopped by adding 0.8 μL of EGTA 0.5 M pH 8.0 and incubating at 65°C during 5 minutes . Then , 280 μL of water were added to all the samples , which were phenol/chloroform extracted , precipitated with @DRUG$ and resuspended in 30 μL of water .", "label": "None"}
{"id": "25465236", "sentence": "( C ) EGFR @VARIANT$ mutant does not resemble pEGFR unlike the EGFR L858R mutant shown in B. ( D–F ) increased inhibition potency for Erlotinib against @GENE$ L858R mutant compared to EGFR WT protein and subsequent decrease in potency for @DRUG$ against EGFR L858R + E884K double mutant .", "label": "resistance or non-response"}
{"id": "25056273", "sentence": "However , mutations of the PP1 binding motif not only affect BRCA1 interaction with PP1α but may also reduce BRCA1 dephosphorylation as the PP1 binding motif deleted BRCA1 protein ( BRCA1GFP DEL ) displayed increased S1423 phosphorylation at the basal level and after @DRUG$ treatment when expressed in the ES2 ovarian cancer cell line . BRCA1 interacts with many proteins , and it is possible that inappropriate phosphorylation patterns may affect these interactions , thereby impacting other BRCA1 functions such as transcription or E3 @GENE$ . These additional adverse effects to BRCA1 function may underlie the DNA repair deficiencies observed for @VARIANT$ .", "label": "None"}
{"id": "21701703", "sentence": "In @GENE$ , the main mutation seen after extended treatment with @DRUG$ is the @VARIANT$ mutation [ ] ; the T766M resistance mutation was correctly predicted in EGFR through homology with resistance mutations seen in BCR-ABL , which was verified in vitro [ ] and discovered several years later in patients [ - ] .", "label": "None"}
{"id": "25285017", "sentence": "In terms of EGFR targeted therapy , resistant mechanisms ( eg , EGFR @VARIANT$ mutation and MET amplification ) emerge as a result of the tumor evolution after @GENE$ inhibition by @DRUG$ or erlotinib .", "label": "resistance or non-response"}
{"id": "21980431", "sentence": "This is in contrast to the overlapping resistance profiles displayed for ABL inhibitors , such as imatinib , nilotinib , and @DRUG$ , which all show resistance to the @VARIANT$ gatekeeper mutation , . There were some similarities observed between the resistance phenotype described in our studies and those reported by others . For instance , Piloto et al. reported activation of the Ras/MEK/MAPK signaling pathway in association with CEP-5214 and CEP-701 resistance , and we similarly observed elevated phospho-ERK1/ERK2 and @GENE$ in MOLM13-R-PKC412 cells , consistent with elevated FLT3 protein levels .", "label": "None"}
{"id": "7317275", "sentence": "Antitumor activity of alkylesters of @GENE$ furanosyl - @DRUG$ 5 ' - phosphate against murine lymphoma @VARIANT$ to 1-fi-D-ribofurano- syl-5-fluorouracil .", "label": "None"}
{"id": "25222496", "sentence": "However , an in vitro study showed that the growth of NSCLC cell lines harboring exon 19 deletion or L858R mutation were almost equally inhibited by equivalent concentrations of @DRUG$ , and the degree of @GENE$ phosphorylation . Secondly , @VARIANT$ mutation , which was associated with acquired resistance to reversible EGFR-TKIs , might occur more frequently in L858R mutation .", "label": "resistance or non-response"}
{"id": "25465236", "sentence": "( C ) EGFR T790M mutant does not resemble pEGFR unlike the EGFR @VARIANT$ mutant shown in B. ( D–F ) increased inhibition potency for @DRUG$ against @GENE$ L858R mutant compared to EGFR WT protein and subsequent decrease in potency for Erlotinib against EGFR L858R + E884K double mutant .", "label": "sensitivity"}
{"id": "24495353", "sentence": "Rank Entrez ID Gene symbol Entrez ID Gene symbol Entrez ID Gene symbol 1 28978 TMEM14A 79776 ZFHX4 1727 CYB5R3 2 1843 DUSP1 4701 NDUFA7 7083 TK1 3 51022 GLRX2 715 @VARIANT$ 1292 COL6A2 4 1434 CSE1L 79818 ZNF552 857 CAV1 5 8522 GAS7 4046 LSP1 5437 POLR2H 6 51668 HSPB11 1727 CYB5R3 9833 MELK 7 10456 HAX1 357 SHROOM2 54861 SNRK 8 9902 MRC2 283298 OLFML1 4830 NME1 9 4706 NDUFAB1 23179 RGL1 231 AKR1B1 10 23560 GTPBP4 1809 DPYSL3 10418 SPON1 11 79633 FAT4 857 CAV1 2350 FOLR2 12 10418 SPON1 274 BIN1 10979 FERMT2 13 471 ATIC 79833 GEMIN6 11096 ADAMTS5 14 6403 SELP 11222 MRPL3 4638 MYLK 15 23421 ITGB3BP 23244 PDS5A 9448 MAP4K4 16 23452 ANGPTL2 6241 RRM2 54922 RASIP1 17 54861 SNRK 1289 COL5A1 6934 TCF7L2 18 2034 EPAS1 8434 RECK 4072 @GENE$ 19 30008 EFEMP2 429 ASCL1 4701 NDUFA7 20 25999 CLIP3 3426 CFI 404672 GTF2H5 21 4311 MME 332 BIRC5 6241 RRM2 22 4747 NEFL 2 A2M 2192 FBLN1 23 1809 DPYSL3 10730 YME1L1 25959 KANK2 24 28998 MRPL13 11130 ZWINT 55651 NHP2 25 25959 KANK2 1292 COL6A2 5050 PAFAH1B3 Lists of the top 25 of most influential genes in influence networks based on coexpression among genes in ER + breast tumors before , during , and after a course of neoadjuvant treatment with the drug @DRUG$ .", "label": "None"}
{"id": "23864840", "sentence": "After re-introduction of @DRUG$ , 25 % achieved partial remission and 75 % showed @GENE$ . A different response to the same EGFR-TKI regimen after a drug holiday can be explained with tumor heterogeneity . In a retrospective analysis of an erlotinib retrial , Becker et al. [ ] reported five cases of the @VARIANT$ mutation and exon 19 deletions in rebiopsy specimens taken before the retrial of erlotinib .", "label": "None"}
{"id": "25157335", "sentence": "Both median PFS and ORR were significantly better in patients treated with @DRUG$ compared with chemotherapy . AZD9291 and CO-1686 are irreversible selective EGFR inhibitors , which demonstrate significant activity in patients with acquired resistance to first-generation @GENE$ , and are currently under development . In patients with tumors harboring @VARIANT$ mutation , AZD9291 and CO-1686 show promising 64 and 58 % ORR , respectively ( , ) .", "label": "response"}
{"id": "24931142", "sentence": "Then she progressed after 1.3 months of experimental therapy with an oncolytic virus and ultimately responded very well to a combination of bevacizumab and @DRUG$ , which she received twice with a PFS of 16.8 months and 10.1 months , respectively . NGS performed on a tumor sample from a liver biopsy obtained at the time of diagnosis revealed NF1 mutation R1241* , @GENE$ truncation ( exon 12 ) , and CTNNB1 mutation @VARIANT$ ( Figure ) .", "label": "None"}
{"id": "25536104", "sentence": "Based on the current knowledge of @GENE$ biology , @DRUG$ or lapatinib therapy may be value in the extracellular domain mutations but could be of limited clinical benefit for kinase domain mutations and no response to either agents was noted in our cases . Bose et al. , noted that @VARIANT$ mutation was associated with negative ERBB2 protein expression and resistance to lapatinib .", "label": "sensitivity"}
{"id": "23085539", "sentence": "OSI-027 has been shown to inhibit the growth of imatinib-resistant CML cells which contain the BCR-ABL @VARIANT$ mutation that are resistant to all @GENE$ inhibitors [ ] .", "label": "None"}
{"id": "25114510", "sentence": "Acquired resistance , including EGFR secondary mutations ( @VARIANT$ and other rare mutations ) , MET gene amplification , @GENE$ gene downregulation , high-level hepatocyte growth factor expression , epithelial–mesenchymal transition , and conversion to small cell lung cancer , – continues to restrict the durable long-term outcomes of @DRUG$ .", "label": "None"}
{"id": "24294007", "sentence": "Although a retrospective study and the PICCOLO ( @DRUG$ , Irinotecan and Ciclosporin in Colorectal Cancer Therapy ) trial have demonstrated a reduced response to cetuximab and panitumumab for patients with NRAS mutations , , further work is required to demonstrate the predictive capacity of these mutations . The serine/threonine-protein kinase B-Raf is an effector in the @GENE$ signaling pathway , downstream of K-Ras . Mutations in the proto-oncogene BRAF are present in 5 % –10 % of the metastatic CRC population and are also mutually exclusive of KRAS mutations . BRAF @VARIANT$ is the most common of all BRAF mutations ( present in 90 % of cases ) , and is enriched in a subset of patients who are female , greater than 70 years of age , with KRAS WT right sided colon cancer .", "label": "None"}
{"id": "25465236", "sentence": "( C ) EGFR T790M mutant does not resemble pEGFR unlike the @GENE$ @VARIANT$ mutant shown in B. ( D–F ) increased inhibition potency for Erlotinib against EGFR L858R mutant compared to EGFR WT protein and subsequent decrease in potency for @DRUG$ against EGFR L858R + E884K double mutant .", "label": "sensitivity"}
{"id": "23852704", "sentence": "While almost all of the known @GENE$ mutations at codons 12 are associated with lack of benefit from @DRUG$ or panitumumab , a specific mutation at codon 13 , i.e. , @VARIANT$ may be an exception .", "label": "resistance or non-response"}
{"id": "23994953", "sentence": "Indeed , the fact that the combination of erlotinib plus IGF-1R inhibitors ( I-OMe-AG538 or AG1024 ) fully prevents the acquired erlotinib-resistant phenotype is consistent with IGF-1R playing a major role in this process . While preparing this manuscript , Cortot et al. reported that PC-9 derived clones with acquired resistance to mutant-selective @GENE$ inhibitors and irreversible quinazoline EGFR inhibitors in the absence of EGFR @VARIANT$ demonstrate a significantly activated IGF-1R signaling , and pharmacological inhibition of IGF-1R restored sensitivity to EGFR inhibitors .", "label": "resistance or non-response"}
{"id": "24223798", "sentence": "In particular , epidermal growth factor receptor tyrosine kinase inhibitors ( @GENE$ ) , such as @DRUG$ and erlotinib , have been developed as a novel treatment option for patients with non–small cell lung cancers ( NSCLCs ) that possess somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene – . Prospective clinical trials of EGFR-TKI treatment in NSCLC patients with activating EGFR mutations , such as delE746-A750 ( exon 19 ) and @VARIANT$ ( exon 21 ) , have demonstrated high clinical response rates of approximately 80 % – .", "label": "sensitivity"}
{"id": "24312144", "sentence": "Sequist et al that studied neratinib to overcome @VARIANT$ resistance mutation reported responses in G719X @GENE$ mutation , supporting the need of genetic information on trials of targeted agents . According to Ramalingam et al , dacomitinib demonstrated significantly improved PFS versus erlotinib , with acceptable toxicity . Moreover , @DRUG$ ( marketed as Erbitux® ; Dako , Copenhagen , Denmark ) is a 152 kDa chimeric monoclonal antibody of the immunoglobulin G1 subclass produced in mammalian cell culture by mouse myeloma cells .", "label": "response"}
{"id": "21437184", "sentence": "Several compounds ( @DRUG$ , PLX4720 , and GDC-0879 ) which selectively inhibit the kinase enzyme BRAF containing the @VARIANT$ mutation are in clinical development [ ] . In BRAF mutant cancer cell lines , these selective BRAF inhibitors potently block RAF-MEK-ERK signaling . However , in those tumors that are BRAF WT , but possess a KRAS mutation , these BRAF inhibitors activate this same pathway and therefore should be avoided in those cancers with @GENE$ mutations [ – ] .", "label": "None"}
{"id": "24244732", "sentence": "Although this hypothesis has not been directly tested for @DRUG$ specifically , @GENE$ hypomorphs in C. elegans do have reduced sensitivity to volatile anaesthetics [ ] emphasizing a potential convergence of cellular effectors of various anaesthetics at the presynaptic terminal . On the other hand , the @VARIANT$ mutation acts to increase Rab3 binding , at least for Munc18 [ ] .", "label": "None"}
{"id": "21814611", "sentence": "In this case , because HBeAg was detected and HBV DNA was still high 3 months after administration of clevudin , it should be clarified that the mutations in the overlapping frame gene regions , S codon L213I ( P codons P221T and @VARIANT$ ) , may be associated with escape mutation as well as drug resistance . An interesting point of this case concerns the sustained HCV suppression , which occurred even with insufficient treatment of @DRUG$ .", "label": "None"}
{"id": "23994953", "sentence": "Using the erlotinib-sensitive EGFR mutant NSCLC cell line HCC4006 harboring the delL747-E749 , @VARIANT$ mutation in EGFR exon 19 , Suda et al. established that mesenchymal status , not a specific oncogenic activated protein , could sufficiently promote loss of EGFR dependence to confer resistance to @DRUG$ . More recently , Chang et al. confirmed that in the absence of the common second-site EGFR mutation T790M or MET amplification , acquired resistance to gefitinib occurs in EGFR mutated @GENE$ cells that have undergone EMT .", "label": "None"}
{"id": "15737014", "sentence": "By contrast , wild-type and mutant EGFRs containing the T790M mutation did not display a significant change in either phosphotyrosine induction or @GENE$ : t-EGFR ratios ( A and B ) . Similar results were obtained using @DRUG$ against wild-type and del E747–L747 ; A750P EGFRs in comparison to the corresponding mutants containing the @VARIANT$ mutation ( C ) .", "label": "resistance or non-response"}
{"id": "24523596", "sentence": "Several studies have reported renal failure and tumor lysis syndrome during TKI based molecular targeted therapies , including with sorafenib for hepatocellular carcinoma , with @DRUG$ for chronic myelogenous leukemia , and with flavopiridol for chronic lymphocytic leukemia.– Because the @VARIANT$ variant of ABCG2/BCRP corresponding to SNP 421C&gt ; A reduces uric acid transport and those TKIs are substrates/inhibitors of ABCG2/BCRP , TKI therapy in patients with the SNP @GENE$ ; A ( Q141K ) may be at higher risk of tumor lysis syndrome .", "label": "None"}
{"id": "15737014", "sentence": "These results suggest that the @VARIANT$ mutation may impair the ability of gefitinib or @DRUG$ to inhibit @GENE$ tyrosine kinase activity , even in EGFR mutants ( i.e. , L858R or an exon 19 deletion ) that are clinically associated with drug sensitivity .", "label": "resistance or non-response"}
{"id": "22436374", "sentence": "H1650 and HCC827 have an in-frame deletion in the @GENE$ tyrosine kinase domain ( EGFR tyrosine kinase domainΔE746-A750 , exon 19 ) . H1650 cells have also a deletion of the 3 ' part of exon 8 and the entire exon 9 of PTEN , which causes loss of the protein [ ] and in addition express the insulin-like growth factor receptor ( IGF1R ) [ ] . The cell line H1975 has a sensitizing @VARIANT$ kinase domain mutation in exon 21 , but also a second mutation ( T790M , in cis , in the kinase domain ) rendering them resistant to the reversible TKIs gefitinib and @DRUG$ [ ] .", "label": "sensitivity"}
{"id": "25099740", "sentence": "Cetuximab-resistant @GENE$ and RAS cells isolated from control treated tumors in panel E were processed in parallel Cal27 cells infected with lentiviruses encoding PIK3CA @VARIANT$ or RAS G12V mutations .", "label": "resistance or non-response"}
{"id": "19893626", "sentence": "The second-generation BCR-ABL inhibitors , dasatinib and @DRUG$ , can circumvent most mutations that confer resistance to imatinib ; the @VARIANT$ mutation , however , causes resistance to all @GENE$ kinase inhibitors developed so far .", "label": "None"}
{"id": "24103790", "sentence": "However , the transport of estradiol-17β-D-glucuronide ( E217βG ) , a glucuronide conjugate and the only physical element other than leukotriene C4 to be transported by ABCC10 , is competitively inhibited by amphiphiles , such as leukotriene C4 , glycolithocholate 3-sulfate , and MK571 , as well as lipophilic compounds , such as cyclosporine A . The transfection of @GENE$ cells with the ABCC10 gene confers resistance to various chemotherapeutic drugs , including docetaxel , paclitaxel , vincristine , @DRUG$ , cytarabine , gemcitabine , 2′,3′-dideoxycytidine , 9- ( 2-phosphonyl methoxyethyl ) adenine ( PMEA ) , and epothilone B , .", "label": "None"}
{"id": "23566546", "sentence": "Case Histrogical type @GENE$ mutation status Brinkman index Treatment agent Response IL-8 ( ng/mL ) IL-10 ( ng/mL ) RANTES ( pg/ml ) 1 Ad Ex21 @VARIANT$ 900 gefitinib PR 5.79 1.67 2 2 Ad Ex21 L858R 0 erlotinib PR_3.33 94.2 1.41 3 Ad Ex19 del 0 erlotinib PR 4.09 126 2.13 4 Ad Ex21 L858R 0 gefitinib PR_3.92 18.1 1.85 5 Ad Ex21 L858R + Ex19 del 370 erlotinib PR 21.9 1.23 2.11 6 Ad Ex19 del 0 erlotinib PR 7.05 1.37 2.56 7 Ad Ex19 del 0 gefitinib PR 4.82 1.59 2.02 8 Ad Ex21 L858R 1640 gefitinib PR 54.9 2.7 2.38 9 Ad negative 400 erlotinib SD 34.9 3.39 3.66 10 Ad negative 0 erlotinib SD 27.1 4.94 2.25 11 Ad unknown 1800 erlotinib SD NE NE NE 12 Sq Ex19 del 3840 gefitinib SD 12.6 1.1 1.98 13 Ad Ex19 del 30 erlotinib SD 5.27 0.69 2.66 14 Ad Ex19 del 0 erlotinib SD 10.5 0.85 2.5 15 Ad unknown 300 erlotinib SD 7.69 2.61 1.7 16 La negative 2080 erlotinib SD NE NE NE 17 Sq Ex21 L858R 750 erlotinib SD 11.6 56.3 3.06 18 Ad unknown 600 erlotinib SD 13.7 1.1 2.82 19 Ad Ex21 L858R 0 erlotinib SD 20.6 11.6 0.783 20 Ad Ex19 del 0 erlotinib SD 14.8 2.07 2.02 21 Ad Ex21 L858R + Ex19 del 0 gefitinib SD 3.04 1.3 1.76 22 Ad Ex19 del 200 gefitinib SD 10.9 1.59 1.91 23 Sq unknown 1560 erlotinib PD NE NE NE 24 Ad negative 1080 erlotinib PD 25.2 8.15 1.57 25 Ad unknown 0 erlotinib PD NE NE NE 26 Ad Ex18 G719A 2000 @DRUG$ PD 11.6 4.48 3.12 27 Ad unknown 1410 erlotinib PD NE NE NE 28 Ad Ex19 del 1000 gefitinib PD 9.44 2.25 2.89 29 Ad negative 1100 erlotinib PD 56.3 5.63 2.16 30 Ad negative 2000 erlotinib PD 15.6 0.85 0.292 31 Ad negative 825 erlotinib PD 8.27 1.59 2.13 32 Ad Ex21 L858R 0 erlotinib PD 5.34 7.05 1.7 33 Ad negative 1680 erlotinib PD 57.7 1.63 2.06", "label": "sensitivity"}
{"id": "23852704", "sentence": "Thus , in two trials , administration of cetuximab to patients with this mutation was associated with a significantly better outcome than that seen in patients with other types of @GENE$ mutations. , Indeed , patients with the @VARIANT$ mutation appeared to benefit to approximately the same extent as patients with K-RAS wild-type tumors from the addition of @DRUG$ to first-line chemotherapy .", "label": "resistance or non-response"}
{"id": "23963283", "sentence": "For example , Caucasian patients harboring activating mutations in the EGFR kinase domain , such as a deletion in exon 19 or @VARIANT$ , have shown significant responses to the EGFR tyrosine kinase inhibitor ( TKI ) erlotinib , including a 70 % response rate , 14-month progression-free survival , and 27-month median survival . Accordingly , the @GENE$ TKIs erlotinib or @DRUG$ have become the standard of care for first-line treatment in patients with advanced NSCLC and whose tumors harbor activating mutations in the kinase domain of EGFR .", "label": "sensitivity"}
{"id": "21333004", "sentence": "Yun et al [ ] showed that @DRUG$ directly binds more tightly to the @VARIANT$ mutant than to the wild type EGFR in vitro , while Fabian et al [ ] indicated that @GENE$ with gefitinib sensitive mutations does not differ from wild type EGFR in terms of gefitinib binding affinity .", "label": "sensitivity"}
{"id": "21333004", "sentence": "According to recent reports , the sensitivity to kinase inhibition reflects intrinsic differences in the binding affinity of the EGFR mutants such as L858R , @VARIANT$ , and exon19 deletions [ , - ] . Yun et al [ ] showed that @DRUG$ directly binds more tightly to the L858R mutant than to the wild type @GENE$ in vitro , while Fabian et al [ ] indicated that EGFR with gefitinib sensitive mutations does not differ from wild type EGFR in terms of gefitinib binding affinity .", "label": "sensitivity"}
{"id": "23691449", "sentence": "Some of the molecular mechanisms of acquired resistance include T790M second mutation , mesenchymal epithelial transition factor ( MET ) amplification , ATP binding cassette (ABC)-G2 transporter ( ABCG2 ) and hepatocyte growth factor (HGF) overexpression , insulin-like growth factor (IGF) binding protein-3 ( IGFBP3 ) downregulation , as well as @GENE$ activation . T790M mutation The @VARIANT$ second mutation accounts for half of all resistances to @DRUG$ and erlotinib [ ] .", "label": "None"}
{"id": "25110867", "sentence": "Dacomitinib inhibited EGFR phosphorylation and downstream signaling molecules , including AKT and ERK1/2 , and induced apoptosis in the @GENE$ @VARIANT$ containing H3255 GR cell line at 10 nmol/L concentration . In xenografted nude mice using HCC827 GFP and HCC827 Del/T790M cells , either @DRUG$ or dacomitinib effectively inhibited the growth of HCC827 GFP xenografts .", "label": "resistance or non-response"}
{"id": "25072314", "sentence": "Antibodies used for immunoblotting and/or immunohistochemistry ( IHC ) were anti-androgen receptor ( Santa Cruz ) , GAPDH ( Cell Signaling ) , c-MYC ( Epitomics ) and activated @GENE$ Cell Signaling ) . For in vivo studies , @DRUG$ was obtained from the Roswell Park Cancer Institute pharmacy and diluted to 1 mg/ml in PBS before administration to animals . NVP-AUY922 was dissolved in 5 % dextrose in distilled water ( @VARIANT$ ) at a concentration of 4 mg/ml .", "label": "None"}
{"id": "23994953", "sentence": "@VARIANT$ mutation reviewed in . The second well-known mechanism of gefitinib/erlotinib resistance is the MET receptor tyrosine kinase ( RTK ) gene amplification . MET creates a bypass signaling track that activates AKT through HER3 mediated activation of PI3K in the presence of @GENE$ TKIs .", "label": "resistance or non-response"}
{"id": "22970424", "sentence": "Moreover , using PIK3CA wild-type human breast immortalized epithelial cells ( hTERT-HME1 ) or non-malignant MCF10A breast cells , knock-in of the @VARIANT$ or H1047R PIK3CA mutant alleles sensitized non transformed human breast cells to the rapalog @DRUG$ ( Di Nicolantonio et al. , ) . Also when focusing on an array of tumor types rather than on a single disease entity , PIK3CA mutant cell lines , or cell line derived xenografts were found to be selectively sensitive to PI3K pathway inhibition ( Table ) . For example , analysis of xenografts derived from pancreatic , prostate , ovarian , NSCLC , and ovarian cancer cells revealed that those harboring PIK3CA mutations were among the most sensitive to the @GENE$ inhibitor PHT-427 ( Meuillet et al. , ) .", "label": "None"}
{"id": "15737014", "sentence": "In GIST and HES , respectively , the analogous T670I mutation in @GENE$ and @VARIANT$ mutation in PDGFR-alpha have been associated with acquired resistance to this drug [ , ] . To determine whether lung cancers that acquire clinical resistance to either @DRUG$ or erlotinib display additional mutations in the EGFR kinase domain , we have examined the status of EGFR exons 18 to 24 in tumors from five patients who initially responded but subsequently progressed while on these drugs .", "label": "None"}
{"id": "22192458", "sentence": "Inhibition of @GENE$ activity in NB cell lines has already been approached by using specific small molecule ALK inhibitors , such as @DRUG$ [ ] , NVP-TAE684 [ ] and CEP14083/CEP14513 [ ] , and more recently by RNA interference molecules [ ] . Particularly , NB cells harboring either R1275Q mutation or ALK amplification showed sensitivity to PF-02341066 and these results were also confirmed in xenografts ( Wood AC et al. , ASCO Annual Meeting , 2009 ) . However , NB cell lines with both @VARIANT$ ALK mutations and wild type ALK were more resistant .", "label": "resistance"}
{"id": "24884501", "sentence": "The mutational frequencies of the 195 KRAS mutations in the NORDIC VII cohort were ; G12A ( 9.7 % ) , G12R ( 1.5 % ) , @VARIANT$ ( 35.4 % ) , G12C ( 9.7 % ) , G12S ( 6.2 % ) , G12V ( 15.4 % ) , and G13D ( 22.1 % ) . @DRUG$ did not add significant benefit to Nordic FLOX and @GENE$ mutation was not predictive for cetuximab effect .", "label": "sensitivity"}
{"id": "24212777", "sentence": "Most B-Raf mutations involve the @VARIANT$ amino acid substitution , resulting in constitutive activation of the MEK-ERK signaling pathway . They are mutually exclusive of KRAS mutations and are thus a candidate for an independent biomarker for CRC [ ] . Studies on WT-KRAS tumors treated by either a combination of chemotherapy and @DRUG$ or cetuximab alone have shown that progression free survival ( PFS ) and OS were significantly better among patient without mutated @GENE$ ( WT-BRAF ) [ ] .", "label": "resistance or non-response"}
{"id": "24634705", "sentence": "@DRUG$ , an @GENE$ and HER2 irreversible inhibitor has been shown to reverse the effects of the @VARIANT$ mutation in preclinical lung cancer studies [ ] .", "label": "response"}
{"id": "24670366", "sentence": "Global induction of apoptosis with @DRUG$ , cycloheximide or puromycin was shown to lead to a loss of cell coupling , probably due to caspase-3 mediated degradation of Cx43 , in primary bovine lens epithelial and mouse NIH3T3 fibroblasts [ ] . In fact , Stat3 inhibition in cells transformed by Src or the Large Tumor antigen of Simian Virus 40 led to apoptosis [ , , ] , possibly due to activation of the transcription factor @VARIANT$ family , potent apoptosis inducers , by these oncogenes .", "label": "None"}
{"id": "25091415", "sentence": "Therefore , to elucidate the structural and dynamic consequences of the DM on the catalytic domain of @GENE$ and its affinity toward gefitinib , we performed molecular dynamic simulations ( 50 ns ) of the wild type ( WT ) -EGFR and three oncogenic mutants : G719S , @VARIANT$ , and DM in complex with @DRUG$ .", "label": "resistance or non-response"}
{"id": "22436374", "sentence": "The cell line H1975 has a sensitizing @VARIANT$ kinase domain mutation in exon 21 , but also a second mutation ( T790M , in cis , in the kinase domain ) rendering them resistant to the reversible TKIs @DRUG$ and erlotinib [ ] . Moreover , these cells express the @GENE$ receptor but without gene amplification [ ] .", "label": "None"}
{"id": "23569389", "sentence": "Dasatinib is active against at least 100 of the BCR-ABL1 mutations known to confer resistance to @DRUG$ that have been tested to date , ( including many in the p-loop region ) , except for the T315I mutation and a few other mutations ( @VARIANT$ , F317L/V , and T315A ) . Dasatinib is able to block downstream intracellular signaling pathways activated by BCR-ABL1 in vitro , including signal transducer and activator of transcription 5 ( Stat5 ) , with downregulation of Stat5 target gene expression and the @GENE$ , Notably , dasatinib is not a substrate of multidrug resistance protein-1 , an efflux protein expressed on normal and leukemic hematopoietic stem cells .", "label": "None"}
{"id": "19687189", "sentence": "Antrodia camphorata solid-state cultured mycelium ( AC-SS , 1 μg ml−1 ) showed adjuvant anti-proliferative effects with cisplatin ( 10 μM ) or @DRUG$ ( 10 μM ) in hepatoma cell lines C3A and PLC/PRF/5 cells ( in vitro ) and , on xenografted cells in tumor implanted nude mice ( in vivo ) . Furthermore , AC-SS showed its adjuvant effects through the inhibition of MDR gene expressions and the pathway of COX-2 dependent inhibition of @GENE$ phosphorylation [ ] .", "label": "None"}
{"id": "24651269", "sentence": "There was no correlation between the cellular activity of sorafenib and BRAF ( @VARIANT$ ) . Another important class of kinase inhibitor drugs are those targeting ABL1 , of which a re-arranged form , i.e. , @GENE$ , drives Philadelphia chromosome positive chronic myelogenous leukemia ( CML ) . Imatinib , @DRUG$ , dasatinib , ponatinib and bosutinib are approved drugs for this indication .", "label": "None"}
{"id": "24052078", "sentence": "In addition , previous reports showed the presence of signaling cross-activation between MET and EGFR in both A549 and H1975 cells , and both the @VARIANT$ mutation of @GENE$ and c-Met amplification are known mechanisms of acquired @DRUG$ ( TKI ) resistance in lung cancer .", "label": "resistance or non-response"}
{"id": "23049365", "sentence": "In a phase I clinical trial ponatinib was used to treat 67 patients resistant to @DRUG$ , dasatinib and nilotinib and passed safety requirements . Among these patients , 72 % presented mutations in @GENE$ at the beginning of the study or had a documented mutation story , including the T315I and @VARIANT$ mutations .", "label": "None"}
{"id": "24523596", "sentence": "Several studies have reported renal failure and tumor lysis syndrome during TKI based molecular targeted therapies , including with sorafenib for hepatocellular carcinoma , with @DRUG$ for chronic myelogenous leukemia , and with flavopiridol for chronic lymphocytic leukemia.– Because the Q141K variant of ABCG2/BCRP corresponding to SNP 421C&gt ; A reduces uric acid transport and those TKIs are substrates/inhibitors of @GENE$ , TKI therapy in patients with the SNP 421C&gt ; A ( Q141K ) may be at higher risk of tumor lysis syndrome . A defect in the pharmacological interaction has been suggested between sunitinib and another ABCG2/BCRP germ-line mutant allele , 1291T & gt ; C. Remarkably , sunitinib reversed wild-type ABCG2/BCRP mediated drug resistance and competitively inhibited ABCG2/BCRP mediated estrone 3-sulfate transport and the binding of 125I-iodoarylazidoprazosin to ABCG2/BCRP . The @VARIANT$ variant of ABCG2/BCRP , which is expressed from a germ-line mutant allele 1291T & gt ; C , was insensitive to sunitinib mediated inhibition .", "label": "None"}
{"id": "17973572", "sentence": "Based on the data obtained from lung cancer cell lines , we further explored the mechanisms by which @VARIANT$ and L747S resistant mutations affect BIM up-regulation and apoptosis . @DRUG$ effectively induced apoptosis in Ba/F3-L858R cells , whereas @GENE$ cells were intermediately resistant and Ba/F3-L858R-T790M completely resistant ( A , top ) .", "label": "None"}
{"id": "24009732", "sentence": "Targeted therapy to inhibit the oncogene FIP1L1-PDGFRα has met with some success : the first-generation tyrosine kinase inhibitor ( TKI ) @DRUG$ has been reported to be effective to @GENE$ , but imatinib-resistant mutations emerged . Several mutations in the kinase domains such as D842V , @VARIANT$ , S601P and L629P , have been demonstrated to be responsible for the drug-resistance .", "label": "None"}
{"id": "24586514", "sentence": "An @GENE$ the activity of specific HDACs . Preclinical data suggest a role for HDACi as a potential new treatment in several tumor types , including hematological malignancies . In this study , we investigated @DRUG$ activity against Ph-positive leukemia cells carrying the @VARIANT$ mutation .", "label": "None"}
{"id": "25286176", "sentence": "Finally , the substrate-free structure ( PDB @GENE$ lacked sufficient electron density for assignment of residues 42-51 in the N-terminal region and 229–239 of the F-G loop ; the 2F9Q further contained a polymorphic V374M substitution and two additional mutations , L230D and L231R , introduced to increase solubility . While the N-terminal region of CYP2D6 was modified by truncation to increase expression and solubility , and a @DRUG$ tag introduced for purification purposes on the C-terminal end , CYP2D6 in the 3QM4 structure otherwise represents CYP2D6*1 . Backbone dependent rotamers were added to *1 to create *34 ( R296C ) , *17-2 ( T107I , R296C ) , *17-3 ( T107I , R296C , S486T ) , and *53 ( @VARIANT$ , A122S ) using UCSF Chimera package .", "label": "None"}
{"id": "25295096", "sentence": "The subsequent @GENE$ mutation analysis revealed a @VARIANT$ point mutation of exon 21 and a Q787Q point mutation of exon 20 . Therefore , @DRUG$ was administered orally at a dose of 150 mg daily as the second-line therapy .", "label": "sensitivity"}
{"id": "19920910", "sentence": "In vivo experiments with CML xenografts in mice demonstrated that @DRUG$ treatment , compared with treatment with vehicle , improved survival of mice infused with either wild type @GENE$ or the imatinib-resistant Bcr-Abl mutant ( @VARIANT$ ) ( ; ) .", "label": "None"}
{"id": "23696715", "sentence": "A recent study compared the effect of four TKIs ( axitinib , sunitinib , @DRUG$ , and XL184 ) on cell proliferation , RET autophosphorylation , and extracellular signal regulated kinase activation in three cell lines : MZ-CRC-1 ( @VARIANT$ RET mutation ) , MTC-TT ( C634W @GENE$ mutation ) , and TPC-1 ( RET/PTC-1 rearrangement ) cells .", "label": "response"}
{"id": "25465236", "sentence": "( G–I ) increased inhibition potency for Gefitinib against EGFR L858R mutant compared to @GENE$ WT protein and subsequent further increase in potency for @DRUG$ against EGFR L858R + E884K double mutant . ( J ) EGFR L861Q activated more than @VARIANT$ but less than L858R .", "label": "resistance or non-response"}
{"id": "24189400", "sentence": "On the basis of these results , we reasoned that combined @DRUG$ and midostaurin could overcome @VARIANT$ mediated resistance , as erlotinib would target wild-type and exon 19 deletion E746-A750 @GENE$ activity while midostaurin would inhibit exon 19 deletion E746-A750+T790M EGFR .", "label": "resistance or non-response"}
{"id": "23566546", "sentence": "Case Histrogical type @GENE$ mutation status Brinkman index Treatment agent Response IL-8 ( ng/mL ) IL-10 ( ng/mL ) RANTES ( pg/ml ) 1 Ad Ex21 @VARIANT$ 900 gefitinib PR 5.79 1.67 2 2 Ad Ex21 L858R 0 erlotinib PR_3.33 94.2 1.41 3 Ad Ex19 del 0 erlotinib PR 4.09 126 2.13 4 Ad Ex21 L858R 0 gefitinib PR_3.92 18.1 1.85 5 Ad Ex21 L858R + Ex19 del 370 erlotinib PR 21.9 1.23 2.11 6 Ad Ex19 del 0 erlotinib PR 7.05 1.37 2.56 7 Ad Ex19 del 0 gefitinib PR 4.82 1.59 2.02 8 Ad Ex21 L858R 1640 gefitinib PR 54.9 2.7 2.38 9 Ad negative 400 erlotinib SD 34.9 3.39 3.66 10 Ad negative 0 erlotinib SD 27.1 4.94 2.25 11 Ad unknown 1800 erlotinib SD NE NE NE 12 Sq Ex19 del 3840 gefitinib SD 12.6 1.1 1.98 13 Ad Ex19 del 30 erlotinib SD 5.27 0.69 2.66 14 Ad Ex19 del 0 erlotinib SD 10.5 0.85 2.5 15 Ad unknown 300 erlotinib SD 7.69 2.61 1.7 16 La negative 2080 erlotinib SD NE NE NE 17 Sq Ex21 L858R 750 erlotinib SD 11.6 56.3 3.06 18 Ad unknown 600 erlotinib SD 13.7 1.1 2.82 19 Ad Ex21 L858R 0 erlotinib SD 20.6 11.6 0.783 20 Ad Ex19 del 0 erlotinib SD 14.8 2.07 2.02 21 Ad Ex21 L858R + Ex19 del 0 @DRUG$ SD 3.04 1.3 1.76 22 Ad Ex19 del 200 gefitinib SD 10.9 1.59 1.91 23 Sq unknown 1560 erlotinib PD NE NE NE 24 Ad negative 1080 erlotinib PD 25.2 8.15 1.57 25 Ad unknown 0 erlotinib PD NE NE NE 26 Ad Ex18 G719A 2000 erlotinib PD 11.6 4.48 3.12 27 Ad unknown 1410 erlotinib PD NE NE NE 28 Ad Ex19 del 1000 gefitinib PD 9.44 2.25 2.89 29 Ad negative 1100 erlotinib PD 56.3 5.63 2.16 30 Ad negative 2000 erlotinib PD 15.6 0.85 0.292 31 Ad negative 825 erlotinib PD 8.27 1.59 2.13 32 Ad Ex21 L858R 0 erlotinib PD 5.34 7.05 1.7 33 Ad negative 1680 erlotinib PD 57.7 1.63 2.06", "label": "sensitivity"}
{"id": "24894453", "sentence": "The absence of both KRAS and BRAF mutations are common features seen in colorectal cancers that are responsive to @DRUG$ [ , ] , thus making the @GENE$ mutation in this case of particular interest . The somatic @VARIANT$ mutation in EGFR occurs at the final glycine of the GxGxxG nucleotide binding motif that is essential for ATP binding and is conserved among all protein kinases ( Figure", "label": "sensitivity"}
{"id": "22331137", "sentence": "This effect was related to the reduction of @VARIANT$ formation and the reduction of the inflammation in the kidneys of @GENE$ treated rats .", "label": "None"}
{"id": "24004697", "sentence": "A : K562 and K562R cells treated with PPP2R5C-siRNA799 , B : 32D-Bcr-Abl WT and 32D-Bcr-Abl T315I cells treated with PPP2R5C-siRNA799 , C : K562 and K562R cells treated with PPP2R5C-siRNA991 , D : 32D-Bcr-Abl WT and @GENE$ T315I cells treated with PPP2R5C-siRNA991 . The apoptosis induction effect of PPP2R5C-siRNAs on imatinib-sensitive and imatinib-resistant cell lines . A : K562 and K562R cells treated with PPP2R5C-siRNA799 , B : 32D-Bcr-Abl WT and 32D-Bcr-Abl @VARIANT$ cells treated with PPP2R5C-siRNA799 , C : K562 and K562R cells treated with PPP2R5C-siRNA991 , D : 32D-Bcr-Abl WT and 32D-Bcr-Abl T315I cells treated with PPP2R5C-siRNA991 .", "label": "None"}
{"id": "23533466", "sentence": "H1975 cancer cell line with mutations in EGFR exons 21 ( @VARIANT$ ) and 20 ( T790M ) was refractory to reversible EGFR-TKIs , gefitinib , and erlotinib [ ] , but was sensitive to irreversible @GENE$ , such as BIBW2992 ( @DRUG$ ) .", "label": "sensitivity"}
{"id": "16187797", "sentence": "Transformation induced by expression of @VARIANT$ , G719S , and L747_E749del A750P EGFR , but not EGF stimulated wild-type @GENE$ or D770_N771insNPG EGFR , was inhibited by 0.1 μM @DRUG$ .", "label": "sensitivity"}
{"id": "24724051", "sentence": "CDKN2A/B is rarely deleted in ALL with translocations of @VARIANT$ [E2A–PBX1 in t ( 1 ; 19 ) ( q23 ; p13 ) and E2A–HLF in t ( 17 ; 19 ) ( q21–22 ; p13 ) ALL ] ( ) . Introduction of p190BCR–ABL1 into Arf -null murine bone marrow decreases the latency and increases resistance to @DRUG$ in the lymphoid malignancy that develops in recipient mice .", "label": "None"}
{"id": "21814597", "sentence": "The most common @GENE$ mutation , @VARIANT$ in exon 18 , is resistant to imatinib. , , In contrast , the substitution V561D in exon 12 results in an isoform of PDGFRA that is highly sensitive to imatinib. , Lasota et al. and Heinrich et al. reported imatinib sensitivities for a deletion/substitution ( SPDGHE566-571R ) and an in-frame insertion mutation ( ER561-562 ) in exon 12 .", "label": "resistance or non-response"}
{"id": "24348666", "sentence": "The mechanisms for acquired resistance include gatekeeper L1196M mutations , ALK gene amplification , and other ALK gene mutations ( @VARIANT$ , C1156Y , F1174L ) - . The first two secondary @GENE$ mutations that conferred resistance to @DRUG$ were reported within the same issue of the New England Journal of Medicine describing the positive clinical results mentioned above .", "label": "resistance"}
{"id": "23088930", "sentence": "Activating mutations in the @GENE$ gene are located in exons 18 through 21 while more than 90 % consist of deletions in exon 19 and @VARIANT$ substitution in exon 21 . These activating mutations are eligible for the treatment with modern tyrosine kinase inhibitors ( TKI ) , e. g. @DRUG$ or erlotinib [ , , ] .", "label": "sensitivity"}
{"id": "21034468", "sentence": "As shown in Figure , ethanol increased the adhesion of MCF7ErbB2 cells to fibronectin and @VARIANT$ significantly inhibited @DRUG$ enhanced adhesion in a concentration dependent manner .", "label": "None"}
{"id": "PMC4041556", "sentence": "Second-generation EGFR TKIs – such as neratinib , afatinib and dacomitinib – are effective in preclinical gefitinib- and erlotinib-resistant EGFR @VARIANT$ models , but to date their delivery in EGFR TKI-resistant patients have shown disappointing results in the clinic . Combination of afatinib with @DRUG$ in EGFR TKI-resistant patients resulted in a 30 % response rate and 75 % disease control rate , with significant gastrointestinal toxicity . Other mechanisms of resistance include MET amplification , with no commercially available inhibitor , @GENE$ amplification potentially amenable to treatment with anti-HER2 monoclonal antibodies or histological transformation to small-cell lung cancer , which requires cytotoxic chemotherapy .", "label": "None"}
{"id": "23817662", "sentence": "Further studies of @DRUG$ revealed that this 4-anilinoquinazoline inhibitor , structurally similar to erlotinib , binds the @GENE$ c.2573T & gt ; G ( @VARIANT$ ) mutant with a 20-fold higher affinity compared to the wild-type enzyme .", "label": "sensitivity"}
{"id": "25563355", "sentence": "In pre-clinical studies , neratinib inhibited the growth of NCI-H1975 bronchoalveolar cancer cells harboring both substitution of arginine for leucine at position 858 ( L858R ) and @VARIANT$ and cell lines harboring the HER2 mutation [ ] . A phase I study of the advanced stage of solid tumors showed that the maximum tolerated dose ( MTD ) of neratinib was 320 mg once daily [ ] . An open-label , single-agent , phase II study revealed only a 3 % RR in patients with an @GENE$ mutation who had been treated with gefitinib or @DRUG$ for more than 12 weeks .", "label": "resistance or non-response"}
{"id": "15737014", "sentence": "This study revealed that the quinazoline rings of erlotinib and lapatinib interact differently with the EGFR kinase domain , suggesting that while the @VARIANT$ mutation may affect inhibition by erlotinib and @DRUG$ , it may not affect inhibition of @GENE$ by compounds similar to lapatinib .", "label": "resistance or non-response"}
{"id": "22382702", "sentence": "This was confirmed in vitro , and @VARIANT$ mutated cancer cells were resistant to @DRUG$ , whereas G13D mutated and @GENE$ wild-type cancer cells were sensitive .", "label": "None"}
{"id": "25079768", "sentence": "Mutation D802V in @GENE$ is equivalent to @VARIANT$ in KIT and was reported as stabilizing the active kinase domain structure to which imatinib does not bind , , as suggested by the resulting resistance to @DRUG$ .", "label": "None"}
{"id": "25505694", "sentence": "@DRUG$ , an oral small-molecule inhibitor of @GENE$ , VEGFR-2 , HER2 and Ephrin type-B receptor 4 (EphB4) , in preclinical studies showed efficacy against EGFR-driven tumors , including those harboring @VARIANT$ [ ] .", "label": "None"}
{"id": "24789720", "sentence": "The new therapy methods , which could be effective in patients with @VARIANT$ mutation includes irreversible EGFR-TKIs ( afatinib , neratinib ) . In LUX-Lung 1 study in patients after failure of @DRUG$ or gefitinib treatment with afatinib led to partial responses and prolongation of progression-free survival compared to placebo to 3,3 months [ , ] . Recently the studies are conducted with combining of irreversible EGFR-TKI and monoclonal antibody against extracellular domain of @GENE$ – cetuximab .", "label": "resistance or non-response"}
{"id": "23606169", "sentence": "SSCP analysis indicated @GENE$ WT status , which qualified him for concomitant targeted therapy ( cetuximab : first dose , 400 mg/m2 day 1 ; subsequent doses : 250 mg/m2 ) and chemotherapy ( @DRUG$ 180 mg/m2 day 1 , 5-fluorouracil 400 mg/m2 bolus and then 2,400 mg/m2 over 48 h ; leucovorin 200 mg/m2 before 5-fluorouracil ) . At first , partial remission was observed , but therapy was stopped after seven cycles due to clinical and radiological progression of the disease . As further genetic analysis showed , the patient did not have mutations in KRAS ( codons 12 , 13 , and 61 ) or @VARIANT$ BRAF .", "label": "None"}
{"id": "23527257", "sentence": "The cell line H1975 has a sensitizing L858R kinase domain mutation in exon 21 , and a second @VARIANT$ in exon 20 , in cis , in the @GENE$ kinase domain , rendering them resistant to the reversible TKIs @DRUG$ and erlotinib .", "label": "resistance or non-response"}
{"id": "24348666", "sentence": "It was initially proposed that the T790M mutation might prevent the proper binding of tyrosine kinase inhibitors via steric hindrance , similar to the corresponding gatekeeper mutations in BCR-ABL ( T315I ) and KIT ( @VARIANT$ ) that confer resistance to imatinib ( @DRUG$ ) in chronic myelogenous leukemia and in patients with gastrointestinal stromal tumors . Interestingly , it was discovered that the T790M mutation does not confer resistance to gefitinib and erlotinib by preventing their binding as originally thought . Instead , the T790M mutation induces resistance by increasing the binding affinity of ATP by one order of magnitude , which is near the affinity for wild-type @GENE$ , thus enabling ATP to compete effectively with the kinase inhibitors .", "label": "None"}
{"id": "23976869", "sentence": "@DRUG$ is a dual SRC/ABL1 inhibitor that also inhibits PDGFRs and FIP1L1-PDGFRA fusion but has no effect on imatinib-resistant FIP1L1-PDGFRA T674I and D842V mutants . Third generation of TKIs : ponatinib Ponatinib has a potent activity towards @GENE$ , as well as numerous imatinib-resistant BCR-ABL1 kinase domain mutants , including the @VARIANT$ mutation .", "label": "None"}
{"id": "22249159", "sentence": "Imatinib mesylate , along with second-generation tyrosine kinase inhibitors ( TKI ) such as nilotinib and @DRUG$ [ - ] , have changed the natural history of CML and have provided important treatment options for this leukemia that in the past was uniformly fatal . Despite such advances in the field , mutations rendering CML and Ph+ ALL patients non-responsive to TKI 's have been identified , including the threonine 315 to isoleucine ( @VARIANT$ ) mutation and several others , which differentially prevent binding of different TKIs to the active site of the @GENE$ kinase domain , thereby evading inhibition [ ] .", "label": "None"}
{"id": "19384426", "sentence": "Transfection of PTEN into the PTEN negative decreased the activation of Akt and the downstream p70 ( @VARIANT$ ) and reversed the resistance to @DRUG$ in these cells , indicating that changes in @GENE$ status/Akt activation modulate the cellular response to doxorubicin [ ] .", "label": "None"}
{"id": "24121633", "sentence": "Based on our data , we hypothesized that PRR of hnRNP L binds to PTB and cooperatively suppresses inclusion of exon @VARIANT$ . We thus examined the role of PRR of hnRNP L on the interaction with PTB . Histidine tagged hnRNP L ( His-L ) , its PRR deleted variant ( His-L-ΔPRR ) , @DRUG$ tagged hnRNP LL ( His-LL ) , and its @GENE$ inserted variant ( His-LL-PRR ) were expressed in SH-SY5Y cells , and they were immunoprecipitated with anti-histidine antibody in the presence of RNase .", "label": "None"}
{"id": "22098950", "sentence": "Overexpression of both the wild-type and @VARIANT$ forms of BCRP conferred resistance to 9-aminocamptothecin , which was associated with reduced intracellular drug accumulation , but did not confer resistance to 9-nitrocamptothecin . These observations , in addition to the knowledge that BCRP confers resistance to topotecan and SN-38 , suggest that polar residues at the 9 or 10 position of @DRUG$ may be important to facilitate interactions with @GENE$ .", "label": "None"}
{"id": "23606169", "sentence": "Also , a clinical trial with the BRAF inhibitor ( @DRUG$ ) demonstrated antitumor activity in tumors with the BRAF @VARIANT$ mutation and confirmed that V600E @GENE$ is a valid therapeutic target in human cancer [ ] .", "label": "None"}
{"id": "23533494", "sentence": "@DRUG$ inhibits pancreatic CSC characteristics in human and @GENE$ ( @VARIANT$ ) transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition [ ] .", "label": "None"}
{"id": "18794843", "sentence": "Mutation at the analogous position to Thr315 in other imatinib targets such as c-KIT ( Thr670 ) and PDGFRA ( Thr674 ) have been linked to imatinib resistance in patients with GIST and @GENE$ , respectively , . Similarly , the gatekeeper mutation @VARIANT$ in EGFR causes resistance to @DRUG$ and erlotinib , and has been detected in lung cancer patients before drug treatment and in the germ line of a family pedigree with several cases of lung cancer , .", "label": "None"}
{"id": "25114510", "sentence": "OPTIMAL People’s Republic of China Erlotinib ( 82 ) versus @DRUG$ plus @GENE$ ( 72 ) Exon 19 deletion or @VARIANT$", "label": "None"}
{"id": "25405807", "sentence": "Inhibition of epidermal growth factor receptor (EGFR) kinase activity by EGFR tyrosine kinase inhibitors ( @GENE$ ) , such as gefitinib and @DRUG$ , can result in improved response and prolonged progression-free survival ( PFS ) in selected non-small cell lung cancer ( NSCLC ) patients harboring sensitizing EGFR mutations , especially the exon 19del and exon 21 L858R mutations – . Unfortunately , almost all patients will ultimately develop resistance to EGFR-TKI , in whom more than 50 % cases were detected harboring the EGFR @VARIANT$ mutation in tumor specimens after EGFR-TKI , .", "label": "resistance or non-response"}
{"id": "25222496", "sentence": "Several studies have reported that advanced NSCLC patients with @GENE$ exon 19 deletion had a longer overall survival ( OS ) and/or progression-free survival ( PFS ) following treatment with @DRUG$ or erlotinib compared with those with the @VARIANT$ mutation , , , but this result has not been shown in all reports , , , , .", "label": "sensitivity"}
{"id": "24303221", "sentence": "Interestingly , studies on different lung cancer cell lines suggested that NCI-H292 , a pulmonary MEC cell line that has wild-type EGFR , is more sensitive to @DRUG$ than other wild-type @GENE$ non-small cell lung cancer cell lines [ ] . O'Neill analyzed the data from multiple studies and raised the interesting question that different ethnic populations may have different EGFR mutations in their pulmonary MEC tumors [ ] . Per review of the literature , 48 pulmonary MEC tumors were tested for EGFR mutations , and nine tumors ( 19 % ) tested positive for mutations including two reports of @VARIANT$ mutations , five L861Q mutations , one I760I mutation , and one exon 19 deletion .", "label": "sensitivity"}
{"id": "24167634", "sentence": "However , the discovery of @GENE$ mutations and the response to EGFR tyrosine kinase inhibitors ( TKIs ) , such as gefitinib and @DRUG$ , deeply changed the management of advanced NSCLC in the last decade [ – ] . Small in-frame deletions in exon 19 and point mutations within exon 21 ( @VARIANT$ ) are the most common EGFR activating mutations both leading to sustained activity of the kinase .", "label": "sensitivity"}
{"id": "24955213", "sentence": "@VARIANT$ @GENE$ Gatekeeper residue mutation blocks @DRUG$ binding [ , , ]", "label": "None"}
{"id": "22164339", "sentence": "The APC protein contains seven 20-amino acid repeats ( 20AARs ) which are involved in degrading the transcriptional @DRUG$ @GENE$ and hence negatively regulate Wnt signaling [ , ] . The germline mutation @VARIANT$ encoded a limited amount of functional APC protein ( 23.4 % of normal APC protein ) and led to the truncated protein , which leaves zero 20AARs , implying a potential unfolding of beta-catenin .", "label": "None"}
{"id": "24294007", "sentence": "Mutations in the proto-oncogene BRAF are present in 5 % –10 % of the metastatic CRC population and are also mutually exclusive of KRAS mutations . BRAF @VARIANT$ is the most common of all BRAF mutations ( present in 90 % of cases ) , and is enriched in a subset of patients who are female , greater than 70 years of age , with KRAS WT right sided colon cancer . This mutation leads to constitutive activation of B-Raf by mimicking a tyrosine-kinase phosphorylation . Emerging evidence from the CRYSTAL , OPUS , and PICCOLO trials supports the use of BRAF mutations as negative predictors of response to such EGFR inhibitors as cetuximab and panitumumab. , , Objective response rates are significantly higher in the WT group , from 17 % to 47 % compared to 0 % –8 % in the @GENE$ mutant group .", "label": "resistance or non-response"}
{"id": "25277203", "sentence": "T790M could be the main cause of acquired resistance to @GENE$ in H1975 . MiR-200c could upregulate the expression of E-cadherin and trigger MET in H1975 , but can not reverse the resistance to @DRUG$ owing to @VARIANT$ existence .", "label": "resistance or non-response"}
{"id": "25309870", "sentence": "While the majority of patient tumors harbored common EGFR mutations ( Del-19 and Point 21 @VARIANT$ ) , approximately 10 % of patients had uncommon @GENE$ mutations . The primary endpoint of this trial was progression-free survival and secondary endpoints included overall survival , objective response rate , and quality of life . @DRUG$ treatment led to an increase in the objective response rate compared with chemotherapy treatment ( 56.1 vs. 22.6 % ) .", "label": "sensitivity"}
{"id": "22191026", "sentence": "The investigated @GENE$ sensitive mutations included G719C , G719S , G719A , L858R , L861Q , and exon 19 deletions , as well as a gefitinib-resistant mutation , @VARIANT$ .", "label": "resistance or non-response"}
{"id": "23356214", "sentence": "In 2009 , the FDA updated the product labels for @DRUG$ and panitumumab , indicating that patients with CRC tumours harbouring @GENE$ mutations were unlikely to derive benefit from these therapies . However , these guidelines may have to be re-visited , as it has been shown ( in one study ) that patients with a @VARIANT$ mutation showed improved survival compared to patients with other mutations , indicating that this patient group may respond to therapy [ ] .", "label": "resistance or non-response"}
{"id": "24472312", "sentence": "The in vivo antineoplastic activity of @DRUG$ as a single agent against imatinib-resistant @VARIANT$ FIP1L1-PDGFRα expressing cells was evaluated in the nude mouse xenograft model . Thirty nu/nu BALB/c mice were subcutaneously injected with @GENE$ PDGFRα cells .", "label": "None"}
{"id": "19680652", "sentence": "@GENE$ mutation tests were available in four patients , in whom three of them were positive for point mutation in exon 21 ( @VARIANT$ and L861Q ) and one was negative . At the time of initiation of @DRUG$ treatment , most of the patients were in good performance status ( & gt ; 90 % in ECOG 0 or 1 ) .", "label": "sensitivity"}
{"id": "25121098", "sentence": "BRCC36 also hydrolyzes K63 linked Ub chains form @VARIANT$ and @GENE$ at the sites of double strand DNA damage [ , ] . Although OTUB1 is not catalytically involved in deubiquitinating these K63 linked chains , it may interact with Ubc13 and inhibit the E3 ligase RNF168 [ ] . USP11 plays a role in the HR in response to DNA damage induced by DSBs caused by agents like bleomycin , mitomycin C , @DRUG$ , and so forth [ ] .", "label": "None"}
{"id": "23818899", "sentence": "EGFR KRAS ( mutation ) Colorectal Cancer ( expressing metastatic colorectal carcinoma , EGFR ) **Therascreen KRAS Test ( Qiagen , Corporate Headquarters , Nederland 's ) **Erbitux , cetuximab ( ImClone , ImClone Systems , NJ ) **Vectibix , @DRUG$ ( Amgen , Amgen Inc , . CA ) [ , , ] @GENE$ @VARIANT$ ( mutation ) Melanoma ( metastatic melanoma with BRAFV600E mutation ) **Cobas 4800 BRAF V600 Mutation Test ( Panagene , Corporate Headquarters , Korea ) **Zelboraf , vemurafenib ( Genentech/Roche ) [ , ]", "label": "resistance or non-response"}
{"id": "23785245", "sentence": "Similar to mutations in BCR-ABL ( T315I ) or in @GENE$ ( @VARIANT$ ) that underlie resistance to @DRUG$ , T790M is thought to interfere with the binding of EGFR-TKIs at the adenosine triphosphate binding cleft of EGFR . , , On the other hand , the affinity of this cleft for adenosine triphosphate is increased by T790M .", "label": "resistance"}
{"id": "24114583", "sentence": "Another second-generation irreversible @GENE$ TKI , dacomitinib , demonstrated preclinical efficacy in NSCLC tumours harbouring the @VARIANT$ gatekeeper mutation , , which is present in ∼50 % of NSCLCs that have acquired resistance to @DRUG$ or gefitinib , .", "label": "resistance or non-response"}
{"id": "22655263", "sentence": "Additionally , AP26113 was evaluated on the @DRUG$ resistant gatekeeper mutant @VARIANT$ both in vitro and in vivo and appeared to be able to overcome resistance to crizotinib . Ki determination demonstrated a very similar biochemical potency on wild-type ALK and the L1196M @GENE$ mutant ( 0.09 and 0.08 nM respectively ) , with both cellular and in vivo data ( using engineered Ba/F3 cells ) indicating that growth of ALK–L1196M mutant driven-cells is inhibited at similar , albeit slightly higher , doses which inhibit cells harboring wild-type ALK ( Katayama et al. , ) .", "label": "resistance"}
{"id": "21333004", "sentence": "Overexpression of wild type EGFR induced high and sustained phosphorylation of EGFR , Shc , MEK ( mitogen activated protein kinase kinase ) and ERK ( extracellular signal regulated kinase ) , while the @VARIANT$ mutation reduced these response levels . In addition , H1299L858R , which is supposed to be more sensitive to @DRUG$ than H1299EGFR-WT , was effectively inhibited by gefitinib administration at the downstream part of the signaling pathway ( @GENE$ and ERK ) compared with H1299EGFR-WT , but , surprisingly , not at the upstream part of the pathway ( EGFR and Shc ) .", "label": "None"}
{"id": "25071018", "sentence": "Notably , regorafenib significantly enhanced SHP-1 activity in wild-type SHP-1 transfected cells , but not in @VARIANT$ or dN1 mutant SHP-1 transfected cells ( Figure ) , suggesting that @DRUG$ increases @GENE$ activity by direct disruption of the association between the N-SH2 domain and the PTP catalytic domain .", "label": "None"}
{"id": "23566546", "sentence": "Case Histrogical type @GENE$ mutation status Brinkman index Treatment agent Response IL-8 ( ng/mL ) IL-10 ( ng/mL ) RANTES ( pg/ml ) 1 Ad Ex21 @VARIANT$ 900 gefitinib PR 5.79 1.67 2 2 Ad Ex21 L858R 0 erlotinib PR_3.33 94.2 1.41 3 Ad Ex19 del 0 erlotinib PR 4.09 126 2.13 4 Ad Ex21 L858R 0 gefitinib PR_3.92 18.1 1.85 5 Ad Ex21 L858R + Ex19 del 370 erlotinib PR 21.9 1.23 2.11 6 Ad Ex19 del 0 @DRUG$ PR 7.05 1.37 2.56 7 Ad Ex19 del 0 gefitinib PR 4.82 1.59 2.02 8 Ad Ex21 L858R 1640 gefitinib PR 54.9 2.7 2.38 9 Ad negative 400 erlotinib SD 34.9 3.39 3.66 10 Ad negative 0 erlotinib SD 27.1 4.94 2.25 11 Ad unknown 1800 erlotinib SD NE NE NE 12 Sq Ex19 del 3840 gefitinib SD 12.6 1.1 1.98 13 Ad Ex19 del 30 erlotinib SD 5.27 0.69 2.66 14 Ad Ex19 del 0 erlotinib SD 10.5 0.85 2.5 15 Ad unknown 300 erlotinib SD 7.69 2.61 1.7 16 La negative 2080 erlotinib SD NE NE NE 17 Sq Ex21 L858R 750 erlotinib SD 11.6 56.3 3.06 18 Ad unknown 600 erlotinib SD 13.7 1.1 2.82 19 Ad Ex21 L858R 0 erlotinib SD 20.6 11.6 0.783 20 Ad Ex19 del 0 erlotinib SD 14.8 2.07 2.02 21 Ad Ex21 L858R + Ex19 del 0 gefitinib SD 3.04 1.3 1.76 22 Ad Ex19 del 200 gefitinib SD 10.9 1.59 1.91 23 Sq unknown 1560 erlotinib PD NE NE NE 24 Ad negative 1080 erlotinib PD 25.2 8.15 1.57 25 Ad unknown 0 erlotinib PD NE NE NE 26 Ad Ex18 G719A 2000 erlotinib PD 11.6 4.48 3.12 27 Ad unknown 1410 erlotinib PD NE NE NE 28 Ad Ex19 del 1000 gefitinib PD 9.44 2.25 2.89 29 Ad negative 1100 erlotinib PD 56.3 5.63 2.16 30 Ad negative 2000 erlotinib PD 15.6 0.85 0.292 31 Ad negative 825 erlotinib PD 8.27 1.59 2.13 32 Ad Ex21 L858R 0 erlotinib PD 5.34 7.05 1.7 33 Ad negative 1680 erlotinib PD 57.7 1.63 2.06", "label": "sensitivity"}
{"id": "25278773", "sentence": "These second-generation EGFR inhibitors have also been shown to drive drug resistance through the acquisition of @VARIANT$ in both preclinical and clinical settings , suggesting low potency against T790M. , As a potential solution , afatinib was combined with the EGFR antibody @DRUG$ in a Phase IIB study , which demonstrated an impressive response rate of 32 % in patients with EGFR mutant lung cancers resistant to first-generation @GENE$ inhibitors .", "label": "response"}
{"id": "25405807", "sentence": "Inhibition of epidermal growth factor receptor (EGFR) kinase activity by @GENE$ tyrosine kinase inhibitors ( EGFR-TKIs ) , such as @DRUG$ and erlotinib , can result in improved response and prolonged progression-free survival ( PFS ) in selected non-small cell lung cancer ( NSCLC ) patients harboring sensitizing EGFR mutations , especially the exon 19del and exon 21 @VARIANT$ mutations – .", "label": "sensitivity"}
{"id": "25347122", "sentence": "PI3K/mTOR/AKT pathway ; @GENE$ NVP-BEZ235 ; 17-DMAG ( HSP90 inhibitor ) However , in these trials , TNBC was unselected based on gene ontologies and differential gene expression profiles . In the randomized open-label phase III CALGB 40502/NCCTG @VARIANT$ , the new and expensive BC treatments , nanoparticle albumin bound nab-paclitaxel ( Abraxane ) and ixabepilone , the latter being a potent epothilone that can be effective after microtubule inhibitor resistance ( Ixempra ) , have failed to demonstrate any superior efficacy versus the standard of weekly paclitaxel in combination with bevacizumab in patients with chemotherapy naïve metastatic BC .", "label": "None"}
{"id": "23139670", "sentence": "In our case , a biopsy ( ‘re-biopsy’ ) revealed the @VARIANT$ mutation in the @GENE$ gene , which was widely known as a second mutation resistant to EGFR TKIs , such as @DRUG$ and erlotinib .", "label": "resistance or non-response"}
{"id": "24009732", "sentence": "Because the FIP1L1-PDGFRα @VARIANT$ mutant in @GENE$ mainly contributes to the imatinib-resistance , , we explored whether DCC-2036 could inhibit PDGFRα in FIP1L1-PDGFRα positive cells regardless of the mutational status .", "label": "None"}
{"id": "21188109", "sentence": "Cyclin D1 , in association with cyclin dependent kinase-4 and -6 , induces the cell to enter the S phase by phosphorylating the retinoblastoma tumor suppressing protein , which binds to transcription factors , including @VARIANT$ . In addition to the overexpression of cyclin D1 , other genes that overexpress in MCL , such as VEGF and Raf-1 , represent further possible targets for mTOR inhibitors . Indeed , a constitutive activation of @GENE$ and mTOR pathways either in MCL cell lines ( Granta 519 , Jeko-1 , and SP-53 ) or in primary cultures from 30 % of MCL patients has been reported. , Moreover , mTOR inhibitors in MCL could synergize with other “canonical” agents , such as @DRUG$ , doxorubicin , bortezomib , and rituximab , with resulting inhibition of Raf-1 , MAPK , and mTOR . ,", "label": "None"}
{"id": "24276379", "sentence": "These mutations result in @GENE$ activation and cellular transformation [ ] . In a clinical study involving 110 patients , none of the patients with the abovementioned PIK3CA gene mutations respond to panitumumab or @DRUG$ [ ] . In another study that included 370 wild-type K-Ras patients , patients with mutant PIK3CA , particularly @VARIANT$ , had a significantly lower response rate than patients with wild-type PIK3CA [ ] .", "label": "None"}
{"id": "23144692", "sentence": "In our case , DNA sequencing of the EGFR gene in a tumor biopsy specimen at relapse showed a second point mutation that changed threonine to methionine at position 790 ( @VARIANT$ ) of @GENE$ . The efficacy of @DRUG$ is of limited duration , mainly due to drug resistance conferred by a second point mutation .", "label": "resistance or non-response"}
{"id": "22343623", "sentence": "In this study , we examined whether the selective KOR agonist U50 ,488H could inhibit the growth of gefitinib-sensitive and @GENE$ mutant ( delE746-A750 , @VARIANT$ ) NSCLC cells ( HCC827 ) and gefitinib-resistant and EGFR mutant ( T790M ) NSCLC cells ( H1975 ) , and investigated the signalling mechanism of the KOR mediated inhibitory effect on tumour cell growth .", "label": "sensitivity"}
{"id": "19774209", "sentence": "Contrarily , a point mutation in the EGFR gene , which results in the substitution of methionine for threonine at position 790 ( @VARIANT$ ) , decreases the ability of erlotinib or @DRUG$ to inhibit @GENE$ .", "label": "resistance or non-response"}
{"id": "22252115", "sentence": "Recently a new @GENE$ mutation of @VARIANT$ was discovered that explained the resistance to @DRUG$ after drug administration [ ] .", "label": "resistance or non-response"}
{"id": "22655263", "sentence": "The L1196M gatekeeper mutation and the @VARIANT$ and L1152R mutants were identified in the relapsed NSCLC cases , and the F1174L mutation in the relapsed IMT ( Choi et al. , ; Sasaki et al. , , ) . The mechanisms underlying decreased activity of @DRUG$ on these secondary @GENE$ mutants were investigated by structural and biochemical analyses , together with cellular data generated in engineered in vitro models .", "label": "resistance"}
{"id": "15737014", "sentence": "@DRUG$ inhibited the activity of wild-type and @VARIANT$ EGFRs progressively with increasing concentrations of drug , as demonstrated by a reduction of tyrosine phosphorylated proteins ( A ) and a decrease in p-EGFR : @GENE$ ratios ( B ) .", "label": "sensitivity"}
{"id": "22970367", "sentence": "Moreover , the second-generation irreversible @GENE$ inhibitors were shown in preclinical models to be more potent targeting @VARIANT$ mutation than gefitinib or @DRUG$ [ ] .", "label": "resistance or non-response"}
{"id": "19547661", "sentence": "Recently , it was demonstrated that wildtype @GENE$ is required for the response of patients with metastatic colorectal cancer to @DRUG$ and panitumumab [ ] . The aim of this study was to determine the BRAF @VARIANT$ mutation frequency in a large cohort of SGCs of the main histopathological types and to design an allele-specific PCR as an effective screening method .", "label": "resistance or non-response"}
{"id": "23207070", "sentence": "The most frequent EGFR mutations are deletions in exon 19 and a point mutation in codon 858 of exon 21 , known as @VARIANT$ ( T2573G ; ID : rs121434568 ) [ ] . Patients who carry these mutations in @GENE$ tend to have a better response to @DRUG$ , an EGFR-TKI , whereas patients with the wild-type genotype show a better response to conventional chemotherapy [ ] .", "label": "sensitivity"}
{"id": "25347122", "sentence": "@GENE$ pathway ; HSP90 NVP-BEZ235 ; 17-DMAG ( HSP90 inhibitor ) However , in these trials , TNBC was unselected based on gene ontologies and differential gene expression profiles . In the randomized open-label phase III CALGB 40502/NCCTG @VARIANT$ , the new and expensive BC treatments , nanoparticle albumin bound nab-paclitaxel ( Abraxane ) and ixabepilone , the latter being a potent epothilone that can be effective after microtubule inhibitor resistance ( Ixempra ) , have failed to demonstrate any superior efficacy versus the standard of weekly paclitaxel in combination with bevacizumab in patients with chemotherapy naïve metastatic BC .", "label": "None"}
{"id": "24516334", "sentence": "It is also active against @VARIANT$ and other imatinib-resistant mutants . However , not all CML patients who are refractory or intolerant to dasatinib or nilotinib are responsive to @DRUG$ . We have shown that the resistance of leukemia stem cells to imatinib does not appear to involve BCR-ABL kinase domain mutations , suggesting that @GENE$ activates some signaling pathways in a kinase independent manner in leukemia stem cells .", "label": "None"}
{"id": "24199791", "sentence": "Finally , we re-expressed the top most down-regulated miRNAs from both families and transfected @VARIANT$ cells with a cocktail of pre-miR-200b+pre-let-7c . We found much more potent inhibition ( 67.69 % ) of TGF-β1 mediated effect on @DRUG$ resistance ( Figure A-B ) . We also confirmed the reversal of @GENE$ by pre-miR-200b+let-7c treatment and the results of real time RT-PCR are shown as Figure C. Pre-treatment with miR-200b+let-7c significantly abrogated the inhibition of E-cadherin expression and also reduced ZEB1 levels ( Figure C ) , all of which are indications of the reversal of EMT .", "label": "None"}
{"id": "23976869", "sentence": "@DRUG$ has a potent activity towards BCR-ABL1 , as well as numerous imatinib-resistant @GENE$ kinase domain mutants , including the @VARIANT$ mutation .", "label": "response"}
{"id": "18645621", "sentence": "@GENE$ amplification is able to activate ERBB3 ( HER3 ) -dependent PI3K/Akt pathway , and ultimately lead to @DRUG$ resistance . Its occurrence is independent of @VARIANT$ .", "label": "None"}
{"id": "23723712", "sentence": "The most common @GENE$ of any grade in patients treated with gefitinib were rash ( 50 % ) , diarrhea ( 25 % ) , and alanine aminotransferase increase ( 21 % ) , with three outwardly related-deaths due to interstitial lung disease , lung infection , and pneumonia . At present , the Genius study ( NCT01579630 ) is ongoing to compare the efficacy and safety of gefitinib/pemetrexed versus pemetrexed alone as maintenance therapy in patients EGFR mutation negative or @VARIANT$ single mutation who responded to pemetrexed/platinum as first-line therapy .", "label": "None"}
{"id": "15737014", "sentence": "After 36 h , cells were serum starved for 24 h , treated with gefitinib or @DRUG$ for 1 h , and then harvested for immunoblot analysis using anti-p-EGFR ( Y1092 ) , @GENE$ , anti-phosphotyrosine ( p-Tyr ) , and anti-actin antibodies as described in Methods . The EGFR T790M mutation , in conjunction with either wild-type EGFR or the drug-sensitive @VARIANT$ EGFR mutant , prevents inhibition of tyrosine phosphorylation ( A ) or p-EGFR ( B ) by gefitinib .", "label": "sensitivity"}
{"id": "24790411", "sentence": "Compared to erlotinib and gefitinib , afatinib shows lower EC50 values and greater potency against wild type ( afatinib vs @DRUG$ vs gefitinib : 60 nM vs 110 nM vs 157 nM ) and @VARIANT$ mutated @GENE$ ( afatinib vs erlotinib vs gefitinib : 0.7 nM vs 40 nM vs 5 nM ) .", "label": "sensitivity"}
{"id": "22536370", "sentence": "KIT W557R V559A/D @VARIANT$ K642E D816H 23 % Acral 16 % Mucosal 28 % CSD , , Sensitive to : @DRUG$ Nilotinib Sunitinib Dasatinib Decreased sensitivity to : Imatinib ( D816H only ) , , , , CTNNB1 S37F/Y S45P/F/Y 4 % Overall , , Preclinical progression of @GENE$ melanomas ,", "label": "None"}
{"id": "25033171", "sentence": "In addition , we have analyzed the energetic contribution to @DRUG$ on residue level as well , which showed that the residue Leu18 ( located just in the P-loop region ) contributed the most to the attenuated binding of crizotinib to @GENE$ as shown in , therefore well supporting the issue that the P-loop conformation governs crizotinib resistance in @VARIANT$ mutated ROS1 tyrosine kinase .", "label": "resistance"}
{"id": "10952784", "sentence": "They were derived by long-term culture in oestrogen-free media and do not represent a model for long-term @DRUG$ treatment . Although it was previously reported that both E2 and 4-OHT are capable of activating the AP-1 pathway ( Astruc et al , 1995 ; Webb et al , 1995 ) , E2 and 4-OHT did not induce @GENE$ activity in either the MCF-7 nor @VARIANT$ PKC cell clones ( Figure 4B and C ) .", "label": "None"}
{"id": "24904824", "sentence": "BCR-ABL1 positive and @GENE$ B-ALL Although tyrosine kinase inhibitors ( TKIs ) targeting mutant ABL1 have revolutionized treatment of Ph+ leukemias in adults and children , resistance mutations are a known sequelae of TKI therapy that often result in eventual treatment failure . One study recently demonstrated improved growth inhibition and induction of apoptosis when sirolimus was added to imatinib-resistant Ph+ ALL cell lines harboring an acquired @VARIANT$ resistance mutation ( ) .", "label": "None"}
{"id": "24419415", "sentence": "The clinical efficacy of @GENE$ inhibitors ( EGFR-TKIs ) , such as gefitinib and @DRUG$ , has been demonstrated in non–small-cell lung cancer ( NSCLC ) patients in whom standard chemotherapy has failed. , Further studies have revealed that the presence of activating mutations in the EGFR kinase domain is strongly associated with the therapeutic efficacy of EGFR-TKIs. , Randomized phase 3 trials have demonstrated that EGFR-TKIs significantly improve median progression-free survival ( PFS ) compared with platinum-doublet therapy in EGFR mutated patients.– However , not all mutations in the EGFR kinase domain are responsive to EGFR-TKI treatment . These phase 3 trials have shown that EGFR-TKIs are effective for patients with common EGFR mutations , such as an exon 19 deletion or the @VARIANT$ point mutation , which account for more than 90 % of EGFR mutations .", "label": "sensitivity"}
{"id": "24810093", "sentence": "Associations between IC50 and ABCB1 genotypes at C1236T ( a ) and ( b ) , G2677T/A ( c ) and ( d ) and @VARIANT$ ( e ) and ( f ) were analysed by Jonckheere-Terpstra test . Correlation matrix between ABCB1 relative expression , bodipy-FL-paclitaxel accumulation and efflux constant KE in lymphoblastoid cell lines and ovarian cancer cell lines using Spearman or Pearson correlation test Lymphoblastoid cell lines Ovarian cancer cell lines ABCB1 expression Paclitaxel accumulation @DRUG$ efflux @GENE$ expression Paclitaxel accumulation Paclitaxel efflux", "label": "None"}
{"id": "24419415", "sentence": "Cells expressing G719X were less resistant to erlotinib than @DRUG$ in vitro ; however , @VARIANT$ was resistant to both erlotinib and gefitinib . In contrast to erlotinib , irreversible TKIs inhibited the growth of cells with G719X or L861Q at a lower concentration than those with wild-type @GENE$ .", "label": "None"}
{"id": "24106980", "sentence": "Cyclin D1 binds to CDK4 and @GENE$ to form a complex , supporting G1–S transition [ ] . Kastl et al. reported that reduced cyclin D1 expression modulated by miR-34a could induce G1 phase arrest , where @DRUG$ exerts little cytotoxicity , in turn leading to the resistance of docetaxel in breast cancer cells [ ] .", "label": "None"}
{"id": "25295230", "sentence": "@VARIANT$ AML @DRUG$ Smith et al. ( ) D835H AML Sorafenib Man et al. ( ) @GENE$ AML ( pediatric ) Sorafenib Baker et al. ( )", "label": "None"}
{"id": "19238632", "sentence": "H1975 cell line was chosen because it expresses the ‘gatekeeper'-resistant @GENE$ mutation ( in-cis with @VARIANT$ ) in the receptor kinase domain hydrophobic pocket , representing a major mechanism of resistance to reversible EGFR-TKI ( erlotinib/gefitinib ) ( ; ) .", "label": "sensitivity"}
{"id": "24348666", "sentence": "Although the resistant cell line @GENE$ does not have the EGFR @VARIANT$ mutation , it was found to have MET amplification . MET is a receptor tyrosine kinase that binds to hepatocyte growth factor (HGF) and is associated with the development of various human cancers . Therefore , EGFR-TKIs fail to inhibit the PI3K/Akt pathway dependent growth signal because the constitutive phosphorylation of HER3 by MET occurs independent of EGFR activation , which causes the cells to acquire resistance to @DRUG$ .", "label": "None"}
{"id": "PMC4034024", "sentence": "Intensive , continuous insulin treatment during the first two weeks after the diagnosis of @VARIANT$ mellitus may improve beta-cell function during the subsequent year [ ] . More recent intervention trials used monoclonal antibody based therapies such as @DRUG$ ( anti-CD-20 ) [ ] , daclizumab ( anti-CD25 ) in combination with mycophenylate mofetil [ ] , anti-CD3 [ , , ] , and glutamate acid decarboxylase (GAD) [ ] . While several studies are still ongoing and thus the results pending , trials of anti-CD3 antibodies and GAD have demonstrated delayed decline of endogenous @GENE$ secretion .", "label": "None"}
{"id": "21165163", "sentence": "2,105 patients were screened and 350 ( 16.6 % ) identified to carry @GENE$ mutations [ ] . Median PFS and OS for the 217 patients who received @DRUG$ were 14 and 27 months , patients with @VARIANT$ had longer PFS than patients with exon 19 deletions and outcomes did not seem to differ whether erlotinib was given in the first or second-line setting .", "label": "sensitivity"}
{"id": "25580271", "sentence": "Most patients with EGFR mutant NSCLC receive an @GENE$ tyrosine kinase inhibitor ( e.g. gefitinib , erlotinib , or @DRUG$ ) as first-line therapy , and unfortunately most patients experience disease progression after approximately 10–15 months of treatment . The most common mechanism of resistance is an EGFR exon 20 @VARIANT$ mutation , which is detected in approximately 50–60 % of tumor samples when a biopsy is performed after disease progression on EGFR tyrosine kinase inhibitors [ , ] .", "label": "response"}
{"id": "23630663", "sentence": "This event is analogous to replacement of threonine 790 with methionine ( @VARIANT$ ) in erlotinib-resistant lung adenocarcinoma . The gatekeeper mutation enhances the affinity of the oncogenic form of the receptor for ATP , allowing continued proliferation in the presence of the drug ( Yun et al. , ) . The potential of irreversible @GENE$ inhibitors to overcome drug resistance due to gatekeeper mutations was recently demonstrated in vitro and in vivo ( Kobayashi et al. , ; Engelman et al. , ; Minami et al. , ; Li et al. , ; Zhou et al. , ) .", "label": "resistance or non-response"}
{"id": "22985168", "sentence": "( B ) Western blot analysis of @GENE$ cells expressing the indicated transgenes using antibodies directed against the indicated proteins . ( C ) Calculation of the combined effect by the MacSynergy program . Taken together , these data suggest that the allosteric inhibition sensitizes BCR/ABL cells harboring the “gatekeeper” mutation @VARIANT$ towards the ATP analogue @DRUG$ .", "label": "None"}
{"id": "24634705", "sentence": "Similar to other tyrosine kinase inhibitors , patients treated with @DRUG$ eventually develop resistance and mutations that lead to resistance have been reported [ , ] . In one report , the patient developed two de novo mutations within the kinase domain of EML4-ALK , @VARIANT$ and L1196M [ ] . The L1196M mutation has been shown to be a “gatekeeper” mutation similar to that observed in @GENE$ that also renders that fusion protein resistant to ALK inhibition [ ] .", "label": "None"}
{"id": "24789720", "sentence": "T790M mutation in EGFR gene seems to be one of the most important genetic abnormalities involving the resistance for reversible @GENE$ kinases inhibitors ( EGFR-TKI ) —erlotinib and gefitinib in NSCLC patients [ – ] . T790M mutation is detected with highest prevalence in patients with common activating mutations of EGFR gene ( @VARIANT$ in exon 21 and deletions in exon 19 ) after long-term and initially effective treatment with EGFR-TKIs .", "label": "sensitivity"}
{"id": "23723712", "sentence": "At present , the Genius study ( NCT01579630 ) is ongoing to compare the efficacy and safety of gefitinib/pemetrexed versus pemetrexed alone as maintenance therapy in patients @GENE$ mutation negative or @VARIANT$ single mutation who responded to pemetrexed/platinum as first-line therapy .", "label": "resistance or non-response"}
{"id": "22655263", "sentence": "When tested in Ba/F3 cells driven by ALK mutants identified in crizotinib relapsed patients , NMS-E628 is circa fivefold more potent than @DRUG$ in inhibiting the proliferation of L1196M @GENE$ and @VARIANT$ ALK-driven-cells in vitro and in vivo ( Ardini et al. , ) .", "label": "resistance"}
{"id": "25336976", "sentence": "PNA-LNA PCR clamp analysis of the spinal fluid revealed the same @GENE$ deletion mutation ; however , the @VARIANT$ mutation could not be detected . Thus , we administered @DRUG$ to control the central nervous system metastasis .", "label": "resistance or non-response"}
{"id": "24004697", "sentence": "A : K562 and K562R cells treated with PPP2R5C-siRNA799 , B : 32D-Bcr-Abl WT and @GENE$ @VARIANT$ cells treated with PPP2R5C-siRNA799 , C : K562 and K562R cells treated with PPP2R5C-siRNA991 , D : 32D-Bcr-Abl WT and 32D-Bcr-Abl T315I cells treated with PPP2R5C-siRNA991 . The apoptosis induction effect of PPP2R5C-siRNAs on imatinib-sensitive and imatinib-resistant cell lines .", "label": "None"}
{"id": "24924344", "sentence": "@DRUG$ rs562 ( C/T ) Chr3 : 183637845 ABCC5 ( UTR3 ) 0.049494 0.392 rs3749445 ( A/G ) Chr3 : 183638506 ABCC5 ( UTR3 ) 0.044895 0.410 rs2292998 ( C/T ) Chr3 : 183663833 ABCC5 ( intronic ) 0.039882 0.277 rs1016752 ( C/G ) Chr3 : 183665062 ABCC5 ( intronic ) 0.039781 0.232 rs4148585 ( C/T ) Chr3 : 183670642 ABCC5 ( intronic ) 0.039781 0.283 rs6443924 ( A/G ) Chr3 : 183679532 ABCC5 ( intronic ) 0.039781 0.279 rs4148579 ( A/G ) Chr3 : 183685249 ABCC5 ( intronic ) 0.039781 0.279 rs939336 ( A/G =&gt ; C594C ) Chr3 : 183685534 @GENE$ ( exonic ) 0.039781 0.279 rs1132776 ( C/T = & gt ; A395A ) Chr3 : 183696402 ABCC5 ( exonic ) 0.044895 0.289 rs2313212 ( C/T ) Chr3 : 183700928 ABCC5 ( intronic ) 0.039781 0.279 rs4148575 ( C/T ) Chr3 : 183702275 ABCC5 ( UTR3 ) 0.044895 0.289 rs1846692 ( C/T ) Chr16 : 56671696 MT1A ( near - gene 5 ) 0.049494 0.360 rs35346959 ( A/G ) Chr16 : 56671867 MT1A ( near- gene 5 ) 0.044895 0.137 rs9922957 ( C/G ) Chr16 : 56672380 MT1A ( near - gene 5 ) 0.039781 0.185 rs9922409 ( A/G ) Chr16 : 56672400 MT1A ( near - gene 5 ) 0.04532 0.103 rs7190725 ( G/T ) Chr16 : 56673290 MT1A ( intronic ) 0.044895 0.170 rs8052394 ( A/G =&gt ; @VARIANT$ ) Chr16 : 56673828 MT1A ( missense ) 0.044895 0.152 rs1800566 ( C/T = & gt ; P187S ) chr16 : 69745145 NQO1 ( exonic ) 0.039781 0.258 rs689455 ( A/C ) Chr16 : 69761661 NQO1 ( near- gene 5 ) 0.039781 0.242", "label": "None"}
{"id": "24501009", "sentence": "Strategies to improve EGFR inhibition in @GENE$ @VARIANT$ cancers include the combination of irreversible EGFR inhibitors with the EGFR‐directed antibody cetuximab ( as reported for afatinib plus @DRUG$ ) 19 ; the development of more potent and specific inhibitors of EGFR T790M20,21 ; and the use of intermittent but high doses of existing irreversible EGFR inhibitors .", "label": "response"}
{"id": "24811491", "sentence": "Acquired resistance EGFR mutations Mutations in the EC domain ( @VARIANT$ ) and in the kinase domain ( codons 714 and 794 ) of EGFR found in patients @DRUG$ remained active in a patient with S492R mutation , which abrogated cetuximab binding . @GENE$ activation CRC cell lines with acquired KRAS/BRAF point mutations and/or KRAS amplification and one patient derived xenograft Combination of cetuximab with pimasertib ( MEK inhibitor ) induced moderate tumor shrinkage in vivo .", "label": "None"}
{"id": "21915354", "sentence": "Intracellular protein aggregation has been linked to many degenerative diseases including @GENE$ . Rhodopsin , a protein present in retinal cells is one such protein , which forms aggregates upon cellular accumulation . Some mutations of rhodopsin such as the point mutation @VARIANT$ ( Proline 23 → @DRUG$ ) result in greater aggregation , .", "label": "None"}
{"id": "22363766", "sentence": "T790M mutations emerge in response to treatment with @GENE$ TKIs . The @VARIANT$ mutation accounts for approximately 50 % of cases in which acquired resistance to erlotinib or @DRUG$ occurs , , .", "label": "resistance or non-response"}
{"id": "24594844", "sentence": "cDzT cleaves EGFR @VARIANT$ mRNA , which leads to a decrease in EGFR protein levels , whereas @DRUG$ is a second-line TKI that irreversibly binds to the intracellular kinase domain of EGFR and suppresses its downstream signaling . A recent report showed that EGFR support of cancer cell survival is independent of its kinase activity , suggesting that a TKI alone could not achieve maximum therapeutic efficacy . In addition to its pivotal role in signaling pathways , EGFR also interacts with and stabilizes the @GENE$ maintain intracellular glucose levels , which prevents against autophagic cell death .", "label": "None"}
{"id": "21605429", "sentence": "The @GENE$ exon 18 @VARIANT$ point mutant activates PDGFRA both in vitro and in vivo [ , ] and is also @DRUG$ resistant in vivo and in vitro [ , , ] , whereas other mutations affecting exon 18 ( D846Y , N848K , Y849K and HDSN845-848P ) are imatinib sensitive [ ] .", "label": "resistance or non-response"}
{"id": "20190765", "sentence": "We also included in this rescue analysis ( and ) an EGFR allele with activating mutation ( L858R ) along with a @VARIANT$ gatekeeper mutation ( T790M ) since our chemical proteomics results strongly implicated mutant EGFR in the HCC827 cells as a direct target of dasatinib . Interestingly , while expression of L858R/T790M resulted in minimal rescue effects in HCC827 , more pronounced effects were seen in H292 cells . Changes in dasatinib and @DRUG$ ( 2 ) induced cell viability were assessed in PC9 cells stably expressing either a mutant drug sensitive @GENE$ allele ( L858R ) or a drug resistant allele ( L858R/T790M ) ( ) .", "label": "resistance or non-response"}
{"id": "19384426", "sentence": "Another study demonstrated that Akt is activated in AML blasts and that p70 ( @VARIANT$ ) and 4EBP-1 , downstream mediators of Akt signaling , also are phosphorylated in AML blasts [ ] . In a short-term culture system , most AML patient samples showed a dose dependent decrease in survival after incubation with LY294002 [ ] . Incubation of AML blasts with @DRUG$ induced only a small decrease in survival of the cells [ ] .", "label": "None"}
{"id": "24649833", "sentence": "In our study , the expression of the most of these gene family members ( Phenylalanine ammonia-lyase ( PAL ) ; 4-coumarate : CoA ligase ( 4CL ) ; Cinnamate-4-hydroxylase ( C4H ) ; Hydroxycinnamoyl : CoA shikimate/quinate hydroxycinnamoyl transferase ( HCT ) ; p-coumarate-3-hydroxylase @VARIANT$ ; @GENE$ O-methyltransferase ; Cinnamyl alcohol dehydrogenase ( CCoAOMT ) ; Cinnamoyl-CoA reductase (CCR) ; and Cinnamyl @DRUG$ dehydrogenase ( CAD ) ) was induced from March to April , and then expression gradually decreased from the peak activity of xylem formation through August ( Figure A , Additional file ) .", "label": "None"}
{"id": "23533466", "sentence": "H1975 cancer cell line with mutations in EGFR exons 21 ( @VARIANT$ ) and 20 ( T790M ) was refractory to reversible EGFR-TKIs , gefitinib , and @DRUG$ [ ] , but was sensitive to irreversible @GENE$ , such as BIBW2992 ( afatinib ) .", "label": "sensitivity"}
{"id": "24634705", "sentence": "The occurrence of these secondary mutations spurred development of second and third generation irreversible TKIs which bind covalently to the cysteinyl-797 residue in the pocket of the @GENE$ domain and overcome resistance driven by the @VARIANT$ mutation [ ] . These agents show greater potency in the inhibition of kinase activity in vitro and in vivo compared to @DRUG$ and are in various stages of clinical testing [ , ] .", "label": "resistance or non-response"}
{"id": "22405425", "sentence": "The tumor tissue was analyzed for the presence of an @GENE$ mutation using the PNAClamp™ EGFR Mutation Detection kit ( PANAGENE , INC. Daejeon , Korea ) . In the cell blocks from the pleural fluid and the ascites , an @VARIANT$ mutation in exon 21 was detected . @DRUG$ therapy was therefore commenced .", "label": "sensitivity"}
{"id": "22909314", "sentence": "HC Stain 1 Actin , muscle specific 26 CK17 51 Myogenin 1 Alcian blue- PAS 2 AE1/AE3 27 CK19 52 Napsin A 2 Argentaffin 3 AFP 28 CK5/6 53 NSE 3 Argyrophil 4 hCG 29 Pancytokeratin 54 OCT-4 4 Colloidal iron stain 5 CA-125 30 Desmin 55 @VARIANT$ 5 Elastic , Verhoeff’s 6 Calcitonin 31 E-cadherin 56 p53 6 Mucicarmine 7 Caldesmon 32 @GENE$ 57 p63 7 PAS 8 Calretinin 33 Estrogen Receptor 58 PAX-2 8 PASD 9 CAM 5.2 34 GCDFP-15 59 PAX5 9 PTAH 10 CD10 35 GFAP 60 PAX-8 10 Reticulum , Gomori’s 11 CD117 36 Glypican-3 61 PLAP 11 Trichrome , Masson’s 12 CD138 37 Hep-Par1 62 @DRUG$ Receptor 13 CD20 38 HMB 45 63 Prostate Specific Antigen 14 CD3_39 HMW Keratin 64 RCC 15 CD30 40 HNF-1 65 S-100 16 CD34 41 Inhibin 66 Synaptophysin 17 CD43 42 CK , Oscar 67 Thrombomodulin 18 CD45RO 43 Leucocyte Common Antigen 68 Thyroglobulin 19 CD56 44 Mammaglobin 69 TTF1 20 CD99 45 Melan-A 70 Uroplakin 21 CDX2 46 MOC-31 71 Villin 22 CEA-polyclonal 47 MUC 1 72 Vimentin 23 Chromogranin 48 MUC 2 73 WT-1 24 CK 20 49 MUC5AC 25 CK 7 50 Myeloperoxidase", "label": "None"}
{"id": "23937717", "sentence": "MPR expression induced by @DRUG$ can facilitate NK cell cytotoxicity in human lung cancer cells with @GENE$ @VARIANT$ + T790M resistance mutation .", "label": "sensitivity"}
{"id": "25465236", "sentence": "Clinically observed EGFR kinase mutations that sensitize patients differentially to the inactive ( non phosphorylated ) @GENE$ kinase inhibitors @DRUG$ and Erlotinib were analyzed . The oncogenic EGFR @VARIANT$ mutation is one of the most common non small cell lung cancer ( NSCLC ) somatic mutations , observed from sequencing of both solid tumor biopsies and circulating tumor cells ( CTCs ) .", "label": "sensitivity"}
{"id": "22970367", "sentence": "Moreover , dual inhibition of EGFR with an irreversible EGFR inhibitor ( @DRUG$ ) and the EGFR neutralizing antibody cetuximab has recently shown promising activity in @GENE$ mutant lung cancers with acquired EGFR TKI resistance that harbor an EGFR @VARIANT$ mutation [ ] .", "label": "response"}
{"id": "25563355", "sentence": "The second-generation EGFR-TKIs , such as dacomitinib and @DRUG$ , have shown promising effects in pre-clinical models , but limited activity in clinical trials for patients with acquired resistance to previous @GENE$ , due to their toxicity . A new class of TKIs is under development to target @VARIANT$ .", "label": "response"}
{"id": "25115383", "sentence": "@DRUG$ markedly suppressed phosphorylation of Akt and Erk in PC9 and PC9BR ( 21M0 ) cells but not in PC9BR ( 10Mo ) and PC9BR ( 11Mo ) cells without affecting Akt and Erk expression ( Figure ) . All of these cell lines did not harbor @VARIANT$ mutation in the @GENE$ gene .", "label": "response"}
{"id": "21333004", "sentence": "Our results revealed that the effectiveness of @DRUG$ in cells is largely affected by not only on its direct binding affinity with @GENE$ but also on the presence of an additional molecule , Mig6 . According to recent reports , the sensitivity to kinase inhibition reflects intrinsic differences in the binding affinity of the EGFR mutants such as @VARIANT$ , G719S , and exon19 deletions [ , - ] .", "label": "sensitivity"}
{"id": "23185274", "sentence": "In this study , we design , synthesize and evaluated a number of novel quinazoline derivatives by exchanging the positions of the C5 and C6 substituents and varying the C4-amino functionality of gefitinib , and report that compound V1801 having a trifluoromethyl group at the C5'-position and a bromine at the C2'-position of the aniline moiety substituted at the C4 position of quinazoline core overcomes @DRUG$ resistance via up-regulation of Noxa , suggesting a novel strategy to fight against NSCLC with @GENE$ @VARIANT$ mutation .", "label": "resistance or non-response"}
{"id": "17973572", "sentence": "The Secondary Resistant Mutations L747S and @VARIANT$ Affect Gefitinib Induced Apoptosis and Inhibit BIM Up-Regulation ( A ) Top : Annexin V apoptosis assay : @GENE$ cells expressing L858R (LR) , L858R-L747S # 4 ( LR-LS ) , or L858R-T790M (LR-TM) cells were grown in the absence or presence of @DRUG$ for 24 h .", "label": "None"}
{"id": "25435999", "sentence": "These mutations include T315I ( in the @DRUG$ binding domain of @GENE$ ) , @VARIANT$ ( in the catalytic domain ) and E255K ( in the ATP binding domain ) ( , ) .", "label": "None"}
{"id": "24276379", "sentence": "The H1047R , @VARIANT$ and E545K mutations , all detected in colorectal cancers , code for mutant proteins with higher lipid kinase activity than the wild-type protein [ , ] . These mutations result in Akt activation and cellular transformation [ ] . In a clinical study involving 110 patients , none of the patients with the abovementioned @GENE$ gene mutations respond to @DRUG$ or cetuximab [ ] .", "label": "resistance or non-response"}
{"id": "24386407", "sentence": "Lung cancers with mutations that activate epidermal growth factor receptor (EGFR) , including exon 19 deletions and the exon 21 @VARIANT$ point mutation , respond to the reversible @GENE$ kinase inhibitors ( EGFR-TKIs ) gefitinib and @DRUG$ [ ] .", "label": "sensitivity"}
{"id": "25562798", "sentence": "The Spanish Lung Cancer Group screened 2105 patients , to identify 350 patients ( 15 % ) with exon 19 deletions and @VARIANT$ of whom 250 patients went on to receive erlotinib in the first or second-line setting . In this population , the response rate was 70 % with median time to progression of 14 months and median overall survival of 27 months [ ] . Six randomized studies have now been reported that demonstrate the superiority of either @DRUG$ or erlotinib over chemotherapy in NSCLC patients with @GENE$ mutations [ , ,, , , ] .", "label": "sensitivity"}
{"id": "25146448", "sentence": "MTNR1B , located on human chromosome 11q21–22 , is a member of the @GENE$ , and one of the functional and high-affinity @DRUG$ membrane receptors . MTNR1B is expressed in human and rodent pancreatic islets . Studies have shown that MTNR1B is a novel candidate gene for @VARIANT$ .", "label": "None"}
{"id": "24367680", "sentence": "Since 1/1/2007 until 31/12/2012 , we prospectively analyzed for @GENE$ @VARIANT$ all patients with newly diagnosed mCRC at the Department of Medical Oncology , University Hospital of Heraklion ( Crete , Greece ) . Five hundred and four consecutive patients , with histologically confirmed mCRC and available tumor material for molecular analysis , who were treated with at least one cycle of systemic chemotherapy with or without the addition of bevacizumab , @DRUG$ or panitumumab were enrolled .", "label": "resistance or non-response"}
{"id": "23186157", "sentence": "The enhanced activity of the combination of GNF-2 with Dasatinib , a dual src/Abl kinase inhibitor , might be due to the inhibitory activity of @DRUG$ on Src kinase which is involved in STAT5α phosphorylation [ ] . In conclusion , our data provide evidence for cooperation between GNF-2 and AKIs in inhibiting proliferation and clonigenicity of @GENE$ cells carrying @VARIANT$ mutated Bcr-Abl construct .", "label": "None"}
{"id": "25110867", "sentence": "In vitro assays have shown that dacomitinib is active in gefitinib-sensitive and gefitinib-resistant cells as well as @GENE$ and HER2 mutated NSCLC cell lines with or without MET amplification . Dacomitinib inhibited EGFR phosphorylation and downstream signaling molecules , including AKT and ERK1/2 , and induced apoptosis in the EGFR @VARIANT$ containing H3255 GR cell line at 10 nmol/L concentration .", "label": "resistance or non-response"}
{"id": "24501009", "sentence": "Strategies to improve @GENE$ inhibition in EGFR @VARIANT$ cancers include the combination of irreversible EGFR inhibitors with the EGFR‐directed antibody @DRUG$ ( as reported for afatinib plus cetuximab ) 19 ; the development of more potent and specific inhibitors of EGFR T790M20,21 ; and the use of intermittent but high doses of existing irreversible EGFR inhibitors .", "label": "response"}
{"id": "21814597", "sentence": "The most common @GENE$ mutation , @VARIANT$ in exon 18 , is resistant to imatinib. , , In contrast , the substitution V561D in exon 12 results in an isoform of PDGFRA that is highly sensitive to imatinib. , Lasota et al. and Heinrich et al. reported imatinib sensitivities for a deletion/substitution ( SPDGHE566-571R ) and an in-frame insertion mutation ( ER561-562 ) in exon 12 .", "label": "resistance or non-response"}
{"id": "24894453", "sentence": "To test whether @VARIANT$ and G724S EGFR mutants are cetuximab-sensitive in vitro , we ectopically expressed these mutants in @GENE$ cells , rendering these cells IL-3 independent but dependent on exogenous oncogenic EGFR signaling [ ] .", "label": "None"}
{"id": "24279718", "sentence": "A : V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog wild type codon 12 + 13 in inguinal lymph node metastasis before starting @DRUG$ treatment B : V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog mutation ( @VARIANT$ ; GGC & gt ; GAC ) in newly appeared inguinal lymph nodal metastasis after 8 months of crizotinib treatment .", "label": "None"}
{"id": "24501009", "sentence": "These observations could be due to the presence of concurrent drug resistance mechanisms ( such as @GENE$ amplification ) , or to the inability of dacomitinib to fully inhibit EGFR in tumors harboring EGFR T790M at the doses currently under clinical investigation . Strategies to improve EGFR inhibition in EGFR @VARIANT$ cancers include the combination of irreversible EGFR inhibitors with the EGFR‐directed antibody @DRUG$ ( as reported for afatinib plus cetuximab ) 19 ; the development of more potent and specific inhibitors of EGFR T790M20,21 ; and the use of intermittent but high doses of existing irreversible EGFR inhibitors .", "label": "None"}
{"id": "24410402", "sentence": "BCRP substrates include glucuronide and sulfate conjugates [ e.g. , estrone-sulfate , estradiol-17β-d-glucuronide ( @VARIANT$ ) , SN-38 glucuronide ] , anticancer drugs ( e.g. , irinotecan , SN-38 , @DRUG$ , daunorubicin , doxorubicin ) , and some statins [ e.g. , pitavastatin , rosuvastatin ( RSV ) ] .− The pharmacokinetics and pharmacodynamics of these drugs may be affected by modulation of @GENE$ expression and/or function resulting from genetic polymorphisms or drug–drug interactions ( DDIs ) .", "label": "None"}
{"id": "24244732", "sentence": "Lof rab-3 worms are resistant to the effects of depressive concentrations of exogenous @DRUG$ [ ] . The @VARIANT$ mutation of Munc18 increases the interaction between Munc18 and @GENE$ [ ] without affecting binding to syntaxin or Mint proteins [ ] .", "label": "None"}
{"id": "24876815", "sentence": "Analyses were also performed for other polymorphisms in the EGFR gene : G216T and @VARIANT$ , and in the EGF gene : A61G . Graziano et al. demonstrated the presence of the short variant of the EGFR gene intron-1 and the G allele in codon 61 of the EGF gene ( higher @GENE$ production ) to be a favourable predictive factor for cetuximab-irinotecan therapy .", "label": "None"}
{"id": "21437184", "sentence": "Several compounds ( @DRUG$ , PLX4720 , and GDC-0879 ) which selectively inhibit the kinase enzyme BRAF containing the @VARIANT$ mutation are in clinical development [ ] . In BRAF mutant cancer cell lines , these selective BRAF inhibitors potently block @GENE$ signaling .", "label": "None"}
{"id": "23139670", "sentence": "In our case , a biopsy ( ‘re-biopsy’ ) revealed the @VARIANT$ mutation in the @GENE$ gene , which was widely known as a second mutation resistant to EGFR TKIs , such as gefitinib and @DRUG$ .", "label": "resistance or non-response"}
{"id": "23319867", "sentence": "Mutational analysis was carried out as part of the trial , and identified 15 patients harboring @VARIANT$ , a @GENE$ mutation associated with poor prognosis . Of these , 12 had a response or stable disease with @DRUG$ , noted by the authors to be in contrast with motesanib , which showed no activity in this subset of patients .", "label": "None"}
{"id": "22852012", "sentence": "Imatinib , masitinib and bafetinib are agents unable to block the kinase activity of KIT @VARIANT$ , whereas midostaurin and @DRUG$ have clear inhibitory activity against @GENE$ D816V [ , , – ] .", "label": "response"}
{"id": "21333004", "sentence": "Yun et al [ ] showed that @DRUG$ directly binds more tightly to the @VARIANT$ mutant than to the wild type EGFR in vitro , while Fabian et al [ ] indicated that EGFR with gefitinib sensitive mutations does not differ from wild type @GENE$ in terms of gefitinib binding affinity .", "label": "sensitivity"}
{"id": "25143820", "sentence": "The 2 patients with mutations in PDGFRA had them in exon 18 @VARIANT$ or exon 12 . The small series does not permit any conclusive considerations on the correlation of DMD involvement with @GENE$ kinase genotype . But as the clinical use of @DRUG$ and regorafenib after imatinib failure does not completely cover the molecular landscape of the progressing GIST , a novel approach that targets dystrophin deregulation may have relevance in GIST treatment .", "label": "None"}
{"id": "22855636", "sentence": "Consequently , standard GIST therapies ( ie , @DRUG$ and sunitinib ) are less efficacious in this clinical group . Although the pathogenesis is largely unknown , recent studies have uncovered germline mutations involving succinate dehydrogenase (SDH) , most commonly in the subunit genes @GENE$ and SDHC , resulting in a complete loss or reduction in SDH protein. , Loss of SDH protein expression is effectively demonstrated using traditional immunohistochemistry. , , The clinical features associated with the presence of SDH germline mutations in wild-type GISTs , which accounted for 12 % of wild-type GISTs in one study , has not been defined . In adult wild-type-GISTs , BRAF exon 15 @VARIANT$ mutations have been detected in 7 % –13 % of GISTs , commonly located in the small bowel. ,", "label": "None"}
{"id": "21333004", "sentence": "Both of these two characteristics seem to contribute to the negative regulation of the @GENE$ signaling pathway . However , no mechanistic explanation has been found for the contributions of these molecules to the @DRUG$ sensitivity of the @VARIANT$ mutation .", "label": "sensitivity"}
{"id": "20190765", "sentence": "cDNA for @VARIANT$ @GENE$ and L858R/T790M EGFR were provided by Dr. William Pao ( Vanderbilt University , Nashville , TN ) , ACK was provided by Dr. Nupam Mahajan ( Moffitt Cancer Center , FL ) , and Human BRK was purchased from ORIGENE ( Rockville , MD ) . Lentiviral plasmids containing WT and gatekeeper SRC , FYN , LYN , LCK , ABL , DDR1 , FRK , EphB1 , EphA2 and EphA4 were generously provided by Dr. Jinyan Du and Dr. Todd Golub ( The Broad Institute , MA ) . @DRUG$ was provided by OSI Pharmaceuticals ( Melville , NY ) and dasatinib by Bristol-Myers Squibb ( New Brunswick , NJ ) .", "label": "sensitivity"}
{"id": "24189400", "sentence": "Furthermore , common proteins utilized by @DRUG$ sensitive and resistant ( @VARIANT$ EGFR ) could be candidate targets to overcome resistance to @GENE$ TKI .", "label": "resistance or non-response"}
{"id": "25278773", "sentence": "For example , the combination trial of @DRUG$ and afatinib has shown promising results , with an overall response rate of 29 % and a median duration of response of 5.7 months in patients with advanced lung adenocarcinoma and acquired resistance to erlotinib/gefitinib . Importantly , this combination conferred robust and durable clinical responses irrespective of @VARIANT$ status ( T790M positive , 32 % , versus T790M negative , 25 % ; P=0.341 ) , as well as an acceptable safety profile . More recently , third-generation @GENE$ mutation-specific inhibitors have shown potential in circumventing toxicities related to wild-type EGFR and overcoming resistance resulting from the acquired T790M mutation .", "label": "response"}
{"id": "19654571", "sentence": "Clinical studies done with @GENE$ inhibitors have examined only single agent effects ( ) and the combinations with cytotoxic agents are likely to be beneficial for cancer treatment . The importance of the MAPK cascade for CC cell survival was demonstrated when we combined a specific MEK1/2 inhibitor ( PD98059 ) with @DRUG$ , resulting in an additive inhibition of Caski and @VARIANT$ cell proliferation .", "label": "None"}
{"id": "25120654", "sentence": "@GENE$ mutation was positive according to the amplification-refractory mutation system method . ( A ) @VARIANT$ point mutation prior to the use of @DRUG$ , and ( B ) L858R and T790M point mutations following treatment with gefitinib .", "label": "sensitivity"}
{"id": "20224651", "sentence": "LY294002 , a specific inhibitor of the p110 catalytic subunit of @GENE$ [ ] , and Wortmannin [ ] , a cell-permeable , irreversible inhibitor of PI3K , were purchased from Calbiochem ( San Diego , CA ) . 2.2. Cell Lines and Treatments The human ovarian A2780 cisplatin-sensitive parental cancer cell line ( designated @VARIANT$ ) , provided by Dr. J. Rebecca Liu ( University of Michigan Medical School , Ann Arbor , MI ) , was originally established from an untreated ovarian cancer patient [ ] .", "label": "None"}
{"id": "25465236", "sentence": "( C ) EGFR @VARIANT$ mutant does not resemble pEGFR unlike the EGFR L858R mutant shown in B. ( D–F ) increased inhibition potency for Erlotinib against EGFR L858R mutant compared to EGFR WT protein and subsequent decrease in potency for Erlotinib against EGFR L858R + E884K double mutant . ( G–I ) increased inhibition potency for @DRUG$ against EGFR L858R mutant compared to @GENE$ WT protein and subsequent further increase in potency for Gefitinib against EGFR L858R + E884K double mutant .", "label": "resistance or non-response"}
{"id": "24349829", "sentence": "Correspondingly , direct injection of a liposome encapsulated miR-7 plasmid into established EGFR-TKI sensitive and resistant tumors bearing the @VARIANT$ EGFR mutant resulted in significant tumor regression in conjunction with repression of EGFR , RAF-1 and IRS-1 expression . In head and neck cancer , miR-7 functioned in a synergistic manner with erlotinib to render FaDu Erlotinib-resistant cells susceptible to the growth inhibitory activities of the drug . Interestingly , expression profiling analysis suggested that the downregulation of @GENE$ and EGFR and its ligand TGF-α by miR-7 was a possible mechanism by which miR-7 orchestrates the inhibition of EGFR signaling at multiple levels115 .", "label": "None"}
{"id": "19707322", "sentence": "Nilotinib is approximately 30-fold more sensitive than @DRUG$ in the killing of BCR-ABL dependent cells derived from patients with CML ( K562 and Ku-812F cells ) and cell lines ( 32D and baF3 ) , and it is active against 32/33 imatinib-resistant cell lines with @GENE$ mutations . The sensitivity of Bcr-Abl mutants to AMN107 can be summarized into 4 categories : high ( IC50 ≤ 70 nmol/L : M244V , G250E , Q252H , F3llL , F317L , M351T , V379I , L387M , @VARIANT$ , H396R ) , medium ( IC50 ≤ 200 nmol/L : Y253F , E255K , F359V ) , low ( IC50 ≤ 450 nmol/L : Y253H , E255V ) , and insensitive ( IC50 & gt ; 2 μmol/L : T315I ) ( ) ( ) .", "label": "None"}
{"id": "23696715", "sentence": "A recent study compared the effect of four TKIs ( axitinib , sunitinib , @DRUG$ , and XL184 ) on cell proliferation , RET autophosphorylation , and extracellular signal regulated kinase activation in three cell lines : MZ-CRC-1 ( @VARIANT$ @GENE$ mutation ) , MTC-TT ( C634W RET mutation ) , and TPC-1 ( RET/PTC-1 rearrangement ) cells .", "label": "response"}
{"id": "15736989", "sentence": "These observations provide convincing evidence that , at least in some patients with NSCLC , resistance to @DRUG$ or erlotinib can be attributed to acquisition of a @VARIANT$ mutation in the context of @GENE$ .", "label": "resistance or non-response"}
{"id": "23475393", "sentence": "Germline competent mouse iPS cell lines , termed “iPS-MEF-Ng-20D-17” , which were generated from mouse embryonic fibroblasts by introducing four factors ( @GENE$ , Sox2 , Klf4 and the c-Myc mutant c-Myc @VARIANT$ ) using retroviral vectors , were provided by Riken Cell Bank with the permission of Dr. S. Yamanaka . In some experiments , another mouse iPS cell line , BM21 , generated from dendritic cells of 21-month-old C57/BL6 mice , was used . iPS cells were maintained in Dulbecco 's modified Eagle 's medium ( Invitrogen ) containing 10 % Knockout Serum Replacement , 1 % fetal bovine serum ( FBS ) , nonessential amino acids , 5.5 mmol/L 2-mercaptoethanol , 50 U/mL penicillin and 50 mg/mL streptomycin on feeder layers of @DRUG$ C–treated mouse embryonic fibroblast cells stably releasing leukemia inhibitory factor (LIF) .", "label": "None"}
{"id": "18645621", "sentence": "T790M is mainly present in relapsed tumors after an initial response and secondary to @GENE$ therapy , , and it accounts for about half of acquired resistance to @DRUG$ or elotinib . Therefore , T790M has been considered a specific marker for acquired resistance to EGFR-TKIs . @VARIANT$ , D761Y and insertions in exon 20 also confer modest resistance to EGFR-TKIs .", "label": "None"}
{"id": "22038681", "sentence": "Preliminary results from an ongoing phase 1 dose-escalation study of the multikinase , @GENE$ inhibitor ponatinib ( AP24534 ) showed antileukemic activity in patients with refractory CML , including patients with the @VARIANT$ mutation . Phase 1 and 2 trials of ponatinib are ongoing in patients with refractory CML and acute lymphoblastic leukemia . Danusertib ( PHA-739358 ) is a multikinase aurora inhibitor with in vitro activity against wild-type ABL and ABL/T315I ; preliminary results from an ongoing phase 1 dose-escalation study indicate antileukemic activity in patients with AP or BC who failed imatinib and/or nilotinib or @DRUG$ .", "label": "None"}
{"id": "24523596", "sentence": "Rudin et al , Lemos et al , van Erp et al 1291T & gt ; C F431L TMD Insensitive to @DRUG$ mediated inhibition . Kawahara et al @GENE$ ; G No change TMD 1465T & gt ; C F489L TMD 1768A&gt ; T N590Y TMD 1858G&gt;A @VARIANT$ TMD 2237G&gt ; T – 2393G&gt ; T –", "label": "None"}
{"id": "24386407", "sentence": "Lung cancers with mutations that activate epidermal growth factor receptor (EGFR) , including exon 19 deletions and the exon 21 @VARIANT$ point mutation , respond to the reversible EGFR-tyrosine kinase inhibitors ( EGFR-TKIs ) gefitinib and erlotinib [ ] . These mutations have been shown to promote the activation of EGFR signaling and tumor dependency on EGFR . Recent clinical trials have shown that progression-free survival ( PFS ) in patients with @GENE$ mutant lung cancer is prolonged by treatment with a reversible EGFR-TKI and the irreversible EGFR-TKI @DRUG$ , which was designed to covalently bind to EGFR [ - ] .", "label": "sensitivity"}
{"id": "24367701", "sentence": "This @GENE$ to the endoplasmic reticulum and has been shown to play a critical role in @DRUG$ ( RIG-I ) gene signaling , acting as a sensor of RNA virus infection [ ] . In fact , many elements of the regulatory pathways governing both the RIG-I pathway and IFN gene expression are themselves regulated by IFN . In turn , IFN may coordinate the upregulation of antiviral factors , as revealed by the A3G , @VARIANT$ , TRIM , tetherin and MxA mRNA expression levels in paired maternal blood and CB samples .", "label": "None"}
{"id": "15737014", "sentence": "Analogously , the @VARIANT$ mutation , in conjunction with the drug-responsive del L747–E749 ; A750P EGFR mutant , prevents inhibition of p-EGFR by @DRUG$ ( C ) . Sensitivity to Gefitinib Differs Among NSCLC Cell Lines Containing Various Mutations in EGFR or @GENE$", "label": "None"}
{"id": "19654571", "sentence": "Isolated @DRUG$ or PD153035 treatments reduced the survival of @VARIANT$ cells in CA by the same proportion , reaching a more modest inhibition of HER2 , AKT and @GENE$ phosphorylation than in Caski cells ( ) .", "label": "None"}
{"id": "24410791", "sentence": "CO-1686 is a third-generation EGFR TKI , which may be more effective in patients with @VARIANT$ . NCT01526928 is an ongoing phase I/II trial that has enrolled patients who have failed prior chemotherapy and @GENE$ targeted therapy including @DRUG$ , gefitinib , neratinib , afatinib , or dacomitinib .", "label": "resistance or non-response"}
{"id": "22002720", "sentence": "We observed that the cellular FTO protein is present in a dot-like manner in nucleoplasm , and partially colocalizes with splicing or splicing related speckle factors SART1 ( U4/U6.U5 tri-snRNP associated protein 1 ) and SC35 ( serine/arginine-rich splicing factor 2 ) , and RNA polymerase II phosphorylated at Ser2 ( Pol II-S2P ) ( and ) , but does not colocalize with telomere marker TRF1 , replication site PCNA , Cajal body marker @GENE$ , cleavage body marker CstF64 , or P-body marker DCP1A ( ) . To investigate whether FTO is related to mRNA processing , we performed the same immunostaining experiment upon inhibition of Pol II-S2P transcription with @DRUG$ ActD ) . Quantitative foci analysis showed that the FTO foci number per cell was significantly decreased from 43±7 ( −ActD ) to 22 ± 5 ( +ActD ) with P-value less than 0.0001 , similar to that observed for Pol–II S2P from 90 ± 12 ( −ActD ) to 24 ± 5 ( +ActD ) , but not SC35 ( ) , upon transcription inhibition ( ) .", "label": "None"}
{"id": "22248868", "sentence": "Subsequently , @GENE$ mutations associated with TKI sensitivity ( exon 19 and L858R ) or resistance ( @VARIANT$ ) were identified [ ] . In colorectal cancer , KRAS mutations were found to be associated with @DRUG$ resistance [ ] .", "label": "response"}
{"id": "23994953", "sentence": "Unfortunately , the EGFR TKI-driven improvement in patient outcome is notably limited because virtually all NSCLC patients with erlotinib/gefitinib sensitizing EGFR mutations eventually acquire resistance after a median of 6–12 months of @GENE$ TKI therapy . In approximately half of cases , the tumor cells present after disease progression contain second-site mutations that alter drug binding to the EGFR TK domain . The most common lesion ( & gt ; 90 % ) is the so-called “gatekeeper mutation , ” which involves a substitution of methionine for threonine at position 790 ( @VARIANT$ ) .", "label": "resistance or non-response"}
{"id": "22751098", "sentence": "To test this hypothesis and to clinically validate our preclinical findings , we measured the expression of AXL by IHC ( immunohistochemistry ) in 35 matched EGFR-mutant NSCLC specimens obtained from patients both prior to treatment with the EGFR TKIs erlotinib or @DRUG$ and upon the development of EGFR TKI acquired resistance . In cases where enough material was available for additional studies , we also examined the specimens for GAS6 and @GENE$ ( as a marker for EMT ) expression by IHC ( scoring system shown in ) , EGFR @VARIANT$ by sequencing , and MET amplification by FISH .", "label": "None"}
{"id": "24419415", "sentence": "Retrospective studies and case reports suggest that some uncommon mutations are associated with sensitivity to EGFR-TKIs.– These mutations include G719X in exon 18 , which accounts for approximately 3 % of EGFR mutations , and @VARIANT$ in exon 21 , which represents approximately 2 % of EGFR mutations . However , these uncommon EGFR mutations have not been clearly shown to be predictive markers for the efficacy of EGFR-TKIs because of their low frequency . To investigate the efficacy of gefitinib in patients with uncommon mutations , we conducted a post-hoc analysis of the NEJ002 , which compared @DRUG$ and carboplatin-paclitaxel as first-line therapies for advanced NSCLC with activating @GENE$ mutations .", "label": "None"}
{"id": "23776354", "sentence": "Activating mutations Frequency at diagnosis , Predictive value for imatinib Secondary mutations of imatinib resistance , – Predictive value for @DRUG$ KIT Exon 9 10 % 70 % –75 % 58 % Exon 11 67 % 90 % –95 % 34 % Exon 13 1 % ± Yes + Exon 14 0 % Yes + Exon 17 1 % ± Yes − Exon 18 0 % Yes − @GENE$ 33 % –60 % Exon 12 1 % + Exon 14 & lt ; 1 % + Exon 18 5 % ± excepted for @VARIANT$ Yes − for D842V", "label": "None"}
{"id": "23717811", "sentence": "Given the prevalence of activation of the PI3K/mTOR axis and BRAF V600E mutations in pediatric tumors , we designed a pre-clinical study to determine whether inhibitors of @GENE$ and of BRAF V600E cooperate to enhance cytotoxicity specifically in pediatric low-grade gliomas . In an in vivo flank model of a pediatric pilocytic astrocytoma , subcutaneous xenografts of BT40 ( which carries a BRAF @VARIANT$ mutation ) were treated with vehicle , PLX4720 , everolimus , or combination of PLX4720 + @DRUG$ , and the outcome measures of tumor size and animal survival were followed .", "label": "None"}
{"id": "23995047", "sentence": "We used the crystal structure of FLT3 crystallized in an inactive conformation and with related inhibitor−kinase complexes : for example , ABL complexed with @DRUG$ in closed and inactive conformation ( PDB:3CS9 ) ; Ppy-A bound to the active conformation of ABL-T315I ( PDB:2Z60 ) ; and JAK2 bound to isoquinoline in active conformation ( @GENE$ ) . In this model , the pyrimidine ring of SAR302503 makes hydrophobic contacts with Leu 616 and Leu 818 . Given the lack of direct interaction of SAR302503 with resistant variants @VARIANT$ and D835F/Y , our model suggests that these mutations would destabilize the open and active conformation rather than inactivating the kinase , therefore having sufficient catalytic activity to support cellular transformation .", "label": "None"}
{"id": "23936763", "sentence": "The @VARIANT$ mutation results in substitution of serine with arginine at position 768 in DDR2 . Proposed DDR2 signaling in lung cancer . In vivo sensitivity of @GENE$ to @DRUG$ was demonstrated by inhibition of tumors induced into athymic nude mice .", "label": "response"}
{"id": "25465236", "sentence": "( G–I ) increased inhibition potency for @DRUG$ against EGFR L858R mutant compared to @GENE$ WT protein and subsequent further increase in potency for Gefitinib against EGFR L858R + E884K double mutant . ( J ) EGFR L861Q activated more than @VARIANT$ but less than L858R .", "label": "resistance or non-response"}
{"id": "24523596", "sentence": "The @VARIANT$ variant of @GENE$ , which is expressed from a germ-line mutant allele 1291T & gt ; C , was insensitive to @DRUG$ mediated inhibition .", "label": "None"}
{"id": "25562798", "sentence": "Despite initial sensitivity and responses that in many cases can be maintained over periods of many months or even years , tumors with EGFR mutations or @GENE$ gene rearrangements treated with specific inhibitors will ultimately progress—a process termed acquired resistance . In the case of acquired resistance to gefitinib and @DRUG$ in EGFR mutant tumors two major mechanisms have been identified . Firstly , a secondary mutation , the @VARIANT$ mutation within exon 20 of EGFR , is responsible for about 50 % of instances of acquired resistance [ , ] .", "label": "None"}
{"id": "23185274", "sentence": "We found a @DRUG$ mimetic , N- ( 2-bromo-5- ( trifluoromethyl ) phenyl ) -6-methoxy-7- ( 3- ( piperidin-1-yl ) propoxy ) quinazolin-4-amine ( hereafter , V1801 ) , moderately inhibited EGFR kinase activity but significantly suppressed cell proliferation and induced apoptosis in @VARIANT$ @GENE$ harboring non-small cell lung cancer ( NSCLC ) cells in vitro and in vivo .", "label": "resistance or non-response"}
{"id": "24455544", "sentence": "@DRUG$ is a promising novel TKI active against the @VARIANT$ @GENE$ mutation , which confers resistance to currently available TKIs .", "label": "response"}
{"id": "21333004", "sentence": "The inhibitory effects of Mig6 and @DRUG$ are indicated by red lines . E11 : EGFR homodimer ; ShcP : free phosphorylated Shc ; E11P : phosphorylated EGFR homodimer ; Raf1A : activated Raf1 ; MEKP : singly phosphorylated MEK ; MEKPP : doubly phosphorylated @GENE$ ; ERKP : singly phosphorylated ERK ; ERKPP : doubly phosphorylated ERK . To investigate cell-specific EGFR signaling dynamics , we constructed an H1299WT model ( WT model ) , an H1299EGFR-WT model ( EGFR-WT model ) , and two alternate H1299L858R models ( @VARIANT$ model A with Mig6 overexpression and L858R model B with Cbl overexpression ) .", "label": "None"}
{"id": "22655263", "sentence": "When tested in Ba/F3 cells driven by ALK mutants identified in @DRUG$ relapsed patients , NMS-E628 is circa fivefold more potent than crizotinib in inhibiting the proliferation of @VARIANT$ @GENE$ and C1156Y ALK-driven-cells in vitro and in vivo ( Ardini et al. , ) .", "label": "resistance"}
{"id": "22039466", "sentence": "Total protein extracts were analyzed by Western blotting for P-Akt S473 and total Akt ( left panels ) or @GENE$ total p70S6K ( @VARIANT$ , right panels ) . Phospho-Akt blots for Hec1A and KLE cells were subjected to a long exposure to visualize low levels of Akt phosphorylation . In contrast to BEZ235 and ZSTK474 , other molecular inhibitors including AZD6244 ( MEK inhibitor ) , LBH589 ( HDAC inhibitor ) , LY29004 ( PI3K inhibitor ) , or AZD2171 ( VEGFR/PDGFR inhibitor ) did not reverse @DRUG$ mediated compensatory Akt phosphorylation in Hec50co and Ishikawa H cells ( and Supporting ) , though these inhibitors have been previously shown to block rapalog induced Akt phosphorylation in other cell lines , , .", "label": "None"}
{"id": "24348666", "sentence": "The two mutations were shown to independently induce @DRUG$ resistance in @GENE$ cells engineered to express the @VARIANT$ and C1156Y mutations .", "label": "None"}
{"id": "23937717", "sentence": "Our present study and those of others showed that geftinib can partially up-regulate NKG2D ligands @GENE$ , ULBP2 or MICA on tumor cells [ ] . We also found @DRUG$ or NK cells could enhance MHC-I expression , which impairs the recognization of NK cells , in lung tumor cells with wild type EGFR , while not in those with EGFR @VARIANT$ + T790M .", "label": "None"}
{"id": "25156441", "sentence": "After phenol-chloroform extraction and @DRUG$ precipitation , the RNAs were incubated with 100 μM preadenylated 3′-adaptor oligonucleotide ( Linker-1 , IDT Inc ; Coralville , Iowa ) , 5 % DMSO ( Sigma-Aldrich ) and 200 units T4 RNA ligase 2 ( truncated @VARIANT$ ; New England Biolabs , Ipswich , MA ) at 16°C for overnight . Next , the ligated products were purified on a 12 % denaturing polyacrylamide gel , followed by incubation with T4 polynucleotide kinase ( New England Biolabs ) at 37°C for 30 min and a second ligation reaction with a 5′-adaptor oligonucleotide , 5′-ACG CTC @GENE$ CGA TCTv−3′ ( uppercase , DNA ; v represents barcode with triple RNA molecules , aaa , ggg , ccc or uuu ; IDT ) at 37oC for 1 hr .", "label": "None"}
{"id": "18937829", "sentence": "Control patients 18 f 72 Rectum 5FU 1 1 0 - 20 0 19 f 54 Gastric 5FU-FA-P 2 1 0 c.1679T & gt ; G , I560S_21 0 20 m 59 Pancreas 5FU-FA-P 0 1 0 c.85T & gt ; C , @VARIANT$ ; c.1627A&gt ; G , I543V ( H ) 20 0 21 m 62 Colon 5FU-FA-P 0 1 0 c.85T & gt ; C , C29R ( H ) ; c.496A&gt ; G , M166V , c.1236G&gt;A , E412E 19 0 22 f 64 Colon 5FU-FA 0 0 0 c.85T & gt ; C , C29R ; c.1627A&gt ; G , I543V 20 0 23 m 63 Oesophagus 5FU-P_1 0 0 - 20 0 24 f 69 Colon 5FU-FA 0 1 0 c.85T & gt ; C , C29R ( H ) ; c.496A&gt ; G , M166V ; c.2194G&gt;A , V732I 20 0 25 m 59 Gastric 5FU-FA_1 1 0 c.85T & gt ; C , C29R ; c.1627A&gt ; G , I543V ; 1896T & gt ; C , F632F 21 0 26 m 59 Colon 5FU-FA-P 1 1 0 c.85T & gt ; C , C29R ( H ) ; @GENE$ ; G , M166V ; c.1627A&gt ; G , I543V 20 0 27 m 62 Gastric E-CAPE-P_2_1 2 c.85T & gt ; C , C29R ( H ) ; c.496A&gt ; G , M166V ; c.1236G&gt;A , E412E c.1627A&gt ; G , I543V 30 0 Abbreviations : FA , @DRUG$ CAPE , capecitabine ; P , platinum compound ; E , epirubicin ; C , cyclophosphamide ; H , homozygous carrier a adenocarcinoma of unknown origin", "label": "None"}
{"id": "20300583", "sentence": "In the one case of discordance between KRAS mutation status before and after combined cetuximab therapy ( case # 4 ) , a mutated KRAS gene ( Exon 2 @VARIANT$ ) was found in the primary CRC , while no @GENE$ mutation was observed in a liver metastasis sample obtained after combined @DRUG$ therapy ( ) .", "label": "sensitivity"}
{"id": "23788917", "sentence": "Presence of @VARIANT$ substitution may be an indication for treatment with irreversible @GENE$ TKI , such as neratinib , keratinib and especially @DRUG$ , which is currently in the third phase of clinical trials .", "label": "response"}
{"id": "25429239", "sentence": "In the case of @DRUG$ , the median PFS in the PROFILE studies was 7.7 months . Similarly , in EGFR mutated tumors , the efficacy of TKIs is limited by the development of resistance mechanisms , the commonest of which is the secondary @VARIANT$ mutation within exon 20 of the @GENE$ gene. , The presence of T790M gatekeeper resistance resulting in failure of treatment accounts for about 50 % of secondary resistance with other mechanisms including activation of bypass mechanisms such as amplification of the MET proto-oncogene and transformation into small-cell lung cancer .", "label": "None"}
{"id": "23861935", "sentence": "The latter binds the @GENE$ to mediate HASMC contraction . Unlike our data showing a decreased expression of CysLT1R in response to Pam3CSK4 , poly ( I:C ) , LPS , @DRUG$ and iE-DAP , Morishima et al. have recently shown that poly ( I:C ) decreased the muscarinic acetylcholine receptor @VARIANT$ and increased M3R expression without affecting histamine receptor H1R or CysLT1R , which correlated to intracellular calcium mobilization .", "label": "None"}
{"id": "23723712", "sentence": "Gefitinib and @DRUG$ represent the first generation of small EGFR tyrosine kinase inhibitors ( TKIs ) that selectively target the intracellular tyrosine kinase domain of @GENE$ , blocking the downstream signaling of the receptor . The EGFR somatic mutations have emerged to be the most relevant predictor of response to these agents. , Thus , several prospective randomized trials have demonstrated that the use of EGFR TKIs in patients with advanced treatment-naive NSCLC with EGFR mutations significantly improved the objective response rate ( ORR ) and progression-free survival ( PFS ) compared with standard platinum based chemotherapy.– Unfortunately , all responders eventually develop resistance , most commonly because of the emergence of a gatekeeper mutation in the kinase domain , such as @VARIANT$ in EGFR mutated NSCLC or amplification of mesenchymal–epithelial transition factor ( c-Met ) .", "label": "resistance or non-response"}
{"id": "23566546", "sentence": "Case Histrogical type @GENE$ mutation status Brinkman index Treatment agent Response IL-8 ( ng/mL ) IL-10 ( ng/mL ) RANTES ( pg/ml ) 1 Ad Ex21 @VARIANT$ 900 gefitinib PR 5.79 1.67 2 2 Ad Ex21 L858R 0 erlotinib PR_3.33 94.2 1.41 3 Ad Ex19 del 0 erlotinib PR 4.09 126 2.13 4 Ad Ex21 L858R 0 gefitinib PR_3.92 18.1 1.85 5 Ad Ex21 L858R + Ex19 del 370 erlotinib PR 21.9 1.23 2.11 6 Ad Ex19 del 0 erlotinib PR 7.05 1.37 2.56 7 Ad Ex19 del 0 gefitinib PR 4.82 1.59 2.02 8 Ad Ex21 L858R 1640 gefitinib PR 54.9 2.7 2.38 9 Ad negative 400 erlotinib SD 34.9 3.39 3.66 10 Ad negative 0 erlotinib SD 27.1 4.94 2.25 11 Ad unknown 1800 @DRUG$ SD NE NE NE 12 Sq Ex19 del 3840 gefitinib SD 12.6 1.1 1.98 13 Ad Ex19 del 30 erlotinib SD 5.27 0.69 2.66 14 Ad Ex19 del 0 erlotinib SD 10.5 0.85 2.5 15 Ad unknown 300 erlotinib SD 7.69 2.61 1.7 16 La negative 2080 erlotinib SD NE NE NE 17 Sq Ex21 L858R 750 erlotinib SD 11.6 56.3 3.06 18 Ad unknown 600 erlotinib SD 13.7 1.1 2.82 19 Ad Ex21 L858R 0 erlotinib SD 20.6 11.6 0.783 20 Ad Ex19 del 0 erlotinib SD 14.8 2.07 2.02 21 Ad Ex21 L858R + Ex19 del 0 gefitinib SD 3.04 1.3 1.76 22 Ad Ex19 del 200 gefitinib SD 10.9 1.59 1.91 23 Sq unknown 1560 erlotinib PD NE NE NE 24 Ad negative 1080 erlotinib PD 25.2 8.15 1.57 25 Ad unknown 0 erlotinib PD NE NE NE 26 Ad Ex18 G719A 2000 erlotinib PD 11.6 4.48 3.12 27 Ad unknown 1410 erlotinib PD NE NE NE 28 Ad Ex19 del 1000 gefitinib PD 9.44 2.25 2.89 29 Ad negative 1100 erlotinib PD 56.3 5.63 2.16 30 Ad negative 2000 erlotinib PD 15.6 0.85 0.292 31 Ad negative 825 erlotinib PD 8.27 1.59 2.13 32 Ad Ex21 L858R 0 erlotinib PD 5.34 7.05 1.7 33 Ad negative 1680 erlotinib PD 57.7 1.63 2.06", "label": "sensitivity"}
{"id": "25120654", "sentence": "In conclusion , the current study reports a rare case of lung cancer harboring an @VARIANT$ point mutation of exon 21 and a compound T790M @GENE$ substitution mutation following treatment with @DRUG$ .", "label": "sensitivity"}
{"id": "23805327", "sentence": "Mutations in the @GENE$ found in many advanced lung cancer patients who respond positively to EGFR tyrosine kinase inhibitors , gefitinib or @DRUG$ , . However , many of these patients eventually relapse and develop resistance to these EGFR inhibitors . The @VARIANT$ mutation on exon 20 of the EGFR receptor has been reported as one of the driving mutations for the acquired resistance to gefitinib treatment .", "label": "resistance or non-response"}
{"id": "25465236", "sentence": "( C ) EGFR @VARIANT$ mutant does not resemble pEGFR unlike the EGFR L858R mutant shown in B. ( D–F ) increased inhibition potency for Erlotinib against EGFR L858R mutant compared to EGFR WT protein and subsequent decrease in potency for Erlotinib against EGFR L858R + E884K double mutant . ( G–I ) increased inhibition potency for @DRUG$ against @GENE$ L858R mutant compared to EGFR WT protein and subsequent further increase in potency for Gefitinib against EGFR L858R + E884K double mutant .", "label": "resistance or non-response"}
{"id": "23134774", "sentence": "Moreover , they demonstrate that the transcriptional response to OH-tamoxifen in @VARIANT$ and ECC1 cells can be , in fact , be inverted by over expressing either co-activator SRC-1 or co-repressor @GENE$ .", "label": "None"}
{"id": "22751098", "sentence": "Our analysis of the clinical specimens shows that AXL upregulation is the second most common mechanism of EGFR TKI acquired resistance ( after EGFR @VARIANT$ ) in EGFR-mutant NSCLCs that has been validated using primary human data . Importantly , we found upregulation of AXL in patients that developed resistance to both @GENE$ TKIs ( erlotinib and @DRUG$ ) that are clinically approved for use in NSCLC patients worldwide .", "label": "resistance or non-response"}
{"id": "19238632", "sentence": "At present , no FDA approved inhibitor drugs have been shown to be successful in overcoming @VARIANT$ mediated resistance clinically . Alternative novel therapies to target lung cancer patients with intrinsic or acquired resistance to @DRUG$ are needed . In this study , we identified that there is frequent co-expression of MET and @GENE$ in NSCLC cell lines .", "label": "resistance or non-response"}
{"id": "15737014", "sentence": "This cell line had previously been shown by others to contain a 2573 T→G mutation in exon 21 ( @VARIANT$ ) [ ] , which we confirmed ( D , upper panel ) ; in addition , H1975 was reported to be more sensitive to @DRUG$ inhibition than other lung cancer cell lines bearing wild-type @GENE$ [ ] .", "label": "sensitivity"}
{"id": "21605429", "sentence": "Lastly , knowledge of the predictive and prognostic value of mutational status could lead physicians to establish the dose of imatinib , identify those patients who would not benefit from @DRUG$ treatment ( @GENE$ exon 18 @VARIANT$ mutant tumors are imatinib resistant ) , chose a second line therapy , and evaluate the different risk of relapse during follow-up .", "label": "resistance or non-response"}
{"id": "22569033", "sentence": "In one large series of 289 GISTs with @GENE$ mutations , 181 ( 63 percent ) had the imatinib-resistant substitution @VARIANT$ .", "label": "resistance or non-response"}
{"id": "20224651", "sentence": "( ii ) The downregulation of ErbB2 and ErbB3/Akt/FLIP and survivin signaling events is necessary for α-TEA induced apoptosis , and ( iii ) ErbB1 is highly expressed in the A2780/CP70R cells and below levels of detection in the @VARIANT$ cells , suggesting that ErbB1 may play a role @DRUG$ @DRUG$ resistance . Taken together with previous data that showed that α-TEA induces apoptosis via @GENE$ Fas ( CD95 ) /FasL mitochondrial dependent signaling events [ ] , we have summarized our current understanding of α-TEA induced apoptosis in human ovarian cancer cells in .", "label": "None"}
{"id": "17927446", "sentence": "Lungs from all EGFR-transgenic animals expressed the induced oncoprotein , as measured by immunoreactivity of lysates with antisera against the specific @VARIANT$ EGFR [ ] ( A ) . At 13 h after treatment , lung tissues from control treated animals expressed high levels of phosphorylated EGFR , while @GENE$ phosphorylation was abolished in lungs from @DRUG$ treated mice .", "label": "sensitivity"}
{"id": "25033171", "sentence": "In addition , we have analyzed the energetic contribution to crizotinib on residue level as well , which showed that the residue Leu18 ( located just in the P-loop region ) contributed the most to the attenuated binding of @DRUG$ to G2032R-ROS1 as shown in , therefore well supporting the issue that the P-loop conformation governs crizotinib resistance in @VARIANT$ mutated @GENE$ tyrosine kinase .", "label": "resistance"}
{"id": "23788917", "sentence": "In vitro studies and some case reports have shown that @DRUG$ is effective ( cell apoptosis and disease stabilisation ) in cells harbouring the @VARIANT$ mutation in NSCLC patients [ , – ] . The mechanism of mutation appearance in NSCLC recurrence in @GENE$ TKI treated patients should be thoroughly examined .", "label": "response"}
{"id": "19774209", "sentence": "Contrarily , a point mutation in the EGFR gene , which results in the substitution of methionine for threonine at position 790 ( @VARIANT$ ) , decreases the ability of @DRUG$ or gefitinib to inhibit @GENE$ .", "label": "resistance or non-response"}
{"id": "25101240", "sentence": "A recent report of a @VARIANT$ mutation in the @GENE$ TK domain leading to @DRUG$ resistance has also been identified ( ) .", "label": "resistance"}
{"id": "23520446", "sentence": "Approximately 50 % of EGFR mutations consist of deletions in exon 19 , whereas 35–45 % consist of the @VARIANT$ mutation and 5 % consist of insertions in exon 20 or the L861Q mutation – . @DRUG$ ( Iressa ) and Erlotinib ( Tarceva ) are EGFR inhibitors that are used clinically for the treatment of advanced NSCLC , primarily that with @GENE$ mutations in the tyrosine kinase domains – .", "label": "sensitivity"}
{"id": "20459770", "sentence": "In NSCLC , approximately 85 % of patients who responded favourably to @DRUG$ or erlotinib , two FDA approved small-molecule EGFR-tyrosine-kinase inhibitors , were shown to have somatic mutations in the @GENE$ gene . Somatic EGFR mutations are primarily located in exons 18 through 21 around the ATP binding pocket of the tyrosine kinase domain [ - ] . The most common mutations are short deletions in exon 19 affecting the amino acid sequence LREA ( DelE746-A750 ) or a point mutation in exon 21 resulting in the amino acid change @VARIANT$ .", "label": "sensitivity"}
{"id": "12644824", "sentence": "Purified @GENE$ protein ( lane 1 ) and aliquots of detergent extracts from @VARIANT$ cells grown in either endogenous steroid containing serum-free medium ( lane 2 ; C whole ) , steroid depleted serum-free medium containing @DRUG$ vehicle ( lane 3 ; C stripped ) or steroid depleted serum-free medium containing 10 nM exogenous E2 ( lane 4 ) were immunoblotted using antifibulin-1 3A11 mAb ( A ) , anti-PR mAb ( B ) , and antiactin mAb ( C ) .", "label": "None"}
{"id": "19390621", "sentence": "One limitation of this study is that having genotyped only one mitochondrial variant , we are unable to categorize the participants of this study into well defined mitochondrial haplogroups as done by @GENE$ et al . However given the prior work published on the non-synonymous A10398G ( @VARIANT$ ) polymorphism in the mitochondrial NADH dehydrogenase subunit 3 (ND3) and breast cancer risk – coupled with the possibility of its putative function , we feel that the a priori hypothesis of an interaction between @DRUG$ consumption and the A10398G polymorphism on breast cancer risk is relatively strong .", "label": "None"}
{"id": "20694077", "sentence": "However , the T315I mutant remained resistant to nilotinib at concentrations & lt ; 10 μM. , Nilotinib also potently inhibited tyrosine autophosphorylation of the E255K , E255V , @VARIANT$ , M351T , and F486S @GENE$ mutants , and these effects were not associated with decreases in Abl or Bcr-Abl protein levels . Overall , these results supported the conclusion that many imatinib-resistant Bcr-Abl mutants were relatively or absolutely more sensitive to nilotinib .", "label": "None"}
{"id": "16173832", "sentence": "Pao et al. and Kobayashi et al. identified four cases with lung adenocarcinoma harboring pre existing mutations of @GENE$ as delL747–E749 plus A750P , delE746–A750 , or delL747–S752 , prior to the use of @DRUG$ or erlotinib [ , ] . All of them had exposure to previous systemic chemotherapies and took a small-molecule tyrosine kinase inhibitor as the second- or third-line therapy , then all acquired a second mutation @VARIANT$ in the following months after disease progression .", "label": "resistance or non-response"}
{"id": "23788917", "sentence": "These patients were treated with erlotinib or @DRUG$ . Activating mutations in @GENE$ were detected in cells obtained from primary tumour , circulating tumour cells in peripheral blood ( consistency of results – 92 % ) and in free circulating DNA ( consistency of results – 33 % ) . The authors also investigated presence of the @VARIANT$ mutation in similar samples , and they detected cells harbouring that mutation in 10 patients ( n = 26 ; 38.5 % ) .", "label": "resistance or non-response"}
{"id": "22970367", "sentence": "Moreover , dual inhibition of EGFR with an irreversible EGFR inhibitor ( afatinib ) and the EGFR neutralizing antibody cetuximab has recently shown promising activity in EGFR mutant lung cancers with acquired EGFR TKI resistance that harbor an EGFR @VARIANT$ mutation [ ] . Recently , a clinical trial was conducted to investigate whether there would be any additional clinical benefit with the addition of systemic chemotherapy to an EGFR TKI in lung cancer patients . In the subgroup of 66 patients with an @GENE$ mutation who received either single-agent @DRUG$ or concurrent combination of chemotherapy and erlotinib , progression free survival was 15.7 and 17.2 months , respectively , in this trial .", "label": "resistance or non-response"}
{"id": "25505694", "sentence": "@DRUG$ , an oral small-molecule inhibitor of EGFR , VEGFR-2 , HER2 and @GENE$ in preclinical studies showed efficacy against EGFR-driven tumors , including those harboring @VARIANT$ [ ] .", "label": "None"}
{"id": "21687596", "sentence": "Analogous secondary mutations of the BCR-ABL gene in case of chronic myelogenous leukemia ( CML ) [ ] and the KIT gene in case of gastrointestinal stromal tumor [ ] have previously been reported as mechanisms of @DRUG$ resistance , which is also a TKI . The structural similarity between ABL and EGFR tyrosine kinases is considerably high , and T315I in ABL corresponds to @VARIANT$ in EGFR [ ] . Using @GENE$ cells , Azam et al. revealed that a gatekeeper threonine mutation stabilizes an active conformation of these tyrosine kinases through a network of hydrophobic interactions known as the hydrophobic spine and has a transforming function [ ] .The authors anticipated that this regulatory mechanism would be conserved across the kinase family .", "label": "None"}
{"id": "24375389", "sentence": "Other examples of useful biomarkers are KRAS mutation testing to predict benefit from monoclonal antibodies against EGFR , @DRUG$ and panitumumab , in metastatic colon cancer [ ] and BRAF @VARIANT$ mutation analysis in metastatic melanoma in order to predict responsiveness to @GENE$ inhibitors such as vemurafenib [ ] .", "label": "resistance or non-response"}
{"id": "21687596", "sentence": "Ercan et al. established a resistant cell line for an irreversible @GENE$ by subjecting a reversible EGFR-TKI resistant cell line with a @VARIANT$ mutation ( established by long-term exposure of exon 19 deletion mutant PC9 cells to @DRUG$ ) to long-term exposure to PF-00299804 [ ] .", "label": "resistance or non-response"}
{"id": "18828913", "sentence": "In various biological assays , P-loop mutants Y253F and @VARIANT$ exhibited an increased transformation potency relative to unmutated BCR-ABL. Overall , the relative transformation potencies of various mutations were found to be as follows : Y253F & gt ; E255K & gt ; native BCR-ABL ≥ T315I & gt ; H396P &gt ; M351T . Transformation potency also correlated with intrinsic @GENE$ kinase activity in this study . Two agents are currently approved for second-line treatment of patients with CML who demonstrate resistance ( or intolerance ) to imatinib : @DRUG$ and nilotinib [ , ] .", "label": "None"}
{"id": "23818899", "sentence": "EGFR KRAS ( mutation ) Colorectal Cancer ( expressing metastatic colorectal carcinoma , EGFR ) **Therascreen KRAS Test ( Qiagen , Corporate Headquarters , Nederland 's ) **Erbitux , cetuximab ( ImClone , ImClone Systems , NJ ) **Vectibix , panitumumab ( Amgen , Amgen Inc , . CA ) [ , , ] @GENE$ @VARIANT$ ( mutation ) Melanoma ( metastatic melanoma with BRAFV600E mutation ) **Cobas 4800 BRAF V600 Mutation Test ( Panagene , Corporate Headquarters , Korea ) **Zelboraf , vemurafenib ( Genentech/Roche ) [ , ]", "label": "resistance or non-response"}
{"id": "23805327", "sentence": "The @VARIANT$ mutation on exon 20 of the @GENE$ receptor has been reported as one of the driving mutations for the acquired resistance to @DRUG$ treatment .", "label": "resistance or non-response"}
{"id": "20532504", "sentence": "MDR1 is a @GENE$ acts as an energy dependent drug efflux pump for chemotherapeutic drugs commonly used against hematologic malignancies [ ] . Therefore , inborn genetic variations leading to a modified expression of these transporters could influence patient outcomes [ ] . In a previous study of the effect of the MDR1 @VARIANT$ single nucleotide polymorphism ( SNP ) in myeloma patients treated with dexamethasone , @DRUG$ and vincristine ( DAV ) , followed by autologous stem cell transplantation (SCT) , this SNP was predictive of the overall survival ( OS ) , but did not modify the response to treatment [ ] .", "label": "None"}
{"id": "21814597", "sentence": "The most common @GENE$ mutation , @VARIANT$ in exon 18 , is resistant to imatinib. , , In contrast , the substitution V561D in exon 12 results in an isoform of PDGFRA that is highly sensitive to imatinib. , Lasota et al. and Heinrich et al. reported @DRUG$ sensitivities for a deletion/substitution ( SPDGHE566-571R ) and an in-frame insertion mutation ( ER561-562 ) in exon 12 .", "label": "resistance or non-response"}
{"id": "15736989", "sentence": "A ribbon structure of @DRUG$ bound to the @GENE$ kinase domain ( ) shows the threonine residue at position 790 in green and the positions of the exon 19 and @VARIANT$ gain-of-function mutations .", "label": "sensitivity"}
{"id": "24982846", "sentence": "Dasatinib @GENE$ Philadelphia chromosome [ t ( 9 ; 22 ) ] positive ; T315I mutation posit Indications and usage , clinical studies , patient counseling information @DRUG$ CD25 antigen positive Indications and usage , warnings and precautions , clinical studies Erlotinib EGFR EGFR protein expression positive EGFR exon 19 deletion or exon 21 substitution ( @VARIANT$ ) positive Clinical pharmacology Indications and usage , dosage and administration , clinical pharmacology , clinical studies", "label": "None"}
{"id": "21687501", "sentence": "Consistently HTR3A rs1062613 ( @VARIANT$ ) and two polymorphisms in HTR3B ( −100 −102 AAG deletion variant and rs1176744 ) have been found to be associated with chemotherapy and @DRUG$ treatment induced vomiting and nausea ( Tremblay et al. , ; Kato et al. , ; Sugai et al. , ; Tanaka et al. , ) . 5-HT6 receptor The 5-HT6 receptor is a @GENE$ is expressed almost exclusively in the brain .", "label": "None"}
{"id": "24789720", "sentence": "The new therapy methods , which could be effective in patients with @VARIANT$ mutation includes irreversible EGFR-TKIs ( afatinib , neratinib ) . In LUX-Lung 1 study in patients after failure of erlotinib or gefitinib treatment with afatinib led to partial responses and prolongation of progression-free survival compared to placebo to 3,3 months [ , ] . Recently the studies are conducted with combining of irreversible @GENE$ and monoclonal antibody against extracellular domain of EGFR – @DRUG$ .", "label": "response"}
{"id": "24555578", "sentence": "Although these limitations exist , the different distribution of the cancer cells that had acquired the @VARIANT$ mutation primarily explains the different response to @DRUG$ observed between the intracranial and extracranial sites in this case . Conclusions It is worth administering EGFR-TKI in patients with brain metastases , even when the patient acquires @GENE$ resistance .", "label": "resistance or non-response"}
{"id": "23696715", "sentence": "A recent study compared the effect of four TKIs ( axitinib , @DRUG$ , vandetanib , and XL184 ) on cell proliferation , RET autophosphorylation , and extracellular signal regulated kinase activation in three cell lines : MZ-CRC-1 ( @VARIANT$ @GENE$ mutation ) , MTC-TT ( C634W RET mutation ) , and TPC-1 ( RET/PTC-1 rearrangement ) cells .", "label": "None"}
{"id": "24672794", "sentence": "Further in vitro studies on immature human CD34+ cells demonstrated that S1P1 upregulation decreases their chemotactic activity towards SDF-1 due to reduced cell surface expression of CXCR4 suggesting a potential interaction between @VARIANT$ and SDF-1 [ ] . These observations were recently corroborated by Golan et al. showing that short-term inhibition of @GENE$ axis during steady state conditions or during CXCR4 inhibition ( via @DRUG$ administration ) caused reduction of SDF-1 in the plasma [ ] .", "label": "None"}
{"id": "25079768", "sentence": "Mutation D802V in CSF1-R is equivalent to @VARIANT$ in @GENE$ and was reported as stabilizing the active kinase domain structure to which @DRUG$ does not bind , , as suggested by the resulting resistance to imatinib .", "label": "None"}
{"id": "20531963", "sentence": "Two patients with classic activating mutations exhibited de novo @DRUG$ resistance and had concurrent genetic anomalies usually associated with acquired TKI resistance , specifically the @VARIANT$ EGFR mutation and @GENE$ amplification .", "label": "None"}
{"id": "24236082", "sentence": "The @VARIANT$ mutant was 10–100 fold more sensitive to erlotinib and @DRUG$ than the wild type kinase , . These basic researches , randomized controlled clinical trials – and meta-analyses , thoroughly demonstrated the better treatment outcomes of the @GENE$ in mutation positive patients .", "label": "sensitivity"}
{"id": "19920910", "sentence": "In a cell-line based mutagenesis study , the emergence of @GENE$ mutations resistant to @DRUG$ , nilotinib and dasatinib were compared : 20 different mutations were identified with imatinib mesylate , 10 with nilotinib ( including only 1 novel mutation , @VARIANT$ ) and 9 with dasatinib .", "label": "None"}
{"id": "23567620", "sentence": "Finally , although molecularly targeted therapies ( that is , gefitinib or erlotinib for EGFR and @DRUG$ for @GENE$ fusions ) are effective in NSCLC , intrinsic or acquired resistances inevitably lead to recurrence and/or metastatic dissemination . This is the case of MET activation/amplification , , or acquired somatic mutations of EGFR ( T790M ) or ALK fusions ( G1269A , @VARIANT$ and ALK amplification ) . , ,", "label": "resistance"}
{"id": "24472312", "sentence": "T674I FIP1L1-PDGFRα is a “gatekeeper” mutation : substitution of the gatekeeper threonine ( T674 ) with a bulky amino acid ( I ) blocks access by imatinib and second-generation tyrosine kinase inhibitors ( TKIs ) , such as @DRUG$ and dasatinib , to a hydrophobic pocket inside the ATP binding site [ ] . This gatekeeper mutation is analogous to the @VARIANT$ mutation in @GENE$ [ , ,, ] .", "label": "None"}
{"id": "23082072", "sentence": "Further , patients with nonsmall cell lung cancer who initially responded to erlotinib or gefitinib therapy showed progression after a median of 12–13 months. , After patients developed acquired resistance confirmed on medical imaging , continuing use of erlotinib or @DRUG$ would lead to a surge in the rate of @GENE$ @VARIANT$ mutation which , in vitro , conferred resistance to treatment with erlotinib and gefitinib .", "label": "resistance or non-response"}
{"id": "25090459", "sentence": "Furthermore , although KRAS mutations are typically associated with non-responsiveness to anti-EGFR antibodies , recent data indicate that @GENE$ @VARIANT$ mutations may be a positive predictor of @DRUG$ response .", "label": "resistance or non-response"}
{"id": "24276379", "sentence": "It has even been observed that cells that have been induced to become cetuximab-resistant by continuously exposing them to cetuximab have acquired either K-Ras @VARIANT$ or K-Ras @GENE$ mutations [ ] .", "label": "None"}
{"id": "21165163", "sentence": "As compared to the large number of secondary resistance mutations noted in acquired imatinib resistance in CML , in the case of @GENE$ , there are currently only several documented resistance point mutations to @DRUG$ and erlotinib , including @VARIANT$ [ , ] , L747S [ ] and D761Y [ ] .", "label": "resistance or non-response"}
{"id": "25429239", "sentence": "It inhibits both @VARIANT$ in ALK+ NSCLC and the T790M in @GENE$ mutants . Phase I/II data for AP26113 have demonstrated efficacy in both @DRUG$ naive and resistant patients .", "label": "None"}
{"id": "20694077", "sentence": "Studies investigating the induction of mutants after exposure to imatinib under conditions that favor mutagenesis using a cell based screen indicated that resistance to @DRUG$ was associated with a limited spectrum of @GENE$ kinase mutations , mostly affecting the P-loop and @VARIANT$ .", "label": "None"}
{"id": "25349473", "sentence": "Despite the fact that the a dose of 30 mg/day showed excellent results in the Phase I trial , researchers proceeded to Phase II study using the 45 mg/day dose to ensure coverage of any and all @GENE$ TKI resistant clones.– The Phase II @DRUG$ Ph+ALL and CML Evaluation (PACE) trial enrolled 449 patients : 267 with CP-CML , 83 with accelerated phase ( AP ) -CML , and 94 with blast crisis ( BC ) -CML or Ph+ALL ( ) . Patients were eligible for the study if they were resistant or had unacceptable side effects to dasatinib or nilotinib , or harbored the @VARIANT$ mutation .", "label": "response"}
{"id": "23566546", "sentence": "Case Histrogical type @GENE$ mutation status Brinkman index Treatment agent Response IL-8 ( ng/mL ) IL-10 ( ng/mL ) RANTES ( pg/ml ) 1 Ad Ex21 @VARIANT$ 900 gefitinib PR 5.79 1.67 2 2 Ad Ex21 L858R 0 erlotinib PR_3.33 94.2 1.41 3 Ad Ex19 del 0 erlotinib PR 4.09 126 2.13 4 Ad Ex21 L858R 0 gefitinib PR_3.92 18.1 1.85 5 Ad Ex21 L858R + Ex19 del 370 erlotinib PR 21.9 1.23 2.11 6 Ad Ex19 del 0 erlotinib PR 7.05 1.37 2.56 7 Ad Ex19 del 0 gefitinib PR 4.82 1.59 2.02 8 Ad Ex21 L858R 1640 gefitinib PR 54.9 2.7 2.38 9 Ad negative 400 erlotinib SD 34.9 3.39 3.66 10 Ad negative 0 erlotinib SD 27.1 4.94 2.25 11 Ad unknown 1800 erlotinib SD NE NE NE 12 Sq Ex19 del 3840 gefitinib SD 12.6 1.1 1.98 13 Ad Ex19 del 30 erlotinib SD 5.27 0.69 2.66 14 Ad Ex19 del 0 erlotinib SD 10.5 0.85 2.5 15 Ad unknown 300 erlotinib SD 7.69 2.61 1.7 16 La negative 2080 @DRUG$ SD NE NE NE 17 Sq Ex21 L858R 750 erlotinib SD 11.6 56.3 3.06 18 Ad unknown 600 erlotinib SD 13.7 1.1 2.82 19 Ad Ex21 L858R 0 erlotinib SD 20.6 11.6 0.783 20 Ad Ex19 del 0 erlotinib SD 14.8 2.07 2.02 21 Ad Ex21 L858R + Ex19 del 0 gefitinib SD 3.04 1.3 1.76 22 Ad Ex19 del 200 gefitinib SD 10.9 1.59 1.91 23 Sq unknown 1560 erlotinib PD NE NE NE 24 Ad negative 1080 erlotinib PD 25.2 8.15 1.57 25 Ad unknown 0 erlotinib PD NE NE NE 26 Ad Ex18 G719A 2000 erlotinib PD 11.6 4.48 3.12 27 Ad unknown 1410 erlotinib PD NE NE NE 28 Ad Ex19 del 1000 gefitinib PD 9.44 2.25 2.89 29 Ad negative 1100 erlotinib PD 56.3 5.63 2.16 30 Ad negative 2000 erlotinib PD 15.6 0.85 0.292 31 Ad negative 825 erlotinib PD 8.27 1.59 2.13 32 Ad Ex21 L858R 0 erlotinib PD 5.34 7.05 1.7 33 Ad negative 1680 erlotinib PD 57.7 1.63 2.06", "label": "sensitivity"}
{"id": "20630094", "sentence": "Patients with @GENE$ V600K mutations are currently excluded from clinical trials with @DRUG$ , although the assay methodology used for the trial may not discriminate between the @VARIANT$ and V600K mutations .", "label": "None"}
{"id": "25465236", "sentence": "( C ) EGFR @VARIANT$ mutant does not resemble pEGFR unlike the EGFR L858R mutant shown in B. ( D–F ) increased inhibition potency for @DRUG$ against EGFR L858R mutant compared to @GENE$ WT protein and subsequent decrease in potency for Erlotinib against EGFR L858R + E884K double mutant .", "label": "resistance or non-response"}
{"id": "24555578", "sentence": "An analysis of the @GENE$ mutation using a PNA-LNA PCR clamp method showed that no resistant mutations ( T790M ) were detected in the sites of brain metastasis , although this mutation was detected in the extracranial sites . The detection of @VARIANT$ was associated with the clinical responsiveness to @DRUG$ in this case .", "label": "resistance or non-response"}
{"id": "25222496", "sentence": "Sequist LV ( 2013 ) LUXLUNG3 ( III ) Afatinib 40 mg/d , po @DRUG$ 500 mg/m2 , d1 , iv , q3w + cisplatin 19 170 ( 113/57 ) 0.28 ( 0.18–0.44 ) 75 mg/m2 , d1 , iv , q3w×≤6 cycles 21 138 ( 91/47 ) 0.73 ( 0.46–1.17 ) Wu YL ( 2014 ) LUXLUNG6 ( III ) Afatinib 40 mg/d , po Gemcitabine 1000 mg/m2 , d1,8 , iv , q3w + 19 186 ( 124/62 ) 0.20 ( 0.13–0.33 ) cisplatin 75 mg/m2 , d1 , iv , q3w×≤6 cycles 21 138 ( 92/46 ) 0.32 ( 0.19–0.52 ) Exon of @GENE$ mutation means either exon 19 deletion or exon 21 @VARIANT$ mutation .", "label": "None"}
{"id": "22655263", "sentence": "For the @VARIANT$ , C1156Y , and L1152R mutants , it appears that binding of the inhibitor to @GENE$ may be negatively affected by steric hindrance or conformational changes in the enzyme . F1174L , which recapitulates the primary mutation found in neuroblastoma previously shown to render the enzyme insensitive to @DRUG$ , appears instead to induce a conformational change in the protein which results in increased affinity for ATP itself .", "label": "resistance"}
{"id": "25146448", "sentence": "@GENE$ , located on human chromosome 11q21–22 , is a member of the G-protein coupled receptor family , and one of the functional and high-affinity @DRUG$ membrane receptors . MTNR1B is expressed in human and rodent pancreatic islets . Studies have shown that MTNR1B is a novel candidate gene for @VARIANT$ .", "label": "None"}
{"id": "22970367", "sentence": "In lung cancer patients , EGFR mutations are generally exclusive with KRAS and BRAF mutations , and tumors with either @GENE$ ( 15–25 % ) or BRAF ( 2-3 % ) mutations are relatively insensitive to EGFR TKIs [ , ] . The most common activating mutations ( ~90 % ) are in-frame deletions in exon 19 of EGFR and a missense mutation at 858 in exon 21 of EGFR resulting in an arginine to leucine substitution ( @VARIANT$ ) [ ] . Therapeutic agents targeting the EGFR signaling pathway , including two EGFR kinase inhibitors @DRUG$ and erlotinib , are clinically effective in treating lung cancer patients harboring these EGFR activating mutations [ – ] .", "label": "None"}
{"id": "25364578", "sentence": "The emergence of the @VARIANT$ EGFR gatekeeper mutation and up-regulation of downstream signaling by MET amplification have been described as the two main mechanisms responsible for acquired resistance . However a phase III trial enrolling only patients with @GENE$ positive tumors was stopped in early March 2014 due to futility ; there was no evidence to suggest a positive effect of addition of onartuzumab to @DRUG$ .", "label": "None"}
{"id": "25027595", "sentence": "The interaction between TM4SF5 and @GENE$ is observed by a co-immunoprecipitation approach using NSCLC expressing TM4SF5 , where the interaction is positively correlated with the @DRUG$ resistance even without EGFR mutation ( e.g. , @VARIANT$ ) following TM4SF5 overexpression .", "label": "resistance or non-response"}
{"id": "25238247", "sentence": "In an in vitro model system , the secondary mutation , ErbB2 T798I imparts the strongest @DRUG$ resistance effect in @GENE$ cells and is analogous to the epidermal growth factor receptor @VARIANT$ – .", "label": "None"}
{"id": "21559393", "sentence": "10.1371/journal.pone.0019273.t002Differently expressed genes with relevance to G2/M transition or mitosis after treatment with high concentrations of sagopilone (SAG) or @DRUG$ ( PAC ) . Identifier Gene Name Gene Symbol Fold Change 40 nM SAG Fold Change 40 nM PAC 232588_at stromal antigen 1 STAG1 12.50 11.37 207331_at centromere protein F , 350/400 ka ( mitosin ) CENPF 5.59 5.25 232466_at Cullin 4A CUL4A 4.90 4.66 1556339_a_at Ubiquitin activating enzyme @VARIANT$ ( UBA3 homolog , yeast ) UBE1C 4.03 3.89 215623_x_at SMC4 structural maintenance of chromosomes 4-like 1 ( yeast ) SMC4L1 3.97 3.75 244427_at Kinesin family member 23 KIF23 3.92 3.33 233940_at Echinoderm @GENE$ 4 EML4 3.51 3.20 242362_at Cullin 3 CUL3 2.74 n.c .", "label": "None"}
{"id": "23186157", "sentence": "In this report we also demonstrated that Dasatinib , an Abl/Src dual inhibitor , is capable of cooperating with GNF-2 in inhibiting the proliferation of @GENE$ cells carrying the native or the @VARIANT$ mutated Bcr-Abl . In fact , our data showed that the cooperation with Dasatinib was more potent than the one observed with Imatinib or @DRUG$ .", "label": "None"}
{"id": "25033171", "sentence": "Energetic contribution of important residues to the binding of @DRUG$ . Energetic spectrums ( enthalpy ) were decomposed into drug-residue pairs for ( A ) wild-type @GENE$ , and ( B ) @VARIANT$ mutated ROS1 , and their corresponding structural descriptions are shown in panel D and panel E , where the P-loop region and important residues on it ( Leu18 and Val26 ) are illustrated in orange cartoon model and stick model , respectively .", "label": "resistance"}
{"id": "15737014", "sentence": "Sequencing Chromatograms with the T790M @GENE$ Exon 20 Mutation in Various Clinical Specimens and the NSCLC Cell Line H1975 ( A–C ) In all three patients—patient 1 ( A ) , patient 2 ( B ) , and patient 3 ( C ) —the secondary T790M mutation was observed only in lesions obtained after progression on either @DRUG$ or erlotinib . ( D ) Cell line H1975 contains both an exon 21 @VARIANT$ mutation ( upper panel ) and the exon 20 T790M mutation ( lower panel ) .", "label": "sensitivity"}
{"id": "23208557", "sentence": "KRAS mutations have recently been reported to be markers of resistance for EGFR-TKI and monoclonal antibodies against EGFR , cetuximab and @DRUG$ [ – ] . @GENE$ is one of the kinase types that most frequently mutate in human tumors . In melanoma , colon and thyroid cancers , the tumor types with highest frequency of BRAF mutation , a single nucleotide substitution resulting in a gulutamic acid for valine substitution within the kinase domain at codon 600 ( @VARIANT$ ) , accounts for the majority of cases [ ] .", "label": "resistance or non-response"}
{"id": "25051360", "sentence": "Some mutations ( @VARIANT$ ) resulted in @DRUG$ resistance ; however this was not an activating mutation . All of the cells containing the HER2 mutations were sensitive to the irreversible @GENE$ kinase inhibitor , neratinib [ ] .", "label": "resistance or non-response"}
{"id": "25465236", "sentence": "On the other hand , the increased inhibition potency for Gefitinib against EGFR @VARIANT$ mutant ( compared to @GENE$ WT protein ) and subsequent further increase in potency for @DRUG$ against the EGFR L858R + E884K double mutant correlates well with the increased global connectivity of the hub residues in the mutants ( – wild type , – L858R , – L858R + E884K ) .", "label": "sensitivity"}
{"id": "25505694", "sentence": "The LUX-LUNG 3 study [ ] , a multicenter , randomized , open-label phase III study compared afatinib with @DRUG$ plus pemetrexed in patients with lung adenocarcinoma , stage IIIb/IV harboring @GENE$ mutations [ , ] . Among the 1,269 screened patients , 345 resulted eligible and were randomized in a two-to-one fashion to afatinib 40 mg daily or chemotherapy up to a maximum of six cycles ( without any maintenance therapy ) . As expected , patients were mainly East Asian , never-smokers and women ; EGFR mutations were predominantly exon 19 deletions and @VARIANT$ point mutations .", "label": "None"}
{"id": "22654561", "sentence": "Verbeek and coworkers set out to compare the efficiency of four recently developed TK inhibitors , XL184 , @DRUG$ , Sunitinib and Axitinib , using three cell lines : the first derived from sporadic MTC expressing a @VARIANT$ RET mutation , the second derived from metastatic sporadic MTC expressing a M918T @GENE$ mutation .", "label": "response"}
{"id": "24643470", "sentence": "@DRUG$ also shows activity against cancers resistant to first-generation @GENE$ inhibitors due to certain activating EGFR mutations , secondary EGFR mutations such as @VARIANT$ or tumours expressing other ErbB family receptors activated by drug induced reprogramming of signalling pathways .", "label": "response"}
{"id": "25215536", "sentence": "Though the exon 19 deletions and @VARIANT$ account for the majority of EGFR mutations , patients harboring other uncommon mutations could also benefit from EGFR-TKIs therapy . Yang et al. has suggested that the absence of an EGFR mutation , as determined by methods that only detect known mutations , should not be used as an exclusion criterion for the EGFR-TKIs therapy . In the present study , 5 of 9 @DRUG$ responders ( 55.6 % ) , who had EGFR-wt tumors by MtS methods , were found to possess @GENE$ mutations by DS .", "label": "sensitivity"}
{"id": "24964744", "sentence": "Cells with @GENE$ mutations @VARIANT$ and E545K showed greatest single agent sensitivity to the PI3K inhibitor . Interestingly , cells with these mutations also showed greater sensitivity to @DRUG$ and erlotinib than cells with the EGFR mutation ( exon 19 deletion ) , which are associated with sensitivity to EGFR inhibitors in NSCLC .", "label": "None"}
{"id": "22705791", "sentence": "We also analyzed ScMre11 Asp109 at the latching loop ( Asp118 in S. pombe , ) , mutated in human NBSLD ( human @GENE$ @VARIANT$ ) . We utilized a plate survival assay to monitor the consequences of the above mutations in response to various genotoxic agents . mre11–R76A cells are as sensitive as mre11Δ cells to methyl methanesulfonate ( MMS ) , hydroxyurea ( HU ) and the Topoisomerase 1 inhibitor @DRUG$ ( CPT ) , whereas the conservative R76K mutation causes no detectable hypersensitivity phenotype ( ) .", "label": "None"}
{"id": "24790411", "sentence": "Eight patients enrolled in the study were known to harbor a @VARIANT$ mutation on archival tissue collected at diagnosis , but authors provided no information on the outcome of these patients . It is likely that better selection on the basis of @GENE$ mutational status and acquired resistance mechanism would have translated into positive results also for the principal end point ( OS ) . LUX-Lung 4 is an exploratory Phase II trial in Japanese patients with advanced lung adenocarcinoma who failed one to two lines of chemotherapy and progressed on @DRUG$ and/or gefitinib .", "label": "resistance or non-response"}
{"id": "24348666", "sentence": "Sasaki et al. reported that cells derived from pleural effusions of patients with @GENE$ lung cancer who developed acquired resistance to @DRUG$ displayed the gatekeeper @VARIANT$ mutation and high levels of expression of EGFR ligands ( EGF and amphiregulin ) .", "label": "resistance"}
{"id": "22662320", "sentence": "Helman described their preclinical results on @DRUG$ , an old antibiotic from streptomyces , which they have identified in a 56,000 natural product EWS-FLI1 signature based screen ( Grohar et al. , ) ( Table ) . He reviewed published molecular ( inhibition of EWS-FLI1 cooperating transcription factors SP1 , @VARIANT$ , and ETS ) and first clinical results in a patient with ES ( Kofman et al. , ) , and reported on their own findings of tumor regression in TC32 xenografts .", "label": "None"}
{"id": "15737014", "sentence": "Using this insight , new small-molecule inhibitors have been identified that retain activity against the majority of imatinib-resistant @GENE$ mutants [ , ] . For example , in CML , a commonly found mutation is a C→T single nucleotide change that replaces threonine with isoleucine at position 315 ( @VARIANT$ ) in the ABL kinase domain [ , , ] .", "label": "None"}
{"id": "17352537", "sentence": "In the liquid assay , three variants for @DRUG$ ( A893S-R669C , A893S-M89T , and R669C ) and five variants for doxorubicin ( @VARIANT$ , S1141T , A893S-M89T , L662R , and R669C ) exhibited statistically significant increases in EC50 values ( p & lt ; 0.05 ) ( C ; ) . P-Gp and Its Variants @GENE$ Similar Protein Level and Subcellular Localization", "label": "None"}
{"id": "25091415", "sentence": "The main hydrogen bonding between @GENE$ ( Met 793 ) and @DRUG$ is common for the WT and mutant models ; however , the aniline ring of gefitinib was shifted upward in DM when compared to WT EGFR . The dictionary of secondary structure of protein ( DSSP ) program was applied to the secondary structure of the EGFR WT and mutant models , and the resulting fluctuations were illustrated in ( A–D ) . In the @VARIANT$ mutation , minimal changes were observed in the coil region that remains near to the point mutant region .", "label": "sensitivity"}
{"id": "15737014", "sentence": "Importantly , we find that the T790M mutation confers drug resistance not just to wild-type @GENE$ but also to mutant EGFRs associated with clinical responsiveness to EGFR tyrosine kinase inhibitors [ , , ] . In tumors from patients not treated with either gefitinib or @DRUG$ , the 2369 C→T mutation ( T790M ) appears to be extremely rare . We have not identified this mutation in 155 tumors ( see above ) , and among nearly 1,300 lung cancers in which analysis of EGFR exons 18 to 21 has been performed [ , ,, , , ] , only one tumor ( which also harbored an @VARIANT$ mutation ) was reported to contain the T790M mutation .", "label": "sensitivity"}
{"id": "25505694", "sentence": "@DRUG$ , an oral small-molecule inhibitor of EGFR , @GENE$ , HER2 and Ephrin type-B receptor 4 (EphB4) , in preclinical studies showed efficacy against EGFR-driven tumors , including those harboring @VARIANT$ [ ] .", "label": "None"}
{"id": "25486409", "sentence": "As the second-generation , irreversible @GENE$ , such as afatinib and dacomitinib , failed to overcome the resistance caused by @VARIANT$ , , other measures , such as EGFR dual targeting with @DRUG$ and afatinib and third-geneneration , mutant-selective EGFR-TKIs – are being actively evaluated .", "label": "response"}
{"id": "25486409", "sentence": "These results suggest that the addition of CX-4945 to EGFR-TKI may overcome @VARIANT$ mediated resistance through the increased activity of EGFR-TKI to suppress EGFR signals by the down-regulation of EGFR . 10.1371/journal.pone.0114000.g004Addition of CX-4945 to @GENE$ substantially suppressed the EGFR signaling pathway in gefitinib/erlotinib-resistant , PC-9 cells .", "label": "resistance or non-response"}
{"id": "17927446", "sentence": "The IC50 values corresponded with the degrees of inhibition of phosphorylation of @GENE$ and key components of downstream signaling cascades ( i.e. , ERK and AKT ) , as seen by immunoblotting lysates derived from the lines treated with various concentrations of drug with phospho-specific antibodies ( ) . H1975 cells were insensitive to @DRUG$ due to the drug-resistant @VARIANT$ mutation [ ] .", "label": "resistance or non-response"}
{"id": "23788917", "sentence": "Unfortunately , more than half of patients with MET gene amplification also presented the @VARIANT$ mutation in the EGFR gene . Despite the lack of unequivocal efficacy , simultaneous inhibition of c-MET and EGFR function seems to be an attractive alternative therapeutic option in resistance to reversible EGFR TKI . There are ongoing second and third phase trials of the c-MET inhibitors tivantinib and PF-2341066 , used together with erlotinib in patients previously untreated with @GENE$ TKI or in case of progression after successful monotherapy with @DRUG$ [ , – ] .", "label": "resistance or non-response"}
{"id": "25100284", "sentence": "In studies where mutation types were reported individually the most common EGFR mutations were exon 19 deletions ( 53 % ) and @VARIANT$ mutations ( 38 % ) . Characteristics of the studies included in the pooled analysis to evaluate the effects of single-agent erlotinib , single-agent @DRUG$ or chemotherapy in patients with @GENE$ mutation positive NSCLC ( studies not included in the original analysis are highlighted )", "label": "sensitivity"}
{"id": "21192840", "sentence": "Tumor type @GENE$ mutation EGFR expression changes EGFR targeting agents ( FDA approved for clinical use ) Resistance mechanisms Non-small cell lung cancer Kinase domain deletions ( exon 19 ) , point mutations ( exon 21 ) Gene amplification @DRUG$ , Gefitinib @VARIANT$ gatekeeper mutation ( 50 % ) , , elevated c-Met/HGF expression ( 20 % ) –", "label": "resistance or non-response"}
{"id": "24339922", "sentence": "Approximately 70–80 % of NSCLCs harbouring a somatic mutation in the tyrosine kinase domain of the @GENE$ gene respond to gefitinib/erlotinib , , . However , acquired resistance to EGFR-TKI therapy almost always develops after a median of approximately 10 months from the onset of treatment , even in patients who exhibit an initial dramatic response to these agents . Acquired resistance has been associated with a secondary mutation in the EGFR gene , @VARIANT$ , , which has been detected in approximately 50 % of cancers with acquired resistance to EGFR-TKIs , .", "label": "resistance or non-response"}
{"id": "25146448", "sentence": "MTNR1B , located on human chromosome 11q21–22 , is a member of the @GENE$ , and one of the functional and high-affinity @DRUG$ membrane receptors . MTNR1B is expressed in human and rodent pancreatic islets . Studies have shown that MTNR1B is a novel candidate gene for @VARIANT$ .", "label": "None"}
{"id": "21364648", "sentence": "To further elucidate the link between p53 dependent transcription and @GENE$ activity , we have screened by qPCR several p53 dependent genes upon 6 h of @DRUG$ treatment . Conversely , no transcription was induced in MEB-Med8A cells , where the p53 pathway was found to be mutated . The high levels of Fas receptor transcripts were reflected in the expression of the receptor at the plasma membrane in D283-MED and MHH-Med1 cells as measured by immunocytochemistry and flow cytometry ( and Supplementary Figure @VARIANT$ ) .", "label": "None"}
{"id": "23935640", "sentence": "@DRUG$ ( AP24534 ) is an orally administered TKI designed to inhibit @GENE$ with mutations , especially @VARIANT$ , which confers resistance to other TKI such as imatinib , dasatinib , nilotinib , and bosutinib ( reviewed in [ , ] ) .", "label": "response"}
{"id": "24401087", "sentence": "The induction of Stat6 mRNA expression by progesterone was inhibited by @DRUG$ an inhibitor of RNA polymerase II ) but not by cycloheximide ( a transcriptional inhibitor of protein synthesis ) ( Figure A , right panel ) , indicating that progesterone bound PR could directly induce @GENE$ gene transcription . Correlating with the mRNA data , Stat6 protein levels increased in progesterone treated @VARIANT$ cells , as shown by Confocal Laser Scanning Microscopy after 24 h of progesterone treatment ( Figure B ) .", "label": "None"}
{"id": "25414382", "sentence": "All mutations with a relative frequency above 2 ( 0.2 % ) were then checked in PubMed by introducing the name of the mutation ( e.g. @VARIANT$ ) and added to the dataset if they were found to have functional effects . EGFR mutations conferring a response rate to @DRUG$ higher than 50 % , according to the @GENE$ somatic mutations database ( http : //www.somaticmutations-egfr.info/ ) , were also added .", "label": "None"}
{"id": "22038681", "sentence": "Preliminary results from an ongoing phase 1 dose-escalation study of the multikinase , @GENE$ inhibitor @DRUG$ ( AP24534 ) showed antileukemic activity in patients with refractory CML , including patients with the @VARIANT$ mutation .", "label": "None"}
{"id": "18937829", "sentence": "Control patients 18 f 72 Rectum 5FU 1 1 0 - 20 0 19 f 54 Gastric 5FU-FA-P 2 1 0 c.1679T & gt ; G , I560S_21 0 20 m 59 Pancreas 5FU-FA-P 0 1 0 c.85T & gt ; C , C29R ; c.1627A&gt ; G , I543V ( H ) 20 0 21 m 62 Colon 5FU-FA-P 0 1 0 c.85T & gt ; C , C29R ( H ) ; c.496A&gt ; G , M166V , c.1236G&gt;A , E412E 19 0 22 f 64 Colon 5FU-FA 0 0 0 c.85T & gt ; C , C29R ; c.1627A&gt ; G , I543V 20 0 23 m 63 Oesophagus 5FU-P_1 0 0 - 20 0 24 f 69 Colon 5FU-FA 0 1 0 c.85T & gt ; C , C29R ( H ) ; c.496A&gt ; G , M166V ; c.2194G&gt;A , V732I 20 0 25 m 59 Gastric 5FU-FA_1 1 0 c.85T & gt ; C , C29R ; c.1627A&gt ; G , I543V ; 1896T & gt ; C , @VARIANT$ 21 0 26 m 59 Colon 5FU-FA-P 1 1 0 c.85T & gt ; C , C29R ( H ) ; c.496A&gt ; G , M166V ; @GENE$ ; G , I543V 20 0 27 m 62 Gastric E-CAPE-P_2_1 2 c.85T & gt ; C , C29R ( H ) ; c.496A&gt ; G , M166V ; c.1236G&gt;A , E412E c.1627A&gt ; G , I543V 30 0 Abbreviations : FA , folinic acid ; CAPE , capecitabine ; P , platinum compound ; E , @DRUG$ ; C , cyclophosphamide ; H , homozygous carrier a adenocarcinoma of unknown origin", "label": "None"}
{"id": "23144978", "sentence": "One mechanism to resistance was recently elucidated : @DRUG$ resistant cells contain an @GENE$ mutation in the extracellular domain ( @VARIANT$ ) that impairs cetuximab , but not epidermal growth factor (EGF) binding .", "label": "resistance"}
{"id": "24959281", "sentence": "The most common type of malignant tumor arising from FD is @GENE$ ( ~70 % ) , followed by fibrosarcoma ( ~20 % ) , and chondrosarcoma ( ~10 % ) , with malignant fibrous histiocytoma ( ~4 % ) occurring less commonly ( ) . Activating missense mutations in the guanine nucleotide binding protein α-subunit ( GNAS ) gene , which encodes the stimulatory α subunit of the G-protein ( Gsα ) , resulting in a change at the Arg 201 codon from arginine to cysteine ( Arg-to-Cys , R201C ) or arginine to @DRUG$ ( Arg-to-His , @VARIANT$ ) have been identified in both the monostotic and polyostotic forms of FD , as well as in McCune-Albright syndrome ( – ) .", "label": "None"}
{"id": "24386407", "sentence": "Several strategies have been proposed to overcome resistance to reversible EGFR-TKIs , including treatment with @DRUG$ , an anti-EGFR antibody [ ] , Hsp90 inhibitors [ ] , PI3K/mTOR inhibitor [ ] , and mutant-selective @GENE$ [ ] . Of them , mutant-selective EGFR-TKIs have shown activity not only against tumors harboring exon19 deletions and the L858R mutation , but against tumors with the @VARIANT$ resistance mutation .", "label": "response"}
{"id": "25431951", "sentence": "Additional inhibition of the upstream or downstream molecules of BCR-ABL might significantly enhance the effect of targeting @GENE$ [ , - ] . These approaches may be potentially applied to targeting imatinib-resistant FIP1L1-PDGFRα . Several compounds have been reported to overcome the @VARIANT$ mutant , such as @DRUG$ [ ] , EXEL-0862 [ ] , PKC412 ( midostaurin ) [ ] , sorafenib [ ] , ponatinib [ ] , and DCC-2036 [ ] in vitro .", "label": "None"}
{"id": "25536104", "sentence": "Bose et al. , noted that @VARIANT$ mutation was associated with negative ERBB2 protein expression and resistance to @DRUG$ . Irreversible small molecule tyrosine kinase inhibitors ( TKIs ) , including afatinib , neratinib and dacomatinib may be of value in this setting . Furthermore , since ERBB2 activation can transactivate several other signaling mechanisms , combinations of ERBB2 directed TKIs with trastuzumab , mTOR or @GENE$ inhibitors may be of value in this disease given its genomic profile .", "label": "None"}
{"id": "24009732", "sentence": "However , the secondary mutation T674I FIP1L1-PDGFRα in its kinase domain has been found in imatinib-refractory @GENE$ or CEL . T674I FIP1L1-PDGFRα , analogous to @VARIANT$ Bcr-Abl in CML , is also resistant to the second-generation TKIs , such as @DRUG$ .", "label": "None"}
{"id": "25278773", "sentence": "There were five ( 8.1 % ) patients who had RECIST partial response , and two patients with secondary T790M mutations ( @VARIANT$ T790M , and deletion in exon 19 T790M ) achieved disease stabilization for 9 months and 1 month , respectively . Afatinib in squamous NSCLC : LUX-Lung 8 study In view of the antitumor activity observed in @GENE$ patients with first-generation EGFR inhibitors , coupled with evidence of benefit with other irreversible pan-HER inhibitors , this study was initiated to assess the activity of afatinib versus @DRUG$ in squamous subtype NSCLC after the failure of at least one prior platinum based chemotherapy ( NCT01523587 ; ) .", "label": "sensitivity"}
{"id": "25405807", "sentence": "Inhibition of epidermal growth factor receptor (EGFR) kinase activity by EGFR tyrosine kinase inhibitors ( EGFR-TKIs ) , such as @DRUG$ and erlotinib , can result in improved response and prolonged progression-free survival ( PFS ) in selected non-small cell lung cancer ( NSCLC ) patients harboring sensitizing @GENE$ mutations , especially the exon 19del and exon 21 @VARIANT$ mutations – .", "label": "sensitivity"}
{"id": "22098950", "sentence": "Interestingly , the IC50 values of SN38 , mitoxantrone , @DRUG$ , daunorubicin , and etoposide for Flp-ln-293 cells expressing other variants were significantly lower than those for cells expressing wild-type @GENE$ . Notably , F208S and S441N were not expressed in the cells , suggesting that the rest of the variants ( S248P , F431L , and F489L ) may also impart impaired function of BCRP . Another study showed that the @VARIANT$ ( C.805OT , Ex7 ; rs34678167 ) and Q126Stop ( C.376OT , Ex4 ; rs72552713 ) alleles were found among Korean subjects , and that the transport activity of the P296S variant decreased based on methotrexate uptake by vesicles expressing this variant .", "label": "None"}
{"id": "24348666", "sentence": "Due to their covalent binding mode , irreversible inhibitors have activity towards EGFR @VARIANT$ , EGFR T790M/L858R as well as wild-type EGFR . Consequently , dose limitation due to the concomitant inhibition of wild-type @GENE$ is a potential concern and , in clinical settings , this accompanying inhibition translates into skin rash and diarrhea . The results of several phase III clinical trials for dacomitinib and @DRUG$ are awaited in 2013 .", "label": "response"}
{"id": "24348666", "sentence": "The concomitant inhibition of MET and EGFR using the monoclonal antiboby MetMab and @DRUG$ proved to beefficacious in a phase II trial and early clinical trials of small-molecule inhibitors of MET given with @GENE$ inhibitors are now currently underway ( ) . The combination of crizotinib ( dual c-MET/anaplastic lymphoma kinase [ALK ] inhibitor ) ( ) and dacomitinib , although in early phase , is particularly interesting since one of its components , dacomitinib , was designed to address the acquired resistance by the @VARIANT$ secondary mutation in EGFR .", "label": "resistance or non-response"}
{"id": "22034911", "sentence": "However , analogous @GENE$ xenografts expressing L1196M , @VARIANT$ , or G1269S mutants were completely insensitive to these doses , with no statistically significant changes in tumor growth rate . @DRUG$ is not efficacious in mouse Ba/F3 xenograft models expressing EML4-ALK mutants .", "label": "None"}
{"id": "23963283", "sentence": "@GENE$ @VARIANT$ and MET amplification account for approximately 60–70 % of all known causes of acquired resistance to @DRUG$ or erlotinib ; these amplifications are not mutually exclusive and can be detected in the same resistant tumor or may occur independently in different metastatic sites in the same patient .", "label": "resistance or non-response"}
{"id": "21444946", "sentence": "Since the first reports of an association between somatic mutations in @GENE$ exons 19 and 21 and response to @DRUG$ , treatment of NSCLC has changed dramatically [ , ] . It has been shown that exon 19 deletions are more sensitive to erlotinib inhibition than the @VARIANT$ mutation , a finding demonstrated by kinetic analysis [ ] and also confirmed in clinical studies [ - ] .", "label": "sensitivity"}
{"id": "15737014", "sentence": "EGFR Mutants Containing the T790M Mutation Are Resistant to Inhibition by @DRUG$ or Erlotinib 293T cells were transiently transfected with plasmids encoding wild-type ( WT ) @GENE$ or EGFR mutants with the following changes : T790M , L858R , L858R + T790M , del L747–E749 ; @VARIANT$ , or del L747–E749 ; A750P + T790M .", "label": "None"}
{"id": "23724098", "sentence": "Contrary to the preclinical data reporting that tumors with KRAS mutations , at least the specific genotype such as @VARIANT$ , would be more sensitive to @DRUG$ , , patients with @GENE$ mutations showed inferior treatment outcomes to the pemetrexed based regimen compared with those with KRAS wild types , irrespective of KRAS genotypes .", "label": "None"}
{"id": "23133538", "sentence": "Similar to gefitinib , @DRUG$ also inhibited the growth of H1819 and HCC827 cell lines ( IC50 5.0 and 0.010 micromol/L , respectively ) but did not affect the H1299 cells ( IC50 50.0 micromol/L ) . Amann et al. reported that IC50 of TKIs showed a more closely correlation with the inhibition of ERK and Akt phosphorylation and also pointed that inhibition of @GENE$ tyrosine kinase activity by means of gefitinib inhibits downstream STAT3 activity . In H3255 cells with @VARIANT$ mutation , Haura et al. found that EGFR tyrosine kinase inhibition by TKI leads to complete inhibition of pSTAT3 .", "label": "sensitivity"}
{"id": "22124674", "sentence": "Wild-type patients do not seem to benefit from adjuvant imatinib [ ] ; however , in vivo studies evaluating sunitinib [ ] and in vitro studies for @DRUG$ and dasatinib [ ] are promising . As for PDGFRA mutated GIST , PDGFRA exon 18 generally benefits from adjuvant imatinib therapy , with the exception of PDGFRA exon @GENE$ GIST [ ] .", "label": "None"}
{"id": "23937717", "sentence": "Two @DRUG$ resistance NSCLC cell lines A549 ( @GENE$ wt ) and H1975 ( EGFR L858R + @VARIANT$ ) were used .", "label": "resistance or non-response"}
{"id": "22034911", "sentence": "Consistent with this , we found that the introduction of R1275Q into EML4-ALK had no negative impact on sensitivity to @DRUG$ ( IC50 47 ± 8 nm ) . As expected , the IC50 values for viability of @GENE$ cells expressing these mutants were all above that for Ba/F3 cells expressing native EML4-ALK , with IC50s ranging from 231 to 981 nm . The three most resistant mutants , @VARIANT$ , S1206R , and G1269S , all had IC50s within twofold of parental , ALK negative , Ba/F3 cells ( IC50 1176 nm ) .", "label": "None"}
{"id": "23994953", "sentence": "Somatic mutations in exons encoding the tyrosine kinase ( TK ) domain of the @GENE$ positively associated with increased sensitivity of non-small cell lung cancer ( NSCLC ) patients to the selective EGFR TK inhibitors ( TKIs ) @DRUG$ ( Iressa™ ) and erlotinib ( Tarceva™ ) . Prospective trials have demonstrated an impressive ~75 % response rate for patients whose tumors harbor these mutations , which occur as either multinucleotide in-frame deletions in exon 19 ( e.g. , delE746-A750 ) or as single missense mutations ( e.g. , @VARIANT$ ) .", "label": "sensitivity"}
{"id": "24375389", "sentence": "Other examples of useful biomarkers are KRAS mutation testing to predict benefit from monoclonal antibodies against @GENE$ , @DRUG$ and panitumumab , in metastatic colon cancer [ ] and BRAF @VARIANT$ mutation analysis in metastatic melanoma in order to predict responsiveness to BRAF inhibitors such as vemurafenib [ ] .", "label": "None"}
{"id": "23674887", "sentence": "Preclinical activity of @DRUG$ has been reported against most IM-resistant mutants of @GENE$ with the exception of @VARIANT$ and V299L. ,", "label": "None"}
{"id": "23316473", "sentence": "In addition , the @GENE$ ratio is reduced in response to imatinib in imatinib-sensitive LAMA84 cells , while the ratio is unaltered in imatinib-resistant cells . Our ability to measure the clinical effectiveness of @VARIANT$ receptor modifying compounds in patients by monitoring effects directly on the S1P receptor would be a major advantage .", "label": "None"}
{"id": "15737014", "sentence": "Sequencing Chromatograms with the T790M EGFR Exon 20 Mutation in Various Clinical Specimens and the NSCLC Cell Line H1975 ( A–C ) In all three patients—patient 1 ( A ) , patient 2 ( B ) , and patient 3 ( C ) —the secondary T790M mutation was observed only in lesions obtained after progression on either gefitinib or @DRUG$ . ( D ) Cell line H1975 contains both an exon 21 @VARIANT$ mutation ( upper panel ) and the exon 20 T790M mutation ( lower panel ) . The asterisks indicate a common SNP ( A or G ) at nucleotide 2361 ; the arrows indicate the mutation at nucleotide 2369 ( C→T ) , which leads to substitution of methonine ( @GENE$ ) for threonine ( ACG ) at position 790 .", "label": "None"}
{"id": "24561406", "sentence": "The @GENE$ based nanohybrids were prepared by simultaneous gelling and polymerization under methoxy @DRUG$ and Fe ( NO3 ) 3·9H2O . From these characterizations , the optimized annealing temperature and mole ratios of oxidation were selected and the operating temperature of the PPy/γ-Fe2O3 nanohybrids was studied at 90 °C . From these results , @VARIANT$ sensors using conducting polymer/metals can be optimized with their kinds , detecting temperature , and annealing temperature .", "label": "None"}
{"id": "23181703", "sentence": "Figure B , C. Compared with the initial computed tomography ( CT ) of thorax ( B ) and the repeated CT at 30 days after @DRUG$ treatment ( C ) . Histology of the primary tumor : ( A ) well differentiated adenocarcinoma component with acinar pattern ( HE ×200 ) . ( B ) Immunohistochemical examination revealed that tumor cells were positive for monoclonal anti-ALK antibody ( 5A4 ) ( ×200 ) . @GENE$ mutation ( @VARIANT$ point mutation ) was showed positive by Cycleave-PCR method .", "label": "sensitivity"}
{"id": "23874486", "sentence": "As we expected , patients bearing low abundance ( & lt ; 30 % ) of @GENE$ mutation had higher disease control rate to @DRUG$ than other groups ( 44.4 % for & lt ; 30 % group vs 5.6 % for 30∼80 % group and 12.5 % for & gt ; 80 % group , P = 0.038 ) . If we excluded a disease control patient who carried a @VARIANT$ mutation in & gt ; 80 % group , the trend that low abundance had higher disease control rate was more obvious .", "label": "resistance or non-response"}
{"id": "24790411", "sentence": "Notably , OS was 23.3 months for patients receiving @DRUG$ as second-line treatment , while the number of events to calculate median OS is still insufficient in the first-line group , suggesting a potentially significant difference in survival if afatinib is given as first or successive lines of treatment of @GENE$ patients . Patients were stratified by mutation type ( exon 19 deletion , @VARIANT$ , or other ) and race ( Asian or non-Asian ) .", "label": "sensitivity"}
{"id": "25093003", "sentence": "She was negative for the Factor V Leiden mutation ( @VARIANT$ ) and BCR-ABL genes translocation ( Philadelphia chromosome ) . The rest of her blood work was within normal limits , including the erythrocyte sedimentation rate ( 1 mm/h ) , ferritin ( 151 ng/mL ) , thyroid stimulating hormone ( 1.3 mIU/mL ) , folate ( 10.2 ng/mL ) , vitamin @GENE$ ( 382 pg/mL ) and bleeding time ( 1.1 min ) . Patient was diagnosed with ET and started on @DRUG$ 1,000 mg twice daily .", "label": "None"}
{"id": "17973572", "sentence": "To prove the functional significance of the @VARIANT$ mutation , we generated Ba/F3 cell lines stably expressing mutant EGFR constructs [ ] . These cell lines , including L858R-L747S , proliferated in the absence of IL3 . @GENE$ cells were extremely sensitive to gefitinib ( D ) , whereas Ba/F3-L858R-T790M cells were highly resistant up to 1 μM @DRUG$ .", "label": "None"}
{"id": "21333004", "sentence": "Yun et al [ ] showed that gefitinib directly binds more tightly to the @VARIANT$ mutant than to the wild type EGFR in vitro , while Fabian et al [ ] indicated that EGFR with @DRUG$ sensitive mutations does not differ from wild type @GENE$ in terms of gefitinib binding affinity .", "label": "sensitivity"}
{"id": "22970367", "sentence": "Gatekeeper mutations have been found in many kinase-driven tumors that develop resistance to kinase inhibitor treatment ( e.g. , CML patients treated with @DRUG$ that develop the @VARIANT$ resistance mutation in BCR-ABL ) . Two potential mechanisms could explain how the EGFR T790M mutation confers @GENE$ TKI resistance .", "label": "None"}
{"id": "22655263", "sentence": "In vitro studies performed on Ba/F3 cells expressing mutated ALK kinase forms supported the biochemical data , confirming potent inhibition of L1196M and @VARIANT$ mutants in a cellular setting . In vivo efficacy was described only for the L1196M gatekeeper mutation , confirming a higher potency with respect to @DRUG$ in inhibiting the in vivo growth of @GENE$ driven Ba/F3 cells .", "label": "resistance"}
{"id": "24114583", "sentence": "The second-generation irreversible EGFR TKI @DRUG$ recently gained FDA approval as first-line therapy for @GENE$ mutation positive NSCLC in conjunction with Qiagen 's therascreen RGQ polymerase chain reaction ( PCR ) diagnostic test . Another second-generation irreversible EGFR TKI , dacomitinib , demonstrated preclinical efficacy in NSCLC tumours harbouring the @VARIANT$ gatekeeper mutation , , which is present in ∼50 % of NSCLCs that have acquired resistance to erlotinib or gefitinib , .", "label": "response"}
{"id": "24348666", "sentence": "The concomitant inhibition of MET and @GENE$ using the monoclonal antiboby MetMab and @DRUG$ proved to beefficacious in a phase II trial and early clinical trials of small-molecule inhibitors of MET given with EGFR inhibitors are now currently underway ( ) . The combination of crizotinib ( dual c-MET/anaplastic lymphoma kinase [ALK ] inhibitor ) ( ) and dacomitinib , although in early phase , is particularly interesting since one of its components , dacomitinib , was designed to address the acquired resistance by the @VARIANT$ secondary mutation in EGFR .", "label": "resistance or non-response"}
{"id": "23567620", "sentence": "Specific genetic alterations of @GENE$ , BRAF , PIK3CA , ALK and , more recently , ROS and RET have been described in well defined subsets of NSCLC. , , , These lesions represent ‘driver mutations ' , as lung cancers depend on their constitutive activation. , Thus , molecular screening of NSCLC is mandatory to guide the most appropriate therapies ( that is , small molecule kinase inhibitors ) . , Cancers harboring the same genetic alterations , however , respond differently to molecular targeted therapies , suggesting coexisting mutations or coactivation of other TKs . Finally , although molecularly targeted therapies ( that is , gefitinib or @DRUG$ for EGFR and crizotinib for ALK fusions ) are effective in NSCLC , intrinsic or acquired resistances inevitably lead to recurrence and/or metastatic dissemination . This is the case of MET activation/amplification , , or acquired somatic mutations of EGFR ( T790M ) or ALK fusions ( G1269A , @VARIANT$ and ALK amplification ) . , ,", "label": "None"}
{"id": "23208557", "sentence": "It is well known that the efficacy of targeted therapies such as @DRUG$ or erlotinib with NSCLC patients depends on the presence of @GENE$ activating mutations including in-frame deletion in exon 19 or L858R in exon 21 [ – ] . However , many patients acquire resistance to EGFR-TKI , which occurs within 9.5 to 14 months [ – ] . A second EGFR mutation , substitution of threonine 790 with methionine ( @VARIANT$ ) , was detected in approximately 50 % of the patients who had acquired resistance to EGFR-TKI [ ] .", "label": "resistance or non-response"}
{"id": "24004697", "sentence": "Moreover , to investigate the PPP2R5C siRNA effects in imatinib-resistant CML cells , we selected two pairs of CML cell lines , including the imatinib-sensitive cell lines K562 and 32D-Bcr-Abl WT and the imatinib-resistant cell lines K565R , which lacks an @GENE$ mutation , and 32D-Bcr-Abl @VARIANT$ , which has an T315I Abl mutation , to compare the different changes induced by PPP2R5C siRNA .", "label": "None"}
{"id": "23320171", "sentence": "Primary results from the EMILIA study , a randomized trial comparing @DRUG$ DM-1 to lapatinib and capecitabine , have shown that Trastuzumab DM-1 significantly improved progression-free survival in patients with metastatic HER2 positive breast cancer . Further research is looking into inhibiting other targets such as mTOR , @VARIANT$ , or @GENE$ pathways .", "label": "None"}
{"id": "23493804", "sentence": "@GENE$ such as gefitinib or @DRUG$ attain a response rate of approximately 70 % and progression-free survival of 9–13 months , although subgroups of patients experience long lasting remission. , Use of EGFR–TKIs as a first-line treatment in patients with advanced NSCLC harboring EGFR mutations improved progression-free survival with acceptable toxicity , compared with standard chemotherapy . EGFR–TKIs are currently considered a standard first-line treatment for this disease entity.– However , these tumors eventually develop resistance to EGFR–TKIs , possibly as a result of a secondary threonine–methionine substitution mutation at position 790 in exon 20 ( @VARIANT$ ) , MET amplification , or hepatocyte growth factor overexpression in relapsed tumors .", "label": "resistance or non-response"}
{"id": "21139621", "sentence": "The H131R and @VARIANT$ variations within the Fcγ RIIa and Fcγ RIIIa have been shown to modify the affinity of the Ig receptors and are therefore predicted to modulate the ADCC in patients receiving anti-EGFR IgG1 mAb . To date , only four studies have found significant association between these polymorphisms and the clinical outcome . In 64 chemorefractory MCRC patients treated with @DRUG$ based CT , found that the @GENE$ 131 H/H and FCGR3A 158 V/V genotypes , predicted to result in a higher affinity of the Ig to the receptor , were significantly associated with better PFS .", "label": "None"}
{"id": "24705275", "sentence": "10.1371/journal.pone.0092948.g002Cervical cancer patients with @VARIANT$ or E542K mutant tumors have inferior survival outcomes after standard chemoradiation ( @DRUG$ plus pelvic RT ) . Kaplan Meier curve for progression-free survival for cervical cancer patients with wild type PIK3CA versus E545K or E542K mutant tumors ( p = .05 ) . @GENE$ inhibitors SC-66 and MK-2206 induce non-apoptotic cell death in PIK3CA and PTEN mutant C33A cells", "label": "None"}
{"id": "22101934", "sentence": "The @VARIANT$ @GENE$ kinase domain is , however , sensitive to @DRUG$ and MIG6 inhibition , .", "label": "sensitivity"}
{"id": "24876815", "sentence": "Analyses were also performed for other polymorphisms in the EGFR gene : G216T and @VARIANT$ , and in the EGF gene : A61G . Graziano et al. demonstrated the presence of the short variant of the EGFR gene intron-1 and the G allele in codon 61 of the EGF gene ( higher @GENE$ production ) to be a favourable predictive factor for cetuximab-irinotecan therapy .", "label": "None"}
{"id": "22331137", "sentence": "Pretreatment of animals with DL-propargylglycine (PAG) , a CSE inhibitor , reduced the formation of tissue @VARIANT$ and inflammation induced by lipopolysaccharide , decreased the activity of hepatic @GENE$ ( a marker for neutrophil infiltration ) and the tissue damage ( ) . In a recent study from our laboratory , we observed that treatment with PAG reduced the renal damage induced by @DRUG$ injection ( ) .", "label": "None"}
{"id": "22536370", "sentence": "Tumors that harbor BRAF V600E mutations display high radiographic response rates to mutant-specific inhibitors such as PLX4032/RG7204/vemurafinib ( Plexxikon/Roche ) , and GSK2118436 ( GlaxoSmithKline ) , while patients whose tumors have certain KIT mutations ( L576P , @VARIANT$ , V559A ) have disease sensitive to the KIT inhibitor , @DRUG$ ( ) , , , , , , , , . Preclinical data suggest that MEK inhibition with drugs like AZD6244 or GSK1120212 may be effective for uveal melanomas carrying @GENE$ or GNA11 mutations .", "label": "None"}
{"id": "19238210", "sentence": "Of the remaining @GENE$ mutant cell lines , two had @VARIANT$ mutation ( one intermediate and one resistant ) and one had a homozygous deletion of PTEN ( resistant ) . KRAS mutant and wild type cell lines were all resistant to @DRUG$ .", "label": "resistance or non-response"}
{"id": "24472312", "sentence": "Therefore , @DRUG$ could efficiently induce apoptosis in CEL cells harboring WT or @VARIANT$ @GENE$ .", "label": "None"}
{"id": "24853121", "sentence": "This was already demonstrated wherein Cetuximab-resistant SCCHN cell lines were re-sensitized to @GENE$ inhibition once ErbB2 and/or ErbB3 inhibitors were added to @DRUG$ . Activating mutations of EGFR have been shown to correlate with response to EGFR inhibition in other human malignancies . While some mutations can confer sensitivity to EGFR targeting , such as the G719C and the L858R mutations , others like the @VARIANT$ mutation have , in fact , been correlated with resistance , .", "label": "response"}
{"id": "24419415", "sentence": "A sixfold or 14-fold higher concentration of gefitinib was required to inhibit the growth of cells expressing G719X or L861Q , respectively , compared with cells expressing @VARIANT$ . These results may explain the lack of response to gefitinib in patients with uncommon @GENE$ mutations . The authors also examined the sensitivity of G719X and L861Q mutations to @DRUG$ and irreversible TKIs .", "label": "sensitivity"}
{"id": "18525120", "sentence": "In addition , Asian women with adeno- carcinoma of the lung show a significantly higher re- sponse rate to @DRUG$ , an @GENE$ tyrosine kindase in- hibitor . Several EGFR kinase domain mutations may confer susceptibility to EGFRinhibitors [ 16 ] whereas @VARIANT$ mutation has emerged as a marker of resistance to these molecular targeted therapies [ 84 ] .", "label": "resistance or non-response"}
{"id": "19687189", "sentence": "Antrodia camphorata solid-state cultured mycelium ( AC-SS , 1 μg ml−1 ) showed adjuvant anti-proliferative effects with cisplatin ( 10 μM ) or @DRUG$ ( 10 μM ) in hepatoma cell lines C3A and PLC/PRF/5 cells ( in vitro ) and , on xenografted cells in tumor implanted nude mice ( in vivo ) . Furthermore , AC-SS showed its adjuvant effects through the inhibition of MDR gene expressions and the pathway of COX-2 dependent inhibition of AKT phosphorylation [ ] . In terms of the very recent literature , Lu et al. [ ] noted that ethanol extract from wild fruiting bodies of A. camphorata ( EEAC ) dose-dependently induced human premyelocytic leukemia HL 60 cells apoptosis via histone hypoacetylation , upregulation of histone deacetyltransferase 1 (HDAC 1) , and downregulation of histone acetyltransferase activities including @GENE$ CBP and PCAF .", "label": "None"}
{"id": "23567620", "sentence": "Finally , although molecularly targeted therapies ( that is , gefitinib or @DRUG$ for EGFR and crizotinib for ALK fusions ) are effective in NSCLC , intrinsic or acquired resistances inevitably lead to recurrence and/or metastatic dissemination . This is the case of MET activation/amplification , , or acquired somatic mutations of EGFR ( @VARIANT$ ) or ALK fusions ( G1269A , L1196M and ALK amplification ) . , , Chromosomal translocations involving the ALK gene have been described in 6 % of NSCLC , where ALK is most frequently fused to the echinoderm @GENE$ ( EML4 ) .", "label": "None"}
{"id": "25091415", "sentence": "By contrast , the T790M mutation confers a higher affinity toward ATP than the @VARIANT$ mutant such that the combined double mutant L858R/T790M results in an activated enzyme that is resistant to ATP-competitive TKIs . Recent report by Yoshikawa , S. et al. ( 2013 ) demonstrated the acquired resistant of double mutant G719S/T790M (DM) to @DRUG$ , G719S mutation occurs within the phosphate binding loop ( P-loop ) and not observed frequently . The structure of the @GENE$ DM ( G719S/T790M ) was solved and deposited in PDB .", "label": "sensitivity"}
{"id": "23419122", "sentence": "The studies that established the relationship between mutations in the EGFR gene and response to the small molecule @GENE$ TKIs gefitinib and @DRUG$ were done using analysis of DNA extracted from the tumor [ ] . The recent availability of antibodies that are specific for the mutations most clearly associated with response to EGFR TKIs , @VARIANT$ and E746_A750del , create the opportunity to exploit an alternative method to evaluate NSCLC for EGFR mutations to aid decisions with regard to EGFR TKI therapy [ ] .", "label": "sensitivity"}
{"id": "24155950", "sentence": "In conclusion , the combination of bortezomib and mitotic inhibitors such as @DRUG$ , docetaxel , vincristine or BI 2536 is an effective strategy for targeting of both TKIs -resistant and -sensitive Bcr-Abl positive leukemic cells . These regimens are able to inhibit Bcr-Abl activity and its downstream signaling , and to activate @GENE$ dependent cell death . In addition , these regimens are able to overcome the resistance to imatinib , dasatinib and nilotinib , brought about by Bcr-Abl protein overexpression or Bcr-Abl mutations ( including @VARIANT$ ) , making them attractive potential therapies for Bcr-Abl positive leukemias such as CML , especially for those resistant to current treatments .", "label": "None"}
{"id": "16434996", "sentence": "Under conditions in which @VARIANT$ caused & gt ; 90 % inhibition of ER-α activity , pretreatment with BRCA1-siRNA ( but not BRCA2- or control-siRNA ) substantially restored E2-stimulated ER-α activity ( P & lt ; 0.001 , two tailed t-test ) . Thus , BRCA1 ( but not @GENE$ or control ) siRNA significantly reversed the @DRUG$ mediated inhibition of E2-stimulated ER-α activity ( P & lt ; 0.001 ) .", "label": "None"}
{"id": "23493883", "sentence": "Combinations of therapy such as cetuximab plus erlotinib and @DRUG$ plus everolimus have also been tried . The most promising drug thus far has been afatinib ( BIBW2992 ; Boehringer-Ingelheim Pharma , Ingelheim , Germany ) , , an ErbB family blocker with reported in vitro and in vivo activity against @GENE$ mutant tumors harboring exon 19 deletions , exon 21 L858R mutations and the exon 20 @VARIANT$ “resistance” mutations .", "label": "resistance or non-response"}
{"id": "17973572", "sentence": "Transient transfection experiments utilizing COS-7 cells demonstrated that auto-phosphorylation of the original @VARIANT$ EGFR was inhibited by lower concentrations of @DRUG$ or erlotinib than the L858R-L747S or L858R-T790M constructs ( A ) . CL-387,785 partially overcame the observed inhibition ( B ) . To prove the functional significance of the L747S mutation , we generated @GENE$ cell lines stably expressing mutant EGFR constructs [ ] .", "label": "None"}
{"id": "24349829", "sentence": "Correspondingly , direct injection of a liposome encapsulated miR-7 plasmid into established EGFR-TKI sensitive and resistant tumors bearing the @VARIANT$ EGFR mutant resulted in significant tumor regression in conjunction with repression of @GENE$ , RAF-1 and IRS-1 expression . In head and neck cancer , miR-7 functioned in a synergistic manner with @DRUG$ to render FaDu Erlotinib-resistant cells susceptible to the growth inhibitory activities of the drug .", "label": "resistance or non-response"}
{"id": "21687596", "sentence": "The authors established gefitinib-resistant clones from a sensitive cell line with @GENE$ exon 19 deletion mutations ( HCC827 ) by exposing the cells to increasing concentrations of @DRUG$ . In these resistant cells , @VARIANT$ mutations were not observed but MET gene amplification occurred .", "label": "resistance or non-response"}
{"id": "21165163", "sentence": "The WJTOG3405 study enrolled 177 chemotherapy-naïve patients aged 75 years or younger and diagnosed with stage IIIB/IV non-small cell lung cancer or postoperative recurrence harboring @GENE$ mutations- either exon 19 deletions or @VARIANT$ [ ] . Patients were randomly assigned to @DRUG$ or cisplatinum/docetaxel for 3-6 cycles .", "label": "sensitivity"}
{"id": "22675625", "sentence": "Multiple analyses have demonstrated that responses to either @DRUG$ or panitumumab occur exclusively within the 60–70 % of patients without activating mutations in codon 12 and 13 of KRAS [ , , , ] . The activating @VARIANT$ @GENE$ mutation is present in an additional 10 % of patients , and it may be predictive of a lack of response to anti-EGFR therapy [ ] in addition to a clear poor prognostic factor .", "label": "resistance or non-response"}
{"id": "24349829", "sentence": "As would be predicted from the prior studies cited above , miR-7 blunted @GENE$ signaling and reversed the radio-resistance . Correspondingly , direct injection of a liposome encapsulated miR-7 plasmid into established EGFR-TKI sensitive and resistant tumors bearing the @VARIANT$ EGFR mutant resulted in significant tumor regression in conjunction with repression of EGFR , RAF-1 and IRS-1 expression . In head and neck cancer , miR-7 functioned in a synergistic manner with @DRUG$ to render FaDu Erlotinib-resistant cells susceptible to the growth inhibitory activities of the drug .", "label": "None"}
{"id": "24348666", "sentence": "The combination of @DRUG$ ( dual c-MET/anaplastic lymphoma kinase [ALK ] inhibitor ) ( ) and dacomitinib , although in early phase , is particularly interesting since one of its components , dacomitinib , was designed to address the acquired resistance by the @VARIANT$ secondary mutation in EGFR . This combination could potentially be effective in patients with acquired resistance via T790M and/or MET amplification . Another potential strategy to overcome acquired resistance is the use of combination therapies including @GENE$ inhibitors .", "label": "None"}
{"id": "25347122", "sentence": "@GENE$ pathway ; HSP90 NVP-BEZ235 ; 17-DMAG ( HSP90 inhibitor ) However , in these trials , TNBC was unselected based on gene ontologies and differential gene expression profiles . In the randomized open-label phase III CALGB 40502/NCCTG @VARIANT$ , the new and expensive BC treatments , nanoparticle albumin bound nab-paclitaxel ( Abraxane ) and ixabepilone , the latter being a potent epothilone that can be effective after microtubule inhibitor resistance ( Ixempra ) , have failed to demonstrate any superior efficacy versus the standard of weekly paclitaxel in combination with bevacizumab in patients with chemotherapy naïve metastatic BC .", "label": "None"}
{"id": "23994953", "sentence": "Somatic mutations in exons encoding the tyrosine kinase ( TK ) domain of the @GENE$ positively associated with increased sensitivity of non-small cell lung cancer ( NSCLC ) patients to the selective EGFR TK inhibitors ( TKIs ) gefitinib ( Iressa™ ) and erlotinib ( Tarceva™ ) . Prospective trials have demonstrated an impressive ~75 % response rate for patients whose tumors harbor these mutations , which occur as either multinucleotide in-frame deletions in exon 19 ( e.g. , delE746-A750 ) or as single missense mutations ( e.g. , @VARIANT$ ) .", "label": "sensitivity"}
{"id": "23864840", "sentence": "Another approach for @VARIANT$ mediated resistance is the dual inhibition of EGFR with @DRUG$ and cetuximab , an EGFR blocking antibody resembling the synergistic combination of lapatinib and trastuzumab in ErbB2 positive breast cancer . Due to promising preliminary results of activity and tolerability , final results of this regimen are being eagerly anticipated [ ] . In selected patients with acquisition of resistance by activated compensatory pathways such as MET and AXL , addition of a @GENE$ [ ] or AXL [ ] inhibitor to EGFR-TKIs could be beneficial .", "label": "None"}
{"id": "23785245", "sentence": "( A ) The @VARIANT$ secondary mutation in exon 20 of @GENE$ is present in 50 % –70 % of NSCLC patients who acquire resistance to EGFR-TKIs , such as gefitinib or @DRUG$ .", "label": "resistance or non-response"}
{"id": "24967590", "sentence": "For example , known enhancers are associated with the unstable histone variants H3.3 and @VARIANT$ .Z , and low nucleosome occupancy , although these chromatin states are not unique to enhancers . Additional features that pinpoint specific classes of active enhancers include binding of the transcriptional @DRUG$ p300/CBP , , , , clusters of @GENE$ sites , , , , and enhancer RNA transcription ( eRNAs ) .", "label": "None"}
{"id": "23776587", "sentence": "Recently , BRAF mutation ( & gt ; 95 % of BRAF point mutations occure at BRAF @VARIANT$ ) is introduced to be associated with resistance to targeted agents . BRAF protein , a serine-threonine kinase , is the principal downstream molecular of KRAS . A meta-analysis by Bokemeyer C , et al , in 2012 based on two RCTs ( the OPUS and CRYSTAL trials ) reported that in KRAS wild-type ( WT ) patients , adding @DRUG$ to chemotherapy was beneficial for @GENE$ WT patients , but not for BRAF mutant patients .", "label": "resistance or non-response"}
{"id": "25275314", "sentence": "Mutations try to mimic the original @GENE$ interactions of arginines when Kemptide is present . Histidines in mutants @VARIANT$ and R19H should be protonated to mimic the original arginines , but the @DRUG$ 18 does not need to be protonated according to our results .", "label": "None"}
{"id": "23935640", "sentence": "@DRUG$ and imatinib mechanisms of binding to @GENE$ are comparable except for the presence of Ponatinib 's characteristic carbon-carbon triple bond , between the methylphenyl and purine groups , which allows it to bind to the @VARIANT$ mutation without steric interference [ , ] .", "label": "response"}
{"id": "24623981", "sentence": "Patients must have had activating EGFR mutations with no @GENE$ TKI treatment before the study . Patients had to have been treated with either @DRUG$ or gefitinib in the study . @VARIANT$ had to have been evaluated in the primary lung-cancer tissue of patients before EGFR TKI treatment , without limitation to the detection methods .", "label": "resistance or non-response"}
{"id": "22043994", "sentence": "The effect of @GENE$ @VARIANT$ mutation on @DRUG$ or panitumumab response was also assessed using cellular models of CRC .", "label": "resistance or non-response"}
{"id": "22613958", "sentence": "More than 90 % of these mutations are observed in two hotspots : in-frame deletions including amino acids at codons 747 to 749 in exon 19 , and an amino acid substitution at codon 858 ( @VARIANT$ ) in exon 21 [ - ] . These mutations are postulated to mediate oncogenic effects by altering downstream signaling and anti-apoptotic mechanisms [ - ] . Prior trials confirmed that the response rate to EGFR-TKI in NSCLC patients with @GENE$ mutations is approximately 70–80 % [ , , ] , and results of recent phase III trials showed that the oral EGFR-TKI @DRUG$ has a superior progression-free survival ( PFS ) to standard chemotherapy as the first-line therapy for NSCLC with mutated EGFR [ , ] .", "label": "sensitivity"}
{"id": "22205962", "sentence": "Recently , TGS was shown to be induced in human cells by exogenous siRNAs that have sequence complementarity to the genomic DNA in the promoter regions of several genes containing Elongation factor-1 ( EF1A ) in 293FT cells – , E-cadherin ( CDH1 ) in HCT116 cells , immunodeficiency virus-1 ( HIV-1 ) coreceptor ( CCR5 ) in HEK293T cells , @DRUG$ @GENE$ cells , , ubiquitin C (UbC) in 293Gt cells , and vascular endothelial growth factor ( VEGF ) in HeLa and ARPE-19 cells .", "label": "None"}
{"id": "21165163", "sentence": "Several preclinical reports showed that other agents , such as the @GENE$ monoclonal Ab @DRUG$ or PI3K/mTOR inhibitors combined with irreversible EGFR inhibitors hold promise to overcome resistance mediated by @VARIANT$ [ ] .", "label": "response"}
{"id": "21687596", "sentence": "A recent analysis showed that T790M mutations do not considerably affect the binding affinity between EGFR and @GENE$ but instead increase the binding affinity between EGFR and ATP , causing a relative decrease in binding with EGFR-TKIs [ ] . The authors reported that increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance . An experiment using cell lines transfected concurrently with activating mutations and a @VARIANT$ mutation also proved that resistance to @DRUG$ and erlotinib is evident when this mutation is present [ – ] .", "label": "resistance or non-response"}
{"id": "24422746", "sentence": "Furthermore , the only one patient with PSCCE identified for @GENE$ mutation was @VARIANT$ missense mutation in exon 21 , termed as @DRUG$ associated mutations .", "label": "sensitivity"}
{"id": "22880063", "sentence": "For HvHMA2 we observed the greatest decrease in HvHMA2 conferred Zn resistance with the mutants @VARIANT$ , P357L ( within the CPC motif ) and D400A ( the phosphorylated aspartate ) . Similarly in ZntA of Escherichia coli the mutation K693N ( TM7 , equivalent to HvHMA2 ( K666 ) ) abolished Zn-stimulated @GENE$ activity completely , although Zn-dependent phosphorylation by ATP still occurred . Also in ZntA , mutants in the CPC motif have been investigated : C392A , P393A , and C394A lost the ability to bind a metal ion with high affinity in the transmembrane domain , while @DRUG$ and serine substitutions at C392 and C394 abolished binding of Pb2+ but not other divalent metal ions .", "label": "None"}
{"id": "24419415", "sentence": "Cells expressing @VARIANT$ were less resistant to erlotinib than @DRUG$ in vitro ; however , L861Q was resistant to both erlotinib and gefitinib . In contrast to erlotinib , irreversible TKIs inhibited the growth of cells with G719X or L861Q at a lower concentration than those with wild-type @GENE$ .", "label": "None"}
{"id": "24276379", "sentence": "Approximately 90 % of the B-Raf mutations codes for a substitution of glutamic acid for the wild-type valine in residue 600 ( i.e. , @VARIANT$ ) , resulting in a constitutively active protein [ ] . In two clinical studies , only 2 out of 26 patients with mutant @GENE$ responded to @DRUG$ or panitumumab , even if these patients had wild type K-Ras [ , ] .", "label": "resistance or non-response"}
{"id": "23994953", "sentence": "@VARIANT$ and MET amplification , which can be detected in up to 20 % of EGFR NSCLCs secondarily refractory to EGFR TKIs , account for approximately 60–70 % of all known causes of acquired resistance to gefitinib/erlotinib . Consequently , ongoing research is attempting to identify the mechanisms that may account for the 30–40 % of EGFR TKI-resistant , EGFR mutated tumors that do not carry EGFR mutations or MET amplification . Although increased activation of insulin-like growth factor-1 receptor ( IGF-1R ) through the loss of IGF binding proteins and loss or reduction of the tumor suppressor @GENE$ have been associated with acquired resistance to EGFR TKIs in laboratory models , these mechanisms have not yet been validated in specimens from EGFR TKI-refractory patients .", "label": "None"}
{"id": "25563355", "sentence": "It was initially proposed based on the crystallographic structure of the @GENE$ tyrosine kinase domain . The bulkier methionine residue @VARIANT$ changes the ATP binding pocket of the tyrosine kinase domain , leading to the blockade of gefitinib or @DRUG$ [ ] .", "label": "resistance or non-response"}
{"id": "24879454", "sentence": "In contrast to the activating biology of BRAF @VARIANT$ , ongoing clinical trials investigate the potency of @DRUG$ in tumors harboring inactivating BRAF exon 11 mutations ( NCT01514864 clinicaltrials.gov ) . 3.3. @GENE$ and KRAS Mutational Status", "label": "None"}
{"id": "24348666", "sentence": "However , almost every patient who responds well to @DRUG$ will , without exception , experience recurrence due to acquired resistance . The mechanisms for acquired resistance include gatekeeper L1196M mutations , ALK gene amplification , and other @GENE$ gene mutations ( @VARIANT$ , C1156Y , F1174L ) - .", "label": "resistance"}
{"id": "19893626", "sentence": "The second-generation @GENE$ inhibitors , dasatinib and nilotinib , can circumvent most mutations that confer resistance to imatinib ; the T315I mutation , however , causes resistance to all BCR-ABL kinase inhibitors developed so far . Similarly , the @VARIANT$ point mutation in the epidermal growth factor receptor (EGFR) confers resistance to the EGFR tyrosine kinase inhibitors gefitinib and @DRUG$ , which are used to treat non-small cell lung cancer .", "label": "None"}
{"id": "20102612", "sentence": "@DRUG$ mitigates the apoptosis induced by chemotherapeutic agents in @VARIANT$ and ZR-75-1 cells , while it is able to increase apoptosis by these compounds in H3396 cells where retinoic acid does not induce cIAP2 expression . Many antiapoptotic proteins , such as Bcl-2 , Mcl-1 and Bcl-XL , have been shown to inhibit chemotherapeutic agent induced apoptosis in diverse cell system models including hematopoietic and neuroblastoma cells . Additionally , it has been shown that the activation of genes encoding @GENE$ and IAP proteins by NF-κB serves to block apoptosis promoted by different insults including chemotherapy induced apoptosis in different cell types [ , ,, ] .", "label": "None"}
{"id": "23566546", "sentence": "Case Histrogical type @GENE$ mutation status Brinkman index Treatment agent Response IL-8 ( ng/mL ) IL-10 ( ng/mL ) RANTES ( pg/ml ) 1 Ad Ex21 @VARIANT$ 900 gefitinib PR 5.79 1.67 2 2 Ad Ex21 L858R 0 erlotinib PR_3.33 94.2 1.41 3 Ad Ex19 del 0 erlotinib PR 4.09 126 2.13 4 Ad Ex21 L858R 0 gefitinib PR_3.92 18.1 1.85 5 Ad Ex21 L858R + Ex19 del 370 erlotinib PR 21.9 1.23 2.11 6 Ad Ex19 del 0 erlotinib PR 7.05 1.37 2.56 7 Ad Ex19 del 0 gefitinib PR 4.82 1.59 2.02 8 Ad Ex21 L858R 1640 gefitinib PR 54.9 2.7 2.38 9 Ad negative 400 erlotinib SD 34.9 3.39 3.66 10 Ad negative 0 erlotinib SD 27.1 4.94 2.25 11 Ad unknown 1800 erlotinib SD NE NE NE 12 Sq Ex19 del 3840 gefitinib SD 12.6 1.1 1.98 13 Ad Ex19 del 30 erlotinib SD 5.27 0.69 2.66 14 Ad Ex19 del 0 erlotinib SD 10.5 0.85 2.5 15 Ad unknown 300 @DRUG$ SD 7.69 2.61 1.7 16 La negative 2080 erlotinib SD NE NE NE 17 Sq Ex21 L858R 750 erlotinib SD 11.6 56.3 3.06 18 Ad unknown 600 erlotinib SD 13.7 1.1 2.82 19 Ad Ex21 L858R 0 erlotinib SD 20.6 11.6 0.783 20 Ad Ex19 del 0 erlotinib SD 14.8 2.07 2.02 21 Ad Ex21 L858R + Ex19 del 0 gefitinib SD 3.04 1.3 1.76 22 Ad Ex19 del 200 gefitinib SD 10.9 1.59 1.91 23 Sq unknown 1560 erlotinib PD NE NE NE 24 Ad negative 1080 erlotinib PD 25.2 8.15 1.57 25 Ad unknown 0 erlotinib PD NE NE NE 26 Ad Ex18 G719A 2000 erlotinib PD 11.6 4.48 3.12 27 Ad unknown 1410 erlotinib PD NE NE NE 28 Ad Ex19 del 1000 gefitinib PD 9.44 2.25 2.89 29 Ad negative 1100 erlotinib PD 56.3 5.63 2.16 30 Ad negative 2000 erlotinib PD 15.6 0.85 0.292 31 Ad negative 825 erlotinib PD 8.27 1.59 2.13 32 Ad Ex21 L858R 0 erlotinib PD 5.34 7.05 1.7 33 Ad negative 1680 erlotinib PD 57.7 1.63 2.06", "label": "sensitivity"}
{"id": "24349829", "sentence": "As would be predicted from the prior studies cited above , miR-7 blunted @GENE$ signaling and reversed the radio-resistance . Correspondingly , direct injection of a liposome encapsulated miR-7 plasmid into established EGFR-TKI sensitive and resistant tumors bearing the @VARIANT$ EGFR mutant resulted in significant tumor regression in conjunction with repression of EGFR , RAF-1 and IRS-1 expression . In head and neck cancer , miR-7 functioned in a synergistic manner with @DRUG$ to render FaDu Erlotinib-resistant cells susceptible to the growth inhibitory activities of the drug .", "label": "None"}
{"id": "22545054", "sentence": "Moreover , the combination of rapamycin and the irreversible EGFR TKI , HKI-272 , resulted in the significant regression of lung tumors in transgenic mice possessing the secondary resistance mutation @VARIANT$ [ ] . Addition of the dual @GENE$ inhibitor PI-103 to @DRUG$ was necessary to induce growth arrest of human glioma cell lines with mutant PTEN [ ] , suggesting that activation of the PI3K/Akt/mTOR pathway by EGFR independent mechanisms confers resistance to EGFR inhibitors , but that this resistance can be overcome by the addition of pathway inhibitors .", "label": "None"}
{"id": "24244732", "sentence": "@VARIANT$ ( P & lt ; 0.001 ) and R39C/E465K ( P & lt ; 0.001 ) were different from Wt , but not from each other ( P=0.71 ) . N = 3 experiments per strain ( 20-25 worms each experiment ) . @DRUG$ sensitivity phenotypes of point mutations in lof rab-3 @GENE$ is a GTPase involved in the trafficking of synaptic vesicles and various aspects of exocytosis [ ] .", "label": "None"}
{"id": "15737014", "sentence": "Somatic gain-of-function mutations in exons encoding the @GENE$ kinase domain are found in about 10 % of non-small cell lung cancers ( NSCLCs ) from the United States [ , , ] , with higher percentages observed in east Asia [ , ,, ] . Some 90 % of NSCLC associated mutations occur as either multi-nucleotide in-frame deletions in exon 19 , involving elimination of four amino acids , Leu-Arg-Glu-Ala , or as a single nucleotide substitution at nucleotide 2573 ( T→G ) in exon 21 , resulting in substitution of arginine for leucine at position 858 ( @VARIANT$ ) . Both of these mutations are associated with sensitivity to the small-molecule kinase inhibitors @DRUG$ or erlotinib [ , , ] .", "label": "sensitivity"}
{"id": "25563355", "sentence": "In both in vitro and in vivo preclinical models , @DRUG$ demonstrated increased affinity to common @GENE$ mutations , as well as the @VARIANT$ mutation [ ] .", "label": "response"}
{"id": "24894453", "sentence": "In order to further examine the efficacy of @DRUG$ , we expanded our studies by generating xenograft mouse models with either SW48 or HCT8 colon cancer cells , which harbor either @GENE$ @VARIANT$ or KRAS G13D mutation , respectively .", "label": "sensitivity"}
{"id": "15737014", "sentence": "EGFR Mutants Containing the T790M Mutation Are Resistant to Inhibition by @DRUG$ or Erlotinib 293T cells were transiently transfected with plasmids encoding wild-type ( WT ) EGFR or @GENE$ mutants with the following changes : T790M , @VARIANT$ , L858R + T790M , del L747–E749 ; A750P , or del L747–E749 ; A750P + T790M .", "label": "sensitivity"}
{"id": "22363766", "sentence": "Of note , mutations within ALK that lead to crizotinib resistance have already been described , analogous to the @VARIANT$ mutation leading to @DRUG$ and gefitinib resistance in @GENE$ .", "label": "resistance or non-response"}
{"id": "24244732", "sentence": "This mutation then also bypasses the requirement of a functional @GENE$ protein in @DRUG$ sensitivity as expression of @VARIANT$ in the lof rab-3 genetic background eliminates the rab-3 phenotype .", "label": "None"}
{"id": "20942962", "sentence": "Of the 8 mutations in the TK domain , 7 were novel ( W731L , E734Q , T785A , C797Y , @VARIANT$ , L831H and E868G ) ( Figure ) . One of the mutations ( L858R ) was previously identified in non-small cell lung cancer ( NSCLC ) patients and this mutation was found to increase sensitivity to @GENE$ inhibitor , @DRUG$ .", "label": "None"}
{"id": "23481642", "sentence": "This became evident in a comparison of the melatonin-proficient mouse strain , @VARIANT$ , with the melatonin-deficient strain , C57BL [ ] . In C3H , protein levels of @GENE$ , CRY2 and BMAL1 were shown to oscillate with robust amplitudes , whereas C57BL exhibited only weak fluctuations and reduced expression of these proteins .", "label": "None"}
{"id": "24124608", "sentence": "In addition to upregulation of IGF1R and VEGF , frequent CN gain and increased mRNA expression of GSTT1 as well as significant overexpression of @GENE$ subfamily members were observed in wild-type/PDGFRA @VARIANT$ GISTs compared to KIT-mutant GISTs . CN gain of GSTT1 was closely associated with @DRUG$ resistance .", "label": "None"}
{"id": "22101934", "sentence": "( c ) Western blot analysis of the expression levels of WT , @VARIANT$ , and Δ746–750 tEGFRs in the presence and absence of the @GENE$ inhibitor @DRUG$ .", "label": "sensitivity"}
{"id": "24966800", "sentence": "Second-generation EGFR TKIs also have modest in vitro activity against the @VARIANT$ gatekeeper mutation and other rare mutations that render first-generation reversible EGFR TKIs ineffective [ ] . These properties might be related to the mechanism of action of second-generation irreversible @GENE$ after first-generation TKIs . As for bone metastasis from NSCLC , @DRUG$ inhibited tumor cell proliferation at bone metastatic sites and induced normal bone formation in some previous reports [ , ] .", "label": "resistance or non-response"}
{"id": "24489728", "sentence": "This type of resistant cell with stem cell features was observed only after exposure to high concentrations of @DRUG$ , whereas the @GENE$ @VARIANT$ mutation or MET amplification were found after the stepwise escalation method .", "label": "resistance or non-response"}
{"id": "25465236", "sentence": "( C ) EGFR @VARIANT$ mutant does not resemble pEGFR unlike the EGFR L858R mutant shown in B. ( D–F ) increased inhibition potency for Erlotinib against EGFR L858R mutant compared to EGFR WT protein and subsequent decrease in potency for Erlotinib against EGFR L858R + E884K double mutant . ( G–I ) increased inhibition potency for Gefitinib against EGFR L858R mutant compared to EGFR WT protein and subsequent further increase in potency for @DRUG$ against @GENE$ L858R + E884K double mutant .", "label": "resistance or non-response"}
{"id": "22343623", "sentence": "In this study , we examined whether the selective KOR agonist U50 ,488H could inhibit the growth of gefitinib-sensitive and EGFR mutant ( delE746-A750 , L858R ) NSCLC cells ( HCC827 ) and gefitinib-resistant and @GENE$ mutant ( @VARIANT$ ) NSCLC cells ( H1975 ) , and investigated the signalling mechanism of the KOR mediated inhibitory effect on tumour cell growth .", "label": "resistance or non-response"}
{"id": "22662154", "sentence": "Group Cell line Mutational status Copy number alterations IC50 ( nM ) @GENE$ PTEN ( mutated exons ) K-Ras PIK3CA PTEN K-Ras BEZ235 @DRUG$ C HEC-1B Mut ( @VARIANT$ ) wild type Mut ( G12D ) Gain nl nl 220 200 HHUA Mut ( R88Q ) Mut 5 ( F ) , 8 ( F ) Mut ( G12V ) nl nl nl 250 & gt ; 1000", "label": "None"}
{"id": "20579378", "sentence": "These missense ( G719S/C and @VARIANT$ ) and deletion mutations ( in the region spanning codons 746-759 ) are located in exons 18 through 21 of @GENE$ and appear to confer tumor susceptibility to @DRUG$ [ , ] .", "label": "sensitivity"}
{"id": "21042543", "sentence": "The possible relationship between of @GENE$ mutational status and response to treatment with @DRUG$ in 48 patients with mCRC was investigated by Benvenuti et al . B-RAF mutations were detected in 12,5 % tumors and they were mutually exclusive with K-RAS alterations . The only B-RAF mutation found was the @VARIANT$ substitution .", "label": "resistance or non-response"}
{"id": "17177598", "sentence": "However , @DRUG$ did induce dose dependent cell death in Ba/F3 subclones expressing the EGFR ectodomain mutants ( missense and vIII truncation ) or @GENE$ kinase domain mutants ( @VARIANT$ and L861Q ) ( A ) .", "label": "sensitivity"}
{"id": "23055691", "sentence": "While @VARIANT$ is found in about half of patients with acquired resistance to erlotinib and @DRUG$ , the other mechanism of resistance – MET amplification – makes up about 5 % –10 % of these patients . There is a significant overlap of these two mechanisms , as about half of the patients with MET amplification also had the T790M mutation. , It is theorized that MET activates an AKT mediated signaling pathway that bypasses the inhibited @GENE$ , a process dubbed “bypass track activation.”", "label": "resistance or non-response"}
{"id": "24790411", "sentence": "Compared to erlotinib and gefitinib , afatinib shows lower EC50 values and greater potency against wild type ( afatinib vs erlotinib vs gefitinib : 60 nM vs 110 nM vs 157 nM ) and @VARIANT$ mutated @GENE$ ( afatinib vs @DRUG$ vs gefitinib : 0.7 nM vs 40 nM vs 5 nM ) .", "label": "sensitivity"}
{"id": "23788917", "sentence": "EGFR TKI , which are effective for the @VARIANT$ mutation of the EGFR gene , may also prove to be effective in patients with mutations in exon 20 of the HER2 gene , but only if they have the ability to block the function of the tyrosine kinase associated with both EGFR and HER2 . A double reversible inhibitor of @GENE$ and HER2 receptors called @DRUG$ has not shown efficacy in this case .", "label": "None"}
{"id": "22855636", "sentence": "Consequently , standard GIST therapies ( ie , @DRUG$ and sunitinib ) are less efficacious in this clinical group . Although the pathogenesis is largely unknown , recent studies have uncovered germline mutations involving succinate dehydrogenase (SDH) , most commonly in the subunit genes SDHB and SDHC , resulting in a complete loss or reduction in @GENE$ protein. , Loss of SDH protein expression is effectively demonstrated using traditional immunohistochemistry. , , The clinical features associated with the presence of SDH germline mutations in wild-type GISTs , which accounted for 12 % of wild-type GISTs in one study , has not been defined . In adult wild-type-GISTs , BRAF exon 15 @VARIANT$ mutations have been detected in 7 % –13 % of GISTs , commonly located in the small bowel. ,", "label": "None"}
{"id": "23637779", "sentence": "The effects of @DRUG$ on c-Kit expression were analyzed in the murine @GENE$ cell line transfected with human @VARIANT$ c-Kit mutant or wt-c-Kit .", "label": "None"}
{"id": "24932869", "sentence": "The values of the coefficient of the variation CV for the features @GENE$ , AVR and RG are calculated for all the sensors in the PEN3 and CAPINose electronic noses in this section . In the PEN3 case , only the six sensors ( W1S , W5S , W3C , W5C , W4S and @VARIANT$ ) more sensible to @DRUG$ are considered .", "label": "None"}
{"id": "25506699", "sentence": "Rabbit anti-human AMPKα , p44/42 MAP kinase , phospho-p44/p42 @GENE$ ( Thr202/Tyr204 ) , Akt , phospho-Akt ( Ser473 ) ( @VARIANT$ ) XP , and caspase-3 polyclonal antibodies ; and rabbit anti-human phospho-AMPKα ( Thr172 ) ( 40H9 ) and phospho-LKB1 ( Ser428 ) ( C6743 ) monoclonal antibodies , were obtained from Cell Signaling Technology Inc ( Danvers , MA ) . Peroxidase conjugated @DRUG$ were from DAKO Diagnostics , S.A. ( Barcelona , Spain ) .", "label": "None"}
{"id": "25054154", "sentence": "We utilised three complexes , namely , native ( ALK-crizotinib ) , @VARIANT$ ( ALK F1174L-crizotinib ) , and R1275Q ( @GENE$ R1275Q-crizotinib ) for our analysis .", "label": "resistance"}
{"id": "21505228", "sentence": "Some MEK1 mutations , including the @VARIANT$ mutation identified in a patient 's AZD6244-resistant melanoma , also led to cross-resistance to BRAF inhibitors , presumably by causing activation of MEK downstream of BRAF . Interestingly , later work by this same group identified a different MEK1 point mutation ( C121S ) in a post-relapse biopsy from a patient with clinically acquired resistance to the BRAF inhibitor @DRUG$ , demonstrating that MEK1 mutations can arise as a potential mechanism of acquired resistance to BRAF inhibitors as well [ ] . Interestingly , although the MEK1 P124L point mutation conferred resistance to MEK or BRAF inhibitors alone , the combination of a @GENE$ inhibitor and BRAF inhibitor could overcome resistance in this setting .", "label": "None"}
{"id": "15736989", "sentence": "Similar mutations in the homologous residues of the kinase domains of @GENE$ ( @VARIANT$ ) and KIT ( T670I ) account for @DRUG$ resistance in some patients with hypereosinophilic syndrome and gastrointestinal stromal cell tumors , respectively [ , ] .", "label": "resistance"}
{"id": "19604390", "sentence": "The results summarized in Table show that MNF , an AhR antagonist , is indeed a powerful agent suppressing the rate of cell proliferation in P20E cells both in the presence and the absence of exogenous @GENE$ In addition , the anti-inflammatory agent parthenolide was also quite effective in suppressing proliferation . @DRUG$ , which has both AhR antagonist [ , ] and anti-inflammatory properties [ ] , was the most effective in proliferation suppression particularly in @VARIANT$ cells .", "label": "None"}
{"id": "23185274", "sentence": "Compared with the parental compound @DRUG$ , V1801 is a relatively weak EGFR inhibitor which bears a much more potent cytotoxicity in @VARIANT$ @GENE$ harboring NCI-H1975 cells ( ) .", "label": "resistance or non-response"}
{"id": "23986642", "sentence": "While the first and second-generation TKIs have demonstrated improved outcomes in patients with CML and Ph+ ALL , resistance still occurs in a subset of patients who harbor @GENE$ mutations , particularly the @VARIANT$ mutant . Until the recent approval of @DRUG$ ( Iclusig® , ARIAD Pharmaceuticals , Cambridge , MA , USA ) , there were no approved therapies for patients who had developed resistance , refractoriness , or intolerance to commercially available TKIs .", "label": "response"}
{"id": "23788917", "sentence": "However , this resistance to @GENE$ TKI has been many times lower than the resistance in cells harbouring both the L858R and T790M mutations . In case of occurrence of both L858R and @VARIANT$ mutations , the concentration of @DRUG$ should be three times higher in order to achieve a therapeutic effect .", "label": "resistance or non-response"}
{"id": "15737014", "sentence": "In GIST and HES , respectively , the analogous T670I mutation in KIT and @VARIANT$ mutation in @GENE$ have been associated with acquired resistance to this drug [ , ] . To determine whether lung cancers that acquire clinical resistance to either gefitinib or @DRUG$ display additional mutations in the EGFR kinase domain , we have examined the status of EGFR exons 18 to 24 in tumors from five patients who initially responded but subsequently progressed while on these drugs .", "label": "None"}
{"id": "23994953", "sentence": "Intense research efforts over the past few years have identified two major mechanisms of acquired resistance to gefitinib/erlotinib : secondary resistance mutations ( e.g. , @VARIANT$ ) and “oncogene kinase switch” systems ( e.g. , MET amplification and AXL activation ) . However , the precise mechanisms underlying acquired resistance in the 30–40 % of @GENE$ TKI-resistant EGFR mutated tumors that do not carry secondary resistance mutations or MET amplification remain largely unclear .", "label": "resistance or non-response"}
{"id": "PMC4041182", "sentence": "The best validated targeted drugs in melanoma are the selective @GENE$ inhibitors vemurafenib ( @DRUG$ , Zelboraf™ ) and dabrafenib ( GSK2118436 , Tafinlar™ ) as well as the LGX818 ( Novartis ) compound that appears to have the highest affinity for the catalytic domain of the kinase . All of them are relatively selective for their intended target @VARIANT$ BRAF , with little cross-reactivity for wild-type BRAF and CRAF .", "label": "None"}
{"id": "23533466", "sentence": "3.2. Bufalin Overcomes the Resistance to Irreversible EGFR-TKIs Induced by HGF via Inhibition of @GENE$ Pathway H1975 cancer cell line with mutations in EGFR exons 21 ( @VARIANT$ ) and 20 ( T790M ) was refractory to reversible EGFR-TKIs , gefitinib , and erlotinib [ ] , but was sensitive to irreversible EGFR-TKIs , such as BIBW2992 ( @DRUG$ ) .", "label": "None"}
{"id": "24623981", "sentence": "Patients must have had activating @GENE$ mutations with no EGFR TKI treatment before the study . Patients had to have been treated with either @DRUG$ or gefitinib in the study . @VARIANT$ had to have been evaluated in the primary lung-cancer tissue of patients before EGFR TKI treatment , without limitation to the detection methods .", "label": "resistance or non-response"}
{"id": "24816724", "sentence": "For this reason , we hypothesized that in the AIO KRK-0104 trial primary tumor location in the left colon might have a favorable prognostic effect in patients with KRAS wild-type tumors , but not in patients with KRAS mutant tumors when receiving @DRUG$ based first-line therapy . In fact , OS and PFS differed significantly when comparing left- to right sided tumors . This effect was driven by patients with KRAS codon 12/13 wild-type tumors and seemed also present in those patients that presented with KRAS codon 12/13 wild-type but @GENE$ @VARIANT$ mutant tumors .", "label": "resistance or non-response"}
{"id": "23515752", "sentence": "H1975 cells [ TKI-resistant , EGFR exon 20 ( @VARIANT$ ) and -21 mutations ] were treated for 24 h with either dasatinib ( 200 nM ) , 17-DMAG ( 50 nM ) , belinostat ( 500 nM ) , panobinostat ( 50 nM ) or @DRUG$ ( 10 nM ) . Lysates were made , western blotted and probed with antibody against EGFR and GAPDH ( loading control ) ( A ) . 17-DMAG and belinostat decreased levels of activated @GENE$ ( p-Akt ) in TKI-resistant cells .", "label": "None"}
{"id": "23029123", "sentence": "The importance of D2 receptor involvement in ethanol actions on PRL production and cell proliferation is evident in the experiment where @DRUG$ actions on lactotropes ' function were evaluated in clonal cell lines expressing various levels of D2 receptor isoforms . It was found that V cells , which lacked functional D2 receptors and had high basal levels of PRL , showed a significant reduction in PRL production following D2S and @VARIANT$ receptor transfection . As described by an extended allosteric ternary complex model of @GENE$ , receptors spontaneously isomerize between active and inactive conformations , so receptors can modulate signaling pathways in the absence of an agonist .", "label": "None"}
{"id": "23852704", "sentence": "Patients with the @VARIANT$ mutation may however , benefit from combined @DRUG$ and chemotherapy but this remains to be confirmed . It is important that the laboratory report indicate the specific @GENE$ mutation analyzed and detected as well the methodology used .", "label": "resistance or non-response"}
{"id": "24260231", "sentence": "10.1371/journal.pone.0079478.g007Sorafenib or GDC-0941 inhibits @DRUG$ induced Chk1 activation and enhances apoptosis in cells expressing @VARIANT$ mutated @GENE$ ( A ) Ton.B210/T315I cells cultured with DOX to induce BCR/ABL with T315I ( BCR/ABL-T315I ) in the absence of IL-3 or cultured without DOX in the presence of IL-3 ( IL-3 ) were left untreated as control ( Cont. ) or treated with 5 µM sorafenib and 1 µM etoposide ( Etop. ) , as indicated , for 16 h , and analyzed for the cellular DNA content .", "label": "None"}
{"id": "24195076", "sentence": "Li and coworkers [ ] have shown that SWCNTs can be functionalized with @GENE$ antibodies and loaded with the anticancer agent doxorubicin . Compared with free doxorubicin , this formulation demonstrated higher cytotoxicity by 2.4-fold against @VARIANT$ leukemia cells . The in vivo administration of SWCNT @DRUG$ conjugate in a murine breast cancer model has been observed with higher efficacy in suppressing tumor growth and less toxic effects to normal organs [ , ] .", "label": "None"}
{"id": "22722193", "sentence": "The @GENE$ and MALAT1 associations in the discovery set also were supported by the validation set analysis . Druggable gene analysis We defined mutations in druggable tyrosine kinase domains including in ERBB2 ( a V777L and a 755–759 LRENT in frame deletion homologous to @DRUG$ activating EGFR mutations in lung cancer ) , as well as in DDR1 ( A829V , R611C ) , DDR2 ( E583D ) , CSF1R ( D735H , @VARIANT$ ) , and PDGFRA ( E924K ) .", "label": "None"}
{"id": "22714415", "sentence": "This year at ASCO , Tejpar et al. further supported this finding by presenting retrospective analyses of two large phase III multicenter trials ( CRYSTAL and OPUS ) representing 83 patients with @VARIANT$ KRAS mutant mCRC tumors who had longer overall survival and progression free survival on average post @DRUG$ treatment then other KRAS mutant subtypes .", "label": "None"}
{"id": "22655263", "sentence": "The L1196M gatekeeper mutation and the C1156Y and @VARIANT$ mutants were identified in the relapsed NSCLC cases , and the F1174L mutation in the relapsed IMT ( Choi et al. , ; Sasaki et al. , , ) . The mechanisms underlying decreased activity of @DRUG$ on these secondary @GENE$ mutants were investigated by structural and biochemical analyses , together with cellular data generated in engineered in vitro models .", "label": "resistance"}
{"id": "22166800", "sentence": "Additionally , deregulation of the cell cycle was extended to @GENE$ and mitotic spindle apparatus inactivation . As many of the target genes altered by combination @VARIANT$ and @DRUG$ were involved in cell cycle control , we explored whether the mechanism of these drugs may act through a common cell-cycle related factor .", "label": "None"}
{"id": "20406486", "sentence": "Another possibility is that PLX4032-resistant BRAFV600E mutants have alternative signaling at the level of Raf , as has been described for cell lines with acquired resistance to a different Raf-inhibitor , AZ628 , which show increased signaling through C-Raf [ ] . The increase in pErk in an NRAS @VARIANT$ mutant cell line could be explained by abrogation of negative feedback loops mediated mainly by dual specificity phosphatases ( MKPs/DUSPs ) , as reported with @GENE$ inhibitors [ , ] , and the recent description of increased C-Raf signaling when heterodimerizing with inhibited B-Raf in BRAF wild type cells [ , ] .", "label": "None"}
{"id": "22970367", "sentence": "In addition to the EGFR T790M mutation , there are three other second-site mutations in EGFR that have been associated with acquired EGFR TKI resistance : T854A in exon21 [ ] , L747S [ ] , and @VARIANT$ [ ] , both in the exon19 . Similar to the @GENE$ T790M mutation , alteration of the drug contact residue T854 to a smaller hydrophobic alanine may increase the size of the selectivity pocket and negatively impact @DRUG$ binding .", "label": "None"}
{"id": "17565683", "sentence": "Histology Immunohistochemistry Mutations KIT CD34 S100 SMA Desmin Gene Site 15 Spindle Positive + - - - C-kit Exon11 , MS 16 Spindle Positive + - - - C-kit Exon11 , IFD 17 Spindle Positive + - - - C-kit Exon11 , MS 18 Spindle Positive + - - - C-kit Exon11 , MS 19 Spindle Positive + - Weak - C-kit Exon11 , IFD 22 Myxoid epithelioid Weak + - + - PDGFRA Exon18 del @VARIANT$ 23 Epithelioid Weak - - - - PDGFRA Exon18 DIMH842-845 26 Epithelioid Weak + NA NA NA PDGFRA Exon18 28 Myxoid epithelioid Weak + - - - PDGFRA Exon12 , V561D MS : miss sense , IFD : in-frame deletion , NA : not available Because of possible relapse even after complete resection of omental GISTs [ - ] and the objective response rate of 67 % of @DRUG$ to the mutation in @GENE$ exon 12 [ ] , our patient received daily oral administration of 300 mg Glevec® , ( we applied 15 % reduced dose , referring to a report by Cormier , et al. after took account of a smaller average of Japanese build than American ) [ , ] .", "label": "resistance or non-response"}
{"id": "23088930", "sentence": "Activating mutations in the @GENE$ gene are located in exons 18 through 21 while more than 90 % consist of deletions in exon 19 and @VARIANT$ substitution in exon 21 . These activating mutations are eligible for the treatment with modern tyrosine kinase inhibitors ( TKI ) , e. g. gefitinib or @DRUG$ [ , , ] .", "label": "sensitivity"}
{"id": "15737014", "sentence": "After 36 h , cells were serum starved for 24 h , treated with gefitinib or @DRUG$ for 1 h , and then harvested for immunoblot analysis using @GENE$ ( Y1092 ) , anti-t-EGFR , anti-phosphotyrosine ( p-Tyr ) , and anti-actin antibodies as described in Methods . The EGFR @VARIANT$ mutation , in conjunction with either wild-type EGFR or the drug-sensitive L858R EGFR mutant , prevents inhibition of tyrosine phosphorylation ( A ) or p-EGFR ( B ) by gefitinib .", "label": "resistance or non-response"}
{"id": "21188109", "sentence": "Cyclin D1 , in association with cyclin dependent kinase-4 and -6 , induces the cell to enter the S phase by phosphorylating the retinoblastoma tumor suppressing protein , which binds to transcription factors , including @VARIANT$ . In addition to the overexpression of cyclin D1 , other genes that overexpress in MCL , such as VEGF and Raf-1 , represent further possible targets for mTOR inhibitors . Indeed , a constitutive activation of Akt and mTOR pathways either in MCL cell lines ( Granta 519 , Jeko-1 , and SP-53 ) or in primary cultures from 30 % of MCL patients has been reported. , Moreover , mTOR inhibitors in MCL could synergize with other “canonical” agents , such as vincristine , @DRUG$ , bortezomib , and rituximab , with resulting inhibition of Raf-1 , @GENE$ , and mTOR . ,", "label": "None"}
{"id": "24244732", "sentence": "@DRUG$ sensitivity phenotypes of single point mutations in unc-18 We recently demonstrated that a single point mutation ( D216N ) in Munc18 acts biochemically by reducing binding to the assembled SNARE complex and that the orthologous mutation in C. elegans unc-18 ( D214N ) reduces sensitivity to both low and high concentrations of exogenous ethanol [ ] . Previously , we have biochemically characterised other point mutations in Munc18 that affect binding to other proteins including R39C ( inhibits binding to closed-conformation @GENE$ ) [ , ] , P242S ( inhibits binding to Mint proteins ) [ ] and @VARIANT$ ( enhances binding to Rab3 ) [ ] .", "label": "None"}
{"id": "23691449", "sentence": "Some of the molecular mechanisms of acquired resistance include T790M second mutation , mesenchymal epithelial transition factor ( @GENE$ ) amplification , ATP binding cassette (ABC)-G2 transporter ( ABCG2 ) and hepatocyte growth factor (HGF) overexpression , insulin-like growth factor (IGF) binding protein-3 ( IGFBP3 ) downregulation , as well as ERBB3 activation . T790M mutation The @VARIANT$ second mutation accounts for half of all resistances to @DRUG$ and erlotinib [ ] .", "label": "None"}
{"id": "23963283", "sentence": "For example , Caucasian patients harboring activating mutations in the @GENE$ kinase domain , such as a deletion in exon 19 or @VARIANT$ , have shown significant responses to the EGFR tyrosine kinase inhibitor ( TKI ) @DRUG$ , including a 70 % response rate , 14-month progression-free survival , and 27-month median survival .", "label": "sensitivity"}
{"id": "20224651", "sentence": "( ii ) The downregulation of ErbB2 and ErbB3/Akt/FLIP and survivin signaling events is necessary for α-TEA induced apoptosis , and ( iii ) ErbB1 is highly expressed in the A2780/CP70R cells and below levels of detection in the @VARIANT$ cells , suggesting that @GENE$ may play a role @DRUG$ @DRUG$ resistance .", "label": "None"}
{"id": "24495353", "sentence": "Rank Entrez ID Gene symbol Entrez ID Gene symbol Entrez ID Gene symbol 1 28978 TMEM14A 79776 ZFHX4 1727 CYB5R3 2 1843 DUSP1 4701 NDUFA7 7083 TK1 3 51022 GLRX2 715 @VARIANT$ 1292 COL6A2 4 1434 CSE1L 79818 @GENE$ 857 CAV1 5 8522 GAS7 4046 LSP1 5437 POLR2H 6 51668 HSPB11 1727 CYB5R3 9833 MELK 7 10456 HAX1 357 SHROOM2 54861 SNRK 8 9902 MRC2 283298 OLFML1 4830 NME1 9 4706 NDUFAB1 23179 RGL1 231 AKR1B1 10 23560 GTPBP4 1809 DPYSL3 10418 SPON1 11 79633 FAT4 857 CAV1 2350 FOLR2 12 10418 SPON1 274 BIN1 10979 FERMT2 13 471 ATIC 79833 GEMIN6 11096 ADAMTS5 14 6403 SELP 11222 MRPL3 4638 MYLK 15 23421 ITGB3BP 23244 PDS5A 9448 MAP4K4 16 23452 ANGPTL2 6241 RRM2 54922 RASIP1 17 54861 SNRK 1289 COL5A1 6934 TCF7L2 18 2034 EPAS1 8434 RECK 4072 EPCAM 19 30008 EFEMP2 429 ASCL1 4701 NDUFA7 20 25999 CLIP3 3426 CFI 404672 GTF2H5 21 4311 MME 332 BIRC5 6241 RRM2 22 4747 NEFL 2 A2M 2192 FBLN1 23 1809 DPYSL3 10730 YME1L1 25959 KANK2 24 28998 MRPL13 11130 ZWINT 55651 NHP2 25 25959 KANK2 1292 COL6A2 5050 PAFAH1B3 Lists of the top 25 of most influential genes in influence networks based on coexpression among genes in ER + breast tumors before , during , and after a course of neoadjuvant treatment with the drug @DRUG$ .", "label": "None"}
{"id": "19238632", "sentence": "Many tumours with intrinsic resistance to erlotinib/gefitinib were found to have wild-type @GENE$ and/or mutant KRAS . At present , no FDA approved inhibitor drugs have been shown to be successful in overcoming @VARIANT$ mediated resistance clinically .", "label": "resistance or non-response"}
{"id": "23927433", "sentence": "Infiltrate of mature lymphoid cells ( hematoxylin & amp ; eosin , H/E ) , which stained for CD20 ( B cell marker ) , DBA44 and @VARIANT$ BRAF ( @GENE$ markers ) . Histology and immunohistology were performed according to standard diagnostic procedures . The severely neutropenic patient was supported with both G-CSF and Epo and underwent ambulatory chemotherapy with the purine analog 2-CDA ( 2-Chlorodeoxyadenosine , @DRUG$ , cladribine ) according to a schedule of 0.1 mg/Kg IV once per week for 4 to 6 weeks .", "label": "None"}
{"id": "23497317", "sentence": "We treated an imatinib-sensitive GIST cell line ( GIST822 ) harboring a @GENE$ exon 13 mutation ( K642E ) and a second cell line , GIST48 , harboring an imatinib-sensitive @VARIANT$ mutation plus a secondary imatinib-insensitive activation loop mutation ( D820A ) with varying concentrations of quizartinib .", "label": "None"}
{"id": "24586383", "sentence": "At higher doses , the CI values resulted in synergism ( Dp44mT and TMX combination in MCF-7 and @VARIANT$ ; ) or even to strong synergism ( NHAPI with @GENE$ using MCF-7 cells ; ) or very strong synergism ( NHAPI with TMX on T47D cells ; ) . 4. Synergism of the Combination of NHAPI and @DRUG$ in MCF-7 cells is Confirmed by Measurement of Electrical Impedance , Mitochondrial Inner Membrane Potential and Cell Cycle Analyses", "label": "None"}
{"id": "23238683", "sentence": "In addition , the IC50 values for @DRUG$ were 0.5 to 30nM in parental cells and 30 to more than 300nM in resistant cells . As a whole our findings confirmed the efficacy of ponatinib on the @VARIANT$ mutation , but also highlighted the notion that ponatinib is effective on all types of imatinib-resistant CML cells , whatever their mode of resistance . Importantly , the IC50 values obtained for ponatinib in the present study for BaF3-WT-BCR-ABL , BaF3-T315I-BCR-ABL and @GENE$ ( 1nM , 8nM and 8nM respectively ) were very similar to the one reported previously by O’ Hare et al. ( 0.5 , 11 and 4.1nM respectively ) [ ] .", "label": "None"}
{"id": "24251962", "sentence": "@VARIANT$ and B , it is likely that inhibition of @GENE$ signalling does not affect hBMSC extravasation , but prevents differentiation of hBMSCs into myofibroblasts along with the secretion of ECM . Furthermore , Antalpa1 attenuated the injury induced by BLM in SCID/Beige mice lung significantly either 7 or 14 days after injection ( data not shown ) . Antalpa1 reduces hBMSC differentiation into myofibroblasts and the secretion of extracellular matrix in the @DRUG$ injured lung .", "label": "None"}
{"id": "PMC4125961", "sentence": "Analysis of the cell-free tumor DNA samples at PD in patient 1 and 2 showed the presence of the KRAS mutation G12V while in patient 3 the @VARIANT$ mutation was detected . Interestingly , pre-cetuximab cell-free tumor DNA was positive for KRAS mutant alleles for patients 2 and 3 , but was not sufficient to test the mutational status of @GENE$ in patient 1 .", "label": "sensitivity"}
{"id": "17877814", "sentence": "Recent structural analyses indicate that enhanced activity of EGFR mutants may derive form the disruption of autoinhibitory interactions that suppress @GENE$ basal activity [ , ] . Our data suggest that exon 20 insertions may disrupt these interactions to a greater extent than the @VARIANT$ point mutation . On the other hand , our functional analysis indicates that the uncommon exon 21 mutation P848L is not a kinase activating mutation and does not confer increased sensitivity to @DRUG$ .", "label": "resistance or non-response"}
{"id": "24555578", "sentence": "Ruppert et al. reported a case of a lung adenocarcinoma with a sensitive EGFR mutation in which the patient developed brain metastases with carcinomatous meningitis and liver metastasis after he stopped taking @GENE$ [ ] . Since a secondary @VARIANT$ mutation was found on a liver biopsy , but not in the CSF , the patient received @DRUG$ , and the brain metastasis responded well to treatment .", "label": "resistance or non-response"}
{"id": "25580268", "sentence": "An ongoing phase II study of the combination of dabrafenib with @GENE$ in BRAF @VARIANT$ melanoma brain metastases uses this strategy ( NCT01721603 ) . An institutional trial using lapatanib/capecitabine or trastuzumab-emtansine ( TDM-1 ) in HER 2+ breast cancer patients with one to 10 brain metastases treated with radiosurgery is in development ( Minesh Mehta and colleagues , personal communication ) .", "label": "None"}
{"id": "20195368", "sentence": "TNF-α is an inflammatory cytokine that can activate an extrinsic , @GENE$ mediated apoptotic pathway upon binding to its cell-surface receptor . This pathway involves the cleavage of caspase 8 , which can cleave Bid ( an antiapoptotic protein ) and subsequently stimulate Bax to induce the release of cytochrome c , and cause cell death . The detrimental role of TNF-α in ALS is supported by the use of thalidomide and @DRUG$ to successfully inhibt TNF-α production , and significantly increase lifespan in @VARIANT$ mice .", "label": "None"}
{"id": "22185378", "sentence": "( D ) Effects of MG132 ( 15 μM ) in combination with @DRUG$ ( 100 μg/mL ) on phosphorylation of EGFR ( Tyr 1068 ) , Akt and ERK1/2 on A431 and Caski cells , detected by Western blotting . Combination of matuzumab with PD98059 , a @GENE$ inhibitor , induces antagonistic effects in A431 , Caski and @VARIANT$ cells", "label": "None"}
{"id": "25099740", "sentence": "A and D ) Detroit 562 cells ( harboring @GENE$ @VARIANT$ mutations ) and UMSCC17B cells ( expressing HRAS Q61L mutant oncogene ) were transplanted into athymic mice , and mice were treated with @DRUG$ or rapamycin alone , or cetuximab together with rapamycin , as indicated .", "label": "resistance or non-response"}
{"id": "22970367", "sentence": "The data suggest that low BRCA1 level may neutralize the negative effects of the EGFR @VARIANT$ mutation on @DRUG$ sensitivity and that high BRCA1 expression may lead to de novo EGFR TKI resistance potentially through increased DNA damage repair capacity [ ] . In addition to EGFR T790M , primary EGFR TKI resistance may also be due to other secondary mutations in EGFR ( e.g. , D761Y ) that occur in @GENE$ with an activating EGFR kinase domain mutation ( e.g. , L858R ) [ ] .", "label": "None"}
{"id": "25210769", "sentence": "Originally , in order to convert cyt c into a peroxidase , we successfully designed cyt c @VARIANT$ and Y67R variants – . Replacement of Tyr67 by His67 is to introduce a distal @DRUG$ , while mutation from @GENE$ to Arg67 is to produce a distal arginine .", "label": "None"}
{"id": "25268163", "sentence": "Even though the transporter expression , localization and function of ABCC1 and ABCC2 have been extensively studied , there are only very limited data that more convincingly suggest any clinical relevance of naturally occurring SNPs in ABCC1 ABCC2 and @GENE$ . Several reports suggesting that ABCG2 SNP analysis might be a useful strategy to predict systemic exposure to ABCG2 substrate drugs is becoming increasingly prevalent [ ] . Of particular importance are recent studies that have demonstrated that subjects with a decreased ABCG2 activity owing to the @VARIANT$ variant are at an increased risk of gefitinib induced diarrhea [ ] , and altered pharmacokinetics of 9-aminocamptothecin [ ] , diflomotecan [ ] , irinotecan [ ] , rosuvastatin [ ] , sulfasalazine [ , ] and @DRUG$ [ ] .", "label": "None"}
{"id": "24855380", "sentence": "Two cases of c-KIT mutated thymic cancers responsive to sorafenib have been reported : in one case , a patient with the missense mutation @VARIANT$ in exon 17 had a partial response lasting more than 15 months , while in the other case , stable disease was achieved in the presence of exon 11 deletion. , Besides inhibiting @GENE$ , @DRUG$ and sorafenib also inhibit VEGFR and PDGFR , which are involved in angiogenesis and might play important roles in the pathogenesis of thymic cancers .", "label": "None"}
{"id": "24924344", "sentence": "@DRUG$ ( A/T ) Chr16 : 56671632 MT1A ( near-gene 5 ) 0.047628 0.138 Oxaliplatin rs562 ( C/T ) Chr3 : 183637845 ABCC5 ( UTR3 ) 0.049494 0.392 rs3749445 ( A/G ) Chr3 : 183638506 ABCC5 ( UTR3 ) 0.044895 0.410 rs2292998 ( C/T ) Chr3 : 183663833 @GENE$ ( intronic ) 0.039882 0.277 rs1016752 ( C/G ) Chr3 : 183665062 ABCC5 ( intronic ) 0.039781 0.232 rs4148585 ( C/T ) Chr3 : 183670642 ABCC5 ( intronic ) 0.039781 0.283 rs6443924 ( A/G ) Chr3 : 183679532 ABCC5 ( intronic ) 0.039781 0.279 rs4148579 ( A/G ) Chr3 : 183685249 ABCC5 ( intronic ) 0.039781 0.279 rs939336 ( A/G =&gt ; @VARIANT$ ) Chr3 : 183685534 ABCC5 ( exonic ) 0.039781 0.279 rs1132776 ( C/T = & gt ; A395A ) Chr3 : 183696402 ABCC5 ( exonic ) 0.044895 0.289 rs2313212 ( C/T ) Chr3 : 183700928 ABCC5 ( intronic ) 0.039781 0.279 rs4148575 ( C/T ) Chr3 : 183702275 ABCC5 ( UTR3 ) 0.044895 0.289 rs1846692 ( C/T ) Chr16 : 56671696 MT1A ( near - gene 5 ) 0.049494 0.360 rs35346959 ( A/G ) Chr16 : 56671867 MT1A ( near- gene 5 ) 0.044895 0.137 rs9922957 ( C/G ) Chr16 : 56672380 MT1A ( near - gene 5 ) 0.039781 0.185 rs9922409 ( A/G ) Chr16 : 56672400 MT1A ( near - gene 5 ) 0.04532 0.103 rs7190725 ( G/T ) Chr16 : 56673290 MT1A ( intronic ) 0.044895 0.170 rs8052394 ( A/G =&gt ; K51R ) Chr16 : 56673828 MT1A ( missense ) 0.044895 0.152 rs1800566 ( C/T = & gt ; P187S ) chr16 : 69745145 NQO1 ( exonic ) 0.039781 0.258 rs689455 ( A/C ) Chr16 : 69761661 NQO1 ( near- gene 5 ) 0.039781 0.242", "label": "None"}
{"id": "21042543", "sentence": "The only B-RAF mutation found was the @VARIANT$ substitution . The most important thing was that patients who received @DRUG$ or cetuximab but had B-RAF alteration , presented no objective response to therapy ; consequently TTP was worse for subjects bearing a mutated @GENE$ although not statistically significant probably due to the limited number of tumors carrying these mutations .", "label": "resistance or non-response"}
{"id": "21333004", "sentence": "According to recent reports , the sensitivity to kinase inhibition reflects intrinsic differences in the binding affinity of the EGFR mutants such as L858R , @VARIANT$ , and exon19 deletions [ , - ] . Yun et al [ ] showed that gefitinib directly binds more tightly to the L858R mutant than to the wild type EGFR in vitro , while Fabian et al [ ] indicated that @GENE$ with @DRUG$ sensitive mutations does not differ from wild type EGFR in terms of gefitinib binding affinity .", "label": "sensitivity"}
{"id": "21045268", "sentence": "P22phox is an essential component of @GENE$ The @VARIANT$ polymor- phism results in an amino acid polymorphism ( His/Tyr ) at residue 72 of p22phox involving a potential heme- binding site [ 12 ] . Because the @DRUG$ residue is con- sidered to be a candidate for the ligand of the heme prosthetic group of cytochrome b , it has been revealed that this polymorphism is associated with the function of p22phox and significantly lower basal and NADPH- stimulated vascular superoxidase production in human blood vessels from patients with atherosclerosis [ 13 , 14 ] .", "label": "None"}
{"id": "23801357", "sentence": "Ponatinib ( @DRUG$ ) is a novel pan–BCR-ABL inhibitor developed using a computational and structure based approach.– It was designed to bind to and inhibit native BCR-ABL and @GENE$ mutants that can arise during treatment with other TKIs and cause resistance , including the @VARIANT$ mutant .", "label": "response"}
{"id": "24523596", "sentence": "Several studies have reported renal failure and tumor lysis syndrome during TKI based molecular targeted therapies , including with sorafenib for hepatocellular carcinoma , with imatinib for chronic myelogenous leukemia , and with @DRUG$ for chronic lymphocytic leukemia.– Because the @VARIANT$ variant of @GENE$ corresponding to SNP 421C&gt ; A reduces uric acid transport and those TKIs are substrates/inhibitors of ABCG2/BCRP , TKI therapy in patients with the SNP 421C&gt ; A ( Q141K ) may be at higher risk of tumor lysis syndrome .", "label": "None"}
{"id": "24416053", "sentence": "New mutations including C1156Y and @VARIANT$ are detected in ALK kinase in biopsy performed in lung cancer recurrent patients administered with @GENE$ inhibitors . The tolerance mechanism of those mutations resembles that of @DRUG$ used in recombination of BCR-ABL rather than T790M mutation which is the tolerance mechanism of EGFR-TKI .", "label": "None"}
{"id": "25344762", "sentence": "MTS assay was used to evaluate the effects of erlotinib ( a ) , @DRUG$ ( c ) , and combination of erlotinib and bevacizumab ( d ) on the growth of NSCLC cell lines , which included cell lines with EGFR mutations : PC9 ( EGFR exon 19 deletion ) , 11–18 ( EGFR L858 ) , H1975 ( @GENE$ @VARIANT$ and T790 M mutations ) and EGFR wild-type cell lines : H157 , H460 and A549 .", "label": "None"}
{"id": "24279718", "sentence": "Furthermore , the identified L862R EGFR mutation , although not reported before , was located near mutations known to be sensitive to EGFR-TKI , such as @VARIANT$ and L861X . Therefore , the tumor clone bearing this EGFR mutation could have been potentially responsive to EGR-TKI therapy . However , a previously described single case of L862V EGFR mutation was associated with lack of response to @DRUG$ and the same could have been the scenario with the L862R @GENE$ mutation .", "label": "sensitivity"}
{"id": "22751098", "sentence": "To test this hypothesis and to clinically validate our preclinical findings , we measured the expression of AXL by IHC ( immunohistochemistry ) in 35 matched EGFR-mutant NSCLC specimens obtained from patients both prior to treatment with the EGFR TKIs erlotinib or @DRUG$ and upon the development of EGFR TKI acquired resistance . In cases where enough material was available for additional studies , we also examined the specimens for GAS6 and vimentin ( as a marker for @GENE$ ) expression by IHC ( scoring system shown in ) , EGFR @VARIANT$ by sequencing , and MET amplification by FISH .", "label": "None"}
{"id": "24982846", "sentence": "@DRUG$ EGFR EGFR protein expression positive @GENE$ exon 19 deletion or exon 21 substitution ( @VARIANT$ ) positive Clinical pharmacology Indications and usage , dosage and administration , clinical pharmacology , clinical studies", "label": "sensitivity"}
{"id": "23976869", "sentence": "Dasatinib is a dual SRC/ABL1 inhibitor that also inhibits PDGFRs and FIP1L1-PDGFRA fusion but has no effect on imatinib-resistant FIP1L1-PDGFRA T674I and @VARIANT$ mutants . Third generation of TKIs : ponatinib @DRUG$ has a potent activity towards BCR-ABL1 , as well as numerous imatinib-resistant @GENE$ kinase domain mutants , including the T315I mutation .", "label": "None"}
{"id": "23606169", "sentence": "SSCP analysis indicated @GENE$ WT status , which qualified her ( the patient ) for concomitant targeted therapy ( @DRUG$ : first dose , 400 mg/m2 ; subsequent doses , 250 mg/m2 ) and chemotherapy ( 5-fluorouracil 400 mg/m2 bolus and then 600 mg/m2 over 22 h for day 1 ; leucovorin 200 mg/m2 before 5-fluorouracil ) . After 4 months of treatment , stabilization of the metastatic lesions within the pelvis was observed , but two new metastatic lesions within the skin layers had occurred . Fine needle aspiration of the new metastatic lesions indicated adenocarcinomas , which were tested for KRAS and @VARIANT$ BRAF mutation using the real-time PCR method ( KRBR-RT50 , Entrogen ) .", "label": "None"}
{"id": "23824671", "sentence": "Third , Montagut et al. reported that @GENE$ @VARIANT$ ectodomain mutation prevents cetuximab binding and confers resistance to @DRUG$ .", "label": "resistance"}
{"id": "23940741", "sentence": "Somatic activating mutations of the EGFR gene have been identified as a major determinant of the clinical response to @GENE$ tyrosine kinase inhibitors ( TKIs ) such as @DRUG$ and erlotinib in patients with NSCLC . Most of these mutations occur in exons 19 to 21 , which encode the tyrosine kinase domain of the receptor , the most common being deletions in exon 19 ( such as delE746-A750 ) and the @VARIANT$ point mutation in exon 21 .", "label": "sensitivity"}
{"id": "25080336", "sentence": "Mifepristone reversed progesterone’s inhibition effect of @GENE$ translocation by LPS for 1 hour . @VARIANT$ : progesterone 10−7 M+LPS ; M9PL : mifepristone 10−9 M+progesterone 10−7 M+LPS ; M8PL : mifepristone 10−8 M+progesterone 10−7 M+LPS ; M7PL : mifepristone 10−7 M+progesterone 10−7 M+LPS .", "label": "None"}
{"id": "19513066", "sentence": "( B ) Srcein lysates of MDA-MB-231 , MCF7 , and @VARIANT$ cells treated for 2 h were immunoblotted as indicated for pSrc-Y416 , stripped and reprobed for total Prot . ( C ) Cells were treated for 48 h with DMSO , 100 nM dasatinib , 100 nM @DRUG$ , or 100 nM of each drug . Whole lysates were immunoblotted for PARP , @GENE$ , and GAPDH .", "label": "None"}
{"id": "25221748", "sentence": "In the advanced NSCLC EGFR-TKI resistant setting , the @GENE$ small molecule inhibitor AUY922 is being evaluated as monotherapy in a phase II clinical trial vs. @DRUG$ or docetaxel in patients with tumors with activating EGFR mutations ( www.clinicaltrials.gov : NCT016461250 ) . This agent is also being assessed in a phase II trial in patients with de novo resistant @VARIANT$ mutations not previously treated with EGFR-TKIs ( www.clinicaltrials.gov : NCT01854034 ) and in patients with EGFR mutations and/or EGFR-TKI resistant disease , as part of a phase II cluster study in Chinese patients evaluating five novel inhibitors of HSP90 , PI3K , ALK , MET , and MEK ( ) .", "label": "None"}
{"id": "23320171", "sentence": "Primary results from the EMILIA study , a randomized trial comparing @DRUG$ DM-1 to lapatinib and capecitabine , have shown that Trastuzumab DM-1 significantly improved progression-free survival in patients with metastatic HER2 positive breast cancer . Further research is looking into inhibiting other targets such as mTOR , @VARIANT$ , or @GENE$ pathways .", "label": "None"}
{"id": "19238632", "sentence": "H1975 cell line was chosen because it expresses the ‘gatekeeper'-resistant T790M-EGFR mutation ( in-cis with @VARIANT$ ) in the receptor kinase domain hydrophobic pocket , representing a major mechanism of resistance to reversible @GENE$ ( erlotinib/gefitinib ) ( ; ) .", "label": "sensitivity"}
{"id": "17973573", "sentence": "H1975 cells harbor two mutations ( @VARIANT$ and T790M ) in the EGFR gene . All cells were maintained in RPMI-1640 medium supplemented with 10 % heat inactivated fetal calf serum ( FCS , JRH Biosciences , Lenexa , Kansas ) . The @GENE$ inhibitor QVD-OPH ( MP Biomedicals , Aurora , Ohio ) was used at 25 μM and added to cells 30 min prior to treatment with @DRUG$ .", "label": "None"}
{"id": "22719810", "sentence": "Based on current studies , we could explain why @GENE$ in this patient had a prompt and dramatic radiologic and clinical improvement . Unfortunately , even in @DRUG$ responders , disease progression occurs and is inevitable . Some reports present that despite initial responses , patients eventually progress by unknown mechanisms of “acquired” resistance , a secondary mutation in exon 20 , which leads to substitution of methionine for threonine at position 790 ( @VARIANT$ ) in the kinase domain [ ] .", "label": "resistance or non-response"}
{"id": "22248929", "sentence": "Inhibition of TORC1 and downstream @VARIANT$ with the rapalog @DRUG$ derepresses levels of insulin receptor substrate (IRS)-1 expression leading to activation of @GENE$ and phosphorylation of AKT at S473 in both cancer cell lines and tumors of patients [ - ] .", "label": "None"}
{"id": "22970367", "sentence": "However , in clinical studies , BIBW2992 did not prolong survival compared to placebo in NSCLC patients who have developed acquired resistance to gefitinib or @DRUG$ [ ] . Another agent in this class of next generation EGFR TKIs , PF-002999804 , inhibits all @GENE$ family members and has been shown to be effective against tumors harboring @VARIANT$ [ , ] .", "label": "resistance or non-response"}
{"id": "24789720", "sentence": "The role of @VARIANT$ mutation , particularly its presence in patients before EGFR-TKIs treatment is still controversial being a subject of intensive discussions . Mechanism of achieving resistance to erlotinib and @DRUG$ remains unclear . The recent reports confirmed , that T790M substitution could be detected in EGFR-TKIs naïve patients independently of other @GENE$ gene mutations ( predominantly L858R substitution and deletions in exon 19 ) .", "label": "resistance or non-response"}
{"id": "24944676", "sentence": "A cisplatin-sensitive ovarian cancer cell line ( OV2008 ) and the resistant variant ( @VARIANT$ ) were supplied by Dr Rakesh Goel from the Ottawa Regional Cancer Center ( Ottawa , ON , Canada ) . Cells were maintained in RPMI-1640 complete medium supplemented with 2 mM @GENE$ and 10 % fetal bovine serum ( FBS ) at 37°C in a humidified atmosphere containing 5 % CO2 .", "label": "None"}
{"id": "24244732", "sentence": "@DRUG$ sensitivity phenotypes of single point mutations in unc-18 We recently demonstrated that a single point mutation ( D216N ) in Munc18 acts biochemically by reducing binding to the assembled SNARE complex and that the orthologous mutation in C. elegans unc-18 ( D214N ) reduces sensitivity to both low and high concentrations of exogenous ethanol [ ] . Previously , we have biochemically characterised other point mutations in Munc18 that affect binding to other proteins including R39C ( inhibits binding to closed-conformation syntaxin ) [ , ] , P242S ( inhibits binding to Mint proteins ) [ ] and @VARIANT$ ( enhances binding to @GENE$ ) [ ] .", "label": "None"}
{"id": "25382104", "sentence": "Ponatinib is the only available drug that is designed to overcome @VARIANT$ gatekeeper mutation and is efficient in inhibiting the mutant @GENE$ @DRUG$ exhibits triple carbon-carbon ( ethynyl linkage ) bond between the methyl phenyl and purine groups .", "label": "response"}
{"id": "22960745", "sentence": "Only one sample had a KRAS codon 61 mutation , and there were no exon 19 deletions or @VARIANT$ mutations in EGFR . However , amplifications of EGFR were found in 7 % of cases as were two instances of the L861Q @GENE$ mutation , which confers sensitivity to erlotinib and @DRUG$ .", "label": "sensitivity"}
{"id": "24307874", "sentence": "As aforementioned , the RMSD values of the ligand in R28C and @VARIANT$ mutants were greater than 4 , which was two times larger than that of wild type . It is clear that the neutral charged cysteine has a sulfur atom in its side chain , which imposes a larger steric restriction compared with arginine . Although it has the same positive charge as arginine , @DRUG$ has a five-member ring that produces more steric hindrance than the side chain of arginine .", "label": "None"}
{"id": "PMC3760629", "sentence": "The EGFR mutant PC9 cell line harbouring EGFR @VARIANT$ , PC9R , has been used as in vitro model of drug resistance . Tumour microvesicles ( TMVs ) shed from cancer cells contain genetic and other molecular information that might be useful for diagnostic purposes to differentiate gefitinib-resistant NSCLC ( non-responders ) from sensitive patients ( drug responders ) . The main objective of this study was to identify unique protein and phospholipid signatures of TMVs derived from gefinitib-resistant @GENE$ cells by proteomics analysis and lipid MALDI profiling .", "label": "None"}
{"id": "17551677", "sentence": "Preliminary data were recently published that show that this agent has clinical activity in 2 patients with advanced NSCLC with @GENE$ mutations and acquired @DRUG$ resistance [ ] . Finally , a recent retrospective analysis of IDEAL trial specimens does not find any @VARIANT$ mutations in the tumours analysed [ ] .", "label": "resistance or non-response"}
{"id": "24489922", "sentence": "Sequencing of 12 clones showed that all contained the exchange E197K in the C-terminal domain ( stemming from RpoH ) either alone or in combination with various exchanges in the N-terminal domain ( stemming from @GENE$ ) . The fastest growing colony contained an rp5H insert encoding the E197K exchange plus the V23I , @VARIANT$ , and M75K substitutions . Following the transformation of Δrpb5 with the different pRS423_rpb5 constructs , the growth of single colonies was compared in liquid minimal medium ( synthetic dropout medium without @DRUG$ ) .", "label": "None"}
{"id": "23380592", "sentence": "Sveinsson’s chorioretinal atrophy is a genetic disease that is caused due to @VARIANT$ point mutation in TEAD1 . This residue is in interface 3 and is involved in a hydrogen bond and a hydrophobic contact with YAP residues . A @DRUG$ at this position would disrupt these interactions and biochemically it has been shown that this substitution would compromise @GENE$ interaction .", "label": "None"}
{"id": "23788917", "sentence": "In case of occurrence of both L858R and @VARIANT$ mutations , the concentration of @DRUG$ should be three times higher in order to achieve a therapeutic effect . Analysis of the @GENE$ structure in patients harbouring the T854A mutation suggests the presence of an additional side chain , localised near the EGFR TKI binding site [ ] .", "label": "resistance or non-response"}
{"id": "25202264", "sentence": "The majority of these patients also had other coexisting @GENE$ mutations . The coexisting point mutations on exon 20 that rendered the patients resistant to @DRUG$ were G719A , @VARIANT$ , W731 Stop , L858R , L 861Q and delE749_T751insVA [ ] .", "label": "None"}
{"id": "24924344", "sentence": "@DRUG$ rs562 ( C/T ) Chr3 : 183637845 ABCC5 ( UTR3 ) 0.049494 0.392 rs3749445 ( A/G ) Chr3 : 183638506 ABCC5 ( UTR3 ) 0.044895 0.410 rs2292998 ( C/T ) Chr3 : 183663833 ABCC5 ( intronic ) 0.039882 0.277 rs1016752 ( C/G ) Chr3 : 183665062 ABCC5 ( intronic ) 0.039781 0.232 rs4148585 ( C/T ) Chr3 : 183670642 ABCC5 ( intronic ) 0.039781 0.283 rs6443924 ( A/G ) Chr3 : 183679532 ABCC5 ( intronic ) 0.039781 0.279 rs4148579 ( A/G ) @GENE$ : 183685249 ABCC5 ( intronic ) 0.039781 0.279 rs939336 ( A/G =&gt ; C594C ) Chr3 : 183685534 ABCC5 ( exonic ) 0.039781 0.279 rs1132776 ( C/T = & gt ; @VARIANT$ ) Chr3 : 183696402 ABCC5 ( exonic ) 0.044895 0.289 rs2313212 ( C/T ) Chr3 : 183700928 ABCC5 ( intronic ) 0.039781 0.279 rs4148575 ( C/T ) Chr3 : 183702275 ABCC5 ( UTR3 ) 0.044895 0.289 rs1846692 ( C/T ) Chr16 : 56671696 MT1A ( near - gene 5 ) 0.049494 0.360 rs35346959 ( A/G ) Chr16 : 56671867 MT1A ( near- gene 5 ) 0.044895 0.137 rs9922957 ( C/G ) Chr16 : 56672380 MT1A ( near - gene 5 ) 0.039781 0.185 rs9922409 ( A/G ) Chr16 : 56672400 MT1A ( near - gene 5 ) 0.04532 0.103 rs7190725 ( G/T ) Chr16 : 56673290 MT1A ( intronic ) 0.044895 0.170 rs8052394 ( A/G =&gt ; K51R ) Chr16 : 56673828 MT1A ( missense ) 0.044895 0.152 rs1800566 ( C/T = & gt ; P187S ) chr16 : 69745145 NQO1 ( exonic ) 0.039781 0.258 rs689455 ( A/C ) Chr16 : 69761661 NQO1 ( near- gene 5 ) 0.039781 0.242", "label": "None"}
{"id": "24614299", "sentence": "( A ) Tomosyn amino acids 540-1116 ( Cter ) or 1028-1116 ( CoiledCoil ) were used as bait in a yeast two-hybrid ( @VARIANT$ ) experiment ( light grey : β-propeller domains , dark grey : synaptobrevin-like coiled coil domain , phosphorylation ( P ) and SUMOylation ( S ) sites are also depicted ) , next to an empty bait vector pBD-GAL4 , in combination with prey constructs expressing ( B ) PIASγ ( light grey : DNA binding SAP-domain , dark grey : MIZ-type zinc finger domain ) or syntaxin sequences , next to an empty prey vector pAct2 . Yeast colonies were incubated on ( C ) @DRUG$ containing medium ( no selection ) , or medium ( D ) lacking histidine ( medium stringent selection ) or ( E ) lacking histidine and adenine ( stringent selection ) . Stringent selection indicated a strong PIASγ interaction with the larger Cter fragment of tomosyn-1 as well as @GENE$ binding to tomosyn-1 CoiledCoil fragment .", "label": "None"}
{"id": "15737014", "sentence": "Using this insight , new small-molecule inhibitors have been identified that retain activity against the majority of imatinib-resistant @GENE$ mutants [ , ] . For example , in CML , a commonly found mutation is a C→T single nucleotide change that replaces threonine with isoleucine at position 315 ( T315I ) in the ABL kinase domain [ , , ] . In GIST and HES , respectively , the analogous @VARIANT$ mutation in KIT and T674I mutation in PDGFR-alpha have been associated with acquired resistance to this drug [ , ] .", "label": "None"}
{"id": "16187797", "sentence": "Sensitivity of Cell Transformation Induced by Expression of Mutant EGFR Characterized by Missense Mutation or Exon 19 Deletion , but not Exon 20 Insertion , to @DRUG$ and Erlotinib ( A ) Anchorage independent growth of clonal NIH-3T3 cells transformed with mutant EGFR or @GENE$ stimulated wild-type EGFR treated with the indicated concentrations of erlotinib immediately prior to suspension in soft agar . Transformation induced by expression of L858R , G719S , and L747_E749del @VARIANT$ EGFR , but not EGF stimulated wild-type EGFR or D770_N771insNPG EGFR , was inhibited by 0.1 μM erlotinib .", "label": "None"}
{"id": "PMC4041556", "sentence": "Second-generation EGFR TKIs – such as neratinib , @DRUG$ and dacomitinib – are effective in preclinical gefitinib- and erlotinib-resistant EGFR @VARIANT$ models , but to date their delivery in @GENE$ TKI-resistant patients have shown disappointing results in the clinic .", "label": "response"}
{"id": "24260231", "sentence": "Sorafenib or the @GENE$ Inhibitor Downregulates Chk1 Activation and Profoundly Enhances Etoposide Sensitivity of Cells Expressing BCR/ABL with T315I We finally examined cells expressing the @VARIANT$ mutant of BCR/ABL , which is resistant not only to imatinib but also to dasatinib or @DRUG$ .", "label": "None"}
{"id": "17877814", "sentence": "Several uncommon EGFR mutants identified in the course of this analysis were tested using the @GENE$ assay . Mutations in exon 20 , most notably @VARIANT$ , are usually associated with resistance to @DRUG$ and erlotinib [ reviewed in [ ] ] .", "label": "resistance or non-response"}
{"id": "24244732", "sentence": "This then indicates that whatever the E465K mutation is doing at high @DRUG$ concentrations , it acts both downstream and independent of functional rab-3 , which itself is downstream of @VARIANT$ . Interestingly , the E465K mutation is modelled on a Sly1p ( yeast Sec1/Munc18 protein ) that bypasses the requirement for a functional @GENE$ protein during ER to Golgi vesicle trafficking [ ] .", "label": "None"}
{"id": "23579627", "sentence": "This findings show that EGFR @VARIANT$ is a common resistance mechanism to both reversible , and when amplified , the irreversible EGFR inhibitors . In our case , the response duration of irreversible EGFR inhibitor was 11 months which was unusually longer than those of initial @DRUG$ ( for 4 months ) and second round gefitinib ( for 6 months ) treatments . Recently an alternative approach is to develop novel strategies , instead of irreversible EGFR inhibitors , to inhibit EGFR and/or EGFR signaling , including the use of inhibitors of HSP90 and/or EGFR downstream signaling ( such as @GENE$ MEK inhibitors ) as these resistant cancers still remain dependent on EGFR signaling for their growth .", "label": "None"}
{"id": "25122428", "sentence": "None of the cell lines showed apparent cytotoxicity in response to doses up to 1 μM @DRUG$ . Conversely , all @GENE$ inhibitors significantly impaired the proliferation of the SCLC cell lines . H1048 , which harbors a PIK3CA mutation ( @VARIANT$ ) , was the most sensitive to all of the PI3K/AKT/mTOR inhibitors , with IC50 values of 3.8 , 5.4 , 99.9 , and 195.4 nM for INK128 , BEZ235 , MK2206 , and BKM120 , respectively .", "label": "None"}
{"id": "24223798", "sentence": "PC9/ZD cells were established as a gefitinib-resistant clone from PC9 cells , and were shown to harbor the @VARIANT$ mutation of @GENE$ .", "label": "resistance or non-response"}
{"id": "24386407", "sentence": "Among the mechanisms by which cancer cells become resistant to reversible EGFR-TKIs are 1 ) gatekeeper mutations in EGFR , such as the @VARIANT$ second mutation [ , ] ; 2 ) activation of bypass signaling caused by Met amplification [ ] , hepatocyte growth factor (HGF) overexpression [ ] , or Gas6-Axl activation [ ] ; 3 ) activation of downstream molecules ( PTEN loss or PIK3CA mutation ) [ , ] ; 4 ) small-cell lung cancer transformation [ ] ; and 5 ) epithelial-to-mesenchymal transition [ ] . The gatekeeper EGFR-T790M mutation is the most frequent , occurring in half of tumors with acquired resistance to reversible EGFR-TKIs . The methionine residue at position 790 generates a bulkier side chain , which enhances the affinity of the EGFR tyrosine kinase pocket with ATP [ ] , decreasing the effective binding of gefitinib and @DRUG$ to the tyrosine kinase pocket of @GENE$ [ ] .", "label": "resistance or non-response"}
{"id": "18544172", "sentence": "Non-responders 10 F 68 0 Folfiri , Xeloda , Xelox SD 17 Wild-type @VARIANT$ trisomy 11 F 74 1 LV5FU Folfiri SD 10 Gly12Val disomy 12 M 61 0 Folfirinox SD 18 Gly13Asp R521K disomy 13 F 71 0 Xelox Avastin-Xeliri SD 15 Gly12Asp disomy 14 M 59 0 LV5FU , Folfiri , Folfox SD 24 Gly12Cys R521K trisomy 15 M 71 0 Folfox , Irinotecan SD 14 Wild-type disomy 16 F 60 1 Fufol Folfiri , Folfox , Cape , LV5FU SD 17 Wild-type trisomy 17 M 65 0 Folfirinox , Folfiri SD 18 Wild-type low polysomy 18 M 66 0 Folfiri SD 17 Wild-type R521K disomy 19 F 45 0 Folfox , Xelox SD 17 Wild-type R521K NE 20 F 42 0 Folfirinox SD 21 Gly12Asp R521K trisomy 21 M 62 1 Folfox Xeliri SD 36 Gly13Asp R521K disomy 22 M 58 1 Folfiri Xelox , Xeliri PD NA Gly13Asp disomy 23 M 75 1 Xelox Xeliri PD NA Wild-type trisomy 24 M 81 0 Xelox , Folfiri PD NA Gly12Val disomy 25 F 55 0 Xelox Avastin-Xeliri PD NA Gly12Asp disomy 26 M 60 1 LV5FU Folfiri , Folfiri , Folfox PD NA Wild-type NE 27 M 59 0 Folfiri , Folfiri/Folfox , Folfox PD NA @GENE$ NE 28 F 58 1 LV5FU Folfiri , Xelox PD NA Gly12Asp disomy 29 M 51 0 Folfox , Folfiri PD NA Wild-type disomy 30 F 66 0 Folfiri , Xelox PD NA Wild-type R521K trisomy 31 F 56 0 - PD NA Wild-type disomy 32 F 78 0 Folfox , Folfiri , Cape PD NA Gly12Val disomy F = female , M = Male , Folfox = oxaliplatin , fluorouracil , and @DRUG$ Xelox = capecitabine , oxaliplatin ; Folfiri = irinotecan , fluorouracil , and folinic acid ; Xeliri = Capecitabine , irinotecan ; Folfirinox = oxaliplatin , irinotecan , fluorouracil , and folinic acid ; LV5FU = infusional FU and folinic acid ; Fufol = bolus fluorouracil and folinic acid ; PR = partial response .", "label": "None"}
{"id": "22034911", "sentence": "However , analogous Ba/F3 xenografts expressing @VARIANT$ , S1206R , or G1269S mutants were completely insensitive to these doses , with no statistically significant changes in tumor growth rate . @DRUG$ is not efficacious in mouse Ba/F3 xenograft models expressing @GENE$ mutants .", "label": "resistance"}
{"id": "24276379", "sentence": "It has even been observed that cells that have been induced to become cetuximab-resistant by continuously exposing them to cetuximab have acquired either @GENE$ G12V or K-Ras @VARIANT$ mutations [ ] .", "label": "resistance or non-response"}
{"id": "23937717", "sentence": "We postulate that the attenuation of inhibitory effect of tumor cells on NK cells may partially attributed to the stat3 inhibition by @DRUG$ . In our present study , we also find that high purity NK cells increase autophagy in A549 cancer cells with wide type EGFR , while not in H1975 cells with @GENE$ @VARIANT$ + T790M .", "label": "sensitivity"}
{"id": "22970367", "sentence": "@VARIANT$ is thought to shift the equilibrium towards the active conformation of the receptor , while D761Y may affect the catalytic cleft of the receptor . Both T854 and D761 were identified in laboratory models of @DRUG$ resistance in addition to clinical samples [ ] . 3.2 . @GENE$ Amplification", "label": "None"}
{"id": "22363766", "sentence": "EGFR TKIs ( such as @DRUG$ or gefitinib ) are selective inhibitors of @GENE$ 's kinase domain that work by competing with ATP for binding at the ATP binding site , thereby preventing autophosphorylation and activation . The @VARIANT$ mutation affects the gatekeeper residue in the catalytic kinase domain and confers drug resistance by increasing EGFR 's affinity for ATP – thus reducing the potency of the ATP-competitive kinase inhibitors .", "label": "resistance or non-response"}
{"id": "24244715", "sentence": "@DRUG$ cycloheximide , @GENE$ inhibitor Z-VAD-FMK , 4 % Paraformaldehyde solution , Annexin V-FITC Apoptosis Assay Kit ( C1063 ) , Nuclear and Cytoplasmic Protein Extraction Kit ( P0027 ) , RIPA lysis buffer ( P0013B ) and NP-40 lysis buffer ( @VARIANT$ ) were from Beyotime Co. ( Jiangsu , China ) .", "label": "None"}
{"id": "24814345", "sentence": "2OG binding also involves other polar residues including alcohols , i.e. a Ser ( βVIII , part of ‘RXS’ motif as present in e.g. DAOCS , ANS , FTO , algal @VARIANT$ ) or Thr ( βII , e.g. as in some KDMs : @GENE$ , JMJD6 , PHF8 , UTX ) or Tyr ( non-DSBH β-strand , e.g. as in FIH , KDM4A , ABH2 , PHD2 ) and sometimes , water molecule ( s ) ( reviewed in , , ) . In an analogous position to the serine of ‘RXS’ motif ( βVIII ) , the hROX have histidine-residues , His253Mina53/His417NO66 ( βVIII ) , that form part of a hydrogen-bond network involving Thr255Mina53/Thr419NO66 ( βVIII ) , a water molecule , and the 2OG carboxylates .", "label": "None"}
{"id": "15737014", "sentence": "Such mutations rarely , if ever , accompany EGFR mutations and are associated with primary resistance to @DRUG$ or erlotinib [ ] . To evaluate the possibility that secondary KRAS mutations confer acquired resistance to these drugs , we performed mutational profiling of @GENE$ exon 2 from tumor specimens from patients 1 to 3 , as well as the three additional patients lacking evidence of the T790M mutation . An Established NSCLC Cell Line Also Contains Both T790M and @VARIANT$ Mutations", "label": "None"}
{"id": "24876815", "sentence": "The cause of refractoriness has been identified in ca. 15 % of mCRC patients as mutations in the BRAF gene , primarily @VARIANT$ substitution . Raf family proteins are downstream of @GENE$ proteins in the signal transduction pathway originating at EGFR . It comes as no surprise , then , that activating mutations in the BRAF gene occurring in cancer cells have a similar clinical effect to KRAS gene mutations , making them refractory both to cetuximab and @DRUG$ [ , , – ] .", "label": "None"}
{"id": "22970367", "sentence": "Moreover , dual inhibition of EGFR with an irreversible @GENE$ inhibitor ( afatinib ) and the EGFR neutralizing antibody @DRUG$ has recently shown promising activity in EGFR mutant lung cancers with acquired EGFR TKI resistance that harbor an EGFR @VARIANT$ mutation [ ] .", "label": "response"}
{"id": "17877814", "sentence": "In a subset of NSCLC patients , the presence of somatic mutations in the kinase domain of EGFR may predict the outcome of treatment with the @GENE$ TKIs @DRUG$ and gefitinib . The favorable clinical response of tumors harboring the common exon 19 deletions or the @VARIANT$ mutation correlates with the high TKI sensitivity of these EGFR mutant proteins at the molecular level .", "label": "sensitivity"}
{"id": "15737014", "sentence": "Analysis of earlier passages of H1975 cells for the @VARIANT$ mutation would be informative in this regard . Recently , new small-molecule inhibitors have been identified that retain activity against the majority of imatinib-resistant @GENE$ mutants .", "label": "None"}
{"id": "24964744", "sentence": "MCF10a cells containing the PI3K mutation @VARIANT$ showed little sensitivity to single agent sirolimus , and in combination with EGFR inhibitors were still seen to be more resistant than their parental counterpart , and were more resistant than MCF10a cells containing the @GENE$ E545K mutation . Chou and Talalay combination indices for each cell line examined Gefitinib + ZSTK474 Erlotinib + ZSTK474 Gefitinib + Rapamycin Erlotinib + Rapamycin Gefitinib + ZSTK474 Erlotinib + ZSTK474 @DRUG$ + Rapamycin Erlotinib + Rapamycin", "label": "None"}
{"id": "PMC4041556", "sentence": "Second-generation EGFR TKIs – such as neratinib , afatinib and dacomitinib – are effective in preclinical gefitinib- and erlotinib-resistant EGFR @VARIANT$ models , but to date their delivery in EGFR TKI-resistant patients have shown disappointing results in the clinic . Combination of afatinib with cetuximab in EGFR TKI-resistant patients resulted in a 30 % response rate and 75 % disease control rate , with significant gastrointestinal toxicity . Other mechanisms of resistance include MET amplification , with no commercially available inhibitor , @GENE$ amplification potentially amenable to treatment with anti-HER2 monoclonal antibodies or histological transformation to small-cell lung cancer , which requires cytotoxic chemotherapy .", "label": "None"}
{"id": "15736989", "sentence": "Several mutations have been identified in the context of epidermal growth factor receptor (EGFR) in patients with NSCLC that are associated with clinical response to the small-molecule @GENE$ inhibitors gefitinib ( Iressa ) or erlotinib ( @DRUG$ ) [ , , ] , including in-frame deletions such as del L747–E749 ; A750P in exon 19 , or @VARIANT$ in exon 21 .", "label": "sensitivity"}
{"id": "23937717", "sentence": "Stat3 is a key factor in gefitinib-resistant @GENE$ @VARIANT$ cells [ ] .", "label": "resistance or non-response"}
{"id": "23937717", "sentence": "Though @DRUG$ can also restore NKG2D ligands and NKG2D interaction , and inhibit stat3 expression , we did not find significant improvement on NK cells cytotoxicity to A549 cells with wild type @GENE$ , while there was significant enhancement to H1975 cells with EGFR L858R + @VARIANT$ resistance mutations .", "label": "resistance or non-response"}
{"id": "24348397", "sentence": "The PDGFRA mutation @VARIANT$ , sporadic wild-type GISTs , mutations with @GENE$ BRAF mutated GISTs are unlikely to respond to @DRUG$ [ ] .", "label": "None"}
{"id": "22928112", "sentence": "In the Crizotinib-resistant DFCI076 cell line , a unique @VARIANT$ @GENE$ secondary mutation and concurrent coactivation of epidermal growth factor receptor (EGFR) signaling imparted resistance .", "label": "resistance"}
{"id": "24455112", "sentence": "A third generation inhibitor was recently tested in resistant/intolerant CML patients : @DRUG$ is a potent , synthetic , oral multi-target @GENE$ inhibitor able to block native and mutated BCR/ABL , including @VARIANT$ mutation , resistant to dasatinib and nilotinib .", "label": "response"}
{"id": "15737014", "sentence": "In GIST and HES , respectively , the analogous T670I mutation in KIT and @VARIANT$ mutation in @GENE$ have been associated with acquired resistance to this drug [ , ] . To determine whether lung cancers that acquire clinical resistance to either @DRUG$ or erlotinib display additional mutations in the EGFR kinase domain , we have examined the status of EGFR exons 18 to 24 in tumors from five patients who initially responded but subsequently progressed while on these drugs .", "label": "None"}
{"id": "15737014", "sentence": "To our knowledge , no NSCLC patient who initially responded to but then progressed on either gefitinib or @DRUG$ has yet been treated with lapatinib . In some of the patient specimens analyzed , the actual sequencing peaks demonstrating the @VARIANT$ mutation were smaller than originally anticipated . These results differ from those of acquired resistance mutation in CML [ ] , GIST [ , ] , and @GENE$ [ ] .", "label": "None"}
{"id": "16173832", "sentence": "In the case of our patient , the patient received no prior systemic chemotherapy , and we identified an initial @DRUG$ sensitizing @VARIANT$ @GENE$ mutation , followed by a T790M mutation concomitantly with L858R in the biopsy taken from the growing tumor nine months after gefitinib use .", "label": "sensitivity"}
{"id": "22933967", "sentence": "In our retrospective study , 26.7 % of patients , all with @GENE$ wild-type tumours , who had previously unresectable liver-only metastases , underwent surgical resection after systemic therapy , with R0 resection achieved in 38 patients ( 21.6 % ) ; one of those was patient with the BRAF @VARIANT$ mutation . Although it is difficult to make any comparison , because our patients were not selected according to specific systemic therapy , these results are comparable with those reported in previous studies claiming that 19 to 23 % patients treated with bevacizumab- and irinotecan based chemotherapy and with previously unresectable liver-only metastases underwent resection.– In a recently published clinical study BOXER , where the patients with unresectable liver-only metastases were treated with oxaliplatin , capecitabine and @DRUG$ , R0 resection was achieved in 40 % of patients .", "label": "None"}
{"id": "23569464", "sentence": "Percentage increase ( mean ± standard deviation ) of cell proliferation and apoptosis of human brain metastasized breast cancer MDA-MB-361 cells ( A : proliferation ; B : apoptosis - caspase 3/7 ) after exposure to different @VARIANT$ concentrations for 18 h. Treatment with only @DRUG$ was used as negative control .", "label": "None"}
{"id": "25361005", "sentence": "Although @DRUG$ extended recipient mouse survival for each xenograft tested , in some instances the effects were relatively modest and in all but one xenograft the mice ultimately died of ALL . Signaling through PI-3K can promote cell survival and proliferation through mTORC1 independent mechanisms [ - ] . Furthermore , inhibition of mTORC1 can result in phosphorylation of @GENE$ on Ser473 by mTORC2 [ ] or on Thr308 due to loss of the negative feedback loop through @VARIANT$ and further activation of PI-3K [ ] .", "label": "None"}
{"id": "24789720", "sentence": "@VARIANT$ mutation in EGFR gene seems to be one of the most important genetic abnormalities involving the resistance for reversible epidermal growth factor receptor tyrosine kinases inhibitors ( @GENE$ ) —erlotinib and gefitinib in NSCLC patients [ – ] .", "label": "resistance or non-response"}
{"id": "24348666", "sentence": "It was initially proposed that the T790M mutation might prevent the proper binding of tyrosine kinase inhibitors via steric hindrance , similar to the corresponding gatekeeper mutations in BCR-ABL ( T315I ) and @GENE$ ( @VARIANT$ ) that confer resistance to @DRUG$ ( Gleevec ) in chronic myelogenous leukemia and in patients with gastrointestinal stromal tumors .", "label": "resistance"}
{"id": "25222836", "sentence": "EGFR TKi @GENE$ TK domain Resistance mutation , e.g. @VARIANT$ ● erlotinib MET amplification ● @DRUG$", "label": "resistance or non-response"}
{"id": "24092472", "sentence": "These systems each incorporate an @GENE$ kinase protein ( WT , @VARIANT$ , delE746_A750 or delL747_P753insS ) and an inhibitor ( @DRUG$ or erlotinib ) .", "label": "sensitivity"}
{"id": "23690695", "sentence": "This , in addition to the prospect of regaining sensitivity after the development of @DRUG$ resistance , has sparked the development of several other @GENE$ inhibitors targeting different sites on the kinase . Early results show that in some cases ( for example the L1196M , @VARIANT$ , or G1269S mutations ) an alternative ALK inhibitor may able to produce/reproduce sensitivity in NSCLC. ,", "label": "resistance"}
{"id": "24944510", "sentence": "Which strategy is better in the management of advanced NSCLCs – the inhibition of mutated @GENE$ with TKIs ( @VARIANT$ mutation increases tyrosine kinase affinity for TKIs ) or a combined approach with @DRUG$ ( an anti-EGFR monoclonal antibody ) plus first-line chemotherapy – is yet to be determined .", "label": "None"}
{"id": "23976869", "sentence": "Sequencing of 87 FIP1L1-PDGFRA negative hypereosinophilic syndrome patients showed several PDGFRA point mutations ( R481G , L507P , @VARIANT$ , H570R , H650Q , N659S , L705P , R748G , and Y849S ) . Four of these in vitro mutations induced growth factor independent cell proliferation and constitutive phosphorylation of PDGFRA and @GENE$ . Mice injected with PDGFRA-mutant cells were treated with oral @DRUG$ .", "label": "None"}
{"id": "24455503", "sentence": "If @DRUG$ is well tolerated , assessing its response rate and durability in treatment-naïve chronic phase CML and Ph +ve patients will be of great interest . DCC-2036 , an allosteric inhibitor of @GENE$ and omacetaxine , are being investigated in phase 1/2 studies for similar purposes. [ ] If the patient has mutation in the kinase domain other than @VARIANT$ , the nature of the mutation would determine the choice between dasatinib vs. nilotinib .", "label": "response"}
{"id": "23986642", "sentence": "In contrast , @DRUG$ was designed to avoid binding with the side chain of @VARIANT$ in native @GENE$ , and instead forms beneficial van der Waals interactions with the isoleucine side chain of the T315I mutant .", "label": "None"}
{"id": "23992330", "sentence": "For tyrosine kinase inhibitors ( TKIs ) [ ] , mutations within the ATP pocket of the kinase domain may affect the interaction of the drug with its target : for example , the single amino acid mutation tyrosine/methionine ( @VARIANT$ ) in the ATP binding pocket of the EGFR mediates secondary resistance to the EGFR TKIs @DRUG$ and gefitinib in non-small cell lung cancer ( NSCLC ) [ , ] . The T790M mutation in EGFR is structurally analogous to drug resistance mutations in other kinases such as @GENE$ ( T315I ) , c-KIT ( T670I ) and platelet derived growth factor receptor-α ( PDGFRα ) ( T674I ) [ ] .", "label": "None"}
{"id": "21194487", "sentence": "Further analyses in other studies have also revealed that clinical factors ( Asians , females , non-smokers , and adenocarcinoma histology ) are associated with the response to @DRUG$ treatment [ ] . @GENE$ mutations , such as the deletion of exon 19 and the single @VARIANT$ mutation in exon 21 , have also been reported to be correlated with a longer survival and were found more frequently in Asian patients [ - ] .", "label": "sensitivity"}
{"id": "23144978", "sentence": "One mechanism to resistance was recently elucidated : cetuximab resistant cells contain an EGFR mutation in the extracellular domain ( @VARIANT$ ) that impairs cetuximab , but not epidermal growth factor (EGF) binding . Therefore , since the response to therapy require the EGFR target to be present , the development of BOI methods for quantitative detection of EGFR protein levels in CRC primary and secondary tumor tissues is necessary , in order to guide the treatment of individual selected for EGFR targeted antibody treatment and in particular those who relapse while on EGFR targeting therapies . The advent of @GENE$ targeted antibodies , cetuximab and @DRUG$ has paved the way to individualized medicine of mCRC .", "label": "response"}
{"id": "24052078", "sentence": "The tyrosine kinase inhibitor ( TKI ) , erlotinib ( @DRUG$ , Tarceva ; OSI Pharmaceuticals/Genentech , New York , NY , USA ) , is an oral small-molecule inhibitor that binds to the kinase domain of @GENE$ and was approved for the treatment of NSCLC in 2004 . Several clinical studies have shown that a secondary point mutation at amino-acid position 790 ( @VARIANT$ ) of EGFR is responsible for approximately half of the cases in which patients with lung adenocarcinoma develop resistance to EGFR targeting TKIs. , In addition , the presence of an intrinsic ( primary ) resistance mechanism ( such as K-Ras mutation ) can also confer resistance to TKIs , although the underlying mechanisms are not yet completely understood .", "label": "resistance or non-response"}
{"id": "22436374", "sentence": "Afatinib ( BIBW 2992 , Boehringer Ingelheim GmbH ) , an irreversible dual inhibitor of EGFR and HER2 kinases , retains some activity in tumors with @VARIANT$ mutations although at doses that are a log higher than what is needed for cancers with only a sensitizing mutation [ ] . Afatinib is currently being evaluated in phase III trials [ - ] . The chimerical IgG1 mAb @DRUG$ ( ERBITUX , ImClone Systems Incorporated , New York , NY , USA and Bristol-Myers Squibb Company , Princeton , NJ , USA ) is the most comprehensively studied @GENE$ antibody .", "label": "response"}
{"id": "25105411", "sentence": "The human lung adenocarcinoma cell lines , A549 ( EGFR wild type ) , H1975 ( EGFR L858R/T790M , gefitinib-resistant ) , H1299 ( EGFR wild type , p53 null ) , and H3255 ( @GENE$ @VARIANT$ ) were purchased from American Type Culture Collection ( ATCC ; Manassas , VA , USA ) .", "label": "sensitivity"}
{"id": "24634705", "sentence": "Similar to other tyrosine kinase inhibitors , patients treated with @DRUG$ eventually develop resistance and mutations that lead to resistance have been reported [ , ] . In one report , the patient developed two de novo mutations within the kinase domain of @GENE$ , C1156Y and @VARIANT$ [ ] .", "label": "resistance"}
{"id": "24348666", "sentence": "Interestingly , it was discovered that the @VARIANT$ mutation does not confer resistance to @DRUG$ and erlotinib by preventing their binding as originally thought . Instead , the T790M mutation induces resistance by increasing the binding affinity of ATP by one order of magnitude , which is near the affinity for wild-type @GENE$ , thus enabling ATP to compete effectively with the kinase inhibitors .", "label": "resistance or non-response"}
{"id": "25364578", "sentence": "Lazzara and colleagues found that SHP2 Y542 phosphorylation was not induced in response to EGF in the H3255 cells , which harbor the missense @VARIANT$ exon 21 mutation , suggesting that @GENE$ activity may be less efficiently promoted by EGFR L858R and the STAT3 pathway may be more active . The main problem is that STAT3 activation is not abrogated by single EGFR TKI treatment with gefitinib , erlotinib , @DRUG$ or dacomitinib , - .", "label": "None"}
{"id": "23818899", "sentence": "EGFR KRAS ( mutation ) Colorectal Cancer ( expressing metastatic colorectal carcinoma , EGFR ) **Therascreen KRAS Test ( Qiagen , Corporate Headquarters , Nederland 's ) **Erbitux , cetuximab ( ImClone , ImClone Systems , NJ ) **Vectibix , panitumumab ( Amgen , Amgen Inc , . CA ) [ , , ] BRAF @VARIANT$ ( mutation ) Melanoma ( metastatic melanoma with BRAFV600E mutation ) **Cobas 4800 @GENE$ V600 Mutation Test ( Panagene , Corporate Headquarters , Korea ) **Zelboraf , vemurafenib ( Genentech/Roche ) [ , ]", "label": "resistance or non-response"}
{"id": "23801357", "sentence": "@DRUG$ ( AP24534 ) is a novel pan–BCR-ABL inhibitor developed using a computational and structure based approach.– It was designed to bind to and inhibit native BCR-ABL and @GENE$ mutants that can arise during treatment with other TKIs and cause resistance , including the @VARIANT$ mutant .", "label": "response"}
{"id": "24386407", "sentence": "Lung cancers with mutations that activate epidermal growth factor receptor (EGFR) , including exon 19 deletions and the exon 21 @VARIANT$ point mutation , respond to the reversible EGFR-tyrosine kinase inhibitors ( @GENE$ ) gefitinib and @DRUG$ [ ] .", "label": "sensitivity"}
{"id": "23937717", "sentence": "We also found @DRUG$ or NK cells could enhance MHC-I expression , which impairs the recognization of NK cells , in lung tumor cells with wild type @GENE$ , while not in those with EGFR L858R + @VARIANT$ .", "label": "resistance or non-response"}
{"id": "25105411", "sentence": "The human lung adenocarcinoma cell lines , A549 ( EGFR wild type ) , H1975 ( EGFR L858R/T790M , gefitinib-resistant ) , H1299 ( @GENE$ wild type , p53 null ) , and H3255 ( EGFR @VARIANT$ ) were purchased from American Type Culture Collection ( ATCC ; Manassas , VA , USA ) .", "label": "sensitivity"}
{"id": "22815900", "sentence": "We next examined whether activating mutant @GENE$ gene in 11–18/ER1-7 and 11–18/ER2-1 cells was affected by the acquisition of @DRUG$ resistance or not . DNA sequence analysis showed the presence of the mutation ( @VARIANT$ ) both in the parental and resistant cells ( , arrows indicate nucleotide 2573 ) , although alternation of the peak heights on nucleotide 2573 was obvious .", "label": "sensitivity"}
{"id": "21333004", "sentence": "According to recent reports , the sensitivity to kinase inhibition reflects intrinsic differences in the binding affinity of the EGFR mutants such as L858R , @VARIANT$ , and exon19 deletions [ , - ] . Yun et al [ ] showed that gefitinib directly binds more tightly to the L858R mutant than to the wild type EGFR in vitro , while Fabian et al [ ] indicated that @GENE$ with gefitinib sensitive mutations does not differ from wild type EGFR in terms of @DRUG$ binding affinity .", "label": "sensitivity"}
{"id": "23239933", "sentence": "In addition to the presence of the @VARIANT$ variation , L747S , D761Y , and G796A variations were identified in NSCLC patients with acquired resistance to @DRUG$ ; the G796A variant is especially known to cause strong resistance to @GENE$ .", "label": "resistance or non-response"}
{"id": "23937717", "sentence": "Two @DRUG$ resistance NSCLC cell lines A549 ( @GENE$ wt ) and H1975 ( EGFR @VARIANT$ + T790M ) were used .", "label": "sensitivity"}
{"id": "19238210", "sentence": "The resistant cell line category was the largest and included two mEGFR cell lines , one having the secondary @VARIANT$ mutation and the other having homozygous deletion of PTEN gene . The remaining resistant lines included all of the wild type lines and all lines having KRAS , BRAF , HER2 , HER4 and PIK3CA mutations . Using univariate tests , we analyzed the association between @DRUG$ sensitivity and mutational status or CNGs of the various @GENE$ pathway genes and found a significant correlation between gefitinib sensitivity with EGFR mutation ( p = 0.002 ) and EGFR copy number gains ( p = 0.001 ) .", "label": "resistance or non-response"}
{"id": "21188126", "sentence": "AKT is a @GENE$ known as a main effector of PI3K signaling . The @VARIANT$ mutation induces an upstream-signal independent constitutive activation of AKT and resistance to @DRUG$ .", "label": "None"}
{"id": "24958351", "sentence": "D ) . Importantly , significantly enhanced growth inhibition was also observed in SKBR3-L cells following combined treatment compared to single agent @DRUG$ ( p = 0.005 ) or OA ( p = 0.012 ) ( Figure E ) . In contrast , treatment of SKBR3-L cells with trastuzumab and okadaic acid did not result in enhanced growth inhibition compared to okadaic acid alone ( Additional file : Figure @VARIANT$ ) .", "label": "None"}
{"id": "23690695", "sentence": "This , in addition to the prospect of regaining sensitivity after the development of @DRUG$ resistance , has sparked the development of several other @GENE$ inhibitors targeting different sites on the kinase . Early results show that in some cases ( for example the @VARIANT$ , F1174L , or G1269S mutations ) an alternative ALK inhibitor may able to produce/reproduce sensitivity in NSCLC. ,", "label": "resistance"}
{"id": "18828913", "sentence": "The sensitivity of @GENE$ mutants to @DRUG$ can be classified as sensitive ( IC50 ≤ 5 nM ) , intermediately sensitive ( IC50 = 5 to 11 nM ; ie , E255K/V and @VARIANT$ ) and insensitive ( IC50 & gt ; 11 nM ; ie , T315I ) ( Table ) .", "label": "None"}
{"id": "22257384", "sentence": "BCRP mRNA expression was higher in hepatic metastases in patients treated with irinotecan based chemotherapy than in patients with irinotecan-naïve metastases , suggesting that @GENE$ is also involved @DRUG$ @DRUG$ resistance in vivo . Mutations of BCRP gene produce varied substrate profiles for mutants as well as wild-type variants . Mutations at codon 482 in BCRP mRNA involving the replacement of arginine with threonine or glycine ( R482T or @VARIANT$ ) caused higher resistance to anthracyclines , .", "label": "None"}
{"id": "22815900", "sentence": "B , Exponentially growing 11–18 , 11–18/GEF10-1 , and 11–18/GEF20-1 cells were exposed to various doses of @DRUG$ for 5 hr , and followed by Western blot analysis . C , Western blots showing expression of @VARIANT$ @GENE$ protein in 11–18 cells and resistant clones .", "label": "sensitivity"}
{"id": "24982846", "sentence": "Ado-trastuzumab emtansine ERBB2 @GENE$ protein overexpression or gene amplification positive Indications and usage , warnings and precautions , adverse reactions , clinical pharmacology , clinical studies @DRUG$ EGFR EGFR exon 19 deletion or exon 21 substitution ( @VARIANT$ ) mutation positive Indications and usage , dosage and administration , adverse reactions , clinical pharmacology , clinical studies , patient counseling information", "label": "None"}
{"id": "15737014", "sentence": "In GIST and @GENE$ , respectively , the analogous T670I mutation in KIT and @VARIANT$ mutation in PDGFR-alpha have been associated with acquired resistance to this drug [ , ] . To determine whether lung cancers that acquire clinical resistance to either @DRUG$ or erlotinib display additional mutations in the EGFR kinase domain , we have examined the status of EGFR exons 18 to 24 in tumors from five patients who initially responded but subsequently progressed while on these drugs .", "label": "None"}
{"id": "23723712", "sentence": "@DRUG$ and erlotinib represent the first generation of small EGFR tyrosine kinase inhibitors ( TKIs ) that selectively target the intracellular tyrosine kinase domain of EGFR , blocking the downstream signaling of the receptor . The EGFR somatic mutations have emerged to be the most relevant predictor of response to these agents. , Thus , several prospective randomized trials have demonstrated that the use of EGFR TKIs in patients with advanced treatment-naive NSCLC with EGFR mutations significantly improved the objective response rate ( ORR ) and progression-free survival ( PFS ) compared with standard platinum based chemotherapy.– Unfortunately , all responders eventually develop resistance , most commonly because of the emergence of a gatekeeper mutation in the kinase domain , such as @VARIANT$ in EGFR mutated NSCLC or amplification of mesenchymal–epithelial transition factor ( @GENE$ ) .", "label": "None"}
{"id": "24155950", "sentence": "@DRUG$ ( also named Velcade , PS-341 , Millennium Pharmaceuticals , Cambridge , MA , USA ) and imatinib mesylate ( also named Gleevec , STI-571 , Novartis , Basel , Switzerland ) were purchased from the Beth Israel Deaconess Medical Center Pharmacy ( approved for research purposes only ) . The sensitivity of K562 , K562-R , LAMA84 , LAMA84-R , Baf3 @GENE$ , and Baf3 Bcr-Abl @VARIANT$ cell lines to the most used Bcr-Abl inhibitors in CML : imatinib , dasatinib ( Santa Cruz Biotechnology , CA , USA , Cat. # sc-218081 ) and nilotinib ( Santa Cruz Biotechnology , CA , USA , Cat. # sc-202245 ) was investigated by treating these cells with increasing concentrations of each drug and measuring cell death using an automated Trypan Blue exclusion method ( see ) .", "label": "None"}
{"id": "24124608", "sentence": "These observations were validated in clinical samples by qRT-PCR : CN gain of GSTT1 was detected in 90 % of wild-type and 100 % of @GENE$ @VARIANT$ GISTs , and all cases with GSTT1 CN gain showed disease progression during @DRUG$ therapy .", "label": "resistance or non-response"}
{"id": "24106980", "sentence": "@VARIANT$ family members play an important role in the control of gene expression in several phases of the cell cycle and in multiple checkpoints . Their targets are diverse and cover genes controlling DNA replication and G1/S transitions , such as Cyclin A/E , Cdc6 , and Mcms , as well as products involved in DNA repair and G2/M transitions , such as Cdc25a , Cdk1 , Aurora-A and Survivin [ ] . In our previous study , E2F3 is also found to be a direct target of miR-200b , and inhibition of miR-200b , which led to E2F3 overexpression , contributed to resistance of lung adenocarcinoma cells to @DRUG$ [ ] ( ) .", "label": "None"}
{"id": "23167739", "sentence": "These data indicate that all AKT isoforms become activated by mutant PI3K ( @VARIANT$ ) in HCC . Whether all AKT isoforms are involved in the oncogenic signalling has to be shown in further experiments . Our data further demonstrate that combining mTOR inhibitor @DRUG$ and AKT inhibitor MK-2206 shows a strong synergistic effect on the proliferation of HCC cell in vitro and in vivo .", "label": "None"}
{"id": "16187797", "sentence": "( B ) Number of colonies formed in soft agar by clonal NIH-3T3 cells expressing @VARIANT$ @GENE$ and D770_N771insNPG EGFR treated with the indicated concentrations of gefitinib or @DRUG$ immediately prior to suspension in soft agar .", "label": "sensitivity"}
{"id": "19229369", "sentence": "In br.21 , when only exon 19 deletion and @VARIANT$ mutations were considered , the difference in response rate as compared with wild-type EGFR or other mutations was significant ( 27 % vs. 7 % , p = 0.035 ) . The subset analysis of tumour samples from the intact 1 and 2 trials evaluating the addition of @DRUG$ to standard first-line chemotherapies demonstrated that patients whose tumours had an @GENE$ mutation had a higher response to chemotherapy plus gefitinib than did those without a mutation ( n = 170 : 72 % vs. 55 % , p = 0.2 ) .", "label": "sensitivity"}
{"id": "23082072", "sentence": "Further , patients with nonsmall cell lung cancer who initially responded to @DRUG$ or gefitinib therapy showed progression after a median of 12–13 months. , After patients developed acquired resistance confirmed on medical imaging , continuing use of erlotinib or gefitinib would lead to a surge in the rate of @GENE$ @VARIANT$ mutation which , in vitro , conferred resistance to treatment with erlotinib and gefitinib .", "label": "resistance or non-response"}
{"id": "24353011", "sentence": "@DRUG$ is an orally bioavailable @GENE$ inhibitor , which is indicated for first-line treatment of patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 ( @VARIANT$ ) substitution mutations [ • ] .", "label": "sensitivity"}
{"id": "24348666", "sentence": "The two mutations were shown to independently induce @DRUG$ resistance in @GENE$ cells engineered to express the L1196M and C1156Y mutations . By mid-2012 , additional patient studies led to the discovery of several other secondary mutations , . That is , three other mutations in the a-Chelix were discovered : a threonine insertion at amino acid 1151 ( 1151Tins ) , a leucine to arginine ( L1152R ) and phenylalanine to leucine ( @VARIANT$ ) .", "label": "None"}
{"id": "17973572", "sentence": "Based on the data obtained from lung cancer cell lines , we further explored the mechanisms by which T790M and @VARIANT$ resistant mutations affect BIM up-regulation and apoptosis . @DRUG$ effectively induced apoptosis in @GENE$ cells , whereas Ba/F3-L858R-L747S cells were intermediately resistant and Ba/F3-L858R-T790M completely resistant ( A , top ) .", "label": "None"}
{"id": "17973572", "sentence": "After the cells were exposed to @DRUG$ for 24 h , Ba/F3-L858R cells were unable to proliferate while @GENE$ and Ba/F3-L858R-T790M cells continued to grow even in the presence of 1 μM gefitinib ( E ) . These results suggest that execution of apoptosis may be impaired by the presence of T790M and , to a lesser extent , @VARIANT$ .", "label": "None"}
{"id": "18796146", "sentence": "Nucleotide* Amino acid Forward Reverse Product size ( bp ) 9 1 ( 5556–5559 ) del Frameshift AGCAACCGGTCAGCCAGAAC GGTGGCATCCCTACACTCTCAG 336 2 5602C→T No change 3 ( 5891–5896 ) del CTCCAAGCTCTAACTTACTAAGCCAA AGTTGCAGCAGGGTCTCAGTT 349 4 5897insCAA Gln1741ins 5 6350delAG Frameshift AGCCAGCACCCCGAAAAGA CTTGCCGCAGGAGTCACAC 360 6 6447delG Frameshift 7 7154C→T R2160W CACCGGCCCAGCCATCAGT AACCCGGACTTGTCTGCCATCT 322 8 8364A→G Gln2564Arg TCAACTCCTCAACAGCTCGCAA GCTTGCACTGGCCTTTTCCTC 333 9 8919C→T A2749V CGCAGGCCCACAGGAGA CAAAGTCTTCAATCCCTTCCACC 321 10 9380A→G S2903G AACTCTTCTAAGCCCTTCCTCCAT CACTGTAGTCCACTGTACCTTCATTG 356 11 9434G→A A2921T CCGAGCTTTTATAGCAAGGAATATG ACTTGGACTTCTTTTCTTTTGCCC 322 10 12 ( 10814–10834 ) del 7 amino acid loss TCCTTACTTTGTACCAGGCTTTTCTC TCTTCTGGTTTGGGGGATTCTTTG 345 13 ( 10814–10837 ) del 8 amino acid loss 14 ( 10826–10846 ) del 7 amino acid loss *ATBF1 mutations previously reported in prostate cancer by Sun et al. [ ] Immunohistochemical staining of ER-α , @DRUG$ @GENE$ human epidermal growth factor receptor 2", "label": "None"}
{"id": "16288556", "sentence": "As previously demonstrated [ , , ] , cells with the deletion mutant and the point mutation L858R were inhibited by the TKIs @DRUG$ and erlotinib , while the exon 20 insertion mutation was resistant . Three patients with lung adenocarcinoma and with exon 20 deletion mutants of @GENE$ failed to show a clinical response ( contrary to the expectation that , since the general response rate of tumors with EGFR mutations to TKIs is about 80 % , two or all three of these particular ones would be responsive ) . However , the cells with the insertion mutation demonstrated increased sensitivity to the irreversible inhibitor CL-387,785 , previously demonstrated to be active against cells with both an activating mutation and the resistance associated point mutation @VARIANT$ on exon 20 .", "label": "resistance or non-response"}
{"id": "21687501", "sentence": "Consistently HTR3A rs1062613 ( @VARIANT$ ) and two polymorphisms in HTR3B ( −100 −102 AAG deletion variant and rs1176744 ) have been found to be associated with chemotherapy and @DRUG$ treatment induced vomiting and nausea ( Tremblay et al. , ; Kato et al. , ; Sugai et al. , ; Tanaka et al. , ) . 5-HT6 receptor The 5-HT6 receptor is a @GENE$ is expressed almost exclusively in the brain .", "label": "None"}
{"id": "24199791", "sentence": "Firstly , we transfected @VARIANT$ cells with a cocktail of @GENE$ and observed 23.77 % inhibition of TGF-β1 mediated effect on @DRUG$ resistance ( Figure A-B ) .", "label": "None"}
{"id": "24832107", "sentence": "@GENE$ xenografts represent a radioresistant model , attributed to increased BCL-2 transcription [ ] . A375 is a human derived melanoma cell line harboring a BRAF mutation due to the substitution of valine for glutamic acid at codon 600 , termed @VARIANT$ resulting in constitutive activation , aggressive proliferation , and high BCL-2 expression . The tumor growth curves for control ( saline ) , PNT2258 , docetaxel , or @DRUG$ as single agents or combination treatments are presented in the left panels , with overall survival shown in the corresponding right panels .", "label": "None"}
{"id": "24603336", "sentence": "Among these , the most relevant one was cytochrome p450 ( CYP3A4 ) , which is the main metabolizing enzyme for FOLFIRI ( folinic acid/fluorouracil/irinotecan ) regimen , etoposide , rapamycin and other antineoplastic drugs ( ) . We tested the effects of mutant @GENE$ on CYP3A4 by ectopic expression of p53 mutants R175H , @VARIANT$ and R282W in the H1299 cells ( p53-null ) .", "label": "None"}
{"id": "24885169", "sentence": "In addition , the presence of common activating mutations in the tyrosine kinase domain of the @GENE$ ( exon 19 deletion and exon 21 @VARIANT$ mutation ) confers strong sensitivity to gefitinib and @DRUG$ , which are selective tyrosine kinase inhibitors of EGFR [ , ] .", "label": "sensitivity"}
{"id": "19707334", "sentence": "Reconstitution studies with PTEN gene therapy in a mouse model for lung cancer , for example , reveals that apoptosis is increased , while @GENE$ and mTOR activation is decreased significantly ( ) . In addition , antisense oligonucleotides to PTEN resulted in @DRUG$ resistance , while rescue of PTEN through @VARIANT$ inhibitors restored trastuzumab sensitivity ( ) .", "label": "None"}
{"id": "22928112", "sentence": "A similar “gatekeeper” mutation ( T315I ) in the @GENE$ fusion kinase in chronic myelogenous leukemia cancer cells renders these leukemias resistant to the ABL kinase inhibitors gleevec and @DRUG$ , suggesting a conserved mechanism of resistance to TKIs [ ] . However , the T790 M mutation may also occur prior to treatment with erlotinib or gefitinib and therefore , may contribute to primary resistance [ ] . Several other EGFR mutations can also confer resistance to first generation TKIs such as D761Y and @VARIANT$ [ , ] .", "label": "None"}
{"id": "21264348", "sentence": "A. @DRUG$ antiproliferative EC50 in the presence of 0.4 to 10 μM GNF‐5 on Ba/F3 cells expressing @VARIANT$ and E505K Bcr‐Abl. B. Inhibition of Bcr‐Abl autophosphoryl‐ation was determined by Bcr‐Abl immunoprecipitation , followed by a immunoblot for phospho‐Tyr ( Tyr412 ) , phospho‐STAT 5 ( Tyr694 ) and total Bcr‐Abl ( antibody K‐12 ) from cell lystates obtained after treatment of T315I Bcr‐Abl expressing @GENE$ with 10 μM of dasatinib and increasing concentrations of GNF‐5 ( 0 , 0.5 , 5 and 10 μM ) for 90 min. ( TIF )", "label": "None"}
{"id": "21085476", "sentence": "A total of 864 Caucasian men ( n = 413 ) and women ( n = 451 ) have been consecutively recruited in the context of a study on @GENE$ resistance at the Department of Medicine , University of Leipzig , to represent a wide range of obesity , insulin sensitivity , and glucose tolerance . @VARIANT$ was defined by 120-min glucose ≥11.1 mmol/l . All individuals fulfilled the following exclusion criteria : 1 ) Any acute or chronic inflammatory disease as determined by a leucocyte count & gt ; 7000 Gpt/l , CRP & gt ; 5.0 mg/dl , or clinical signs of infection ; 2 ) antibodies against glutamic acid decarboxylase (GAD) ; 3 ) history of hypertension or systolic blood pressure (SBP) & gt ; 140 mmHg and diastolic blood pressure (DBP) & gt ; 85 mmHg ; 4 ) clinical evidence of either cardiovascular or peripheral artery disease ; 5 ) thyroid dysfunction ; 6 ) @DRUG$ or drug abuse ; 7 ) pregnancy .", "label": "None"}
{"id": "23208557", "sentence": "Rheumatoid arthritis IL-10 @GENE$ ; T Related to antigen production MTHFR @VARIANT$ Drug efficacy prediction of @DRUG$", "label": "None"}
{"id": "22815900", "sentence": "Furthermore , these activating mutations gained addiction to @GENE$ in lung cancer cells , resulting in enhanced susceptibility to EGFR-TKI such as gefitinib and @DRUG$ , – . One serious problem with EGFR-TKI treatment is the appearance of drug-resistant tumors . For acquired resistance , secondary mutation in the EGFR gene @VARIANT$ – or alternative EGFR independent activation of cell growth signaling pathways including c-Met activation is well-known , .", "label": "resistance or non-response"}
{"id": "24349829", "sentence": "While the @VARIANT$ mutation represents a direct mechanism for drug resistance that occurs at the level of drug accessibility to the target , there are a number of indirect mechanisms that involve the increased expression or activation of alternative growth factor receptors to maintain signal flux , despite @GENE$ inhibition . Perhaps the best characterized of these is the amplification of the Met receptor and/or elevated levels of its ligand HGF . In @DRUG$ resistant NSCLC cell lines , Met drives ErbB3 dependent activation of the PI3K pathway .", "label": "resistance or non-response"}
{"id": "25275314", "sentence": "To prepare the mutants , we mutated arginines of the WT sequence inside the transformed @GENE$ model and obtained the models that contain PKA and the peptides LARASLG ( R18A ) , LRAASLG ( R19A ) , LKRASLG ( R18K ) , LRKASLG ( R19K ) , LHRASLG ( @VARIANT$ ) , and LRHASLG ( R19H ) . We also prepared the models including the shorter chain peptides RRASLG , RASLG , and LRRASL . For the mutants that contain histidine we prepared the models containing neutral histidine with the hydrogen atoms at position δ or ε ( Hδ and Hε ) , and the models containing the protonated @DRUG$ Hp ( see the next section ) .", "label": "None"}
{"id": "19669220", "sentence": "Other tyrosine kinase inhibitors like midostaurin ( PKC 412 ) and @DRUG$ ( AMN 107 ) ) that are capable of inhibiting activating @GENE$ @VARIANT$ may also have potential in the treatment of t ( 8 ; 21 ) AML that carry this mutation [ , ] .", "label": "None"}
{"id": "25054154", "sentence": "The symbol coding scheme is as follows : native ( green colour ) , mutant @VARIANT$ ( red colour ) , and R1275Q ( blue colour ) . Analysis of intermolecular NH bond of native and mutant @GENE$ complex at 20000 ps. Average number of intermolecular hydrogen bonds in native and mutant versus time .", "label": "resistance"}
{"id": "24369725", "sentence": "Other possible resistance mechanisms , specifically PIK3CA mutation and conversion to wild-type EGFR were noted in some cases , although PIK3CA mutation concomitantly occurred with @VARIANT$ mutation . In a previous in vitro study , @DRUG$ induced apoptosis was abrogated when PIK3CA mutation was introduced in HCC827 cells with a deletion mutation in exon 19 of the @GENE$ gene [ ] .", "label": "resistance or non-response"}
{"id": "23202889", "sentence": "Not all specific point mutations in KRAS may underlie the resistance to @GENE$ monoclonal antibodies . De Roock et al. demonstrated in a pooled analysis of 579 patients compiled from seven clinical trials examining metastatic colorectal cancer patients , that patients overall with KRAS mutation had decreased survival but those with KRAS @VARIANT$ mutation had better overall survival and progression-free survival after treatment with @DRUG$ compared to other KRAS mutant tumors [ ] .", "label": "None"}
{"id": "23788917", "sentence": "These substitutions were reported for the first time in NSCLC patients with progression , bearing activating mutations , after @DRUG$ therapy . In vitro cultures of cell lines harbouring the @VARIANT$ substitution showed slightly more resistance to EGFR TKI than cells with wild type @GENE$ .", "label": "None"}
{"id": "17551677", "sentence": "Finally , a recent study shows not only that EGFR mutations are statistically associated with Asian ethnicity and never-smoker status , but also that patients with @GENE$ exon 19 deletions have significantly longer median survival than patients with EGFR @VARIANT$ mutation ( 34 vs. 8 months , p=0.01 ) after treatment with @DRUG$ or erlotinib [ ] .", "label": "sensitivity"}
{"id": "21445332", "sentence": "The single factor H mutation ( @VARIANT$ ) in the PROMISSE cohort was extensively investigated and not shown to have a functional defect ( normal secretion in a transfection system , normal plasma levels , and normal to increased @GENE$ binding and @DRUG$ activity ) ( unpublished data ) .", "label": "None"}
{"id": "22719242", "sentence": "For each given position , we considered the mutation from the amino acid present in E. coli thioredoxin ( the “Ec” aminoacid ) to the amino acid “X” defined as the amino acid different from “Ec” that has the highest frequency ( largest number of occurrences in the sequence alignment ) when there @DRUG$ a @DRUG$ at position 34 . Large positive values for the score indicate that the @GENE$ substitution shifts the statistics strongly towards amino acid X . We retained for experimental analysis the 10 positions ( and the corresponding Ec→X mutations ) for which the score was positive ( see ) : I4V , D26E , W28Y , E30P , I38L , K57A , N59D , D61T , @VARIANT$ , L94R .", "label": "None"}
{"id": "24189400", "sentence": "PC9ein targets of midostaurin were enriched using immobilized midostaurin and protein lysates from either @GENE$ or ProtGR cells . On the basis of these results , we reasoned that combined erlotinib and midostaurin could overcome @VARIANT$ mediated resistance , as @DRUG$ would target wild-type and exon 19 deletion E746-A750 EGFR activity while midostaurin would inhibit exon 19 deletion E746-A750+T790M EGFR .", "label": "None"}
{"id": "24004697", "sentence": "Moreover , whether @GENE$ siRNAs could potentiate the efficacy of TKIs in imatinib-resistant cells is worthy of further investigation . One study has shown a synergistic effect between AMN107 and arsenic trioxide ( ATO ) or Bcr-Abl-siRNA in the @VARIANT$ imatinib-resistant cells or those with an H396P abl mutation , indicating that the combination of @DRUG$ and ATO or siRNA may represent a new strategy for the treatment of imatinib-resistant CML patients [ , ] .", "label": "None"}
{"id": "16187797", "sentence": "del , L747_E749del @VARIANT$ ; ins , D770_N771insNPG ; wt , wild-type EGFR . Sensitivity of Cell Transformation Induced by Expression of Mutant EGFR Characterized by Missense Mutation or Exon 19 Deletion , but not Exon 20 Insertion , to @DRUG$ and Erlotinib ( A ) Anchorage independent growth of clonal NIH-3T3 cells transformed with mutant @GENE$ or EGF stimulated wild-type EGFR treated with the indicated concentrations of erlotinib immediately prior to suspension in soft agar .", "label": "None"}
{"id": "15737014", "sentence": "These results suggest that the T790M mutation may impair the ability of gefitinib or @DRUG$ to inhibit @GENE$ tyrosine kinase activity , even in EGFR mutants ( i.e. , @VARIANT$ or an exon 19 deletion ) that are clinically associated with drug sensitivity .", "label": "sensitivity"}
{"id": "15696205", "sentence": "In gefitinib treated patients , six EGFR mutations involved exon 19 deletions that lacked the amino acids @GENE$ , and two were exon 21 amino acid substitutions ( @VARIANT$ ) . A seventh case with an exon 19 deletion ( involving 12 nucleotides ) was detected by fluorescent capillary electrophoresis only , so exact sequence deletion information was unavailable ( see Methods ) . KRAS Exon 2 Mutations Found in Non-Small-Cell Lung Cancers Refractory to Treatment with Gefitinib or @DRUG$ a Bold indicates mutations", "label": "None"}
{"id": "21873989", "sentence": "We also performed additional studies using a subclone of GIST-T1 called GIST-T1R , which became resistant to @DRUG$ after chronic , intermittent exposure to the drug during culture . GIST-T1R cells acquired a secondary mutation in @GENE$ exon 13 , @VARIANT$ , as can occur in human GIST patients .", "label": "resistance"}
{"id": "23606169", "sentence": "In the case of patient no. 39 , during the targeted @GENE$ treatment , it came to the selection of KRAS @VARIANT$ cells ( which were present from the beginning in the tumor but at a low level of around 5 % , Fig. a ) and in consequence to the metastasis ( Fig. b ) . On the other hand , patient no. 40 did not respond to cetuximab—we even confirmed KRAS WT and BRAF WT status by real-time PCR methods . This reminds us that the patient could have a KRAS mutation in codon 146 [ ] or another molecular mechanism is involved in his lack of response to @DRUG$ .", "label": "None"}
{"id": "23520446", "sentence": "Approximately 50 % of EGFR mutations consist of deletions in exon 19 , whereas 35–45 % consist of the @VARIANT$ mutation and 5 % consist of insertions in exon 20 or the L861Q mutation – . Gefitinib ( Iressa ) and Erlotinib ( @DRUG$ ) are @GENE$ inhibitors that are used clinically for the treatment of advanced NSCLC , primarily that with EGFR mutations in the tyrosine kinase domains – .", "label": "sensitivity"}
{"id": "20633291", "sentence": "Viability experiments were performed once and representative curves are shown ( @VARIANT$ was not evaluated because @GENE$ cells expressing this mutant could not be established ) . Similarly , motesanib inhibited autophosphorylation of the imatinib-resistant activation loop mutant Y823 D ( IC50 = 64 nM ) more potently than imatinib ( IC50 & gt ; 3000 nM ) ( Table : Figure ) .", "label": "None"}
{"id": "24922058", "sentence": "It would be interesting to study in the future if @VARIANT$ , @GENE$ , MECP2 , LSD1 or other yet-to-be identified REST interactors are involved . Notably , we did not observe pathways specifically enriched in any group of REST targets with different @DRUG$ occupancies .", "label": "None"}
{"id": "23493883", "sentence": "Both in vivo and in vitro models have shown that @DRUG$ has increased affinity for the @GENE$ @VARIANT$ mutation compared to the first-generation EGFR-TKIs .", "label": "sensitivity"}
{"id": "23569389", "sentence": "BCR-ABL1 mutations were detected in 160 of 363 patients ( 44 % ) , with G250E and @VARIANT$ mutants being the most frequently found . No differences in overall response rate were observed in patients with @GENE$ mutations at baseline , in particular for p-loop mutations . A subanalysis was conducted by Branford et al on the emergence of new detectable mutations in 479 patients treated with dasatinib after @DRUG$ failure , and development of new mutations , including T315A , F317L , and V299L , was rare ( 13 % ) .", "label": "None"}
{"id": "21042543", "sentence": "Di Nicolantonio et al also demonstrated that introduction of the @GENE$ @VARIANT$ allele could confer resistance to either @DRUG$ or panitumumab in wild-type B-RAF colorectal cancer cells .", "label": "resistance or non-response"}
{"id": "21165163", "sentence": "The @VARIANT$ mutation results in alteration of the topology of the ATP binding pocket not only interrupting the physicochemical binding of gefitinib/erlotinib , but also leading to much increased affinity of the @GENE$ protein to ATP resulting in resistance to EGFR-TKIs [ ] .", "label": "resistance or non-response"}
{"id": "24212777", "sentence": "Most B-Raf mutations involve the @VARIANT$ amino acid substitution , resulting in constitutive activation of the @GENE$ signaling pathway . They are mutually exclusive of KRAS mutations and are thus a candidate for an independent biomarker for CRC [ ] . Studies on WT-KRAS tumors treated by either a combination of chemotherapy and cetuximab or @DRUG$ alone have shown that progression free survival ( PFS ) and OS were significantly better among patient without mutated BRAF ( WT-BRAF ) [ ] .", "label": "None"}
{"id": "15737014", "sentence": "Sequencing Chromatograms with the T790M @GENE$ Exon 20 Mutation in Various Clinical Specimens and the NSCLC Cell Line H1975 ( A–C ) In all three patients—patient 1 ( A ) , patient 2 ( B ) , and patient 3 ( C ) —the secondary T790M mutation was observed only in lesions obtained after progression on either gefitinib or @DRUG$ . ( D ) Cell line H1975 contains both an exon 21 @VARIANT$ mutation ( upper panel ) and the exon 20 T790M mutation ( lower panel ) .", "label": "sensitivity"}
{"id": "22912935", "sentence": "@DRUG$ consumption , @GENE$ @VARIANT$ genotype , and prostate cancer risk ( 37 cases ; 146 controls ) .", "label": "None"}
{"id": "23776354", "sentence": "In short , almost all GIST with exon 11 mutations responded to @DRUG$ , patients with exon 9 mutations should receive a 800 mg daily dose of imatinib , and @VARIANT$ @GENE$ mutation is predictive of primary resistance .", "label": "resistance or non-response"}
{"id": "22655263", "sentence": "In vivo efficacy was described only for the L1196M gatekeeper mutation , confirming a higher potency with respect to @DRUG$ in inhibiting the in vivo growth of @GENE$ driven Ba/F3 cells . For the @VARIANT$ mutant , activity in Ba/F3 cells was not described , but the compound was able to effectively inhibit proliferation of a neuroblastoma cell line naturally bearing the mutation .", "label": "resistance"}
{"id": "22655263", "sentence": "In vitro studies performed on Ba/F3 cells expressing mutated ALK kinase forms supported the biochemical data , confirming potent inhibition of L1196M and @VARIANT$ mutants in a cellular setting . In vivo efficacy was described only for the L1196M gatekeeper mutation , confirming a higher potency with respect to @DRUG$ in inhibiting the in vivo growth of ALK–L1196M driven @GENE$ cells .", "label": "None"}
{"id": "23691449", "sentence": "However , the @VARIANT$ mutation may exist in only a small fraction of tumor cells before drug treatment , and the tumor cells harboring this mutation may be enriched over time during treatment with @DRUG$ or erlotinib [ ] . MET amplification MET , also known as hepatocyte growth factor receptor , is a proto-oncogenic receptor TK . MET amplification was detected in up to 20 % of NSCLC with @GENE$ mutations progressing after an initial response to TKI therapy [ ] .", "label": "resistance or non-response"}
{"id": "25382104", "sentence": "To compare their efficacy and binding pattern with our screened compounds we again docked FDA approved drugs with wild-type of @GENE$ . As shown in , DB07107 and DB06977 showed better docking scores than existing drugs while others showed results comparable to those of marketed drugs like ponatinib , bosutinib , bafetinib , dasatinib , @DRUG$ and imatinib . In the case of DB06977 , although one H_bond is missing ( Met318 ) with the wild-type of BCR-ABL complex compared to @VARIANT$ mutant type , it still exhibits a favorable binding score of −10.94 kcal/mol .", "label": "None"}
{"id": "20942962", "sentence": "Of the 8 mutations in the TK domain , 7 were novel ( W731L , @VARIANT$ , T785A , C797Y , Y801H , L831H and E868G ) ( Figure ) . One of the mutations ( L858R ) was previously identified in non-small cell lung cancer ( NSCLC ) patients and this mutation was found to increase sensitivity to @GENE$ inhibitor , @DRUG$ .", "label": "None"}
{"id": "24189400", "sentence": "On the basis of these results , we reasoned that combined @DRUG$ and midostaurin could overcome @VARIANT$ mediated resistance , as erlotinib would target wild-type and exon 19 deletion E746-A750 EGFR activity while midostaurin would inhibit exon 19 deletion E746-A750+T790M @GENE$ .", "label": "resistance or non-response"}
{"id": "25336973", "sentence": "On the contrary , the mutation @VARIANT$ in exon 2 has been associated with better response to EGFR antibodies than other KRAS mutations , but the data are mixed. , In addition to the exon 2 KRAS mutation , other mutations such as KRAS mutation exons 3–4 and NRAS mutation exons 2–4 have also emerged to be clinically relevant biomarkers of a lack of response to EGFR antibodies . For example , treating @GENE$ tumor patients with @DRUG$ may even have a detrimental effect on survival as shown in the Panitumumab Randomized Trial in Combination With Chemotherapy for Metastatic CRC to Determine Efficacy ( PRIME ) study , where patients were randomized to first-line chemotherapy with or without panitumumab .", "label": "None"}
{"id": "25051360", "sentence": "In studies by a different research group which were aimed at determining the mechanism of resistance of breast cancer cells containing the HER2 @VARIANT$ mutation to lapatinib , it was shown that the cells overexpressed EGFR ligands [ ] . In BT474 and MCF10A breast cancer cells transfected with the construct encoding HER2-T798M mutation , elevated HER2 kinase activity was detected and lapatinib did not block phosphorylation of HER2 , EGFR3 or downstream Akt and ERK1/2 . Increased levels of EGFR2 associated with @GENE$ were detected in the transfected cells and the BT474/HER2-T798M cells were also resistant to @DRUG$ .", "label": "None"}
{"id": "22997553", "sentence": "NO based recovery of @DRUG$ analogues associated deformities is presumably due to common mode of action which restores angiogenesis ( See online ) . Further to determine the role of eNOS in NO mediated recovery , Zebrafish eggs ( 72 hpf ) ( n = 20 ) were transfected with eNOS GFP or chronically active @GENE$ plasmid ( @VARIANT$ ) .", "label": "None"}
{"id": "22912935", "sentence": "Total @DRUG$ intake per week Adjusted for age ≤5 drinks 22 ( 32 ) 133 ( 46 ) 1.00 ( ref ) & gt ; 5 drinks 46 ( 68 ) 159 ( 54 ) 1.75 ( 1.00–3.06 ) Adjusted for age , folate , @GENE$ @VARIANT$ genotype , and multiplicative folate-genotype interaction ≤5 drinks 8 ( 22 ) 68 ( 47 ) 1.00 ( ref ) & gt ; 5 drinks 29 ( 78 ) 78 ( 53 ) 3.22 ( 1.36–7.59 )", "label": "None"}
{"id": "25465236", "sentence": "( C ) EGFR T790M mutant does not resemble pEGFR unlike the EGFR L858R mutant shown in B. ( D–F ) increased inhibition potency for Erlotinib against EGFR L858R mutant compared to @GENE$ WT protein and subsequent decrease in potency for @DRUG$ against EGFR L858R + E884K double mutant . ( G–I ) increased inhibition potency for Gefitinib against EGFR L858R mutant compared to EGFR WT protein and subsequent further increase in potency for Gefitinib against EGFR L858R + E884K double mutant . ( J ) EGFR @VARIANT$ activated more than T790M but less than L858R .", "label": "None"}
{"id": "24790411", "sentence": "Compared to erlotinib and gefitinib , afatinib shows lower EC50 values and greater potency against wild type ( afatinib vs erlotinib vs @DRUG$ : 60 nM vs 110 nM vs 157 nM ) and L858R mutated @GENE$ ( afatinib vs erlotinib vs gefitinib : 0.7 nM vs 40 nM vs 5 nM ) . Moreover , afatinib is able to inhibit the kinase activity in vitro and in animal models when a resistant @VARIANT$ mutation is concomitant to a sensitivity mutation .", "label": "resistance or non-response"}
{"id": "23566546", "sentence": "Case Histrogical type EGFR mutation status Brinkman index Treatment agent Response IL-8 ( ng/mL ) IL-10 ( ng/mL ) RANTES ( pg/ml ) 1 Ad Ex21 @VARIANT$ 900 gefitinib PR 5.79 1.67 2 2 Ad Ex21 L858R 0 erlotinib @GENE$ 94.2 1.41 3 Ad Ex19 del 0 erlotinib PR 4.09 126 2.13 4 Ad Ex21 L858R 0 gefitinib PR_3.92 18.1 1.85 5 Ad Ex21 L858R + Ex19 del 370 erlotinib PR 21.9 1.23 2.11 6 Ad Ex19 del 0 erlotinib PR 7.05 1.37 2.56 7 Ad Ex19 del 0 gefitinib PR 4.82 1.59 2.02 8 Ad Ex21 L858R 1640 gefitinib PR 54.9 2.7 2.38 9 Ad negative 400 erlotinib SD 34.9 3.39 3.66 10 Ad negative 0 erlotinib SD 27.1 4.94 2.25 11 Ad unknown 1800 erlotinib SD NE NE NE 12 Sq Ex19 del 3840 gefitinib SD 12.6 1.1 1.98 13 Ad Ex19 del 30 erlotinib SD 5.27 0.69 2.66 14 Ad Ex19 del 0 erlotinib SD 10.5 0.85 2.5 15 Ad unknown 300 erlotinib SD 7.69 2.61 1.7 16 La negative 2080 erlotinib SD NE NE NE 17 Sq Ex21 L858R 750 @DRUG$ SD 11.6 56.3 3.06 18 Ad unknown 600 erlotinib SD 13.7 1.1 2.82 19 Ad Ex21 L858R 0 erlotinib SD 20.6 11.6 0.783 20 Ad Ex19 del 0 erlotinib SD 14.8 2.07 2.02 21 Ad Ex21 L858R + Ex19 del 0 gefitinib SD 3.04 1.3 1.76 22 Ad Ex19 del 200 gefitinib SD 10.9 1.59 1.91 23 Sq unknown 1560 erlotinib PD NE NE NE 24 Ad negative 1080 erlotinib PD 25.2 8.15 1.57 25 Ad unknown 0 erlotinib PD NE NE NE 26 Ad Ex18 G719A 2000 erlotinib PD 11.6 4.48 3.12 27 Ad unknown 1410 erlotinib PD NE NE NE 28 Ad Ex19 del 1000 gefitinib PD 9.44 2.25 2.89 29 Ad negative 1100 erlotinib PD 56.3 5.63 2.16 30 Ad negative 2000 erlotinib PD 15.6 0.85 0.292 31 Ad negative 825 erlotinib PD 8.27 1.59 2.13 32 Ad Ex21 L858R 0 erlotinib PD 5.34 7.05 1.7 33 Ad negative 1680 erlotinib PD 57.7 1.63 2.06", "label": "None"}
{"id": "22928112", "sentence": "A similar “gatekeeper” mutation ( T315I ) in the @GENE$ fusion kinase in chronic myelogenous leukemia cancer cells renders these leukemias resistant to the ABL kinase inhibitors gleevec and dasatinib , suggesting a conserved mechanism of resistance to TKIs [ ] . However , the T790 M mutation may also occur prior to treatment with erlotinib or @DRUG$ and therefore , may contribute to primary resistance [ ] . Several other EGFR mutations can also confer resistance to first generation TKIs such as @VARIANT$ and T854A [ , ] .", "label": "None"}
{"id": "25221748", "sentence": "In the advanced NSCLC EGFR-TKI resistant setting , the HSP90 small molecule inhibitor AUY922 is being evaluated as monotherapy in a phase II clinical trial vs. @DRUG$ or docetaxel in patients with tumors with activating EGFR mutations ( www.clinicaltrials.gov : NCT016461250 ) . This agent is also being assessed in a phase II trial in patients with de novo resistant @VARIANT$ mutations not previously treated with EGFR-TKIs ( www.clinicaltrials.gov : NCT01854034 ) and in patients with EGFR mutations and/or EGFR-TKI resistant disease , as part of a phase II cluster study in Chinese patients evaluating five novel inhibitors of HSP90 , @GENE$ , ALK , MET , and MEK ( ) .", "label": "None"}
{"id": "23866929", "sentence": "The entry of tyrosine kinase inhibitors ( TKIs ) gefitinib ( Iressa® , AstraZeneca , Wilmington , Delaware ) and @DRUG$ ( Tarceva® , Genentech , South San Francisco , California ) , which target epidermal growth factor receptor (EGFR) , is one of the most recent , gratifying events in the treatment of advanced non-small-cell lung cancer ( NSCLC ) . Clinical trials have revealed significant variability in response to EGFR-TKIs , and patient characteristics such as sex , dominantly female , East Asian ethnicity , non smoking history , and @GENE$ have been associated with an increased likelihood of EGFR-TKI effectiveness [ - ] . Furthermore , a high response rate ( 60 to 90 % ) to treatment with EGFR-TKIs has been observed in patients harboring mutations in exons 18 to 21 of the tyrosine kinase domain of EGFR , with exon 19 deletions and exon 21 @VARIANT$ point mutations comprising about 90 % of all mutations [ , ] .", "label": "None"}
{"id": "25465236", "sentence": "( C ) EGFR T790M mutant does not resemble pEGFR unlike the EGFR @VARIANT$ mutant shown in B. ( D–F ) increased inhibition potency for @DRUG$ against EGFR L858R mutant compared to @GENE$ WT protein and subsequent decrease in potency for Erlotinib against EGFR L858R + E884K double mutant .", "label": "sensitivity"}
{"id": "24885690", "sentence": "The antibody @DRUG$ , which is directed against the epidermal growth factor receptor (EGFR) , provides survival advantage in the subgroup of patients carrying wild type @GENE$ alleles [ ] . The KRAS mutational status is predictive in terms of response to therapy with antibodies targeting the EGFR . In CRC , BRAF is mutated with a prevalence of 9.6 % [ ] and the @VARIANT$ mutation accounts for more than 80 % of these mutation events , resulting in a hyperactivating substitution of valine600 by glutamic acid [ ] .", "label": "None"}
{"id": "23584600", "sentence": "Rarer mutations include c.1798_1799delinsAG p.Val600Arg ( V600R ) , c.1801A &gt ; G p.Lys601Glu ( @VARIANT$ ) and c.1799_1800delinsAA p.Val600Glu ( V600E2 ) . BRAF mutation results in hyperactivation of the @GENE$ signalling pathway , causing deregulation of cell proliferation and oncogenesis without the requirement for Ras activation . Braf is the most potent of the Raf proteins to activate the downstream signalling cascade , hence mutant Braf was identified as a novel target for kinase inhibitors such as vemurafenib ( PLX4032/RG7204 ) and dabrafenib .", "label": "None"}
{"id": "24894453", "sentence": "Furthermore , both G719S and G724S mutants undergo constitutive tyrosine-phosphorylation , which is further increased by EGF treatment , whereas phosphorylation of wild-type EGFR requires induction by @GENE$ ( Additional file : Figure S2B ) . These data demonstrate that colon-cancer derived G719S and G724S mutants are oncogenically active in the absence of ligand stimulation . To test whether G719S and @VARIANT$ EGFR mutants are cetuximab-sensitive in vitro , we ectopically expressed these mutants in Ba/F3 cells , rendering these cells IL-3 independent but dependent on exogenous oncogenic EGFR signaling [ ] .", "label": "None"}
{"id": "23994953", "sentence": "Using the erlotinib-sensitive @GENE$ mutant NSCLC cell line HCC4006 harboring the delL747-E749 , A750P mutation in EGFR exon 19 , Suda et al. established that mesenchymal status , not a specific oncogenic activated protein , could sufficiently promote loss of EGFR dependence to confer resistance to erlotinib . More recently , Chang et al. confirmed that in the absence of the common second-site EGFR mutation @VARIANT$ or MET amplification , acquired resistance to gefitinib occurs in EGFR mutated PC9 cells that have undergone EMT .", "label": "resistance or non-response"}
{"id": "21556318", "sentence": "Y253H , E255K , and @VARIANT$ were deemed less sensitive , but not inherently resistant , as was the T315I identified in three patients receiving nilotinib . Six of 16 imatinib treated patients ( 38 % ) with @GENE$ mutations progressed to accelerated phase/blast crisis CML , as compared with 1/13 ( 8 % ) of nilotinib treated patients . Investigators at MD Anderson Cancer Center also recently presented their institutional history with nilotinib ( n = 90 ) and @DRUG$ ( n = 82 ) used in frontline CML therapy or for accelerated phase CML patients who had not been previously treated .", "label": "None"}
{"id": "24025253", "sentence": "The patient was offered off-label sorafenib ( to inhibit @GENE$ @VARIANT$ ) and @DRUG$ ( to inhibit ERBB1 signaling ) .", "label": "resistance or non-response"}
{"id": "24244696", "sentence": "Data represent percent inhibition by 100 mM @DRUG$ in cells expressing GluN1 or @GENE$ ( @VARIANT$ ) with either GluN2A ( F/F , n = 5 ; F/A , n = 14 ; A/A , n = 10 ) or GluN2B subunits ( F/F , n = 6 ; F/A , n = 8 ; A/A , n = 9 ) .", "label": "None"}
{"id": "23185274", "sentence": "To overcome such drug resistance , novel mutant-selective EGFR kinase inhibitors against @GENE$ @VARIANT$ were reported , and 4-pyrrylamino quinazolines as new @DRUG$ analogues were synthesized .", "label": "resistance or non-response"}
{"id": "25505694", "sentence": "The firstly described and the most common event responsible for resistance is the acquisition of the @VARIANT$ missense mutation , which is found in ≈ 50 % of patients progressing after an initial response to erlotinib or @DRUG$ [ , ] . Other less frequent mechanisms include secondary mutations within EGFR [ , ] , MET amplification [ ] , @GENE$ amplification [ , ] , small cell histologic transformation [ ] .", "label": "None"}
{"id": "24278442", "sentence": "For example , detecting the @VARIANT$ mutation in blood samples would be useful for patient selection for treatment with new @GENE$ for lung cancers that are resistant to gefitinib and @DRUG$ [ ] .", "label": "resistance or non-response"}
{"id": "17973572", "sentence": "Transient transfection experiments utilizing COS-7 cells demonstrated that auto-phosphorylation of the original @VARIANT$ @GENE$ was inhibited by lower concentrations of gefitinib or @DRUG$ than the L858R-L747S or L858R-T790M constructs ( A ) .", "label": "sensitivity"}
{"id": "24419415", "sentence": "We conducted a post-hoc analysis of the NEJ002 study to evaluate the effectiveness of gefitinib against NSCLC with @VARIANT$ or L861Q . The NEJ002 study , comparing gefitinib and standard carboplatin-paclitaxel chemotherapy as the first-line treatment for patients with @GENE$ mutations , demonstrated no significant difference in OS between gefitinib and carboplatin-paclitaxel .", "label": "None"}
{"id": "21605429", "sentence": "The @GENE$ exon 18 @VARIANT$ point mutant activates PDGFRA both in vitro and in vivo [ , ] and is also imatinib resistant in vivo and in vitro [ , , ] , whereas other mutations affecting exon 18 ( D846Y , N848K , Y849K and HDSN845-848P ) are @DRUG$ sensitive [ ] .", "label": "resistance or non-response"}
{"id": "22815900", "sentence": "Both erlotinib and @DRUG$ show similar kinase inhibition selectivity based on quantitative analysis of small molecule-kinase interaction maps for 38 kinase inhibitors , and show therapeutic efficacy against progressive NSCLC patients – . The most common activating @GENE$ mutations are in-frame deletion in exon 19 ( delE746-A750 ) and the point mutation replacing leucine with arginine at codon 858 of exon21 ( @VARIANT$ ) – .", "label": "sensitivity"}
{"id": "25146448", "sentence": "MTNR1B , located on human chromosome 11q21–22 , is a member of the @GENE$ , and one of the functional and high-affinity @DRUG$ membrane receptors . MTNR1B is expressed in human and rodent pancreatic islets . Studies have shown that MTNR1B is a novel candidate gene for @VARIANT$ .", "label": "None"}
{"id": "24121633", "sentence": "Based on our data , we hypothesized that PRR of hnRNP L binds to PTB and cooperatively suppresses inclusion of exon @VARIANT$ . We thus examined the role of PRR of hnRNP L on the interaction with PTB . Histidine tagged hnRNP L ( His-L ) , its PRR deleted variant ( His-L-ΔPRR ) , histidine tagged hnRNP LL ( His-LL ) , and its @GENE$ inserted variant ( His-LL-PRR ) were expressed in SH-SY5Y cells , and they were immunoprecipitated with anti-histidine antibody in the presence of RNase .", "label": "None"}
{"id": "23238683", "sentence": "We first investigated the effect of these ITKs on the viability of murine Ba/F3 cells , carrying wild type ( WT ) BCR-ABL , @VARIANT$ or G250E-BCR-ABL mutation . As shown in Figure , BaF3 cells expressing native @GENE$ were highly sensitive to imatinib , dasatinib and ponatinib , whereas BaF3-T315I-BCR-ABL and BaF3-G250E-BCR-ABL cells were resistant to both @DRUG$ and dasatinib .", "label": "None"}
{"id": "22034911", "sentence": "Consistent with this , we found that the introduction of R1275Q into @GENE$ had no negative impact on sensitivity to @DRUG$ ( IC50 47 ± 8 nm ) . As expected , the IC50 values for viability of Ba/F3 cells expressing these mutants were all above that for Ba/F3 cells expressing native EML4-ALK , with IC50s ranging from 231 to 981 nm . The three most resistant mutants , @VARIANT$ , S1206R , and G1269S , all had IC50s within twofold of parental , ALK negative , Ba/F3 cells ( IC50 1176 nm ) .", "label": "resistance"}
{"id": "23691449", "sentence": "Some of the molecular mechanisms of acquired resistance include T790M second mutation , mesenchymal epithelial transition factor ( MET ) amplification , @GENE$ ( ABCG2 ) and hepatocyte growth factor (HGF) overexpression , insulin-like growth factor (IGF) binding protein-3 ( IGFBP3 ) downregulation , as well as ERBB3 activation . T790M mutation The @VARIANT$ second mutation accounts for half of all resistances to gefitinib and @DRUG$ [ ] .", "label": "None"}
{"id": "22076124", "sentence": "One such challenge with kinase inhibitors is the development of drug resistance , and particularly appearance of “gatekeeper” mutations that block @DRUG$ binding . Acquired inhibitor resistance is a serious complication in cancer treatment , where the objective is a chronic maintenance of tumor control rather than a “quick fix” . Indeed , this has already been documented for a patient with NSCLC who relapsed after the appearance of @VARIANT$ and L1196M mutations in @GENE$ [ ] .", "label": "None"}
{"id": "22655263", "sentence": "When tested in @GENE$ cells driven by ALK mutants identified in crizotinib relapsed patients , NMS-E628 is circa fivefold more potent than @DRUG$ in inhibiting the proliferation of @VARIANT$ ALK and C1156Y ALK-driven-cells in vitro and in vivo ( Ardini et al. , ) .", "label": "None"}
{"id": "22815900", "sentence": "In our present study , erlotinib-resistant cell lines were established ; PC9/ER1 from PC9 cells harboring delE746-A750 mutation , and 11–18/ER1-7 and 11–18/ER2-1 from 11–18 cells harboring @VARIANT$ mutation . Gefitinib-resistant cell lines were also established ( 11–18/GEF10-1 and 11–18/GEF20-1 ) from 11–18 cells . Gene amplification and increased copy number of the EGFR gene associated with the response rate to @GENE$ targeted drugs in NSCLC , breast cancer and colon cancer , .", "label": "sensitivity"}
{"id": "25264741", "sentence": "MMC , mitomycin C ; MMS , methyl methanesulfonate ; ETOP , etoposide , HU , hydroxyurea ; EMS , ethyl methanesulfonate ; CP , @DRUG$ ; and ADE , adenine . KIF20A has been reported to strongly bind @VARIANT$ [ ] , and its expression is regulated by E2F [ ] .", "label": "None"}
{"id": "23535590", "sentence": "A similar situation is found in the tethered membrane complex caa3-type @GENE$ Thermus thermophilus where the ET pathway from heme c to the CuA centre does not involve water , but rather the D-pyrrole and D-propionate of heme c to the cis amide N and α C of Phe126 of the cupredoxin domain . The mutations had no significant effect on the specific activity of the enzyme and in single turnover experiments where reduced RpNiR was reoxidised by nitrite , the ET efficiency from heme to T2Cu was similar to the wild-type enzyme , with @VARIANT$ variant showing a small decrease in rate ( see ) . These small effects suggests that the conserved water molecule H-bonded to the solvent exposed T1Cu @DRUG$ ligand and the carbonyl of the peptide bond of Ala138 plays a dominant role in ET in this tethered complex .", "label": "None"}
{"id": "23527257", "sentence": "Our results implicate that this combined targeting ( @DRUG$ plus su11274 ) may represent a novel strategy to overcome resistance to @GENE$ TKIs ( late use ) or prevent such a resistance from emerging ( early use ) . A combined strategy in a first line setting might be preferable to prevent the outgrowth of @VARIANT$ subclones .", "label": "response"}
{"id": "24729716", "sentence": "Two patients harboring @GENE$ @VARIANT$ mutation had received EGFR-TKI treatment : one received @DRUG$ and had an occurrence of brain metastasis in the sixth month ; the other received erlotinib to control the metastasis to the liver .", "label": "resistance or non-response"}
{"id": "15737014", "sentence": "In GIST and HES , respectively , the analogous @VARIANT$ mutation in KIT and T674I mutation in PDGFR-alpha have been associated with acquired resistance to this drug [ , ] . To determine whether lung cancers that acquire clinical resistance to either @DRUG$ or erlotinib display additional mutations in the @GENE$ kinase domain , we have examined the status of EGFR exons 18 to 24 in tumors from five patients who initially responded but subsequently progressed while on these drugs .", "label": "None"}
{"id": "23493838", "sentence": "@GENE$ ( wild-type mutation ) @DRUG$ IC50 value ( nM ) Wild-type 41.61 Location of mutation P loop L248V 147.4 G250E 179.2 Q252H 33.67 Y253F 40 @VARIANT$ 394 E255V 230.1", "label": "None"}
{"id": "25050082", "sentence": "Two EGFR mutations ( exon 19 deletion and exon 21 @VARIANT$ substitution ) that cluster around the adenosine-5′-triphosphate binding pocket of the EGFR tyrosine kinase ( TK ) domain are highly responsive to @GENE$ TK inhibitors ( TKIs ) like @DRUG$ or erlotinib [ ] .", "label": "sensitivity"}
{"id": "25505694", "sentence": "The lack of efficacy could probably be related to the high concentrations of neratinib required in preclinical studies to inhibit EGFR @VARIANT$ and the limitations of clinical dosing . Dacomitinib Dacomitinib is an irreversible EGFR , HER2 and HER4 inhibitor with a higher kinase inhibition than gefitinib/erlotinib in both gefitinib/erlotinib-sensitive and in @GENE$ and HER2 mutated cell lines [ ] .", "label": "resistance or non-response"}
{"id": "24586514", "sentence": "We previously reported that an HDACi , depsipeptide , is effective against @GENE$ positive leukemia cells . Therefore , we examined the activity of an HDACi against T315I mutant cells . We examined whether treatment with @DRUG$ and vorinostat induced cell death in @VARIANT$ mutant cells .", "label": "response"}
{"id": "20224651", "sentence": "( ii ) The downregulation of ErbB2 and ErbB3/Akt/FLIP and survivin signaling events is necessary for α-TEA induced apoptosis , and ( iii ) ErbB1 is highly expressed in the A2780/CP70R cells and below levels of detection in the @VARIANT$ cells , suggesting that ErbB1 may play a role @DRUG$ @DRUG$ resistance . Taken together with previous data that showed that α-TEA induces apoptosis via Fas Fas ( @GENE$ ) /FasL mitochondrial dependent signaling events [ ] , we have summarized our current understanding of α-TEA induced apoptosis in human ovarian cancer cells in .", "label": "None"}
{"id": "25465236", "sentence": "The increased inhibition potency for @DRUG$ against the oncogenic @GENE$ @VARIANT$ mutant ( over the EGFR WT protein ) correlates with decreased global connectivity of the hub residues ( Arg-958 , Glu-884 , Gln-894 and Asp-896 ) in the mutant ( – wild type , – L858R mutant ) .", "label": "sensitivity"}
{"id": "25364260", "sentence": "Our study revealed that Mus81 suppression by siRNA could affect the cell cycle distribution of MCF-7 and @VARIANT$ cells by 5-FU treatment and that the proportion of G2 period was significantly increased in the siMus81 group compared to in the siCtrl group . Moreover , another study has shown that @GENE$ silenced by gene targeting could activate the intra-S-phase and G2/M checkpoints of cancer cells , thereby inducing an increase in sensitivity to MMC , MMS , @DRUG$ , ultraviolet radiation , ionizing radiation , and hydroxyurea .", "label": "None"}
{"id": "22928112", "sentence": "Overall , adding @DRUG$ to chemotherapy does not appear to improve the survival for patients with mutations in @GENE$ [ , ] . In order to study the effects of the most common EGFR mutations in vivo , Politi et al. created doxycylcine inducible , transgenic mice that expressed an exon 19 deletion mutant or the @VARIANT$ mutant in type II pneumocytes [ ] .", "label": "sensitivity"}
{"id": "17877814", "sentence": "In a subset of NSCLC patients , the presence of somatic mutations in the kinase domain of @GENE$ may predict the outcome of treatment with the EGFR TKIs erlotinib and @DRUG$ . The favorable clinical response of tumors harboring the common exon 19 deletions or the @VARIANT$ mutation correlates with the high TKI sensitivity of these EGFR mutant proteins at the molecular level .", "label": "sensitivity"}
{"id": "15737014", "sentence": "For example , in CML , a commonly found mutation is a C→T single nucleotide change that replaces threonine with isoleucine at position 315 ( @VARIANT$ ) in the ABL kinase domain [ , , ] . In GIST and HES , respectively , the analogous T670I mutation in KIT and T674I mutation in @GENE$ have been associated with acquired resistance to this drug [ , ] . To determine whether lung cancers that acquire clinical resistance to either gefitinib or @DRUG$ display additional mutations in the EGFR kinase domain , we have examined the status of EGFR exons 18 to 24 in tumors from five patients who initially responded but subsequently progressed while on these drugs .", "label": "None"}
{"id": "23805228", "sentence": "In brief , the expression vector RcSRα-263–9 , which contains a deletion of the coding sequence for amino acids 3–9 of CD26 , was transfected into the dihydrofolate reductase-deficient Chinese hamster ovary ( CHO ) cell line DXB-11 by electroporation , together with plasmid pMT-2 , which provided the @GENE$ . Mutant sCD26 without DPPIV activity ( sCD26/DPPIV– ) was produced using the same method , except that RcSRα-263–9 was further modified to yield RcSRα-263–9 @VARIANT$ , which contains a point mutation at the active site of the DPPIV enzyme ( Ser630 replaced by Ala ) created using oligonucleotide mediated site directed mutagenesis . The transfected CHO cells , which produce either sCD26 or mutant sCD26 , were cultured in serum-free CHO-S-SFM II medium ( Life Technologies ) supplemented with 1 µM @DRUG$ ( Sigma-Aldrich ) .", "label": "None"}
{"id": "23533466", "sentence": "H1975 cancer cell line with mutations in EGFR exons 21 ( L858R ) and 20 ( @VARIANT$ ) was refractory to reversible @GENE$ , gefitinib , and @DRUG$ [ ] , but was sensitive to irreversible EGFR-TKIs , such as BIBW2992 ( afatinib ) .", "label": "resistance or non-response"}
{"id": "23325047", "sentence": "This conserved @GENE$ has been proposed to flip and facilitate nicotinamide binding and thus hydride transfer [ , ] . To investigate the contribution of such difference in rotameric conformation in nicotinamide binding and catalysis of AnCYPOR , we replaced W678 with alanine and @DRUG$ as both replacements play critical role in catalytic activity and nicotinamide binding of human and rat CYPORs [ , ] . In contrast to @VARIANT$ construct , the Ala and His replacements at W678 , ( L86F/L219F/W678A-Δ55AnCYPOR and L86F/L219F/W678H-Δ55AnCYPOR ) neither increased FAD binding nor cytochrome c reduction activity ( and ) .", "label": "None"}
{"id": "23864840", "sentence": "A different response to the same @GENE$ regimen after a drug holiday can be explained with tumor heterogeneity . In a retrospective analysis of an @DRUG$ retrial , Becker et al. [ ] reported five cases of the @VARIANT$ mutation and exon 19 deletions in rebiopsy specimens taken before the retrial of erlotinib .", "label": "resistance or non-response"}
{"id": "23861935", "sentence": "The latter binds the @GENE$ to mediate HASMC contraction . Unlike our data showing a decreased expression of CysLT1R in response to Pam3CSK4 , poly ( I:C ) , LPS , @DRUG$ and iE-DAP , Morishima et al. have recently shown that poly ( I:C ) decreased the muscarinic acetylcholine receptor M2R and increased M3R expression without affecting histamine receptor @VARIANT$ or CysLT1R , which correlated to intracellular calcium mobilization .", "label": "None"}
{"id": "24279718", "sentence": "Therefore , the tumor clone bearing this EGFR mutation could have been potentially responsive to @GENE$ therapy . However , a previously described single case of L862V EGFR mutation was associated with lack of response to @DRUG$ and the same could have been the scenario with the @VARIANT$ EGFR mutation .", "label": "None"}
{"id": "24386407", "sentence": "Recent clinical trials have shown that progression-free survival ( PFS ) in patients with EGFR mutant lung cancer is prolonged by treatment with a reversible EGFR-TKI and the irreversible EGFR-TKI @DRUG$ , which was designed to covalently bind to @GENE$ [ - ] . Nevertheless , almost all responders relapse after acquiring resistance to these EGFR-TKIs [ , ] . Among the mechanisms by which cancer cells become resistant to reversible EGFR-TKIs are 1 ) gatekeeper mutations in EGFR , such as the @VARIANT$ second mutation [ , ] ; 2 ) activation of bypass signaling caused by Met amplification [ ] , hepatocyte growth factor (HGF) overexpression [ ] , or Gas6-Axl activation [ ] ; 3 ) activation of downstream molecules ( PTEN loss or PIK3CA mutation ) [ , ] ; 4 ) small-cell lung cancer transformation [ ] ; and 5 ) epithelial-to-mesenchymal transition [ ] .", "label": "response"}
{"id": "20482850", "sentence": "E2F1 TRRAP [ ] TRRAP is required as a @DRUG$ for @VARIANT$ transcriptional activation EGFR ANXA1 @GENE$ protein and other annexins are involved in degradation of EGFR protein", "label": "None"}
{"id": "19292913", "sentence": "The anti-allergy drug cromolyn binds @VARIANT$ and will block S100P-RAGE interaction . It inhibits tumor growth and increases the effectiveness of @DRUG$ in experimental animal models [ ] .", "label": "None"}
{"id": "23493804", "sentence": "EGFR–TKIs such as gefitinib or @DRUG$ attain a response rate of approximately 70 % and progression-free survival of 9–13 months , although subgroups of patients experience long lasting remission. , Use of @GENE$ as a first-line treatment in patients with advanced NSCLC harboring EGFR mutations improved progression-free survival with acceptable toxicity , compared with standard chemotherapy . EGFR–TKIs are currently considered a standard first-line treatment for this disease entity.– However , these tumors eventually develop resistance to EGFR–TKIs , possibly as a result of a secondary threonine–methionine substitution mutation at position 790 in exon 20 ( @VARIANT$ ) , MET amplification , or hepatocyte growth factor overexpression in relapsed tumors .", "label": "resistance or non-response"}
{"id": "24223226", "sentence": "The phosphorylated bands of @VARIANT$ at Thr389 were detected and disappeared by rapamycin treatment , whereas the phosphorylation of Akt at Ser473 was observed with lower levels which was resistant to rapamycin . However , both mTORC1 and mTORC2 activities were not affected by the treatment with @DRUG$ , suggesting that the @GENE$ pathways themselves were not involved in DNA damage response .", "label": "None"}
{"id": "25364578", "sentence": "Lazzara and colleagues found that @GENE$ Y542 phosphorylation was not induced in response to EGF in the H3255 cells , which harbor the missense @VARIANT$ exon 21 mutation , suggesting that SHP2 activity may be less efficiently promoted by EGFR L858R and the STAT3 pathway may be more active . The main problem is that STAT3 activation is not abrogated by single EGFR TKI treatment with @DRUG$ , erlotinib , afatinib or dacomitinib , - .", "label": "None"}
{"id": "24885169", "sentence": "In addition , the presence of common activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene ( exon 19 deletion and exon 21 @VARIANT$ mutation ) confers strong sensitivity to gefitinib and @DRUG$ , which are selective tyrosine kinase inhibitors of @GENE$ [ , ] .", "label": "sensitivity"}
{"id": "23691449", "sentence": "However , the @VARIANT$ mutation may exist in only a small fraction of tumor cells before drug treatment , and the tumor cells harboring this mutation may be enriched over time during treatment with gefitinib or @DRUG$ [ ] . MET amplification MET , also known as hepatocyte growth factor receptor , is a proto-oncogenic receptor TK . MET amplification was detected in up to 20 % of NSCLC with @GENE$ mutations progressing after an initial response to TKI therapy [ ] .", "label": "resistance or non-response"}
{"id": "24924344", "sentence": "@DRUG$ rs562 ( C/T ) Chr3 : 183637845 ABCC5 ( UTR3 ) 0.049494 0.392 rs3749445 ( A/G ) Chr3 : 183638506 ABCC5 ( UTR3 ) 0.044895 0.410 rs2292998 ( C/T ) Chr3 : 183663833 ABCC5 ( intronic ) 0.039882 0.277 rs1016752 ( C/G ) Chr3 : 183665062 ABCC5 ( intronic ) 0.039781 0.232 rs4148585 ( C/T ) Chr3 : 183670642 ABCC5 ( intronic ) 0.039781 0.283 rs6443924 ( A/G ) Chr3 : 183679532 ABCC5 ( intronic ) 0.039781 0.279 rs4148579 ( A/G ) Chr3 : 183685249 ABCC5 ( intronic ) 0.039781 0.279 rs939336 ( A/G =&gt ; C594C ) Chr3 : 183685534 ABCC5 ( exonic ) 0.039781 0.279 rs1132776 ( C/T = & gt ; A395A ) Chr3 : 183696402 ABCC5 ( exonic ) 0.044895 0.289 rs2313212 ( C/T ) Chr3 : 183700928 ABCC5 ( intronic ) 0.039781 0.279 rs4148575 ( C/T ) Chr3 : 183702275 ABCC5 ( UTR3 ) 0.044895 0.289 rs1846692 ( C/T ) Chr16 : 56671696 MT1A ( near - gene 5 ) 0.049494 0.360 rs35346959 ( A/G ) Chr16 : 56671867 MT1A ( near- gene 5 ) 0.044895 0.137 rs9922957 ( C/G ) Chr16 : 56672380 MT1A ( near - gene 5 ) 0.039781 0.185 rs9922409 ( A/G ) Chr16 : 56672400 MT1A ( near - gene 5 ) 0.04532 0.103 rs7190725 ( G/T ) Chr16 : 56673290 MT1A ( intronic ) 0.044895 0.170 rs8052394 ( A/G =&gt ; K51R ) Chr16 : 56673828 MT1A ( missense ) 0.044895 0.152 rs1800566 ( C/T = & gt ; @VARIANT$ ) chr16 : 69745145 @GENE$ ( exonic ) 0.039781 0.258 rs689455 ( A/C ) Chr16 : 69761661 NQO1 ( near- gene 5 ) 0.039781 0.242", "label": "None"}
{"id": "24982846", "sentence": "Dasatinib BCR/ABL1 Philadelphia chromosome [ t ( 9 ; 22 ) ] positive ; @VARIANT$ mutation posit Indications and usage , clinical studies , patient counseling information Denileukin diftitox IL2RA CD25 antigen positive Indications and usage , warnings and precautions , clinical studies @DRUG$ @GENE$ EGFR protein expression positive EGFR exon 19 deletion or exon 21 substitution ( L858R ) positive Clinical pharmacology Indications and usage , dosage and administration , clinical pharmacology , clinical studies", "label": "None"}
{"id": "24348666", "sentence": "However , almost every patient who responds well to @DRUG$ will , without exception , experience recurrence due to acquired resistance . The mechanisms for acquired resistance include gatekeeper @VARIANT$ mutations , @GENE$ gene amplification , and other ALK gene mutations ( L1152R , C1156Y , F1174L ) - .", "label": "resistance"}
{"id": "24555578", "sentence": "Ruppert et al. reported a case of a lung adenocarcinoma with a sensitive @GENE$ mutation in which the patient developed brain metastases with carcinomatous meningitis and liver metastasis after he stopped taking EGFR-TKI [ ] . Since a secondary @VARIANT$ mutation was found on a liver biopsy , but not in the CSF , the patient received @DRUG$ , and the brain metastasis responded well to treatment .", "label": "resistance or non-response"}
{"id": "21457545", "sentence": "These observations are the basis for a number of ongoing clinical trials which are exploring the role of monoclonal antibodies against @GENE$ such as cetuximab and EGFR tyrosine kinase inhibitors such as @DRUG$ in triple negative breast cancer . Many mutations in the EGFR gene have been reported in NSCLC but only a few have been validated , either from in vitro studies or from tumour responses in NSCLC patients , to be associated with responses to EGFR tyrosine kinase drugs [ , ] . These mutations are usually found in exons 18 , 19 , 20 and 21 , and include missense substitutions such as G719A/S and @VARIANT$ and deletions like E746 to A750 ( removal of amino acids Glucine-Leucine-Arginine-Glucine-Alanine ( ELREA ) ) which are associated with sensitivity to tyrosine kinase inhibitors [ , ] .", "label": "sensitivity"}
{"id": "20190765", "sentence": "Changes in dasatinib and @DRUG$ ( 2 ) induced cell viability were assessed in PC9 cells stably expressing either a mutant drug sensitive @GENE$ allele ( @VARIANT$ ) or a drug resistant allele ( L858R/T790M ) ( ) .", "label": "sensitivity"}
{"id": "25538894", "sentence": "In the LUX-lung 1 trial , @DRUG$ had a significant longer PFS in comparison with placebo , but showed no improvement of OS . For neratinib , a phase II trial showed disappointing results ( ) and the dacomitinib data showed possible benefit in patients with erlotinib resistance ( ) , but further investigations are necessary . In preclinical studies , third-generation EGFR inhibitors ( WZ4002 and CO-1686 ) showed hopeful results , with activity against @VARIANT$ mutations and sparing wild-type @GENE$ ( – ) .", "label": "response"}
{"id": "23888935", "sentence": "@DRUG$ is a novel , synthetic , orally active , potent @GENE$ inhibitor and multi targeted TKI that was discovered using a computational and structure based drug design approach.– Ponatinib was specifically designed to inhibit native BCR-ABL and mutant forms that can arise during treatment with other TKIs and cause resistance , including the @VARIANT$ gatekeeper mutant .", "label": "response"}
{"id": "15737014", "sentence": "Sequencing Chromatograms with the @VARIANT$ EGFR Exon 20 Mutation in Various Clinical Specimens and the NSCLC Cell Line H1975 ( A–C ) In all three patients—patient 1 ( A ) , patient 2 ( B ) , and patient 3 ( C ) —the secondary T790M mutation was observed only in lesions obtained after progression on either gefitinib or @DRUG$ . ( D ) Cell line H1975 contains both an exon 21 L858R mutation ( upper panel ) and the exon 20 T790M mutation ( lower panel ) . The asterisks indicate a common SNP ( A or G ) at nucleotide 2361 ; the arrows indicate the mutation at nucleotide 2369 ( C→T ) , which leads to substitution of methonine ( @GENE$ ) for threonine ( ACG ) at position 790 .", "label": "None"}
{"id": "19707322", "sentence": "The biochemical structure of MK-0457 makes it able to bind and inhibit @GENE$ kinase despite the presence of @VARIANT$ mutation that prevents the inhibitory activity of all other kinase inhibitors tested in the clinic including imatinib , dasatinib and @DRUG$ .", "label": "None"}
{"id": "24982846", "sentence": "@DRUG$ EGFR EGFR exon 19 deletion or exon 21 substitution ( @VARIANT$ ) mutation positive Indications and usage , dosage and administration , adverse reactions , clinical pharmacology , clinical studies , patient counseling information Anastrozole ESR1 , @GENE$ Hormone receptor positive Indications and usage , clinical pharmacology , clinical studies", "label": "None"}
{"id": "15737014", "sentence": "Sequencing Chromatograms with the T790M EGFR Exon 20 Mutation in Various Clinical Specimens and the NSCLC Cell Line H1975 ( A–C ) In all three patients—patient 1 ( A ) , patient 2 ( B ) , and patient 3 ( C ) —the secondary T790M mutation was observed only in lesions obtained after progression on either @DRUG$ or erlotinib . ( D ) Cell line H1975 contains both an exon 21 @VARIANT$ mutation ( upper panel ) and the exon 20 T790M mutation ( lower panel ) . The asterisks indicate a common SNP ( A or G ) at nucleotide 2361 ; the arrows indicate the mutation at nucleotide 2369 ( C→T ) , which leads to substitution of methonine ( @GENE$ ) for threonine ( ACG ) at position 790 .", "label": "None"}
{"id": "24594844", "sentence": "Combined therapy with DzT and @DRUG$ synergistically inhibited the growth of xenograft tumors derived from cells harboring the @GENE$ @VARIANT$ mutant , suggesting that DzT may overcome T790M based TKI resistance in NSCLC .", "label": "response"}
{"id": "24982846", "sentence": "@DRUG$ EGFR EGFR exon 19 deletion or exon 21 substitution ( @VARIANT$ ) mutation positive Indications and usage , dosage and administration , adverse reactions , clinical pharmacology , clinical studies , patient counseling information Anastrozole @GENE$ , PGR Hormone receptor positive Indications and usage , clinical pharmacology , clinical studies", "label": "None"}
{"id": "24982846", "sentence": "Dasatinib @GENE$ Philadelphia chromosome [ t ( 9 ; 22 ) ] positive ; @VARIANT$ mutation posit Indications and usage , clinical studies , patient counseling information @DRUG$ CD25 antigen positive Indications and usage , warnings and precautions , clinical studies", "label": "None"}
{"id": "23388220", "sentence": "ACTH , Adrenocorticotropic hormone ; DHEAS , Dehydroepiandrosterone-sulfate ; min , Minute ; 17-OHP , 17-hydroxyprogesterone ; RV ♂ , Reference values for the male population . After informed consent was obtained from the patient , a genetic study was performed with deoxyribonucleic acid ( DNA ) extraction from whole blood followed by polymerase chain reaction and direct genetic sequencing techniques . Two distinct mutations affecting the @GENE$ gene were detected : heterozygous R124H ( moderate defect ) ; and homozygous @VARIANT$ ( severe defect ) .", "label": "None"}
{"id": "23864840", "sentence": "The ability of irreversible pan-HER inhibitors such as afatinib and dacomitinib to overcome @VARIANT$ mediated resistance to gefitinib has been demonstrated in some preclinical studies ; therefore , they are being actively investigated . Dacomitinib showed a better response rate and prolonged response duration compared to @DRUG$ in patients without prior @GENE$ targeted therapy [ ] .", "label": "resistance or non-response"}
{"id": "22848428", "sentence": "The carboxylate group of @GENE$ and terminal NH2 of R563 moved away from each other ( 2.7 to 8.4 Å ) because of the missing E271 . A short beta sheet formed by the residues V306-N308 of HEXXH- ( X ) 18-E motif that possess two catalytically conserved @DRUG$ residues coordinating with Zn2+ ion disappeared in @VARIANT$ system .", "label": "None"}
{"id": "22719242", "sentence": "For each given position , we considered the mutation from the amino acid present in E. coli thioredoxin ( the “Ec” aminoacid ) to the amino acid “X” defined as the amino acid different from “Ec” that has the highest frequency ( largest number of occurrences in the sequence alignment ) when there @DRUG$ a @DRUG$ at position 34 . Large positive values for the score indicate that the @GENE$ substitution shifts the statistics strongly towards amino acid X . We retained for experimental analysis the 10 positions ( and the corresponding Ec→X mutations ) for which the score was positive ( see ) : I4V , @VARIANT$ , W28Y , E30P , I38L , K57A , N59D , D61T , I75Y , L94R .", "label": "None"}
{"id": "24691136", "sentence": "The @VARIANT$ @GENE$ mutant has increased affinity for ATP , which is the primary mechanism responsible for the development of resistance to small molecule tyrosine kinase inhibitors ( TKIs ) , such as @DRUG$ and erlotinib .", "label": "resistance or non-response"}
{"id": "23785245", "sentence": "Most NSCLC patients who harbor activating @GENE$ mutations , including deletions in exon 19 or the point mutation @VARIANT$ in exon 21 , experience an initial marked response to the EGFR-TKIs gefitinib or @DRUG$ .", "label": "sensitivity"}
{"id": "21444946", "sentence": "The most commonly identified mechanism of resistance is an @GENE$ mutation at position 790 ( @VARIANT$ ) , resulting in substitution of a threonine residue with methionine , which abrogates the ability of gefitinib or @DRUG$ to inhibit EGFR [ , ] .", "label": "resistance or non-response"}
{"id": "23493883", "sentence": "Some data suggest that patients with EGFR exon 19 deletions are more susceptible to the activity of reversible EGFR-TKIs compared to those with the exon 21 @VARIANT$ mutation. , Further studies then compared first-generation EGFR-TKIs ( erlotinib and @DRUG$ ) to chemotherapy in patients with @GENE$ activating mutations in advanced NSCLC .", "label": "sensitivity"}
{"id": "24124608", "sentence": "In addition to upregulation of IGF1R and VEGF , frequent CN gain and increased mRNA expression of GSTT1 as well as significant overexpression of @GENE$ subfamily members were observed in wild-type/PDGFRA @VARIANT$ GISTs compared to KIT-mutant GISTs . CN gain of GSTT1 was closely associated with @DRUG$ resistance .", "label": "None"}
{"id": "23992330", "sentence": "The most common mutations are an in-frame deletion in exon 19 around codons 746–750 ( 45 % –50 % of all somatic EGFR mutations ) and a missense mutation leading to leucine to arginine substitution at codon 858 ( @VARIANT$ ) in exon 21 ( 35 % –45 % of mutations ) [ ] . Several NSCLC cell lines lacking the above cited mutations are considered valuable models to study intrinsic resistance to the @GENE$ TKIs gefitinib and @DRUG$ , such as A549 , H460 , H1299 and GLC-82 .", "label": "sensitivity"}
{"id": "25562798", "sentence": "Prospective studies of @GENE$ TKIs in patients with EGFR mutations have consistently identified high response rates and prolonged progression free survival . The Spanish Lung Cancer Group screened 2105 patients , to identify 350 patients ( 15 % ) with exon 19 deletions and @VARIANT$ of whom 250 patients went on to receive @DRUG$ in the first or second-line setting .", "label": "sensitivity"}
{"id": "21701703", "sentence": "In EGFR , the main mutation seen after extended treatment with @DRUG$ is the @VARIANT$ mutation [ ] ; the T766M resistance mutation was correctly predicted in EGFR through homology with resistance mutations seen in @GENE$ , which was verified in vitro [ ] and discovered several years later in patients [ - ] .", "label": "None"}
{"id": "25465236", "sentence": "( G–I ) increased inhibition potency for Gefitinib against @GENE$ L858R mutant compared to EGFR WT protein and subsequent further increase in potency for @DRUG$ against EGFR L858R + E884K double mutant . ( J ) EGFR @VARIANT$ activated more than T790M but less than L858R .", "label": "None"}
{"id": "PMC3949555", "sentence": "In the multivariate analysis of overall survival , PS 1 , male sex , the presence of the @VARIANT$ mutation , brain metastases , and the presence of bronchioloalveolar adenocarcinoma were associated with poor prognosis . Large-scale screening of patients for EGFR mutations , with subsequent customisation of erlotinib treatment , was demonstrated to be feasible and to improve outcomes . Subsequently , two phase III trials of Asian patients with @GENE$ mutations demonstrated that progression-free survival was longer for patients receiving @DRUG$ treatment than for those receiving chemotherapy .", "label": "sensitivity"}
{"id": "25170609", "sentence": "Since no significant changes in growth inhibition with concurrent inhibitors treatment were observed in MDA-MB-231 cells ( ) , drug effects on the activity of @GENE$ and PI3K signaling pathways were assessed in the remaining three cell lines : MCF-7 , T47D and SKBr3 ( ) . @DRUG$ ( 1 nM ) with or without trametinib was observed to up-regulate p-AKT and markedly reduce p-rpS6 in MCF-7 and SKBr3 cells ( ) , and reduce p-p70S6K in MCF-7 cells ( ) . For NVP-BEZ235 , increased p-AKT was observed in SKBr3 cells alone or in combination with trametinib , while GSK2126458 , with or without trametinib , reduced p-AKT in the @VARIANT$ and SKBr3 cell lines .", "label": "None"}
{"id": "24533047", "sentence": "In the last decade , a series of RCTs have confirmed the non-inferior efficacy and relatively low toxicity of @DRUG$ and gefitinib in treatment naïve or previously treated NSCLC patients compared with the standard chemotherapy – . Meanwhile , pre planned or post-study biomarker analyses indicated that the presence of @GENE$ mutation , which mainly refers to deletions in exon 19 or the @VARIANT$ substitution in exon 21 , was the strongest predictor of efficacy for EGFR-TKIs .", "label": "sensitivity"}
{"id": "24939055", "sentence": "In addition , because HGF overexpression was frequently observed in tumors with the gatekeeper @VARIANT$ mutation [ ] , monotherapy with a mutant-selective @GENE$ may not be sufficient to inhibit the growth of tumors with acquired resistance to @DRUG$ .", "label": "resistance or non-response"}
{"id": "23082072", "sentence": "Further , patients with nonsmall cell lung cancer who initially responded to erlotinib or gefitinib therapy showed progression after a median of 12–13 months. , After patients developed acquired resistance confirmed on medical imaging , continuing use of erlotinib or gefitinib would lead to a surge in the rate of @GENE$ @VARIANT$ mutation which , in vitro , conferred resistance to treatment with erlotinib and @DRUG$ .", "label": "resistance or non-response"}
{"id": "25465236", "sentence": "( C ) EGFR T790M mutant does not resemble pEGFR unlike the @GENE$ @VARIANT$ mutant shown in B. ( D–F ) increased inhibition potency for @DRUG$ against EGFR L858R mutant compared to EGFR WT protein and subsequent decrease in potency for Erlotinib against EGFR L858R + E884K double mutant .", "label": "sensitivity"}
{"id": "15737014", "sentence": "Consistent with this , the T790M mutation has been shown not to abrogate the catalytic activity of wild-type @GENE$ [ ] . The T790M mutation could also affect the kinase activity or alter the substrate specificity of mutant EGFRs , such that a proliferative advantage would be conferred upon cells bearing the mutation . Consistent with this , the H1975 NSCLC cell line reported here to contain both @VARIANT$ and L858R did not to our knowledge undergo any prior treatment with @DRUG$ or erlotinib ; the doubly mutated cells must have become dominant over time through multiple passages in vitro .", "label": "resistance or non-response"}
{"id": "19920925", "sentence": "Other protein kinase targets of nilotinib include TEL-PDGFR β , FIP1L1-PDGFR α and @VARIANT$ mutated KIT .– @DRUG$ , therefore , may have a place in the treatment of idiopathic @GENE$ chronic myelomonocytic leukemia ( CMML ) and systemic mastocytosis ( SM ) .", "label": "None"}
{"id": "23144692", "sentence": "Effects of a selective GPCR agonist or antagonist on the growth of gefitinib-resistant H1975 cells An adenosine A2a receptor ( CGS-21680 ) , an angiotensin II receptor-like 1 agonist ( angiotensin II ) and a purinergic receptor @VARIANT$ G-protein coupled 2 agonist ( 2- ( methylthio ) adenosine 5′-triphosphate tetrasodium salt hydrate ) , which were all agonists of up-regulated GPCRs in the microarray list , had no effect on tumor cell growth . Similarly , cell growth was not affected by a @GENE$ ( beraprost sodium ) , a 5-hydroxytryptamine receptor 2B agonist ( BW723C86 ) and an arginine vasopressin receptor 1A agonist ( [ Arg8 ] -vasopressin acetate salt ) , which were all classified as “down regulated GPCRs” .", "label": "None"}
{"id": "23992330", "sentence": "In the colorectal cancer setting , preclinical in vitro models of resistance to the anti-EGFR mAbs @DRUG$ and panitumumab include cell lines showing mutations of the K-Ras gene , most frequently in codon 12 of exon 2 , such as SW480 , LS174T , HCT116 , LoVo cells . These mutations produce a single amino acid change resulting in mutant Ras proteins that are insensitive to GAP function and constitutively active , with consequent activation of the Ras/MAPK signaling [ ] . Furthermore , several colorectal cancer cell lines ( VAC0432 , SNU-C5 , HT29 , KM20 , WiDr ) are considered valuable models of resistance to the @GENE$ @VARIANT$ ) inhibitor vemurafenib [ ] because of the high levels of EGFR expression .", "label": "resistance or non-response"}
{"id": "20617155", "sentence": "More recently , Ramakrishnan and colleagues showed in a murine model that paclitaxel , @DRUG$ , and doxorubicin all sensitize tumor cells to more efficient killing by CTL [ ] . In this system , however , the responsible mechanism on murine as well and human cancer cells went via upregulation of the mannose-6-phosphate @VARIANT$ receptor on cancer cells which is required for @GENE$ killing [ ] .", "label": "None"}
{"id": "22101934", "sentence": "While clearly an increase , this 5–8-fold change is substantially lower than the 50- to 200-fold Km differences for ATP among these @GENE$ forms , suggesting that the ATP Km differences result largely from changes in rate determining steps in catalysis , rather than simply changes in binding affinities for nucleotide . The @VARIANT$ and Δ746–750 tEGFR forms were potently inhibited by erlotinib with apparent Kis in the range of 0.1–0.4 µM , about equal to the apparent Ki of @DRUG$ for WT tEGFR complexed with EGF .", "label": "sensitivity"}
{"id": "22249430", "sentence": "Antitumor effects were shown against tumors with @GENE$ activating mutations , found in 30–50 % of Asian patients with lung cancer [ ] , and also against tumors with @VARIANT$ , a mutation detected in the tumors of approximately 50 % of patients with lung adenocarcinoma who develop acquired resistance to gefitinib or @DRUG$ [ – ] .", "label": "resistance or non-response"}
{"id": "25099740", "sentence": "A and D ) Detroit 562 cells ( harboring @GENE$ @VARIANT$ mutations ) and UMSCC17B cells ( expressing HRAS Q61L mutant oncogene ) were transplanted into athymic mice , and mice were treated with cetuximab or rapamycin alone , or @DRUG$ together with rapamycin , as indicated .", "label": "resistance or non-response"}
{"id": "25275294", "sentence": "( C ) Over expressing mutated V600E BRAF in HEK293 cells for 48 hours resulted in activation of the @GENE$ pathway and the down-regulation of miR-524-5p expression . ( D ) SK-Mel-19 cells were treated with or without 50 nM of MEK1/2 inhibitors PD0325901 for 24 hours , and the cells were collected for analyses . ( E ) SK-Mel-19 cells were treated with or without 5 μM of @VARIANT$ BRAF inhibitors @DRUG$ for 8 hours , and the cells were collected for analyses .", "label": "None"}
{"id": "22655263", "sentence": "For the L1196M , C1156Y , and L1152R mutants , it appears that binding of the inhibitor to @GENE$ may be negatively affected by steric hindrance or conformational changes in the enzyme . @VARIANT$ , which recapitulates the primary mutation found in neuroblastoma previously shown to render the enzyme insensitive to @DRUG$ , appears instead to induce a conformational change in the protein which results in increased affinity for ATP itself .", "label": "resistance"}
{"id": "25382104", "sentence": "Results showed that ponatinib has the highest binding affinity towards the @VARIANT$ mutant @GENE$ with a docking score of −11.050 kcal/mol while bosutinib , bafetinib , @DRUG$ , nilotinib and imatinib showed −5.513 kcal/mol , −4.689 kcal/mol , −4.702 kcal/mol , −3.772 kcal/mol , −3.593 kcal/mol and −3.78 kcal/mol , respectively ( ) .", "label": "None"}
{"id": "24294007", "sentence": "Although a retrospective study and the PICCOLO ( Panitumumab , Irinotecan and Ciclosporin in Colorectal Cancer Therapy ) trial have demonstrated a reduced response to cetuximab and @DRUG$ for patients with NRAS mutations , , further work is required to demonstrate the predictive capacity of these mutations . The serine/threonine-protein kinase B-Raf is an effector in the @GENE$ signaling pathway , downstream of K-Ras . Mutations in the proto-oncogene BRAF are present in 5 % –10 % of the metastatic CRC population and are also mutually exclusive of KRAS mutations . BRAF @VARIANT$ is the most common of all BRAF mutations ( present in 90 % of cases ) , and is enriched in a subset of patients who are female , greater than 70 years of age , with KRAS WT right sided colon cancer .", "label": "None"}
{"id": "22655263", "sentence": "When tested in Ba/F3 cells driven by ALK mutants identified in crizotinib relapsed patients , NMS-E628 is circa fivefold more potent than @DRUG$ in inhibiting the proliferation of L1196M ALK and @VARIANT$ @GENE$ in vitro and in vivo ( Ardini et al. , ) .", "label": "resistance"}
{"id": "23935939", "sentence": "DPCPX , MRS1754 , SCH58261 and @DRUG$ , respectively , the selective antagonist for A1 , @VARIANT$ , A2B , A3 adenosine receptor and Dimethylsulphoxide ( DMSO ) , @GENE$ propidium iodide ( PI ) , collagenase type I were all obtained from Sigma Chemical ( St Louis , MO , USA ) .", "label": "None"}
{"id": "23632482", "sentence": "In contrast , no significant changes in the phosphorylation of CENP-A were observed in tumour tissues from mice treated with @DRUG$ , suggesting that 212Pb-TCMC-trastuzumab may interfere with the affinity of BubR1 for kinetocores , thus perturbing the mitotic spindle checkpoint induced by paclitaxel . @VARIANT$ is involved in DNA replication , DNA repair and mitosis , suggesting E2F affects cell cycle progression both at S-phase and during mitosis .", "label": "None"}
{"id": "21605429", "sentence": "Patients with @GENE$ exon 9 mutant tumors achieve a better response to sunitinib , than those with exon 11 mutations . The PDGFRA exon 18 D842V point mutant activates PDGFRA both in vitro and in vivo [ , ] and is also @DRUG$ resistant in vivo and in vitro [ , , ] , whereas other mutations affecting exon 18 ( D846Y , @VARIANT$ , Y849K and HDSN845-848P ) are imatinib sensitive [ ] .", "label": "None"}
{"id": "23299535", "sentence": "A similar theme exists in NSCLCs with a mutation in the EGFR – secondary mutations confer insensitivity to the EGFR tyrosine kinase inhibitor ( @GENE$ ) gefitinib , and have been identified in patients with clinical resistance to @DRUG$ , but also in untreated patients ( ) . analysed NSCLC samples for one such mutation in EGFR , the @VARIANT$ mutation , from treatment-naïve patients , and from patients before and during treatment with EGFR-TKIs .", "label": "resistance or non-response"}
{"id": "16434996", "sentence": "For dose–response studies , MCF-7 ( C ) , @VARIANT$ ( D ) , DU-145 ( G ) , or LNCaP ( H ) cells were treated with the indicated dose of @DRUG$ for 24 h and assayed for @GENE$ and BRCA2 protein expression , as described above .", "label": "None"}
{"id": "25054064", "sentence": "We also tested the ability of @GENE$ to synergize with a @DRUG$ (CPM) based chemo-radiation regimen using the same glioblastoma model . CPM has been used to treat glioblastoma in the clinic [ ] and has been widely studied in the context of immunotherapy [ , ] . We used a dose ( 100 mg/kg ) that exhibited no therapeutic benefit as a single agent ( Additional file : Figure @VARIANT$ ) and did not prolong survival when added to RT alone ( Additional file : Figure S3B ) .", "label": "None"}
{"id": "19654571", "sentence": "The combination of @DRUG$ with a TKI inhibits cell proliferation and @GENE$ phosphorylation in Caski but not in @VARIANT$ cells", "label": "None"}
{"id": "24223798", "sentence": "All of the patients had the @GENE$ gene mutations in exon 19 ( delE746-A750 ) or exon 21 ( @VARIANT$ ) , and had received or were receiving gefitinib or @DRUG$ for treatment against advanced diseases at the blood sampling .", "label": "sensitivity"}
{"id": "17927446", "sentence": "Here , tumor bearing transgenic animals ( as determined by magnetic resonance imaging ) were treated with a single dose of vehicle ( n = 5 ) or @DRUG$ ( 50 mg/kg ; n = 5 ) intraperitoneally and humanely killed 13 h later . Lungs from all @GENE$ animals expressed the induced oncoprotein , as measured by immunoreactivity of lysates with antisera against the specific @VARIANT$ EGFR [ ] ( A ) .", "label": "sensitivity"}
{"id": "24894453", "sentence": "To test whether @VARIANT$ and G724S @GENE$ mutants are cetuximab-sensitive in vitro , we ectopically expressed these mutants in Ba/F3 cells , rendering these cells IL-3 independent but dependent on exogenous oncogenic EGFR signaling [ ] .", "label": "sensitivity"}
{"id": "23976869", "sentence": "Dasatinib is a dual SRC/ABL1 inhibitor that also inhibits PDGFRs and FIP1L1-PDGFRA fusion but has no effect on imatinib-resistant @GENE$ @VARIANT$ and D842V mutants .", "label": "resistance"}
{"id": "23186157", "sentence": "Interestingly , @DRUG$ was the most efficient AKI in cooperation with GNF-2 in inhibiting clonigenicity of @GENE$ cells containing the @VARIANT$ mutated Bcr-Abl .", "label": "None"}
{"id": "22536370", "sentence": "Tumors that harbor BRAF V600E mutations display high radiographic response rates to mutant-specific inhibitors such as PLX4032/RG7204/vemurafinib ( Plexxikon/Roche ) , and GSK2118436 ( GlaxoSmithKline ) , while patients whose tumors have certain KIT mutations ( L576P , K642E , @VARIANT$ ) have disease sensitive to the @GENE$ inhibitor , @DRUG$ ( ) , , , , , , , , .", "label": "None"}
{"id": "24787964", "sentence": "As the theoretical advantage of afatinib versus the first-generation @GENE$ did not translate into progression-free survival gains , maybe the clinical relevance of possible inhibition of @VARIANT$ is minimal , at least in the first-line setting , when T790M positive clones are rarely detected . A limitation of our study is the indirect comparison of gefitinib , @DRUG$ , and afatinib with one another , which relies on the quality of variance component estimates .", "label": "resistance or non-response"}
{"id": "24944510", "sentence": "The reversible dual @GENE$ inhibitor AP26113 is a more potent ALK inhibitor than @DRUG$ and demonstrates preclinical activity against various secondary mutations resistant to crizotinib , including L1196 and @VARIANT$ .", "label": "resistance"}
{"id": "23139867", "sentence": "In contrast , silencing of RB1 , indicated by an increase in @GENE$ E due to the activation of @VARIANT$ , had no detectable effect on RRM2B in the presence or absence of @DRUG$ .", "label": "None"}
{"id": "24416052", "sentence": "Further , they represented a SQCLC patient with a wild type @GENE$ who showed radiological response after treatment with both dasatinib and @DRUG$ in their clinical trial . The patient was confirmed to have a new mutation ( @VARIANT$ ) in the DDR2 kinase domain .", "label": "None"}
{"id": "22655263", "sentence": "The mechanisms underlying decreased activity of @DRUG$ on these secondary @GENE$ mutants were investigated by structural and biochemical analyses , together with cellular data generated in engineered in vitro models . For the @VARIANT$ , C1156Y , and L1152R mutants , it appears that binding of the inhibitor to ALK may be negatively affected by steric hindrance or conformational changes in the enzyme .", "label": "resistance"}
{"id": "22928112", "sentence": "In order to study the effects of the most common @GENE$ mutations in vivo , Politi et al. created doxycylcine inducible , transgenic mice that expressed an exon 19 deletion mutant or the @VARIANT$ mutant in type II pneumocytes [ ] . Not surprisingly , both models could recapitulate the human lung adenocarcinoma development , and were responsive to dox removal , or treatment with @DRUG$ .", "label": "sensitivity"}
{"id": "20672050", "sentence": "Emerging data suggest that patients with NSCLC and @GENE$ exon 19 deletion have a longer survival following treatment with @DRUG$ or erlotinib compared with those with @VARIANT$ mutation [ – ] .", "label": "sensitivity"}
{"id": "21976973", "sentence": "Abbreviations : ASOND , antisense oligonucleotide ; DOX , @DRUG$ ; EGFR , epidermal growth factor receptor ; NAC-C , N-acetyl cysteine-chitosan ; @GENE$ , N-acetyl penicillamine-chitosan ; LMWC , low-molecular-weight chitosan ; RPMI , Roswell Park Memorial Institute medium ; FBS , fetal bovine serum ; PBS , phosphate buffered saline ; SD , standard deviation . Analysis of EGFR protein expression in @VARIANT$ cells .", "label": "None"}
{"id": "23493838", "sentence": "A complete hematological response and a major cytogenetic response were observed broadly across the @GENE$ mutants , including individuals harboring the dasatinib-resistant F317L , the nilotinib-resistant Y253H , and F359C/I/V mutations , but not T315I . Nine individuals developed new mutations in the course of bosutinib treatment ( V299L , n = 4 ; L248V , n = 2 ; T315I , n = 2 ; F359C , n = 1 ; @VARIANT$ , n = 1 ) and eight of these individuals discontinued bosutinib because of progressive disease or unsatisfactory response .", "label": "None"}
{"id": "15737014", "sentence": "To determine how the @VARIANT$ mutation would affect @GENE$ proteins already containing mutations associated with sensitivity to EGFR tyrosine kinase inhibitors , we introduced the specific mutation into EGFR cDNAs that encoded the exon 21 and 19 mutations found in patients 1 and 2 , respectively . Various lysates from cells that were serum starved and pre treated with gefitinib or @DRUG$ were analyzed by immunoblotting .", "label": "resistance or non-response"}
{"id": "20694077", "sentence": "However , the T315I mutant remained resistant to @DRUG$ at concentrations & lt ; 10 μM. , Nilotinib also potently inhibited tyrosine autophosphorylation of the @VARIANT$ , E255V , F317L , M351T , and F486S Bcr-Abl mutants , and these effects were not associated with decreases in Abl or @GENE$ protein levels .", "label": "None"}
{"id": "25364578", "sentence": "Studies of @GENE$ rearranged lung cancers with acquired resistance to @DRUG$ have identified ALK fusion gene amplification and secondary ALK TK domain mutations ( L1196M and @VARIANT$ ) in about one third of cases .", "label": "resistance"}
{"id": "19629158", "sentence": "Examples include the @VARIANT$ mutation in the @DRUG$ binding pocket of @GENE$ ; the T164I mutation within the epinephrine binding pocket of β2-adrenergic receptor ; and the polymorphism within binding pocket of STI-571 to c-Abl .", "label": "resistance or non-response"}
{"id": "24199791", "sentence": "We found significantly higher number of proliferating @VARIANT$ cells than A549 cells ( p & lt ; 0.05 ) at all the tested doses of erlotinib ( Figure A ) as well as cisplatin ( Figure B ) , suggesting that A549M cells are indeed more resistant to erlotinib or @DRUG$ , consistent with the @GENE$ phenotype .", "label": "None"}
{"id": "15696205", "sentence": "In @DRUG$ treated patients , six EGFR mutations involved exon 19 deletions that lacked the amino acids @GENE$ , and two were exon 21 amino acid substitutions ( @VARIANT$ ) .", "label": "None"}
{"id": "22916261", "sentence": "The JAK2 @VARIANT$ mutation is thought to relieve the negative regulatory role of the dual-specificity kinase domain and is thus is weakly oncogenic , able to transform specific cell lines to cytokine independence . Chronic myeloid leukemia ( CML ) is a Philadelphia chromosome positive MPN characterized by the presence of the t ( 9 ; 22 ) ( q34 ; q11 ) chromosomal translocation and the consequent expression of the BCR-ABL fusion protein . Treatment of CML was revolutionized in 2001 with the development of the small-molecule inhibitor @DRUG$ mesylate ( IM ) , , , which binds to the @GENE$ kinase domain and that prevents its ability to phosphorylate target substrates , .", "label": "None"}
{"id": "18030354", "sentence": "We examined 29 of the 194 genes by quantitative PCR and validated that 19 ( 68 % ) of them were differentially expressed between @GENE$ and –wild-type cell lines ( ) . 10.1371/journal.pone.0001226.g001Hierarchical analysis of gene expression profiles in eight NSCLC cell lines . Dendrogram illustrating the relatedness of expression profiles from cell lines treated with ( + ) or without ( − ) @DRUG$ . The presence or absence of EGFR somatic mutations and the type of mutations , including @VARIANT$ point mutation ( P ) or Δ746–750 deletion mutation ( D ) , are indicated .", "label": "sensitivity"}
{"id": "23238683", "sentence": "In BaF3-WT-BCR-ABL and @VARIANT$ cells , ponatinib efficiently inhibited @GENE$ phosphorylation , but dephosphorylation of CRLK necessitated higher doses of @DRUG$ ( Figure ) .", "label": "response"}
{"id": "24533047", "sentence": "In the last decade , a series of RCTs have confirmed the non-inferior efficacy and relatively low toxicity of @DRUG$ and gefitinib in treatment naïve or previously treated NSCLC patients compared with the standard chemotherapy – . Meanwhile , pre planned or post-study biomarker analyses indicated that the presence of EGFR mutation , which mainly refers to deletions in exon 19 or the @VARIANT$ substitution in exon 21 , was the strongest predictor of efficacy for @GENE$ .", "label": "sensitivity"}
{"id": "25539768", "sentence": "Emodin inhibits cancer growth by suppressing tyrosine kinases and down regulating @GENE$ . In the combination of erlotinib and @DRUG$ , erlotinib is an epidermal growth factor receptor (EGFR) inhibitor , typically used in non-small-cell lung cancer . However , the acquired @VARIANT$ mutation of EGFR leads to erlotinib resistance .", "label": "None"}
{"id": "21042543", "sentence": "The possible relationship between of B-RAF mutational status and response to treatment with @DRUG$ in 48 patients with mCRC was investigated by Benvenuti et al . @GENE$ mutations were detected in 12,5 % tumors and they were mutually exclusive with K-RAS alterations . The only B-RAF mutation found was the @VARIANT$ substitution .", "label": "resistance or non-response"}
{"id": "22855636", "sentence": "Some PDGFRA mutant GISTs show at least partial response to @DRUG$ ; however , the most common @GENE$ mutation in GISTs ( @VARIANT$ ) confers a complete resistance to the drug. , In KIT mutant GISTs , a mutation in exon 11 was associated with a higher response rate ( 67 % –83 % ) than a mutation in exon 9 ( 35 % –48 % ) .", "label": "resistance or non-response"}
{"id": "23861935", "sentence": "Unlike our data showing a decreased expression of CysLT1R in response to Pam3CSK4 , poly ( I:C ) , LPS , @DRUG$ and @GENE$ , Morishima et al. have recently shown that poly ( I:C ) decreased the muscarinic acetylcholine receptor M2R and increased M3R expression without affecting histamine receptor @VARIANT$ or CysLT1R , which correlated to intracellular calcium mobilization .", "label": "None"}
{"id": "24121633", "sentence": "Based on our data , we hypothesized that PRR of hnRNP L binds to PTB and cooperatively suppresses inclusion of exon @VARIANT$ . We thus examined the role of PRR of hnRNP L on the interaction with PTB . @DRUG$ tagged hnRNP L ( His-L ) , its @GENE$ deleted variant ( His-L-ΔPRR ) , histidine tagged hnRNP LL ( His-LL ) , and its PRR inserted variant ( His-LL-PRR ) were expressed in SH-SY5Y cells , and they were immunoprecipitated with anti-histidine antibody in the presence of RNase .", "label": "None"}
{"id": "24276379", "sentence": "Patients with @VARIANT$ respond better to @DRUG$ than patients with @GENE$ codon 12 mutations [ ] .", "label": "resistance or non-response"}
{"id": "15737014", "sentence": "Using this insight , new small-molecule inhibitors have been identified that retain activity against the majority of imatinib-resistant BCR-ABL mutants [ , ] . For example , in CML , a commonly found mutation is a C→T single nucleotide change that replaces threonine with isoleucine at position 315 ( @VARIANT$ ) in the ABL kinase domain [ , , ] . In GIST and HES , respectively , the analogous T670I mutation in KIT and T674I mutation in @GENE$ have been associated with acquired resistance to this drug [ , ] .", "label": "None"}
{"id": "PMC3760629", "sentence": "The most common mechanism of acquired drug resistance @DRUG$ is the secondary EGFR @VARIANT$ mutation , which is detected in up to 60 % of @GENE$ mutant NSCLC patients .", "label": "resistance or non-response"}
{"id": "25465236", "sentence": "On the other hand , the increased inhibition potency for Gefitinib against @GENE$ @VARIANT$ mutant ( compared to EGFR WT protein ) and subsequent further increase in potency for @DRUG$ against the EGFR L858R + E884K double mutant correlates well with the increased global connectivity of the hub residues in the mutants ( – wild type , – L858R , – L858R + E884K ) .", "label": "sensitivity"}
{"id": "17973572", "sentence": "The Secondary Resistant Mutations L747S and T790M Affect @DRUG$ Induced Apoptosis and Inhibit BIM Up-Regulation ( A ) Top : @GENE$ assay : Ba/F3 cells expressing @VARIANT$ (LR) , L858R-L747S # 4 ( LR-LS ) , or L858R-T790M (LR-TM) cells were grown in the absence or presence of gefitinib for 24 h .", "label": "None"}
{"id": "24790411", "sentence": "Compared to erlotinib and gefitinib , afatinib shows lower EC50 values and greater potency against wild type ( @DRUG$ vs erlotinib vs gefitinib : 60 nM vs 110 nM vs 157 nM ) and @VARIANT$ mutated @GENE$ ( afatinib vs erlotinib vs gefitinib : 0.7 nM vs 40 nM vs 5 nM ) .", "label": "sensitivity"}
{"id": "19707322", "sentence": "Nilotinib is approximately 30-fold more sensitive than @DRUG$ in the killing of BCR-ABL dependent cells derived from patients with CML ( K562 and Ku-812F cells ) and cell lines ( 32D and baF3 ) , and it is active against 32/33 imatinib-resistant cell lines with @GENE$ mutations . The sensitivity of Bcr-Abl mutants to AMN107 can be summarized into 4 categories : high ( IC50 ≤ 70 nmol/L : M244V , G250E , @VARIANT$ , F3llL , F317L , M351T , V379I , L387M , H396P , H396R ) , medium ( IC50 ≤ 200 nmol/L : Y253F , E255K , F359V ) , low ( IC50 ≤ 450 nmol/L : Y253H , E255V ) , and insensitive ( IC50 & gt ; 2 μmol/L : T315I ) ( ) ( ) .", "label": "None"}
{"id": "25505694", "sentence": "In vitro studies showed that exposing EGFR-mutant lung cancer cell lines to a mutagen and culturing them in the presence of an EGFR-TKI , the resistant clones with the @VARIANT$ mutation maintained a persistent phosphorylation [ ] . Given this role of persistent EGFR signaling , many trials evaluated the intensification of EGFR inhibition through the use of drug molecules with additional activity against other receptors in the EGFR family , as the second-generation neratinib , dacomitinib and afatinib [ ] . These inhibitors are mainly different from @DRUG$ and gefitinib for two features : each forms a covalent and irreversible attachment to the EGFR kinase domain , and each also inhibits other members of the @GENE$ family ( Figure ) .", "label": "resistance or non-response"}
{"id": "24495353", "sentence": "Rank Entrez ID Gene symbol Entrez ID Gene symbol Entrez ID Gene symbol 1 28978 TMEM14A 79776 ZFHX4 1727 CYB5R3 2 1843 DUSP1 4701 NDUFA7 7083 TK1 3 51022 GLRX2 715 C1R 1292 COL6A2 4 1434 CSE1L 79818 ZNF552 857 CAV1 5 8522 GAS7 4046 LSP1 5437 POLR2H 6 51668 HSPB11 1727 CYB5R3 9833 MELK 7 10456 HAX1 357 SHROOM2 54861 SNRK 8 9902 MRC2 283298 OLFML1 4830 NME1 9 4706 NDUFAB1 23179 RGL1 231 AKR1B1 10 23560 GTPBP4 1809 DPYSL3 10418 SPON1 11 79633 FAT4 857 CAV1 2350 FOLR2 12 10418 SPON1 274 BIN1 10979 FERMT2 13 471 ATIC 79833 GEMIN6 11096 ADAMTS5 14 6403 SELP 11222 MRPL3 4638 MYLK 15 23421 ITGB3BP 23244 PDS5A 9448 MAP4K4 16 23452 ANGPTL2 6241 @GENE$ 54922 RASIP1 17 54861 SNRK 1289 COL5A1 6934 TCF7L2 18 2034 EPAS1 8434 RECK 4072 EPCAM 19 30008 EFEMP2 429 ASCL1 4701 NDUFA7 20 25999 CLIP3 3426 CFI 404672 GTF2H5 21 4311 MME 332 BIRC5 6241 RRM2 22 4747 NEFL 2 @VARIANT$ 2192 FBLN1 23 1809 DPYSL3 10730 YME1L1 25959 KANK2 24 28998 MRPL13 11130 ZWINT 55651 NHP2 25 25959 KANK2 1292 COL6A2 5050 PAFAH1B3 Lists of the top 25 of most influential genes in influence networks based on coexpression among genes in ER + breast tumors before , during , and after a course of neoadjuvant treatment with the drug @DRUG$ .", "label": "None"}
{"id": "24941944", "sentence": "Historically antifolate drugs such as @DRUG$ or edatrexate have shown very little activity in clinical trials with melanoma patients although these trials were performed before the discovery of BRAF and RAS as drivers of melanomagenesis [ , ] . The lack of response in melanoma patients can be explained by several mechanisms of resistance such as melanosomal sequestration of drugs , the upregulation of both DHFR and the pro-survival transcription factor MITF in response to MTX , or the @VARIANT$ and Chk1 mediated effects , as recently described [ - ] .", "label": "None"}
{"id": "24349524", "sentence": "In phase II clinical trials , nilotinib proved safe and effective for long-term use in CML patients who were intolerant of or resistant to @DRUG$ [ ] . Although successful hematologic and cytogenetic responses have been obtained in the vast majority of nilotinib treated patients , cases showing resistance to nilotinib have been observed [ , ] . Several causes of nilotinib resistance have been described : @VARIANT$ mutation in the kinase domain of BCR-ABL1 [ - ] , overexpression of BCR-ABL1 itself or overexpression of multidrug resistance protein 1 (MDR1) or the @GENE$ kinase [ ] and down-regulation of apoptotic BAX and CERS1 ( ceramide synthase 1 ) [ ] .", "label": "None"}
{"id": "23493838", "sentence": "A complete hematological response and a major cytogenetic response were observed broadly across the @GENE$ mutants , including individuals harboring the dasatinib-resistant F317L , the nilotinib-resistant @VARIANT$ , and F359C/I/V mutations , but not T315I .", "label": "None"}
{"id": "17973572", "sentence": "The activation loop is orange , helix αC yellow , the glycine-rich P-loop green , and the inhibitor @DRUG$ yellow . The figure was made using the program PYMOL ( http : //pymol.sourceforge.net/ ) . ( D ) Top : Dose dependent growth inhibition of @GENE$ cells expressing EGFR @VARIANT$ (LR) , L858R-T790M (LR-TM) , or L858R-L747S ( LR-LS ) detected by the MTS assay .", "label": "None"}
{"id": "23935374", "sentence": "First , GIST mutational status appears to be important , and there is a consensus that patients with the imatinib-insensitive @VARIANT$ mutation of @GENE$ should not receive adjuvant @DRUG$ .", "label": "resistance or non-response"}
{"id": "25032217", "sentence": "Notably , the Evaluation of Genomic Applications in Practice and Prevention ( EGAPP ) Working Group ( EWG ) found insufficient evidence to recommend or discourage testing for mutations in BRAF @VARIANT$ , NRAS , or PIK3CA and/or loss of PTEN or AKT protein . Therefore , the EWG discourages the use of these tests for deciding whether to introduce anti-EGFR therapy with cetuximab or @DRUG$ until more evidence supports improved clinical outcomes [ ] . Moreover , a meta-analysis suggests that mutations in KRAS exons 3 and 4 , NRAS , @GENE$ , PIK3CA , and nonfunctional PTEN predict resistance to anti-EGFR therapies [ ] and concluded that these biomarkers should be implemented for prediction of clinical benefit from anti-EGFR antibodies in mCRC .", "label": "resistance or non-response"}
{"id": "23963283", "sentence": "@VARIANT$ and MET amplification account for approximately 60–70 % of all known causes of acquired resistance to gefitinib or @DRUG$ ; these amplifications are not mutually exclusive and can be detected in the same resistant tumor or may occur independently in different metastatic sites in the same patient . Consequently , ongoing research has been focused on identifying the molecular mechanisms accounting for the 30–40 % of EGFR TKI-resistant , @GENE$ tumors that do not carry EGFR mutations or MET amplification .", "label": "resistance or non-response"}
{"id": "24369725", "sentence": "The deletion mutation on exon 19 of @GENE$ gene was present in 16 patients ( 61.5 % ) , while the @VARIANT$ point mutation on exon 21 was noted in 10 ( 38.5 % ) . All patients were treated with @DRUG$ and showed a partial response .", "label": "sensitivity"}
{"id": "24964744", "sentence": "Cells with PIK3CA mutations H1047R and @VARIANT$ showed greatest single agent sensitivity to the PI3K inhibitor . Interestingly , cells with these mutations also showed greater sensitivity to @DRUG$ and erlotinib than cells with the EGFR mutation ( exon 19 deletion ) , which are associated with sensitivity to EGFR inhibitors in NSCLC . Mutations in @GENE$ ( H1047R ) have been shown to enhance HER2 mediated transformation by amplifying the ligand induced signaling output of the HER family of RTKs [ ] .", "label": "resistance or non-response"}
{"id": "25462529", "sentence": "The fact that @VARIANT$ or K substitutions do not reduce IN enzymatic activity , but slightly affect RT and interaction with p75/LEDGF , points to a change in @GENE$ processing due to a modified trend of interactions between IN monomers , between IN and RT , or between IN and a cellular factor such as p75/LEDGF . @DRUG$ is a versatile amino acid that can assume positive charge , but remains usually neutral at physiological pH .", "label": "None"}
{"id": "15737014", "sentence": "Using this insight , new small-molecule inhibitors have been identified that retain activity against the majority of imatinib-resistant BCR-ABL mutants [ , ] . For example , in CML , a commonly found mutation is a C→T single nucleotide change that replaces threonine with isoleucine at position 315 ( T315I ) in the ABL kinase domain [ , , ] . In GIST and @GENE$ , respectively , the analogous T670I mutation in KIT and @VARIANT$ mutation in PDGFR-alpha have been associated with acquired resistance to this drug [ , ] .", "label": "None"}
{"id": "25505694", "sentence": "In vitro studies showed that exposing EGFR-mutant lung cancer cell lines to a mutagen and culturing them in the presence of an EGFR-TKI , the resistant clones with the @VARIANT$ mutation maintained a persistent phosphorylation [ ] . Given this role of persistent EGFR signaling , many trials evaluated the intensification of @GENE$ inhibition through the use of drug molecules with additional activity against other receptors in the EGFR family , as the second-generation neratinib , dacomitinib and @DRUG$ [ ] .", "label": "response"}
{"id": "24586842", "sentence": "Successful examples of this include the co-development ( and co-approval ) of the BRAF inhibitor vemurafenib and its companion diagnostic @GENE$ @VARIANT$ mutation assay for BRAF-mutant metastatic melanoma , and the ALK inhibitor crizotinib and its companion diagnostic ALK fusion gene test in advanced ALK-fusion positive non-small cell lung cancer ( NSCLC ) patients. , , However , in some cases , predictive biomarkers for a targeted therapy are not recognized until after the drug is first approved . As an example , the anti-EGFR antibody @DRUG$ was first approved in the US for the treatment of metastatic colorectal cancer in 2004 .", "label": "resistance or non-response"}
{"id": "22038681", "sentence": "Preliminary results from an ongoing phase 1 dose-escalation study of the multikinase , @GENE$ inhibitor ponatinib ( @DRUG$ ) showed antileukemic activity in patients with refractory CML , including patients with the @VARIANT$ mutation .", "label": "None"}
{"id": "21152424", "sentence": "Chronic myelogenous leukemia ( CML ) patients treated with @DRUG$ , a @GENE$ inhibitor , can undergo relapse due to the acquisition of a secondary mutation within the Abl coding sequence , that renders imatinib ineffective . Similarly , EGFR TKI responsive patients acquire secondary mutations , @VARIANT$ in the ATP binding cleft , which increases EGFR affinity for ATP ( reviewed in ) .", "label": "None"}
{"id": "15737014", "sentence": "Somatic gain-of-function mutations in exons encoding the @GENE$ kinase domain are found in about 10 % of non-small cell lung cancers ( NSCLCs ) from the United States [ , , ] , with higher percentages observed in east Asia [ , ,, ] . Some 90 % of NSCLC associated mutations occur as either multi-nucleotide in-frame deletions in exon 19 , involving elimination of four amino acids , Leu-Arg-Glu-Ala , or as a single nucleotide substitution at nucleotide 2573 ( T→G ) in exon 21 , resulting in substitution of arginine for leucine at position 858 ( @VARIANT$ ) . Both of these mutations are associated with sensitivity to the small-molecule kinase inhibitors gefitinib or @DRUG$ [ , , ] .", "label": "sensitivity"}
{"id": "23986642", "sentence": "In summary , preclinical data supports the conclusion that @DRUG$ is an orally active , pan-TKI that inhibits native BCR-ABL and most @GENE$ mutants , including the clinically relevant @VARIANT$ mutant , with high potency .", "label": "response"}
{"id": "23976869", "sentence": "Dasatinib is a dual SRC/ABL1 inhibitor that also inhibits PDGFRs and @GENE$ fusion but has no effect on imatinib-resistant FIP1L1-PDGFRA @VARIANT$ and D842V mutants .", "label": "resistance"}
{"id": "25563355", "sentence": "A phase II study supported by the above preclinical data was then conducted using the combination of cetuximab and @DRUG$ in NSCLC patients who developed acquired resistance to first-generation @GENE$ by clinical definition [ , ] . There were confirmed partial responses reported in eight of 22 patients ( 36 % , 95 % CI : 0.17–0.59 ) , including 4/13 patients ( 29 % ) with a positive @VARIANT$ mutation .", "label": "response"}
{"id": "17877814", "sentence": "The @VARIANT$ mutation abrogated the effect of erlotinib on L858R , and the L858R/T790M double mutant readily induced Akt phosphorylation even in the presence of 10 μM erlotinib . Discussion In a subset of NSCLC patients , the presence of somatic mutations in the kinase domain of @GENE$ may predict the outcome of treatment with the EGFR TKIs erlotinib and @DRUG$ .", "label": "resistance or non-response"}
{"id": "21333004", "sentence": "The inhibitory effects of Mig6 and @DRUG$ are indicated by red lines . E11 : EGFR homodimer ; ShcP : free phosphorylated Shc ; E11P : phosphorylated EGFR homodimer ; Raf1A : activated Raf1 ; MEKP : singly phosphorylated @GENE$ ; MEKPP : doubly phosphorylated MEK ; ERKP : singly phosphorylated ERK ; ERKPP : doubly phosphorylated ERK . To investigate cell-specific EGFR signaling dynamics , we constructed an H1299WT model ( WT model ) , an H1299EGFR-WT model ( EGFR-WT model ) , and two alternate H1299L858R models ( @VARIANT$ model A with Mig6 overexpression and L858R model B with Cbl overexpression ) .", "label": "None"}
{"id": "22815900", "sentence": "In particular , overexpression of IGF1R has been in @GENE$ resistant cell lines derived from 11–18 . Our erlotinib- and gefitnib-resistant cell lines show similar sensitivity to c-Met-TKI ( SU11274 ) ( ) , and the IGF1R-TKI ( Picropodophyllin ) ( unpublished data ) , as their parental cell lines . Furthermore , DNA sequence analysis showed no acquisition of a representative secondary mutation of drug resistance in lung cancer cells , @VARIANT$ mutation .", "label": "resistance or non-response"}
{"id": "24981574", "sentence": "These results are in agreement with previous study showing curcumin upregulated BTG2 expression by blocking the NFκB activity in U937 cells , a human leukemic monocyte lymphoma cell line although other early study indicated that NFκB is the activator of BTG2 expression in @VARIANT$ cells , a human ductal breast epithelial tumor cell line . Further transient gene expression assays showed cisplatin treatment lost the activation on BTG2 promoter activity when the NFκB response element was mutated from GGAAAGTCC to GGAAAGGAA in the @GENE$ reporter vector , confirming that @DRUG$ upregulated BTG2 expression through the NFκB pathway in PC-3 cells .", "label": "None"}
{"id": "24124608", "sentence": "To explore potential target genes or mechanisms underlying imatinib resistance in wild-type GISTs , we integrated CGH and expression profiling in 32 gastric GISTs , including four wild-type GISTs and one imatinib-resistant @GENE$ @VARIANT$ mutant GIST .", "label": "resistance or non-response"}
{"id": "24623981", "sentence": "In addition to the documented changes , such as secondary T790M mutation , altered EGFR trafficking , and @GENE$ gene amplification , –, EGFR genetic heterogeneity might also contribute to acquired TKI resistance through the selection of preexisting resistant wild clones , at least in a proportion of NSCLCs . The lack of an established therapeutic option for NSCLC patients who have progressive disease after EGFR TKI failure poses a great challenge to physicians in terms of how best to manage this growing group of lung-cancer patients . Second-generation TKIs that irreversibly inhibit the EGFR TKI domain may offer the potential for overcoming the resistance of @VARIANT$ mutation to erlotinib and @DRUG$ .", "label": "None"}
{"id": "24455112", "sentence": "A third generation inhibitor was recently tested in resistant/intolerant CML patients : @DRUG$ is a potent , synthetic , oral multi-target pan-BCR/ABL inhibitor able to block native and mutated @GENE$ , including @VARIANT$ mutation , resistant to dasatinib and nilotinib .", "label": "response"}
{"id": "22655263", "sentence": "For the L1196M , @VARIANT$ , and L1152R mutants , it appears that binding of the inhibitor to @GENE$ may be negatively affected by steric hindrance or conformational changes in the enzyme . F1174L , which recapitulates the primary mutation found in neuroblastoma previously shown to render the enzyme insensitive to @DRUG$ , appears instead to induce a conformational change in the protein which results in increased affinity for ATP itself .", "label": "resistance"}
{"id": "24244732", "sentence": "Bristol N2 88.7±2.5 unc-18 ( e81 ) + unc-18 Wt 67.5±2.6 unc-18 ( e81 ) + unc-18 @VARIANT$ 51.9±2.1 unc-18 ( e81 ) + unc-18 P240S 69.6±2.6 unc-18 ( e81 ) + unc-18 E465K 61.5±3.9 unc-18 ( e81 ) + unc-18 @GENE$ rab-3 ( y250 ) 78.9±2.0 rab-3 ( y250 ) + unc-18 Wt 72.6±1.6 rab-3 ( y250 ) + unc-18 R39C 60.9±2.1 rab-3 ( y250 ) + unc-18 E465K 65.2±3.0 rab-3 ( y250 ) + unc-18 R39C/E465K 70.1±2.4 Exposing worms to high external ethanol concentrations ( 400 mM ) causes a depression in locomotion [ , ] .", "label": "None"}
{"id": "23238683", "sentence": "As shown in Figure , BaF3 cells expressing native BCR-ABL were highly sensitive to imatinib , dasatinib and ponatinib , whereas @GENE$ and BaF3-G250E-BCR-ABL cells were resistant to both imatinib and @DRUG$ . By contrast , ponatinib induced loss of cell viability in BaF3 cells carrying the @VARIANT$ or G250E mutation , in agreement with previous results from the literature [ , ] .", "label": "None"}
{"id": "23319867", "sentence": "Of note was that a response was seen in three patients with medullary thyroid cancer who had been pretreated with @DRUG$ or sorafenib ( which also target VEGFR and @GENE$ ) , supporting the concept of MET being a VEGF inhibition escape pathway and thus a valid target . Mutational analysis was carried out as part of the trial , and identified 15 patients harboring @VARIANT$ , a RET mutation associated with poor prognosis .", "label": "response"}
{"id": "22350019", "sentence": "@DRUG$ was designed through SAR optimization of lead 5-H-pyrimido [ 5,4-d ] [ 2 ] benzazepine . It is currently in numerous Phase II clinical studies . It does not appear to have any significant off-target effects towards other kinases included in the panel , but it has been shown to inhibit wild-type @GENE$ and @VARIANT$ BCR-ABL effectively in both kinase assays and in vitro cell cultures [ ] .", "label": "None"}
{"id": "23937717", "sentence": "Collectively , these results suggested that @DRUG$ and NK cells could up-regulate the MHC-I in human lung cells with wild type EGFR , while not significantly influence the MHC-I expression on human lung cells with wild type @GENE$ @VARIANT$ + T790M .", "label": "sensitivity"}
{"id": "23805327", "sentence": "Many of the patients that do relapse often harbor pre existing @VARIANT$ @GENE$ mutation at very low levels within the original tumor population , leading to resistance after @DRUG$ treatment .", "label": "resistance or non-response"}
{"id": "15737014", "sentence": "To determine whether additional mutations in the EGFR kinase domain were associated with progression of disease in these patients , we performed direct sequencing of all of the exons ( 18 through 24 ) encoding the @GENE$ catalytic region in the available tumor specimens . However , careful analysis of the exon 20 sequence chromatograms in both forward and reverse directions from this patient 's lung biopsy specimen obtained after disease progression on @DRUG$ demonstrated an additional small peak at nucleotide 2369 , suggesting a C→T mutation ( A , upper panels ; ) . This nucleotide change leads to substitution of methionine for threonine at position 790 ( @VARIANT$ ) .", "label": "resistance or non-response"}
{"id": "24455112", "sentence": "Also in advanced phase of disease , @DRUG$ was found to be active in mutated patients . Ponatinib A third generation inhibitor was recently tested in resistant/intolerant CML patients : ponatinib is a potent , synthetic , oral multi-target @GENE$ inhibitor able to block native and mutated BCR/ABL , including @VARIANT$ mutation , resistant to dasatinib and nilotinib .", "label": "None"}
{"id": "15737014", "sentence": "Such mutations rarely , if ever , accompany EGFR mutations and are associated with primary resistance to @DRUG$ or erlotinib [ ] . To evaluate the possibility that secondary @GENE$ mutations confer acquired resistance to these drugs , we performed mutational profiling of KRAS2 exon 2 from tumor specimens from patients 1 to 3 , as well as the three additional patients lacking evidence of the T790M mutation . An Established NSCLC Cell Line Also Contains Both T790M and @VARIANT$ Mutations", "label": "None"}
{"id": "16626260", "sentence": "Although several previous studies have suggested that tumors harboring mutations in the EGFR kinase domain were sensitive to TKIs such as @DRUG$ or erlotinib , others had reported an association between the @VARIANT$ mutation in exon 20 and the resistance to TKIs . As we learn more about the relationship between EGFR status ( including gene copy number , mutation status , and mutation type ) and drug sensitivity , decisions about treatment with TKIs for patients with non-small-cell lung cancer ( NSCLC ) become more complex . Previously , we reported @GENE$ mutational status , as well as EGFR and KRAS , in a large number of NSCLCs .", "label": "None"}
{"id": "25465236", "sentence": "( G–I ) increased inhibition potency for @DRUG$ against @GENE$ L858R mutant compared to EGFR WT protein and subsequent further increase in potency for Gefitinib against EGFR L858R + E884K double mutant . ( J ) EGFR L861Q activated more than @VARIANT$ but less than L858R .", "label": "resistance or non-response"}
{"id": "22257384", "sentence": "BCRP mRNA expression was higher in hepatic metastases in patients treated with @DRUG$ based chemotherapy than in patients with irinotecan-naïve metastases , suggesting that @GENE$ is also involved in irinotecan resistance in vivo . Mutations of BCRP gene produce varied substrate profiles for mutants as well as wild-type variants . Mutations at codon 482 in BCRP mRNA involving the replacement of arginine with threonine or glycine ( @VARIANT$ or R482G ) caused higher resistance to anthracyclines , .", "label": "None"}
{"id": "24790411", "sentence": "Compared to erlotinib and gefitinib , @DRUG$ shows lower EC50 values and greater potency against wild type ( afatinib vs erlotinib vs gefitinib : 60 nM vs 110 nM vs 157 nM ) and @VARIANT$ mutated @GENE$ ( afatinib vs erlotinib vs gefitinib : 0.7 nM vs 40 nM vs 5 nM ) .", "label": "sensitivity"}
{"id": "24803900", "sentence": "At this time , @GENE$ showed a progression of the disease in the cervical , mediastinal and retroperitoneal lymph nodes . Carboplatin was discontinued and PLD was initiated as a second-line chemotherapy . For the first cycle , a total of 85 mg ( 40 mg/m2 ) of liposomal @DRUG$ in 250 ml of @VARIANT$ ( 5 % glucose solution ) was prescribed with the same premedications used for the prior carboplatin .", "label": "None"}
{"id": "19920910", "sentence": "@VARIANT$ remained resistant to all the three drugs . In vivo experiments with CML xenografts in mice demonstrated that nilotinib treatment , compared with treatment with vehicle , improved survival of mice infused with either wild type @GENE$ or the imatinib-resistant Bcr-Abl mutant ( E255V ) ( ; ) .", "label": "None"}
{"id": "21556318", "sentence": "Two further patients in this study discontinued nilotinib due to intolerance and later progressed to blast crisis , one of whom developed a @VARIANT$ mutation . Although @GENE$ mutations are still being identified despite nilotinib use in frontline therapy , accounting for the number of patients receiving this therapy and comparing @DRUG$ data , it does not appear that the use of nilotinib is associated with an increased risk of inducing BCR–ABL mutations .", "label": "None"}
{"id": "25259585", "sentence": "The examination consisted of 2-dimensional double inversion recovery fast spin echo T1-weighted axial images ( @GENE$ T1WI ) , fat suppressed fast spin echo T2-weighted ( FSE @VARIANT$ ) and proton density weighted imaging ( PDWI ) . Subsequently , 0.1 mmol/kg Gd-DTPA ( @DRUG$ , Schering , Germany ) was injected through an ear vein .", "label": "None"}
{"id": "24121633", "sentence": "Based on our data , we hypothesized that PRR of hnRNP L binds to PTB and cooperatively suppresses inclusion of exon @VARIANT$ . We thus examined the role of PRR of hnRNP L on the interaction with PTB . Histidine tagged @GENE$ His-L ) , its PRR deleted variant ( His-L-ΔPRR ) , @DRUG$ tagged hnRNP LL ( His-LL ) , and its PRR inserted variant ( His-LL-PRR ) were expressed in SH-SY5Y cells , and they were immunoprecipitated with anti-histidine antibody in the presence of RNase .", "label": "None"}
{"id": "24790411", "sentence": "Compared to erlotinib and gefitinib , afatinib shows lower EC50 values and greater potency against wild type ( afatinib vs erlotinib vs @DRUG$ : 60 nM vs 110 nM vs 157 nM ) and @VARIANT$ mutated @GENE$ ( afatinib vs erlotinib vs gefitinib : 0.7 nM vs 40 nM vs 5 nM ) .", "label": "sensitivity"}
{"id": "17973572", "sentence": "A similar clinical benefit is observed in patients with lung cancers harboring the two most common EGFR activating mutations , @VARIANT$ and exon 19 deletions [ – , ] . The striking initial response to small molecule tyrosine kinase inhibitors is thought to stem from the phenomenon of “oncogene addiction” [ ] , and a common signaling cascade may be involved in the apoptosis induced by multiple TKIs [ ] . Rapid inactivation of phosphorylated ERK , AKT , and STAT3/5 , and the delayed accumulation of phosphorylated p38 are commonly observed in SRC- , @GENE$ , and EGFR dependent cells after exposure to the specific inhibitors SU6655 , imatinib , and @DRUG$ , respectively [ ] .", "label": "None"}
{"id": "22436374", "sentence": "Afatinib ( BIBW 2992 , Boehringer Ingelheim GmbH ) , an irreversible dual inhibitor of EGFR and HER2 kinases , retains some activity in tumors with @VARIANT$ mutations although at doses that are a log higher than what is needed for cancers with only a sensitizing mutation [ ] . Afatinib is currently being evaluated in phase III trials [ - ] . The chimerical IgG1 mAb cetuximab ( @DRUG$ , ImClone Systems Incorporated , New York , NY , USA and Bristol-Myers Squibb Company , Princeton , NJ , USA ) is the most comprehensively studied @GENE$ antibody .", "label": "response"}
{"id": "23340652", "sentence": "The authors sequenced exons 18–21 of the @GENE$ gene using DNA extracted from tumor and normal lung tissue obtained at a previous resection : the @VARIANT$ mutation was detected . This point mutation in the activation loop of the kinase domain is linked to @DRUG$ responses [ ] .", "label": "sensitivity"}
{"id": "24790411", "sentence": "@DRUG$ and gefitinib belong to the first generation of TKIs and have reversible binding features . The principal predictive factor for response to such drugs is the presence of somatic “activating” mutations in the @GENE$ gene that cause an aberrant and constitutive activation of the receptor at the membrane level , resulting in a growth advantage of tumor cells through the activation of Ras/MAPK , PI3K/Akt , and STAT signaling pathways . In about 50 % of cases , a secondary mutation ( @VARIANT$ ) is supposed to be responsible for resistance. , Other mechanisms involve MET gene amplification ( 5 % –20 % ) ,", "label": "resistance or non-response"}
{"id": "23055691", "sentence": "Patients who had progressed on erlotinib or gefitinib were given @DRUG$ and cetuximab , a monoclonal antibody against @GENE$ . Approximately 94 % of patients , regardless of @VARIANT$ mutation status , had a partial response or stable disease .", "label": "response"}
{"id": "22586398", "sentence": "In addition , no support was found for interactions between @GENE$ A2AR , or A1 and mGlu5 , suggesting this reduction in alcohol self-administration and @DRUG$ seeking behavior was specific to a functional interaction between @VARIANT$ and mGlu5 receptors ( Adams et al. , , ) .", "label": "None"}
{"id": "24419415", "sentence": "We conducted a post-hoc analysis of the NEJ002 study to evaluate the effectiveness of gefitinib against NSCLC with G719X or @VARIANT$ . The NEJ002 study , comparing gefitinib and standard carboplatin-paclitaxel chemotherapy as the first-line treatment for patients with @GENE$ mutations , demonstrated no significant difference in OS between gefitinib and carboplatin-paclitaxel .", "label": "None"}
{"id": "21364582", "sentence": "We further analysed the effect of endogenous @GENE$ on DSC3 expression by treatment of CX-2 , WiDr , and HRT-18 with @DRUG$ ( ADR ) , an inducer of endogenous p53 expression . Induction of p53 mRNA expression was achieved in the three cell lines by ADR modification with different concentrations ( Supplementary Figure @VARIANT$ ) , while increased expression of p53 was only observed in the cell line HRT-18 ( Figure S2B ) but not in the p53-mutant cell lines CX-2 and WiDr ( Supplementary Figure S2B ) .", "label": "None"}
{"id": "22363766", "sentence": "The @VARIANT$ mutation accounts for approximately 50 % of cases in which acquired resistance to @DRUG$ or gefitinib occurs , , . A small percentage of patients may carry the mutation prior to @GENE$ TKI treatment .", "label": "resistance or non-response"}
{"id": "20942962", "sentence": "One of the mutations ( @VARIANT$ ) was previously identified in non-small cell lung cancer ( NSCLC ) patients and this mutation was found to increase sensitivity to @GENE$ inhibitor , @DRUG$ .", "label": "sensitivity"}
{"id": "25054154", "sentence": "The symbol coding scheme is as follows : native ( green colour ) , mutant F1174L ( red colour ) , and @VARIANT$ ( blue colour ) . Analysis of intermolecular NH bond of native and mutant @GENE$ complex at 20000 ps. Average number of intermolecular hydrogen bonds in native and mutant versus time .", "label": "sensitivity"}
{"id": "22933967", "sentence": "In our retrospective study , 26.7 % of patients , all with KRAS wild-type tumours , who had previously unresectable liver-only metastases , underwent surgical resection after systemic therapy , with R0 resection achieved in 38 patients ( 21.6 % ) ; one of those was patient with the @GENE$ @VARIANT$ mutation . Although it is difficult to make any comparison , because our patients were not selected according to specific systemic therapy , these results are comparable with those reported in previous studies claiming that 19 to 23 % patients treated with bevacizumab- and irinotecan based chemotherapy and with previously unresectable liver-only metastases underwent resection.– In a recently published clinical study BOXER , where the patients with unresectable liver-only metastases were treated with @DRUG$ , capecitabine and bevacizumab , R0 resection was achieved in 40 % of patients .", "label": "None"}
{"id": "24586514", "sentence": "( B ) Immunohistochemical staining for hematoxylin and eosin ( HE ) at a magnification of 40× , Ki67 ( magnification , 400× ) , and TUNEL ( magnification , 400× ) in Ba/F3 @VARIANT$ xenograft sections . ( C ) Tumor cells treated with or without @DRUG$ and vorinostat were examined by immunoblot analysis . Analysis of ABL TKI resistant Ba/F3 @GENE$ cells", "label": "response"}
{"id": "24894453", "sentence": "In addition , these @GENE$ mutations were found to be mutually exclusive with well known KRAS , BRAF and PIK3CA oncogenic driver mutations , demonstrating their potential role in tumorigenesis ( COSMIC database ) . Colon-cancer derived G719S and @VARIANT$ mutants are oncogenic and sensitive to @DRUG$", "label": "sensitivity"}
{"id": "23112741", "sentence": "Aryl hydrocarbon (Ah) receptor ( in- ) activation Recombinant cell based assays , e.g. , H4IIE-luc , @GENE$ , DR-CALUX® Dioxins , coplanar polychlorinated biphenyls ( PCBs ) , poly-aromatic hydrocarbons ( PAHs ) [ ] BioDetection Systems BV , Amsterdam , NL [ ] ( US EPA , Method 4435 , 2007 ) [ ] ( Anti- ) Estrogenicity ( anti- ) Yeast estrogen screen ( YES ) Natural and synthetic @DRUG$ , bisphenol A , nonylphenol , phthalates ( anti ) , and others . Cell based reporter gene assays , such as @VARIANT$ .", "label": "None"}
{"id": "25054064", "sentence": "We also tested the ability of IDO-inhibitors to synergize with a @DRUG$ @GENE$ regimen using the same glioblastoma model . CPM has been used to treat glioblastoma in the clinic [ ] and has been widely studied in the context of immunotherapy [ , ] . We used a dose ( 100 mg/kg ) that exhibited no therapeutic benefit as a single agent ( Additional file : Figure @VARIANT$ ) and did not prolong survival when added to RT alone ( Additional file : Figure S3B ) .", "label": "None"}
{"id": "15737014", "sentence": "The EGFR T790M mutation , in conjunction with either wild-type @GENE$ or the drug-sensitive @VARIANT$ EGFR mutant , prevents inhibition of tyrosine phosphorylation ( A ) or p-EGFR ( B ) by @DRUG$ .", "label": "sensitivity"}
{"id": "24802226", "sentence": "For example , @GENE$ exon 9 mutations and exon 11 deletions involving codons 557–558 are associated with poor outcome , and the PDGFRA mutation @VARIANT$ is associated with resistance to @DRUG$ [ , , – ] .", "label": "None"}
{"id": "22185378", "sentence": "To further characterize the expression of EGFR in these cells , we have examined cell surface EGFR expression by FACS and observed that both a murine anti-EGFR MAb and @DRUG$ were able to detect elevated , intermediate and low levels of membrane bound @GENE$ on A431 , Caski and @VARIANT$ cells , respectively ( Figure ) .", "label": "None"}
{"id": "23994953", "sentence": "Using the erlotinib-sensitive EGFR mutant NSCLC cell line HCC4006 harboring the delL747-E749 , A750P mutation in EGFR exon 19 , Suda et al. established that mesenchymal status , not a specific oncogenic activated protein , could sufficiently promote loss of @GENE$ dependence to confer resistance to @DRUG$ . More recently , Chang et al. confirmed that in the absence of the common second-site EGFR mutation @VARIANT$ or MET amplification , acquired resistance to gefitinib occurs in EGFR mutated PC9 cells that have undergone EMT .", "label": "resistance or non-response"}
{"id": "23497317", "sentence": "The gastrointestinal stromal tumor cell lines GIST822 , harboring a KIT exon 13 mutation ( K642E ) , and GIST48 , harboring an imatinib-sensitive V560D mutation plus a secondary imatinib-insensitive activation loop mutation ( @VARIANT$ ) were generously provided by Dr. Kopp ( University of Tübingen ) [ , ] . Site directed mutagenesis and generation of a @GENE$ cell line expressing KIT or FLT3 isoforms", "label": "None"}
{"id": "21192840", "sentence": "Tumor type EGFR mutation EGFR expression changes @GENE$ targeting agents ( FDA approved for clinical use ) Resistance mechanisms Non-small cell lung cancer Kinase domain deletions ( exon 19 ) , point mutations ( exon 21 ) Gene amplification Erlotinib , Gefitinib @VARIANT$ gatekeeper mutation ( 50 % ) , , elevated c-Met/HGF expression ( 20 % ) – Colorectal cancer ( metastatic ) Rare , Overexpression , copy number increase @DRUG$ , Panitumumab K-ras– , B-raf , PIK3CA , PTEN mutations", "label": "response"}
{"id": "23801357", "sentence": "Ponatinib ( @DRUG$ ) is a novel @GENE$ inhibitor developed using a computational and structure based approach.– It was designed to bind to and inhibit native BCR-ABL and BCR-ABL mutants that can arise during treatment with other TKIs and cause resistance , including the @VARIANT$ mutant .", "label": "response"}
{"id": "15737014", "sentence": "Analogously , the T790M mutation , in conjunction with the drug-responsive del L747–E749 ; @VARIANT$ EGFR mutant , prevents inhibition of @GENE$ by @DRUG$ ( C ) .", "label": "None"}
{"id": "23606169", "sentence": "Moreover , the presence of the @VARIANT$ mutation in the @GENE$ gene is more and more frequently taken into consideration before patient targeted therapy qualification , because wild-type BRAF is required for a response to @DRUG$ or cetuximab [ , ] .", "label": "resistance or non-response"}
{"id": "22740817", "sentence": "Whether the survival difference between BRAF WT and mutant patients is only due to the fact that BRAF mutational status has prognostic value or if @GENE$ mutational status may also be predictive for a combination treatment with @DRUG$ and temozolomide can not be concluded definitively from our data set , but should be prospectively studied . If the 2 most frequent BRAF mutations , @VARIANT$ and V600K , are the alterations with predictive value in melanoma patients , techniques identical or similar to method 1 described in this paper may be the detection system of choice .", "label": "sensitivity"}
{"id": "22185378", "sentence": "Combination of @DRUG$ with PD98059 , a @GENE$ inhibitor , induces antagonistic effects in A431 , Caski and @VARIANT$ cells", "label": "None"}
{"id": "17973572", "sentence": "Mutations in the analogous residue of ABL1 ( L273M ) and @GENE$ ( @VARIANT$ or P) (C ) have been described in patients with imatinib-resistant chronic myelogenous leukemia ( CML ) and solid tumors including gastric , breast , and lung cancers , respectively [ – ] .", "label": "None"}
{"id": "21444946", "sentence": "It has been shown that exon 19 deletions are more sensitive to @DRUG$ inhibition than the @VARIANT$ mutation , a finding demonstrated by kinetic analysis [ ] and also confirmed in clinical studies [ - ] . On the other hand , cetuximab is not as potent as @GENE$ TKIs in tumors with exon 19 deletion or L858R EGFR mutations [ ] .", "label": "sensitivity"}
{"id": "11461094", "sentence": "@VARIANT$ binding ( Morozov et al , 1997 ) . After we determined that the PI-3K/Akt and @GENE$ pathways were not involved , we examined the possible involvement of the JNK pathway and found that the mechanism by which EGF protected SiHa cells from @DRUG$ induced apoptosis was sensitive to inhibition of JNK activity by SB202190 .", "label": "None"}
{"id": "21347248", "sentence": "C : The gatekeeper mutation ( @VARIANT$ ) , which prevents imatinib from binding to the ATP binding pocket of BCR-ABL , was introduced into the @GENE$ backbone to test whether @DRUG$ enables the nuclear import of the kinase-defective protein through direct binding to its kinase domain .", "label": "None"}
{"id": "22436374", "sentence": "H1650 cells have also a deletion of the 3 ' part of exon 8 and the entire exon 9 of @GENE$ , which causes loss of the protein [ ] and in addition express the insulin-like growth factor receptor ( IGF1R ) [ ] . The cell line H1975 has a sensitizing @VARIANT$ kinase domain mutation in exon 21 , but also a second mutation ( T790M , in cis , in the kinase domain ) rendering them resistant to the reversible TKIs gefitinib and @DRUG$ [ ] .", "label": "None"}
{"id": "19742137", "sentence": "Our data shows that suppressing Topo IIα expression through Sp1 and @GENE$ plays important role @DRUG$ @DRUG$ induction of HeLa cell @VARIANT$ arrest and apoptosis .", "label": "None"}
{"id": "24523596", "sentence": "Several studies have reported renal failure and tumor lysis syndrome during TKI based molecular targeted therapies , including with sorafenib for hepatocellular carcinoma , with @DRUG$ for chronic myelogenous leukemia , and with flavopiridol for chronic lymphocytic leukemia.– Because the @VARIANT$ variant of ABCG2/BCRP corresponding to SNP 421C&gt ; A reduces uric acid transport and those TKIs are substrates/inhibitors of @GENE$ , TKI therapy in patients with the SNP 421C&gt ; A ( Q141K ) may be at higher risk of tumor lysis syndrome .", "label": "None"}
{"id": "19547661", "sentence": "BRAF ( v-raf murine sarcoma viral oncogene homolog B1 ) , a @GENE$ is the downstream effector of KRAS in the RAS-RAF-MAPK signaling pathway . A somatic mutation ( @VARIANT$ ) in exon 15 of BRAF has been identified in multiple human cancers with a mutation rate of 66 % in malignant melanomas [ ] and at lower frequency in other human carcinomas . Recently , it was demonstrated that wildtype BRAF is required for the response of patients with metastatic colorectal cancer to @DRUG$ and panitumumab [ ] .", "label": "None"}
{"id": "25091415", "sentence": "As in , the histogram plot shows T790 mutant exhibited a higher average distance between M793 and the drug , though the G719 mutation caused @DRUG$ to move closer to the binding site . This result proves that the T790M secondary mutation effectively restores the nucleotide binding property of the G719S mutant as observed for the @VARIANT$ mutant . To identify the specific structural change in the binding pocket that resulted in the observed ligand movements , we calculated time dependent distances among the @GENE$ pharmacophore residues in the hydrophobic region ( L718 and G796 ) .", "label": "sensitivity"}
{"id": "23785245", "sentence": "Most NSCLC patients who harbor activating @GENE$ mutations , including deletions in exon 19 or the point mutation L858R in exon 21 , experience an initial marked response to the EGFR-TKIs gefitinib or @DRUG$ . However , almost all such individuals eventually develop acquired resistance to these drugs within 1 year . In addition , 20 % –30 % of NSCLC patients with EGFR mutations do not show an initial response to EGFR-TKIs. , , Therapeutic strategies to overcome EGFR-TKI resistance in NSCLC patients with EGFR mutations have been developed on the basis of the biological mechanisms of such resistance , which include a @VARIANT$ secondary mutation in EGFR as well as amplification of the gene for the receptor tyrosine kinase MET , which serves as the receptor for hepatocyte growth factor .", "label": "resistance or non-response"}
{"id": "22802746", "sentence": "For example , GIST patients with the @VARIANT$ mutation in @GENE$ exon 18 are known to be unresponsive to @DRUG$ .", "label": "resistance or non-response"}
{"id": "24495353", "sentence": "Rank Entrez ID Gene symbol Entrez ID Gene symbol Entrez ID Gene symbol 1 28978 TMEM14A 79776 ZFHX4 1727 CYB5R3 2 1843 @GENE$ 4701 NDUFA7 7083 TK1 3 51022 GLRX2 715 C1R 1292 COL6A2 4 1434 CSE1L 79818 ZNF552 857 CAV1 5 8522 GAS7 4046 LSP1 5437 POLR2H 6 51668 HSPB11 1727 CYB5R3 9833 MELK 7 10456 HAX1 357 SHROOM2 54861 SNRK 8 9902 MRC2 283298 OLFML1 4830 NME1 9 4706 NDUFAB1 23179 RGL1 231 AKR1B1 10 23560 GTPBP4 1809 DPYSL3 10418 SPON1 11 79633 FAT4 857 CAV1 2350 FOLR2 12 10418 SPON1 274 BIN1 10979 FERMT2 13 471 ATIC 79833 GEMIN6 11096 ADAMTS5 14 6403 SELP 11222 MRPL3 4638 MYLK 15 23421 ITGB3BP 23244 PDS5A 9448 MAP4K4 16 23452 ANGPTL2 6241 RRM2 54922 RASIP1 17 54861 SNRK 1289 COL5A1 6934 TCF7L2 18 2034 EPAS1 8434 RECK 4072 EPCAM 19 30008 EFEMP2 429 ASCL1 4701 NDUFA7 20 25999 CLIP3 3426 CFI 404672 GTF2H5 21 4311 MME 332 BIRC5 6241 RRM2 22 4747 NEFL 2 @VARIANT$ 2192 FBLN1 23 1809 DPYSL3 10730 YME1L1 25959 KANK2 24 28998 MRPL13 11130 ZWINT 55651 NHP2 25 25959 KANK2 1292 COL6A2 5050 PAFAH1B3 Lists of the top 25 of most influential genes in influence networks based on coexpression among genes in ER + breast tumors before , during , and after a course of neoadjuvant treatment with the drug @DRUG$ .", "label": "None"}
{"id": "23566546", "sentence": "Case Histrogical type EGFR mutation status Brinkman index Treatment agent Response IL-8 ( ng/mL ) IL-10 ( ng/mL ) RANTES ( pg/ml ) 1 Ad Ex21 L858R 900 gefitinib PR 5.79 1.67 2 2 Ad Ex21 L858R 0 erlotinib PR_3.33 94.2 1.41 3 Ad Ex19 del 0 erlotinib PR 4.09 126 2.13 4 Ad Ex21 L858R 0 gefitinib @GENE$ 18.1 1.85 5 Ad Ex21 L858R + Ex19 del 370 erlotinib PR 21.9 1.23 2.11 6 Ad Ex19 del 0 erlotinib PR 7.05 1.37 2.56 7 Ad Ex19 del 0 gefitinib PR 4.82 1.59 2.02 8 Ad Ex21 L858R 1640 gefitinib PR 54.9 2.7 2.38 9 Ad negative 400 erlotinib SD 34.9 3.39 3.66 10 Ad negative 0 erlotinib SD 27.1 4.94 2.25 11 Ad unknown 1800 erlotinib SD NE NE NE 12 Sq Ex19 del 3840 gefitinib SD 12.6 1.1 1.98 13 Ad Ex19 del 30 erlotinib SD 5.27 0.69 2.66 14 Ad Ex19 del 0 erlotinib SD 10.5 0.85 2.5 15 Ad unknown 300 erlotinib SD 7.69 2.61 1.7 16 La negative 2080 erlotinib SD NE NE NE 17 Sq Ex21 L858R 750 erlotinib SD 11.6 56.3 3.06 18 Ad unknown 600 erlotinib SD 13.7 1.1 2.82 19 Ad Ex21 L858R 0 erlotinib SD 20.6 11.6 0.783 20 Ad Ex19 del 0 erlotinib SD 14.8 2.07 2.02 21 Ad Ex21 L858R + Ex19 del 0 @DRUG$ SD 3.04 1.3 1.76 22 Ad Ex19 del 200 gefitinib SD 10.9 1.59 1.91 23 Sq unknown 1560 erlotinib PD NE NE NE 24 Ad negative 1080 erlotinib PD 25.2 8.15 1.57 25 Ad unknown 0 erlotinib PD NE NE NE 26 Ad Ex18 @VARIANT$ 2000 erlotinib PD 11.6 4.48 3.12 27 Ad unknown 1410 erlotinib PD NE NE NE 28 Ad Ex19 del 1000 gefitinib PD 9.44 2.25 2.89 29 Ad negative 1100 erlotinib PD 56.3 5.63 2.16 30 Ad negative 2000 erlotinib PD 15.6 0.85 0.292 31 Ad negative 825 erlotinib PD 8.27 1.59 2.13 32 Ad Ex21 L858R 0 erlotinib PD 5.34 7.05 1.7 33 Ad negative 1680 erlotinib PD 57.7 1.63 2.06", "label": "None"}
{"id": "24294007", "sentence": "Although a retrospective study and the PICCOLO ( Panitumumab , @DRUG$ and Ciclosporin in Colorectal Cancer Therapy ) trial have demonstrated a reduced response to cetuximab and panitumumab for patients with NRAS mutations , , further work is required to demonstrate the predictive capacity of these mutations . The serine/threonine-protein kinase B-Raf is an effector in the @GENE$ signaling pathway , downstream of K-Ras . Mutations in the proto-oncogene BRAF are present in 5 % –10 % of the metastatic CRC population and are also mutually exclusive of KRAS mutations . BRAF @VARIANT$ is the most common of all BRAF mutations ( present in 90 % of cases ) , and is enriched in a subset of patients who are female , greater than 70 years of age , with KRAS WT right sided colon cancer .", "label": "None"}
{"id": "20617155", "sentence": "More recently , Ramakrishnan and colleagues showed in a murine model that paclitaxel , cisplatin , and @DRUG$ all sensitize tumor cells to more efficient killing by CTL [ ] . In this system , however , the responsible mechanism on murine as well and human cancer cells went via upregulation of the @GENE$ cancer cells which is required for granzyme B associated killing [ ] .", "label": "None"}
{"id": "25114575", "sentence": "In vitro studies have shown that IC50 of @DRUG$ was less than 0.16 mol/L in A431 , HN5 , BT474 , N87 , and CaLu-3 cell lines , and was about 3 mol/L in MCF-7 and @VARIANT$ cell lines . Compared to EGFR- or/and @GENE$ positive cell lines , breast cancer cells with low EGFR or/and HER2 expression had 25 times higher IC50 .", "label": "None"}
{"id": "23922791", "sentence": "In CML , this can result from further point mutations leading to additional changes in @GENE$ , for example @VARIANT$ , Y253H , and F255K . In GIST , secondary KIT mutations in exons 13 , 14 , or 17 other than exon 11 are reported to be important events in acquired @DRUG$ resistance .", "label": "None"}
{"id": "23286345", "sentence": "Etienne-Grimaldi et al. examined the effect of @GENE$ H131R and FCGR3A @VARIANT$ SNPs on the efficacy of cetuximab in metastatic colorectal cancer patients treated with @DRUG$ and irinotecan in combination with oral tegafur-uracil [ ] .", "label": "None"}
{"id": "24416052", "sentence": "Further , they represented a SQCLC patient with a wild type EGFR who showed radiological response after treatment with both @DRUG$ and erlotinib in their clinical trial . The patient was confirmed to have a new mutation ( @VARIANT$ ) in the @GENE$ kinase domain .", "label": "response"}
{"id": "25562798", "sentence": "Firstly , a secondary mutation , the @VARIANT$ mutation within exon 20 of EGFR , is responsible for about 50 % of instances of acquired resistance [ , ] . This mutation increases the affinity of the @GENE$ for ATP approximately 10-fold and allows ATP to competitively displace @DRUG$ and erlotinib from EGFR [ ] .", "label": "resistance or non-response"}
{"id": "24594844", "sentence": "H1975 contains EGFR T790M and @VARIANT$ mutations ( designated H1975TM/LR ) and T790M mutation in both alleles was confirmed by genomic DNA sequencing analysis ( Supplementary Figure S1 ) . However , the phosphorylation level of @GENE$ in EGFR T790M mutant cells ( H1975TM/LR ) was not suppressed by @DRUG$ treatment .", "label": "sensitivity"}
{"id": "18544172", "sentence": "Non-responders 10 F 68 0 Folfiri , Xeloda , Xelox SD 17 Wild-type @VARIANT$ trisomy 11 F 74 1 LV5FU Folfiri SD 10 Gly12Val disomy 12 M 61 0 Folfirinox SD 18 Gly13Asp R521K disomy 13 F 71 0 Xelox Avastin-Xeliri SD 15 Gly12Asp disomy 14 M 59 0 LV5FU , Folfiri , Folfox SD 24 Gly12Cys R521K trisomy 15 M 71 0 Folfox , Irinotecan SD 14 Wild-type disomy 16 F 60 1 Fufol Folfiri , Folfox , Cape , LV5FU SD 17 Wild-type trisomy 17 M 65 0 Folfirinox , Folfiri SD 18 Wild-type low polysomy 18 M 66 0 Folfiri SD 17 Wild-type R521K disomy 19 F 45 0 Folfox , Xelox SD 17 Wild-type R521K NE 20 F 42 0 Folfirinox SD 21 Gly12Asp R521K trisomy 21 M 62 1 Folfox Xeliri SD 36 Gly13Asp R521K disomy 22 M 58 1 Folfiri Xelox , Xeliri PD NA Gly13Asp disomy 23 M 75 1 Xelox Xeliri PD NA Wild-type trisomy 24 M 81 0 Xelox , Folfiri PD NA Gly12Val disomy 25 F 55 0 Xelox Avastin-Xeliri PD NA @GENE$ disomy 26 M 60 1 LV5FU Folfiri , Folfiri , Folfox PD NA Wild-type NE 27 M 59 0 Folfiri , Folfiri/Folfox , Folfox PD NA Gly12Asp NE 28 F 58 1 LV5FU Folfiri , Xelox PD NA Gly12Asp disomy 29 M 51 0 Folfox , Folfiri PD NA Wild-type disomy 30 F 66 0 Folfiri , Xelox PD NA Wild-type R521K trisomy 31 F 56 0 - PD NA Wild-type disomy 32 F 78 0 Folfox , Folfiri , Cape PD NA Gly12Val disomy F = female , M = Male , Folfox = oxaliplatin , fluorouracil , and folinic acid ; Xelox = capecitabine , oxaliplatin ; Folfiri = irinotecan , fluorouracil , and folinic acid ; Xeliri = Capecitabine , irinotecan ; Folfirinox = oxaliplatin , irinotecan , fluorouracil , and folinic acid ; LV5FU = infusional FU and @DRUG$ Fufol = bolus fluorouracil and folinic acid ; PR = partial response .", "label": "None"}
{"id": "25110867", "sentence": "These preclinical models suggest that dacomitinib may be quite effective against lung cancer that becomes resistant to gefitinib or @DRUG$ via acquisition of a @VARIANT$ mutation in @GENE$ [ ] .", "label": "resistance or non-response"}
{"id": "25215298", "sentence": "When we investigated the response of p53 to DNA damaging reagent @DRUG$ , a significantly decreased induction of @GENE$ expression and its transactivity toward downstream genes were found in NNK transformed cells , confirming the aberrant function of p53-R273H . Moreover , in addition to abrogating the tumor suppressor functions of wild-type TP53 , @VARIANT$ mutant has also been found to acquire new oncogenic activities to promote cancer , including metastasis promotion and increased resistance to anticancer treatments [ , ] .", "label": "None"}
{"id": "23690929", "sentence": "Epidermal growth factor receptor (EGFR) activating mutations , such as exon 19 deletion and exon 21 @VARIANT$ point mutation , are found in a population of NSCLC , and are associated with a clinical response to the @GENE$ tyrosine kinase inhibitors ( EGF-TKIs ) , gefitinib and @DRUG$ – .", "label": "sensitivity"}
{"id": "15737014", "sentence": "@DRUG$ inhibited the activity of wild-type and L858R EGFRs progressively with increasing concentrations of drug , as demonstrated by a reduction of tyrosine phosphorylated proteins ( A ) and a decrease in @GENE$ : t-EGFR ratios ( B ) . By contrast , wild-type and mutant EGFRs containing the @VARIANT$ mutation did not display a significant change in either phosphotyrosine induction or p-EGFR : t-EGFR ratios ( A and B ) .", "label": "resistance or non-response"}
{"id": "23994953", "sentence": "Using the erlotinib-sensitive EGFR mutant NSCLC cell line HCC4006 harboring the delL747-E749 , A750P mutation in EGFR exon 19 , Suda et al. established that mesenchymal status , not a specific oncogenic activated protein , could sufficiently promote loss of EGFR dependence to confer resistance to erlotinib . More recently , Chang et al. confirmed that in the absence of the common second-site EGFR mutation @VARIANT$ or @GENE$ amplification , acquired resistance to gefitinib occurs in EGFR mutated PC9 cells that have undergone EMT .", "label": "None"}
{"id": "25033171", "sentence": "In addition , we have analyzed the energetic contribution to crizotinib on residue level as well , which showed that the residue Leu18 ( located just in the P-loop region ) contributed the most to the attenuated binding of crizotinib to G2032R-ROS1 as shown in , therefore well supporting the issue that the P-loop conformation governs @DRUG$ resistance in @VARIANT$ mutated @GENE$ tyrosine kinase .", "label": "resistance"}
{"id": "16187797", "sentence": "del , L747_E749del @VARIANT$ ; ins , D770_N771insNPG ; wt , wild-type EGFR . Sensitivity of Cell Transformation Induced by Expression of Mutant EGFR Characterized by Missense Mutation or Exon 19 Deletion , but not Exon 20 Insertion , to Gefitinib and @DRUG$ ( A ) Anchorage independent growth of clonal NIH-3T3 cells transformed with mutant EGFR or @GENE$ stimulated wild-type EGFR treated with the indicated concentrations of erlotinib immediately prior to suspension in soft agar .", "label": "None"}
{"id": "21264348", "sentence": "A. Dasatinib antiproliferative EC50 in the presence of 0.4 to 10 μM GNF‐5 on Ba/F3 cells expressing @VARIANT$ and E505K @GENE$ B. Inhibition of Bcr‐Abl autophosphoryl‐ation was determined by Bcr‐Abl immunoprecipitation , followed by a immunoblot for phospho‐Tyr ( Tyr412 ) , phospho‐STAT 5 ( Tyr694 ) and total Bcr‐Abl ( antibody K‐12 ) from cell lystates obtained after treatment of T315I Bcr‐Abl expressing Ba/F3 with 10 μM of dasatinib and increasing concentrations of GNF‐5 ( 0 , 0.5 , 5 and 10 μM ) for 90 min. ( TIF )", "label": "None"}
{"id": "22185378", "sentence": "In contrast , we have demonstrated that the combination of @DRUG$ and PD153035 ( a specific EGFR TKI ) proved to be antagonistic in @VARIANT$ cell line , with no reduction in proliferation and @GENE$ , HER2 , AKT and MAPK phosphorylation status when compared to either drug alone [ ] .", "label": "None"}
{"id": "24789720", "sentence": "T790M mutation in EGFR gene seems to be one of the most important genetic abnormalities involving the resistance for reversible epidermal growth factor receptor tyrosine kinases inhibitors ( @GENE$ ) —erlotinib and gefitinib in NSCLC patients [ – ] . T790M mutation is detected with highest prevalence in patients with common activating mutations of EGFR gene ( @VARIANT$ in exon 21 and deletions in exon 19 ) after long-term and initially effective treatment with EGFR-TKIs .", "label": "sensitivity"}
{"id": "17973572", "sentence": "After the cells were exposed to gefitinib for 24 h , @GENE$ cells were unable to proliferate while Ba/F3-L858R-L747S and Ba/F3-L858R-T790M cells continued to grow even in the presence of 1 μM @DRUG$ ( E ) . These results suggest that execution of apoptosis may be impaired by the presence of @VARIANT$ and , to a lesser extent , L747S .", "label": "None"}
{"id": "25101240", "sentence": "AP26113 ( Ariad Pharmaceuticals ) is a novel inhibitor of ALK with activity against @VARIANT$ gatekeeper mutation as well as against @GENE$ and EGFR ( including mutant form with the T790M gatekeeper mutation ) ( ) . Objective response was observed in 15/24 ( 63 % ) patients ( 1 complete response and 14 partial responses ) , including 12/16 ( 75 % ) in patients resistant to @DRUG$ .", "label": "None"}
{"id": "20300583", "sentence": "In the one case of discordance between KRAS mutation status before and after combined cetuximab therapy ( case # 4 ) , a mutated @GENE$ gene ( Exon 2 @VARIANT$ ) was found in the primary CRC , while no KRAS mutation was observed in a liver metastasis sample obtained after combined @DRUG$ therapy ( ) .", "label": "sensitivity"}
{"id": "23994953", "sentence": "However , it should be noted that these studies were largely based on NSCLC cells expressing wild-type EGFR ; therefore , these studies did not mimic clinical usage of EGFR TKIs because @GENE$ wild-type NSCLC cells are intrinsically resistant to EGFR TKIs . In this scenario , it might appear reasonable to suggest that in addition to the presence of the @VARIANT$ mutation , immunohistochemical and/or microarray based transcriptional profiling studies dedicated to specific alterations of EMT drivers ( e.g. , SLUG ) and/or effectors ( e.g. , vimentin ) may be helpful in monitoring for @DRUG$ responders and non-responders based on the loss of biomarkers associated with epithelial status and gain of biomarkers associated with mesenchymal status .", "label": "resistance or non-response"}
{"id": "21931765", "sentence": "Although Daoy cells harbor a p53 homozygote mutation ( @VARIANT$ ) , they retain a 22,8 % @GENE$ promoter-specific transcriptional activity , as measured in yeast functional assays on WAF1 ( expressed as percent of wild-type activity ; see additionally the data from a p53 database available at “http : //www-p53.iarc.fr/” ) , because of these reported data we reason @DRUG$ stimulation may be due in Daoy cells to an enhancement of miR34a transcription .", "label": "None"}
{"id": "23836985", "sentence": "Jin et al also reported that the HDAC inhibitor , @DRUG$ , inhibits HDAC activity by downregulating cyclin D1 protein expression in colonic carcinoma cells in xenografted mice . In conclusion , our study confirms that valproic acid significantly suppresses growth of Kasumi-1 cell xenograft tumors in nude mice via cell cycle arrest . The antitumor activity of valproic acid is possibly attributable to its direct downregulation of cyclin D1 , CDK4/6 , and cyclin E1 expression , blockage of Rb phosphorylation , reduction of free @VARIANT$ , inhibition of HDAC activity , attenuation of histone acetylation in the p21 promoter region , upregulation of p21 expression , and induction of cell cycle arrest .", "label": "None"}
{"id": "24348666", "sentence": "It was initially proposed that the T790M mutation might prevent the proper binding of tyrosine kinase inhibitors via steric hindrance , similar to the corresponding gatekeeper mutations in @GENE$ ( @VARIANT$ ) and KIT ( T670I ) that confer resistance to @DRUG$ ( Gleevec ) in chronic myelogenous leukemia and in patients with gastrointestinal stromal tumors .", "label": "None"}
{"id": "24789720", "sentence": "The role of T790M mutation , particularly its presence in patients before @GENE$ treatment is still controversial being a subject of intensive discussions . Mechanism of achieving resistance to erlotinib and @DRUG$ remains unclear . The recent reports confirmed , that T790M substitution could be detected in EGFR-TKIs naïve patients independently of other EGFR gene mutations ( predominantly @VARIANT$ substitution and deletions in exon 19 ) .", "label": "sensitivity"}
{"id": "24058902", "sentence": "In an effort to overcome TKI resistance after first line treatment , the molecule CUDC-101 incorporates the @GENE$ inhibitory hydroxamic acid structure with the phenylaminoquinazoline moiety of the efficacious TKIs . The authors show that the activity of CUDC-101 in 10 NSCLC cell lines was generally more effective than a combination of @DRUG$ and erlotinib . Their results do include CUDC-101 treatment using two EGFR mutant cell lines H1975 ( activating @VARIANT$ and EGFR T790M resistance mutation ) and HCC827R ( EGFR activating deletion with acquired TKI resistance ) .", "label": "None"}
{"id": "18923525", "sentence": "The F1245C mutation corresponds to L833V in @GENE$ , a gefitinib-resistant mutation in lung cancer ( Greulich & amp ; Meyerson , unpublished observations ) . The R1275Q mutation is located adjacent to @VARIANT$ in EGFR , which is the most common EGFR mutation in lung cancer , .", "label": "sensitivity"}
{"id": "24223799", "sentence": "Results of DNA Sanger sequencing of PCR products of exons 18–21 from H2170 and H358 parental and resistant cells showed no secondary erlotinib/gefitinib @VARIANT$ or D761Y resistance point mutations . These results confirm that our cells do not have known secondary mutations that would cause resistance . Thus , the mechanism by which they are resistant may be due to alternative signaling through receptors other than @GENE$ .", "label": "resistance or non-response"}
{"id": "24955213", "sentence": "@VARIANT$ EML-ALKpm Alters @GENE$ @DRUG$ binding cavity , reducing crizotinib-protein interactions [ , , ]", "label": "resistance"}
{"id": "24915153", "sentence": "All elements were cloned between the CaMV 35S promoter ( @VARIANT$ ) and the 5′-UTR sequence of the Arabidopsis @DRUG$ Dehydrogenase gene ( ADH5′-UTR ) and terminator sequence of the Heat Shock Protein gene ( THSP ) in the pRI201-AN binary vector .", "label": "None"}
{"id": "23727938", "sentence": "These results support the concept that @DRUG$ treatment may be of benefit in either syngeneic or allogeneic islet transplantation for the treatment of @VARIANT$ . 2.5 . Inflammatory Bowel Disease 2 .5.1 . Pathogenesis of @GENE$", "label": "None"}
{"id": "22192147", "sentence": "Conversely , the presence of @GENE$ activating mutations is highly predictive of response to treatment with gefitinib or @DRUG$ [ , ] . These mutations are usually exon 19 deletions and the @VARIANT$ substitution in exon 21 , as well as , rarely , exon 18 mutations .", "label": "sensitivity"}
{"id": "25580271", "sentence": "There are several promising agents for patients with activating EGFR mutations who experience disease progression of an EGFR tyrosine kinase inhibitor and have a @VARIANT$ resistance mutation , and multiple clinical trials will be available . Trials investigating adjuvant @DRUG$ in @GENE$ mutant NSCLC and comparing erlotinib to erlotinib plus bevacizumab in metastatic EGFR mutant NSCLC are ongoing .", "label": "resistance or non-response"}
{"id": "25054154", "sentence": "In 2010 , Choi et al. [ ] identified two secondary mutations ( C1156Y and @VARIANT$ ) within the kinase domain of @GENE$ fusion protein , which confer marked @DRUG$ resistance .", "label": "resistance"}
{"id": "15737014", "sentence": "This scenario could explain the seemingly contradictory report by others who found the H1975 cell line to be highly sensitive to @DRUG$ [ ] ; our H1975 cells could represent a subclone that emerged over time . Analysis of earlier passages of H1975 cells for the @VARIANT$ mutation would be informative in this regard . Recently , new small-molecule inhibitors have been identified that retain activity against the majority of imatinib-resistant @GENE$ mutants .", "label": "None"}
{"id": "24121633", "sentence": "Based on our data , we hypothesized that PRR of hnRNP L binds to PTB and cooperatively suppresses inclusion of exon @VARIANT$ . We thus examined the role of PRR of hnRNP L on the interaction with PTB . Histidine tagged hnRNP L ( His-L ) , its @GENE$ deleted variant ( His-L-ΔPRR ) , @DRUG$ tagged hnRNP LL ( His-LL ) , and its PRR inserted variant ( His-LL-PRR ) were expressed in SH-SY5Y cells , and they were immunoprecipitated with anti-histidine antibody in the presence of RNase .", "label": "None"}
{"id": "21613978", "sentence": "Left : HEK cells expressing a fusion protein of the catalytic domain of Raf-1 with oestrogen receptor binding domain show no feedback regulation post-Mek inhibition when stimulated with @DRUG$ ( 4OHT ) , but show feedback regulation when stimulated with @GENE$ . Right : CaCo2 cells expressing B-Raf @VARIANT$ show no feedback post-Mek inhibition , while cells with control constructs show strong feedback regulation .", "label": "None"}
{"id": "16434996", "sentence": "On the other hand , the @VARIANT$ inhibition of ER-α activity is due mostly to BRCA1 , and not BRCA2 . Indole-3carbinol and @DRUG$ may exert BRCA1 dependent and BRCA1 independent effects on ER-α and AR signalling , since @GENE$ can influence ER-α and AR activity in the absence of phytochemicals .", "label": "None"}
{"id": "24263064", "sentence": "The detection rate of EGFR mutation positive status among patients with evaluable tumour samples was 13.7 % ( 118 out of 859 ) ; 65.1 % of patients with a positive EGFR mutation status had tumours with exon 19 deletions and 31.1 % with @VARIANT$ point mutations . @DRUG$ treatment was started in 107 patients , of whom 106 had activating , sensitising @GENE$ mutations and one had a resistant EGFR mutation .", "label": "sensitivity"}
{"id": "17877814", "sentence": "Images show that @GENE$ @VARIANT$ did not effectively induce phosphorylation of endogenous Akt in MCF-7 cells , and did not relocate into fibrils upon @DRUG$ treatment .", "label": "resistance or non-response"}
{"id": "24472312", "sentence": "T674I @GENE$ is a “gatekeeper” mutation : substitution of the gatekeeper threonine ( T674 ) with a bulky amino acid ( I ) blocks access by imatinib and second-generation tyrosine kinase inhibitors ( TKIs ) , such as nilotinib and @DRUG$ , to a hydrophobic pocket inside the ATP binding site [ ] . This gatekeeper mutation is analogous to the @VARIANT$ mutation in Bcr-Abl [ , ,, ] .", "label": "None"}
{"id": "24944510", "sentence": "Poziotinib ( also known as HM781-36B ) , a new potent irreversible inhibitor of EGFR , HER2 , HER4 , and transient erythroblastopenia of childhood family of kinases inhibitor ( BTK , BLK , and BMX ) , demonstrated preclinical efficacy against @VARIANT$ mutant at eightfold lower doses compared to afatinib . A different approach in addressing EGFR-TKI resistance involves the use of combination regimens . Therefore , the combination of erlotinib with cetuximab , and the combination of @DRUG$ with MM-121 ( a fully human mAb that targets @GENE$ ) , in patients with acquired resistance to EGFR-TKIs did not show sufficient clinical activity for further investigation in this population .", "label": "None"}
{"id": "24009732", "sentence": "Because tyrosine kinase inhibitor sorafenib was effective for imatinib-resistant FIP1L1-PDGFRα @VARIANT$ mutation cells , we also compared the inhibitory effect of DCC-2036 with sorafenib in the @GENE$ cells .", "label": "None"}
{"id": "24069582", "sentence": "Hershman et al. Phase II NCT00930579 Metformin 35 Women with early invasive breast cancer or DCIS Measurement of effects on @GENE$ fasting serum insulin levels Harris et al. Phase III NCT01266486 Metformin 40 Participants with locally advanced breast cancer IHC analysis of effects on phosphorylation of @VARIANT$ , 4E-BP-1 , and AMPK Han et al. Phase II NCT01589367 Metformin vs. placebo in @DRUG$ and no letrozole arms 208 Postmenopausal women with stage I/II ER-positive breast cancer Clinical response rate at 24 weeks and comparison with RECIST 1.1 at baseline", "label": "None"}
{"id": "24025253", "sentence": "The patient presented with metastatic disease ( stage IV ) and received FOLFOX with @DRUG$ as standard of care treatment , however they exhibited disease progression on this regimen . Genetic analysis revealed that these colon tumors expressed the mutant activated form of @GENE$ , @VARIANT$ .", "label": "sensitivity"}
{"id": "24367701", "sentence": "This @GENE$ to the endoplasmic reticulum and has been shown to play a critical role in @DRUG$ ( RIG-I ) gene signaling , acting as a sensor of RNA virus infection [ ] . In fact , many elements of the regulatory pathways governing both the RIG-I pathway and IFN gene expression are themselves regulated by IFN . In turn , IFN may coordinate the upregulation of antiviral factors , as revealed by the A3G , @VARIANT$ , TRIM , tetherin and MxA mRNA expression levels in paired maternal blood and CB samples .", "label": "None"}
{"id": "24065105", "sentence": "In experiments in lung cancer cells devoid of p53 , overexpression of the oncomorph @VARIANT$ @GENE$ enhances resistance to both etoposide and @DRUG$ [ ] .", "label": "None"}
{"id": "21931717", "sentence": "Receptor Agonist/ Tastant @VARIANT$ Receptor ligand Denatonium Benzoate 0.05–10 mM Y R* , H* 0.01–10 mM , , , Phenylthiourea 0.05–5 mM Y H* 2–5 mM Quinine @GENE$ 0.05–1 mM Y R* 0.0082–250 mM , TRPV1 Receptor Agonist Capsaicin 0.01–0.3 mM Y S 0.04–0.4 mg/kg , Resiniferatoxin 1 µM , 10 µM N S 0.1–1000 µg/kg , , , Cytotoxic Cytotoxic/DNA Damage ? ? 5-Fluorouracil 250 µM N F , R,S , H_35–100 mg/kg – Actinomycin D_10 µM , 700 µM N D , R 0.13–0.25 mg/kg , Cisplatin 50 µM , 300 µM N F , D,R , S, H 3–20 mg/kg , , – Cycloheximide 5 mM N F , D 20 mg/kg @DRUG$ 50 µM , 250 µM N S , H 80 mg/kg , Streptozotocin 1 µM N H_14–27 mg/kg – Vincristine 1 µM N R 0.1–1 mg/kg", "label": "None"}
{"id": "23606169", "sentence": "These samples were found not to carry mutations in KRAS codons 12 and 13 ; however , the patients , after @DRUG$ treatment and a short remission ( 2 months ) , had new metastasis . Finally , three additional controls were added to our study : the HT29 cell line was included as an internal control for the @VARIANT$ @GENE$ mutation and KRAS WT .", "label": "resistance or non-response"}
{"id": "17973572", "sentence": "After the cells were exposed to @DRUG$ for 24 h , Ba/F3-L858R cells were unable to proliferate while Ba/F3-L858R-L747S and @GENE$ cells continued to grow even in the presence of 1 μM gefitinib ( E ) . These results suggest that execution of apoptosis may be impaired by the presence of T790M and , to a lesser extent , @VARIANT$ .", "label": "None"}
{"id": "16173832", "sentence": "In the case of our patient , the patient received no prior systemic chemotherapy , and we identified an initial gefitinib sensitizing L858R @GENE$ mutation , followed by a @VARIANT$ mutation concomitantly with L858R in the biopsy taken from the growing tumor nine months after @DRUG$ use .", "label": "resistance or non-response"}
{"id": "21785682", "sentence": "Most of the mutations are in frame deletions in exon 19 and a point mutation in exon 21 ( @VARIANT$ ) [ ] . A deletion between codons 746 and 750 accounts for 65–75.5 % of the deletions in exon 19 [ ] . Erlotinib and @DRUG$ are compounds that reversibly inhibit the tyrosine kinase activity of @GENE$ and have been employed in the treatment of patients with NSCLC .", "label": "sensitivity"}
{"id": "25162713", "sentence": "Many evidences showed that patients with advanced lung adenocarcinomas harbor @GENE$ mutations , @VARIANT$ missense mutations at exon 21 or deletions in exon 19 were more sensitive to the EGFR-TKI @DRUG$ or gefitinib , , .", "label": "sensitivity"}
{"id": "19707304", "sentence": "The majority of activating mutations are of 3 dominant types , deletions in exon 19 , insertions in exon 20 or a single point mutation @VARIANT$ . More recent data have focused on patients with known mutations in @GENE$ who initially respond and subsequently become resistant to @DRUG$ .", "label": "sensitivity"}
{"id": "23493838", "sentence": "@GENE$ ( wild-type mutation ) @DRUG$ IC50 value ( nM ) Wild-type 41.61 Location of mutation P loop L248V 147.4 @VARIANT$ 179.2 Q252H 33.67 Y253F 40 E255K 394 E255V 230.1", "label": "None"}
{"id": "19707322", "sentence": "Nilotinib is approximately 30-fold more sensitive than imatinib in the killing of BCR-ABL dependent cells derived from patients with CML ( K562 and Ku-812F cells ) and cell lines ( 32D and baF3 ) , and it is active against 32/33 imatinib-resistant cell lines with @GENE$ mutations . The sensitivity of Bcr-Abl mutants to AMN107 can be summarized into 4 categories : high ( IC50 ≤ 70 nmol/L : M244V , G250E , Q252H , F3llL , F317L , M351T , V379I , L387M , H396P , H396R ) , medium ( IC50 ≤ 200 nmol/L : Y253F , E255K , F359V ) , low ( IC50 ≤ 450 nmol/L : Y253H , E255V ) , and insensitive ( IC50 & gt ; 2 μmol/L : @VARIANT$ ) ( ) ( ) .", "label": "None"}
{"id": "24223798", "sentence": "In particular , @GENE$ kinase inhibitors ( EGFR-TKIs ) , such as gefitinib and @DRUG$ , have been developed as a novel treatment option for patients with non–small cell lung cancers ( NSCLCs ) that possess somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene – . Prospective clinical trials of EGFR-TKI treatment in NSCLC patients with activating EGFR mutations , such as delE746-A750 ( exon 19 ) and @VARIANT$ ( exon 21 ) , have demonstrated high clinical response rates of approximately 80 % – .", "label": "sensitivity"}
{"id": "23788917", "sentence": "These substitutions were reported for the first time in NSCLC patients with progression , bearing activating mutations , after @DRUG$ therapy . In vitro cultures of cell lines harbouring the @VARIANT$ substitution showed slightly more resistance to @GENE$ TKI than cells with wild type EGFR .", "label": "None"}
{"id": "22436374", "sentence": "@DRUG$ ( BIBW 2992 , Boehringer Ingelheim GmbH ) , an irreversible dual inhibitor of EGFR and @GENE$ kinases , retains some activity in tumors with @VARIANT$ mutations although at doses that are a log higher than what is needed for cancers with only a sensitizing mutation [ ] .", "label": "None"}
{"id": "20190765", "sentence": "B PC9 cells expressing either @VARIANT$ @GENE$ ( left panel ) or L858R/T790M EGFR ( right panel ) were exposed to indicated concentrations of @DRUG$ ( E ) or dasatinib ( D ) for 24 hr. Protein lysates were transferred to membranes and probed with indicated antibodies .", "label": "sensitivity"}
{"id": "24894453", "sentence": "Dimerization impairing cis mutations in @GENE$ , L704N and I941R , significantly reduced the ability of the cetuximab-sensitive @VARIANT$ and G724S mutants to promote colony formation upon retroviral transduction ( Figure", "label": "sensitivity"}
{"id": "25197630", "sentence": "The active form , hypophosphorylated Rb , blocks entry into S-phase by inhibiting the @VARIANT$ transcriptional program [ , ] . In summary , the effects of 1α,25 @DRUG$ @DRUG$ @DRUG$ @DRUG$ on myoblast proliferation remain inconclusive .", "label": "None"}
{"id": "23493883", "sentence": "Some data suggest that patients with EGFR exon 19 deletions are more susceptible to the activity of reversible EGFR-TKIs compared to those with the exon 21 @VARIANT$ mutation. , Further studies then compared first-generation @GENE$ ( @DRUG$ and gefitinib ) to chemotherapy in patients with EGFR activating mutations in advanced NSCLC .", "label": "sensitivity"}
{"id": "25429239", "sentence": "Other amino acid substitutions observed include G1269A , @VARIANT$ , and S1206Y substitutions , as well as a 1151 threonine insertion . Another described resistance mechanism involves amplification of the @GENE$ fusion gene and activation of other bypass mechanisms.– KIT gene amplification and EGFR activation have also been reported as mechanisms of acquired @DRUG$ resistance. , ,", "label": "resistance"}
{"id": "23691449", "sentence": "Some of the molecular mechanisms of acquired resistance include T790M second mutation , mesenchymal epithelial transition factor ( MET ) amplification , ATP binding cassette (ABC)-G2 transporter ( @GENE$ ) and hepatocyte growth factor (HGF) overexpression , insulin-like growth factor (IGF) binding protein-3 ( IGFBP3 ) downregulation , as well as ERBB3 activation . T790M mutation The @VARIANT$ second mutation accounts for half of all resistances to gefitinib and @DRUG$ [ ] .", "label": "None"}
{"id": "24106980", "sentence": "@VARIANT$ family members play an important role in the control of gene expression in several phases of the cell cycle and in multiple checkpoints . Their targets are diverse and cover genes controlling DNA replication and G1/S transitions , such as Cyclin A/E , Cdc6 , and Mcms , as well as products involved in DNA repair and G2/M transitions , such as Cdc25a , Cdk1 , Aurora-A and Survivin [ ] . In our previous study , E2F3 is also found to be a direct target of miR-200b , and inhibition of @GENE$ , which led to E2F3 overexpression , contributed to resistance of lung adenocarcinoma cells to @DRUG$ [ ] ( ) .", "label": "None"}
{"id": "22586398", "sentence": "In addition , no support was found for interactions between @GENE$ A2AR , or A1 and mGlu5 , suggesting this reduction in @DRUG$ self-administration and alcohol seeking behavior was specific to a functional interaction between @VARIANT$ and mGlu5 receptors ( Adams et al. , , ) .", "label": "None"}
{"id": "19547661", "sentence": "BRAF ( v-raf murine sarcoma viral oncogene homolog B1 ) , a serine/threonine kinase , is the downstream effector of KRAS in the @GENE$ signaling pathway . A somatic mutation ( @VARIANT$ ) in exon 15 of BRAF has been identified in multiple human cancers with a mutation rate of 66 % in malignant melanomas [ ] and at lower frequency in other human carcinomas . Recently , it was demonstrated that wildtype BRAF is required for the response of patients with metastatic colorectal cancer to @DRUG$ and panitumumab [ ] .", "label": "None"}
{"id": "24832107", "sentence": "@GENE$ xenografts represent a radioresistant model , attributed to increased BCL-2 transcription [ ] . A375 is a human derived melanoma cell line harboring a BRAF mutation due to the substitution of valine for glutamic acid at codon 600 , termed @VARIANT$ resulting in constitutive activation , aggressive proliferation , and high BCL-2 expression . The tumor growth curves for control ( saline ) , PNT2258 , @DRUG$ , or rituximab as single agents or combination treatments are presented in the left panels , with overall survival shown in the corresponding right panels .", "label": "None"}
{"id": "25486409", "sentence": "10.1371/journal.pone.0114000.g003CX-4945 enhanced the efficacy of @GENE$ to overcome drug resistance caused by @VARIANT$ . Cells were treated with CX-4945 ( 5 µM ) , gefitinib ( 1 µM ) , and erlotinib ( 1 µM ) or a combination of CX-4945 and gefitinib or CX-4945 and @DRUG$ for 48 h .", "label": "resistance or non-response"}
{"id": "23986642", "sentence": "This is reflected by the inhibition of in vitro tyrosine kinase activity of ABL and @VARIANT$ mutant ABL with a half maximal inhibitory concentration ( IC50 ) of 0.4 nM and 2.0 nM , respectively . @DRUG$ also inhibits the in vitro activity of additional oncogenic kinases with IC50 between 0.1 nM and 20 nM , including members of the vascular endothelial growth factor receptor ( VEGFR ) , PDGFR , @GENE$ ephrin receptor , Src family kinases , c-Kit , RET , TIE2 , and FLT3 .", "label": "None"}
{"id": "23937717", "sentence": "Therapeutic significance of our finding is that administration of @DRUG$ may offer a novel adjuvant strategy to enhance NK cells based immunotherapy in NSCLC with @GENE$ L858R + @VARIANT$ resistance mutation .", "label": "resistance or non-response"}
{"id": "21605429", "sentence": "Lastly , knowledge of the predictive and prognostic value of mutational status could lead physicians to establish the dose of imatinib , identify those patients who would not benefit from imatinib treatment ( @GENE$ exon 18 @VARIANT$ mutant tumors are @DRUG$ resistant ) , chose a second line therapy , and evaluate the different risk of relapse during follow-up .", "label": "resistance or non-response"}
{"id": "17551677", "sentence": "A phase I dose escalation study was conducted in Japanese patients in order to test the efficacy of @GENE$ , an oral EGFR inhibitor . Preliminary data were recently published that show that this agent has clinical activity in 2 patients with advanced NSCLC with EGFR mutations and acquired @DRUG$ resistance [ ] . Finally , a recent retrospective analysis of IDEAL trial specimens does not find any @VARIANT$ mutations in the tumours analysed [ ] .", "label": "None"}
{"id": "17927446", "sentence": "This change leads to substitution of methionine for threonine at position 790 ( @VARIANT$ ) and is associated with acquired resistance to @DRUG$ and erlotinib [ ] . Sensitivity of @GENE$ Lung Adenocarcinoma Cell Lines to Erlotinib", "label": "resistance or non-response"}
{"id": "21333004", "sentence": "According to recent reports , the sensitivity to kinase inhibition reflects intrinsic differences in the binding affinity of the EGFR mutants such as L858R , @VARIANT$ , and exon19 deletions [ , - ] . Yun et al [ ] showed that @DRUG$ directly binds more tightly to the L858R mutant than to the wild type EGFR in vitro , while Fabian et al [ ] indicated that EGFR with gefitinib sensitive mutations does not differ from wild type @GENE$ in terms of gefitinib binding affinity .", "label": "sensitivity"}
{"id": "24959087", "sentence": "A final mechanism of resistance in gastric cancer cell lines has been demonstrated when MET amplified SNU6838 gastric cancer cell lines were treated with the @GENE$ inhibitors PHA-665752 and PF2341066 ; a novel mutation occurred in the activation loop of MET , causing a conformal change that blocked inhibitor binding analogous to the gatekeeper mutations seen in EGFR ( @VARIANT$ ) following @DRUG$ treatment and in ABL ( T315I ) following imatinib .", "label": "None"}
{"id": "21165163", "sentence": "The @VARIANT$ mutation results in alteration of the topology of the ATP binding pocket not only interrupting the physicochemical binding of gefitinib/erlotinib , but also leading to much increased affinity of the EGFR protein to ATP resulting in resistance to @GENE$ [ ] .", "label": "resistance or non-response"}
{"id": "24944510", "sentence": "Poziotinib ( also known as HM781-36B ) , a new potent irreversible inhibitor of EGFR , HER2 , HER4 , and transient erythroblastopenia of childhood family of kinases inhibitor ( BTK , BLK , and BMX ) , demonstrated preclinical efficacy against @VARIANT$ mutant at eightfold lower doses compared to afatinib . A different approach in addressing EGFR-TKI resistance involves the use of combination regimens . Therefore , the combination of erlotinib with cetuximab , and the combination of @DRUG$ with MM-121 ( a fully human mAb that targets HER3 ) , in patients with acquired resistance to @GENE$ did not show sufficient clinical activity for further investigation in this population .", "label": "resistance or non-response"}
{"id": "23238683", "sentence": "Cell lines were incubated for 48h with increasing concentrations of imatinib , dasatinib or @DRUG$ and cell viability was assessed using the XTT assay . We first investigated the effect of these ITKs on the viability of murine Ba/F3 cells , carrying wild type ( WT ) @GENE$ , @VARIANT$ or G250E-BCR-ABL mutation .", "label": "response"}
{"id": "24410791", "sentence": "Second generation @GENE$ TKIs e.g. , BIBW 2992 ( @DRUG$ ) and PF00299804 ( dacomitinib ) , and third generation EGFR TKIs e.g. , CO-1686 and AZD9291 are irreversible inhibitors that could overcome the AR caused by @VARIANT$ .", "label": "response"}
{"id": "24634705", "sentence": "An in vitro model of EML4-ALK with the @VARIANT$ mutation showed that the cells were still dependent on @GENE$ mediated signaling for tumor maintenance but are resistant to ALK inhibition [ , ] . Several other drugs have shown activity in inhibiting mutations induced by @DRUG$ and are in various stages of pre-clinical and clinical testing [ ] .", "label": "resistance"}
{"id": "23723712", "sentence": "In the LUX-Lung 2 Phase II trial , @DRUG$ showed activity in the treatment of patients with advanced lung ADC with @GENE$ mutations , especially in patients with deletion 19 or @VARIANT$ mutation .", "label": "sensitivity"}
{"id": "22384074", "sentence": "Malic enzyme activity was also inhibited by SNP treatment , which , together with malate dehydrogenase , is involved in reoxidation of the NADH produced during glycolysis under partial aerobic conditions where @GENE$ is inhibited . These results highlight that energy metabolism is highly impaired by NO , leading to a decrease in the levels of their end-products – @DRUG$ and ATP – and maybe in the redox potential . These results also correlate with high glucose-6-phosphate ( @VARIANT$ ) , fructose-6-phosphate ( F6P ) and dihydroxyacetone-phosphate ( DHAP ) concentrations in NO-treated trophozoites ; these accumulated metabolites are intermediates of reactions upstream of PFOR in the glycolytic pathway .", "label": "None"}
{"id": "24894453", "sentence": "Furthermore , these results are consistent with our model that @GENE$ variants that are dependent on dimerization can be inhibited by @DRUG$ . Dimerization disruption has effects on the transforming activity of @VARIANT$ and G724S EGFR proteins .", "label": "sensitivity"}
{"id": "23515752", "sentence": "The H1975 and H820 cell lines had @GENE$ @VARIANT$ mutations in exon 20 , associated with gefitinib and @DRUG$ resistance .", "label": "resistance or non-response"}
{"id": "19707322", "sentence": "Furthermore , @DRUG$ ( like imatinib and dasatinib ) do not overcome the @GENE$ mutation , which may drive the majority of acquired resistance cases to these compounds . Strategies to override resistance mediated by the @VARIANT$ mutation represent the next major goal in the targeted treatment of CML. Compounds such as VX-680 , an aurora kinase inhibitor , capable of binding to and inhibiting kinase activity of the T315I-Bcr-Abl mutation , are very encouraging .", "label": "None"}
{"id": "19597551", "sentence": "NIH3T3 @DRUG$ Microtubule stabilization With spindle – No 2C 80 % n = 57 Without spindle - Yes_2D 20 % n = 57 NIH3T3 Cyclin B1-DM Metaphase/Anaphase arrest Close to spindle – No Far from spindle - Yes 3 @VARIANT$ 100 % n = 64 20 % n = 64 Cyclin B1 DM +Nocodazole Metaphase/Anaphase arrest+ Microtubule depolymerization Yes S5B 92 % n = 135 NIH3T3 Monastrol Monopolar spindles due to Eg5 inhibition and lack of @GENE$ separation No 89 % n = 65", "label": "None"}
{"id": "22076124", "sentence": "L1196M represents a mutation of the “gatekeeper” residue , similar to the @VARIANT$ gefitinib-resistance mutations observed in EGFR , and T315I mutations in ABL . Mutations in the gatekeeper site are thought to increase the affinity for ATP significantly , outcompeting the effects of ATP competitive inhibitors [ ] . The effect of the C1156Y mutation is unclear , although it may have an indirect effect on @DRUG$ binding , and further studies will be required to establish its mechanism . A number of @GENE$ inhibitors that are able to inhibit ALK variants with “gatekeeper” mutations at L1196M have been developed .", "label": "None"}
{"id": "22933967", "sentence": "In our retrospective study , 26.7 % of patients , all with KRAS wild-type tumours , who had previously unresectable liver-only metastases , underwent surgical resection after systemic therapy , with R0 resection achieved in 38 patients ( 21.6 % ) ; one of those was patient with the @GENE$ @VARIANT$ mutation . Although it is difficult to make any comparison , because our patients were not selected according to specific systemic therapy , these results are comparable with those reported in previous studies claiming that 19 to 23 % patients treated with bevacizumab- and irinotecan based chemotherapy and with previously unresectable liver-only metastases underwent resection.– In a recently published clinical study BOXER , where the patients with unresectable liver-only metastases were treated with oxaliplatin , capecitabine and @DRUG$ , R0 resection was achieved in 40 % of patients .", "label": "sensitivity"}
{"id": "17973572", "sentence": "After the cells were exposed to @DRUG$ for 24 h , Ba/F3-L858R cells were unable to proliferate while @GENE$ and Ba/F3-L858R-T790M cells continued to grow even in the presence of 1 μM gefitinib ( E ) . These results suggest that execution of apoptosis may be impaired by the presence of T790M and , to a lesser extent , @VARIANT$ .", "label": "None"}
{"id": "16255777", "sentence": "This drug was designed as a specific inhibitor of the BCR-ABL oncogene @GENE$ known to be responsible for chronic myeloid leukemia ( CML ) cells [ ] . The therapeutic effectiveness of @DRUG$ and relative absence of detrimental side-effects has made it a model for the development of an array of new therapeutic agents targeted to inhibit signal transduction enzymes , especially protein kinases . The recent discovery that 60–70 % of human melanomas have activating mutations in B-Raf ( with 80 % of these mutations caused by a single substitution @VARIANT$ ) make this protein kinase an especially promising target for inhibition [ , ] .", "label": "None"}
{"id": "25222836", "sentence": "EGFR TKi EGFR TK domain Resistance mutation , e.g. @VARIANT$ ● erlotinib MET amplification ● @DRUG$ @GENE$ amplification", "label": "resistance or non-response"}
{"id": "25033171", "sentence": "The energetic difference between @GENE$ and WT-ROS1 are shown in panel C ( ΔΔG = ΔGG2032R−ΔGWT , a positive ΔG indicates a weaker binding affinity in the mutated protein , and a negative ΔG indicates a stronger binding affinity ) , where the residue Leu18 ( on the P-loop region ) contributes the most to the attenuated binding of @DRUG$ to G2032R mutated ROS1 , indicating that the P-loop conformation governs the binding of crizotinib .", "label": "resistance"}
{"id": "25382104", "sentence": "As shown in , DB07107 and DB06977 showed better docking scores than existing drugs while others showed results comparable to those of marketed drugs like ponatinib , bosutinib , bafetinib , @DRUG$ , nilotinib and imatinib . In the case of DB06977 , although one H_bond is missing ( Met318 ) with the wild-type of @GENE$ complex compared to @VARIANT$ mutant type , it still exhibits a favorable binding score of −10.94 kcal/mol .", "label": "None"}
{"id": "15736989", "sentence": "For example , @DRUG$ is effective in treatment of chronic myelomonocytic leukemia with gene rearrangements that constitutively activate PDGFRB [ ] , of hypereosinophilic syndrome with activating mutations in @GENE$ [ ] , and of gastrointestinal stromal cell tumors associated with activating mutations in KIT [ ] ( all reviewed in [ ] ) . More recently , this paradigm has been extended to treatment of non-small cell lung cancer ( NSCLC ) . Several mutations have been identified in the context of epidermal growth factor receptor (EGFR) in patients with NSCLC that are associated with clinical response to the small-molecule EGFR inhibitors gefitinib ( Iressa ) or erlotinib ( Tarceva ) [ , , ] , including in-frame deletions such as del L747–E749 ; @VARIANT$ in exon 19 , or L858R in exon 21 .", "label": "None"}
{"id": "22655263", "sentence": "In vivo efficacy was described only for the @VARIANT$ gatekeeper mutation , confirming a higher potency with respect to @DRUG$ in inhibiting the in vivo growth of @GENE$ driven Ba/F3 cells .", "label": "resistance"}
{"id": "23232076", "sentence": "The deletion of the four amino acid sequence ( del 746–750 ) in the exon 19 and the substitution of leucine by arginine at codon 858 ( @VARIANT$ ) in exon 21 are two of the most common mutations in the kinase domain of @GENE$ gene in NSCLC patients [ ] . The small-molecule tyrosine kinase inhibitors including @DRUG$ and erlotinib have recently been approved for the treatment of patients with NSCLC [ , - ] .", "label": "sensitivity"}
{"id": "21188109", "sentence": "Cyclin D1 , in association with cyclin dependent kinase-4 and -6 , induces the cell to enter the S phase by phosphorylating the retinoblastoma tumor suppressing protein , which binds to transcription factors , including @VARIANT$ . In addition to the overexpression of cyclin D1 , other genes that overexpress in MCL , such as VEGF and Raf-1 , represent further possible targets for mTOR inhibitors . Indeed , a constitutive activation of Akt and mTOR pathways either in MCL cell lines ( Granta 519 , Jeko-1 , and SP-53 ) or in primary cultures from 30 % of MCL patients has been reported. , Moreover , mTOR inhibitors in MCL could synergize with other “canonical” agents , such as @DRUG$ , doxorubicin , bortezomib , and rituximab , with resulting inhibition of Raf-1 , @GENE$ , and mTOR . ,", "label": "None"}
{"id": "19920910", "sentence": "The pattern of resistance to nilotinib and @DRUG$ differed ; those with greatest resistance to nilotinib ( Y253H and E255V ) were susceptible to dasatinib . @VARIANT$ remained resistant to all the three drugs . In vivo experiments with CML xenografts in mice demonstrated that nilotinib treatment , compared with treatment with vehicle , improved survival of mice infused with either wild type @GENE$ or the imatinib-resistant Bcr-Abl mutant ( E255V ) ( ; ) .", "label": "None"}
{"id": "23927433", "sentence": "Infiltrate of mature lymphoid cells ( hematoxylin & amp ; eosin , H/E ) , which stained for CD20 ( B cell marker ) , DBA44 and @VARIANT$ BRAF ( HCL markers ) . Histology and immunohistology were performed according to standard diagnostic procedures . The severely neutropenic patient was supported with both G-CSF and @GENE$ and underwent ambulatory chemotherapy with the purine analog 2-CDA ( 2-Chlorodeoxyadenosine , @DRUG$ , cladribine ) according to a schedule of 0.1 mg/Kg IV once per week for 4 to 6 weeks .", "label": "None"}
{"id": "25431951", "sentence": "However , the development of acquired resistance to @DRUG$ has emerged , most often due to point mutations in the ATP binding sites ( e.g. T674I and D842V in PDGFRα , @VARIANT$ in @GENE$ , D816V in KIT ) [ - ] .", "label": "None"}
{"id": "21333004", "sentence": "The @DRUG$ effect was simulated by multiplying the kinetic parameter of k3 ( the rate constant for the forward reaction of @GENE$ phosphorylation ) . The multiplying coefficient α is given by α = ( k3 ) / ( k3 in EGFR-WT model or @VARIANT$ models ) .", "label": "sensitivity"}
{"id": "23852704", "sentence": "However , adjuvant @DRUG$ was not recommended for patients with primary GISTs containing @GENE$ @VARIANT$ mutations .", "label": "resistance or non-response"}
{"id": "23696845", "sentence": "The construct NTS1-GW5-Δi3 ( here referred to as @GENE$ ) consists of the hemagglutinin signal peptide and the Flag tag , , followed by the stabilized rat neurotensin receptor NTS1-GW5 ( T43-K396 containing the mutations A86L , E166A , G215A , L310A , @VARIANT$ , V360A ) with the intracellular loop 3 residues G275-E296 deleted . A deca-histidine tag was present at the C-terminus .", "label": "None"}
{"id": "23788917", "sentence": "Inhibition of phosphorylation by @GENE$ tyrosine kinase in tumour cells after afatinib exposure remains active for 48 hours ( after @DRUG$ only 8 hours ) , and phosphorylation activity of the kinase after that time ranges from 50 to 70 % of the primary activity . In vitro studies and some case reports have shown that afatinib is effective ( cell apoptosis and disease stabilisation ) in cells harbouring the @VARIANT$ mutation in NSCLC patients [ , – ] .", "label": "resistance or non-response"}
{"id": "23326482", "sentence": "( A ) Ba/F3-wt . @GENE$ , -M351T und –T315I cells were incubated with @DRUG$ ( IM ) , Nilotinib ( NILO ) , Dasatinib ( DASA ) or Danusertib ( DANU ) for 24 hours .", "label": "None"}
{"id": "17973572", "sentence": "To prove the functional significance of the @VARIANT$ mutation , we generated Ba/F3 cell lines stably expressing mutant EGFR constructs [ ] . These cell lines , including L858R-L747S , proliferated in the absence of IL3 . Ba/F3-L858R cells were extremely sensitive to gefitinib ( D ) , whereas @GENE$ cells were highly resistant up to 1 μM @DRUG$ .", "label": "None"}
{"id": "22721004", "sentence": "This is due to point mutations in the @GENE$ kinase domain , including the most frequent T315I and @VARIANT$ mutations [ , ,, ] . Second-generation tyrosine kinase inhibitors , such as @DRUG$ , dasatinib and bosutinib are capable of targeting the majority of imatinib-resistant mutations , but none of them are effective against leukemia cells harboring the T315I mutation [ - ] .", "label": "None"}
{"id": "19680652", "sentence": "@GENE$ mutation tests were available in four patients , in whom three of them were positive for point mutation in exon 21 ( L858R and @VARIANT$ ) and one was negative . At the time of initiation of gefitinib treatment , most of the patients were in good performance status ( & gt ; 90 % in ECOG 0 or 1 ) . Gefitinib was prescribed at standard dosage of 250 mg daily and @DRUG$ at 150 mg daily .", "label": "None"}
{"id": "16187797", "sentence": "Sensitivity of Cell Transformation Induced by Expression of Mutant @GENE$ Characterized by Missense Mutation or Exon 19 Deletion , but not Exon 20 Insertion , to @DRUG$ and Erlotinib ( A ) Anchorage independent growth of clonal NIH-3T3 cells transformed with mutant EGFR or EGF stimulated wild-type EGFR treated with the indicated concentrations of erlotinib immediately prior to suspension in soft agar . Transformation induced by expression of @VARIANT$ , G719S , and L747_E749del A750P EGFR , but not EGF stimulated wild-type EGFR or D770_N771insNPG EGFR , was inhibited by 0.1 μM erlotinib .", "label": "sensitivity"}
{"id": "22034911", "sentence": "@VARIANT$ may therefore stabilize an active conformation that is both more oncogenic and less favored for @DRUG$ binding . This screen has several potential limitations . @GENE$ cells in vitro are unlikely to faithfully recapitulate the cellular context of ALK-driven primary human tumors .", "label": "None"}
{"id": "23986642", "sentence": "In addition to BCR-ABL , @DRUG$ inhibits other oncogenic kinases including the @GENE$ family kinases , c-Kit , and platelet derived growth factor receptors ( PDGFR ) . Nilotinib inhibits kinase targets including BCR-ABL , PDGFR , and c-Kit , but not the Src family kinases . While the first and second-generation TKIs have demonstrated improved outcomes in patients with CML and Ph+ ALL , resistance still occurs in a subset of patients who harbor BCR-ABL mutations , particularly the @VARIANT$ mutant .", "label": "None"}
{"id": "24244612", "sentence": "Functional in vitro analyses of mutational and non-mutational TKI-resistance of @GENE$ ALL have relied on leukemic cell lines , given the lack of cell culture models using primary ALL cells . We employed the 6 ALL-LTC without TKD mutations described above to determine whether the cells differed in their innate responsiveness to the clinically available TKI imatinib , dasatinib and @DRUG$ , facilitating further studies of non-mutational resistance . The presence of the @VARIANT$ mutation in KÖ cells was associated with resistance to all three TKI , as described above .", "label": "None"}
{"id": "22191026", "sentence": "The investigated @GENE$ sensitive mutations included G719C , @VARIANT$ , G719A , L858R , L861Q , and exon 19 deletions , as well as a gefitinib-resistant mutation , T790M .", "label": "sensitivity"}
{"id": "24367701", "sentence": "This @GENE$ to the endoplasmic reticulum and has been shown to play a critical role in @DRUG$ ( RIG-I ) gene signaling , acting as a sensor of RNA virus infection [ ] . In fact , many elements of the regulatory pathways governing both the RIG-I pathway and IFN gene expression are themselves regulated by IFN . In turn , IFN may coordinate the upregulation of antiviral factors , as revealed by the @VARIANT$ , A3F , TRIM , tetherin and MxA mRNA expression levels in paired maternal blood and CB samples .", "label": "None"}
{"id": "21333004", "sentence": "Overexpression of wild type EGFR induced high and sustained phosphorylation of EGFR , Shc , MEK ( mitogen activated protein kinase kinase ) and ERK ( extracellular signal regulated kinase ) , while the @VARIANT$ mutation reduced these response levels . In addition , H1299L858R , which is supposed to be more sensitive to @DRUG$ than @GENE$ , was effectively inhibited by gefitinib administration at the downstream part of the signaling pathway ( MEK and ERK ) compared with H1299EGFR-WT , but , surprisingly , not at the upstream part of the pathway ( EGFR and Shc ) .", "label": "sensitivity"}
{"id": "23227361", "sentence": "The gatekeeper mutant displayed higher affinity for ATP , providing a potential explanation for resistance to the reversible TKI @DRUG$ . In contrast , irreversible TKIs CL-387785 and WZ-4002 bound irreversibly to an active conformation of HER2 and suppressed @GENE$ signaling and growth in stable clones of wild-type or mutant T798M , L755P , or @VARIANT$ HER2 [ ] .", "label": "resistance or non-response"}
{"id": "23788917", "sentence": "The role of rare mutations in exon 20 such as @VARIANT$ and V769L in development of acquired resistance to @GENE$ TKI is still unknown . These substitutions were reported for the first time in NSCLC patients with progression , bearing activating mutations , after @DRUG$ therapy .", "label": "None"}
{"id": "24991413", "sentence": "Mass-spectrometry genotyping ( Sequenom ) revealed no known mutations that affect the gene encoding serine-threonine protein kinase BRAF ( e.g. , the @GENE$ @VARIANT$ mutation ) . Three weeks later , the patient began treatment with @DRUG$ ( 3 mg/kg ) .", "label": "None"}
{"id": "23055691", "sentence": "Patients who had progressed on erlotinib or gefitinib were given afatinib and @DRUG$ , a monoclonal antibody against @GENE$ . Approximately 94 % of patients , regardless of @VARIANT$ mutation status , had a partial response or stable disease .", "label": "response"}
{"id": "24124608", "sentence": "In addition to upregulation of IGF1R and VEGF , frequent CN gain and increased mRNA expression of GSTT1 as well as significant overexpression of @GENE$ subfamily members were observed in wild-type/PDGFRA @VARIANT$ GISTs compared to KIT-mutant GISTs . CN gain of GSTT1 was closely associated with @DRUG$ resistance .", "label": "None"}
{"id": "23776354", "sentence": "Moreover , the @VARIANT$ @GENE$ mutation , classically resistant to @DRUG$ , confers also a sunitinib resistance in vitro .", "label": "resistance or non-response"}
{"id": "24894453", "sentence": "FDA approved @GENE$ targeted inhibitors include the low-molecular-weight ATP-competitive kinase inhibitors , such as gefitinib and @DRUG$ , and humanized monoclonal antibodies directed against the extracellular domain , notably cetuximab and panitumumab [ ] . Although high-level expression of EGFR ligands and/or increased EGFR gene copy numbers may be predictive markers for antitumor response by cetuximab in colon cancer [ - ] , and patients with RAS driven cancers are known not to benefit from cetuximab treatment , a clear molecular explanation of cancer response to cetuximab has remained elusive . Genomic studies identify @VARIANT$ mutant in colorectal carcinomas", "label": "None"}
{"id": "19238632", "sentence": "Acquired MET amplification was identified to be a potential alternative mechanism to enable the mutant EGFR expressing HCC827 to become secondarily resistant ( HCC827-GR ) without a @VARIANT$ mutation . In the course of our study , reported the presence of MET amplification that occurred independently with and without T790M-EGFR mutation in lung tumours . Interestingly , another recent report adopted a global phosphoproteomic approach using cell lines sensitive to @DRUG$ ( HCC827 ) and sensitive to SU11274 ( MKN45 ) , and showed that besides @GENE$ inhibition , gefitinib also inhibited p-MET ( that is indeed constitutively activated ) in HCC827 , but not vice versa ( ) .", "label": "resistance or non-response"}
{"id": "23994953", "sentence": "Prospective trials have demonstrated an impressive ~75 % response rate for patients whose tumors harbor these mutations , which occur as either multinucleotide in-frame deletions in exon 19 ( e.g. , delE746-A750 ) or as single missense mutations ( e.g. , @VARIANT$ ) . Unfortunately , the @GENE$ TKI-driven improvement in patient outcome is notably limited because virtually all NSCLC patients with erlotinib/gefitinib sensitizing EGFR mutations eventually acquire resistance after a median of 6–12 months of EGFR TKI therapy .", "label": "sensitivity"}
{"id": "25053989", "sentence": "( B) PI3K and @GENE$ pathway markers were assessed after 21 days of treatment . Five tumors are represented in each group . ( C ) SW48 @VARIANT$ resistant ( clone 10A ) tumor bearing mice were treated orally and daily with vehicle ( 0.5 % methylcellulose , 0.2 % tween-80 + 7.5 % captisol ) , 75 mg/kg GDC-0941 , 25 mg/kg @DRUG$ , or GDC-0941 and erlotinib in combination .", "label": "None"}
{"id": "15737014", "sentence": "This study revealed that the quinazoline rings of erlotinib and @DRUG$ interact differently with the EGFR kinase domain , suggesting that while the @VARIANT$ mutation may affect inhibition by erlotinib and gefitinib , it may not affect inhibition of @GENE$ by compounds similar to lapatinib .", "label": "None"}
{"id": "20500904", "sentence": "LY294002 was from Calbiochem , U0126 from Promega , PHA-665752 from Tocris Bioscience , @DRUG$ from Sequoia Research Product . The @GENE$ @VARIANT$ vector was kindly provided by Dr. Yarden [ ] .", "label": "sensitivity"}
{"id": "15737014", "sentence": "Collectively , these findings imply that the exon 20 @VARIANT$ mutation was present on the same allele as the exon 21 L858R mutation , and that a subclone of cells harboring these mutations emerged during drug treatment . In patient 2 , the tumor-rich sample obtained prior to treatment with @DRUG$ did not contain any additional mutations in the exons encoding the @GENE$ tyrosine kinase domain ( B , upper panels ; ) .", "label": "resistance or non-response"}
{"id": "15737014", "sentence": "To our knowledge , no NSCLC patient who initially responded to but then progressed on either gefitinib or erlotinib has yet been treated with @DRUG$ . In some of the patient specimens analyzed , the actual sequencing peaks demonstrating the @VARIANT$ mutation were smaller than originally anticipated . These results differ from those of acquired resistance mutation in CML [ ] , GIST [ , ] , and @GENE$ [ ] .", "label": "None"}
{"id": "16187797", "sentence": "del , L747_E749del @VARIANT$ ; ins , D770_N771insNPG ; wt , wild-type EGFR . Sensitivity of Cell Transformation Induced by Expression of Mutant @GENE$ Characterized by Missense Mutation or Exon 19 Deletion , but not Exon 20 Insertion , to @DRUG$ and Erlotinib ( A ) Anchorage independent growth of clonal NIH-3T3 cells transformed with mutant EGFR or EGF stimulated wild-type EGFR treated with the indicated concentrations of erlotinib immediately prior to suspension in soft agar .", "label": "None"}
{"id": "23674887", "sentence": "Preclinical activity of @DRUG$ has been reported against most IM-resistant mutants of @GENE$ with the exception of @VARIANT$ and V299L. ,", "label": "None"}
{"id": "17973572", "sentence": "Transient transfection experiments utilizing COS-7 cells demonstrated that auto-phosphorylation of the original @VARIANT$ EGFR was inhibited by lower concentrations of gefitinib or @DRUG$ than the L858R-L747S or L858R-T790M constructs ( A ) . CL-387,785 partially overcame the observed inhibition ( B ) . To prove the functional significance of the L747S mutation , we generated @GENE$ cell lines stably expressing mutant EGFR constructs [ ] .", "label": "None"}
{"id": "22815900", "sentence": "A , Comparison of the expression of @GENE$ , p-EGFR , HER2 , p-HER2 , HER3 , p-HER3 , PTEN , Akt , p-Akt , ERK1/2 , and p-ERK1/2 in 11–18 , 11–18/GEF10-1 , and 11–18/GEF20-1 cells by western blot analysis . B , Exponentially growing 11–18 , 11–18/GEF10-1 , and 11–18/GEF20-1 cells were exposed to various doses of @DRUG$ for 5 hr , and followed by Western blot analysis . C , Western blots showing expression of @VARIANT$ EGFR protein in 11–18 cells and resistant clones .", "label": "sensitivity"}
{"id": "25285017", "sentence": "In terms of @GENE$ targeted therapy , resistant mechanisms ( eg , EGFR @VARIANT$ mutation and MET amplification ) emerge as a result of the tumor evolution after EGFR inhibition by @DRUG$ or erlotinib .", "label": "resistance or non-response"}
{"id": "24649247", "sentence": "The patient received 4 courses of @DRUG$ based chemotherapy and the response was evaluated as partial . Two months following the completion of chemotherapy , the patient developed dyspnea on exertion due to reaccumulation of left pleural fluid and the cytological pleural fluid specimens showed an @GENE$ mutation ( @VARIANT$ point mutation in exon 21 ) .", "label": "None"}
{"id": "24523812", "sentence": "A prospective study assessed efficacy of discontinuation and re-initiation of @GENE$ in patients with acquired resistance to the drug . The eligible 10 patients had stage IV NSCLC and were treated with gefitinib or @DRUG$ monotherapy for more than 6 months . They had achieved radiographic response before EGFR-TKI failure or documentation of either EGFR exon 19 deletion or an EGFR @VARIANT$ mutation .", "label": "sensitivity"}
{"id": "15737014", "sentence": "In GIST and HES , respectively , the analogous @VARIANT$ mutation in @GENE$ and T674I mutation in PDGFR-alpha have been associated with acquired resistance to this drug [ , ] . To determine whether lung cancers that acquire clinical resistance to either @DRUG$ or erlotinib display additional mutations in the EGFR kinase domain , we have examined the status of EGFR exons 18 to 24 in tumors from five patients who initially responded but subsequently progressed while on these drugs .", "label": "None"}
{"id": "25275314", "sentence": "At the same time , the backbone NH of @GENE$ forms an HB interaction with the side chain carboxylate of the PKA residue Glu170 ; this interaction is conserved when Arg19 is changed by other amino acids in all the studied mutants . shows that the side chain groups of the mutated residues Lys and the protonated histidine at position 19 of the WT substrate ( in mutants @VARIANT$ and R19Hp ) also form HB interactions with the side chain carboxylate group of the PKA residue Glu170 , while the mutated residue @DRUG$ δ at the same position 19 ( in mutant R19Hδ ) also forms an HB interaction with the side chain carboxylate group of the PKA residue Glu203 ( ) .", "label": "None"}
{"id": "24348666", "sentence": "It was initially proposed that the T790M mutation might prevent the proper binding of tyrosine kinase inhibitors via steric hindrance , similar to the corresponding gatekeeper mutations in @GENE$ ( T315I ) and KIT ( T670I ) that confer resistance to imatinib ( Gleevec ) in chronic myelogenous leukemia and in patients with gastrointestinal stromal tumors . Interestingly , it was discovered that the @VARIANT$ mutation does not confer resistance to gefitinib and @DRUG$ by preventing their binding as originally thought .", "label": "None"}
{"id": "24223799", "sentence": "We studied two NSCLC model cell lines which showed either upregulation ( H2170 ) or downregulation ( H358 ) of @GENE$ and downregulation p-c-Met ( H2170 and H358 ) . Resistant cells did not display either the @VARIANT$ or D761Y mutations , suggesting the use of an alternative signaling mechanism to overcome @DRUG$ susceptibility .", "label": "resistance or non-response"}
{"id": "24386407", "sentence": "Taken together , these findings indicated that the Met inhibitor crizotinib plus a new generation EGFR-TKI , either @DRUG$ or WZ4002 , circumvented resistance to HGF in an autocrine manner , in the presence or absence of the @GENE$ @VARIANT$ mutation or Met gene amplification .", "label": "response"}
{"id": "16187797", "sentence": "@GENE$ is constitutively phosphorylated in cells expressing mutant EGFR . del , L747_E749del @VARIANT$ ; ins , D770_N771insNPG ; wt , wild-type EGFR . Sensitivity of Cell Transformation Induced by Expression of Mutant EGFR Characterized by Missense Mutation or Exon 19 Deletion , but not Exon 20 Insertion , to @DRUG$ and Erlotinib ( A ) Anchorage independent growth of clonal NIH-3T3 cells transformed with mutant EGFR or EGF stimulated wild-type EGFR treated with the indicated concentrations of erlotinib immediately prior to suspension in soft agar .", "label": "None"}
{"id": "24052078", "sentence": "In addition , previous reports showed the presence of signaling cross-activation between MET and EGFR in both A549 and H1975 cells , and both the @VARIANT$ mutation of EGFR and c-Met amplification are known mechanisms of acquired gefitinib ( TKI ) resistance in lung cancer . As c-Met has a critical role in NSCLC , co-treatment with a c-Met inhibitor plus a reversible or irreversible EGFR kinase inhibitor ( i.e. , to achieve dual c-Met @GENE$ inhibition ) may represent an alternative strategy to circumvent T790M-EGFR mediated resistance in lung cancer . Here , we report for the first time that erlotinib/MPT0E028 co-treatment inhibits HER-2 , IGF-IR , and c-Met in erlotinib-resistant lung cancer cells .", "label": "resistance or non-response"}
{"id": "25058005", "sentence": "Activating mutations such as exon 21 missense point mutation @VARIANT$ and in-frame deletions in exon 19 are the most commonly studied predictive biomarkers of response to @GENE$ ( gefitinib and @DRUG$ ) , .", "label": "sensitivity"}
{"id": "23994953", "sentence": "@VARIANT$ and MET amplification , which can be detected in up to 20 % of @GENE$ NSCLCs secondarily refractory to EGFR TKIs , account for approximately 60–70 % of all known causes of acquired resistance to gefitinib/erlotinib .", "label": "resistance or non-response"}
{"id": "20190765", "sentence": "cDNA for @VARIANT$ EGFR and L858R/T790M EGFR were provided by Dr. William Pao ( Vanderbilt University , Nashville , TN ) , ACK was provided by Dr. Nupam Mahajan ( Moffitt Cancer Center , FL ) , and Human BRK was purchased from ORIGENE ( Rockville , MD ) . Lentiviral plasmids containing WT and gatekeeper SRC , FYN , LYN , LCK , ABL , DDR1 , FRK , EphB1 , EphA2 and @GENE$ were generously provided by Dr. Jinyan Du and Dr. Todd Golub ( The Broad Institute , MA ) . @DRUG$ was provided by OSI Pharmaceuticals ( Melville , NY ) and dasatinib by Bristol-Myers Squibb ( New Brunswick , NJ ) .", "label": "None"}
{"id": "23407898", "sentence": "The irreversible TKI BIBW 2992 ( @DRUG$ ) is currently being investigated in advanced clinical trials ( Yap et al. , ; Murakami et al. , ) . Another novel irreversible pan-HER inhibitor HM781-36B has recently shown promise in the inhibition of @GENE$ , HER2 , and HER4 as well as against the gatekeeper mutation – EGFR @VARIANT$ that is responsible for acquired drug resistance in lung cancer patients ( Cha et al. , ) .", "label": "response"}
{"id": "23109866", "sentence": "The first-generation of reversible @GENE$ TKIs usually generated resistance within one-year of treatment [ ] prompting the development of a second-generation ( ) . The second-generation TKIs may overcome resistance to the treatment of erlotinib or @DRUG$ via the @VARIANT$ gatekeeper mutation .", "label": "resistance or non-response"}
{"id": "25295230", "sentence": "@VARIANT$ AML @DRUG$ Smith et al. ( ) @GENE$ AML AC220 Albers et al. ( ) Ba/F3 AML ( pediatric ) Sorafenib Baker et al. ( )", "label": "None"}
{"id": "24419415", "sentence": "Our group has undertaken a randomized phase 3 trial to compare @DRUG$ plus carboplatin plus pemetrexed with gefitinib monotherapy for patients with NSCLC with an exon 19 deletion or an L858R , G719X , or @VARIANT$ EGFR mutation ( NEJ009 ; University Hospital Medical Information Network Clinical Trials Registry [ @GENE$ ] number , UMIN000006340 ) .", "label": "None"}
{"id": "24884501", "sentence": "BRAF mutations ( @VARIANT$ ) were present in 12 % of the tumors . The mutational frequencies of the 195 KRAS mutations in the NORDIC VII cohort were ; G12A ( 9.7 % ) , G12R ( 1.5 % ) , G12D ( 35.4 % ) , G12C ( 9.7 % ) , G12S ( 6.2 % ) , G12V ( 15.4 % ) , and @GENE$ ( 22.1 % ) . @DRUG$ did not add significant benefit to Nordic FLOX and KRAS mutation was not predictive for cetuximab effect .", "label": "None"}
{"id": "23569389", "sentence": "BCR-ABL1 mutations were detected in 160 of 363 patients ( 44 % ) , with @VARIANT$ and T315I mutants being the most frequently found . No differences in overall response rate were observed in patients with @GENE$ mutations at baseline , in particular for p-loop mutations . A subanalysis was conducted by Branford et al on the emergence of new detectable mutations in 479 patients treated with @DRUG$ after imatinib failure , and development of new mutations , including T315A , F317L , and V299L , was rare ( 13 % ) .", "label": "None"}
{"id": "24419415", "sentence": "In contrast to @DRUG$ , irreversible TKIs inhibited the growth of cells with @VARIANT$ or L861Q at a lower concentration than those with wild-type @GENE$ .", "label": "None"}
{"id": "25465236", "sentence": "( G–I ) increased inhibition potency for Gefitinib against @GENE$ L858R mutant compared to EGFR WT protein and subsequent further increase in potency for @DRUG$ against EGFR L858R + E884K double mutant . ( J ) EGFR L861Q activated more than @VARIANT$ but less than L858R .", "label": "resistance or non-response"}
{"id": "25580271", "sentence": "When cross-over to @GENE$ tyrosine kinase inhibitor therapy was examined , 75 % of patients who received @DRUG$ and pemetrexed received an EGFR tyrosine kinase inhibitor and 56 % of patients who received cisplatin and gemcitabine received an EGFR tyrosine kinase inhibitor . The rate of second-line EGFR tyrosine kinase inhibitors in countries with insurance coverage was 91 % and without insurance coverage was 52 % . Overall survival of patients with common EGFR mutations ( defined as exon 19 deletion and exon 21 @VARIANT$ point mutation ) in LUX-3 , LUX-6 , and combined cohorts [ ]", "label": "None"}
{"id": "21042543", "sentence": "Di Nicolantonio et al also demonstrated that introduction of the B-RAF @VARIANT$ allele could confer resistance to either @DRUG$ or panitumumab in wild-type @GENE$ colorectal cancer cells .", "label": "resistance or non-response"}
{"id": "11355953", "sentence": "Comparison of paired cell lines expressing the P-glycoprotein (Pgp) multidrug transporter ( K562 and @VARIANT$ , 8226 and 8226/Dox40 ) reportedly failed to demonstrate Pgp mediated alterations in drug sensitivity ( Schlege et al , 1999 ) . Likewise , examination of a flavopiridol-resistant ovarian cancer line revealed no cross-resistance to the @GENE$ substrates paclitaxel , etoposide or @DRUG$ ( Bible et al , 2000 ) , suggesting that Pgp does not play a role in flavopiridol resistance of this particular cell line .", "label": "None"}
{"id": "23610714", "sentence": "Mutational analysis is helpful in detecting the development of secondary mutations in tumors that are responding poorly to tyrosine kinase inhibitors and in identifying the @GENE$ exon 18 codon @VARIANT$ missense mutation , which is associated with a good prognosis , but conversely confers resistance to imatinib. , Exon 9 is reported to benefit from a high dose ( 800 mg/day ) of @DRUG$ in some studies .", "label": "resistance or non-response"}
{"id": "23527257", "sentence": "@DRUG$ ( BIBW 2992 , Boehringer Ingelheim GmbH ) , is an irreversible inhibitor of both @GENE$ , HER2 and HER4 kinases and retains some activity in tumors with @VARIANT$ mutations , but at doses that are a log higher than what is needed for cancers harboring sensitizing mutations , , , , , .", "label": "response"}
{"id": "25382104", "sentence": "To compare their efficacy and binding pattern with our screened compounds we again docked FDA approved drugs with wild-type of @GENE$ . As shown in , DB07107 and DB06977 showed better docking scores than existing drugs while others showed results comparable to those of marketed drugs like ponatinib , bosutinib , bafetinib , dasatinib , nilotinib and @DRUG$ . In the case of DB06977 , although one H_bond is missing ( Met318 ) with the wild-type of BCR-ABL complex compared to @VARIANT$ mutant type , it still exhibits a favorable binding score of −10.94 kcal/mol .", "label": "None"}
{"id": "23606169", "sentence": "These samples were found not to carry mutations in KRAS codons 12 and 13 ; however , the patients , after @DRUG$ treatment and a short remission ( 2 months ) , had new metastasis . Finally , three additional controls were added to our study : the HT29 cell line was included as an internal control for the @VARIANT$ BRAF mutation and KRAS WT . Then two KRAS controls ( @GENE$ 8 with the G12D mutation and Ctrl 9 with the G13D mutation found previously by the TheraScreen® : K-RAS Mutation Kit for the detection of seven mutations ( by DxS Diagnostic Innovations ) [ ] .", "label": "None"}
{"id": "23787070", "sentence": "Ponatinib ( @DRUG$ ) an orally active @GENE$ Tyrosine Kinase Inhibitor effective against the @VARIANT$ mutation had been approved for a phase II clinical trial [ ] .", "label": "response"}
{"id": "20190765", "sentence": "After overnight incubation , cells were infected with 30μl of viruses per well for 48 hours , and then treated with a series dilution of @DRUG$ for 5 days for CellTiter-Glo cell viability assay . Stable cell lines such as EGFR T790M or @VARIANT$ PC9 cell lines were generated by blasticidin selection two weeks after @GENE$ T790M or L858R lentivirus infection .", "label": "None"}
{"id": "24959087", "sentence": "Further evidence of the efficacy of combination therapy in overcoming resistance is demonstrated by NSCLC cell lines resistant to erlotinib and the MET inhibitor SU11274 , which display upregulation of both mTOR ( @GENE$ and Wnt pathway components and restoration of sensitivity to EGFR/MET inhibition by the addition of @DRUG$ . A final mechanism of resistance in gastric cancer cell lines has been demonstrated when MET amplified SNU6838 gastric cancer cell lines were treated with the MET inhibitors PHA-665752 and PF2341066 ; a novel mutation occurred in the activation loop of MET , causing a conformal change that blocked inhibitor binding analogous to the gatekeeper mutations seen in EGFR ( T790M ) following erlotinib treatment and in ABL ( T315I ) following imatinib . Although the MET @VARIANT$ mutation renders cancers insensitive to type I MET inhibitors , conformal differences between these and type II compounds may allow treatment of MET Y1230H mutant cancers or prevent the emergence of resistance due to the mutation. ,", "label": "None"}
{"id": "17973572", "sentence": "Transient transfection experiments utilizing COS-7 cells demonstrated that auto-phosphorylation of the original L858R EGFR was inhibited by lower concentrations of @DRUG$ or erlotinib than the L858R-L747S or L858R-T790M constructs ( A ) . CL-387,785 partially overcame the observed inhibition ( B ) . To prove the functional significance of the @VARIANT$ mutation , we generated @GENE$ cell lines stably expressing mutant EGFR constructs [ ] .", "label": "None"}
{"id": "24991762", "sentence": "mTORC1 controls cell growth and translation through the phosphorylation of ribosomal protein S6 kinase @VARIANT$ and of eukaryotic translation initiation factor 4EBP1 , which regulate either the translation of @GENE$ the cap dependent translation by inhibition of eukaryotic translation initiation factor 4E , respectively. , The activated mTOR pathway has been identified in several human malignancies , thus being an attractive target for anticancer therapy . mTORC1 activity is inhibited by rapalogs such as rapamycin ( sirolimus ) and associated analogs ( temsirolimus/CCI-779 , RAD001 , ridaforolimus/AP23573 ) .", "label": "None"}
{"id": "25091415", "sentence": "Cells bearing mutant @GENE$ proteins show oncogenic properties but typically also exhibit enhanced sensitivity toward inhibitors than the wild-type ( WT ) EGFR protein . @DRUG$ , the most common TK inhibitor ( TKI ) , blocks signal transduction pathways implicated in cancers . NSCLC patients who initially respond to TKIs but eventually results in acquired drug resistance by the initiation of secondary mutation @VARIANT$ .", "label": "resistance or non-response"}
{"id": "17973572", "sentence": "Based on the data obtained from lung cancer cell lines , we further explored the mechanisms by which T790M and @VARIANT$ resistant mutations affect BIM up-regulation and apoptosis . @DRUG$ effectively induced apoptosis in Ba/F3-L858R cells , whereas Ba/F3-L858R-L747S cells were intermediately resistant and @GENE$ completely resistant ( A , top ) .", "label": "None"}
{"id": "25364578", "sentence": "Lazzara and colleagues found that SHP2 Y542 phosphorylation was not induced in response to EGF in the H3255 cells , which harbor the missense @VARIANT$ exon 21 mutation , suggesting that @GENE$ activity may be less efficiently promoted by EGFR L858R and the STAT3 pathway may be more active . The main problem is that STAT3 activation is not abrogated by single EGFR TKI treatment with gefitinib , @DRUG$ , afatinib or dacomitinib , - .", "label": "None"}
{"id": "18974832", "sentence": "( B ) Murine BM cells transduced with unmutated BCR-ABL and single point mutation @VARIANT$ , E255K , and T315I genes were tested for the effectiveness of 1R-Chl ( 125 nM to 1000 nM ) , 1S-Chl ( 500 nM and 1000 nM ) , imatinib ( 500 nM and 5000 nM ; IC50 = 260 nM for the native @GENE$ transduced cells ) , and @DRUG$ ( 10 nM and 100 nM ; IC50 = 0.8 nM for the native BCR-ABL transduced cells ) .", "label": "None"}
{"id": "23696715", "sentence": "A recent study compared the effect of four TKIs ( axitinib , @DRUG$ , vandetanib , and XL184 ) on cell proliferation , RET autophosphorylation , and extracellular signal regulated kinase activation in three cell lines : MZ-CRC-1 ( @VARIANT$ RET mutation ) , MTC-TT ( C634W RET mutation ) , and TPC-1 ( @GENE$ rearrangement ) cells .", "label": "None"}
{"id": "25091415", "sentence": "Therefore , to elucidate the structural and dynamic consequences of the DM on the catalytic domain of EGFR and its affinity toward @DRUG$ , we performed molecular dynamic simulations ( 50 ns ) of the wild type ( WT ) @GENE$ and three oncogenic mutants : G719S , @VARIANT$ , and DM in complex with gefitinib .", "label": "resistance or non-response"}
{"id": "25250341", "sentence": "Three initial base models were compared : model 1 contained only environmental factors , including the type of platinum , baseline Scr , smoking status , coadministration of @DRUG$ , and the number of chemotherapy cycles ; model 2 contained only genetic factors , including @GENE$ Arg72Pro and ERCC1 @VARIANT$ ; and model 3 contained both genetic and environmental factors .", "label": "None"}
{"id": "25032006", "sentence": "Survival for CML-CP patients with the @VARIANT$ point mutation treated with TKIs is estimated to be reduced by 50 % compared with patients without the T315I mutation ( median survival of 22 months vs. more than 10 years for TKI-responsive CML patients ; Nicolini et al. , 2009 ) . Additionally , omacetaxine has been shown to potentiate the effects of @DRUG$ and nilotinib by overcoming cytokine rescue of @GENE$ leukemic cells thought to be mediated primarily by interleukin-3 ( Allan , Holyoake , Craig , & amp ; Jorgensen , 2011 ; Klag et al. , 2012 ) , offering promising new options for combination therapies .", "label": "None"}
{"id": "18974832", "sentence": "( B ) Murine BM cells transduced with unmutated BCR-ABL and single point mutation Y253H , @VARIANT$ , and T315I genes were tested for the effectiveness of 1R-Chl ( 125 nM to 1000 nM ) , 1S-Chl ( 500 nM and 1000 nM ) , imatinib ( 500 nM and 5000 nM ; IC50 = 260 nM for the native @GENE$ transduced cells ) , and @DRUG$ ( 10 nM and 100 nM ; IC50 = 0.8 nM for the native BCR-ABL transduced cells ) .", "label": "None"}
{"id": "18645621", "sentence": "@VARIANT$ is mainly present in relapsed tumors after an initial response and secondary to @GENE$ therapy , , and it accounts for about half of acquired resistance to @DRUG$ or elotinib .", "label": "resistance or non-response"}
{"id": "24594844", "sentence": "Both cDzT and @DRUG$ alone inhibited growth and signaling in @GENE$ @VARIANT$ mutant cells ( H1975TM/LR and CL97TM/GA ) , albeit through different mechanisms .", "label": "response"}
{"id": "19503843", "sentence": "In the superfamily of phosphotransferases , the conserved residues that form a corresponding motif ( DXG in actin , GTG in hexokinase/glycerol kinase , and @GENE$ in acetate and propionate kinases ) are observed to be present in binding to a- and b-phosphate groups of the nucleotide . We used site directed mutagenesis to construct two mutants ( see ) : one in which the @DRUG$ at position H247 was changed to a glutamine ( @VARIANT$ ) , and the other in which the glycine at position G392 was changed to alanine ( G392A ) .", "label": "None"}
{"id": "23696715", "sentence": "Similar results were found in another clinical trial with @DRUG$ at the same doses . Of the 15 patients with disseminated MTC treated for up to 12 months , four patients had SD over 24 months . A recent study compared the effect of four TKIs ( axitinib , sunitinib , vandetanib , and XL184 ) on cell proliferation , RET autophosphorylation , and extracellular signal regulated kinase activation in three cell lines : MZ-CRC-1 ( M918T RET mutation ) , MTC-TT ( @VARIANT$ RET mutation ) , and TPC-1 ( @GENE$ rearrangement ) cells .", "label": "None"}
{"id": "22970367", "sentence": "One possibility is that the T790M mutation could lead to altered drug binding in the ATP pocket of EGFR in a manner analogous to the effects of the @VARIANT$ mutation in the @GENE$ kinase in the context of @DRUG$ resistance [ ] .", "label": "None"}
{"id": "24009732", "sentence": "@VARIANT$ FIP1L1-PDGFRα , analogous to T315I Bcr-Abl in CML , is also resistant to the second-generation TKIs , such as nilotinib . Novel agents for imatinib-resistant @GENE$ are needed .", "label": "None"}
{"id": "17973572", "sentence": "It is possible to conceive that an increase in the clinical doses of gefitinib or switching to @DRUG$ , which is given at its maximal tolerated dose [ ] , may lead to beneficial clinical effects , possibly by increasing BIM expression , in patients with @GENE$ mutations who acquired L747S after exposure to gefitinib . The data presented here indicate that BIM is both a marker and an effector of TKI induced apoptosis in EGFR-mutant NSCLC cells . Furthermore , we identified a novel acquired EGFR secondary mutation , L747S , and showed that both the L747S and the common T790M in cis to an activating EGFR mutation ( either @VARIANT$ or an exon 19 deletion ) cause resistance to EGFR TKI induced apoptosis and attenuate the up-regulation of BIM .", "label": "sensitivity"}
{"id": "24944510", "sentence": "@GENE$ ( such as gefitinib or @DRUG$ ) treatment of lung-cancer harboring EGFR gene mutation is one of the prototypes of such therapies . Several clinical trials clearly demonstrated that progression-free survival of patients treated with EGFR-TKI therapy is significantly longer than that of those treated by conventional platinum doublet chemotherapy.– EGFR-TKI therapy dramatically changed the paradigm of lung cancer treatment . Which strategy is better in the management of advanced NSCLCs – the inhibition of mutated EGFR with TKIs ( @VARIANT$ mutation increases tyrosine kinase affinity for TKIs ) or a combined approach with cetuximab ( an anti-EGFR monoclonal antibody ) plus first-line chemotherapy – is yet to be determined .", "label": "sensitivity"}
{"id": "23710459", "sentence": "Finally , Shin and coworkers engineered the S. cerevisiae strain ( W303-1A ) with four heterologous genes , the PAL gene from Rhodosporidium toruloides , the @VARIANT$ and the 4CL1 genes from A. thaliana , and the STS gene from Arachis hypogea [ ] . Overexpression of the acetyl-CoA carboxylase ( ACC1 ) gene for increasing the pool of @GENE$ resulted in an engineered strain termed W303-1A/ACC1 harboring the p425PAL , p423C4H , and pESCTRP4CL1-STS plasmids capable of synthesizing 5.8 mg/L @DRUG$ upon feeding with 12 mM tyrosine in YP medium containing 2 % galactose .", "label": "None"}
{"id": "20531963", "sentence": "The point mutation @VARIANT$ of the @GENE$ gene and MET amplification are known to be involved in the majority of cases of acquired resistance to @DRUG$ .", "label": "resistance or non-response"}
{"id": "24790411", "sentence": "Compared to erlotinib and gefitinib , afatinib shows lower EC50 values and greater potency against wild type ( afatinib vs @DRUG$ vs gefitinib : 60 nM vs 110 nM vs 157 nM ) and L858R mutated @GENE$ ( afatinib vs erlotinib vs gefitinib : 0.7 nM vs 40 nM vs 5 nM ) . Moreover , afatinib is able to inhibit the kinase activity in vitro and in animal models when a resistant @VARIANT$ mutation is concomitant to a sensitivity mutation .", "label": "resistance or non-response"}
{"id": "23785245", "sentence": "Most NSCLC patients who harbor activating EGFR mutations , including deletions in exon 19 or the point mutation @VARIANT$ in exon 21 , experience an initial marked response to the EGFR-TKIs gefitinib or @DRUG$ . However , almost all such individuals eventually develop acquired resistance to these drugs within 1 year . In addition , 20 % –30 % of NSCLC patients with EGFR mutations do not show an initial response to EGFR-TKIs. , , Therapeutic strategies to overcome EGFR-TKI resistance in NSCLC patients with EGFR mutations have been developed on the basis of the biological mechanisms of such resistance , which include a T790M secondary mutation in EGFR as well as amplification of the gene for the receptor tyrosine kinase MET , which serves as the receptor for @GENE$", "label": "None"}
{"id": "22093436", "sentence": "Combination of chemotherapy and/or new monoclonal antibody that overcomes CTLA-4 mediated T-cell suppression ( @DRUG$ ) improved overall survival [ , ] . Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the @GENE$ @VARIANT$ mutation [ ] .", "label": "None"}
{"id": "25505694", "sentence": "The lack of efficacy could probably be related to the high concentrations of neratinib required in preclinical studies to inhibit EGFR @VARIANT$ and the limitations of clinical dosing . Dacomitinib Dacomitinib is an irreversible EGFR , @GENE$ and HER4 inhibitor with a higher kinase inhibition than gefitinib/erlotinib in both gefitinib/erlotinib-sensitive and in EGFR-T790M and HER2 mutated cell lines [ ] .", "label": "None"}
{"id": "20098681", "sentence": "The equilibrium binding constant ( KD ) , which has an inverse relationship to the affinity of various peptides to the Aβ40 fibrils , was the highest for rodent Aβ40 @VARIANT$ , Y10F , H13R followed by Aβ40H13R , Aβ40 , @GENE$ , and Aβ40 H13 , 14G . The results from SPR studies demonstrate that whether Aβ40 is in a monomeric or randomly oriented structure , removal of the imidazole side chain from @DRUG$ at position 13 and 14 results in increased affinity when it interacts with the β-sheet Aβ40 fibrils .", "label": "None"}
{"id": "16187797", "sentence": "Tumors from patients with clinical responses to the @GENE$ inhibitors gefitinib or @DRUG$ have been shown to contain EGFR deletion mutations or substitution mutations [ , ,, ] , but no exon 20 insertion mutations have been reported in this group of clinical responders . Although exon 20 mutations were not widely reported at first , recently five large-scale studies that sequenced EGFR exons 18 through 21 reported a total of 18 exon 20 insertions out of 350 EGFR mutations identified in 1,108 non-small-cell lung cancers [ – ] . Patients who responded to gefitinib and subsequently relapsed were found to have @VARIANT$ secondary mutations , also in exon 20 [ , ] .", "label": "resistance or non-response"}
{"id": "24092989", "sentence": "Another critical serine-threonine protein kinase involved in the @GENE$ pathway that has been targeted to block its constitutive kinase activation is BRAF . , BRAF mutation ( V600E ) is reported in 24 % of papillary derived ATC . Preclinical and clinical studies investigating combination therapy with agents such as selective ( PLX4032 ) and potent ( @DRUG$ ARQ 736 ) small-molecule BRAF inhibitors , and MAP/ERK kinase inhibitors ( AZD6244 ) hold great promise in the treatment of BRAF ( @VARIANT$ ) ATC . , ,", "label": "None"}
{"id": "19680652", "sentence": "An acquired @GENE$ mutation ( @VARIANT$ ) has been reported to occur upon failure of gefitinib and is also predictive of resistance to @DRUG$ [ , ] .", "label": "resistance or non-response"}
{"id": "22192147", "sentence": "Conversely , the presence of @GENE$ activating mutations is highly predictive of response to treatment with @DRUG$ or erlotinib [ , ] . These mutations are usually exon 19 deletions and the @VARIANT$ substitution in exon 21 , as well as , rarely , exon 18 mutations .", "label": "sensitivity"}
{"id": "24643470", "sentence": "@DRUG$ also shows activity against cancers resistant to first-generation EGFR inhibitors due to certain activating EGFR mutations , secondary @GENE$ mutations such as @VARIANT$ or tumours expressing other ErbB family receptors activated by drug induced reprogramming of signalling pathways .", "label": "response"}
{"id": "20300583", "sentence": "BRAF d 5′-TGC TTG CTC TGA TAG @GENE$ AAT-3′ r 5′-CTG ATG GGA CCC ACT CCA T-3′ Overview of the clinical patient data . 20 of 21 patients show concordance of the KRAS ( exon 2 , Gly 12/13 ) and BRAF ( exon 15 , @VARIANT$ ) mutation status between samples of primary CRCs and/or corresponding metastases before and after combined @DRUG$ therapy .", "label": "None"}
{"id": "24555578", "sentence": "However , because of the technical limitation of fixation of formalin of an autopsy case , we could not extract adequate deoxyribonucleic acid ( DNA ) to investigate their @GENE$ mutation status . Other types of resistance , such as met amplification and/or HGF overexpression , have different effects on brain metastases . Although these limitations exist , the different distribution of the cancer cells that had acquired the @VARIANT$ mutation primarily explains the different response to @DRUG$ observed between the intracranial and extracranial sites in this case .", "label": "resistance or non-response"}
{"id": "19238210", "sentence": "Depending on the previously determined in vitro threshold for @DRUG$ and the bimodal curve we classified our NSCLC cell lines into 3 categories : sensitive , intermediate and resistant . We had nine sensitive cell lines which included seven of the 10 @GENE$ mutant cell lines , one cell line with EGFR CNG and one with HER2 CNG . Of the remaining 3 EGFR mutant cell lines , two had the resistance associated secondary @VARIANT$ mutation .", "label": "resistance or non-response"}
{"id": "21333004", "sentence": "As a result , the combination of a lower k3 ( the rate constant for the forward reaction of the EGFR phosphorylation ) and k8 ( the rate constant for the forward reaction of binding of EGFR to Shc ) contributed to effectively inhibit the total phosphorylation of @GENE$ in the presence of @DRUG$ ( Figure ) . The values in each panel indicate RShc/RERK calculated by using the values of parameters in @VARIANT$ model A for two changing parameters and those in EGFR-WT model for two unchanging parameters .", "label": "None"}
{"id": "25538894", "sentence": "In the LUX-lung 1 trial , @DRUG$ had a significant longer PFS in comparison with placebo , but showed no improvement of OS . For neratinib , a phase II trial showed disappointing results ( ) and the dacomitinib data showed possible benefit in patients with erlotinib resistance ( ) , but further investigations are necessary . In preclinical studies , third-generation @GENE$ inhibitors ( WZ4002 and CO-1686 ) showed hopeful results , with activity against @VARIANT$ mutations and sparing wild-type EGFR ( – ) .", "label": "response"}
{"id": "25051360", "sentence": "Some mutations ( @VARIANT$ ) resulted in @DRUG$ resistance ; however this was not an activating mutation . All of the cells containing the @GENE$ mutations were sensitive to the irreversible HER2 kinase inhibitor , neratinib [ ] .", "label": "resistance or non-response"}
{"id": "24497964", "sentence": "Thirty-eight patients ( 90 % ) had adenocarcinoma , 34 ( 81 % ) had a good performance status ( Eastern Cooperative Oncology Group 0 ) , and 15 ( 36 % ) received @DRUG$ as first-line chemotherapy . With regard to the type of @GENE$ mutation , 8 patients ( 19 % ) had deletions in exon 19 , 13 ( 31 % ) had the @VARIANT$ missense mutation in exon 21 , and 21 ( 50 % ) had the wild-type EGFR .", "label": "sensitivity"}
{"id": "24729716", "sentence": "This molecular change had been found in samples with gefitinib or @DRUG$ resistance in vivo or in vitro . c-MET amplification has also occasionally been found to coexist with @GENE$ @VARIANT$ mutation .", "label": "resistance or non-response"}
{"id": "23811600", "sentence": "3xFLAG tagged native BCR-ABL and the gatekeeper mutant @VARIANT$ were transfected into 293T cells stably expressing Renilla luciferase-Hsp90 fusion protein . Cells were treated with increasing concentrations of inhibitors for 1 hour prior to cell lysis and the LUMIER assay . Treatment of cells with type II inhibitors imatinib ( b ) and ponatinib ( d ) or type I inhibitor @DRUG$ ( c ) lead to decreased @GENE$ interaction .", "label": "None"}
{"id": "24778999", "sentence": "Due to steric interaction of the kitD816V mutation at the receptor @DRUG$ is effective only in patients with SM lacking this mutation . Indeed it demonstrates in vitro efficacy against wild-type KIT and certain transmembrane ( @VARIANT$ ) and juxta-membrane ( V560G ) @GENE$ mutants , but not the common kinase ( D816V ) domain mutants .", "label": "None"}
{"id": "25054154", "sentence": "We utilised three complexes , namely , native ( ALK-crizotinib ) , F1174L ( @GENE$ F1174L-crizotinib ) , and @VARIANT$ ( ALK R1275Q-crizotinib ) for our analysis .", "label": "sensitivity"}
{"id": "15737014", "sentence": "These results suggest that the @VARIANT$ mutation may impair the ability of gefitinib or @DRUG$ to inhibit EGFR tyrosine kinase activity , even in @GENE$ mutants ( i.e. , L858R or an exon 19 deletion ) that are clinically associated with drug sensitivity .", "label": "resistance or non-response"}
{"id": "22166800", "sentence": "Given that @VARIANT$ and @DRUG$ inhibit the @GENE$ E pathway using independent mechanisms ( ; , ; ) , we considered whether overexpression of cyclin E would cause an enhanced response to combination therapy .", "label": "None"}
{"id": "24533047", "sentence": "Small-molecule EGFR-tyrosine kinase inhibitors ( TKIs ) could competitively block the @GENE$ dependent pathway . In the last decade , a series of RCTs have confirmed the non-inferior efficacy and relatively low toxicity of @DRUG$ and gefitinib in treatment naïve or previously treated NSCLC patients compared with the standard chemotherapy – . Meanwhile , pre planned or post-study biomarker analyses indicated that the presence of EGFR mutation , which mainly refers to deletions in exon 19 or the @VARIANT$ substitution in exon 21 , was the strongest predictor of efficacy for EGFR-TKIs .", "label": "sensitivity"}
{"id": "25414829", "sentence": "The first example of a clinically relevant NSCLC driver oncogene was the identification of somatic mutations in the epidermal growth factor receptor (EGFR) gene ( – ) .Common @GENE$ alterations ( the @VARIANT$ point mutation and exon 19 deletions ) are present in 10–30 % of patients with NSCLC and confer sensitivity to gefitinib , @DRUG$ , and afatinib .", "label": "sensitivity"}
{"id": "24167634", "sentence": "However , the discovery of @GENE$ mutations and the response to EGFR tyrosine kinase inhibitors ( TKIs ) , such as @DRUG$ and erlotinib , deeply changed the management of advanced NSCLC in the last decade [ – ] . Small in-frame deletions in exon 19 and point mutations within exon 21 ( @VARIANT$ ) are the most common EGFR activating mutations both leading to sustained activity of the kinase .", "label": "sensitivity"}
{"id": "23824064", "sentence": "The synergistic anti-proliferative activity of either belinostat or panobinostat combined with either pazopanib or @DRUG$ in the thyroid cancers carrying either RET/PTC1 rearrangement ( BHP2-7 ) , KRAS G12R mutation ( Cal62 ) or BRAF @VARIANT$ mutation ( SW1736 ) is of interest . The mutations in these three lines are important components in the @GENE$ cascade .", "label": "None"}
{"id": "17551677", "sentence": "The appearance of a second mutation represents a mechanism of resistance : in fact the authors demonstrate that the insertion of @VARIANT$ into test cells renders them resistant to @DRUG$ in vitro . They also find that when test cells transfected with both mutations are treated with other @GENE$ inhibitors , such as AG1478 , cetuximab , erlotinib or CL-387,785 , no objective response is obtained using the first three agents , while the fourth is effective .", "label": "resistance or non-response"}
{"id": "15737014", "sentence": "Such mutations rarely , if ever , accompany EGFR mutations and are associated with primary resistance to @DRUG$ or erlotinib [ ] . To evaluate the possibility that secondary @GENE$ mutations confer acquired resistance to these drugs , we performed mutational profiling of KRAS2 exon 2 from tumor specimens from patients 1 to 3 , as well as the three additional patients lacking evidence of the @VARIANT$ mutation .", "label": "None"}
{"id": "24121633", "sentence": "Based on our data , we hypothesized that PRR of hnRNP L binds to PTB and cooperatively suppresses inclusion of exon @VARIANT$ . We thus examined the role of PRR of hnRNP L on the interaction with PTB . Histidine tagged hnRNP L ( His-L ) , its PRR deleted variant ( His-L-ΔPRR ) , histidine tagged hnRNP LL ( His-LL ) , and its PRR inserted variant ( @GENE$ ) were expressed in SH-SY5Y cells , and they were immunoprecipitated with anti-histidine antibody in the presence of RNase .", "label": "None"}
{"id": "23493804", "sentence": "@GENE$ such as @DRUG$ or erlotinib attain a response rate of approximately 70 % and progression-free survival of 9–13 months , although subgroups of patients experience long lasting remission. , Use of EGFR–TKIs as a first-line treatment in patients with advanced NSCLC harboring EGFR mutations improved progression-free survival with acceptable toxicity , compared with standard chemotherapy . EGFR–TKIs are currently considered a standard first-line treatment for this disease entity.– However , these tumors eventually develop resistance to EGFR–TKIs , possibly as a result of a secondary threonine–methionine substitution mutation at position 790 in exon 20 ( @VARIANT$ ) , MET amplification , or hepatocyte growth factor overexpression in relapsed tumors .", "label": "resistance or non-response"}
{"id": "22935382", "sentence": "To explore potential @DRUG$ resistance mechanisms in model EC039 , we screened for mutations in a panel of genes ( EGFR , K-ras , B-raf and PIK3CA ) across all 5 PDECX models and their corresponding patient EC tissues . Screened gene locations included ; exons 18 , 19 , 20 , 21 of EGFR gene , exons 2 and 3 of K-ras gene , exons 11 and 15 of B-raf gene , and exons 9 and 20 of @GENE$ gene . Interestingly , PIK3CA G1624A ( @VARIANT$ ) mutation was identified within exon 9 of the PIK3CA gene helical domain in both EC039 model and the corresponding patient’s EC tissue .", "label": "None"}
{"id": "19654571", "sentence": "For combination experiments , cells were treated as described above , plus 4 h of incubation with @DRUG$ ( 10 μg ml−1 ) , or 1 h of incubation with PD98059 ( 25 μM ) or PD153035 ( 0.1 μM ) alone or combined with cetuximab before the incubation with EGF . As @VARIANT$ cells express low levels of EGFR , more protein was loaded ( 80 μg , as opposed to 50 μg for the other cells ) on the gels to observe the phosphorylation status of the receptor . Primary antibodies against total and phosphorylated EGFR , HER2 , AKT and @GENE$ ( all from Cell Signaling Technology , Beverly , MA , USA ) were used .", "label": "None"}
{"id": "23139670", "sentence": "Furthermore , the biopsy of the breast metastasis revealed the second mutation of resistance to @DRUG$ in the @GENE$ ( @VARIANT$ ) .", "label": "resistance or non-response"}
{"id": "25120654", "sentence": "@GENE$ mutation was positive according to the amplification-refractory mutation system method . ( A ) @VARIANT$ point mutation prior to the use of gefitinib , and ( B ) L858R and T790M point mutations following treatment with @DRUG$ .", "label": "sensitivity"}
{"id": "25110867", "sentence": "These preclinical models suggest that dacomitinib may be quite effective against lung cancer that becomes resistant to @DRUG$ or erlotinib via acquisition of a @VARIANT$ mutation in @GENE$ [ ] .", "label": "resistance or non-response"}
{"id": "22935382", "sentence": "In clinical studies of metastatic colon cancer , patients with wild type K-ras , B-raf and @GENE$ genes gain benefit from cetuximab therapy [ ] , whilst lung cancer patients with mutations in exons 19 and 21 of the EGFR gene benefit from @DRUG$ or Tarceva therapy . These findings suggest that gene mutation ( s ) may play a key role in resistance to Trastuzumab treatment . After screening for EGFR , K-ras , B-raf and PIK3CA gene mutations in the 5 PDECX mouse models and their corresponding primary tumors , we found that model EC039 ( and the corresponding patient tissue ) had a helical domain mutation ( G1624A , @VARIANT$ ) in exon 9 of the PIK3CA gene ( Figure and Table ) .", "label": "None"}
{"id": "22523564", "sentence": "Ba/F3 cells expressing @VARIANT$ F/P resistant to @DRUG$ ( IR ) have been described previously . After obtaining blood from the above mentioned patients , polymorphonuclear leucocytes were separated by standard laboratory procedures . Eosinophils were then separated by depletion of neutrophils with anti-CD16 coated magnetic microbeads using the magnetic cell separation system ( @GENE$ ; Miltenyi Biotec GmbH , Bergisch- Gladbach , Germany ) according to the following method ( http : //www.miltenyibiotec.com/download/datasheets_en/23/DS130_045_701.pdf ) .", "label": "None"}
{"id": "16187797", "sentence": "Sensitivity of Cell Transformation Induced by Expression of Mutant EGFR Characterized by Missense Mutation or Exon 19 Deletion , but not Exon 20 Insertion , to @DRUG$ and Erlotinib ( A ) Anchorage independent growth of clonal NIH-3T3 cells transformed with mutant @GENE$ or EGF stimulated wild-type EGFR treated with the indicated concentrations of erlotinib immediately prior to suspension in soft agar . Transformation induced by expression of @VARIANT$ , G719S , and L747_E749del A750P EGFR , but not EGF stimulated wild-type EGFR or D770_N771insNPG EGFR , was inhibited by 0.1 μM erlotinib .", "label": "sensitivity"}
{"id": "3358916", "sentence": "Immunoblotting shows that all breast tumours analysed contained a cytochrome P-450 form associated with the P-450 @VARIANT$ locus . Isozymes within this locus appear to be invovled in steroid hydroxylations which may relate to hormone homeostasis with the tumour and the metabolism of drugs such as @DRUG$ . The metabolism of 7-ethoxyresorufin ( a marker substrate for @GENE$ could also be detected in these tumours .", "label": "None"}
{"id": "19758442", "sentence": "The region important for interaction with the Cul5 @GENE$ marked in green and includes a conserved histidine-cysteine-cysteine-histidine motif and a suppressor of cytokine signaling Box domain . The scale at the bottom indicates amino acid positions . The structural determination of full-length @VARIANT$ has so far been unsuccessful .", "label": "None"}
{"id": "24884501", "sentence": "@GENE$ mutations ( V600E ) were present in 12 % of the tumors . The mutational frequencies of the 195 KRAS mutations in the NORDIC VII cohort were ; G12A ( 9.7 % ) , G12R ( 1.5 % ) , G12D ( 35.4 % ) , G12C ( 9.7 % ) , G12S ( 6.2 % ) , @VARIANT$ ( 15.4 % ) , and G13D ( 22.1 % ) . @DRUG$ did not add significant benefit to Nordic FLOX and KRAS mutation was not predictive for cetuximab effect .", "label": "None"}
{"id": "24889765", "sentence": "Detailed estimates for the best fitting model are presented in Table , while only the fixed effect parameters are presented for other models specified in Table ( random effects for these models can be found in Additional file : Table @VARIANT$ ) . Model fit indices and comparison of LCS models for total weekly alcohol consumption and mental health in the Whitehall II study Baseline Alcohol → ΔMCS MCS → Δalcohol Reciprocal Age and sex adjusted Fit statistics Log likelihood -146158.161 -146158.041 -146155.151 -146154.760 χ2 ( df ) 274.233 ( 12 ) 273.995 ( 11 ) 268.214 ( 11 ) 267.432 ( 10 ) RMSEA 0.059 0.061 0.061 0.064 AIC 292380.321 292382.083 292376.302 292377.520 @GENE$ BIC 292494.731 292500.068 292494.288 292499.081 CFI 0.982 0.982 0.982 0.982 TLI 0.959 0.955 0.956 0.952 Model comparison ( difference in χ2 fit ( df ) ) Versus baseline – 0.238 ( 1 ) , P = 0.63 6.019 ( 1 ) , P = 0.01 6.801 ( 2 ) , P = 0.03 Versus previous best – – – 0.782 ( 1 ) , P = 0.38", "label": "None"}
{"id": "23515752", "sentence": "H1975 cells ( @VARIANT$ ) were treated with 17-DMAG ( 50 nM ) and @DRUG$ ( 500 nM ) for 24 h. Cells were harvested , lysates made , subjected to Western blotting and probed with antibody against p-Akt ( Ser473 ) , @GENE$ and GAPDH ( loading control ) ( B ) .", "label": "None"}
{"id": "24634705", "sentence": "The D761Y mutation is located on the α-C-helix of EGFR and is similar to a mutation in @GENE$ , D276G , that is associated with acquired resistance after @DRUG$ treatment [ ] . The @VARIANT$ mutation lies at the start of the β3 strand and the α-C-helix [ ] and has analogous residues in BCR-ABL ( L237M ) and ERBB2 ( L755S or P ) that have been identified in TKI resistant disease [ ] .", "label": "None"}
{"id": "21108851", "sentence": "Further clinical studies of @DRUG$ are ongoing , most notably a single-arm phase 2 study in patients with CML or Ph+ acute lymphoblastic leukemia ( ALL ) who either are resistant or intolerant to either dasatinib or nilotinib , or who harbor the @VARIANT$ mutation ( Ponatinib Ph+ ALL and CML evaluation [PACE ] ; NCT01207440 ) . Switch pocket kinase inhibitors , such as DCC-2036 and DCC-2157 , target the sites involved in controlling the conformation of @GENE$ , which ultimately controls the activity state of the kinase .", "label": "response"}
{"id": "23702846", "sentence": "In rat liver epithelial cells , GN4 , peroxisome proliferator activated receptor ligand induced not only the Pyk2-p38 MAPK pathway but also the Y845 phosphorylation induced @GENE$ pathway , the latter of which can be blocked by the application of either PP2 or the antioxidant N-acetyl-l-cysteine , suggesting that Src and ROS are involved in this signaling system [ ] . In the cell proliferation and malignancy of MCF7 and SUM149 breast cancer cells , Src dependent ( i.e. , dasatinib-sensitive ) Y845 phosphorylation ( i.e. , @VARIANT$ mutation-sensitive ) signaling was shown to require the activity of p38 MAPK , but not the activity of the EGFR/kinase ERK/MAPK , as well as Akt [ ] . ROS that are produced by @DRUG$ and nocodazole , both of which disrupt microtubules , have also been reported to promote Y845 phosphorylation in vascular smooth muscle cells , R22 , by which ERK/MAPK signaling is triggered to activate plasminogen activator inhibitor-1 ( PAI-1 ) expression [ ] .", "label": "None"}
{"id": "23493838", "sentence": "A complete hematological response and a major cytogenetic response were observed broadly across the BCR-ABL mutants , including individuals harboring the dasatinib-resistant F317L , the nilotinib-resistant Y253H , and @GENE$ mutations , but not T315I . Nine individuals developed new mutations in the course of @DRUG$ treatment ( V299L , n = 4 ; L248V , n = 2 ; T315I , n = 2 ; F359C , n = 1 ; @VARIANT$ , n = 1 ) and eight of these individuals discontinued bosutinib because of progressive disease or unsatisfactory response .", "label": "None"}
{"id": "24294007", "sentence": "Although a retrospective study and the PICCOLO ( Panitumumab , Irinotecan and Ciclosporin in Colorectal Cancer Therapy ) trial have demonstrated a reduced response to @DRUG$ and panitumumab for patients with NRAS mutations , , further work is required to demonstrate the predictive capacity of these mutations . The serine/threonine-protein kinase B-Raf is an effector in the @GENE$ signaling pathway , downstream of K-Ras . Mutations in the proto-oncogene BRAF are present in 5 % –10 % of the metastatic CRC population and are also mutually exclusive of KRAS mutations . BRAF @VARIANT$ is the most common of all BRAF mutations ( present in 90 % of cases ) , and is enriched in a subset of patients who are female , greater than 70 years of age , with KRAS WT right sided colon cancer .", "label": "None"}
{"id": "16187797", "sentence": "del , L747_E749del @VARIANT$ ; ins , D770_N771insNPG ; wt , wild-type EGFR . Sensitivity of Cell Transformation Induced by Expression of Mutant EGFR Characterized by Missense Mutation or Exon 19 Deletion , but not Exon 20 Insertion , to Gefitinib and @DRUG$ ( A ) Anchorage independent growth of clonal NIH-3T3 cells transformed with mutant EGFR or EGF stimulated wild-type @GENE$ treated with the indicated concentrations of erlotinib immediately prior to suspension in soft agar .", "label": "None"}
{"id": "17877814", "sentence": "Several uncommon @GENE$ mutants identified in the course of this analysis were tested using the YFP-EGFR-ICD assay . Mutations in exon 20 , most notably @VARIANT$ , are usually associated with resistance to @DRUG$ and erlotinib [ reviewed in [ ] ] .", "label": "resistance or non-response"}
{"id": "24618737", "sentence": "One common hypothesis of Cetuximab-resistance is EGFR or downstream molecular mutation within tumor cells , such as acquired @GENE$ ectodomain mutation @VARIANT$ .", "label": "resistance"}
{"id": "25563355", "sentence": "They also have in vitro activity against the @VARIANT$ mutation . Of the second generation EGFR-TKIs , neratinib , dacomitinib and @DRUG$ have been getting more attention recently ( ) . Neratinib ( HKI-272 ) is an oral , irreversible inhibitor of EGFR and @GENE$ [ ] .", "label": "None"}
{"id": "22927847", "sentence": "Downregulation of endogenous miR-100 in @VARIANT$ and SW-13 cells increased protein expression of mTOR , raptor , and IGF-IR [ ] . In order to evaluate the functional consequences of IGF-IR inhibition in adrenal carcinomas , Barlaskar et al. analyzed a large series of benign and malignant human adrenal tumors and a panel of ACC cell lines using a tyrosine kinase inhibitor , NVP-AEW541 , and a fully human monoclonal antibody anti-IGF-IR , @DRUG$ , both specifically targeting @GENE$ .", "label": "None"}
{"id": "23091721", "sentence": "It has been shown that higher levels of AREG and EREG have a positive predictive value in determining response to @DRUG$ , and when treated with cetuximab these tumors have better PFS [ ] . Although attempts at developing drugs targeting KRAS have largely been unsuccessful , several @GENE$ inhibitors have been discovered . Sorafenib is an oral multikinase inhibitor that targets both wtBRAF and oncogenic BRAF @VARIANT$ and has in vitro activity in CRC cell lines with this mutation .", "label": "resistance or non-response"}
{"id": "24495353", "sentence": "Rank Entrez ID Gene symbol Entrez ID Gene symbol Entrez ID Gene symbol 1 28978 TMEM14A 79776 ZFHX4 1727 CYB5R3 2 1843 DUSP1 4701 NDUFA7 7083 TK1 3 51022 GLRX2 715 @VARIANT$ 1292 COL6A2 4 1434 CSE1L 79818 ZNF552 857 CAV1 5 8522 GAS7 4046 LSP1 5437 POLR2H 6 51668 HSPB11 1727 CYB5R3 9833 MELK 7 10456 HAX1 357 SHROOM2 54861 SNRK 8 9902 MRC2 283298 OLFML1 4830 @GENE$ 9 4706 NDUFAB1 23179 RGL1 231 AKR1B1 10 23560 GTPBP4 1809 DPYSL3 10418 SPON1 11 79633 FAT4 857 CAV1 2350 FOLR2 12 10418 SPON1 274 BIN1 10979 FERMT2 13 471 ATIC 79833 GEMIN6 11096 ADAMTS5 14 6403 SELP 11222 MRPL3 4638 MYLK 15 23421 ITGB3BP 23244 PDS5A 9448 MAP4K4 16 23452 ANGPTL2 6241 RRM2 54922 RASIP1 17 54861 SNRK 1289 COL5A1 6934 TCF7L2 18 2034 EPAS1 8434 RECK 4072 EPCAM 19 30008 EFEMP2 429 ASCL1 4701 NDUFA7 20 25999 CLIP3 3426 CFI 404672 GTF2H5 21 4311 MME 332 BIRC5 6241 RRM2 22 4747 NEFL 2 A2M 2192 FBLN1 23 1809 DPYSL3 10730 YME1L1 25959 KANK2 24 28998 MRPL13 11130 ZWINT 55651 NHP2 25 25959 KANK2 1292 COL6A2 5050 PAFAH1B3 Lists of the top 25 of most influential genes in influence networks based on coexpression among genes in ER + breast tumors before , during , and after a course of neoadjuvant treatment with the drug @DRUG$ .", "label": "None"}
{"id": "21194487", "sentence": "after 1st PS Response PFS to 2nd TKI OS from 2nd TKI 1 50 F Current Ad NA 9.8 G→E 7.9 CBDCA+GEM 1 PD 0.9 13.1 2 46 F Never Ad NA 11.8 G→G 4.5 DOC_1 PR 6.4 24.6 3 58 F Ex Ad 19 deletion 38.4 G→G 2.8 DOC_1 SD 7.3 24.1 4 70 F Never Sq NA 10.2 G→E_12.8 GEM 1 SD 1.7 4.3 5 60 F Never Ad NA 13 G→G 5.4 GEM 1 PD_1.6 2.1 6 63 F Never Ad NA 7.4 G→E 2.6 - 3 SD 3.6 7.8 7 52 M Never Ad L858R 5.8 G→E_1 - 4 SD 6.4 6.4 8 51 M Current Ad NA 4.3 G→E_1.6 AMR 3 PD 0.6 0.9 9 61 F Never Ad NA 8.5 G→E 2.3 VNR 3 SD 2.9 4 10 53 F Never Ad NA 12.9 G→E 0 - 4 SD 6.2 7.3 11 54 M Current Ad 19 deletion 3.8 G→E 7.3 VNR 1 SD 3.2 5 Response to the initial gefitinib treatment During the 1st @GENE$ treatment with @DRUG$ , 8 patients achieved PR as the best response ( 73 % , Table ) , and 3 patients ( 27 % ) were SD .", "label": "sensitivity"}
{"id": "24195468", "sentence": "Serum SLX level was elevated to 14 U/mL , while plasma @GENE$ level remained stable ( 102 pg/mL ) . TBLB of the primary tumor was performed again , and only adenocarcinoma with the EGFR @VARIANT$ mutation was detected ( Figure ) . Treatment with @DRUG$ ( 150 mg daily ) was thus started .", "label": "None"}
{"id": "22655263", "sentence": "In vivo efficacy was described only for the @VARIANT$ gatekeeper mutation , confirming a higher potency with respect to @DRUG$ in inhibiting the in vivo growth of ALK–L1196M driven @GENE$ cells .", "label": "None"}
{"id": "23497317", "sentence": "Notably , inhibition of phosphorylation of the @VARIANT$ mutation was significantly reduced compared to the D816Y and D816F isoforms . This observation is not unique to quizartinib – but is in line with previous data for other @GENE$ tyrosine kinase inhibitors , such @DRUG$ @DRUG$ [ ] .", "label": "response"}
{"id": "25562798", "sentence": "This shows how vemurafenib can be beneficial for tumors of one molecular phenotype ( @VARIANT$ mutant ) but potentially adverse for another ( HRAS/NRAS mutant ) . Molecular therapeutics in melanoma are not just restricted to treatments directed at the @GENE$ pathway . In a recent Phase II study of 43 patients with metastatic melanoma with KIT aberrations ( mutation or amplification ) treated with @DRUG$ an overall response rate of 23.3 % was observed [ ] .", "label": "None"}
{"id": "22655263", "sentence": "When tested in Ba/F3 cells driven by @GENE$ mutants identified in @DRUG$ relapsed patients , NMS-E628 is circa fivefold more potent than crizotinib in inhibiting the proliferation of L1196M ALK and @VARIANT$ ALK-driven-cells in vitro and in vivo ( Ardini et al. , ) .", "label": "resistance"}
{"id": "25120654", "sentence": "In conclusion , the current study reports a rare case of lung cancer harboring an L858R point mutation of exon 21 and a compound @VARIANT$ @GENE$ substitution mutation following treatment with @DRUG$ .", "label": "resistance or non-response"}
{"id": "23569389", "sentence": "Dasatinib is active against at least 100 of the BCR-ABL1 mutations known to confer resistance to @DRUG$ that have been tested to date , ( including many in the p-loop region ) , except for the T315I mutation and a few other mutations ( V299L , F317L/V , and @VARIANT$ ) . Dasatinib is able to block downstream intracellular signaling pathways activated by BCR-ABL1 in vitro , including signal transducer and activator of transcription 5 ( Stat5 ) , with downregulation of Stat5 target gene expression and the @GENE$ , Notably , dasatinib is not a substrate of multidrug resistance protein-1 , an efflux protein expressed on normal and leukemic hematopoietic stem cells .", "label": "None"}
{"id": "23690929", "sentence": "HGF induces resistance to irreversible EGFR-TKIs and mutant EGFR-selective TKIs , which were developed to overcome @VARIANT$ mediated EGFR-TKI resistance . Recent clinical trials with irreversible TKI monotherapy failed to demonstrate an objective response in EGFR mutant lung cancer patients that were refractory to treatment with the reversible @GENE$ and @DRUG$ .", "label": "resistance or non-response"}
{"id": "23419122", "sentence": "The studies that established the relationship between mutations in the @GENE$ gene and response to the small molecule EGFR TKIs gefitinib and @DRUG$ were done using analysis of DNA extracted from the tumor [ ] . The recent availability of antibodies that are specific for the mutations most clearly associated with response to EGFR TKIs , @VARIANT$ and E746_A750del , create the opportunity to exploit an alternative method to evaluate NSCLC for EGFR mutations to aid decisions with regard to EGFR TKI therapy [ ] .", "label": "sensitivity"}
{"id": "24790411", "sentence": "A head-to-head trial comparing afatinib to @DRUG$ is still missing . Considering that it is at a minimum equivalent to reversible TKIs , afatinib should be currently considered an alternative drug to use for front-line treatment of @GENE$ mutated patients . In particular , afatinib should be used in patients with classical mutations in the EGFR gene ( exon 19 deletions and exon 21 point mutations ) and could be considered in the presence of @VARIANT$ and L861Q mutations .", "label": "None"}
{"id": "23493838", "sentence": "A complete hematological response and a major cytogenetic response were observed broadly across the @GENE$ mutants , including individuals harboring the dasatinib-resistant F317L , the nilotinib-resistant Y253H , and F359C/I/V mutations , but not T315I . Nine individuals developed new mutations in the course of bosutinib treatment ( V299L , n = 4 ; L248V , n = 2 ; T315I , n = 2 ; @VARIANT$ , n = 1 ; G250E , n = 1 ) and eight of these individuals discontinued bosutinib because of progressive disease or unsatisfactory response .", "label": "None"}
{"id": "16091759", "sentence": "The antimetabolites methotrexate and @DRUG$ as antimetabolites mainly inhibit the cell proliferation in the S phase , and docetaxel , which is a microtubulin stabiliser , exerts its cytotoxic effect in the @VARIANT$ phase . Since @GENE$ A is active and detectable from the beginning of the S phase to the beginning of mitosis , it should theoretically label the proportion of cells that are sensitive to chemotherapeutic drugs used in our study .", "label": "None"}
{"id": "24790411", "sentence": "In particular , @DRUG$ should be used in patients with classical mutations in the @GENE$ gene ( exon 19 deletions and exon 21 point mutations ) and could be considered in the presence of G719X and L861Q mutations . Patients with exon 20 insertions and de novo @VARIANT$ should best be treated with chemotherapy or included in clinical trials with novel agents .", "label": "response"}
{"id": "24729716", "sentence": "c-MET amplification was considered to be a mechanism for acquired resistance to @GENE$ . This molecular change had been found in samples with gefitinib or @DRUG$ resistance in vivo or in vitro . c-MET amplification has also occasionally been found to coexist with EGFR @VARIANT$ mutation .", "label": "resistance or non-response"}
{"id": "24955213", "sentence": "@VARIANT$ EML-ALKpm A mutation-specific strong H-bond pulls @DRUG$ out of the position found in the non-crizotinib resistant EML-ALK fusion gene [ , ] 1151Tins Thr insertion is predicted to alter ATP binding to @GENE$ [ ]", "label": "resistance"}
{"id": "24071646", "sentence": "Atorvastatin could still enhance gefitinib efficacy in H460 cells ( gefitinib treatment versus 1 or 5 μM atorvastatin+gefitinib treatment , IC50=16.4 versus 4.06 or 1 μM ) . Besides , we transfected @GENE$ mutation plasmid-PIK3CA ( @VARIANT$ ) into A549 and Calu1 cells .", "label": "resistance or non-response"}
{"id": "25344762", "sentence": "MTS assay was used to evaluate the effects of erlotinib ( a ) , bevacizumab ( c ) , and combination of erlotinib and @DRUG$ ( d ) on the growth of NSCLC cell lines , which included cell lines with EGFR mutations : @GENE$ ( EGFR exon 19 deletion ) , 11–18 ( EGFR L858 ) , H1975 ( EGFR @VARIANT$ and T790 M mutations ) and EGFR wild-type cell lines : H157 , H460 and A549 .", "label": "None"}
{"id": "24964744", "sentence": "Mutations in @GENE$ ( H1047R ) have been shown to enhance HER2 mediated transformation by amplifying the ligand induced signaling output of the HER family of RTKs [ ] . It could be therefore be assumed that because PIK3CA mutations drive HER related receptor addiction in these cells it would make them more susceptible to RTK inhibition ( as seen here with @DRUG$ and erlotinib ) ( Figure ) . Cells containing the PIK3CA mutation E545K were found to be more sensitive than those with the PIK3CA mutation @VARIANT$ , suggesting that not all activating mutations found within a given gene will result in the same activity to targeted therapy .", "label": "None"}
{"id": "PMC3965223", "sentence": "As it was shown previously , the sensitivity of Co(III)- and Pt ( II ) TPP towards aliphatic alcohols decreases in a following order [ ] : @DRUG$ & gt ; methanol & gt ; isobutyl alcohol ; while in [ and ] the response of 5,10,15,20-tetraphenyl porphyrin ( H2TPP ) and its Co(II) complexes based sensors , towards the changes in acetic acid , ethanol , ammonia , NaCl , @GENE$ , quinine , glucose , monosodium glutamate , dissolved SO2 , and @VARIANT$ content was evolved .", "label": "None"}
{"id": "23921604", "sentence": "These results suggest that acquired resistance to adjuvant imatinib was infrequent , especially since both arms included patients with mutations known to be less sensitive or resistant to @DRUG$ ( e.g. , platelet derived growth factor receptor alpha @GENE$ ] @VARIANT$ ) [ ] .", "label": "resistance or non-response"}
{"id": "25562798", "sentence": "As has proven to be the case in @VARIANT$ BRAF mutant melanoma there is a compelling rationale for targeting this population of patients with @GENE$ inhibitors . Mutations within exon 20 that encodes part of the kinase domain of Her2 have been reported with a frequency of approximately 2–4 % and tend to occur in never smokers with adenocarcinoma [ , , ] . These mutations may be sensitive to treatment with traztuzumab or with panHer inhibitors such as dacomitinib ( PF299804 , Pfizer ) or @DRUG$ ( BIBW 2992 , Bohringer-Ingelheim ) .", "label": "None"}
{"id": "23425968", "sentence": "The angiostatic control @DRUG$ RA ) was used at 1 μg ; n ≥ 8 , * , # , † P & lt ; 0.001 compared to Control , bFGF and @GENE$ respectively ( one-way ANOVA , Tukey test ) . Representative images for ( a ) are shown in . For ( b,c) 10 pmol of purified recombinant TARS , BC194-resistant mutant TARS ( @VARIANT$ ) and/or BC194 were applied .", "label": "None"}
{"id": "24348666", "sentence": "The two mutations were shown to independently induce @DRUG$ resistance in @GENE$ cells engineered to express the L1196M and C1156Y mutations . By mid-2012 , additional patient studies led to the discovery of several other secondary mutations , . That is , three other mutations in the a-Chelix were discovered : a threonine insertion at amino acid 1151 ( 1151Tins ) , a leucine to arginine ( @VARIANT$ ) and phenylalanine to leucine ( F1174L ) .", "label": "None"}
{"id": "19758442", "sentence": "The regions responsible for interaction with A3G ( red ) and @VARIANT$ ( blue ) are discontinuous . They overlap but are not identical . The region important for interaction with the Cul5 @GENE$ marked in green and includes a conserved histidine-cysteine-cysteine-histidine motif and a suppressor of cytokine signaling Box domain .", "label": "None"}
{"id": "25538894", "sentence": "In May 2010 , an EGFR mutation ( @VARIANT$ c.2573T & gt ; G ) positive adenocarcinoma of the right lower lobe of the lung with metastasis in the contra-lateral lung was diagnosed ( Figure A ) . In June 2010 , afatinib , a irreversible @GENE$ , was started in a clinical trial ( Gilotrif® in @DRUG$ @DRUG$ trial ) .", "label": "sensitivity"}
{"id": "24489728", "sentence": "Specifically , @DRUG$ concentrations were increased stepwise from 1 to 100 nM when cells resumed growth kinetics that were similar to untreated parental cells . Acquired resistance by genetic alterations , such as the EGFR @VARIANT$ mutation or amplified MET , were caused by the stepwise escalation method of @GENE$ exposure after prolonged treatment , .", "label": "resistance or non-response"}
{"id": "23493883", "sentence": "Many drugs have been studied in patients who progressed after treatment with a reversible @GENE$ , including XL-647 , dasatinib , and neratinib , with little success . Combinations of therapy such as cetuximab plus erlotinib and @DRUG$ plus everolimus have also been tried . The most promising drug thus far has been afatinib ( BIBW2992 ; Boehringer-Ingelheim Pharma , Ingelheim , Germany ) , , an ErbB family blocker with reported in vitro and in vivo activity against EGFR mutant tumors harboring exon 19 deletions , exon 21 L858R mutations and the exon 20 @VARIANT$ “resistance” mutations .", "label": "resistance or non-response"}
{"id": "25580271", "sentence": "There are several promising agents for patients with activating EGFR mutations who experience disease progression of an EGFR tyrosine kinase inhibitor and have a @VARIANT$ resistance mutation , and multiple clinical trials will be available . Trials investigating adjuvant erlotinib in @GENE$ mutant NSCLC and comparing erlotinib to @DRUG$ plus bevacizumab in metastatic EGFR mutant NSCLC are ongoing .", "label": "resistance or non-response"}
{"id": "24932312", "sentence": "@GENE$ activating mutations were defined as those with exon 19 deletions or exon 21 @VARIANT$ . Efficacy evaluation A chest computed tomography scan ( including the liver and adrenal glands ) was performed within three weeks prior to the initiation of erlotinib treatment , at one and three months following the initiation of @DRUG$ treatment and then every three months thereafter .", "label": "sensitivity"}
{"id": "25025064", "sentence": "@DRUG$ 20 mg i.th [ d+1320 , d+1334 , d+1341 , d+1356 , d+1369 , d+1382 , d+1554 , d+1560 , d+1567 , d+1618 , d+1671 , d+1740 ] T315I , @VARIANT$ 847 MRD negativity 1786 Systemic ( peritoneum ) 4 15 c-ALL ALL-BFM2000 , alloSCT . DLI , Ifn , @GENE$ , imatinib , and ALLRez2002 80 Headache , vomiting , and seizures Clinical signs and symptoms , csf BCR-ABL , and BM BCR-ABL Dasatinib [ d−60–182 ]", "label": "None"}
{"id": "25277176", "sentence": "( B ) Drugs such as the 4-anilinoquinazolines gefitinib ( Iressa ) [ ] and erlotinib ( @DRUG$ ) [ ] can inhibit the activity of @GENE$ @VARIANT$ mutant .", "label": "sensitivity"}
{"id": "22436374", "sentence": "H1650 and HCC827 have an in-frame deletion in the EGFR tyrosine kinase domain ( @GENE$ tyrosine kinase domainΔE746-A750 , exon 19 ) . H1650 cells have also a deletion of the 3 ' part of exon 8 and the entire exon 9 of PTEN , which causes loss of the protein [ ] and in addition express the insulin-like growth factor receptor ( IGF1R ) [ ] . The cell line H1975 has a sensitizing @VARIANT$ kinase domain mutation in exon 21 , but also a second mutation ( T790M , in cis , in the kinase domain ) rendering them resistant to the reversible TKIs @DRUG$ and erlotinib [ ] .", "label": "sensitivity"}
{"id": "24594844", "sentence": "Furthermore , we showed a synergistic effect of cDzT and @DRUG$ on growth inhibition in vitro and in vivo in cancer cells harboring the @GENE$ @VARIANT$ mutant .", "label": "response"}
{"id": "24349829", "sentence": "Correspondingly , direct injection of a liposome encapsulated miR-7 plasmid into established EGFR-TKI sensitive and resistant tumors bearing the @VARIANT$ @GENE$ mutant resulted in significant tumor regression in conjunction with repression of EGFR , RAF-1 and IRS-1 expression . In head and neck cancer , miR-7 functioned in a synergistic manner with erlotinib to render FaDu Erlotinib-resistant cells susceptible to the growth inhibitory activities of the drug .", "label": "resistance or non-response"}
{"id": "23963283", "sentence": "For example , Caucasian patients harboring activating mutations in the EGFR kinase domain , such as a deletion in exon 19 or @VARIANT$ , have shown significant responses to the EGFR tyrosine kinase inhibitor ( TKI ) erlotinib , including a 70 % response rate , 14-month progression-free survival , and 27-month median survival . Accordingly , the EGFR TKIs erlotinib or @DRUG$ have become the standard of care for first-line treatment in patients with advanced NSCLC and whose tumors harbor activating mutations in the kinase domain of @GENE$ .", "label": "sensitivity"}
{"id": "24189400", "sentence": "PC9GR cells ( @DRUG$ resistant ) were shown to harbor a secondary @VARIANT$ mutation in @GENE$ , whereas HCC827ER cells ( erlotinib resistant ) demonstrated MET overexpression , as previously reported ( ) .", "label": "resistance or non-response"}
{"id": "24260231", "sentence": "10.1371/journal.pone.0079478.g007Sorafenib or GDC-0941 inhibits etoposide induced Chk1 activation and enhances apoptosis in cells expressing @VARIANT$ mutated BCR/ABL. ( A ) Ton.B210/T315I cells cultured with DOX to induce @GENE$ with T315I ( BCR/ABL-T315I ) in the absence of IL-3 or cultured without DOX in the presence of IL-3 ( IL-3 ) were left untreated as control ( Cont. ) or treated with 5 µM sorafenib and 1 µM @DRUG$ ( Etop. ) , as indicated , for 16 h , and analyzed for the cellular DNA content .", "label": "None"}
{"id": "23881452", "sentence": "Analysis was carried out for wild-type ( G395 ) and mutant ( A395 ) sequences in the mRNA transcripts for @GENE$ with the latter resulting in a substitution of arginine for @DRUG$ at amino acid position 132 ( R132H ; ) . Functional studies have revealed that the H132 mutant protein catalyzes the conversion of α-ketoglutarate into 2-hydroxyglutarate ( 2-HG ) , a suspected oncometabolite. , Mutant IDH1 was first reported in colorectal cancer and has been identified in acute myelogenous leukemia and in GBM through genome wide mutational analysis. , A subsequent study found mutations in IDH1/2 in almost 80 % of grades II and III astrocytomas , oligodendrogliomas and secondary GBMs , with the most common mutant being the @VARIANT$ substitution .", "label": "None"}
{"id": "24497964", "sentence": "Log-rank test revealed that @DRUG$ treatment significantly prolonged PFS ( A ) , but not OS ( B ) , in NSCLC patients with @GENE$ mutations . Significant differences in PFS ( C ) , but not in OS ( D ) , between patients with and without EGFR mutations were also apparent for mutations in both EGFR exon 19 ( E746-A750del ) and exon 21 ( @VARIANT$ ) .", "label": "sensitivity"}
{"id": "25091415", "sentence": "Therefore , to elucidate the structural and dynamic consequences of the DM on the catalytic domain of EGFR and its affinity toward @DRUG$ , we performed molecular dynamic simulations ( 50 ns ) of the wild type ( WT ) @GENE$ and three oncogenic mutants : @VARIANT$ , T790M , and DM in complex with gefitinib .", "label": "sensitivity"}
{"id": "25486409", "sentence": "As the second-generation , irreversible @GENE$ , such as afatinib and dacomitinib , failed to overcome the resistance caused by @VARIANT$ , , other measures , such as EGFR dual targeting with cetuximab and @DRUG$ and third-geneneration , mutant-selective EGFR-TKIs – are being actively evaluated .", "label": "response"}
{"id": "23186157", "sentence": "Levels of pSTAT5α were also marginally reduced when GNF-2 was applied in the presence of Imatinib , Nilotinib ( Figure ) and significantly reduced in the presence of @DRUG$ ( Figure ) . Cooperation between GNF-2 and AKIs in inhibition phosphorylation of Bcr-Abl and STAT5α . @GENE$ , a laboratory model of Ph + cells carrying native Bcr-Abl ( A and B ) , @VARIANT$ mutated Bcr-Abl ( C ) and SupB15 , a patient derived Ph+ ALL cell line ( D-E ) were treated with various concentrations of GNF-2 in the presence of AKIs , as indicated in each figure .", "label": "None"}
{"id": "24124361", "sentence": "For example , patients with epidermal growth factor receptor (EGFR) mutations , most frequently exon 19 deletions and exon 21 point mutation @VARIANT$ may respond to @GENE$ , like @DRUG$ or erlotinib .", "label": "sensitivity"}
{"id": "15736989", "sentence": "Several mutations have been identified in the context of epidermal growth factor receptor (EGFR) in patients with NSCLC that are associated with clinical response to the small-molecule @GENE$ inhibitors gefitinib ( Iressa ) or @DRUG$ ( Tarceva ) [ , , ] , including in-frame deletions such as del L747–E749 ; A750P in exon 19 , or @VARIANT$ in exon 21 .", "label": "sensitivity"}
{"id": "PMC3760629", "sentence": "The EGFR mutant PC9 cell line harbouring EGFR @VARIANT$ , @GENE$ , has been used as in vitro model of drug resistance . Tumour microvesicles ( TMVs ) shed from cancer cells contain genetic and other molecular information that might be useful for diagnostic purposes to differentiate gefitinib-resistant NSCLC ( non-responders ) from sensitive patients ( drug responders ) .", "label": "None"}
{"id": "23864840", "sentence": "Another approach for @VARIANT$ mediated resistance is the dual inhibition of EGFR with afatinib and cetuximab , an @GENE$ blocking antibody resembling the synergistic combination of @DRUG$ and trastuzumab in ErbB2 positive breast cancer .", "label": "None"}
{"id": "22076124", "sentence": "L1196M represents a mutation of the “gatekeeper” residue , similar to the T790M gefitinib-resistance mutations observed in EGFR , and @VARIANT$ mutations in ABL . Mutations in the gatekeeper site are thought to increase the affinity for ATP significantly , outcompeting the effects of ATP competitive inhibitors [ ] . The effect of the C1156Y mutation is unclear , although it may have an indirect effect on @DRUG$ binding , and further studies will be required to establish its mechanism . A number of @GENE$ inhibitors that are able to inhibit ALK variants with “gatekeeper” mutations at L1196M have been developed .", "label": "None"}
{"id": "22038681", "sentence": "Preliminary results from an ongoing phase 1 dose-escalation study of the multikinase , @GENE$ inhibitor @DRUG$ ( AP24534 ) showed antileukemic activity in patients with refractory CML , including patients with the @VARIANT$ mutation .", "label": "None"}
{"id": "25054154", "sentence": "We utilised three complexes , namely , native ( ALK-crizotinib ) , @VARIANT$ ( @GENE$ F1174L-crizotinib ) , and R1275Q ( ALK R1275Q-crizotinib ) for our analysis .", "label": "resistance"}
{"id": "22347457", "sentence": "Gene expression level of GDF15 , HIST1H2BD , CCL20 , CXCL5 , @GENE$ , KLF4 , DUSP5 , NOV , CDKN1A , CXCL2 , DUSP1 , KLF6 , TOP2A , PPP1R15A , CAV2 , @VARIANT$ , GADD45A , and TUBA1A in PC treated with 0 or 20 µM CAPE for 24 h or 72 h was determined by qRT-PCR . Co-treatment of CAPE with chemotherapeutic drugs suppressed proliferation of PC-3 cells Finally , we investigated if co-treatment of CAPE at serum-available dosage ( 0–20 µM ) with commonly used chemotherapy drugs ( etoposide , paclitaxol , @DRUG$ , mitoxantrone , and estramustin ) can suppress growth of PC-3 cells more effectively than treatment with chemotherapy drugs alone .", "label": "None"}
{"id": "20224651", "sentence": "( ii ) The downregulation of ErbB2 and @GENE$ and survivin signaling events is necessary for α-TEA induced apoptosis , and ( iii ) ErbB1 is highly expressed in the A2780/CP70R cells and below levels of detection in the @VARIANT$ cells , suggesting that ErbB1 may play a role @DRUG$ @DRUG$ resistance .", "label": "None"}
{"id": "25033171", "sentence": "The averaged structures ( derived from the equilibrium trajectories ) of WT and @VARIANT$ mutated @GENE$ complexes were used as the initial structures for the metadynamics simulations .", "label": "resistance"}
{"id": "24244732", "sentence": "Although this hypothesis has not been directly tested for @DRUG$ specifically , syntaxin hypomorphs in C. elegans do have reduced sensitivity to volatile anaesthetics [ ] emphasizing a potential convergence of cellular effectors of various anaesthetics at the presynaptic terminal . On the other hand , the @VARIANT$ mutation acts to increase @GENE$ binding , at least for Munc18 [ ] .", "label": "None"}
{"id": "24944510", "sentence": "Poziotinib ( also known as HM781-36B ) , a new potent irreversible inhibitor of EGFR , HER2 , HER4 , and transient erythroblastopenia of childhood family of kinases inhibitor ( BTK , BLK , and BMX ) , demonstrated preclinical efficacy against @VARIANT$ mutant at eightfold lower doses compared to @DRUG$ . A different approach in addressing EGFR-TKI resistance involves the use of combination regimens . Therefore , the combination of erlotinib with cetuximab , and the combination of erlotinib with MM-121 ( a fully human mAb that targets @GENE$ ) , in patients with acquired resistance to EGFR-TKIs did not show sufficient clinical activity for further investigation in this population .", "label": "None"}
{"id": "24280348", "sentence": "In addition , 2nd generation EGFR TKI ( @DRUG$ ) aiming to overcome the @GENE$ @VARIANT$ mutation has failed to show the expected clinical efficacy [ , ] .", "label": "response"}
{"id": "17973573", "sentence": "H1975 cells harbor two mutations ( @VARIANT$ and T790M ) in the EGFR gene . All cells were maintained in RPMI-1640 medium supplemented with 10 % heat inactivated fetal calf serum ( FCS , JRH Biosciences , Lenexa , Kansas ) . The @GENE$ inhibitor QVD-OPH ( MP Biomedicals , Aurora , Ohio ) was used at 25 μM and added to cells 30 min prior to treatment with @DRUG$ .", "label": "None"}
{"id": "24155950", "sentence": "@GENE$ Bcr-Abl T315 cells are resistant to imatinib , @DRUG$ , dasatinib treatments ( in support of ) . Murine Baf3 Bcr-Abl and Baf3 Bcr-Abl @VARIANT$ cells were plated in 75cm2 flasks ( 4 x 106 cells/35 ml/flask ) and treated with 0.5 or 1 µM imatinib .", "label": "None"}
{"id": "24790411", "sentence": "The rationale of the combination lies in some preclinical work in which mice with @GENE$ mutated lung cancer and acquired resistance to EGFR TKIs showed tumor regression under treatment with afatinib and @DRUG$ . In the clinical trial , results from the first 96 evaluable patients showed impressive objective response rate ( ORR ) and disease control rate ( DCR ; 30 % and 75 % , respectively ) . Response to treatment was observed both in patients bearing a @VARIANT$ mutation or other mechanisms of resistance .", "label": "response"}
{"id": "25254214", "sentence": "Also in the same cells , @DRUG$ upregulated miR-574-3p and overexpression of this miRNA inhibited cell proliferation , migration , and invasion in vitro and in vivo , and apoptosis was induced through reduction of B cell lymphocyte xL (Bcl-xL) and activation of caspase-3 and -9 . The Ras related C3 botulinum toxin substrate 1 ( RAC1 ) , epidermal growth factor receptor (EGFR) , and @VARIANT$ binding protein p300 (EP300) were confirmed as targets of miR-574-3p , and inhibition in cell proliferation , migration , and invasion was observed when these three targets were knocked down . The expression of miR-574-3p was found to be significantly lower in @GENE$ and DU145 and prostate tumour tissues compared with RWPE-1 normal prostate cells and adjacent normal tissues , respectively .", "label": "None"}
{"id": "21333004", "sentence": "As a result , the combination of a lower k3 ( the rate constant for the forward reaction of the EGFR phosphorylation ) and k8 ( the rate constant for the forward reaction of binding of EGFR to @GENE$ ) contributed to effectively inhibit the total phosphorylation of ERK in the presence of @DRUG$ ( Figure ) . The values in each panel indicate RShc/RERK calculated by using the values of parameters in @VARIANT$ model A for two changing parameters and those in EGFR-WT model for two unchanging parameters .", "label": "None"}
{"id": "24555578", "sentence": "Although these limitations exist , the different distribution of the cancer cells that had acquired the @VARIANT$ mutation primarily explains the different response to @DRUG$ observed between the intracranial and extracranial sites in this case . Conclusions It is worth administering @GENE$ in patients with brain metastases , even when the patient acquires EGFR-TKI resistance .", "label": "resistance or non-response"}
{"id": "22363766", "sentence": "Sub-type Description Pathway Potentially relevant therapies Relevant histological subtypes Strength of evidence for clinical use* 1 .1 EGFR sensitizing mutations EGFR TKIs & amp ; chemotherapy Adenocarcinoma High 1.2 EGFR resistance mutations including @VARIANT$ EGFR Dual EGFR/HER2 TKI , c-MET inhibitors +/− 1st or 2nd generation EGFR TKIs , Hsp90 inhibitors , dual MET/VEGFR2 inhibitors , Chk1 inhibitors Adenocarcinoma High 1.3 VeriStrat proteomic signature EGFR TKIs & amp ; @DRUG$ Adenocarcinoma High 2.1 K-ras mutations K-ras Dual @GENE$ & amp ; AKT/PI3K inhibitors , Hsp90 inhibitors Adenocarcinoma High 3.1 EML4-ALK EML4-ALK ALK inhibitors , Hsp90 inhibitors Adenocarcinoma High 10.1371/journal.pone.0031906.t002Secondary lung cancer molecular subtypes .", "label": "None"}
{"id": "24279718", "sentence": "The EGFR mutation L862R has to our knowledge not previously been described in the literature , but given its proximity to mutations known to be sensitive to @GENE$ ( @VARIANT$ and L861X ) , tumor clones bearing the L862R mutation could also be potentially responsive to EGFR-TKI . Meanwhile , because of rapid worsening while waiting for these new molecular tests the patient received third-line pemetrexed , showing further progression in abdomen and pelvis , but still no sign of relapse in the thorax . Unfortunately , the patient rapidly deteriorated and died before being able to attempt a palliative radiation of the lymph nodes in pelvis and a fourth-line treatment with @DRUG$ .", "label": "sensitivity"}
{"id": "22275966", "sentence": "Patients received a traditional anthracycline based ( FEC ) or a taxane containing regimen ( @GENE$ : docetaxel-〉epirubicin/docetaxel ) . Pathological complete response ( pCR ) defined chemosensitivity . RNA was prepared from sections of frozen biopsies taken at diagnosis and hybridised to Affymetrix @VARIANT$ microarrays .", "label": "None"}
{"id": "23940741", "sentence": "Prospective clinical trials of EGFR-TKI treatment for NSCLC patients with activating EGFR mutations , such as delE746-A750 ( exon 19 ) and @VARIANT$ ( exon 21 ) , have demonstrated high clinical response rates of approximately 80 % – . In the IPASS study comparing @DRUG$ with carboplatin and paclitaxel as the first-line therapy in Asian patients , NSCLC patients with @GENE$ mutation had a higher response rate than patients without EGFR mutations when they received carboplatin and paclitaxel .", "label": "sensitivity"}
{"id": "24928511", "sentence": "More than 50 % of lung adenocarcinomas (LAD) from East Asian non-smokers harbor EGFR mutations , and these tumors have been termed oncogene addicted to reflect their dependence on EGFR mediated pro-survival signaling and their high susceptibility to apoptosis induced by @GENE$ ( e.g. @DRUG$ and erlotinib ) ( ) . The most frequently occurring mutations in the EGFR gene ( in-frame deletion in exon 19 at codons 746–750 or a single-base substitution @VARIANT$ in exon 21 ) predict an improved clinical response to first-line oral EGFR-TKIs compared with standard platinum based chemotherapy in patients with advanced non-small-cell lung carcinoma ( NSCLC ) ( , ) .", "label": "sensitivity"}
{"id": "25099740", "sentence": "Mass cultures ( MC ) of wild-type Cal27 cells ( wt ) , and Cal27 cells infected with empty lentiviral virus ( vector ) , or expressing PIK3CA H1047R ( PIK3CA ) or RAS G12V ( RAS ) , were serum starved overnight , and lysates were analyzed for PI3K , pAKT , AKT , Ras , pERK , @GENE$ , pS6 , S6 , and GAPDH , as indicated . Cetuximab-resistant PIK3CA and RAS cells isolated from control treated tumors in panel E were processed in parallel Cal27 cells infected with lentiviruses encoding PIK3CA H1047R or RAS @VARIANT$ mutations .", "label": "None"}
{"id": "22038681", "sentence": "Preliminary results from an ongoing phase 1 dose-escalation study of the multikinase , pan–BCR-ABL inhibitor ponatinib ( AP24534 ) showed antileukemic activity in patients with refractory CML , including patients with the @VARIANT$ mutation . Phase 1 and 2 trials of ponatinib are ongoing in patients with refractory CML and acute lymphoblastic leukemia . Danusertib ( PHA-739358 ) is a multikinase aurora inhibitor with in vitro activity against wild-type ABL and @GENE$ ; preliminary results from an ongoing phase 1 dose-escalation study indicate antileukemic activity in patients with AP or BC who failed @DRUG$ and/or nilotinib or dasatinib .", "label": "None"}
{"id": "18030354", "sentence": "Dendrogram illustrating the relatedness of expression profiles from cell lines treated with ( + ) or without ( − ) @DRUG$ . The presence or absence of @GENE$ somatic mutations and the type of mutations , including @VARIANT$ point mutation ( P ) or Δ746–750 deletion mutation ( D ) , are indicated .", "label": "sensitivity"}
{"id": "23776375", "sentence": "Mutations of the @GENE$ gene are observed in 16 % –40 % of female breast cancers and in about 18 % of male breast cancers. , –PIK3CA mutations are associated with a positive estrogen receptor and @DRUG$ receptor status , nodal involvement , and high histological grade , suggesting that they could be strong prognostic factors in breast cancer.– The great majority ( 85 % ) of PIK3CA mutations are in exons 9 and 20 , encoding the helical and kinase domains , respectively . The majority of mutations are located in two hot spot regions , including the central helical domain and the COOH terminal kinase domain . The three most common hot spot mutations lead to amino acid changes in the helical domain ( E542K and @VARIANT$ ) and in the kinase domain ( H1047R ) .", "label": "None"}
{"id": "25033171", "sentence": "Alternatively , it seems that the up-moved P-loop region in G2032R-ROS1 could attribute to the crizotinib resistance by attenuating the interactions between the drug and the enlarged binding pocket , which has also been observed in the @VARIANT$ induced @DRUG$ resistance in the @GENE$ tyrosine kinase .", "label": "resistance"}
{"id": "23029123", "sentence": "The importance of D2 receptor involvement in @DRUG$ actions on PRL production and cell proliferation is evident in the experiment where ethanol actions on lactotropes ' function were evaluated in clonal cell lines expressing various levels of D2 receptor isoforms . It was found that V cells , which lacked functional D2 receptors and had high basal levels of PRL , showed a significant reduction in PRL production following @VARIANT$ and D2L receptor transfection . As described by an extended allosteric ternary complex model of @GENE$ , receptors spontaneously isomerize between active and inactive conformations , so receptors can modulate signaling pathways in the absence of an agonist .", "label": "None"}
{"id": "25505694", "sentence": "The firstly described and the most common event responsible for resistance is the acquisition of the @VARIANT$ missense mutation , which is found in ≈ 50 % of patients progressing after an initial response to erlotinib or @DRUG$ [ , ] . Other less frequent mechanisms include secondary mutations within @GENE$ [ , ] , MET amplification [ ] , HER2 amplification [ , ] , small cell histologic transformation [ ] .", "label": "resistance or non-response"}
{"id": "23994953", "sentence": "Somatic mutations in exons encoding the tyrosine kinase ( TK ) domain of the epidermal growth factor receptor (EGFR) are positively associated with increased sensitivity of non-small cell lung cancer ( NSCLC ) patients to the selective @GENE$ TK inhibitors ( TKIs ) gefitinib ( Iressa™ ) and erlotinib ( Tarceva™ ) . Prospective trials have demonstrated an impressive ~75 % response rate for patients whose tumors harbor these mutations , which occur as either multinucleotide in-frame deletions in exon 19 ( e.g. , delE746-A750 ) or as single missense mutations ( e.g. , @VARIANT$ ) .", "label": "sensitivity"}
{"id": "21333004", "sentence": "Yun et al [ ] showed that gefitinib directly binds more tightly to the @VARIANT$ mutant than to the wild type @GENE$ in vitro , while Fabian et al [ ] indicated that EGFR with gefitinib sensitive mutations does not differ from wild type EGFR in terms of @DRUG$ binding affinity .", "label": "sensitivity"}
{"id": "23992330", "sentence": "The @VARIANT$ mutation in EGFR is structurally analogous to drug resistance mutations in other kinases such as BCR-ABL ( T315I ) , c-KIT ( T670I ) and platelet derived growth factor receptor-α ( PDGFRα ) ( T674I ) [ ] . Furthermore , acquired resistance may be mediated by activation of redundant signaling pathways able to bypass the blockade of single proteins involved in cancer cells proliferation , survival , or migration . Having again the EGFR inhibitors as a paradigm , this is the case of K-Ras mutations leading to constitutive activation of the Ras/MAPK signaling pathway and mediating both intrinsic or acquired resistance to the @GENE$ mAb @DRUG$ in colorectal cancers [ ] .", "label": "response"}
{"id": "25050621", "sentence": "Tetra-O-methyl @DRUG$ @VARIANT$ ; 40 µM for 4 days ) was used as a global transcription inhibitor as previously described . After harvesting the cells , miRNAs were extracted and measured using TaqMan miRNAs assays kits ( @GENE$ , Foster City , CA , USA ) .", "label": "None"}
{"id": "16187797", "sentence": "del , L747_E749del @VARIANT$ ; ins , D770_N771insNPG ; wt , wild-type EGFR . Sensitivity of Cell Transformation Induced by Expression of Mutant @GENE$ Characterized by Missense Mutation or Exon 19 Deletion , but not Exon 20 Insertion , to Gefitinib and Erlotinib ( A ) Anchorage independent growth of clonal NIH-3T3 cells transformed with mutant EGFR or EGF stimulated wild-type EGFR treated with the indicated concentrations of @DRUG$ immediately prior to suspension in soft agar .", "label": "None"}
{"id": "24348666", "sentence": "In cancer tissues from lung adenocarcinoma patients who showed resistance to gefitinib , high expression levels of HGF were observed in the lung cancer cells that did not harbor the @VARIANT$ mutation or MET amplification . Overexpression of HGF was shown to induce resistance to gefitinib or @DRUG$ in lung adenocarcinoma cells harboring the @GENE$ mutation .", "label": "resistance or non-response"}
{"id": "25156441", "sentence": "After phenol-chloroform extraction and @DRUG$ precipitation , the RNAs were incubated with 100 μM preadenylated 3′-adaptor oligonucleotide ( Linker-1 , IDT Inc ; Coralville , Iowa ) , 5 % DMSO ( Sigma-Aldrich ) and 200 units T4 RNA ligase 2 ( truncated @VARIANT$ ; New England Biolabs , Ipswich , MA ) at 16°C for overnight . Next , the ligated products were purified on a 12 % denaturing polyacrylamide gel , followed by incubation with T4 polynucleotide kinase ( New England Biolabs ) at 37°C for 30 min and a second ligation reaction with a 5′-adaptor oligonucleotide , 5′-ACG CTC TTC CGA TCTv−3′ ( uppercase , DNA ; v represents barcode with triple RNA molecules , aaa , ggg , ccc or uuu ; IDT ) at 37oC for 1 hr . The doubly ligated RNA molecules were reverse transcribed using 150 units Superscript II ( Invitrogen ) and RT primer , 5′-ATT GAT @GENE$ GCC TAC AG-3′ .", "label": "None"}
{"id": "23805327", "sentence": "Additionally , the present approach provides a greater discrimination for the detection of the @VARIANT$ mutation compared to our previous report where two consecutive rounds of COLD-PCR combined with TaqMan were necessary to detect 0.05 % mutant abundances . We anticipate that DISSECT-PNA-LNA PCR will prove useful in detecting low-level mutations in tumor tissue prior to , or after administering @DRUG$ treatment to NSCLC patients . Moreover , the combined method can be used to detect other mutations , such as those identified in KRAS via FLAG ( Fluorescent Amplicon Generation ) or CO-amplification at Lower Denaturation temperature-PCR ( COLD-PCR ) – , or other @GENE$ mutations in NSCLC ( ie .", "label": "resistance or non-response"}
{"id": "23533466", "sentence": "H1975 cancer cell line with mutations in @GENE$ exons 21 ( @VARIANT$ ) and 20 ( T790M ) was refractory to reversible EGFR-TKIs , gefitinib , and erlotinib [ ] , but was sensitive to irreversible EGFR-TKIs , such as BIBW2992 ( @DRUG$ ) .", "label": "sensitivity"}
{"id": "17973572", "sentence": "After the cells were exposed to @DRUG$ for 24 h , @GENE$ cells were unable to proliferate while Ba/F3-L858R-L747S and Ba/F3-L858R-T790M cells continued to grow even in the presence of 1 μM gefitinib ( E ) . These results suggest that execution of apoptosis may be impaired by the presence of T790M and , to a lesser extent , @VARIANT$ .", "label": "None"}
{"id": "19949544", "sentence": "The @VARIANT$ mutation is most common ( comprising 50 % of mutations ) . KIT gene amplification also occurs [ , ] . @GENE$ mutations are mutually exclusive with BRAF and NRAS , and may identify a subset of melanoma that preferentially respond to the KIT inhibitors such as imatinib ( @DRUG$ ) [ , ] or sorafenib [ , ] .", "label": "resistance or non-response"}
{"id": "23186157", "sentence": "Data presented in Figure showed that @DRUG$ and Nilotinib at 1 μM exhibited no inhibition of @GENE$ JAK2 @VARIANT$ proliferation ( Figure ) .", "label": "None"}
{"id": "23843700", "sentence": "Therefore , Phase II trials were conducted with @DRUG$ in patients with acral or mucosal melanoma or melanomas on chronically sun damaged skin that harbored @GENE$ mutations or amplifications . Response rates of 16 % –23 % with a small number of complete long-term responses have been seen , with no difference in response rates between the various melanoma subtypes.– Notably , the same KIT mutations ( K642E and N822K ) that have shown response to treatment in gastrointestinal stromal tumors also show response in the treatment of melanoma . Meanwhile , resistance to specific KIT mutations ( @VARIANT$ and D820Y ) are observed in both gastrointestinal stromal tumors and melanoma .", "label": "resistance"}
{"id": "21414214", "sentence": "Five patients ( Table , case 3 and cases 20 to 23 ) were given @DRUG$ as neoadjunvant treatment after the @GENE$ sensitive mutations were detected in their biopsies of mediastinal lymph nodes metastases by DNA direct sequencing . Of the five patients , three harbored delE746-A750 in exon 19 and the other two harbored @VARIANT$ in exon 21 .", "label": "sensitivity"}
{"id": "24348666", "sentence": "The presence of a secondary mutation of the @GENE$ gene in the T790M was reported in 2005 . The threonine residue 790 is known as the `` gatekeeper residue '' and is located in the ATP binding site , adjacent to the catalytic cleft of the kinase domain . It was initially proposed that the T790M mutation might prevent the proper binding of tyrosine kinase inhibitors via steric hindrance , similar to the corresponding gatekeeper mutations in BCR-ABL ( T315I ) and KIT ( @VARIANT$ ) that confer resistance to @DRUG$ ( Gleevec ) in chronic myelogenous leukemia and in patients with gastrointestinal stromal tumors .", "label": "None"}
{"id": "24071646", "sentence": "Atorvastatin could still enhance @DRUG$ efficacy in H460 cells ( gefitinib treatment versus 1 or 5 μM atorvastatin+gefitinib treatment , IC50=16.4 versus 4.06 or 1 μM ) . Besides , we transfected PI3K mutation @GENE$ ( @VARIANT$ ) into A549 and Calu1 cells .", "label": "resistance or non-response"}
{"id": "24894453", "sentence": "The results are indicated as mean +/- SD of sextuplicate wells and are representative of three independent experiments ( B and C ) @DRUG$ is effective against SW48 ( EGFR G719S mutant ) -induced tumors but not HCT8 ( @GENE$ @VARIANT$ mutant ) induced-tumors in xenografted mice .", "label": "resistance or non-response"}
{"id": "24982846", "sentence": "@DRUG$ @GENE$ EGFR protein expression positive EGFR exon 19 deletion or exon 21 substitution ( @VARIANT$ ) positive Clinical pharmacology Indications and usage , dosage and administration , clinical pharmacology , clinical studies", "label": "sensitivity"}
{"id": "23520479", "sentence": "Yamauchi M , et al also found N-cadherin expression was significantly upregulated in gefitinib-resistant PC9/ZD cells harboring the acquired resistant mutation @VARIANT$ in the @GENE$ gene , other cells expressing N-cadherin were found resistant to @DRUG$ ( A549 , H157 , and H322 ) and that inhibition of N-cadherin expression using siRNA led to a significant decrease in viability in A549 and H322 cells .", "label": "resistance or non-response"}
{"id": "24651269", "sentence": "There was no correlation between the cellular activity of sorafenib and BRAF ( @VARIANT$ ) . Another important class of kinase inhibitor drugs are those targeting ABL1 , of which a re-arranged form , i.e. , @GENE$ , drives Philadelphia chromosome positive chronic myelogenous leukemia ( CML ) . Imatinib , nilotinib , dasatinib , ponatinib and @DRUG$ are approved drugs for this indication .", "label": "None"}
{"id": "22997594", "sentence": "It is now well established that Imatinib does not have direct effect on the @VARIANT$ KIT mutation , but it may affect other sporadic mutations [ , , ] . @DRUG$ demonstrates significant inhibitory activity against WT @GENE$ as well as juxtamembrane domain mutant KIT [ , ] .", "label": "response"}
{"id": "24084983", "sentence": "The PVA ( polyvinyl @DRUG$ ) was used as low-dielectric insulating films with a thickness of 20 nm or 50 nm to sandwich the donor : acceptor ( PVK : TCNB ) composite film with the device architecture of ITO/PVA/PVK : TCNB/PVA/Al to explore polarization and transport contributions during the generation of magneto-capacitance . The magneto-capacitance measurements were performed on the fabricated devices located in a magnetic field by using an Agilent @VARIANT$ LCR meter with zero DC bias and 50 mV AC field @GENE$ .", "label": "None"}
{"id": "24944510", "sentence": "Poziotinib ( also known as HM781-36B ) , a new potent irreversible inhibitor of EGFR , HER2 , HER4 , and transient erythroblastopenia of childhood family of kinases inhibitor ( BTK , BLK , and @GENE$ ) , demonstrated preclinical efficacy against @VARIANT$ mutant at eightfold lower doses compared to afatinib . A different approach in addressing EGFR-TKI resistance involves the use of combination regimens . Therefore , the combination of erlotinib with @DRUG$ , and the combination of erlotinib with MM-121 ( a fully human mAb that targets HER3 ) , in patients with acquired resistance to EGFR-TKIs did not show sufficient clinical activity for further investigation in this population .", "label": "None"}
{"id": "24212940", "sentence": "We also found that DIM plus Herceptin could reverse @GENE$ phenotype by modulating miR-21 expression ( unpublished data ) . We believe that combination of DIM and Herceptin is more potent than individual compounds , which could maximize the effect of Herceptin based therapies . Interestingly , other researchers have demonstrated such action of @VARIANT$ where this indole enhanced @DRUG$ as well as cisplatin induced cytotoxicity [ ] .", "label": "None"}
{"id": "15737014", "sentence": "The @VARIANT$ mutation was shown in vitro in the context of wild-type @GENE$ to confer resistance to @DRUG$ [ ] and a related quinazoline inhibitor , PD153035 [ ] .", "label": "resistance or non-response"}
{"id": "25091415", "sentence": "Therefore , to elucidate the structural and dynamic consequences of the DM on the catalytic domain of @GENE$ and its affinity toward @DRUG$ , we performed molecular dynamic simulations ( 50 ns ) of the wild type ( WT ) -EGFR and three oncogenic mutants : G719S , @VARIANT$ , and DM in complex with gefitinib .", "label": "resistance or non-response"}
{"id": "24955213", "sentence": "@VARIANT$ EML-ALKpm Lowers crizotinib-protein affinity by eliminating two H-bonds between crizotinib and the @GENE$ binding site [ , , ]", "label": "resistance"}
{"id": "25146448", "sentence": "MTNR1B , located on human chromosome 11q21–22 , is a member of the @GENE$ , and one of the functional and high-affinity @DRUG$ membrane receptors . MTNR1B is expressed in human and rodent pancreatic islets . Studies have shown that MTNR1B is a novel candidate gene for @VARIANT$ .", "label": "None"}
{"id": "21042543", "sentence": "The only B-RAF mutation found was the @VARIANT$ substitution . The most important thing was that patients who received @DRUG$ or cetuximab but had @GENE$ alteration , presented no objective response to therapy ; consequently TTP was worse for subjects bearing a mutated B-RAF although not statistically significant probably due to the limited number of tumors carrying these mutations .", "label": "resistance or non-response"}
{"id": "24349829", "sentence": "Correspondingly , direct injection of a liposome encapsulated miR-7 plasmid into established EGFR-TKI sensitive and resistant tumors bearing the @VARIANT$ EGFR mutant resulted in significant tumor regression in conjunction with repression of EGFR , @GENE$ and IRS-1 expression . In head and neck cancer , miR-7 functioned in a synergistic manner with erlotinib to render FaDu Erlotinib-resistant cells susceptible to the growth inhibitory activities of the drug .", "label": "None"}
{"id": "23469114", "sentence": "Cloned cDNA encoding human @GENE$ ectodomain ( residues F1-N1088 ) and containing the @VARIANT$ substitution in CD11bA were fused in-frame and upstream to a cDNA sequence encoding a single cysteine residue ( replacing P1089 in CD11b ) that is followed by a PreScission protease site , an Acid coiled-coil motif and a 6-Histidine tag .", "label": "None"}
{"id": "25486409", "sentence": "To investigate whether CX-4945 can inhibit the growth of lung cancer cells with @VARIANT$ mediated resistance to @GENE$ , cells were treated with CX-4945 in a dose dependent manner . As shown in , CX-4945 treatment did not show a significant growth inhibition in gefitinib/erlotinib-resistant cells .", "label": "resistance or non-response"}
{"id": "12721514", "sentence": "Mutant @VARIANT$ Receptor-ligand [ 18F ] FESP @GENE$ [ ] Somatostatin receptor Affinity binding [ 111In ] DTPA-D-Phe1-octreotide Gamma camera [ ] [ 64Cu ] -TETA-octreotide Tissue dose counting [ ] [ 188Re ] -somatostatin analogue , 99mTc somatostatin analogue Gamma camera [ , , ]", "label": "None"}
{"id": "21573178", "sentence": "Depicted is the average read frequency of T790M separately for @GENE$ wildtype and EGFR mutated tumor specimens . Tumor specimen 10b with a high allele frequency of @VARIANT$ and clinical resistance to @DRUG$ treatment is not shown in this diagram .", "label": "resistance or non-response"}
{"id": "21838876", "sentence": "However , 0.5 % v/v @DRUG$ was unable to increase the invasive ability of @VARIANT$ cells overexpressing Nm23 ( Figure , @GENE$ 0.05 ) , suggesting that Nm23 expression is critical in alcohol induced T47D breast cancer cell invasion .", "label": "None"}
{"id": "24810093", "sentence": "Associations between IC50 and ABCB1 genotypes at @VARIANT$ ( a ) and ( b ) , G2677T/A ( c ) and ( d ) and C3435T ( e ) and ( f ) were analysed by Jonckheere-Terpstra test . Correlation matrix between ABCB1 relative expression , bodipy-FL-paclitaxel accumulation and efflux constant KE in lymphoblastoid cell lines and ovarian cancer cell lines using Spearman or Pearson correlation test Lymphoblastoid cell lines Ovarian cancer cell lines @GENE$ expression @DRUG$ accumulation Paclitaxel efflux ABCB1 expression Paclitaxel accumulation Paclitaxel efflux", "label": "None"}
{"id": "12569391", "sentence": "Significantly , our studies elucidated a potential mechanism involved in @GENE$ associated susceptibility to doxorubicin and @DRUG$ induced G2/M arrest by revealing a correlation between topoisomerase II α activity and protein level and CD26 associated sensitivity to the topoisomerase II inhibitors . However , we detected similar levels of topoisomerase II α mRNA in wtCD26 , @VARIANT$ and parental Jurkat cells .", "label": "None"}
{"id": "25344762", "sentence": "MTS assay was used to evaluate the effects of erlotinib ( a ) , bevacizumab ( c ) , and combination of erlotinib and @DRUG$ ( d ) on the growth of NSCLC cell lines , which included cell lines with EGFR mutations : PC9 ( EGFR exon 19 deletion ) , 11–18 ( EGFR L858 ) , H1975 ( @GENE$ @VARIANT$ and T790 M mutations ) and EGFR wild-type cell lines : H157 , H460 and A549 .", "label": "None"}
{"id": "25505694", "sentence": "The lack of efficacy could probably be related to the high concentrations of neratinib required in preclinical studies to inhibit EGFR @VARIANT$ and the limitations of clinical dosing . Dacomitinib Dacomitinib is an irreversible EGFR , HER2 and HER4 inhibitor with a higher kinase inhibition than gefitinib/erlotinib in both gefitinib/erlotinib-sensitive and in EGFR-T790M and @GENE$ mutated cell lines [ ] .", "label": "None"}
{"id": "23864840", "sentence": "Another approach for @VARIANT$ mediated resistance is the dual inhibition of EGFR with afatinib and @DRUG$ , an EGFR blocking antibody resembling the synergistic combination of lapatinib and trastuzumab in ErbB2 positive breast cancer . Due to promising preliminary results of activity and tolerability , final results of this regimen are being eagerly anticipated [ ] . In selected patients with acquisition of resistance by activated compensatory pathways such as @GENE$ and AXL , addition of a MET [ ] or AXL [ ] inhibitor to EGFR-TKIs could be beneficial .", "label": "None"}
{"id": "23674887", "sentence": "Bosutinib effectively targets most IM-resistance conferring @GENE$ mutations , with the exception of the highly resistant T315I ( resistant to IM , dasatinib , @DRUG$ , and bosutinib ) and @VARIANT$ mutations ( resistant to dasatinib and bosutinib ) .", "label": "None"}
{"id": "25505694", "sentence": "In 2004 , EGFR gene mutations were firstly identified : classical activating EGFR mutations are localized in exon 19 , mainly consisting of an in-frame deletion ( 45-50 % ) , and in exon 21 , consisting of the @VARIANT$ point mutation ( 40-45 % ) , even if there are less common mutations localized in other exons [ – ] . Since their identification , it was clear that EGFR mutations , more frequently observed in never smokers , adenocarcinoma histology , women and Asiatic patients , outline a distinct subgroup of NSCLC . During the last years , six phase III trials ( Table ) established that patients harboring activating EGFR mutations benefit more from a first line treatment with an @GENE$ tyrosine kinase inhibitor ( TKI ) , such as erlotinib or @DRUG$ , than from standard chemotherapy , at least in terms of response rate ( RR ) , progression-free survival ( PFS ) and quality of life [ – ] .", "label": "sensitivity"}
{"id": "22558339", "sentence": "Wild type KRAS is now considered a pre-condition to treat CRC patients with EGFR inhibitors like @DRUG$ or Panitumumab , . Oncogenic BRAF mutations occur in up to 15 % of all human tumors , the vast majority ( & gt ; 90 % ) being c.1799 : T & gt ; A substitutions that lead to the replacement of valine with aspartic acid ( @VARIANT$ ) causing constitutive @GENE$ activation .", "label": "resistance or non-response"}
{"id": "17973572", "sentence": "The activation loop is orange , helix αC yellow , the glycine-rich P-loop green , and the inhibitor @DRUG$ yellow . The figure was made using the program PYMOL ( http : //pymol.sourceforge.net/ ) . ( D ) Top : Dose dependent growth inhibition of @GENE$ cells expressing EGFR @VARIANT$ (LR) , L858R-T790M (LR-TM) , or L858R-L747S ( LR-LS ) detected by the MTS assay .", "label": "None"}
{"id": "22655263", "sentence": "Additionally , AP26113 was evaluated on the crizotinib resistant gatekeeper mutant @VARIANT$ both in vitro and in vivo and appeared to be able to overcome resistance to @DRUG$ . Ki determination demonstrated a very similar biochemical potency on wild-type ALK and the L1196M ALK mutant ( 0.09 and 0.08 nM respectively ) , with both cellular and in vivo data ( using engineered Ba/F3 cells ) indicating that growth of ALK–L1196M mutant driven-cells is inhibited at similar , albeit slightly higher , doses which inhibit cells harboring wild-type @GENE$ ( Katayama et al. , ) .", "label": "resistance"}
{"id": "25465236", "sentence": "The increased inhibition potency for Erlotinib against the oncogenic EGFR L858R mutant ( over the EGFR WT protein ) correlates with decreased global connectivity of the hub residues ( @GENE$ , Glu-884 , Gln-894 and Asp-896 ) in the mutant ( – wild type , – L858R mutant ) . The subsequent decrease in potency for Erlotinib against the oncogenic EGFR L858R + E884K double mutant correlates well with the increased global connectivity of the hub residues ( – wild type , – L858R + E884K mutant ) . On the other hand , the increased inhibition potency for @DRUG$ against EGFR L858R mutant ( compared to EGFR WT protein ) and subsequent further increase in potency for Gefitinib against the EGFR L858R + @VARIANT$ double mutant correlates well with the increased global connectivity of the hub residues in the mutants ( – wild type , – L858R , – L858R + E884K ) .", "label": "None"}
{"id": "23610714", "sentence": "Whenever possible , mutational analysis is suggested for identifying a baseline mutation and the presence of @GENE$ @VARIANT$ mutation , which is known to be resistant to @DRUG$ .", "label": "resistance or non-response"}
{"id": "21687501", "sentence": "Consistently HTR3A rs1062613 ( @VARIANT$ ) and two polymorphisms in HTR3B ( −100 −102 AAG deletion variant and rs1176744 ) have been found to be associated with chemotherapy and @DRUG$ treatment induced vomiting and nausea ( Tremblay et al. , ; Kato et al. , ; Sugai et al. , ; Tanaka et al. , ) . 5-HT6 receptor The 5-HT6 receptor is a @GENE$ is expressed almost exclusively in the brain .", "label": "None"}
{"id": "24294007", "sentence": "Although a retrospective study and the PICCOLO ( @DRUG$ , Irinotecan and Ciclosporin in Colorectal Cancer Therapy ) trial have demonstrated a reduced response to cetuximab and panitumumab for patients with @GENE$ mutations , , further work is required to demonstrate the predictive capacity of these mutations . The serine/threonine-protein kinase B-Raf is an effector in the MAPK signaling pathway , downstream of K-Ras . Mutations in the proto-oncogene BRAF are present in 5 % –10 % of the metastatic CRC population and are also mutually exclusive of KRAS mutations . BRAF @VARIANT$ is the most common of all BRAF mutations ( present in 90 % of cases ) , and is enriched in a subset of patients who are female , greater than 70 years of age , with KRAS WT right sided colon cancer .", "label": "None"}
{"id": "23185274", "sentence": "To overcome such drug resistance , novel mutant-selective @GENE$ kinase inhibitors against EGFR @VARIANT$ were reported , and 4-pyrrylamino quinazolines as new @DRUG$ analogues were synthesized .", "label": "resistance or non-response"}
{"id": "23787070", "sentence": "The @VARIANT$ is a unique mutation because of its resistance to all approved @GENE$ inhibitors , prior to @DRUG$ [ ] .", "label": "response"}
{"id": "21285991", "sentence": "Abbreviations : CNS=central nervous system ; ECOG=Eastern Cooperative Oncology Group ; EGFR=epidermal growth factor receptor ; PS=performance status ; well=well differentiated adenocarcinoma ; mod=moderately differentiated adenocarcinoma ; por=poorly differentiated adenocarcinoma ; muc=mucinous carcinoma ; sig=signet ring cell carcinoma ; CNS=central nervous system ; IRI=irinotecan ; OXA=oxaliplatin , ALP=alkaline phosphatase ; WNL=within normal range ; WBC=white blood cells . Patients with both wild-type KRAS and wild-type BRAF were designated as wild/wild . All patients with KRAS mutations ( n=79 ) either in codon 12 ( @VARIANT$ ) or in codon 13 ( @GENE$ ) are shown as total ( G12X+G13X ) .", "label": "None"}
{"id": "21556318", "sentence": "Cortes et al reported that one patient who had never achieved a major molecular remission developed a @VARIANT$ mutation after 8 months on frontline nilotinib therapy . Two further patients in this study discontinued nilotinib due to intolerance and later progressed to blast crisis , one of whom developed a F359C mutation . Although BCR–ABL mutations are still being identified despite nilotinib use in frontline therapy , accounting for the number of patients receiving this therapy and comparing @DRUG$ data , it does not appear that the use of nilotinib is associated with an increased risk of inducing @GENE$ mutations .", "label": "None"}
{"id": "22590613", "sentence": "The ratio of the percentage of cells in @VARIANT$ on the percentage of cells in G0G1 was calculated and is shown here as a measure of the cell cycle profile variation . D HeLa cells were co-treated with 0.1 µM of @GENE$ and vehicle , α-tocopherol ( 100 µM ) or NAC ( 3 mM ) for 24 h or 48 h. Cells were fixed and colored with Hoechst .", "label": "None"}
{"id": "21457545", "sentence": "In vitro studies showed that exon 19 deleted mutants and @VARIANT$ mutant receptors appear to be more sensitive to @DRUG$ inhibition as compared to wild type receptors [ , ] . This could explain why NSCLC patients harboring such mutations respond better to @GENE$ tyrosine kinase inhibitors ( TKIs ) than patients without such mutations .", "label": "sensitivity"}
{"id": "21188126", "sentence": "AKT is a @GENE$ known as a main effector of PI3K signaling . The @VARIANT$ mutation induces an upstream-signal independent constitutive activation of AKT and resistance to @DRUG$ .", "label": "None"}
{"id": "23493838", "sentence": "A complete hematological response and a major cytogenetic response were observed broadly across the @GENE$ mutants , including individuals harboring the dasatinib-resistant F317L , the nilotinib-resistant Y253H , and F359C/I/V mutations , but not T315I . Nine individuals developed new mutations in the course of bosutinib treatment ( V299L , n = 4 ; L248V , n = 2 ; T315I , n = 2 ; @VARIANT$ , n = 1 ; G250E , n = 1 ) and eight of these individuals discontinued bosutinib because of progressive disease or unsatisfactory response .", "label": "None"}
{"id": "25100284", "sentence": "Furthermore , although common mutations , such as exon 19 deletions and @VARIANT$ mutations in exon 21 have been associated with response to EGFR TKIs , many other mutations are detected only occasionally , and correlations with response are not defined . A recent study screened 681 cases and found 18 rare mutations ; responses to @GENE$ TKIs were reported on a case by case basis and varied by mutation [ ] . For example , exon 20 and 21 mutations were more likely to confer resistance to @DRUG$ or gefitinib , while exon 18 and 19 mutations were more often associated with improved efficacy outcome .", "label": "sensitivity"}
{"id": "24586514", "sentence": "The BCR-ABL positive cell line Ba/F3 BCR-ABL with wild-type and mutant Ba/F3 cells ( @VARIANT$ ) was previously established . These cells were maintained in RPMI1640 medium supplemented with 10 % heat inactivated fetal bovine serum containing 1 % penicillin/streptomycin in a humidified incubator at 37°C . Ponatinib-resistant @GENE$ cells were established previously .", "label": "None"}
{"id": "23329883", "sentence": "There were no interactions between PCSK9 @VARIANT$ genotypes and @DRUG$ consumption on the levels of TG , HDL-C , ApoA1 and ApoB , and the ratio of @GENE$ to ApoB ( P &gt ; 0.05 for all ) .", "label": "None"}
{"id": "24223799", "sentence": "Thus , our results may apply to patients with acquired resistance to a combination of @DRUG$ and tivantinib , as our cells demonstrate decreased sensitivity to tivantinib . Previous studies have shown that an @GENE$ @VARIANT$ mutation is the primary cause of resistance and many have focused on developing irreversible TKIs against EGFR that would prevent or maintain efficacy against the T790M mutation .", "label": "resistance or non-response"}
{"id": "21687596", "sentence": "Analogous secondary mutations of the BCR-ABL gene in case of chronic myelogenous leukemia ( CML ) [ ] and the KIT gene in case of gastrointestinal stromal tumor [ ] have previously been reported as mechanisms of @DRUG$ resistance , which is also a TKI . The structural similarity between ABL and EGFR tyrosine kinases is considerably high , and @VARIANT$ in ABL corresponds to T790M in EGFR [ ] . Using @GENE$ cells , Azam et al. revealed that a gatekeeper threonine mutation stabilizes an active conformation of these tyrosine kinases through a network of hydrophobic interactions known as the hydrophobic spine and has a transforming function [ ] .The authors anticipated that this regulatory mechanism would be conserved across the kinase family .", "label": "None"}
{"id": "15737014", "sentence": "@GENE$ Mutants Containing the T790M Mutation Are Resistant to Inhibition by @DRUG$ or Erlotinib 293T cells were transiently transfected with plasmids encoding wild-type ( WT ) EGFR or EGFR mutants with the following changes : T790M , @VARIANT$ , L858R + T790M , del L747–E749 ; A750P , or del L747–E749 ; A750P + T790M .", "label": "sensitivity"}
{"id": "23238683", "sentence": "As shown in Figure , BaF3 cells expressing native BCR-ABL were highly sensitive to imatinib , dasatinib and ponatinib , whereas @GENE$ and BaF3-G250E-BCR-ABL cells were resistant to both imatinib and @DRUG$ . By contrast , ponatinib induced loss of cell viability in BaF3 cells carrying the T315I or @VARIANT$ mutation , in agreement with previous results from the literature [ , ] .", "label": "None"}
{"id": "25486409", "sentence": "These results suggest that the addition of CX-4945 to EGFR-TKI may overcome @VARIANT$ mediated resistance through the increased activity of EGFR-TKI to suppress EGFR signals by the down-regulation of EGFR . 10.1371/journal.pone.0114000.g004Addition of CX-4945 to EGFR-TKIs substantially suppressed the @GENE$ signaling pathway in gefitinib/erlotinib-resistant , PC-9 cells .", "label": "resistance or non-response"}
{"id": "24623980", "sentence": "Two secondary mutations of ALK associated with @DRUG$ resistance – @VARIANT$ and C1156Y – were first detected in the same patient , who relapsed after achieving a partial response to the drug . The L1196M substitution occurs at the gatekeeper position of ALK ( a position that controls the binding of nucleotides and TKIs ) , and corresponds to the T790M substitution in @GENE$ and the T315I substitution in the Bcr–Abl fusion protein , both of which confer resistance to corresponding TKIs .", "label": "None"}
{"id": "22101934", "sentence": "As shown in , the apparent Ki of lapatinib for EGF–bound @VARIANT$ I706Q tEGFR is 700 nM , about 6-fold lower than the apparent Ki of @DRUG$ for @GENE$ L858R tEGFR .", "label": "None"}
{"id": "21165163", "sentence": "2,105 patients were screened and 350 ( 16.6 % ) identified to carry @GENE$ mutations [ ] . Median PFS and OS for the 217 patients who received erlotinib were 14 and 27 months , patients with @VARIANT$ had longer PFS than patients with exon 19 deletions and outcomes did not seem to differ whether @DRUG$ was given in the first or second-line setting .", "label": "sensitivity"}
{"id": "23566546", "sentence": "Case Histrogical type @GENE$ mutation status Brinkman index Treatment agent Response IL-8 ( ng/mL ) IL-10 ( ng/mL ) RANTES ( pg/ml ) 1 Ad Ex21 @VARIANT$ 900 gefitinib PR 5.79 1.67 2 2 Ad Ex21 L858R 0 erlotinib PR_3.33 94.2 1.41 3 Ad Ex19 del 0 erlotinib PR 4.09 126 2.13 4 Ad Ex21 L858R 0 gefitinib PR_3.92 18.1 1.85 5 Ad Ex21 L858R + Ex19 del 370 erlotinib PR 21.9 1.23 2.11 6 Ad Ex19 del 0 erlotinib PR 7.05 1.37 2.56 7 Ad Ex19 del 0 gefitinib PR 4.82 1.59 2.02 8 Ad Ex21 L858R 1640 gefitinib PR 54.9 2.7 2.38 9 Ad negative 400 erlotinib SD 34.9 3.39 3.66 10 Ad negative 0 erlotinib SD 27.1 4.94 2.25 11 Ad unknown 1800 erlotinib SD NE NE NE 12 Sq Ex19 del 3840 @DRUG$ SD 12.6 1.1 1.98 13 Ad Ex19 del 30 erlotinib SD 5.27 0.69 2.66 14 Ad Ex19 del 0 erlotinib SD 10.5 0.85 2.5 15 Ad unknown 300 erlotinib SD 7.69 2.61 1.7 16 La negative 2080 erlotinib SD NE NE NE 17 Sq Ex21 L858R 750 erlotinib SD 11.6 56.3 3.06 18 Ad unknown 600 erlotinib SD 13.7 1.1 2.82 19 Ad Ex21 L858R 0 erlotinib SD 20.6 11.6 0.783 20 Ad Ex19 del 0 erlotinib SD 14.8 2.07 2.02 21 Ad Ex21 L858R + Ex19 del 0 gefitinib SD 3.04 1.3 1.76 22 Ad Ex19 del 200 gefitinib SD 10.9 1.59 1.91 23 Sq unknown 1560 erlotinib PD NE NE NE 24 Ad negative 1080 erlotinib PD 25.2 8.15 1.57 25 Ad unknown 0 erlotinib PD NE NE NE 26 Ad Ex18 G719A 2000 erlotinib PD 11.6 4.48 3.12 27 Ad unknown 1410 erlotinib PD NE NE NE 28 Ad Ex19 del 1000 gefitinib PD 9.44 2.25 2.89 29 Ad negative 1100 erlotinib PD 56.3 5.63 2.16 30 Ad negative 2000 erlotinib PD 15.6 0.85 0.292 31 Ad negative 825 erlotinib PD 8.27 1.59 2.13 32 Ad Ex21 L858R 0 erlotinib PD 5.34 7.05 1.7 33 Ad negative 1680 erlotinib PD 57.7 1.63 2.06", "label": "sensitivity"}
{"id": "23320171", "sentence": "Primary results from the EMILIA study , a randomized trial comparing Trastuzumab DM-1 to lapatinib and capecitabine , have shown that @DRUG$ @GENE$ significantly improved progression-free survival in patients with metastatic HER2 positive breast cancer . Further research is looking into inhibiting other targets such as mTOR , @VARIANT$ , or AKT pathways .", "label": "None"}
{"id": "24419415", "sentence": "The NEJ002 study , comparing gefitinib and standard carboplatin-paclitaxel chemotherapy as the first-line treatment for patients with @GENE$ mutations , demonstrated no significant difference in OS between gefitinib and carboplatin-paclitaxel . In contrast to other phase 3 trials investigating EGFR-TKIs for patients with common EGFR mutations of exon 19 deletion and L858R , the NEJ002 is the only study that included uncommon EGFR mutations of G719X and @VARIANT$ .", "label": "None"}
{"id": "23864840", "sentence": "Another approach for @VARIANT$ mediated resistance is the dual inhibition of EGFR with afatinib and @DRUG$ , an EGFR blocking antibody resembling the synergistic combination of lapatinib and trastuzumab in ErbB2 positive breast cancer . Due to promising preliminary results of activity and tolerability , final results of this regimen are being eagerly anticipated [ ] . In selected patients with acquisition of resistance by activated compensatory pathways such as MET and AXL , addition of a MET [ ] or @GENE$ [ ] inhibitor to EGFR-TKIs could be beneficial .", "label": "None"}
{"id": "16552419", "sentence": "Although the sequence analysis of @GENE$ might be necessary for clinical trials using TKI such as @DRUG$ or erlotinib , these simple methods established in this study for detection of exon 19 deletion and exon 21 @VARIANT$ mutation are very useful for screening .", "label": "sensitivity"}
{"id": "23992330", "sentence": "The @VARIANT$ mutation in EGFR is structurally analogous to drug resistance mutations in other kinases such as BCR-ABL ( T315I ) , c-KIT ( T670I ) and platelet derived growth factor receptor-α ( PDGFRα ) ( T674I ) [ ] . Furthermore , acquired resistance may be mediated by activation of redundant signaling pathways able to bypass the blockade of single proteins involved in cancer cells proliferation , survival , or migration . Having again the @GENE$ inhibitors as a paradigm , this is the case of K-Ras mutations leading to constitutive activation of the Ras/MAPK signaling pathway and mediating both intrinsic or acquired resistance to the anti-EGFR mAb @DRUG$ in colorectal cancers [ ] .", "label": "response"}
{"id": "25079768", "sentence": "The second-line treatment , after imatinib failure , is provided by less specific kinase inhibitors , such as sunitinib that shows potency against imatinib-resistant @GENE$ mutated in the ATP binding pocket ( @VARIANT$ and T670I ) .", "label": "resistance"}
{"id": "24944510", "sentence": "Multiple secondary mutations have already been identified in patients treated with @DRUG$ . Homologous to the gatekeeper EGFR T790M mutation is the L1196M substitution , which , unlike EGFR T790M , does not appear to confer a growth disadvantage to cells . Other secondary mutations such as @VARIANT$ , C1156Y , L1152R , and 1151Tins may affect affinity of the mutant @GENE$ for either ATP or drug , and these differences have ramifications on the development of next-generation ALK inhibitors , which have varied mutation-specific efficacy among different agents .", "label": "resistance"}
{"id": "24586514", "sentence": "Thus , vorinostat may inhibit the growth of @GENE$ positive cells by changing BCR-ABL conformation via acetylation and inhibition of the chaperone protein HSP90 . Phosphorylated γH2A.X is associated with early DNA damage and repair processes that occur in response to double-strand breaks in eukaryotic cells . Vorinostat induced growth arrest and apoptosis , thus aggravating the apoptotic and cytotoxic effects of @DRUG$ on Ba/F3 @VARIANT$ mutant cells .", "label": "response"}
{"id": "24279718", "sentence": "Furthermore , the identified L862R EGFR mutation , although not reported before , was located near mutations known to be sensitive to EGFR-TKI , such as @VARIANT$ and L861X . Therefore , the tumor clone bearing this EGFR mutation could have been potentially responsive to EGR-TKI therapy . However , a previously described single case of L862V @GENE$ mutation was associated with lack of response to @DRUG$ and the same could have been the scenario with the L862R EGFR mutation .", "label": "sensitivity"}
{"id": "25232318", "sentence": "Similarly , another CUP patient was identified as harboring a somatic EGFR @VARIANT$ alteration via hotspot testing and responded to @DRUG$ , an @GENE$ targeted therapy [ ] .", "label": "sensitivity"}
{"id": "22192458", "sentence": "Inhibition of ALK activity in NB cell lines has already been approached by using specific small molecule @GENE$ inhibitors , such as @DRUG$ [ ] , NVP-TAE684 [ ] and CEP14083/CEP14513 [ ] , and more recently by RNA interference molecules [ ] . Particularly , NB cells harboring either @VARIANT$ mutation or ALK amplification showed sensitivity to PF-02341066 and these results were also confirmed in xenografts ( Wood AC et al. , ASCO Annual Meeting , 2009 ) .", "label": "sensitivity"}
{"id": "23208557", "sentence": "It is well known that the efficacy of targeted therapies such as gefitinib or @DRUG$ with NSCLC patients depends on the presence of @GENE$ activating mutations including in-frame deletion in exon 19 or L858R in exon 21 [ – ] . However , many patients acquire resistance to EGFR-TKI , which occurs within 9.5 to 14 months [ – ] . A second EGFR mutation , substitution of threonine 790 with methionine ( @VARIANT$ ) , was detected in approximately 50 % of the patients who had acquired resistance to EGFR-TKI [ ] .", "label": "resistance or non-response"}
{"id": "24212786", "sentence": "The @GENE$ mutations are distributed throughout the kinase domain , but a deletion in exon 19 and the point mutation @VARIANT$ in exon 21 account for approximately 90 % , which confer a greater response to @DRUG$ treatment , compared with other types of EGFR mutations .", "label": "sensitivity"}
{"id": "25122428", "sentence": "None of the cell lines showed apparent cytotoxicity in response to doses up to 1 μM @DRUG$ . Conversely , all @GENE$ inhibitors significantly impaired the proliferation of the SCLC cell lines . H1048 , which harbors a PIK3CA mutation ( @VARIANT$ ) , was the most sensitive to all of the PI3K/AKT/mTOR inhibitors , with IC50 values of 3.8 , 5.4 , 99.9 , and 195.4 nM for INK128 , BEZ235 , MK2206 , and BKM120 , respectively .", "label": "None"}
{"id": "23340652", "sentence": "The authors sequenced exons 18–21 of the @GENE$ gene using DNA extracted from tumor and normal lung tissue obtained at a previous resection : the @VARIANT$ mutation was detected . This point mutation in the activation loop of the kinase domain is linked to erlotinib responses [ ] . In a phase II trial , Ceresoli and colleagues assessed the efficacy of @DRUG$ in 41 patients with NSCLC metastatic to the brain .", "label": "sensitivity"}
{"id": "25330516", "sentence": "On the other hand , 2 of the transcription factor @VARIANT$ subunits , E2F7 and E2F8 , were highly overexpressed in the vincristine-resistant U-266 subline .", "label": "None"}
{"id": "21192839", "sentence": "Such successes include the use of HER2 fluorescent in situ hybridization ( FISH ) assay for selecting HER2 positive breast cancer patients receiving Herceptin treatment , @GENE$ mutation assay for selecting non-small cell lung cancer patients to be treated with gefitinib/erlotinib , and applying KRAS mutation assay to avoid exposing colorectal cancer patients with KRAS mutations to anti-EGFR mAbs . Recently , such biomarker based prospective patient selection strategy was applied to Phase 1 studies to expedite clinical development of several new targeted agents . Overall response rates from 50 % to near 80 % were achieved in early phase trials of crizotinib ( ALK inhibitor ) , as well as PLX-4032 ( R7204 ) and GSK2118436 ( bRAF @VARIANT$ inhibitors ) .", "label": "None"}
{"id": "24555578", "sentence": "In addition , the case indicates that extended @DRUG$ exposure in the systemic lung cancer sites was associated with the development of a systemic @VARIANT$ resistance mutation , whereas CNS metastases did not undergo this secondary change . Ruppert et al. reported a case of a lung adenocarcinoma with a sensitive EGFR mutation in which the patient developed brain metastases with carcinomatous meningitis and liver metastasis after he stopped taking EGFR-TKI [ ] . Since a secondary T790M mutation was found on a liver biopsy , but not in the @GENE$ , the patient received erlotinib , and the brain metastasis responded well to treatment .", "label": "None"}
{"id": "25562798", "sentence": "Firstly , a secondary mutation , the @VARIANT$ mutation within exon 20 of EGFR , is responsible for about 50 % of instances of acquired resistance [ , ] . This mutation increases the affinity of the @GENE$ for ATP approximately 10-fold and allows ATP to competitively displace gefitinib and @DRUG$ from EGFR [ ] .", "label": "resistance or non-response"}
{"id": "25486409", "sentence": "These results suggest that the addition of CX-4945 to EGFR-TKI may overcome @VARIANT$ mediated resistance through the increased activity of EGFR-TKI to suppress EGFR signals by the down-regulation of EGFR . 10.1371/journal.pone.0114000.g004Addition of CX-4945 to EGFR-TKIs substantially suppressed the @GENE$ signaling pathway in gefitinib/erlotinib-resistant , PC-9 cells .", "label": "resistance or non-response"}
{"id": "PMC4041182", "sentence": "In both studies , certain mutations in exon 11 and 13 of c-KIT ( particularly @VARIANT$ mutation in exon 11 ) were associated with the highest response rate . In addition @DRUG$ , a tyrosine kinase inhibitor used in imatinib-resistant chronic myelogenous leukaemia ( CML ) , seems another promising agent in the treatment of @GENE$ mutated metastatic melanoma and is currently under clinical investigation .", "label": "resistance or non-response"}
{"id": "23320171", "sentence": "Primary results from the EMILIA study , a randomized trial comparing @DRUG$ DM-1 to lapatinib and capecitabine , have shown that Trastuzumab @GENE$ significantly improved progression-free survival in patients with metastatic HER2 positive breast cancer . Further research is looking into inhibiting other targets such as mTOR , @VARIANT$ , or AKT pathways .", "label": "None"}
{"id": "19920910", "sentence": "The pattern of resistance to nilotinib and dasatinib differed ; those with greatest resistance to nilotinib ( @VARIANT$ and E255V ) were susceptible to @DRUG$ . T315I remained resistant to all the three drugs . In vivo experiments with CML xenografts in mice demonstrated that nilotinib treatment , compared with treatment with vehicle , improved survival of mice infused with either wild type @GENE$ or the imatinib-resistant Bcr-Abl mutant ( E255V ) ( ; ) .", "label": "None"}
{"id": "24713856", "sentence": "In contrast to GISTs , MCTs expressing @VARIANT$ KIT genes are imatinib-resistant . Thus , other approaches to control the mutated KIT-driven growth of MCTs are of clinical relevance . We have reported that the activation of the inhibitory molecule @GENE$ could inhibit the growth of HMC1.2 cells , a rapidly proliferating human mast cell line driven by V560G and D816V KIT .", "label": "None"}
{"id": "19216789", "sentence": "To investigate the effects of AZD0530 on Bcr-Abl harbouring mutations conferring Imatinib-resistance ( Y253F , E255K and @VARIANT$ ) Ba/F3 cells expressing these mutants were treated with the dual Src/Abl kinase inhibitor AZD0530 , and proliferation was assessed comparing them with the @GENE$ infected p185Bcr-Abl cells treated in a similar manner ( Figure ) .", "label": "None"}
{"id": "19830249", "sentence": "Here we asked if preventing generation of p25 would affect @GENE$ activity and cell death . We exposed C8 cells , which are primary mouse embryonic fibroblast cells transformed with @VARIANT$ and ras , to @DRUG$ ( CPT ) and measured cell death by trypan blue dye exclusion .", "label": "None"}
{"id": "25115383", "sentence": "All of these cell lines did not harbor @VARIANT$ mutation in the @GENE$ gene . Enhanced expression of FGFR1 by selection of @DRUG$ resistance", "label": "response"}
{"id": "23580227", "sentence": "Cells were treated with DMSO ( control ) or @VARIANT$ ( 50 µM ) and @DRUG$ ( 20 µM ) and @GENE$ ( 10 , 20 , and 50 ng/mL ) alone or in combination for 24 hr. Cell viability was measured by MTT assay and the results were expressed in percentage of viable cells .", "label": "None"}
{"id": "25562363", "sentence": "Zelboraf ( vemurafenib , Plexxikon / Diiachi-Sankyo/ Roche ) 56,400 Cobas 4800 BRAF V600 Mutation Test ( Roche Molecular ) 120-150 Co-development ( BRAF @VARIANT$ mutation ~40 % ) 144M ( 213M* ) @DRUG$ ( trastuzumab , Genentech / Roche ) 70,000 HercepTest ( Dako ) 500 Rescue ( HER-2 expression score 3+ ~ 10 % ) 620M* Well ahead of projected view timelines , the FDA also approved Zelboraf ( vemurafenib , Plexxikon / Diiachi-Sankyo / Roche ) for the treatment of BRAF V600E mutation positive , inoperable or metastatic melanoma , and co-approved the Cobas 4800 @GENE$ V600 Mutation Test , a diagnostic test developed by Roche to identify patients eligible for treatment .", "label": "None"}
{"id": "24634705", "sentence": "This @VARIANT$ mutation is analogous to the gatekeeper residue T3151 in @GENE$ kinase that is associated with acquired resistance to gleevec and @DRUG$ in chronic myelogenous leukemia [ ] .", "label": "None"}
{"id": "15737014", "sentence": "In GIST and @GENE$ , respectively , the analogous T670I mutation in KIT and @VARIANT$ mutation in PDGFR-alpha have been associated with acquired resistance to this drug [ , ] . To determine whether lung cancers that acquire clinical resistance to either gefitinib or @DRUG$ display additional mutations in the EGFR kinase domain , we have examined the status of EGFR exons 18 to 24 in tumors from five patients who initially responded but subsequently progressed while on these drugs .", "label": "None"}
{"id": "24416053", "sentence": "New mutations including C1156Y and L1196M are detected in ALK kinase in biopsy performed in lung cancer recurrent patients administered with @GENE$ inhibitors . The tolerance mechanism of those mutations resembles that of @DRUG$ used in recombination of BCR-ABL rather than @VARIANT$ mutation which is the tolerance mechanism of EGFR-TKI .", "label": "None"}
{"id": "22751098", "sentence": "To test this hypothesis and to clinically validate our preclinical findings , we measured the expression of AXL by IHC ( immunohistochemistry ) in 35 matched EGFR-mutant NSCLC specimens obtained from patients both prior to treatment with the EGFR TKIs erlotinib or @DRUG$ and upon the development of EGFR TKI acquired resistance . In cases where enough material was available for additional studies , we also examined the specimens for GAS6 and vimentin ( as a marker for EMT ) expression by IHC ( scoring system shown in ) , EGFR @VARIANT$ by sequencing , and @GENE$ amplification by FISH .", "label": "None"}
{"id": "22792530", "sentence": "In this study , SW480 and HCT116 cells were more resistant to apoptosis when treated with regimens containing cetuximab than when treated with regimens containing @DRUG$ . This finding is related to the fact that both cell lines harbor a KRAS mutation , with SW480 and HCT116 cells expressing G12V and @VARIANT$ @GENE$ mutants , respectively .", "label": "None"}
{"id": "24790411", "sentence": "Compared to erlotinib and @DRUG$ , afatinib shows lower EC50 values and greater potency against wild type ( afatinib vs erlotinib vs gefitinib : 60 nM vs 110 nM vs 157 nM ) and L858R mutated @GENE$ ( afatinib vs erlotinib vs gefitinib : 0.7 nM vs 40 nM vs 5 nM ) . Moreover , afatinib is able to inhibit the kinase activity in vitro and in animal models when a resistant @VARIANT$ mutation is concomitant to a sensitivity mutation .", "label": "resistance or non-response"}
{"id": "24964744", "sentence": "MCF10a cells containing the @GENE$ mutation H1047R showed little sensitivity to single agent sirolimus , and in combination with EGFR inhibitors were still seen to be more resistant than their parental counterpart , and were more resistant than MCF10a cells containing the PIK3CA @VARIANT$ mutation . Chou and Talalay combination indices for each cell line examined Gefitinib + ZSTK474 Erlotinib + ZSTK474 Gefitinib + Rapamycin Erlotinib + Rapamycin Gefitinib + ZSTK474 Erlotinib + ZSTK474 @DRUG$ + Rapamycin Erlotinib + Rapamycin", "label": "resistance or non-response"}
{"id": "19920910", "sentence": "In a cell-line based mutagenesis study , the emergence of @GENE$ mutations resistant to imatinib , nilotinib and @DRUG$ were compared : 20 different mutations were identified with imatinib mesylate , 10 with nilotinib ( including only 1 novel mutation , E292V ) and 9 with dasatinib . In contrast to imatinib mesylate , mutations recovered in the presence of 50 nM nilotinib were limited to L248V , G250E , Y253H , E255K ( p-loop ) , @VARIANT$ , F359C , L384M and L387F .", "label": "None"}
{"id": "15737014", "sentence": "In either scenario , treatment with @DRUG$ or erlotinib subsequently allows these resistant subclones to become apparent , because most cells bearing sensitivity conferring mutations die , while cells with the @VARIANT$ mutation persist . From analysis of the crystal structure of the @GENE$ kinase domain bound to erlotinib , it is has been shown that the wild-type threonine residue at position 790 is located in the hydrophobic ATP binding pocket of the catalytic region , where it forms a critical hydrogen bond with the drug [ ] .", "label": "resistance or non-response"}
{"id": "25099740", "sentence": "Briefly , Cal27 cells stably expressing an activated allele of PIK3CA and RAS were generated by infection with pLESIP HA-PIK3CA H1047A or pLESIP GFP-KRAS @VARIANT$ lentiviruses . @DRUG$ solution was purchased from Imclone LLC ( Bridgewater , NJ ) . Rapamcyin and @GENE$ were from LC Laboratories ( Woburn , MA ) .", "label": "None"}
{"id": "PMC3949555", "sentence": "In the multivariate analysis of overall survival , @GENE$ male sex , the presence of the @VARIANT$ mutation , brain metastases , and the presence of bronchioloalveolar adenocarcinoma were associated with poor prognosis . Large-scale screening of patients for EGFR mutations , with subsequent customisation of @DRUG$ treatment , was demonstrated to be feasible and to improve outcomes .", "label": "None"}
{"id": "25562700", "sentence": "Molecule Target Biomarker Indication vemurafenib BRAF kinase BRAF @VARIANT$ mutant melanoma vandetanib VEGFR , EGFR , RETR not included on the label thyroid cancer abiraterone CYP 17A1 not included on the label prostate cancer @DRUG$ CTLA-4 not included on the label melanoma brentuximab vedotin @GENE$ ( ACD technology ) not included on the label lymphoma crizotinib ALK ALK-EML4 fusion protein lung cancer", "label": "None"}
{"id": "22185378", "sentence": "Previously , we demonstrated that @VARIANT$ cells do not rely on EGFR signaling to proliferate and that @DRUG$ has no effect upon EGFR , HER2 , AKT and MAPK phosphorylation status , and even the combination of cetuximab and the @GENE$ tyrosine kinase inhibitor PD153035 , did not display enhanced toxicity when compared to either agent alone [ ] .", "label": "None"}
{"id": "25146448", "sentence": "MTNR1B , located on human chromosome 11q21–22 , is a member of the @GENE$ , and one of the functional and high-affinity @DRUG$ membrane receptors . MTNR1B is expressed in human and rodent pancreatic islets . Studies have shown that MTNR1B is a novel candidate gene for @VARIANT$ .", "label": "None"}
{"id": "23788917", "sentence": "Appearance of the most frequent activating mutation – deletion of 15 nucleotides in codons 746-750 in exon 19 and the @VARIANT$ substitution in exon 21 of the EGFR gene – is associated with permanent stimulation of the receptor , but they also lead to an increase in both efficiency of reversible EGFR TKI and effectiveness of radiotherapy . Activating mutations of the EGFR gene have been reported in only about 10 % of Caucasians patients with NSCLC , more often in non-smokers , women , and patients with adenocarcinoma . Therefore , the first studies on the efficacy of erlotinib and @DRUG$ in second-line treatment ( BR.21 , ISEL , INTEREST ) have shown that an objective response to @GENE$ TKI treatment occurs in less than 10 % of patients in the general population [ – ] .", "label": "sensitivity"}
{"id": "15737014", "sentence": "We have not identified this mutation in 155 tumors ( see above ) , and among nearly 1,300 lung cancers in which analysis of @GENE$ exons 18 to 21 has been performed [ , ,, , , ] , only one tumor ( which also harbored an L858R mutation ) was reported to contain the @VARIANT$ mutation . Whether the patient from which this tumor was resected had received @DRUG$ or erlotinib is unclear , and the report did not note an association with acquired resistance to either drug [ ] .", "label": "resistance or non-response"}
{"id": "21884621", "sentence": "Tyrosine kinase inhibitors ( TKIs ) targeting the epidermal growth factor receptor (EGFR) , such as gefitinib and @DRUG$ , have shown remarkable activity in the patients with NSCLC , and particularly these TKIs are more effective to NSCLC with @GENE$ mutations in 19 exon ( in-frame deletions ) and exon 21 ( @VARIANT$ point mutation ) , which are found to be more prevalent in Asian patients [ , ] .", "label": "sensitivity"}
{"id": "24294007", "sentence": "However these studies were small , with only 32 and 83 patients , respectively , with the @VARIANT$ mutation . On the other hand , a number of studies have demonstrated no benefit for either @DRUG$ or panitumumab by specific KRAS mutations .", "label": "None"}
{"id": "24638075", "sentence": "A number of effective EGFR-specific therapeutic compounds against NSCLC , with @GENE$ activating mutations ( exon 19 deletions and @VARIANT$ point mutations ) , have been developed and approved for clinical use . These include both small molecule ( i.e. @DRUG$ and Gefitinib ) and antibody ( i.e. Cetuximab and Panitumumab ) inhibitors .", "label": "sensitivity"}
{"id": "23888935", "sentence": "Soon after the advent of the @GENE$ TKI imatinib , it became evident that Philadelphia chromosome–positive cells could evolve to evade inhibition . In particular , the @VARIANT$ gatekeeper mutant – the most commonly observed point mutation in clinical practice – confers universal resistance to these agents.– At present , the only TKI that is effective in patients with the T315I mutation is @DRUG$ ( ARIAD Pharmaceuticals , Inc. , Cambridge , MA , USA ) .", "label": "None"}
{"id": "23977264", "sentence": "And pyridoxal has been discovered as a potent antagonist of @VARIANT$ purinergic receptor , which accelerates repair of the skin barrier and prevents epithelial hyperplasia . Pyridoxine has been used successfully at dose of 50 to 800 mg/day for treating and preventing fluorouracil- , docetaxel- , etoposide- , doxorubicin- and sorafenib related PPE , , , , , , , . In a case report , pyridoxine 100 mg three times daily was used successfully to treat @GENE$ related HFS .", "label": "None"}
{"id": "24189400", "sentence": "On the basis of these results , we reasoned that combined erlotinib and midostaurin could overcome @VARIANT$ mediated resistance , as @DRUG$ would target wild-type and exon 19 deletion E746-A750 @GENE$ activity while midostaurin would inhibit exon 19 deletion E746-A750+T790M EGFR .", "label": "resistance or non-response"}
{"id": "23986642", "sentence": "This is reflected by the inhibition of in vitro tyrosine kinase activity of ABL and @VARIANT$ mutant @GENE$ with a half maximal inhibitory concentration ( IC50 ) of 0.4 nM and 2.0 nM , respectively . @DRUG$ also inhibits the in vitro activity of additional oncogenic kinases with IC50 between 0.1 nM and 20 nM , including members of the vascular endothelial growth factor receptor ( VEGFR ) , PDGFR , fibroblast growth factor receptor (FGFR) , ephrin receptor , Src family kinases , c-Kit , RET , TIE2 , and FLT3 .", "label": "response"}
{"id": "24894453", "sentence": "B ) , suggesting the anti-tumor effect of @DRUG$ against tumors harboring @GENE$ @VARIANT$ mutant .", "label": "sensitivity"}
{"id": "20628392", "sentence": "In this study , we report that BMS-690514 has in vivo efficacy on a panel of NSLCC xenografts , including those with @VARIANT$ mutations , conferring resistance to @GENE$ therapies such as @DRUG$ or Gefitinib .", "label": "resistance or non-response"}
{"id": "23935640", "sentence": "Ponatinib ( AP24534 ) is an orally administered TKI designed to inhibit @GENE$ with mutations , especially T315I , which confers resistance to other TKI such as imatinib , @DRUG$ , nilotinib , and bosutinib ( reviewed in [ , ] ) . Ponatinib inhibits both native and mutated BCR-ABL including M244V , @VARIANT$ , Q252H , Y253F/H , E255 K/V , F317L , M351T , and F359V [ , ] .", "label": "None"}
{"id": "19920910", "sentence": "The pattern of resistance to nilotinib and dasatinib differed ; those with greatest resistance to nilotinib ( @VARIANT$ and E255V ) were susceptible to dasatinib . T315I remained resistant to all the three drugs . In vivo experiments with CML xenografts in mice demonstrated that nilotinib treatment , compared with treatment with vehicle , improved survival of mice infused with either wild type @GENE$ or the imatinib-resistant Bcr-Abl mutant ( E255V ) ( ; ) .", "label": "None"}
{"id": "24236082", "sentence": "Additionally , cells bearing the mutant @GENE$ were in general more sensitive to EGFR–TKIs than cells expressing the wild type kinase . The @VARIANT$ mutant was 10–100 fold more sensitive to erlotinib and @DRUG$ than the wild type kinase , .", "label": "sensitivity"}
{"id": "24853121", "sentence": "This was already demonstrated wherein Cetuximab-resistant SCCHN cell lines were re-sensitized to @GENE$ inhibition once ErbB2 and/or ErbB3 inhibitors were added to Cetuximab . Activating mutations of EGFR have been shown to correlate with response to EGFR inhibition in other human malignancies . While some mutations can confer sensitivity to EGFR targeting , such as the G719C and the L858R mutations , others like the @VARIANT$ mutation have , in fact , been correlated with resistance , .", "label": "response"}
{"id": "24634705", "sentence": "An in vitro model of EML4-ALK with the @VARIANT$ mutation showed that the cells were still dependent on ALK mediated signaling for tumor maintenance but are resistant to ALK inhibition [ , ] . Several other drugs have shown activity in inhibiting mutations induced by @DRUG$ and are in various stages of pre-clinical and clinical testing [ ] . ALK Copy Number Gain and Emergence of @GENE$ - Fusion Negative Tumors", "label": "resistance"}
{"id": "24876815", "sentence": "@GENE$ et al. , investigating a group of 246 patients with CRC to determine polymorphism @VARIANT$ ( 818A &gt ; C ) and the efficacy of @DRUG$ , found that the C allele was an unfavourable predictive factor for cetuximab treatment .", "label": "None"}
{"id": "18794843", "sentence": "Similarly , the gatekeeper mutation @VARIANT$ in @GENE$ causes resistance to @DRUG$ and erlotinib , and has been detected in lung cancer patients before drug treatment and in the germ line of a family pedigree with several cases of lung cancer , .", "label": "resistance or non-response"}
{"id": "23493883", "sentence": "Some data suggest that patients with EGFR exon 19 deletions are more susceptible to the activity of reversible EGFR-TKIs compared to those with the exon 21 @VARIANT$ mutation. , Further studies then compared first-generation @GENE$ ( erlotinib and gefitinib ) to chemotherapy in patients with EGFR activating mutations in advanced NSCLC . In the first-line setting , a European randomized trial , EURTAC , compared erlotinib 150 mg daily to platinum containing chemotherapy regimens ( cisplatin or @DRUG$ with docetaxel or gemcitabine ) in 174 patients with advanced NSCLC .", "label": "None"}
{"id": "15737014", "sentence": "In GIST and @GENE$ , respectively , the analogous T670I mutation in KIT and @VARIANT$ mutation in PDGFR-alpha have been associated with acquired resistance to this drug [ , ] . To determine whether lung cancers that acquire clinical resistance to either gefitinib or @DRUG$ display additional mutations in the EGFR kinase domain , we have examined the status of EGFR exons 18 to 24 in tumors from five patients who initially responded but subsequently progressed while on these drugs .", "label": "None"}
{"id": "23476798", "sentence": "The conclusion was that trametinib improved PFS and OS in patients with @GENE$ @VARIANT$ mutation or V600K [ ] . Other drugs are currently under investigation in combination with chemotherapy such as Lenvatinib , Pazopanib , Dabrafenib , Axitinib , Everolimus , @DRUG$ , and so forth [ , ] .", "label": "sensitivity"}
{"id": "24594844", "sentence": "Combined treatment of cDzT and @DRUG$ exerts a synergistic inhibitory effect on cell viability in cells harboring @GENE$ @VARIANT$ mutants .", "label": "response"}
{"id": "23527151", "sentence": "WT_Apo : Wild type Apo-form , WT_Sub : wild type in presence of NAD and acetylated lysine ; WT_Inhi : wild type in presence of inhibitor ; @VARIANT$ : Glutamine mutate to Alanine @GENE$ , Q167A_Sub : Glutamine mutate to Alanine in presence of NAD and acetylated lysine ; Q167A_Inhi : Glutamine mutate to Alanine in presence of inhibitor ; H187A : Histidine mutate to Alanine Apo-form , H187A_Sub : Histidine mutate to Alanine in presence of NAD and acetylated lysine ; H187A_Inhi : @DRUG$ mutate to Alanine in presence of inhibitor .", "label": "None"}
{"id": "22076124", "sentence": "Indeed , this has already been documented for a patient with NSCLC who relapsed after the appearance of C1156Y and L1196M mutations in @GENE$ [ ] . L1196M represents a mutation of the “gatekeeper” residue , similar to the T790M gefitinib-resistance mutations observed in EGFR , and T315I mutations in ABL . Mutations in the gatekeeper site are thought to increase the affinity for ATP significantly , outcompeting the effects of ATP competitive inhibitors [ ] . The effect of the @VARIANT$ mutation is unclear , although it may have an indirect effect on crizotinib binding , and further studies will be required to establish its mechanism .", "label": "None"}
{"id": "23284261", "sentence": "Responses were observed in all @GENE$ genotypes , except in the presence of the @VARIANT$ mutation , which resulted in resistance to imatinib and @DRUG$ .", "label": "None"}
{"id": "17973572", "sentence": "Our data indicate that the intrinsic mitochondrial pathway is involved in @DRUG$ induced cell death and that the up-regulation of the proapoptotic polypeptide BIM was consistently seen during TKI induced apoptosis . In addition , sustained activation of EGFR , @GENE$ , and/or ERK caused by the T790M and @VARIANT$ resistant mutations delayed BIM up-regulation and apoptosis .", "label": "None"}
{"id": "25580268", "sentence": "A randomized phase II study of WBRT with or without @DRUG$ in patients with HER2+ breast cancer with brain metastases is ongoing ( NCT01622868 ) . Inhibitors targeting BRAF in melanoma Activating BRAF mutations that result in constitutive activation of the @GENE$ affect approximately half of patients with melanoma , and more than 95 % of these are the @VARIANT$ mutation ( substitution of valine by glutamic acid at the 600th amino acid position ) [ ] .", "label": "None"}
{"id": "23994953", "sentence": "Unfortunately , the EGFR TKI-driven improvement in patient outcome is notably limited because virtually all NSCLC patients with erlotinib/gefitinib sensitizing @GENE$ mutations eventually acquire resistance after a median of 6–12 months of EGFR TKI therapy . In approximately half of cases , the tumor cells present after disease progression contain second-site mutations that alter drug binding to the EGFR TK domain . The most common lesion ( & gt ; 90 % ) is the so-called “gatekeeper mutation , ” which involves a substitution of methionine for threonine at position 790 ( @VARIANT$ ) .", "label": "resistance or non-response"}
{"id": "24729716", "sentence": "Two patients harboring EGFR @VARIANT$ mutation had received @GENE$ treatment : one received @DRUG$ and had an occurrence of brain metastasis in the sixth month ; the other received erlotinib to control the metastasis to the liver .", "label": "resistance or non-response"}
{"id": "25465236", "sentence": "( C ) EGFR @VARIANT$ mutant does not resemble pEGFR unlike the EGFR L858R mutant shown in B. ( D–F ) increased inhibition potency for Erlotinib against EGFR L858R mutant compared to EGFR WT protein and subsequent decrease in potency for @DRUG$ against @GENE$ L858R + E884K double mutant .", "label": "resistance or non-response"}
{"id": "25505694", "sentence": "BMS-690514 , a reversible oral inhibitor of EGFR , HER-2 and −4 , VEGFRs-1 to −3 , showed antitumour activity in tumour xenograft models and in cell lines containing the @GENE$ @VARIANT$ mutation , suggesting a role against erlotinib-resistant tumours [ ] .", "label": "resistance or non-response"}
{"id": "24276379", "sentence": "It is possible that the benefit seen among patients with @GENE$ @VARIANT$ mutants in response to cetuximab but not panitumumab is brought about in part by the ability of @DRUG$ to induce antibody dependent cellular cytotoxicity ( ADCC ) [ ] .", "label": "resistance or non-response"}
{"id": "16626260", "sentence": "Although several previous studies have suggested that tumors harboring mutations in the @GENE$ kinase domain were sensitive to TKIs such as @DRUG$ or erlotinib , others had reported an association between the @VARIANT$ mutation in exon 20 and the resistance to TKIs .", "label": "resistance or non-response"}
{"id": "23691449", "sentence": "NSCLC patients with exon 20 mutations showed a @DRUG$ response rate of 25 % , far lower than that of patients with exon 19 deletions and @VARIANT$ mutations [ ] . Exon 20 mutations are relatively rare . This finding suggests that other mechanisms may be involved in @GENE$ intrinsic resistance [ ] .", "label": "sensitivity"}
{"id": "23801357", "sentence": "@DRUG$ ( AP24534 ) is a novel @GENE$ inhibitor developed using a computational and structure based approach.– It was designed to bind to and inhibit native BCR-ABL and BCR-ABL mutants that can arise during treatment with other TKIs and cause resistance , including the @VARIANT$ mutant .", "label": "response"}
{"id": "24419415", "sentence": "Our group has undertaken a randomized phase 3 trial to compare gefitinib plus @DRUG$ plus pemetrexed with gefitinib monotherapy for patients with NSCLC with an exon 19 deletion or an L858R , G719X , or @VARIANT$ @GENE$ mutation ( NEJ009 ; University Hospital Medical Information Network Clinical Trials Registry [ UMIN-CTR ] number , UMIN000006340 ) .", "label": "None"}
{"id": "25278773", "sentence": "For example , the combination trial of cetuximab and afatinib has shown promising results , with an overall response rate of 29 % and a median duration of response of 5.7 months in patients with advanced lung adenocarcinoma and acquired resistance to erlotinib/gefitinib . Importantly , this combination conferred robust and durable clinical responses irrespective of @VARIANT$ status ( T790M positive , 32 % , versus T790M negative , 25 % ; P=0.341 ) , as well as an acceptable safety profile . More recently , third-generation @GENE$ mutation-specific inhibitors have shown potential in circumventing toxicities related to wild-type EGFR and overcoming resistance resulting from the acquired T790M mutation .", "label": "resistance or non-response"}
{"id": "22970367", "sentence": "The data suggest that low BRCA1 level may neutralize the negative effects of the @GENE$ @VARIANT$ mutation on @DRUG$ sensitivity and that high BRCA1 expression may lead to de novo EGFR TKI resistance potentially through increased DNA damage repair capacity [ ] .", "label": "resistance or non-response"}
{"id": "23348520", "sentence": "Indeed , in non-small cell lung cancers treated with gefitinib or @DRUG$ , sensitive patients have the EGFR @VARIANT$ mutation in only a few cells , whereas resistant patients exhibit @GENE$ T790M in the majority of the tumour cells ( ; ) .", "label": "resistance or non-response"}
{"id": "24969320", "sentence": "@DRUG$ ( Yervoy® ) 2011 CTLA4 expressed on T cells Immunotherapy ( mAb ) Humanised mAb targeting the inhibitory receptor CTLA4 activates immune system enhancing T cell activation and targeting CTLA4 expressing Tregs Verumafenib ( Zelboraf® ) 2011 @GENE$ @VARIANT$ , mutated form of BRAF Small molecule inhibitor Blocks mitogen activated protein kinase pathway reducing protein proliferation of melanoma cells carrying mutation", "label": "None"}
{"id": "24212832", "sentence": "This is in keeping with an earlier study by Di Nicolantonio and colleagues [ ] , where the response to @DRUG$ or cetuximab was found to be impeded by the presence of BRAF @VARIANT$ mutation and restored ( in a cellular model of CRC cells ) by @GENE$ inhibitor sorafenib [ ] .", "label": "resistance or non-response"}
{"id": "23497588", "sentence": "miRNA upregulation has been linked to @DRUG$ and fulvestrant resistance [ , ] . Crosstalk may occur between certain classes of miRNAs such as miR-101 , @GENE$ , and miR-221/222 , which translationally repress the estrogen receptor alpha ( ERα ) and could also be responsible for the decreased sensitivity to anti-estrogen drugs [ , , ] . Further , on comparing ERα negative breast cancer cells lines such as MDA-MB 468 , HS578T and MDAMD-231 with ERα positive cell lines such as MCF-7 , @VARIANT$ and MDA-MB 361 , there was an expressional difference in miR-221 and miR-222 .", "label": "None"}
{"id": "15737014", "sentence": "Analysis of earlier passages of H1975 cells for the @VARIANT$ mutation would be informative in this regard . Recently , new small-molecule inhibitors have been identified that retain activity against the majority of imatinib-resistant @GENE$ mutants .", "label": "None"}
{"id": "23606169", "sentence": "SSCP analysis indicated KRAS WT status , which qualified her ( the patient ) for concomitant targeted therapy ( @DRUG$ : first dose , 400 mg/m2 ; subsequent doses , 250 mg/m2 ) and chemotherapy ( 5-fluorouracil 400 mg/m2 bolus and then 600 mg/m2 over 22 h for day 1 ; leucovorin 200 mg/m2 before 5-fluorouracil ) . After 4 months of treatment , stabilization of the metastatic lesions within the pelvis was observed , but two new metastatic lesions within the skin layers had occurred . Fine needle aspiration of the new metastatic lesions indicated adenocarcinomas , which were tested for KRAS and @VARIANT$ @GENE$ mutation using the real-time PCR method ( KRBR-RT50 , Entrogen ) .", "label": "resistance or non-response"}
{"id": "23520446", "sentence": "Approximately 50 % of EGFR mutations consist of deletions in exon 19 , whereas 35–45 % consist of the @VARIANT$ mutation and 5 % consist of insertions in exon 20 or the L861Q mutation – . Gefitinib ( Iressa ) and @DRUG$ ( Tarceva ) are EGFR inhibitors that are used clinically for the treatment of advanced NSCLC , primarily that with @GENE$ mutations in the tyrosine kinase domains – .", "label": "sensitivity"}
{"id": "22191026", "sentence": "The investigated @GENE$ sensitive mutations included G719C , G719S , G719A , @VARIANT$ , L861Q , and exon 19 deletions , as well as a gefitinib-resistant mutation , T790M .", "label": "sensitivity"}
{"id": "18544172", "sentence": "Non-responders 10 F 68 0 Folfiri , Xeloda , Xelox SD 17 Wild-type @VARIANT$ trisomy 11 F 74 1 LV5FU Folfiri SD 10 Gly12Val disomy 12 M 61 0 Folfirinox SD 18 Gly13Asp R521K disomy 13 F 71 0 Xelox Avastin-Xeliri SD 15 Gly12Asp disomy 14 M 59 0 LV5FU , Folfiri , Folfox SD 24 Gly12Cys R521K trisomy 15 M 71 0 Folfox , Irinotecan SD 14 Wild-type disomy 16 F 60 1 Fufol Folfiri , Folfox , Cape , LV5FU SD 17 Wild-type trisomy 17 M 65 0 Folfirinox , Folfiri SD 18 Wild-type low polysomy 18 M 66 0 Folfiri SD 17 Wild-type R521K disomy 19 F 45 0 Folfox , Xelox SD 17 Wild-type R521K NE 20 F 42 0 Folfirinox SD 21 Gly12Asp R521K trisomy 21 M 62 1 Folfox Xeliri SD 36 @GENE$ R521K disomy 22 M 58 1 Folfiri Xelox , Xeliri PD NA Gly13Asp disomy 23 M 75 1 Xelox Xeliri PD NA Wild-type trisomy 24 M 81 0 Xelox , Folfiri PD NA Gly12Val disomy 25 F 55 0 Xelox Avastin-Xeliri PD NA Gly12Asp disomy 26 M 60 1 LV5FU Folfiri , Folfiri , Folfox PD NA Wild-type NE 27 M 59 0 Folfiri , Folfiri/Folfox , Folfox PD NA Gly12Asp NE 28 F 58 1 LV5FU Folfiri , Xelox PD NA Gly12Asp disomy 29 M 51 0 Folfox , Folfiri PD NA Wild-type disomy 30 F 66 0 Folfiri , Xelox PD NA Wild-type R521K trisomy 31 F 56 0 - PD NA Wild-type disomy 32 F 78 0 Folfox , Folfiri , Cape PD NA Gly12Val disomy F = female , M = Male , Folfox = oxaliplatin , fluorouracil , and folinic acid ; Xelox = capecitabine , oxaliplatin ; Folfiri = irinotecan , fluorouracil , and folinic acid ; Xeliri = Capecitabine , irinotecan ; Folfirinox = @DRUG$ , irinotecan , fluorouracil , and folinic acid ; LV5FU = infusional FU and folinic acid ; Fufol = bolus fluorouracil and folinic acid ; PR = partial response .", "label": "None"}
{"id": "21188111", "sentence": "In a recent report , the @GENE$ mutation @VARIANT$ was associated with resistance to multiple KIT inhibitors including @DRUG$ , nilotinib , and sorafenib , but objective tumor responses could be induced in 2 patients bearing the KIT L576P mutation after treatment with dasatinib .", "label": "resistance or non-response"}
{"id": "23723712", "sentence": "Otherwise , CO-1686 is a novel irreversible mutant-selective inhibitor of EGFR , able to target both the initial activating EGFR mutations as well as the @VARIANT$ secondary acquired resistance mutation . To investigate its use as a single agent , CO-1686 is being evaluated in a Phase I/II trial in @GENE$ NSCLC patients previously treated with first-line @DRUG$ or erlotinib ( NCT01526928 ) .", "label": "resistance or non-response"}
{"id": "19102745", "sentence": "See de la Lastra and Villegas [ ] for a review of the reported @DRUG$ effects . Stilbenes are synthesized via the phenylpropanoid/malonate pathway from phenylalanine that , in turn , is converted into cinnamic acid by phenylalanine ammonia lyase ( PAL ) . The consecutive action of cinnamate 4-hydroxylase ( @VARIANT$ ) and 4-coumarate @GENE$ ligase ( 4CL ) transform cinnamic acid into p-coumaryl-CoA .", "label": "None"}
{"id": "23866929", "sentence": "The entry of tyrosine kinase inhibitors ( TKIs ) @DRUG$ ( Iressa® , AstraZeneca , Wilmington , Delaware ) and erlotinib ( Tarceva® , Genentech , South San Francisco , California ) , which target @GENE$ is one of the most recent , gratifying events in the treatment of advanced non-small-cell lung cancer ( NSCLC ) . Clinical trials have revealed significant variability in response to EGFR-TKIs , and patient characteristics such as sex , dominantly female , East Asian ethnicity , non smoking history , and adenocarcinoma (ADC) histology have been associated with an increased likelihood of EGFR-TKI effectiveness [ - ] . Furthermore , a high response rate ( 60 to 90 % ) to treatment with EGFR-TKIs has been observed in patients harboring mutations in exons 18 to 21 of the tyrosine kinase domain of EGFR , with exon 19 deletions and exon 21 @VARIANT$ point mutations comprising about 90 % of all mutations [ , ] .", "label": "sensitivity"}
{"id": "15736989", "sentence": "Furthermore , the NSCLC cell line H1975 harbors both the @VARIANT$ and T790M mutations , and is resistant to inhibition by @DRUG$ or erlotinib , unlike cell lines that express the L858R allele alone . In the H1975 cell line , it was possible to obtain adequate quantities of RNA to confirm that the L858R and T790M mutations are present on the same allele , as would be predicted if T790M confers resistance to inhibition of the L858R allele . Structural models of @GENE$ provide structural insights into these biological data .", "label": "sensitivity"}
{"id": "23527257", "sentence": "In the erlotinib-resistant cells from PC9 established by Tabara et al , constitutive PI3K/Akt activation was effectively inhibited by @DRUG$ . Moreover , HER2 overexpression and amplification were reported recently to be a potential mechanism of acquired resistance to EGFR inhibition in EGFR mutant lung cancers that lack the second-site @GENE$ @VARIANT$ mutation .", "label": "response"}
{"id": "23937717", "sentence": "We postulate that the attenuation of inhibitory effect of tumor cells on NK cells may partially attributed to the stat3 inhibition by @DRUG$ . In our present study , we also find that high purity NK cells increase autophagy in A549 cancer cells with wide type @GENE$ , while not in H1975 cells with EGFR @VARIANT$ + T790M .", "label": "sensitivity"}
{"id": "24387695", "sentence": "In conclusion , our study shows that MK-2206 , using a QOD , QW , or @VARIANT$ dosing schedule in combination with carboplatin and @DRUG$ , docetaxel , or erlotinib , was well tolerated at doses that inhibit @GENE$ signaling .", "label": "None"}
{"id": "24789720", "sentence": "Mechanism of achieving resistance to erlotinib and @DRUG$ remains unclear . The recent reports confirmed , that T790M substitution could be detected in @GENE$ naïve patients independently of other EGFR gene mutations ( predominantly @VARIANT$ substitution and deletions in exon 19 ) .", "label": "sensitivity"}
{"id": "23208557", "sentence": "Cancer @GENE$ exon18 G719X Drug efficacy prediction of @DRUG$ and erlotinib exon19 deletion exon20 T790M exon21 @VARIANT$", "label": "sensitivity"}
{"id": "15737014", "sentence": "EGFR Mutants Containing the @VARIANT$ Mutation Are Resistant to Inhibition by Gefitinib or @DRUG$ 293T cells were transiently transfected with plasmids encoding wild-type ( WT ) @GENE$ or EGFR mutants with the following changes : T790M , L858R , L858R + T790M , del L747–E749 ; A750P , or del L747–E749 ; A750P + T790M .", "label": "resistance or non-response"}
{"id": "PMC4041556", "sentence": "Second-generation EGFR TKIs – such as neratinib , afatinib and dacomitinib – are effective in preclinical gefitinib- and erlotinib-resistant EGFR @VARIANT$ models , but to date their delivery in EGFR TKI-resistant patients have shown disappointing results in the clinic . Combination of afatinib with cetuximab in EGFR TKI-resistant patients resulted in a 30 % response rate and 75 % disease control rate , with significant gastrointestinal toxicity . Other mechanisms of resistance include @GENE$ amplification , with no commercially available inhibitor , HER2 amplification potentially amenable to treatment with anti-HER2 monoclonal antibodies or histological transformation to small-cell lung cancer , which requires cytotoxic chemotherapy .", "label": "None"}
{"id": "25203004", "sentence": "The two most common genetic mutations are the in-frame deletion in exon 19 ( E746-A750 ) and the substitution of leucine 858 by arginine in the exon 21 ( @VARIANT$ ) . These two mutations constitute about 90 % of all mutations and are known as the “classical” mutations . These two @GENE$ mutations are strong predictors of the response to small-molecule EGFR-tyrosine kinase inhibitors such as @DRUG$ , and erlotinib .", "label": "sensitivity"}
{"id": "24879454", "sentence": "Beyond that , it recently became evident that we need to predict therapeutic response to cetuximab/panitumumab in mCRC not only by KRAS mutational status , but also by NRAS mutational status [ ] , highlighting the increasing importance of mutations in downstream or interacting pathways . As depicted above , it becomes also clear that combined approaches , like the inhibition of the EGFR/BRAF-axis in @GENE$ @VARIANT$ mutated colorectal cancers [ ] , could be used to overcome primary resistance in histological subtypes .", "label": "resistance or non-response"}
{"id": "PMC4041556", "sentence": "Second-generation EGFR TKIs – such as neratinib , afatinib and dacomitinib – are effective in preclinical gefitinib- and erlotinib-resistant EGFR @VARIANT$ models , but to date their delivery in EGFR TKI-resistant patients have shown disappointing results in the clinic . Combination of afatinib with @DRUG$ in EGFR TKI-resistant patients resulted in a 30 % response rate and 75 % disease control rate , with significant gastrointestinal toxicity . Other mechanisms of resistance include @GENE$ amplification , with no commercially available inhibitor , HER2 amplification potentially amenable to treatment with anti-HER2 monoclonal antibodies or histological transformation to small-cell lung cancer , which requires cytotoxic chemotherapy .", "label": "None"}
{"id": "25563355", "sentence": "Of the second generation @GENE$ , neratinib , dacomitinib and @DRUG$ have been getting more attention recently ( ) . Neratinib ( HKI-272 ) is an oral , irreversible inhibitor of EGFR and HER2 [ ] . In pre-clinical studies , neratinib inhibited the growth of NCI-H1975 bronchoalveolar cancer cells harboring both substitution of arginine for leucine at position 858 ( @VARIANT$ ) and T790M and cell lines harboring the HER2 mutation [ ] .", "label": "sensitivity"}
{"id": "18794843", "sentence": "Mutation at the analogous position to Thr315 in other @DRUG$ targets such as c-KIT ( Thr670 ) and PDGFRA ( Thr674 ) have been linked to imatinib resistance in patients with GIST and @GENE$ , respectively , . Similarly , the gatekeeper mutation @VARIANT$ in EGFR causes resistance to gefitinib and erlotinib , and has been detected in lung cancer patients before drug treatment and in the germ line of a family pedigree with several cases of lung cancer , .", "label": "None"}
{"id": "25505694", "sentence": "Neratinib is an oral , irreversible inhibitor of both EGFR and @GENE$ ; in preclinical studies conducted on cell lines with both an activating EGFR mutation and the @VARIANT$ , neratinib was more effective at suppressing cell proliferation than @DRUG$ [ ] .", "label": "None"}
{"id": "25193854", "sentence": "Acquired resistance to IM mediated by the amplification and mutation of @GENE$ presents a great challenge to the therapy of CML [ ] . New generations of tyrosine kinase inhibitors have been designed ( e.g. , @DRUG$ , dasatinib , sunitinib , ponatinib and GZD824 ) to overcome the acquired resistance to IM [ , ] . Although these novel inhibitors can effectively inhibit the phosphorylation of the mutated Bcr-Abl ( E255K , @VARIANT$ ) , most of them had little effect on Bcr-Abl-T315I .", "label": "None"}
{"id": "24811491", "sentence": "Mutations of BRAF , which encodes the cytoplasmic serine/threonine kinase immediately downstream of RAS , are found in 4–13 % of advanced CRCs and are usually mutually exclusive with @GENE$ mutations [ , ] . The BRAF @VARIANT$ mutation has been described as a predictor of tumor aggressiveness in metastatic disease [ , , ] and also of low RRs to @DRUG$ and panitumumab [ , , , ] .", "label": "None"}
{"id": "24495353", "sentence": "Rank Entrez ID Gene symbol Entrez ID Gene symbol Entrez ID Gene symbol 1 28978 TMEM14A 79776 ZFHX4 1727 CYB5R3 2 1843 DUSP1 4701 NDUFA7 7083 TK1 3 51022 GLRX2 715 @VARIANT$ 1292 COL6A2 4 1434 CSE1L 79818 ZNF552 857 CAV1 5 8522 GAS7 4046 LSP1 5437 POLR2H 6 51668 HSPB11 1727 CYB5R3 9833 MELK 7 10456 HAX1 357 SHROOM2 54861 SNRK 8 9902 MRC2 283298 OLFML1 4830 NME1 9 4706 NDUFAB1 23179 RGL1 231 AKR1B1 10 23560 GTPBP4 1809 DPYSL3 10418 SPON1 11 79633 FAT4 857 CAV1 2350 FOLR2 12 10418 SPON1 274 BIN1 10979 FERMT2 13 471 ATIC 79833 GEMIN6 11096 ADAMTS5 14 6403 SELP 11222 MRPL3 4638 MYLK 15 23421 ITGB3BP 23244 PDS5A 9448 MAP4K4 16 23452 ANGPTL2 6241 RRM2 54922 RASIP1 17 54861 SNRK 1289 COL5A1 6934 TCF7L2 18 2034 EPAS1 8434 RECK 4072 EPCAM 19 30008 EFEMP2 429 ASCL1 4701 NDUFA7 20 25999 CLIP3 3426 CFI 404672 GTF2H5 21 4311 MME 332 BIRC5 6241 RRM2 22 4747 NEFL 2 A2M 2192 FBLN1 23 1809 DPYSL3 10730 YME1L1 25959 KANK2 24 28998 MRPL13 11130 @GENE$ 55651 NHP2 25 25959 KANK2 1292 COL6A2 5050 PAFAH1B3 Lists of the top 25 of most influential genes in influence networks based on coexpression among genes in ER + breast tumors before , during , and after a course of neoadjuvant treatment with the drug @DRUG$ .", "label": "None"}
{"id": "24276379", "sentence": "The H1047R , @VARIANT$ and E545K mutations , all detected in colorectal cancers , code for mutant proteins with higher lipid kinase activity than the wild-type protein [ , ] . These mutations result in Akt activation and cellular transformation [ ] . In a clinical study involving 110 patients , none of the patients with the abovementioned @GENE$ gene mutations respond to panitumumab or @DRUG$ [ ] .", "label": "resistance or non-response"}
{"id": "24811491", "sentence": "Acquired resistance @GENE$ mutations Mutations in the EC domain ( @VARIANT$ ) and in the kinase domain ( codons 714 and 794 ) of EGFR found in patients @DRUG$ remained active in a patient with S492R mutation , which abrogated cetuximab binding .", "label": "response"}
{"id": "21556318", "sentence": "Two further patients in this study discontinued nilotinib due to intolerance and later progressed to blast crisis , one of whom developed a @VARIANT$ mutation . Although BCR–ABL mutations are still being identified despite nilotinib use in frontline therapy , accounting for the number of patients receiving this therapy and comparing @DRUG$ data , it does not appear that the use of nilotinib is associated with an increased risk of inducing @GENE$ mutations .", "label": "None"}
{"id": "23493883", "sentence": "Inhibition of @GENE$ cell lines by @DRUG$ compared to erlotinib as shown by EC50 values Wild-type L858R mutation L858R + @VARIANT$", "label": "response"}
{"id": "23992330", "sentence": "Through this approach , they showed that Src Family Kinases (SFKs) , as well as @GENE$ , are relevant targets for the Src inhibitor dasatinib and that acquired @VARIANT$ mutations render cells resistant not only to @DRUG$ and gefitinib , but also to dasatinib [ ] .", "label": "resistance or non-response"}
{"id": "23555954", "sentence": "The cell line H1975 has a sensitizing @VARIANT$ kinase domain mutation in exon 21 , but also a second mutation ( T790M , in cis , in the kinase domain ) rendering them resistant to the reversible TKIs gefitinib and @DRUG$ . miR-146a was expressed in all the five cell lines studied , with the similar magnitude , independent of the genomic status of the @GENE$ .", "label": "sensitivity"}
{"id": "22558350", "sentence": "Nevertheless , we decided to test the ability of the mutant strains MG1655ΔacpP/pKO3-ACPwt , -ACP ( T64A+Ct ) , -ACP ( M44I ) , @GENE$ , and -ACP ( L42M ) to synthesize ppGpp in response to fatty acid synthesis inhibition triggered by the @DRUG$ antibiotic .", "label": "None"}
{"id": "19920925", "sentence": "Other protein kinase targets of nilotinib include TEL-PDGFR β , @GENE$ α and @VARIANT$ mutated KIT .– @DRUG$ , therefore , may have a place in the treatment of idiopathic hypereosinophilic syndrome (HES) , chronic myelomonocytic leukemia ( CMML ) and systemic mastocytosis ( SM ) .", "label": "None"}
{"id": "23527257", "sentence": "In the erlotinib-resistant cells from PC9 established by Tabara et al , constitutive PI3K/Akt activation was effectively inhibited by afatinib . Moreover , HER2 overexpression and amplification were reported recently to be a potential mechanism of acquired resistance to EGFR inhibition in @GENE$ mutant lung cancers that lack the second-site EGFR @VARIANT$ mutation .", "label": "resistance or non-response"}
{"id": "22808015", "sentence": "In the 8–9 loop , Trp-309 was substituted with a valine ( W309V ) , @GENE$ and Arg-313 were both changed to alanine residues ( D312A and R313A ) , and Ile-317 was substituted with @DRUG$ and tyrosine ( I317H and I317Y ) , respectively . Asp-54 and Asp-57 in the DGXD motif of TM1 were both substituted with alanine residues ( D54A and D57A ) and glutamate residues ( D54E and D57E ) , respectively , and Arg-386 in TM11 was changed to an alanine residue ( @VARIANT$ ) .", "label": "None"}
{"id": "23566546", "sentence": "Case Histrogical type @GENE$ mutation status Brinkman index Treatment agent Response IL-8 ( ng/mL ) IL-10 ( ng/mL ) RANTES ( pg/ml ) 1 Ad Ex21 @VARIANT$ 900 gefitinib PR 5.79 1.67 2 2 Ad Ex21 L858R 0 erlotinib PR_3.33 94.2 1.41 3 Ad Ex19 del 0 erlotinib PR 4.09 126 2.13 4 Ad Ex21 L858R 0 gefitinib PR_3.92 18.1 1.85 5 Ad Ex21 L858R + Ex19 del 370 erlotinib PR 21.9 1.23 2.11 6 Ad Ex19 del 0 erlotinib PR 7.05 1.37 2.56 7 Ad Ex19 del 0 gefitinib PR 4.82 1.59 2.02 8 Ad Ex21 L858R 1640 gefitinib PR 54.9 2.7 2.38 9 Ad negative 400 erlotinib SD 34.9 3.39 3.66 10 Ad negative 0 erlotinib SD 27.1 4.94 2.25 11 Ad unknown 1800 erlotinib SD NE NE NE 12 Sq Ex19 del 3840 gefitinib SD 12.6 1.1 1.98 13 Ad Ex19 del 30 erlotinib SD 5.27 0.69 2.66 14 Ad Ex19 del 0 erlotinib SD 10.5 0.85 2.5 15 Ad unknown 300 erlotinib SD 7.69 2.61 1.7 16 La negative 2080 erlotinib SD NE NE NE 17 Sq Ex21 L858R 750 erlotinib SD 11.6 56.3 3.06 18 Ad unknown 600 erlotinib SD 13.7 1.1 2.82 19 Ad Ex21 L858R 0 erlotinib SD 20.6 11.6 0.783 20 Ad Ex19 del 0 erlotinib SD 14.8 2.07 2.02 21 Ad Ex21 L858R + Ex19 del 0 gefitinib SD 3.04 1.3 1.76 22 Ad Ex19 del 200 gefitinib SD 10.9 1.59 1.91 23 Sq unknown 1560 erlotinib PD NE NE NE 24 Ad negative 1080 erlotinib PD 25.2 8.15 1.57 25 Ad unknown 0 erlotinib PD NE NE NE 26 Ad Ex18 G719A 2000 erlotinib PD 11.6 4.48 3.12 27 Ad unknown 1410 erlotinib PD NE NE NE 28 Ad Ex19 del 1000 gefitinib PD 9.44 2.25 2.89 29 Ad negative 1100 erlotinib PD 56.3 5.63 2.16 30 Ad negative 2000 erlotinib PD 15.6 0.85 0.292 31 Ad negative 825 @DRUG$ PD 8.27 1.59 2.13 32 Ad Ex21 L858R 0 erlotinib PD 5.34 7.05 1.7 33 Ad negative 1680 erlotinib PD 57.7 1.63 2.06", "label": "sensitivity"}
{"id": "24885169", "sentence": "In addition , the presence of common activating mutations in the tyrosine kinase domain of the @GENE$ ( exon 19 deletion and exon 21 @VARIANT$ mutation ) confers strong sensitivity to @DRUG$ and erlotinib , which are selective tyrosine kinase inhibitors of EGFR [ , ] .", "label": "sensitivity"}
{"id": "24155950", "sentence": "The sensitivity of K562 , K562-R , LAMA84 , LAMA84-R , @GENE$ Bcr-Abl , and Baf3 Bcr-Abl @VARIANT$ cell lines to the most used Bcr-Abl inhibitors in CML : imatinib , @DRUG$ ( Santa Cruz Biotechnology , CA , USA , Cat. # sc-218081 ) and nilotinib ( Santa Cruz Biotechnology , CA , USA , Cat. # sc-202245 ) was investigated by treating these cells with increasing concentrations of each drug and measuring cell death using an automated Trypan Blue exclusion method ( see ) .", "label": "None"}
{"id": "21165163", "sentence": "The @VARIANT$ mutation results in alteration of the topology of the ATP binding pocket not only interrupting the physicochemical binding of gefitinib/erlotinib , but also leading to much increased affinity of the EGFR protein to ATP resulting in resistance to @GENE$ [ ] .", "label": "resistance or non-response"}
{"id": "24894453", "sentence": "C ) . Taken together , we found that G719S and @VARIANT$ mutants are oncogenic in the absence of ligand stimulation and effectively respond to @DRUG$ in vivo and in vitro . Asymmetric dimerization is required for oncogenic activity of G719S and G724S mutant Recently , we reported that a subset of lung cancer derived oncogenic @GENE$ mutants such as L858R require asymmetric dimerization for biochemical activation and oncogenic transforming activity , meaning that their oncogenic ability depend on formation of an EGFR homodimer in which two distinct regions of the two molecule dimerize [ ] .", "label": "sensitivity"}
{"id": "25133174", "sentence": "Intracellular @VARIANT$ produced by SphK1 can bind to TRAF2 ( tumor necrosis factor receptor associated factor 2 ) and function as a @DRUG$ required for its E3 ubiquitin ligase activity and consequently , Lys-63 linked polyubiquitination of RIP1 ( receptor interacting protein 1 ) and NF-κB ( nuclear factor kappa-light-chain-enhancer of activated B cells ) activation [ ] . Similarly , it has been shown that S1P enhances cIAP2 ( cellular inhibitor of apoptosis 2 ) mediated K63 linked polyubiquitination of IRF-1 ( interferon regulatory factor-1 ) , which is essential for IL-1 induced production of chemokines CXCL10 and CCL5 [ ] . Furthermore , S1P produced by SphK2 in the nucleus acts as an endogenous inhibitor of specific histone deacetylases ( HDAC1 and HDAC2 ) , thereby regulating gene transcription , including that of the @GENE$ p21 [ ] .", "label": "None"}
{"id": "24065105", "sentence": "Studies analyzing sensitivity to drugs in hepatocellular carcinoma cells found that the mutant @VARIANT$ confers chemoresistance to doxorubicin and @DRUG$ . This effect is mediated by the upregulation of multidrug resistance gene 1 ( MDR1 , also @GENE$ or P-glycoprotein ) [ ] .", "label": "None"}
{"id": "25364578", "sentence": "These results reinforce the need for 2nd and 3rd generation @GENE$ TKIs , while taking into account existing data that suggest use of erlotinib or @DRUG$ beyond progression , with added chemotherapy , radiotherapy or best supportive care may improve survival . Although afatinib and dacomitinib have been introduced to overcome acquired resistance , they showed limited efficacy in NSCLC with @VARIANT$ and were more than 100-fold less potent in NSCLC cells with EGFR T790M mutation than in NSCLC cells with EGFR activating mutation .", "label": "resistance or non-response"}
{"id": "24638075", "sentence": "A number of effective EGFR-specific therapeutic compounds against NSCLC , with @GENE$ activating mutations ( exon 19 deletions and @VARIANT$ point mutations ) , have been developed and approved for clinical use . These include both small molecule ( i.e. Erlotinib and @DRUG$ ) and antibody ( i.e. Cetuximab and Panitumumab ) inhibitors .", "label": "sensitivity"}
{"id": "24212826", "sentence": "In comparison with docetaxel , @DRUG$ therapy offers comparable clinical efficacy and a better quality of life when used as second-line treatment in previously treated NSCLC patients [ ] . In a previous study of EGFR-TKI treatment in chemonaive patients with specific @GENE$ mutations , such as exon 19 deletions and substitutions at @VARIANT$ , the treatment effect of EGFR-TKIs was sustained for up to 8–9 months and was significantly superior to the treatment effect of platinum based chemotherapy [ ] .", "label": "sensitivity"}
{"id": "24501009", "sentence": "Strategies to improve EGFR inhibition in EGFR @VARIANT$ cancers include the combination of irreversible EGFR inhibitors with the @GENE$ antibody @DRUG$ ( as reported for afatinib plus cetuximab ) 19 ; the development of more potent and specific inhibitors of EGFR T790M20,21 ; and the use of intermittent but high doses of existing irreversible EGFR inhibitors .", "label": "response"}
{"id": "24501009", "sentence": "Strategies to improve @GENE$ inhibition in EGFR @VARIANT$ cancers include the combination of irreversible EGFR inhibitors with the EGFR‐directed antibody cetuximab ( as reported for afatinib plus @DRUG$ ) 19 ; the development of more potent and specific inhibitors of EGFR T790M20,21 ; and the use of intermittent but high doses of existing irreversible EGFR inhibitors .", "label": "response"}
{"id": "25033171", "sentence": "The energetic difference between @GENE$ and WT-ROS1 are shown in panel C ( ΔΔG = ΔGG2032R−ΔGWT , a positive ΔG indicates a weaker binding affinity in the mutated protein , and a negative ΔG indicates a stronger binding affinity ) , where the residue Leu18 ( on the P-loop region ) contributes the most to the attenuated binding of crizotinib to G2032R mutated ROS1 , indicating that the P-loop conformation governs the binding of @DRUG$ .", "label": "resistance"}
{"id": "24963635", "sentence": "The presence of the inhibitors was found to significantly reduce expression of Opn mRNA in MLE12 ( Figures @VARIANT$ and S3B ) . These data suggest that @DRUG$ induces OPN expression via activation of the @GENE$ dependent signaling pathway in AEC II .", "label": "None"}
{"id": "24886861", "sentence": "1×107 @VARIANT$ cells suspended in 0.1 ml culture medium were inoculated by 1 ml syringe with @GENE$ ( BD302008 ) beside the lowest right nipple , and the needle was left around 5 seconds to minimize back flow or solution loss on Day zero of the study . After 3 weeks , palpable tumor masses had been observed , and regimens were started at Day 42 when all tumors reached the volume of 100 mm3 . The individual or combination regimens of each drug ( 25 µg @DRUG$ per mouse or/and 2.5 µg risperidone per mouse ) dissolved or suspended in 100 µl PBS were injected intraperitoneally ( i.p. ) every 2 days by 1 ml syringe and 25G 5/8 needle ( BD302104 ) .", "label": "None"}
{"id": "23566546", "sentence": "Case Histrogical type @GENE$ mutation status Brinkman index Treatment agent Response IL-8 ( ng/mL ) IL-10 ( ng/mL ) RANTES ( pg/ml ) 1 Ad Ex21 @VARIANT$ 900 gefitinib PR 5.79 1.67 2 2 Ad Ex21 L858R 0 erlotinib PR_3.33 94.2 1.41 3 Ad Ex19 del 0 erlotinib PR 4.09 126 2.13 4 Ad Ex21 L858R 0 gefitinib PR_3.92 18.1 1.85 5 Ad Ex21 L858R + Ex19 del 370 erlotinib PR 21.9 1.23 2.11 6 Ad Ex19 del 0 erlotinib PR 7.05 1.37 2.56 7 Ad Ex19 del 0 gefitinib PR 4.82 1.59 2.02 8 Ad Ex21 L858R 1640 gefitinib PR 54.9 2.7 2.38 9 Ad negative 400 erlotinib SD 34.9 3.39 3.66 10 Ad negative 0 erlotinib SD 27.1 4.94 2.25 11 Ad unknown 1800 erlotinib SD NE NE NE 12 Sq Ex19 del 3840 gefitinib SD 12.6 1.1 1.98 13 Ad Ex19 del 30 erlotinib SD 5.27 0.69 2.66 14 Ad Ex19 del 0 erlotinib SD 10.5 0.85 2.5 15 Ad unknown 300 erlotinib SD 7.69 2.61 1.7 16 La negative 2080 erlotinib SD NE NE NE 17 Sq Ex21 L858R 750 erlotinib SD 11.6 56.3 3.06 18 Ad unknown 600 erlotinib SD 13.7 1.1 2.82 19 Ad Ex21 L858R 0 erlotinib SD 20.6 11.6 0.783 20 Ad Ex19 del 0 erlotinib SD 14.8 2.07 2.02 21 Ad Ex21 L858R + Ex19 del 0 gefitinib SD 3.04 1.3 1.76 22 Ad Ex19 del 200 gefitinib SD 10.9 1.59 1.91 23 Sq unknown 1560 @DRUG$ PD NE NE NE 24 Ad negative 1080 erlotinib PD 25.2 8.15 1.57 25 Ad unknown 0 erlotinib PD NE NE NE 26 Ad Ex18 G719A 2000 erlotinib PD 11.6 4.48 3.12 27 Ad unknown 1410 erlotinib PD NE NE NE 28 Ad Ex19 del 1000 gefitinib PD 9.44 2.25 2.89 29 Ad negative 1100 erlotinib PD 56.3 5.63 2.16 30 Ad negative 2000 erlotinib PD 15.6 0.85 0.292 31 Ad negative 825 erlotinib PD 8.27 1.59 2.13 32 Ad Ex21 L858R 0 erlotinib PD 5.34 7.05 1.7 33 Ad negative 1680 erlotinib PD 57.7 1.63 2.06", "label": "sensitivity"}
{"id": "24594844", "sentence": "However , the phosphorylation level of @GENE$ in EGFR @VARIANT$ mutant cells ( H1975TM/LR ) was not suppressed by @DRUG$ treatment .", "label": "resistance or non-response"}
{"id": "22043994", "sentence": "The introduction of @GENE$ @VARIANT$ allele impaired the therapeutic effect of @DRUG$ or panitumumab .", "label": "resistance or non-response"}
{"id": "24348666", "sentence": "Moreover , in all the 4 cases with MET amplification , a higher expression of HGF was observed after @DRUG$ treatment than before treatment . These results indicate that HGF accelerates the expansion of the tumor cells with MET amplification . The cells with MET amplification as the @VARIANT$ mutation was present in a small proportion of the tumor cells before EGFR-TKI treatment and became dominant during treatment with @GENE$ , suggesting that HGF may play an important role in this process .", "label": "resistance or non-response"}
{"id": "23994953", "sentence": "Development of EMT was observed in a NSCLC patient who acquired resistance to @DRUG$ in the absence of known resistance mechanisms , such as the @GENE$ @VARIANT$ mutation and MET amplification .", "label": "resistance or non-response"}
{"id": "23788917", "sentence": "Presence of @VARIANT$ substitution may be an indication for treatment with irreversible EGFR TKI , such as neratinib , keratinib and especially afatinib , which is currently in the third phase of clinical trials . The LUX-Lung 1 study has shown that afatinib induces an objective response and prolongation of progression-free survival ( PFS ) in NSCLC patients who have been previously treated with @GENE$ TKI for at least 12 weeks . The rationale for this type of study is the fact that afatinib has a different molecular structure when compared to gefitinib and @DRUG$ .", "label": "resistance or non-response"}
{"id": "25033171", "sentence": "They had found a de novo secondary mutation @VARIANT$ in @GENE$ , and this mutation conferred serious resistance to @DRUG$ .", "label": "resistance"}
{"id": "19920910", "sentence": "The pattern of resistance to nilotinib and @DRUG$ differed ; those with greatest resistance to nilotinib ( @VARIANT$ and E255V ) were susceptible to dasatinib . T315I remained resistant to all the three drugs . In vivo experiments with CML xenografts in mice demonstrated that nilotinib treatment , compared with treatment with vehicle , improved survival of mice infused with either wild type @GENE$ or the imatinib-resistant Bcr-Abl mutant ( E255V ) ( ; ) .", "label": "None"}
{"id": "23533466", "sentence": "H1975 cancer cell line with mutations in @GENE$ exons 21 ( L858R ) and 20 ( @VARIANT$ ) was refractory to reversible EGFR-TKIs , gefitinib , and @DRUG$ [ ] , but was sensitive to irreversible EGFR-TKIs , such as BIBW2992 ( afatinib ) .", "label": "resistance or non-response"}
{"id": "23320171", "sentence": "Primary results from the EMILIA study , a randomized trial comparing Trastuzumab DM-1 to lapatinib and @DRUG$ , have shown that Trastuzumab DM-1 significantly improved progression-free survival in patients with metastatic HER2 positive breast cancer . Further research is looking into inhibiting other targets such as @GENE$ , @VARIANT$ , or AKT pathways .", "label": "None"}
{"id": "23664091", "sentence": "In NSCLC , resistance to the EGFR TKI @DRUG$ is associated with the positive selection of cells harbouring the gatekeeper @VARIANT$ mutation known to confer insensitivity to gefitinib [ ] . Su et al. [ ] demonstrated that in patients with EGFR mutations treated with EGFR TKIs , the presence of low frequency subclones harbouring T790M mutations before the onset of treatment was associated with shorter progression-free survival , and Turke et al. [ ] showed that the presence of subclones with @GENE$ amplification was associated with EGFR TKI resistance .", "label": "None"}
{"id": "21445332", "sentence": "Given the lower binding to @GENE$ , we suspected that the @VARIANT$ mutant form of MCP would have a decreased capacity to serve as a @DRUG$ for CFI mediated cleavage of C4b .", "label": "None"}
{"id": "23185274", "sentence": "However , treatment with @DRUG$ and erlotinib will eventually fail because of the development of acquired drug resistance resulting from amplification of the MET proto-oncogene or the threonine-to-methionine amino acid substitution at position 790 ( @VARIANT$ ) of @GENE$ , which is detected in 50 % of clinically resistant patients , .", "label": "resistance or non-response"}
{"id": "24244732", "sentence": "This then indicates that whatever the @VARIANT$ mutation is doing at high @DRUG$ concentrations , it acts both downstream and independent of functional rab-3 , which itself is downstream of R39C . Interestingly , the E465K mutation is modelled on a Sly1p ( yeast Sec1/Munc18 protein ) that bypasses the requirement for a functional @GENE$ protein during ER to Golgi vesicle trafficking [ ] .", "label": "None"}
{"id": "24737397", "sentence": "@GENE$ overexpression counteracted the drug sensitivity of AML cells to @DRUG$ , but the PRL-3 mutant ( @VARIANT$ ) did not ( A , B ) .", "label": "None"}
{"id": "24594844", "sentence": "cDzT cleaves @GENE$ @VARIANT$ mRNA , which leads to a decrease in EGFR protein levels , whereas @DRUG$ is a second-line TKI that irreversibly binds to the intracellular kinase domain of EGFR and suppresses its downstream signaling .", "label": "response"}
{"id": "23233904", "sentence": "Enhancement of @GENE$ oligomerization was obtained regardless of the cell type or apoptosis inducer used , including STS , curcumin , As2O3 , etoposide , @DRUG$ , selenite , TNF-α , H2O2 , or UV , all affecting mitochondria yet acting through different mechanisms ( ; Figure ) . Furthermore , it was demonstrated that in cells expressing a VDAC1 dimeric fusion protein comprising wild type and the RuR-insensitive @VARIANT$ mutated VDAC1 showed no protection against STS induced apoptosis .", "label": "None"}
{"id": "23776375", "sentence": "Mutations of the PIK3CA gene are observed in 16 % –40 % of female breast cancers and in about 18 % of male breast cancers. , @GENE$ mutations are associated with a positive estrogen receptor and @DRUG$ receptor status , nodal involvement , and high histological grade , suggesting that they could be strong prognostic factors in breast cancer.– The great majority ( 85 % ) of PIK3CA mutations are in exons 9 and 20 , encoding the helical and kinase domains , respectively . The majority of mutations are located in two hot spot regions , including the central helical domain and the COOH terminal kinase domain . The three most common hot spot mutations lead to amino acid changes in the helical domain ( @VARIANT$ and E545K ) and in the kinase domain ( H1047R ) .", "label": "None"}
{"id": "23888935", "sentence": "@DRUG$ is a novel , synthetic , orally active , potent pan–BCR-ABL inhibitor and multi targeted TKI that was discovered using a computational and structure based drug design approach.– Ponatinib was specifically designed to inhibit native @GENE$ and mutant forms that can arise during treatment with other TKIs and cause resistance , including the @VARIANT$ gatekeeper mutant .", "label": "None"}
{"id": "24497964", "sentence": "Somatic mutations in the EGFR gene have been identified as a major determinant of the clinical response to treatment with @GENE$ tyrosine kinase inhibitors ( TKIs ) , such as @DRUG$ and erlotinib , in patients with non-small cell lung cancer ( NSCLC ) . Most of the EGFR mutations occur in exons 19 to 21 , which encode the tyrosine kinase domain of the receptor . Deletions in exon 19 ( such as delE746-A750 ) and the @VARIANT$ point mutation in exon 21 are the commonest mutations found in NSCLC , accounting for about 90 % of all EGFR mutations .", "label": "sensitivity"}
{"id": "22933967", "sentence": "The KRAS status is the first molecular marker to predict the response to @GENE$ monoclonal antibodies @DRUG$ and panitumumab in metastatic CRC ( mCRC ) patients , and it needs to be determined before deciding in favor of treatment with anti-EGFR antibodies . Previous retrospective studies suggested that mt-BRAF was a marker of resistance to anti-EGFR therapy and that the patients with mt-BRAF had significantly shorter PFS and OS than the patients with wt-BRAF tumours . The mutations in the KRAS and BRAF genes have been reported to be mutually exclusive. , In the retrospective analysis by Fariña- Sarasqueta et al. , it was also shown that the BRAF @VARIANT$ mutation was an independent prognostic factor for the survival of patients with colon cancer in stages II and III , while the KRAS mutations did not have any effect on the overall survival of these patients .", "label": "None"}
{"id": "25562700", "sentence": "Molecule Target Biomarker Indication vemurafenib BRAF kinase BRAF @VARIANT$ mutant melanoma vandetanib VEGFR , EGFR , RETR not included on the label thyroid cancer abiraterone CYP 17A1 not included on the label prostate cancer @DRUG$ CTLA-4 not included on the label melanoma brentuximab vedotin CD30 ( ACD technology ) not included on the label lymphoma crizotinib ALK ALK-EML4 fusion protein lung cancer BRAF : Serine/threonine-protein kinase B-Raf ; VEGFR : Vascular endothelial growth factor receptor ; EGFR : epidermal growth factor receptor ; RETR : RET proto-oncogen receptor ; CYP 17A1 : cytochrome P450 17A1 ; CTLA-4 : Cytotoxic T-Lymphocyte Antigen 4 ; CD30 : Cluster of Differentiation 30 ; @GENE$ : Antibody Conjugated Drug ; ALK-EML4 : anaplastic lymphoma kinase (ALK) ; echinoderm microtubule associated protein-like 4 ( EML4 ) fusion .", "label": "None"}
{"id": "23976869", "sentence": "Sequencing of 87 FIP1L1-PDGFRA negative hypereosinophilic syndrome patients showed several PDGFRA point mutations ( R481G , L507P , I562M , H570R , @VARIANT$ , N659S , L705P , R748G , and Y849S ) . Four of these in vitro mutations induced growth factor independent cell proliferation and constitutive phosphorylation of PDGFRA and STAT5 . Mice injected with @GENE$ cells were treated with oral @DRUG$ .", "label": "None"}
{"id": "22970367", "sentence": "One of these agents , BIBW2992 ( afatinib ) , is able to target both @GENE$ and ERBB2 and overcome T790M-driven acquired resistance [ ] . However , in clinical studies , BIBW2992 did not prolong survival compared to placebo in NSCLC patients who have developed acquired resistance to gefitinib or @DRUG$ [ ] . Another agent in this class of next generation EGFR TKIs , PF-002999804 , inhibits all ERBB family members and has been shown to be effective against tumors harboring @VARIANT$ [ , ] .", "label": "resistance or non-response"}
{"id": "25277203", "sentence": "Interestingly , upregulation of miR-200c increased @DRUG$ sensitivity in A549 and H1299 , but not in H1975 ( Figure ) . @VARIANT$ could be the main cause of acquired resistance to @GENE$ in H1975 .", "label": "resistance or non-response"}
{"id": "24724051", "sentence": "@DRUG$ and nilotinib are effective against the vast majority of reported @GENE$ TKD mutants with one crucial exception : the @VARIANT$ mutation .", "label": "None"}
{"id": "21333004", "sentence": "Our results revealed that the effectiveness of @DRUG$ in cells is largely affected by not only on its direct binding affinity with @GENE$ but also on the presence of an additional molecule , Mig6 . According to recent reports , the sensitivity to kinase inhibition reflects intrinsic differences in the binding affinity of the EGFR mutants such as L858R , @VARIANT$ , and exon19 deletions [ , - ] .", "label": "sensitivity"}
{"id": "17973572", "sentence": "After the cells were exposed to gefitinib for 24 h , Ba/F3-L858R cells were unable to proliferate while Ba/F3-L858R-L747S and @GENE$ cells continued to grow even in the presence of 1 μM @DRUG$ ( E ) . These results suggest that execution of apoptosis may be impaired by the presence of @VARIANT$ and , to a lesser extent , L747S .", "label": "None"}
{"id": "24501009", "sentence": "Strategies to improve @GENE$ inhibition in EGFR @VARIANT$ cancers include the combination of irreversible EGFR inhibitors with the EGFR‐directed antibody cetuximab ( as reported for @DRUG$ plus cetuximab ) 19 ; the development of more potent and specific inhibitors of EGFR T790M20,21 ; and the use of intermittent but high doses of existing irreversible EGFR inhibitors .", "label": "response"}
{"id": "24959087", "sentence": "Further evidence of the efficacy of combination therapy in overcoming resistance is demonstrated by NSCLC cell lines resistant to erlotinib and the MET inhibitor SU11274 , which display upregulation of both mTOR ( mammalian target of rapamycin ) and @GENE$ pathway components and restoration of sensitivity to EGFR/MET inhibition by the addition of everolimus . A final mechanism of resistance in gastric cancer cell lines has been demonstrated when MET amplified SNU6838 gastric cancer cell lines were treated with the MET inhibitors PHA-665752 and PF2341066 ; a novel mutation occurred in the activation loop of MET , causing a conformal change that blocked inhibitor binding analogous to the gatekeeper mutations seen in EGFR ( T790M ) following erlotinib treatment and in ABL ( @VARIANT$ ) following @DRUG$ .", "label": "None"}
{"id": "19758442", "sentence": "The region important for interaction with the Cul5 ubiquitin ligase complex is marked in green and includes a conserved histidine-cysteine-cysteine-histidine motif and a @GENE$ domain . The scale at the bottom indicates amino acid positions . The structural determination of full-length @VARIANT$ has so far been unsuccessful .", "label": "None"}
{"id": "25091415", "sentence": "Therefore , to elucidate the structural and dynamic consequences of the DM on the catalytic domain of EGFR and its affinity toward gefitinib , we performed molecular dynamic simulations ( 50 ns ) of the wild type ( WT ) @GENE$ and three oncogenic mutants : @VARIANT$ , T790M , and DM in complex with @DRUG$ .", "label": "sensitivity"}
{"id": "23994953", "sentence": "@VARIANT$ mutation reviewed in . The second well-known mechanism of gefitinib/erlotinib resistance is the MET receptor tyrosine kinase ( RTK ) gene amplification . MET creates a bypass signaling track that activates AKT through HER3 mediated activation of PI3K in the presence of @GENE$ TKIs .", "label": "resistance or non-response"}
{"id": "25465236", "sentence": "On the other hand , the increased inhibition potency for @DRUG$ against EGFR @VARIANT$ mutant ( compared to @GENE$ WT protein ) and subsequent further increase in potency for Gefitinib against the EGFR L858R + E884K double mutant correlates well with the increased global connectivity of the hub residues in the mutants ( – wild type , – L858R , – L858R + E884K ) .", "label": "sensitivity"}
{"id": "22545132", "sentence": "Polyclonal antibodies against p38 and @GENE$ , and monoclonal antibodies against p-AKT ( @VARIANT$ ) , cleaved caspase 8 ( Asp391 ) , p-p38 ( 3D7 ) , Erk1/2 ( C-16 ) , p-Erk1/2 ( D13.14.4E ) , p-JNK ( 81E11 ) , and JNK ( 2C6 ) were from Cell Signaling Technology . Polyclonal p85α antibody was from Millipore and anti-mouse IgG conjugated with Cy3 from Chemicon . Monoclonal antibodies against glyceraldehyde-3-phosphatedehydro-genase ( GAPDH ) and β-actin , and chemicals including tripotide , @DRUG$ , 5-fluorouracil ( 5-Fu ) , MG132 , SP600125 , SB203580 , TNFα , epidermal growth factor (EGF) were from Sigma .", "label": "None"}
{"id": "22140458", "sentence": "The second generation @GENE$ inhibitors dasatinib and nilotinib are effective in most CML patients following failure of @DRUG$ therapy . However , one potential limitation of these therapies is that their increased potency may be associated with additional side-effects . In addition , none of these inhibitors have demonstrated significant activity against cells harboring the @VARIANT$ resistance mutation .", "label": "None"}
{"id": "24709958", "sentence": "Likewise , the @VARIANT$ mutation in the @GENE$ gene rose after chronic exposure to @DRUG$ in NSCLC , conferring resistance to this inhibitor [ ] .", "label": "resistance or non-response"}
{"id": "22551149", "sentence": "Interestingly , caspase-3 activity was not observed in Aspc1 cells ( Additional file figure @VARIANT$ ) , a cell line with less sensitivity to PB282 ( Additional file figure S3D ) . Caspase-3 inhibition by lipophilic antioxidant correlates with @GENE$ dependence . ( A ) Caspase-3 inhibition by the hydrophobic antioxidant α-tocopherol ( α-toco ) , hydrophilic antioxidant N-acetylcyteine (NAC) , or caspase-3 inhibitor DEVD-FMK ( 1 μM ) in Bxpc3 cells following 24 hour treatment with SW43 ( 30 μM ) , PB282 ( 90 μM ) , or HCQ ( 90 μM ) .", "label": "None"}
{"id": "24348666", "sentence": "However , almost every patient who responds well to @DRUG$ will , without exception , experience recurrence due to acquired resistance . The mechanisms for acquired resistance include gatekeeper L1196M mutations , ALK gene amplification , and other @GENE$ gene mutations ( L1152R , @VARIANT$ , F1174L ) - .", "label": "resistance"}
{"id": "25033171", "sentence": "As shown in , the separation PMF in G2032R-ROS1 was much lower than that in @GENE$ , suggesting that serious @DRUG$ resistance could be induced by the mutation @VARIANT$ in the ROS1 tyrosine kinase .", "label": "resistance"}
{"id": "23232076", "sentence": "The deletion of the four amino acid sequence ( del 746–750 ) in the exon 19 and the substitution of leucine by arginine at codon 858 ( @VARIANT$ ) in exon 21 are two of the most common mutations in the kinase domain of @GENE$ gene in NSCLC patients [ ] . The small-molecule tyrosine kinase inhibitors including gefitinib and @DRUG$ have recently been approved for the treatment of patients with NSCLC [ , - ] .", "label": "sensitivity"}
{"id": "22436374", "sentence": "An additional mechanism is the activation , either at baseline or acquired , of @GENE$ over-expression . Afatinib ( @DRUG$ Boehringer Ingelheim GmbH ) , an irreversible dual inhibitor of EGFR and HER2 kinases , retains some activity in tumors with @VARIANT$ mutations although at doses that are a log higher than what is needed for cancers with only a sensitizing mutation [ ] .", "label": "None"}
{"id": "24790411", "sentence": "Compared to erlotinib and gefitinib , afatinib shows lower EC50 values and greater potency against wild type ( afatinib vs erlotinib vs gefitinib : 60 nM vs 110 nM vs 157 nM ) and @VARIANT$ mutated @GENE$ ( afatinib vs erlotinib vs @DRUG$ : 0.7 nM vs 40 nM vs 5 nM ) .", "label": "sensitivity"}
{"id": "24419415", "sentence": "In contrast to other phase 3 trials investigating EGFR-TKIs for patients with common EGFR mutations of exon 19 deletion and L858R , the NEJ002 is the only study that included uncommon EGFR mutations of @VARIANT$ and L861Q . This study showed that the PFS and OS tended to be shorter among patients treated with first-line gefitinib compared with PFS and OS among those treated with first-line carboplatin-paclitaxel in the uncommon @GENE$ mutation group ( supplementary Table S2 , Supplemental Digital Content 1 , http : //links.lww.com/JTO/A494 ) .", "label": "None"}
{"id": "25505694", "sentence": "The lack of efficacy could probably be related to the high concentrations of neratinib required in preclinical studies to inhibit EGFR @VARIANT$ and the limitations of clinical dosing . Dacomitinib Dacomitinib is an irreversible EGFR , HER2 and HER4 inhibitor with a higher kinase inhibition than gefitinib/erlotinib in both gefitinib/erlotinib-sensitive and in EGFR-T790M and @GENE$ mutated cell lines [ ] .", "label": "None"}
{"id": "25221748", "sentence": "The newer second-generation pan-HER irreversible inhibitors provide compensatory pathway inhibition by direct targeting of the resistant @VARIANT$ mutation and bind irreversibly to 2 or more receptors of the @GENE$ domain , thus providing enhanced EGFR pathway blockade . Of the second-generation inhibitors , @DRUG$ and dacomitinib have been the most extensively studied , in both heavily pre treated patients and in the first-line setting .", "label": "response"}
{"id": "24052078", "sentence": "The tyrosine kinase inhibitor ( TKI ) , @DRUG$ ( OSI-774 , Tarceva ; OSI Pharmaceuticals/Genentech , New York , NY , USA ) , is an oral small-molecule inhibitor that binds to the kinase domain of @GENE$ and was approved for the treatment of NSCLC in 2004 . Several clinical studies have shown that a secondary point mutation at amino-acid position 790 ( @VARIANT$ ) of EGFR is responsible for approximately half of the cases in which patients with lung adenocarcinoma develop resistance to EGFR targeting TKIs. , In addition , the presence of an intrinsic ( primary ) resistance mechanism ( such as K-Ras mutation ) can also confer resistance to TKIs , although the underlying mechanisms are not yet completely understood .", "label": "resistance or non-response"}
{"id": "21264348", "sentence": "While 10 µM dasatinib was not able to inhibit Bcr-Abl autophosphorylation and STAT5 phosphorylation in @VARIANT$ @GENE$ expressing Ba/F3 cells , the combined treatment with 10 µM @DRUG$ plus 0.5 , 5 , or 10 µM GNF-5 significantly blocked T315I Bcr-Abl signaling ( Supplemental ) .", "label": "None"}
{"id": "24256696", "sentence": "In mammals , mTOR associates with mammalian lethal with SEC13 protein 8 ( mLST8 ) , @GENE$ AKT substrate of 40 kDa ( AKT1S1 ) and regulatory associated protein of mTOR ( RAPTOR ) to form the rapamycin-sensitive mTOR complex 1 (mTORC1) . The mTORC1 activates protein synthesis through modulation of the 40S ribosomal protein S6 kinase ( @VARIANT$ ) and the translational initiation factor eIF-4E binding protein 1 ( 4E-BP1 ) . mTORC1 is acutely sensitive to inhibition by Sirolimus/Everolimus .", "label": "None"}
{"id": "PMC4041556", "sentence": "Second-generation EGFR TKIs – such as neratinib , afatinib and dacomitinib – are effective in preclinical gefitinib- and erlotinib-resistant @GENE$ @VARIANT$ models , but to date their delivery in EGFR TKI-resistant patients have shown disappointing results in the clinic .", "label": "resistance or non-response"}
{"id": "24594844", "sentence": "cDzT cleaves EGFR @VARIANT$ mRNA , which leads to a decrease in EGFR protein levels , whereas @DRUG$ is a second-line TKI that irreversibly binds to the intracellular kinase domain of @GENE$ and suppresses its downstream signaling .", "label": "response"}
{"id": "24092472", "sentence": "Parts ( b ) and ( d ) present the distributions of total binding free energies of the mutants ( with WT protein included ) with two inhibitors @DRUG$ and erlotinib . The red lines and solid blue circles show the binding free energy for the WT @GENE$ and the @VARIANT$ mutant respectively .", "label": "sensitivity"}
{"id": "24497964", "sentence": "Somatic mutations in the @GENE$ gene have been identified as a major determinant of the clinical response to treatment with EGFR tyrosine kinase inhibitors ( TKIs ) , such as gefitinib and @DRUG$ , in patients with non-small cell lung cancer ( NSCLC ) . Most of the EGFR mutations occur in exons 19 to 21 , which encode the tyrosine kinase domain of the receptor . Deletions in exon 19 ( such as delE746-A750 ) and the @VARIANT$ point mutation in exon 21 are the commonest mutations found in NSCLC , accounting for about 90 % of all EGFR mutations .", "label": "sensitivity"}
{"id": "24416053", "sentence": "New mutations including @VARIANT$ and L1196M are detected in @GENE$ kinase in biopsy performed in lung cancer recurrent patients administered with ALK inhibitors . The tolerance mechanism of those mutations resembles that of @DRUG$ used in recombination of BCR-ABL rather than T790M mutation which is the tolerance mechanism of EGFR-TKI .", "label": "None"}
{"id": "25405807", "sentence": "Inhibition of epidermal growth factor receptor (EGFR) kinase activity by EGFR tyrosine kinase inhibitors ( @GENE$ ) , such as @DRUG$ and erlotinib , can result in improved response and prolonged progression-free survival ( PFS ) in selected non-small cell lung cancer ( NSCLC ) patients harboring sensitizing EGFR mutations , especially the exon 19del and exon 21 @VARIANT$ mutations – .", "label": "sensitivity"}
{"id": "22655263", "sentence": "In vivo efficacy was described only for the @VARIANT$ gatekeeper mutation , confirming a higher potency with respect to @DRUG$ in inhibiting the in vivo growth of ALK–L1196M driven @GENE$ cells .", "label": "None"}
{"id": "24959087", "sentence": "Again , the activity of this resistance mechanism could be suppressed through combined MET and BRAF or @GENE$ inhibition . Further evidence of the efficacy of combination therapy in overcoming resistance is demonstrated by NSCLC cell lines resistant to erlotinib and the MET inhibitor SU11274 , which display upregulation of both mTOR ( mammalian target of rapamycin ) and Wnt pathway components and restoration of sensitivity to EGFR/MET inhibition by the addition of @DRUG$ . A final mechanism of resistance in gastric cancer cell lines has been demonstrated when MET amplified SNU6838 gastric cancer cell lines were treated with the MET inhibitors PHA-665752 and PF2341066 ; a novel mutation occurred in the activation loop of MET , causing a conformal change that blocked inhibitor binding analogous to the gatekeeper mutations seen in EGFR ( T790M ) following erlotinib treatment and in ABL ( @VARIANT$ ) following imatinib .", "label": "None"}
{"id": "24523596", "sentence": "Δ-235A −113A&gt ; G −29A&gt ; G 34G&gt;A @VARIANT$ N-terminal 114T & gt ; C No change N-terminal @GENE$ ; T G51C N-terminal 369C&gt ; T No change NBD 376C&gt ; T Q126stop NBD 421C&gt ; A Q141K NBD Increased bioavailability of @DRUG$ and lactone form of 9-aminocamptotecin .", "label": "None"}
{"id": "24922058", "sentence": "It would be interesting to study in the future if @VARIANT$ , @GENE$ , MECP2 , LSD1 or other yet-to-be identified REST interactors are involved . Notably , we did not observe pathways specifically enriched in any group of REST targets with different @DRUG$ occupancies .", "label": "None"}
{"id": "23493838", "sentence": "A complete hematological response and a major cytogenetic response were observed broadly across the @GENE$ mutants , including individuals harboring the dasatinib-resistant F317L , the nilotinib-resistant Y253H , and F359C/I/V mutations , but not T315I . Nine individuals developed new mutations in the course of bosutinib treatment ( V299L , n = 4 ; @VARIANT$ , n = 2 ; T315I , n = 2 ; F359C , n = 1 ; G250E , n = 1 ) and eight of these individuals discontinued bosutinib because of progressive disease or unsatisfactory response .", "label": "None"}
{"id": "22655263", "sentence": "Ki determination demonstrated a very similar biochemical potency on wild-type ALK and the @VARIANT$ ALK mutant ( 0.09 and 0.08 nM respectively ) , with both cellular and in vivo data ( using engineered @GENE$ cells ) indicating that growth of ALK–L1196M mutant driven-cells is inhibited at similar , albeit slightly higher , doses which inhibit cells harboring wild-type ALK ( Katayama et al. , ) . AP26113 was also described to be active on a series of in vitro induced crizotinib resistant mutations , which however have not been observed to date in clinical cases of acquired @DRUG$ resistance ( Zhang et al. , ) .", "label": "None"}
{"id": "22649765", "sentence": "( B ) Senescence assay in @VARIANT$ breast cancer cells . Sagopilone ( @GENE$ ) , @DRUG$ ( Dox , positive control ) , or vehicle ( ethanol ) were added 24 h after seeding of cells for 6 days .", "label": "None"}
{"id": "23662132", "sentence": "The data demonstrated that @DRUG$ could prevent @VARIANT$ via a direct protective action on β cells without alteration of periphery insulin sensitivity [ ] . Moreover , its antidiabetic mechanism involves activation of @GENE$ extracellular-signal regulated kinases ( ERK)1/2 .", "label": "None"}
{"id": "25505694", "sentence": "The lack of efficacy could probably be related to the high concentrations of neratinib required in preclinical studies to inhibit EGFR @VARIANT$ and the limitations of clinical dosing . Dacomitinib Dacomitinib is an irreversible EGFR , @GENE$ and HER4 inhibitor with a higher kinase inhibition than gefitinib/erlotinib in both gefitinib/erlotinib-sensitive and in EGFR-T790M and HER2 mutated cell lines [ ] .", "label": "None"}
{"id": "21188111", "sentence": "In a recent report , the c-KIT mutation @VARIANT$ was associated with resistance to multiple @GENE$ inhibitors including imatinib , @DRUG$ , and sorafenib , but objective tumor responses could be induced in 2 patients bearing the KIT L576P mutation after treatment with dasatinib .", "label": "resistance or non-response"}
{"id": "23533466", "sentence": "3.2. Bufalin Overcomes the Resistance to Irreversible EGFR-TKIs Induced by HGF via Inhibition of @GENE$ Pathway H1975 cancer cell line with mutations in EGFR exons 21 ( L858R ) and 20 ( @VARIANT$ ) was refractory to reversible EGFR-TKIs , gefitinib , and erlotinib [ ] , but was sensitive to irreversible EGFR-TKIs , such as BIBW2992 ( @DRUG$ ) .", "label": "None"}
{"id": "24944510", "sentence": "The reversible dual ALK/EGFR inhibitor AP26113 is a more potent @GENE$ inhibitor than @DRUG$ and demonstrates preclinical activity against various secondary mutations resistant to crizotinib , including L1196 and @VARIANT$ .", "label": "resistance"}
{"id": "25580271", "sentence": "The overall survival difference observed is most likely related to the larger size of this analysis compared to previous trials of @GENE$ tyrosine kinase inhibitors vs. platinum based chemotherapy , rather than the specific activity of @DRUG$ . A randomized phase II trial compared erlotinib to erlotinib plus bevacizumab in patients with activating EGFR mutations ( defined as exon 19 deletion and exon 21 @VARIANT$ point mutations ) and advanced stage NSCLC ( n = 152 ) [ ] .", "label": "sensitivity"}
{"id": "20300583", "sentence": "In the one case of discordance between @GENE$ mutation status before and after combined @DRUG$ therapy ( case # 4 ) , a mutated KRAS gene ( Exon 2 @VARIANT$ ) was found in the primary CRC , while no KRAS mutation was observed in a liver metastasis sample obtained after combined cetuximab therapy ( ) .", "label": "sensitivity"}
{"id": "24623981", "sentence": "Patients had to have been treated with either @DRUG$ or gefitinib in the study . @VARIANT$ had to have been evaluated in the primary lung-cancer tissue of patients before @GENE$ TKI treatment , without limitation to the detection methods .", "label": "resistance or non-response"}
{"id": "24876815", "sentence": "The cause of refractoriness has been identified in ca. 15 % of mCRC patients as mutations in the BRAF gene , primarily @VARIANT$ substitution . Raf family proteins are downstream of Ras proteins in the signal transduction pathway originating at @GENE$ . It comes as no surprise , then , that activating mutations in the BRAF gene occurring in cancer cells have a similar clinical effect to KRAS gene mutations , making them refractory both to cetuximab and @DRUG$ [ , , – ] .", "label": "None"}
{"id": "17177598", "sentence": "However , @DRUG$ did induce dose dependent cell death in @GENE$ subclones expressing the EGFR ectodomain mutants ( missense and vIII truncation ) or EGFR kinase domain mutants ( @VARIANT$ and L861Q ) ( A ) .", "label": "None"}
{"id": "16288556", "sentence": "As previously demonstrated [ , , ] , cells with the deletion mutant and the point mutation @VARIANT$ were inhibited by the TKIs @DRUG$ and erlotinib , while the exon 20 insertion mutation was resistant . Three patients with lung adenocarcinoma and with exon 20 deletion mutants of EGFR failed to show a clinical response ( contrary to the expectation that , since the general response rate of tumors with @GENE$ mutations to TKIs is about 80 % , two or all three of these particular ones would be responsive ) .", "label": "sensitivity"}
{"id": "24944510", "sentence": "Multiple secondary mutations have already been identified in patients treated with @DRUG$ . Homologous to the gatekeeper EGFR T790M mutation is the L1196M substitution , which , unlike EGFR T790M , does not appear to confer a growth disadvantage to cells . Other secondary mutations such as G1269A , C1156Y , @VARIANT$ , and 1151Tins may affect affinity of the mutant ALK for either ATP or drug , and these differences have ramifications on the development of next-generation @GENE$ inhibitors , which have varied mutation-specific efficacy among different agents .", "label": "resistance"}
{"id": "21333004", "sentence": "Yun et al [ ] showed that @DRUG$ directly binds more tightly to the @VARIANT$ mutant than to the wild type @GENE$ in vitro , while Fabian et al [ ] indicated that EGFR with gefitinib sensitive mutations does not differ from wild type EGFR in terms of gefitinib binding affinity .", "label": "sensitivity"}
{"id": "25333255", "sentence": "Further TKI improvement came from the higher binding affinity and selectivity than imatinib through the follow-up substance @DRUG$ ( AMN107 ) [ ] . In addition , bosutinib ( SKI-606 ) was developed , a second line inhibitor which has the broadest target spectrum inhibiting SRC , ABL and @GENE$ , as well as serine kinases CAMK2G and STE20 , but bosutinib does not target PDGFR and KIT [ , ] . Finally , the third line inhibitor ponatinib has been developed and shown to exhibit substantial efficacy in patients with CML in whom the polyresistant BCR-ABL1 @VARIANT$ mutation is expressed in leukemic cells [ ] .", "label": "None"}
{"id": "23423475", "sentence": "Exon 19 deletions and the @VARIANT$ mutation constitute ∼90 % of the EGFR mutations identified to date . EGFR MuT+ lead to structural changes , which stabilize the active form of the tyrosine kinase domain and result in a high affinity for binding @GENE$ tyrosine kinase inhibitors ( TKIs ; Carey et al. , ) . In patients with tumors that are positive for these mutations , the current data supports sensitivity to @DRUG$ or erlotinib ( NCCN Practice Guidelines in Oncology , , ) .", "label": "sensitivity"}
{"id": "19568750", "sentence": "@GENE$ ( Ile 105 Val ) Forward primer : 5′-CAGGGCTCTATGGGAAGGAC-3′ ( @VARIANT$ , rs1695 ) Reverse primer : 5′-Acrydite™-CAGGAGATCAGAAACCACCAGTT-3′ Probe : 5′-Cy3-AAATACATCTCCC-3′ 5′-Cy5-AAATACGTCTCCC-3′ After PCR amplification and gel electrophoresis test , PCR products were processed by @DRUG$ precipitation , evaporation , or left untreated .", "label": "None"}
{"id": "21687501", "sentence": "Consistently HTR3A rs1062613 ( @VARIANT$ ) and two polymorphisms in HTR3B ( −100 −102 AAG deletion variant and rs1176744 ) have been found to be associated with chemotherapy and @DRUG$ treatment induced vomiting and nausea ( Tremblay et al. , ; Kato et al. , ; Sugai et al. , ; Tanaka et al. , ) . 5-HT6 receptor The 5-HT6 receptor is a @GENE$ is expressed almost exclusively in the brain .", "label": "None"}
{"id": "23994953", "sentence": "While preparing this manuscript , Cortot et al. reported that PC-9 derived clones with acquired resistance to mutant-selective EGFR inhibitors and irreversible quinazoline EGFR inhibitors in the absence of EGFR @VARIANT$ demonstrate a significantly activated IGF-1R signaling , and pharmacological inhibition of IGF-1R restored sensitivity to EGFR inhibitors . Despite no patient data supporting the role of IGF-1R in acquired resistance to gefitinib/erlotinib , we are beginning to accumulate evidence from preclinical models indicating that clinical trials of IGF-1R inhibitors with demonstrated activity in unselected NSCLC patients might play a role in association with @GENE$ inhibitors in the management of NSCLCs with acquired resistance to gefitinib/erlotinib .", "label": "resistance or non-response"}
{"id": "22655263", "sentence": "When tested in Ba/F3 cells driven by ALK mutants identified in crizotinib relapsed patients , NMS-E628 is circa fivefold more potent than @DRUG$ in inhibiting the proliferation of @VARIANT$ ALK and C1156Y @GENE$ in vitro and in vivo ( Ardini et al. , ) .", "label": "resistance"}
{"id": "24944510", "sentence": "Multiple secondary mutations have already been identified in patients treated with @DRUG$ . Homologous to the gatekeeper EGFR T790M mutation is the L1196M substitution , which , unlike EGFR T790M , does not appear to confer a growth disadvantage to cells . Other secondary mutations such as G1269A , C1156Y , @VARIANT$ , and 1151Tins may affect affinity of the mutant @GENE$ for either ATP or drug , and these differences have ramifications on the development of next-generation ALK inhibitors , which have varied mutation-specific efficacy among different agents .", "label": "resistance"}
{"id": "23527257", "sentence": "In the erlotinib-resistant cells from PC9 established by Tabara et al , constitutive PI3K/Akt activation was effectively inhibited by @DRUG$ . Moreover , HER2 overexpression and amplification were reported recently to be a potential mechanism of acquired resistance to EGFR inhibition in @GENE$ mutant lung cancers that lack the second-site EGFR @VARIANT$ mutation .", "label": "response"}
{"id": "23610714", "sentence": "@DRUG$ has been found to be effective not only for GIST with C-KIT mutations but also for GIST with @GENE$ mutations and for wild-type GISTs. , However , no adjuvant treatment is recommended in GISTs with the @VARIANT$ missense mutation in the PDGFRA exon 18 , which are known to be unresponsive to imatinib and showed very favorable outcome after surgery .", "label": "resistance or non-response"}
{"id": "24052078", "sentence": "In addition , previous reports showed the presence of signaling cross-activation between MET and EGFR in both A549 and H1975 cells , and both the @VARIANT$ mutation of EGFR and c-Met amplification are known mechanisms of acquired gefitinib ( TKI ) resistance in lung cancer . As c-Met has a critical role in NSCLC , co-treatment with a c-Met inhibitor plus a reversible or irreversible EGFR kinase inhibitor ( i.e. , to achieve dual c-Met @GENE$ inhibition ) may represent an alternative strategy to circumvent T790M-EGFR mediated resistance in lung cancer . Here , we report for the first time that erlotinib/MPT0E028 co-treatment inhibits HER-2 , IGF-IR , and c-Met in erlotinib-resistant lung cancer cells .", "label": "resistance or non-response"}
{"id": "15737014", "sentence": "EGFR Mutants Containing the @VARIANT$ Mutation Are Resistant to Inhibition by Gefitinib or @DRUG$ 293T cells were transiently transfected with plasmids encoding wild-type ( WT ) EGFR or @GENE$ mutants with the following changes : T790M , L858R , L858R + T790M , del L747–E749 ; A750P , or del L747–E749 ; A750P + T790M .", "label": "resistance or non-response"}
{"id": "24516334", "sentence": "For example , three @GENE$ mutations ( T315I , Y253H , and @VARIANT$ ) have a predicted role in abrogating binding of @DRUG$ to BCR-ABL in resistant patients .", "label": "None"}
{"id": "25568936", "sentence": "Moreover , interactions between @DRUG$ and MYO2 or MYH9 have been described , and a MYH9 inhibitor synergizes with @GENE$ inhibitors to induce apoptosis in cells carrying the drug-resistant mutation @VARIANT$ .", "label": "resistance or non-response"}
{"id": "22013387", "sentence": "Recently , Peng et al. reported that ethanol mediated increases in extracellular adenosine , which act via @GENE$ A2BR , link the ingestion and metabolism of @DRUG$ to the development of hepatic steatosis .", "label": "None"}
{"id": "23199147", "sentence": "For example , decreased enzyme activity has been determined for variant forms of the enzyme @GENE$ @VARIANT$ , G460A , and A719G are the prevalent mutations in Caucasians , and A719G is the prevalent variant in Asian , African and African-American populations that lead to 80–95 % decreased activity resulting in thiopurine drug toxicity in childhood ALL treatment with 6-mercaptopurine , @DRUG$ and azathiopurine .", "label": "None"}
{"id": "21188111", "sentence": "In a recent report , the @GENE$ mutation @VARIANT$ was associated with resistance to multiple KIT inhibitors including imatinib , @DRUG$ , and sorafenib , but objective tumor responses could be induced in 2 patients bearing the KIT L576P mutation after treatment with dasatinib .", "label": "resistance or non-response"}
{"id": "25110867", "sentence": "In vitro assays have shown that dacomitinib is active in gefitinib-sensitive and gefitinib-resistant cells as well as @GENE$ and HER2 mutated NSCLC cell lines with or without MET amplification . Dacomitinib inhibited EGFR phosphorylation and downstream signaling molecules , including AKT and ERK1/2 , and induced apoptosis in the EGFR @VARIANT$ containing H3255 GR cell line at 10 nmol/L concentration .", "label": "resistance or non-response"}
{"id": "22898871", "sentence": "The cell cycle arrest and the senescent response detected in @DRUG$ treated K562 cells could be linked to some other @GENE$ substrates , such as the retinoblastoma protein ( Rb ) involved in @VARIANT$ binding and proliferation or TAF6 , a transcription factor involved in p21 expression even in the absence of p53 . ,", "label": "None"}
{"id": "24768818", "sentence": "@DRUG$ is a third-generation TKI developed for the treatment of CML patients with resistance to imatinib . It was selected primarily to circumvent the steric hindrance introduced by the @GENE$ @VARIANT$ “gatekeeper” mutation and has proven to be a more potent but considerably less selective inhibitor than imatinib .", "label": "response"}
{"id": "25033171", "sentence": "In addition , we have analyzed the energetic contribution to @DRUG$ on residue level as well , which showed that the residue Leu18 ( located just in the P-loop region ) contributed the most to the attenuated binding of crizotinib to G2032R-ROS1 as shown in , therefore well supporting the issue that the P-loop conformation governs crizotinib resistance in @VARIANT$ mutated @GENE$ tyrosine kinase .", "label": "resistance"}
{"id": "22076124", "sentence": "Indeed , this has already been documented for a patient with NSCLC who relapsed after the appearance of @VARIANT$ and L1196M mutations in EML4–ALK [ ] . L1196M represents a mutation of the “gatekeeper” residue , similar to the T790M gefitinib-resistance mutations observed in EGFR , and T315I mutations in @GENE$ . Mutations in the gatekeeper site are thought to increase the affinity for ATP significantly , outcompeting the effects of ATP competitive inhibitors [ ] .", "label": "None"}
{"id": "23238683", "sentence": "In @GENE$ and @VARIANT$ cells , @DRUG$ efficiently inhibited BCR-ABL phosphorylation , but dephosphorylation of CRLK necessitated higher doses of ponatinib ( Figure ) .", "label": "response"}
{"id": "25580271", "sentence": "There are several promising agents for patients with activating EGFR mutations who experience disease progression of an EGFR tyrosine kinase inhibitor and have a @VARIANT$ resistance mutation , and multiple clinical trials will be available . Trials investigating adjuvant erlotinib in EGFR mutant NSCLC and comparing erlotinib to @DRUG$ plus bevacizumab in metastatic EGFR mutant NSCLC are ongoing . Crizotinib , when compared to platinum pemetrexed , results in a superior ORR and progression-free survival in patients with @GENE$ rearranged NSCLC , and ceritinib is a second-line option for this patient population , but patients need to be monitored closely for adverse events and the need for dose reductions .", "label": "None"}
{"id": "23566546", "sentence": "Case Histrogical type EGFR mutation status Brinkman index Treatment agent Response @GENE$ ( ng/mL ) IL-10 ( ng/mL ) RANTES ( pg/ml ) 1 Ad Ex21 L858R 900 gefitinib PR 5.79 1.67 2 2 Ad Ex21 L858R 0 erlotinib PR_3.33 94.2 1.41 3 Ad Ex19 del 0 erlotinib PR 4.09 126 2.13 4 Ad Ex21 L858R 0 gefitinib PR_3.92 18.1 1.85 5 Ad Ex21 L858R + Ex19 del 370 erlotinib PR 21.9 1.23 2.11 6 Ad Ex19 del 0 erlotinib PR 7.05 1.37 2.56 7 Ad Ex19 del 0 gefitinib PR 4.82 1.59 2.02 8 Ad Ex21 L858R 1640 gefitinib PR 54.9 2.7 2.38 9 Ad negative 400 erlotinib SD 34.9 3.39 3.66 10 Ad negative 0 erlotinib SD 27.1 4.94 2.25 11 Ad unknown 1800 erlotinib SD NE NE NE 12 Sq Ex19 del 3840 gefitinib SD 12.6 1.1 1.98 13 Ad Ex19 del 30 @DRUG$ SD 5.27 0.69 2.66 14 Ad Ex19 del 0 erlotinib SD 10.5 0.85 2.5 15 Ad unknown 300 erlotinib SD 7.69 2.61 1.7 16 La negative 2080 erlotinib SD NE NE NE 17 Sq Ex21 L858R 750 erlotinib SD 11.6 56.3 3.06 18 Ad unknown 600 erlotinib SD 13.7 1.1 2.82 19 Ad Ex21 L858R 0 erlotinib SD 20.6 11.6 0.783 20 Ad Ex19 del 0 erlotinib SD 14.8 2.07 2.02 21 Ad Ex21 L858R + Ex19 del 0 gefitinib SD 3.04 1.3 1.76 22 Ad Ex19 del 200 gefitinib SD 10.9 1.59 1.91 23 Sq unknown 1560 erlotinib PD NE NE NE 24 Ad negative 1080 erlotinib PD 25.2 8.15 1.57 25 Ad unknown 0 erlotinib PD NE NE NE 26 Ad Ex18 @VARIANT$ 2000 erlotinib PD 11.6 4.48 3.12 27 Ad unknown 1410 erlotinib PD NE NE NE 28 Ad Ex19 del 1000 gefitinib PD 9.44 2.25 2.89 29 Ad negative 1100 erlotinib PD 56.3 5.63 2.16 30 Ad negative 2000 erlotinib PD 15.6 0.85 0.292 31 Ad negative 825 erlotinib PD 8.27 1.59 2.13 32 Ad Ex21 L858R 0 erlotinib PD 5.34 7.05 1.7 33 Ad negative 1680 erlotinib PD 57.7 1.63 2.06", "label": "None"}
{"id": "24244732", "sentence": "Exocytotic phenotypes of point mutations in lof rab-3 The @VARIANT$ mutation enhances the interaction between Munc18 and @GENE$ [ ] , without affecting syntaxin binding [ ] . Despite this biochemical characterisation , the effect of the mutation on sensitivity to high concentrations of @DRUG$ was surprisingly independent of functional rab-3 .", "label": "None"}
{"id": "24737415", "sentence": "A low tumor mitotic count , gastric location , and patient allocation to the 3-year adjuvant @DRUG$ arm were strongly associated with favorable RFS in univariable survival analyses ( each P & lt ; .001 ; ; ) . Tumor rupture , KIT exon 9 mutation , and a large body mass index were also associated with unfavorable RFS , whereas tumor @GENE$ mutation @VARIANT$ was associated with favorable RFS ( ) .", "label": "resistance or non-response"}
{"id": "24939055", "sentence": "The EGF receptor tyrosine kinase inhibitors ( @GENE$ ) gefitinib and @DRUG$ have shown marked therapeutic effects against NSCLCs with EGFR activating mutations , such as exon 19 deletions and L858R point mutations [ ] . Almost all tumors , however , acquire resistance to EGFR-TKIs after varying periods of time . Common mechanisms for acquired resistance include emergence of an EGFR gatekeeper mutation ( @VARIANT$ ) and MET gene amplification [ , ] .", "label": "resistance or non-response"}
{"id": "23029123", "sentence": "The importance of D2 receptor involvement in ethanol actions on PRL production and cell proliferation is evident in the experiment where @DRUG$ actions on lactotropes ' function were evaluated in clonal cell lines expressing various levels of D2 receptor isoforms . It was found that V cells , which lacked functional D2 receptors and had high basal levels of PRL , showed a significant reduction in PRL production following @VARIANT$ and D2L receptor transfection . As described by an extended allosteric ternary complex model of @GENE$ , receptors spontaneously isomerize between active and inactive conformations , so receptors can modulate signaling pathways in the absence of an agonist .", "label": "None"}
{"id": "25221748", "sentence": "As a molecular chaperone for proteins involved in @GENE$ , HGF , and EML4/ALK fusion , the inhibition of heat shock protein 90 (HSP90) is also being considered as a target for compensatory pathway inhibition and has fueled combination therapies in both EGFR-TKI and ALK inhibitor-resistant disease . In the advanced NSCLC EGFR-TKI resistant setting , the HSP90 small molecule inhibitor AUY922 is being evaluated as monotherapy in a phase II clinical trial vs. pemetrexed or @DRUG$ in patients with tumors with activating EGFR mutations ( www.clinicaltrials.gov : NCT016461250 ) . This agent is also being assessed in a phase II trial in patients with de novo resistant @VARIANT$ mutations not previously treated with EGFR-TKIs ( www.clinicaltrials.gov : NCT01854034 ) and in patients with EGFR mutations and/or EGFR-TKI resistant disease , as part of a phase II cluster study in Chinese patients evaluating five novel inhibitors of HSP90 , PI3K , ALK , MET , and MEK ( ) .", "label": "None"}
{"id": "21264348", "sentence": "One of the most interesting findings was that a number of peptides in @VARIANT$ Abl that showed no reduction in deuterium incorporation in the presence of @DRUG$ alone ( , bottom left ) showed nearly the same reduction in deuterium incorporation in dasatinib+GNF-5 ( ) as was seen for dasatinib binding to wild-type @GENE$ ( , top left ) .", "label": "None"}
{"id": "24981574", "sentence": "Since previous studies have suggested that a putative NFκB response element ( 5′-GGGRNWYYCC-3′ ) is located at 5′-flanking region of @GENE$ gene , we further evaluated whether @DRUG$ modulates BTG2 through the NFκB pathway in PC-3 cells . These results are in agreement with previous study showing curcumin upregulated BTG2 expression by blocking the NFκB activity in U937 cells , a human leukemic monocyte lymphoma cell line although other early study indicated that NFκB is the activator of BTG2 expression in @VARIANT$ cells , a human ductal breast epithelial tumor cell line .", "label": "None"}
{"id": "23555954", "sentence": "The cell line H1975 has a sensitizing L858R kinase domain mutation in exon 21 , but also a second mutation ( @VARIANT$ , in cis , in the kinase domain ) rendering them resistant to the reversible TKIs gefitinib and @DRUG$ . miR-146a was expressed in all the five cell lines studied , with the similar magnitude , independent of the genomic status of the @GENE$ .", "label": "resistance or non-response"}
{"id": "25562700", "sentence": "Molecule Target Biomarker Indication vemurafenib BRAF kinase BRAF @VARIANT$ mutant melanoma @DRUG$ VEGFR , EGFR , RETR not included on the label thyroid cancer abiraterone CYP 17A1 not included on the label prostate cancer ipilimumab CTLA-4 not included on the label melanoma brentuximab vedotin CD30 ( ACD technology ) not included on the label lymphoma crizotinib ALK ALK-EML4 fusion protein lung cancer BRAF : Serine/threonine-protein kinase B-Raf ; VEGFR : Vascular endothelial growth factor receptor ; EGFR : epidermal growth factor receptor ; RETR : RET proto-oncogen receptor ; CYP 17A1 : cytochrome P450 17A1 ; CTLA-4 : Cytotoxic T-Lymphocyte Antigen 4 ; CD30 : Cluster of Differentiation 30 ; ADC : Antibody Conjugated Drug ; ALK-EML4 : anaplastic lymphoma kinase (ALK) ; echinoderm @GENE$ ( EML4 ) fusion .", "label": "None"}
{"id": "25563355", "sentence": "In the xenograft model of mice , the combination of cetuximab and afatinib can lead to a significant reduction of erlotinib-resistant tumor harboring @VARIANT$ , compared to gefitinib plus cetuximab [ ] . A phase II study supported by the above preclinical data was then conducted using the combination of cetuximab and afatinib in NSCLC patients who developed acquired resistance to first-generation @GENE$ by clinical definition [ , ] .", "label": "resistance or non-response"}
{"id": "23717811", "sentence": "Therefore , in pre-clinical studies , vemurafenib is strongly synergistic with EFGR inhibitors like @DRUG$ for colon cancers expressing @GENE$ @VARIANT$ mutations ( Prahallad et al. , ) .", "label": "resistance or non-response"}
{"id": "23527257", "sentence": "In the erlotinib-resistant cells from PC9 established by Tabara et al , constitutive PI3K/Akt activation was effectively inhibited by @DRUG$ . Moreover , HER2 overexpression and amplification were reported recently to be a potential mechanism of acquired resistance to @GENE$ inhibition in EGFR mutant lung cancers that lack the second-site EGFR @VARIANT$ mutation .", "label": "response"}
{"id": "25162713", "sentence": "Many evidences showed that patients with advanced lung adenocarcinomas harbor @GENE$ mutations , @VARIANT$ missense mutations at exon 21 or deletions in exon 19 were more sensitive to the EGFR-TKI erlotinib or @DRUG$ , , .", "label": "sensitivity"}
{"id": "24137565", "sentence": "These results are consistent with the requirement for tight XRCC1-pol β interaction for strong PARPi mediated sensitization ( @VARIANT$ in Figure B ) . However , the extremely low PARPi mediated sensitization in the cells expressing the reduced @GENE$ protein suggests there may be additional XRCC1 effects linked to its ability to take the oxidized form . Pol β null cells are minimally hypersensitive to DNA oxidants such as peroxynitrite , IR , and @DRUG$ where repair of oxidative DNA damage does not involve significant formation of an intermediate with a 5′-sugar phosphate .", "label": "None"}
{"id": "23994953", "sentence": "Indeed , the fact that the combination of @DRUG$ plus IGF-1R inhibitors ( I-OMe-AG538 or AG1024 ) fully prevents the acquired erlotinib-resistant phenotype is consistent with IGF-1R playing a major role in this process . While preparing this manuscript , Cortot et al. reported that PC-9 derived clones with acquired resistance to mutant-selective EGFR inhibitors and irreversible quinazoline @GENE$ inhibitors in the absence of EGFR @VARIANT$ demonstrate a significantly activated IGF-1R signaling , and pharmacological inhibition of IGF-1R restored sensitivity to EGFR inhibitors .", "label": "resistance or non-response"}
{"id": "17931419", "sentence": "H1975 cells , which also contain a second mutation ( @VARIANT$ ) linked to gefitinib resistance [ ] , responded poorly to either agent . Dose- and time dependent responses of wild-type EGFR and tyrosine kinase domain mutated @GENE$ cells to @DRUG$ and gefitinib treatment .", "label": "response"}
{"id": "12838322", "sentence": "To further confirm our results obtained with LY294002 and PD98059 , we investigated whether expression of dominant negative ( dn ) PI-3K ( delta p85 ) or dn MEK ( @VARIANT$ ) will have similar effects on sensitising the MCF7RasG12V cells to the drug induced apoptosis . Effects of dn PI-3K ( Δp85 ) and dn MEK ( K97 M ) on @GENE$ induced drug resistance . MCF7RasG12V cells were transfected with plasmid containing HA-tagged MEK ( K97 M ) or HA-tagged PI-3K ( Δp85 ) for 16 h for transient expression , followed by a 8-h exposure to doxorubicin , @DRUG$ , or 5-fluorauracil , and a 16-h postdrug period in a medium containing 10 % CS FBS .", "label": "None"}
{"id": "23840353", "sentence": "When either of the MYB proteins was heterologously expressed in tobacco , the vascular tissue lignin content was markedly reduced , and transcript abundance of the genes encoding 4-coumarate : CoA ligase ( 4CL1 ) , cinnamate-4-hydroxylase ( @VARIANT$ ) and cinnamyl @DRUG$ @GENE$ ) was reduced .", "label": "None"}
{"id": "24294007", "sentence": "Recent data have suggested that tumors with specific @GENE$ mutations , especially the glycine-to-aspartate mutation in codon 13 ( @VARIANT$ ) mutation , may be sensitive to @DRUG$ or panitumumab .", "label": "resistance or non-response"}
{"id": "23994953", "sentence": "Prospective trials have demonstrated an impressive ~75 % response rate for patients whose tumors harbor these mutations , which occur as either multinucleotide in-frame deletions in exon 19 ( e.g. , delE746-A750 ) or as single missense mutations ( e.g. , @VARIANT$ ) . Unfortunately , the EGFR TKI-driven improvement in patient outcome is notably limited because virtually all NSCLC patients with erlotinib/gefitinib sensitizing @GENE$ mutations eventually acquire resistance after a median of 6–12 months of EGFR TKI therapy .", "label": "sensitivity"}
{"id": "22436374", "sentence": "Recently , the addition of @DRUG$ to afatinib has yielded impressive results in the treatment of @GENE$ reversible TKI resistant lung cancer due to @VARIANT$ mutation [ ] .", "label": "response"}
{"id": "25264741", "sentence": "Compound group ( iii ) includes CHX , cycloheximide ; COLCE , colcemid ; COLCH , colchicines ; NaCl , sodium chloride ; ADE , adenine ; TXL , @DRUG$ ; and 2-DA , 2-deoxyadenosine . The means ± standard deviation ( SD ) of cycle threshold ( Ct ) values were shown ( single experiment in duplicate ) . 2.2. Expression Changes of Retinoblastoma ( RB ) @GENE$ Genes", "label": "None"}
{"id": "15737014", "sentence": "This study revealed that the quinazoline rings of erlotinib and lapatinib interact differently with the @GENE$ kinase domain , suggesting that while the @VARIANT$ mutation may affect inhibition by erlotinib and @DRUG$ , it may not affect inhibition of EGFR by compounds similar to lapatinib .", "label": "resistance or non-response"}
{"id": "22343623", "sentence": "In this study , we examined whether the selective KOR agonist U50 ,488H could inhibit the growth of gefitinib-sensitive and @GENE$ mutant ( delE746-A750 , L858R ) NSCLC cells ( HCC827 ) and gefitinib-resistant and EGFR mutant ( @VARIANT$ ) NSCLC cells ( H1975 ) , and investigated the signalling mechanism of the KOR mediated inhibitory effect on tumour cell growth .", "label": "resistance or non-response"}
{"id": "19159467", "sentence": "At the molecular level , most patients with partial or complete responses to @DRUG$ and erlotinib harbored specific mutations in the gene that encodes @GENE$ , located on chromosome 7p12 [ ] . Exon 19 mutations , characterized by in-frame deletions of amino-acids 747–750 , account for 45 % of mutations , exon 21 mutations , resulting in @VARIANT$ substitutions , account for 40–45 % of mutations , and the remaining 10 % of mutations involve exon 18 and 20 [ - ] .", "label": "sensitivity"}
{"id": "24884501", "sentence": "The mutational frequencies of the 195 KRAS mutations in the NORDIC VII cohort were ; G12A ( 9.7 % ) , G12R ( 1.5 % ) , @VARIANT$ ( 35.4 % ) , G12C ( 9.7 % ) , G12S ( 6.2 % ) , G12V ( 15.4 % ) , and G13D ( 22.1 % ) . Cetuximab did not add significant benefit to Nordic FLOX and @GENE$ mutation was not predictive for @DRUG$ effect .", "label": "sensitivity"}
{"id": "24964744", "sentence": "Interestingly , cells with these mutations also showed greater sensitivity to gefitinib and @DRUG$ than cells with the EGFR mutation ( exon 19 deletion ) , which are associated with sensitivity to EGFR inhibitors in NSCLC . Mutations in PI3K ( @VARIANT$ ) have been shown to enhance @GENE$ mediated transformation by amplifying the ligand induced signaling output of the HER family of RTKs [ ] .", "label": "None"}
{"id": "19536092", "sentence": "The results of this analysis suggest that ATM and @GENE$ might be involved in the efficacy of @DRUG$ containing chemotherapy for ACC . The current report , although explorative in nature , may serve as a basis for further studies in other patient populations . Two genetic variations in the ATM gene have already been studied in association with OS , including the intronic @VARIANT$ ( rs664143 ) and the T-77C ( rs664677 ) SNP .", "label": "None"}
{"id": "24501009", "sentence": "Strategies to improve EGFR inhibition in @GENE$ @VARIANT$ cancers include the combination of irreversible EGFR inhibitors with the EGFR‐directed antibody cetuximab ( as reported for @DRUG$ plus cetuximab ) 19 ; the development of more potent and specific inhibitors of EGFR T790M20,21 ; and the use of intermittent but high doses of existing irreversible EGFR inhibitors .", "label": "response"}
{"id": "23186157", "sentence": "In this report we showed that GNF-2 cooperated with the Abl kinase inhibitors (AKIs) , Imatinib , Nilotinib and @DRUG$ , in inhibiting clonigenicity of Bcr-Abl @VARIANT$ transformed @GENE$ cells .", "label": "None"}
{"id": "19758442", "sentence": "The region important for interaction with the Cul5 @GENE$ marked in green and includes a conserved histidine-cysteine-cysteine-histidine motif and a suppressor of cytokine signaling Box domain . The scale at the bottom indicates amino acid positions . The structural determination of full-length @VARIANT$ has so far been unsuccessful .", "label": "None"}
{"id": "24932312", "sentence": "@GENE$ activating mutations were defined as those with exon 19 deletions or exon 21 @VARIANT$ . Efficacy evaluation A chest computed tomography scan ( including the liver and adrenal glands ) was performed within three weeks prior to the initiation of @DRUG$ treatment , at one and three months following the initiation of erlotinib treatment and then every three months thereafter .", "label": "sensitivity"}
{"id": "23569389", "sentence": "No differences in overall response rate were observed in patients with @GENE$ mutations at baseline , in particular for p-loop mutations . A subanalysis was conducted by Branford et al on the emergence of new detectable mutations in 479 patients treated with dasatinib after @DRUG$ failure , and development of new mutations , including @VARIANT$ , F317L , and V299L , was rare ( 13 % ) .", "label": "None"}
{"id": "22185378", "sentence": "( A ) Effects of combined treatment of matuzumab ( 100 μg/mL ) with a @GENE$ pathway inhibitor , PD98059 ( 25 μM ) , on cell viability by MTT assay and ( B ) Western blotting analysis of phosphorylation of p44/42 ( ERK) 1/2 on Caski and @VARIANT$ cells . Blockade of Akt signaling is a determinant factor to overcome resistance to matuzumab Previous results of our group showed that when in combination to cetuximab , that triggered EGFR degradation , matuzumab induced further reduction in cell signaling and survival when compared to @DRUG$ alone [ ] .", "label": "None"}
{"id": "25364578", "sentence": "On the basis of this study , in May 2013 the U.S Food and Drug Administration ( FDA ) approved erlotinib for use in patients with lung cancers harboring EGFR exon 19 deletions and EGFR @VARIANT$ substitutions . Whereas reversible EGFR TKIs compete with ATP in the kinase domain of EGFR , 2nd generation EGFR TKIs , also compete for ATP binding but then covalently bind at the edge of the ATP binding cleft on Cys773 of EGFR via the Michael mechanism ( addition of nucleophile to an α , β unsaturated carbonyl ) . Currently there are two lead 2nd generation EGFR TKI candidates , afatinib and dacomitinib , that are active against @GENE$ mutations with acquired resistance to erlotinib or @DRUG$ .", "label": "sensitivity"}
{"id": "25364578", "sentence": "Surprisingly , the EGFR @VARIANT$ mutation leads to decreased ability to activate ERK compared to WT EGFR which correlates with decreased @GENE$ internalization , reduced phosphorylation of SHP2 , hyperactivity of STAT3 and reduced sensitivity to @DRUG$ .", "label": "sensitivity"}
{"id": "24634705", "sentence": "An in vitro model of EML4-ALK with the @VARIANT$ mutation showed that the cells were still dependent on ALK mediated signaling for tumor maintenance but are resistant to @GENE$ inhibition [ , ] . Several other drugs have shown activity in inhibiting mutations induced by @DRUG$ and are in various stages of pre-clinical and clinical testing [ ] .", "label": "resistance"}
{"id": "24969320", "sentence": "@DRUG$ ( Yervoy® ) 2011 @GENE$ expressed on T cells Immunotherapy ( mAb ) Humanised mAb targeting the inhibitory receptor CTLA4 activates immune system enhancing T cell activation and targeting CTLA4 expressing Tregs Verumafenib ( Zelboraf® ) 2011 BRAF @VARIANT$ , mutated form of BRAF Small molecule inhibitor Blocks mitogen activated protein kinase pathway reducing protein proliferation of melanoma cells carrying mutation", "label": "None"}
{"id": "23811600", "sentence": "3xFLAG tagged native BCR-ABL and the gatekeeper mutant @VARIANT$ were transfected into 293T cells stably expressing Renilla luciferase-Hsp90 fusion protein . Cells were treated with increasing concentrations of inhibitors for 1 hour prior to cell lysis and the LUMIER assay . Treatment of cells with type II inhibitors imatinib ( b ) and ponatinib ( d ) or type I inhibitor @DRUG$ ( c ) lead to decreased @GENE$ interaction .", "label": "None"}
{"id": "25505694", "sentence": "The lack of efficacy could probably be related to the high concentrations of neratinib required in preclinical studies to inhibit EGFR @VARIANT$ and the limitations of clinical dosing . Dacomitinib Dacomitinib is an irreversible EGFR , HER2 and HER4 inhibitor with a higher kinase inhibition than gefitinib/erlotinib in both gefitinib/erlotinib-sensitive and in @GENE$ and HER2 mutated cell lines [ ] .", "label": "resistance or non-response"}
{"id": "24501009", "sentence": "Strategies to improve EGFR inhibition in EGFR @VARIANT$ cancers include the combination of irreversible @GENE$ inhibitors with the EGFR‐directed antibody cetuximab ( as reported for @DRUG$ plus cetuximab ) 19 ; the development of more potent and specific inhibitors of EGFR T790M20,21 ; and the use of intermittent but high doses of existing irreversible EGFR inhibitors .", "label": "response"}
{"id": "PMC3337264", "sentence": "Pan J et al reported that EXEL-0862 is effective against Gleevec-resistant @VARIANT$ KIT and T674I PDGFRα ( 2007 ) . Recently , in vitro and animal data supported that several novel tyrosine kinase inhibitors including ( but not limited ) AP24534 ( ponatinib ) and DCC-2036 have been demonstrated effective against T315I @GENE$ .", "label": "None"}
{"id": "24255704", "sentence": "Somatic mutation of @GENE$ defines a specific subclass of lung adenocarcinomas with sensitivity to treatment with the EGFR inhibitors gefitinib or @DRUG$ [ - ] . The two major classes of EGFR mutations are an @VARIANT$ point mutation and small , in-frame deletions in exon 19 ; both types of mutation enhance the activity and oncogenicity of EGFR compared to the wild-type protein [ ] .", "label": "sensitivity"}
{"id": "24212826", "sentence": "In comparison with docetaxel , @DRUG$ therapy offers comparable clinical efficacy and a better quality of life when used as second-line treatment in previously treated NSCLC patients [ ] . In a previous study of @GENE$ treatment in chemonaive patients with specific EGFR mutations , such as exon 19 deletions and substitutions at @VARIANT$ , the treatment effect of EGFR-TKIs was sustained for up to 8–9 months and was significantly superior to the treatment effect of platinum based chemotherapy [ ] .", "label": "sensitivity"}
{"id": "24419415", "sentence": "Retrospective studies and case reports suggest that some uncommon mutations are associated with sensitivity to EGFR-TKIs.– These mutations include @VARIANT$ in exon 18 , which accounts for approximately 3 % of EGFR mutations , and L861Q in exon 21 , which represents approximately 2 % of EGFR mutations . However , these uncommon EGFR mutations have not been clearly shown to be predictive markers for the efficacy of EGFR-TKIs because of their low frequency . To investigate the efficacy of gefitinib in patients with uncommon mutations , we conducted a post-hoc analysis of the NEJ002 , which compared gefitinib and carboplatin-paclitaxel as first-line therapies for advanced NSCLC with activating @GENE$ mutations .", "label": "None"}
{"id": "23691449", "sentence": "Some of the molecular mechanisms of acquired resistance include T790M second mutation , mesenchymal epithelial transition factor ( @GENE$ ) amplification , ATP binding cassette (ABC)-G2 transporter ( ABCG2 ) and hepatocyte growth factor (HGF) overexpression , insulin-like growth factor (IGF) binding protein-3 ( IGFBP3 ) downregulation , as well as ERBB3 activation . T790M mutation The @VARIANT$ second mutation accounts for half of all resistances to gefitinib and @DRUG$ [ ] .", "label": "None"}
{"id": "20972475", "sentence": "Also available is a second assay , the BRAF ( @VARIANT$ Sequencing ) ( V6S ) , which uses sequencing to detect the @GENE$ p.Val600Glu sequence variant . Public Health Importance Available evidence indicates that the clinical benefit from treatment with EGFR monoclonal antibody inhibitors cetuximab and @DRUG$ is limited to a subgroup of only 10 % to 30 % of CRC patients .", "label": "resistance or non-response"}
{"id": "25505694", "sentence": "In 2004 , EGFR gene mutations were firstly identified : classical activating EGFR mutations are localized in exon 19 , mainly consisting of an in-frame deletion ( 45-50 % ) , and in exon 21 , consisting of the @VARIANT$ point mutation ( 40-45 % ) , even if there are less common mutations localized in other exons [ – ] . Since their identification , it was clear that EGFR mutations , more frequently observed in never smokers , adenocarcinoma histology , women and Asiatic patients , outline a distinct subgroup of NSCLC . During the last years , six phase III trials ( Table ) established that patients harboring activating @GENE$ mutations benefit more from a first line treatment with an EGFR tyrosine kinase inhibitor ( TKI ) , such as @DRUG$ or gefitinib , than from standard chemotherapy , at least in terms of response rate ( RR ) , progression-free survival ( PFS ) and quality of life [ – ] .", "label": "sensitivity"}
{"id": "23874880", "sentence": "However , despite these dramatic benefits of @GENE$ TKIs , all of these patients inevitably develop resistance to gefitinib and @DRUG$ , usually 6–12 months after initiation of TKI treatment . Several mechanisms , including a @VARIANT$ mutation in the EGFR , MET amplification , and overexpression of hepatocyte growth factor (HGF) , induce acquired resistance to reversible EGFR-TKIs for NSCLC with EGFR activating mutations – .", "label": "resistance or non-response"}
{"id": "24516298", "sentence": "After transplant his @GENE$ levels showed a rising trend after 3 months . He was planned for donor lymphocyte infusion ( DLI ) but has extensive skin graft-versus-host disease ( GVHD ) and also liver involvement . He was negative for the @VARIANT$ mutation after transplant and he is currently on @DRUG$ .", "label": "None"}
{"id": "24472312", "sentence": "The in vivo antineoplastic activity of @DRUG$ as a single agent against imatinib-resistant @VARIANT$ FIP1L1-PDGFRα expressing cells was evaluated in the nude mouse xenograft model . Thirty nu/nu BALB/c mice were subcutaneously injected with @GENE$ PDGFRα cells .", "label": "None"}
{"id": "24348666", "sentence": "Therefore , PTEN downregulation or Akt activation may be one of the mechanisms for acquired resistance to @DRUG$ . 2. Acquired resistance mechanism 1 ) Secondary @VARIANT$ mutation of the @GENE$ gene", "label": "resistance or non-response"}
{"id": "24586308", "sentence": "The effect of this is a regulation of mTORC 1 and a consecutive up regulation of eukaryotic initiation factor 4E-binding protein ( 4E-BP1 ) and the ribosomal protein S6 kinase @VARIANT$ . The phosphorylation of these proteins eventually leads to increased levels of several proteins that are important in cellular proliferation , migration and angiogenesis in RPE and vascular endothelial cells – , being crucial cellular features in the pathogenesis of retinal vascular diseases such as neovascular AMD or proliferative DR . In our experiments , a significant dose dependent effect on RPE cells as well as on HUVECs was seen in terms of inhibiting proliferation ( ) as well as migration ( ) after treatment with three different concentrations of @DRUG$ , suggesting that a significant reduction of these properties can be reached by directly targeting mTOR without specifically blocking @GENE$ or other involved cytokines .", "label": "None"}
{"id": "23994953", "sentence": "Earlier studies have suggested an active involvement of EMT in resistance to @GENE$ TKIs , and accordingly , E-cadherin expression has been reported to operate as a biomarker capable of predicting the clinical efficacy of @DRUG$ . However , it should be noted that these studies were largely based on NSCLC cells expressing wild-type EGFR ; therefore , these studies did not mimic clinical usage of EGFR TKIs because EGFR wild-type NSCLC cells are intrinsically resistant to EGFR TKIs . In this scenario , it might appear reasonable to suggest that in addition to the presence of the @VARIANT$ mutation , immunohistochemical and/or microarray based transcriptional profiling studies dedicated to specific alterations of EMT drivers ( e.g. , SLUG ) and/or effectors ( e.g. , vimentin ) may be helpful in monitoring for erlotinib responders and non-responders based on the loss of biomarkers associated with epithelial status and gain of biomarkers associated with mesenchymal status .", "label": "resistance or non-response"}
{"id": "23965851", "sentence": "The EGFR ( HER1 ) -Tyrosine Kinase Inhibitor ( TKI ) gefitinib ( ZD1839 ; Iressa ) was kindly provided by AstraZeneca ( AstraZeneca PLC Headquarters , 15 Stanhope Gate , @VARIANT$ 1 LN , London , UK ) . The @GENE$ ( HER1 ) TKI erlotinib ( Tarceva® ) was a kind gift from Roche Pharmaceuticals ( Neuilly sur Seine , France ) .", "label": "None"}
{"id": "25222496", "sentence": "We conducted this study and found that patients with exon 19 deletion had significantly reduced disease progression risk than those with exon 21 @VARIANT$ mutation after front-line TKIs . Additionally , similar trends of favorable outcome of PFS in exon 19 deletion among different first-line @GENE$ targeted agents ( @DRUG$ , erlotinib and afatinib ) , were presented in our work , but the statistical significances were not approached .", "label": "sensitivity"}
{"id": "23029123", "sentence": "The importance of D2 receptor involvement in @DRUG$ actions on PRL production and cell proliferation is evident in the experiment where ethanol actions on lactotropes ' function were evaluated in clonal cell lines expressing various levels of D2 receptor isoforms . It was found that V cells , which lacked functional D2 receptors and had high basal levels of PRL , showed a significant reduction in PRL production following @VARIANT$ and D2L receptor transfection . As described by an extended allosteric ternary complex model of @GENE$ , receptors spontaneously isomerize between active and inactive conformations , so receptors can modulate signaling pathways in the absence of an agonist .", "label": "None"}
{"id": "20102612", "sentence": "Retinoic acid significantly mitigates the apoptosis induced by chemotherapeutic agents in @VARIANT$ and ZR-75-1 cells , while it is able to increase apoptosis by these compounds in H3396 cells where @DRUG$ not induce cIAP2 expression . Many antiapoptotic proteins , such as Bcl-2 , Mcl-1 and Bcl-XL , have been shown to inhibit chemotherapeutic agent induced apoptosis in diverse cell system models including hematopoietic and neuroblastoma cells . Additionally , it has been shown that the activation of genes encoding @GENE$ and IAP proteins by NF-κB serves to block apoptosis promoted by different insults including chemotherapy induced apoptosis in different cell types [ , ,, ] .", "label": "None"}
{"id": "23696715", "sentence": "Similar results were found in another clinical trial with @DRUG$ at the same doses . Of the 15 patients with disseminated MTC treated for up to 12 months , four patients had SD over 24 months . A recent study compared the effect of four TKIs ( axitinib , sunitinib , vandetanib , and XL184 ) on cell proliferation , RET autophosphorylation , and extracellular signal regulated kinase activation in three cell lines : MZ-CRC-1 ( M918T RET mutation ) , MTC-TT ( @VARIANT$ @GENE$ mutation ) , and TPC-1 ( RET/PTC-1 rearrangement ) cells .", "label": "None"}
{"id": "25336973", "sentence": "On the contrary , the mutation @VARIANT$ in exon 2 has been associated with better response to EGFR antibodies than other KRAS mutations , but the data are mixed. , In addition to the exon 2 KRAS mutation , other mutations such as KRAS mutation exons 3–4 and NRAS mutation exons 2–4 have also emerged to be clinically relevant biomarkers of a lack of response to EGFR antibodies . For example , treating @GENE$ tumor patients with @DRUG$ may even have a detrimental effect on survival as shown in the Panitumumab Randomized Trial in Combination With Chemotherapy for Metastatic CRC to Determine Efficacy ( PRIME ) study , where patients were randomized to first-line chemotherapy with or without panitumumab .", "label": "None"}
{"id": "17973572", "sentence": "Identification of a Novel Secondary Resistant EGFR Mutation , L747S ( A ) Sequencing chromatograms with the EGFR L747S exon 19 and @VARIANT$ exon 21 by RT-PCR . ( B ) Amino acid alignments of the tyrosine kinase domain in EGFR , ErbB2 , and ABL1 . ( C ) Active conformation crystal structure of the kinase domain of @GENE$ in complex with @DRUG$ [ ] .", "label": "sensitivity"}
{"id": "23299535", "sentence": "A similar theme exists in NSCLCs with a mutation in the EGFR – secondary mutations confer insensitivity to the @GENE$ tyrosine kinase inhibitor ( EGFR-TKI ) gefitinib , and have been identified in patients with clinical resistance to @DRUG$ , but also in untreated patients ( ) . analysed NSCLC samples for one such mutation in EGFR , the @VARIANT$ mutation , from treatment-naïve patients , and from patients before and during treatment with EGFR-TKIs .", "label": "resistance or non-response"}
{"id": "23935640", "sentence": "Ponatinib ( @DRUG$ ) is an orally administered TKI designed to inhibit @GENE$ with mutations , especially @VARIANT$ , which confers resistance to other TKI such as imatinib , dasatinib , nilotinib , and bosutinib ( reviewed in [ , ] ) .", "label": "response"}
{"id": "10993652", "sentence": "@VARIANT$ proteins in cell growth control and apoptosis . Proc Natl @GENE$ Sci USA 94 : 7245-7250 Del Bino G and Darzynkiewicz Z ( 1991 ) Camptothecin , tenioside , or 4- ( 9-acridinylamino ) -3-methanesulfon-m-anisidide , but not mitoxantrone or @DRUG$ , induces degradation of nuclear DNA in the S phase of HL-60 cells .", "label": "None"}
{"id": "24894453", "sentence": "To test whether G719S and @VARIANT$ @GENE$ mutants are cetuximab-sensitive in vitro , we ectopically expressed these mutants in Ba/F3 cells , rendering these cells IL-3 independent but dependent on exogenous oncogenic EGFR signaling [ ] .", "label": "sensitivity"}
{"id": "24279718", "sentence": "The EGFR mutation @VARIANT$ has to our knowledge not previously been described in the literature , but given its proximity to mutations known to be sensitive to @GENE$ ( L858R and L861X ) , tumor clones bearing the L862R mutation could also be potentially responsive to EGFR-TKI . Meanwhile , because of rapid worsening while waiting for these new molecular tests the patient received third-line @DRUG$ , showing further progression in abdomen and pelvis , but still no sign of relapse in the thorax .", "label": "None"}
{"id": "24964744", "sentence": "MCF10a cells containing the @GENE$ mutation H1047R showed little sensitivity to single agent sirolimus , and in combination with EGFR inhibitors were still seen to be more resistant than their parental counterpart , and were more resistant than MCF10a cells containing the PIK3CA @VARIANT$ mutation . Chou and Talalay combination indices for each cell line examined Gefitinib + ZSTK474 Erlotinib + ZSTK474 @DRUG$ + Rapamycin Erlotinib + Rapamycin Gefitinib + ZSTK474 Erlotinib + ZSTK474 Gefitinib + Rapamycin Erlotinib + Rapamycin", "label": "resistance or non-response"}
{"id": "24124608", "sentence": "In addition to upregulation of IGF1R and VEGF , frequent CN gain and increased mRNA expression of GSTT1 as well as significant overexpression of @GENE$ subfamily members were observed in wild-type/PDGFRA @VARIANT$ GISTs compared to KIT-mutant GISTs . CN gain of GSTT1 was closely associated with @DRUG$ resistance .", "label": "None"}
{"id": "24465383", "sentence": "In summary , we have discovered that tolerogenic DC engineered ex vivo for low co-stimulation ability increase frequency and numbers of IL-10 expressing B-cells in vitro and in vivo , consequent to concomitant proliferation of pre existing IL-10+ B-cells and conversion of @GENE$ B-lymphcytes into IL-10 expressing cells without affecting their immunosuppressive potential in vitro . We also discovered that these DC-sensitive putative Bregs expressed receptors for @DRUG$ is produced by the tolerogenic dendritic cells . Taken together , our findings usher a potential new therapeutic approach to @VARIANT$ immunotherapy which involves suppresisve B-cells , possibly homogeneous Bregs , together with approaches and molecules that stabilise their suppressive ability and expand their numbers in vitro ( e.g. RA , IL-10 , IL-21 ) .", "label": "None"}
{"id": "19707322", "sentence": "Nilotinib is approximately 30-fold more sensitive than @DRUG$ in the killing of @GENE$ dependent cells derived from patients with CML ( K562 and Ku-812F cells ) and cell lines ( 32D and baF3 ) , and it is active against 32/33 imatinib-resistant cell lines with BCR-ABL mutations . The sensitivity of Bcr-Abl mutants to AMN107 can be summarized into 4 categories : high ( IC50 ≤ 70 nmol/L : M244V , G250E , Q252H , F3llL , F317L , M351T , V379I , L387M , H396P , H396R ) , medium ( IC50 ≤ 200 nmol/L : Y253F , E255K , F359V ) , low ( IC50 ≤ 450 nmol/L : @VARIANT$ , E255V ) , and insensitive ( IC50 & gt ; 2 μmol/L : T315I ) ( ) ( ) .", "label": "None"}
{"id": "25465236", "sentence": "( G–I ) increased inhibition potency for @DRUG$ against EGFR @VARIANT$ mutant compared to EGFR WT protein and subsequent further increase in potency for Gefitinib against EGFR L858R + E884K double mutant . ( J ) EGFR L861Q activated more than T790M but less than L858R . An orthosteric @GENE$ dictates potency of inhibitors targeting phosphorylated ( activated ) TYK2 .", "label": "None"}
{"id": "24982846", "sentence": "@DRUG$ KIT @GENE$ @VARIANT$ mutation negative Indications and usage , dosage and administration clinical pharmacology , clinical studies BCR/ABL1 Philadelphia chromosome [ t ( 9 ; 22 ) ] positive PDGFRβ PDGFR gene rearrangement positive FIP1L1/PDGFRα FIP1L1/PDGFRα fusion kinase ( or CHIC2 deletion ) positive Indications and usage , dosage and administration , clinical studies", "label": "None"}
{"id": "23238683", "sentence": "In @GENE$ and @VARIANT$ cells , ponatinib efficiently inhibited BCR-ABL phosphorylation , but dephosphorylation of CRLK necessitated higher doses of @DRUG$ ( Figure ) .", "label": "response"}
{"id": "21716602", "sentence": "While in healthy tissues , BRCA proteins may compensate for the @GENE$ inhibition of single stranded DNA break repair , such buffering is lost in BRCA mutated tumors . Other examples of addiction dependent on tumor suppressor genes are the loss of PTEN and pRB , which lead to the stimulation of PI3K/mTOR ( Neshat et al. , ) and E2F ( Sellers and Kaelin , ) , respectively . Those defects consequently render tumor cells particularly sensitive to mTOR inhibitors and @DRUG$ ( which inhibits @VARIANT$ activated topoisomerase II ) .", "label": "None"}
{"id": "17626639", "sentence": "The second hypothesis is that the presence of increased gene copy number of @GENE$ or HER2 is a better predictor of response [ - ] . When investigating the relevance of these features to our own population of lung cancer patients treated with @DRUG$ , our study detected all of these features occurring both independently and coincidentally in microdissected tumour cells . Tumours from four of thirty-eight patients contained a form of the exon 19 L747-A750 deletion and one tumour harboured the exon 21 @VARIANT$ point mutation .", "label": "sensitivity"}
{"id": "22500155", "sentence": "It is considered an important problem to deal with how @GENE$ studies should be conducted in the case of such a compound . Rapid improvement of therapeutic responses using combined vemurafenib plus @DRUG$ therapy for BRAF @VARIANT$ mutation positive melanoma is expected .", "label": "None"}
{"id": "17973572", "sentence": "After the cells were exposed to @DRUG$ for 24 h , Ba/F3-L858R cells were unable to proliferate while Ba/F3-L858R-L747S and @GENE$ cells continued to grow even in the presence of 1 μM gefitinib ( E ) . These results suggest that execution of apoptosis may be impaired by the presence of T790M and , to a lesser extent , @VARIANT$ .", "label": "None"}
{"id": "25347122", "sentence": "PI3K/mTOR/AKT pathway ; HSP90 NVP-BEZ235 ; 17-DMAG ( @GENE$ inhibitor ) However , in these trials , TNBC was unselected based on gene ontologies and differential gene expression profiles . In the randomized open-label phase III CALGB 40502/NCCTG @VARIANT$ , the new and expensive BC treatments , nanoparticle albumin bound nab-paclitaxel ( Abraxane ) and ixabepilone , the latter being a potent epothilone that can be effective after microtubule inhibitor resistance ( Ixempra ) , have failed to demonstrate any superior efficacy versus the standard of weekly @DRUG$ in combination with bevacizumab in patients with chemotherapy naïve metastatic BC .", "label": "None"}
{"id": "23992330", "sentence": "Briefly , they demonstrated the different effects of the G12 and G13 @GENE$ alleles on response to @DRUG$ and found a significant association between the presence of a @VARIANT$ mutation and survival benefit after cetuximab treatment in metastatic colorectal cancer patients [ ] .", "label": "resistance or non-response"}
{"id": "25285017", "sentence": "@VARIANT$ resulting from deletion in exon 19 is located at the head of the loop between strand β3 and helix αC of the receptor and is believed to attenuate BIM upregulation and mitochondrial apoptosis induced by TKIs . D761Y from exon 19 mutation occurs in the middle of the helix αC and forms a salt bridge that interacts with the α- and β-phosphates when ATP is present , reducing sensitivity of the @GENE$ to TKIs . T854A mutation in exon 21 interferes the contact of @DRUG$ to the ATP pocket of the receptor , hence abrogating the inhibition of tyrosine phosphorylation by erlotinib .", "label": "None"}
{"id": "24634705", "sentence": "Afatinib , an EGFR and HER2 irreversible inhibitor has been shown to reverse the effects of the @VARIANT$ mutation in preclinical lung cancer studies [ ] . In clinical trials , afatinib did not improve overall survival but showed a modest improvement in progression free survival after failure of @DRUG$ or gefitinib [ , ] . Several drawbacks are associated with these irreversible @GENE$ .", "label": "resistance or non-response"}
{"id": "25054154", "sentence": "Overall RMSD curve of native type and mutant @GENE$ @DRUG$ at 20 ns . Three independent simulations of each Protein-crizotinib complex . Time evolution of backbone RMSD is shown as a function of time for A ) native type , B ) @VARIANT$ and C ) R1275Q .", "label": "resistance"}
{"id": "16953242", "sentence": "In fact , the pleiotropic effect of BCR/ABL transformation is mostly dependent on post-translational modifications ( e.g. phosphorylation ) of signalling molecules , like those involved in the @GENE$ , PI3K/Akt and STATs pathways , which control cell growth , survival and differentiation of haematopoietic cells by modulating the expression and/or activity of downstream effectors ( ; ) ( ) . Being the deregulated BCR/ABL kinase activity the cause of CML , targeting its catalytic domain was the most rationale approach for the rational development of small molecules that inhibit ABL kinase activity . In these CML-BC patients , imatinib resistance often depends on reactivation of BCR/ABL tyrosine kinase activity via mechanisms involving BCR/ABL overexpression , gene amplification or mutations that suppress imatinib mediated kinase inhibition ( i.e. E255V and G250E ) or disrupt @DRUG$ binding ( i.e. @VARIANT$ ) ( ) .", "label": "None"}
{"id": "24127549", "sentence": "In fact , when simultaneous SIRT1 overexpression and exposure to @DRUG$ were performed , levels of @VARIANT$ .Z modestly decreased , depicting that proteasome has a major importance in @GENE$ .Z degradation , as previously described [ ] .", "label": "None"}
{"id": "24052078", "sentence": "In addition , previous reports showed the presence of signaling cross-activation between MET and EGFR in both A549 and H1975 cells , and both the @VARIANT$ mutation of EGFR and c-Met amplification are known mechanisms of acquired gefitinib ( TKI ) resistance in lung cancer . As c-Met has a critical role in NSCLC , co-treatment with a c-Met inhibitor plus a reversible or irreversible @GENE$ kinase inhibitor ( i.e. , to achieve dual c-Met /EGFR inhibition ) may represent an alternative strategy to circumvent T790M-EGFR mediated resistance in lung cancer . Here , we report for the first time that erlotinib/MPT0E028 co-treatment inhibits HER-2 , IGF-IR , and c-Met in erlotinib-resistant lung cancer cells .", "label": "resistance or non-response"}
{"id": "24495353", "sentence": "Rank Entrez ID Gene symbol Entrez ID Gene symbol Entrez ID Gene symbol 1 28978 TMEM14A 79776 ZFHX4 1727 CYB5R3 2 1843 DUSP1 4701 NDUFA7 7083 TK1 3 51022 GLRX2 715 @VARIANT$ 1292 COL6A2 4 1434 CSE1L 79818 ZNF552 857 CAV1 5 8522 GAS7 4046 LSP1 5437 POLR2H 6 51668 HSPB11 1727 CYB5R3 9833 MELK 7 10456 HAX1 357 SHROOM2 54861 SNRK 8 9902 MRC2 283298 OLFML1 4830 NME1 9 4706 NDUFAB1 23179 RGL1 231 AKR1B1 10 23560 GTPBP4 1809 DPYSL3 10418 SPON1 11 79633 FAT4 857 CAV1 2350 FOLR2 12 10418 SPON1 274 BIN1 10979 FERMT2 13 471 ATIC 79833 @GENE$ 11096 ADAMTS5 14 6403 SELP 11222 MRPL3 4638 MYLK 15 23421 ITGB3BP 23244 PDS5A 9448 MAP4K4 16 23452 ANGPTL2 6241 RRM2 54922 RASIP1 17 54861 SNRK 1289 COL5A1 6934 TCF7L2 18 2034 EPAS1 8434 RECK 4072 EPCAM 19 30008 EFEMP2 429 ASCL1 4701 NDUFA7 20 25999 CLIP3 3426 CFI 404672 GTF2H5 21 4311 MME 332 BIRC5 6241 RRM2 22 4747 NEFL 2 A2M 2192 FBLN1 23 1809 DPYSL3 10730 YME1L1 25959 KANK2 24 28998 MRPL13 11130 ZWINT 55651 NHP2 25 25959 KANK2 1292 COL6A2 5050 PAFAH1B3 Lists of the top 25 of most influential genes in influence networks based on coexpression among genes in ER + breast tumors before , during , and after a course of neoadjuvant treatment with the drug @DRUG$ .", "label": "None"}
{"id": "24276125", "sentence": "Inhibition of these dually specific threonine/tyrosine kinases leads to down-regulation of the @GENE$ signalling pathway . In a phase III open-label clinical trial ( METRIC ) [ ] trametinib was shown to significantly improve rates of progression-free and overall survival compared with chemotherapy with dacarbazine or @DRUG$ ( 6 month overall survival of 81 % and 67 % respectively , patient crossover included , p = 0.01 ) , in patients with @VARIANT$ or V600K BRAF mutation positive metastatic melanoma .", "label": "None"}
{"id": "23186157", "sentence": "Although 1 μM of @DRUG$ was active in inhibiting the clonigenicity of Ba/F3 @GENE$ @VARIANT$ cells ( data not shown ) , we found that concentrations below 30 nM have a marginal effect on clonigenicity of the above cells ( data not shown ) .", "label": "None"}
{"id": "24590311", "sentence": "Pretreatment with @DRUG$ followed by addition of imatinib resulted in a significant reduction in viability in @GENE$ T315I , Ba/F3 @VARIANT$ , LAMA84R and KCL22R ( P⩽0.04 ) .", "label": "None"}
{"id": "24252550", "sentence": "In a study of four categories of imatinib- and dasatinib treated patients ( imatinib resistant/dasatinib-responsive ; dasatinib-resistant ; blast crisis or CML progression and T315I or @VARIANT$ mutated patient receiving omacetaxine treatment ) [ ] , transcriptional and translational levels of HCK , LYN and another SFK related gene BTK were elevated in more than 50 % of resistant CML patients . This increase more significantly correlates with disease progression in a large population of CML patients . Interestingly , activation of SFKs expression is not likely caused by BCR-ABL mutation , as four @GENE$ mutated patients showed concomitant SFK activation similar to that seen in patients expressing a wild-type BCR-ABL [ ] .", "label": "None"}
{"id": "20740181", "sentence": "@DRUG$ and gefitinib inhibit the tyrosine kinase activity of @GENE$ and have been studied extensively . Since Lynch et al. have identified specific activating mutations within the tyrosine kinase domain of EGFR [ ] , the missense mutation @VARIANT$ in exon 21 and the in-frame deletion in exon 19 , nested around the amino acid residues 747 to 750 of the EGFR polypeptide , account for & gt ; 85 % of all clinically important mutations related to TKI sensitivity [ ] .", "label": "sensitivity"}
{"id": "25054154", "sentence": "We utilised three complexes , namely , native ( ALK-crizotinib ) , F1174L ( ALK F1174L-crizotinib ) , and @VARIANT$ ( @GENE$ R1275Q-crizotinib ) for our analysis .", "label": "sensitivity"}
{"id": "23242156", "sentence": "The stability of ErbB2 and GAPDH mRNA was analyzed in shRNA control ( C ) and shEBP1 transduced ( E ) @VARIANT$ cells . Total cellular RNA was isolated at the indicated times after treatment with @DRUG$ The remaining levels of ErbB2 and @GENE$ mRNAs were measured by RT-qPCR analysis .", "label": "None"}
{"id": "21165163", "sentence": "As compared to the large number of secondary resistance mutations noted in acquired imatinib resistance in CML , in the case of @GENE$ , there are currently only several documented resistance point mutations to gefitinib and @DRUG$ , including @VARIANT$ [ , ] , L747S [ ] and D761Y [ ] .", "label": "resistance or non-response"}
{"id": "23520446", "sentence": "In addition to the EGFR overexpressed cells , we also showed the phosphorylation status of @GENE$ endogenous @VARIANT$ mutant cells ( H1975 ) under treatment of VE-465 and @DRUG$ ( ) .", "label": "sensitivity"}
{"id": "22038681", "sentence": "Preliminary results from an ongoing phase 1 dose-escalation study of the multikinase , pan–BCR-ABL inhibitor ponatinib ( AP24534 ) showed antileukemic activity in patients with refractory CML , including patients with the @VARIANT$ mutation . Phase 1 and 2 trials of ponatinib are ongoing in patients with refractory CML and acute lymphoblastic leukemia . Danusertib ( PHA-739358 ) is a multikinase aurora inhibitor with in vitro activity against wild-type @GENE$ and ABL/T315I ; preliminary results from an ongoing phase 1 dose-escalation study indicate antileukemic activity in patients with AP or BC who failed imatinib and/or nilotinib or @DRUG$ .", "label": "None"}
{"id": "24982846", "sentence": "@DRUG$ @GENE$ Philadelphia chromosome [ t ( 9 ; 22 ) ] positive , BCR–ABL @VARIANT$ mutation Indications and usage , warnings and precautions , adverse reactions , use in specific populations , clinical pharmacology , clinical studies", "label": "response"}
{"id": "24939055", "sentence": "In this study , we show that the combination of a selective MEK inhibitor and a PI3K/mTOR inhibitor is effective against tumor cell lines refractory to @DRUG$ by three different mechanisms : an @GENE$ gatekeeper @VARIANT$ mutation , MET amplification , and KRAS/PIK3CA mutation .", "label": "resistance or non-response"}
{"id": "19229369", "sentence": "In br.21 , when only exon 19 deletion and @VARIANT$ mutations were considered , the difference in response rate as compared with wild-type EGFR or other mutations was significant ( 27 % vs. 7 % , p = 0.035 ) . The subset analysis of tumour samples from the intact 1 and 2 trials evaluating the addition of gefitinib to standard first-line chemotherapies demonstrated that patients whose tumours had an @GENE$ mutation had a higher response to chemotherapy plus @DRUG$ than did those without a mutation ( n = 170 : 72 % vs. 55 % , p = 0.2 ) .", "label": "sensitivity"}
{"id": "24472312", "sentence": "To examine whether @DRUG$ is active against @VARIANT$ FIP1L1-PDGFRα , we exposed @GENE$ FIP1L1-PDGFRα cells to ponatinib , sorafenib and imatinib ( the latter two serving as positive and negative controls , respectively ) ; levels of phosphorylated and total PDGFRα were measured by immunoblotting .", "label": "None"}
{"id": "15736989", "sentence": "Resistance mutations identified via in vitro screens have shown a high degree of correlation with those that develop in vivo , as shown in screens for imatinib-resistant BCR-ABL mutants [ ] and PKC412-resistant @GENE$ mutants [ ] , as well as the @VARIANT$ resistance mutation to @DRUG$ in the context of EGFR [ ] .", "label": "None"}
{"id": "25505694", "sentence": "Although cetuximab-afatinib combination showed promising results , current data do not justify its use outside clinical trials . Targeting a specific alteration of the @GENE$ downstreamingsignalling Recently , investigators have identified covalent pyrimidine EGFR inhibitors , which are 30–100 fold more potent than quinazoline based EGFR inhibitors against EGFR @VARIANT$ cells , and up to 100 fold less potent against wild type EGFR cells , as CO-1686 and AP26113 [ ] .", "label": "response"}
{"id": "19758442", "sentence": "The region important for interaction with the Cul5 ubiquitin ligase complex is marked in green and includes a conserved histidine-cysteine-cysteine-histidine motif and a @GENE$ domain . The scale at the bottom indicates amino acid positions . The structural determination of full-length @VARIANT$ has so far been unsuccessful .", "label": "None"}
{"id": "24939055", "sentence": "The EGF receptor tyrosine kinase inhibitors ( EGFR-TKIs ) gefitinib and @DRUG$ have shown marked therapeutic effects against NSCLCs with @GENE$ activating mutations , such as exon 19 deletions and L858R point mutations [ ] . Almost all tumors , however , acquire resistance to EGFR-TKIs after varying periods of time . Common mechanisms for acquired resistance include emergence of an EGFR gatekeeper mutation ( @VARIANT$ ) and MET gene amplification [ , ] .", "label": "resistance or non-response"}
{"id": "21682901", "sentence": "Pro-apoptotic agents ` Oblimersen ' , an antisense inhibitor of Bcl-2 , and ` Sorafenib ' , an orally active small molecule inhibitor of wild type and mutant BRAF or @DRUG$ a potent inhibitor of @GENE$ with the @VARIANT$ mutation are at the forefront of novel therapies developed for advanced metastatic disease [ , ] .", "label": "None"}
{"id": "24649259", "sentence": "Mutation analysis of lung cancer specimens obtained prior to the administration of first-line chemotherapy revealed the presence of an @VARIANT$ point mutation of the @GENE$ . The patient was administered @DRUG$ ( 250 mg daily ) as a first-line therapy ; however , progressive multiple brain metastases were detected after 4 months of therapy .", "label": "sensitivity"}
{"id": "24959087", "sentence": "Again , the activity of this resistance mechanism could be suppressed through combined MET and BRAF or @GENE$ inhibition . Further evidence of the efficacy of combination therapy in overcoming resistance is demonstrated by NSCLC cell lines resistant to erlotinib and the MET inhibitor SU11274 , which display upregulation of both mTOR ( mammalian target of rapamycin ) and Wnt pathway components and restoration of sensitivity to EGFR/MET inhibition by the addition of everolimus . A final mechanism of resistance in gastric cancer cell lines has been demonstrated when MET amplified SNU6838 gastric cancer cell lines were treated with the MET inhibitors PHA-665752 and PF2341066 ; a novel mutation occurred in the activation loop of MET , causing a conformal change that blocked inhibitor binding analogous to the gatekeeper mutations seen in EGFR ( @VARIANT$ ) following erlotinib treatment and in ABL ( T315I ) following @DRUG$ .", "label": "None"}
{"id": "22876876", "sentence": "First , numbers are low in particular in the @DRUG$ group and secondly addition of cetuximab was not randomized for . There seems to be a selection of patients with good performance status and good prognosis who received third line therapy compared to those who did not . Therefore , we can not draw definite conclusions from our analysis whether anti-EGFR antibodies are effective in patients with @GENE$ @VARIANT$ mutations or not .", "label": "resistance or non-response"}
{"id": "24155950", "sentence": "Our results show that bortezomib and paclitaxel combined treatment is able to target the TKIs-resistant cell lines with the @VARIANT$ mutation in Bcr-Abl . Bortezomib in combination with the PLK1 inhibitor BI 2536 induces a significant downregulation of the total levels and phosphorylation of @GENE$ , a decrease of downstream phosphorylated STAT5 and caspase dependent cell death in imatinib- , dasatinib- and nilotinib-resistant and -sensitive K562 cell lines", "label": "None"}
{"id": "24894453", "sentence": "A and B expressing @VARIANT$ ( C ) , and G724S ( D ) mutants with or/and without dimerization impairing mutations ( L704N or I941R ) in the absence or presence of EGF treatment for 15 minutes ( 25 ng/ml ) were subjected to immunoblotting with antibodies against phospho-tyrosine ( 4G10 ) and EGFR . In summary , our findings suggest that @GENE$ mutation may underlie at least some cases of @DRUG$ responsiveness in colorectal carcinoma .", "label": "sensitivity"}
{"id": "25505694", "sentence": "The firstly described and the most common event responsible for resistance is the acquisition of the @VARIANT$ missense mutation , which is found in ≈ 50 % of patients progressing after an initial response to @DRUG$ or gefitinib [ , ] . Other less frequent mechanisms include secondary mutations within EGFR [ , ] , MET amplification [ ] , @GENE$ amplification [ , ] , small cell histologic transformation [ ] .", "label": "None"}
{"id": "20298590", "sentence": "We also determined that lovastatin did not synergize with cisplatin in either parental A2780 cells ( Additional file : Supplemental Figure S1A ) or the drug-resistant A2780CIS cells ( Additional file : Supplemental Figure S1B ) , both of which had little to no P-gp expression compared to A2780ADR cells ( Additional file : Supplemental Figure @VARIANT$ ) . Furthermore , lovastatin and @DRUG$ were borderline synergistic or additive in A2780 and @GENE$ ( Additional file : Supplemental Figure S1 ) cells treated in a similar manner .", "label": "None"}
{"id": "24489728", "sentence": "Most of the previously reported NSCLC cells that were resistant to @GENE$ were established using the stepwise escalation of EGFR-TKI concentrations , . Specifically , @DRUG$ concentrations were increased stepwise from 1 to 100 nM when cells resumed growth kinetics that were similar to untreated parental cells . Acquired resistance by genetic alterations , such as the EGFR @VARIANT$ mutation or amplified MET , were caused by the stepwise escalation method of EGFR-TKI exposure after prolonged treatment , .", "label": "resistance or non-response"}
{"id": "23493804", "sentence": "We aimed to select an effective chemotherapeutic agent based on @GENE$ status , taking pre- or post-treatment T790M emergence into consideration . Here we present a case of successful treatment using single-agent @DRUG$ in a patient with NSCLC harboring both the pretreatment @VARIANT$ and exon 19 deletion mutations .", "label": "None"}
{"id": "25146448", "sentence": "MTNR1B , located on human chromosome 11q21–22 , is a member of the @GENE$ , and one of the functional and high-affinity @DRUG$ membrane receptors . MTNR1B is expressed in human and rodent pancreatic islets . Studies have shown that MTNR1B is a novel candidate gene for @VARIANT$ .", "label": "None"}
{"id": "18937829", "sentence": "Control patients 18 f 72 Rectum 5FU 1 1 0 - 20 0 19 f 54 Gastric 5FU-FA-P 2 1 0 c.1679T & gt ; G , I560S_21 0 20 m 59 Pancreas 5FU-FA-P 0 1 0 c.85T & gt ; C , C29R ; c.1627A&gt ; G , I543V ( H ) 20 0 21 m 62 Colon 5FU-FA-P 0 1 0 c.85T & gt ; C , C29R ( H ) ; c.496A&gt ; G , M166V , c.1236G&gt;A , E412E 19 0 22 f 64 Colon 5FU-FA 0 0 0 c.85T & gt ; C , C29R ; c.1627A&gt ; G , I543V 20 0 23 m 63 Oesophagus 5FU-P_1 0 0 - 20 0 24 f 69 Colon 5FU-FA 0 1 0 c.85T & gt ; C , C29R ( H ) ; c.496A&gt ; G , M166V ; c.2194G&gt;A , @VARIANT$ 20 0 25 m 59 Gastric 5FU-FA_1 1 0 c.85T & gt ; C , C29R ; c.1627A&gt ; G , I543V ; 1896T & gt ; C , F632F 21 0 26 m 59 Colon @GENE$ 1 1 0 c.85T & gt ; C , C29R ( H ) ; c.496A&gt ; G , M166V ; c.1627A&gt ; G , I543V 20 0 27 m 62 Gastric E-CAPE-P_2_1 2 c.85T & gt ; C , C29R ( H ) ; c.496A&gt ; G , M166V ; c.1236G&gt;A , E412E c.1627A&gt ; G , I543V 30 0 Abbreviations : FA , folinic acid ; CAPE , capecitabine ; P , platinum compound ; E , @DRUG$ ; C , cyclophosphamide ; H , homozygous carrier a adenocarcinoma of unknown origin", "label": "None"}
{"id": "25232318", "sentence": "Similarly , another CUP patient was identified as harboring a somatic @GENE$ @VARIANT$ alteration via hotspot testing and responded to @DRUG$ , an EGFR targeted therapy [ ] .", "label": "sensitivity"}
{"id": "24419415", "sentence": "We conducted a post-hoc analysis of the NEJ002 study to evaluate the effectiveness of gefitinib against NSCLC with @VARIANT$ or L861Q . The NEJ002 study , comparing gefitinib and standard carboplatin-paclitaxel chemotherapy as the first-line treatment for patients with @GENE$ mutations , demonstrated no significant difference in OS between gefitinib and carboplatin-paclitaxel .", "label": "None"}
{"id": "20531963", "sentence": "The most common mutations are exon 19 deletions and exon 21 point mutation ( @VARIANT$ ) , which can be found in approximately 10 % –20 % of NSCLC patients , more frequently in never smokers , women , Asians and with adenocarcinoma.– These alterations in structure of the self phosphorylating domain enhance EGFR activation and also favor binding of TKIs to their site of action . Patients who harbor these mutations experience response rates higher than 65 % and median survival of 20–30 months , as demonstrated in several retrospective studies.– Such results led investigators to test @DRUG$ as a first-line therapy in @GENE$ mutated patients in prospective trials .", "label": "sensitivity"}
{"id": "21457545", "sentence": "Patients with exon 19 harboring deletions were found to have longer survival following treatment with gefitinib or @DRUG$ compared with those having @VARIANT$ mutations in NSCLC [ , ] ; however , Marks et al. reported no difference in survival between exon 19 deletions and L858R mutations in the absence of @GENE$ targeted therapy [ ] .", "label": "sensitivity"}
{"id": "24777052", "sentence": "Examples of this are @DRUG$ for @GENE$ over expressing or amplified breast and gastric cancer , , imatinib for chronic myeloid leukemia ( CML ) , vemurafenib for metastatic melanoma with ( @VARIANT$ ) B-RAF mutations and crizotinib for non-small cell lung cancer patients with anaplastic lymphoma kinase (ALK) rearrangements , .", "label": "None"}
{"id": "PMC3337264", "sentence": "Pan J et al reported that EXEL-0862 is effective against Gleevec-resistant D816V KIT and T674I PDGFRα ( 2007 ) . Recently , in vitro and animal data supported that several novel tyrosine kinase inhibitors including ( but not limited ) AP24534 ( ponatinib ) and DCC-2036 have been demonstrated effective against @VARIANT$ @GENE$ .", "label": "None"}
{"id": "16953242", "sentence": "In these CML-BC patients , imatinib resistance often depends on reactivation of @GENE$ tyrosine kinase activity via mechanisms involving BCR/ABL overexpression , gene amplification or mutations that suppress imatinib mediated kinase inhibition ( i.e. E255V and G250E ) or disrupt @DRUG$ binding ( i.e. @VARIANT$ ) ( ) .", "label": "None"}
{"id": "24790411", "sentence": "The rationale of the combination lies in some preclinical work in which mice with EGFR mutated lung cancer and acquired resistance to @GENE$ TKIs showed tumor regression under treatment with @DRUG$ and cetuximab . In the clinical trial , results from the first 96 evaluable patients showed impressive objective response rate ( ORR ) and disease control rate ( DCR ; 30 % and 75 % , respectively ) . Response to treatment was observed both in patients bearing a @VARIANT$ mutation or other mechanisms of resistance .", "label": "response"}
{"id": "22209766", "sentence": "On the other hand , @DRUG$ could not inhibit EGFR phosphorylation in H1975 cells because the @VARIANT$ mutation in @GENE$ causes a conformation change at the ATP binding pocket , thus decreasing the affinity between erlotinib and EGFR .", "label": "resistance or non-response"}
{"id": "23144978", "sentence": "One mechanism to resistance was recently elucidated : cetuximab resistant cells contain an EGFR mutation in the extracellular domain ( @VARIANT$ ) that impairs cetuximab , but not @GENE$ . Therefore , since the response to therapy require the EGFR target to be present , the development of BOI methods for quantitative detection of EGFR protein levels in CRC primary and secondary tumor tissues is necessary , in order to guide the treatment of individual selected for EGFR targeted antibody treatment and in particular those who relapse while on EGFR targeting therapies . The advent of EGFR targeted antibodies , cetuximab and @DRUG$ has paved the way to individualized medicine of mCRC .", "label": "None"}
{"id": "24555578", "sentence": "Repeat cytology of her right pleural fluid showed adenocarcinoma with an EGFR exon 19 deletion and a second mutation of @VARIANT$ associated with @GENE$ resistance . We introduced cytotoxic chemotherapy . After five cycles of carboplatin @DRUG$ , a relapse in her right pleural effusion was noted ( Figure c ) .", "label": "None"}
{"id": "23552882", "sentence": "For example , HCC827 cells undergo MET amplification and AXL induction upon adaption to gefitinib , , , and PC9 cells acquire the @VARIANT$ mutation in @GENE$ that confers resistance to @DRUG$ and gefitinib .", "label": "resistance or non-response"}
{"id": "24634705", "sentence": "The @VARIANT$ mutation is located on the α-C-helix of EGFR and is similar to a mutation in @GENE$ , D276G , that is associated with acquired resistance after @DRUG$ treatment [ ] .", "label": "None"}
{"id": "23727938", "sentence": "However , treatment of NOD mice with recombinant human IL-10 prevents the onset of @VARIANT$ [ ] . IL-10-deficient mice spontaneously develop chronic enterocolitis [ ] , which can be prevented by transferring IL-10 producing CD4 T cells [ ] . Given the ability of @DRUG$ to elicit IL-10 production and increase the number of @GENE$ producing CD4 T cells [ – ] , melatonin treatment might be applicable for the therapy of autoimmune diseases such as MS , SLE , and IBD .", "label": "None"}
{"id": "22909314", "sentence": "HC Stain 1 Actin , muscle specific 26 CK17 51 Myogenin 1 Alcian blue- PAS 2 AE1/AE3 27 CK19 52 Napsin A 2 Argentaffin 3 AFP 28 CK5/6 53 NSE 3 Argyrophil 4 hCG 29 Pancytokeratin 54 OCT-4 4 Colloidal iron stain 5 CA-125 30 Desmin 55 @VARIANT$ 5 Elastic , Verhoeff’s 6 Calcitonin 31 E-cadherin 56 p53 6 Mucicarmine 7 Caldesmon 32 EMA 57 p63 7 PAS 8 Calretinin 33 Estrogen Receptor 58 PAX-2 8 PASD 9 CAM 5.2 34 GCDFP-15 59 PAX5 9 PTAH 10 CD10 35 GFAP 60 PAX-8 10 Reticulum , Gomori’s 11 CD117 36 Glypican-3 61 PLAP 11 Trichrome , Masson’s 12 CD138 37 Hep-Par1 62 @DRUG$ Receptor 13 CD20 38 HMB 45 63 Prostate Specific Antigen 14 CD3_39 HMW Keratin 64 RCC 15 CD30 40 HNF-1 65 S-100 16 CD34 41 Inhibin 66 Synaptophysin 17 CD43 42 CK , Oscar 67 Thrombomodulin 18 CD45RO 43 Leucocyte Common Antigen 68 Thyroglobulin 19 CD56 44 Mammaglobin 69 TTF1 20 CD99 45 Melan-A 70 Uroplakin 21 CDX2 46 MOC-31 71 Villin 22 @GENE$ 47 MUC 1 72 Vimentin 23 Chromogranin 48 MUC 2 73 WT-1 24 CK 20 49 MUC5AC 25 CK 7 50 Myeloperoxidase", "label": "None"}
{"id": "21366910", "sentence": "A small molecule Met inhibitor combined with an @GENE$ TKI has proven to be a reasonable strategy to overcome erlotinib-resistant @VARIANT$ NSCLC [ ] .", "label": "resistance or non-response"}
{"id": "19920910", "sentence": "Corresponding experiments with mutant @GENE$ kinase domains revealed that a 20-fold improved potency of nilotinib compared with @DRUG$ is also seen with the imatinib-resistant mutants . The mutants , other than @VARIANT$ , that were least responsive to nilotinib in all three cellular assays were Y253H and E255V .", "label": "None"}
{"id": "24594844", "sentence": "H1975 contains EGFR T790M and @VARIANT$ mutations ( designated H1975TM/LR ) and T790M mutation in both alleles was confirmed by genomic DNA sequencing analysis ( Supplementary Figure S1 ) . However , the phosphorylation level of EGFR in @GENE$ T790M mutant cells ( H1975TM/LR ) was not suppressed by @DRUG$ treatment .", "label": "sensitivity"}
{"id": "23864840", "sentence": "Another approach for @VARIANT$ mediated resistance is the dual inhibition of EGFR with @DRUG$ and cetuximab , an @GENE$ blocking antibody resembling the synergistic combination of lapatinib and trastuzumab in ErbB2 positive breast cancer .", "label": "response"}
{"id": "22655263", "sentence": "When tested in Ba/F3 cells driven by ALK mutants identified in @DRUG$ relapsed patients , NMS-E628 is circa fivefold more potent than crizotinib in inhibiting the proliferation of L1196M ALK and @VARIANT$ @GENE$ in vitro and in vivo ( Ardini et al. , ) .", "label": "resistance"}
{"id": "21915126", "sentence": "Therefore , CPT-11 and gefitinib should have a synergistic beneficial effect in NSCLC patients with acquired resistance to @DRUG$ . The mechanistic reasons behind the resistance to @GENE$ TKI are different , probably involving @VARIANT$ secondary mutation and MET amplification .", "label": "resistance or non-response"}
{"id": "17973572", "sentence": "Mutations in the analogous residue of @GENE$ ( @VARIANT$ ) and ErbB2 ( L755S or P) (C ) have been described in patients with imatinib-resistant chronic myelogenous leukemia ( CML ) and solid tumors including gastric , breast , and lung cancers , respectively [ – ] .", "label": "None"}
{"id": "23929941", "sentence": "Double-strand DNA ( dsDNA ) breaks activate the ataxia telangiectasia mutated (ATM) and @GENE$ ( ATR ) pathways , leading to phosphorylation ( Ser139 ) of histone @VARIANT$ ( γ-H2AX ) . We detected increased γ-H2AX phosphorylation at 2 , 3 and 6 days after injecting 60 μg tamoxifen/g body weight ( a single injection was given on days 1 , 2 and 3 ) , indicating activation of a DNA damage response ( ) that coincided with the induction of apoptosis .", "label": "None"}
{"id": "22034911", "sentence": "@VARIANT$ may therefore stabilize an active conformation that is both more oncogenic and less favored for @DRUG$ binding . This screen has several potential limitations . Ba/F3 cells in vitro are unlikely to faithfully recapitulate the cellular context of @GENE$ primary human tumors .", "label": "resistance"}
{"id": "24212826", "sentence": "In a previous study of EGFR-TKI treatment in chemonaive patients with specific EGFR mutations , such as exon 19 deletions and substitutions at @VARIANT$ , the treatment effect of EGFR-TKIs was sustained for up to 8–9 months and was significantly superior to the treatment effect of platinum based chemotherapy [ ] . In the Phase III randomized control trial of gefitinib vs. carboplatin/paclitaxel in Asia ( IPASS ) [ ] , @DRUG$ treatment led to significantly longer progression-free survival ( PFS ) than carboplatin-paclitaxel treatment among the patients who had pulmonary adenocarcinoma with @GENE$ mutations ( hazard ratio for progression or death : 0.48 ; 95 % confidence interval : 0.36–0.64 ; p & lt ; 0.001 ) .", "label": "sensitivity"}
{"id": "24778999", "sentence": "Indeed it demonstrates in vitro efficacy against wild-type KIT and certain transmembrane ( F522C ) and juxta-membrane ( V560G ) KIT mutants , but not the common kinase ( @VARIANT$ ) domain mutants . Furthermore , imatinib showed efficacy in patients with one of subvariant of ASM , lymphadenophatic systemic mastocytosis with eosinophilia : this particular subset has a FIP1-like-1(FIPL1)/platelet derivated growth factor receptor alpha ( PDGFRα ) fusion gene defect . New tyrosine kinase inhibitors under clinical investigation for blocking @GENE$ are @DRUG$ , nilotinib , masatinib mesilate and PKC412 ( midostaurine ) .", "label": "response"}
{"id": "15737014", "sentence": "Importantly , we find that the T790M mutation confers drug resistance not just to wild-type @GENE$ but also to mutant EGFRs associated with clinical responsiveness to EGFR tyrosine kinase inhibitors [ , , ] . In tumors from patients not treated with either gefitinib or @DRUG$ , the 2369 C→T mutation ( @VARIANT$ ) appears to be extremely rare .", "label": "resistance or non-response"}
{"id": "23976869", "sentence": "Sequencing of 87 FIP1L1-PDGFRA negative hypereosinophilic syndrome patients showed several PDGFRA point mutations ( R481G , L507P , I562M , H570R , H650Q , N659S , L705P , R748G , and @VARIANT$ ) . Four of these in vitro mutations induced growth factor independent cell proliferation and constitutive phosphorylation of PDGFRA and STAT5 . Mice injected with @GENE$ cells were treated with oral @DRUG$ .", "label": "None"}
{"id": "21165163", "sentence": "Given that @VARIANT$ and MET amplification collectively account for approximately 60 % of the acquired resistance cases , there are clearly additional mechanisms that underlie resistance to EGFR TKIs . Other mechanisms that have been implicated in acquired resistance include overexpression of AXL tyrosine kinase receptor [ ] , altered EGFR trafficking [ ] , expression of insulin-like growth factor-1 [ ] , amplification of mutant @GENE$ or hyperactivation of components of downstream signaling pathways [ ] , and expression of the ABCG2 drug-efflux transporter [ ] . Recently , it has been shown that activation of TGF-β/IL-6 signaling leads to epithelial-to-mesenchymal transition and @DRUG$ resistance [ ] .", "label": "resistance or non-response"}
{"id": "23935640", "sentence": "Ponatinib ( AP24534 ) is an orally administered TKI designed to inhibit @GENE$ with mutations , especially T315I , which confers resistance to other TKI such as imatinib , @DRUG$ , nilotinib , and bosutinib ( reviewed in [ , ] ) . Ponatinib inhibits both native and mutated BCR-ABL including M244V , G250E , Q252H , Y253F/H , E255 K/V , F317L , @VARIANT$ , and F359V [ , ] .", "label": "None"}
{"id": "25054154", "sentence": "We utilised three complexes , namely , native ( @GENE$ ) , F1174L ( ALK F1174L-crizotinib ) , and @VARIANT$ ( ALK R1275Q-crizotinib ) for our analysis .", "label": "sensitivity"}
{"id": "22815900", "sentence": "We finally examined whether expression of activating mutant @GENE$ could restore drug sensitivity to @DRUG$ in drug resistant cell lines , PC9/ER1 and 11–18/ER1-7 . As shown in , out of 11 patients who first received gefitinib after lung surgery and then showed recurrence , 8 patients had the delE746-A750 mutation and 3 had L858R mutation in their primary lung tumors . Four had the @VARIANT$ mutation in dissemination or metastatic cytological samples .", "label": "resistance or non-response"}
{"id": "24348666", "sentence": "The mechanisms for acquired resistance include gatekeeper @VARIANT$ mutations , ALK gene amplification , and other ALK gene mutations ( L1152R , C1156Y , F1174L ) - . The first two secondary @GENE$ mutations that conferred resistance to @DRUG$ were reported within the same issue of the New England Journal of Medicine describing the positive clinical results mentioned above .", "label": "resistance"}
{"id": "22997594", "sentence": "Nilotinib displays also equipotent activity to @DRUG$ in @VARIANT$ @GENE$ negative patients and WT Kit cell line [ , ] .", "label": "None"}
{"id": "15737014", "sentence": "For example , in CML , a commonly found mutation is a C→T single nucleotide change that replaces threonine with isoleucine at position 315 ( @VARIANT$ ) in the ABL kinase domain [ , , ] . In GIST and @GENE$ , respectively , the analogous T670I mutation in KIT and T674I mutation in PDGFR-alpha have been associated with acquired resistance to this drug [ , ] . To determine whether lung cancers that acquire clinical resistance to either gefitinib or @DRUG$ display additional mutations in the EGFR kinase domain , we have examined the status of EGFR exons 18 to 24 in tumors from five patients who initially responded but subsequently progressed while on these drugs .", "label": "None"}
{"id": "24944510", "sentence": "Multiple secondary mutations have already been identified in patients treated with @DRUG$ . Homologous to the gatekeeper EGFR T790M mutation is the @VARIANT$ substitution , which , unlike EGFR T790M , does not appear to confer a growth disadvantage to cells . Other secondary mutations such as G1269A , C1156Y , L1152R , and 1151Tins may affect affinity of the mutant @GENE$ for either ATP or drug , and these differences have ramifications on the development of next-generation ALK inhibitors , which have varied mutation-specific efficacy among different agents .", "label": "resistance"}
{"id": "24107858", "sentence": "They described a 3.5-fold greater mean increase in log transformed PC20 for methacholine in asthmatic children with @GENE$ variants compared to those homozygous for @DRUG$ 33 TBX21 rs2240017 after 4 years of treatment with ICS . However , the allele frequency of the minor allele @VARIANT$ was only 4.5 % and no minor homozygotes were detected .", "label": "None"}
{"id": "24004697", "sentence": "Both PPP2R5C siRNAs demonstrated significant effects on the knockdown of PPP2R5C expression in CML cell lines , and PPP2R5C-siRNA799 , which targets exon six , demonstrated robust knockdown of PPP2R5C expression in @VARIANT$ cells at all time points . There are reports that siRNAs targeting Bcr-abl increased sensitivity to @DRUG$ in Bcr-Abl overexpressing cells and cells expressing the imatinib-resistant @GENE$ kinase domain mutations H396P and Y253F [ , ] .", "label": "None"}
{"id": "25100284", "sentence": "In studies where mutation types were reported individually the most common EGFR mutations were exon 19 deletions ( 53 % ) and @VARIANT$ mutations ( 38 % ) . Characteristics of the studies included in the pooled analysis to evaluate the effects of single-agent @DRUG$ , single-agent gefitinib or chemotherapy in patients with @GENE$ mutation positive NSCLC ( studies not included in the original analysis are highlighted )", "label": "sensitivity"}
{"id": "25054154", "sentence": "We utilised three complexes , namely , native ( ALK-crizotinib ) , F1174L ( ALK F1174L-crizotinib ) , and @VARIANT$ ( @GENE$ R1275Q-crizotinib ) for our analysis .", "label": "sensitivity"}
{"id": "22912856", "sentence": "The genes for CCL3 , CCL4 , and CCL5 were codon optimized for E. coli expression , synthesized ( Bio Basic ) and cloned into the Champion™ pET SUMO expression vector , resulting in a @GENE$ fusion protein containing a 6-histidine tag fused to N-terminus of the SUMO domain and an AviTag-biotinylation sequence ( Avidity , Aurora , CO ) fused to the C-terminus of the chemokine domain . Single point mutations in the regions associated with chemokine oligomerization were introduced to aid in their expression and solubility , as previously reported ( @VARIANT$ in CCL3 , E67S in CCL4 , and E66S in CCL5 ) .", "label": "None"}
{"id": "25486409", "sentence": "10.1371/journal.pone.0114000.g003CX-4945 enhanced the efficacy of @GENE$ to overcome drug resistance caused by @VARIANT$ . Cells were treated with CX-4945 ( 5 µM ) , gefitinib ( 1 µM ) , and @DRUG$ ( 1 µM ) or a combination of CX-4945 and gefitinib or CX-4945 and erlotinib for 48 h .", "label": "resistance or non-response"}
{"id": "22970367", "sentence": "One possibility is that the T790M mutation could lead to altered drug binding in the ATP pocket of @GENE$ in a manner analogous to the effects of the @VARIANT$ mutation in the ABL kinase in the context of @DRUG$ resistance [ ] .", "label": "None"}
{"id": "24586514", "sentence": "( B ) Immunohistochemical staining for hematoxylin and eosin ( HE ) at a magnification of 40× , Ki67 ( magnification , 400× ) , and TUNEL ( magnification , 400× ) in Ba/F3 @VARIANT$ xenograft sections . ( C ) Tumor cells treated with or without @DRUG$ and vorinostat were examined by immunoblot analysis . Analysis of ABL TKI resistant @GENE$ BCR-ABL cells", "label": "None"}
{"id": "15737014", "sentence": "Importantly , we find that the T790M mutation confers drug resistance not just to wild-type EGFR but also to mutant EGFRs associated with clinical responsiveness to @GENE$ tyrosine kinase inhibitors [ , , ] . In tumors from patients not treated with either gefitinib or @DRUG$ , the 2369 C→T mutation ( T790M ) appears to be extremely rare . We have not identified this mutation in 155 tumors ( see above ) , and among nearly 1,300 lung cancers in which analysis of EGFR exons 18 to 21 has been performed [ , ,, , , ] , only one tumor ( which also harbored an @VARIANT$ mutation ) was reported to contain the T790M mutation .", "label": "sensitivity"}
{"id": "25486409", "sentence": "As the second-generation , irreversible EGFR-TKIs , such as afatinib and dacomitinib , failed to overcome the resistance caused by @VARIANT$ , , other measures , such as EGFR dual targeting with cetuximab and @DRUG$ and third-geneneration , mutant-selective @GENE$ – are being actively evaluated .", "label": "response"}
{"id": "23963283", "sentence": "The most common lesion is the so-called “gatekeeper mutation” , which involves a substitution of methionine for threonine at position 790 ( @VARIANT$ ) . The second well-known mechanism of resistance to gefitinib or @DRUG$ is the amplification of the MET receptor tyrosine kinase ( RTK ) gene , which activates downstream intracellular signaling independently of @GENE$ .", "label": "resistance or non-response"}
{"id": "24036898", "sentence": "@DRUG$ and bevacizumab were provided by Chugai Pharmaceutical Co. ( Tokyo , Japan ) . Rabbit polyclonal antibodies ( Abs ) against ubiquitin and actin ( Santa Cruz Biotechnology , Santa Cruz , CA ) , Akt , phospho-Erk , and Erk ( Cell Signaling Technology , Danvers , MA ) , and CD31 and Ki67 ( Abcam , Cambridge , England ) were used . Mouse monoclonal Abs against CD16 ( 3G8 ) and CD54 ( HCD54 ) ( BioLegend , San Diego , CA ) and CD11a ( Ancell , North Bayport , MN ) , rabbit monoclonal Abs against HER2 ( D8F12 ) , @GENE$ ( 6B12 ) and phospho-Akt ( @VARIANT$ ) ( Cell Signaling Technology ) , and rat monoclonal Ab against CD18 ( YFC118.3 ) ( Chemicon International , Temecula , CA ) are also commercially available .", "label": "None"}
{"id": "23937717", "sentence": "B ) . Those results suggested that @DRUG$ enhanced cytotoxicity of NK cells to human lung cancer with @GENE$ L858R + @VARIANT$ .", "label": "resistance or non-response"}
{"id": "23866929", "sentence": "Furthermore , a high response rate ( 60 to 90 % ) to treatment with EGFR-TKIs has been observed in patients harboring mutations in exons 18 to 21 of the tyrosine kinase domain of EGFR , with exon 19 deletions and exon 21 @VARIANT$ point mutations comprising about 90 % of all mutations [ , ] . Although the mechanism of lethal interstitial pneumonia as a side effect of EGFR-TKI is still unknown , EGFR-TKI can be striking in cancer reduction and quality of life improvement in patients with advanced NSCLC harboring EGFR gene mutations . Currently , @GENE$ is considered third-line chemotherapy for patients with inoperable and recurrent NSCLC after first-line platinum based combination chemotherapy and second-line chemotherapy with @DRUG$ ; however , in future the combination of cytotoxic agents and EGFR-TKI may become first- or second-line standard chemotherapy .", "label": "None"}
{"id": "25033171", "sentence": "In addition , we have analyzed the energetic contribution to crizotinib on residue level as well , which showed that the residue Leu18 ( located just in the P-loop region ) contributed the most to the attenuated binding of @DRUG$ to @GENE$ as shown in , therefore well supporting the issue that the P-loop conformation governs crizotinib resistance in @VARIANT$ mutated ROS1 tyrosine kinase .", "label": "resistance"}
{"id": "24501009", "sentence": "Strategies to improve EGFR inhibition in EGFR @VARIANT$ cancers include the combination of irreversible @GENE$ inhibitors with the EGFR‐directed antibody cetuximab ( as reported for afatinib plus @DRUG$ ) 19 ; the development of more potent and specific inhibitors of EGFR T790M20,21 ; and the use of intermittent but high doses of existing irreversible EGFR inhibitors .", "label": "response"}
{"id": "23091721", "sentence": "It has been shown that higher levels of AREG and EREG have a positive predictive value in determining response to cetuximab , and when treated with @DRUG$ these tumors have better PFS [ ] . Although attempts at developing drugs targeting KRAS have largely been unsuccessful , several @GENE$ inhibitors have been discovered . Sorafenib is an oral multikinase inhibitor that targets both wtBRAF and oncogenic BRAF @VARIANT$ and has in vitro activity in CRC cell lines with this mutation .", "label": "resistance or non-response"}
{"id": "25382104", "sentence": "The availability of 3D-structure of the target protein and the structural details of @DRUG$ and @VARIANT$ mutant @GENE$ protein complex renders an opportunity to identify the most active drug candidate that can efficiently block the catalytic activity of BCR-ABL .", "label": "response"}
{"id": "24894453", "sentence": "Key genomic features of these tumors involve inactivation of tumor suppressors such as APC , TP53 and SMAD4 and mutational activation of oncogenes including KRAS , NRAS , BRAF and @GENE$ [ ] . Given the role of @DRUG$ in therapy of these cancers , initial efforts to identify activating EGFR mutations identified few such events , though potentially activating events such as @VARIANT$ were seen [ ] .", "label": "None"}
{"id": "22970367", "sentence": "Gatekeeper mutations have been found in many kinase-driven tumors that develop resistance to kinase inhibitor treatment ( e.g. , CML patients treated with @DRUG$ that develop the @VARIANT$ resistance mutation in @GENE$ ) .", "label": "None"}
{"id": "25580268", "sentence": "A randomized phase II study of WBRT with or without @DRUG$ in patients with HER2+ breast cancer with brain metastases is ongoing ( NCT01622868 ) . Inhibitors targeting BRAF in melanoma Activating BRAF mutations that result in constitutive activation of the @GENE$ affect approximately half of patients with melanoma , and more than 95 % of these are the @VARIANT$ mutation ( substitution of valine by glutamic acid at the 600th amino acid position ) [ ] .", "label": "None"}
{"id": "25462529", "sentence": "Residue D167 of IN was mutated in this study because it is well conserved in HIV and it is embedded within a short stretch of amino acids ( 161–173 ) with nuclear localization signal properties and important for IN–p75/LEDGF interaction. , , We initially chose @DRUG$ to replace a polar acid residue by a polar basic/neutral one with the purpose to induce a mild phenotype with an integration rate between WT and @VARIANT$ vectors . Integrase mutations D167A and D167K induced opposite effect on single round infectivity of HIV with D167A increasing it to 140 % while D167K reduced it to 5 % of WT indicating a critical role played by this residue in the processing of the @GENE$ .", "label": "None"}
{"id": "15737014", "sentence": "In tumors from patients not treated with either @DRUG$ or erlotinib , the 2369 C→T mutation ( T790M ) appears to be extremely rare . We have not identified this mutation in 155 tumors ( see above ) , and among nearly 1,300 lung cancers in which analysis of @GENE$ exons 18 to 21 has been performed [ , ,, , , ] , only one tumor ( which also harbored an @VARIANT$ mutation ) was reported to contain the T790M mutation .", "label": "sensitivity"}
{"id": "24419415", "sentence": "In contrast to other phase 3 trials investigating EGFR-TKIs for patients with common EGFR mutations of exon 19 deletion and L858R , the NEJ002 is the only study that included uncommon EGFR mutations of @VARIANT$ and L861Q . This study showed that the PFS and OS tended to be shorter among patients treated with first-line @DRUG$ compared with PFS and OS among those treated with first-line carboplatin-paclitaxel in the uncommon @GENE$ mutation group ( supplementary Table S2 , Supplemental Digital Content 1 , http : //links.lww.com/JTO/A494 ) .", "label": "None"}
{"id": "24586514", "sentence": "Until now , no viable treatment options were available for patients in whom @GENE$ TKIs fail because of the presence of T315I mutation . Thus , alternative strategies are required to improve the outcome of CML patients carrying the @VARIANT$ mutation . @DRUG$ , also known as AP24534 , is an oral , multi targeted TKI .", "label": "response"}
{"id": "24908327", "sentence": "The patients who had a diagnosis of advanced NSCLC with stage III–IV and the patients harboring activating EGFR mutations ( either exon 19 deletion or @VARIANT$ in exon 21 ) . All patients received @GENE$ TKIs ( gefitinib or @DRUG$ ) for monotherapy , first line or otherwise .", "label": "sensitivity"}
{"id": "24348666", "sentence": "Although the resistant cell line HCG827GR does not have the EGFR @VARIANT$ mutation , it was found to have MET amplification . MET is a receptor tyrosine kinase that binds to hepatocyte growth factor (HGF) and is associated with the development of various human cancers . Therefore , EGFR-TKIs fail to inhibit the @GENE$ pathway dependent growth signal because the constitutive phosphorylation of HER3 by MET occurs independent of EGFR activation , which causes the cells to acquire resistance to @DRUG$ .", "label": "None"}
{"id": "20694077", "sentence": "However , the @VARIANT$ mutant remained resistant to nilotinib at concentrations & lt ; 10 μM. , @DRUG$ also potently inhibited tyrosine autophosphorylation of the E255K , E255V , F317L , M351T , and F486S Bcr-Abl mutants , and these effects were not associated with decreases in Abl or @GENE$ protein levels .", "label": "None"}
{"id": "23994953", "sentence": "Prospective trials have demonstrated an impressive ~75 % response rate for patients whose tumors harbor these mutations , which occur as either multinucleotide in-frame deletions in exon 19 ( e.g. , delE746-A750 ) or as single missense mutations ( e.g. , @VARIANT$ ) . Unfortunately , the EGFR TKI-driven improvement in patient outcome is notably limited because virtually all NSCLC patients with erlotinib/gefitinib sensitizing EGFR mutations eventually acquire resistance after a median of 6–12 months of @GENE$ TKI therapy .", "label": "sensitivity"}
{"id": "22751098", "sentence": "To test this hypothesis and to clinically validate our preclinical findings , we measured the expression of AXL by IHC ( immunohistochemistry ) in 35 matched EGFR-mutant NSCLC specimens obtained from patients both prior to treatment with the @GENE$ TKIs erlotinib or @DRUG$ and upon the development of EGFR TKI acquired resistance . In cases where enough material was available for additional studies , we also examined the specimens for GAS6 and vimentin ( as a marker for EMT ) expression by IHC ( scoring system shown in ) , EGFR @VARIANT$ by sequencing , and MET amplification by FISH .", "label": "resistance or non-response"}
{"id": "16187797", "sentence": "Sensitivity of Cell Transformation Induced by Expression of Mutant @GENE$ Characterized by Missense Mutation or Exon 19 Deletion , but not Exon 20 Insertion , to @DRUG$ and Erlotinib ( A ) Anchorage independent growth of clonal NIH-3T3 cells transformed with mutant EGFR or EGF stimulated wild-type EGFR treated with the indicated concentrations of erlotinib immediately prior to suspension in soft agar . Transformation induced by expression of L858R , @VARIANT$ , and L747_E749del A750P EGFR , but not EGF stimulated wild-type EGFR or D770_N771insNPG EGFR , was inhibited by 0.1 μM erlotinib .", "label": "sensitivity"}
{"id": "24465383", "sentence": "In summary , we have discovered that tolerogenic DC engineered ex vivo for low co-stimulation ability increase frequency and numbers of IL-10 expressing B-cells in vitro and in vivo , consequent to concomitant proliferation of pre existing IL-10+ B-cells and conversion of CD19+ B-lymphcytes into @GENE$ expressing cells without affecting their immunosuppressive potential in vitro . We also discovered that these DC-sensitive putative Bregs expressed receptors for @DRUG$ is produced by the tolerogenic dendritic cells . Taken together , our findings usher a potential new therapeutic approach to @VARIANT$ immunotherapy which involves suppresisve B-cells , possibly homogeneous Bregs , together with approaches and molecules that stabilise their suppressive ability and expand their numbers in vitro ( e.g. RA , IL-10 , IL-21 ) .", "label": "None"}
{"id": "PMC4041556", "sentence": "Resistance mechanisms to @DRUG$ are multiple , and include ALK-dominant mechanisms such as resistance mutations and copy number gain , and @GENE$ non-dominant mechanisms through the outgrowth of clones containing a separate activated oncogene . In contrast to the EGFR setting , where the @VARIANT$ mutation predominates , the spectrum of ALK resistance mutations is broad .", "label": "None"}
{"id": "16187797", "sentence": "Sensitivity of Cell Transformation Induced by Expression of Mutant EGFR Characterized by Missense Mutation or Exon 19 Deletion , but not Exon 20 Insertion , to @DRUG$ and Erlotinib ( A ) Anchorage independent growth of clonal NIH-3T3 cells transformed with mutant EGFR or EGF stimulated wild-type @GENE$ treated with the indicated concentrations of erlotinib immediately prior to suspension in soft agar . Transformation induced by expression of @VARIANT$ , G719S , and L747_E749del A750P EGFR , but not EGF stimulated wild-type EGFR or D770_N771insNPG EGFR , was inhibited by 0.1 μM erlotinib .", "label": "sensitivity"}
{"id": "23520442", "sentence": "However , it is unknown whether the status of EGFR mutation and downstream resistance related genes aberrances ( i.e. , KRAS mutations , @VARIANT$ , or c-MET amplification ) are consistent in pre- and post-chemotherapy samples . Therefore , it is necessary to evaluate the impact of chemotherapy on tumor molecular profiles . Chin et al reported that prior exposure to platinum agents may reduce the benefit from subsequent treatment with @GENE$ for an erlotinib-sensitive EGFR-mutant NSCLC cell via the phosphatidylinositol 3-kinase/AKT survival pathway .", "label": "resistance or non-response"}
{"id": "25562363", "sentence": "Zelboraf ( vemurafenib , Plexxikon / Diiachi-Sankyo/ Roche ) 56,400 Cobas 4800 BRAF V600 Mutation Test ( Roche Molecular ) 120-150 Co-development ( BRAF @VARIANT$ mutation ~40 % ) 144M ( 213M* ) Herceptin ( @DRUG$ , Genentech / Roche ) 70,000 HercepTest ( Dako ) 500 Rescue ( HER-2 expression score 3+ ~ 10 % ) 620M* Well ahead of projected view timelines , the FDA also approved Zelboraf ( vemurafenib , Plexxikon / Diiachi-Sankyo / Roche ) for the treatment of @GENE$ V600E mutation positive , inoperable or metastatic melanoma , and co-approved the Cobas 4800 BRAF V600 Mutation Test , a diagnostic test developed by Roche to identify patients eligible for treatment .", "label": "None"}
{"id": "24672248", "sentence": "@GENE$ mutation @VARIANT$ confers @DRUG$ resistance .", "label": "resistance"}
{"id": "21333004", "sentence": "As a result , the combination of a lower k3 ( the rate constant for the forward reaction of the EGFR phosphorylation ) and k8 ( the rate constant for the forward reaction of binding of @GENE$ to Shc ) contributed to effectively inhibit the total phosphorylation of ERK in the presence of @DRUG$ ( Figure ) . The values in each panel indicate RShc/RERK calculated by using the values of parameters in @VARIANT$ model A for two changing parameters and those in EGFR-WT model for two unchanging parameters .", "label": "sensitivity"}
{"id": "25091415", "sentence": "By contrast , the @VARIANT$ mutation confers a higher affinity toward ATP than the L858R mutant such that the combined double mutant L858R/T790M results in an activated enzyme that is resistant to ATP-competitive TKIs . Recent report by Yoshikawa , S. et al. ( 2013 ) demonstrated the acquired resistant of double mutant G719S/T790M (DM) to @DRUG$ , G719S mutation occurs within the phosphate binding loop ( P-loop ) and not observed frequently . The structure of the @GENE$ DM ( G719S/T790M ) was solved and deposited in PDB .", "label": "resistance or non-response"}
{"id": "24155778", "sentence": "@GENE$ was a protein identified as differentially expressed proteins between the cisplatin-sensitive ( @VARIANT$ ) and cisplatin-resistant ( A2780-CP ) ovarian cancer cell lines .", "label": "None"}
{"id": "22152101", "sentence": "We did not detect any @VARIANT$ BRAF mutations in our study while the frequency of @GENE$ mutations was 12 % in the aforementioned study of @DRUG$ plus chemotherapy in advanced OGJ cancer patients [ ] .", "label": "resistance or non-response"}
{"id": "24987354", "sentence": "Multikinase small molecule inhibitors such as sorafenib and @DRUG$ can be used per recent NCCN guidelines ( Version 2.2013 ) , but prospective clinical trials have not yet demonstrated a distinct molecular subgroup of @GENE$ patients that derives large benefit from such targeted therapies [ ] . BRAF @VARIANT$ is present in approximately 45 % of all PTC [ ] , with alterations of CTNNB1 , HRAS , IDH1 , KRAS , NRAS , PIK3CA and TP53 being less common .", "label": "None"}
{"id": "24634785", "sentence": "It was demonstrated that @DRUG$ is effective on CML cells harboring different mutations in @GENE$ , including highly multiresistant @VARIANT$ [ ] .", "label": "response"}
{"id": "17973572", "sentence": "Based on the data obtained from lung cancer cell lines , we further explored the mechanisms by which T790M and @VARIANT$ resistant mutations affect BIM up-regulation and apoptosis . @DRUG$ effectively induced apoptosis in Ba/F3-L858R cells , whereas @GENE$ cells were intermediately resistant and Ba/F3-L858R-T790M completely resistant ( A , top ) .", "label": "None"}
{"id": "18974832", "sentence": "Of particular interest , 1R-Chl shows comparable anti-proliferative activity on BM cells transduced with the @VARIANT$ mutant , which is resistant to the @DRUG$ and dasatinib treatment , compared to unmutated @GENE$ .", "label": "None"}
{"id": "23992330", "sentence": "Briefly , they demonstrated the different effects of the G12 and G13 @GENE$ alleles on response to cetuximab and found a significant association between the presence of a @VARIANT$ mutation and survival benefit after @DRUG$ treatment in metastatic colorectal cancer patients [ ] .", "label": "resistance or non-response"}
{"id": "24472312", "sentence": "In vitro screening assay has demonstrated that @DRUG$ , the first TKI effective against @VARIANT$ @GENE$ , is also a potent inhibitor of KIT , PDGFRα , Flt3 , Src , VEGFR and FGFR [ , , ] .", "label": "response"}
{"id": "24348666", "sentence": "The mechanisms for acquired resistance include gatekeeper L1196M mutations , ALK gene amplification , and other ALK gene mutations ( L1152R , @VARIANT$ , F1174L ) - . The first two secondary @GENE$ mutations that conferred resistance to @DRUG$ were reported within the same issue of the New England Journal of Medicine describing the positive clinical results mentioned above .", "label": "resistance"}
{"id": "24594844", "sentence": "cDzT specifically degraded EGFR @VARIANT$ mRNA and decreased EGFR protein levels , whereas @DRUG$ inhibited autophosphorylation of EGFR without affecting @GENE$ protein level .", "label": "response"}
{"id": "23569389", "sentence": "No differences in overall response rate were observed in patients with @GENE$ mutations at baseline , in particular for p-loop mutations . A subanalysis was conducted by Branford et al on the emergence of new detectable mutations in 479 patients treated with @DRUG$ after imatinib failure , and development of new mutations , including @VARIANT$ , F317L , and V299L , was rare ( 13 % ) .", "label": "None"}
{"id": "24523596", "sentence": "Several studies have reported renal failure and tumor lysis syndrome during TKI based molecular targeted therapies , including with sorafenib for hepatocellular carcinoma , with imatinib for chronic myelogenous leukemia , and with @DRUG$ for chronic lymphocytic leukemia.– Because the Q141K variant of @GENE$ corresponding to SNP 421C&gt ; A reduces uric acid transport and those TKIs are substrates/inhibitors of ABCG2/BCRP , TKI therapy in patients with the SNP 421C&gt ; A ( Q141K ) may be at higher risk of tumor lysis syndrome . A defect in the pharmacological interaction has been suggested between sunitinib and another ABCG2/BCRP germ-line mutant allele , 1291T & gt ; C. Remarkably , sunitinib reversed wild-type ABCG2/BCRP mediated drug resistance and competitively inhibited ABCG2/BCRP mediated estrone 3-sulfate transport and the binding of 125I-iodoarylazidoprazosin to ABCG2/BCRP . The @VARIANT$ variant of ABCG2/BCRP , which is expressed from a germ-line mutant allele 1291T & gt ; C , was insensitive to sunitinib mediated inhibition .", "label": "None"}
{"id": "23584600", "sentence": "@GENE$ is the most potent of the Raf proteins to activate the downstream signalling cascade , hence mutant Braf was identified as a novel target for kinase inhibitors such as vemurafenib ( PLX4032/RG7204 ) and dabrafenib . In a recent phase 3 trial , treatment with vemurafenib was associated with improved survival of metastatic melanoma patients with the BRAF 600E mutation . As a result of these clinical findings , vemurafenib was approved by the US Food and Drug Administration ( FDA ) for the treatment of advanced stage melanoma harbouring the @VARIANT$ mutation .", "label": "None"}
{"id": "20684776", "sentence": "We found that all cyclin mRNA expression levels were greatly reduced respect to untreated controls ( Figure ) , except for cyclin A1 , whose basal levels were substantially lower than the other cyclins and were not downregulated but remained fairly constant upon Roscovitine treatment consistent with its @VARIANT$ independent transcriptional regulation ( Figure ) . Therefore , we treated A549 cells for 24 hours with increasing doses of @DRUG$ ( as previously stated ) alone or in combination with a fixed dose of 20 μM Roscovitine .", "label": "None"}
{"id": "23674887", "sentence": "However , remarkably , an exposure–response relationship for bosutinib has been observed for patients with newly diagnosed CP-CML with regard to CCyR , @GENE$ , and cumulative CHR at 1 year . Bosutinib effectively targets most IM-resistance conferring BCR-ABL mutations , with the exception of the highly resistant T315I ( resistant to IM , dasatinib , @DRUG$ , and bosutinib ) and @VARIANT$ mutations ( resistant to dasatinib and bosutinib ) .", "label": "None"}
{"id": "23976869", "sentence": "@DRUG$ is a dual @GENE$ inhibitor that also inhibits PDGFRs and FIP1L1-PDGFRA fusion but has no effect on imatinib-resistant FIP1L1-PDGFRA @VARIANT$ and D842V mutants .", "label": "None"}
{"id": "24939055", "sentence": "Although irreversible @GENE$ , including BIBW2992 , have been developed to overcome @VARIANT$ mediated resistance to @DRUG$ [ ] , recent clinical trials have failed to show that monotherapy with irreversible EGFR-TKIs has benefits in patients with NSCLC refractory to gefitinib [ ] .", "label": "resistance or non-response"}
{"id": "24348666", "sentence": "It was initially proposed that the T790M mutation might prevent the proper binding of tyrosine kinase inhibitors via steric hindrance , similar to the corresponding gatekeeper mutations in BCR-ABL ( T315I ) and @GENE$ ( T670I ) that confer resistance to imatinib ( Gleevec ) in chronic myelogenous leukemia and in patients with gastrointestinal stromal tumors . Interestingly , it was discovered that the @VARIANT$ mutation does not confer resistance to gefitinib and @DRUG$ by preventing their binding as originally thought .", "label": "None"}
{"id": "25033171", "sentence": "The energetic difference between G2032R-ROS1 and WT-ROS1 are shown in panel C ( ΔΔG = ΔGG2032R−ΔGWT , a positive ΔG indicates a weaker binding affinity in the mutated protein , and a negative ΔG indicates a stronger binding affinity ) , where the residue Leu18 ( on the P-loop region ) contributes the most to the attenuated binding of crizotinib to G2032R mutated @GENE$ , indicating that the P-loop conformation governs the binding of @DRUG$ .", "label": "resistance"}
{"id": "23307622", "sentence": "The EGFR ( HER1 ) -Tyrosine Kinase Inhibitor ( TKI ) gefitinib ( ZD1839 ; Iressa® ) was kindly provided by AstraZeneca ( AstraZeneca PLC Headquarters , 15 Stanhope Gate , @VARIANT$ 1LN , London , UK ) . The @GENE$ ( HER1 ) TKI @DRUG$ ( Tarceva® ) was a kind gift from Roche", "label": "None"}
{"id": "22815900", "sentence": "We further compared expression levels of wild-type EGFR and mutant EGFR by a specific antibody that recognizes the @VARIANT$ mutant EGFR by western blot analysis . We next examined whether activating mutant @GENE$ gene in 11–18/ER1-7 and 11–18/ER2-1 cells was affected by the acquisition of @DRUG$ resistance or not .", "label": "sensitivity"}
{"id": "21333004", "sentence": "According to recent reports , the sensitivity to kinase inhibition reflects intrinsic differences in the binding affinity of the EGFR mutants such as L858R , @VARIANT$ , and exon19 deletions [ , - ] . Yun et al [ ] showed that gefitinib directly binds more tightly to the L858R mutant than to the wild type EGFR in vitro , while Fabian et al [ ] indicated that EGFR with @DRUG$ sensitive mutations does not differ from wild type @GENE$ in terms of gefitinib binding affinity .", "label": "sensitivity"}
{"id": "23292247", "sentence": "When @VARIANT$ human breast cancer cells are exposed to @DRUG$ , the expression of ROS1 is upregulated , and autophosphorylated ROS1 , in turn , activates MSK1 via ERK1/2 in the @GENE$ pathway .", "label": "None"}
{"id": "24944510", "sentence": "Poziotinib ( also known as HM781-36B ) , a new potent irreversible inhibitor of @GENE$ , HER2 , HER4 , and transient erythroblastopenia of childhood family of kinases inhibitor ( BTK , BLK , and BMX ) , demonstrated preclinical efficacy against @VARIANT$ mutant at eightfold lower doses compared to @DRUG$ .", "label": "response"}
{"id": "24876815", "sentence": "In the study by Pentheroudakis et al. , patients with a mutation in codon 12 of the KRAS gene who received chemotherapy combined with @DRUG$ had a median overall survival of 19 months , whereas patients with other KRAS mutations and KRAS-wild type gene subjects treated with the same modality had a considerably longer median survival of nearly 30 months [ – ] . Furthermore , there are many reports on patients with the wild-type KRAS gene who are refractory to @GENE$ treatment . The cause of refractoriness has been identified in ca. 15 % of mCRC patients as mutations in the BRAF gene , primarily @VARIANT$ substitution .", "label": "None"}
{"id": "22997553", "sentence": "Zebrafish eggs ( 2 cell stages ) were electroporated with @GENE$ GFP plasmid or @VARIANT$ . The live embryos ( 10 hpf ) ( n = 20 fishes ) were grown in presence and absence of 2 mg/ml @DRUG$ containing water .", "label": "None"}
{"id": "23937717", "sentence": "The secondary @VARIANT$ mutation within the EGFR kinase domain is a major mechanism of acquired resistance to EGFR tyrosine kinase inhibitors ( TKI ) in NSCLC [ ] . However , clinical response to @DRUG$ has been demonstrated to be not correlated with @GENE$ levels , and several other molecular mechanisms are also important in predicting clinical response [ , ] .", "label": "resistance or non-response"}
{"id": "24928511", "sentence": "More than 50 % of lung adenocarcinomas (LAD) from East Asian non-smokers harbor @GENE$ mutations , and these tumors have been termed oncogene addicted to reflect their dependence on EGFR mediated pro-survival signaling and their high susceptibility to apoptosis induced by EGFR-TKIs ( e.g. @DRUG$ and erlotinib ) ( ) . The most frequently occurring mutations in the EGFR gene ( in-frame deletion in exon 19 at codons 746–750 or a single-base substitution @VARIANT$ in exon 21 ) predict an improved clinical response to first-line oral EGFR-TKIs compared with standard platinum based chemotherapy in patients with advanced non-small-cell lung carcinoma ( NSCLC ) ( , ) .", "label": "sensitivity"}
{"id": "19646278", "sentence": "Given the limited sample size , the extent of tumor shrinkage could not be correlated either to mutational status or to other clinical features , such as tumor site , initial tumor size , @DRUG$ duration , and extent of pathologic response . In light of these results the presence of a less sensitive mutation like Exon 9 or of a wild-type @GENE$ mutational status should not be considered per se a contraindication to a preoperative treatment , the only exception being those point mutations with known complete resistance ( i.e. @VARIANT$ in Exon 18 on PDGRα gene ) .", "label": "None"}
{"id": "23986642", "sentence": "This trial provided valuable evidence of ponatinib’s direct kinase inhibiting activity in patients with a variety of BCR-ABL mutations , including the @VARIANT$ mutant , leading to further evaluation of its effects . Preclinical @DRUG$ has been observed to achieve marked reductions in levels of phosphorylated @GENE$ and CrkL within 6 hours of administration in a mouse model injected with T315I-variant BCR-ABL expressing Ba/F3 cells .", "label": "response"}
{"id": "21722394", "sentence": "Furthermore , @GENE$ and BV8S2 are absent in the @DRUG$ treated group ( a treatment known to destroy regulatory T cells ) , but present in 50 % of the B cell reconstituted animals . BV8S1 has been previously described as a predominant clonotype infiltrating the islets of partially diabetes-resistant male NOD mice [ ] and , interestingly , is also present in the blood of @VARIANT$ patients [ ] .", "label": "None"}
{"id": "23888935", "sentence": "@DRUG$ is a novel , synthetic , orally active , potent pan–BCR-ABL inhibitor and multi targeted TKI that was discovered using a computational and structure based drug design approach.– Ponatinib was specifically designed to inhibit native @GENE$ and mutant forms that can arise during treatment with other TKIs and cause resistance , including the @VARIANT$ gatekeeper mutant .", "label": "response"}
{"id": "22496900", "sentence": "Examples of some the most effective and widely used , anti-cancer therapeutic antibody drugs include trastuzumab ( Herceptin® , a HER2 inhibitor ) , bevacizumab ( Avastin® , a @GENE$ inhibitor ) , and panitumumab ( Vectibix™ , an EGFR inhibitor ) . Sphingosine 1-phosphate @VARIANT$ is a lipid signaling molecule ( ) that is present in serum at biologically relevant concentrations ( high nanomolar range ) .", "label": "None"}
{"id": "23320171", "sentence": "Primary results from the EMILIA study , a randomized trial comparing Trastuzumab DM-1 to lapatinib and capecitabine , have shown that @DRUG$ DM-1 significantly improved progression-free survival in patients with metastatic HER2 positive breast cancer . Further research is looking into inhibiting other targets such as mTOR , @VARIANT$ , or @GENE$ pathways .", "label": "None"}
{"id": "22970367", "sentence": "Gatekeeper mutations have been found in many kinase-driven tumors that develop resistance to kinase inhibitor treatment ( e.g. , CML patients treated with @DRUG$ that develop the T315I resistance mutation in BCR-ABL ) . Two potential mechanisms could explain how the EGFR @VARIANT$ mutation confers @GENE$ TKI resistance .", "label": "None"}
{"id": "22382702", "sentence": "This was confirmed in vitro , and G12V mutated cancer cells were resistant to @DRUG$ , whereas @VARIANT$ mutated and @GENE$ wild-type cancer cells were sensitive .", "label": "resistance or non-response"}
{"id": "25562700", "sentence": "Molecule Target Biomarker Indication vemurafenib BRAF kinase BRAF @VARIANT$ mutant melanoma @DRUG$ VEGFR , EGFR , RETR not included on the label thyroid cancer abiraterone CYP 17A1 not included on the label prostate cancer ipilimumab CTLA-4 not included on the label melanoma brentuximab vedotin CD30 ( ACD technology ) not included on the label lymphoma crizotinib ALK ALK-EML4 fusion protein lung cancer BRAF : Serine/threonine-protein kinase B-Raf ; VEGFR : Vascular endothelial growth factor receptor ; EGFR : epidermal growth factor receptor ; RETR : RET proto-oncogen receptor ; CYP 17A1 : cytochrome P450 17A1 ; CTLA-4 : Cytotoxic T-Lymphocyte Antigen 4 ; CD30 : Cluster of Differentiation 30 ; ADC : Antibody Conjugated Drug ; ALK-EML4 : anaplastic lymphoma kinase (ALK) ; echinoderm @GENE$ ( EML4 ) fusion .", "label": "None"}
{"id": "24894453", "sentence": "To test the hypothesis that @DRUG$ sensitivity of @VARIANT$ and G724S mutants is a function of their dimerization dependence , we generated G719S and G724S mutants with compound substitution mutations at the dimerization interface in the N-lobe or C-lobe that disrupt the asymmetric dimerization of @GENE$ [ ] .", "label": "sensitivity"}
{"id": "25054154", "sentence": "We utilised three complexes , namely , native ( @GENE$ ) , @VARIANT$ ( ALK F1174L-crizotinib ) , and R1275Q ( ALK R1275Q-crizotinib ) for our analysis .", "label": "resistance"}
{"id": "24618737", "sentence": "One common hypothesis of Cetuximab-resistance is EGFR or downstream molecular mutation within tumor cells , such as acquired EGFR ectodomain mutation @VARIANT$ . In addition , persistent EGFR blocking enhances pathways other than the EGFR pathway , such as the @GENE$ , Her3 , insulin-like growth factor (IGF)-I receptor ( IGF –IR ) signaling pathways – .", "label": "None"}
{"id": "23232076", "sentence": "The deletion of the four amino acid sequence ( del 746–750 ) in the exon 19 and the substitution of leucine by arginine at codon 858 ( @VARIANT$ ) in exon 21 are two of the most common mutations in the kinase domain of EGFR gene in NSCLC patients [ ] . The small-molecule tyrosine kinase inhibitors including gefitinib and @DRUG$ have recently been approved for the treatment of patients with NSCLC [ , - ] . In addition , mutations in the epidermal growth factor receptor (EGFR) have been confirmed as predictors of the efficacy of treatment with @GENE$ kinase inhibitors .", "label": "sensitivity"}
{"id": "21333004", "sentence": "As a result , the combination of a lower k3 ( the rate constant for the forward reaction of the @GENE$ phosphorylation ) and k8 ( the rate constant for the forward reaction of binding of EGFR to Shc ) contributed to effectively inhibit the total phosphorylation of ERK in the presence of @DRUG$ ( Figure ) . The values in each panel indicate RShc/RERK calculated by using the values of parameters in @VARIANT$ model A for two changing parameters and those in EGFR-WT model for two unchanging parameters .", "label": "sensitivity"}
{"id": "25268163", "sentence": "Even though the transporter expression , localization and function of ABCC1 and @GENE$ have been extensively studied , there are only very limited data that more convincingly suggest any clinical relevance of naturally occurring SNPs in ABCC1 ABCC2 and ABCC10 . Several reports suggesting that ABCG2 SNP analysis might be a useful strategy to predict systemic exposure to ABCG2 substrate drugs is becoming increasingly prevalent [ ] . Of particular importance are recent studies that have demonstrated that subjects with a decreased ABCG2 activity owing to the @VARIANT$ variant are at an increased risk of @DRUG$ induced diarrhea [ ] , and altered pharmacokinetics of 9-aminocamptothecin [ ] , diflomotecan [ ] , irinotecan [ ] , rosuvastatin [ ] , sulfasalazine [ , ] and topotecan [ ] .", "label": "None"}
{"id": "23866929", "sentence": "The entry of tyrosine kinase inhibitors ( TKIs ) gefitinib ( Iressa® , AstraZeneca , Wilmington , Delaware ) and erlotinib ( Tarceva® , Genentech , South San Francisco , California ) , which target @GENE$ is one of the most recent , gratifying events in the treatment of advanced non-small-cell lung cancer ( NSCLC ) . Clinical trials have revealed significant variability in response to EGFR-TKIs , and patient characteristics such as sex , dominantly female , East Asian ethnicity , non smoking history , and adenocarcinoma (ADC) histology have been associated with an increased likelihood of EGFR-TKI effectiveness [ - ] . Furthermore , a high response rate ( 60 to 90 % ) to treatment with EGFR-TKIs has been observed in patients harboring mutations in exons 18 to 21 of the tyrosine kinase domain of EGFR , with exon 19 deletions and exon 21 @VARIANT$ point mutations comprising about 90 % of all mutations [ , ] .", "label": "sensitivity"}
{"id": "22397365", "sentence": "DHPLC patterns shows a suspicious peak in cases with @GENE$ or IDH2 mutations as compared to cases with the wild type ( WT ) ; Six missense IDH1 mutations ; R132H , R132C , R132S , R132G , @VARIANT$ , and I99M and 1 silent mutation ( G105G ) , and 2 missense IDH2 mutations ; R140Q and R172K , are demonstrated . ( Abbreviation : C , cysteine ; G , glycine ; H , @DRUG$ ; I , isoleucine ; K , lysine ; L , leucine ; M , methionine ; Q , glutamine ; S , serine ) .", "label": "None"}
{"id": "25309870", "sentence": "The pooled analysis showed an important improvement in overall survival in patients whose tumors had the most common @GENE$ mutations , Del-19 and Point 21 @VARIANT$ . In the sub-population of patients with these mutations , the median overall survival in the @DRUG$ arm was 27.3 months , which was significantly improved over median overall survival of 24.3 months in the chemotherapy arm ( HR 0.81 , p = 0.037 ) .", "label": "sensitivity"}
{"id": "24155950", "sentence": "Additionally , we have used the @GENE$ Bcr-Abl @VARIANT$ cell line , derived from Baf3 ( an immortalized murine pro-B cell line ) , which is also resistant to 1μM @DRUG$ and at least partially resistant to dasatinib and nilotinib treatments ( -6 ) .", "label": "None"}
{"id": "22277029", "sentence": "Second , along the same line of inquiry , unlike @DRUG$ which is preferentially active in tumor cells bearing the @VARIANT$ mutation of BRAF , reducing levels of pERK1 and/or 2 does not depend on the mutation status of the melanoma cell . Indeed , it has been observed that within melanoma lesions , there can be both clones containing both BRAF mutant alleles as well as wild-type BRAF [ ] . Third , by silencing ERK1 and/or ERK2 , the feedback loop between ERK and RAF and MEK is interrupted as clearly observed by comparing treatment of cells with MEK inhibitor which led to increased phospho-MEK as reported by others [ ] , in contrast to the decrease in @GENE$ after our shRNA approach ( see below for more discussion ) .", "label": "None"}
{"id": "16187797", "sentence": "( B ) Number of colonies formed in soft agar by clonal NIH-3T3 cells expressing @VARIANT$ EGFR and D770_N771insNPG @GENE$ treated with the indicated concentrations of @DRUG$ or erlotinib immediately prior to suspension in soft agar .", "label": "sensitivity"}
{"id": "16187797", "sentence": "Transformation induced by expression of L858R , G719S , and L747_E749del @VARIANT$ EGFR , but not @GENE$ stimulated wild-type EGFR or D770_N771insNPG EGFR , was inhibited by 0.1 μM @DRUG$ .", "label": "None"}
{"id": "24894453", "sentence": "C ) . Taken together , we found that G719S and @VARIANT$ mutants are oncogenic in the absence of ligand stimulation and effectively respond to @DRUG$ in vivo and in vitro . Asymmetric dimerization is required for oncogenic activity of G719S and G724S mutant Recently , we reported that a subset of lung cancer derived oncogenic EGFR mutants such as L858R require asymmetric dimerization for biochemical activation and oncogenic transforming activity , meaning that their oncogenic ability depend on formation of an @GENE$ homodimer in which two distinct regions of the two molecule dimerize [ ] .", "label": "sensitivity"}
{"id": "15737014", "sentence": "In tumors from patients not treated with either @DRUG$ or erlotinib , the 2369 C→T mutation ( @VARIANT$ ) appears to be extremely rare . We have not identified this mutation in 155 tumors ( see above ) , and among nearly 1,300 lung cancers in which analysis of @GENE$ exons 18 to 21 has been performed [ , ,, , , ] , only one tumor ( which also harbored an L858R mutation ) was reported to contain the T790M mutation .", "label": "resistance or non-response"}
{"id": "23788917", "sentence": "EGFR TKI , which are effective for the @VARIANT$ mutation of the EGFR gene , may also prove to be effective in patients with mutations in exon 20 of the HER2 gene , but only if they have the ability to block the function of the tyrosine kinase associated with both EGFR and HER2 . A double reversible inhibitor of EGFR and @GENE$ receptors called @DRUG$ has not shown efficacy in this case .", "label": "None"}
{"id": "24832599", "sentence": "In spite of recent improvements in NSCLC management , such as the use of targeted therapy including @DRUG$ and erlotinib , which have led to improved progression-free survival and quality of life in NSCLC patients with an activating @GENE$ mutation , progression or metastasis because of resistance to targeted therapy remains a major clinical problem . Apart from @VARIANT$ and c-MET amplification , a recent study has reported that Axl kinase is upregulated in humans with acquired resistance to EGFR-TKI .", "label": "resistance or non-response"}
{"id": "25162038", "sentence": "A. Lima and colleagues report in this special issue the role of methylenetetrahydrofolate reductase ( @GENE$ ) C677T , aminoimidazole carboxamide adenosine ribonucleotide transformylase ( ATIC ) @VARIANT$ polymorphisms , and clinicopathological variables in clinical response to @DRUG$ (MTX) in Portuguese patients with RA .", "label": "None"}
{"id": "19920910", "sentence": "In a cell-line based mutagenesis study , the emergence of @GENE$ mutations resistant to imatinib , nilotinib and @DRUG$ were compared : 20 different mutations were identified with imatinib mesylate , 10 with nilotinib ( including only 1 novel mutation , E292V ) and 9 with dasatinib . In contrast to imatinib mesylate , mutations recovered in the presence of 50 nM nilotinib were limited to L248V , G250E , Y253H , @VARIANT$ ( p-loop ) , T315I , F359C , L384M and L387F .", "label": "None"}
{"id": "25119968", "sentence": "Nevertheless , the decrease in the amount of double stranded DNA was observed with the increasing concentrations of @DRUG$ and time of treatment in all of the three examined cell lines , proving that at least a portion of DNA acquires double strand breaks upon treatment with doxorubicin . Generally , @GENE$ deficient cells have impaired DNA repair . This process seems to be more severe in the @VARIANT$ than in the S4 cells due to the lower level of the BRCA1 protein , which doesn’t interact with ATM in the S3R cells .", "label": "None"}
{"id": "22815900", "sentence": "The presence of activating EGFR mutations is closely associated with a more favorable outcome following treatment with @GENE$ targeted drugs . In our present study , erlotinib-resistant cell lines were established ; PC9/ER1 from PC9 cells harboring delE746-A750 mutation , and 11–18/ER1-7 and 11–18/ER2-1 from 11–18 cells harboring @VARIANT$ mutation .", "label": "sensitivity"}
{"id": "25563357", "sentence": "Both focus on the two predominant EGFR mutations , the deletion in exon 19 and the @VARIANT$ point mutation , and they will look at the T790M point mutation as a potential predictor of response to combination treatment . The T790M mutation is known to mediate secondary resistance to @GENE$ TKIs [ ] , yet there is evidence that it can be detected even before treatment with @DRUG$ or gefitinib when a high sensitivity method of detection is applied [ ] .", "label": "sensitivity"}
{"id": "15737014", "sentence": "Importantly , we find that the T790M mutation confers drug resistance not just to wild-type @GENE$ but also to mutant EGFRs associated with clinical responsiveness to EGFR tyrosine kinase inhibitors [ , , ] . In tumors from patients not treated with either @DRUG$ or erlotinib , the 2369 C→T mutation ( T790M ) appears to be extremely rare . We have not identified this mutation in 155 tumors ( see above ) , and among nearly 1,300 lung cancers in which analysis of EGFR exons 18 to 21 has been performed [ , ,, , , ] , only one tumor ( which also harbored an @VARIANT$ mutation ) was reported to contain the T790M mutation .", "label": "sensitivity"}
{"id": "24501009", "sentence": "Strategies to improve EGFR inhibition in EGFR @VARIANT$ cancers include the combination of irreversible EGFR inhibitors with the EGFR‐directed antibody @DRUG$ ( as reported for afatinib plus cetuximab ) 19 ; the development of more potent and specific inhibitors of @GENE$ T790M20,21 ; and the use of intermittent but high doses of existing irreversible EGFR inhibitors .", "label": "response"}
{"id": "18989397", "sentence": "OMIM alleles are documented by the change they cause , e.g. @VARIANT$ would refer to a variant that changes a @DRUG$ located at position 35 to a lysine .", "label": "None"}
{"id": "17211472", "sentence": "S100C is a @GENE$ in cell cycle progression and differentiation , which is localised in the cytoplasm and nucleus of many cell types . This protein has been shown to be downregulated in a range of malignant tissues , compared to normal tissues including the bronchus , mammary duct , renal tube , prostate , uterus and testis . @VARIANT$ secretion is upregulated in response to Gefitinib and , therefore , @DRUG$ could be , in part , reversing the malignant phenotype .", "label": "None"}
{"id": "24410791", "sentence": "CO-1686 is a third-generation EGFR TKI , which may be more effective in patients with @VARIANT$ . NCT01526928 is an ongoing phase I/II trial that has enrolled patients who have failed prior chemotherapy and @GENE$ targeted therapy including erlotinib , @DRUG$ , neratinib , afatinib , or dacomitinib .", "label": "resistance or non-response"}
{"id": "22655263", "sentence": "Ki determination demonstrated a very similar biochemical potency on wild-type ALK and the @VARIANT$ ALK mutant ( 0.09 and 0.08 nM respectively ) , with both cellular and in vivo data ( using engineered Ba/F3 cells ) indicating that growth of @GENE$ mutant driven-cells is inhibited at similar , albeit slightly higher , doses which inhibit cells harboring wild-type ALK ( Katayama et al. , ) . AP26113 was also described to be active on a series of in vitro induced crizotinib resistant mutations , which however have not been observed to date in clinical cases of acquired @DRUG$ resistance ( Zhang et al. , ) .", "label": "resistance"}
{"id": "24212665", "sentence": "Such an example could be represented by the study of Park and co-workers who investigated the relationship of the p53 status and chemo-sensitivity to @DRUG$ in two human malignant glioblastoma cell lines ( A172 and @VARIANT$ , harboring wild-type and mutant-type @GENE$ , respectively ) .", "label": "None"}
{"id": "24124608", "sentence": "In addition to upregulation of IGF1R and VEGF , frequent CN gain and increased mRNA expression of GSTT1 as well as significant overexpression of @GENE$ subfamily members were observed in wild-type/PDGFRA @VARIANT$ GISTs compared to KIT-mutant GISTs . CN gain of GSTT1 was closely associated with @DRUG$ resistance .", "label": "None"}
{"id": "24155950", "sentence": "Our results show that bortezomib and @DRUG$ combined treatment is able to target the TKIs-resistant cell lines with the @VARIANT$ mutation in Bcr-Abl . Bortezomib in combination with the PLK1 inhibitor BI 2536 induces a significant downregulation of the total levels and phosphorylation of Bcr-Abl , a decrease of downstream phosphorylated STAT5 and @GENE$ dependent cell death in imatinib- , dasatinib- and nilotinib-resistant and -sensitive K562 cell lines", "label": "None"}
{"id": "22970367", "sentence": "Moreover , dual inhibition of EGFR with an irreversible @GENE$ inhibitor ( @DRUG$ ) and the EGFR neutralizing antibody cetuximab has recently shown promising activity in EGFR mutant lung cancers with acquired EGFR TKI resistance that harbor an EGFR @VARIANT$ mutation [ ] .", "label": "response"}
{"id": "23029123", "sentence": "Previous studies identified that D2 receptors are positively coupled with @GENE$ Gi3 proteins , which inhibit Gs protein expression to reduce cellular level of cAMP and thereby PRL gene production and cell proliferation in lactotropes . We showed here that a Gi3 blocker was able to stimulate the basal level of PRL while a Gs blocker was able to inhibit @DRUG$ action on PRL production in @VARIANT$ cells , but not in D2L cells .", "label": "None"}
{"id": "19893626", "sentence": "Similarly , the @VARIANT$ point mutation in the @GENE$ resistance to the EGFR tyrosine kinase inhibitors gefitinib and @DRUG$ , which are used to treat non-small cell lung cancer .", "label": "resistance or non-response"}
{"id": "23976869", "sentence": "However , Stover et al reported that nilotinib could not overcome the @DRUG$ resistance conferred by the point mutation @VARIANT$ in @GENE$ in the same cellular model , even at high concentrations .", "label": "None"}
{"id": "23788917", "sentence": "In vitro studies demonstrated that the effective concentration of @DRUG$ in tumour cells harbouring both the L858R and @VARIANT$ mutations has to be 300 times higher to induce apoptosis than in cells only with an activating mutation in codon 858 [ , ] . Presence of a mutation in exon 20 of the EGFR gene is a potential prognostic and predictive marker of @GENE$ TKI therapy and may play an important role in the planning of therapy .", "label": "resistance or non-response"}
{"id": "20628392", "sentence": "In this study , we report that BMS-690514 has in vivo efficacy on a panel of NSLCC xenografts , including those with @VARIANT$ mutations , conferring resistance to @GENE$ therapies such as Erlotinib or @DRUG$ .", "label": "resistance or non-response"}
{"id": "24472312", "sentence": "Gatekeeper mutants ( e.g. @VARIANT$ @GENE$ , T670I KIT and T674I PDGFRα ) are particularly multi-drug resistant . In the present study , @DRUG$ potently inhibited the phosphorylation of the WT and gatekeeper mutant T674I FIP1L1-PDGFRα and their downstream signaling .", "label": "response"}
{"id": "22163042", "sentence": "To determine the role of the catalytic activity of the OTU domain in IFN antagonism , we changed the cysteine at position 40 and the @DRUG$ at position 151 , two components of the catalytic triad , to alanine ( @VARIANT$ and H151A respectively ) .", "label": "None"}
{"id": "22034911", "sentence": "By contrast , p-ALK levels were reduced by approximately 25–35 % at 6 h in tumors expressing @VARIANT$ or S1206R , with a partial recovery at 24 h . There was no significant inhibition in tumors expressing the G1269S mutation . Drug exposure was similar in all models , confirming that @DRUG$ inactivity in the mutant @GENE$ efficacy studies is because of the inadequate target inhibition .", "label": "resistance"}
{"id": "24955213", "sentence": "@VARIANT$ EML-ALKpm A mutation-specific strong H-bond pulls @DRUG$ out of the position found in the non-crizotinib resistant @GENE$ fusion gene [ , ] 1151Tins Thr insertion is predicted to alter ATP binding to ALK [ ]", "label": "resistance"}
{"id": "22059905", "sentence": "Meanwhile , NVP-BEZ235 showed greater antiproliferative activity than the allosteric selective @GENE$ inhibitor @DRUG$ in all cancer cell lines tested . In a xenograft model of BT474 derived breast cancer cells overexpressing either the p110α H1047R oncogenic mutation or the empty vector , NVP-BEZ235 significantly inhibited tumor growth of both xenografts . Consistently , NVP-BEZ235 at nanomolar concentrations suppressed phosphorylation of Akt , @VARIANT$ , and 4E-BP1 and inhibited cell growth in a panel of cancer cells , including myeloma cells , as well as human glioma , osteosarcoma , Ewing 's sarcoma , and rhabdomyosarcoma .", "label": "None"}
{"id": "21695180", "sentence": "A polymorphism ( @VARIANT$ ) in the @GENE$ gene has been identified in the coding region at nucleotide 638 ( a G to A transition ) . This base change results in a change in the amino acid sequence from arginine to @DRUG$ ( Arg213His ) , leading to a decrease in enzymatic activity .", "label": "None"}
{"id": "23843700", "sentence": "The most common point mutation is @VARIANT$ in exon 11 , but point mutations also occur in exons 13 , 17 , and 18 . Other tumors , including gastrointestinal stromal tumors with @GENE$ mutations have been responsive to the tyrosine kinase inhibitor , @DRUG$ .", "label": "resistance or non-response"}
{"id": "22997553", "sentence": "We hypothesized that @GENE$ S1179D electroporated fish will be protected against @DRUG$ mediated teratogenicity . A mutant plasmid ( @VARIANT$ ) which did not express eNOS was also used in the experiment .", "label": "None"}
{"id": "25285017", "sentence": "In terms of EGFR targeted therapy , resistant mechanisms ( eg , @GENE$ @VARIANT$ mutation and MET amplification ) emerge as a result of the tumor evolution after EGFR inhibition by @DRUG$ or erlotinib .", "label": "resistance or non-response"}
{"id": "21915126", "sentence": "@GENE$ mutations were analysed in 10 of 27 patients by direct sequencing of paraffin embedded tumour samples extracted before initiation of @DRUG$ therapy . The EGFR mutations were detected in 4 of 10 patients . In-frame deletions within exon 19 were detected in three patients , and a mutation of @VARIANT$ was detected within exon 21 in one patient .", "label": "sensitivity"}
{"id": "25100284", "sentence": "@DRUG$ and icotinib were not included in the pooled analysis calculations , but studies were identified that included 129 afatinib treated patients ( US and Taiwanese ) and 29 icotinib treated patients ( all Chinese ) . In studies where mutation types were reported individually the most common @GENE$ mutations were exon 19 deletions ( 53 % ) and @VARIANT$ mutations ( 38 % ) .", "label": "sensitivity"}
{"id": "23880860", "sentence": "The obtained cinnamic acid is activated by ligation to coenzyme A by 4-coumaroyl : CoA ligase ( @VARIANT$ ) . @DRUG$ is then synthesized by the stilbene synthase (STS) which acts to condense three successive units of @GENE$ with p-coumaroyl-CoA .", "label": "None"}
{"id": "23566546", "sentence": "Case Histrogical type @GENE$ mutation status Brinkman index Treatment agent Response IL-8 ( ng/mL ) IL-10 ( ng/mL ) RANTES ( pg/ml ) 1 Ad Ex21 L858R 900 gefitinib PR 5.79 1.67 2 2 Ad Ex21 L858R 0 erlotinib PR_3.33 94.2 1.41 3 Ad Ex19 del 0 erlotinib PR 4.09 126 2.13 4 Ad Ex21 L858R 0 gefitinib PR_3.92 18.1 1.85 5 Ad Ex21 L858R + Ex19 del 370 erlotinib PR 21.9 1.23 2.11 6 Ad Ex19 del 0 erlotinib PR 7.05 1.37 2.56 7 Ad Ex19 del 0 gefitinib PR 4.82 1.59 2.02 8 Ad Ex21 L858R 1640 gefitinib PR 54.9 2.7 2.38 9 Ad negative 400 erlotinib SD 34.9 3.39 3.66 10 Ad negative 0 erlotinib SD 27.1 4.94 2.25 11 Ad unknown 1800 erlotinib SD NE NE NE 12 Sq Ex19 del 3840 gefitinib SD 12.6 1.1 1.98 13 Ad Ex19 del 30 erlotinib SD 5.27 0.69 2.66 14 Ad Ex19 del 0 erlotinib SD 10.5 0.85 2.5 15 Ad unknown 300 erlotinib SD 7.69 2.61 1.7 16 La negative 2080 erlotinib SD NE NE NE 17 Sq Ex21 L858R 750 erlotinib SD 11.6 56.3 3.06 18 Ad unknown 600 erlotinib SD 13.7 1.1 2.82 19 Ad Ex21 L858R 0 erlotinib SD 20.6 11.6 0.783 20 Ad Ex19 del 0 erlotinib SD 14.8 2.07 2.02 21 Ad Ex21 L858R + Ex19 del 0 gefitinib SD 3.04 1.3 1.76 22 Ad Ex19 del 200 gefitinib SD 10.9 1.59 1.91 23 Sq unknown 1560 erlotinib PD NE NE NE 24 Ad negative 1080 erlotinib PD 25.2 8.15 1.57 25 Ad unknown 0 @DRUG$ PD NE NE NE 26 Ad Ex18 @VARIANT$ 2000 erlotinib PD 11.6 4.48 3.12 27 Ad unknown 1410 erlotinib PD NE NE NE 28 Ad Ex19 del 1000 gefitinib PD 9.44 2.25 2.89 29 Ad negative 1100 erlotinib PD 56.3 5.63 2.16 30 Ad negative 2000 erlotinib PD 15.6 0.85 0.292 31 Ad negative 825 erlotinib PD 8.27 1.59 2.13 32 Ad Ex21 L858R 0 erlotinib PD 5.34 7.05 1.7 33 Ad negative 1680 erlotinib PD 57.7 1.63 2.06", "label": "None"}
{"id": "24348666", "sentence": "The two mutations were shown to independently induce @DRUG$ resistance in @GENE$ cells engineered to express the L1196M and @VARIANT$ mutations .", "label": "None"}
{"id": "16626260", "sentence": "Although several previous studies have suggested that tumors harboring mutations in the @GENE$ kinase domain were sensitive to TKIs such as gefitinib or @DRUG$ , others had reported an association between the @VARIANT$ mutation in exon 20 and the resistance to TKIs .", "label": "resistance or non-response"}
{"id": "25054154", "sentence": "We utilised three complexes , namely , native ( ALK-crizotinib ) , @VARIANT$ ( @GENE$ F1174L-crizotinib ) , and R1275Q ( ALK R1275Q-crizotinib ) for our analysis .", "label": "resistance"}
{"id": "24811491", "sentence": "The @GENE$ @VARIANT$ mutation has been described as a predictor of tumor aggressiveness in metastatic disease [ , , ] and also of low RRs to @DRUG$ and panitumumab [ , , , ] .", "label": "resistance or non-response"}
{"id": "23976869", "sentence": "Treatment of two patients resistant to @DRUG$ with nilotinib was successful. , Another patient intolerant to imatinib responded to nilotinib and dasatinib. , The sensitivity of the @VARIANT$ mutation to second generation TKIs has been a matter of debate . Vo n Bubnoff et al reported that nilotinib suppresses the growth of Ba/F3 cells transfected with the T674I @GENE$ mutant .", "label": "resistance"}
{"id": "22272737", "sentence": "Members of the zinc finger transcription factors are characterized by the number and arrangement of cysteine ( C ) and @DRUG$ ( H ) within the zinc finger ( C2H2 , @VARIANT$ , C2C2 , C3HC4 , @GENE$ ) in combination with other hydrophobic amino acids essential for stabilizing the zinc finger [ , ] .", "label": "None"}
{"id": "22569033", "sentence": "Crenolanib was effective in blocking the activity of single or compound PDGFRA @VARIANT$ mutant kinases . In contrast , @DRUG$ had no significant activity against these same mutant kinases . A phase II clinical study of crenolanib for treatment of GIST patients with primary or secondary @GENE$ D842V mutation is currently recruiting patients ( ClinicalTrials.gov Identifier : NCT01243346 ) .", "label": "resistance or non-response"}
{"id": "24623980", "sentence": "Two secondary mutations of @GENE$ associated with @DRUG$ resistance – L1196M and C1156Y – were first detected in the same patient , who relapsed after achieving a partial response to the drug . The L1196M substitution occurs at the gatekeeper position of ALK ( a position that controls the binding of nucleotides and TKIs ) , and corresponds to the T790M substitution in EGFR and the @VARIANT$ substitution in the Bcr–Abl fusion protein , both of which confer resistance to corresponding TKIs .", "label": "None"}
{"id": "25435999", "sentence": "@DRUG$ resistance can be induced by point mutations ( such as @VARIANT$ and M351T ) of transgenic @GENE$ and this results in increased expression of the oncogenic BCR-ABL fusion protein .", "label": "None"}
{"id": "24594844", "sentence": "Besides , after EGF treatment , cDzT remained its suppression effect on EGFR protein expression and downstream signaling including EGFR , STAT3 , @GENE$ , and ERK ( Supplementary Figure S5 ) . Synergistic antitumor effect of combined treatment with cDzT and @DRUG$ in vitro and in vivo cDzT could be used as single agent or as part of combination therapy with second generation TKIs to increase efficacy in the treatment of NSCLCs that harbor the EGFR @VARIANT$ mutant .", "label": "None"}
{"id": "25382104", "sentence": "Ponatinib is the only available drug that is designed to overcome @VARIANT$ gatekeeper mutation and is efficient in inhibiting the mutant @GENE$ Ponatinib exhibits triple carbon-carbon ( ethynyl linkage ) bond between the methyl phenyl and purine groups . It holds the Isoleucine side chain without steric interference and without any loss of hydrogen bond ( H_bond ) . It also showed similar binding pattern ( DFG-out ) as @DRUG$ and nilotinib which interacts with Met318 , Asp381 and the side chain of Glu286 .", "label": "None"}
{"id": "24920920", "sentence": "In 40 patients harboring @VARIANT$ , five revealed complex mutations , including two with T790M . In 61 patients with @GENE$ TKI as first-line therapy , 46 received gefitinib , 13 received erlotinib , and two received @DRUG$ .", "label": "sensitivity"}
{"id": "23937717", "sentence": "The functional relevance of restoration of NKG2D–NKG2DL interaction by @DRUG$ was demonstrated by the enhanced cytotoxicity , degranulation and IFN-γ production of NK cells in response to lung cancer cells with @GENE$ L858R + @VARIANT$ resistance mutation .", "label": "resistance or non-response"}
{"id": "23892415", "sentence": "Grommes et al. also reported a study involving treatment of a very small group of patients ( n = 9 ) treated with pulsatile , high-dose @DRUG$ with CNS metastases and with @GENE$ mutation diagnosed outside of CNS metastases . A partial response of CNS metastases was observed in six patients . Corresponding tissue from the CNS metastases was available for four patients with response after tyrosine kinase inhibitor ( TKI ) -EGFR therapy diagnosed with EGFR mutation matching to those diagnosed outside the CNS metastases ( three @VARIANT$ substitution and one deletion in exon 19 ) [ ] .", "label": "sensitivity"}
{"id": "21192840", "sentence": "Along with Shc , Grb2 also mediates activation of Ras signaling by recruitment of the guanine nucleotide exchange factor , @GENE$ . The kinase domain mutations documented in non-small cell lung cancer ( NSCLC ) and deletion mutations found in glioblastoma ( GBM ) are detailed , with the most frequent alterations ( @VARIANT$ and ΔEGFR/EGFRvlll respectively ) shown in bold , . The T790M “gatekeeper mutation” is associated with acquired resistance to @DRUG$ in NSCLC ( see text for details and further references ) .", "label": "None"}
{"id": "25486409", "sentence": "10.1371/journal.pone.0114000.g003CX-4945 enhanced the efficacy of @GENE$ to overcome drug resistance caused by @VARIANT$ . Cells were treated with CX-4945 ( 5 µM ) , gefitinib ( 1 µM ) , and erlotinib ( 1 µM ) or a combination of CX-4945 and @DRUG$ or CX-4945 and erlotinib for 48 h .", "label": "resistance or non-response"}
{"id": "24939055", "sentence": "The EGF receptor tyrosine kinase inhibitors ( @GENE$ ) @DRUG$ and erlotinib have shown marked therapeutic effects against NSCLCs with EGFR activating mutations , such as exon 19 deletions and L858R point mutations [ ] . Almost all tumors , however , acquire resistance to EGFR-TKIs after varying periods of time . Common mechanisms for acquired resistance include emergence of an EGFR gatekeeper mutation ( @VARIANT$ ) and MET gene amplification [ , ] .", "label": "resistance or non-response"}
{"id": "15696205", "sentence": "In @DRUG$ treated patients , six @GENE$ mutations involved exon 19 deletions that lacked the amino acids Leu-Arg-Glu-Ala , and two were exon 21 amino acid substitutions ( @VARIANT$ ) .", "label": "sensitivity"}
{"id": "22101934", "sentence": "Cell based assays with full-length @VARIANT$ and Δ746–750 EGFRs show enhanced autophosphorylation of the EGFR C-terminal tails and other proteins relative to WT EGFR , ,, but the enzymologic basis for this increased phosphorylation has been difficult to establish because of the complex environment of the cell . Previously , we demonstrated the feasibility of expressing , purifying , and analyzing the kinetics for near-full length @GENE$ ( tEGFR , aa25–1022 ) , which lacks only part of the C-terminal tail . It was shown that the EGF bound form of WT tEGFR had a kcat that was 150-fold greater and a sensitivity to @DRUG$ that was ~25-fold higher than the Cetuximab–bound form , consistent with EGF–driven activation .", "label": "sensitivity"}
{"id": "19159467", "sentence": "At the molecular level , most patients with partial or complete responses to gefitinib and @DRUG$ harbored specific mutations in the gene that encodes @GENE$ , located on chromosome 7p12 [ ] . Exon 19 mutations , characterized by in-frame deletions of amino-acids 747–750 , account for 45 % of mutations , exon 21 mutations , resulting in @VARIANT$ substitutions , account for 40–45 % of mutations , and the remaining 10 % of mutations involve exon 18 and 20 [ - ] .", "label": "sensitivity"}
{"id": "19774209", "sentence": "This alteration leads to increased affinity for ATP , which can then out-compete @DRUG$ and/or erlotinib for binding to the receptor . Irreversible inhibitors of @GENE$ tyrosine kinase are currently in development that form permanent covalent bonds to the binding domain rather than having to compete with ATP for temporary interactions . They have been shown to successfully inhibit EGFR bearing the @VARIANT$ mutation in vitro .", "label": "resistance or non-response"}
{"id": "20349044", "sentence": "The two main neurotransmitters eliciting contraction in human and rodent urinary bladder are adenosine triphosphate and acetylcholine , which act on a ligand gated ion channel ( @VARIANT$ receptor ) and two G-protein coupled receptors ( M2 and M3 muscarinic ) , respectively ( de Groat and Yoshimura ) . A common approach for studying how the functions of these receptors change in diabetes mellitus is to examine their contractile roles in isolated urinary bladder from animals treated with @DRUG$ (STZ) . In smooth muscle , cAMP mediates relaxation , and activation of the M2 receptor inhibits @GENE$ the relaxation elicited by forskolin and activation of β-adrenoceptors in gastrointestinal and urinary bladder smooth muscle ( Ehlert ) .", "label": "None"}
{"id": "24212826", "sentence": "Furthermore , three of the four responders with exon 20 mutations also had concurrent sensitizing @GENE$ mutations ( L858R ) [ ] . According to previous studies , the average response rate for @DRUG$ treatment in patients with exon 20 mutations was only 34 % . These mutations in exon 20 could be point mutations , such as V765M , S768I , H773R , and @VARIANT$ .", "label": "resistance or non-response"}
{"id": "21444946", "sentence": "The most commonly identified mechanism of resistance is an EGFR mutation at position 790 ( @VARIANT$ ) , resulting in substitution of a threonine residue with methionine , which abrogates the ability of @DRUG$ or erlotinib to inhibit @GENE$ [ , ] .", "label": "resistance or non-response"}
{"id": "22970367", "sentence": "Moreover , dual inhibition of EGFR with an irreversible EGFR inhibitor ( @DRUG$ ) and the EGFR neutralizing antibody cetuximab has recently shown promising activity in EGFR mutant lung cancers with acquired EGFR TKI resistance that harbor an @GENE$ @VARIANT$ mutation [ ] .", "label": "response"}
{"id": "23864840", "sentence": "After re-introduction of gefitinib , 25 % achieved partial remission and 75 % showed @GENE$ . A different response to the same EGFR-TKI regimen after a drug holiday can be explained with tumor heterogeneity . In a retrospective analysis of an @DRUG$ retrial , Becker et al. [ ] reported five cases of the @VARIANT$ mutation and exon 19 deletions in rebiopsy specimens taken before the retrial of erlotinib .", "label": "None"}
{"id": "24455544", "sentence": "When considering a change in therapy , it is important to consider a BCR-ABL kinase domain mutational analysis. [ ] @GENE$ mutation @VARIANT$ is resistant to all of the currently approved TKIs . Some mutations ( Y253H , E255K/V , and F359V/C ) are less sensitive to @DRUG$ , and others ( F317L and V299L ) are less sensitive to dasatinib .", "label": "None"}
{"id": "15737014", "sentence": "The T790M mutation was shown in vitro in the context of wild-type @GENE$ to confer resistance to gefitinib [ ] and a related quinazoline inhibitor , PD153035 [ ] . We show here , through molecular analysis of tumor material from three patients and one NSCLC cell line , as well as additional biochemical studies , that acquired clinical drug resistance to gefitinib or @DRUG$ is indeed associated with the @VARIANT$ mutation .", "label": "resistance or non-response"}
{"id": "24276379", "sentence": "It has even been observed that cells that have been induced to become cetuximab-resistant by continuously exposing them to cetuximab have acquired either K-Ras G12V or K-Ras G13D mutations [ ] . Moreover , in a large retrospective study of patients treated with @DRUG$ , the outcome in patients with the @VARIANT$ mutation was not better than other KRas mutations .", "label": "None"}
{"id": "24928511", "sentence": "More than 50 % of lung adenocarcinomas (LAD) from East Asian non-smokers harbor EGFR mutations , and these tumors have been termed oncogene addicted to reflect their dependence on @GENE$ mediated pro-survival signaling and their high susceptibility to apoptosis induced by EGFR-TKIs ( e.g. @DRUG$ and erlotinib ) ( ) . The most frequently occurring mutations in the EGFR gene ( in-frame deletion in exon 19 at codons 746–750 or a single-base substitution @VARIANT$ in exon 21 ) predict an improved clinical response to first-line oral EGFR-TKIs compared with standard platinum based chemotherapy in patients with advanced non-small-cell lung carcinoma ( NSCLC ) ( , ) .", "label": "sensitivity"}
{"id": "24939055", "sentence": "The EGF receptor tyrosine kinase inhibitors ( EGFR-TKIs ) gefitinib and @DRUG$ have shown marked therapeutic effects against NSCLCs with @GENE$ activating mutations , such as exon 19 deletions and @VARIANT$ point mutations [ ] .", "label": "sensitivity"}
{"id": "22343623", "sentence": "In this study , we examined whether the selective KOR agonist U50 ,488H could inhibit the growth of gefitinib-sensitive and @GENE$ mutant ( delE746-A750 , L858R ) NSCLC cells ( HCC827 ) and gefitinib-resistant and EGFR mutant ( @VARIANT$ ) NSCLC cells ( H1975 ) , and investigated the signalling mechanism of the KOR mediated inhibitory effect on tumour cell growth .", "label": "resistance or non-response"}
{"id": "22209766", "sentence": "On the other hand , erlotinib could not inhibit EGFR phosphorylation in H1975 cells because the @VARIANT$ mutation in EGFR causes a conformation change at the ATP binding pocket , thus decreasing the affinity between @DRUG$ and @GENE$ .", "label": "resistance or non-response"}
{"id": "23237215", "sentence": "Patients with @GENE$ exon 20 @VARIANT$ mutation before treatment were excluded from this study . The TKI used in this study was gefitinib or @DRUG$ .", "label": "resistance or non-response"}
{"id": "15737014", "sentence": "For example , in CML , a commonly found mutation is a C→T single nucleotide change that replaces threonine with isoleucine at position 315 ( @VARIANT$ ) in the ABL kinase domain [ , , ] . In GIST and @GENE$ , respectively , the analogous T670I mutation in KIT and T674I mutation in PDGFR-alpha have been associated with acquired resistance to this drug [ , ] . To determine whether lung cancers that acquire clinical resistance to either gefitinib or @DRUG$ display additional mutations in the EGFR kinase domain , we have examined the status of EGFR exons 18 to 24 in tumors from five patients who initially responded but subsequently progressed while on these drugs .", "label": "None"}
{"id": "24987354", "sentence": "Multikinase small molecule inhibitors such as sorafenib and @DRUG$ can be used per recent NCCN guidelines ( Version 2.2013 ) , but prospective clinical trials have not yet demonstrated a distinct molecular subgroup of PTC patients that derives large benefit from such targeted therapies [ ] . @GENE$ @VARIANT$ is present in approximately 45 % of all PTC [ ] , with alterations of CTNNB1 , HRAS , IDH1 , KRAS , NRAS , PIK3CA and TP53 being less common .", "label": "None"}
{"id": "24944510", "sentence": "Poziotinib ( also known as HM781-36B ) , a new potent irreversible inhibitor of EGFR , HER2 , HER4 , and transient erythroblastopenia of childhood family of kinases inhibitor ( BTK , BLK , and BMX ) , demonstrated preclinical efficacy against @VARIANT$ mutant at eightfold lower doses compared to afatinib . A different approach in addressing EGFR-TKI resistance involves the use of combination regimens . Therefore , the combination of @DRUG$ with cetuximab , and the combination of erlotinib with MM-121 ( a fully human mAb that targets HER3 ) , in patients with acquired resistance to @GENE$ did not show sufficient clinical activity for further investigation in this population .", "label": "resistance or non-response"}
{"id": "23976869", "sentence": "Sequencing of 87 FIP1L1-PDGFRA negative hypereosinophilic syndrome patients showed several PDGFRA point mutations ( R481G , L507P , I562M , H570R , H650Q , N659S , L705P , R748G , and @VARIANT$ ) . Four of these in vitro mutations induced growth factor independent cell proliferation and constitutive phosphorylation of PDGFRA and @GENE$ . Mice injected with PDGFRA-mutant cells were treated with oral @DRUG$ .", "label": "None"}
{"id": "24236021", "sentence": "The development of second-generation ABL inhibitors like nilotinib and dasatinib are active against many imatinib-resistant mutants – . Ponatinib ( AP24534 ) , a third generation pan-BCR-ABL kinase inhibitor generated from the structure guided drug design strategy , is able to inhibit native @GENE$ kinase , most of the clinically relevant mutants including @VARIANT$ mutation .", "label": "None"}
{"id": "22714415", "sentence": "This year at ASCO , Tejpar et al. further supported this finding by presenting retrospective analyses of two large phase III multicenter trials ( CRYSTAL and OPUS ) representing 83 patients with @VARIANT$ @GENE$ mutant mCRC tumors who had longer overall survival and progression free survival on average post @DRUG$ treatment then other KRAS mutant subtypes .", "label": "resistance or non-response"}
{"id": "23976869", "sentence": "However , the clinical response was short because of the emergence of another @VARIANT$ mutation . This mutation is highly resistant to sorafenib , @DRUG$ , and dasatinib . Sorafenib also failed to block S601P mutated @GENE$ .", "label": "resistance or non-response"}
{"id": "19046449", "sentence": "The EnzChek Caspase-3 fluorescent assay was used to determine the protease activity of caspase-3 in @VARIANT$ . @GENE$ cells in the presence and absence of 40 μM @DRUG$ pretreatment ( 16 hrs ) followed by induction of apoptosis using 0.8 mg/ml of Rec-1 or Enol-1 for 8 , 16 , and 24 hrs .", "label": "None"}
{"id": "24353011", "sentence": "@DRUG$ is an orally bioavailable EGFR inhibitor , which is indicated for first-line treatment of patients with metastatic NSCLC whose tumors have @GENE$ exon 19 deletions or exon 21 ( @VARIANT$ ) substitution mutations [ • ] .", "label": "sensitivity"}
{"id": "25295230", "sentence": "@VARIANT$ AML @DRUG$ Smith et al. ( ) @GENE$ AML AC220 Albers et al. ( ) Ba/F3 AML ( pediatric ) Sorafenib Baker et al. ( )", "label": "None"}
{"id": "25536104", "sentence": "In our cases with ERBB2 mutation , IHC expression of ERBB2 was not detectable in our study ; one of the ERBB2 mutations was in the kinase domain ( @VARIANT$ ) while 3 involved the extracellular domain ( S310F ) . Based on the current knowledge of @GENE$ biology , trastuzumab or @DRUG$ therapy may be value in the extracellular domain mutations but could be of limited clinical benefit for kinase domain mutations and no response to either agents was noted in our cases .", "label": "sensitivity"}
{"id": "24634785", "sentence": "Despite the higher rates of molecular response , @VARIANT$ mutation is emerging as a common mechanism of failure of second-line TKIs [ ] . It was reported that combined treatment with nilotinib or dasatinib with SGX393 ( inhibitor of native and T315I-mutant BCR/ABL ) might be useful for reduction of BCR/ABL mutants in Ph-chromosome positive leukemia [ ] . In addition , it was shown that combined treatment with dasatinib and @DRUG$ ( suberoylanilide hydroxamic acid ( SAHA ) @GENE$ ) led to depletion of wild-type and mutant forms of BCR/ABL expressing cells [ ] .", "label": "None"}
{"id": "23569389", "sentence": "@DRUG$ is active against at least 100 of the @GENE$ mutations known to confer resistance to imatinib that have been tested to date , ( including many in the p-loop region ) , except for the T315I mutation and a few other mutations ( @VARIANT$ , F317L/V , and T315A ) .", "label": "None"}
{"id": "23238683", "sentence": "As shown in Figure , @GENE$ cells expressing native BCR-ABL were highly sensitive to imatinib , dasatinib and ponatinib , whereas BaF3-T315I-BCR-ABL and BaF3-G250E-BCR-ABL cells were resistant to both imatinib and @DRUG$ . By contrast , ponatinib induced loss of cell viability in BaF3 cells carrying the @VARIANT$ or G250E mutation , in agreement with previous results from the literature [ , ] .", "label": "None"}
{"id": "24009732", "sentence": "Targeted therapy to inhibit the oncogene FIP1L1-PDGFRα has met with some success : the first-generation tyrosine kinase inhibitor ( TKI ) @DRUG$ has been reported to be effective to @GENE$ , but imatinib-resistant mutations emerged . Several mutations in the kinase domains such as D842V , T674I , S601P and L629P , have been demonstrated to be responsible for the drug-resistance . Of note , the “gate-keeper” mutant T674I FIP1L1-PDGFRα in HES , similar to @VARIANT$ Bcr-Abl in CML , was also refractory to some second-generation TKIs , such as nilotinib , sorafenib .", "label": "None"}
{"id": "23292247", "sentence": "To further investigate the role of @DRUG$ in the activation of the @GENE$ pathway , cell proliferation was examined in the alcohol- and/or MEK1/2 inhibitor U0126 treated @VARIANT$ cells .", "label": "None"}
{"id": "19216789", "sentence": "Based on this rationale , we investigated the effects of a new dual Src/Abl kinase inhibitor , AZD0530 with the aim of inhibiting both Src and @GENE$ kinases irrespective of their conformations to explore the possibility of overcoming resistance to @DRUG$ with the use of AZD0530 . Methods p185Bcr-Abl mutant constructs Bcr-Abl cDNAs harbouring E255K , @VARIANT$ , and Y253F mutations were obtained by site directed mutagenesis using a modification of Stratagene 's QuickChange site directed mutagenesis Kit protocol .", "label": "None"}
{"id": "23708675", "sentence": "The E7 oncoprotein binds to pRb family members and disrupts their ability to form complexes with @VARIANT$ , increased expression of @GENE$ genes , many of which are required for cell cycle progression ( , ) . However , the E5 coding sequence is frequently deleted from the episomal viral DNA during integration into the host genome ( ) . Several recent studies have demonstrated that there are two distinct HNSCC etiologic risk groups : those who develop cancer in association with tobacco and @DRUG$ and those who develop HNC as a result of HPV infection ( – , ) .", "label": "None"}
{"id": "23049365", "sentence": "Ponatinib ( @DRUG$ ) was developed to interact with the inactive @GENE$ conformation at multiple sites and with the @VARIANT$ mutation , providing high affinity and efficacy .", "label": "response"}
{"id": "23569389", "sentence": "Dasatinib is active against at least 100 of the BCR-ABL1 mutations known to confer resistance to @DRUG$ that have been tested to date , ( including many in the p-loop region ) , except for the T315I mutation and a few other mutations ( @VARIANT$ , F317L/V , and T315A ) . Dasatinib is able to block downstream intracellular signaling pathways activated by BCR-ABL1 in vitro , including signal transducer and activator of transcription 5 ( Stat5 ) , with downregulation of Stat5 target gene expression and the @GENE$ , Notably , dasatinib is not a substrate of multidrug resistance protein-1 , an efflux protein expressed on normal and leukemic hematopoietic stem cells .", "label": "None"}
{"id": "25203004", "sentence": "The two most common genetic mutations are the in-frame deletion in exon 19 ( E746-A750 ) and the substitution of leucine 858 by arginine in the exon 21 ( @VARIANT$ ) . These two mutations constitute about 90 % of all mutations and are known as the “classical” mutations . These two EGFR-specific mutations are strong predictors of the response to small-molecule @GENE$ kinase inhibitors such as @DRUG$ , and erlotinib .", "label": "sensitivity"}
{"id": "21931765", "sentence": "Although Daoy cells harbor a p53 homozygote mutation ( @VARIANT$ ) , they retain a 22,8 % p53 promoter-specific transcriptional activity , as measured in yeast functional assays on @GENE$ ( expressed as percent of wild-type activity ; see additionally the data from a p53 database available at “http : //www-p53.iarc.fr/” ) , because of these reported data we reason @DRUG$ stimulation may be due in Daoy cells to an enhancement of miR34a transcription .", "label": "None"}
{"id": "22721004", "sentence": "This is due to point mutations in the @GENE$ kinase domain , including the most frequent T315I and @VARIANT$ mutations [ , ,, ] . Second-generation tyrosine kinase inhibitors , such as nilotinib , @DRUG$ and bosutinib are capable of targeting the majority of imatinib-resistant mutations , but none of them are effective against leukemia cells harboring the T315I mutation [ - ] .", "label": "None"}
{"id": "22496672", "sentence": "Conversely , dasatinib treated mice with unmutated BCR-ABL tumors or @VARIANT$ ( imatinib-resistant ) tumors appeared to be healthy ( no weight loss , lethargy , or ruffled fur ) , and showed a &gt ; 1-log decrease in @GENE$ kinase activity ( measured by bioluminescence assay ) , normal spleen weight , and significantly longer survival compared with vehicle treated animals .", "label": "None"}
{"id": "19619277", "sentence": "In K562/R and HCT116/R cell lines , 10 μM JAI-51 restored the intracellular accumulation of @DRUG$ ( Figure ) or mitoxantrone ( Figure ) with the same rate as the P-gp and @GENE$ cyclosporine A , showing that JAI-51 is also an inhibitor of these pumps . Figure shows that 10 μM JAI-51 was able to induce a cell cycle arrest in the G2/M phase , and an increase in both the percentage of apoptotic cells and the mitotic index ( data not shown ) of K562/R and S and HCT116/R and S cells . As the same effect of JAI-51 on the cell cycle was observed on all the cell lines tested , irrespective of the presence or not of an efflux pump , this shows that JAI-51 is not extruded by ( i.e. is not a substrate of ) P-gp ( @VARIANT$ cells ) nor of BCRP ( HCT116R cells ) .", "label": "None"}
{"id": "25465236", "sentence": "Clinically observed @GENE$ kinase mutations that sensitize patients differentially to the inactive ( non phosphorylated ) EGFR kinase inhibitors @DRUG$ and Erlotinib were analyzed . The oncogenic EGFR @VARIANT$ mutation is one of the most common non small cell lung cancer ( NSCLC ) somatic mutations , observed from sequencing of both solid tumor biopsies and circulating tumor cells ( CTCs ) .", "label": "sensitivity"}
{"id": "24092989", "sentence": "The antitumoral activity is increased with the association of @DRUG$ . Another critical serine-threonine protein kinase involved in the @GENE$ pathway that has been targeted to block its constitutive kinase activation is BRAF . , BRAF mutation ( @VARIANT$ ) is reported in 24 % of papillary derived ATC .", "label": "None"}
{"id": "14520473", "sentence": "Similarly , pretreatment with z-LEHD-fmk significantly decreases the effect of @DRUG$ on wtCD26 Jurkat transfectants , as measured by cleavage of @GENE$ and procaspase-9 . Effect of the DPPIV enzyme inhibitor DFP on topoisomerase II alpha expression We previously showed that topoisomerase II alpha expression and catalytic activity are higher in wtCD26 Jurkat transfectant than @VARIANT$ or parental cells ( ) ( Effect of inhibition of DPPIV activity on topoisomerase II alpha expression .", "label": "None"}
{"id": "23994953", "sentence": "Indeed , the fact that the combination of @DRUG$ plus IGF-1R inhibitors ( I-OMe-AG538 or AG1024 ) fully prevents the acquired erlotinib-resistant phenotype is consistent with IGF-1R playing a major role in this process . While preparing this manuscript , Cortot et al. reported that PC-9 derived clones with acquired resistance to mutant-selective @GENE$ inhibitors and irreversible quinazoline EGFR inhibitors in the absence of EGFR @VARIANT$ demonstrate a significantly activated IGF-1R signaling , and pharmacological inhibition of IGF-1R restored sensitivity to EGFR inhibitors .", "label": "resistance or non-response"}
{"id": "16987420", "sentence": "Also , @GENE$ amplification induced by a transient G1/S arrest because of the presence of @DRUG$ , generated aneuploidy both in human and MEFs with pRb dysfunction [ ] . However , it is still controversial whether p53 loss/inactivation plays a direct role in centrosome amplification [ ] and chromosome instability [ ] . Indeed , recently it has been reported that p53 deficient cells need cyclin E over-expression , a target of @VARIANT$ transcription factor , to induce chromosome instability and centrosome amplification [ ] .", "label": "None"}
{"id": "24523596", "sentence": "Ponatinib @GENE$ with mutations , including T315I + + Sen et al @DRUG$ BCR-ABL mutations , except V299L and @VARIANT$ SRC family ± ± Hegedus et al", "label": "None"}
{"id": "21333004", "sentence": "The multiplying coefficient α is given by α = ( k3 ) / ( k3 in @GENE$ model or @VARIANT$ models ) . α = 1 means without @DRUG$ .", "label": "sensitivity"}
{"id": "23329883", "sentence": "TC , total cholesterol ; TG , triglyceride ; HDL-C , high-density lipoprotein cholesterol ; LDL-C , low-density lipoprotein cholesterol ; ApoA1 , apolipoprotein A1 ; ApoB , @GENE$ All data are expressed as mean ± SD [ the values of TG are presented as median ( interquartile range ) ] . The values of F1 and P1 of the drinkers are the interactions between the PCSK9 @VARIANT$ genotypes and @DRUG$ consumption on serum lipid parameters .", "label": "None"}
{"id": "24729716", "sentence": "c-MET amplification was considered to be a mechanism for acquired resistance to @GENE$ . This molecular change had been found in samples with @DRUG$ or erlotinib resistance in vivo or in vitro . c-MET amplification has also occasionally been found to coexist with EGFR @VARIANT$ mutation .", "label": "resistance or non-response"}
{"id": "25465236", "sentence": "( C ) EGFR T790M mutant does not resemble pEGFR unlike the EGFR L858R mutant shown in B. ( D–F ) increased inhibition potency for Erlotinib against EGFR L858R mutant compared to EGFR WT protein and subsequent decrease in potency for @DRUG$ against @GENE$ L858R + E884K double mutant . ( G–I ) increased inhibition potency for Gefitinib against EGFR L858R mutant compared to EGFR WT protein and subsequent further increase in potency for Gefitinib against EGFR L858R + E884K double mutant . ( J ) EGFR @VARIANT$ activated more than T790M but less than L858R .", "label": "None"}
{"id": "22970367", "sentence": "Moreover , dual inhibition of @GENE$ with an irreversible EGFR inhibitor ( afatinib ) and the EGFR neutralizing antibody @DRUG$ has recently shown promising activity in EGFR mutant lung cancers with acquired EGFR TKI resistance that harbor an EGFR @VARIANT$ mutation [ ] .", "label": "response"}
{"id": "22719810", "sentence": "After this diagnosis , the patient received the three courses of first-line chemotherapy with docetaxel plus @DRUG$ as stage IV ( T4N0M1 ) with lung-to-lung metastasis . Thus , the patient began to take gefitinib at 250 mg/day because @GENE$ gene analysis in this patient showed a deletion mutation in exon 19 and point mutation @VARIANT$ in exon 21 by direct sequence method ( ) .", "label": "None"}
{"id": "16187797", "sentence": "Sensitivity of Cell Transformation Induced by Expression of Mutant EGFR Characterized by Missense Mutation or Exon 19 Deletion , but not Exon 20 Insertion , to @DRUG$ and Erlotinib ( A ) Anchorage independent growth of clonal NIH-3T3 cells transformed with mutant EGFR or EGF stimulated wild-type @GENE$ treated with the indicated concentrations of erlotinib immediately prior to suspension in soft agar . Transformation induced by expression of L858R , @VARIANT$ , and L747_E749del A750P EGFR , but not EGF stimulated wild-type EGFR or D770_N771insNPG EGFR , was inhibited by 0.1 μM erlotinib .", "label": "sensitivity"}
{"id": "24212826", "sentence": "Furthermore , three of the four responders with exon 20 mutations also had concurrent sensitizing @GENE$ mutations ( @VARIANT$ ) [ ] . According to previous studies , the average response rate for @DRUG$ treatment in patients with exon 20 mutations was only 34 % .", "label": "sensitivity"}
{"id": "23208557", "sentence": "Cancer @GENE$ exon18 G719X Drug efficacy prediction of gefitinib and erlotinib exon19 deletion exon20 T790M exon21 @VARIANT$ KRAS codon12 , 13 Drug efficacy prediction of @DRUG$", "label": "None"}
{"id": "15737014", "sentence": "These results suggest that the T790M mutation may impair the ability of @DRUG$ or erlotinib to inhibit EGFR tyrosine kinase activity , even in @GENE$ mutants ( i.e. , @VARIANT$ or an exon 19 deletion ) that are clinically associated with drug sensitivity .", "label": "sensitivity"}
{"id": "25465236", "sentence": "Patients harboring the oncogenic EGFR kinase double mutation L858R + @VARIANT$ have a clearly defined differential clinical response to these drugs . The increased inhibition potency for @DRUG$ against the oncogenic @GENE$ L858R mutant ( over the EGFR WT protein ) correlates with decreased global connectivity of the hub residues ( Arg-958 , Glu-884 , Gln-894 and Asp-896 ) in the mutant ( – wild type , – L858R mutant ) .", "label": "None"}
{"id": "24676216", "sentence": "In addition , the @GENE$ ectodomain mutation @VARIANT$ has recently been found to confer resistance to @DRUG$ .", "label": "resistance"}
{"id": "24052078", "sentence": "The tyrosine kinase inhibitor ( TKI ) , erlotinib ( OSI-774 , @DRUG$ ; OSI Pharmaceuticals/Genentech , New York , NY , USA ) , is an oral small-molecule inhibitor that binds to the kinase domain of @GENE$ and was approved for the treatment of NSCLC in 2004 . Several clinical studies have shown that a secondary point mutation at amino-acid position 790 ( @VARIANT$ ) of EGFR is responsible for approximately half of the cases in which patients with lung adenocarcinoma develop resistance to EGFR targeting TKIs. , In addition , the presence of an intrinsic ( primary ) resistance mechanism ( such as K-Ras mutation ) can also confer resistance to TKIs , although the underlying mechanisms are not yet completely understood .", "label": "resistance or non-response"}
{"id": "25077070", "sentence": "@GENE$ Not distinctive 2-4 % Mixed reports Not distinctive ADC and SqCC Mutations in E545K AND @VARIANT$ ( most common ) , also E542K and H1047L @DRUG$ , Tensirolimus , GDC-0941 , XL-147 , Others", "label": "None"}
{"id": "24495353", "sentence": "Rank Entrez ID Gene symbol Entrez ID Gene symbol Entrez ID Gene symbol 1 28978 TMEM14A 79776 ZFHX4 1727 CYB5R3 2 1843 DUSP1 4701 NDUFA7 7083 TK1 3 51022 GLRX2 715 C1R 1292 COL6A2 4 1434 CSE1L 79818 ZNF552 857 CAV1 5 8522 @GENE$ 4046 LSP1 5437 POLR2H 6 51668 HSPB11 1727 CYB5R3 9833 MELK 7 10456 HAX1 357 SHROOM2 54861 SNRK 8 9902 MRC2 283298 OLFML1 4830 NME1 9 4706 NDUFAB1 23179 RGL1 231 AKR1B1 10 23560 GTPBP4 1809 DPYSL3 10418 SPON1 11 79633 FAT4 857 CAV1 2350 FOLR2 12 10418 SPON1 274 BIN1 10979 FERMT2 13 471 ATIC 79833 GEMIN6 11096 ADAMTS5 14 6403 SELP 11222 MRPL3 4638 MYLK 15 23421 ITGB3BP 23244 PDS5A 9448 MAP4K4 16 23452 ANGPTL2 6241 RRM2 54922 RASIP1 17 54861 SNRK 1289 COL5A1 6934 TCF7L2 18 2034 EPAS1 8434 RECK 4072 EPCAM 19 30008 EFEMP2 429 ASCL1 4701 NDUFA7 20 25999 CLIP3 3426 CFI 404672 GTF2H5 21 4311 MME 332 BIRC5 6241 RRM2 22 4747 NEFL 2 @VARIANT$ 2192 FBLN1 23 1809 DPYSL3 10730 YME1L1 25959 KANK2 24 28998 MRPL13 11130 ZWINT 55651 NHP2 25 25959 KANK2 1292 COL6A2 5050 PAFAH1B3 Lists of the top 25 of most influential genes in influence networks based on coexpression among genes in ER + breast tumors before , during , and after a course of neoadjuvant treatment with the drug @DRUG$ .", "label": "None"}
{"id": "22034911", "sentence": "Impact of @VARIANT$ on @GENE$ activity of @DRUG$ and TAE684 .", "label": "resistance"}
{"id": "17666112", "sentence": "@GENE$ is mutated in 70 % of human melanomas , with a valine to glutamic acid substitution at position 600 ( @VARIANT$ ) being the most common mutation ; this elevates the kinase activity of BRAF 500-fold . He described the generation of tamoxifen-inducible V600EBRAF mice and reported that six months after the application of @DRUG$ to the skin , these animals develop melanomas , indicating that V600EBRAF is an initiating oncogene .", "label": "None"}
{"id": "19547661", "sentence": "BRAF ( v-raf murine sarcoma viral oncogene homolog B1 ) , a serine/threonine kinase , is the downstream effector of KRAS in the @GENE$ signaling pathway . A somatic mutation ( @VARIANT$ ) in exon 15 of BRAF has been identified in multiple human cancers with a mutation rate of 66 % in malignant melanomas [ ] and at lower frequency in other human carcinomas . Recently , it was demonstrated that wildtype BRAF is required for the response of patients with metastatic colorectal cancer to @DRUG$ and panitumumab [ ] .", "label": "None"}
{"id": "22655263", "sentence": "For the L1196M , C1156Y , and @VARIANT$ mutants , it appears that binding of the inhibitor to @GENE$ may be negatively affected by steric hindrance or conformational changes in the enzyme . F1174L , which recapitulates the primary mutation found in neuroblastoma previously shown to render the enzyme insensitive to @DRUG$ , appears instead to induce a conformational change in the protein which results in increased affinity for ATP itself .", "label": "resistance"}
{"id": "21605429", "sentence": "Lastly , knowledge of the predictive and prognostic value of mutational status could lead physicians to establish the dose of @DRUG$ , identify those patients who would not benefit from imatinib treatment ( @GENE$ exon 18 @VARIANT$ mutant tumors are imatinib resistant ) , chose a second line therapy , and evaluate the different risk of relapse during follow-up .", "label": "resistance or non-response"}
{"id": "25465236", "sentence": "The increased inhibition potency for @DRUG$ against the oncogenic EGFR @VARIANT$ mutant ( over the @GENE$ WT protein ) correlates with decreased global connectivity of the hub residues ( Arg-958 , Glu-884 , Gln-894 and Asp-896 ) in the mutant ( – wild type , – L858R mutant ) .", "label": "sensitivity"}
{"id": "PMC3760629", "sentence": "The @GENE$ mutant PC9 cell line harbouring EGFR @VARIANT$ , PC9R , has been used as in vitro model of drug resistance . Tumour microvesicles ( TMVs ) shed from cancer cells contain genetic and other molecular information that might be useful for diagnostic purposes to differentiate gefitinib-resistant NSCLC ( non-responders ) from sensitive patients ( drug responders ) .", "label": "resistance or non-response"}
{"id": "22714415", "sentence": "Patients with @VARIANT$ KRAS mutant tumors and treated with cetuximab/chemotherapy regimes had overall survival and progression free survival of average 7.6 and 4.0 mo vs. 5.7 and 1.9 mo in other KRAS mutant tumor subtypes .", "label": "None"}
{"id": "22933967", "sentence": "In another phase II POCHER trial , the proportion of R0 resection was even higher ; it was achieved in 60 % of patients who were treated with chronomodulated chemotherapy with @DRUG$ , oxaliplatin , 5- fluorouracil and leucovorin . In conclusion , the results of our retrospective study showed that the patients with @GENE$ @VARIANT$ mutation had worse prognosis than those with wt-BRAF , with lower response rates and progressed early during systemic treatment , consequently , with less possibilities to achieve resectability of metastatic disease .", "label": "None"}
{"id": "24353011", "sentence": "Erlotinib is an orally bioavailable EGFR inhibitor , which is indicated for first-line treatment of patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 ( @VARIANT$ ) substitution mutations [ • ] . The drug is also approved as maintenance therapy in patients whose disease has not progressed after four cycles of platinum containing first-line therapy . Evaluation of the efficacy of @GENE$ inhibitors , including erlotinib and @DRUG$ , in patients with brain metastases from NSCLC comes from case reports , case series , and small prospective clinical trials [ ] .", "label": "sensitivity"}
{"id": "24189400", "sentence": "This included PC9GR cells as well as two cell lines ( HCC827 and HCC4006 ) that were engineered to have exon 19 deletion E746-A750 plus @VARIANT$ EGFR through retroviral mediated transduction . These results are shown in . @DRUG$ or midostaurin alone had modest effects on total EGFR phosphorylation across the three cell lines ; however , when combined , the two inhibitors had more pronounced effects on @GENE$ and downstream ERK phosphorylation .", "label": "resistance or non-response"}
{"id": "21182469", "sentence": "cAMP ( cyclic adenosine monophosphate ) , cGMP ( cyclic guanosine monophosphate ) , LTC4 ( leukotriene C4 ) , DNP-SG ( S- ( 2,4-dinitrophenyl ) -glutathione ) , @VARIANT$ ( estrone 3-sulfate ) , DHEAS ( dehydroepiandrosterone 3-sulfate ) , and E217βG ( estradiol 17-β-D-glucuronide ) . ( B ) Anticancer drugs that are transported by ABCC11 . @GENE$ ( pemetrexed ) , MTX , ( @DRUG$ ) , Ara-C ( Cytosine arabinoside ) , PMEA ( 9’- ( 2’-phosphonyl-methoxyethyl ) adenine ) are substrate for ABCC11 .", "label": "None"}
{"id": "25360523", "sentence": "@GENE$ binding specificity of LRRK2-N . bait plasmid prey plasmid QDO+X-α-gal+aureobasidin A pAS2-1-Rab32 wt pACT2-LRRK2-N_+ pAS2-1-Rab38 wt + pAS2-1-Rab1B Q67L − pAS2-1-Rab1B Q67R − pAS2-1-Rab11A wt − pAS2-1-Rab5A wt − pAS2-1-Rab6A Q72L − pAS2-1-Rab6A Q72R − pAS2-1-Rab7ΔC − pAS2-1-tau − After co-transformation of the yeast strain Gold with the indicated plasmids , cells were grown on synthetic media lacking adenine and @DRUG$ supplemented with 125 ng/ml aureobasidin and 40 µg/ml X-α-gal .", "label": "None"}
{"id": "24790411", "sentence": "Compared to erlotinib and gefitinib , afatinib shows lower EC50 values and greater potency against wild type ( afatinib vs erlotinib vs gefitinib : 60 nM vs 110 nM vs 157 nM ) and L858R mutated @GENE$ ( afatinib vs @DRUG$ vs gefitinib : 0.7 nM vs 40 nM vs 5 nM ) . Moreover , afatinib is able to inhibit the kinase activity in vitro and in animal models when a resistant @VARIANT$ mutation is concomitant to a sensitivity mutation .", "label": "resistance or non-response"}
{"id": "25054154", "sentence": "We utilised three complexes , namely , native ( ALK-crizotinib ) , @VARIANT$ ( ALK F1174L-crizotinib ) , and R1275Q ( @GENE$ R1275Q-crizotinib ) for our analysis .", "label": "resistance"}
{"id": "23817662", "sentence": "In fact , the patient with @GENE$ c.2573T & gt ; G ( L858R ) and EGFR c.2369C&gt ; T ( @VARIANT$ ) was treated with @DRUG$ and a short-term improvement was observed .", "label": "resistance or non-response"}
{"id": "17877814", "sentence": "Surprisingly , Y1092 phosphorylation of @GENE$ Del746 was still detected in these fibrils ( Figure ) . In line with previous observations [ ] the @VARIANT$ mutation abrogated @DRUG$ sensitivity .", "label": "resistance or non-response"}
{"id": "24348666", "sentence": "The two mutations were shown to independently induce @DRUG$ resistance in @GENE$ cells engineered to express the L1196M and C1156Y mutations . By mid-2012 , additional patient studies led to the discovery of several other secondary mutations , . That is , three other mutations in the a-Chelix were discovered : a threonine insertion at amino acid 1151 ( 1151Tins ) , a leucine to arginine ( @VARIANT$ ) and phenylalanine to leucine ( F1174L ) .", "label": "None"}
{"id": "23527257", "sentence": "Afatinib ( @DRUG$ Boehringer Ingelheim GmbH ) , is an irreversible inhibitor of both @GENE$ , HER2 and HER4 kinases and retains some activity in tumors with @VARIANT$ mutations , but at doses that are a log higher than what is needed for cancers harboring sensitizing mutations , , , , , .", "label": "response"}
{"id": "15737014", "sentence": "Using this insight , new small-molecule inhibitors have been identified that retain activity against the majority of imatinib-resistant BCR-ABL mutants [ , ] . For example , in CML , a commonly found mutation is a C→T single nucleotide change that replaces threonine with isoleucine at position 315 ( T315I ) in the ABL kinase domain [ , , ] . In GIST and @GENE$ , respectively , the analogous T670I mutation in KIT and @VARIANT$ mutation in PDGFR-alpha have been associated with acquired resistance to this drug [ , ] .", "label": "None"}
{"id": "24348666", "sentence": "The two mutations were shown to independently induce @DRUG$ resistance in @GENE$ cells engineered to express the L1196M and C1156Y mutations . By mid-2012 , additional patient studies led to the discovery of several other secondary mutations , . That is , three other mutations in the a-Chelix were discovered : a threonine insertion at amino acid 1151 ( 1151Tins ) , a leucine to arginine ( L1152R ) and phenylalanine to leucine ( @VARIANT$ ) .", "label": "None"}
{"id": "22235232", "sentence": "Some rely on genetic defects that predispose animals to obesity ( e.g. , Ob/Ob mice ) or diabetes ( e.g. , Zucker diabetic fatty ( ZDF ) rats ) or chemicals that induce such disorders ( e.g. , @DRUG$ or alloxan ) . Others use dietary interventions that cause metabolic disturbances in animals that resemble the spectrum spanning from insulin resistance to @VARIANT$ . The CIHR-TAAM has experimented with many of these models [ , ] , and the @GENE$ in mice has been found to provide stable and reliable results .", "label": "None"}
{"id": "24071646", "sentence": "Atorvastatin could still enhance @DRUG$ efficacy in H460 cells ( gefitinib treatment versus 1 or 5 μM atorvastatin+gefitinib treatment , IC50=16.4 versus 4.06 or 1 μM ) . Besides , we transfected @GENE$ mutation plasmid-PIK3CA ( @VARIANT$ ) into A549 and Calu1 cells .", "label": "resistance or non-response"}
{"id": "25382104", "sentence": "Results showed that ponatinib has the highest binding affinity towards the @VARIANT$ mutant @GENE$ with a docking score of −11.050 kcal/mol while bosutinib , bafetinib , @DRUG$ , nilotinib and imatinib showed −5.513 kcal/mol , −4.689 kcal/mol , −4.702 kcal/mol , −3.772 kcal/mol , −3.593 kcal/mol and −3.78 kcal/mol , respectively ( ) .", "label": "None"}
{"id": "19758442", "sentence": "The regions responsible for interaction with @VARIANT$ ( red ) and A3F ( blue ) are discontinuous . They overlap but are not identical . The region important for interaction with the Cul5 ubiquitin ligase complex is marked in green and includes a conserved histidine-cysteine-cysteine-histidine motif and a @GENE$ domain .", "label": "None"}
{"id": "25054154", "sentence": "We utilised three complexes , namely , native ( ALK-crizotinib ) , F1174L ( @GENE$ F1174L-crizotinib ) , and @VARIANT$ ( ALK R1275Q-crizotinib ) for our analysis .", "label": "sensitivity"}
{"id": "22558339", "sentence": "Wild type KRAS is now considered a pre-condition to treat CRC patients with EGFR inhibitors like Cetuximab or @DRUG$ , . Oncogenic @GENE$ mutations occur in up to 15 % of all human tumors , the vast majority ( & gt ; 90 % ) being c.1799 : T & gt ; A substitutions that lead to the replacement of valine with aspartic acid ( @VARIANT$ ) causing constitutive BRAF activation .", "label": "resistance or non-response"}
{"id": "19893626", "sentence": "Similarly , the @VARIANT$ point mutation in the epidermal growth factor receptor (EGFR) confers resistance to the @GENE$ tyrosine kinase inhibitors gefitinib and @DRUG$ , which are used to treat non-small cell lung cancer .", "label": "resistance or non-response"}
{"id": "20842231", "sentence": "Molecular mimicry of naturally phosphorylated human PRL at the major phosphorylation site S179 , S179D ( PRL ) , sensitizes relatively vitamin D-insensitive prostate cancer cells DU-145 and PC3 to calcitriol mediated anti-proliferative effect and apoptosis , which is associated with increased VDR and p21 expression . Secreted protein acidic and rich in cysteine ( SPARC ; @GENE$ , BM-40 ) , a family member of matricellular proteins including thrombospondins , tenascin , and osteopontin , may serve as a tumor suppressor .", "label": "None"}
{"id": "19920910", "sentence": "The pattern of resistance to nilotinib and @DRUG$ differed ; those with greatest resistance to nilotinib ( Y253H and @VARIANT$ ) were susceptible to dasatinib . T315I remained resistant to all the three drugs . In vivo experiments with CML xenografts in mice demonstrated that nilotinib treatment , compared with treatment with vehicle , improved survival of mice infused with either wild type Bcr-Abl or the imatinib-resistant @GENE$ mutant ( E255V ) ( ; ) .", "label": "None"}
{"id": "25110867", "sentence": "Dacomitinib inhibited @GENE$ phosphorylation and downstream signaling molecules , including AKT and ERK1/2 , and induced apoptosis in the EGFR @VARIANT$ containing H3255 GR cell line at 10 nmol/L concentration . In xenografted nude mice using HCC827 GFP and HCC827 Del/T790M cells , either @DRUG$ or dacomitinib effectively inhibited the growth of HCC827 GFP xenografts .", "label": "resistance or non-response"}
{"id": "22038681", "sentence": "Preliminary results from an ongoing phase 1 dose-escalation study of the multikinase , pan–BCR-ABL inhibitor ponatinib ( AP24534 ) showed antileukemic activity in patients with refractory CML , including patients with the @VARIANT$ mutation . Phase 1 and 2 trials of ponatinib are ongoing in patients with refractory CML and acute lymphoblastic leukemia . Danusertib ( PHA-739358 ) is a multikinase aurora inhibitor with in vitro activity against wild-type @GENE$ and ABL/T315I ; preliminary results from an ongoing phase 1 dose-escalation study indicate antileukemic activity in patients with AP or BC who failed imatinib and/or @DRUG$ or dasatinib .", "label": "None"}
{"id": "24959087", "sentence": "Further evidence of the efficacy of combination therapy in overcoming resistance is demonstrated by NSCLC cell lines resistant to erlotinib and the MET inhibitor SU11274 , which display upregulation of both mTOR ( mammalian target of rapamycin ) and @GENE$ pathway components and restoration of sensitivity to EGFR/MET inhibition by the addition of everolimus . A final mechanism of resistance in gastric cancer cell lines has been demonstrated when MET amplified SNU6838 gastric cancer cell lines were treated with the MET inhibitors PHA-665752 and PF2341066 ; a novel mutation occurred in the activation loop of MET , causing a conformal change that blocked inhibitor binding analogous to the gatekeeper mutations seen in EGFR ( T790M ) following erlotinib treatment and in ABL ( T315I ) following @DRUG$ . Although the MET @VARIANT$ mutation renders cancers insensitive to type I MET inhibitors , conformal differences between these and type II compounds may allow treatment of MET Y1230H mutant cancers or prevent the emergence of resistance due to the mutation. ,", "label": "None"}
{"id": "23986642", "sentence": "This trial provided valuable evidence of ponatinib’s direct kinase inhibiting activity in patients with a variety of BCR-ABL mutations , including the @VARIANT$ mutant , leading to further evaluation of its effects . Preclinical @DRUG$ has been observed to achieve marked reductions in levels of phosphorylated BCR-ABL and CrkL within 6 hours of administration in a mouse model injected with T315I-variant @GENE$ expressing Ba/F3 cells .", "label": "response"}
{"id": "24884501", "sentence": "The mutational frequencies of the 195 KRAS mutations in the NORDIC VII cohort were ; G12A ( 9.7 % ) , G12R ( 1.5 % ) , G12D ( 35.4 % ) , G12C ( 9.7 % ) , @VARIANT$ ( 6.2 % ) , G12V ( 15.4 % ) , and @GENE$ ( 22.1 % ) . @DRUG$ did not add significant benefit to Nordic FLOX and KRAS mutation was not predictive for cetuximab effect .", "label": "None"}
{"id": "23976869", "sentence": "However , the clinical response was short because of the emergence of another @VARIANT$ mutation . This mutation is highly resistant to sorafenib , imatinib , and @DRUG$ . Sorafenib also failed to block S601P mutated @GENE$ .", "label": "sensitivity"}
{"id": "25580271", "sentence": "When cross-over to EGFR tyrosine kinase inhibitor therapy was examined , 75 % of patients who received cisplatin and pemetrexed received an EGFR tyrosine kinase inhibitor and 56 % of patients who received @DRUG$ and gemcitabine received an @GENE$ tyrosine kinase inhibitor . The rate of second-line EGFR tyrosine kinase inhibitors in countries with insurance coverage was 91 % and without insurance coverage was 52 % . Overall survival of patients with common EGFR mutations ( defined as exon 19 deletion and exon 21 @VARIANT$ point mutation ) in LUX-3 , LUX-6 , and combined cohorts [ ]", "label": "None"}
{"id": "21264348", "sentence": "A. Dasatinib antiproliferative EC50 in the presence of 0.4 to 10 μM GNF‐5 on Ba/F3 cells expressing T315I and @VARIANT$ @GENE$ B. Inhibition of Bcr‐Abl autophosphoryl‐ation was determined by Bcr‐Abl immunoprecipitation , followed by a immunoblot for phospho‐Tyr ( Tyr412 ) , phospho‐STAT 5 ( Tyr694 ) and total Bcr‐Abl ( antibody K‐12 ) from cell lystates obtained after treatment of T315I Bcr‐Abl expressing Ba/F3 with 10 μM of dasatinib and increasing concentrations of GNF‐5 ( 0 , 0.5 , 5 and 10 μM ) for 90 min. ( TIF )", "label": "None"}
{"id": "23099808", "sentence": "Acquired clinical resistance to EGFR-TKI was also documented in lung cancer patients , who had an EGFR mutation in exon 20 ( @VARIANT$ ) ( ) . Therefore , in this study , we first examined the effects of @DRUG$ or erlotinib on cell proliferation of the cell lines including those originated from lung adenocarcinoma ( LADCA ) . We then evaluated gene profiles of EGFR-TKI-sensitive cells using a microarray analysis in order to further characterise the possible differential mRNA expression patterns among @GENE$ cells .", "label": "resistance or non-response"}
{"id": "23189150", "sentence": "Exposure of HCT116bax−/−bak−/− cells , or cells expressing a BAK mutant that had a negatively charged residue replacing @VARIANT$ ( @VARIANT$ ) , failed to release cytochrome c after @DRUG$ treatment ( ) . Taken together , our results now provide evidence that the PP2A B56α subunit is involved in and is required for BAK activation to proceed to completion , indicating that PP2A acts not only on anti-apoptotic @GENE$ proteins but also directly impinges upon pro-apoptotic cell death effectors .", "label": "None"}
{"id": "23976869", "sentence": "Treatment of two patients resistant to imatinib with nilotinib was successful. , Another patient intolerant to @DRUG$ responded to nilotinib and dasatinib. , The sensitivity of the @VARIANT$ mutation to second generation TKIs has been a matter of debate . Vo n Bubnoff et al reported that nilotinib suppresses the growth of Ba/F3 cells transfected with the T674I @GENE$ mutant .", "label": "resistance"}
{"id": "16933962", "sentence": "The DNA in the water phase was subsequently @DRUG$ precipitated . After centrifugation , the pellet was resuspended in 200 μl of 10 mM @GENE$ and 10 mM EDTA ( pH 8.0 ) , and frozen at −20 °C until further analysis . The factor V Leiden mutation ( G1691A ) and the prothrombin mutation ( @VARIANT$ ) were simultaneously detected by duplex polymerase chain reaction [ , ] .", "label": "None"}
{"id": "16721371", "sentence": "However , since the @VARIANT$ mutation of BCR-ABL is highly resistant to imatinib , AMN107 and @DRUG$ , this approach needs to be extended to include inhibitors of T315I @GENE$ to prevent this mutation from becoming more prevalent .", "label": "None"}
{"id": "22034911", "sentence": "The three most resistant mutants , L1196M , S1206R , and G1269S , all had IC50s within twofold of parental , ALK negative , @GENE$ cells ( IC50 1176 nm ) . However , the ability of @DRUG$ to inhibit ALK phosphorylation was substantially reduced in all mutants tested , with IC50s & gt ; 1000 nm for @VARIANT$ and G1269S ( ) .", "label": "None"}
{"id": "24982846", "sentence": "@DRUG$ @GENE$ EGFR exon 19 deletion or exon 21 substitution ( @VARIANT$ ) mutation positive Indications and usage , dosage and administration , adverse reactions , clinical pharmacology , clinical studies , patient counseling information", "label": "sensitivity"}
{"id": "23606169", "sentence": "Moreover , the presence of the @VARIANT$ mutation in the BRAF gene is more and more frequently taken into consideration before patient targeted therapy qualification , because wild-type @GENE$ is required for a response to @DRUG$ or cetuximab [ , ] .", "label": "resistance or non-response"}
{"id": "22997553", "sentence": "@GENE$ = Non transfected fish ; TF = Transfected fish ; Thal = Thalidomide treated fish ; Thal+Tf = @DRUG$ treated transfected fish . *p & lt ; 0.01 vs eNOS GFP ; # p = 0.01 vs S1179D . Inset shows eNOS @VARIANT$ expression in transfected zebrafish embryos confirmed using reverse transcriptase PCR .", "label": "None"}
{"id": "23937717", "sentence": "Collectively , these results suggested that @DRUG$ and NK cells could up-regulate the MHC-I in human lung cells with wild type @GENE$ , while not significantly influence the MHC-I expression on human lung cells with wild type EGFR L858R + @VARIANT$ .", "label": "resistance or non-response"}
{"id": "24982846", "sentence": "@DRUG$ BCR/ABL1 Philadelphia chromosome [ t ( 9 ; 22 ) ] positive , BCR–ABL @VARIANT$ mutation Indications and usage , warnings and precautions , adverse reactions , use in specific populations , clinical pharmacology , clinical studies Rasburicase G6PD G6PD deficient Boxed warning , contraindications Rituximab MS4A1 @GENE$ positive Indication and usage , clinical pharmacology , description , precautions", "label": "None"}
{"id": "23994953", "sentence": "Indeed , the fact that the combination of @DRUG$ plus IGF-1R inhibitors ( I-OMe-AG538 or AG1024 ) fully prevents the acquired erlotinib-resistant phenotype is consistent with IGF-1R playing a major role in this process . While preparing this manuscript , Cortot et al. reported that PC-9 derived clones with acquired resistance to mutant-selective EGFR inhibitors and irreversible quinazoline EGFR inhibitors in the absence of EGFR @VARIANT$ demonstrate a significantly activated IGF-1R signaling , and pharmacological inhibition of IGF-1R restored sensitivity to @GENE$ inhibitors .", "label": "resistance or non-response"}
{"id": "23569389", "sentence": "Dasatinib is active against at least 100 of the BCR-ABL1 mutations known to confer resistance to @DRUG$ that have been tested to date , ( including many in the p-loop region ) , except for the @VARIANT$ mutation and a few other mutations ( V299L , F317L/V , and T315A ) . Dasatinib is able to block downstream intracellular signaling pathways activated by BCR-ABL1 in vitro , including signal transducer and activator of transcription 5 ( Stat5 ) , with downregulation of Stat5 target gene expression and the @GENE$ , Notably , dasatinib is not a substrate of multidrug resistance protein-1 , an efflux protein expressed on normal and leukemic hematopoietic stem cells .", "label": "None"}
{"id": "24348666", "sentence": "However , almost every patient who responds well to @DRUG$ will , without exception , experience recurrence due to acquired resistance . The mechanisms for acquired resistance include gatekeeper L1196M mutations , @GENE$ gene amplification , and other ALK gene mutations ( L1152R , @VARIANT$ , F1174L ) - .", "label": "resistance"}
{"id": "21722394", "sentence": "Furthermore , BV8S1 and BV8S2 are absent in the @DRUG$ treated group ( a treatment known to destroy regulatory T cells ) , but present in 50 % of the B cell reconstituted animals . BV8S1 has been previously described as a predominant clonotype infiltrating the islets of partially diabetes-resistant male @GENE$ mice [ ] and , interestingly , is also present in the blood of @VARIANT$ patients [ ] .", "label": "None"}
{"id": "25486409", "sentence": "Even knock-down of the @VARIANT$ transcript by siRNAs , when combined with @DRUG$ , was efficacious in controlling T790M-mutant , lung cancer cells . In line with this , we also confirmed the persistence of @GENE$ dependency in T790M-mutant , lung cancer cells .", "label": "response"}
{"id": "PMC4036652", "sentence": "It has been shown that urothelial cells express various receptors and channels including receptors for bradykinin ( B1 and B2 ) , prostaglandin ( EP1 and EP3 ) , neurotrophins ( TrkA ) , purines ( P2X and @VARIANT$ ) , noradrenalin ( α1 and β3 ) , acetylcholine ( muscarinic and nicotinic ) , pituitary @GENE$ peptide , protease activated receptors and several members of Deg/ENaC and TRP channel families ( see below ; ) [ , ] . Activation of these receptors and channels can leads to ATP release from the urothelial cells . These agonist induced ATP release may increase in @DRUG$ induced cystitis [ ] .", "label": "None"}
{"id": "23251089", "sentence": "The first selective @GENE$ inhibitor to enter clinical trials was vemurafenib ( also designated @DRUG$ , PLX4720 , and RG7204 ) . Vemurafenib was developed alongside a companion real-time polymerase chain reaction based assay ( cobas® 4800 BRAF V600 Mutation Test ; Roche Molecular Diagnostics , Inc , Pleasanton , CA ) designed to detect the BRAFV600E mutation . This test is highly sensitive and specific for the V600E BRAF mutation but is less so for other V600 BRAF mutations ( eg , V600K , @VARIANT$ , V600D , or the 1799_1800TG & gt ; AA V600E mutation ) .–", "label": "None"}
{"id": "23079208", "sentence": "A ) . Adenocarcinoma with an @GENE$ gene mutation ( exon 19 deletion L747-E749 ; @VARIANT$ ) was detected in a transbronchial biopsy specimen ; the patient was diagnosed with stage IV ( cT2N2M1b ) non-small cell lung cancer ( NSCLC ) . The tumor marker carcinoembryonic antigen (CEA) was elevated to 71.2ng/mL ( normal range & lt ; 5ng/mL ) . Brain magnetic resonance image.A : Showing an intra-orbital mass on the right side before @DRUG$ therapy .", "label": "None"}
{"id": "25505694", "sentence": "The lack of efficacy could probably be related to the high concentrations of neratinib required in preclinical studies to inhibit EGFR @VARIANT$ and the limitations of clinical dosing . Dacomitinib Dacomitinib is an irreversible EGFR , HER2 and HER4 inhibitor with a higher kinase inhibition than gefitinib/erlotinib in both gefitinib/erlotinib-sensitive and in EGFR-T790M and @GENE$ mutated cell lines [ ] .", "label": "None"}
{"id": "23320171", "sentence": "Primary results from the EMILIA study , a randomized trial comparing Trastuzumab @GENE$ to @DRUG$ and capecitabine , have shown that Trastuzumab DM-1 significantly improved progression-free survival in patients with metastatic HER2 positive breast cancer . Further research is looking into inhibiting other targets such as mTOR , @VARIANT$ , or AKT pathways .", "label": "None"}
{"id": "16173832", "sentence": "Gefitinib responsiveness results in large part from the drug 's effective inhibition of essential antiapoptotic signals transduced by the mutant receptor , and @VARIANT$ is the most commonly detected mutation [ ] . The T790M mutation is rarely found in tumors from patients not treated with either gefitinib or @DRUG$ , and could be discovered only in progressing tumors , in addition to a primary drug-sensitive mutation in @GENE$ .", "label": "sensitivity"}
{"id": "24533047", "sentence": "Meanwhile , pre planned or post-study biomarker analyses indicated that the presence of EGFR mutation , which mainly refers to deletions in exon 19 or the @VARIANT$ substitution in exon 21 , was the strongest predictor of efficacy for EGFR-TKIs . Thus , @DRUG$ and gefitinib have been included in NCCN guideline since 2010 as first-line treatment option for advanced NSCLC patients who harbor @GENE$ mutation .", "label": "sensitivity"}
{"id": "23994953", "sentence": "More recently , in addition to other second-site mutations associated with acquired resistance to EGFR TKIs ( e.g. , @VARIANT$ and D761Y in exon 19 or T854A in exon 21 ) , novel EGFR independent mechanisms have been discovered that contribute to EGFR TKI resistance either in the absence or presence of the EGFR T790M mutation reviewed in . The second well-known mechanism of gefitinib/erlotinib resistance is the @GENE$ receptor tyrosine kinase ( RTK ) gene amplification .", "label": "None"}
{"id": "21264348", "sentence": "In addition , other new ATP-competitive inhibitors capable of inhibiting @VARIANT$ @GENE$ have been reported in conjunction with co-crystal structures : PPY-A , SGX393 , and PHA-739358 , AP24163 , DSA series compounds , HG-7-85-01 and @DRUG$ ; see also .", "label": "response"}
{"id": "23186157", "sentence": "In ( C ) and ( D ) percentage of viable Ba/F3 p185 @GENE$ ( C ) and Ba/F3 p185 Bcr-Abl @VARIANT$ ( D ) cells treated with suboptimal concentration of Imatinib and @DRUG$ for 72 h as described in Materials and Methods .", "label": "None"}
{"id": "23329883", "sentence": "TC , total cholesterol ; TG , triglyceride ; HDL-C , high-density lipoprotein cholesterol ; LDL-C , low-density @GENE$ cholesterol ; ApoA1 , apolipoprotein A1 ; ApoB , apolipoprotein B . All data are expressed as mean ± SD [ the values of TG are presented as median ( interquartile range ) ] . The values of F1 and P1 of the drinkers are the interactions between the PCSK9 @VARIANT$ genotypes and @DRUG$ consumption on serum lipid parameters .", "label": "None"}
{"id": "25222836", "sentence": "@GENE$ TKi EGFR TK domain Resistance mutation , e.g. @VARIANT$ ● erlotinib MET amplification ● @DRUG$", "label": "resistance or non-response"}
{"id": "24523596", "sentence": "@DRUG$ @GENE$ with mutations , including @VARIANT$ + + Sen et al", "label": "response"}
{"id": "24789720", "sentence": "@VARIANT$ mutation in EGFR gene seems to be one of the most important genetic abnormalities involving the resistance for reversible epidermal growth factor receptor tyrosine kinases inhibitors ( @GENE$ ) —erlotinib and @DRUG$ in NSCLC patients [ – ] .", "label": "resistance or non-response"}
{"id": "25580271", "sentence": "When cross-over to EGFR tyrosine kinase inhibitor therapy was examined , 75 % of patients who received cisplatin and @DRUG$ received an EGFR tyrosine kinase inhibitor and 56 % of patients who received cisplatin and gemcitabine received an @GENE$ tyrosine kinase inhibitor . The rate of second-line EGFR tyrosine kinase inhibitors in countries with insurance coverage was 91 % and without insurance coverage was 52 % . Overall survival of patients with common EGFR mutations ( defined as exon 19 deletion and exon 21 @VARIANT$ point mutation ) in LUX-3 , LUX-6 , and combined cohorts [ ]", "label": "None"}
{"id": "23994953", "sentence": "Somatic mutations in exons encoding the tyrosine kinase ( TK ) domain of the @GENE$ positively associated with increased sensitivity of non-small cell lung cancer ( NSCLC ) patients to the selective EGFR TK inhibitors ( TKIs ) gefitinib ( Iressa™ ) and erlotinib ( Tarceva™ ) . Prospective trials have demonstrated an impressive ~75 % response rate for patients whose tumors harbor these mutations , which occur as either multinucleotide in-frame deletions in exon 19 ( e.g. , delE746-A750 ) or as single missense mutations ( e.g. , @VARIANT$ ) .", "label": "sensitivity"}
{"id": "24759962", "sentence": "Samowitz et al. reported that the BRAF @VARIANT$ mutation in MSS colon cancer was associated with a significantly poorer survival in stage II to IV colon cancer , but did not have an effect on the excellent prognosis of @GENE$ tumors [ ] . Some patients in these trials were treated with @DRUG$ after relapse .", "label": "None"}
{"id": "23493838", "sentence": "Transformation to accelerated phase CML occurred in four third-line patients ( dasatinib-resistant , n = 3 ; nilotinib-resistant , n = 1 ) and one fourth-line patient . Response rates were analyzed with respect to the mutational status of @GENE$ . The most frequent BCR-ABL mutations at baseline were @VARIANT$ , T315I , G250E , and Y253H .", "label": "None"}
{"id": "24634705", "sentence": "This @VARIANT$ mutation is analogous to the gatekeeper residue T3151 in @GENE$ kinase that is associated with acquired resistance to @DRUG$ and imatinib in chronic myelogenous leukemia [ ] .", "label": "None"}
{"id": "25364419", "sentence": "@GENE$ fusion was identified to be negative by reverse transcription-polymerase chain reaction analysis and no c-kit @VARIANT$ mutation was detected . Following the above mentioned assessments , the diagnosis of ABL was determined . Induction therapy with daunorubicin ( 45 mg/m2 daily ) intravenously for three days and @DRUG$ ( 100 mg/m2 daily ) intravenously via continuous infusion for seven days was initiated at the First Affiliated Hospital of Chongqing Medical University ( Chongqing , China ) on day 13 .", "label": "None"}
{"id": "25222496", "sentence": "Small-molecule tyrosine kinase inhibitors ( TKIs ) , including @DRUG$ and erlotinib , which specifically block the @GENE$ dependent pathway , were the first targeted drugs to enter the clinical use for the treatment of lung cancer . It has been extensively proved that NSCLC patients harboring sensitive EGFR mutations , which mainly refer to exon 19 deletions or @VARIANT$ substitution in exon 21 , usually benefit more from EGFR-TKIs than wild-type patients , .", "label": "sensitivity"}
{"id": "25032217", "sentence": "Notably , the Evaluation of Genomic Applications in Practice and Prevention ( EGAPP ) Working Group ( EWG ) found insufficient evidence to recommend or discourage testing for mutations in @GENE$ @VARIANT$ , NRAS , or PIK3CA and/or loss of PTEN or AKT protein . Therefore , the EWG discourages the use of these tests for deciding whether to introduce anti-EGFR therapy with @DRUG$ or panitumumab until more evidence supports improved clinical outcomes [ ] .", "label": "resistance or non-response"}
{"id": "24114583", "sentence": "The second-generation irreversible @GENE$ TKI @DRUG$ recently gained FDA approval as first-line therapy for EGFR mutation positive NSCLC in conjunction with Qiagen 's therascreen RGQ polymerase chain reaction ( PCR ) diagnostic test . Another second-generation irreversible EGFR TKI , dacomitinib , demonstrated preclinical efficacy in NSCLC tumours harbouring the @VARIANT$ gatekeeper mutation , , which is present in ∼50 % of NSCLCs that have acquired resistance to erlotinib or gefitinib , .", "label": "response"}
{"id": "23992330", "sentence": "For tyrosine kinase inhibitors ( TKIs ) [ ] , mutations within the ATP pocket of the kinase domain may affect the interaction of the drug with its target : for example , the single amino acid mutation tyrosine/methionine ( T790M ) in the ATP binding pocket of the EGFR mediates secondary resistance to the EGFR TKIs erlotinib and @DRUG$ in non-small cell lung cancer ( NSCLC ) [ , ] . The T790M mutation in EGFR is structurally analogous to drug resistance mutations in other kinases such as BCR-ABL ( T315I ) , @GENE$ ( @VARIANT$ ) and platelet derived growth factor receptor-α ( PDGFRα ) ( T674I ) [ ] .", "label": "None"}
{"id": "20740181", "sentence": "Erlotinib and @DRUG$ inhibit the tyrosine kinase activity of @GENE$ and have been studied extensively . Since Lynch et al. have identified specific activating mutations within the tyrosine kinase domain of EGFR [ ] , the missense mutation @VARIANT$ in exon 21 and the in-frame deletion in exon 19 , nested around the amino acid residues 747 to 750 of the EGFR polypeptide , account for & gt ; 85 % of all clinically important mutations related to TKI sensitivity [ ] .", "label": "sensitivity"}
{"id": "24069311", "sentence": "Dual p97/proteasome inhibition substantially decreased levels of phosphorylated and total @VARIANT$ in all MMCs lines , whereas treatment with only bortezomib or Eer1 resulted in a reduction in the levels of phosphorylated and total S6P in two of the four MMC lines in each case ( U-266 and @GENE$ for @DRUG$ ; OPM-2 and KMS-11 for Eer1 ) .", "label": "None"}
{"id": "25091415", "sentence": "The main hydrogen bonding between EGFR ( Met 793 ) and gefitinib is common for the WT and mutant models ; however , the aniline ring of @DRUG$ was shifted upward in DM when compared to WT @GENE$ . The dictionary of secondary structure of protein ( DSSP ) program was applied to the secondary structure of the EGFR WT and mutant models , and the resulting fluctuations were illustrated in ( A–D ) . In the @VARIANT$ mutation , minimal changes were observed in the coil region that remains near to the point mutant region .", "label": "sensitivity"}
{"id": "22709873", "sentence": "Interestingly , CCND1 links all of these genes together both at the TF level ( it is predicted to be targeted by AHR/ARNT , @GENE$ and PAX9 ) and at the gene level via several interactions . CCND1 was downregulated in response to @DRUG$ in our panel of cell lines which is consistent with previous studies [ - ] and which may also be related to its known interactions with our other genes of interest . FOXO3A has been shown to down-regulate CCND1 during cell cycle inhibition [ ] , while Erbb3 receptors are thought to be required to reduce transcription of @VARIANT$ mediated transcription factors , which include CCND1 [ ] .", "label": "None"}
{"id": "22191026", "sentence": "The investigated @GENE$ sensitive mutations included @VARIANT$ , G719S , G719A , L858R , L861Q , and exon 19 deletions , as well as a gefitinib-resistant mutation , T790M .", "label": "None"}
{"id": "PMC3965223", "sentence": "As it was shown previously , the sensitivity of Co(III)- and Pt ( II ) TPP towards aliphatic alcohols decreases in a following order [ ] : ethanol & gt ; methanol & gt ; isobutyl alcohol ; while in [ and ] the response of 5,10,15,20-tetraphenyl porphyrin ( H2TPP ) and its Co(II) complexes based sensors , towards the changes in acetic acid , @DRUG$ , ammonia , NaCl , @GENE$ , quinine , glucose , monosodium glutamate , dissolved SO2 , and @VARIANT$ content was evolved .", "label": "None"}
{"id": "12093370", "sentence": "Searching for a mechanism for LMO4 function , Visvader and colleagues identified both the @DRUG$ carboxy-terminal binding protein ( @GENE$ , a protein targeted by adenoviral @VARIANT$ ) and tumor suppressor protein BRCA1 as binding partners for LMO4 and demonstrated repression by LMO4 of BRCA1 mediated transactivation in mammalian cells .", "label": "None"}
{"id": "25033171", "sentence": "The energetic difference between G2032R-ROS1 and @GENE$ are shown in panel C ( ΔΔG = ΔGG2032R−ΔGWT , a positive ΔG indicates a weaker binding affinity in the mutated protein , and a negative ΔG indicates a stronger binding affinity ) , where the residue Leu18 ( on the P-loop region ) contributes the most to the attenuated binding of @DRUG$ to G2032R mutated ROS1 , indicating that the P-loop conformation governs the binding of crizotinib .", "label": "resistance"}
{"id": "23994953", "sentence": "While preparing this manuscript , Cortot et al. reported that PC-9 derived clones with acquired resistance to mutant-selective EGFR inhibitors and irreversible quinazoline EGFR inhibitors in the absence of EGFR @VARIANT$ demonstrate a significantly activated IGF-1R signaling , and pharmacological inhibition of IGF-1R restored sensitivity to EGFR inhibitors . Despite no patient data supporting the role of IGF-1R in acquired resistance to gefitinib/erlotinib , we are beginning to accumulate evidence from preclinical models indicating that clinical trials of IGF-1R inhibitors with demonstrated activity in unselected NSCLC patients might play a role in association with @GENE$ inhibitors in the management of NSCLCs with acquired resistance to gefitinib/erlotinib .", "label": "resistance or non-response"}
{"id": "25465236", "sentence": "The differential genetically induced drug sensitivities for the FDA approved targeted lung cancer drugs @DRUG$ and Gefitinib was examined . Patients harboring the oncogenic @GENE$ kinase double mutation @VARIANT$ + E884K have a clearly defined differential clinical response to these drugs .", "label": "sensitivity"}
{"id": "22174597", "sentence": "Approximately 5 % to 7 % of GIST harbour oncogenic mutations in @GENE$ , typically in the juxtamembrane domain ( exon 12 ) or activation loop ( exon 18 ) ; the @VARIANT$ substitution in exon 18 , is highly resistant to @DRUG$ .", "label": "resistance or non-response"}
{"id": "20531963", "sentence": "Two patients with classic activating mutations exhibited de novo @DRUG$ resistance and had concurrent genetic anomalies usually associated with acquired TKI resistance , specifically the @VARIANT$ @GENE$ mutation and MET amplification .", "label": "resistance or non-response"}
{"id": "24263064", "sentence": "The detection rate of EGFR mutation positive status among patients with evaluable tumour samples was 13.7 % ( 118 out of 859 ) ; 65.1 % of patients with a positive EGFR mutation status had tumours with exon 19 deletions and 31.1 % with @VARIANT$ point mutations . @DRUG$ treatment was started in 107 patients , of whom 106 had activating , sensitising EGFR mutations and one had a resistant @GENE$ mutation .", "label": "sensitivity"}
{"id": "17973572", "sentence": "BIM expression correlated with the amount of apoptosis in @VARIANT$ , L858R-L747S , and L858R-T790M cells . ( B ) Modulation of signaling following @DRUG$ treatment in @GENE$ cells expressing EGFR mutants .", "label": "None"}
{"id": "24729716", "sentence": "Two patients harboring @GENE$ @VARIANT$ mutation had received EGFR-TKI treatment : one received gefitinib and had an occurrence of brain metastasis in the sixth month ; the other received @DRUG$ to control the metastasis to the liver .", "label": "resistance or non-response"}
{"id": "23888935", "sentence": "Soon after the advent of the @GENE$ TKI @DRUG$ , it became evident that Philadelphia chromosome–positive cells could evolve to evade inhibition . In particular , the @VARIANT$ gatekeeper mutant – the most commonly observed point mutation in clinical practice – confers universal resistance to these agents.– At present , the only TKI that is effective in patients with the T315I mutation is ponatinib ( ARIAD Pharmaceuticals , Inc. , Cambridge , MA , USA ) .", "label": "None"}
{"id": "24498211", "sentence": "Results of the NIH sponsored TINSAL-T2D clinical studies have demonstrated that salsalate , a non-steroidal anti-inflammatory drug , lowers @GENE$ , fasting glucose and markers of inflammation in @VARIANT$ patients . The pleiotropic effects of many natural compounds ( e.g. , @DRUG$ , curcumin , EGCG ) are well documented .", "label": "None"}
{"id": "PMC4041556", "sentence": "Second-generation EGFR TKIs – such as neratinib , afatinib and dacomitinib – are effective in preclinical gefitinib- and erlotinib-resistant EGFR @VARIANT$ models , but to date their delivery in EGFR TKI-resistant patients have shown disappointing results in the clinic . Combination of afatinib with @DRUG$ in @GENE$ TKI-resistant patients resulted in a 30 % response rate and 75 % disease control rate , with significant gastrointestinal toxicity .", "label": "response"}
{"id": "25538894", "sentence": "In May 2010 , an EGFR mutation ( @VARIANT$ c.2573T & gt ; G ) positive adenocarcinoma of the right lower lobe of the lung with metastasis in the contra-lateral lung was diagnosed ( Figure A ) . In June 2010 , @DRUG$ , a irreversible @GENE$ , was started in a clinical trial ( Gilotrif® in BIBW 2992 trial ) .", "label": "sensitivity"}
{"id": "24009492", "sentence": "Abbreviations : 6PDG , 6-phospho-d-gluconate ; ADE , Adenosine ; ALA , Alanine ; ARG , Arginine ; ATP , ATP ; CHO , Choline ; CTP , CTP ; CYD , Cytidine ; CYT , Cytosine ; DHAP , Dihydroxyacetone-Phosphate ; DOG , Deoxyguanosine ; DS7P , D-sedoheptulose-7-phosphate ; @VARIANT$ , Fructose-1,6-bisphosphate ; GLN , Glutamine ; GLU , Glutamate ; GUA , Guanosine ; HIS , @DRUG$ ; INO , Inosine ; LEU , Leucine/isoleucine ; LYS , Lysine ; NAD , NAD+ ; NAG1P , N-acetyl-glucosamine-1-phosphate ; NIC , Nicotinate ; ORN , Ornithine ; PHP , Phenylpyruvate ; PYR , Pyruvate ; RIBP , Ribose-phosphate ; SER , Serine ; SUC , Sucrose ; THR , Threonine ; TRE , Trehalose ; TRP , Tryptophan ; UDPG , UDP-D-glucose ; @GENE$ , UTP .", "label": "None"}
{"id": "23181703", "sentence": "We conducted re-biopsy to the patient to check @GENE$ mutation analysis by cycleave polymerase chain reaction technique ( cycleave-PCR ) . @VARIANT$ point mutation ( in which leucine at amino acid 858 is replaced by arginine ) was detected in the tumor cell ( Figure ) . Therefore we treated the patient with @DRUG$ ( 150mg ) therapy once a day .", "label": "sensitivity"}
{"id": "19680652", "sentence": "However , subsequent resistance to gefitinib is inevitable even among the initial good responders , mostly related to acquired EGFR mutation ( @VARIANT$ ) or c-met amplification [ , ] . Large-scale phase III clinical trials have demonstrated survival benefit with @DRUG$ but not gefitinib as second- or third-line treatment of advanced NSCLC , suggesting pharmacological differences between the two @GENE$ [ , ] .", "label": "resistance or non-response"}
{"id": "24501009", "sentence": "The remaining members of the HER family comprise @GENE$ and HER4 tyrosine kinases , and the kinase‐null HER3 .1 HER family members act together via hetero‐ and homodimerization to enable downstream signaling pathways modulating a range of cellular activities , including growth , proliferation , differentiation , and migration . In contrast to patients with EGFR‐mutation‐positive tumors , patients with KRAS‐mutant NSCLC are unlikely to respond to gefitinib or erlotinib and do not have an improved progression‐free survival ( PFS ) compared with those who have placebo following @DRUG$ therapy . Dacomitinib ( PF‐00299804 ) is a potent , irreversible , oral small‐molecule inhibitor of HER1/EGFR , HER2 , and HER4 tyrosine kinases with antitumor activity in both gefitinib‐sensitive and gefitinib‐resistant , including EGFR @VARIANT$ , preclinical NSCLC models .", "label": "None"}
{"id": "22132735", "sentence": "EGFR gene mutations indicate sensitivity to gefitinib , and it was demonstrated that about 85 % of patients with NSCLC who obtained benefit from @DRUG$ treatment were found to have mutations in exons 18 to 21 of the tyrosine kinase domain of the EGFR gene [ - ] . EGFR mutations in exon 19 ( short in-frame deletions ) or 21 @VARIANT$ ( point mutation ) affect the adenosine triphosphate ( ATP ) pocket of the tyrosine kinase domain leading to the activation of 4-anilinoquinazoline compounds , which function to compete with ATP [ ] . Anti-EGFR therapy can consequently lead to the downregulation of downstream signaling cascades , such as the PI3K/Akt , RAS/Erk , @GENE$ , and STAT pathways , responsible for cell proliferation and survival , resulting in the inhibition of cell proliferation and induction of cell apoptosis , respectively .", "label": "None"}
{"id": "24155950", "sentence": "Murine Baf3 Bcr-Abl and @GENE$ Bcr-Abl @VARIANT$ cells were plated in 75cm2 flasks ( 4 x 106 cells/35 ml/flask ) and treated with 0.5 or 1 µM imatinib . For nilotinib and dasatinib treatments , the cells were plated in 25cm2 flasks ( 2 x 106 cells/10 ml/flask ) and treated with 0.125 µM or 0.5 µM nilotinib and 0.056 µM or 0.112 µM @DRUG$ for 48h .", "label": "None"}
{"id": "21698178", "sentence": "@VARIANT$ is also resistant to @DRUG$ ( Gleevec™ ) treatment , which has motivated to study its role in KIT activation mechanisms . Biochemical studies of KIT gave insights into the molecular mechanism of the ligand independent activation of the D816V mutant receptor but whether dimerization is required remains unclear , . In the inactive state , the DFG triad adopts a “DFG-out” orientation for D810 points out of the ATP binding pocket , while F811 is oriented toward the site and JMR is bound to @GENE$ ; in the active state , a canonical “DFG-in” conformation positions the catalytic D810 in the back of the site for chelation of magnesium while F811 is buried away and A-loop extends toward a completely solvent exposed JMR .", "label": "None"}
{"id": "24009492", "sentence": "Abbreviations : 6PDG , 6-phospho-d-gluconate ; ADE , Adenosine ; ALA , Alanine ; ARG , Arginine ; ATP , ATP ; CHO , Choline ; CTP , CTP ; CYD , Cytidine ; CYT , Cytosine ; DHAP , Dihydroxyacetone-Phosphate ; DOG , Deoxyguanosine ; DS7P , D-sedoheptulose-7-phosphate ; @VARIANT$ , Fructose-1,6-bisphosphate ; GLN , Glutamine ; GLU , Glutamate ; GUA , Guanosine ; HIS , @DRUG$ ; INO , Inosine ; LEU , Leucine/isoleucine ; LYS , Lysine ; NAD , NAD+ ; NAG1P , N-acetyl-glucosamine-1-phosphate ; NIC , Nicotinate ; ORN , Ornithine ; PHP , Phenylpyruvate ; PYR , Pyruvate ; RIBP , Ribose-phosphate ; SER , Serine ; SUC , Sucrose ; THR , Threonine ; TRE , Trehalose ; TRP , Tryptophan ; UDPG , UDP-D-glucose ; UTP , @GENE$ .", "label": "None"}
{"id": "23567620", "sentence": "Finally , although molecularly targeted therapies ( that is , gefitinib or erlotinib for EGFR and @DRUG$ for @GENE$ fusions ) are effective in NSCLC , intrinsic or acquired resistances inevitably lead to recurrence and/or metastatic dissemination . This is the case of MET activation/amplification , , or acquired somatic mutations of EGFR ( T790M ) or ALK fusions ( @VARIANT$ , L1196M and ALK amplification ) . , ,", "label": "resistance"}
{"id": "23405260", "sentence": "Only the CAL-33 cell line exhibited a mutation in exons 9 or 20 of PI3K ( a heterozygous H1047R mutant ) and only UMSCC-74A exhibited a @GENE$ mutation ( a heterozygous @VARIANT$ mutant ) . Both of these cell lines had a lower sensitivity to dacomitinib although CAL33 was somewhat responsive to @DRUG$ .", "label": "sensitivity"}
{"id": "25465236", "sentence": "( G–I ) increased inhibition potency for Gefitinib against EGFR @VARIANT$ mutant compared to EGFR WT protein and subsequent further increase in potency for @DRUG$ against @GENE$ L858R + E884K double mutant .", "label": "sensitivity"}
{"id": "23186157", "sentence": "In this report we also demonstrated that Dasatinib , an Abl/Src dual inhibitor , is capable of cooperating with GNF-2 in inhibiting the proliferation of @GENE$ cells carrying the native or the @VARIANT$ mutated Bcr-Abl . In fact , our data showed that the cooperation with Dasatinib was more potent than the one observed with @DRUG$ or Nilotinib .", "label": "None"}
{"id": "23186157", "sentence": "Interestingly , @DRUG$ was the most efficient AKI in cooperation with GNF-2 in inhibiting clonigenicity of @GENE$ cells containing the @VARIANT$ mutated Bcr-Abl .", "label": "None"}
{"id": "25414766", "sentence": "The specificity can be confirmed using let-60 ( n1046 ) gain-of-function mutant or a transgenic worm expressing LET-23 chimeras in which the TK domain was replaced with the human mutant TK domain ( @VARIANT$ or T790M-L858R ) . Both animals with hyperactive Ras-ERK MAPK signaling in somatic vulva precursor cells induce a multivulva ( Muv ) phenotype . Notably , these muv phenotypes were rescued by the treatment of Ras-ERK MAPK inhibitors , including AG1478 ( an @GENE$ inhibitor ) , U0126 ( a MEK inhibitor ) , @DRUG$ , Manumycin , and Gliotoxin ( ; ) .", "label": "sensitivity"}
{"id": "24276379", "sentence": "It has even been observed that cells that have been induced to become cetuximab-resistant by continuously exposing them to cetuximab have acquired either K-Ras G12V or K-Ras @VARIANT$ mutations [ ] . Moreover , in a large retrospective study of patients treated with panitumumab , the outcome in patients with the G13D mutation was not better than other KRas mutations .", "label": "None"}
{"id": "15737014", "sentence": "The 2369 C→T mutant peak was even more prominent in cells from the patient 's pleural fluid , which were obtained after further disease progression on @DRUG$ ( A , lower panels ; ) . Collectively , these findings imply that the exon 20 T790M mutation was present on the same allele as the exon 21 @VARIANT$ mutation , and that a subclone of cells harboring these mutations emerged during drug treatment . In patient 2 , the tumor-rich sample obtained prior to treatment with erlotinib did not contain any additional mutations in the exons encoding the @GENE$ tyrosine kinase domain ( B , upper panels ; ) .", "label": "sensitivity"}
{"id": "23414419", "sentence": "Our findings are in accordance with a prior report by Carlson and colleagues , who demonstrated that @DRUG$ causes cell cytotoxicity by G1-S phase arrest in MDA-MB-468 breast carcinoma cells [ ] . RB protein , a tumor suppressor that blocks @VARIANT$ @GENE$ transcription of E2F-responsive genes involved in cell cycle progression from G1 to S phase .", "label": "None"}
{"id": "24048338", "sentence": "Environmentally hazardous gases can be classified into oxidizing gases ( such as NO2 , @GENE$ , and Cl2 ) and reducing gases ( such as NO , @VARIANT$ , CO , and @DRUG$ ) .", "label": "None"}
{"id": "24212777", "sentence": "Most B-Raf mutations involve the @VARIANT$ amino acid substitution , resulting in constitutive activation of the MEK-ERK signaling pathway . They are mutually exclusive of KRAS mutations and are thus a candidate for an independent biomarker for CRC [ ] . Studies on WT-KRAS tumors treated by either a combination of chemotherapy and @DRUG$ or cetuximab alone have shown that progression free survival ( PFS ) and OS were significantly better among patient without mutated BRAF ( @GENE$ ) [ ] .", "label": "resistance or non-response"}
{"id": "21188111", "sentence": "In a recent report , the c-KIT mutation @VARIANT$ was associated with resistance to multiple KIT inhibitors including imatinib , @DRUG$ , and sorafenib , but objective tumor responses could be induced in 2 patients bearing the @GENE$ L576P mutation after treatment with dasatinib .", "label": "resistance or non-response"}
{"id": "25275294", "sentence": "We used either the specific MEK1/2 inhibitor PD325901 or @VARIANT$ BRAF inhibitor @DRUG$ to block highly activated BRAF signaling in SK-Mel-19 or A375 cells . We then examined the expression level of @GENE$ .", "label": "None"}
{"id": "15736989", "sentence": "Several mutations have been identified in the context of epidermal growth factor receptor (EGFR) in patients with NSCLC that are associated with clinical response to the small-molecule @GENE$ inhibitors gefitinib ( @DRUG$ ) or erlotinib ( Tarceva ) [ , , ] , including in-frame deletions such as del L747–E749 ; A750P in exon 19 , or @VARIANT$ in exon 21 .", "label": "sensitivity"}
{"id": "23459666", "sentence": "This finding has led to the selection of patients for EGFR blockade therapy based on KRAS status , with @DRUG$ only offered to those patients with no KRAS mutation in the primary tumor- . In a similar fashion , a small percentage of primary CRC contains a mutation in the @GENE$ gene . The BRAF ( @VARIANT$ ) mutation in CRC confers poor survival with standard chemotherapy regimens , .", "label": "resistance or non-response"}
{"id": "20300583", "sentence": "2. Materials and Methods 49 individual specimens of 21 metastatic CRCs and corresponding metastases collected before and after combined therapy with @DRUG$ were examined using CGH , certified PCR/DNA sequencing protocols ( KRAS exon 2 , Gl12/13 ; @GENE$ exon 15 , @VARIANT$ ) as well as allele-specific PCR [ ] .", "label": "resistance or non-response"}
{"id": "25382104", "sentence": "Results showed that ponatinib has the highest binding affinity towards the @VARIANT$ mutant @GENE$ with a docking score of −11.050 kcal/mol while @DRUG$ , bafetinib , dasatinib , nilotinib and imatinib showed −5.513 kcal/mol , −4.689 kcal/mol , −4.702 kcal/mol , −3.772 kcal/mol , −3.593 kcal/mol and −3.78 kcal/mol , respectively ( ) .", "label": "None"}
{"id": "21559393", "sentence": "10.1371/journal.pone.0019273.t002Differently expressed genes with relevance to G2/M transition or mitosis after treatment with high concentrations of sagopilone (SAG) or @DRUG$ ( PAC ) . Identifier Gene Name Gene Symbol Fold Change 40 nM SAG Fold Change 40 nM PAC 232588_at stromal antigen 1 STAG1 12.50 11.37 207331_at centromere protein F , 350/400 ka ( mitosin ) CENPF 5.59 5.25 232466_at Cullin 4A CUL4A 4.90 4.66 1556339_a_at Ubiquitin activating enzyme @VARIANT$ ( UBA3 homolog , yeast ) UBE1C 4.03 3.89 215623_x_at SMC4 structural maintenance of chromosomes 4-like 1 ( yeast ) SMC4L1 3.97 3.75 244427_at Kinesin family member 23 KIF23 3.92 3.33 233940_at Echinoderm microtubule associated protein like 4 EML4 3.51 3.20 242362_at Cullin 3 CUL3 2.74 n.c . 228729_at cyclin B1 @GENE$ 2.52 2.35 204641_at NIMA ( never in mitosis gene a ) -related kinase 2 NEK2 2.25 2.09 221258_s_at kinesin family member 18A KIF18A n.c .", "label": "None"}
{"id": "24803900", "sentence": "Carboplatin was discontinued and @GENE$ was initiated as a second-line chemotherapy . For the first cycle , a total of 85 mg ( 40 mg/m2 ) of liposomal @DRUG$ in 250 ml of @VARIANT$ ( 5 % glucose solution ) was prescribed with the same premedications used for the prior carboplatin .", "label": "None"}
{"id": "25055117", "sentence": "We found that inhibition of MET signaling with @DRUG$ or @GENE$ siRNA induced apoptosis that was accompanied by attenuation of the phosphorylation ( activation ) of AKT and the MAPK extracellular signal regulated kinase ( ERK ) in NSCLC cells with MET amplification but not in those positive for a non-kinase domain mutation ( @VARIANT$ or deletion of exon 14 ) of MET [ ] .", "label": "None"}
{"id": "23520446", "sentence": "In addition to the @GENE$ overexpressed cells , we also showed the phosphorylation status of EGFR-Thr654 and -Ser1046 in endogenous @VARIANT$ mutant cells ( H1975 ) under treatment of VE-465 and @DRUG$ ( ) .", "label": "sensitivity"}
{"id": "23227361", "sentence": "Mutation T798M at the gatekeeper residue and an ATP binding site mutation ( @VARIANT$ and L755P ) showed reduced response to @DRUG$ , with IC50s of up to 50 times higher relative to wild-type @GENE$ [ ] .", "label": "resistance or non-response"}
{"id": "24025253", "sentence": "Off-label use of @DRUG$ plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with @VARIANT$ @GENE$ metastatic colon cancer", "label": "resistance or non-response"}
{"id": "23055691", "sentence": "Patients who had progressed on @DRUG$ or gefitinib were given afatinib and cetuximab , a monoclonal antibody against @GENE$ . Approximately 94 % of patients , regardless of @VARIANT$ mutation status , had a partial response or stable disease .", "label": "resistance or non-response"}
{"id": "23423768", "sentence": "The magenta ball-stick ( located just above the @DRUG$ molecule in the active site ) indicates the gatekeeper residue ( threonine790 ) that is commonly mutated to methionine ( @VARIANT$ ) , resulting in reduced inhibitor binding and drug resistance . ( C ) Simplified pathway diagram of @GENE$ signaling through RAS/MEK/ERK and PI3K/PDK1/AKT indicating the points of mutation/amplification in EGFR TKI resistance as reported by Sequist and colleagues .", "label": "resistance or non-response"}
{"id": "2297491", "sentence": "The in vivo response of a @VARIANT$ mammary carcinoma to treatment with misonidazole , @DRUG$ and radiation .", "label": "None"}
{"id": "24982846", "sentence": "@DRUG$ BCR/ABL1 Philadelphia chromosome [ t ( 9 ; 22 ) ] positive ; T315I mutation posit Indications and usage , clinical studies , patient counseling information Denileukin diftitox IL2RA CD25 antigen positive Indications and usage , warnings and precautions , clinical studies Erlotinib EGFR EGFR protein expression positive @GENE$ exon 19 deletion or exon 21 substitution ( @VARIANT$ ) positive Clinical pharmacology Indications and usage , dosage and administration , clinical pharmacology , clinical studies", "label": "None"}
{"id": "21445332", "sentence": "Right panel : @GENE$ @VARIANT$ has similar C3b @DRUG$ activity to wild type .", "label": "None"}
{"id": "25364578", "sentence": "In the pooled analysis from LUX-Lung 3 and 6 , presented this year at ASCO , @DRUG$ prolonged survival of lung cancer patients whose tumors have common @GENE$ mutations by a median of three months compared with standard chemotherapy and significantly reduced the risk of death by 19 % . The most pronounced reduction in risk of death was 41 % in patients whose tumors had the most common exon 19 deletion EGFR mutation ; for patients with the @VARIANT$ mutation there was no impact on overall survival .", "label": "None"}
{"id": "25505694", "sentence": "The firstly described and the most common event responsible for resistance is the acquisition of the @VARIANT$ missense mutation , which is found in ≈ 50 % of patients progressing after an initial response to @DRUG$ or gefitinib [ , ] . Other less frequent mechanisms include secondary mutations within EGFR [ , ] , @GENE$ amplification [ ] , HER2 amplification [ , ] , small cell histologic transformation [ ] .", "label": "None"}
{"id": "23788917", "sentence": "The T790M mutation leads to a substitution of threonine to methionine in the catalytic centre of @GENE$ tyrosine kinase , which is located in the binding pocket of TKI and ATP . Substitution of threonine at codon 790 into larger methionine probably results in blocking of the binding sites of erlotinib and @DRUG$ aromatic residues with their point of action . In vitro studies demonstrated that the effective concentration of erlotinib in tumour cells harbouring both the @VARIANT$ and T790M mutations has to be 300 times higher to induce apoptosis than in cells only with an activating mutation in codon 858 [ , ] .", "label": "sensitivity"}
{"id": "23151593", "sentence": "In addition , we found that E2 treatment markedly reduced the @GENE$ protein level in MCF-7 and @VARIANT$ cells whereas 4OHT , the active metabolite of @DRUG$ , significantly increased the PEDF protein level in both cell lines ( Figure ) .", "label": "None"}
{"id": "16173832", "sentence": "Pao et al. and Kobayashi et al. identified four cases with lung adenocarcinoma harboring pre existing mutations of @GENE$ as delL747–E749 plus @VARIANT$ , delE746–A750 , or delL747–S752 , prior to the use of @DRUG$ or erlotinib [ , ] .", "label": "None"}
{"id": "21333004", "sentence": "Yun et al [ ] showed that gefitinib directly binds more tightly to the @VARIANT$ mutant than to the wild type @GENE$ in vitro , while Fabian et al [ ] indicated that EGFR with @DRUG$ sensitive mutations does not differ from wild type EGFR in terms of gefitinib binding affinity .", "label": "sensitivity"}
{"id": "20500904", "sentence": "Phosphorylation of both AKT and MAPK was abrogated in the presence of @DRUG$ , demonstrating its dependency on @GENE$ activation ( data not shown ) . Constitutive activation of HER family members prevent the in vitro and in vivo effectiveness of MET inhibition The most common EGFR activating alterations in human tumors are receptor point mutations ( such as the @VARIANT$ mutation , [ ] ) and the onset of TGFα autocrine production [ , ] .", "label": "sensitivity"}
{"id": "24278442", "sentence": "Despite the clear correlation between @VARIANT$ and the @GENE$ status in the above validation study , dynamics of T790M during the disease course was not as clear as that of activation of mutations ; T790M often appeared before acquiring resistance . Three patients are described in more detail . Patient 226 was treated with @DRUG$ as first line chemotherapy .", "label": "resistance or non-response"}
{"id": "23407898", "sentence": "For such patients , irreversible @GENE$ TKIs hold a lot of promise . The irreversible TKI BIBW 2992 ( @DRUG$ ) is currently being investigated in advanced clinical trials ( Yap et al. , ; Murakami et al. , ) . Another novel irreversible pan-HER inhibitor HM781-36B has recently shown promise in the inhibition of EGFR , HER2 , and HER4 as well as against the gatekeeper mutation – EGFR @VARIANT$ that is responsible for acquired drug resistance in lung cancer patients ( Cha et al. , ) .", "label": "response"}
{"id": "25429239", "sentence": "Other amino acid substitutions observed include G1269A , G1202R , and @VARIANT$ substitutions , as well as a 1151 threonine insertion . Another described resistance mechanism involves amplification of the @GENE$ fusion gene and activation of other bypass mechanisms.– KIT gene amplification and EGFR activation have also been reported as mechanisms of acquired @DRUG$ resistance. , ,", "label": "resistance"}
{"id": "24523596", "sentence": "Several studies have reported renal failure and tumor lysis syndrome during TKI based molecular targeted therapies , including with sorafenib for hepatocellular carcinoma , with @DRUG$ for chronic myelogenous leukemia , and with flavopiridol for chronic lymphocytic leukemia.– Because the Q141K variant of @GENE$ corresponding to SNP 421C&gt ; A reduces uric acid transport and those TKIs are substrates/inhibitors of ABCG2/BCRP , TKI therapy in patients with the SNP 421C&gt ; A ( Q141K ) may be at higher risk of tumor lysis syndrome . A defect in the pharmacological interaction has been suggested between sunitinib and another ABCG2/BCRP germ-line mutant allele , 1291T & gt ; C. Remarkably , sunitinib reversed wild-type ABCG2/BCRP mediated drug resistance and competitively inhibited ABCG2/BCRP mediated estrone 3-sulfate transport and the binding of 125I-iodoarylazidoprazosin to ABCG2/BCRP . The @VARIANT$ variant of ABCG2/BCRP , which is expressed from a germ-line mutant allele 1291T & gt ; C , was insensitive to sunitinib mediated inhibition .", "label": "None"}
{"id": "23723712", "sentence": "Otherwise , CO-1686 is a novel irreversible mutant-selective inhibitor of EGFR , able to target both the initial activating EGFR mutations as well as the @VARIANT$ secondary acquired resistance mutation . To investigate its use as a single agent , CO-1686 is being evaluated in a Phase I/II trial in @GENE$ NSCLC patients previously treated with first-line gefitinib or @DRUG$ ( NCT01526928 ) .", "label": "resistance or non-response"}
{"id": "17877814", "sentence": "Graph shows that the common L858R mutation confers higher autophosphorylation levels to @GENE$ than P848L and A859T . Images show that , unlike L858R , these uncommon exon 21 mutants did not induce phosphorylation of endogenous Akt . @DRUG$ blocked @VARIANT$ induced pAkt at 10 nM , and caused relocation of the ectopic protein into fibrils at 100 nM .", "label": "sensitivity"}
{"id": "15737014", "sentence": "For example , in CML , a commonly found mutation is a C→T single nucleotide change that replaces threonine with isoleucine at position 315 ( @VARIANT$ ) in the ABL kinase domain [ , , ] . In GIST and @GENE$ , respectively , the analogous T670I mutation in KIT and T674I mutation in PDGFR-alpha have been associated with acquired resistance to this drug [ , ] . To determine whether lung cancers that acquire clinical resistance to either @DRUG$ or erlotinib display additional mutations in the EGFR kinase domain , we have examined the status of EGFR exons 18 to 24 in tumors from five patients who initially responded but subsequently progressed while on these drugs .", "label": "None"}
{"id": "24189400", "sentence": "PC9GR cells ( gefitinib resistant ) were shown to harbor a secondary @VARIANT$ mutation in @GENE$ , whereas HCC827ER cells ( @DRUG$ resistant ) demonstrated MET overexpression , as previously reported ( ) .", "label": "resistance or non-response"}
{"id": "24244732", "sentence": "Alcohol sensitivity phenotypes of single point mutations in unc-18 We recently demonstrated that a single point mutation ( D216N ) in Munc18 acts biochemically by reducing binding to the assembled SNARE complex and that the orthologous mutation in C. elegans unc-18 ( D214N ) reduces sensitivity to both low and high concentrations of exogenous @DRUG$ [ ] . Previously , we have biochemically characterised other point mutations in Munc18 that affect binding to other proteins including R39C ( inhibits binding to closed-conformation syntaxin ) [ , ] , P242S ( inhibits binding to Mint proteins ) [ ] and @VARIANT$ ( enhances binding to @GENE$ ) [ ] .", "label": "None"}
{"id": "19707322", "sentence": "Nilotinib is approximately 30-fold more sensitive than imatinib in the killing of BCR-ABL dependent cells derived from patients with CML ( K562 and Ku-812F cells ) and cell lines ( 32D and baF3 ) , and it is active against 32/33 imatinib-resistant cell lines with @GENE$ mutations . The sensitivity of Bcr-Abl mutants to AMN107 can be summarized into 4 categories : high ( IC50 ≤ 70 nmol/L : M244V , G250E , Q252H , F3llL , F317L , M351T , V379I , L387M , H396P , H396R ) , medium ( IC50 ≤ 200 nmol/L : Y253F , E255K , F359V ) , low ( IC50 ≤ 450 nmol/L : @VARIANT$ , E255V ) , and insensitive ( IC50 & gt ; 2 μmol/L : T315I ) ( ) ( ) .", "label": "None"}
{"id": "19646278", "sentence": "Given the limited sample size , the extent of tumor shrinkage could not be correlated either to mutational status or to other clinical features , such as tumor site , initial tumor size , @DRUG$ duration , and extent of pathologic response . In light of these results the presence of a less sensitive mutation like Exon 9 or of a wild-type KIT/PDGFRα mutational status should not be considered per se a contraindication to a preoperative treatment , the only exception being those point mutations with known complete resistance ( i.e. @VARIANT$ in Exon 18 on PDGRα gene ) . The only precaution is to strictly monitor the response , by early @GENE$ re-evaluation [ ] .", "label": "None"}
{"id": "19920910", "sentence": "In a cell-line based mutagenesis study , the emergence of @GENE$ mutations resistant to imatinib , nilotinib and dasatinib were compared : 20 different mutations were identified with imatinib mesylate , 10 with nilotinib ( including only 1 novel mutation , E292V ) and 9 with @DRUG$ . In contrast to imatinib mesylate , mutations recovered in the presence of 50 nM nilotinib were limited to L248V , G250E , Y253H , @VARIANT$ ( p-loop ) , T315I , F359C , L384M and L387F .", "label": "None"}
{"id": "19543508", "sentence": "Years have passed since mutations of the @GENE$ tyrosine kinase domain were discovered in patients with NSCLC , and these patients had dramatic clinical responses to treatment with @DRUG$ . Mutations in the exons encoding the tyrosine kinase domains of EGFR , including in-frame deletions in exon 19 and a T-to-G substitution in exon 21 ( @VARIANT$ ) , have been found in a subset of lung adenocarcinoma ( - ) .", "label": "sensitivity"}
{"id": "23927433", "sentence": "Infiltrate of mature lymphoid cells ( hematoxylin & amp ; eosin , H/E ) , which stained for CD20 ( B cell marker ) , DBA44 and @VARIANT$ BRAF ( @GENE$ markers ) . Histology and immunohistology were performed according to standard diagnostic procedures . The severely neutropenic patient was supported with both G-CSF and Epo and underwent ambulatory chemotherapy with the purine analog 2-CDA ( @DRUG$ , leustatin , cladribine ) according to a schedule of 0.1 mg/Kg IV once per week for 4 to 6 weeks .", "label": "None"}
{"id": "21931712", "sentence": "@GENE$ was found to harbor mutations in close to 10 % of cases , and EGFR inhibitors such as @DRUG$ could be tested in this subset of cancers . In lung cancer , these inhibitors are used to treat cancers that harbor exon 20 variants , codon 719 variants , and @VARIANT$ substitutions in addition to other types of EGFR mutations , .", "label": "sensitivity"}
{"id": "21192840", "sentence": "Tumor type EGFR mutation EGFR expression changes @GENE$ targeting agents ( FDA approved for clinical use ) Resistance mechanisms Non-small cell lung cancer Kinase domain deletions ( exon 19 ) , point mutations ( exon 21 ) Gene amplification Erlotinib , @DRUG$ @VARIANT$ gatekeeper mutation ( 50 % ) , , elevated c-Met/HGF expression ( 20 % ) –", "label": "resistance or non-response"}
{"id": "22152101", "sentence": "We did not detect any @VARIANT$ @GENE$ mutations in our study while the frequency of BRAF mutations was 12 % in the aforementioned study of @DRUG$ plus chemotherapy in advanced OGJ cancer patients [ ] .", "label": "resistance or non-response"}
{"id": "21814611", "sentence": "In this case , because HBeAg was detected and HBV DNA was still high 3 months after administration of clevudin , it should be clarified that the mutations in the overlapping frame gene regions , S codon @VARIANT$ ( P codons P221T and A222T ) , may be associated with escape mutation as well as drug resistance . An interesting point of this case concerns the sustained HCV suppression , which occurred even with insufficient treatment of @DRUG$ .", "label": "None"}
{"id": "22192458", "sentence": "Inhibition of ALK activity in NB cell lines has already been approached by using specific small molecule ALK inhibitors , such as @DRUG$ [ ] , NVP-TAE684 [ ] and @GENE$ [ ] , and more recently by RNA interference molecules [ ] . Particularly , NB cells harboring either @VARIANT$ mutation or ALK amplification showed sensitivity to PF-02341066 and these results were also confirmed in xenografts ( Wood AC et al. , ASCO Annual Meeting , 2009 ) .", "label": "None"}
{"id": "23418490", "sentence": "Erlotinib and @DRUG$ are inhibitors of @GENE$ that show significant efficacy in treating NSCLC patients harboring EGFR mutations , . At the same time , a secondary point mutation in exon 20 of EGFR ( @VARIANT$ ) is associated with acquired resistance to EGFR inhibitors , including Erlotinib .", "label": "resistance or non-response"}
{"id": "22933967", "sentence": "The KRAS status is the first molecular marker to predict the response to anti-EGFR monoclonal antibodies cetuximab and @DRUG$ in metastatic CRC ( mCRC ) patients , and it needs to be determined before deciding in favor of treatment with anti-EGFR antibodies . Previous retrospective studies suggested that @GENE$ was a marker of resistance to anti-EGFR therapy and that the patients with mt-BRAF had significantly shorter PFS and OS than the patients with wt-BRAF tumours . The mutations in the KRAS and BRAF genes have been reported to be mutually exclusive. , In the retrospective analysis by Fariña- Sarasqueta et al. , it was also shown that the BRAF @VARIANT$ mutation was an independent prognostic factor for the survival of patients with colon cancer in stages II and III , while the KRAS mutations did not have any effect on the overall survival of these patients .", "label": "resistance or non-response"}
{"id": "22436374", "sentence": "Afatinib was more potent than @DRUG$ , erlotinib , and lapatinib in inducing the cell death of NSCLC cell lines , including those harboring wild-type @GENE$ , and the erlotinib-resistant @VARIANT$ mutation [ ] .", "label": "resistance or non-response"}
{"id": "25295095", "sentence": "To further investigate the association between LKB1 and gemcitabine , and as gemcitabine inhibited DNA synthesis and caused DNA damage , the extent of DNA damage was evaluated in LKB1 transfected , mock transfected and wild-type MDA-MB-231 cells following exposure to @DRUG$ . γH2AX is a generally accepted sensitive marker of DNA damage , and in particular DSBs . γH2AX is the phosphorylated form of H2AX , a member of the @VARIANT$ family .", "label": "None"}
{"id": "21108851", "sentence": "@DRUG$ ( AP24534 ) is a multitargeted BCR-ABL/SRC kinase inhibitor with potent in vitro activity against all tested mutants of @GENE$ including @VARIANT$ , and clinical activity has been reported in patients with a T315I mutation [ - ] .", "label": "response"}
{"id": "17973572", "sentence": "It is possible to conceive that an increase in the clinical doses of gefitinib or switching to @DRUG$ , which is given at its maximal tolerated dose [ ] , may lead to beneficial clinical effects , possibly by increasing BIM expression , in patients with @GENE$ mutations who acquired L747S after exposure to gefitinib . The data presented here indicate that BIM is both a marker and an effector of TKI induced apoptosis in EGFR-mutant NSCLC cells . Furthermore , we identified a novel acquired EGFR secondary mutation , L747S , and showed that both the L747S and the common @VARIANT$ in cis to an activating EGFR mutation ( either L858R or an exon 19 deletion ) cause resistance to EGFR TKI induced apoptosis and attenuate the up-regulation of BIM .", "label": "resistance or non-response"}
{"id": "23493883", "sentence": "Both in vivo and in vitro models have shown that @DRUG$ has increased affinity for the EGFR @VARIANT$ mutation compared to the first-generation @GENE$ .", "label": "sensitivity"}
{"id": "21464994", "sentence": "It would be interesting to study the relationship between circulating levels of @DRUG$ in patients with prolactinomas and their response to DA agonist treatment . Our study shows that the apoptosis of lactotropes induced by DA is mediated by @VARIANT$ and is an estrogen dependent process , involving p38 @GENE$ activation .", "label": "None"}
{"id": "19547661", "sentence": "BRAF ( v-raf murine sarcoma viral oncogene homolog B1 ) , a @GENE$ is the downstream effector of KRAS in the RAS-RAF-MAPK signaling pathway . A somatic mutation ( @VARIANT$ ) in exon 15 of BRAF has been identified in multiple human cancers with a mutation rate of 66 % in malignant melanomas [ ] and at lower frequency in other human carcinomas . Recently , it was demonstrated that wildtype BRAF is required for the response of patients with metastatic colorectal cancer to @DRUG$ and panitumumab [ ] .", "label": "None"}
{"id": "17973572", "sentence": "Based on the data obtained from lung cancer cell lines , we further explored the mechanisms by which @VARIANT$ and L747S resistant mutations affect BIM up-regulation and apoptosis . @DRUG$ effectively induced apoptosis in Ba/F3-L858R cells , whereas @GENE$ cells were intermediately resistant and Ba/F3-L858R-T790M completely resistant ( A , top ) .", "label": "None"}
{"id": "25465236", "sentence": "( C ) EGFR @VARIANT$ mutant does not resemble pEGFR unlike the @GENE$ L858R mutant shown in B. ( D–F ) increased inhibition potency for @DRUG$ against EGFR L858R mutant compared to EGFR WT protein and subsequent decrease in potency for Erlotinib against EGFR L858R + E884K double mutant .", "label": "resistance or non-response"}
{"id": "22098950", "sentence": "Notably , F208S and S441N were not expressed in the cells , suggesting that the rest of the variants ( @VARIANT$ , F431L , and F489L ) may also impart impaired function of @GENE$ . Another study showed that the P269S ( C.805OT , Ex7 ; rs34678167 ) and Q126Stop ( C.376OT , Ex4 ; rs72552713 ) alleles were found among Korean subjects , and that the transport activity of the P296S variant decreased based on @DRUG$ uptake by vesicles expressing this variant .", "label": "None"}
{"id": "25033171", "sentence": "In addition , we have analyzed the energetic contribution to crizotinib on residue level as well , which showed that the residue Leu18 ( located just in the P-loop region ) contributed the most to the attenuated binding of crizotinib to @GENE$ as shown in , therefore well supporting the issue that the P-loop conformation governs @DRUG$ resistance in @VARIANT$ mutated ROS1 tyrosine kinase .", "label": "resistance"}
{"id": "23566546", "sentence": "Case Histrogical type @GENE$ mutation status Brinkman index Treatment agent Response IL-8 ( ng/mL ) IL-10 ( ng/mL ) RANTES ( pg/ml ) 1 Ad Ex21 @VARIANT$ 900 gefitinib PR 5.79 1.67 2 2 Ad Ex21 L858R 0 erlotinib PR_3.33 94.2 1.41 3 Ad Ex19 del 0 erlotinib PR 4.09 126 2.13 4 Ad Ex21 L858R 0 gefitinib PR_3.92 18.1 1.85 5 Ad Ex21 L858R + Ex19 del 370 erlotinib PR 21.9 1.23 2.11 6 Ad Ex19 del 0 erlotinib PR 7.05 1.37 2.56 7 Ad Ex19 del 0 gefitinib PR 4.82 1.59 2.02 8 Ad Ex21 L858R 1640 @DRUG$ PR 54.9 2.7 2.38 9 Ad negative 400 erlotinib SD 34.9 3.39 3.66 10 Ad negative 0 erlotinib SD 27.1 4.94 2.25 11 Ad unknown 1800 erlotinib SD NE NE NE 12 Sq Ex19 del 3840 gefitinib SD 12.6 1.1 1.98 13 Ad Ex19 del 30 erlotinib SD 5.27 0.69 2.66 14 Ad Ex19 del 0 erlotinib SD 10.5 0.85 2.5 15 Ad unknown 300 erlotinib SD 7.69 2.61 1.7 16 La negative 2080 erlotinib SD NE NE NE 17 Sq Ex21 L858R 750 erlotinib SD 11.6 56.3 3.06 18 Ad unknown 600 erlotinib SD 13.7 1.1 2.82 19 Ad Ex21 L858R 0 erlotinib SD 20.6 11.6 0.783 20 Ad Ex19 del 0 erlotinib SD 14.8 2.07 2.02 21 Ad Ex21 L858R + Ex19 del 0 gefitinib SD 3.04 1.3 1.76 22 Ad Ex19 del 200 gefitinib SD 10.9 1.59 1.91 23 Sq unknown 1560 erlotinib PD NE NE NE 24 Ad negative 1080 erlotinib PD 25.2 8.15 1.57 25 Ad unknown 0 erlotinib PD NE NE NE 26 Ad Ex18 G719A 2000 erlotinib PD 11.6 4.48 3.12 27 Ad unknown 1410 erlotinib PD NE NE NE 28 Ad Ex19 del 1000 gefitinib PD 9.44 2.25 2.89 29 Ad negative 1100 erlotinib PD 56.3 5.63 2.16 30 Ad negative 2000 erlotinib PD 15.6 0.85 0.292 31 Ad negative 825 erlotinib PD 8.27 1.59 2.13 32 Ad Ex21 L858R 0 erlotinib PD 5.34 7.05 1.7 33 Ad negative 1680 erlotinib PD 57.7 1.63 2.06", "label": "sensitivity"}
{"id": "15737014", "sentence": "We show here , through molecular analysis of tumor material from three patients and one NSCLC cell line , as well as additional biochemical studies , that acquired clinical drug resistance to gefitinib or @DRUG$ is indeed associated with the @VARIANT$ mutation . Importantly , we find that the T790M mutation confers drug resistance not just to wild-type @GENE$ but also to mutant EGFRs associated with clinical responsiveness to EGFR tyrosine kinase inhibitors [ , , ] .", "label": "resistance or non-response"}
{"id": "24939055", "sentence": "The EGF receptor tyrosine kinase inhibitors ( EGFR-TKIs ) @DRUG$ and erlotinib have shown marked therapeutic effects against NSCLCs with @GENE$ activating mutations , such as exon 19 deletions and L858R point mutations [ ] . Almost all tumors , however , acquire resistance to EGFR-TKIs after varying periods of time . Common mechanisms for acquired resistance include emergence of an EGFR gatekeeper mutation ( @VARIANT$ ) and MET gene amplification [ , ] .", "label": "resistance or non-response"}
{"id": "21984124", "sentence": "Disruption of the microtubule network by chemical agents , such as nocodazole and @DRUG$ , leads to ligand independent @GENE$ nuclear accumulation and transcription of TGF-β-responsive genes . Paclitaxel is an anticancer agent which , by stabilizing polymerized microtubules and maintaining microtubular assembly , arrests the cell cycle in the G0–G1 and G2–M phases and induces cell death , .", "label": "None"}
{"id": "21573178", "sentence": "For example , we detected the @DRUG$ resistance mutation , T790M , in tumor sample 10 ( 80 % tumor cell content ) obtained at the time of relapse ( Supplementary ) and this sample also harbored the L747_S752del_P753S deletion initially detected by dideoxy sequencing ( and ) . We further found a previously undetected @VARIANT$ substitution in exon 2 of KRAS in sample 11 ( 50 % tumor cell content , Supplementary ) and confirmed this mutation by subcloning of @GENE$ exon 2 amplicons and subsequent dideoxy sequencing ( data not shown ) .", "label": "resistance or non-response"}
{"id": "19265549", "sentence": "The mRNA levels of most of these genes except for BAX decreased at the end of the first @DRUG$ infusion , 18–24 h after start of treatment . The dendrogram and heat map presentations demonstrate the consistently upregulated p53 related genes during treatment ( Figure and ) . Genes induced during the first hours of treatment also included the proliferative constellation of ATF3 ( activating transcription factor 3 ) , CREB1 ( @GENE$ ) , PCNA ( proliferating cell nuclear antigen ) and EP400 ( @VARIANT$ binding protein p400 ) .", "label": "None"}
{"id": "22500115", "sentence": "In thyroid cancer cell lines , it was shown to be effective in inhibiting RET/PTC1 and RET/PTC3 mutations in some PTCs and @VARIANT$ RET mutations in MEN2B and some sporadic MTCs . @GENE$ mutations in certain inherited forms of MTC , as in codon 804 and 806 , seem to confer resistance to vandetanib. ,", "label": "response"}
{"id": "23621958", "sentence": "However , clinical trials with these agents revealed that in most cases , responders harbored specific activating mutations in exons 18–21 which collectively encode the kinase domain of the @GENE$ gene [ - ] . The majority of mutations that have been associated with sensitivity to @DRUG$ and erlotinib are located in exon 19 ( 45 % ) and exon 21 ( 40–45 % ) , although ~5 % are located in exon 18 and & lt ; 1 % in exon 20 [ ] . In addition , certain mutations in exon 20 , such as @VARIANT$ , predict resistance to these TKIs [ ] .", "label": "resistance or non-response"}
{"id": "25048790", "sentence": "( C ) Proliferation assay of MCF7 cells treated with 10 μM DIM with or without @DRUG$ @DRUG$ @DRUG$ . ( D ) Proliferation assay of MCF7 cells treated with 10 μM DIM with or without H89 . In order to further confirm the effects of DIM on the cell cycle , we performed cell cycle assays using flow cytometry ( FACS ) in @VARIANT$ cells ( Additional file : Figure @GENE$ ) .", "label": "None"}
{"id": "19238210", "sentence": "The resistant cell line category was the largest and included two mEGFR cell lines , one having the secondary @VARIANT$ mutation and the other having homozygous deletion of PTEN gene . The remaining resistant lines included all of the wild type lines and all lines having KRAS , BRAF , HER2 , HER4 and PIK3CA mutations . Using univariate tests , we analyzed the association between gefitinib sensitivity and mutational status or CNGs of the various EGFR pathway genes and found a significant correlation between @DRUG$ sensitivity with EGFR mutation ( p = 0.002 ) and @GENE$ copy number gains ( p = 0.001 ) .", "label": "resistance or non-response"}
{"id": "19369254", "sentence": "These mutant proteins ( Q83A , E84A , @VARIANT$ ) also rescued the impairments of NCT maturation and PS1 endoproteolysis in APH1 knock-out fibroblasts , indicating that they are functionally active . These findings support the conclusion that the TM3 polar residues are not essential for @GENE$ incorporation into the γ-secretase complex . However , two conserved @DRUG$ residues located on TM5 , His-171 , and TM6 , His-197 , were also investigated and had more pronounced effects .", "label": "None"}
{"id": "20300583", "sentence": "In the one case of discordance between KRAS mutation status before and after combined @DRUG$ therapy ( case # 4 ) , a mutated KRAS gene ( Exon 2 @VARIANT$ ) was found in the primary CRC , while no @GENE$ mutation was observed in a liver metastasis sample obtained after combined cetuximab therapy ( ) .", "label": "sensitivity"}
{"id": "19707322", "sentence": "The sensitivity of Bcr-Abl mutants to @DRUG$ can be summarized into 4 categories : high ( IC50 ≤ 70 nmol/L : M244V , G250E , Q252H , F3llL , F317L , M351T , V379I , L387M , @VARIANT$ , H396R ) , medium ( IC50 ≤ 200 nmol/L : Y253F , E255K , F359V ) , low ( IC50 ≤ 450 nmol/L : Y253H , E255V ) , and insensitive ( IC50 & gt ; 2 μmol/L : T315I ) ( ) ( ) .", "label": "None"}
{"id": "19654571", "sentence": "Based on this assumption , the inhibition of the EGFR/HER2 @GENE$ by anti-EGFR ( @DRUG$ ) and anti-HER2 ( trastuzumab ) MAbs should interfere with @VARIANT$ cell proliferation .", "label": "None"}
{"id": "22846499", "sentence": "In patients with metastatic melanoma featuring BRAF @VARIANT$ mutation , phase 1 and 2 clinical trials of the @GENE$ kinase inhibitor vemurafenib ( @DRUG$ ) have shown response rates of more than 50 % [ ] .", "label": "None"}
{"id": "25122428", "sentence": "The dual inhibition of PI3K and mTOR might be advantageous over single inhibition by suppressing a @VARIANT$ feedback loop that leads to the pathway reactivation . Based on this idea , an on-going phase I study of the PI3K and mTORC1/2 dual inhibitor , BEZ235 , was designed for the patients with advanced solid tumors harboring @GENE$ or PTEN alteration ( NCT01195376 ) . In this study , we showed that the survival of the cisplatin-resistant SCLC cell lines was well suppressed by BEZ235 , accompanied by the suppression of S6RP phosphorylation .", "label": "None"}
{"id": "17973572", "sentence": "Bottom : Expression of EGFR in @GENE$ cells expressing @VARIANT$ , L858R-L747S #1–4 , or L858R-T790M . ( E ) @DRUG$ release assay .", "label": "None"}
{"id": "24594844", "sentence": "We also demonstrated that cDzT and @DRUG$ functioned in a synergistic manner against @GENE$ signaling pathways to suppress the growth of EGFR @VARIANT$ harboring NSCLC cells .", "label": "response"}
{"id": "24155950", "sentence": "The sensitivity of K562 , K562-R , LAMA84 , LAMA84-R , Baf3 @GENE$ , and Baf3 Bcr-Abl @VARIANT$ cell lines to the most used Bcr-Abl inhibitors in CML : imatinib , @DRUG$ ( Santa Cruz Biotechnology , CA , USA , Cat. # sc-218081 ) and nilotinib ( Santa Cruz Biotechnology , CA , USA , Cat. # sc-202245 ) was investigated by treating these cells with increasing concentrations of each drug and measuring cell death using an automated Trypan Blue exclusion method ( see ) .", "label": "None"}
{"id": "25532027", "sentence": "In particular , epidermal growth factor receptor-tyrosine kinase inhibitors ( @GENE$ ) , such as @DRUG$ and erlotinib , demonstrated marked clinical activity against NSCLC harboring an activating EGFR mutation ( – ) . Additionally , some reports suggest that the EGFR @VARIANT$ mutation may not be rare and may exist in a small population of in tumor cells before TKI treatment ( – ) .", "label": "resistance or non-response"}
{"id": "24623981", "sentence": "Second-generation TKIs that irreversibly inhibit the @GENE$ TKI domain may offer the potential for overcoming the resistance of @VARIANT$ mutation to @DRUG$ and gefitinib .", "label": "resistance or non-response"}
{"id": "25119470", "sentence": "However , factor V Leiden , @GENE$ @VARIANT$ , and the MTHFR mutation are either absent or irrelevant in the Asian population , – . Because the etiologies of ONFH are miscellaneous , most genetic association studies on ONFH segregated their patients into different subgroups based on the risk factors ( e.g. , @DRUG$ , steroids , and smoking ) .", "label": "None"}
{"id": "24386407", "sentence": "Recent clinical trials have shown that progression-free survival ( PFS ) in patients with EGFR mutant lung cancer is prolonged by treatment with a reversible EGFR-TKI and the irreversible @GENE$ @DRUG$ , which was designed to covalently bind to EGFR [ - ] . Nevertheless , almost all responders relapse after acquiring resistance to these EGFR-TKIs [ , ] . Among the mechanisms by which cancer cells become resistant to reversible EGFR-TKIs are 1 ) gatekeeper mutations in EGFR , such as the @VARIANT$ second mutation [ , ] ; 2 ) activation of bypass signaling caused by Met amplification [ ] , hepatocyte growth factor (HGF) overexpression [ ] , or Gas6-Axl activation [ ] ; 3 ) activation of downstream molecules ( PTEN loss or PIK3CA mutation ) [ , ] ; 4 ) small-cell lung cancer transformation [ ] ; and 5 ) epithelial-to-mesenchymal transition [ ] .", "label": "response"}
{"id": "25563357", "sentence": "The @VARIANT$ mutation is known to mediate secondary resistance to @GENE$ TKIs [ ] , yet there is evidence that it can be detected even before treatment with @DRUG$ or gefitinib when a high sensitivity method of detection is applied [ ] .", "label": "resistance or non-response"}
{"id": "24787964", "sentence": "As the theoretical advantage of afatinib versus the first-generation @GENE$ did not translate into progression-free survival gains , maybe the clinical relevance of possible inhibition of @VARIANT$ is minimal , at least in the first-line setting , when T790M positive clones are rarely detected . A limitation of our study is the indirect comparison of @DRUG$ , erlotinib , and afatinib with one another , which relies on the quality of variance component estimates .", "label": "resistance or non-response"}
{"id": "24996221", "sentence": "SPC-A1 cells overexpressing HMGB1 showed no distinct change in the level of phosphor-Akt ( Ser473 ) , phosphor-mTOR ( Ser2448 ) , phosphor-S6RP ( Additional file : Figure S4A ) , nor did the docetaxel-resistant SPC-A1/DTX cells transfected with HMGB1 shRNA ( Additional file : Figure S4B ) . Suppression of mTORC1 activity is considered as a crucial step in the initiation of autophagy [ ] . Additionally , rapamycin , a specific inhibitor of @GENE$ [ ] , enhanced the accumulation of LC3-II in SPC-A1 cells transfected with the control vector but not in cells transfected with HMGB1 shRNA ( Additional file : Figure @VARIANT$ ) .", "label": "None"}
{"id": "24789720", "sentence": "The new therapy methods , which could be effective in patients with @VARIANT$ mutation includes irreversible EGFR-TKIs ( afatinib , neratinib ) . In LUX-Lung 1 study in patients after failure of erlotinib or @DRUG$ treatment with afatinib led to partial responses and prolongation of progression-free survival compared to placebo to 3,3 months [ , ] . Recently the studies are conducted with combining of irreversible @GENE$ and monoclonal antibody against extracellular domain of EGFR – cetuximab .", "label": "resistance or non-response"}
{"id": "24623980", "sentence": "Two secondary mutations of ALK associated with @DRUG$ resistance – L1196M and @VARIANT$ – were first detected in the same patient , who relapsed after achieving a partial response to the drug . The L1196M substitution occurs at the gatekeeper position of ALK ( a position that controls the binding of nucleotides and TKIs ) , and corresponds to the T790M substitution in EGFR and the T315I substitution in the @GENE$ fusion protein , both of which confer resistance to corresponding TKIs .", "label": "None"}
{"id": "15736989", "sentence": "The mechanism of resistance in three patients was acquisition of a @VARIANT$ substitution in @GENE$ that was not present at time of diagnosis , but was detected with progression of disease after initial response to gefitinib or @DRUG$ .", "label": "resistance or non-response"}
{"id": "21264348", "sentence": "Finally , in a combination experiment , hydrogen exchange in the @VARIANT$ protein in the presence of both dasatinib and GNF-5 demonstrated changes in exchange near the ATP site that were nearly the same as those seen when dasatinib bound to wild-type @GENE$ . Taken together , the results provide evidence for allosteric communication between the two sites and indicate that the factors leading to @DRUG$ resistance are somehow overcome by simultaneous binding of GNF-5 some 25 Å away .", "label": "None"}
{"id": "22655263", "sentence": "Ki determination demonstrated a very similar biochemical potency on wild-type ALK and the @VARIANT$ ALK mutant ( 0.09 and 0.08 nM respectively ) , with both cellular and in vivo data ( using engineered Ba/F3 cells ) indicating that growth of ALK–L1196M mutant driven-cells is inhibited at similar , albeit slightly higher , doses which inhibit cells harboring wild-type @GENE$ ( Katayama et al. , ) . AP26113 was also described to be active on a series of in vitro induced @DRUG$ resistant mutations , which however have not been observed to date in clinical cases of acquired crizotinib resistance ( Zhang et al. , ) .", "label": "resistance"}
{"id": "20694077", "sentence": "However , the T315I mutant remained resistant to nilotinib at concentrations & lt ; 10 μM. , @DRUG$ also potently inhibited tyrosine autophosphorylation of the E255K , E255V , F317L , @VARIANT$ , and F486S @GENE$ mutants , and these effects were not associated with decreases in Abl or Bcr-Abl protein levels .", "label": "None"}
{"id": "25033171", "sentence": "The same well equilibrated structures of WT and @VARIANT$ mutated @GENE$ complexes as those used in metadynamics simulations were employed as the initial structures for the US and ABF simulations .", "label": "resistance"}
{"id": "22436374", "sentence": "Afatinib was more potent than gefitinib , erlotinib , and lapatinib in inducing the cell death of NSCLC cell lines , including those harboring wild-type @GENE$ , and the erlotinib-resistant @VARIANT$ mutation [ ] .", "label": "resistance or non-response"}
{"id": "22994622", "sentence": "Therefore , the low KRAS mutation frequency of HNSCC may cause difficulty in predicting the effect of @DRUG$ and other EGFR inhibitors . We analyzed exon 15 of @GENE$ to search for a @VARIANT$ substitution , the most common activating mutation of BRAF , which is observed at high frequencies in various cancers [ ] .", "label": "resistance or non-response"}
{"id": "23299535", "sentence": "A similar theme exists in NSCLCs with a mutation in the EGFR – secondary mutations confer insensitivity to the @GENE$ tyrosine kinase inhibitor ( EGFR-TKI ) @DRUG$ , and have been identified in patients with clinical resistance to gefitinib , but also in untreated patients ( ) . analysed NSCLC samples for one such mutation in EGFR , the @VARIANT$ mutation , from treatment-naïve patients , and from patients before and during treatment with EGFR-TKIs .", "label": "resistance or non-response"}
{"id": "22655263", "sentence": "X-296/X-396 ( Xcovery ) are aminopyridazine based ALK kinase inhibitors which display good anti-tumor activity in vitro and in vivo on different @GENE$ dependent tumor models . X-396 was also evaluated on L1196M and @VARIANT$ mutations and data suggest that it can potentially overcome at least these @DRUG$ resistance mutations .", "label": "resistance"}
{"id": "22666783", "sentence": "KRAS is downstream in the @GENE$ tyrosine kinase pathway ; therefore , tyrosine kinase based treatment with @DRUG$ and erlotinib is ineffective when KRAS is constitutively activated ( , ) . EGFR mutations occur most frequently in exons 18 to 21 . The most common mutations , small in-frame deletions in exon 19 ( & gt ; 50 % ) and @VARIANT$ substitutions in exon 21 ( 40 % ) , are reported to be the most closely associated with EGFR inhibitor therapy response ( , ) .", "label": "sensitivity"}
{"id": "24223799", "sentence": "Thus , our results may apply to patients with acquired resistance to a combination of @DRUG$ and tivantinib , as our cells demonstrate decreased sensitivity to tivantinib . Previous studies have shown that an EGFR @VARIANT$ mutation is the primary cause of resistance and many have focused on developing irreversible TKIs against @GENE$ that would prevent or maintain efficacy against the T790M mutation .", "label": "resistance or non-response"}
{"id": "24348666", "sentence": "The presence of a secondary mutation of the @GENE$ gene in the T790M was reported in 2005 . The threonine residue 790 is known as the `` gatekeeper residue '' and is located in the ATP binding site , adjacent to the catalytic cleft of the kinase domain . It was initially proposed that the T790M mutation might prevent the proper binding of tyrosine kinase inhibitors via steric hindrance , similar to the corresponding gatekeeper mutations in BCR-ABL ( @VARIANT$ ) and KIT ( T670I ) that confer resistance to imatinib ( @DRUG$ ) in chronic myelogenous leukemia and in patients with gastrointestinal stromal tumors .", "label": "None"}
{"id": "25349473", "sentence": "Response rates were similar for those with and without mutant @GENE$ , with MCyR occurring in 56 % of all patients , 49 % of patients with native BCR-ABL , 64 % for those with one mutation , 62 % for those with two or more mutations , and 74 % for those with the @VARIANT$ mutant . Though no single point mutation has shown resistance against @DRUG$ , compound mutations developed in 21 patients , mainly those in BC-CML or Ph+ALL .", "label": "response"}
{"id": "24419415", "sentence": "Progression-free survival curves in the gefitinib group ( A ) and the carboplatin-paclitaxel group ( B ) according to the type of @GENE$ . DISCUSSION Recent studies suggest that NSCLC patients with uncommon EGFR mutations are less responsive to EGFR-TKIs compared with patients with @VARIANT$ and exon 19 deletions.– However , the efficacy of EGFR-TKIs in NSCLC patients with uncommon mutations has not been fully elucidated .", "label": "None"}
{"id": "24634705", "sentence": "Afatinib , an EGFR and HER2 irreversible inhibitor has been shown to reverse the effects of the @VARIANT$ mutation in preclinical lung cancer studies [ ] . In clinical trials , afatinib did not improve overall survival but showed a modest improvement in progression free survival after failure of erlotinib or @DRUG$ [ , ] . Several drawbacks are associated with these irreversible @GENE$ .", "label": "resistance or non-response"}
{"id": "23637779", "sentence": "UT-7/Epo , BaF-3 hKit WT and BaF-3 hKit @VARIANT$ cultivated with Epo ( 1 UI/ml ) or IL3 ( 1 ng/ml ) were incubated 4 h with 2 µM @DRUG$ or 5 µM sorafenib or vehicle or stimulated 10 minutes with 50 ng/mL SCF . A. Cell surface expression of c-Kit by flow cytometry using @GENE$ antibody ( black line ) compared to isotypic antibody ( grey line ) .", "label": "resistance"}
{"id": "25505733", "sentence": "Activating mutations are significantly associated with response to @GENE$ TKIs , with @DRUG$ , gefitinib , and afatinib established as initial standard therapy . However , resistance mutations have been identified , such as @VARIANT$ in exon 20 .", "label": "resistance or non-response"}
{"id": "11237392", "sentence": "We chose 2 inhibitors which would affect all pathways downstream of @GENE$ ( simvastatin and @DRUG$ ) and a third inhibitor which should primarily affect the Ras-Raf-MEK-ERK pathway by depleting Raf ( 17-AAG ) . Whereas the spectrum of NIH 3T3 cells was not affected by treatment , @VARIANT$ cells showed a drop in PC levels after treatment .", "label": "None"}
{"id": "23606169", "sentence": "Patients with the KRAS @VARIANT$ mutation , treated with @DRUG$ ( Erbitux ) had stabilization for a short period , and then novel metastatic foci occurred with KRAS mutated in the same codon 12 . Therefore , we might conclude that outcome of personalized treatment is highly associated with tumor heterogeneity observed in patients because the detected mutation was probably present in only 5 % of tumor cells . In the case of patient no. 39 , during the targeted @GENE$ treatment , it came to the selection of KRAS G12C cells ( which were present from the beginning in the tumor but at a low level of around 5 % , Fig. a ) and in consequence to the metastasis ( Fig. b ) .", "label": "None"}
{"id": "23145123", "sentence": "A. Selection of PC9 cells in media containing increasing concentrations of @DRUG$ resulted in the PC9-ER line , which is unaffected by doses of erlotinib up to 1 µM . B. The IL3 independent Ba/F3 clone 1C8 recovered by cDNA library screening of PC9-ER cells contains both the Δex19 activating mutation and the @VARIANT$ mutation in @GENE$ .", "label": "resistance or non-response"}
{"id": "20102612", "sentence": "Retinoic acid significantly mitigates the apoptosis induced by chemotherapeutic agents in @VARIANT$ and ZR-75-1 cells , while it is able to increase apoptosis by these compounds in H3396 cells where @DRUG$ not induce cIAP2 expression . Many antiapoptotic proteins , such as Bcl-2 , Mcl-1 and Bcl-XL , have been shown to inhibit chemotherapeutic agent induced apoptosis in diverse cell system models including hematopoietic and neuroblastoma cells . Additionally , it has been shown that the activation of genes encoding TRAF and @GENE$ proteins by NF-κB serves to block apoptosis promoted by different insults including chemotherapy induced apoptosis in different cell types [ , ,, ] .", "label": "None"}
{"id": "24495353", "sentence": "Rank Entrez ID Gene symbol Entrez ID Gene symbol Entrez ID Gene symbol 1 28978 TMEM14A 79776 ZFHX4 1727 CYB5R3 2 1843 DUSP1 4701 NDUFA7 7083 TK1 3 51022 GLRX2 715 @VARIANT$ 1292 COL6A2 4 1434 CSE1L 79818 ZNF552 857 CAV1 5 8522 GAS7 4046 LSP1 5437 POLR2H 6 51668 HSPB11 1727 CYB5R3 9833 MELK 7 10456 HAX1 357 SHROOM2 54861 SNRK 8 9902 MRC2 283298 OLFML1 4830 NME1 9 4706 NDUFAB1 23179 RGL1 231 AKR1B1 10 23560 GTPBP4 1809 DPYSL3 10418 SPON1 11 79633 FAT4 857 CAV1 2350 FOLR2 12 10418 SPON1 274 BIN1 10979 FERMT2 13 471 ATIC 79833 GEMIN6 11096 ADAMTS5 14 6403 SELP 11222 MRPL3 4638 MYLK 15 23421 ITGB3BP 23244 PDS5A 9448 MAP4K4 16 23452 ANGPTL2 6241 RRM2 54922 RASIP1 17 54861 SNRK 1289 COL5A1 6934 @GENE$ 18 2034 EPAS1 8434 RECK 4072 EPCAM 19 30008 EFEMP2 429 ASCL1 4701 NDUFA7 20 25999 CLIP3 3426 CFI 404672 GTF2H5 21 4311 MME 332 BIRC5 6241 RRM2 22 4747 NEFL 2 A2M 2192 FBLN1 23 1809 DPYSL3 10730 YME1L1 25959 KANK2 24 28998 MRPL13 11130 ZWINT 55651 NHP2 25 25959 KANK2 1292 COL6A2 5050 PAFAH1B3 Lists of the top 25 of most influential genes in influence networks based on coexpression among genes in ER + breast tumors before , during , and after a course of neoadjuvant treatment with the drug @DRUG$ .", "label": "None"}
{"id": "19758442", "sentence": "The region important for interaction with the Cul5 @GENE$ marked in green and includes a conserved histidine-cysteine-cysteine-histidine motif and a suppressor of cytokine signaling Box domain . The scale at the bottom indicates amino acid positions . The structural determination of full-length @VARIANT$ has so far been unsuccessful .", "label": "None"}
{"id": "22382702", "sentence": "Furthermore , De Roock and colleagues recently reported that chemotherapy-refractory metastatic colorectal cancers harboring a @VARIANT$ KRAS mutation were more sensitive to treatment with the epidermal growth factor receptor (EGFR) inhibitor @DRUG$ compared to tumors with other @GENE$ mutations [ ] .", "label": "resistance or non-response"}
{"id": "19238632", "sentence": "H1975 cell line was chosen because it expresses the ‘gatekeeper'-resistant T790M-EGFR mutation ( in-cis with @VARIANT$ ) in the receptor kinase domain hydrophobic pocket , representing a major mechanism of resistance to reversible @GENE$ ( erlotinib/gefitinib ) ( ; ) .", "label": "sensitivity"}
{"id": "21605429", "sentence": "The PDGFRA exon @GENE$ mutant activates PDGFRA both in vitro and in vivo [ , ] and is also imatinib resistant in vivo and in vitro [ , , ] , whereas other mutations affecting exon 18 ( D846Y , @VARIANT$ , Y849K and HDSN845-848P ) are @DRUG$ sensitive [ ] .", "label": "None"}
{"id": "22655263", "sentence": "When tested in Ba/F3 cells driven by ALK mutants identified in @DRUG$ relapsed patients , NMS-E628 is circa fivefold more potent than crizotinib in inhibiting the proliferation of L1196M @GENE$ and @VARIANT$ ALK-driven-cells in vitro and in vivo ( Ardini et al. , ) .", "label": "resistance"}
{"id": "24121633", "sentence": "Based on our data , we hypothesized that PRR of hnRNP L binds to PTB and cooperatively suppresses inclusion of exon @VARIANT$ . We thus examined the role of PRR of hnRNP L on the interaction with PTB . Histidine tagged hnRNP L ( His-L ) , its PRR deleted variant ( His-L-ΔPRR ) , histidine tagged hnRNP LL ( His-LL ) , and its PRR inserted variant ( His-LL-PRR ) were expressed in SH-SY5Y cells , and they were immunoprecipitated with anti-histidine antibody in the presence of @GENE$ .", "label": "None"}
{"id": "21333004", "sentence": "Overexpression of wild type EGFR induced high and sustained phosphorylation of EGFR , Shc , MEK ( mitogen activated protein kinase kinase ) and ERK ( extracellular signal regulated kinase ) , while the @VARIANT$ mutation reduced these response levels . In addition , H1299L858R , which is supposed to be more sensitive to @DRUG$ than H1299EGFR-WT , was effectively inhibited by gefitinib administration at the downstream part of the signaling pathway ( MEK and ERK ) compared with H1299EGFR-WT , but , surprisingly , not at the upstream part of the pathway ( EGFR and @GENE$ ) .", "label": "None"}
{"id": "24920920", "sentence": "In 40 patients harboring @VARIANT$ , five revealed complex mutations , including two with T790M . In 61 patients with @GENE$ TKI as first-line therapy , 46 received @DRUG$ , 13 received erlotinib , and two received afatinib .", "label": "sensitivity"}
{"id": "24121633", "sentence": "Based on our data , we hypothesized that PRR of hnRNP L binds to PTB and cooperatively suppresses inclusion of exon @VARIANT$ . We thus examined the role of PRR of hnRNP L on the interaction with PTB . Histidine tagged hnRNP L ( His-L ) , its PRR deleted variant ( His-L-ΔPRR ) , histidine tagged hnRNP LL ( His-LL ) , and its PRR inserted variant ( @GENE$ ) were expressed in SH-SY5Y cells , and they were immunoprecipitated with anti-histidine antibody in the presence of RNase .", "label": "None"}
{"id": "15736989", "sentence": "For example , imatinib is effective in treatment of chronic myelomonocytic leukemia with gene rearrangements that constitutively activate PDGFRB [ ] , of hypereosinophilic syndrome with activating mutations in PDGFRA [ ] , and of gastrointestinal stromal cell tumors associated with activating mutations in @GENE$ [ ] ( all reviewed in [ ] ) . More recently , this paradigm has been extended to treatment of non-small cell lung cancer ( NSCLC ) . Several mutations have been identified in the context of epidermal growth factor receptor (EGFR) in patients with NSCLC that are associated with clinical response to the small-molecule EGFR inhibitors gefitinib ( Iressa ) or erlotinib ( @DRUG$ ) [ , , ] , including in-frame deletions such as del L747–E749 ; @VARIANT$ in exon 19 , or L858R in exon 21 .", "label": "None"}
{"id": "18923525", "sentence": "The F1245C mutation corresponds to L833V in EGFR , a gefitinib-resistant mutation in lung cancer ( Greulich & amp ; Meyerson , unpublished observations ) . The R1275Q mutation is located adjacent to L858R in EGFR , which is the most common EGFR mutation in lung cancer , . The functional consequences of four of the mutations , T1151M , F1174L , @VARIANT$ , and R1275Q , were determined by testing their abilities to transform interleukin-3 (IL-3) dependent murine lymphoid @GENE$ cells to cytokine independent growth .", "label": "None"}
{"id": "21716602", "sentence": "Other examples of addiction dependent on tumor suppressor genes are the loss of @GENE$ and pRB , which lead to the stimulation of PI3K/mTOR ( Neshat et al. , ) and E2F ( Sellers and Kaelin , ) , respectively . Those defects consequently render tumor cells particularly sensitive to mTOR inhibitors and @DRUG$ ( which inhibits @VARIANT$ activated topoisomerase II ) .", "label": "None"}
{"id": "22809298", "sentence": "Consequently , administrating intermittent @DRUG$ with pemetrexed was shown to be safe and tolerable . When evaluated on the basis of RECIST two @GENE$ mutated patients did not respond in our study . However , one patient with a @VARIANT$ mutation in exon 21 practically achieved a PR .", "label": "sensitivity"}
{"id": "21192840", "sentence": "Tumor type @GENE$ mutation EGFR expression changes EGFR targeting agents ( FDA approved for clinical use ) Resistance mechanisms Non-small cell lung cancer Kinase domain deletions ( exon 19 ) , point mutations ( exon 21 ) Gene amplification Erlotinib , Gefitinib @VARIANT$ gatekeeper mutation ( 50 % ) , , elevated c-Met/HGF expression ( 20 % ) – Colorectal cancer ( metastatic ) Rare , Overexpression , copy number increase @DRUG$ , Panitumumab K-ras– , B-raf , PIK3CA , PTEN mutations", "label": "response"}
{"id": "PMC4041556", "sentence": "Resistance mechanisms to @DRUG$ are multiple , and include @GENE$ mechanisms such as resistance mutations and copy number gain , and ALK non-dominant mechanisms through the outgrowth of clones containing a separate activated oncogene . In contrast to the EGFR setting , where the @VARIANT$ mutation predominates , the spectrum of ALK resistance mutations is broad .", "label": "None"}
{"id": "21333004", "sentence": "The inhibitory effects of Mig6 and @DRUG$ are indicated by red lines . E11 : EGFR homodimer ; ShcP : free phosphorylated Shc ; E11P : phosphorylated EGFR homodimer ; Raf1A : activated Raf1 ; MEKP : singly phosphorylated MEK ; MEKPP : doubly phosphorylated @GENE$ ; ERKP : singly phosphorylated ERK ; ERKPP : doubly phosphorylated ERK . To investigate cell-specific EGFR signaling dynamics , we constructed an H1299WT model ( WT model ) , an H1299EGFR-WT model ( EGFR-WT model ) , and two alternate H1299L858R models ( @VARIANT$ model A with Mig6 overexpression and L858R model B with Cbl overexpression ) .", "label": "None"}
{"id": "24939055", "sentence": "Although irreversible EGFR-TKIs , including BIBW2992 , have been developed to overcome @VARIANT$ mediated resistance to @DRUG$ [ ] , recent clinical trials have failed to show that monotherapy with irreversible @GENE$ has benefits in patients with NSCLC refractory to gefitinib [ ] .", "label": "resistance or non-response"}
{"id": "23847534", "sentence": "Further differentiation of iPSC derived definitive endoderm cells within transwell plates , by addition of @GENE$ @DRUG$ produced layers of cells with developing spheroid structures at Stage 2 in many of the iPSC lines ( Figure , top row ) . CDX2 expression at Stage 2 was relatively uniform within layers of cells differentiating in transwells ( Figure , bottom row ) . However , @VARIANT$ showed more intense expression around spheroid structures .", "label": "None"}
{"id": "23788917", "sentence": "EGFR TKI , which are effective for the @VARIANT$ mutation of the EGFR gene , may also prove to be effective in patients with mutations in exon 20 of the HER2 gene , but only if they have the ability to block the function of the tyrosine kinase associated with both EGFR and HER2 . A double reversible inhibitor of @GENE$ and HER2 receptors called lapatinib has not shown efficacy in this case . However , irreversible inhibitors , such as @DRUG$ and neratinib , which additionally have a likely inhibition effect on the HER4 tyrosine kinase , may be effective in the case of mutations in both genes .", "label": "response"}
{"id": "23566546", "sentence": "Case Histrogical type EGFR mutation status Brinkman index Treatment agent Response IL-8 ( ng/mL ) @GENE$ ( ng/mL ) RANTES ( pg/ml ) 1 Ad Ex21 @VARIANT$ 900 gefitinib PR 5.79 1.67 2 2 Ad Ex21 L858R 0 erlotinib PR_3.33 94.2 1.41 3 Ad Ex19 del 0 erlotinib PR 4.09 126 2.13 4 Ad Ex21 L858R 0 gefitinib PR_3.92 18.1 1.85 5 Ad Ex21 L858R + Ex19 del 370 erlotinib PR 21.9 1.23 2.11 6 Ad Ex19 del 0 erlotinib PR 7.05 1.37 2.56 7 Ad Ex19 del 0 gefitinib PR 4.82 1.59 2.02 8 Ad Ex21 L858R 1640 gefitinib PR 54.9 2.7 2.38 9 Ad negative 400 erlotinib SD 34.9 3.39 3.66 10 Ad negative 0 erlotinib SD 27.1 4.94 2.25 11 Ad unknown 1800 @DRUG$ SD NE NE NE 12 Sq Ex19 del 3840 gefitinib SD 12.6 1.1 1.98 13 Ad Ex19 del 30 erlotinib SD 5.27 0.69 2.66 14 Ad Ex19 del 0 erlotinib SD 10.5 0.85 2.5 15 Ad unknown 300 erlotinib SD 7.69 2.61 1.7 16 La negative 2080 erlotinib SD NE NE NE 17 Sq Ex21 L858R 750 erlotinib SD 11.6 56.3 3.06 18 Ad unknown 600 erlotinib SD 13.7 1.1 2.82 19 Ad Ex21 L858R 0 erlotinib SD 20.6 11.6 0.783 20 Ad Ex19 del 0 erlotinib SD 14.8 2.07 2.02 21 Ad Ex21 L858R + Ex19 del 0 gefitinib SD 3.04 1.3 1.76 22 Ad Ex19 del 200 gefitinib SD 10.9 1.59 1.91 23 Sq unknown 1560 erlotinib PD NE NE NE 24 Ad negative 1080 erlotinib PD 25.2 8.15 1.57 25 Ad unknown 0 erlotinib PD NE NE NE 26 Ad Ex18 G719A 2000 erlotinib PD 11.6 4.48 3.12 27 Ad unknown 1410 erlotinib PD NE NE NE 28 Ad Ex19 del 1000 gefitinib PD 9.44 2.25 2.89 29 Ad negative 1100 erlotinib PD 56.3 5.63 2.16 30 Ad negative 2000 erlotinib PD 15.6 0.85 0.292 31 Ad negative 825 erlotinib PD 8.27 1.59 2.13 32 Ad Ex21 L858R 0 erlotinib PD 5.34 7.05 1.7 33 Ad negative 1680 erlotinib PD 57.7 1.63 2.06", "label": "None"}
{"id": "24294007", "sentence": "On the other hand , a number of studies have demonstrated no benefit for either cetuximab or @DRUG$ by specific @GENE$ mutations . Although the preclinical work delineating different KRAS mutations is promising , prospective , multicenter clinical studies are required to recruit the numbers of patients necessary for the validation of @VARIANT$ and other mutations in KRAS as positive biomarkers of response to EGFR targeted therapies .", "label": "None"}
{"id": "23566546", "sentence": "Case Histrogical type @GENE$ mutation status Brinkman index Treatment agent Response IL-8 ( ng/mL ) IL-10 ( ng/mL ) RANTES ( pg/ml ) 1 Ad Ex21 @VARIANT$ 900 gefitinib PR 5.79 1.67 2 2 Ad Ex21 L858R 0 erlotinib PR_3.33 94.2 1.41 3 Ad Ex19 del 0 erlotinib PR 4.09 126 2.13 4 Ad Ex21 L858R 0 gefitinib PR_3.92 18.1 1.85 5 Ad Ex21 L858R + Ex19 del 370 erlotinib PR 21.9 1.23 2.11 6 Ad Ex19 del 0 erlotinib PR 7.05 1.37 2.56 7 Ad Ex19 del 0 gefitinib PR 4.82 1.59 2.02 8 Ad Ex21 L858R 1640 gefitinib PR 54.9 2.7 2.38 9 Ad negative 400 erlotinib SD 34.9 3.39 3.66 10 Ad negative 0 erlotinib SD 27.1 4.94 2.25 11 Ad unknown 1800 erlotinib SD NE NE NE 12 Sq Ex19 del 3840 gefitinib SD 12.6 1.1 1.98 13 Ad Ex19 del 30 @DRUG$ SD 5.27 0.69 2.66 14 Ad Ex19 del 0 erlotinib SD 10.5 0.85 2.5 15 Ad unknown 300 erlotinib SD 7.69 2.61 1.7 16 La negative 2080 erlotinib SD NE NE NE 17 Sq Ex21 L858R 750 erlotinib SD 11.6 56.3 3.06 18 Ad unknown 600 erlotinib SD 13.7 1.1 2.82 19 Ad Ex21 L858R 0 erlotinib SD 20.6 11.6 0.783 20 Ad Ex19 del 0 erlotinib SD 14.8 2.07 2.02 21 Ad Ex21 L858R + Ex19 del 0 gefitinib SD 3.04 1.3 1.76 22 Ad Ex19 del 200 gefitinib SD 10.9 1.59 1.91 23 Sq unknown 1560 erlotinib PD NE NE NE 24 Ad negative 1080 erlotinib PD 25.2 8.15 1.57 25 Ad unknown 0 erlotinib PD NE NE NE 26 Ad Ex18 G719A 2000 erlotinib PD 11.6 4.48 3.12 27 Ad unknown 1410 erlotinib PD NE NE NE 28 Ad Ex19 del 1000 gefitinib PD 9.44 2.25 2.89 29 Ad negative 1100 erlotinib PD 56.3 5.63 2.16 30 Ad negative 2000 erlotinib PD 15.6 0.85 0.292 31 Ad negative 825 erlotinib PD 8.27 1.59 2.13 32 Ad Ex21 L858R 0 erlotinib PD 5.34 7.05 1.7 33 Ad negative 1680 erlotinib PD 57.7 1.63 2.06", "label": "sensitivity"}
{"id": "23109866", "sentence": "The tumor cells harboring either C1156Y or L1196M mutations had a very low response to @GENE$ inhibitors . L1196M mutant cells were more resistant to @DRUG$ than @VARIANT$ mutant cells .", "label": "resistance"}
{"id": "25077070", "sentence": "ADC Mutations in @VARIANT$ , K57N and D67N AZD6244 , Pimasertib , Refametinib , others @GENE$ Not distinctive 2-4 % Mixed reports Not distinctive ADC and SqCC Mutations in E545K AND H1047R ( most common ) , also E542K and H1047L @DRUG$ , Tensirolimus , GDC-0941 , XL-147 , Others", "label": "None"}
{"id": "23238683", "sentence": "In the present study , we took advantage of the availability of these cell lines to evaluate the effect of @DRUG$ in comparison to other TKIs on cell metabolism , proliferation and apoptosis . In addition , we used the murine BaF3 cell line carrying either a wild-type @GENE$ protein or its @VARIANT$ and G250E mutated counterparts to decipher the mechanisms of action of this TKI .", "label": "response"}
{"id": "25285017", "sentence": "D761Y from exon 19 mutation occurs in the middle of the helix αC and forms a salt bridge that interacts with the α- and β-phosphates when ATP is present , reducing sensitivity of the @GENE$ to TKIs . @VARIANT$ mutation in exon 21 interferes the contact of @DRUG$ to the ATP pocket of the receptor , hence abrogating the inhibition of tyrosine phosphorylation by erlotinib .", "label": "None"}
{"id": "22655263", "sentence": "The mechanisms underlying decreased activity of @DRUG$ on these secondary @GENE$ mutants were investigated by structural and biochemical analyses , together with cellular data generated in engineered in vitro models . For the L1196M , C1156Y , and @VARIANT$ mutants , it appears that binding of the inhibitor to ALK may be negatively affected by steric hindrance or conformational changes in the enzyme .", "label": "resistance"}
{"id": "22815900", "sentence": "We finally examined whether expression of activating mutant @GENE$ could restore drug sensitivity to erlotinib in drug resistant cell lines , PC9/ER1 and 11–18/ER1-7 . As shown in , out of 11 patients who first received @DRUG$ after lung surgery and then showed recurrence , 8 patients had the delE746-A750 mutation and 3 had L858R mutation in their primary lung tumors . Four had the @VARIANT$ mutation in dissemination or metastatic cytological samples .", "label": "resistance or non-response"}
{"id": "24590311", "sentence": "Pretreatment with carfilzomib followed by addition of imatinib resulted in a significant reduction in viability in Ba/F3 T315I , @GENE$ @VARIANT$ , LAMA84R and KCL22R ( P⩽0.04 ) . ( c ) Western blot analysis of phosphorylated-CRKL in imatinib-sensitive and -resistant cell lines following exposure to carfilzomib , imatinib or a combination of carfilzomib at t=0 , followed by imatinib at t=24 ; whole cell lysates were prepared 48 h after exposure to the first drug . ( d ) CML CD34+ cells ( n=3 ) were cultured in the presence of carfilzomib , imatinib , nilotinib or a combination of carfilzomib plus imatinib/nilotinib either simultaneously or carfilzomib at t=0 , followed by imatinib/nilotinib at t=24 ; after 48 h , cells were transferred to LTC-IC assays .", "label": "None"}
{"id": "24280348", "sentence": "@DRUG$ has shown measurable efficacy at early stage of treatment , but patients become insensitive to this drug after 6 to 9 months , which finally leads to treatment failure [ ] . Several resistance mechanisms , such as @GENE$ @VARIANT$ secondary mutation that leads to a higher ATP binding capacity , and MET amplification resulting in an aberrantly activated alternative pathway that bypasses the inhibited EGF receptors , had been discovered .", "label": "resistance or non-response"}
{"id": "22815900", "sentence": "In these patients , pleural dissemination of cancer cells was observed in the pleural cavity and cerebrospinal fluid after @DRUG$ treatment . Out of 11patients , 3 cases showed loss of activating mutant @GENE$ after recurrence . However , 1 out of 3 cases harbored wild-type EGFR with @VARIANT$ mutation ( case 6 ) .", "label": "resistance or non-response"}
{"id": "19920910", "sentence": "In a cell-line based mutagenesis study , the emergence of @GENE$ mutations resistant to imatinib , nilotinib and @DRUG$ were compared : 20 different mutations were identified with imatinib mesylate , 10 with nilotinib ( including only 1 novel mutation , E292V ) and 9 with dasatinib . In contrast to imatinib mesylate , mutations recovered in the presence of 50 nM nilotinib were limited to L248V , G250E , Y253H , E255K ( p-loop ) , T315I , F359C , L384M and @VARIANT$ .", "label": "None"}
{"id": "21188109", "sentence": "Cyclin D1 , in association with cyclin dependent kinase-4 and -6 , induces the cell to enter the S phase by phosphorylating the retinoblastoma tumor suppressing protein , which binds to transcription factors , including @VARIANT$ . In addition to the overexpression of cyclin D1 , other genes that overexpress in MCL , such as VEGF and Raf-1 , represent further possible targets for mTOR inhibitors . Indeed , a constitutive activation of Akt and mTOR pathways either in MCL cell lines ( Granta 519 , Jeko-1 , and SP-53 ) or in primary cultures from 30 % of MCL patients has been reported. , Moreover , mTOR inhibitors in MCL could synergize with other “canonical” agents , such as @DRUG$ , doxorubicin , bortezomib , and rituximab , with resulting inhibition of Raf-1 , MAPK , and @GENE$ . ,", "label": "None"}
{"id": "PMC4001129", "sentence": "Introduction : Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors ( TKIs ) such as @DRUG$ are one of gold standard treatment options for non-small-cell lung cancer ( NSCLC ) patients , which eventually fail due to the acquired resistance and relapse because of the development of secondary activating mutations such as @VARIANT$ in @GENE$ .", "label": "resistance or non-response"}
{"id": "19774209", "sentence": "Contrarily , a point mutation in the @GENE$ gene , which results in the substitution of methionine for threonine at position 790 ( @VARIANT$ ) , decreases the ability of @DRUG$ or gefitinib to inhibit EGFR .", "label": "resistance or non-response"}
{"id": "16187797", "sentence": "( B ) Number of colonies formed in soft agar by clonal NIH-3T3 cells expressing @VARIANT$ EGFR and D770_N771insNPG @GENE$ treated with the indicated concentrations of gefitinib or @DRUG$ immediately prior to suspension in soft agar .", "label": "sensitivity"}
{"id": "23940741", "sentence": "Somatic activating mutations of the @GENE$ gene have been identified as a major determinant of the clinical response to EGFR tyrosine kinase inhibitors ( TKIs ) such as gefitinib and @DRUG$ in patients with NSCLC . Most of these mutations occur in exons 19 to 21 , which encode the tyrosine kinase domain of the receptor , the most common being deletions in exon 19 ( such as delE746-A750 ) and the @VARIANT$ point mutation in exon 21 .", "label": "sensitivity"}
{"id": "24386407", "sentence": "Lung cancers with mutations that activate @GENE$ including exon 19 deletions and the exon 21 @VARIANT$ point mutation , respond to the reversible EGFR-tyrosine kinase inhibitors ( EGFR-TKIs ) @DRUG$ and erlotinib [ ] .", "label": "sensitivity"}
{"id": "23029123", "sentence": "The importance of D2 receptor involvement in @DRUG$ actions on PRL production and cell proliferation is evident in the experiment where ethanol actions on lactotropes ' function were evaluated in clonal cell lines expressing various levels of D2 receptor isoforms . It was found that V cells , which lacked functional D2 receptors and had high basal levels of PRL , showed a significant reduction in PRL production following D2S and @VARIANT$ receptor transfection . As described by an extended allosteric ternary complex model of @GENE$ , receptors spontaneously isomerize between active and inactive conformations , so receptors can modulate signaling pathways in the absence of an agonist .", "label": "None"}
{"id": "23418490", "sentence": "Erlotinib and @DRUG$ are inhibitors of EGFR that show significant efficacy in treating NSCLC patients harboring @GENE$ mutations , . At the same time , a secondary point mutation in exon 20 of EGFR ( @VARIANT$ ) is associated with acquired resistance to EGFR inhibitors , including Erlotinib .", "label": "resistance or non-response"}
{"id": "24501009", "sentence": "Strategies to improve EGFR inhibition in EGFR @VARIANT$ cancers include the combination of irreversible EGFR inhibitors with the @GENE$ antibody cetuximab ( as reported for @DRUG$ plus cetuximab ) 19 ; the development of more potent and specific inhibitors of EGFR T790M20,21 ; and the use of intermittent but high doses of existing irreversible EGFR inhibitors .", "label": "response"}
{"id": "25031955", "sentence": "In this patient who developed resistance to @DRUG$ after 5 months of treatment , molecular analyses showed the tumor had two acquired mutations within the kinase domain of @GENE$ , @VARIANT$ , and the gatekeeper mutation L1196M ( Katayama et al. , 2011 ) .", "label": "resistance"}
{"id": "20349044", "sentence": "The two main neurotransmitters eliciting contraction in human and rodent urinary bladder are adenosine triphosphate and acetylcholine , which act on a ligand gated ion channel ( @VARIANT$ receptor ) and two G-protein coupled receptors ( M2 and M3 muscarinic ) , respectively ( de Groat and Yoshimura ) . A common approach for studying how the functions of these receptors change in diabetes mellitus is to examine their contractile roles in isolated urinary bladder from animals treated with @DRUG$ (STZ) . In smooth muscle , cAMP mediates relaxation , and activation of the M2 receptor inhibits @GENE$ the relaxation elicited by forskolin and activation of β-adrenoceptors in gastrointestinal and urinary bladder smooth muscle ( Ehlert ) .", "label": "None"}
{"id": "25465236", "sentence": "( C ) @GENE$ T790M mutant does not resemble pEGFR unlike the EGFR @VARIANT$ mutant shown in B. ( D–F ) increased inhibition potency for Erlotinib against EGFR L858R mutant compared to EGFR WT protein and subsequent decrease in potency for @DRUG$ against EGFR L858R + E884K double mutant .", "label": "sensitivity"}
{"id": "22569033", "sentence": "Crenolanib Selective for @VARIANT$ mutation - In vitro - Blocks the kinase activity of @GENE$ D842V mutants . PTK787/ZK222584 @DRUG$ resistant 1,250 mg o.d Phase 2 15 ORR 67 % [ ]", "label": "resistance or non-response"}
{"id": "24386407", "sentence": "Several strategies have been proposed to overcome resistance to reversible @GENE$ , including treatment with @DRUG$ , an anti-EGFR antibody [ ] , Hsp90 inhibitors [ ] , PI3K/mTOR inhibitor [ ] , and mutant-selective EGFR-TKIs [ ] . Of them , mutant-selective EGFR-TKIs have shown activity not only against tumors harboring exon19 deletions and the L858R mutation , but against tumors with the @VARIANT$ resistance mutation .", "label": "response"}
{"id": "25465236", "sentence": "( G–I ) increased inhibition potency for Gefitinib against EGFR L858R mutant compared to EGFR WT protein and subsequent further increase in potency for @DRUG$ against @GENE$ L858R + E884K double mutant . ( J ) EGFR L861Q activated more than @VARIANT$ but less than L858R .", "label": "resistance or non-response"}
{"id": "PMC4041556", "sentence": "Second-generation @GENE$ TKIs – such as neratinib , @DRUG$ and dacomitinib – are effective in preclinical gefitinib- and erlotinib-resistant EGFR @VARIANT$ models , but to date their delivery in EGFR TKI-resistant patients have shown disappointing results in the clinic .", "label": "response"}
{"id": "19707322", "sentence": "Nilotinib is approximately 30-fold more sensitive than @DRUG$ in the killing of BCR-ABL dependent cells derived from patients with CML ( K562 and Ku-812F cells ) and cell lines ( 32D and baF3 ) , and it is active against 32/33 imatinib-resistant cell lines with BCR-ABL mutations . The sensitivity of @GENE$ mutants to AMN107 can be summarized into 4 categories : high ( IC50 ≤ 70 nmol/L : M244V , G250E , Q252H , F3llL , F317L , M351T , V379I , L387M , H396P , H396R ) , medium ( IC50 ≤ 200 nmol/L : @VARIANT$ , E255K , F359V ) , low ( IC50 ≤ 450 nmol/L : Y253H , E255V ) , and insensitive ( IC50 & gt ; 2 μmol/L : T315I ) ( ) ( ) .", "label": "None"}
{"id": "22028641", "sentence": "A p53 tester yeast strain expressing the URA3 gene under control of a p53 dependent promoter was transformed with centromeric plasmids ( @GENE$ selection marker ) expressing either wild-type human p53 , or the mutants @VARIANT$ , R273H_N239S , R273H_R282S , R272H_L114G , G245S_E286D , Y220C , Y220C_A138G , Y220C_L137R , and Y220C_L114G . Serial dilutions cells ( 10,000 ; 2,000 ; and 400 ) grown to mid-log phase were spotted onto agar plates lacking either @DRUG$ or uracil .", "label": "None"}
{"id": "25465236", "sentence": "( G–I ) increased inhibition potency for Gefitinib against EGFR L858R mutant compared to @GENE$ WT protein and subsequent further increase in potency for @DRUG$ against EGFR L858R + E884K double mutant . ( J ) EGFR @VARIANT$ activated more than T790M but less than L858R .", "label": "None"}
{"id": "24348666", "sentence": "It was initially proposed that the @VARIANT$ mutation might prevent the proper binding of tyrosine kinase inhibitors via steric hindrance , similar to the corresponding gatekeeper mutations in @GENE$ ( T315I ) and KIT ( T670I ) that confer resistance to @DRUG$ ( Gleevec ) in chronic myelogenous leukemia and in patients with gastrointestinal stromal tumors .", "label": "None"}
{"id": "15737014", "sentence": "EGFR Mutants Containing the @VARIANT$ Mutation Are Resistant to Inhibition by @DRUG$ or Erlotinib 293T cells were transiently transfected with plasmids encoding wild-type ( WT ) EGFR or @GENE$ mutants with the following changes : T790M , L858R , L858R + T790M , del L747–E749 ; A750P , or del L747–E749 ; A750P + T790M .", "label": "resistance or non-response"}
{"id": "20406486", "sentence": "Another possibility is that PLX4032-resistant BRAFV600E mutants have alternative signaling at the level of Raf , as has been described for cell lines with acquired resistance to a different Raf-inhibitor , AZ628 , which show increased signaling through C-Raf [ ] . The increase in pErk in an NRAS @VARIANT$ mutant cell line could be explained by abrogation of negative feedback loops mediated mainly by dual specificity phosphatases ( MKPs/DUSPs ) , as reported with Mek inhibitors [ , ] , and the recent description of increased C-Raf signaling when heterodimerizing with inhibited B-Raf in @GENE$ wild type cells [ , ] .", "label": "None"}
{"id": "24223798", "sentence": "All of the patients had the @GENE$ gene mutations in exon 19 ( delE746-A750 ) or exon 21 ( @VARIANT$ ) , and had received or were receiving @DRUG$ or erlotinib for treatment against advanced diseases at the blood sampling .", "label": "sensitivity"}
{"id": "22933967", "sentence": "In our retrospective study , 26.7 % of patients , all with KRAS wild-type tumours , who had previously unresectable liver-only metastases , underwent surgical resection after systemic therapy , with R0 resection achieved in 38 patients ( 21.6 % ) ; one of those was patient with the @GENE$ @VARIANT$ mutation . Although it is difficult to make any comparison , because our patients were not selected according to specific systemic therapy , these results are comparable with those reported in previous studies claiming that 19 to 23 % patients treated with bevacizumab- and irinotecan based chemotherapy and with previously unresectable liver-only metastases underwent resection.– In a recently published clinical study BOXER , where the patients with unresectable liver-only metastases were treated with oxaliplatin , capecitabine and bevacizumab , R0 resection was achieved in 40 % of patients .", "label": "sensitivity"}
{"id": "16173832", "sentence": "The @VARIANT$ mutation is rarely found in tumors from patients not treated with either @DRUG$ or erlotinib , and could be discovered only in progressing tumors , in addition to a primary drug-sensitive mutation in @GENE$ .", "label": "resistance or non-response"}
{"id": "22655263", "sentence": "Ki determination demonstrated a very similar biochemical potency on wild-type ALK and the @VARIANT$ ALK mutant ( 0.09 and 0.08 nM respectively ) , with both cellular and in vivo data ( using engineered Ba/F3 cells ) indicating that growth of ALK–L1196M mutant driven-cells is inhibited at similar , albeit slightly higher , doses which inhibit cells harboring wild-type @GENE$ ( Katayama et al. , ) . AP26113 was also described to be active on a series of in vitro induced crizotinib resistant mutations , which however have not been observed to date in clinical cases of acquired @DRUG$ resistance ( Zhang et al. , ) .", "label": "resistance"}
{"id": "23238683", "sentence": "In addition , the IC50 values for @DRUG$ were 0.5 to 30nM in parental cells and 30 to more than 300nM in resistant cells . As a whole our findings confirmed the efficacy of ponatinib on the @VARIANT$ mutation , but also highlighted the notion that ponatinib is effective on all types of imatinib-resistant CML cells , whatever their mode of resistance . Importantly , the IC50 values obtained for ponatinib in the present study for BaF3-WT-BCR-ABL , @GENE$ and BaF3-G250E-BCR-ABL ( 1nM , 8nM and 8nM respectively ) were very similar to the one reported previously by O’ Hare et al. ( 0.5 , 11 and 4.1nM respectively ) [ ] .", "label": "None"}
{"id": "15737014", "sentence": "Sequencing Chromatograms with the @VARIANT$ @GENE$ Exon 20 Mutation in Various Clinical Specimens and the NSCLC Cell Line H1975 ( A–C ) In all three patients—patient 1 ( A ) , patient 2 ( B ) , and patient 3 ( C ) —the secondary T790M mutation was observed only in lesions obtained after progression on either @DRUG$ or erlotinib .", "label": "resistance or non-response"}
{"id": "25505694", "sentence": "In vitro studies showed that exposing EGFR-mutant lung cancer cell lines to a mutagen and culturing them in the presence of an EGFR-TKI , the resistant clones with the @VARIANT$ mutation maintained a persistent phosphorylation [ ] . Given this role of persistent EGFR signaling , many trials evaluated the intensification of EGFR inhibition through the use of drug molecules with additional activity against other receptors in the EGFR family , as the second-generation neratinib , dacomitinib and afatinib [ ] . These inhibitors are mainly different from erlotinib and @DRUG$ for two features : each forms a covalent and irreversible attachment to the @GENE$ kinase domain , and each also inhibits other members of the ERBB family ( Figure ) .", "label": "resistance or non-response"}
{"id": "23515890", "sentence": "The drug resistance mutation @VARIANT$ was detected in CTCs collected from patients with @GENE$ mutations that had received tyrosine kinase inhibitors Gefitinib ( Iressa ) or @DRUG$ ( Tarceva ) .", "label": "resistance or non-response"}
{"id": "17973572", "sentence": "The Secondary Resistant Mutations L747S and T790M Affect @DRUG$ Induced Apoptosis and Inhibit BIM Up-Regulation ( A ) Top : Annexin V apoptosis assay : @GENE$ cells expressing @VARIANT$ (LR) , L858R-L747S # 4 ( LR-LS ) , or L858R-T790M (LR-TM) cells were grown in the absence or presence of gefitinib for 24 h .", "label": "None"}
{"id": "24187524", "sentence": "Indeed , there are three currently approved antibodies in clinical use : herceptin ( an anti-HER2 approved to treat breast cancer overexpressing HER2 ) , cetuximab , and panitumumab ( @GENE$ approved for treating metastatic colorectal cancer ) [ ] . Furthermore , there are three small-molecule inhibitors of the tyrosine kinase domain ( TKIs ) that interfere with the binding of ATP , also approved to treat non-small cell lung cancer ( i.e. , gefitinib , @DRUG$ , and lapatinib ) [ ] . These therapeutic molecules are limited by the development of resistance mutations such as @VARIANT$ in EGFR , which necessitates the screening of new inhibitors .", "label": "resistance or non-response"}
{"id": "22076124", "sentence": "L1196M represents a mutation of the “gatekeeper” residue , similar to the @VARIANT$ gefitinib-resistance mutations observed in EGFR , and T315I mutations in ABL . Mutations in the gatekeeper site are thought to increase the affinity for ATP significantly , outcompeting the effects of ATP competitive inhibitors [ ] . The effect of the C1156Y mutation is unclear , although it may have an indirect effect on @DRUG$ binding , and further studies will be required to establish its mechanism . A number of ALK inhibitors that are able to inhibit @GENE$ variants with “gatekeeper” mutations at L1196M have been developed .", "label": "None"}
{"id": "22569033", "sentence": "In contrast , @DRUG$ had no significant activity against these same mutant kinases . A phase II clinical study of crenolanib for treatment of GIST patients with primary or secondary @GENE$ @VARIANT$ mutation is currently recruiting patients ( ClinicalTrials.gov Identifier : NCT01243346 ) .", "label": "resistance or non-response"}
{"id": "20482842", "sentence": "Furthermore , pristimerin may be effective against CML cells bearing the Bcr-Abl with mutations other than @VARIANT$ because of its effect on @GENE$ mRNA , and this remains to be confirmed . It also remains to be investigated whether pristimerin has activity against CML stem cells , which is believed to be a critical cause of imatinib-resistance and an obstacle to curing CML .", "label": "None"}
{"id": "24971888", "sentence": "A ) FACS profiles of the stable HeLa cell line expressing tagged SUMO2 @VARIANT$ used for purification of conjugates . The FACS profile of asynchronous cells and cells synchronized with @DRUG$ are shown and the percentage of cells in G1 and G2/M is indicated . B ) Scatter plot with the correlation between the screen I and screen II log2 ( H/L ) ratios of identified @GENE$ target proteins .", "label": "None"}
{"id": "24623980", "sentence": "Two secondary mutations of ALK associated with @DRUG$ resistance – L1196M and C1156Y – were first detected in the same patient , who relapsed after achieving a partial response to the drug . The L1196M substitution occurs at the gatekeeper position of ALK ( a position that controls the binding of nucleotides and TKIs ) , and corresponds to the @VARIANT$ substitution in @GENE$ and the T315I substitution in the Bcr–Abl fusion protein , both of which confer resistance to corresponding TKIs .", "label": "None"}
{"id": "25580271", "sentence": "There are several promising agents for patients with activating EGFR mutations who experience disease progression of an EGFR tyrosine kinase inhibitor and have a @VARIANT$ resistance mutation , and multiple clinical trials will be available . Trials investigating adjuvant erlotinib in EGFR mutant NSCLC and comparing erlotinib to erlotinib plus bevacizumab in metastatic EGFR mutant NSCLC are ongoing . @DRUG$ , when compared to platinum pemetrexed , results in a superior ORR and progression-free survival in patients with @GENE$ rearranged NSCLC , and ceritinib is a second-line option for this patient population , but patients need to be monitored closely for adverse events and the need for dose reductions .", "label": "None"}
{"id": "24386407", "sentence": "Several strategies have been proposed to overcome resistance to reversible @GENE$ , including treatment with @DRUG$ , an anti-EGFR antibody [ ] , Hsp90 inhibitors [ ] , PI3K/mTOR inhibitor [ ] , and mutant-selective EGFR-TKIs [ ] . Of them , mutant-selective EGFR-TKIs have shown activity not only against tumors harboring exon19 deletions and the @VARIANT$ mutation , but against tumors with the T790M resistance mutation .", "label": "sensitivity"}
{"id": "25146448", "sentence": "MTNR1B , located on human chromosome 11q21–22 , is a member of the @GENE$ , and one of the functional and high-affinity @DRUG$ membrane receptors . MTNR1B is expressed in human and rodent pancreatic islets . Studies have shown that MTNR1B is a novel candidate gene for @VARIANT$ .", "label": "None"}
{"id": "17551677", "sentence": "The appearance of a second mutation represents a mechanism of resistance : in fact the authors demonstrate that the insertion of @VARIANT$ into test cells renders them resistant to gefitinib in vitro . They also find that when test cells transfected with both mutations are treated with other @GENE$ inhibitors , such as AG1478 , @DRUG$ , erlotinib or CL-387,785 , no objective response is obtained using the first three agents , while the fourth is effective .", "label": "response"}
{"id": "24963318", "sentence": "A recent study indicated that mutation of SOD1 gene has genetic linkage in ALS disease , @GENE$ associated SOD 1 mutations including alanine 4 by valine ( A4V ) [ – ] , @DRUG$ 46 by arginine ( @VARIANT$ ) [ – ] , and I113T mutation [ – ] .", "label": "None"}
{"id": "23527257", "sentence": "The cell line H1975 has a sensitizing @VARIANT$ kinase domain mutation in exon 21 , and a second T790M in exon 20 , in cis , in the @GENE$ kinase domain , rendering them resistant to the reversible TKIs @DRUG$ and erlotinib .", "label": "sensitivity"}
{"id": "24612546", "sentence": "A number of small-molecule tyrosine kinase inhibitors ( TKIs ) ( e.g. , @DRUG$ , erlotinib , lapatinib ) and antibodies ( eg , trastuzumab , cetuximab , panitumumab ) targeting the erbB family have been developed to treat breast , colorectal , lung , gastric and head and neck squamous cell cancers [ ] . Despite the improvements achieved in patients treated with reversible inhibitors of EGFR or @GENE$ and HER2 , primary and acquired resistances to these agents remain a clinical challenge . This is exemplified by the development of resistance to EGFR tyrosine kinase inhibitor ( TKI ) , through emergence of a secondary @VARIANT$ EGFR mutation in non-small-cell lung carcinoma ( NSCLC ) [ ] , which occurs in 50 % of the patients with lung adenocarcinoma [ ] .", "label": "resistance or non-response"}
{"id": "23238683", "sentence": "In addition , we used the murine @GENE$ cell line carrying either a wild-type BCR-ABL protein or its T315I and @VARIANT$ mutated counterparts to decipher the mechanisms of action of this TKI . We show that ponatinib is highly efficient to induce cell growth inhibition and induction of apoptosis on different @DRUG$ CML cell lines , whatever their mode of resistance .", "label": "None"}
{"id": "20404937", "sentence": "The R26R-RERT or R26R-EYFP-RERT mice lines were used for clonal analysis ; these are crosses between lines carrying the @VARIANT$ or R26R-EYFP reporter and RERTn transgenes . Labelled cells are produced by the activity of CreERT2 , an inducible recombinase activated by 4-hydroxy-tamoxifen ( TM ) . Ubiquitous CreERT2 expression is provided by a knock-in insertion of the CreERT2 cDNA into the 3′ UTR of the @GENE$ , which yields viable homozygotes with no obvious phenotype .", "label": "None"}
{"id": "24466541", "sentence": "Similarly , our case demonstrated BRAF @VARIANT$ mutation , wild-type KRAS and no evidence of microsatellite instability on immunohistochemical workup . However , we did not assess our case for CpG island methylation status . From the therapeutic standpoint , wild-type @GENE$ status would imply tumor responsiveness to novel biological molecules such as @DRUG$ or anti-epidermal growth factor receptor (EGFR) compounds ; however , a BRAF mutation and rhabdoid morphology would signify the opposite : a poor response to conventional and novel chemotherapy regimens and a likely refractory disease with relapses .", "label": "None"}
{"id": "24386407", "sentence": "Among the mechanisms by which cancer cells become resistant to reversible EGFR-TKIs are 1 ) gatekeeper mutations in EGFR , such as the @VARIANT$ second mutation [ , ] ; 2 ) activation of bypass signaling caused by Met amplification [ ] , hepatocyte growth factor (HGF) overexpression [ ] , or Gas6-Axl activation [ ] ; 3 ) activation of downstream molecules ( PTEN loss or PIK3CA mutation ) [ , ] ; 4 ) small-cell lung cancer transformation [ ] ; and 5 ) epithelial-to-mesenchymal transition [ ] . The gatekeeper EGFR-T790M mutation is the most frequent , occurring in half of tumors with acquired resistance to reversible EGFR-TKIs . The methionine residue at position 790 generates a bulkier side chain , which enhances the affinity of the EGFR tyrosine kinase pocket with ATP [ ] , decreasing the effective binding of @DRUG$ and erlotinib to the tyrosine kinase pocket of @GENE$ [ ] .", "label": "resistance or non-response"}
{"id": "21845098", "sentence": "@DRUG$ @GENE$ was kindly donated by Cipla Pharmaceutical Co , India . Total protein kit ( Micro Lowry ) was from Sigma ( Saint Louis , USA ) . @VARIANT$ , a human breast cancer cell line and SKOV3 , a human ovarian cancer cell line , were obtained from American Type Culture .", "label": "None"}
{"id": "21188109", "sentence": "Cyclin D1 , in association with cyclin dependent kinase-4 and -6 , induces the cell to enter the S phase by phosphorylating the retinoblastoma tumor suppressing protein , which binds to transcription factors , including @VARIANT$ . In addition to the overexpression of cyclin D1 , other genes that overexpress in MCL , such as VEGF and Raf-1 , represent further possible targets for mTOR inhibitors . Indeed , a constitutive activation of @GENE$ and mTOR pathways either in MCL cell lines ( Granta 519 , Jeko-1 , and SP-53 ) or in primary cultures from 30 % of MCL patients has been reported. , Moreover , mTOR inhibitors in MCL could synergize with other “canonical” agents , such as vincristine , doxorubicin , @DRUG$ , and rituximab , with resulting inhibition of Raf-1 , MAPK , and mTOR . ,", "label": "None"}
{"id": "24876815", "sentence": "Analyses were also performed for other polymorphisms in the EGFR gene : G216T and G497A , and in the EGF gene : @VARIANT$ . Graziano et al. demonstrated the presence of the short variant of the EGFR gene intron-1 and the G allele in codon 61 of the @GENE$ gene ( higher EGF production ) to be a favourable predictive factor for cetuximab-irinotecan therapy .", "label": "None"}
{"id": "24294007", "sentence": "In vitro data has shown that cancer cell lines with the @VARIANT$ mutation have a lower transforming potential and attenuated proliferation in the presence of @DRUG$ , compared to other @GENE$ mutations .", "label": "resistance or non-response"}
{"id": "24212826", "sentence": "In a previous study of EGFR-TKI treatment in chemonaive patients with specific EGFR mutations , such as exon 19 deletions and substitutions at @VARIANT$ , the treatment effect of EGFR-TKIs was sustained for up to 8–9 months and was significantly superior to the treatment effect of platinum based chemotherapy [ ] . In the Phase III randomized control trial of @DRUG$ vs. carboplatin/paclitaxel in Asia ( IPASS ) [ ] , gefitinib treatment led to significantly longer progression-free survival ( PFS ) than carboplatin-paclitaxel treatment among the patients who had pulmonary adenocarcinoma with @GENE$ mutations ( hazard ratio for progression or death : 0.48 ; 95 % confidence interval : 0.36–0.64 ; p & lt ; 0.001 ) .", "label": "sensitivity"}
{"id": "19687189", "sentence": "Antrodia camphorata solid-state cultured mycelium ( AC-SS , 1 μg ml−1 ) showed adjuvant anti-proliferative effects with cisplatin ( 10 μM ) or mitomycin ( 10 μM ) in hepatoma cell lines C3A and PLC/PRF/5 cells ( in vitro ) and , on xenografted cells in tumor implanted nude mice ( in vivo ) . Furthermore , AC-SS showed its adjuvant effects through the inhibition of MDR gene expressions and the pathway of COX-2 dependent inhibition of AKT phosphorylation [ ] . In terms of the very recent literature , Lu et al. [ ] noted that @DRUG$ extract from wild fruiting bodies of A. camphorata ( EEAC ) dose-dependently induced human premyelocytic leukemia HL 60 cells apoptosis via histone hypoacetylation , upregulation of @GENE$ and downregulation of histone acetyltransferase activities including GCN 5 , CBP and PCAF .", "label": "None"}
{"id": "PMC4041556", "sentence": "Second-generation EGFR TKIs – such as neratinib , afatinib and dacomitinib – are effective in preclinical gefitinib- and erlotinib-resistant EGFR @VARIANT$ models , but to date their delivery in @GENE$ TKI-resistant patients have shown disappointing results in the clinic .", "label": "resistance or non-response"}
{"id": "24501009", "sentence": "In contrast to patients with EGFR‐mutation‐positive tumors , patients with @GENE$ NSCLC are unlikely to respond to @DRUG$ or erlotinib and do not have an improved progression‐free survival ( PFS ) compared with those who have placebo following erlotinib therapy . Dacomitinib ( PF‐00299804 ) is a potent , irreversible , oral small‐molecule inhibitor of HER1/EGFR , HER2 , and HER4 tyrosine kinases with antitumor activity in both gefitinib‐sensitive and gefitinib‐resistant , including EGFR @VARIANT$ , preclinical NSCLC models .", "label": "None"}
{"id": "24724051", "sentence": "@DRUG$ is a multi targeted TKI with strong activity against @GENE$ and imatinib-resistant mutants including , for the first time , @VARIANT$ .", "label": "response"}
{"id": "24958351", "sentence": "PI3K mutation and/or loss of PTEN have been shown to contribute to maintained activation of @GENE$ and are associated with innate resistance to trastuzumab [ ] and @DRUG$ [ ] . In our study , SKBR3-L cells exhibit a dramatic decrease in p-AKT compared to parental cells , suggesting a decreased dependence on the @VARIANT$ pathway for growth and survival , and no alteration in PTEN levels was observed .", "label": "None"}
{"id": "24278442", "sentence": "For example , detecting the @VARIANT$ mutation in blood samples would be useful for patient selection for treatment with new @GENE$ for lung cancers that are resistant to @DRUG$ and erlotinib [ ] .", "label": "resistance or non-response"}
{"id": "25486409", "sentence": "Chen et al. demonstrated that EGFR-specific siRNAs strongly inhibited cell growth and induced apoptosis in H1975 cells harboring both @VARIANT$ and T790M . Even knock-down of the T790M transcript by siRNAs , when combined with @DRUG$ , was efficacious in controlling T790M-mutant , lung cancer cells . In line with this , we also confirmed the persistence of @GENE$ dependency in T790M-mutant , lung cancer cells .", "label": "sensitivity"}
{"id": "24586514", "sentence": "@DRUG$ induced growth arrest and apoptosis , thus aggravating the apoptotic and cytotoxic effects of ponatinib on @GENE$ @VARIANT$ mutant cells .", "label": "None"}
{"id": "19547661", "sentence": "BRAF ( v-raf murine sarcoma viral oncogene homolog B1 ) , a @GENE$ is the downstream effector of KRAS in the RAS-RAF-MAPK signaling pathway . A somatic mutation ( @VARIANT$ ) in exon 15 of BRAF has been identified in multiple human cancers with a mutation rate of 66 % in malignant melanomas [ ] and at lower frequency in other human carcinomas . Recently , it was demonstrated that wildtype BRAF is required for the response of patients with metastatic colorectal cancer to @DRUG$ and panitumumab [ ] .", "label": "None"}
{"id": "24859318", "sentence": "Sections were then rinsed with DEPC and RNase inhibitor ( 0.5 U/µl , BioLabs , @VARIANT$ ) -treated PBS , incubated with NeuN ( 1∶10 , Millipore , MAB377 ) for 1 min at room temperature ( RT ) , and washed with DEPC- and RNase inhibitor treated PBS two times . We then incubated the sections with Alexa Fluor 546 goat anti-mouse IgG1 ( γ1 ) ( 1∶10 , Invitrogen , A21123 ) in DEPC- and @GENE$ inhibitor treated PBS and washed two times with DEPC- and RNase inhibitor treated PBS . Finally , sections were dehydrated by 75 , 95 , 100 % @DRUG$ and 100 % Xylene and then air dried .", "label": "None"}
{"id": "25580268", "sentence": "An ongoing phase II study of the combination of dabrafenib with @GENE$ in BRAF @VARIANT$ melanoma brain metastases uses this strategy ( NCT01721603 ) . An institutional trial using lapatanib/capecitabine or @DRUG$ ( TDM-1 ) in HER 2+ breast cancer patients with one to 10 brain metastases treated with radiosurgery is in development ( Minesh Mehta and colleagues , personal communication ) .", "label": "None"}
{"id": "24276379", "sentence": "Twenty percent of K-Ras mutations are in codon 13 , substituting an aspartate for the glycine ( i.e. , @VARIANT$ ) [ , ] . Clinical studies have shown that @DRUG$ and panitumumab are not effective in patients with a @GENE$ mutation in codon 12 or 13 [ , ,, , ] .", "label": "resistance or non-response"}
{"id": "20406486", "sentence": "Another possibility is that PLX4032-resistant BRAFV600E mutants have alternative signaling at the level of Raf , as has been described for cell lines with acquired resistance to a different Raf-inhibitor , AZ628 , which show increased signaling through C-Raf [ ] . The increase in pErk in an NRAS @VARIANT$ mutant cell line could be explained by abrogation of negative feedback loops mediated mainly by dual specificity phosphatases ( MKPs/DUSPs ) , as reported with @GENE$ inhibitors [ , ] , and the recent description of increased C-Raf signaling when heterodimerizing with inhibited B-Raf in BRAF wild type cells [ , ] .", "label": "None"}
{"id": "24672248", "sentence": "KIT is a type III receptor tyrosine kinase that initiates multiple downstream signaling pathways , such as the @GENE$ and JAK/STAT pathways . KIT gene mutations are mainly found in melanomas , and @DRUG$ is an effective inhibitor of this oncogene . Here , we observed mutations @VARIANT$ and V559A , which are the most common KIT mutation types .", "label": "None"}
{"id": "19216789", "sentence": "To investigate the effects of AZD0530 on Bcr-Abl harbouring mutations conferring Imatinib-resistance ( Y253F , E255K and @VARIANT$ ) @GENE$ cells expressing these mutants were treated with the dual Src/Abl kinase inhibitor AZD0530 , and proliferation was assessed comparing them with the Ba/F3 infected p185Bcr-Abl cells treated in a similar manner ( Figure ) .", "label": "None"}
{"id": "23788881", "sentence": "Among CML patients , 19 had advanced disease , 16 were resistant to @DRUG$ , and 6 had @GENE$ domain mutations ( M244V , E255K , @VARIANT$ , M351T and 2 with F317L ) .", "label": "None"}
{"id": "22870311", "sentence": "Patients with EGFR mutations have shown a positive response to therapy with @DRUG$ , although many of these patients relapse later , frequently due to a secondary @GENE$ mutation , @VARIANT$ .", "label": "resistance or non-response"}
{"id": "24375389", "sentence": "The relatively low incidence of @GENE$ and ALK aberrations in non-Asian patients , however , account for the fact that ∼87 % of patients with NSCLC still receive conventional chemotherapy with no suitable biomarkers for therapy selection . The same accounts for women with triple negative breast cancer who do not benefit from anti-hormonal therapy or @DRUG$ and for whom effective treatment is limited [ ] . Other examples of useful biomarkers are KRAS mutation testing to predict benefit from monoclonal antibodies against EGFR , cetuximab and panitumumab , in metastatic colon cancer [ ] and BRAF @VARIANT$ mutation analysis in metastatic melanoma in order to predict responsiveness to BRAF inhibitors such as vemurafenib [ ] .", "label": "None"}
{"id": "24623980", "sentence": "In contrast to @DRUG$ , alectinib also shows substantial inhibitory activity against the @VARIANT$ mutant of @GENE$ , apparently because it is able to maintain an efficient ( CH/π ) interaction with position 1196 even after the substitution of methionine for leucine .", "label": "resistance"}
{"id": "25100284", "sentence": "Exon 19 deletions and @VARIANT$ mutations have shown similar in vitro sensitivity to gefitinib [ ] ; however , erlotinib and @DRUG$ have shown different clinical efficacy depending on whether exon 19 deletions and L858R mutations are present [ , ] . Despite these differences , both drugs have efficacy in patients with both of these mutations and these differences would not influence treatment selection . As the number of clinical trials evaluating @GENE$ TKIs continues to increase , the number of patients eligible for pooled analyses such as this one will increase .", "label": "sensitivity"}
{"id": "24634705", "sentence": "The L747S mutation lies at the start of the β3 strand and the α-C-helix [ ] and has analogous residues in BCR-ABL ( L237M ) and ERBB2 ( @VARIANT$ or P ) that have been identified in TKI resistant disease [ ] . The occurrence of these secondary mutations spurred development of second and third generation irreversible TKIs which bind covalently to the cysteinyl-797 residue in the pocket of the @GENE$ domain and overcome resistance driven by the T790M mutation [ ] . These agents show greater potency in the inhibition of kinase activity in vitro and in vivo compared to @DRUG$ and are in various stages of clinical testing [ , ] .", "label": "None"}
{"id": "23493883", "sentence": "Many drugs have been studied in patients who progressed after treatment with a reversible @GENE$ , including XL-647 , dasatinib , and neratinib , with little success . Combinations of therapy such as cetuximab plus @DRUG$ and gefitinib plus everolimus have also been tried . The most promising drug thus far has been afatinib ( BIBW2992 ; Boehringer-Ingelheim Pharma , Ingelheim , Germany ) , , an ErbB family blocker with reported in vitro and in vivo activity against EGFR mutant tumors harboring exon 19 deletions , exon 21 @VARIANT$ mutations and the exon 20 T790M “resistance” mutations .", "label": "sensitivity"}
{"id": "25170609", "sentence": "We have used the inhibitors @DRUG$ ( mTOR ) , NVP-BEZ235 and GSK2126458 ( PI3K/mTOR ) – to test for possible pathway interactions with trametinib ( ) . Initially , we selected four breast cancer cell lines : MCF-7 and T47D ( ER+ , mutant PIK3CA E545K and H1047R , respectively ) , SKBr3 ( HER2+ ) and MDA-MB-231 ( triple negative/basal B , mutant KRAS G13D , BRAF @VARIANT$ ) , to determine whether firstly the sensitivities to the @GENE$ pathway inhibitor trametinib correlate with the activity of the corresponding pathway .", "label": "None"}
{"id": "19384426", "sentence": "These tumors were marked by increased angiogenesis and an activation of the @GENE$ pathway [ ] . The TOR inhibitor @DRUG$ blocked tumor growth induced by the @VARIANT$ p110α mutant [ ] .", "label": "None"}
{"id": "23817662", "sentence": "Further studies of gefitinib revealed that this 4-anilinoquinazoline inhibitor , structurally similar to @DRUG$ , binds the @GENE$ c.2573T & gt ; G ( L858R ) mutant with a 20-fold higher affinity compared to the wild-type enzyme . Both mutations , the activating EGFR c.2573T & gt ; G ( L858R ) and the inhibiting EGFR c.2369C&gt ; T ( @VARIANT$ ) were found in our cytological assessment .", "label": "resistance or non-response"}
{"id": "24472312", "sentence": "Our molecular docking analysis revealed that ponatinib could target native or T674I @GENE$ in the DFG-out ( inactive ) binding mode , similar to @DRUG$ docking in @VARIANT$ Bcr-Abl .", "label": "None"}
{"id": "24212940", "sentence": "@VARIANT$ has been reported to sensitize multidrug resistant tumors to chemotherapeutic drugs without any associated toxicity [ ] . FoxM1 is an oncogenic @GENE$ aggressive human breast cancers [ , ] and we have recently showed that targeting FoxM1 by DIM enhances sensitivity of breast cancer cells to chemotherapeutic agents such as @DRUG$ [ ] .", "label": "None"}
{"id": "24223798", "sentence": "All of the patients had the @GENE$ gene mutations in exon 19 ( delE746-A750 ) or exon 21 ( L858R ) , and had received or were receiving gefitinib or @DRUG$ for treatment against advanced diseases at the blood sampling . For analysis of EGFR gene mutations in exon 19 ( delE746-A750 ) or exon 21 ( L858R ) , the peptic nucleic acid locked nucleic acid ( PNA-LNA ) polymerase chain reaction ( PCR ) clamp method was adopted , using protocols described previously . The EGFR @VARIANT$ mutation was examined in cell-free DNA obtained from plasma of the patients , since no biopsy specimens for DNA analysis could be obtained because of difficult accessibility of tumors during or after EGFR-TKI-treatment .", "label": "resistance or non-response"}
{"id": "25079768", "sentence": "The second-line treatment , after @DRUG$ failure , is provided by less specific kinase inhibitors , such as sunitinib that shows potency against imatinib-resistant @GENE$ mutated in the ATP binding pocket ( V654A and @VARIANT$ ) .", "label": "resistance"}
{"id": "24212777", "sentence": "Most B-Raf mutations involve the @VARIANT$ amino acid substitution , resulting in constitutive activation of the MEK-ERK signaling pathway . They are mutually exclusive of KRAS mutations and are thus a candidate for an independent biomarker for CRC [ ] . Studies on WT-KRAS tumors treated by either a combination of chemotherapy and cetuximab or @DRUG$ alone have shown that progression free survival ( PFS ) and OS were significantly better among patient without mutated BRAF ( @GENE$ ) [ ] .", "label": "resistance or non-response"}
{"id": "19920910", "sentence": "Corresponding experiments with mutant @GENE$ kinase domains revealed that a 20-fold improved potency of nilotinib compared with @DRUG$ is also seen with the imatinib-resistant mutants . The mutants , other than T315I , that were least responsive to nilotinib in all three cellular assays were @VARIANT$ and E255V .", "label": "None"}
{"id": "15737014", "sentence": "This study revealed that the quinazoline rings of @DRUG$ and lapatinib interact differently with the EGFR kinase domain , suggesting that while the @VARIANT$ mutation may affect inhibition by erlotinib and gefitinib , it may not affect inhibition of @GENE$ by compounds similar to lapatinib .", "label": "resistance or non-response"}
{"id": "24501009", "sentence": "These observations could be due to the presence of concurrent drug resistance mechanisms ( such as @GENE$ amplification ) , or to the inability of dacomitinib to fully inhibit EGFR in tumors harboring EGFR T790M at the doses currently under clinical investigation . Strategies to improve EGFR inhibition in EGFR @VARIANT$ cancers include the combination of irreversible EGFR inhibitors with the EGFR‐directed antibody cetuximab ( as reported for afatinib plus @DRUG$ ) 19 ; the development of more potent and specific inhibitors of EGFR T790M20,21 ; and the use of intermittent but high doses of existing irreversible EGFR inhibitors .", "label": "None"}
{"id": "23994953", "sentence": "Using the erlotinib-sensitive EGFR mutant NSCLC cell line HCC4006 harboring the delL747-E749 , A750P mutation in EGFR exon 19 , Suda et al. established that mesenchymal status , not a specific oncogenic activated protein , could sufficiently promote loss of @GENE$ dependence to confer resistance to erlotinib . More recently , Chang et al. confirmed that in the absence of the common second-site EGFR mutation @VARIANT$ or MET amplification , acquired resistance to gefitinib occurs in EGFR mutated PC9 cells that have undergone EMT .", "label": "resistance or non-response"}
{"id": "23569464", "sentence": "The MDA-MB-361 cells were plated in 96-well plates and grown to 70 - 80 % confluence before being treated with @VARIANT$ at concentrations of 1 µM and 10 µM . Treatment with @DRUG$ was used as negative control .", "label": "None"}
{"id": "25091415", "sentence": "Recent report by Yoshikawa , S. et al. ( 2013 ) demonstrated the acquired resistant of double mutant G719S/T790M (DM) to @DRUG$ , @VARIANT$ mutation occurs within the phosphate binding loop ( P-loop ) and not observed frequently . The structure of the @GENE$ DM ( G719S/T790M ) was solved and deposited in PDB .", "label": "sensitivity"}
{"id": "24492479", "sentence": "Consistent with this model , microtubule regrowth analysis revealed that an enhancement of microtubule nucleation/regrowth occurs in DNA-PKcs-deficient cells and that such dysregulation can be corrected by expression of the phosphomimetic Chk2 @VARIANT$ mutant ( and ) . It is likely that , in the absence of DNA-PKcs , inadequate activation of the Chk2–Brca1 signaling pathway leads to excessive microtubule nucleation and aberrant @GENE$ attachment . It has been reported that loss of Brca1 in cancer cells confers resistance to @DRUG$ treatment , , which causes microtubule stabilization and mitotic cell death .", "label": "None"}
{"id": "25278773", "sentence": "One of the most critical mechanisms for acquired resistance is the gatekeeper EGFR @VARIANT$ missense mutation , which is found in approximately 49 % –63 % of patients who have developed resistance to EGFR inhibitors. , Preliminary studies also indicate that the T790M mutation may play a crucial role in primary resistance to first-generation EGFR inhibitors because of clonal evolution in tumor cells with preexisting T790M mutations . Different strategies have been pursued in the management of progressive disease after treatment with first-generation @GENE$ TKIs , including monotherapies such as dasatinib and neratinib , as well as the rational combinations of @DRUG$ plus erlotinib and of erlotinib/gefitinib plus everolimus .", "label": "response"}
{"id": "24276379", "sentence": "It has even been observed that cells that have been induced to become cetuximab-resistant by continuously exposing them to @DRUG$ have acquired either K-Ras G12V or @GENE$ @VARIANT$ mutations [ ] .", "label": "resistance or non-response"}
{"id": "25115383", "sentence": "Phosphorylation of @GENE$ was susceptible to affatinib at 100 nM and 1000 nM in all of PC9 BR ( 10Mo ) , PC9BR ( 11Mo ) , PC9 and PC9BR ( 21Mo ) cell lines . @DRUG$ markedly suppressed phosphorylation of Akt and Erk in PC9 and PC9BR ( 21M0 ) cells but not in PC9BR ( 10Mo ) and PC9BR ( 11Mo ) cells without affecting Akt and Erk expression ( Figure ) . All of these cell lines did not harbor @VARIANT$ mutation in the EGFR gene .", "label": "response"}
{"id": "24294007", "sentence": "Although a retrospective study and the PICCOLO ( @DRUG$ , Irinotecan and Ciclosporin in Colorectal Cancer Therapy ) trial have demonstrated a reduced response to cetuximab and panitumumab for patients with NRAS mutations , , further work is required to demonstrate the predictive capacity of these mutations . The serine/threonine-protein kinase B-Raf is an effector in the @GENE$ signaling pathway , downstream of K-Ras . Mutations in the proto-oncogene BRAF are present in 5 % –10 % of the metastatic CRC population and are also mutually exclusive of KRAS mutations . BRAF @VARIANT$ is the most common of all BRAF mutations ( present in 90 % of cases ) , and is enriched in a subset of patients who are female , greater than 70 years of age , with KRAS WT right sided colon cancer .", "label": "None"}
{"id": "23238683", "sentence": "Cell lines were incubated for 48h with increasing concentrations of imatinib , dasatinib or @DRUG$ and cell viability was assessed using the XTT assay . We first investigated the effect of these ITKs on the viability of murine Ba/F3 cells , carrying wild type ( WT ) BCR-ABL , @VARIANT$ or @GENE$ mutation .", "label": "response"}
{"id": "24502453", "sentence": "In non-clinical models they are 30 to 300 times more potent than @DRUG$ and can inhibit most Imatinib-resistant @GENE$ mutations ( EPARs for Imatinib , Dasatinib , and Nilotinib [ ] ) . Comparable with the experience in anti-infective drugs , multidrug-resistant BCR/ABL mutations occur which preclude further use of the approved TKI . For example , patients with @VARIANT$ mutation respond only on treatment with third generation TKI Ponatinib , which was specifically designed as a treatment option for these populations .", "label": "None"}
{"id": "23144692", "sentence": "In our case , DNA sequencing of the @GENE$ gene in a tumor biopsy specimen at relapse showed a second point mutation that changed threonine to methionine at position 790 ( @VARIANT$ ) of EGFR . The efficacy of @DRUG$ is of limited duration , mainly due to drug resistance conferred by a second point mutation .", "label": "resistance or non-response"}
{"id": "24574860", "sentence": "Whether this strategy can overcome the oncogenic effect of the recurrent somatic @VARIANT$ mutation in the first fibronectin Type III domain of EphA2 reported in 7 % of squamous cell lung carcinomas ( SQCLC ) is unknown . This mutation promotes cell survival and metastasis through activation of p130Cas which appears to be responsive to mTOR inhibition. [ ] In comparison , several kinase domain mutations in EPHA3 result in diminished phosphorylation of the EPHA3 receptor , which functionally attenuates the tumor-suppressive effects of wild-type EPHA3 through regulation of @GENE$ activity. [ ] Various multikinase inhibitors currently in clinical use potently target Eph receptors , such as dasatinib and @DRUG$ .", "label": "None"}
{"id": "24348666", "sentence": "The mechanisms for acquired resistance include gatekeeper L1196M mutations , ALK gene amplification , and other ALK gene mutations ( L1152R , C1156Y , @VARIANT$ ) - . The first two secondary @GENE$ mutations that conferred resistance to @DRUG$ were reported within the same issue of the New England Journal of Medicine describing the positive clinical results mentioned above .", "label": "resistance"}
{"id": "24419415", "sentence": "Our group has undertaken a randomized phase 3 trial to compare @DRUG$ plus carboplatin plus pemetrexed with gefitinib monotherapy for patients with NSCLC with an exon 19 deletion or an L858R , @VARIANT$ , or L861Q @GENE$ mutation ( NEJ009 ; University Hospital Medical Information Network Clinical Trials Registry [ UMIN-CTR ] number , UMIN000006340 ) .", "label": "None"}
{"id": "15737014", "sentence": "Using this insight , new small-molecule inhibitors have been identified that retain activity against the majority of imatinib-resistant @GENE$ mutants [ , ] . For example , in CML , a commonly found mutation is a C→T single nucleotide change that replaces threonine with isoleucine at position 315 ( T315I ) in the ABL kinase domain [ , , ] . In GIST and HES , respectively , the analogous @VARIANT$ mutation in KIT and T674I mutation in PDGFR-alpha have been associated with acquired resistance to this drug [ , ] .", "label": "None"}
{"id": "23788917", "sentence": "In case of occurrence of both L858R and T790M mutations , the concentration of @DRUG$ should be three times higher in order to achieve a therapeutic effect . Analysis of the EGFR structure in patients harbouring the T854A mutation suggests the presence of an additional side chain , localised near the @GENE$ TKI binding site [ ] . The role of rare mutations in exon 20 such as @VARIANT$ and V769L in development of acquired resistance to EGFR TKI is still unknown .", "label": "None"}
{"id": "17973572", "sentence": "Transient transfection experiments utilizing COS-7 cells demonstrated that auto-phosphorylation of the original L858R EGFR was inhibited by lower concentrations of @DRUG$ or erlotinib than the L858R-L747S or L858R-T790M constructs ( A ) . CL-387,785 partially overcame the observed inhibition ( B ) . To prove the functional significance of the @VARIANT$ mutation , we generated @GENE$ cell lines stably expressing mutant EGFR constructs [ ] .", "label": "None"}
{"id": "20459770", "sentence": "In NSCLC , approximately 85 % of patients who responded favourably to @DRUG$ or erlotinib , two FDA approved small-molecule @GENE$ inhibitors , were shown to have somatic mutations in the EGFR gene . Somatic EGFR mutations are primarily located in exons 18 through 21 around the ATP binding pocket of the tyrosine kinase domain [ - ] . The most common mutations are short deletions in exon 19 affecting the amino acid sequence LREA ( DelE746-A750 ) or a point mutation in exon 21 resulting in the amino acid change @VARIANT$ .", "label": "sensitivity"}
{"id": "22098950", "sentence": "cReported substrates for wild-type @GENE$ ( R482 ) . IC50 , 50 % inhibition concentration ; @VARIANT$ , estrone 3-sulfate ; TPT , @DRUG$ ; MTX , methotrexate ; H33342 , Hoechst 33342 dye ; DOX , doxorubicin ; MX , mitoxantrone ; BM , bone marrow .", "label": "None"}
{"id": "23493883", "sentence": "Some data suggest that patients with EGFR exon 19 deletions are more susceptible to the activity of reversible EGFR-TKIs compared to those with the exon 21 @VARIANT$ mutation. , Further studies then compared first-generation EGFR-TKIs ( @DRUG$ and gefitinib ) to chemotherapy in patients with @GENE$ activating mutations in advanced NSCLC .", "label": "sensitivity"}
{"id": "23207070", "sentence": "Patients who carry these mutations in @GENE$ tend to have a better response to @DRUG$ , an EGFR-TKI , whereas patients with the wild-type genotype show a better response to conventional chemotherapy [ ] . This could be explained by the fact that the mutated receptor possess a greater affinity to the drug in comparison with ATP , and therefore can not initiate the phosphorylation cascade downstream through the signaling pathways that lead to proliferation and cell survival . However , about 50 % of lung cancer patients treated with EGFR-TKI acquire a secondary mutation that confers drug resistance , the @VARIANT$ ( C2369G ; ID : rs121434569 ) , located in exon 21 of the gene , which reduces the affinity of the ATP binding site for the drug [ ] .", "label": "resistance or non-response"}
{"id": "25232318", "sentence": "In our patient , a somatic @GENE$ amplification was identified by genomic profiling , and the patient experienced a durable response to crizotinib , all without knowledge of the site of tumor origin . Similarly , another CUP patient was identified as harboring a somatic EGFR @VARIANT$ alteration via hotspot testing and responded to @DRUG$ , an EGFR targeted therapy [ ] .", "label": "None"}
{"id": "21573178", "sentence": "We established sensitive ( 5–10 % mutant allele ) , reproducible and linear pyrosequencing assays for the most prominent mutation hotspots in @GENE$ and KRAS ( Supplementary , , , , , , , , ) . However , we also detected four additional mutations in our sample cohort that had been missed by dideoxy sequencing ( , and Supplementary , , ) . For example , we detected the @DRUG$ resistance mutation , @VARIANT$ , in tumor sample 10 ( 80 % tumor cell content ) obtained at the time of relapse ( Supplementary ) and this sample also harbored the L747_S752del_P753S deletion initially detected by dideoxy sequencing ( and ) .", "label": "resistance or non-response"}
{"id": "19319137", "sentence": "@GENE$ mutation was detected in OZ ( @VARIANT$ ) and HuCCT1 ( G12D ) cell lines , but not in TKKK and TGBC24TKB cell lines . Anti-proliferative effect of @DRUG$ in vitro", "label": "None"}
{"id": "22970367", "sentence": "The presence of a germline @GENE$ T790M mutation may be associated with increased risk of developing lung cancer [ – ] . In pretreated patients harboring a @VARIANT$ mutation , low expression of BRCA1 mRNA is correlated with a prolonged progression-free survival to @DRUG$ treatment .", "label": "resistance or non-response"}
{"id": "15737014", "sentence": "After 36 h , cells were serum starved for 24 h , treated with gefitinib or @DRUG$ for 1 h , and then harvested for immunoblot analysis using @GENE$ ( Y1092 ) , anti-t-EGFR , anti-phosphotyrosine ( p-Tyr ) , and anti-actin antibodies as described in Methods . The EGFR T790M mutation , in conjunction with either wild-type EGFR or the drug-sensitive @VARIANT$ EGFR mutant , prevents inhibition of tyrosine phosphorylation ( A ) or p-EGFR ( B ) by gefitinib .", "label": "sensitivity"}
{"id": "25568936", "sentence": "Moreover , interactions between @DRUG$ and @GENE$ or MYH9 have been described , and a MYH9 inhibitor synergizes with EGFR inhibitors to induce apoptosis in cells carrying the drug-resistant mutation @VARIANT$ .", "label": "None"}
{"id": "24788138", "sentence": "Combination therapy with @DRUG$ and low-dose decitabine in TET2 mutated SM Next , we exploited the cooperation between loss of function of TET2 and @GENE$ @VARIANT$ in the HMC-1.2 cell line to validate possible combinatorial approaches to treatment for ASM and MCL , .", "label": "response"}
{"id": "24982846", "sentence": "Pazopanib UGT1A1 ( TA ) 7/ ( TA ) 7 genotype ( @GENE$ ) Clinical pharmacology , warnings and precautions @DRUG$ ERBB2 HER2 protein overexpression positive Indications and usage , warnings and precautions , adverse reactions , clinical studies , clinical pharmacology Ponatinib BCR/ABL1 Philadelphia chromosome [ t ( 9 ; 22 ) ] positive , BCR–ABL @VARIANT$ mutation Indications and usage , warnings and precautions , adverse reactions , use in specific populations , clinical pharmacology , clinical studies", "label": "None"}
{"id": "24894453", "sentence": "In addition , these @GENE$ mutations were found to be mutually exclusive with well known KRAS , BRAF and PIK3CA oncogenic driver mutations , demonstrating their potential role in tumorigenesis ( COSMIC database ) . Colon-cancer derived @VARIANT$ and G724S mutants are oncogenic and sensitive to @DRUG$", "label": "sensitivity"}
{"id": "25328417", "sentence": "Similar to @DRUG$ , tivantinib induced G2–M cell cycle arrest in EBC1 cells , whereas other @GENE$ inhibitors induced G0–G1 cell cycle arrest .", "label": "None"}
{"id": "24167634", "sentence": "However , the discovery of epidermal growth factor receptor (EGFR) activating mutations and the response to @GENE$ tyrosine kinase inhibitors ( TKIs ) , such as @DRUG$ and erlotinib , deeply changed the management of advanced NSCLC in the last decade [ – ] . Small in-frame deletions in exon 19 and point mutations within exon 21 ( @VARIANT$ ) are the most common EGFR activating mutations both leading to sustained activity of the kinase .", "label": "sensitivity"}
{"id": "22060015", "sentence": "Staining of @VARIANT$ glioma cells with @GENE$ propidium iodide ( PI ) indicated the average percentages of late apoptotic cells at 17 % , 26 % , 20 % , and 51 % in untreated , untreated with Fas mAb , @DRUG$ treated alone , and decitabine treated with Fas mAb , respectively ( Figure ) .", "label": "None"}
{"id": "24349829", "sentence": "While the @VARIANT$ mutation represents a direct mechanism for drug resistance that occurs at the level of drug accessibility to the target , there are a number of indirect mechanisms that involve the increased expression or activation of alternative growth factor receptors to maintain signal flux , despite EGFR inhibition . Perhaps the best characterized of these is the amplification of the Met receptor and/or elevated levels of its ligand HGF . In @DRUG$ resistant NSCLC cell lines , @GENE$ drives ErbB3 dependent activation of the PI3K pathway .", "label": "None"}
{"id": "22655263", "sentence": "Additionally , AP26113 was evaluated on the crizotinib resistant gatekeeper mutant @VARIANT$ both in vitro and in vivo and appeared to be able to overcome resistance to @DRUG$ . Ki determination demonstrated a very similar biochemical potency on wild-type @GENE$ and the L1196M ALK mutant ( 0.09 and 0.08 nM respectively ) , with both cellular and in vivo data ( using engineered Ba/F3 cells ) indicating that growth of ALK–L1196M mutant driven-cells is inhibited at similar , albeit slightly higher , doses which inhibit cells harboring wild-type ALK ( Katayama et al. , ) .", "label": "resistance"}
{"id": "24501009", "sentence": "In contrast to patients with @GENE$ tumors , patients with KRAS‐mutant NSCLC are unlikely to respond to gefitinib or @DRUG$ and do not have an improved progression‐free survival ( PFS ) compared with those who have placebo following erlotinib therapy . Dacomitinib ( PF‐00299804 ) is a potent , irreversible , oral small‐molecule inhibitor of HER1/EGFR , HER2 , and HER4 tyrosine kinases with antitumor activity in both gefitinib‐sensitive and gefitinib‐resistant , including EGFR @VARIANT$ , preclinical NSCLC models .", "label": "resistance or non-response"}
{"id": "25114928", "sentence": "Strain @VARIANT$ demonstrated thus a high tolerance to ROS generating stresses gamma- and UV-radiation , @DRUG$ hydrogen peroxide , and desiccation comparable to the positive control G. obscurus DSM 43160T and , in general terms , to DNA damaging-resistant D. radiodurans R1 . This correlative tolerance between ROS generating stresses was already widely described [ , ] and support the hypothesis of efficient and common cellular DNA repair mechanisms . Strain G18T showed the highest tolerance to AsO43− ( @GENE$ = 8.0 mM ) followed by Pb2+ ( MIC = 4.0 mM ) , CrO42− ( MIC = 4.0 mM ) and Ag1+ ( MIC = 1.0 mM ) .", "label": "None"}
{"id": "24286313", "sentence": "To find novel candidates for bortezomib resistance , we selected candidate genes not involved in mechanisms in the action of @DRUG$ ( Table @VARIANT$ ) . Among the candidate genes , we evaluated @GENE$ gene , for association with resistance .", "label": "None"}
{"id": "17973572", "sentence": "The Secondary Resistant Mutations @VARIANT$ and T790M Affect Gefitinib Induced Apoptosis and Inhibit BIM Up-Regulation ( A ) Top : Annexin V apoptosis assay : @GENE$ cells expressing L858R (LR) , L858R-L747S # 4 ( LR-LS ) , or L858R-T790M (LR-TM) cells were grown in the absence or presence of @DRUG$ for 24 h .", "label": "None"}
{"id": "24789720", "sentence": "The role of @VARIANT$ mutation , particularly its presence in patients before EGFR-TKIs treatment is still controversial being a subject of intensive discussions . Mechanism of achieving resistance to @DRUG$ and gefitinib remains unclear . The recent reports confirmed , that T790M substitution could be detected in @GENE$ naïve patients independently of other EGFR gene mutations ( predominantly L858R substitution and deletions in exon 19 ) .", "label": "resistance or non-response"}
{"id": "23555924", "sentence": "Moreover , the orphan receptor @GENE$ site has been identified as the response element in the proximal promoter PII of the rat aromatase gene , and TGF-β1 has been proved to inhibit SF-1 expression both at the transcriptional and translational levels in the mouse adrenocortical cell Y-1 and human adrenocortical cell @VARIANT$ . It has been proved that stimulation of testosterone production by hCG is associated with a decrease in Cx43 mRNA levels in Leydig cells both in vitro and in vivo . Given that Leydig cells are the main site of conversion of androgens into @DRUG$ in the testis , and that GJ-protein expression is regulated in part by steroid hormones in steroid-sensitive organs , it is essential to investigate whether there is a correlation between E2 synthesized by Leydig cells and Cx43 mediated intercellular communication .", "label": "None"}
{"id": "17599352", "sentence": "We measured the apparent dissociation constant ( Kd , @GENE$ ) of ATP for WT and mutant Rho proteins in the absence of the RNA @DRUG$ by using the UV-cross linking technique . The apparent affinity of ATP for mutants Y274D , P279S and G324D was observed to be reduced by five-to eightfold , whereas it was comparable to WT for mutants @VARIANT$ , G51V and I382N ( ) .", "label": "None"}
{"id": "23569389", "sentence": "Baseline @GENE$ mutation data were available for 95 % of patients . Very high @DRUG$ resistance mutations ( M244V , G250E , Y253H , E255K , E255V , T315I , @VARIANT$ , H396R ) were associated with the lowest response rates to dasatinib .", "label": "None"}
{"id": "21556318", "sentence": "Y253H , @VARIANT$ , and F359V were deemed less sensitive , but not inherently resistant , as was the T315I identified in three patients receiving nilotinib . Six of 16 imatinib treated patients ( 38 % ) with @GENE$ mutations progressed to accelerated phase/blast crisis CML , as compared with 1/13 ( 8 % ) of nilotinib treated patients . Investigators at MD Anderson Cancer Center also recently presented their institutional history with nilotinib ( n = 90 ) and @DRUG$ ( n = 82 ) used in frontline CML therapy or for accelerated phase CML patients who had not been previously treated .", "label": "None"}
{"id": "25465236", "sentence": "Clinically observed EGFR kinase mutations that sensitize patients differentially to the inactive ( non phosphorylated ) @GENE$ kinase inhibitors Gefitinib and @DRUG$ were analyzed . The oncogenic EGFR @VARIANT$ mutation is one of the most common non small cell lung cancer ( NSCLC ) somatic mutations , observed from sequencing of both solid tumor biopsies and circulating tumor cells ( CTCs ) .", "label": "sensitivity"}
{"id": "15736989", "sentence": "For example , imatinib is effective in treatment of chronic myelomonocytic leukemia with gene rearrangements that constitutively activate PDGFRB [ ] , of hypereosinophilic syndrome with activating mutations in PDGFRA [ ] , and of gastrointestinal stromal cell tumors associated with activating mutations in @GENE$ [ ] ( all reviewed in [ ] ) . More recently , this paradigm has been extended to treatment of non-small cell lung cancer ( NSCLC ) . Several mutations have been identified in the context of epidermal growth factor receptor (EGFR) in patients with NSCLC that are associated with clinical response to the small-molecule EGFR inhibitors gefitinib ( Iressa ) or @DRUG$ ( Tarceva ) [ , , ] , including in-frame deletions such as del L747–E749 ; @VARIANT$ in exon 19 , or L858R in exon 21 .", "label": "None"}
{"id": "24523596", "sentence": "MCF7/AdVp3000 and S1-M1-80 cells express @VARIANT$ and R482G variants of @GENE$ , respectively , and are highly resistant to both mitoxantrone and @DRUG$ .", "label": "None"}
{"id": "16173832", "sentence": "In the case of our patient , the patient received no prior systemic chemotherapy , and we identified an initial @DRUG$ sensitizing L858R @GENE$ mutation , followed by a @VARIANT$ mutation concomitantly with L858R in the biopsy taken from the growing tumor nine months after gefitinib use .", "label": "resistance or non-response"}
{"id": "21646685", "sentence": "Also , in MCF10A cells expressing high levels of HER2/Neu , a kinase domain mutant of PIK3CA ( @VARIANT$ ) induced expression of Heregulin , the ligand that activates HER2/HER3 signaling through the PI3K pathway [ ] . In contrast , a helical domain mutant ( E545K ) enhanced transformation without inducing Heregulin expression [ ] . Therefore , in @GENE$ subtype breast cancers with PIK3CAH1047R or other kinase domain mutant alleles , therapy with Herceptin/Trastuzumab together with an antibody that blocks Heregulin could be particularly effective .", "label": "None"}
{"id": "24894453", "sentence": "Dimerization impairing cis mutations in @GENE$ , L704N and I941R , significantly reduced the ability of the cetuximab-sensitive G719S and @VARIANT$ mutants to promote colony formation upon retroviral transduction ( Figure", "label": "sensitivity"}
{"id": "23186157", "sentence": "Addition of AKIs at 10 nM with various concentration of GNF-2 did not sensitize Ba/F3 p185 @GENE$ @VARIANT$ cells to GNF-2 dependent clonigenicity inhibition ( data not shown ) . However , presence of AKIs at 100 nM showed a marginal cooperation between GNF-2 and @DRUG$ and Nilotinib ( Figure - ) and a greater cooperation with Dasatinib ( Figure ) .", "label": "None"}
{"id": "24052078", "sentence": "In addition , previous reports showed the presence of signaling cross-activation between MET and @GENE$ in both A549 and H1975 cells , and both the @VARIANT$ mutation of EGFR and c-Met amplification are known mechanisms of acquired @DRUG$ ( TKI ) resistance in lung cancer .", "label": "resistance or non-response"}
{"id": "24124608", "sentence": "To identify additional drivers or modifiers of GIST biology that can be targeted , we integrated array based analysis of DNA CN and gene expression results from tumors resistant to @DRUG$ , i.e. wild-type and @GENE$ @VARIANT$ GISTs ( summarized in ) .", "label": "resistance or non-response"}
{"id": "12569391", "sentence": "Effect of CD26/DPPIV expression on @DRUG$ mediated growth inhibition and cell cycle arrest at @GENE$ of Jurkat cells", "label": "None"}
{"id": "23238683", "sentence": "As shown in Figure , BaF3 cells expressing native BCR-ABL were highly sensitive to imatinib , dasatinib and ponatinib , whereas BaF3-T315I-BCR-ABL and @GENE$ cells were resistant to both @DRUG$ and dasatinib . By contrast , ponatinib induced loss of cell viability in BaF3 cells carrying the T315I or @VARIANT$ mutation , in agreement with previous results from the literature [ , ] .", "label": "None"}
{"id": "24495353", "sentence": "Rank Entrez ID Gene symbol Entrez ID Gene symbol Entrez ID Gene symbol 1 28978 TMEM14A 79776 ZFHX4 1727 CYB5R3 2 1843 DUSP1 4701 NDUFA7 7083 TK1 3 51022 GLRX2 715 @VARIANT$ 1292 COL6A2 4 1434 CSE1L 79818 ZNF552 857 CAV1 5 8522 GAS7 4046 LSP1 5437 POLR2H 6 51668 HSPB11 1727 CYB5R3 9833 MELK 7 10456 HAX1 357 SHROOM2 54861 SNRK 8 9902 MRC2 283298 OLFML1 4830 NME1 9 4706 NDUFAB1 23179 RGL1 231 AKR1B1 10 23560 GTPBP4 1809 DPYSL3 10418 SPON1 11 79633 FAT4 857 CAV1 2350 FOLR2 12 10418 SPON1 274 BIN1 10979 FERMT2 13 471 ATIC 79833 GEMIN6 11096 @GENE$ 14 6403 SELP 11222 MRPL3 4638 MYLK 15 23421 ITGB3BP 23244 PDS5A 9448 MAP4K4 16 23452 ANGPTL2 6241 RRM2 54922 RASIP1 17 54861 SNRK 1289 COL5A1 6934 TCF7L2 18 2034 EPAS1 8434 RECK 4072 EPCAM 19 30008 EFEMP2 429 ASCL1 4701 NDUFA7 20 25999 CLIP3 3426 CFI 404672 GTF2H5 21 4311 MME 332 BIRC5 6241 RRM2 22 4747 NEFL 2 A2M 2192 FBLN1 23 1809 DPYSL3 10730 YME1L1 25959 KANK2 24 28998 MRPL13 11130 ZWINT 55651 NHP2 25 25959 KANK2 1292 COL6A2 5050 PAFAH1B3 Lists of the top 25 of most influential genes in influence networks based on coexpression among genes in ER + breast tumors before , during , and after a course of neoadjuvant treatment with the drug @DRUG$ .", "label": "None"}
{"id": "23940741", "sentence": "Somatic activating mutations of the @GENE$ gene have been identified as a major determinant of the clinical response to EGFR tyrosine kinase inhibitors ( TKIs ) such as @DRUG$ and erlotinib in patients with NSCLC . Most of these mutations occur in exons 19 to 21 , which encode the tyrosine kinase domain of the receptor , the most common being deletions in exon 19 ( such as delE746-A750 ) and the @VARIANT$ point mutation in exon 21 .", "label": "sensitivity"}
{"id": "24497964", "sentence": "To examine whether IgG titers against each of the 60 different peptides were associated with EGFR mutation status , their median values were compared among patients with @GENE$ mutations ( delE746-A750 and @VARIANT$ ) and the wild-type EGFR using the Wilcoxon rank-sum test . PFS was calculated from the date of initiation of @DRUG$ treatment until either the date of disease progression or the date of last contact .", "label": "sensitivity"}
{"id": "23567620", "sentence": "Finally , although molecularly targeted therapies ( that is , gefitinib or @DRUG$ for @GENE$ and crizotinib for ALK fusions ) are effective in NSCLC , intrinsic or acquired resistances inevitably lead to recurrence and/or metastatic dissemination . This is the case of MET activation/amplification , , or acquired somatic mutations of EGFR ( @VARIANT$ ) or ALK fusions ( G1269A , L1196M and ALK amplification ) . , ,", "label": "resistance or non-response"}
{"id": "24523596", "sentence": "Δ-235A −113A&gt ; G −29A&gt ; G 34G&gt;A @VARIANT$ N-terminal 114T & gt ; C No change N-terminal @GENE$ ; T G51C N-terminal 369C&gt ; T No change NBD 376C&gt ; T Q126stop NBD 421C&gt ; A Q141K NBD Increased bioavailability of topotecan and lactone form of 9-aminocamptotecin . Increased plasma concentration of diflomotecan . Increased risk of @DRUG$ induced diarrhea .", "label": "None"}
{"id": "24349829", "sentence": "While the @VARIANT$ mutation represents a direct mechanism for drug resistance that occurs at the level of drug accessibility to the target , there are a number of indirect mechanisms that involve the increased expression or activation of alternative growth factor receptors to maintain signal flux , despite EGFR inhibition . Perhaps the best characterized of these is the amplification of the Met receptor and/or elevated levels of its ligand HGF . In @DRUG$ resistant NSCLC cell lines , Met drives @GENE$ dependent activation of the PI3K pathway .", "label": "None"}
{"id": "25505694", "sentence": "In vitro studies showed that exposing EGFR-mutant lung cancer cell lines to a mutagen and culturing them in the presence of an EGFR-TKI , the resistant clones with the @VARIANT$ mutation maintained a persistent phosphorylation [ ] . Given this role of persistent EGFR signaling , many trials evaluated the intensification of EGFR inhibition through the use of drug molecules with additional activity against other receptors in the EGFR family , as the second-generation neratinib , dacomitinib and afatinib [ ] . These inhibitors are mainly different from erlotinib and @DRUG$ for two features : each forms a covalent and irreversible attachment to the EGFR kinase domain , and each also inhibits other members of the @GENE$ family ( Figure ) .", "label": "resistance or non-response"}
{"id": "24276379", "sentence": "Panitumumab can still bind to an @GENE$ mutant @VARIANT$ to which @DRUG$ can not bind to .", "label": "resistance"}
{"id": "24982846", "sentence": "Imatinib KIT c-KIT @VARIANT$ mutation negative Indications and usage , dosage and administration clinical pharmacology , clinical studies BCR/ABL1 Philadelphia chromosome [ t ( 9 ; 22 ) ] positive PDGFRβ PDGFR gene rearrangement positive FIP1L1/PDGFRα FIP1L1/PDGFRα fusion kinase ( or CHIC2 deletion ) positive Indications and usage , dosage and administration , clinical studies @DRUG$ UGT1A1 @GENE$ allele carriers Dosage and administration , warnings , clinical pharmacology", "label": "None"}
{"id": "22343623", "sentence": "In this study , we examined whether the selective KOR agonist U50 ,488H could inhibit the growth of gefitinib-sensitive and EGFR mutant ( delE746-A750 , @VARIANT$ ) NSCLC cells ( HCC827 ) and gefitinib-resistant and @GENE$ mutant ( T790M ) NSCLC cells ( H1975 ) , and investigated the signalling mechanism of the KOR mediated inhibitory effect on tumour cell growth .", "label": "sensitivity"}
{"id": "22185378", "sentence": "( A ) Effects of combined treatment of matuzumab ( 100 μg/mL ) with a @GENE$ pathway inhibitor , PD98059 ( 25 μM ) , on cell viability by MTT assay and ( B ) Western blotting analysis of phosphorylation of p44/42 ( ERK) 1/2 on Caski and @VARIANT$ cells . Blockade of Akt signaling is a determinant factor to overcome resistance to matuzumab Previous results of our group showed that when in combination to cetuximab , that triggered EGFR degradation , matuzumab induced further reduction in cell signaling and survival when compared to @DRUG$ alone [ ] .", "label": "None"}
{"id": "24623980", "sentence": "Two secondary mutations of @GENE$ associated with @DRUG$ resistance – L1196M and @VARIANT$ – were first detected in the same patient , who relapsed after achieving a partial response to the drug .", "label": "resistance"}
{"id": "24501009", "sentence": "Strategies to improve EGFR inhibition in EGFR @VARIANT$ cancers include the combination of irreversible EGFR inhibitors with the EGFR‐directed antibody cetuximab ( as reported for @DRUG$ plus cetuximab ) 19 ; the development of more potent and specific inhibitors of EGFR T790M20,21 ; and the use of intermittent but high doses of existing irreversible @GENE$ inhibitors .", "label": "response"}
{"id": "23610714", "sentence": "Imatinib has been found to be effective not only for GIST with C-KIT mutations but also for GIST with PDGFRA mutations and for wild-type GISTs. , However , no adjuvant treatment is recommended in GISTs with the @VARIANT$ missense mutation in the @GENE$ exon 18 , which are known to be unresponsive to @DRUG$ and showed very favorable outcome after surgery .", "label": "resistance or non-response"}
{"id": "15736989", "sentence": "Similar mutations in the homologous residues of the kinase domains of PDGFRA ( T674I ) and @GENE$ ( @VARIANT$ ) account for @DRUG$ resistance in some patients with hypereosinophilic syndrome and gastrointestinal stromal cell tumors , respectively [ , ] .", "label": "resistance"}
{"id": "23667466", "sentence": "BeZ235 is an inhibitor of @GENE$ and mTOR , and its inhibitory effect on the growth of NSCLC cells and tumor xenografts can be strengthened by mTORC1 inhibitor @DRUG$ , . The synergistic effect was interpreted by the uncouple feedback inhibition between @VARIANT$ and PI3K .", "label": "None"}
{"id": "15737014", "sentence": "In GIST and HES , respectively , the analogous T670I mutation in KIT and @VARIANT$ mutation in PDGFR-alpha have been associated with acquired resistance to this drug [ , ] . To determine whether lung cancers that acquire clinical resistance to either gefitinib or @DRUG$ display additional mutations in the @GENE$ kinase domain , we have examined the status of EGFR exons 18 to 24 in tumors from five patients who initially responded but subsequently progressed while on these drugs .", "label": "None"}
{"id": "24155950", "sentence": "The sensitivity of K562 , K562-R , LAMA84 , LAMA84-R , Baf3 Bcr-Abl , and Baf3 Bcr-Abl @VARIANT$ cell lines to the most used @GENE$ inhibitors in CML : imatinib , @DRUG$ ( Santa Cruz Biotechnology , CA , USA , Cat. # sc-218081 ) and nilotinib ( Santa Cruz Biotechnology , CA , USA , Cat. # sc-202245 ) was investigated by treating these cells with increasing concentrations of each drug and measuring cell death using an automated Trypan Blue exclusion method ( see ) .", "label": "None"}
{"id": "24788138", "sentence": "We reasoned that if the same hypermethylator phenotype was caused by loss of TET2 in the @GENE$ @VARIANT$ positive HMC-1.2 cell line , resulting silencing of gene expression in these cells could potentially be reversed by treatment with epigenetic modifiers , providing an enhanced effect to @DRUG$ ( DASA ) .", "label": "response"}
{"id": "23320171", "sentence": "Primary results from the EMILIA study , a randomized trial comparing Trastuzumab DM-1 to lapatinib and capecitabine , have shown that Trastuzumab DM-1 significantly improved progression-free survival in patients with metastatic @GENE$ positive breast cancer . Further research is looking into inhibiting other targets such as mTOR , @VARIANT$ , or AKT pathways . Two randomized trials are evaluating the addition of the mTOR inhibitor , @DRUG$ , to chemotherapy and Trastuzumab in the first-line and Trastuzumab-resistance metastatic setting .", "label": "None"}
{"id": "24252457", "sentence": "Resistance due to @VARIANT$ can potentially overcome by second generation irreversible EGFR TKIs , which appear to be well tolerated in early clinical studies [ ] . Although did not demonstrated an overall survival benefit , Afatinib , an irreversible @GENE$ , Her-2 , and ErbB4 blocker has led to significant PFS in patients who progressed after a 12 week course of Gefitinib or @DRUG$ when compared to placebo in a phase 2b/3 trial [ ] .", "label": "resistance or non-response"}
{"id": "16187797", "sentence": "Insertion mutant autophosphorylation is less sensitive to inhibition by gefitinib than that of @VARIANT$ , but CL-387,785 is more effective than gefitinib at inhibiting insertion mutant ( and L858R ) autophosphorylation . Discussion Treatment with the @GENE$ inhibitors gefitinib and @DRUG$ has led to dramatic responses in many lung cancer patients , predominantly for those cancers in which EGFR mutations can be detected .", "label": "sensitivity"}
{"id": "22034911", "sentence": "The 16 mutations are located around the kinase active site and can be categorized into five groups , involved in either direct or indirect contacts with @DRUG$ . The three mutations that conferred the strongest resistance were the @VARIANT$ gatekeeper residue , S1206R at the solvent front , and G1269S near the DFG motif . @GENE$ cells expressing native EML4-ALK grew robustly as subcutaneous xenografts in SCID mice .", "label": "None"}
{"id": "24789720", "sentence": "The role of @VARIANT$ mutation , particularly its presence in patients before @GENE$ treatment is still controversial being a subject of intensive discussions . Mechanism of achieving resistance to @DRUG$ and gefitinib remains unclear .", "label": "resistance or non-response"}
{"id": "15737014", "sentence": "After 36 h , cells were serum starved for 24 h , treated with gefitinib or @DRUG$ for 1 h , and then harvested for immunoblot analysis using anti-p-EGFR ( Y1092 ) , @GENE$ , anti-phosphotyrosine ( p-Tyr ) , and anti-actin antibodies as described in Methods . The EGFR @VARIANT$ mutation , in conjunction with either wild-type EGFR or the drug-sensitive L858R EGFR mutant , prevents inhibition of tyrosine phosphorylation ( A ) or p-EGFR ( B ) by gefitinib .", "label": "resistance or non-response"}
{"id": "24167634", "sentence": "However , the discovery of epidermal growth factor receptor (EGFR) activating mutations and the response to @GENE$ tyrosine kinase inhibitors ( TKIs ) , such as gefitinib and @DRUG$ , deeply changed the management of advanced NSCLC in the last decade [ – ] . Small in-frame deletions in exon 19 and point mutations within exon 21 ( @VARIANT$ ) are the most common EGFR activating mutations both leading to sustained activity of the kinase .", "label": "sensitivity"}
{"id": "24790411", "sentence": "The rationale of the combination lies in some preclinical work in which mice with @GENE$ mutated lung cancer and acquired resistance to EGFR TKIs showed tumor regression under treatment with @DRUG$ and cetuximab . In the clinical trial , results from the first 96 evaluable patients showed impressive objective response rate ( ORR ) and disease control rate ( DCR ; 30 % and 75 % , respectively ) . Response to treatment was observed both in patients bearing a @VARIANT$ mutation or other mechanisms of resistance .", "label": "response"}
{"id": "22655263", "sentence": "Ki determination demonstrated a very similar biochemical potency on wild-type ALK and the @VARIANT$ ALK mutant ( 0.09 and 0.08 nM respectively ) , with both cellular and in vivo data ( using engineered Ba/F3 cells ) indicating that growth of @GENE$ mutant driven-cells is inhibited at similar , albeit slightly higher , doses which inhibit cells harboring wild-type ALK ( Katayama et al. , ) . AP26113 was also described to be active on a series of in vitro induced @DRUG$ resistant mutations , which however have not been observed to date in clinical cases of acquired crizotinib resistance ( Zhang et al. , ) .", "label": "resistance"}
{"id": "23785245", "sentence": "Similar to mutations in BCR-ABL ( T315I ) or in KIT ( @VARIANT$ ) that underlie resistance to @DRUG$ , T790M is thought to interfere with the binding of @GENE$ at the adenosine triphosphate binding cleft of EGFR . , , On the other hand , the affinity of this cleft for adenosine triphosphate is increased by T790M .", "label": "None"}
{"id": "23664091", "sentence": "In NSCLC , resistance to the EGFR TKI gefitinib is associated with the positive selection of cells harbouring the gatekeeper @VARIANT$ mutation known to confer insensitivity to @DRUG$ [ ] . Su et al. [ ] demonstrated that in patients with EGFR mutations treated with EGFR TKIs , the presence of low frequency subclones harbouring T790M mutations before the onset of treatment was associated with shorter progression-free survival , and Turke et al. [ ] showed that the presence of subclones with @GENE$ amplification was associated with EGFR TKI resistance .", "label": "None"}
{"id": "24276379", "sentence": "The H1047R , E542K and @VARIANT$ mutations , all detected in colorectal cancers , code for mutant proteins with higher lipid kinase activity than the wild-type protein [ , ] . These mutations result in @GENE$ activation and cellular transformation [ ] . In a clinical study involving 110 patients , none of the patients with the abovementioned PIK3CA gene mutations respond to @DRUG$ or cetuximab [ ] .", "label": "None"}
{"id": "23493838", "sentence": "A complete hematological response and a major cytogenetic response were observed broadly across the @GENE$ mutants , including individuals harboring the dasatinib-resistant F317L , the nilotinib-resistant Y253H , and F359C/I/V mutations , but not @VARIANT$ .", "label": "None"}
{"id": "24278035", "sentence": "To test whether functional interactions between NF1 and ALK exist in human cells , we used the SK-SY5Y and Kelly neuroblastoma cells , both of which harbor constitutively active @VARIANT$ ALK alleles , and both of which are highly sensitive to pharmacological ALK inhibition . Compatible with a role for NF1 as a negative regulator of mitogenic ALK/RAS signals , qRT-PCR verified NF1 knockdown with two shRNA retroviral vectors increased the resistance of both lines to @GENE$ inhibitors NVP-TAE684 and @DRUG$ ( and ) .", "label": "resistance"}
{"id": "19909554", "sentence": "Moreover , recent studies have suggested that @GENE$ or survivin is positively regulated by Akt [ , ] . It has been also reported that @VARIANT$ or @DRUG$ alone inhibits the phosphorylation of Akt [ , ] .", "label": "None"}
{"id": "23691449", "sentence": "Some of the molecular mechanisms of acquired resistance include T790M second mutation , mesenchymal epithelial transition factor ( MET ) amplification , ATP binding cassette (ABC)-G2 transporter ( @GENE$ ) and hepatocyte growth factor (HGF) overexpression , insulin-like growth factor (IGF) binding protein-3 ( IGFBP3 ) downregulation , as well as ERBB3 activation . T790M mutation The @VARIANT$ second mutation accounts for half of all resistances to @DRUG$ and erlotinib [ ] .", "label": "None"}
{"id": "23630663", "sentence": "In vitro analyses identified three point mutations , L755S , L755P , and @VARIANT$ to confer resistance to @DRUG$ ( Kancha et al. , ) . Threonine 798 is the ERBB2 “gatekeeper” residue that is located at the periphery of the nucleotide binding site of @GENE$ kinase ( Aertgeerts et al. , ) , and regulates access to a deep hydrophobic pocket in the active site ( Schindler et al. , ) .", "label": "None"}
{"id": "19774209", "sentence": "Contrarily , a point mutation in the @GENE$ gene , which results in the substitution of methionine for threonine at position 790 ( @VARIANT$ ) , decreases the ability of erlotinib or @DRUG$ to inhibit EGFR .", "label": "resistance or non-response"}
{"id": "21887377", "sentence": "Preventing nuclear entry of IRF2BP2 by mutating @VARIANT$ was sufficient to render the protein inactive to regulate VEGFA promoter activity . Surprisingly , forced nuclear localization did not make IRF2BP2 a better transactivator of @GENE$ . This result indicates that nuclear localization is not sufficient to ensure transcriptional activity of IRF2BP2 and that the S360D mutation might affect the interaction of IRF2BP2 with a putative transcription @DRUG$ or affect a transactivation function of IRF2BP2 .", "label": "None"}
{"id": "23493883", "sentence": "Intermittent , high-dose afatinib ( NCT01647711 ) I Must have known @VARIANT$ mutation 2nd/3rd line after progression on 1st-generation @GENE$ @DRUG$ at pulsatile , high doses MTD None , trial ongoing", "label": "response"}
{"id": "24755925", "sentence": "The @VARIANT$ resistance mutation was modelled in the 3FQQ dimer and , while some of the possible @DRUG$ side-chain conformations did not impact on the binding of BMS-790052 , other conformations of the histidine side-chain prevented BMS-790052 from binding as deeply into the cleft compared to wild type NS5A ( as illustrated in ) . In the 1ZH1 NS5A dimer model Y93H is flanked on either side by T56 and G33 ( both from the same NS5A monomer as Y93H ) , and an interaction between Y93H and T56 should not impact on the binding of BMS-790052 . For genotype 1b ( con1 ) , the common L31V resistance mutation confers 23-fold resistance against BMS-790052 in replicon assays , whereas in the MST in vitro assay there was no detectable binding of the inhibitor to the @GENE$ NS5A26–20 mutant .", "label": "None"}
{"id": "23994953", "sentence": "While preparing this manuscript , Cortot et al. reported that PC-9 derived clones with acquired resistance to mutant-selective EGFR inhibitors and irreversible quinazoline EGFR inhibitors in the absence of EGFR @VARIANT$ demonstrate a significantly activated IGF-1R signaling , and pharmacological inhibition of IGF-1R restored sensitivity to EGFR inhibitors . Despite no patient data supporting the role of IGF-1R in acquired resistance to gefitinib/erlotinib , we are beginning to accumulate evidence from preclinical models indicating that clinical trials of IGF-1R inhibitors with demonstrated activity in unselected NSCLC patients might play a role in association with @GENE$ inhibitors in the management of NSCLCs with acquired resistance to gefitinib/erlotinib .", "label": "resistance or non-response"}
{"id": "23865062", "sentence": "In patients chronically infected by HCV , a significant increase in @VARIANT$ expression was seen in hepatocytes and in lymphocytes [ ] . Overexpression of APOBEC has also been observed in HCV/HBV coinfection [ ] . APOBEC3 also appears to play an important role on treatment with exogenous @DRUG$ IFNα ) in vivo .", "label": "None"}
{"id": "24665456", "sentence": "Ponatinib is a potent @GENE$ inhibitor with activity against the @VARIANT$ mutation. [ ] However on October 31 , 2013 , the Food and Drug Administration asked the manufacturer of the leukemia chemotherapy drug @DRUG$ hydrochloride to suspend marketing and sales of this drug because of the risk of life threatening blood clots and severe narrowing of blood vessels .", "label": "None"}
{"id": "15736989", "sentence": "@VARIANT$ in the context of either transiently expressed wild-type @GENE$ or the mutant alleles del L474–E749 ; A750P or L858R impairs inhibition by @DRUG$ or erlotinib as assessed by autophosphorylation .", "label": "resistance or non-response"}
{"id": "24924344", "sentence": "@DRUG$ ( A/T ) Chr16 : 56671632 MT1A ( near-gene 5 ) 0.047628 0.138 Oxaliplatin rs562 ( C/T ) Chr3 : 183637845 ABCC5 ( UTR3 ) 0.049494 0.392 rs3749445 ( A/G ) Chr3 : 183638506 ABCC5 ( UTR3 ) 0.044895 0.410 rs2292998 ( C/T ) Chr3 : 183663833 ABCC5 ( intronic ) 0.039882 0.277 rs1016752 ( C/G ) Chr3 : 183665062 ABCC5 ( intronic ) 0.039781 0.232 rs4148585 ( C/T ) Chr3 : 183670642 ABCC5 ( intronic ) 0.039781 0.283 rs6443924 ( A/G ) Chr3 : 183679532 ABCC5 ( intronic ) 0.039781 0.279 rs4148579 ( A/G ) Chr3 : 183685249 @GENE$ ( intronic ) 0.039781 0.279 rs939336 ( A/G =&gt ; C594C ) Chr3 : 183685534 ABCC5 ( exonic ) 0.039781 0.279 rs1132776 ( C/T = & gt ; A395A ) Chr3 : 183696402 ABCC5 ( exonic ) 0.044895 0.289 rs2313212 ( C/T ) Chr3 : 183700928 ABCC5 ( intronic ) 0.039781 0.279 rs4148575 ( C/T ) Chr3 : 183702275 ABCC5 ( UTR3 ) 0.044895 0.289 rs1846692 ( C/T ) Chr16 : 56671696 MT1A ( near - gene 5 ) 0.049494 0.360 rs35346959 ( A/G ) Chr16 : 56671867 MT1A ( near- gene 5 ) 0.044895 0.137 rs9922957 ( C/G ) Chr16 : 56672380 MT1A ( near - gene 5 ) 0.039781 0.185 rs9922409 ( A/G ) Chr16 : 56672400 MT1A ( near - gene 5 ) 0.04532 0.103 rs7190725 ( G/T ) Chr16 : 56673290 MT1A ( intronic ) 0.044895 0.170 rs8052394 ( A/G =&gt ; K51R ) Chr16 : 56673828 MT1A ( missense ) 0.044895 0.152 rs1800566 ( C/T = & gt ; @VARIANT$ ) chr16 : 69745145 NQO1 ( exonic ) 0.039781 0.258 rs689455 ( A/C ) Chr16 : 69761661 NQO1 ( near- gene 5 ) 0.039781 0.242", "label": "None"}
{"id": "24009732", "sentence": "Targeted therapy to inhibit the oncogene FIP1L1-PDGFRα has met with some success : the first-generation tyrosine kinase inhibitor ( TKI ) imatinib has been reported to be effective to @GENE$ , but imatinib-resistant mutations emerged . Several mutations in the kinase domains such as @VARIANT$ , T674I , S601P and L629P , have been demonstrated to be responsible for the drug-resistance .", "label": "None"}
{"id": "24876815", "sentence": "The cause of refractoriness has been identified in ca. 15 % of mCRC patients as mutations in the BRAF gene , primarily @VARIANT$ substitution . Raf family proteins are downstream of Ras proteins in the signal transduction pathway originating at EGFR . It comes as no surprise , then , that activating mutations in the @GENE$ gene occurring in cancer cells have a similar clinical effect to KRAS gene mutations , making them refractory both to cetuximab and @DRUG$ [ , , – ] .", "label": "resistance or non-response"}
{"id": "21333004", "sentence": "According to recent reports , the sensitivity to kinase inhibition reflects intrinsic differences in the binding affinity of the EGFR mutants such as L858R , @VARIANT$ , and exon19 deletions [ , - ] . Yun et al [ ] showed that gefitinib directly binds more tightly to the L858R mutant than to the wild type @GENE$ in vitro , while Fabian et al [ ] indicated that EGFR with gefitinib sensitive mutations does not differ from wild type EGFR in terms of @DRUG$ binding affinity .", "label": "sensitivity"}
{"id": "17973572", "sentence": "A similar clinical benefit is observed in patients with lung cancers harboring the two most common EGFR activating mutations , @VARIANT$ and exon 19 deletions [ – , ] . The striking initial response to small molecule tyrosine kinase inhibitors is thought to stem from the phenomenon of “oncogene addiction” [ ] , and a common signaling cascade may be involved in the apoptosis induced by multiple TKIs [ ] . Rapid inactivation of phosphorylated ERK , AKT , and STAT3/5 , and the delayed accumulation of phosphorylated p38 are commonly observed in @GENE$ , BCR-ABL- , and EGFR dependent cells after exposure to the specific inhibitors SU6655 , imatinib , and @DRUG$ , respectively [ ] .", "label": "None"}
{"id": "24634785", "sentence": "Despite the higher rates of molecular response , @VARIANT$ mutation is emerging as a common mechanism of failure of second-line TKIs [ ] . It was reported that combined treatment with nilotinib or dasatinib with SGX393 ( inhibitor of native and T315I-mutant BCR/ABL ) might be useful for reduction of BCR/ABL mutants in Ph-chromosome positive leukemia [ ] . In addition , it was shown that combined treatment with dasatinib and @DRUG$ ( suberoylanilide hydroxamic acid ( SAHA ) @GENE$ ) led to depletion of wild-type and mutant forms of BCR/ABL expressing cells [ ] .", "label": "None"}
{"id": "19707322", "sentence": "Nilotinib is approximately 30-fold more sensitive than imatinib in the killing of BCR-ABL dependent cells derived from patients with CML ( K562 and Ku-812F cells ) and cell lines ( 32D and baF3 ) , and it is active against 32/33 imatinib-resistant cell lines with @GENE$ mutations . The sensitivity of Bcr-Abl mutants to AMN107 can be summarized into 4 categories : high ( IC50 ≤ 70 nmol/L : M244V , G250E , Q252H , F3llL , F317L , M351T , V379I , @VARIANT$ , H396P , H396R ) , medium ( IC50 ≤ 200 nmol/L : Y253F , E255K , F359V ) , low ( IC50 ≤ 450 nmol/L : Y253H , E255V ) , and insensitive ( IC50 & gt ; 2 μmol/L : T315I ) ( ) ( ) .", "label": "None"}
{"id": "25562700", "sentence": "Molecule Target Biomarker Indication vemurafenib BRAF kinase BRAF @VARIANT$ mutant melanoma vandetanib VEGFR , EGFR , RETR not included on the label thyroid cancer @DRUG$ CYP 17A1 not included on the label prostate cancer ipilimumab CTLA-4 not included on the label melanoma brentuximab vedotin CD30 ( ACD technology ) not included on the label lymphoma crizotinib ALK ALK-EML4 fusion protein lung cancer BRAF : Serine/threonine-protein kinase B-Raf ; VEGFR : Vascular endothelial growth factor receptor ; EGFR : epidermal growth factor receptor ; RETR : RET proto-oncogen receptor ; CYP 17A1 : cytochrome P450 17A1 ; CTLA-4 : Cytotoxic T-Lymphocyte Antigen 4 ; CD30 : Cluster of Differentiation 30 ; ADC : Antibody Conjugated Drug ; ALK-EML4 : anaplastic lymphoma kinase (ALK) ; echinoderm @GENE$ ( EML4 ) fusion .", "label": "None"}
{"id": "24212826", "sentence": "In comparison with docetaxel , @DRUG$ therapy offers comparable clinical efficacy and a better quality of life when used as second-line treatment in previously treated NSCLC patients [ ] . In a previous study of EGFR-TKI treatment in chemonaive patients with specific EGFR mutations , such as exon 19 deletions and substitutions at @VARIANT$ , the treatment effect of @GENE$ was sustained for up to 8–9 months and was significantly superior to the treatment effect of platinum based chemotherapy [ ] .", "label": "sensitivity"}
{"id": "25295230", "sentence": "@VARIANT$ AML @DRUG$ Smith et al. ( ) Ba/F3 AML AC220 Albers et al. ( ) @GENE$ AML ( pediatric ) Sorafenib Baker et al. ( )", "label": "None"}
{"id": "23875003", "sentence": "Exogenous lipoic acid equilibrates among different intracellular and extracellular compartments but can not substitute for covalently bound lipoic acid ( as the @DRUG$ of mitochondrial complexes such as pyruvate dehydrogenase and α-ketoglutarate dehydrogenase ) . This study is aimed at establishing the effects of lipoic acid , on glucose uptake , @GENE$ signaling through the PI3K/Akt pathway , and synaptic plasticity on a triple transgenic mouse model of Alzheimer’s disease ( 3xTg-AD ) . This transgenic model harbors PS1 ( M146V ) , APP ( Swe ) , and tau ( @VARIANT$ ) transgenes , shows progressive development of both plaques and tangles with increasing age in a region specific manner : ~6 month-old 3xTg-AD mice show diffuse amyloid plaques in different regions but tangle pathology is established at ~12 months [ ] .", "label": "None"}
{"id": "21687596", "sentence": "Many of these irreversible inhibitors have demonstrated activity in preclinical studies against @VARIANT$ mutations . HKI-272 [ , ] and @DRUG$ , ] , which are dual inhibitors against @GENE$ and HER2 , and PF-00299804 [ ] , which is a multi-inhibitor against EGFR , HER2 , and HER4 , are representative agents currently undergoing clinical trial .", "label": "response"}
{"id": "23233201", "sentence": "Moreover , as shown in , SHP2 physically associated with PECAM-1 more prominently in cells expressing the @VARIANT$ or T315I mutant as compared with cells expressing native BCR/ABL , while these mutants had less significant effects on complex formation between SHP2 and Gab2 . We next examined the effect of dasatinib on tyrosine phosphorylation of PECAM-1 in @GENE$ cells expressing the T315I mutant , which is totally resistant to @DRUG$ as well as imatinib but sensitive to the multi-kinase inhibitor sorafenib ( , ) .", "label": "None"}
{"id": "24533047", "sentence": "Small-molecule @GENE$ kinase inhibitors ( TKIs ) could competitively block the EGFR dependent pathway . In the last decade , a series of RCTs have confirmed the non-inferior efficacy and relatively low toxicity of @DRUG$ and gefitinib in treatment naïve or previously treated NSCLC patients compared with the standard chemotherapy – . Meanwhile , pre planned or post-study biomarker analyses indicated that the presence of EGFR mutation , which mainly refers to deletions in exon 19 or the @VARIANT$ substitution in exon 21 , was the strongest predictor of efficacy for EGFR-TKIs .", "label": "sensitivity"}
{"id": "23569389", "sentence": "Dasatinib is active against at least 100 of the BCR-ABL1 mutations known to confer resistance to @DRUG$ that have been tested to date , ( including many in the p-loop region ) , except for the T315I mutation and a few other mutations ( @VARIANT$ , F317L/V , and T315A ) . Dasatinib is able to block downstream intracellular signaling pathways activated by BCR-ABL1 in vitro , including signal transducer and activator of transcription 5 ( Stat5 ) , with downregulation of Stat5 target gene expression and the @GENE$ , Notably , dasatinib is not a substrate of multidrug resistance protein-1 , an efflux protein expressed on normal and leukemic hematopoietic stem cells .", "label": "None"}
{"id": "19672255", "sentence": "Similarly , tumour response to @DRUG$ may be influenced by polymorphisms in genes involved in the nucleotide excision repair pathway ( ; ) . These include polymorphisms in codon 118 ( AAC to AAT ) of the excision repair cross complementing group 1 ( ERCC1 ) gene and codon 399 ( CGG to CAG ) of the X-ray repair cross complementing group 1 ( XRCC1 ) . The aim of this study was to evaluate three genetic alterations ( TP53 mutation , @GENE$ mutation and MSI ) and three polymorphisms ( MTHFR @VARIANT$ , ERCC1-118 and XRCC1-399 ) for their ability to predict response and toxicity to FOLFOX first line chemotherapy in the treatment of mCRC .", "label": "None"}
{"id": "22569033", "sentence": "Crenolanib was effective in blocking the activity of single or compound @GENE$ D842V mutant kinases . In contrast , @DRUG$ had no significant activity against these same mutant kinases . A phase II clinical study of crenolanib for treatment of GIST patients with primary or secondary PDGFRA @VARIANT$ mutation is currently recruiting patients ( ClinicalTrials.gov Identifier : NCT01243346 ) .", "label": "resistance or non-response"}
{"id": "23527257", "sentence": "Afatinib ( @DRUG$ Boehringer Ingelheim GmbH ) , is an irreversible inhibitor of both EGFR , @GENE$ and HER4 kinases and retains some activity in tumors with @VARIANT$ mutations , but at doses that are a log higher than what is needed for cancers harboring sensitizing mutations , , , , , .", "label": "None"}
{"id": "23320171", "sentence": "Further research is looking into inhibiting other targets such as mTOR , @VARIANT$ , or @GENE$ pathways . Two randomized trials are evaluating the addition of the mTOR inhibitor , @DRUG$ , to chemotherapy and Trastuzumab in the first-line and Trastuzumab-resistance metastatic setting .", "label": "None"}
{"id": "23788917", "sentence": "Unfortunately , more than half of patients with MET gene amplification also presented the @VARIANT$ mutation in the EGFR gene . Despite the lack of unequivocal efficacy , simultaneous inhibition of c-MET and EGFR function seems to be an attractive alternative therapeutic option in resistance to reversible EGFR TKI . There are ongoing second and third phase trials of the c-MET inhibitors tivantinib and @DRUG$ , used together with erlotinib in patients previously untreated with @GENE$ TKI or in case of progression after successful monotherapy with erlotinib [ , – ] .", "label": "None"}
{"id": "21192840", "sentence": "Tumor type EGFR mutation EGFR expression changes @GENE$ targeting agents ( FDA approved for clinical use ) Resistance mechanisms Non-small cell lung cancer Kinase domain deletions ( exon 19 ) , point mutations ( exon 21 ) Gene amplification @DRUG$ , Gefitinib @VARIANT$ gatekeeper mutation ( 50 % ) , , elevated c-Met/HGF expression ( 20 % ) –", "label": "resistance or non-response"}
{"id": "24197907", "sentence": "Six ( 5 % ) tumor samples harbored EGFR mutations : four exon 19 deletions and two @VARIANT$ mutations in exon 21 . The presence of @GENE$ mutations was not associated with outcome . At the time of data collection , one of the six patients had received erlotinib as second-line treatment for more than one month and another had received @DRUG$ as second-line treatment for three weeks .", "label": "sensitivity"}
{"id": "24223799", "sentence": "Targeting additional pathways other than @GENE$ in NSCLC patients has already been shown to be effective in clinical trials combining @DRUG$ with tivantinib or MetMab , . Therefore , concurrent targeting of mTOR and Wnt pathways may further improve drug efficacy and prevent resistance . Furthermore , in the event that the @VARIANT$ mutation can be targeted by TKIs , additional pathways such as mTOR and Wnt may cause additional tumorigenicity even after downregulation of p-EGFR .", "label": "resistance or non-response"}
{"id": "24349829", "sentence": "As would be predicted from the prior studies cited above , miR-7 blunted @GENE$ signaling and reversed the radio-resistance . Correspondingly , direct injection of a liposome encapsulated miR-7 plasmid into established EGFR-TKI sensitive and resistant tumors bearing the @VARIANT$ EGFR mutant resulted in significant tumor regression in conjunction with repression of EGFR , RAF-1 and IRS-1 expression . In head and neck cancer , miR-7 functioned in a synergistic manner with @DRUG$ to render FaDu Erlotinib-resistant cells susceptible to the growth inhibitory activities of the drug .", "label": "None"}
{"id": "24590311", "sentence": "Pretreatment with carfilzomib followed by addition of imatinib resulted in a significant reduction in viability in Ba/F3 @VARIANT$ , Ba/F3 M351T , LAMA84R and KCL22R ( P⩽0.04 ) . ( c ) Western blot analysis of phosphorylated-CRKL in imatinib-sensitive and -resistant cell lines following exposure to carfilzomib , imatinib or a combination of carfilzomib at t=0 , followed by imatinib at t=24 ; whole cell lysates were prepared 48 h after exposure to the first drug . ( d ) CML @GENE$ cells ( n=3 ) were cultured in the presence of carfilzomib , imatinib , @DRUG$ or a combination of carfilzomib plus imatinib/nilotinib either simultaneously or carfilzomib at t=0 , followed by imatinib/nilotinib at t=24 ; after 48 h , cells were transferred to LTC-IC assays .", "label": "None"}
{"id": "19216789", "sentence": "To investigate the effects of AZD0530 on @GENE$ harbouring mutations conferring Imatinib-resistance ( Y253F , E255K and @VARIANT$ ) Ba/F3 cells expressing these mutants were treated with the dual Src/Abl kinase inhibitor AZD0530 , and proliferation was assessed comparing them with the Ba/F3 infected p185Bcr-Abl cells treated in a similar manner ( Figure ) .", "label": "None"}
{"id": "24523596", "sentence": "Rudin et al , Lemos et al , van Erp et al 1291T & gt ; C @VARIANT$ TMD Insensitive to @DRUG$ mediated inhibition . Kawahara et al @GENE$ ; G No change TMD 1465T & gt ; C F489L TMD 1768A&gt ; T N590Y TMD 1858G&gt;A D620N TMD 2237G&gt ; T – 2393G&gt ; T –", "label": "None"}
{"id": "25580271", "sentence": "When cross-over to EGFR tyrosine kinase inhibitor therapy was examined , 75 % of patients who received cisplatin and @DRUG$ received an @GENE$ tyrosine kinase inhibitor and 56 % of patients who received cisplatin and gemcitabine received an EGFR tyrosine kinase inhibitor . The rate of second-line EGFR tyrosine kinase inhibitors in countries with insurance coverage was 91 % and without insurance coverage was 52 % . Overall survival of patients with common EGFR mutations ( defined as exon 19 deletion and exon 21 @VARIANT$ point mutation ) in LUX-3 , LUX-6 , and combined cohorts [ ]", "label": "None"}
{"id": "25349473", "sentence": "The cumulative incidence of CMR on imatinib therapy was 0.5 % @GENE$ and 8.3 % at 5 years in newly diagnosed CP-CML patients . Studies with the second-generation TKI nilotinib showed that patients on @DRUG$ were more likely to be in CMR at 24 months than those on imatinib ( 22.1 % versus 8.7 % ) . The PACE trial results indicated that 15 % of patients who entered treatment with CP-CML and 23 % of patients with the @VARIANT$ mutation were in CMR at 12 months .", "label": "None"}
{"id": "22970367", "sentence": "The data suggest that low BRCA1 level may neutralize the negative effects of the EGFR T790M mutation on @DRUG$ sensitivity and that high BRCA1 expression may lead to de novo @GENE$ TKI resistance potentially through increased DNA damage repair capacity [ ] . In addition to EGFR T790M , primary EGFR TKI resistance may also be due to other secondary mutations in EGFR ( e.g. , D761Y ) that occur in cis with an activating EGFR kinase domain mutation ( e.g. , @VARIANT$ ) [ ] .", "label": "sensitivity"}
{"id": "22792530", "sentence": "SW480 cells are considered functionally p53-deficient because the endogenous p53 protein contains two point mutations , @VARIANT$ and P309S , which result in an abnormal p53 protein [ ] . A study by Toscano et al. [ ] reported that @DRUG$ enhances @GENE$ induced apoptosis in p53-mutant CRC cell lines , including SW480 cells [ ] .", "label": "None"}
{"id": "25347122", "sentence": "PI3K/mTOR/AKT pathway ; @GENE$ NVP-BEZ235 ; 17-DMAG ( HSP90 inhibitor ) However , in these trials , TNBC was unselected based on gene ontologies and differential gene expression profiles . In the randomized open-label phase III CALGB 40502/NCCTG @VARIANT$ , the new and expensive BC treatments , nanoparticle albumin bound nab-paclitaxel ( Abraxane ) and ixabepilone , the latter being a potent epothilone that can be effective after microtubule inhibitor resistance ( Ixempra ) , have failed to demonstrate any superior efficacy versus the standard of weekly @DRUG$ in combination with bevacizumab in patients with chemotherapy naïve metastatic BC .", "label": "None"}
{"id": "24294007", "sentence": "Although a retrospective study and the PICCOLO ( @DRUG$ , Irinotecan and Ciclosporin in Colorectal Cancer Therapy ) trial have demonstrated a reduced response to cetuximab and panitumumab for patients with NRAS mutations , , further work is required to demonstrate the predictive capacity of these mutations . The @GENE$ an effector in the MAPK signaling pathway , downstream of K-Ras . Mutations in the proto-oncogene BRAF are present in 5 % –10 % of the metastatic CRC population and are also mutually exclusive of KRAS mutations . BRAF @VARIANT$ is the most common of all BRAF mutations ( present in 90 % of cases ) , and is enriched in a subset of patients who are female , greater than 70 years of age , with KRAS WT right sided colon cancer .", "label": "resistance or non-response"}
{"id": "22970367", "sentence": "However , in clinical studies , BIBW2992 did not prolong survival compared to placebo in NSCLC patients who have developed acquired resistance to gefitinib or @DRUG$ [ ] . Another agent in this class of next generation @GENE$ TKIs , PF-002999804 , inhibits all ERBB family members and has been shown to be effective against tumors harboring @VARIANT$ [ , ] .", "label": "resistance or non-response"}
{"id": "25378985", "sentence": "Possible mechanisms of acquired or secondary resistance to @DRUG$ include second mutations in the EGFR gene such as @VARIANT$ , activation of an alternative pathway including Met or @GENE$ amplification , histological transformation to small cell lung cancer ( SCLC ) and epithelial to mesenchymal transition [ ] .", "label": "None"}
{"id": "23566546", "sentence": "Case Histrogical type @GENE$ mutation status Brinkman index Treatment agent Response IL-8 ( ng/mL ) IL-10 ( ng/mL ) RANTES ( pg/ml ) 1 Ad Ex21 L858R 900 gefitinib PR 5.79 1.67 2 2 Ad Ex21 L858R 0 erlotinib PR_3.33 94.2 1.41 3 Ad Ex19 del 0 erlotinib PR 4.09 126 2.13 4 Ad Ex21 L858R 0 gefitinib PR_3.92 18.1 1.85 5 Ad Ex21 L858R + Ex19 del 370 erlotinib PR 21.9 1.23 2.11 6 Ad Ex19 del 0 erlotinib PR 7.05 1.37 2.56 7 Ad Ex19 del 0 gefitinib PR 4.82 1.59 2.02 8 Ad Ex21 L858R 1640 gefitinib PR 54.9 2.7 2.38 9 Ad negative 400 erlotinib SD 34.9 3.39 3.66 10 Ad negative 0 erlotinib SD 27.1 4.94 2.25 11 Ad unknown 1800 erlotinib SD NE NE NE 12 Sq Ex19 del 3840 gefitinib SD 12.6 1.1 1.98 13 Ad Ex19 del 30 erlotinib SD 5.27 0.69 2.66 14 Ad Ex19 del 0 erlotinib SD 10.5 0.85 2.5 15 Ad unknown 300 erlotinib SD 7.69 2.61 1.7 16 La negative 2080 @DRUG$ SD NE NE NE 17 Sq Ex21 L858R 750 erlotinib SD 11.6 56.3 3.06 18 Ad unknown 600 erlotinib SD 13.7 1.1 2.82 19 Ad Ex21 L858R 0 erlotinib SD 20.6 11.6 0.783 20 Ad Ex19 del 0 erlotinib SD 14.8 2.07 2.02 21 Ad Ex21 L858R + Ex19 del 0 gefitinib SD 3.04 1.3 1.76 22 Ad Ex19 del 200 gefitinib SD 10.9 1.59 1.91 23 Sq unknown 1560 erlotinib PD NE NE NE 24 Ad negative 1080 erlotinib PD 25.2 8.15 1.57 25 Ad unknown 0 erlotinib PD NE NE NE 26 Ad Ex18 @VARIANT$ 2000 erlotinib PD 11.6 4.48 3.12 27 Ad unknown 1410 erlotinib PD NE NE NE 28 Ad Ex19 del 1000 gefitinib PD 9.44 2.25 2.89 29 Ad negative 1100 erlotinib PD 56.3 5.63 2.16 30 Ad negative 2000 erlotinib PD 15.6 0.85 0.292 31 Ad negative 825 erlotinib PD 8.27 1.59 2.13 32 Ad Ex21 L858R 0 erlotinib PD 5.34 7.05 1.7 33 Ad negative 1680 erlotinib PD 57.7 1.63 2.06", "label": "None"}
{"id": "18060053", "sentence": "@DRUG$ and antiestrogens control proliferation of breast cancer cells by regulating the expression of multiple components of the cell cycle machinery including cyclins D1 and A , cdc25a and the @GENE$ p21Waf1/Cip1 ( p21 ) , and p27 Kip1 ( p27 ) , , . These molecules regulate the activity of the cyclin dependent kinases (cdks) , cdk4 and cdk2 , which in turn phosphorylate and inactivate tumor suppressors of the retinoblastoma protein ( pRb ) family . The pRb family of proteins inhibit the G1 to S phase transition by sequestering the @VARIANT$ family of transcription factors .", "label": "None"}
{"id": "17973572", "sentence": "After the cells were exposed to @DRUG$ for 24 h , Ba/F3-L858R cells were unable to proliferate while @GENE$ and Ba/F3-L858R-T790M cells continued to grow even in the presence of 1 μM gefitinib ( E ) . These results suggest that execution of apoptosis may be impaired by the presence of @VARIANT$ and , to a lesser extent , L747S .", "label": "None"}
{"id": "15736989", "sentence": "Furthermore , the NSCLC cell line H1975 harbors both the L858R and @VARIANT$ mutations , and is resistant to inhibition by @DRUG$ or erlotinib , unlike cell lines that express the L858R allele alone . In the H1975 cell line , it was possible to obtain adequate quantities of RNA to confirm that the L858R and T790M mutations are present on the same allele , as would be predicted if T790M confers resistance to inhibition of the L858R allele . Structural models of @GENE$ provide structural insights into these biological data .", "label": "resistance or non-response"}
{"id": "22927847", "sentence": "Downregulation of endogenous miR-100 in @VARIANT$ and SW-13 cells increased protein expression of mTOR , raptor , and IGF-IR [ ] . In order to evaluate the functional consequences of @GENE$ inhibition in adrenal carcinomas , Barlaskar et al. analyzed a large series of benign and malignant human adrenal tumors and a panel of ACC cell lines using a tyrosine kinase inhibitor , NVP-AEW541 , and a fully human monoclonal antibody anti-IGF-IR , @DRUG$ , both specifically targeting IGF-IR .", "label": "None"}
{"id": "23208557", "sentence": "Cancer EGFR exon18 @VARIANT$ Drug efficacy prediction of @DRUG$ and erlotinib exon19 deletion exon20 T790M exon21 L858R @GENE$ codon12 , 13 Drug efficacy prediction of cetuximab", "label": "None"}
{"id": "23232076", "sentence": "The deletion of the four amino acid sequence ( del 746–750 ) in the exon 19 and the substitution of leucine by arginine at codon 858 ( @VARIANT$ ) in exon 21 are two of the most common mutations in the kinase domain of EGFR gene in NSCLC patients [ ] . The small-molecule tyrosine kinase inhibitors including @DRUG$ and erlotinib have recently been approved for the treatment of patients with NSCLC [ , - ] . In addition , mutations in the @GENE$ been confirmed as predictors of the efficacy of treatment with EGFR-tyrosine kinase inhibitors .", "label": "sensitivity"}
{"id": "22563238", "sentence": "Purified imiglucerase is a monomeric @GENE$ of 497 amino acids , containing four N-linked glycosylation sites ( Mr = 60,430 ) : it differs from placental glucocerebrosidase by one amino acid at position 495 , where @DRUG$ is substituted for arginine ( @VARIANT$ ) .", "label": "None"}
{"id": "15737014", "sentence": "To determine how the @VARIANT$ mutation would affect EGFR proteins already containing mutations associated with sensitivity to EGFR tyrosine kinase inhibitors , we introduced the specific mutation into EGFR cDNAs that encoded the exon 21 and 19 mutations found in patients 1 and 2 , respectively . Various lysates from cells that were serum starved and pre treated with gefitinib or @DRUG$ were analyzed by immunoblotting . Amounts of total EGFR ( t-EGFR ) were determined using an @GENE$ monoclonal antibody , and actin served as an indicator of relative levels of protein per sample .", "label": "resistance or non-response"}
{"id": "20190765", "sentence": "A . PC9 cells expressing either @VARIANT$ EGFR or L858R/T790M @GENE$ were exposed to indicated concentrations of dasatinib ( D ) or @DRUG$ ( E ) for 120 hr and cell viability was accessed .", "label": "sensitivity"}
{"id": "23935374", "sentence": "First , GIST mutational status appears to be important , and there is a consensus that patients with the imatinib-insensitive @VARIANT$ mutation of @GENE$ should not receive adjuvant imatinib .", "label": "resistance or non-response"}
{"id": "15737014", "sentence": "Using this insight , new small-molecule inhibitors have been identified that retain activity against the majority of imatinib-resistant BCR-ABL mutants [ , ] . For example , in CML , a commonly found mutation is a C→T single nucleotide change that replaces threonine with isoleucine at position 315 ( @VARIANT$ ) in the ABL kinase domain [ , , ] . In GIST and @GENE$ , respectively , the analogous T670I mutation in KIT and T674I mutation in PDGFR-alpha have been associated with acquired resistance to this drug [ , ] .", "label": "None"}
{"id": "22787448", "sentence": "Such discrepancy can be explained by the difference in the nature of the substituted amino-acid ( cysteine in one case and @DRUG$ in the other ) or by differences in experimental conditions ( whole-cell configuration on oocytes and giant-patch configuration on COS-7 cells , respectively ) . Furthermore , Matavel et al. showed that @VARIANT$ and R243C mutants exhibited an impaired activation by both @GENE$ and PKC , whereas C-terminal KCNQ1 mutants presented an increased activation .", "label": "None"}
{"id": "20485284", "sentence": "Moreover , the introduction/presence of the BRAF @VARIANT$ allele in CRC ( DiFi-BRAF , COLO-205 and HT-29 ) cell lines impaired the therapeutic potential of anti-EGFR moAbs . Thus , in the clinical setting , the therapeutic effect of anti-EGFR moAbs could be restored by a two-hit approach that blocks the EGFR pathway in multiple locations . In accordance with previous reports ( ; ) , we found that @GENE$ mutation predicted resistance to @DRUG$ treatment in the subpopulation of patients that have received this kind of therapy .", "label": "resistance or non-response"}
{"id": "25032217", "sentence": "Notably , the Evaluation of Genomic Applications in Practice and Prevention ( EGAPP ) Working Group ( EWG ) found insufficient evidence to recommend or discourage testing for mutations in BRAF @VARIANT$ , NRAS , or PIK3CA and/or loss of PTEN or AKT protein . Therefore , the EWG discourages the use of these tests for deciding whether to introduce anti-EGFR therapy with @DRUG$ or panitumumab until more evidence supports improved clinical outcomes [ ] . Moreover , a meta-analysis suggests that mutations in KRAS exons 3 and 4 , NRAS , @GENE$ , PIK3CA , and nonfunctional PTEN predict resistance to anti-EGFR therapies [ ] and concluded that these biomarkers should be implemented for prediction of clinical benefit from anti-EGFR antibodies in mCRC .", "label": "resistance or non-response"}
{"id": "23520446", "sentence": "Approximately 50 % of EGFR mutations consist of deletions in exon 19 , whereas 35–45 % consist of the @VARIANT$ mutation and 5 % consist of insertions in exon 20 or the L861Q mutation – . Gefitinib ( Iressa ) and @DRUG$ ( Tarceva ) are @GENE$ inhibitors that are used clinically for the treatment of advanced NSCLC , primarily that with EGFR mutations in the tyrosine kinase domains – .", "label": "sensitivity"}
{"id": "24603336", "sentence": "Among these , the most relevant one was cytochrome p450 ( CYP3A4 ) , which is the main metabolizing enzyme for FOLFIRI ( folinic acid/fluorouracil/irinotecan ) regimen , etoposide , rapamycin and other antineoplastic drugs ( ) . We tested the effects of mutant p53 on CYP3A4 by ectopic expression of p53 mutants R175H , R273H and @VARIANT$ in the H1299 cells ( @GENE$ ) .", "label": "None"}
{"id": "23994953", "sentence": "Somatic mutations in exons encoding the tyrosine kinase ( TK ) domain of the epidermal growth factor receptor (EGFR) are positively associated with increased sensitivity of non-small cell lung cancer ( NSCLC ) patients to the selective @GENE$ TK inhibitors ( TKIs ) gefitinib ( Iressa™ ) and @DRUG$ ( Tarceva™ ) . Prospective trials have demonstrated an impressive ~75 % response rate for patients whose tumors harbor these mutations , which occur as either multinucleotide in-frame deletions in exon 19 ( e.g. , delE746-A750 ) or as single missense mutations ( e.g. , @VARIANT$ ) .", "label": "sensitivity"}
{"id": "25462529", "sentence": "Residue D167 of IN was mutated in this study because it is well conserved in HIV and it is embedded within a short stretch of amino acids ( 161–173 ) with nuclear localization signal properties and important for IN–p75/LEDGF interaction. , , We initially chose @DRUG$ to replace a polar acid residue by a polar basic/neutral one with the purpose to induce a mild phenotype with an integration rate between WT and @VARIANT$ vectors . Integrase mutations D167A and D167K induced opposite effect on single round infectivity of HIV with D167A increasing it to 140 % while D167K reduced it to 5 % of WT indicating a critical role played by this residue in the processing of the @GENE$ .", "label": "None"}
{"id": "23843700", "sentence": "While initial studies of first-generation CDK inhibitors , such as @DRUG$ , failed to demonstrate efficacy in preclinical studies , second-generation CDK inhibitors ( SCH 727965 ) , have shown more promising results in halting melanoma progression in mouse xenografts . This effect is potentiated when CDK inhibitors are combined with paclitaxel. , RB1 is the central piece of the pathway controlled by p16INK4A , serving in its unphosphorylated form to sequester @VARIANT$ @GENE$ it from inducing gene expression critical for transition from the G1 to the S phase of the cell cycle .", "label": "None"}
{"id": "23152055", "sentence": "Thus , knockout of STAT1 gene suppresses development of diabetes in the nonobese diabetic mice and protects against @DRUG$ induced diabetes . These data suggest that regulators of type I IFN signaling pathways may be potential therapeutic targets for the prevention of @VARIANT$ . Ubiquitin-specific peptidase 18 ( USP18 ; UBP43 ) is a major IFN stimulated gene 15 (ISG15)-specific protease and its activity is crucial for proper regulation of @GENE$ conjugated proteins .", "label": "None"}
{"id": "23091721", "sentence": "It has been shown that higher levels of AREG and EREG have a positive predictive value in determining response to @DRUG$ , and when treated with cetuximab these tumors have better PFS [ ] . Although attempts at developing drugs targeting @GENE$ have largely been unsuccessful , several BRAF inhibitors have been discovered . Sorafenib is an oral multikinase inhibitor that targets both wtBRAF and oncogenic BRAF @VARIANT$ and has in vitro activity in CRC cell lines with this mutation .", "label": "None"}
{"id": "21687596", "sentence": "In the gefitinib-resistant cell line , clones with amplified @VARIANT$ mutant alleles existed in small quantities . Selective proliferation of these clones occurred on long-term exposure to PF-00299804 . The researchers suggested that although irreversible EGFR-TKI may be transiently effective against cancers harboring T790M mutations , clones harboring amplified EGFR T790M will rapidly emerge in vitro and in vivo through selection of pre existing @GENE$ T790M or high expressing clones , leading to clinical drug resistance .", "label": "resistance or non-response"}
{"id": "22655263", "sentence": "Ki determination demonstrated a very similar biochemical potency on wild-type ALK and the @VARIANT$ @GENE$ mutant ( 0.09 and 0.08 nM respectively ) , with both cellular and in vivo data ( using engineered Ba/F3 cells ) indicating that growth of ALK–L1196M mutant driven-cells is inhibited at similar , albeit slightly higher , doses which inhibit cells harboring wild-type ALK ( Katayama et al. , ) . AP26113 was also described to be active on a series of in vitro induced @DRUG$ resistant mutations , which however have not been observed to date in clinical cases of acquired crizotinib resistance ( Zhang et al. , ) .", "label": "resistance"}
{"id": "15737014", "sentence": "Importantly , we find that the T790M mutation confers drug resistance not just to wild-type @GENE$ but also to mutant EGFRs associated with clinical responsiveness to EGFR tyrosine kinase inhibitors [ , , ] . In tumors from patients not treated with either @DRUG$ or erlotinib , the 2369 C→T mutation ( @VARIANT$ ) appears to be extremely rare .", "label": "resistance or non-response"}
{"id": "22252115", "sentence": "This hypothesis may explain the sensitivity to @DRUG$ of the patients with @GENE$ @VARIANT$ mutation .", "label": "sensitivity"}
{"id": "22101934", "sentence": "@GENE$ GnTi− cells were transfected with the plasmid DNA encoding tEGFR , and cultured in the presence and absence of 50 nM @DRUG$ . ( d ) Coomassie blue stained SDS-PAGE analysis of the purified @VARIANT$ tEGFR and Δ746–750 tEGFR with either EGF or Cetuximab ( Cetux ) as ligand .", "label": "None"}
{"id": "15736989", "sentence": "A ribbon structure of erlotinib bound to the EGFR kinase domain ( ) shows the threonine residue at position 790 in green and the positions of the exon 19 and @VARIANT$ gain-of-function mutations . These observations provide convincing evidence that , at least in some patients with NSCLC , resistance to @DRUG$ or erlotinib can be attributed to acquisition of a T790M mutation in the context of @GENE$ .", "label": "sensitivity"}
{"id": "25580271", "sentence": "When cross-over to EGFR tyrosine kinase inhibitor therapy was examined , 75 % of patients who received cisplatin and pemetrexed received an @GENE$ tyrosine kinase inhibitor and 56 % of patients who received @DRUG$ and gemcitabine received an EGFR tyrosine kinase inhibitor . The rate of second-line EGFR tyrosine kinase inhibitors in countries with insurance coverage was 91 % and without insurance coverage was 52 % . Overall survival of patients with common EGFR mutations ( defined as exon 19 deletion and exon 21 @VARIANT$ point mutation ) in LUX-3 , LUX-6 , and combined cohorts [ ]", "label": "None"}
{"id": "24789720", "sentence": "Mechanism of achieving resistance to erlotinib and @DRUG$ remains unclear . The recent reports confirmed , that T790M substitution could be detected in EGFR-TKIs naïve patients independently of other @GENE$ gene mutations ( predominantly @VARIANT$ substitution and deletions in exon 19 ) .", "label": "sensitivity"}
{"id": "24971022", "sentence": "@DRUG$ Glycopeptide antibiotic Cytotoxic action by induction of DNA strand breaks Ipilimumab Humanized IgG monoclonal antibody Overcoming @GENE$ suppression to enhance the immune response against tumors Vemurafenib , dabrafenib Synthetic small molecules Binding to the ATP binding site of BRAF ( @VARIANT$ ) kinase with inhibition of downstream pathway", "label": "None"}
{"id": "23976869", "sentence": "The @VARIANT$ mutation within the kinase domain of @GENE$ ( adenosine-5′-triphosphate [ ATP ] -binding region ) seems to be the most frequent mutation that appears under @DRUG$ treatment and that causes resistance through steric hindrance mechanisms .", "label": "resistance"}
{"id": "25426931", "sentence": "To determine active concentrations of both inhibitors , we treated BCR-ABL negative and positive Ba/F3 cells , including the IM-resistant BCR-ABL mutants @VARIANT$ , Y253F and F317L , with increasing concentrations of PHA-739358 and R763/AS703569 . PHA-739358 strongly inhibited cell proliferation in parental and BCR-ABL expressing Ba/F3 cells in a dose dependent manner . Thus , sensitivity of individual BCR-ABL mutants to PHA-739358 and R763/AS703569 did not correlate with the degree of resistance to IM , and the highly @DRUG$ resistant BCR-ABL/T315I mutation displayed similar dose-response compared to @GENE$ wt cells .", "label": "None"}
{"id": "24280348", "sentence": "This type of drugs selectively bind to the ATP binding pocket of the phosphorylation sites on the EGFR tyrosine kinase domain , thus suppress @GENE$ activation and block downstream signaling pathways . @DRUG$ has shown measurable efficacy at early stage of treatment , but patients become insensitive to this drug after 6 to 9 months , which finally leads to treatment failure [ ] . Several resistance mechanisms , such as EGFR @VARIANT$ secondary mutation that leads to a higher ATP binding capacity , and MET amplification resulting in an aberrantly activated alternative pathway that bypasses the inhibited EGF receptors , had been discovered .", "label": "resistance or non-response"}
{"id": "24741343", "sentence": "Prior to scanning electron microscopy ( SEM ) measurements , the mixed-culture biofilm attached electrode was first fixed in a 2.5 % glutaraldehyde solution for 1 h , then in a series of @DRUG$ dehydration solution ( i.e. , 25 % , 50 % , 75 % , and 100 % v/v EtOH ; 0.5 h each treatment ) , and after that , dried at the @GENE$ point for 3 h . The resultant specimen was coated with gold using a coating device ( Emitech @VARIANT$ ; UK ) and observed under a SEM ( JEOL , JSM-6330F ; Japan ) at 20 kV .", "label": "None"}
{"id": "25465236", "sentence": "( C ) EGFR T790M mutant does not resemble pEGFR unlike the EGFR L858R mutant shown in B. ( D–F ) increased inhibition potency for @DRUG$ against EGFR L858R mutant compared to EGFR WT protein and subsequent decrease in potency for Erlotinib against @GENE$ L858R + E884K double mutant . ( G–I ) increased inhibition potency for Gefitinib against EGFR L858R mutant compared to EGFR WT protein and subsequent further increase in potency for Gefitinib against EGFR L858R + E884K double mutant . ( J ) EGFR @VARIANT$ activated more than T790M but less than L858R .", "label": "None"}
{"id": "23992330", "sentence": "In the colorectal cancer setting , preclinical in vitro models of resistance to the anti-EGFR mAbs cetuximab and @DRUG$ include cell lines showing mutations of the K-Ras gene , most frequently in codon 12 of exon 2 , such as SW480 , LS174T , HCT116 , LoVo cells . These mutations produce a single amino acid change resulting in mutant Ras proteins that are insensitive to GAP function and constitutively active , with consequent activation of the @GENE$ signaling [ ] . Furthermore , several colorectal cancer cell lines ( VAC0432 , SNU-C5 , HT29 , KM20 , WiDr ) are considered valuable models of resistance to the B- Raf ( @VARIANT$ ) inhibitor vemurafenib [ ] because of the high levels of EGFR expression .", "label": "None"}
{"id": "24501009", "sentence": "Strategies to improve EGFR inhibition in EGFR @VARIANT$ cancers include the combination of irreversible @GENE$ inhibitors with the EGFR‐directed antibody @DRUG$ ( as reported for afatinib plus cetuximab ) 19 ; the development of more potent and specific inhibitors of EGFR T790M20,21 ; and the use of intermittent but high doses of existing irreversible EGFR inhibitors .", "label": "response"}
{"id": "25221748", "sentence": "This agent is also being assessed in a phase II trial in patients with de novo resistant @VARIANT$ mutations not previously treated with EGFR-TKIs ( www.clinicaltrials.gov : NCT01854034 ) and in patients with EGFR mutations and/or EGFR-TKI resistant disease , as part of a phase II cluster study in Chinese patients evaluating five novel inhibitors of HSP90 , PI3K , ALK , MET , and MEK ( ) . Further , AUY922 is also being assessed in combination with @DRUG$ in patients who have previously responded to EGFR-TKIs and/or whose tumors harbor activating @GENE$ mutations ( www.clinicaltrials.gov : NCT01259089 ) , with results expected in the near future .", "label": "resistance or non-response"}
{"id": "24650752", "sentence": "However , we are not aware of any studies that have examined a correlation between hyperbilirubinemia and the UGT1A9 @VARIANT$ &gt ; T polymorphism . The goals of the present study were as follows : 1 ) to determine the major molecular response rate (MMR) at 12 months of twice daily ( BID ) treatment with 400 mg nilotinib in patients with imatinib-resistant/intolerant CML-CP or -AP; 2 ) to evaluate molecular responses associated with @GENE$ mutation status or plasma concentrations of nilotinib ; and 3 ) to evaluate the safety of administering 400 mg nilotinib BID , including hyperbilirubinemia development , based on plasma concentrations of @DRUG$ or polymorphisms of UGT1A1 and UGT1A9 .", "label": "None"}
{"id": "23690929", "sentence": "HGF induces resistance to irreversible EGFR-TKIs and mutant EGFR-selective TKIs , which were developed to overcome @VARIANT$ mediated EGFR-TKI resistance . Recent clinical trials with irreversible TKI monotherapy failed to demonstrate an objective response in @GENE$ mutant lung cancer patients that were refractory to treatment with the reversible EGFR-TKIs—gefitinib and @DRUG$ .", "label": "resistance or non-response"}
{"id": "24944510", "sentence": "Multiple secondary mutations have already been identified in patients treated with @DRUG$ . Homologous to the gatekeeper EGFR T790M mutation is the L1196M substitution , which , unlike EGFR T790M , does not appear to confer a growth disadvantage to cells . Other secondary mutations such as G1269A , @VARIANT$ , L1152R , and 1151Tins may affect affinity of the mutant @GENE$ for either ATP or drug , and these differences have ramifications on the development of next-generation ALK inhibitors , which have varied mutation-specific efficacy among different agents .", "label": "resistance"}
{"id": "15737014", "sentence": "Consistent with this , the T790M mutation has been shown not to abrogate the catalytic activity of wild-type @GENE$ [ ] . The T790M mutation could also affect the kinase activity or alter the substrate specificity of mutant EGFRs , such that a proliferative advantage would be conferred upon cells bearing the mutation . Consistent with this , the H1975 NSCLC cell line reported here to contain both T790M and @VARIANT$ did not to our knowledge undergo any prior treatment with @DRUG$ or erlotinib ; the doubly mutated cells must have become dominant over time through multiple passages in vitro .", "label": "sensitivity"}
{"id": "19547661", "sentence": "A somatic mutation ( @VARIANT$ ) in exon 15 of BRAF has been identified in multiple human cancers with a mutation rate of 66 % in malignant melanomas [ ] and at lower frequency in other human carcinomas . Recently , it was demonstrated that wildtype @GENE$ is required for the response of patients with metastatic colorectal cancer to cetuximab and @DRUG$ [ ] .", "label": "resistance or non-response"}
{"id": "24922058", "sentence": "It would be interesting to study in the future if @VARIANT$ , CTBP , MECP2 , @GENE$ or other yet-to-be identified REST interactors are involved . Notably , we did not observe pathways specifically enriched in any group of REST targets with different @DRUG$ occupancies .", "label": "None"}
{"id": "18828913", "sentence": "@DRUG$ and XL-228 have demonstrated activity in cell culture and in mice bearing xenograft tumors expressing @VARIANT$ @GENE$ mutants [ , ] .", "label": "response"}
{"id": "22655263", "sentence": "X-296/X-396 ( Xcovery ) are aminopyridazine based @GENE$ kinase inhibitors which display good anti-tumor activity in vitro and in vivo on different ALK dependent tumor models . X-396 was also evaluated on L1196M and @VARIANT$ mutations and data suggest that it can potentially overcome at least these @DRUG$ resistance mutations .", "label": "resistance"}
{"id": "23959225", "sentence": "Previous studies showed that Ile , Met , and several non-standard amino acids could be misactivated by LeuRS in vitro , and further charged to tRNALeu by editing defective mutants such as E. coli LeuRS ( EcLeuRS ) @VARIANT$ , yielding mischarged tRNALeu . Therefore , SptRNALeu was methionylated at 37°C in a 300-μL volume containing 100 mM @GENE$ ( pH 7.8 ) , 30 mM KCl , 12 mM MgCl2 , 0.5 mM dithiothreitol ( DTT ) , 4 mM ATP , 40 μM [ 3H ] Met , 20 μM purified SptRNALeu , and 0.5 μM EcLeuRS-D345A mutant for 30 min . The mixtures were isolated by acid phenol/chloroform extraction ( pH 4.5 ) and @DRUG$ precipitation followed by resuspension in 50 mM potassium phosphate buffer ( pH 5.2 ) .", "label": "None"}
{"id": "23234355", "sentence": "@DRUG$ is an effective treatment for NSCLC patients and has been registered as a second and third-line treatment of NSCLC regardless of @GENE$ mutation status [ ] . Gefitinib has been registered for the therapy of advanced NSCLC harbouring activating EGFR mutations in the tyrosine kinase domain , the most frequent being @VARIANT$ in exon 21 and Del ( 746–750 ) in exon 19 [ ] .", "label": "sensitivity"}
{"id": "23209816", "sentence": "Secondly , panel B of indicates that pretreatment with Gö6976 prevented the activation of ERα induced for @VARIANT$ indicating that the cPKC activation occurs before that ERα . 10.1371/journal.pone.0050711.g005Activation of estrogen receptor α (ER α) and classic protein-kinase C α ( PKCα ) in the presence of the cross inhibitors Gö6976 ( Gö ) and @DRUG$ @DRUG$ ( ICI ) , respectively .", "label": "None"}
{"id": "22970367", "sentence": "Moreover , dual inhibition of EGFR with an irreversible EGFR inhibitor ( afatinib ) and the @GENE$ neutralizing antibody @DRUG$ has recently shown promising activity in EGFR mutant lung cancers with acquired EGFR TKI resistance that harbor an EGFR @VARIANT$ mutation [ ] .", "label": "response"}
{"id": "23776354", "sentence": "Activating mutations Frequency at diagnosis , Predictive value for imatinib Secondary mutations of @DRUG$ resistance , – Predictive value for sunitinib KIT Exon 9 10 % 70 % –75 % 58 % Exon 11 67 % 90 % –95 % 34 % Exon 13 1 % ± Yes + Exon 14 0 % Yes + Exon 17 1 % ± Yes − Exon 18 0 % Yes − @GENE$ 33 % –60 % Exon 12 1 % + Exon 14 & lt ; 1 % + Exon 18 5 % ± excepted for @VARIANT$ Yes − for D842V", "label": "resistance or non-response"}
{"id": "14612909", "sentence": "In one NHL , we also found @VARIANT$ BRAF mutation that has also been detected in colon tumours previously . The most impressive examples of recent cancer therapies used protein kinase inhibitors such as Imanitib ( @DRUG$ ) ( ) . Since @GENE$ kinase pathway is activated by protein kinase , therapies that target this signalling pathway would therefore be very valuable in treating tumours that have activating mutations of BRAF .", "label": "None"}
{"id": "24713856", "sentence": "In contrast to GISTs , MCTs expressing D816V KIT genes are imatinib-resistant . Thus , other approaches to control the mutated KIT-driven growth of MCTs are of clinical relevance . We have reported that the activation of the inhibitory molecule @GENE$ could inhibit the growth of HMC1.2 cells , a rapidly proliferating human mast cell line driven by @VARIANT$ and D816V KIT .", "label": "None"}
{"id": "19452042", "sentence": "Several researchers have identified somatic mutations in the @GENE$ gene and have discovered that these mutations were associated with a higher likelihood of clinical response to treatment with @DRUG$ and erlotinib [ - , ] . EGFR gene mutations were most frequently detected in a subpopulation of NSCLC patients with characteristics associated with a better treatment outcome : female sex , non smokers patients , Asian origin , adenocarcinoma histology . The more common EGFR mutations are an in frame deletion in exon 19 around codons 746 to 750 and a missense mutation leading to leucine to arginine substitution at codon 858 ( @VARIANT$ ) in exon 21 [ ] .", "label": "sensitivity"}
{"id": "22249159", "sentence": "Resveratrol , a naturally occurring substance found in grapes , has been shown to modulate @GENE$ in BCR-ABL transformed cells and to exhibit antileukemic effects [ - ] . Treatment of either imatinib mesylate-sensitive or @DRUG$ mesylate-resistant CML cells with resveratrol resulted in cell cycle arrest and apoptotic cell death [ ] . Notably , among the resistant cells that were sensitive to resveratrol , there were also cells expressing the @VARIANT$ BCR-ABL mutant [ ] .", "label": "None"}
{"id": "21333004", "sentence": "Overexpression of wild type EGFR induced high and sustained phosphorylation of EGFR , Shc , MEK ( mitogen activated protein kinase kinase ) and ERK ( extracellular signal regulated kinase ) , while the @VARIANT$ mutation reduced these response levels . In addition , H1299L858R , which is supposed to be more sensitive to gefitinib than H1299EGFR-WT , was effectively inhibited by @DRUG$ administration at the downstream part of the signaling pathway ( MEK and ERK ) compared with @GENE$ , but , surprisingly , not at the upstream part of the pathway ( EGFR and Shc ) .", "label": "sensitivity"}
{"id": "24516334", "sentence": "It is also active against @VARIANT$ and other imatinib-resistant mutants . However , not all CML patients who are refractory or intolerant to dasatinib or nilotinib are responsive to @DRUG$ . We have shown that the resistance of leukemia stem cells to imatinib does not appear to involve BCR-ABL kinase domain mutations , suggesting that @GENE$ activates some signaling pathways in a kinase independent manner in leukemia stem cells .", "label": "response"}
{"id": "19687189", "sentence": "Antrodia camphorata solid-state cultured mycelium ( AC-SS , 1 μg ml−1 ) showed adjuvant anti-proliferative effects with cisplatin ( 10 μM ) or @DRUG$ ( 10 μM ) in hepatoma cell lines C3A and PLC/PRF/5 cells ( in vitro ) and , on xenografted cells in tumor implanted nude mice ( in vivo ) . Furthermore , AC-SS showed its adjuvant effects through the inhibition of MDR gene expressions and the pathway of COX-2 dependent inhibition of AKT phosphorylation [ ] . In terms of the very recent literature , Lu et al. [ ] noted that ethanol extract from wild fruiting bodies of A. camphorata ( EEAC ) dose-dependently induced human premyelocytic leukemia HL 60 cells apoptosis via histone hypoacetylation , upregulation of histone deacetyltransferase 1 (HDAC 1) , and downregulation of histone acetyltransferase activities including GCN 5 , @GENE$ and PCAF .", "label": "None"}
{"id": "23992330", "sentence": "Briefly , they demonstrated the different effects of the G12 and @GENE$ K-Ras alleles on response to cetuximab and found a significant association between the presence of a G13D mutation and survival benefit after @DRUG$ treatment in metastatic colorectal cancer patients [ ] . Moreover , a paper by Di Nicolantonio et al. demonstrated the different role of PI3K and K-Ras mutations in the response to the mammalian Target Of Rapamycin (mTOR) inhibitor everolimus . In fact , while cells knocked-in for the PIK3-CA alleles H1047R and @VARIANT$ showed an increased response to everolimus , oncogenic K-Ras mutations conferred resistance to this agents [ ] .", "label": "None"}
{"id": "21333004", "sentence": "Overexpression of wild type EGFR induced high and sustained phosphorylation of EGFR , Shc , MEK ( mitogen activated protein kinase kinase ) and ERK ( extracellular signal regulated kinase ) , while the @VARIANT$ mutation reduced these response levels . In addition , H1299L858R , which is supposed to be more sensitive to @DRUG$ than H1299EGFR-WT , was effectively inhibited by gefitinib administration at the downstream part of the signaling pathway ( @GENE$ and ERK ) compared with H1299EGFR-WT , but , surprisingly , not at the upstream part of the pathway ( EGFR and Shc ) .", "label": "None"}
{"id": "16953242", "sentence": "In fact , the pleiotropic effect of BCR/ABL transformation is mostly dependent on post-translational modifications ( e.g. phosphorylation ) of signalling molecules , like those involved in the @GENE$ , PI3K/Akt and STATs pathways , which control cell growth , survival and differentiation of haematopoietic cells by modulating the expression and/or activity of downstream effectors ( ; ) ( ) . Being the deregulated BCR/ABL kinase activity the cause of CML , targeting its catalytic domain was the most rationale approach for the rational development of small molecules that inhibit ABL kinase activity . In these CML-BC patients , imatinib resistance often depends on reactivation of BCR/ABL tyrosine kinase activity via mechanisms involving BCR/ABL overexpression , gene amplification or mutations that suppress imatinib mediated kinase inhibition ( i.e. @VARIANT$ and G250E ) or disrupt @DRUG$ binding ( i.e. T315I ) ( ) .", "label": "None"}
{"id": "25368674", "sentence": "The data are mean ± standard deviations of triplicates ( * , P & lt ; 0.001 vs @GENE$ 121463 ; ** , P & lt ; 0.05 vs EMD 121463 ; *** , P & lt ; 0.001 vs gefitinib ; # , P&gt ; 0.05 vs @DRUG$ ) . Matrigel assay in TNBC cell lines , and @VARIANT$ .", "label": "None"}
{"id": "23824064", "sentence": "The synergistic anti-proliferative activity of either @DRUG$ or panobinostat combined with either pazopanib or dasatinib in the thyroid cancers carrying either RET/PTC1 rearrangement ( BHP2-7 ) , KRAS @VARIANT$ mutation ( Cal62 ) or BRAF V600E mutation ( SW1736 ) is of interest . The mutations in these three lines are important components in the @GENE$ cascade .", "label": "None"}
{"id": "25061320", "sentence": "Both the EGFR and @GENE$ genes predict the prognosis of NSCLC. , Exon 19 deletion mutation and a mutation in exon 21 ( @VARIANT$ ) are the two main types of EGFR mutation . Riely et al found that patients with the EGFR exon 19 mutation had a longer median survival time than those with the EGFR exon 21 mutation after receiving @DRUG$ or erlotinib ( 34 versus 8 months , respectively ; P=0.01 , log-rank ) .", "label": "None"}
{"id": "23579627", "sentence": "( G ) Both lung nodules were markedly aggravated 1 month after @DRUG$ retreatment . ( H ) Dramatic response was shown after PF-00299804 trial , but metastatic subcarinal lymphadenopathy was noted in 11-month follow-up scan . The @GENE$ detected by peptide nucleic acid ( PNA ) clamping after treatment with EGFR-tyrosine kinase inhibitor indicate two mutations in exon 21 ( L858R/L861Q ) and exon 20 ( @VARIANT$ ) .", "label": "resistance or non-response"}
{"id": "22768234", "sentence": "Tyrosine kinase inhibitors ( TKI ) targeting EGFR , including @DRUG$ and erlotinib , have become the standard first line therapy for patients with advanced non-small cell lung cancer ( NSCLC ) that harbor activating @GENE$ mutations , . However , almost all patients eventually develop resistance to EGFR TKIs . A number of mechanisms of resistance including KRAS mutation , EGFR exon 20 @VARIANT$ mutation , and MET gene amplification , have been reported .", "label": "resistance or non-response"}
{"id": "24939055", "sentence": "We concluded that the combination of a selective MEK inhibitor and a PI3K/mTOR inhibitor was effective in suppressing the growth of gefitinib-resistant tumors caused by @GENE$ @VARIANT$ mutation , MET amplification , and KRAS/PIK3CA mutation .", "label": "resistance or non-response"}
{"id": "17931419", "sentence": "In particular , H1975 cells contain a second mutation ( @VARIANT$ ) reported to be linked to gefitinib resistance [ ] , but we found that these cells also responded poorly to @DRUG$ . It has been proposed that mutations in the tyrosine kinase domain of @GENE$ cause repositioning of several critical residues surrounding the ATP binding cleft of the tyrosine kinase domain ; this repositioning stabilizes the interactions between the ATP binding site and reversible inhibitors such as gefitinib [ , ] .", "label": "response"}
{"id": "24472312", "sentence": "Gatekeeper mutants ( e.g. T315I @GENE$ , T670I KIT and T674I PDGFRα ) are particularly multi-drug resistant . In the present study , @DRUG$ potently inhibited the phosphorylation of the WT and gatekeeper mutant @VARIANT$ FIP1L1-PDGFRα and their downstream signaling .", "label": "None"}
{"id": "17877814", "sentence": "Akt phosphorylation was readily detected in cells transfected with S768I , Ins770SVD or Ins774HV , but not in cells expressing @VARIANT$ ( Figure ) . The phosphorylation of @GENE$ induced by S768I was abrogated by 100 nM @DRUG$ , and fibril formation was noted upon treatment with 1 μM or higher concentration of the drug .", "label": "None"}
{"id": "23533466", "sentence": "H1975 cancer cell line with mutations in EGFR exons 21 ( L858R ) and 20 ( @VARIANT$ ) was refractory to reversible EGFR-TKIs , gefitinib , and erlotinib [ ] , but was sensitive to irreversible @GENE$ , such as BIBW2992 ( @DRUG$ ) .", "label": "response"}
{"id": "23244248", "sentence": "Global induction of apoptosis with @DRUG$ , cycloheximide or puromycin was shown to lead to a loss of cell coupling , probably due to caspase-3 mediated degradation of Cx43 , in primary bovine lens epithelial and mouse NIH3T3 fibroblasts [ ] . Interestingly , we previously demonstrated that Stat3 inhibition in cells transformed by Src or the Large Tumor antigen of Simian Virus 40 leads to apoptosis [ , ] , possibly due to activation of the transcription factor @VARIANT$ family , potent apoptosis inducers , by these oncogenes .", "label": "None"}
{"id": "22091350", "sentence": "Endothelial cell VEGFR-2 activation by extracellular NM23/NDPK results in Erk1/2 phosphorylation which is prevented by @DRUG$ the NM23/NDPK substrate site inhibitor [ ] , and suramin a non-specific P2YR antagonist . Together these results indicate that activation of @VARIANT$ receptors by extracellular NM23/NDPK is crucial in the transactivation of VEGFR-2 and subsequent down-stream regulation of the @GENE$ pathway that regulates growth and migration of endothelial cells [ ] .", "label": "None"}
{"id": "17877814", "sentence": "No fibrils were observed in the case of @GENE$ T790M or Ins774HV at any of the @DRUG$ concentrations tested . On the other hand , YFP-EGFR-ICD proteins bearing the uncommon exon 21 mutation P848L and A859T showed markedly lower autophosphorylation levels than YFP-EGFR-ICD @VARIANT$ ( Figure ) .", "label": "sensitivity"}
{"id": "24964744", "sentence": "Greatest sensitivity was seen within the @GENE$ mutated cells where IndexSUM values decreased from a relatively resistant index of 423 to 120 and 64 for the H1407R and @VARIANT$ mutations of PI3KCA respectively . MCF10a cells were more sensitive to erlotinib ( IndexSUM = 188 ) than @DRUG$ ( IndexSUM = 423 ) .", "label": "resistance or non-response"}
{"id": "24586514", "sentence": "( B ) K562 or Ba/F3 @VARIANT$ cells were treated with @DRUG$ and/or vorinostat for 24 h , and total extracts were examined by immunoblot analysis with anti-phospho @GENE$ , Crk-L , γH2A.X , cleaved caspase 3 , PARP , acetyl histone H4 , and tubulin antibodies .", "label": "response"}
{"id": "23723712", "sentence": "@DRUG$ and erlotinib represent the first generation of small @GENE$ tyrosine kinase inhibitors ( TKIs ) that selectively target the intracellular tyrosine kinase domain of EGFR , blocking the downstream signaling of the receptor . The EGFR somatic mutations have emerged to be the most relevant predictor of response to these agents. , Thus , several prospective randomized trials have demonstrated that the use of EGFR TKIs in patients with advanced treatment-naive NSCLC with EGFR mutations significantly improved the objective response rate ( ORR ) and progression-free survival ( PFS ) compared with standard platinum based chemotherapy.– Unfortunately , all responders eventually develop resistance , most commonly because of the emergence of a gatekeeper mutation in the kinase domain , such as @VARIANT$ in EGFR mutated NSCLC or amplification of mesenchymal–epithelial transition factor ( c-Met ) .", "label": "resistance or non-response"}
{"id": "16434996", "sentence": "The ability of @DRUG$ to induce endoplasmic reticulum stress response signalling could , in part , explain how low doses of genistein induce @GENE$ gene expression . This research was supported , in part , by United States Public Health Service Grants R01-CA104546 , R01-CA82599 , R01-CA80000 , RO1-ES09169 ( to EMR ) , R21-AA13122 ( to SF ) , and by a grant from the Susan G Komen Breast Cancer Foundation ( BCTR0201295 ) to EMR . Indole-3-carbinol ( @VARIANT$ ) upregulates BRCA1 and BRCA2 mRNA expression in human breast cancer cells in a time- and dose dependent manner .", "label": "None"}
{"id": "23691449", "sentence": "Some of the molecular mechanisms of acquired resistance include T790M second mutation , mesenchymal epithelial transition factor ( MET ) amplification , ATP binding cassette (ABC)-G2 transporter ( ABCG2 ) and hepatocyte growth factor (HGF) overexpression , insulin-like growth factor (IGF) binding protein-3 ( @GENE$ ) downregulation , as well as ERBB3 activation . T790M mutation The @VARIANT$ second mutation accounts for half of all resistances to @DRUG$ and erlotinib [ ] .", "label": "None"}
